PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Luque, A; Gomez, M; Puzon, W; Takada, Y; SanchezMadrid, F; Cabanas, C				Luque, A; Gomez, M; Puzon, W; Takada, Y; SanchezMadrid, F; Cabanas, C			Activated conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355-425) of the common beta 1 chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; INTERCELLULAR-ADHESION MOLECULE-1; PLATELET GPIIB-IIIA; CELL-ADHESION; MONOCLONAL-ANTIBODY; PHORBOL ESTER; LEUKOCYTE INTEGRINS; BINDING-SITE; T-CELLS; LIGAND	The very late activation antigens (VLA) or beta 1 integrins mediate cell attachment to different extracellular matrix proteins and intercellular adhesions. The ligand binding activity of these adhesion receptors is not constitutive and can be regulated by temperature, presence of extracellular divalent cations, stimulatory monoclonal antibodies (mAbs), and cellular activation. We have generated three novel mAbs, HUTS-4, HUTS-7, and HUTS-21, recognizing specific epitopes on the common beta 1 subunit (CD29) of VLA integrins whose expression correlates with the ligand binding activity of these heterodimeric glycoproteins. This correlation has been demonstrated for several integrin heterodimers in different cell systems using a variety of extracellular and intracellular stimuli for integrin activation. Thus, the presence of micromolar concentrations of extracellular Mn2+, preincubation with the activating anti-beta 1 mAb TS2/16, and cell treatment with phorbol esters or calcium ionophores, induced the expression of the HUTS beta 1 epitopes on T lymphoblasts. Using a panel of human-mouse beta 1 chimeric molecules, we have mapped these epitopes to the 355-425 sequence of the beta 1 polypeptide. This segment represents therefore a novel regulatory region of beta 1 that is exposed upon integrin activation. Interestingly, binding of HUTS mAbs to partially activated VLA integrins results in maximal activation of these adhesion receptors and enhancement of cell adhesion to beta 1 integrin ligands collagen, laminin, and fibronectin.	UNIV COMPLUTENSE MADRID, FAC MED, DEPT BIOQUIM & BIOL MOLEC, E-28040 MADRID, SPAIN; UAM, HOSP PRINCESA, SERV IMMUNOL, E-28006 MADRID, SPAIN; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Complutense University of Madrid; Autonomous University of Madrid; Hospital de La Princesa; Scripps Research Institute			Luque, Alfonso/C-5846-2018; Sanchez-Madrid, Francisco/M-7889-2016; CABAÑAS, CARLOS/J-4595-2012	Sanchez-Madrid, Francisco/0000-0001-5303-0762; CABAÑAS, CARLOS/0000-0002-8767-060X; takada, yoshikazu/0000-0001-5481-9589	NIGMS NIH HHS [GM 47157, GM 49899] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049899, R01GM047157] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; ARROYO AG, 1994, J CELL BIOL, V126, P1277, DOI 10.1083/jcb.126.5.1277; ARROYO AG, 1993, J BIOL CHEM, V268, P9863; ARROYO AG, 1995, EUR J IMMUNOL, V25, P1720, DOI 10.1002/eji.1830250635; BEDNARCZYK JL, 1994, J BIOL CHEM, V269, P8348; CABANAS C, 1993, P NATL ACAD SCI USA, V90, P5838, DOI 10.1073/pnas.90.12.5838; CABANAS C, 1988, HYBRIDOMA, V7, P167, DOI 10.1089/hyb.1988.7.167; CAMPANERO MR, 1994, J CELL BIOL, V127, P867, DOI 10.1083/jcb.127.3.867; CAMPANERO MR, 1992, EUR J IMMUNOL, V22, P3111, DOI 10.1002/eji.1830221213; CAMPANERO MR, 1990, J CELL BIOL, V110, P2157, DOI 10.1083/jcb.110.6.2157; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DRANSFIELD I, 1992, J CELL BIOL, V116, P1527, DOI 10.1083/jcb.116.6.1527; DRANSFIELD I, 1990, IMMUNOL REV, V114, P29, DOI 10.1111/j.1600-065X.1990.tb00560.x; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GIANCOTTI FG, 1994, BBA-REV CANCER, V1198, P47, DOI 10.1016/0304-419X(94)90005-1; GRZESIAK JJ, 1992, J CELL BIOL, V117, P1109, DOI 10.1083/jcb.117.5.1109; HARTFIELD PJ, 1993, BIOCHEM BIOPH RES CO, V196, P1183, DOI 10.1006/bbrc.1993.2376; HEMLER ME, 1990, CELL DIFFER DEV, V32, P229, DOI 10.1016/0922-3371(90)90035-U; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; Kuhn K, 1994, Trends Cell Biol, V4, P256, DOI 10.1016/0962-8924(94)90124-4; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; LUQUE A, 1994, FEBS LETT, V346, P278, DOI 10.1016/0014-5793(94)00490-0; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MELERO I, 1993, EUR J IMMUNOL, V23, P1859, DOI 10.1002/eji.1830230819; MIYAKE K, 1994, INT IMMUNOL, V6, P1221, DOI 10.1093/intimm/6.8.1221; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PICKER LJ, 1993, EUR J IMMUNOL, V23, P2751, DOI 10.1002/eji.1830231105; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; Sanchez-Madrid F, 1992, Semin Cell Biol, V3, P199; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; VANKOOYK Y, 1993, CELL ADHES COMMUN, V1, P21, DOI 10.3109/15419069309095679; VANKOOYK Y, 1994, J CELL BIOL, V124, P1061, DOI 10.1083/jcb.124.6.1061; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2	57	268	280	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11067	11075		10.1074/jbc.271.19.11067	http://dx.doi.org/10.1074/jbc.271.19.11067			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626649	hybrid			2022-12-27	WOS:A1996UJ94400009
J	Larsson, O; Deeney, JT; Branstrom, R; Berggren, PO; Corkey, BE				Larsson, O; Deeney, JT; Branstrom, R; Berggren, PO; Corkey, BE			Activation of the ATP-sensitive K+ channel by long chain acyl-CoA - A role in modulation of pancreatic beta-cell glucose sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN-SECRETION; FATTY-ACIDS; COENZYME-A; POTASSIUM CHANNELS; MALONYL-COA; METABOLISM; RAT; INHIBITION; ISLETS; ESTERS	Long term exposure to elevated levels of long chain free fatty acids decreases glucose-induced insulin secretion from pancreatic islets and clonal pancreatic beta-cells. The mechanism for this loss of glucose sensitivity is at present not known, In this study, we evaluated the possibility that increases in long chain acyl-CoA esters (LC-CoA), the metabolically active form of free fatty acids, might mediate the loss of glucose sensitivity, We observed that cellular levels of LC-CoA increased more than 100% in response to overnight incubation with 0.5 mM palmitic acid complexed to albumin, In the same studies, the total CoA pool increased by about 40%. Patch-clamp studies demonstrated that saturated and unsaturated LC-CoA, but not malonyl-CoA or free CoASH, induced a rapid and slowly reversible opening of ATP-sensitive K+ channels, The effect was concentration-dependent between 10 nn and 1 mu M. These findings indicate that the ATP-regulated K+ channel is a sensitive target for LC-CoA and suggest that high levels of LC-CoA, which accumulate in response to hyperglycemia or prolonged exposure to free fatty acids, may prevent channel closure and contribute to the development of beta-cell glucose insensitivity.	BOSTON UNIV, MED CTR,SCH MED,EVANS DEPT MED,DIABET & METAB UNIT, BOSTON, MA 02118 USA; BOSTON UNIV, MED CTR, DEPT BIOCHEM, BOSTON, MA 02118 USA; KAROLINSKA INST, ROLF LUFT CTR DIABET RES, DEPT MOLEC MED, S-17176 STOCKHOLM, SWEDEN	Boston University; Boston University; Karolinska Institutet			Corkey, Barbara/E-7712-2015	Corkey, Barbara/0000-0002-5467-1630; Deeney, Jude/0000-0003-0988-9419; Branstrom, Robert/0000-0001-6245-7223; Berggren, Per-Olof/0000-0001-8991-413X	NIDDK NIH HHS [DK46200, DK35914] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK035914, R37DK035914, R01DK035914, P30DK046200] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; ASHCROFT FM, 1990, BIOCHEM SOC T, V18, P109, DOI 10.1042/bst0180109; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; BERNE C, 1975, BIOCHEM J, V152, P667, DOI 10.1042/bj1520667; BERNE C, 1975, BIOCHEM J, V152, P661, DOI 10.1042/bj1520661; BOKVIST K, 1991, P ROY SOC B-BIOL SCI, V243, P139, DOI 10.1098/rspb.1991.0022; CAPITO K, 1992, ACTA DIABETOL, V28, P193, DOI 10.1007/BF00778997; CORKEY BE, 1988, METHOD ENZYMOL, V166, P55; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; CORKEY BE, 1990, PROG CLIN BIOL RES, V321, P217; DEENEY JT, 1992, J BIOL CHEM, V267, P19840; ELKS ML, 1993, ENDOCRINOLOGY, V133, P208, DOI 10.1210/en.133.1.208; Foster D W, 1982, Ciba Found Symp, V87, P120, DOI 10.1002/9780470720691.ch7; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOPKINS WF, 1992, J MEMBRANE BIOL, V129, P287; HUANG WH, 1989, J BIOL CHEM, V264, P2605; HUANG WH, 1986, BIOCHEM INT, V12, P521; KAKAR SS, 1987, J BIOL CHEM, V262, P42; KAKEI M, 1986, FEBS LETT, V208, P63, DOI 10.1016/0014-5793(86)81533-2; KATIYAR SS, 1991, BIOCHEM BIOPH RES CO, V175, P1104, DOI 10.1016/0006-291X(91)91679-7; LARSSON O, 1993, J PHYSIOL-LONDON, V463, P349, DOI 10.1113/jphysiol.1993.sp019598; MULLER M, 1992, BIOCHEMISTRY-US, V31, P4656; PETROU S, 1995, PROSTAG LEUKOTR ESS, V52, P173, DOI 10.1016/0952-3278(95)90018-7; POWELL GL, 1985, FED PROC, V44, P81; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; SAKO Y, 1990, ENDOCRINOLOGY, V127, P1580, DOI 10.1210/endo-127-4-1580; TIPPETT PS, 1982, J BIOL CHEM, V257, P2839; TIPPETT PS, 1982, J BIOL CHEM, V257, P2846; TSUURA Y, 1993, DIABETES, V42, P1446, DOI 10.2337/diabetes.42.10.1446; VARA E, 1986, METABOLISM, V35, P266, DOI 10.1016/0026-0495(86)90212-X; Williamson J R, 1979, Methods Enzymol, V55, P200; WOLDEGIORGIS G, 1982, J BIOL CHEM, V257, P4783; ZHOU YP, 1994, J CLIN INVEST, V93, P870, DOI 10.1172/JCI117042	33	138	144	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10623	10626		10.1074/jbc.271.18.10623	http://dx.doi.org/10.1074/jbc.271.18.10623			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631866				2022-12-27	WOS:A1996UJ34200034
J	Barroso, MR; Bernd, KK; DeWitt, ND; Chang, A; Mills, K; Sztul, ES				Barroso, MR; Bernd, KK; DeWitt, ND; Chang, A; Mills, K; Sztul, ES			A novel Ca2+-binding protein, p22, is required for constitutive membrane traffic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; ESCHERICHIA-COLI; PLASMA-MEMBRANE; RECOVERIN; FUSION; CELLS; FAMILY; MYRISTOYLATION; RECONSTITUTION; SYNAPTOTAGMIN	We have identified a novel protein, p22, required for ''constitutive'' exocytic membrane traffic. p22 belongs to the EF-hand superfamily of Ca2+-binding proteins and shows extensive similarity to the regulatory subunit of protein phosphatase 2B, calcineurin B. p22 is a cytosolic N-myristoylated protein that undergoes conformational changes upon binding of Ca2+. Antibodies against a p22 peptide block the targeting/fusion of transcytotic vesicles with the apical plasma membrane, but recombinant wild-type p22 overcomes that inhibition. Nonmyristoylated p22, or p22 incapable of undergoing Ca2+-induced conformational changes, cannot reverse the antibody-mediated inhibition. The data suggest that p22 may act by transducing cellular Ca2+ signals to downstream effecters. p22 is ubiquitously expressed, and we propose that its function is required for membrane trafficking events common to many cells.	UNIV ALABAMA, MED CTR, DEPT CELL BIOL, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham			Bernd, Karen K/K-2774-2012; Barroso, Margarida/A-9901-2010	Bernd, Karen K/0000-0002-0743-2848; Barroso, Margarida/0000-0002-0407-3181				AITKEN A, 1984, EUR J BIOCHEM, V139, P663, DOI 10.1111/j.1432-1033.1984.tb08055.x; BABU A, 1992, J BIOL CHEM, V267, P15469; BARROSO M, 1988, EUR J BIOCHEM, V172, P363, DOI 10.1111/j.1432-1033.1988.tb13895.x; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; CHAKRAVARTI S, 1990, J BIOL CHEM, V265, P10597; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; DECURTIS I, 1988, P NATL ACAD SCI USA, V85, P8052, DOI 10.1073/pnas.85.21.8052; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; Harlow E., 1988, ANTIBODIES LAB MANUA; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAWASAKI H, 1994, PROTEIN PROFILE, V1, P343; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; LEW DJ, 1991, J MEMBRANE BIOL, V123, P261, DOI 10.1007/BF01870409; LI E, 1987, J BIOL CHEM, V262, P13773; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MAYORGA LS, 1994, J BIOL CHEM, V269, P30927; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; MORIMOTO T, 1995, CELL, V15, P689; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; POPOV SV, 1993, CELL, V73, P1247, DOI 10.1016/0092-8674(93)90352-Q; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SCHELLER RH, 1995, NEURON, V14, P893; SCHWEIZER FE, 1995, NEURON, V14, P689, DOI 10.1016/0896-6273(95)90213-9; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; SZTUL E, 1993, J BIOL CHEM, V268, P1876; SZTUL E, 1991, CELL, V64, P81, DOI 10.1016/0092-8674(91)90210-P; SZTUL ES, 1985, J CELL BIOL, V100, P1248, DOI 10.1083/jcb.100.4.1248; TENG DHF, 1994, J BIOL CHEM, V269, P31900; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; TURNER MD, 1992, J CELL BIOL, V117, P269, DOI 10.1083/jcb.117.2.269; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WICE BM, 1992, J CELL BIOL, V116, P405, DOI 10.1083/jcb.116.2.405	48	71	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10183	10187		10.1074/jbc.271.17.10183	http://dx.doi.org/10.1074/jbc.271.17.10183			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626580	hybrid			2022-12-27	WOS:A1996UG25700052
J	Woods, A; Cheung, PCF; Smith, FC; Davison, MD; Scott, J; Beri, RK; Carling, D				Woods, A; Cheung, PCF; Smith, FC; Davison, MD; Scott, J; Beri, RK; Carling, D			Characterization of AMP-activated protein kinase beta and gamma subunits - Assembly of the heterotrimeric complex in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GLUCOSE REPRESSION; SNF4 PROTEIN; FATTY-ACID; YEAST; PHOSPHORYLATION; GENE; METABOLISM; MUTATIONS; MECHANISM	There is growing evidence that mammalian AMP-activated protein kinase (AMPK) plays a role in protecting cells from stresses that cause ATP depletion by switching off ATP-consuming biosynthetic pathways. The active form of AMPK from rat liver exists as a heterotrimeric complex and we have previously shown that the catalytic subunit is structurally and functionally related to the SNF1 protein kinase from Saccharomyces cerevisiae. Here we describe the isolation and characterization of the two other polypeptides, termed AMPK beta and AMPK gamma, that together with the catalytic subunit (AMPK alpha) form the active kinase complex in mammalian liver. Sequence analysis of cDNA clones encoding these subunits reveals that they are related to yeast proteins that interact with SNF1, providing further evidence that the regulation and function of AMPK and SNF1 have been conserved throughout evolution. The amino acid sequence of the beta subunit is most closely related to SIP2 (35% identity), while the amino acid sequence of the gamma subunit is 35% identical with SNF4. We show that both AMPK beta and AMPK gamma mRNA and protein are expressed widely in rat tissues. We show that AMPK beta interacts with both AMPK alpha and AMPK gamma in vitro, whereas AMPK alpha does not interact with AMPK gamma under the same conditions. These results suggest that AMPK beta mediates the association of the heterotrimeric AMPK complex in vitro, and will facilitate future studies aimed at investigating the regulation of AMPK in vivo.	ROYAL POSTGRAD MED SCH,MRC,CTR CLIN SCI,DEPT MOLEC MED,LONDON W12 0NN,ENGLAND; ZENECA PHARMACEUT,CARDIOVASC DEPT,MACCLESFIELD SK10 4TG,CHESHIRE,ENGLAND; ZENECA PHARMACEUT,INFECT DEPT,MACCLESFIELD SK10 4TG,CHESHIRE,ENGLAND	Imperial College London			Carling, David/F-1943-2014; Cheung, Peter/A-2213-2011	Carling, David/0000-0002-2316-1830; Leiper, Fiona/0000-0001-6681-681X				CARLING D, 1989, BIOCHIM BIOPHYS ACTA, V1012, P81, DOI 10.1016/0167-4889(89)90014-1; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CARLING D, 1994, J BIOL CHEM, V269, P11442; CARLSON M, 1981, GENETICS, V98, P25; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CELENZA JL, 1989, MOL CELL BIOL, V9, P5045, DOI 10.1128/MCB.9.11.5045; CELENZA JL, 1989, MOL CELL BIOL, V9, P5034, DOI 10.1128/MCB.9.11.5034; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; DAVIES SP, 1994, EUR J BIOCHEM, V223, P351, DOI 10.1111/j.1432-1033.1994.tb19001.x; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; ERICKSON JR, 1993, GENETICS, V135, P655; ESTRUCH F, 1992, GENETICS, V132, P639; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GANCEDO JM, 1992, EUR J BIOCHEM, V206, P297, DOI 10.1111/j.1432-1033.1992.tb16928.x; Hardie D. Grahame, 1994, Seminars in Cell Biology, V5, P409, DOI 10.1006/scel.1994.1048; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; HARDIE DG, 1994, NATURE, V370, P599, DOI 10.1038/370599a0; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; Harlow E., 1988, ANTIBODIES LAB MANUA; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; MATSUMOTO K, 1981, MOL CELL BIOL, V1, P19; Miller J.H., 1972, EXPT MOL GENETICS; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; STAPLETON D, 1994, J BIOL CHEM, V269, P29343; SULLIVAN JE, 1994, BIOCHEM BIOPH RES CO, V200, P1551, DOI 10.1006/bbrc.1994.1627; THOMPSONJAEGER S, 1991, GENETICS, V129, P697; VERHOEVEN AJM, 1995, EUR J BIOCHEM, V228, P236; WEEKES J, 1994, EUR J BIOCHEM, V219, P751, DOI 10.1111/j.1432-1033.1994.tb18554.x; WOODS A, 1994, J BIOL CHEM, V269, P19509; YANG XL, 1994, EMBO J, V13, P5878, DOI 10.1002/j.1460-2075.1994.tb06933.x; YANG XO, 1992, SCIENCE, V257, P680, DOI 10.1126/science.1496382	44	213	226	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10282	10290		10.1074/jbc.271.17.10282	http://dx.doi.org/10.1074/jbc.271.17.10282			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626596	hybrid			2022-12-27	WOS:A1996UG25700068
J	Knudsen, ES; Wang, JYJ				Knudsen, ES; Wang, JYJ			Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT; CELL-CYCLE; TRANSCRIPTION FACTOR; GROWTH SUPPRESSION; BINDING PROTEIN; REPRESSION; REGIONS; DOMAINS; KINASE; PRB	The retinoblastoma tumor suppressor protein, RE, contains at least three distinct protein binding domains. The A/B pocket binds proteins with the LXCXE motif, the C pocket binds the nuclear c-Abl tyrosine kinase, and the large A/B pocket binds the transcription factor E2F. Dissociation of RE from its targets is observed as RE becomes phosphorylated during G(1)/S progression. There are 16 Cdk consensus phosphorylation sites in RE. It was previously unknown whether the many phosphorylation sites had redundant or distinct functions in the regulation of RE. Using RE mutant proteins lacking specific phosphorylation sites, we show that each of the binding domains is inhibited by different sites. Thr-821/826 phosphorylation is required to inhibit the binding to LXCXE containing proteins. Mutation of these two sites does not interfere with the hyperphosphorylation of RE. However, this phosphorylated mutant retains the ability to bind T-Ag, E7, and Elf-1, all of which contain the LXCXE motif. In contrast, Ser-807/811 phosphorylation is required to disrupt c-Abl binding. Mutation of Ser-807/811 and Thr-821/826 does not abolish the regulation of E2F binding. Taken together, these results show that the protein binding domains of RE are each regulated by distinct Cdk phosphorylation sites.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR GENET MOLEC,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R01CA058320] Funding Source: NIH RePORTER; NCI NIH HHS [CA58320, R01 CA058320] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEYERLE KL, 1989, J VIROL, V63, P356, DOI 10.1128/JVI.63.1.356-365.1989; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAMEL PA, 1992, ONCOGENE, V7, P693; HAMEL PA, 1990, MOL CELL BIOL, V10, P6586, DOI 10.1128/MCB.10.12.6586; HANSEN MF, 1990, CANCER GENET CYTOGEN, V49, P15, DOI 10.1016/0165-4608(90)90159-8; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LIN BTY, 1992, CIBA F SYMP, V170, P227; MELENDY T, 1991, J BIOL CHEM, V266, P1942; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4	29	274	277	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8313	8320		10.1074/jbc.271.14.8313	http://dx.doi.org/10.1074/jbc.271.14.8313			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626527	hybrid			2022-12-27	WOS:A1996UD60000067
J	Sakane, F; Imai, S; Kai, M; Wada, I; Kanoh, H				Sakane, F; Imai, S; Kai, M; Wada, I; Kanoh, H			Molecular cloning of a novel diacylglycerol kinase isozyme with a pleckstrin homology domain and a C-terminal tail similar to those the EPH family of protein-tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; PHOSPHATIDIC-ACID; REGULATORY DOMAIN; CDNA-CLONING; ZINC-FINGER; HAND MOTIFS; RAT-BRAIN; GENE; EXPRESSION; PURIFICATION	A fourth member of the diacylglycerol kinase (DGK) gene family termed DGK delta was cloned from the human testis cDNA library. The cDNA sequence contains an open reading frame of 3,507 nucleotides encoding a putative DGK protein of 130,006 Da. Interestingly, the new DGK isozyme contains a pleckstrin homology domain found in a number of proteins involved in signal transduction. Furthermore, the C-terminal tail of this isozyme is very similar to those of the EPH family of receptor tyrosine kinases. The primary structure of the delta-isozyme also has two cysteine-rich zinc finger-like structures (C3 region) and the C-terminal C4 region, both of which have been commonly found in the three isozymes previously cloned (DGKs alpha, beta and gamma). However, DGK delta lacks the EF-hand motifs (C2) and contains a long Glu- and Ser-rich insertion (317 residues), which divides the C4 region into two portions. Taken together, these structural features of DGK delta indicate that this isozyme belongs to a DGK subfamily distinct from that consisting of DGKs alpha, beta, and gamma. Increased DGK activity without marked preference to arachidonoyl type of diacylglycerol was detected in the particulate fraction of COS-7 cells expressing the transfected DGK delta cDNA. The enzyme activity was independent of phosphatidylserine, which is a common activator for the previously sequenced DGKs. Northern blot analysis showed that the DGK delta mRNA (similar to 6.3 kilobases) is most abundant in human skeletal muscle but undetectable in the brain, thymus, and retina. This expression pattern is different from those of the previously cloned DGKs. Our results show that the DGK gene family consists of at least two subfamilies consisting of enzymes with distinct structural characteristics and that each cell type probably expresses its own characteristic repertoire of DGKs whose functions may be regulated through different signal transduction pathways.			Sakane, F (corresponding author), SAPPORO MED UNIV,SCH MED,DEPT BIOCHEM,SOUTH-1,WEST-17,SAPPORO,HOKKAIDO 060,JAPAN.		Sakane, Fumio/H-2693-2017	Sakane, Fumio/0000-0003-0857-0377; Wada, Ikuo/0000-0001-5668-6994				AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; AUSSEL C, 1992, CELL IMMUNOL, V139, P333, DOI 10.1016/0008-8749(92)90075-Z; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCKCROFT S, 1992, BIOCHEM J, V288, P1; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1983, J BIOL CHEM, V258, P1767; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KANOH H, 1993, CELL SIGNAL, V5, P495, DOI 10.1016/0898-6568(93)90045-N; KATO M, 1990, J BIOL CHEM, V265, P794; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KIYOKAWA E, 1994, CANCER RES, V54, P3645; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LOHTAK V, 1991, MOL CELL BIOL, V11, P2496; MACDONALD ML, 1988, J BIOL CHEM, V263, P1575; MARU Y, 1990, ONCOGENE, V5, P445; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MASAI I, 1992, P NATL ACAD SCI USA, V89, P6030, DOI 10.1073/pnas.89.13.6030; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SAKANE F, 1991, BIOCHEM BIOPH RES CO, V181, P1015, DOI 10.1016/0006-291X(91)92038-L; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; SDAMBROOK J, 1989, MOL CLONING LAB MANU; SIEVER DA, 1994, GENE, V148, P219, DOI 10.1016/0378-1119(94)90692-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WALSH JP, 1994, J BIOL CHEM, V269, P21155; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; YADA Y, 1990, J BIOL CHEM, V265, P19237; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	62	133	137	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8394	8401		10.1074/jbc.271.14.8394	http://dx.doi.org/10.1074/jbc.271.14.8394			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626538	hybrid			2022-12-27	WOS:A1996UD60000078
J	Bandaru, B; Gopal, J; Bhagwat, AS				Bandaru, B; Gopal, J; Bhagwat, AS			Overproduction of DNA cytosine methyltransferases causes methylation and C->T mutations at non-canonical sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; RESTRICTION-MODIFICATION SYSTEM; DEOXYRIBONUCLEIC-ACID; MISMATCH-REPAIR; INDUCED DEAMINATION; MODIFICATION ENZYME; 5-METHYLCYTOSINE; ENDONUCLEASE; GENE; RECOGNITION	Multicopy clones of Escherichia coli cytosine methyltransferases Dcm and EcoRII methylase (M. EcoRII) cause similar to 50-fold increase in C --> T mutations at their canonical site of methylation, 5'-CmeCAGG (meC is 5-methylcytosine). These plasmids also cause transition mutations at the second cytosine in the sequences CCGGG at similar to 10-fold lower frequency. Similarly, M. HpaII was found to cause a significant increase in C --> T mutations at a CCAG site, in addition to causing mutations at its canonical site of methylation, CCGG. Using a plasmid that substantially overproduces M. EcoRII, in vivo methylation at CCSGG (S is C or G) and other noncanonical sites could be detected using a gel electrophoretic assay. There is a direct correlation between the level of M. EcoRII activity in cells, the extent of methylation at non-canonical sites and frequency of mutations at these same sites. Overproduction of M. EcoRII in cells also causes degradation of DNA and induction of the SOS response. In vitro, M. EcoRII methylates an oligonucleotide duplex containing a CCGGG site at a slow rate, suggesting that overproduction of the enzyme is essential for significant amounts of such methylation to occur. Together these results show that cytosine methyltransferases occasionally methylate cellular DNA at non-canonical sites and suggest that in E. coli, methylation-specific restriction systems and sequence specificity of the DNA mismatch correction systems may have evolved to accommodate this fact. These results also suggest that mutational effects of cytosine methyltransferases may be much broader than previously imagined.	WAYNE STATE UNIV,DEPT CHEM,DETROIT,MI 48202	Wayne State University			Bhagwat, Ashok/AAU-4186-2021; Bhagwat, Ashok/ABA-3861-2020	Bhagwat, Ashok/0000-0003-1188-0579; 	NHGRI NIH HHS [HG 00004] Funding Source: Medline; NIGMS NIH HHS [GM 45860] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANDARU B, 1995, J BACTERIOL, V177, P2950, DOI 10.1128/jb.177.10.2950-2952.1995; BANNISTE.D, 1968, BIOCHEM BIOPH RES CO, V30, P735, DOI 10.1016/0006-291X(68)90575-5; BHAGWAT AS, 1986, J BACTERIOL, V166, P751, DOI 10.1128/jb.166.3.751-755.1986; BHAGWAT AS, 1990, J BIOL CHEM, V265, P767; BHAGWAT AS, 1981, MOL GEN GENET, V182, P505, DOI 10.1007/BF00293943; BIGGER CH, 1973, NATURE-NEW BIOL, V244, P7, DOI 10.1038/newbio244007a0; BOYER HW, 1973, NATURE-NEW BIOL, V244, P40, DOI 10.1038/newbio244040a0; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; BUTKUS V, 1987, NUCLEIC ACIDS RES, V15, P7091, DOI 10.1093/nar/15.17.7091; CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0; DAVIS R, 1993, APPL ENVIRON MICROB, V59, P777, DOI 10.1128/AEM.59.3.777-785.1993; DOBRITSA AP, 1980, GENE, V10, P105, DOI 10.1016/0378-1119(80)90128-6; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; FRIEDMAN S, 1993, J BACTERIOL, V175, P6293, DOI 10.1128/JB.175.19.6293-6298.1993; GLASNER W, 1995, J MOL BIOL, V245, P1; GLASNER W, 1992, STRUCTURAL TOOLS ANA, P65; GOPAL J, 1994, NUCLEIC ACIDS RES, V22, P4482, DOI 10.1093/nar/22.21.4482; GOPAL J, 1995, NUCLEIC ACIDS RES, V23, P29, DOI 10.1093/nar/23.1.29; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HEITMAN J, 1991, GENE, V103, P1, DOI 10.1016/0378-1119(91)90383-M; HEITMAN J, 1987, J BACTERIOL, V169, P3243, DOI 10.1128/jb.169.7.3243-3250.1987; HENNECKE F, 1991, NATURE, V353, P776, DOI 10.1038/353776a0; JONES M, 1987, CELL, V50, P621, DOI 10.1016/0092-8674(87)90035-3; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; KARYAGINA AS, 1990, GENE, V87, P113, DOI 10.1016/0378-1119(90)90501-H; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; KELLEHER JE, 1991, J BACTERIOL, V173, P5220, DOI 10.1128/jb.173.16.5220-5223.1991; KLIMASAUSKAS S, 1995, NUCLEIC ACIDS RES, V23, P1388, DOI 10.1093/nar/23.8.1388; KRETZ PL, 1991, J BACTERIOL, V173, P4707, DOI 10.1128/jb.173.15.4707-4716.1991; KULAKAUSKAS S, 1994, GENE, V142, P9, DOI 10.1016/0378-1119(94)90348-4; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LIEB M, 1991, GENETICS, V128, P23; LIEB M, 1987, J BACTERIOL, V169, P5241, DOI 10.1128/jb.169.11.5241-5246.1987; LIEB M, 1986, GENETICS, V114, P1041; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; MANN MB, 1977, NUCLEIC ACIDS RES, V4, P4211, DOI 10.1093/nar/4.12.4211; MARINUS MG, 1973, J BACTERIOL, V114, P1143, DOI 10.1128/JB.114.3.1143-1150.1973; MAY MS, 1975, J BACTERIOL, V122, P129, DOI 10.1128/JB.122.1.129-138.1975; Miller JH., 1992, SHORT COURSE BACTERI, P72; NELSON M, 1984, NUCLEIC ACIDS RES, V12, P5165, DOI 10.1093/nar/12.13.5165; RALEIGH EA, 1992, MOL MICROBIOL, V6, P1079, DOI 10.1111/j.1365-2958.1992.tb01546.x; RALEIGH EA, 1986, P NATL ACAD SCI USA, V83, P9070, DOI 10.1073/pnas.83.23.9070; REICH NO, 1992, J BIOL CHEM, V267, P15802; RINGQUIST S, 1992, P NATL ACAD SCI USA, V89, P4539, DOI 10.1073/pnas.89.10.4539; SCHLAGMAN S, 1976, J BACTERIOL, V126, P990, DOI 10.1128/JB.126.2.990-996.1976; SHEN JC, 1992, NUCLEIC ACIDS RES, V20, P5119, DOI 10.1093/nar/20.19.5119; SHEN JC, 1992, CELL, V71, P1; SMITH DW, 1992, NUCLEIC ACIDS RES, V20, P6091, DOI 10.1093/nar/20.22.6091; SOM S, 1993, EMBO J, V12, P4297, DOI 10.1002/j.1460-2075.1993.tb06114.x; SOM S, 1994, NUCLEIC ACIDS RES, V22, P5347, DOI 10.1093/nar/22.24.5347; SOM S, 1987, NUCLEIC ACIDS RES, V15, P313, DOI 10.1093/nar/15.1.313; SUTHERLAND E, 1992, J MOL BIOL, V225, P327, DOI 10.1016/0022-2836(92)90925-A; TAYLOR JD, 1990, BIOCHEMISTRY-US, V29, P10727, DOI 10.1021/bi00500a003; VAIRAPANDI M, 1993, NUCLEIC ACIDS RES, V21, P5323, DOI 10.1093/nar/21.23.5323; WALDER RY, 1983, J BIOL CHEM, V258, P1235; WANG RYH, 1982, BIOCHIM BIOPHYS ACTA, V697, P371, DOI 10.1016/0167-4781(82)90101-4; WOODBURY CP, 1980, J BIOL CHEM, V255, P1526; WYSZYNSKI M, 1994, P NATL ACAD SCI USA, V91, P1574, DOI 10.1073/pnas.91.4.1574; WYSZYNSKI MW, 1992, NUCLEIC ACIDS RES, V20, P319, DOI 10.1093/nar/20.2.319; YANG AS, 1995, NUCLEIC ACIDS RES, V23, P1380, DOI 10.1093/nar/23.8.1380; YEBRA MJ, 1995, BIOCHEMISTRY-US, V34, P14752, DOI 10.1021/bi00045a016; YOSHIMORI R, 1972, J BACTERIOL, V112, P1275, DOI 10.1128/JB.112.3.1275-1279.1972; ZELL R, 1987, EMBO J, V6, P1809, DOI 10.1002/j.1460-2075.1987.tb02435.x	65	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7851	7859		10.1074/jbc.271.13.7851	http://dx.doi.org/10.1074/jbc.271.13.7851			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631830	hybrid			2022-12-27	WOS:A1996UC77400098
J	Overholtzer, MH; Yakowec, PS; Cameron, V				Overholtzer, MH; Yakowec, PS; Cameron, V			The effect of amino acid substitutions in the conserved aromatic region of subunit II of cytochrome c oxidase in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL-MEMBRANE SYSTEM; NUCLEOTIDE-SEQUENCE; GENE; DNA	Mitochondrial encoded subunit II of cytochrome c oxidase carries the metal center, which acts as the initial acceptor of electrons from cytochrome c. Among the conserved features of this protein is a region in which five aromatic and three non-aromatic amino acids are conserved in a wide variety of organisms. This aromatic region has been postulated to be involved in transfer of electrons from the copper center in subunit II to the remaining metal centers of cytochrome oxidase in subunit I. To test the functional importance of two conserved, aromatic tryptophan residues and one conserved, non-aromatic glycine residue, yeast strains with alterations at these positions were characterized. The strains with altered codons were tested for their ability to carry out cellular respiration, for their growth rates on non-fermentable carbon sources, and for their cytochrome c oxidase activity. The results demonstrate that the aromatic character of the tryptophan residues appears necessary for subunit II function, while the conserved glycine can be replaced with other, small, uncharged residues.	ITHACA COLL, DEPT BIOL, ITHACA, NY 14850 USA									BLACKBURN NJ, 1994, BIOCHEMISTRY-US, V33, P10401, DOI 10.1021/bi00200a022; BONITZ SG, 1980, J BIOL CHEM, V255, P1927; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CORUZZI G, 1981, J BIOL CHEM, V256, P2780; FOSTER PL, 1994, SCIENCE, V265, P407, DOI 10.1126/science.8023164; GENNIS RB, 1993, BIOCHEM SOC T, V21, P992, DOI 10.1042/bst0210992; GRIVELL LA, 1989, GENETIC MAPS LOCUS M; HALTIA T, 1991, EMBO J, V10, P2015, DOI 10.1002/j.1460-2075.1991.tb07731.x; HILL BC, 1994, J BIOL CHEM, V269, P2419; HOLM L, 1987, EMBO J, V6, P2819, DOI 10.1002/j.1460-2075.1987.tb02578.x; HOSLER JP, 1992, J BIOL CHEM, V267, P24264; KOTYLAK Z, 1977, GENETICS BIOGENESIS, P83; LAPPALAIMEN P, 1994, BIOCHIM BIOPHYS ACTA, V1187, P22; MCEWEN JE, 1985, J BACTERIOL, V161, P831, DOI 10.1128/JB.161.3.831-835.1985; MULLER PP, 1984, J MOL BIOL, V175, P431, DOI 10.1016/0022-2836(84)90178-5; NOBREGA FG, 1980, J BIOL CHEM, V255, P9828; RICKWOOD D, 1988, YEAST PRACTICAL APPR, P185; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEELE DF, 1992, GENETICS, V132, P9; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; WEISSBRUMMER B, 1979, CURR GENET, V1, P75, DOI 10.1007/BF00413308; WILSON TM, 1994, CURR GENET, V25, P233, DOI 10.1007/BF00357167; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627	24	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7719	7724		10.1074/jbc.271.13.7719	http://dx.doi.org/10.1074/jbc.271.13.7719			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631812				2022-12-27	WOS:A1996UC77400080
J	Sugimoto, H; Hayashi, H; Yamashita, S				Sugimoto, H; Hayashi, H; Yamashita, S			Purification, cDNA cloning, and regulation of lysophospholipase from rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LYMPHOCYTE-T ACTIVATION; CANINE PURKINJE-FIBERS; CELL-LINE P388D1; HL-60 CELLS; SIGNAL TRANSDUCTION; POTENTIAL ROLE; MESSENGER-RNA; LYSOPHOSPHATIDYLCHOLINE; EXPRESSION	A lysophospholipase was purified 506-fold from rat liver supernatant. The preparation gave a single 24-kDa protein band on SDS-polyacrylamide gel electrophoresis. The enzyme hydrolyzed lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylinositol, lysophosphatidylserine, and 1-oleoyl-2-acetyl-sn-glycero-3-phosphocholine at pH 6-8. The purified enzyme was used for the preparation of antibody and peptide sequencing. A cDNA clone was isolated by screening a rat liver lambda gt11 cDNA library with the antibody, followed by the selection of further extended clones from a lambda gt10 library. The isolated cDNA was 2,362 base pairs in length and contained an open reading frame encoding 230 amino acids with a M(r) of 24,708. The peptide sequences determined were found in the reading frame. When the cDNA was expressed in Escherichia coli cells as the beta-galactosidase fusion, lysophosphatidylcholine-hydrolyzing activity was markedly increased. The deduced amino acid sequence showed significant similarity to Pseudomonas fluorescence esterase A and Spirulina platensis esterase. The three sequences contained the GXSXG consensus at similar positions. The transcript was found in various tissues with the following order of abundance: spleen, heart, kidney, brain, lung, stomach, and testis = liver. In contrast, the enzyme protein was abundant in the following order: testis, liver, kidney, heart, stomach, lung, brain, and spleen. Thus the mRNA abundance disagreed with the level of the enzyme protein in liver, testis, and spleen. When HL-60 cells were induced to differentiate into granulocytes with dimethyl sulfoxide, the 24-kDa lysophospholipase protein increased significantly, but the mRNA abundance remained essentially unchanged. Thus a posttranscriptional control mechanism is present for the regulation of 24-kDa lysophospholipase.	GUNMA UNIV,SCH MED,DEPT BIOCHEM,MAEBASHI,GUMMA 371,JAPAN; GUNMA UNIV,INST ENDOCRINOL,MAEBASHI,GUMMA 371,JAPAN	Gunma University; Gunma University								AARSMAN AJ, 1991, EUR J BIOCHEM, V200, P187, DOI 10.1111/j.1432-1033.1991.tb21066.x; ACKERMAN SJ, 1993, J IMMUNOL, V150, P456; ASAOKA Y, 1991, BIOCHEM BIOPH RES CO, V178, P1378, DOI 10.1016/0006-291X(91)91046-F; ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CORR PB, 1979, CIRC RES, V44, P822, DOI 10.1161/01.RES.44.6.822; DEJONG JGN, 1974, BIOCHIM BIOPHYS ACTA, V369, P50, DOI 10.1016/0005-2760(74)90191-X; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DUAN RD, 1993, BIOCHIM BIOPHYS ACTA, V1167, P326, DOI 10.1016/0005-2760(93)90236-3; FISCHKOFF SA, 1986, BLOOD, V68, P185; GARSETTI D, 1992, BIOCHEM J, V288, P831, DOI 10.1042/bj2880831; GARSETTI DE, 1992, BIOCHIM BIOPHYS ACTA, V1165, P229, DOI 10.1016/0005-2760(92)90191-W; GOERIG M, 1988, J BIOL CHEM, V263, P19384; GROSS RW, 1982, CIRC RES, V51, P27, DOI 10.1161/01.RES.51.1.27; GROSS RW, 1983, J BIOL CHEM, V258, P5221; GROSS RW, 1983, J BIOL CHEM, V258, P5165; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HAYASHI H, 1992, EUR J BIOCHEM, V205, P105, DOI 10.1111/j.1432-1033.1992.tb16756.x; HONG KH, 1991, AGR BIOL CHEM TOKYO, V55, P2839, DOI 10.1080/00021369.1991.10871052; HORIGUCHI J, 1989, MOL CELL BIOL, V9, P252, DOI 10.1128/MCB.9.1.252; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JARVIS AA, 1984, J BIOL CHEM, V259, P5188; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; KYGER EM, 1989, BIOCHEM BIOPH RES CO, V164, P1302, DOI 10.1016/0006-291X(89)91811-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN YN, 1979, ARCH BIOCHEM BIOPHYS, V193, P213, DOI 10.1016/0003-9861(79)90025-0; MARQUARDT DL, 1991, J ALLERGY CLIN IMMUN, V88, P721, DOI 10.1016/0091-6749(91)90178-Q; OISHI K, 1988, J BIOL CHEM, V263, P6865; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; Rudd E.A., 1984, P185; SAITO T, 1988, P NATL ACAD SCI USA, V85, P8246, DOI 10.1073/pnas.85.21.8246; SALVI S, 1994, MOL GEN GENET, V243, P124, DOI 10.1007/BF00283885; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIER WT, 1976, P NATL ACAD SCI USA, V73, P1586, DOI 10.1073/pnas.73.5.1586; SOBEL BE, 1978, J CLIN INVEST, V62, P546, DOI 10.1172/JCI109159; STAFFORD RE, 1993, BIOCHIM BIOPHYS ACTA, V1167, P43, DOI 10.1016/0005-2760(93)90215-U; SUGIMOTO H, 1994, J BIOL CHEM, V269, P6252; SUNAGA H, 1995, BIOCHEM J, V308, P551, DOI 10.1042/bj3080551; VANDENBOSCH H, 1973, BIOCHIM BIOPHYS ACTA, V296, P94, DOI 10.1016/0005-2760(73)90048-9; WAITE M, 1991, BIOCH LIPIDS LIPOPRO, P269; WELLER PF, 1984, J BIOL CHEM, V259, P5100; WELTZIEN HU, 1979, BIOCHIM BIOPHYS ACTA, V559, P259, DOI 10.1016/0304-4157(79)90004-2; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; WILUSZ J, 1989, NUCLEIC ACIDS RES, V17, P3899, DOI 10.1093/nar/17.10.3899; ZHANG Y, 1988, J BIOL CHEM, V263, P9965; ZIBOH VA, 1986, BIOCHEM BIOPH RES CO, V140, P515, DOI 10.1016/0006-291X(86)90762-X	51	89	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7705	7711		10.1074/jbc.271.13.7705	http://dx.doi.org/10.1074/jbc.271.13.7705			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631810	hybrid			2022-12-27	WOS:A1996UC77400078
J	Cawley, NX; Chen, HC; Beinfeld, MC; Loh, YP				Cawley, NX; Chen, HC; Beinfeld, MC; Loh, YP			Specificity and kinetic studies on the cleavage of various prohormone mono- and paired-basic residue sites by yeast aspartic protease 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPIOMELANOCORTIN-CONVERTING ENZYME; KEX2-LIKE ENDOPROTEASE; CELL-LINE; PRECURSOR CLEAVAGE; MONOBASIC SITES; PURIFICATION; FURIN; PITUITARY; GENE; RAT	The specificity and relative efficiency of cleavage of mono and paired-basic residue processing sites by YAP3p was determined in vitro for a number of prohormone substrates: human ACTH(1-39), bovine proinsulin, porcine cholecystokinin 33, cholecystokinin (CCK) 13-33, dynorphin A(1-11), dynorphin B(1-13), and amidorphin. YAP3p generated ACTH(1-15) from ACTH(1-39) It cleaved proinsulin at the paired-basic residue sites of the B-C junction as well as the C-A junction. Leu-enkephalin-Arg and Leu-enkephalin-Arg-Arg were generated from dynorphin A and dynorphin B, respectively. YAP3p generated Met-enkephalin-Lys-Lys from amidorphin showing that cleavage by this enzyme can occur at a lone pair of Lys residues. CCK33 was cleaved at Lys(23) and Arg(9), each containing an upstream Arg residue at the P6 and P5 position, respectively, K-m values were between 10(-4) and 10(-5) M for the various substrates, with the highest affinity exhibited for the tetrabasic site of ACTH(1-39) (1.8 x 10(-5) M) The tetrabasic residue site of ACTH(1-39) was cleaved with the highest relative efficiency (k(cat)/K-m = 3.1 x 10(6) M(-1) s(-1)), while that of the monobasic site of CCK13-33 and the paired-basic site of proinsulin B-C junction, were cleaved less efficiently at 4.2 x 10(4) M(-1) s(-1) and 1.6 x 10(4) M(-1) s(-1), respectively.	NICHHD, DEV NEUROBIOL LAB, NIH, BETHESDA, MD 20892 USA; NICHHD, ENDOCRINE & REPROD RES BRANCH, NIH, BETHESDA, MD 20892 USA; UNIFORMED SERV UNIV HLTH SCI, DEPT BIOCHEM, BETHESDA, MD 20814 USA; ST LOUIS UNIV, MED CTR, DEPT PHARMACOL & PHYSIOL SCI, ST LOUIS, MO 63104 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Uniformed Services University of the Health Sciences - USA; Saint Louis University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031602, R01NS018667] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31602, NS18667] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AZARYAN AV, 1993, J BIOL CHEM, V268, P11968; BEINFELD MC, 1980, J LIQ CHROMATOGR, V3, P1367, DOI 10.1080/01483918008062782; BEINFELD MC, 1981, BRAIN RES, V212, P51, DOI 10.1016/0006-8993(81)90031-7; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BIRCH NP, 1991, BIOCHEM BIOPH RES CO, V177, P920, DOI 10.1016/0006-291X(91)90626-I; BOURBONNAIS Y, 1993, EMBO J, V12, P285, DOI 10.1002/j.1460-2075.1993.tb05655.x; BRENNAN SO, 1994, FEBS LETT, V347, P80, DOI 10.1016/0014-5793(94)00511-7; BRESLIN MB, 1993, J BIOL CHEM, V268, P27084; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CAWLEY NX, 1993, FEBS LETT, V332, P273, DOI 10.1016/0014-5793(93)80648-E; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; EGELMITANI M, 1990, YEAST, V6, P127, DOI 10.1002/yea.320060206; ESTIVARIZ FE, 1989, J BIOL CHEM, V264, P17796; FRIEDMAN TC, 1994, ENDOCRINOLOGY, V135, P854, DOI 10.1210/en.135.3.854; GRECO L, 1992, NEUROENDOCRINOLOGY, V55, P351, DOI 10.1159/000126136; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; KAGEYAMA T, 1995, J BIOL CHEM, V270, P19135, DOI 10.1074/jbc.270.32.19135; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P10752, DOI 10.1073/pnas.92.23.10752; KRIEGER TJ, 1992, J NEUROCHEM, V59, P26, DOI 10.1111/j.1471-4159.1992.tb08871.x; KRIEGER TJ, 1992, BIOCHEMISTRY-US, V31, P4223, DOI 10.1021/bi00132a011; LEDGERWOOD EC, 1995, BIOCHEM J, V308, P321, DOI 10.1042/bj3080321; LINDBERG I, 1991, MOL ENDOCRINOL, V5, P1361, DOI 10.1210/mend-5-10-1361; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; Loh Y. P., 1993, MECHANISMS INTRACELL, P179; LOH YP, 1986, J BIOL CHEM, V261, P1949; LOH YP, 1985, J BIOL CHEM, V260, P7194; LOH YP, 1995, ADV EXP MED BIOL, V362, P519; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P1951, DOI 10.1210/endo-129-4-1951; MAINS RE, 1990, FRONT NEUROENDOCRIN, V11, P52; MCCAMAN MT, 1986, J BIOL CHEM, V261, P5345; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; RICHO GR, 1994, J BIOL CHEM, V269, P14806; ROUILLE Y, 1994, P NATL ACAD SCI USA, V91, P3242, DOI 10.1073/pnas.91.8.3242; RUFAUT NW, 1993, J BIOL CHEM, V268, P20291; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; STEINER DF, 1992, J BIOL CHEM, V267, P23435; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VIERECK JC, 1992, J BIOL CHEM, V267, P19475; YI Z, 1993, J BIOL CHEM, V268, P5615	43	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4168	4176						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626758				2022-12-27	WOS:A1996TW96000036
J	Nagy, L; Saydak, M; Shipley, N; Lu, S; Basilion, JP; Yan, ZH; Syka, P; Chandraratna, RAS; Stein, JP; Heyman, RA; Davies, PJA				Nagy, L; Saydak, M; Shipley, N; Lu, S; Basilion, JP; Yan, ZH; Syka, P; Chandraratna, RAS; Stein, JP; Heyman, RA; Davies, PJA			Identification and characterization of a versatile retinoid response element (retinoic acid receptor response element-retinoid X receptor response element) in the mouse tissue transglutaminase gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; PERITONEAL-MACROPHAGES; INDUCED EXPRESSION; NUCLEAR RECEPTORS; CELLS; INDUCTION; RXR; BINDING; RAR; TRANSCRIPTION	Tissue transglutaminase (transglutaminase type II) is an intracellular protein cross-linking enzyme that accumulates in connective tissue and in cells undergoing apoptosis. Retinoids regulate the transcription of the mouse tissue transglutaminase gene via activation of regulatory elements contained within 4 kilobases of the 5'-end of the gene. Co-transfection studies with retinoid receptor expression vectors in CV-1 cells demonstrated that the mouse tissue transglutaminase promoter is activated by ligand activation of either retinoic acid receptor-retinoid X receptor (RAR . RXR) heterodimers or RXR homodimers. Optimal induction is achieved with retinoid receptor panagonists; partial activation can also be achieved with either RAR-specific or RXR-specific retinoids. Retinoid-dependent activation of the tissue transglutaminase promoter depends on both a proximal regulatory region containing sequences highly conserved between the human and the mouse tissue transglutaminase promoters and a distal region that includes a 30-base pair retinoid response element (mTGRRE1). mTGRRE1 contains three hexanucleotide half-sites (two canonical and one non-canonical) in a DR7/DR5 motif that bind both RAR . RXR heterodimers and RXR homodimers. These studies suggest that retinoid-dependent expression of the mouse tissue transglutaminase gene is mediated by a versatile tripartite retinoid response element located 1.7 kilobases upstream of the transcription start site.	UNIV TEXAS,HLTH SCI CTR,SCH MED,DEPT PHARMACOL,HOUSTON,TX 77225; SUNY HLTH SCI CTR,DEPT PHARMACOL,SYRACUSE,NY 13210; LIGAND PHARMACEUT INC,SAN DIEGO,CA 92121; ALLERGAN PHARMACEUT INC,IRVINE,CA 92713	University of Texas System; University of Texas Health Science Center Houston; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Ligand Pharmaceuticals; AbbVie; Allergan			Nagy, Laszlo/A-3814-2008; Basilion, James/ABB-6732-2021	Nagy, Laszlo/0000-0001-6653-2155; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027078] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK27078] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; Barsigian C, 1990, Blood Coagul Fibrinolysis, V1, P551, DOI 10.1097/00001721-199010000-00037; BEARD RL, 1994, BIOORG MED CHEM LETT, V4, P1447, DOI 10.1016/S0960-894X(01)80511-4; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BERGER TS, 1992, J STEROID BIOCHEM, V41, P733, DOI 10.1016/0960-0760(92)90414-E; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; BOEHM MF, 1994, J MED CHEM, V37, P408, DOI 10.1021/jm00029a013; BOWNESS JM, 1988, BIOCHIM BIOPHYS ACTA, V967, P234; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN HW, 1995, P NATL ACAD SCI USA, V92, P422, DOI 10.1073/pnas.92.2.422; CHIOCCA EA, 1988, J BIOL CHEM, V263, P11584; CHIOCCA EA, 1989, J CELL BIOCHEM, V39, P293, DOI 10.1002/jcb.240390309; CLIFFORD JL, 1990, MOL ENDOCRINOL, V4, P1546, DOI 10.1210/mend-4-10-1546; DAVIES PJA, 1985, J BIOL CHEM, V260, P5166; Dawson Marcia I., 1994, P5; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; FESUS L, 1989, FEBS LETT, V245, P150, DOI 10.1016/0014-5793(89)80210-8; FESUS L, 1991, EUR J CELL BIOL, V56, P170; GENTILE V, 1991, J BIOL CHEM, V266, P478; GEORGE MD, 1990, J BIOL CHEM, V265, P11098; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Gudas Lorraine J., 1994, P443; HASHIMOTO Y, 1991, CELL BIOL REV, V25, P209; HASHIMOTO Y, 1991, CELL BIOL REV, V25, P233; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; JIANG H, 1992, TERATOLOGY, V46, P333, DOI 10.1002/tera.1420460404; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LICHTI U, 1988, CANCER RES, V48, P74; LOELIGER P, 1980, EUR J MED CHEM, V15, P9; Lorand L, 1988, Adv Exp Med Biol, V231, P79; LU S, 1995, J BIOL CHEM, V270, P9748, DOI 10.1074/jbc.270.17.9748; MADDOX AM, 1985, EXP CELL BIOL, V53, P294; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; MOORE WT, 1984, J BIOL CHEM, V259, P2794; MURTAUGH MP, 1983, J BIOL CHEM, V258, P1074; NAGY L, 1995, MOL CELL BIOL, V15, P3540; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; Pfahl Magnus, 1994, Seminars in Cell Biology, V5, P95, DOI 10.1006/scel.1994.1013; PIACENTINI M, 1991, CELL TISSUE RES, V263, P227, DOI 10.1007/BF00318764; PIACENTINI M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P171, DOI 10.1016/0167-4889(92)90134-W; RUIZ MDMV, 1991, EMBO J, V10, P3829, DOI 10.1002/j.1460-2075.1991.tb04952.x; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; STRICKLAND S, 1983, CANCER RES, V43, P5268; SUGAWARA A, 1994, ENDOCRINOLOGY, V135, P1956, DOI 10.1210/en.135.5.1956; SUTO N, 1993, J BIOL CHEM, V268, P7469; THOMAZY V, 1989, CELL TISSUE RES, V255, P215; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; VERMA AK, 1992, J NUTR, V122, P2144, DOI 10.1093/jn/122.11.2144; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	69	125	128	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4355	4365						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626785				2022-12-27	WOS:A1996TW96000063
J	Singer, WD; Brown, HA; Jiang, XJ; Sternweis, PC				Singer, WD; Brown, HA; Jiang, XJ; Sternweis, PC			Regulation of phospholipase D by protein kinase C is synergistic with ADP-ribosylation factor and independent of protein kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; PURIFICATION; PHOSPHATASE; ACTIVATION; CLEAVAGE; ASSAY	Phospholipase D (PLD) which was partially purified from membranes of porcine brain could be stimulated by multiple cytosolic components; these included ADP-ribosylation factor (Arf) and RhoA, which required guanine nucleotides for activity, and an unidentified factor which activated the enzyme in a nucleotide-independent manner (Singer, W. D., Brown, H. A., Bokoch, G. M., and Sternweis, P. C. (1995) J. Biol. Chem. 270, 14944-14950). Here, we report purification of the latter factor, its identification as the alpha isoform of protein kinase C (PKC alpha), and characterization of its regulation of PLD activity. Stimulation of PLD by purified PKC alpha or recombinant PKC alpha (rPKC alpha) occurred in the absence of any nucleotide and required activators such as Ca2+ or phorbol ester. This action was synergistic with stimulation of PLD evoked by either Arf or RhoA. Dephosphorylation of rPKC alpha with protein phosphatase 1 or 2A resulted in a loss of its kinase activity, but had little effect on its ability to stimulate PLD either alone or in conjunction with Arf. Staurosporine inhibited the kinase activity of PKC alpha without affecting activation of PLD. Finally, gel filtration of PKC alpha that had been cleaved with trypsin demonstrated that stimulatory activity for PLD coeluted with the regulatory domain of the enzyme. These data indicate that PKC may regulate signaling events through direct molecular interaction with downstream effectors as well as through its well characterized catalytic modification of proteins by phosphorylation.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [GM31954, GM15817] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015817, R01GM031954] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BILLAH MM, 1993, CURR OPIN IMMUNOL, V5, P114; BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1994, FEBS LETT, V342, P149, DOI 10.1016/0014-5793(94)80490-7; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; EXTON JH, 1990, J BIOL CHEM, V265, P1; FUJISE A, 1994, J BIOL CHEM, V269, P31642; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Heller M, 1978, Adv Lipid Res, V16, P267; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; LEE MH, 1986, J BIOL CHEM, V261, P4867; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LISCOVITCH M, 1994, SIGNAL ACTIVATED PHO, P31; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MARTIN A, 1991, METHOD ENZYMOL, V197, P553; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MOCHLYROSEN D, 1995, BIOCHEM SOC T, V23, P596, DOI 10.1042/bst0230596; NAKADATE T, 1988, BIOCHEM PHARMACOL, V37, P1541, DOI 10.1016/0006-2952(88)90016-0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OHGUCHI K, 1995, BIOCHEM BIOPH RES CO, V211, P306, DOI 10.1006/bbrc.1995.1811; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; SAITO M, 1975, ARCH BIOCHEM BIOPHYS, V169, P318, DOI 10.1016/0003-9861(75)90346-X; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1994, J BIOL CHEM, V269, P19796; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z	42	227	230	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4504	4510						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626805				2022-12-27	WOS:A1996TW96000083
J	Chow, NW; Korenberg, JR; Chen, XN; Neve, RL				Chow, NW; Korenberg, JR; Chen, XN; Neve, RL			APP-BP1, a novel protein that binds to the carboxyl-terminal region of the amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-ACTIVATING ENZYME; HEPARAN-SULFATE PROTEOGLYCANS; ALZHEIMERS-DISEASE; BETA-PROTEIN; CELL-ADHESION; EXTRACELLULAR-MATRIX; GROWTH-FACTOR; CHROMOSOMAL LOCALIZATION; MOLECULAR-CLONING; NEURITE OUTGROWTH	beta-Amyloid protein precursors (APPs, 695-770 amino acids) are the source of the 39-43-amino acid beta-amyloid (A beta) peptides that comprise diffuse and fibrillar deposits in the cerebral cortex and vasculature of Alzheimer's disease brains. A beta is thought to play a role in the pathogenesis of Alzheimer's disease, and, hence, considerable effort has been invested in defining the means by which A beta is generated from the APPs. Knowledge of the normal function of the APPs is sure to provide insights into the genesis and pathological persistence of A beta in Alzheimer's disease. APP is a cell surface protein with a large extracellular amino terminal domain, a single transmembrane segment, and a short cytoplasmic tail. Its location and structural features characteristic of a receptor for signal transduction led us to search for potential effector proteins capable of binding and interacting with its cytoplasmic domain. Here, we report the cloning of a cDNA encoding one such protein. This ubiquitously expressed 59-kDa APP-binding protein, called APP-BP1, is 61% similar to a protein encoded by the Arabidopsis AXR1 gene, required for normal response to the hormone auxin, and is a relative of the ubiquitin activating enzyme E1.	MCLEAN HOSP,MOLEC NEUROGENET LAB,BELMONT,MA 02178; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; UNIV CALIF LOS ANGELES,CEDARS SINAI RES INST,AHMANSON DEPT PEDIAT,DEPT GENET,LOS ANGELES,CA 92717	Harvard University; McLean Hospital; Harvard University; Harvard Medical School; Cedars Sinai Medical Center; University of California System; University of California Los Angeles					NATIONAL INSTITUTE ON AGING [R01AG012954] Funding Source: NIH RePORTER; NIA NIH HHS [AG12954] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ASHALL F, 1994, TRENDS BIOCHEM SCI, V19, P42, DOI 10.1016/0968-0004(94)90173-2; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P2; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; FIELD SJ, 1993, BIOTECHNIQUES, V14, P530; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FRIEDMAN KD, 1988, NUCLEIC ACIDS RES, V16, P8718, DOI 10.1093/nar/16.17.8718; GHISO J, 1992, BIOCHEM J, V288, P1053, DOI 10.1042/bj2881053; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GOLDSMITH MHM, 1993, P NATL ACAD SCI USA, V90, P11442, DOI 10.1073/pnas.90.24.11442; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUTHRIE KM, 1991, J COMP NEUROL, V313, P95, DOI 10.1002/cne.903130107; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; HATFIELD PM, 1992, J BIOL CHEM, V267, P14799; HAY JM, 1992, BIOTECHNIQUES, V13, P856; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; IMAI N, 1992, GENE, V118, P279, DOI 10.1016/0378-1119(92)90200-9; JIN LW, 1994, J NEUROSCI, V14, P5461; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KALARIA RN, 1992, NEUROSCIENCE, V51, P177, DOI 10.1016/0306-4522(92)90482-H; KALLAPUR SG, 1992, J NEUROSCI RES, V33, P538, DOI 10.1002/jnr.490330406; KAMMESHEIDT A, 1992, P NATL ACAD SCI USA, V89, P10857, DOI 10.1073/pnas.89.22.10857; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KOK K, 1993, P NATL ACAD SCI USA, V90, P6071, DOI 10.1073/pnas.90.13.6071; KOO EH, 1993, P NATL ACAD SCI USA, V90, P4748, DOI 10.1073/pnas.90.10.4748; KORENBERG JR, 1993, GENOMICS, V16, P546, DOI 10.1006/geno.1993.1228; KORENBERG JR, 1995, CYTOGENET CELL GENET, V71, P56; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBLANC AC, 1992, J NEUROSCI RES, V31, P635, DOI 10.1002/jnr.490310407; LEYSER HMO, 1993, NATURE, V364, P161, DOI 10.1038/364161a0; LINCOLN C, 1990, PLANT CELL, V2, P1071, DOI 10.1105/tpc.2.11.1071; LUO LQ, 1992, NEURON, V9, P595, DOI 10.1016/0896-6273(92)90024-8; Maniatis T., 1989, MOL CLONING LAB MAN; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; MORI S, 1992, J BIOL CHEM, V267, P6429; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; MULLER U, 1994, CELL, V79, P755, DOI 10.1016/0092-8674(94)90066-3; NEVE RL, 1986, MOL BRAIN RES, V1, P271, DOI 10.1016/0169-328X(86)90033-1; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; QIU WQ, 1995, J NEUROSCI, V15, P2157, DOI 10.1523/JNEUROSCI.15-03-02157.1995; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; RON D, 1992, BIOTECHNIQUES, V13, P866; RUTISHAUSER U, 1988, PHYSIOL REV, V68, P819, DOI 10.1152/physrev.1988.68.3.819; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHUBERT D, 1988, SCIENCE, V241, P223, DOI 10.1126/science.2968652; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SHEA TB, 1994, BIOTECHNIQUES, V16, P1126; SMALL DH, 1994, J NEUROSCI, V14, P2117; SMALL DH, 1992, J NEUROSCI, V12, P4143; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; SU JH, 1992, NEUROSCIENCE, V51, P801, DOI 10.1016/0306-4522(92)90521-3; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TANZI RE, 1987, SCIENCE, V238, P666, DOI 10.1126/science.2890207; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X	72	116	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11339	11346		10.1074/jbc.271.19.11339	http://dx.doi.org/10.1074/jbc.271.19.11339			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626687	hybrid			2022-12-27	WOS:A1996UJ94400047
J	Han, JS; Chung, JK; Kang, HS; Donaldson, J; Bae, YS; Rhee, SG				Han, JS; Chung, JK; Kang, HS; Donaldson, J; Bae, YS; Rhee, SG			Multiple forms of phospholipase D inhibitor from rat brain cytosol - Purification and characterization of heat-labile form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLCHOLINE HYDROLYSIS; PLASMA-MEMBRANES; G-PROTEIN; PHOSPHORYLATION; IDENTIFICATION; NEUTROPHILS; ACTIVATION; RECEPTOR; CELLS	Rat brain cytosol contains proteins that markedly inhibit the activity of partially purified brain membrane phospholipase D (PLD) stimulated by ADP-ribosylation factor (Arf) and phosphatidylinositol 4,5-bisphosphate (PIP2). Sequential chromatography of the brain cytosol yielded four inhibitor fractions, which exhibited different kinetics to heat treatment at 70 degrees C. Purification of the most heat-labile inhibitor to homogeneity yielded two preparations, which displayed apparent molecular masses of 150 kDa and 135 kDa, respectively, on SDS-polyacrylamide gels. Tryptic digests of the 150- and 135-kDa proteins yielded similar elution profiles on a C-18 reverse-phase column, suggesting that the 135-kDa form is a truncated form of the 150-kDa form. Sequences of two tryptic peptides were determined. A data base search revealed no proteins with these sequences. The purified 150-kDa inhibitor negated the PLD activity stimulated by Arf, RhoA, or Cdc42. The concentration required for half-maximal inhibition was 0.4 nM. Concentration dependence on the 150-kDa inhibitor was not affected by changes in the concentrations of Arf, PIP2, or phosphatidylcholine used in the assays, suggesting that the inhibition is not due to competition with the activators or substrate for PLD. The purified inhibitor did not affect the PIP2-hydrolyzing activity of a phospholipase C isozyme that was measured with substrate vesicles of lipid composition identical with that used for the PLD assay. Thus, the mechanism of inhibition appears to be a specific allosteric modification of PLD rather than disruption of substrate vesicles.	NHLBI,LAB CELL SIGNALLING,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Han, Joong-Soo/P-2072-2015	Han, Joong-Soo/0000-0002-0875-6158				AHMED A, 1994, AM J PHYSIOL, V266, pC206, DOI 10.1152/ajpcell.1994.266.1.C206; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHALIFA V, 1990, J BIOL CHEM, V265, P17512; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1994, FEBS LETT, V342, P149, DOI 10.1016/0014-5793(94)80490-7; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GENY B, 1995, EUR J BIOCHEM, V231, P31, DOI 10.1111/j.1432-1033.1995.tb20666.x; GUSTAVSSON L, 1994, J BIOL CHEM, V269, P849; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HONG JX, 1994, J BIOL CHEM, V269, P9743; HUANG CF, 1992, J BIOL CHEM, V267, P16859; INOUE H, 1995, BIOCHEM BIOPH RES CO, V210, P542, DOI 10.1006/bbrc.1995.1694; KANFER JN, 1994, FEBS LETT, V337, P251, DOI 10.1016/0014-5793(94)80202-5; KISS Z, 1994, BIOCHEM J, V300, P751, DOI 10.1042/bj3000751; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LEE YH, 1994, J BIOL CHEM, V269, P26842; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MARTIN TW, 1989, J BIOL CHEM, V264, P8847; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MOEHREN G, 1994, J BIOL CHEM, V269, P838; MOHN H, 1992, J BIOL CHEM, V267, P11131; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SIDDIQUI RA, 1992, J BIOL CHEM, V267, P5755; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; UINGS IJ, 1992, BIOCHEM J, V281, P597, DOI 10.1042/bj2810597	34	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11163	11169		10.1074/jbc.271.19.11163	http://dx.doi.org/10.1074/jbc.271.19.11163			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626662	hybrid			2022-12-27	WOS:A1996UJ94400022
J	Karzai, AW; McMacken, R				Karzai, AW; McMacken, R			A bipartite signaling mechanism involved in DnaJ-mediated activation of the Escherichia coli DnaK protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; BACTERIOPHAGE-LAMBDA; NUCLEOPROTEIN STRUCTURES; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; BINDING-SPECIFICITY; REPLICATION ORIGIN; PEPTIDE-BINDING; GRPE; INITIATION	The DnaK and DnaJ heat shock proteins function as the primary Hsp70 and Hsp40 homologues, respectively, of Escherichia coli. Intensive studies of various Hsp70 and DnaJ-like proteins over the past decade have led to the suggestion that interactions between specific pairs of these two types of proteins permit them to serve as molecular chaperones in a diverse array of protein metabolic events, including protein folding, protein trafficking, and assembly and disassembly of multisubunit protein complexes. To further our understanding of the nature of Hsp70-DnaJ interactions, we have sought to define the minimal sequence elements of DnaJ required for stimulation of the intrinsic ATPase activity of DnaK. As judged by proteolysis sensitivity, DnaJ is composed of three separate regions, a 9-kDa NH2-terminal domain, a 30-kDa COOH-terminal domain, and a protease-sensitive glycine- and phenylalanine-rich (G/F-rich) segment of 30 amino acids that serves as a flexible linker between the two domains. The stable 9-kDa proteolytic fragment was identified as the highly conserved J-region found in all DnaJ homologues. Using this structural information as a guide, we constructed, expressed, purified, and characterized several mutant DnaJ proteins that contained either NH2-terminal or C00H-terminal deletions. At variance with current models of DnaJ action, DnaJ1-75, a polypeptide containing an intact J-region, mas found to be incapable of stimulating ATP hydrolysis by DnaK protein. We found, instead, that two sequence elements of DnaJ, the J-region and the G/F-rich linker segment, are each required for activation of DnaJ-mediated ATP hydrolysis and for minimal DnaJ function in the initiation of bacteriophage lambda DNA replication. Further analysis indicated that maximal activation of ATP hydrolysis by DnaK requires two independent but simultaneous protein-protein interactions: (i) interaction of DnaK with the J-region of DnaJ and (ii) binding of a peptide or polypeptide to the polypeptide-binding site associated with the COOH-terminal domain of DnaK. This dual signaling process required for activation of DnaK function has mechanistic implications for those protein metabolic events, such as polypeptide translocation into the endoplasmic reticulum in eukaryotic cells, that are dependent on interactions between Hsp70-like and DnaJ-like proteins.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205	Johns Hopkins University					NIEHS NIH HHS [ES-03819] Funding Source: Medline; NIGMS NIH HHS [GM36526, GM32253] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032253, R01GM036526] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFANO C, 1989, J BIOL CHEM, V264, P10709; ALFANO C, 1989, J BIOL CHEM, V264, P10699; BAKER TA, 1992, ANNU REV GENET, V26, P447; BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; CYR DM, 1994, J BIOL CHEM, V269, P9798; DESHAIES RJ, 1988, NATURE, V332, P80; DODSON M, 1989, J BIOL CHEM, V264, P10719; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; Georgopoulos C., 1971, BACTERIOPHAGE LAMBDA, P553; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAGEROV A, 1994, J MOL BIOL, V241, P133, DOI 10.1006/jmbi.1994.1482; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; GROSS CA, 1990, STRESS PROTEINS BIOL, P167; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HILL RB, 1995, BIOCHEMISTRY-US, V34, P5587, DOI 10.1021/bi00016a033; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; KANG PJ, 1990, J BACTERIOL, V172, P2055, DOI 10.1128/jb.172.4.2055-2064.1990; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MENSAWILMOT K, 1989, J BIOL CHEM, V264, P2853; MILMAN G, 1987, METHOD ENZYMOL, V153, P482; MOTOHASHI K, 1994, J BIOL CHEM, V269, P27074; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, P1334; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROUVIEREYANIV J, 1979, FEBS LETT, V106, P297, DOI 10.1016/0014-5793(79)80518-9; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SAITO H, 1977, J MOL BIOL, V113, P1, DOI 10.1016/0022-2836(77)90038-9; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLENSTEDT G, 1995, J BIOL CHEM, V129, P949; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SEIDMORE MA, 1993, MOL BIOL CELL, V4, P1145; SHI WY, 1992, J BACTERIOL, V174, P6256, DOI 10.1128/JB.174.19.6256-6263.1992; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; TILLY K, 1983, CELL, V34, P641, DOI 10.1016/0092-8674(83)90396-3; WALL D, 1994, J BIOL CHEM, V269, P5446; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19307, DOI 10.1074/jbc.270.33.19307; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; YOCHEM J, 1978, MOL GEN GENET, V164, P9, DOI 10.1007/BF00267593; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	71	196	198	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11236	11246		10.1074/jbc.271.19.11236	http://dx.doi.org/10.1074/jbc.271.19.11236			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626673	hybrid			2022-12-27	WOS:A1996UJ94400033
J	Gong, JH; Uguccioni, M; Dewald, B; Baggiolini, M; ClarkLewis, I				Gong, JH; Uguccioni, M; Dewald, B; Baggiolini, M; ClarkLewis, I			RANTES and MCP-3 antagonists bind multiple chemokine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; CDNA; IDENTIFICATION; INTERLEUKIN-8; CYTOKINES; FAMILY; CELLS	Antagonists of multiple chemokines could be more effective than inhibitors of specific chemokines for controlling cell migration and inflammation. To attempt to identify such antagonists we characterized a number of truncated analogs of regulated on activation normal T cell expressed protein (RANTES), monocyte chemoattractant protein (MCP)-3, and MCP-1. On the basis of their ability to compete for binding of their parent chemokines, three analogs were selected for cross-reactivity studies: RANTES (9-68), MCP-3 (10-76), and MCP-1 (9-76), These analogs bound to THP-1 monocytic cells with dissociation constants that were within 4-6-fold of their native counterparts, but they did not promote detectable chemotaxis of THP-1 cells or enzyme release from purified human monocytes, The RANTES (9-68) analog competed for the binding and inhibited the activities of all three chemokines. In contrast, native RANTES was specific for RANTES binding sites, However, truncation of either MCP-1 or MCP-3 did not change their respective binding specificity, MCP-3 and MCP-S (10-76) competed for binding of all three labeled chemokines. MCP-1 (9-76) competed strongly for binding of labeled MCP-1, but only weakly for the other two labeled ligands and inhibited the activities induced by MCP-1 and MCP-3 but not RANTES. Although RANTES (9-68) and MCP-3 (10-76) inhibited all three chemokines, the RANTES analog was significantly more potent for RANTES induced activity, The results indicate that NH2-terminal residues partly determine the receptor specificity of RANTES, and deletions within this region permit binding to multiple chemokine receptors, The findings suggest the feasibility of design of high affinity multi-specific CC chemokine antagonists.	UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC V6T 1Z3,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOLEC BIOL,VANCOUVER,BC V6T 1Z3,CANADA; UNIV BERN,THEODOR KOCHER INST,CH-3000 BERN,SWITZERLAND	University of British Columbia; University of British Columbia; University of Bern				Uguccioni, Mariagrazia/0000-0002-9570-7011	NIGMS NIH HHS [R01 GM-50969-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050969] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; COLOTTA F, 1984, J IMMUNOL, V132, P936; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; FRANCI C, 1995, J IMMUNOL, V154, P6511; FURIE MB, 1995, AM J PATHOL, V146, P1287; FURUTANI Y, 1989, BIOCHEM BIOPH RES CO, V159, P249, DOI 10.1016/0006-291X(89)92430-3; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; OPDENAKKER G, 1993, BIOCHEM BIOPH RES CO, V191, P535, DOI 10.1006/bbrc.1993.1251; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; SOZZANI S, 1993, J IMMUNOL, V150, P1544; UGUCCIONI M, 1995, EUR J IMMUNOL, V25, P64, DOI 10.1002/eji.1830250113; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; VANRIPER G, 1993, J EXP MED, V177, P851, DOI 10.1084/jem.177.3.851; WANG JM, 1993, J EXP MED, V177, P699, DOI 10.1084/jem.177.3.699; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918	34	143	186	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10521	10527		10.1074/jbc.271.18.10521	http://dx.doi.org/10.1074/jbc.271.18.10521			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631850	hybrid			2022-12-27	WOS:A1996UJ34200018
J	Nag, B; Arimilli, S; Mukku, PV; Astafieva, I				Nag, B; Arimilli, S; Mukku, PV; Astafieva, I			Functionally active recombinant alpha and beta chain-peptide complexes of human major histocompatibility class II molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECOGNITION; ANTIGENIC PEPTIDES; LIPID-MEMBRANES; BINDING; STIMULATION; INDUCTION; CLONES; PH	Major histocompatibility (MHC) class II molecules are cell surface heterodimeric (alpha beta) glycoproteins that display processed antigens to T cell receptors (TCRs) of CD4-positive T cells. The present study describes that individual recombinant alpha and beta chains of human MHC class II molecules lacking the transmembrane region (alpha-Tm and beta-Tm) are capable of binding antigenic peptide and that these complexes of chain-peptide are recognized by TCRs to induce antigen-specific apoptosis in restricted T cells. The alpha-Tm and the beta-Tm of human HLA-DR2 (DRB5*0101) were cloned, expressed in Escherichia coli, and purified in large scale by conventional chromatographic methods. The in vitro binding of an immunodominant epitope from the myelin basic protein (MBP-(83-102)Y-83) to purified DR2 alpha-Tm and DR2 beta-Tm was demonstrated with biotinylated and fluoresceinated MBP-(83-102)Y-83 peptide. The specificity of the MBP-(83-102)Y-83 peptide binding to both DR2 alpha-Tm and DR2 beta-Tm was demonstrated in a competitive peptide binding assay. When exposed to a transformed T cell clone (SS8T) restricted to DR2(DRB5*0101) and MBP-(84-102) peptide, complexes of DR2 alpha-Tm and DR2 beta-Tm with MBP-(83-102)Y-83 peptide were able to specifically recognize TCRs as measured by the increase in gamma-interferon (gamma-IFN) cytokine. Such recognition of TCRs by soluble alpha-MBP-(83-102)Y-83 and beta-MBP-(83-102)Y-83 complexes led to the induction of antigen-specific apoptosis in SS8T cells as measured by double fluorescence flow cytometry and electron microscop. These results provide the first evidence that soluble complexes of antigenic peptide and individual chains of human MHC class II molecules lacking the transmembrane region can recognize TCRs and induce antigen-specific apoptosis in T cells. Since activated CD4-positive T cells are involved in pathogenesis of various autoimmune diseases, the apoptosis triggered by individual soluble chain-peptide complexes has significant potential for eliminating autoreactive T cells.			Nag, B (corresponding author), ANERGEN INC,REDWOOD CITY,CA 94063, USA.							ARIMILLI S, 1995, J BIOL CHEM, V270, P971, DOI 10.1074/jbc.270.2.971; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BUSS S, 1986, P NATL ACAD SCI USA, V83, P3968; DALTON TA, 1992, AM J MED, V92, P183, DOI 10.1016/0002-9343(92)90110-W; DORNMAIR K, 1989, COLD SPRING HARB SYM, V54, P409; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GOLDING H, 1985, NATURE, V317, P425, DOI 10.1038/317425a0; GORCZYCA W, 1993, LEUKEMIA, V7, P659; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; LANZAVECCHIA A, 1988, NATURE, V334, P530, DOI 10.1038/334530a0; MCCLUSKEY J, 1988, J IMMUNOL, V140, P2081; MUKKU PV, 1995, MOL IMMUNOL, V32, P555, DOI 10.1016/0161-5890(95)00030-I; NAG B, 1993, J IMMUNOL, V150, P1358; NAG B, 1992, J IMMUNOL, V148, P2040; NAG B, 1994, J BIOL CHEM, V269, P10061; NAG B, 1994, MOL IMMUNOL, V31, P1161, DOI 10.1016/0161-5890(94)90030-2; NAG B, 1992, J IMMUNOL, V148, P369; NAG B, 1993, P NATL ACAD SCI USA, V87, P352; PASSMORE D, 1992, J IMMUNOL METHODS, V155, P193, DOI 10.1016/0022-1759(92)90285-2; PICHLER WJ, 1994, IMMUNOL TODAY, V15, P312, DOI 10.1016/0167-5699(94)90078-7; QUILL H, 1987, J IMMUNOL, V138, P3704; ROTHENHAUSLER B, 1990, P NATL ACAD SCI USA, V87, P352, DOI 10.1073/pnas.87.1.352; SETTE A, 1992, J IMMUNOL, V148, P844; SHARMA SD, 1991, P NATL ACAD SCI USA, V88, P11465, DOI 10.1073/pnas.88.24.11465; Spack EG, 1995, J AUTOIMMUN, V8, P787, DOI 10.1016/S0896-8411(95)80018-2; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; VALLI A, 1993, J CLIN INVEST, V91, P616, DOI 10.1172/JCI116242; WATTS TH, 1986, P NATL ACAD SCI USA, V83, P9660, DOI 10.1073/pnas.83.24.9660; WEBER F, 1993, P NATL ACAD SCI USA, V90, P11049, DOI 10.1073/pnas.90.23.11049; WITT SN, 1991, P NATL ACAD SCI USA, V88, P8164, DOI 10.1073/pnas.88.18.8164; WUCHERPFENNIG KW, 1994, J EXP MED, V179, P279, DOI 10.1084/jem.179.1.279	34	18	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10413	10418		10.1074/jbc.271.17.10413	http://dx.doi.org/10.1074/jbc.271.17.10413			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626615	hybrid			2022-12-27	WOS:A1996UG25700087
J	Klatt, P; Pfeiffer, S; List, BM; Lehner, D; Glatter, O; Bachinger, HP; Werner, ER; Schmidt, K; Mayer, B				Klatt, P; Pfeiffer, S; List, BM; Lehner, D; Glatter, O; Bachinger, HP; Werner, ER; Schmidt, K; Mayer, B			Characterization of heme-deficient neuronal nitric-oxide synthase reveals a role for heme in subunit dimerization and binding of the amino acid substrate and tetrahydrobiopterin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN; PURIFICATION; CALMODULIN; REDUCTASE; FLAVIN; CYTOCHROME-P-450; BACTERIOPHAGE-T4; INTERMEDIATE; ENZYME; CELLS	Neuronal nitric-oxide (NO) synthase contains FAD, FMN, heme, and tetrahydrobiopterin as prosthetic groups and represents a multifunctional oxidoreductase catalyzing oxidation of L-arginine to L-citrulline and NO, reduction of molecular oxygen to superoxide, and electron transfer to cytochromes. To investigate how binding of the prosthetic heme moiety is related to enzyme activities, cofactor, and L-arginine binding, as well as to secondary and quaternary protein structure, we have purified and characterized heme-deficient neuronal NO synthase. The heme-deficient enzyme, which had preserved its cytochrome c reductase activity, contained FAD and FMN, but virtually no tetrahydrobiopterin, and exhibited only marginal NO synthase activity. By means of gel filtration and static light scattering, we demonstrate that the heme-deficient enzyme is a monomer and provide evidence that heme is the sole prosthetic group controlling the quaternary structure of neuronal NO synthase. CD spectroscopy showed that most of the structural elements found in the dimeric holoenzyme were conserved in heme-deficient monomeric NO synthase. However, in spite of being properly folded, the heme-deficient enzyme did bind neither tetrahydrobiopterin nor the substrate analog N-G-nitro-L-arginine. Our results demonstrate that the prosthetic heme group of neuronal NO synthase is requisite for dimerization of enzyme subunits and for the binding of amino acid substrate and tetrahydrobiopterin.	KARL FRANZENS UNIV GRAZ, INST PHARMAKOL & TOXIKOL, A-8010 GRAZ, AUSTRIA; KARL FRANZENS UNIV GRAZ, INST PHYS CHEM, A-8010 GRAZ, AUSTRIA; OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA; SHRINERS HOSP CRIPPLED CHILDREN, RES DEPT, PORTLAND, OR 97201 USA; UNIV INNSBRUCK, INST MED CHEM & BIOCHEM, A-6020 INNSBRUCK, AUSTRIA	University of Graz; University of Graz; Oregon Health & Science University; University of Innsbruck			Mayer, Bernd/B-9391-2008	Werner, Ernst R./0000-0003-1948-3391; Mayer, Bernd/0000-0002-2921-3494				ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUNNER F, 1991, BRIT J PHARMACOL, V102, P373, DOI 10.1111/j.1476-5381.1991.tb12181.x; Chu B, 1991, LASER LIGHT SCATTERI; COMPTON LA, 1987, J BIOL CHEM, V262, P13039; COMPTON LA, 1992, EUR J BIOCHEM, V206, P927, DOI 10.1111/j.1432-1033.1992.tb17002.x; DEGTYARENKO KN, 1993, FEBS LETT, V332, P1, DOI 10.1016/0014-5793(93)80470-F; DELEVIE R, 1986, J CHEM EDUC, V63, P10, DOI 10.1021/ed063p10; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; HARTENECK C, 1994, BIOCHEM J, V304, P683, DOI 10.1042/bj3040683; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; Huglin M. B., 1972, LIGHT SCATTERING POL; KLATT P, 1994, J BIOL CHEM, V269, P1674; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; KLATT P, 1993, J BIOL CHEM, V268, P14781; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; KLATT P, 1992, J BIOL CHEM, V267, P11374; KLATT P, 1996, IN PRESS METHODS ENZ; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1994, NEUROPHARMACOLOGY, V33, P1253, DOI 10.1016/0028-3908(94)90024-8; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MAYER B, 1995, IN PRESS METHODS ENZ; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NISHIMURA JS, 1995, BIOCHEM BIOPH RES CO, V210, P288, DOI 10.1006/bbrc.1995.1659; PINNIX IB, 1994, ARCH BIOCHEM BIOPHYS, V312, P447, DOI 10.1006/abbi.1994.1331; POU S, 1992, J BIOL CHEM, V267, P24173; RENAUD JP, 1993, BIOCHEM BIOPH RES CO, V192, P53, DOI 10.1006/bbrc.1993.1380; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14743; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; WANG JL, 1993, J BIOL CHEM, V268, P22255; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; WERNER ER, 1994, BIOCHEM J, V304, P189, DOI 10.1042/bj3040189	52	166	166	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7336	7342		10.1074/jbc.271.13.7336	http://dx.doi.org/10.1074/jbc.271.13.7336			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631754	hybrid			2022-12-27	WOS:A1996UC77400022
J	Arand, M; Wagner, H; Oesch, F				Arand, M; Wagner, H; Oesch, F			Asp(333), Asp(495), and His(523) form the catalytic triad of rat soluble epoxide hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOALKANE DEHALOGENASE; PSEUDOMONAS-PUTIDA; LIVER; DNA; EXPRESSION; PROTEINS; DEGRADATION; SEQUENCE; CLONING; MECHANISM	On the basis of the sequence similarity between mammalian epoxide hydrolases and bacterial haloalkane dehalogenase reported earlier (Arand, M., Grant, D. F., Beetham, J. K., Friedberg, T., Oesch, F., and Hammock, B. D. (1994) FEES Lett. 338, 251-256; Beetham, J. K, Grant, D., Arand, M., Garbarino, J., Kiyosue, T., Pinot, F., Oesch, F., Bellnap, W R., Shinozaki, It., and Hammock, B. D. (1995) DNA Cell Biol 14, 61-71) we selected candidate amino acid residues for the putative catalytic triad of the rat soluble epoxide hydrolase. The predicted amino acid residues were exchanged by site-directed mutagenesis of the epoxide hydrolase cDNA, followed by the expression of the respective mutant enzymes in Escherichia coli. A total of 25 different mutants were analyzed for their epoxide hydrolase activity toward the model substrate trans-stilbene oxide. In case of impaired catalytic activity of a given mutant, the structural integrity of the recombinant enzyme protein was assessed either by its ability to covalently bind the substrate trans-stilbene oxide or by affinity purification on benzyl thio-Sepharose, using the soluble epoxide hydrolase-specific competitive inhibitor 4-fluorochalcone oxide to release the bound enzyme from the affinity matrix. Of the mutants under investigation, only those with changes in the positions Asp(333), Asp(495) and His(523) were completely inactive toward the model substrate trans-stilbene oxide while retaining the proper protein fold. These amino acids were exactly those previously predicted by sequence alignment. Exchange of the amino acid residues flanking the catalytic nucleophile Asp(333) significantly changed the kinetic properties of the enzyme. Mutation of His(332) to Gln had no apparent effect on the K-m but led to a heavily reduced V-max (5% that of the wild type) of the mutant enzyme, while the exchange of Trp(334) against Phe strongly increased the K-m (7-fold) and also moderately enhanced the V-max (2-fold) of the corresponding mutant. Mutation of Trp(540) apparently had a strong effect on the protein conformation.			Arand, M (corresponding author), UNIV MAINZ, INST TOXICOL, OBERE ZAHLBACHER STR 67, D-55131 MAINZ, GERMANY.		Oesch, Franz/AAA-8746-2020; Arand, Michael/J-3926-2014	Arand, Michael/0000-0003-2413-3177				ARAND M, 1994, FEBS LETT, V338, P251, DOI 10.1016/0014-5793(94)80278-5; ARAND M, 1991, FEBS LETT, V294, P19, DOI 10.1016/0014-5793(91)81333-4; BEETHAM JK, 1995, DNA CELL BIOL, V14, P61, DOI 10.1089/dna.1995.14.61; BEETHAM JK, 1993, ARCH BIOCHEM BIOPHYS, V305, P197, DOI 10.1006/abbi.1993.1411; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FRANKEN SM, 1991, EMBO J, V10, P1297, DOI 10.1002/j.1460-2075.1991.tb07647.x; FRIEDBERG T, 1991, METHOD ENZYMOL, V206, P193; GEBEL T, 1992, FEBS LETT, V309, P37, DOI 10.1016/0014-5793(92)80734-X; GILL SS, 1974, J AGR FOOD CHEM, V22, P386, DOI 10.1021/jf60193a058; GRANT DF, 1993, J BIOL CHEM, V268, P17628; HAMMOCK BD, 1994, BIOCHEM BIOPH RES CO, V198, P850, DOI 10.1006/bbrc.1994.1121; HAYASE N, 1990, J BACTERIOL, V172, P1160, DOI 10.1128/jb.172.2.1160-1164.1990; HECHT HJ, 1994, NAT STRUCT BIOL, V1, P532, DOI 10.1038/nsb0894-532; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HORN JM, 1991, MOL MICROBIOL, V5, P2459, DOI 10.1111/j.1365-2958.1991.tb02091.x; JANSSEN DB, 1989, J BACTERIOL, V171, P6791, DOI 10.1128/jb.171.12.6791-6799.1989; KENNES C, 1995, EUR J BIOCHEM, V228, P403; KIYOSUE T, 1994, PLANT J, V6, P259, DOI 10.1046/j.1365-313X.1994.6020259.x; KNEHR M, 1993, J BIOL CHEM, V268, P17623; KOONIN EV, 1994, J MOL BIOL, V244, P125, DOI 10.1006/jmbi.1994.1711; LACOURCIERE GM, 1993, J AM CHEM SOC, V115, P10466, DOI 10.1021/ja00075a115; LACOURCIERE GM, 1994, CHEM RES TOXICOL, V7, P121, DOI 10.1021/tx00038a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NORDLUND I, 1990, BIOCHIM BIOPHYS ACTA, V1049, P227, DOI 10.1016/0167-4781(90)90046-5; OESCH F, 1973, XENOBIOTICA, V3, P305, DOI 10.3109/00498257309151525; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; OTA K, 1980, SCIENCE, V207, P1479, DOI 10.1126/science.7361100; PINOT F, 1995, J BIOL CHEM, V270, P7968, DOI 10.1074/jbc.270.14.7968; PORTER TD, 1986, ARCH BIOCHEM BIOPHYS, V248, P121, DOI 10.1016/0003-9861(86)90408-X; PRIES F, 1994, BIOCHEMISTRY-US, V33, P1242, DOI 10.1021/bi00171a026; PUENTE XS, 1995, J BIOL CHEM, V270, P12926, DOI 10.1074/jbc.270.21.12926; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLADT L, 1986, BIOCHEM PHARMACOL, V35, P3309, DOI 10.1016/0006-2952(86)90428-4; STAPLETON A, 1994, PLANT J, V6, P251, DOI 10.1046/j.1365-313X.1994.6020251.x; THOMAS H, 1990, FRONTIERS BIOTRANSFO, V2, P278; TOMIC M, 1990, NUCLEIC ACIDS RES, V18, P1656, DOI 10.1093/nar/18.6.1656; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WIXTROM RN, 1988, ANAL BIOCHEM, V169, P71, DOI 10.1016/0003-2697(88)90256-4	41	110	117	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4223	4229						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626766				2022-12-27	WOS:A1996TW96000044
J	Muda, M; Boschert, U; Dickinson, R; Martinou, JC; Martinou, I; Camps, M; Schlegel, W; Arkinstall, S				Muda, M; Boschert, U; Dickinson, R; Martinou, JC; Martinou, I; Camps, M; Schlegel, W; Arkinstall, S			MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; DUAL-SPECIFICITY PHOSPHATASE; GROWTH-FACTOR; MAP KINASE; EXPRESSION; SEQUENCE; P21(RAS); ENCODES; 3CH134; CL100	MKP-1 (also known as CL100, 3CH134, Erp, and hVH-1) exemplifies a class of dual-specificity phosphatase able to reverse the activation of mitogen-activated protein (MAP) kinase family members by dephosphorylating critical tyrosine and threonine residues. We now report the cloning of MKP-3, a novel protein phosphatase that also suppresses MAP kinase activation state. The deduced amino acid sequence of MKP-3 is 36% identical to MKP-1 and contains the characteristic extended active-site sequence motif VXVHCXXGXSRSXTXXXAYLM (where X is any amino acid) as well as two N-terminal CH2 domains displaying homology to the cell cycle regulator Cdc25 phosphatase. When expressed in COS-7 cells, MKP-3 blocks both the phosphorylation and enzymatic activation of ERK2 by mitogens. Northern analysis reveals a single mRNA species of 2.7 kilobases with an expression pattern distinct from other dual-specificity phosphatases. MKP-3 is expressed in lung, heart, brain, and kidney, but not significantly in skeletal muscle or testis. In situ hybridization studies of MKP-3 in brain reveal enrichment within the CA1, CA3, and CA4 layers of the hippocampus. Metrazole-stimulated seizure activity triggers rapid (<1 h) but transient up-regulation of MKP-3 mRNA in the cortex, piriform cortex, and some amygdala nuclei. Metrazole stimulated similar regional up-regulation of MKP-1, although this was additionally induced within the thalamus. MKP-3 mRNA also undergoes powerful induction in PC12 cells after 3 h of nerve growth factor treatment. This response appears specific insofar as epidermal growth factor and dibutyryl cyclic AMP fail to induce significant MKP-3 expression. Subcellular localization of epitope-tagged MKP-3 in sympathetic neurons reveals expression in the cytosol with exclusion from the nucleus. Together, these observations indicate that MKP-3 is a novel dual-specificity phosphatase that displays a distinct tissue distribution, subcellular localization, and regulated expression, suggesting a unique function in controlling MAP kinase family members. Identification of a second partial cDNA clone (MKP-X) encoding the C-terminal 280 amino acids of an additional phosphatase that is 76% identical to MKP-3 suggests the existence of a distinct structurally homologous subfamily of MAP kinase phosphatases.	GLAXO INST MOL BIOL,CH-1228 PLAN LES OUATES,GENEVA,SWITZERLAND; UNIV GENEVA,DEPT MED,FDN RECH MED,CH-1211 GENEVA 4,SWITZERLAND	GlaxoSmithKline; University of Geneva				martinou, Jean-claude/0000-0002-9847-2051; Camps, Montserrat/0000-0002-9849-8657				ALESSI DR, 1993, ONCOGENE, V8, P2015; ARKINSTALL S, 1995, MOL CELL BIOL, V15, P1431; Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; BERETTA L, 1995, EUR J BIOCHEM, V227, P388, DOI 10.1111/j.1432-1033.1995.tb20401.x; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; FUKUDA M, 1995, ONCOGENE, V11, P239; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WISDEN W, 1991, MOL NEUROBIOLOGY PRA, P205; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	61	315	321	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4319	4326						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626780				2022-12-27	WOS:A1996TW96000058
J	Sun, QH; DeLisser, HM; Zukowski, MM; Paddock, C; Albelda, SM; Newman, PJ				Sun, QH; DeLisser, HM; Zukowski, MM; Paddock, C; Albelda, SM; Newman, PJ			Individually distinct Ig homology domains in PECAM-1 regulate hemophilic binding and modulate receptor affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; PLATELET GLYCOPROTEIN-IIIA; HUMAN-ENDOTHELIAL CELLS; MONOCLONAL-ANTIBODY; CD31; FIBRINOGEN; INTEGRINS; PROTEIN; LEUKOCYTES; ACTIVATION	PECAM-1 (CD31) is a 130-kDa member of the immunoglobulin (Ig) gene superfamily that is constitutively expressed at high concentration at endothelial cell intercellular junctions and at moderate density on the surface of circulating leukocytes and platelets, Recent in vitro and in vivo studies have shown that PECAM-1 plays a central, role in mediating the extravasation of leukocytes from the vessel wall in response to inflammatory mediators. To study the binding characteristics of PECAM-1, phospholipid vesicles were prepared and examined by flow cytometry and immunofluorescence microscopy for their ability to associate with each other and with cells. Proteoliposomes containing high concentrations of PECAM-1 interacted homophilically with each other, forming large self-aggregates. PECAM-1 proteoliposomes, as well as soluble bivalent PECAM-1 in the form of a PECAM-1/IgG immunoadhesin, associated homophilically with cells expressing human, but not murine, PECAM-1. This binding could be completely inhibited by monoclonal antibody Fab fragments specific for Ig homology Domain 1 or Domains 1 + 2. Binding studies using cells expressing human PECAM-1 deletion mutants and murine/human chimeras confirmed that both Ig Domains 1 and 2 were both necessary and sufficient for homophilic binding. In contrast, engagement of membrane-proximal Domain 6 with monoclonal antibody Fab fragments had the opposite effect and augmented the binding of PECAM-1 proteoliposomes to cells. Thus, PECAM-1, like certain integrins, appears to be capable of antibody-induced conformational changes that alter affinity for its ligand. Similar changes induced by physiologic stimuli could be important in regulating the function of PECAM-1 in vascular cells.	BLOOD CTR SE WISCONSIN INC, BLOOD RES INST, MILWAUKEE, WI 53233 USA; UNIV PENN, MED CTR, DEPT MED, PHILADELPHIA, PA 19104 USA; AMGEN BOULDER INC, BOULDER, CO 80301 USA; MED COLL WISCONSIN, DEPT PHARMACOL, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, DEPT CELLULAR BIOL, MILWAUKEE, WI 53226 USA	Versiti Blood Center of Wisconsin; University of Pennsylvania; Medical College of Wisconsin; Medical College of Wisconsin			DeLisser, Horace/AFM-1942-2022		NHLBI NIH HHS [HL-43611, HL-40926, HL-03382] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K14HL003382, R01HL043611, R01HL040926] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; AYALON O, 1994, J CELL BIOL, V126, P247, DOI 10.1083/jcb.126.1.247; BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BERMAN ME, 1995, J IMMUNOL, V154, P299; BOGEN S, 1994, J EXP MED, V179, P1059, DOI 10.1084/jem.179.3.1059; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; DU XP, 1993, J BIOL CHEM, V268, P23087; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FAWCETT J, 1995, J CELL BIOL, V128, P1229, DOI 10.1083/jcb.128.6.1229; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; HAWIGER J, 1982, P NATL ACAD SCI-BIOL, V79, P2068, DOI 10.1073/pnas.79.6.2068; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; KIRSCHBAUM NE, 1994, BLOOD, V84, P4028, DOI 10.1182/blood.V84.12.4028.bloodjournal84124028; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOUNS WC, 1991, BLOOD, V78, P3215; KOUNS WC, 1992, J BIOL CHEM, V267, P18844; LAMPUGNANI MG, 1991, J CELL BIOL, V112, P479, DOI 10.1083/jcb.112.3.479; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LIAO F, 1995, J EXP MED, V182, P1337, DOI 10.1084/jem.182.5.1337; MARTIN S, 1993, J VIROL, V67, P3561, DOI 10.1128/JVI.67.6.3561-3568.1993; MULLER WA, 1992, J EXP MED, V175, P1401, DOI 10.1084/jem.175.5.1401; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; NEWMAN PJ, 1992, J CELL BIOL, V119, P239, DOI 10.1083/jcb.119.1.239; NEWMAN PJ, 1994, ANN NY ACAD SCI, V714, P165, DOI 10.1111/j.1749-6632.1994.tb12041.x; NEWMAN PJ, 1985, BLOOD, V65, P227; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; OTOOLE TE, 1991, SCIENCE, V254, P345; PIALI L, 1993, EUR J IMMUNOL, V23, P2464, DOI 10.1002/eji.1830231013; PIALI L, 1994, ADV EXP MED BIOL, V355, P147; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; RENZ ME, 1994, J CELL BIOL, V125, P1395, DOI 10.1083/jcb.125.6.1395; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STOCKINGER H, 1990, J IMMUNOL, V145, P3889; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; THIAGARAJAN P, 1985, J CLIN INVEST, V75, P896, DOI 10.1172/JCI111789; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; YAN HC, 1995, J BIOL CHEM, V270, P23672, DOI 10.1074/jbc.270.40.23672; YAN HC, 1995, CELL ADHES COMMUN, V3, P45, DOI 10.3109/15419069509081277; ZEHNDER JL, 1992, J BIOL CHEM, V267, P5243	50	149	155	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11090	11098		10.1074/jbc.271.19.11090	http://dx.doi.org/10.1074/jbc.271.19.11090			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626652	hybrid			2022-12-27	WOS:A1996UJ94400012
J	Przywara, DA; Guo, X; Angelilli, ML; Wakade, TD; Wakade, AR				Przywara, DA; Guo, X; Angelilli, ML; Wakade, TD; Wakade, AR			A non-cholinergic transmitter, pituitary adenylate cyclase-activating polypeptide, utilizes a novel mechanism to evoke catecholamine secretion in rat adrenal chromaffin cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; HYPOTHALAMIC PEPTIDE; TYROSINE-HYDROXYLASE; MEDULLA; VIP; NEUROTRANSMITTER; PHOSPHORYLATION; EXOCYTOSIS; OUTGROWTH; NEURONS	Pituitary adenylate cyclase-activating polypeptide (PACAP) is the most potent non-cholinergic neurotransmitter to stimulate catecholamine secretion from rat chromaffin cells; however, the mechanism of action is not clear, We used amperometric detection of exocytosis and indo-1 monitoring of [Ca2+](i) to identify PACAP actions in cultured chromaffin cells, PACAP (100 nM) required external Ca2+ to evoke secretion, However, unlike nicotine and KCl which caused immediate and relatively brief secretion, PACAP had a latency of 6.8 +/- 0.96 s to the first secretory response and secretion continued for up to 2 min, PACAP elevation of [Ca2+](i) showed similar latency and often remained above base line for several minutes following a brief exposure, ZnCl2 (100 ECM) selectively inhibited PACAP-stimulated secretion and [Ca2+](i) with little effect on nicotine-evoked responses, Nifedipine (10 mu M) had little effect on PACAP-evoked secretion but inhibited nicotine-evoked secretion by more than 80%, while omega-conotoxin (100 nM) failed to affect either agonist, PACAP-stimulated cAMP levels required 5 s to significantly increase, consistent with the latency of exocytotic and Ca2+ responses. Forskolin (10 mu M) caused responses similar to PACAP. PACAP-evoked exocytosis was blocked by the protein kinase A inhibitor adenosine 3',5'-cyclic monophosphorothioate R(p)-diastereomer (R(p)-cAMPS). These data show that PACAP stimulates exocytosis by a mechanism distinctly different from cholinergic transmitters that appears to involve cAMP-mediated Ca2+ influx, Differences in receptor coupling mechanisms and pharmacology of Ca2+ entry stimulated by cholinergic and peptidergic agonists support the idea that the peptidergic system maintains catecholamine secretion under conditions where the cholinergic system desensitizes or otherwise fails.	WAYNE STATE UNIV,SCH MED,DEPT PEDIAT,DETROIT,MI 48201	Wayne State University	Przywara, DA (corresponding author), WAYNE STATE UNIV,SCH MED,DEPT PHARMACOL,540 E CANFIELD AVE,DETROIT,MI 48201, USA.							ARIMURA A, 1991, P NATL ACAD SCI USA, V81, P6388; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; CHOWDHURY PS, 1994, NEUROSCIENCE, V59, P1, DOI 10.1016/0306-4522(94)90092-2; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; EDWARDS AV, 1994, AM J PHYSIOL, V266, pE870, DOI 10.1152/ajpendo.1994.266.6.E870; GOTTSCHALL PE, 1990, ENDOCRINOLOGY, V127, P272, DOI 10.1210/endo-127-1-272; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUO X, 1994, J PHYSIOL-LONDON, V475, P539, DOI 10.1113/jphysiol.1994.sp020092; GUO X, 1996, IN PRESS J NEUROCHEM; HAYCOCK JW, 1992, J NEUROCHEM, V58, P57, DOI 10.1111/j.1471-4159.1992.tb09276.x; HILLE B, 1992, IONIC CHANNELS EXCIT, P177; HOKFELT T, 1981, ACTA PHYSIOL SCAND, V113, P575, DOI 10.1111/j.1748-1716.1981.tb06944.x; HOLZWARTH MA, 1984, J AUTONOM NERV SYST, V11, P283; HONG Y, 1993, NEUROSCIENCE, V57, P1121, DOI 10.1016/0306-4522(93)90054-J; ISOBE K, 1993, ENDOCRINOLOGY, V132, P1757, DOI 10.1210/en.132.4.1757; KOVES K, 1990, ENDOCRINOLOGY, V127, P264; LESZCZYSZYN DJ, 1990, J BIOL CHEM, V265, P14736; LILLIEN LE, 1985, NATURE, V317, P623; MALHOTRA RK, 1989, J NEUROSCI, V9, P4150; MARLEY PD, 1995, BRIT J PHARMACOL, V114, P1687, DOI 10.1111/j.1476-5381.1995.tb14958.x; MAUBERT E, 1990, NEUROSCI LETT, V113, P121, DOI 10.1016/0304-3940(90)90290-P; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; OOMORI Y, 1994, CELL TISSUE RES, V275, P201, DOI 10.1007/BF00319418; PRZYWARA DA, 1991, J PHYSIOL-LONDON, V437, P201, DOI 10.1113/jphysiol.1991.sp018591; PRZYWARA DA, 1993, P NATL ACAD SCI USA, V90, P557, DOI 10.1073/pnas.90.2.557; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; TABARIN A, 1994, NEUROENDOCRINOLOGY, V59, P113, DOI 10.1159/000126647; TISCHLER AS, 1982, CELL TISSUE RES, V255, P525; UNSICKER K, 1978, P NATL ACAD SCI USA, V75, P3498, DOI 10.1073/pnas.75.7.3498; WAKADE AR, 1992, REGUL PEPTIDES, V37, P331, DOI 10.1016/0167-0115(92)90643-9; WAKADE TD, 1991, J PHYSIOL-LONDON, V444, P349, DOI 10.1113/jphysiol.1991.sp018882; WATANABE T, 1992, BIOCHEM BIOPH RES CO, V182, P403, DOI 10.1016/S0006-291X(05)80159-7; WAYMIRE JC, 1991, J NEUROCHEM, V57, P1313, DOI 10.1111/j.1471-4159.1991.tb08296.x; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10074	34	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10545	10550		10.1074/jbc.271.18.10545	http://dx.doi.org/10.1074/jbc.271.18.10545			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631854	hybrid			2022-12-27	WOS:A1996UJ34200022
J	Aqvist, J; Fothergill, M				Aqvist, J; Fothergill, M			Computer simulation of the triosephosphate isomerase catalyzed reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBONIC ANHYDRASE-I; FREE-ENERGY; ENZYME CATALYSIS; REACTION PATHWAY; MODEL; ENERGETICS; MECHANISM; LOOP; STEP; PKA	A major challenge for theoretical simulation methods is the calculation of enzymic reaction rates directly from the three-dimensional protein structure together with some idea of the chemical reaction mechanism. Here, we report the evaluation of a complete free energy profile for all the elementary steps of the triosephosphate isomerase catalyzed reaction using such an approach. The results are compatible with available experimental data and also suggest which of the possible reaction intermediates is kinetically observable. In addition to previously identified catalytic residues, the simulations show that a crystallographically observed active site water molecule plays an important role during catalysis and an intersubunit interaction that could explain the low activity of the monomeric enzyme is also observed. The calculations clearly demonstrate the important catalytic effects associated with stabilization of charged high energy intermediates and reduction of reorganization energy, which are likely to be general principles of enzyme catalyzed charge transfer and separation reactions.			Aqvist, J (corresponding author), UPPSALA UNIV,BIOMED CTR,DEPT BIOL MOLEC,BOX 590,S-75124 UPPSALA,SWEDEN.							ALAGONA G, 1984, J AM CHEM SOC, V106, P3623, DOI 10.1021/ja00324a035; ALAGONA G, 1995, J AM CHEM SOC, V117, P9855, DOI 10.1021/ja00144a011; ALBERY WJ, 1980, ANNU REV PHYS CHEM, V31, P227, DOI 10.1146/annurev.pc.31.100180.001303; AQVIST J, 1992, J MOL BIOL, V224, P7, DOI 10.1016/0022-2836(92)90572-2; AQVIST J, 1990, J PHYS CHEM-US, V94, P8021, DOI 10.1021/j100384a009; AQVIST J, 1993, J AM CHEM SOC, V115, P631; AQVIST J, 1993, CHEM REV, V93, P2523, DOI 10.1021/cr00023a010; BASH PA, 1991, BIOCHEMISTRY-US, V30, P5826, DOI 10.1021/bi00238a003; BEVERIDGE DL, 1989, ANNU REV BIOPHYS BIO, V18, P431, DOI 10.1146/annurev.bb.18.060189.002243; BLACKLOW SC, 1990, BIOCHEMISTRY-US, V29, P4099, DOI 10.1021/bi00469a012; BORCHERT TV, 1994, P NATL ACAD SCI USA, V91, P1515, DOI 10.1073/pnas.91.4.1515; BROWN FK, 1987, J MOL BIOL, V198, P533, DOI 10.1016/0022-2836(87)90298-1; CHIANG Y, 1984, J AM CHEM SOC, V106, P460, DOI 10.1021/ja00314a055; COHEN AO, 1968, J PHYS CHEM-US, V72, P4249, DOI 10.1021/j100858a052; CRAMER CJ, 1992, SCIENCE, V256, P213, DOI 10.1126/science.256.5054.213; DAGGETT V, 1989, J AM CHEM SOC, V111, P8247, DOI 10.1021/ja00203a028; DAVENPORT RC, 1991, BIOCHEMISTRY-US, V30, P5821, DOI 10.1021/bi00238a002; EIGEN M, 1963, ADV ENZYMOL REL S BI, V25, P1; EIGEN M, 1964, ANGEW CHEM INT EDIT, V3, P1, DOI 10.1002/anie.196400011; GUTHRIE JP, 1979, CAN J CHEM, V57, P1177, DOI 10.1139/v79-193; JORGENSEN WL, 1989, ACCOUNTS CHEM RES, V22, P184, DOI 10.1021/ar00161a004; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KING G, 1989, J CHEM PHYS, V91, P3647, DOI 10.1063/1.456845; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; KNOWLES JR, 1977, ACCOUNTS CHEM RES, V10, P105, DOI 10.1021/ar50112a001; LODI PJ, 1991, BIOCHEMISTRY-US, V30, P6948, DOI 10.1021/bi00242a020; LODI PJ, 1993, BIOCHEMISTRY-US, V32, P4338, DOI 10.1021/bi00067a024; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6609, DOI 10.1021/bi00480a009; MENGER FM, 1992, BIOCHEMISTRY-US, V31, P5368, DOI 10.1021/bi00138a018; NICKBARG EB, 1988, BIOCHEMISTRY-US, V27, P5948, DOI 10.1021/bi00416a019; NICKBARG EB, 1988, BIOCHEMISTRY-US, V27, P5939, DOI 10.1021/bi00416a018; PAGE MI, 1987, ENZYME MECH, pCHY; Pauling L., 1945, NATURE CHEM BOND; RICHARD JP, 1984, J AM CHEM SOC, V106, P4926, DOI 10.1021/ja00329a050; RIEDER SV, 1959, J BIOL CHEM, V234, P1007; STRAATSMA TP, 1992, ANNU REV PHYS CHEM, V43, P407; van Gunsteren W. F., 1987, GRONINGEN MOL SIMULA; WARSHEL A, 1992, FARADAY DISCUSS, V93, P225, DOI 10.1039/fd9929300225; Warshel A, 1991, COMPUTER MODELING CH; YADAV A, 1991, J AM CHEM SOC, V113, P4800, DOI 10.1021/ja00013a013	40	68	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10010	10016		10.1074/jbc.271.17.10010	http://dx.doi.org/10.1074/jbc.271.17.10010			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626554	hybrid			2022-12-27	WOS:A1996UG25700026
J	Binnerts, ME; vanKooyk, Y; Edwards, CP; Champe, M; Presta, L; Bodary, SC; Figdor, CG; Berman, PW				Binnerts, ME; vanKooyk, Y; Edwards, CP; Champe, M; Presta, L; Bodary, SC; Figdor, CG; Berman, PW			Antibodies that selectively inhibit leukocyte function-associated antigen 1 binding to intercellular adhesion molecule-3 recognize a unique epitope within the CD11a I domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; CR3-DEPENDENT ADHESION; COUNTER-RECEPTOR; LYMPHOCYTES-T; LFA-1; INTEGRIN; CLONING; LIGAND; ACTIVATION; EXPRESSION	Several studies indicate that the I domain located in the alpha chain (CD11a) of leukocyte function-associated antigen-1 (LFA-1; CD11a/CD18) plays an essential role in ligand recognition. me recently identified three distinct epitopes (IdeA, IdeB, and IdeC) within the CD11a I domain, recognized by antibodies that block binding of LFA-1 to intercellular adhesion molecules (ICAM) 1, 2, and 3. In the present study, we used a series of human/ murine CD11a I domain chimeras, to localize a fourth I domain epitope (IdeD), recognized by three independently derived anti-CD11a antibodies that selectively block the binding of LFA-1 to ICAM-3, but not to ICAM-1. The IdeD epitope depended on human CD11a residues Asp(182) and Ser(184) and was not present in CD11b or CD11c. Although mutation of Asp(182) and Ser(184) failed to abolish ICAM-3 adhesion of LFA-1 transfectants, alignment of these residues with the crystal structure of the CD11a I domain suggested that the IdeD epitope is located in close proximity to residues (Ile(126) and Asn(129)) recently implicated in the ICAM-3 binding site (1). Interestingly, the IdeB and IdeC epitopes appeared to be in close proximity of a divalent cation binding pocket within the CD11a I domain that regulates both ICAM-1 and ICAM-3 adhesion. Taken together, these data indicate that distinct regions of the CD11a I domain contain epitopes for antibodies that either selectively inhibit binding of LFA-1 to ICAM-3, or interfere with both ICAM-1 and ICAM-3 binding of LFA-1.	UNIV NIJMEGEN ST RADBOUD HOSP, DEPT TUMOR IMMUNOL, 6525 EX NIJMEGEN, NETHERLANDS; GENENTECH INC, DEPT IMMUNOL, San Francisco, CA 94080 USA	Radboud University Nijmegen; Roche Holding; Genentech			Figdor, Carl G/A-4232-2010	Figdor, Carl G/0000-0002-2366-9212				ACEVEDO A, 1993, AM J PATHOL, V143, P774; ANDREW D, 1993, EUR J IMMUNOL, V23, P2217, DOI 10.1002/eji.1830230925; ARROYO AG, 1994, J CELL BIOL, V126, P1277, DOI 10.1083/jcb.126.5.1277; BERGELSON JM, 1995, CURR BIOL, V5, P615, DOI 10.1016/S0960-9822(95)00124-2; BERMAN PW, 1993, J CELL BIOCHEM, V52, P183, DOI 10.1002/jcb.240520210; BINNERTS ME, 1994, EUR J IMMUNOL, V24, P2155, DOI 10.1002/eji.1830240933; CHAMPE M, 1995, J BIOL CHEM, V270, P1388, DOI 10.1074/jbc.270.3.1388; CORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; DEFOUGEROLLES AR, 1993, J EXP MED, V177, P1187, DOI 10.1084/jem.177.4.1187; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DIACOVO TG, 1994, J CLIN INVEST, V94, P1243, DOI 10.1172/JCI117442; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DUSTIN ML, 1986, J IMMUNOL, V137, P245; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EDWARDS CP, 1995, J BIOL CHEM, V270, P12635, DOI 10.1074/jbc.270.21.12635; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; FIGDOR CG, 1990, IMMUNOL TODAY, V11, P277, DOI 10.1016/0167-5699(90)90112-M; HILDRETH JEK, 1983, EUR J IMMUNOL, V13, P202, DOI 10.1002/eji.1830130305; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; KEIZER GD, 1985, EUR J IMMUNOL, V15, P1142, DOI 10.1002/eji.1830151114; KERN A, 1994, J BIOL CHEM, V269, P22811; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LANDIS RC, 1994, J CELL BIOL, V126, P529, DOI 10.1083/jcb.126.2.529; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MARTZ E, 1987, HUM IMMUNOL, V18, P3, DOI 10.1016/0198-8859(87)90110-8; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; NORTAMO P, 1991, EUR J IMMUNOL, V21, P2629, DOI 10.1002/eji.1830211049; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RANDI AM, 1994, J BIOL CHEM, V269, P12395; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; SADHU C, 1994, CELL ADHES COMMUN, V2, P429, DOI 10.3109/15419069409004453; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SIMS MJ, 1993, J IMMUNOL, V151, P2296; SPITS H, 1983, HYBRIDOMA, V2, P423, DOI 10.1089/hyb.1983.2.423; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; TUFTY RM, 1975, SCIENCE, V187, P167, DOI 10.1126/science.1111094; vanKooyk Y, 1996, J EXP MED, V183, P1247, DOI 10.1084/jem.183.3.1247; VANKOOYK Y, 1994, J CELL BIOL, V124, P1061, DOI 10.1083/jcb.124.6.1061; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	53	37	37	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9962	9968		10.1074/jbc.271.17.9962	http://dx.doi.org/10.1074/jbc.271.17.9962			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626634	Green Published, hybrid			2022-12-27	WOS:A1996UG25700018
J	Lee, HJ; Young, WJ; Shih, CCY; Chang, CS				Lee, HJ; Young, WJ; Shih, CCY; Chang, CS			Suppression of the human erythropoietin gene expression by the TR2 orphan receptor, a member of the steroid receptor superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; INSITU HYBRIDIZATION; HORMONE RECEPTORS; ENHANCER ELEMENT; RETINOIC ACID; CELL-LINES; PROTEIN; HYPOXIA; LOCALIZATION; ACTIVATION	A DNA response element, TR2RE-EPO (5'-TCTGACCTCTCGACCTAC-3') has been identified in the 3'-minimal hypoxia-inducible enhancer of the human erythropoietin gene for the TR2 orphan receptor, an androgen-repressed transcription factor and a member of the steroid/thyroid hormone receptor superfamily. Electrophoretic mobility shift assay showed a specific binding with high affinity (K-d = 0.14 nM) between the TR2 orphan receptor and the TR2RE-EPO. Our data further indicated that this specific binding is not due to the homo-dimerization of the TR2 orphan receptor. In addition, reporter gene expression using chloramphenicol acetyltransferase assay demonstrated that the TR2 orphan receptor may suppress the expression of the chloramphenicol acetyltransferase activities via the TR2RE-EPO in the hypoxic/normoxic human hepatoma HepG2 cells. Finally, our in situ hybridization data also indicated that the TR2 orphan receptor and the erythropoietin transcripts can be co-expressed in mouse kidney and liver. Together, our data suggest that the human erythropoietin gene could represent the first human target gene regulated directly by the human TR2 orphan receptor.	UNIV WISCONSIN, CTR COMPREHENS CANC, ENDOCRINOL REPROD PHYSIOL PROGRAM, MADISON, WI 53792 USA						NCI NIH HHS [CA55639] Funding Source: Medline; NIDDK NIH HHS [DK47258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055639, R29CA055639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECK I, 1991, J BIOL CHEM, V266, P15563; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BURBACH JPH, 1994, J BIOL CHEM, V269, P15046; CHANG C, 1988, BIOCHEM BIOPH RES CO, V155, P971, DOI 10.1016/S0006-291X(88)80591-6; CHANG C, 1989, J STEROID BIOCHEM, V34, P391; CHANG C, 1989, BIOCHEM BIOPH RES CO, V165, P735, DOI 10.1016/S0006-291X(89)80028-2; Chang C, 1993, ENDOCR J, V1, P541; CHANG CS, 1989, ENDOCRINOLOGY, V125, P1097, DOI 10.1210/endo-125-2-1097; CHANG CS, 1992, P NATL ACAD SCI USA, V89, P5946, DOI 10.1073/pnas.89.13.5946; CHANG CS, 1994, P NATL ACAD SCI USA, V91, P6040, DOI 10.1073/pnas.91.13.6040; ESCHBACH JW, 1995, NEPHROL DIAL TRANSPL, V10, P96, DOI 10.1093/ndt/10.supp2.96; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HIROSE T, 1994, MOL ENDOCRINOL, V8, P1667, DOI 10.1210/me.8.12.1667; HO V, 1995, J BIOL CHEM, V270, P10084, DOI 10.1074/jbc.270.17.10084; IDETA R, 1995, ENDOCRINE, V3, P277, DOI 10.1007/BF03021406; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; JACOBSON LO, 1957, NATURE, V179, P633, DOI 10.1038/179633a0; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; JEPSON JH, 1967, ENDOCRINOLOGY, V80, P430, DOI 10.1210/endo-80-3-430; Kokontis J, 1991, Receptor, V1, P261; KOURY ST, 1988, BLOOD, V71, P524; KOURY ST, 1991, BLOOD, V77, P2497; KRANTZ SB, 1991, BLOOD, V77, P419; LAI PH, 1986, J BIOL CHEM, V261, P3116; LEE HJ, 1993, BIOCHEM BIOPH RES CO, V194, P97, DOI 10.1006/bbrc.1993.1790; LEE HJ, 1995, J BIOL CHEM, V270, P5434, DOI 10.1074/jbc.270.10.5434; LEE HJ, 1995, J BIOL CHEM, V270, P30129; LEE HJ, 1993, ENDOCR J, V1, P203; LEEHUANG S, 1993, GENE, V128, P227, DOI 10.1016/0378-1119(93)90567-M; LEEHUANG S, 1993, GENE, V137, P203; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; LIN TM, 1995, J BIOL CHEM, V270, P30121; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MASUDA S, 1994, J BIOL CHEM, V269, P19488; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; MOWSZOWICZ I, 1993, MOL ENDOCRINOL, V7, P861, DOI 10.1210/me.7.7.861; NAUGHTON BA, 1977, SCIENCE, V196, P301, DOI 10.1126/science.847471; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; OMALLEY BW, 1992, MOL ENDOCRINOL, V6, P1359, DOI 10.1210/me.6.9.1359; PAULO LG, 1974, BLOOD, V43, P39, DOI 10.1182/blood.V43.1.39.39; PAULSEN RE, 1992, J BIOL CHEM, V267, P16491; RIDLEY DM, 1994, J NATL MED ASSOC, V86, P129; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WIESENBERG I, 1995, NUCLEIC ACIDS RES, V23, P327, DOI 10.1093/nar/23.3.327; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; ZUCALI JR, 1977, BRIT J HAEMATOL, V35, P639, DOI 10.1111/j.1365-2141.1977.tb00627.x	60	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10405	10412		10.1074/jbc.271.17.10405	http://dx.doi.org/10.1074/jbc.271.17.10405			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626614	hybrid			2022-12-27	WOS:A1996UG25700086
J	Garwood, J; Kohiyama, M				Garwood, J; Kohiyama, M			Novel cytoplasmic hemimethylated oriC binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; REPLICATION ORIGIN; DNA-REPLICATION; DAM METHYLATION; SALMONELLA-TYPHIMURIUM; INITIATION; PROTEIN; MEMBRANE; COMPLEX; SITES	Using hemimethylated, fully methylated, and unmethylated oligonucleotide probes corresponding to part of the origin of Escherichia coli DNA replication, oriC (+81-136), we have characterized a novel hemimethylated DNA-specific protein binding activity. This activity appears to be located in the cytoplasm rather than in membrane fractions. It has been partially purified and, in DNase footprinting analysis, found to preferentially protect only a subset of the hemimethylated GATC sites present in the minimal oriC. These sites are found adjacent to the DnaA binding box, R1, and overlap the integration host factor binding site. The activity does not correspond to known hemimethylated binding proteins, although in the seqA deletion mutant, there is a 3-fold reduction of the activity. The stage of the cell cycle in synchronized PC2 cultures does not seem to significantly affect the relative levels of this binding activity. A possible role in sequestration of the newly replicated hemimethylated origin is discussed.	UNIV PARIS 07, INST JACQUES MONOD, BIOCHEM GENET GRP, F-75251 PARIS, FRANCE	UDICE-French Research Universities; Universite Paris Cite								AU KG, 1992, J BIOL CHEM, V267, P12142; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; CARL PL, 1970, MOL GEN GENET, V109, P107, DOI 10.1007/BF00269647; CHAKRABORTI A, 1992, J BACTERIOL, V174, P7202, DOI 10.1128/jb.174.22.7202-7206.1992; CROOKE E, 1993, J MOL BIOL, V233, P16, DOI 10.1006/jmbi.1993.1481; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; GAYAMA S, 1990, EMBO J, V9, P3761, DOI 10.1002/j.1460-2075.1990.tb07589.x; GILLE H, 1991, EMBO J, V10, P1579, DOI 10.1002/j.1460-2075.1991.tb07678.x; HANSEN FG, 1991, RES MICROBIOL, V142, P161, DOI 10.1016/0923-2508(91)90025-6; HANSEN FG, 1991, J BACTERIOL, V173, P5194, DOI 10.1128/jb.173.16.5194-5199.1991; HENDRICKSON WG, 1982, CELL, V30, P915, DOI 10.1016/0092-8674(82)90296-3; HERRICK J, 1994, EMBO J, V13, P4695, DOI 10.1002/j.1460-2075.1994.tb06793.x; HUPP TR, 1993, J BIOL CHEM, V268, P13128; HWANG DS, 1992, J BIOL CHEM, V267, P23083; ISHIDATE K, 1986, J BIOL CHEM, V261, P428; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; JOSELEAUPETIT D, 1975, BIOCHIM BIOPHYS ACTA, V406, P36, DOI 10.1016/0005-2736(75)90040-1; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KUSANO T, 1984, J BACTERIOL, V158, P313, DOI 10.1128/JB.158.1.313-316.1984; LANDOULSI A, 1990, CELL, V63, P1053, DOI 10.1016/0092-8674(90)90508-C; LANDOULSI A, 1989, MOL GEN GENET, V216, P217, DOI 10.1007/BF00334359; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; MAHAFFY JM, 1989, J THEOR BIOL, V140, P453, DOI 10.1016/S0022-5193(89)80109-2; MARSH RC, 1978, MOL GEN GENET, V166, P299, DOI 10.1007/BF00267622; MESSER W, 1985, EMBO J, V4, P1327, DOI 10.1002/j.1460-2075.1985.tb03780.x; MESSER W, 1988, CELL, V54, P735, DOI 10.1016/S0092-8674(88)90911-7; MESSER W, 1995, ESCHERICHIA COLI SAL; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; NAGAI K, 1980, P NATL ACAD SCI-BIOL, V77, P262, DOI 10.1073/pnas.77.1.262; OGDEN GB, 1988, CELL, V54, P127, DOI 10.1016/0092-8674(88)90186-9; OKA A, 1980, MOL GEN GENET, V178, P9, DOI 10.1007/BF00267207; POLACZEK P, 1990, New Biologist, V2, P265; ROTH A, 1994, BIOCHIMIE, V76, P917, DOI 10.1016/0300-9084(94)90016-7; RUSSELL DW, 1987, CELL, V50, P1071, DOI 10.1016/0092-8674(87)90173-5; SAMITT CE, 1989, EMBO J, V8, P989, DOI 10.1002/j.1460-2075.1989.tb03462.x; SCHAECHTER M, 1990, AM SOC MICROBIOL, P313; SCHAEFER C, 1991, MOL GEN GENET, V226, P34, DOI 10.1007/BF00273584; SKARSTAD K, 1986, EMBO J, V5, P1711, DOI 10.1002/j.1460-2075.1986.tb04415.x; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; SMITH DW, 1985, EMBO J, V4, P1319, DOI 10.1002/j.1460-2075.1985.tb03779.x; THEISEN PW, 1993, MOL MICROBIOL, V10, P575, DOI 10.1111/j.1365-2958.1993.tb00929.x; VONFREIESLEBEN U, 1994, MOL MICROBIOL, V14, P763; WOELKER B, 1993, NUCLEIC ACIDS RES, V21, P5025, DOI 10.1093/nar/21.22.5025; YOSHIKAWA H, 1991, MOL MICROBIOL, V5, P2589, DOI 10.1111/j.1365-2958.1991.tb01967.x; ZYSKIND JW, 1986, CELL, V46, P489, DOI 10.1016/0092-8674(86)90873-1	48	5	5	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7404	7411		10.1074/jbc.271.13.7404	http://dx.doi.org/10.1074/jbc.271.13.7404			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631765	hybrid			2022-12-27	WOS:A1996UC77400033
J	Parks, CL; Shenk, T				Parks, CL; Shenk, T			The serotonin 1a receptor gene contains a TATA-less promoter that responds to MAZ and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; RNA POLYMERASE-II; 5-HT1A RECEPTOR; MESSENGER-RNA; GEL-ELECTROPHORESIS; RAT-BRAIN; C-MYC; TRANSCRIPTIONAL INTERFERENCE; ACTIVATES TRANSCRIPTION; POSTNATAL-DEVELOPMENT	The structure and function of the 5'-flanking region of the mouse and human serotonin la receptor gene have been analyzed by RNA 5' end mapping, DNA-protein interaction, and transient expression assays. A large number of mRNA 5' termini, detected by mapping 5' ends from mouse brain RNA, were found dispersed over a region of about 700 base pairs flanking the receptor coding sequence. Consistent with the apparently heterogeneous pattern of transcription initiation, the flanking DNA sequence lacked typical TATA box elements and was rich in guanine and cytosine. The mouse and human 5'-flanking sequences were 63% homologus and similarly organized. A guanine-cytosine-rich DNA sequence motif related to the sequence 5'-GGGG(C/A)GGGG-3' was repeated within the 5'-flanking region and located at or near several mRNA 5' ends. This DNA sequence motif bound to proteins in a crude HeLa cell nuclear extract. A cDNA encoding a protein that interacts with this sequence was cloned and found to be the MAZ (Pur-1, Zif87) protein. The interaction between MAZ and the receptor gene 5'-flanking region proximal to the protein coding sequence was examined by DNase I footprinting, and four sites of MAZ interaction were identified. Three of the four MAZ binding sites also were shown to interact with transcription factor Sp1. Overproduction of MAZ or Sp1 in transient transfection assays increased expression directed by the human 5'-flanking sequence, although MAZ was substantially more effective. This result suggests that MAZ and Sp1 both participate in regulating expression from the serotonin 1a receptor gene promoter, and it raises the possibility that MAZ may act at a variety of promoters through the guanosine-cytosine-rich sequences generally thought to serve as binding sites for the Sp1 family of transcription factors. Analysis of one of the guanosine-cytosine-rich DNA sequences also revealed that it can serve as a transcription initiator sequence in vitro. This initiator sequence differs from previously characterized initiators and may represent a new class of this transcriptional control sequence.	PRINCETON UNIV, HOWARD HUGHES MED INST, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Howard Hughes Medical Institute; Princeton University								ADHYA S, 1982, CELL, V29, P939, DOI 10.1016/0092-8674(82)90456-1; ALBERT PR, 1990, J BIOL CHEM, V265, P5825; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; AZMITIA EC, 1987, NEUROSCIENCE, V20, P47, DOI 10.1016/0306-4522(87)90005-4; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BATEMAN E, 1988, CELL, V54, P985, DOI 10.1016/0092-8674(88)90113-4; Bencini DA, 1984, BIOTECHNIQUES, V2, P4; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BOESS FG, 1994, NEUROPHARMACOLOGY, V33, P275, DOI 10.1016/0028-3908(94)90059-0; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; CHALMERS DT, 1993, J NEUROSCI, V13, P914; CHALMERS DT, 1991, BRAIN RES, V561, P51, DOI 10.1016/0006-8993(91)90748-K; CHAREST A, 1993, J NEUROSCI, V13, P5164, DOI 10.1523/JNEUROSCI.13-12-05164.1993; CHARRIER D, 1994, PHARMACOL BIOCHEM BE, V48, P281, DOI 10.1016/0091-3057(94)90528-2; CUELLO AC, 1983, BRAIN MICRODISSECTIO, V2; CULLEN BR, 1984, NATURE, V307, P241, DOI 10.1038/307241a0; DAVAL G, 1987, INT J DEV NEUROSCI, V5, P171, DOI 10.1016/0736-5748(87)90027-X; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DING DM, 1993, MOL BRAIN RES, V20, P181, DOI 10.1016/0169-328X(93)90040-V; DISCIULLO A, 1990, ENDOCRINOLOGY, V127, P567, DOI 10.1210/endo-127-2-567; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; DUTTON GR, 1990, METHODS NEUROSCIENCE, V2, P87; EISON M S, 1990, Journal of Clinical Psychopharmacology, V10, p26S; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; FARGIN A, 1989, J BIOL CHEM, V264, P14848; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GIRAL P, 1988, BIOL PSYCHIAT, V23, P237, DOI 10.1016/0006-3223(88)90034-0; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMON M, 1994, TRENDS PHARMACOL SCI, V15, P36, DOI 10.1016/0165-6147(94)90104-X; HENDRICKSON W, 1984, J MOL BIOL, V178, P611, DOI 10.1016/0022-2836(84)90241-9; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HOGAN B, 1986, MANIPULATING MOUSE E; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JHANWARUNIYAL M, 1994, BRAIN RES, V646, P247, DOI 10.1016/0006-8993(94)90086-8; JULIUS D, 1991, ANNU REV NEUROSCI, V14, P335, DOI 10.1146/annurev.neuro.14.1.335; KADESCH T, 1986, MOL CELL BIOL, V6, P2593, DOI 10.1128/MCB.6.7.2593; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KOBILKA BK, 1987, NATURE, V329, P75, DOI 10.1038/329075a0; LAUDER JM, 1983, PSYCHONEUROENDOCRINO, V8, P121, DOI 10.1016/0306-4530(83)90053-7; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maniatis T., 1982, MOL CLONING; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MARROCCO RT, 1994, CURR OPIN NEUROBIOL, V4, P166, DOI 10.1016/0959-4388(94)90067-1; MATSUDA T, 1991, EUR J PHARMACOL, V200, P299; MATTHIESSEN L, 1992, NEUROSCIENCE, V51, P475, DOI 10.1016/0306-4522(92)90331-U; MATTHIESSEN L, 1993, NEUROREPORT, V4, P763, DOI 10.1097/00001756-199306000-00042; Maxam A M, 1980, Methods Enzymol, V65, P499; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MENDELSON SD, 1991, NEUROENDOCRINOLOGY, V54, P454, DOI 10.1159/000125951; MIQUEL MC, 1991, NEUROCHEM INT, V19, P453, DOI 10.1016/0197-0186(91)90063-J; PARKS CL, 1988, J VIROL, V62, P54, DOI 10.1128/JVI.62.1.54-67.1988; PARKS CL, 1991, NUCLEIC ACIDS RES, V19, P7155, DOI 10.1093/nar/19.25.7155; POMPEIANO M, 1992, J NEUROSCI, V12, P440; PROUDFOOT NJ, 1986, NATURE, V322, P562, DOI 10.1038/322562a0; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHELNESS GS, 1984, J BIOL CHEM, V259, P9929; SHEPERD GM, 1988, NEUROBIOLOGY; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Singh H, 1990, Genet Eng (N Y), V12, P317; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SPECTOR DJ, 1982, J VIROL, V44, P544, DOI 10.1128/JVI.44.2.544-554.1982; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TRABER J, 1987, TRENDS PHARMACOL SCI, V8, P432, DOI 10.1016/0165-6147(87)90231-8; VALES LD, 1989, GENE DEV, V3, P49, DOI 10.1101/gad.3.1.49; VERGE D, 1991, NEUROCHEM INT, V19, P425, DOI 10.1016/0197-0186(91)90059-M; YOUNG AH, 1992, NEUROPHARMACOLOGY, V31, P433, DOI 10.1016/0028-3908(92)90080-9	81	196	204	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4417	4430						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626793				2022-12-27	WOS:A1996TW96000071
J	Uren, A; Yu, JC; Li, WQ; Chung, IY; Mahadevan, D; Pierce, JH; Heidaran, MA				Uren, A; Yu, JC; Li, WQ; Chung, IY; Mahadevan, D; Pierce, JH; Heidaran, MA			Identification of a domain within the carboxyl-terminal region of the beta platelet-derived growth factor (PDGF) receptor that mediates the high transforming activity of PDGF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; GTPASE-ACTIVATING PROTEIN; PHOSPHOLIPASE-C-GAMMA; SIGNAL TRANSDUCTION; TYROSINE KINASES; PHOSPHORYLATION SITES; BINDING; EXPRESSION; SUBUNIT; CELLS	We have reported previously that a chimeric platelet-derived growth factor receptor (PDGFR) possessing the ligand binding domain of the alpha PDGFR and the intracellular domain of the beta PDGFR (alpha(340)beta(342)R) was markedly more efficient than the wild type alpha PDGFR (alpha RWT) in its ability to enhance PDGF-A transforming activity in NIH/3T3 fibroblasts. To determine the region within the cytoplasmic domain of beta PDGFR that confers this higher transforming activity, we generated several additional alpha/beta PDGFR chimerae. When a chimeric PDGFR possessing the first 933 amino-terminal amino acids from the alpha PDGFR and the final 165 amino acids from the carboxyl-terminal of the beta PDGFR (alpha(933)beta(942)R) was cotransfected with the PDGF-A gene into NIH/3T3 cells, it showed a similar high efficiency to enhance PDGF-A chain transforming activity as alpha(340)beta(342)R. However, when chimeric PDGFRs in which either the kinase insert domain (alpha beta RKI) or the last 79 amino acids from the carboxyl-terminal end of the beta PDGFR (alpha(1024)beta(1028)R) were substituted into alpha PDGFR sequences were cotransfected with PDGF-A, they showed similar low efficiencies in enhancing transforming activity as the alpha RWT. These results predicted that the 86 amino acids following the tyrosine kinase 2 domain of beta PDGFR (amino acid residues 942-1027) were responsible for the higher transforming activity of beta PDGFR. To confirm this finding, we next constructed a chimera in which amino acid residues 942-1028 of the beta PDGFR (alpha beta(942-1028)R) were substituted for those in the alpha PDGFR. Cotransfection experiments indicated that alpha beta(942-1028)R increased transforming activity of PDGF-A to similar extent as the alpha(933)beta(942)R or alpha(340)beta(342)R. Therefore, our findings define a critical domain within the noncatalytic region of beta PDGFR intracellular domain that confers the higher focus forming activity mediated by the beta PDGFR.	NCI,CELLULAR & MOLEC BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BAZANET CE, 1994, ONCOGENE, V9, P517; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EK B, 1982, NATURE, V295, P419, DOI 10.1038/295419a0; ERIKSSON A, 1995, J BIOL CHEM, V270, P7773, DOI 10.1074/jbc.270.13.7773; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KIM HRC, 1994, J BIOL CHEM, V269, P30604; LAROCHELLE WJ, 1993, CELL GROWTH DIFFER, V4, P547; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MORI S, 1993, J BIOL CHEM, V268, P577; MORI S, 1994, J BIOL CHEM, V266, P21158; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; YU JC, 1995, J BIOL CHEM, V270, P7033, DOI 10.1074/jbc.270.13.7033; YU JC, 1994, J BIOL CHEM, V269, P10668	43	9	9	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11051	11054		10.1074/jbc.271.19.11051	http://dx.doi.org/10.1074/jbc.271.19.11051			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626645	hybrid			2022-12-27	WOS:A1996UJ94400005
J	Kolla, V; Lindner, DJ; Weihua, X; Borden, EC; Kalvakolanu, DV				Kolla, V; Lindner, DJ; Weihua, X; Borden, EC; Kalvakolanu, DV			Modulation of interferon (IFN)-inducible gene expression by retinoic acid - Up-regulation of STAT1 protein in IFN-unresponsive cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; FACTOR-ALPHA; GAMMA	Interferons (IFN) and retinoids failed to inhibit the growth of a number of breast tumor cell lines, However, a combination of these two biological response modifiers significantly suppressed the cell growth at pharmacologically achievable doses. The molecular basis for such enhancement was investigated in MCF-7, a breast tumor cell line resistant to growth inhibition by IFN-beta. Pretrentment of cells with retinoic acid (RA) for 16 h followed by IFN-beta, but not the converse, induced cytotoxic effects in the cells. Continuous presence of RA was not necessary, although it enhanced the degree of cell death when present. Further analyses revealed that IFN-beta failed to activate IFN-stimulated gene transcription. However, IFN-beta strongly up-regulated the gene expression in RA-pretreated cells. Both IFN-beta- and IFN-gamma-inducible gene expression were enhanced via a modulation of the transcriptional factor IFN-stimulated gene factors-3 and GAF binding to respective cognate regulatory elements. STAT1 was undetectable in these cells prior to RA treatment: RA increased the levels of this crucial regulator, thereby restoring IFN responses. Thus, BA augmentation of STAT1 may be an early step in the cooperative anti-tumor effects of IFN and RA.	UNIV MARYLAND,SCH MED,CTR CANC,DEPT MICROBIOL & IMMUNOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR CANC,DEPT MED,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR CANC,DEPT PHARMACOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR CANC,PROGRAM ONCOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR CANC,MOLEC & CELLULAR BIOL PROGRAM,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore			Lindner, Daniel/ABB-5440-2020; Xiao, Weihua/N-2775-2013	Xiao, Weihua/0000-0001-9102-6326				ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P4387, DOI 10.1093/nar/19.16.4387; AUGRET M, 1981, VIROLOGY, V114, P585; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BANDYOPADHYAY SK, 1995, J BIOL CHEM, V270, P19624, DOI 10.1074/jbc.270.33.19624; BOLLAG W, 1994, J CELL BIOCHEM, V56, P427, DOI 10.1002/jcb.240560402; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FONTANA JA, 1992, CANCER RES, V52, P3938; FOSTER GR, 1991, P NATL ACAD SCI USA, V88, P2888, DOI 10.1073/pnas.88.7.2888; GOLDSTEIN D, 1986, CANCER RES, V46, P4315; Gudas Lorraine J., 1994, P443; GUTCH MJ, 1991, P NATL ACAD SCI USA, V88, P7913, DOI 10.1073/pnas.88.18.7913; HIGUCHI T, 1991, CANCER RES, V51, P3958; HONG WK, 1994, RETINOIDS BIOL CHEM; Kalvakolanu DV, 1996, CANCER INVEST, V14, P25, DOI 10.3109/07357909609018435; KALVAKOLANU DVR, 1991, P NATL ACAD SCI USA, V88, P7459, DOI 10.1073/pnas.88.17.7459; KANDA K, 1992, MOL CELL BIOL, V12, P4930, DOI 10.1128/MCB.12.11.4930; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0; LIPPMAN SM, 1983, EUR J CANC A S5, V29, pS9; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Mangelsdorf David J., 1994, P319; MARTH C, 1987, INT J CANCER, V40, P840, DOI 10.1002/ijc.2910400623; MARTH C, 1986, J NATL CANCER I, V77, P1197; MATIKAINEN S, 1995, J INTERFERON CYTOKIN, V15, pS216; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PETRICOIN E, 1994, MOL CELL BIOL, V14, P1477, DOI 10.1128/MCB.14.2.1477; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; SILVERMAN RH, 1994, J INTERFERON RES, V14, P101, DOI 10.1089/jir.1994.14.101; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; WAKELING AE, 1989, J STEROID BIOCHEM, V34, P183, DOI 10.1016/0022-4731(89)90081-2; WONG LH, 1995, J INTERFERON CYTOKIN, V15, pS172; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	35	104	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10508	10514		10.1074/jbc.271.18.10508	http://dx.doi.org/10.1074/jbc.271.18.10508			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631848	hybrid			2022-12-27	WOS:A1996UJ34200016
J	Peist, H; SchneiderFresenius, C; Boos, W				Peist, H; SchneiderFresenius, C; Boos, W			The MalT-dependent and malZ-encoded maltodextrin glucosidase of Escherichia coli can be converted into a dextrinyltransferase by a single mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERIZATION; CLONING VEHICLES; STRUCTURAL GENE; ALPHA-AMYLASE; IDENTIFICATION; SYSTEM; DNA; REGULON; AMYLOMALTASE; CONSTRUCTION	malZ is a member of the mat regulon, It is controlled by MalT, the transcriptional activator of the maltose system, MalZ has been purified and identified as an enzyme hydrolyzing maltotriose and longer maltodextrins to glucose and maltose, MalZ is dispensable for growth on maltose or maltodextrins, Mutants lacking amylomaltase (encoded by malQ), the major maltose utilizing enzyme, cannot grow on maltose, maltotriose, or maltotetraose, despite the fact that they contain an effective transport system and MalZ, From such a mole mutant a pseudorevertant was isolated that was able to grow on maltose, The suppressor mutation was mapped in malZ, The mutant gene was cloned: It contained a Trp to Cys exchange at position 292 of the deduced protein sequence. Surprisingly, the purified mutant enzyme was still unable to hydrolyze maltose as was the wild type enzyme, while both were able to release glucose from maltodextrins. However, the mutant enzyme had gained the ability to transfer dextrinyl moieties to glucose, maltose, and other maltodextrins. Thus, it had gained an activity associated with amylomaltase, It was the MalZ292 associated transferase reaction that allowed the utilization of maltose, In addition, we discovered that mutant and wild type enzymes alike were highly active as gamma-cyclodextrinases.	UNIV KONSTANZ,DEPT BIOL,D-78434 CONSTANCE,GERMANY	University of Konstanz								ADHYA S, 1971, J BACTERIOL, V108, P621, DOI 10.1128/JB.108.2.621-626.1971; BELEV TN, 1991, PLASMID, V26, P147, DOI 10.1016/0147-619X(91)90056-3; BENDER H, 1994, CARBOHYD RES, V260, P119, DOI 10.1016/0008-6215(94)80026-X; BENDER H, 1994, CARBOHYD RES, V263, P123, DOI 10.1016/0008-6215(94)00145-6; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BOOS W, 1996, REGULATION GENE EXPR; BOOS W, 1996, IN PRESS ESCHERICHIA; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DECKER K, 1993, J BACTERIOL, V175, P5655, DOI 10.1128/JB.175.17.5655-5665.1993; DESSEIN A, 1974, EUR J BIOCHEM, V45, P363, DOI 10.1111/j.1432-1033.1974.tb03561.x; EHRMANN M, 1987, J BACTERIOL, V169, P3539, DOI 10.1128/jb.169.8.3539-3545.1987; FREUNDLIEB S, 1988, J BIOL CHEM, V263, P314; FREUNDLIEB S, 1986, J BIOL CHEM, V261, P2946; GAREN A, 1960, BIOCHIM BIOPHYS ACTA, V38, P470, DOI 10.1016/0006-3002(60)91282-8; HATFIELD D, 1969, J BACTERIOL, V98, P559, DOI 10.1128/JB.98.2.559-567.1969; HENGGEARONIS R, 1992, MOL MICROBIOL, V6, P1877, DOI 10.1111/j.1365-2958.1992.tb01360.x; HOFNUNG M, 1971, J MOL BIOL, V61, P681, DOI 10.1016/0022-2836(71)90072-6; HOFNUNG M, 1976, MOL GEN GENET, V145, P207, DOI 10.1007/BF00269595; LU M, 1994, J BACTERIOL, V176, P5847, DOI 10.1128/JB.176.18.5847-5851.1994; LUCHT JM, 1992, J BACTERIOL, V174, P1709, DOI 10.1128/jb.174.5.1709-1710.1992; Miller J.H., 1972, EXPT MOL GENETICS; PALM D, 1985, NATURE, V313, P500, DOI 10.1038/313500a0; PALMER TN, 1976, EUR J BIOCHEM, V69, P105, DOI 10.1111/j.1432-1033.1976.tb10863.x; PODKOVYROV SM, 1992, J BACTERIOL, V174, P5400, DOI 10.1128/JB.174.16.5400-5405.1992; PUGSLEY AP, 1988, MOL MICROBIOL, V2, P473, DOI 10.1111/j.1365-2958.1988.tb00053.x; RAIBAUD O, 1989, J MOL BIOL, V205, P471, DOI 10.1016/0022-2836(89)90218-0; RAIBAUD O, 1987, J BACTERIOL, V169, P3059, DOI 10.1128/jb.169.7.3059-3061.1987; REYES M, 1986, J BACTERIOL, V165, P918, DOI 10.1128/jb.165.3.918-922.1986; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER E, 1992, J BIOL CHEM, V267, P5148; SCHWARTZ M, 1967, EUR J BIOCHEM, V2, P132, DOI 10.1111/j.1432-1033.1967.tb00117.x; SCHWARTZ M, 1987, ESCHERICHIA COLI SAL, V2, P1482; Silhavy T. J., 1984, EXPT GENE FUSIONS; SINGER M, 1989, MICROBIOL REV, V53, P1; TAPIO S, 1991, J BIOL CHEM, V266, P19450; WEICHART D, 1993, MOL MICROBIOL, V10, P407, DOI 10.1111/j.1365-2958.1993.tb02672.x; WIESMEYER H, 1960, BIOCHIM BIOPHYS ACTA, V39, P427, DOI 10.1016/0006-3002(60)90195-5; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220	42	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10681	10689		10.1074/jbc.271.18.10681	http://dx.doi.org/10.1074/jbc.271.18.10681			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631875	hybrid			2022-12-27	WOS:A1996UJ34200043
J	Straus, DB; Chan, AC; Patai, B; Weiss, A				Straus, DB; Chan, AC; Patai, B; Weiss, A			SH2 domain function is essential for the role of the Lck tyrosine kinase in T cell receptor signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; ZETA-CHAIN; PHOSPHOLIPASE C-GAMMA-1; THYMOCYTE DEVELOPMENT; MICE LACKING; P56LCK; ACTIVATION; PHOSPHORYLATION; ZAP-70; LINE	Tyrosine kinase activity is required for signal transduction through the T cell antigen receptor (TCR), The Src family tyrosine kinase Lck appears to play a key role in the initiation of TCR signaling events. We have investigated the role of the phosphotyrosine-binding Src homology-2 (SH2), domain of Lck in TCR signaling. Lck containing a mutation in the phosphotyrosine binding pocket of the SH2 domain was expressed in an Lck-deficient cell line, We found that, in contrast to wild-type Lck, the SH2 domain mutant was unable to restore even the earliest TCR-mediated signaling events, To investigate the role of the Lck SH2 domain, we examined the association of tyrosine phosphoproteins with Lck, The predominant associated phosphoprotein was the ZAP-70 tyrosine kinase, which has also been implicated in the initiation of TCR signaling, In addition, the zeta subunit of the T cell receptor was found to weakly associate with Lck. Further analysis indicated that the SH2 domain of Lck can directly recognize both ZAP-70 and zeta in immunoprecipitates from TCR-stimulated cells. Our findings demonstrate that the SH2 domain of Lck is essential for the initiation of signaling events following TCR stimulation probably as a result of-its ability to mediate an interaction between Lck and the ZAP-70 tyrosine kinase and/or the zeta subunit of the T cell receptor.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT MED, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco	Straus, DB (corresponding author), UNIV CHICAGO, DEPT MED, 5841 S MARYLAND AVE, MC6084, CHICAGO, IL 60637 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039553] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39553] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BU JY, 1995, P NATL ACAD SCI USA, V92, P5106, DOI 10.1073/pnas.92.11.5106; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P2183, DOI 10.1002/eji.1830191202; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LUO KX, 1992, MOL CELL BIOL, V12, P4724, DOI 10.1128/MCB.12.10.4724; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; SALCEDO TW, 1993, J EXP MED, V177, P1475, DOI 10.1084/jem.177.5.1475; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SEFTON BM, 1994, CURR OPIN IMMUNOL, V6, P372, DOI 10.1016/0952-7915(94)90115-5; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; VEILLETTE A, 1992, ONCOGENE, V7, P971; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	48	91	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9976	9981		10.1074/jbc.271.17.9976	http://dx.doi.org/10.1074/jbc.271.17.9976			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626636	hybrid			2022-12-27	WOS:A1996UG25700020
J	Sasaguri, T; Ishida, A; Kosaka, C; Nojima, H; Ogata, J				Sasaguri, T; Ishida, A; Kosaka, C; Nojima, H; Ogata, J			Phorbol ester inhibits the phosphorylation of the retinoblastoma protein without suppressing cyclin D-associated kinase in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MEDIATED INHIBITION; GENE-PRODUCT; DNA-SYNTHESIS; GROWTH-INHIBITION; DEPENDENT KINASE; TGF-BETA; EXPRESSION; PROLIFERATION; ACTIVATION; ARREST	To elucidate the role of protein kinase C in vascular smooth muscle cell proliferation, we examined the effects of phorbol 12-myristate 13-acetate (PMA) on G(1) events in human arterial cells. About 15 h after G(0) cells were stimulated with fetal bovine serum and basic fibroblast growth factor, [H-3]thymidine incorporation started. PMA (10 nM) inhibited the incorporation over 90% when added earlier than 3 h after stimulation, but had no effect when added 12 h or later. PMA inhibited the phosphorylation of the retinoblastoma protein (pRb), which normally began at about 9 h. PMA did not inhibit the gene expression of Cdk2, Cdk3, Cdk4, Cdk5, and cyclins G, C, and D, all of which began at 0-3 h. However, PMA reduced the expression of cyclins E and A, which usually began at 3-9 h and about 15 h, respectively. PMA inhibited the histone H1 kinase activity of Cdk2, which increased from about 9 h, whereas PMA did not inhibit the pRb kinase activities of cyclin D-associated kinase(s) and Cdk4, detectable from 0-3 h. These results suggested that the PMA-induced inhibition of pRb phosphorylation is not mediated by suppressing cyclin D-associated kinase(s) including Cdk4, but involves the suppression of Cdk2 activity that results hom the reduced expression of cyclins E and A.	OSAKA UNIV, MICROBIAL DIS RES INST, SUITA, OSAKA 565, JAPAN	Osaka University	Sasaguri, T (corresponding author), NATL CARDIOVASC CTR, RES INST, DEPT BIOSCI, 5-7-1 FUJISHIRO DAI, SUITA, OSAKA 565, JAPAN.							AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COCKS BG, 1992, J BIOL CHEM, V267, P12307; COPPOCK DL, 1992, CELL GROWTH DIFFER, V3, P485; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HASS R, 1993, CELL GROWTH DIFFER, V4, P159; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HUANG CL, 1987, NATURE, V329, P849, DOI 10.1038/329849a0; JACKSON CL, 1992, HYPERTENSION, V20, P713, DOI 10.1161/01.HYP.20.6.713; KARIYA K, 1987, EXP CELL RES, V173, P504, DOI 10.1016/0014-4827(87)90290-4; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kosaka C, 1996, AM J PHYSIOL-CELL PH, V270, pC170, DOI 10.1152/ajpcell.1996.270.1.C170; KOSAKA C, 1993, BIOCHEM BIOPH RES CO, V193, P991, DOI 10.1006/bbrc.1993.1723; LEE MW, 1994, AM J PHYSIOL, V267, pC659, DOI 10.1152/ajpcell.1994.267.3.C659; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLASHAW NE, 1988, ADV SEC MESS PHOSPH, V22, P139; OWEN NE, 1985, J CELL BIOL, V101, P454, DOI 10.1083/jcb.101.2.454; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; SASAGURI T, 1992, EXP CELL RES, V200, P351, DOI 10.1016/0014-4827(92)90182-8; SASAGURI T, 1993, EXP CELL RES, V208, P311, DOI 10.1006/excr.1993.1251; SASAGURI T, 1994, INT CONGR SER, V1051, P177; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SING GK, 1990, CELL GROWTH DIFFER, V1, P549; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; TOKER A, 1994, J BIOL CHEM, V269, P32358; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YOKOTA T, 1992, ARTERIOSCLER THROMB, V12, P1393, DOI 10.1161/01.ATV.12.12.1393	56	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8345	8351		10.1074/jbc.271.14.8345	http://dx.doi.org/10.1074/jbc.271.14.8345			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626531	hybrid			2022-12-27	WOS:A1996UD60000071
J	Sasaoka, T; Langlois, WJ; Bai, F; Rose, DW; Leitner, JW; Decker, SJ; Saltiel, AR; Gill, GN; Kobayashi, M; Draznin, B; Olefsky, JM				Sasaoka, T; Langlois, WJ; Bai, F; Rose, DW; Leitner, JW; Decker, SJ; Saltiel, AR; Gill, GN; Kobayashi, M; Draznin, B; Olefsky, JM			Involvement of ErbB2 in the signaling pathway leading to cell cycle progression from a truncated epidermal growth factor receptor lacking the C-terminal autophosphorylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; TYROSINE PHOSPHORYLATION; EGF RECEPTOR; GUANINE-NUCLEOTIDES; MOLECULAR-CLONING; RAS; PROTEIN; GRB2; KINASE; TRANSFORMATION	To investigate the mechanisms underlying the enhanced mitogenic activity of the truncated epidermal growth factor receptor (EGFR) lacking the C-terminal autophosphorylation sites (Delta 973-EGFR), we studied the intracellular signaling pathways in NR6 cells expressing human wild type EGFR and Delta 973-EGFR. Microinjection of dominant/negative p21(ras) (N17) completely inhibited EGF-induced DNA synthesis in both cell types. EGF stimulated Shc phosphorylation as well as the formation of mild type EGFR . Shc complexes. In contrast, EGF stimulated Shc phosphorylation without formation of Delta 973-EGFR . Shc complexes. Tyrosine-phosphorylated Shc formed complexes with Grb2 . Sos, and microinjection of anti-ghc antibody and Shc-SH2 GST fusion protein inhibited EGF stimulation of DNA synthesis in both cell lines. EGF markedly increased ErbB2 tyrosine phosphorylation in wild type EGFR cells. In Delta 973-EGFR cells, ErbB2 was tyrosine phosphorylated in the basal state and EGFR stimulated further phosphorylation of ErbB2. In addition to ErbB2, additional proteins were tyrosine phosphorylated in Delta 973-EGFR cells, mostly in the molecular mass range of 120-170 kDa. Taken together with our findings indicating coupling of ErbB2 to Shc, these data suggest the importance of an alternative signaling pathway in Delta 973-EGFR cells mediated by the formation of heterodimeric structures between the truncated EGFR and ErbB2, followed by coupling through Shc to Grb2 . Sos and the p21(ras) pathway, ultimately leading to mitogenesis.	UNIV CALIF SAN DIEGO,DEPT MED 0673,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; TOYAMA MED & PHARMACEUT UNIV,DEPT MED 1,TOYAMA 93001,JAPAN; VET ADM MED CTR,MED RES SERV,SAN DIEGO,CA 92161; WARNER LAMBERT PARKE DAVIS,PHARMACEUT RES DIV,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80220; VET AFFAIRS MED CTR,DEPT MED,DENVER,CO 80220; VET AFFAIRS MED CTR,MED RES SERV,DENVER,CO 80220	University of California System; University of California San Diego; University of Toyama; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pfizer; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NIDDK NIH HHS [DK13149, DK33651] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013149, R37DK033651, R37DK013149, R01DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DECKER SJ, 1989, J BIOL CHEM, V264, P17641; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; JHUN BH, 1994, J BIOL CHEM, V269, P5699; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LANGLOIS WJ, 1994, ENDOCRINOLOGY, V135, P2412, DOI 10.1210/en.135.6.2412; LI BQ, 1993, P NATL ACAD SCI USA, V90, P8504, DOI 10.1073/pnas.90.18.8504; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MASUI H, 1991, CANCER RES, V51, P6170; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; QIAN XL, 1994, ONCOGENE, V9, P1507; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SEGATTO O, 1993, ONCOGENE, V8, P2105; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SOLER C, 1994, J BIOL CHEM, V269, P12320; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; ULLICH A, 1984, NATURE, V309, P418; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	52	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8338	8344		10.1074/jbc.271.14.8338	http://dx.doi.org/10.1074/jbc.271.14.8338			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626530	hybrid			2022-12-27	WOS:A1996UD60000070
J	Sekar, MC; Sambandam, V; Grizzle, WE; McDonald, JM				Sekar, MC; Sambandam, V; Grizzle, WE; McDonald, JM			Dissociation of cyclic inositol phosphohydrolase activity from annexin III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-BINDING-PROTEINS; 1,2-CYCLIC 4,5-TRISPHOSPHATE; PHOSPHATE 2-PHOSPHOHYDROLASE; BILAYER-MEMBRANES; HUMAN NEUTROPHILS; CELLS; CALCIUM; STIMULATION; MYOINOSITOL; EXPRESSION	Cyclic inositol phosphohydrolase is a phosphodiesterase that cleaves the cyclic bond of cyclic inositol monophosphate, In 1990, Boss ct at (Boss, T. S., Tait, J. F., and Majerus, P. W. (1990) Science 248, 605-607) purified this enzyme from human placenta and reported that cyclic inositol phosphohydrolase is identical to annexin III, Independent confirmation of this finding has not been provided. The relative distribution of annexin III and cyclic inositol phosphohydrolase activity in rat kidney and spleen indicated that annexin III can be dissociated hom cyclic inositol phosphohydrolase activity, Rat spleen contains large quantities of annexin III, but has very little cyclic inositol phosphohydrolase activity, In contrast, rat kidney, one of the richest sources of cyclic inositol phosphohydrolase activity, possesses very little (immunohistochemistry) or no (Western blot) annexin IIIm. similar to cytosol of human placenta, cytosol of guinea pig kidney contains both annexin III and cyclic inositol phosphohydrolase. On SDS-gel electrophoresis, guinea pig kidney annexin III has a slightly different mobility than the human placental annexin III. Human placental annexin III co-migrates with cyclic inositol phosphohydrolase on ion exchange chromatography, while guinea pig kidney annexin III is clearly dissociated from cyclic inositol phosphohydrolase on ion exchange chromatography. Both guinea pig kidney annexin III and human placental annexin III pellet with the addition of calcium and centrifugation, while cyclic inositol phosphohydrolase activity in both of these tissues remains in the supernatant. Our studies clearly show that cyclic inositol phosphohydrolase and annexin III are two different proteins.			Sekar, MC (corresponding author), UNIV ALABAMA,DEPT PATHOL,LHRB 528,BIRMINGHAM,AL 35294, USA.				NCI NIH HHS [CA57381] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA057381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BINDER H, 1985, ANAL BIOCHEM, V148, P220, DOI 10.1016/0003-2697(85)90649-9; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; CRUMPTON MJ, 1990, NATURE, V345, P212, DOI 10.1038/345212a0; DAWSON RMC, 1972, BIOCHEM J, V127, P113, DOI 10.1042/bj1270113; DIAZMUNOZ M, 1990, J BIOL CHEM, V265, P15894; DIXON JF, 1987, BIOCHEM BIOPH RES CO, V149, P1208, DOI 10.1016/0006-291X(87)90536-5; DOLHOFER R, 1987, J CLIN CHEM CLIN BIO, V25, P733; ERNST JD, 1989, BIOCHEM BIOPH RES CO, V161, P959, DOI 10.1016/0006-291X(89)91336-3; ERNST JD, 1990, J CLIN INVEST, V85, P1065, DOI 10.1172/JCI114537; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; HULLIN F, 1989, J BIOL CHEM, V264, P3506; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3392; ISHII H, 1986, P NATL ACAD SCI USA, V83, P6397, DOI 10.1073/pnas.83.17.6397; JUNGALWALA FB, 1971, BIOCHEM J, V123, P19, DOI 10.1042/bj1230019; KAETZEL MA, 1989, J BIOL CHEM, V264, P14463; KOCH MA, 1974, BIOCHEM BIOPH RES CO, V58, P361, DOI 10.1016/0006-291X(74)90373-8; LECABEC V, 1992, BIOCHEM BIOPH RES CO, V189, P1471, DOI 10.1016/0006-291X(92)90240-L; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MYERS RB, 1993, MODERN PATHOL, V6, P733; PEPINSKY RB, 1988, J BIOL CHEM, V263, P10799; POLLARD HB, 1988, P NATL ACAD SCI USA, V85, P2974, DOI 10.1073/pnas.85.9.2974; ROJAS E, 1990, J BIOL CHEM, V265, P21207; ROSS TS, 1991, J BIOL CHEM, V266, P9086; ROSS TS, 1991, J BIOL CHEM, V266, P851; ROSS TS, 1992, J BIOL CHEM, V267, P19924; ROSS TS, 1986, J BIOL CHEM, V261, P1119; ROSS TS, 1990, SCIENCE, V248, P605, DOI 10.1126/science.2159184; SALLES JP, 1993, J BIOL CHEM, V268, P12805; SEKAR MC, 1987, J BIOL CHEM, V262, P340; SHAYMAN JA, 1986, BIOCHIM BIOPHYS ACTA, V888, P171, DOI 10.1016/0167-4889(86)90018-2; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; TARVER AP, 1987, J BIOL CHEM, V262, P17268; WILSON DB, 1985, P NATL ACAD SCI USA, V82, P4013, DOI 10.1073/pnas.82.12.4013; WILSON KM, 1990, J BIOL CHEM, V265, P17601; WIRL G, 1990, J CELL PHYSIOL, V144, P511, DOI 10.1002/jcp.1041440320	36	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8295	8299		10.1074/jbc.271.14.8295	http://dx.doi.org/10.1074/jbc.271.14.8295			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626524	hybrid			2022-12-27	WOS:A1996UD60000064
J	Ladner, RD; Carr, SA; Huddleston, MJ; McNulty, DE; Caradonna, SJ				Ladner, RD; Carr, SA; Huddleston, MJ; McNulty, DE; Caradonna, SJ			Identification of a consensus cyclin-dependent kinase phosphorylation site unique to the nuclear form of human deoxyuridine triphosphate nucleotidohydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; DUTP NUCLEOTIDOHYDROLASE; PROTEIN-KINASES; FAMILY; MITOSIS; CELLS	In the preceding report (Ladner, R. D., McNulty, D. E., Carr, S. A., Roberts, G. D., and Caradonna, S. J. (1996) J. Biol. Chem. 271, 7745-7751, we identified two distinct isoforms of dUTPase in human cells. These isoforms are individually targeted to the nucleus (DUT-N) and mitochondria (DUT-M). The proteins are nearly identical, differing only in a short region of their amino termini. Despite the structural differences between these proteins, they retain identical affinities for dUTP (preceding article). In previous work, this laboratory demonstrated that dUTPase is posttranslationally phosphorylated on serine residue(s) (Lirette, R., and Caradonna, S. (1990) J. Cell. Biochem. 43, 339-353). To extend this work and determine if both isoforms of dUTPase are phosphorylated, a more in depth analysis of dUTPase phosphorylation was undertaken. [P-32]Orthophosphate-labeled dUTPase was purified from HeLa cells, revealing that only the nuclear form of dUTPase is phosphorylated. Electrospray tandem mass spectrometry was used to identify the phosphorylation site as Ser-11 in the amino-terminal tryptic peptide PCSEETPAIpSPSKR (the NH2-terminal Met is removed in the mature protein). Mutation of Ser-11 by replacement with Ala blocks phosphorylation of dUTPase in vivo. Analysis of the wild type and Ser-11 --> Ala mutant indicates that phosphorylation does not regulate the enzymatic activity of the DUT-N protein in vitro. Additionally, experiments with the Ser-11 --> Ala mutant indicate that phosphorylation does not appear to play a role in subunit association of the nuclear form of dUTPase. The amino acid context of this phosphorylation site corresponds to the consensus target sequence for the cyclin-dependent protein kinase p34(cdc2). Recombinant DUT-N was specifically phosphorylated on Ser-11 in vitro with immunoprecipitated p34(cdc2). Together, these data suggest that the nuclear form of dUTPase may be a target for cyclin-dependent kinase phosphorylation in vivo.	SMITHKLINE BEECHAM PHARMACEUT, DEPT PROT BIOCHEM, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT PHYS & STRUCT CHEM, KING OF PRUSSIA, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline	Ladner, RD (corresponding author), UNIV MED & DENT NEW JERSEY, SCH OSTEOPATH MED, DEPT MOLEC BIOL, 2 MED CTR DR, STRATFORD, NJ 08084 USA.		Caradonna, Salvatore/AFU-8514-2022; Carr, Steven A./AAH-8366-2019	Caradonna, Salvatore/0000-0002-2104-581X; 	NCI NIH HHS [CA42605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042605] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; CARADONNA SJ, 1984, J BIOL CHEM, V259, P5459; CARR SA, 1991, ANAL CHEM, V63, P2802, DOI 10.1021/ac00024a003; CEDERGRENZEPPEZAUER ES, 1992, NATURE, V355, P740, DOI 10.1038/355740a0; CLIMIE S, 1994, PROTEIN EXPRES PURIF, V5, P252, DOI 10.1006/prep.1994.1038; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Ladner RD, 1996, J BIOL CHEM, V271, P7745, DOI 10.1074/jbc.271.13.7745; LIRETTE R, 1990, J CELL BIOCHEM, V43, P339, DOI 10.1002/jcb.240430406; MCGEOCH DJ, 1990, NUCLEIC ACIDS RES, V18, P4105, DOI 10.1093/nar/18.14.4105; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; PINES J, 1990, New Biologist, V2, P389; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SEFTON BM, 1991, METHOD ENZYMOL, V201, P245; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SMITH RD, 1990, ANAL CHEM, V62, P882, DOI 10.1021/ac00208a002; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAHLER JR, 1993, P NATL ACAD SCI USA, V90, P4991, DOI 10.1073/pnas.90.11.4991; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241	22	36	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7752	7757		10.1074/jbc.271.13.7752	http://dx.doi.org/10.1074/jbc.271.13.7752			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631817	hybrid			2022-12-27	WOS:A1996UC77400085
J	Cvejic, S; Trapaidze, N; Cyr, C; Devi, LK				Cvejic, S; Trapaidze, N; Cyr, C; Devi, LK			Thr(353), located within the COOH-terminal tail of the delta opiate receptor, is involved in receptor down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; NG108-15 HYBRID-CELLS; OPIOID RECEPTOR; C ACTIVATION; DESENSITIZATION; EXPRESSION; TRUNCATION; INCREASES	Prolonged exposure to abused drugs such as opiates causes decreased response to the drug; this reduced sensitivity is thought to be due to the loss of receptors, or down-regulation. The molecular mechanism of the opiate receptor down-regulation is not known. In order to address this, we generated a number of mutants of the delta opiate receptor COOH-terminal tail, When expressed in the Chinese hamster ovary cells, both the wild type and the receptor with a deletion of 37 COOH-terminal residues bind diprenorphine with comparable affinities and show similar decreases in cAMP levels in response to D-Ala(2), D-Leu(5), enkephalin (DADLE), However, the truncated receptor does not show down-regulation from the cell surface upon prolonged exposure (2-48 h) to DADLE, In contrast, both the wild type receptor and the receptor with the deletion of only 15 COOH-terminal residues show substantial down-regulation upon long term DADLE treatment, These results suggest that the region located between 15 and 37 residues from the COOH terminus is involved in the receptor down-regulation, In order to identify residues that play a key role in down-regulation, point mutations of residues within this region were examined for their ability to modulate receptor down-regulation. The receptor with a mutation of Thr(353) to Ala does not down-regulate, whereas the receptor with a mutation of Ser(344) to Gly down-regulates with a time course similar to that of the wild type receptor, Taken together, these results suggest that the COOH-terminal tail is not essential for functional coupling but is necessary for down-regulation and that Thr(353) is critical for the agonist-mediated down-regulation of the delta opiate receptor.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University					NIDA NIH HHS [DA-07254, DA8863] Funding Source: Medline; NINDS NIH HHS [NS1788] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA008863, R56DA008863, T32DA007254, R01DA008863] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BENYA RV, 1995, J BIOL CHEM, V270, P3346, DOI 10.1074/jbc.270.7.3346; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CHEN Y, 1994, J BIOL CHEM, V269, P7839; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; GUCKER S, 1992, MOL PHARMACOL, V42, P656; HERTEL C, 1990, J BIOL CHEM, V265, P17988; Herz A., 1993, OPIOIDS; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; LAW PY, 1994, J PHARMACOL EXP THER, V271, P1686; LAW PY, 1982, MOL PHARMACOL, V22, P1; LAW PY, 1984, J BIOL CHEM, V259, P4096; LAW PY, 1995, J PHARMACOL EXP THER, V272, P322; LIGETT SB, 1989, MOL PHARMACOL, V36, P641; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; MIYAMAE T, 1993, FEBS LETT, V333, P311, DOI 10.1016/0014-5793(93)80677-M; PARKER EM, 1991, J BIOL CHEM, V266, P9987; PEI G, 1995, MOL PHARMACOL, V48, P173; PETANCESKA S, 1992, J BIOL CHEM, V267, P26038; PRATHER PL, 1995, MOL BRAIN RES, V29, P336, DOI 10.1016/0169-328X(94)00264-F; RAYNOR K, 1993, MOL PHARMACOL, V44, P385; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; SWOPE SL, 1990, MOL PHARMACOL, V37, P758; UHL GR, 1994, TRENDS NEUROSCI, V17, P89, DOI 10.1016/0166-2236(94)90110-4; VANETTI M, 1993, FEBS LETT, V331, P260, DOI 10.1016/0014-5793(93)80349-Y; WANG Z, 1994, LIFE SCI, V54, P330; YANG J, 1993, MOL PHARMACOL, V44, P1158	27	90	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4073	4076						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626742				2022-12-27	WOS:A1996TW96000020
J	Kuo, YM; Emmerling, MR; VigoPelfrey, C; Kasunic, TC; Kirkpatrick, JB; Murdoch, GH; Ball, MJ; Roher, AE				Kuo, YM; Emmerling, MR; VigoPelfrey, C; Kasunic, TC; Kirkpatrick, JB; Murdoch, GH; Ball, MJ; Roher, AE			Water-soluble A beta (N-40, N-42) oligomers in normal and Alzheimer disease brains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLAQUE CORE PROTEIN; AMYLOID DEPOSITS; APOLIPOPROTEIN-E; MUSCLE-CELLS; PEPTIDE; DEGENERATION; DIAGNOSIS	Ultracentrifugation and graded molecular sieving, as well as a sensitive sandwich enzyme-linked immunosorbent assay were used to isolate and quantitate the amounts of water-soluble oligomers of beta amyloid (A beta) peptides N-40 and N-42 in cerebral cortex of normal and Alzheimer disease (AD) brains. AD brains contained 6-fold more water-soluble A beta (wsA beta) than control brains. The majority of water-soluble peptides in most AD cases was A beta N-42, representing 12 times the amount found in control brains, The wsA beta was present in the form of monomers and oligomers ranging from less than 10 kDa to greater than 100 kDa. The amount of wsA beta N-42 in AD brains is about 50 times greater than the level of soluble A beta N-42 found in the CSF of AD patients. This disparity may be due to the rapid association of wsA beta N-42 into fibrillar deposits and/or to the integrity of the anatomical barriers which separate the two extracellular spaces. In this paper, me consider soluble any form of A beta which has not yet polymerized into its insoluble, filamentous form. This includes both the newly synthesized forms of A beta and those peptides which may be loosely attached to insoluble filaments but which can, nevertheless, still be considered soluble. It has been previously shown that, once it has aggregated into its filamentous form, the A beta peptides are resistant to disaggregation and degradation by a number of denaturing agents and aqueous buffers containing proteolytic enzymes. Therefore, it is likely that the water-soluble A beta peptides we quantified are precursors to its insoluble, filamentous form. Consequently, reducing the levels of soluble A beta in AD brains could have profound effects on AD pathophysiology.	SUN HLTH RES INST,SUN CITY,AZ 85372; WARNER LAMBERT PARKE DAVIS,ANN ARBOR,MI 48106; ATHENA NEUROSCI INC,S SAN FRANCISCO,CA 94080; WAYNE STATE UNIV,SCH MED,DEPT ANAT & CELL BIOL,DETROIT,MI 48201; OREGON HLTH SCI UNIV,DEPT PATHOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT NEUROL,PORTLAND,OR 97201; BAYLOR COLL MED,DEPT PATHOL,ALZHEIMER DIS RES CTR,HOUSTON,TX 77030	Banner Research; Banner Health; Banner Sun Health Research Institute; Pfizer; Wayne State University; Oregon Health & Science University; Oregon Health & Science University; Baylor College of Medicine			Kuo, Yu-Min/A-9050-2013	Kuo, Yu-Min/0000-0003-4867-2482	NATIONAL INSTITUTE ON AGING [R01AG011925, P50AG008664, P30AG008017] Funding Source: NIH RePORTER; NIA NIH HHS [5P50AG-08664, AG-11925, P30AG-08017] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; CORIA F, 1989, J NEUROPATH EXP NEUR, V48, P368, DOI 10.1097/00005072-198905000-00207; GOWING E, 1994, J BIOL CHEM, V269, P10987; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HARIGAYA Y, 1995, BIOCHEM BIOPH RES CO, V211, P1015, DOI 10.1006/bbrc.1995.1912; HIXSON JE, 1990, J LIPID RES, V31, P545; KAWAI M, 1993, BRAIN RES, V623, P142, DOI 10.1016/0006-8993(93)90021-E; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MIRRA SS, 1993, ARCH PATHOL LAB MED, V117, P132; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; POTTER H, 1992, PROG BRAIN RES, V94, P447; ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016; ROHER A, 1986, P NATL ACAD SCI USA, V83, P2662, DOI 10.1073/pnas.83.8.2662; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; TABATON M, 1994, BIOCHEM BIOPH RES CO, V200, P1598, DOI 10.1006/bbrc.1994.1634; TAMAOKA A, 1994, BIOCHEM BIOPH RES CO, V205, P834, DOI 10.1006/bbrc.1994.2740; VIGOPELFREY C, 1994, SOC NEUROSCI, V20, P437; ZHANG ET, 1990, J ANAT, V170, P111	27	535	587	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4077	4081						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626743				2022-12-27	WOS:A1996TW96000021
J	Morii, M; Hayata, Y; Mizoguchi, K; Takeguchi, N				Morii, M; Hayata, Y; Mizoguchi, K; Takeguchi, N			Oligomeric regulation of gastric H+,K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATPASE ACTIVITY; H,K-ATPASE; BINDING; PHOSPHOENZYME; CONDUCTANCE; OMEPRAZOLE; INHIBITORS; SCH-28080; E3810; SITE	The H+,K+-ATPase of intact gastric vesicles has two K-m values for ATP hydrolysis, 7 and 80 mu M. Irradiation of vesicles with ultraviolet light in the presence of 1 mM ATP resulted in K+-ATPase activity that shows only the low affinity ATP binding, The irradiation stimulated or inhibited proton uptake rate compared with control vesicles at high or low ATP concentrations, respectively, The relation between proton uptake rate and K+-ATPase activity at different ATP concentrations was linear with irradiated vesicles and nonlinear with control vesicles. These results indicate that hydrolysis at the high affinity ATP binding site regulates the energy transport coupling in negative and positive manners at high and low ATP concentrations, respectively. The complete inhibition of K+-ATPase by a specific proton pump inhibitor E3810 (rabeprazole) (2-{[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl}-1H-benzimidazole sodium salt) occurred when E3810 bound to half of the alpha-subunit of H+,K+-ATPase in unirradiated vesicles at both 200 and 10 mu M ATP, whereas the complete inhibition of proton uptake occurred when E3810 bound to half or a quarter of the alpha-subunit at 200 or 10 mu M ATP, respectively, These results suggest that dimeric interaction between the alpha-subunits is necessary for the enzyme activity at all ATP concentrations and that dimeric or tetrameric interaction is necessary for proton transport at high or low ATP concentrations, respectively.			Morii, M (corresponding author), TOYAMA MED & PHARMACEUT UNIV,FAC PHARMACEUT SCI,2630 SUGITANI,TOYAMA 93001,JAPAN.							ADAM H, 1961, BIOCHEM Z, V335, P25; ASANO S, 1992, J BIOL CHEM, V267, P6590; ASKARI A, 1982, BIOCHEM BIOPH RES CO, V104, P1447, DOI 10.1016/0006-291X(82)91412-7; BLANCO G, 1994, P NATL ACAD SCI USA, V91, P8542, DOI 10.1073/pnas.91.18.8542; CHOW DC, 1992, AM J PHYSIOL, V263, pC39, DOI 10.1152/ajpcell.1992.263.1.C39; FALLER LD, 1991, BIOCHEMISTRY-US, V30, P3503, DOI 10.1021/bi00228a022; GANSER AL, 1973, BIOCHIM BIOPHYS ACTA, V307, P169, DOI 10.1016/0005-2736(73)90035-7; HEBERT H, 1992, FEBS LETT, V299, P159, DOI 10.1016/0014-5793(92)80237-B; HELMICHDEJONG ML, 1986, BIOCHIM BIOPHYS ACTA, V860, P641, DOI 10.1016/0005-2736(86)90564-X; KEELING DJ, 1988, BIOCHEM PHARMACOL, V37, P2231, DOI 10.1016/0006-2952(88)90586-2; KOSTER JC, 1995, J BIOL CHEM, V270, P14332, DOI 10.1074/jbc.270.24.14332; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORII M, 1993, J BIOL CHEM, V268, P21553; MORII M, 1990, BIOCHEM PHARMACOL, V39, P661, DOI 10.1016/0006-2952(90)90143-9; OLIVER IT, 1955, BIOCHEM J, V61, P116, DOI 10.1042/bj0610116; RABON E, 1986, J BIOL CHEM, V261, P1434; RABON EC, 1990, J BIOL CHEM, V265, P19594; SCHARSCHMIDT BF, 1979, J LAB CLIN MED, V93, P790; SHULL GE, 1986, J BIOL CHEM, V261, P6788; TAKEGUCHI N, 1983, J BIOL CHEM, V258, P3094; TAKEGUCHI N, 1986, J BIOL CHEM, V261, P2560; WALLMARK B, 1980, J BIOL CHEM, V255, P5313; WALLMARK B, 1979, J BIOL CHEM, V254, P1899; WALLMARK B, 1987, J BIOL CHEM, V262, P2077; WARD DG, 1993, P NATL ACAD SCI USA, V90, P5332, DOI 10.1073/pnas.90.11.5332; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X; ZOLOTARJOVA N, 1995, J BIOL CHEM, V270, P3989, DOI 10.1074/jbc.270.8.3989	28	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4068	4072						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626741				2022-12-27	WOS:A1996TW96000019
J	Ruetz, S; Brault, M; Kast, C; Hemenway, C; Heitman, J; Grant, CE; Cole, SPC; Deeley, RG; Gros, P				Ruetz, S; Brault, M; Kast, C; Hemenway, C; Heitman, J; Grant, CE; Cole, SPC; Deeley, RG; Gros, P			Functional expression of the multidrug resistance-associated protein in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER CELL-LINE; P-GLYCOPROTEIN; MOUSE MDR1; GENE; TRANSPORTER; ADRIAMYCIN; ENCODES; REGION; FAMILY; MRP	The multidrug resistance associated protein (MRP) is a member of the ATP binding cassette superfamily of transporters which includes the mammalian P-glycoproteins (P-gp) family, In order to facilitate the biochemical and genetic analyses of MRP, we have expressed human MRP in the yeast Saccharomyces cerevisiae and have compared its functional properties to those of the mouse Mdr3 P-gp isoform, Expression of both MRP and Mdr3 in the anthracycline hypersensitive mutant VASY2563 restored cellular resistance to Adriamycin in this mutant, MRP and Mdr3 expression produced pleiotropic effects on drug resistance in this mutant, as corresponding VASY2563 transformants also acquired resistance to the anti-fungal agent FK506 and to the K+/H+ ionophore valinomycin, The appearance of increased cellular resistance to the toxic effect of Adriamycin (ADM) in MRP and Mdr3 transformants was concomitant with a reduced intracellular accumulation of [C-14]ADM in spheroplasts prepared from these cells, Moreover, MRP and Mdr3, but not control spheroplasts, could mediate a time-dependent reduction in the overall cell-associated [C-14]ADM from preloaded cells, suggesting the presence of an active ADM transport mechanism in MRP and Mdr3 transformants, Finally, human MRP was found to complement the biological activity of the yeast peptide pheromone transporter Ste6 and partially restored mating in a sterile ste6 null mutant, These findings suggest that despite their relatively low level of structural homology, MRP and P-gp share similar functional aspects, since both proteins can mediate transport of chemotherapeutic drugs and the a mating peptide pheromone in yeast.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; DUKE UNIV,MED CTR,DEPT GENET,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; QUEENS UNIV,CANC RES LABS,KINGSTON,ON K7L 3N6,CANADA	McGill University; Duke University; Duke University; Queens University - Canada			Cole, Susan P.C./I-6389-2017; Deeley, Roger/J-4828-2012	Cole, Susan P.C./0000-0001-6571-6884; 				ALMQUIST KC, 1995, CANCER RES, V55, P102; BARRAND MA, 1994, J NATL CANCER I, V86, P1100; BOSANQUET AG, 1986, CANCER CHEMOTH PHARM, V17, P1, DOI 10.1007/BF00299858; CHALFIE M, 1995, SCIENCE, V262, P802; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; ERB N, 1986, CANCER CHEMOTH PHARM, V17, P53, DOI 10.1007/BF00299866; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; GABER RF, 1989, MOL CELL BIOL, V9, P3447, DOI 10.1128/MCB.9.8.3447; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRANT CE, 1994, CANCER RES, V54, P357; Gros P, 1993, Int Rev Cytol, V137C, P169; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P565; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; KRISHNAMACHARY N, 1993, CANCER RES, V53, P3658; LEIER I, 1994, J BIOL CHEM, V269, P27807; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MIRSKI SEL, 1987, CANCER RES, V47, P2594; MUELLER M, 1994, P NATL ACAD SCI USA, V91, P13033; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; RAYMOND M, 1994, MOL CELL BIOL, V14, P277, DOI 10.1128/MCB.14.1.277; RIORDAN JR, 1989, SCIENCE, V245, P1066; RUETZ S, 1993, P NATL ACAD SCI USA, V90, P11588, DOI 10.1073/pnas.90.24.11588; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; RUETZ S, 1994, J BIOL CHEM, V269, P12277; SCHURR E, 1989, CANCER RES, V49, P2729; SLOVAK ML, 1993, CANCER RES, V53, P3221; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; ZAMAN GJR, 1993, CANCER RES, V53, P1747	36	31	32	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4154	4160						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626756				2022-12-27	WOS:A1996TW96000034
J	Meyer, DF; Mabuchi, Y; Grabarek, Z				Meyer, DF; Mabuchi, Y; Grabarek, Z			The role of Phe-92 in the Ca2+-induced conformational transition in the C-terminal domain of calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; TROPONIN-C; ANGSTROM RESOLUTION; TRYPTIC FRAGMENTS; PEPTIDE COMPLEX; DISULFIDE BOND; PROTEIN; BINDING; PHOSPHODIESTERASE; PSEUDOSUBSTRATE	Recent studies have shown that substitution of Ala for one or more Phe residues in calmodulin (CaM) imparts a temperature-sensitive phenotype to yeast (Ohya, Y., and Botstein, D. (1994) Science 263, 963-966). The Phe residue immediately preceding the first Ca2+ ligand in site III of CaM (Phe-92) was found to be of particular importance because the mutation at this position alone was sufficient to induce this phenotype. In the present work we have studied the functional and structural consequences of the Phe-92 --> Ala mutation in human liver calmodulin. We found that the mutant (CaMF92A) is incapable of activating phosphodiesterase, and the maximal activation of calcineurin is reduced by 40% as compared with the wild type CaM. Impaired regulatory properties of CaMF92A are accompanied by an increase in affinity for Ca2+ at the C-terminal domain. To investigate the structural consequences of the F92A mutation, we constructed four recombinant C-terminal domain fragments (C-CaM) of calmodulin (residues 78-148): 1) wild type (C-CaMW); 2) Ala substituted for Phe-92 (C-CaMF92A); 3) cysteine residues introduced at position 85 and 112 to lock the domain with a disulfide bond in the Ca2+-free (closed) conformation (C-CaM85/112); and 4) mutations 2 and 3 combined (C-CaM85/112F92A). The Cys-containing mutants readily form intramolecular disulfide bonds regardless whether Phe or Ala is present at position 92. The F92A mutation causes a decrease in stability of the domain in the absence of Ca2+ as indicated by an 11.8 degrees C shift in the far UV circular dichroism thermal unfolding curve. This effect is reversed by the disulfide bond in the C-CaM85/112F92A mutant. The C-CaMW peptide shows a characteristic Ca2+-dependent increase in solvent-exposed hydrophobic surface which was monitored by an increase in the fluorescence of the hydrophobic probe 1,1'-bis(4-anilino)-naphthalene-5,5'-disulfonic acid. The fluorescence increase induced by C-CaMF92A is similar to 45% lower than that induced by C-CaMW suggesting that the F92A mutation causes a decrease in the accessibility of several hydrophobic side chains in the C-terminal domain of CaM in the presence of Ca2+. The Cys-85-Cys-112 disulfide bond causes a 10- or 5.9-fold decrease in Ca2+ affinity depending on whether Phe or Ala is present at position 92, respectively, suggesting that coupling between Ca2+ binding and the conformational transition is weaker in the absence of the phenyl ring at position 92. Our results indicate that Phe-92 makes an important contribution to the Ca2+-induced transition in the C-terminal domain of CaM. This is most likely the reason for the severely impaired regulatory properties of the CaM mutants having Ala substituted for Phe-92.	BOSTON BIOMED RES INST, MUSCLE RES GRP, BOSTON, MA 02114 USA	Boston Biomedical Research Institute				Grabarek, Zenon/0000-0002-3636-5701	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01AR-41637, AR-41156] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; Cohen P, 1988, CALMODULIN MOL ASPEC, V5; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; FINN BE, 1995, NAT STRUCT BIOL, V2, P777, DOI 10.1038/nsb0995-777; FORSEN S, 1990, ADV EXP MED BIOL, V269, P37; FOSTER CJ, 1990, ARCH BIOCHEM BIOPHYS, V280, P397, DOI 10.1016/0003-9861(90)90348-3; GRABAREK Z, 1990, NATURE, V345, P132, DOI 10.1038/345132a0; GRABAREK Z, 1995, BIOCHEMISTRY-US, V34, P11872, DOI 10.1021/bi00037a027; GUSEV NB, 1991, J BIOL CHEM, V266, P16622; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JOHNSON ML, 1992, METHOD ENZYMOL, V210, P1; KLEE CB, 1983, METHOD ENZYMOL, V102, P227; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MARTIN SR, 1985, EUR J BIOCHEM, V151, P543, DOI 10.1111/j.1432-1033.1985.tb09137.x; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEANS AR, 1988, RECENT PROG HORM RES, V44, P223; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NEWTON DL, 1984, J BIOL CHEM, V259, P4419; OHYA Y, 1994, GENETICS, V138, P1041; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; RAO ST, 1993, PROTEIN SCI, V2, P436; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHELLMAN JA, 1980, PROTEIN FOLDING, P331; SILLEN LG, 1964, SPECIAL PUBLICATION, V17; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; Tan RY, 1996, J BIOL CHEM, V271, P7479, DOI 10.1074/jbc.271.13.7479; TAYLOR DA, 1991, J BIOL CHEM, V266, P21375; WALLACE RW, 1983, METHOD ENZYMOL, V102, P39; WALSH M, 1977, J BIOL CHEM, V252, P7440; WAWRZYNCZAK EJ, 1984, BIOCHEM INT, V9, P177; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758	42	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11284	11290		10.1074/jbc.271.19.11284	http://dx.doi.org/10.1074/jbc.271.19.11284			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626680	hybrid			2022-12-27	WOS:A1996UJ94400040
J	CervantesLaurean, D; Jacobson, EL; Jacobson, MK				CervantesLaurean, D; Jacobson, EL; Jacobson, MK			Glycation and glycoxidation of histones by ADP-ribose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINK; PROTEIN; INVIVO; GLUCOSE; N-EPSILON-(CARBOXYMETHYL)LYSINE; IDENTIFICATION; GLYCOSYLATION; AUTOXIDATION; DEGRADATION; PENTOSIDINE	The reaction of long lived proteins with reducing sugars has been implicated in the pathophysiology of aging and age-related diseases, A likely intranuclear source of reducing sugar is ADP-ribose, which is generated following DNA damage from the turnover of ADP-ribose polymers, In this study, ADP-ribose has been shown to be a potent histone glycation and glycoxidation agent in vitro. Incubation of ADP ribose with histones H1, H2A, H2B, and H4 at pH 7.5 resulted in the formation of ketoamine glycation conjugates, Incubation of histone H1 with ADP-ribose also rapidly resulted in the formation of protein carboxymethyllysine residues, protein-protein cross-links, and highly fluorescent products with properties similar to the advanced glycosylation end product pentosidine. The formation of glycoxidation products was related to the degradation of ketoamine glycation conjugates by two different pathways, One pathway resulted in the formation of protein carboxymethyllysine residues and release of an ADP moiety containing a glyceric acid fragment, A second pathway resulted in the release of ADP, and it is postulated that this pathway is involved in the formation of histone-histone cross-links and fluorescent advanced glycosylation end products.	UNIV KENTUCKY, COLL PHARM, DIV MED CHEM & PHARMACEUT, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, LUCILLE P MARKEY CANC CTR, DEPT CLIN SCI, LEXINGTON, KY 40536 USA	University of Kentucky; University of Kentucky			YAMAMOTO, MASAHIRO/F-9094-2011	YAMAMOTO, MASAHIRO/0000-0003-3859-0125	NATIONAL CANCER INSTITUTE [R01CA043894] Funding Source: NIH RePORTER; NCI NIH HHS [CA43894] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED MU, 1986, J BIOL CHEM, V261, P4889; ALTHAUS FR, 1987, ADP RIBOSYLATION PRO; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BERNET D, 1994, BIOCHEM J, V299, P679, DOI 10.1042/bj2990679; Bernofsky C, 1980, Methods Enzymol, V66, P23; BOJANOVI.JJ, 1970, GERONTOLOGY, V16, P304, DOI 10.1159/000211792; BONNER WM, 1980, EUR J BIOCHEM, V109, P17, DOI 10.1111/j.1432-1033.1980.tb04762.x; Bucala R, 1992, Adv Pharmacol, V23, P1; BUCALA R, 1984, P NATL ACAD SCI-BIOL, V81, P105, DOI 10.1073/pnas.81.1.105; CERAMI A, 1986, TRENDS PHARMACOL SCI, V7, P271, DOI 10.1016/0165-6147(86)90350-0; CERAMI A, 1986, J CELL BIOCHEM, V30, P111, DOI 10.1002/jcb.240300203; CERVANTESLAUREAN D, 1993, BIOCHEMISTRY-US, V32, P1528, DOI 10.1021/bi00057a017; DEPETROCELLIS L, 1986, EUR J BIOCHEM, V156, P143; DUNN JA, 1991, BIOCHEMISTRY-US, V30, P1205, DOI 10.1021/bi00219a007; DUNN JA, 1990, BIOCHEMISTRY-US, V29, P10964, DOI 10.1021/bi00501a014; DYER DG, 1991, J BIOL CHEM, V266, P11654; DYRKS T, 1992, J BIOL CHEM, V267, P18210; FU MX, 1994, DIABETES, V43, P676, DOI 10.2337/diabetes.43.5.676; GERHARDINGER C, 1995, J BIOL CHEM, V270, P218, DOI 10.1074/jbc.270.1.218; GRANDHEE SK, 1991, J BIOL CHEM, V266, P11649; GUGLIUCCI A, 1995, BIOCHEM BIOPH RES CO, V212, P56, DOI 10.1006/bbrc.1995.1935; GUGLIUCCI A, 1994, BIOCHEM BIOPH RES CO, V203, P588, DOI 10.1006/bbrc.1994.2223; HARDING JJ, 1985, ADV PROTEIN CHEM, V37, P247, DOI 10.1016/S0065-3233(08)60066-2; HORIUCHI T, 1991, AGR BIOL CHEM TOKYO, V55, P333, DOI 10.1080/00021369.1991.10870584; JACOBSON EL, 1994, MOL CELL BIOCHEM, V138, P207, DOI 10.1007/BF00928463; JACOBSON MK, 1990, ADP RIBOSYLATING TOX, P479; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; KREIMEYER A, 1984, J BIOL CHEM, V259, P890; LEE HC, 1994, CELL SIGNAL, V6, P591, DOI 10.1016/0898-6568(94)90042-6; LIEBICH HM, 1993, BIOL MASS SPECTROM, V22, P121, DOI 10.1002/bms.1200220204; MIWA M, 1977, NUCLEIC ACIDS RES, V4, P3997, DOI 10.1093/nar/4.11.3997; MONNIER VM, 1990, J GERONTOL, V45, pB105, DOI 10.1093/geronj/45.4.B105; OKA J, 1984, J BIOL CHEM, V259, P986; PAPOULIS A, 1995, BIOCHEMISTRY-US, V34, P648, DOI 10.1021/bi00002a032; SELL DR, 1989, J BIOL CHEM, V264, P21597; SMITH MA, 1994, P NATL ACAD SCI USA, V91, P5710, DOI 10.1073/pnas.91.12.5710; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; VLASSARA H, 1994, LAB INVEST, V70, P138; Williamson K., 1990, ADP RIBOSYLATING TOX, P493; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243; WONG M, 1983, P NATL ACAD SCI-BIOL, V80, P205, DOI 10.1073/pnas.80.1.205; YAMADA H, 1994, J BIOL CHEM, V269, P20275	44	117	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10461	10469		10.1074/jbc.271.18.10461	http://dx.doi.org/10.1074/jbc.271.18.10461			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631841	hybrid			2022-12-27	WOS:A1996UJ34200009
J	Chen, L; Sumbilla, C; Lewis, D; Zhong, LL; Strock, C; Kirtley, ME; Inesi, G				Chen, L; Sumbilla, C; Lewis, D; Zhong, LL; Strock, C; Kirtley, ME; Inesi, G			Short and long range functions of amino acids in the transmembrane region of the sarcoplasmic reticulum ATPase - A mutational study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT ATPASE; CA2+-ATPASE; DOMAIN; CELLS; PHOSPHORYLATION; CA-2+-ATPASE; CONSEQUENCES; EXPRESSION; MUSCLE; SITE	Mutational analysis of several amino acids in the transmembrane region of the sarcoplasmic reticulum ATPase was performed by expressing wild type ATPase and 32 site-directed mutants in COS-1 cells followed by functional characterization of the microsomal fraction, Four different phenotype characteristics were observed in the mutants: (a) functions similar to those sustained by the wild type ATPase; (b) Ca2+ transport inhibited to a greater extent than ATPase hydrolytic activity; (c) inhibition of transport and hydrolytic activity in the presence of high levels of phosphorylated enzyme intermediate; and (d) total inhibition of ATP utilization by the enzyme while retaining the ability to form phosphoenzyme by utilization of P-i, Analysis of experimental observations and molecular models revealed short and long range functions of several amino acids within the transmembrane region, Short range functions include: (a) direct involvement of five amino acids in Ca2+ binding within a channel formed by clustered transmembrane helices M4, M5, M6, and M8; (b) roles of several amino acids in structural stabilization of the helical cluster for optimal channel function; and (c) a specific role of Lys(297) in sealing the distal end of the channel, suggesting that the M4 helix rotates to allow vectorial flux of Ca2+ upon enzyme phosphorylation, Long range functions are related to the influence of several transmembrane amino acids on phosphorylation reactions with ATP or P-i, transmitted to the extramembranous region of the ATPase in the presence or in the absence of Ca2+.	UNIV MARYLAND, SCH MED, DEPT BIOCHEM & MOLEC BIOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore					NHLBI NIH HHS [P01HL-27867] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1994, FEBS LETT, V354, P93, DOI 10.1016/0014-5793(94)01100-1; ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; AURORA R, 1994, SCIENCE, V264, P1126, DOI 10.1126/science.8178170; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMES MA, 1982, J MOL BIOL, V160, P623, DOI 10.1016/0022-2836(82)90319-9; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1992, ADV ENZYMOL RAMB, V65, P185; INESI G, 1990, J MEMBRANE BIOL, V116, P1, DOI 10.1007/BF01871666; KARIN NJ, 1989, MOL CELL BIOL, V9, P1978, DOI 10.1128/MCB.9.5.1978; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; NAYAL M, 1994, P NATL ACAD SCI USA, V91, P817, DOI 10.1073/pnas.91.2.817; RICE WJ, 1994, BIOPHYS J, V66, pA121; RICE WJ, 1995, BIOPHYS J, V68, P315; SKERJANC IS, 1993, J BIOL CHEM, V268, P15944; SUMBILLA C, 1993, J BIOL CHEM, V268, P21185; SUMBILLA C, 1991, J BIOL CHEM, V266, P12682; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VILSEN B, 1992, FEBS LETT, V306, P247, DOI 10.1016/0014-5793(92)81010-J; WEBER K, 1969, J BIOL CHEM, V244, P4406; YU X, 1994, J BIOL CHEM, V269, P16656; ZHANG Z, 1995, J BIOL CHEM, V270, P16283	30	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10745	10752		10.1074/jbc.271.18.10745	http://dx.doi.org/10.1074/jbc.271.18.10745			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631884	hybrid			2022-12-27	WOS:A1996UJ34200052
J	Edelman, AM; Mitchelhill, KI; Selbert, MA; Anderson, KA; Hook, SS; Stapleton, D; Goldstein, EG; Means, AR; Kemp, BE				Edelman, AM; Mitchelhill, KI; Selbert, MA; Anderson, KA; Hook, SS; Stapleton, D; Goldstein, EG; Means, AR; Kemp, BE			Multiple Ca2+-calmodulin-dependent protein kinase kinases from rat brain - Purification, regulation by Ca2+-calmodulin, and partial amino acid sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN; PHOSPHORYLATION; IDENTIFICATION; EXPRESSION; GENE; IV; GR; AUTOPHOSPHORYLATION; SITE; IA	We have purified to near homogeneity from rat brain two Ca2+-calmodulin-dependent protein kinase I (CaM kinase I) activating kinases, termed here CaM kinase I kinase-alpha and CaM kinase I kinase-beta (CaMKIK alpha and CaMKIK beta, respectively). Both CaMKIK alpha and CaMKIK beta are also capable of activating CaM kinase IV, Activation of CaM kinase I and CaM kinase TV occurs via phosphorylation of an equivalent Thr residue within the ''activation loop'' region of both kinases, Thr-177 and Thr-196, respectively. The activities of CaMKIK alpha and CaMKIK beta are themselves strongly stimulated by the presence of Ca2+-CaM, and both appear to be capable of Ca2+-CaM-dependent autophosphorylation. Automated microsequence analysis of the purified enzymes established that CaMKIK alpha and -beta are the products of distinct genes, In addition to rat, homologous nucleic acids corresponding to these CaM kinase kinases are present in humans and the nematode, Caenorhabditis elegans. CaMKIK alpha and CaMKIK beta are thus representatives of a family of enzymes, which may function as key intermediaries in Ca2+-CaM-driven signal transduction cascades in a wide variety of eukaryotic organisms.	ST VINCENTS INST MED RES,FITZROY,VIC 3065,AUSTRALIA; DUKE UNIV,DEPT PHARMACOL,DURHAM,NC 27710	St. Vincent's Institute of Medical Research; Duke University	Edelman, AM (corresponding author), SUNY BUFFALO,DEPT PHARMACOL & TOXICOL,BUFFALO,NY 14214, USA.		Kemp, Bruce/G-9602-2019; Kemp, Bruce E/L-2633-2014	Kemp, Bruce/0000-0001-6735-5082; Kemp, Bruce E/0000-0001-6735-5082	NICHD NIH HHS [HD07503] Funding Source: Medline; NIGMS NIH HHS [GM33976] Funding Source: Medline; NINDS NIH HHS [NS24738] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024738, R29NS024738] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; DEREMER MF, 1992, J BIOL CHEM, V267, P13460; DEREMER MF, 1992, J BIOL CHEM, V267, P13466; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P15792; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HANKS SK, 1995, PROTEIN KINASE FACTS, P7; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; HAYGOOD MG, 1993, BIOTECHNIQUES, V15, P1084; ITO T, 1994, ARCH BIOCHEM BIOPHYS, V312, P278, DOI 10.1006/abbi.1994.1310; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; LEE JC, 1995, BIOCHEM BIOPH RES CO, V210, P631, DOI 10.1006/bbrc.1995.1705; LEE JSC, 1994, J BIOL CHEM, V269, P2158; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCDONALD OB, 1993, J BIOL CHEM, V268, P10054; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; MIYANO O, 1992, J BIOL CHEM, V267, P1198; MOCHIZUKI H, 1993, BIOCHEM BIOPH RES CO, V197, P1595, DOI 10.1006/bbrc.1993.2661; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; OKUNO S, 1995, J BIOCHEM-TOKYO, V117, P686, DOI 10.1093/oxfordjournals.jbchem.a124764; ORR JW, 1994, J BIOL CHEM, V269, P27715; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; SAKAGAMI H, 1992, MOL BRAIN RES, V16, P20, DOI 10.1016/0169-328X(92)90189-I; SAKAGAMI H, 1994, BRAIN RES, V666, P173, DOI 10.1016/0006-8993(94)90769-2; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; SUGITA R, 1994, BIOCHEM BIOPH RES CO, V203, P694, DOI 10.1006/bbrc.1994.2238; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	42	91	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10806	10810		10.1074/jbc.271.18.10806	http://dx.doi.org/10.1074/jbc.271.18.10806			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631893				2022-12-27	WOS:A1996UJ34200061
J	Hu, E; Liang, P; Spiegelman, BM				Hu, E; Liang, P; Spiegelman, BM			AdipoQ is a novel adipose-specific gene dysregulated in obesity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULMONARY SURFACTANT APOPROTEIN; RESPONSIVE GLUCOSE TRANSPORTER; MESSENGER-RNA CONTENT; TUMOR-NECROSIS-FACTOR; GROWTH FACTOR-I; 3T3-L1 CELLS; BINDING-PROTEIN; DIFFERENTIAL DISPLAY; ELECTRON-MICROSCOPY; CLASSICAL PATHWAY	Adipose differentiation is accompanied by changes in cellular morphology, a dramatic accumulation of intracellular lipid and activation of a specific program of gene expression, Using an mRNA differential display technique, we have isolated a novel adipose cDNA, termed adipoQ. The adipoQ cDNA encodes a polypeptide of 247 amino acids with a secretory signal sequence at the amino terminus, a collagenous region (Gly-X-Y repeats), and a globular domain. The globular domain of adipoQ shares significant homology with subunits of complement factor Clq, collagen alpha 1(X), and the brain-specific factor cerebellin, The expression of adipoQ is highly specific to adipose tissue in both mouse and rat, Expression of adipoQ is observed exclusively in mature fat cells as the stromal-vascular fraction of fat tissue does not contain adipoQ mRNA. In cultured 3T3-F442A and 3T3-L1 preadipocytes, hormone-induced differentiation dramatically increases the level of expression for adipoQ, Furthermore, the expression of adipoQ mRNA is significantly reduced in the adipose tissues from obese mice and humans. Whereas the biological function of this polypeptide is presently unknown, the tissue-specific expression of a putative secreted protein suggests that this factor may function as a novel signaling molecule for adipose tissue.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042539] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42539] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER M, 1985, J BIOL CHEM, V260, P1978; BALDO A, 1993, J CLIN INVEST, V92, P1543, DOI 10.1172/JCI116733; BEALE EG, 1992, BIOCHEM BIOPH RES CO, V189, P925, DOI 10.1016/0006-291X(92)92292-6; BOBAK DA, 1987, J IMMUNOL, V138, P1150; BRODSKYDOYLE B, 1976, BIOCHEM J, V159, P279, DOI 10.1042/bj1590279; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOY LN, 1992, J BIOL CHEM, V267, P12736; COOK KS, 1985, P NATL ACAD SCI USA, V82, P6480, DOI 10.1073/pnas.82.19.6480; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; CORNELIUS P, 1988, BIOCHEM J, V249, P765, DOI 10.1042/bj2490765; DOGLIO A, 1987, EMBO J, V6, P4011, DOI 10.1002/j.1460-2075.1987.tb02744.x; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; ELIMA K, 1993, BIOCHEM J, V289, P247, DOI 10.1042/bj2890247; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; ERDEI A, 1990, J IMMUNOL, V145, P1754; FEVE B, 1990, J BIOL CHEM, V265, P16343; FINEBERG AP, 1984, ANAL BIOCHEM, V137, P266; FLIER JS, 1987, SCIENCE, V237, P405, DOI 10.1126/science.3299706; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GHEBREHIWET B, 1978, J IMMUNOL, V120, P27; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREGOIRE F, 1990, BIOL CELL, V69, P215, DOI 10.1016/0248-4900(90)90348-7; GUEST SJ, 1990, J BIOL CHEM, V265, P5370; HABICHT GS, 1987, J IMMUNOL, V138, P2593; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; IKEDA K, 1987, J BIOL CHEM, V262, P7451; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A; KNOBEL HR, 1975, EUR J IMMUNOL, V5, P78, DOI 10.1002/eji.1830050119; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1994, P NATL ACAD SCI USA, V91, P12515, DOI 10.1073/pnas.91.26.12515; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LIANG P, 1994, NUCLEIC ACIDS RES, V22, P5763, DOI 10.1093/nar/22.25.5763; LU J, 1990, J IMMUNOL, V144, P2287; MALHOTRA R, 1990, J EXP MED, V172, P955, DOI 10.1084/jem.172.3.955; MALHOTRA R, 1993, BIOCHEM J, V293, P15, DOI 10.1042/bj2930015; Maniatis T, 1989, DECONTAMINATION DILU; Martin H, 1990, EUR J IMMUNOL, V20, P1641, DOI 10.1002/eji.1830200804; MOUSTAID N, 1991, J BIOL CHEM, V266, P18550; OIKI S, 1988, J IMMUNOL, V141, P3177; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PETRY F, 1991, J IMMUNOL, V147, P3988; PETRY F, 1992, EUR J BIOCHEM, V209, P129, DOI 10.1111/j.1432-1033.1992.tb17269.x; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; ROSEN BS, 1989, SCIENCE, V244, P1483, DOI 10.1126/science.2734615; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SIM RB, 1991, IMMUNOL TODAY, V12, P307, DOI 10.1016/0167-5699(91)90004-D; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; SPIEGELMAN BM, 1993, CELL, V73, P625, DOI 10.1016/0092-8674(93)90243-J; SPIEGELMAN BM, 1993, J BIOL CHEM, V268, P6823; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; URADE Y, 1991, P NATL ACAD SCI USA, V88, P1069, DOI 10.1073/pnas.88.3.1069; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; WISE LS, 1984, J BIOL CHEM, V259, P4827; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	68	1722	1834	4	67	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10697	10703		10.1074/jbc.271.18.10697	http://dx.doi.org/10.1074/jbc.271.18.10697			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631877	hybrid, Green Published			2022-12-27	WOS:A1996UJ34200045
J	Junghans, RP; Stone, AL; Lewis, MS				Junghans, RP; Stone, AL; Lewis, MS			Biophysical characterization of a recombinant soluble interleukin 2 receptor (Tac) - Evidence for a monomeric structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM; IL-2 RECEPTOR; PROTEIN; ANTIGEN; FORM; EXPRESSION; TARGET; SYSTEM; CELLS; CORE	The interleukin 2 receptor (IL2R) plays a prominent role in the biology of T cells, B cells, and NK cells during activation, Of the three chains described, the alpha-chain of the receptor (Tac; IL2R alpha; CD25) is the most subject to regulation and is shed from the surface of activated cells to generate a soluble form in serum and tissues, Conflicting results have been reported on the native structure of soluble Tac, suggesting variously a monomer, a dimer, or higher noncovalent forms, spawning different models for its mechanism of action, We similarly show a large M(r(app)) by HPLC sieving chromatography, suggesting a tetrameric form, However, stoichiometry-ordered size (SOS) analysis of antibody-antigen complexes indicated only a single epitope per Tac molecule, compatible with a monomeric form, This larger M(r(app)) also conflicted with prior in vivo data showing rapid filtration of soluble Tac through the renal glomerulus that was not expected of a larger complex, Using different solvents, denaturants, and columns in the chromatography suggested that the elevated M(r(app)) values were an artifact of solute column interactions, termed ''ionic exclusion,'' rather than reflecting larger native structures, Analytical ultracentrifugation using a new type of analysis specific to glycoproteins demonstrated monomeric masses under all salt conditions with no tendency to form dimers or higher aggregates, Finally, circular dichroism spectroscopy showed no salt-dependent changes to suggest conformational alterations that might correlate with mobility changes on high pressure liquid chromatography, We conclude therefore that Tac is monomeric under physiologic conditions, Assessments of higher molecular weight for the purified soluble protein by other methods may be explained by the highly acidic nature of the molecule, which hampers matrix penetration with chromatographic media and by the high carbohydrate content and low partial specific volumes that accelerate the molecule in sedimentation media relative to pure protein standards.	NICHHD,DEV & MOLEC IMMUN LAB,NIH,BETHESDA,MD 20892; NIH,NATL CTR RES RESOURCES,BIOMED ENGN & INSTRUMENTAT PROGRAM,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA	Junghans, RP (corresponding author), HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,BIOTHERAPEUT DEV LAB,DIV HEMATOL ONCOL,BOSTON,MA 02215, USA.							ATTRI AK, 1992, ANAL ULTRACENTRIFUGA, P138; BARTH HG, 1980, J CHROMATOGR SCI, V18, P409, DOI 10.1093/chromsci/18.9.409; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; DEPPER JM, 1984, J IMMUNOL, V133, P3054; DISCIPIO RG, 1982, BIOCHIM BIOPHYS ACTA, V709, P58, DOI 10.1016/0167-4838(82)90421-6; DOWER SK, 1990, J CLIN IMMUNOL, V10, P289, DOI 10.1007/BF00917473; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; HAKIMI J, 1987, J BIOL CHEM, V262, P17336; JACQUES Y, 1990, J BIOL CHEM, V265, P20252; JUNGHANS RP, 1996, IN PRESS J EXP MED, V183; KATO K, 1987, BIOCHEMISTRY-US, V26, P5359, DOI 10.1021/bi00391a021; KNOTT GD, 1979, COMPUT PROG BIOMED, V10, P271, DOI 10.1016/0010-468X(79)90075-8; LAMBERT G, 1989, J BIOL CHEM, V264, P12730; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LEONARD WJ, 1983, P NATL ACAD SCI-BIOL, V80, P6957, DOI 10.1073/pnas.80.22.6957; LEONARD WJ, 1985, SCIENCE, V230, P633, DOI 10.1126/science.2996141; MANOUSSAKIS MN, 1989, CLIN IMMUNOL IMMUNOP, V50, P321, DOI 10.1016/0090-1229(89)90140-2; MIEDEL MC, 1989, J BIOL CHEM, V264, P21097; MIEDEL MC, 1988, BIOCHEM BIOPH RES CO, V154, P372, DOI 10.1016/0006-291X(88)90695-X; MIOSSEC P, 1990, ARTHRITIS RHEUM, V33, P1688, DOI 10.1002/art.1780331112; NELSON DL, 1986, ANN INTERN MED, V105, P560; PAULSON JC, 1990, PROTEINS FORM FUNCTI, P209; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; ROBB RJ, 1987, J IMMUNOL, V139, P855; RUSK CM, 1988, J IMMUNOL, V140, P2249; SARAGOVI H, 1987, J IMMUNOL, V139, P1918; SMITH KA, 1989, ANNU REV CELL BIOL, V5, P397; SMITH MH, 1968, HDB BIOCH, pC3; STONE AL, 1985, BIOCHEMISTRY-US, V24, P6666, DOI 10.1021/bi00344a055; SVEDBERG T, 1940, ULTRACENTRIFUGE, P35; SYMONS JA, 1988, J IMMUNOL, V141, P2612; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; WALDMANN TA, 1992, ANN INTERN MED, V116, P148, DOI 10.7326/0003-4819-116-2-148; WALDMANN TA, 1993, BLOOD, V82, P1701; WANO Y, 1984, J IMMUNOL, V132, P3005; WANO Y, 1985, MICROBIOL IMMUNOL, V29, P45; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; YANG JT, 1986, METHOD ENZYMOL, V130, P208	39	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10453	10460		10.1074/jbc.271.18.10453	http://dx.doi.org/10.1074/jbc.271.18.10453			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631840	hybrid			2022-12-27	WOS:A1996UJ34200008
J	Keri, RA; Nilson, JH				Keri, RA; Nilson, JH			A steroidogenic factor-1 binding site is required for activity of the luteinizing hormone beta subunit promoter in gonadotropes of transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORIONIC-GONADOTROPIN; GENE-EXPRESSION; EVOLUTION; PITUITARY; ENCODES; PROTEIN	Analysis of luteinizing hormone (LH) beta subunit promoters from a broad range of species including teleosts and humans revealed strict conservation of a sequence homologous to the steroidogenic factor-1 (SF-1) regulatory element of cytochrome P-450 steroid hydroxylase genes. Interaction between SF-1 and this putative response element in the bovine LH beta promoter was confirmed by electrophoretic mobility shift assays. Furthermore, cotransfection of alpha T3-1 cells with an expression vector encoding; SF-1 induced binding site-dependent transcription from the bovine LH beta promoter. Physiological significance of the LH beta SF-1 consensus sequence was established using transgenic mice containing either the wild type bovine promoter or a promoter with a site-specific mutation of this site. Mutation of the SF-1 binding site nearly eliminated promoter activity, and the mutant transgene remained inactive following induction of gonadotropin-releasing hormone accomplished by castrating male and female mice. Thus, increases of gonadotropin-releasing hormone within a physiological range did not compensate for the loss of the SF-1 binding site. Together, these findings indicate that the SF-1 binding site is a key regulator of LH beta promoter activity in vivo and implicate SF-1 as at least one of the transcription factors that acts through this site.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHARMACOL,CLEVELAND,OH 44106	Case Western Reserve University			Keri, Ruth/ABF-2209-2021	Keri, Ruth/0000-0002-1640-3088				ALBARRACIN CT, 1994, ENDOCRINOLOGY, V135, P2300, DOI 10.1210/en.135.6.2300; BARNHART KM, 1994, MOL ENDOCRINOL, V8, P878, DOI 10.1210/me.8.7.878; Conn P. Michael, 1994, P1815; FIDDES JC, 1984, RECENT PROG HORM RES, V40, P43; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; HECKERT LL, 1995, J BIOL CHEM, V270, P26497, DOI 10.1074/jbc.270.44.26497; HORN F, 1992, MOL CELL BIOL, V12, P2143, DOI 10.1128/MCB.12.5.2143; HSIEH KP, 1992, MOL ENDOCRINOL, V6, P1673, DOI 10.1210/me.6.10.1673; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; IKEDA Y, 1995, MOL ENDOCRINOL, V9, P478, DOI 10.1210/me.9.4.478; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; JAMESON L, 1984, J BIOL CHEM, V259, P5474; KERI RA, 1994, MOL ENDOCRINOL, V8, P1807, DOI 10.1210/me.8.12.1807; KUMAR TR, 1992, MOL ENDOCRINOL, V6, P81, DOI 10.1210/me.6.1.81; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; LUO XR, 1995, MOL ENDOCRINOL, V9, P1233, DOI 10.1210/me.9.9.1233; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SHERMAN GB, 1992, MOL ENDOCRINOL, V6, P951, DOI 10.1210/me.6.6.951; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; VIRGIN JB, 1985, J BIOL CHEM, V260, P7072; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; XIONG F, 1994, MOL ENDOCRINOL, V8, P771, DOI 10.1210/me.8.6.771	25	141	143	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10782	10785		10.1074/jbc.271.18.10782	http://dx.doi.org/10.1074/jbc.271.18.10782			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631889	hybrid			2022-12-27	WOS:A1996UJ34200057
J	Ostermeier, M; DeSutter, K; Georgiou, G				Ostermeier, M; DeSutter, K; Georgiou, G			Eukaryotic protein disulfide isomerase complements Escherichia coli dsbA mutants and increases the yield of a heterologous secreted protein with disulfide bonds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; FORMATION INVIVO; BETA-LACTAMASE; KINETIC ROLE; IDENTIFICATION; CATALYSIS; PATHWAY; STATE; BPTI	Eukaryotic protein disulfide isomerase (PDI) is a 55-kDa enzyme with cysteine oxidoreductase, chaperone, and antichaperone activities that catalyze disulfide formation and rearrangement in the eukaryotic endoplasmic reticulum, In Gram-negative bacteria, the formation of disulfide bonds in the periplasm is mediated by DsbA, a strong cysteine oxidase but an inefficient catalyst of disulfide bond isomerization with no known chaperone activity, We show that rat PDI (rPDI) secreted in the periplasmic space of Escherichia coli can catalyze the formation of disulfide bonds and complement several of the phenotypes of dsbA mutants, The function of rPDI was dependent on the dsbB gene, suggesting that the reoxidation of this eukaryotic enzyme involves direct interactions with bacterial redox proteins, Co-expression of rPDI increased the yield of bovine pancreatic trypsin inhibitor (BPTI) severalfold, an effect that was enhanced when reduced glutathione was added to the growth medium, Whereas PDI is thought to function primarily as an isomerase in the eukaryotic endoplasmic reticulum, rPDI failed to decrease the accumulation of two-disulfide folding intermediates of BPTI and thus did not appear to appreciably catalyze the rate-limiting step in the oxidative folding pathway of BPTI. These results demonstrate that expression of eukaryotic foldases in E, coli can be exploited to better understand their function in vivo and also to increase the yield of biotechnologically valuable proteins.	UNIV TEXAS, DEPT CHEM ENGN, AUSTIN, TX 78712 USA; STATE UNIV GHENT, MOLEC BIOL LAB, B-9000 GHENT, BELGIUM	University of Texas System; University of Texas Austin; Ghent University			Ostermeier, Marc/A-2697-2010	Ostermeier, Marc/0000-0003-0900-3665	NIGMS NIH HHS [GM47520-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047520] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1988, MOL REPROD DEV; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; CAI H, 1994, J BIOL CHEM, V269, P24550; CREIGHTON TE, 1980, J MOL BIOL, V142, P43, DOI 10.1016/0022-2836(80)90205-3; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1993, J MOL BIOL, V232, P1176, DOI 10.1006/jmbi.1993.1470; CREIGHTON TE, 1992, BIOESSAYS, V14, P195, DOI 10.1002/bies.950140310; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; DARBY NJ, 1994, BIOCHEMISTRY-US, V33, P7937, DOI 10.1021/bi00191a022; DESUTTER K, 1992, MOL MICROBIOL, V6, P2201; DESUTTER K, 1994, GENE, V141, P163, DOI 10.1016/0378-1119(94)90566-5; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GOLDENBERG DP, 1992, TRENDS BIOCHEM SCI, V17, P257, DOI 10.1016/0968-0004(92)90405-X; GOLDENBERG DP, 1988, BIOCHEMISTRY-US, V27, P2481, DOI 10.1021/bi00407a034; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; HUMPHREYS DP, 1995, J BIOL CHEM, V270, P28210; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JANDER G, 1994, EMBO J, V13, P5121, DOI 10.1002/j.1460-2075.1994.tb06841.x; JOLY JC, 1994, BIOCHEMISTRY-US, V33, P4231, DOI 10.1021/bi00180a017; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KISHIGAMI S, 1995, FEBS LETT, V364, P55, DOI 10.1016/0014-5793(95)00354-C; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; LYLES MM, 1994, J BIOL CHEM, V269, P30946; MCGRATH ME, 1991, J BIOL CHEM, V266, P6620; MISSIAKAS D, 1993, P NATL ACAD SCI USA, V90, P7084, DOI 10.1073/pnas.90.15.7084; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; NEU HC, 1965, J BIOL CHEM, V240, P3685; OSTERMEIER M, 1994, J BIOL CHEM, V269, P21072; POLLITT S, 1983, J BACTERIOL, V153, P27, DOI 10.1128/JB.153.1.27-32.1983; PUIG A, 1994, J BIOL CHEM, V269, P7764; PUIG A, 1994, J BIOL CHEM, V269, P19128; SILHAVY T, 1983, EXPT GENE FUSIONS; VINCENT JP, 1972, BIOCHEMISTRY-US, V11, P2967, DOI 10.1021/bi00766a007; WALKER KW, 1994, J BIOL CHEM, V269, P28487; WEISSMAN JS, 1992, P NATL ACAD SCI USA, V89, P9900, DOI 10.1073/pnas.89.20.9900; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WITTRUP KD, 1995, IN PRESS CURR OPIN B; WULFING C, 1994, MOL MICROBIOL, V12, P685, DOI 10.1111/j.1365-2958.1994.tb01056.x; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P5202, DOI 10.1021/bi00183a025; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	45	73	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10616	10622		10.1074/jbc.271.18.10616	http://dx.doi.org/10.1074/jbc.271.18.10616			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631865	hybrid			2022-12-27	WOS:A1996UJ34200033
J	Faurobert, E; Chen, CK; Hurley, JB; Teng, DHF				Faurobert, E; Chen, CK; Hurley, JB; Teng, DHF			Drosophila neurocalcin, a fatty acylated, Ca2+-binding protein that associates with membranes and inhibits in vitro phosphorylation of bovine rhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; COUPLED RECEPTOR KINASES; MOLECULAR-CLONING; NERVOUS-SYSTEM; S-MODULIN; RECOVERIN; FAMILY; HIPPOCALCIN; MECHANISM; TERMINUS	Neurocalcins belong to a family of neuronal specific EF hand Ca2+-binding proteins defined by recoverin. Previously, we reported the cloning and initial characterization of neurocalcin in Drosophila melanogaster (Teng, D. H.-F., Chen, C.K., and Hurley, J. B. (1994) J. Biol. Chem. 269, 31900-31907). We showed that the Drosophila neurocalcin protein (DrosNCa) is expressed in neurons and that bacterially expressed recombinant DrosNCa (rDrosNCa) can be myristoylated. Here, we present two lines of evidence that DrosNCa is fatty acylated its vivo. First, the mobility of affinity-purified native DrosNCa on two-dimensional gel electrophoresis is identical to that of myristoylated rDrosNCa and distinct from that of nonacylated rDrosNCa. Second, the membrane binding properties of native DrosNCa are similar to those of myristoylated rDrosNCa; both of these proteins bind to membranes at 0.2 mM Ca2+, whereas nonacylated rDrosNCa always remains soluble. It has been shown that recoverin inhibits the phosphorylation of rhodopsin when Ca2+ is present (Kawamura et al., 1993) and that a dependent recoverin/rhodopsin kinase interaction underlies the inhibitory effect of recoverin (Chen ct at, 1995). Given the similarities between recoverin and neurocalcin, we examined the effect of DrosNCa on rhodopsin phosphorylation. We find that rDrosNCa is capable of inhibiting bovine rhodopsin phosphorylation in vitro in a Ca2+-dependent manner. The inhibitors activity of rDrosNCa is enhanced by myristoylation, and the potency of its effect is similar to that of recoverin. Two other related EF hand proteins, guanylate cyclase-activating protein-2 and calmodulin, are only poor inhibitors in these phosphorylation assays. in vitro inhibition of rhodopsin phosphorylation therefore appears to be an assayable property of a subset of recoverin-like proteins.	UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Faurobert, Eva/M-2735-2013	Faurobert, Eva/0000-0002-2714-8537	PHS HHS [E406641] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CALVERT PD, 1995, J BIOL CHEM, V270, P24127, DOI 10.1074/jbc.270.41.24127; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; COX JA, 1994, J BIOL CHEM, V269, P32807; DECASTRO E, 1995, BIOCHEM BIOPH RES CO, V216, P133, DOI 10.1006/bbrc.1995.2601; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GRAYKELLER MP, 1993, NEURON, V10, P523, DOI 10.1016/0896-6273(93)90339-S; HIDAKA H, 1993, NEUROSCI RES, V16, P73, DOI 10.1016/0168-0102(93)90074-Z; HUGHES RE, 1995, BIOCHEMISTRY-US, V34, P11410, DOI 10.1021/bi00036a013; HURLEY JB, 1993, SCIENCE, V260, P740, DOI 10.1126/science.8097896; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KAJIMOTO Y, 1993, J NEUROCHEM, V61, P1091, DOI 10.1111/j.1471-4159.1993.tb03624.x; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; LADANT D, 1995, J BIOL CHEM, V270, P3179; LENZ SE, 1992, MOL BRAIN RES, V15, P133, DOI 10.1016/0169-328X(92)90160-D; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; OKAZAKI K, 1995, BIOCHEM J, V306, P551, DOI 10.1042/bj3060551; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; TENG DHF, 1994, J BIOL CHEM, V269, P31900; TERASAWA M, 1992, J BIOL CHEM, V267, P19596; YAMAGATA K, 1990, NEURON, V2, P459; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	34	43	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10256	10262		10.1074/jbc.271.17.10256	http://dx.doi.org/10.1074/jbc.271.17.10256			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626592				2022-12-27	WOS:A1996UG25700064
J	Hu, ZZ; Zhuang, L; Dufau, ML				Hu, ZZ; Zhuang, L; Dufau, ML			Multiple and tissue-specific promoter control of gonadal and non-gonadal prolactin receptor gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT OVARY; CELLS	Prolactin receptors (PRLRs) are widely expressed, and multiple mRNA transcripts encoding PRLRs are present in prolactin target tissues. The molecular basis for the control of the PRLR gene expression is currently unknown. Analyses of the 5'-untranslated regions of PRLR mRNAs expressed in gonadal and non-gonadal tissues and their genomic organization revealed three alternative first exons designated as El(1), El(2), and El(3). Each of these exons is alternatively spliced to a common noncoding exon (exon 2, nucleotides -115 to -56) that precedes the third exon containing the translation initiation codon. Alternative utilization of exons El(1), El(2), and El(3), as well as alternative splicing of exon 2, generates multiple 5'-untranslated regions in PRLR transcripts. These alternative first exons (El(1), El(2), and El(3)) were found to be utilized in a tissue-specific manner in vivo. El(1) is predominantly expressed in the ovary, El(2) is specifically expressed in the liver, and El(3) is expressed as a predominant form in the Leydig cell and as a minor form in the ovary and liver. Genomic 5'-flanking regions containing the three putative PRLR gene promoters (PI, PII, and PIII) that initiate the transcription of El(1), El(2), and El(3), respectively, were identified. El(1) was found to initiate from a single site at -549, El(2) from multiple sites at -405, -461, and -506, and El(3) from two major sites at -340 and -351. These findings indicate that multiple promoters control transcription of the PRLR gene and provide a molecular basis for the differential regulation of PRLR expression in diverse tissues.	NICHHD, SECT MOL ENDOCRINOL, ENDOCRINOL & REPROD RES BRANCH, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								AQUILANO DR, 1984, ENDOCRINOLOGY, V114, P499, DOI 10.1210/endo-114-2-499; Bonifacino J.S., 1984, Serono Symposia Publications from Raven Press, V9, P149; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; DAVIES TF, 1980, NATURE, V283, P863, DOI 10.1038/283863a0; DOPPLER W, 1994, REV PHYSIOL BIOCH P, V124, P93, DOI 10.1007/BFb0031032; GRANDIEN K, 1995, ENDOCRINOLOGY, V136, P2223, DOI 10.1210/en.136.5.2223; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HU ZZ, 1990, FEBS LETT, V274, P181, DOI 10.1016/0014-5793(90)81359-V; HU ZZ, 1991, BIOCHEM BIOPH RES CO, V181, P219, DOI 10.1016/S0006-291X(05)81405-6; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; MAHENDROO MS, 1993, J BIOL CHEM, V268, P19463; ROMEO DS, 1993, MOL ENDOCRINOL, V7, P759, DOI 10.1210/me.7.6.759; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STRAHLE U, 1992, P NATL ACAD SCI USA, V89, P6731, DOI 10.1073/pnas.89.15.6731; SUZUKI H, 1995, J BIOL CHEM, V270, P9676, DOI 10.1074/jbc.270.16.9676; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG R, 1990, BIOCHEM BIOPH RES CO, V168, P415, DOI 10.1016/0006-291X(90)92337-Y	19	58	59	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10242	10246		10.1074/jbc.271.17.10242	http://dx.doi.org/10.1074/jbc.271.17.10242			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626590	hybrid			2022-12-27	WOS:A1996UG25700062
J	Mikus, P; Ny, T				Mikus, P; Ny, T			Intracellular polymerization of the serpin plasminogen activator inhibitor type 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MONOCYTES-MACROPHAGES; SEMLIKI FOREST VIRUS; HAMSTER OVARY CELLS; ALPHA-1-PROTEINASE INHIBITOR; SITE LOOP; ALPHA-1-ANTITRYPSIN; PROTEIN; SECRETION; U-937; BETA	Plasminogen activator inhibitor type 2 (PAI-2) is synthesized in two molecular forms: an intracellular, nonglycosylated form and an extracellular, glycosylated form. The bitopological distribution of PAI-2 is caused by an inefficient internal secretion signal. In addition, the secretion efficiency of PAI-2 seems to differ, depending on the cell type, differentiation state, and culture conditions. In recombinant cell clones designed for the synthesis of the secreted form of PAI-2, the fraction of secreted PAI-2 decreased with increasing expression levels. Subcellular fractionation of cell clones with higher expression levels revealed that PAI-2 accumulating in the cell was mainly associated with the organelles of the secretory pathway. Electrophoresis under nondenaturating conditions revealed that the PAI-2 retained at higher expression levels was mainly polymerized. Polymers of PAI-2 were also detected in cytosolic extracts prepared from human placenta and phorbol ester-stimulated U 937 cells, indicating that intracellular polymerization of PAI-2 may occur in the cytosols of cells that normally express PAI-2 under physiological conditions. When purified PAI-2 or cellular extracts were incubated at 37 degrees C for 24 h most of the PAI-2 protein was found to polymerize. Polymer formation was prevented by the addition of synthetic peptides with sequences corresponding to residues P2 to P14 in the reactive center loop of PAI-2 and antithrombin. These synthetic peptides also caused dissociation of prepolymerized purified PAI-2 and PAI-2 polymers in cellular extracts. Incubation with unrelated peptides of the same size had no effect on polymer formation or dissociation of preformed polymers, indicating that polymerization of PAI-2 occurs by the loop-sheet mechanism. Taken together, our data suggest that the wild-type form of PAI-2, like some natural pathological genetic variants of alpha(1)-antitrypsin, antithrombin, and C1 inhibitor readily polymerizes intracellularly and that polymerization may lead to a reduced secretion efficiency.	UMEA UNIV,DEPT MED BIOCHEM & BIOPHYS,S-90187 UMEA,SWEDEN; SAS BRATISLAVA,INST MOLEC PHYSIOL & GENET,BRATISLAVA,SLOVAKIA	Umea University; Slovak Academy of Sciences								ASTEDT B, 1985, THROMB HAEMOSTASIS, V53, P122; ASTEDT B, 1987, Fibrinolysis, V1, P203, DOI 10.1016/0268-9499(87)90037-3; AULAK KS, 1993, J BIOL CHEM, V268, P18088; BELIN D, 1989, EMBO J, V8, P3287, DOI 10.1002/j.1460-2075.1989.tb08489.x; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; CARELL R, 1985, TRENDS BIOCHEM SCI, V10, P20; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1986, J CLIN INVEST, V78, P1427, DOI 10.1172/JCI112731; CARRELL RW, 1992, CURR OPIN STRUC BIOL, V2, P488; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; EVANS DL, 1991, THESIS CAMBRIDGE U U; FA M, 1995, BIOCHEMISTRY-US, V34, P13833, DOI 10.1021/bi00042a015; GENTON C, 1987, J CELL BIOL, V104, P705, DOI 10.1083/jcb.104.3.705; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; JENSEN PH, 1994, J BIOL CHEM, V269, P15394; KAWANO T, 1968, NATURE, V217, P253, DOI 10.1038/217253a0; KRUITHOF EKO, 1986, J BIOL CHEM, V261, P1207; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; LAWRENCE DA, 1995, J BIOL CHEM, V270, P1; LECANDER I, 1984, BRIT J HAEMATOL, V57, P407, DOI 10.1111/j.1365-2141.1984.tb02914.x; LECANDER I, 1986, BRIT J HAEMATOL, V62, P221, DOI 10.1111/j.1365-2141.1986.tb02925.x; LILJESTROM P, 1991, J VIROL, V65, P4107; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MIKUS P, 1993, EUR J BIOCHEM, V218, P1071, DOI 10.1111/j.1432-1033.1993.tb18467.x; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; NY T, 1989, FIBRINOLYSIS, V3, P189, DOI 10.1016/0268-9499(89)90045-3; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RIOS RM, 1992, EMBO J, V11, P1723, DOI 10.1002/j.1460-2075.1992.tb05224.x; RIOS RM, 1994, J CELL BIOL, V125, P997, DOI 10.1083/jcb.125.5.997; SCHREUDER HA, 1994, STRUCT BIOL, V1, P48; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SCHULZE AJ, 1992, BIOCHEMISTRY-US, V31, P7560, DOI 10.1021/bi00148a017; SHARP HL, 1969, J LAB CLIN MED, V73, P934; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VASSALLI JD, 1984, J EXP MED, V159, P1653, DOI 10.1084/jem.159.6.1653; VONHEIJNE G, 1991, J BIOL CHEM, V266, P15240; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; WOHLWEND A, 1987, J EXP MED, V165, P320, DOI 10.1084/jem.165.2.320; YE RD, 1988, J BIOL CHEM, V263, P4869; ZETTLMEISSL G, 1987, BIO-TECHNOL, V5, P720, DOI 10.1038/nbt0787-720	46	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10048	10053		10.1074/jbc.271.17.10048	http://dx.doi.org/10.1074/jbc.271.17.10048			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626560	hybrid			2022-12-27	WOS:A1996UG25700032
J	Nagayama, Y; Tanaka, K; Hara, T; Namba, H; Yamashita, S; Taniyama, K; Niwa, M				Nagayama, Y; Tanaka, K; Hara, T; Namba, H; Yamashita, S; Taniyama, K; Niwa, M			Involvement of G protein-coupled receptor kinase 5 in homologous desensitization of the thyrotropin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID CELL-LINE; MOLECULAR-CLONING; MULTIGENE FAMILY; RNA ISOLATION; RAT; EXPRESSION; MECHANISM; REFRACTORINESS; STIMULATION; MEMBER	Homologous desensitization of G protein-coupled receptors involves agonist-dependent phosphorylation of receptors by G protein-coupled receptor kinases (GRKs). To identify GRK(s) that play a role in homologous desensitization of the thyrotropin (TSH) receptor, thyroid cDNA was amplified by polymerase chain reaction using degenerate oligonucleotide primers from highly conserved regions in GRK family. GRK5 is found in the predominant isoform expressed in the thyroid. Rat GRK5 cDNA was then isolated, which encodes a 590-amino acid protein with 95% homology to human and bovine homologs. Northern blot identified GRK5 mRNA of similar to 3, 8, and 10 kilobases with highest expression levels in lung > heart, kidney, colon > thyroid. In functional studies using a normal rat thyroid FRTL5 cells, overexpression of GRK5 by transfecting the plasmid capable of expressing the sense GRK5 RNA suppressed basal cAMP levels and augmented the extent of TSH receptor desensitization, whereas suppression of endogenous GRK5 expression by transfecting the antisense GRK5 construct increased basal cAMP levels and attenuated the extent of receptor desensitization. Although exogenously overexpressed GRK6 also enhanced TSH receptor desensitization, we conclude that GRK5, the predominant GRK isoform in the thyroid, appears to be mainly involved in homologous desensitization of the TSH receptor.	NAGASAKI UNIV,SCH MED,DEPT PHARMACOL,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,INST ATOM DIS,DEPT CELL PHYSIOL,NAGASAKI 852,JAPAN	Nagasaki University; Nagasaki University			Yamashita, Shunichi/GVS-9508-2022	Yamashita, Shunichi/0000-0001-6399-6261				AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CHAZENBALK GD, 1995, J BIOL CHEM, V270, P1543, DOI 10.1074/jbc.270.4.1543; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONTRERA JG, 1993, J PHARMACOL EXP THER, V265, P433; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P224; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FOTI D, 1991, J ENDOCRINOL INVEST, V14, P213, DOI 10.1007/BF03346791; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HARAGUCHI K, 1994, J MOL ENDOCRINOL, V13, P283, DOI 10.1677/jme.0.0130283; HARIBABU B, 1993, P NATL ACAD SCI USA, V90, P9398, DOI 10.1073/pnas.90.20.9398; HIRAYU H, 1985, MOL CELL ENDOCRINOL, V42, P21, DOI 10.1016/0303-7207(85)90003-6; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KANEKO Y, 1976, HORM METAB RES, V8, P202, DOI 10.1055/s-0028-1093660; KONG GH, 1994, J BIOL CHEM, V269, P13084; KOZAK M, 1983, MICROBIOL REV, V47, P1; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MISRAHI M, 1994, EUR J BIOCHEM, V222, P711, DOI 10.1111/j.1432-1033.1994.tb18916.x; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; NAGAYAMA Y, 1994, ENDOCRINOLOGY, V135, P1060, DOI 10.1210/en.135.3.1060; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PEI G, 1994, P NATL ACAD SCI USA, V91, P3633, DOI 10.1073/pnas.91.9.3633; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RAPOPORT B, 1976, J BIOL CHEM, V251, P6653; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHI Y, 1993, ENDOCR J, V1, P157; SHIH ML, 1994, P NATL ACAD SCI USA, V91, P12193, DOI 10.1073/pnas.91.25.12193; SHUMAN SJ, 1976, J CLIN INVEST, V57, P1132, DOI 10.1172/JCI108380	42	57	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10143	10148		10.1074/jbc.271.17.10143	http://dx.doi.org/10.1074/jbc.271.17.10143			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626574	hybrid			2022-12-27	WOS:A1996UG25700046
J	Szczesna, D; Guzman, G; Miller, T; Zhao, JJ; Farokhi, K; Ellemberger, H; Potter, JD				Szczesna, D; Guzman, G; Miller, T; Zhao, JJ; Farokhi, K; Ellemberger, H; Potter, JD			The role of the four Ca2+ binding sites of troponin C in the regulation of skeletal muscle contraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; MUTATION; CALCIUM; EXPRESSION; AFFINITY; 4-MALEIMIDOBENZOPHENONE; CYSTEINE-98; MUTAGENESIS; RESOLUTION; PROTEINS	In order to study the role of the Ca2+-specific sites (I and II) and the high affinity Ca2+-Mg2+ sites (III and IV) of TnC in the regulation of muscle contraction, we have constructed four mutants and the wild type (WTnC) of chicken skeletal TnC, with inactivated Ca2+ binding sites I and II (TnC1,2-), site III (TnC3-), site IV (TnC4-), and sites III and TV (TnC3,4C-), All CdC binding site mutations were generated by replacing the Asp at the X-coordinating position of the Ca2+ binding loop with Ala. The binding of these mutated proteins to TnC-depleted skinned skeletal muscle fibers was investigated as well as the rate of their dissociation from these fibers. The proteins were also tested for their ability to restore steady state force to TnC-depleted fibers. We found that although the NH2-terminal mutant of TnC (TnC1,2-) bound to the TnC-depleted fibers (with a lower affinity than wild type TnC (WTnC)), it was unable to reactivate Ca2+-dependent force. This supports earlier findings that the low affinity Ca2+ binding sites (I and II) in TnC are responsible for the Ca2+-dependent activation of skeletal muscle contraction. All three COOH-terminal mutants of TnC bound to the TnC-depleted fibers, had different rates of dissociation, and could restore steady state force to the level of unextracted fibers, Although both high affinity Ca2+ binding sites (III and IV) are important for binding to the fibers, site III appears to be the primary determinant for maintaining the structural stability of TnC in the thin filament, Moreover, our results suggest an interaction between the NH2- and COOH-terminal domains of TnC, since alteration of sites I and II lowers the binding affinity of TnC to the fibers, and mutations in sites III and IV affect the Ca2+ sensitivity of force development.	UNIV MIAMI,SCH MED,DEPT MOLEC & CELLULAR PHARMACOL,MIAMI,FL 33101	University of Miami					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037701, R01AR040727] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40727, AR37701] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRITO RM, 1993, J BIOL CHEM, V168, P966; DALGARNO DC, 1982, FEBS LETT, V150, P54, DOI 10.1016/0014-5793(82)81303-3; DOTSON DG, 1993, J BIOL CHEM, V268, P24067; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FRANCOIS JM, 1995, J BIOL CHEM, V270, P19287, DOI 10.1074/jbc.270.33.19287; GOLOSINSKA K, 1991, J BIOL CHEM, V266, P15797; GUTH K, 1987, J BIOL CHEM, V262, P13627; GUTH K, 1986, PFLUG ARCH EUR J PHY, V407, P552, DOI 10.1007/BF00657515; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7042, DOI 10.1021/bi00396a028; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P6983, DOI 10.1021/bi00418a047; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; NEGELE JC, 1992, J BIOL CHEM, V267, P825; POTTER JD, 1975, J BIOL CHEM, V250, P4628; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; REINACH FC, 1988, J BIOL CHEM, V263, P2371; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; SHENG ZL, 1990, J BIOL CHEM, V265, P21554; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; SORENSON MM, 1995, J BIOL CHEM, V270, P9770, DOI 10.1074/jbc.270.17.9770; XU GQ, 1988, J BIOL CHEM, V263, P13962; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535; ZOT HG, 1982, J BIOL CHEM, V257, P7678	26	57	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8381	8386		10.1074/jbc.271.14.8381	http://dx.doi.org/10.1074/jbc.271.14.8381			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626536	hybrid			2022-12-27	WOS:A1996UD60000076
J	Akha, AAS; Willmott, NJ; Brickley, K; Dolphin, AC; Galione, A; Hunt, SV				Akha, AAS; Willmott, NJ; Brickley, K; Dolphin, AC; Galione, A; Hunt, SV			Anti-Ig-induced calcium influx in rat B lymphocytes mediated by cGMP through a dihydropyridine-sensitive channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SMOOTH-MUSCLE CELLS; CYCLIC-GMP; INTRACELLULAR CA-2+; PLASMA-MEMBRANE; STIMULATION; ANTIIMMUNOGLOBULIN; ALPHA-1-SUBUNIT; IDENTIFICATION; THAPSIGARGIN	In contrast to excitable tissues where calcium channels are well characterized, the nature of the B lymphocyte calcium channel is unresolved. Here, we demonstrate by single cell analysis of freshly isolated rat B cells that the anti-immunoglobulin (Ig)-induced calcium influx takes place through a channel which shares pharmacologic and serologic properties with the L-type calcium channel found in excitable tissues, It is sensitive to the dihydropyridines nicardipine and Bay K 8644, to calciseptine, and to an anti-peptide antibody raised against the alpha(1) subunit of the L-type calcium channel, but is voltage-insensitive. Anti-alpha(1) and anti-alpha(2) antibodies stain B but not T lymphocytes, Application of a cGMP agonist, measurement of cGMP levels in anti-Ig-stimulated B cells, and examining the effect of a guanylyl cyclase inhibitor on the anti-Ig response show that cGMP mediates the influx, This possibly involves a cGMP-dependent protein kinase, The anti-Ig-induced response is not abolished by prior treatment of B cells with a high dose of thapsigargin. These findings undermine the widely held belief of a categorical divide between excitable and non-excitable tissue calcium channels, demonstrate the limitations of the capacitative calcium influx theory, and point to a distinction between the calcium response mechanisms utilized by B and T lymphocytes.	UNIV OXFORD,DEPT PHARMACOL,OXFORD OX1 3QT,ENGLAND; ROYAL FREE HOSP,SCH MED,DEPT PHARMACOL,LONDON NW3 2PF,ENGLAND	University of Oxford; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Akha, AAS (corresponding author), UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,S PARKS RD,OXFORD OX1 3RE,ENGLAND.		Galione, Antony/E-5884-2011; Dolphin, Annette C/F-7416-2010	Dolphin, Annette C/0000-0003-4626-4856; Galione, Antony/0000-0002-4132-7646				BAZIN H, 1978, J IMMUNOL, V121, P2077; BERROW NS, 1995, J PHYSIOL-LONDON, V482, P481, DOI 10.1113/jphysiol.1995.sp020534; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BRAUGHLER JM, 1979, J BIOL CHEM, V254, P2450; BRICKLEY K, 1995, FEBS LETT, V364, P129, DOI 10.1016/0014-5793(95)00371-F; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CAMPBELL V, 1995, J PHYSIOL-LONDON, V487P, pP130; CAMPBELL V, 1994, J PHYSIOL-LONDON, V480P, pP29; CATTERALL WA, 1994, CURR OPIN CELL BIOL, V6, P607, DOI 10.1016/0955-0674(94)90083-3; CLAPHAM DE, 1994, ANNU REV NEUROSCI, V17, P441; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; DEFRANCO AL, 1994, CURR OPIN IMMUNOL, V6, P364, DOI 10.1016/0952-7915(94)90114-7; DEWEILLE JR, 1991, P NATL ACAD SCI USA, V88, P2437, DOI 10.1073/pnas.88.6.2437; DOSHI M, 1985, EXP EYE RES, V41, P61, DOI 10.1016/0014-4835(85)90094-6; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GALIONE A, 1993, NATURE, V365, P457; GELFAND EW, 1989, J EXP MED, V170, P315, DOI 10.1084/jem.170.1.315; HUI A, 1991, NEURON, V7, P35, DOI 10.1016/0896-6273(91)90072-8; HUNT SV, 1981, CELL TISSUE KINET, V14, P445, DOI 10.1111/j.1365-2184.1981.tb00551.x; HUNT SV, 1986, HDB EXPT IMMUNOLOGY; HUNT SV, 1987, LYMPHOCYTES PRACTICA, P1; KOKUBUN S, 1984, P NATL ACAD SCI-BIOL, V81, P4824, DOI 10.1073/pnas.81.15.4824; LABAER J, 1986, J IMMUNOL, V137, P1836; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA YS, 1995, J BIOL CHEM, V270, P483, DOI 10.1074/jbc.270.1.483; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MASON MJ, 1991, J BIOL CHEM, V266, P10872; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; MERINEY SD, 1994, NATURE, V369, P336, DOI 10.1038/369336a0; MILLER GL, 1959, ANAL CHEM, V31, P964, DOI 10.1021/ac60149a611; MORTON ME, 1988, J BIOL CHEM, V263, P613; ODONNELL ME, 1986, J BIOL CHEM, V261, P5461; OLKEN NM, 1993, BIOCHEMISTRY-US, V32, P9677, DOI 10.1021/bi00088a020; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; SAKUMA I, 1988, P NATL ACAD SCI USA, V85, P8664, DOI 10.1073/pnas.85.22.8664; SARKADI B, 1991, J MEMBRANE BIOL, V123, P9, DOI 10.1007/BF01993958; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; VONDERHEIDE RH, 1990, EUR J IMMUNOL, V20, P79, DOI 10.1002/eji.1830200112; WOLFE L, 1989, J BIOL CHEM, V264, P7734; YAU KW, 1994, P NATL ACAD SCI USA, V91, P3481, DOI 10.1073/pnas.91.9.3481; ZIMMERMAN AL, 1995, CURR OPIN NEUROBIOL, V5, P296, DOI 10.1016/0959-4388(95)80041-7	46	61	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7297	7300		10.1074/jbc.271.13.7297	http://dx.doi.org/10.1074/jbc.271.13.7297			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631746	hybrid			2022-12-27	WOS:A1996UC77400014
J	Bang, OS; Ruscetti, FW; Lee, MH; Kim, SJ; BirchenallRoberts, MC				Bang, OS; Ruscetti, FW; Lee, MH; Kim, SJ; BirchenallRoberts, MC			Transforming growth factor-beta 1 modulates p107 function in myeloid cells - Correlation with cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; FACTOR-BETA; TGF-BETA; NEGATIVE REGULATION; CATALYTIC SUBUNIT; DEPENDENT KINASE; MAMMALIAN-CELLS; PROTEIN-KINASE; DNA-SYNTHESIS	Transforming growth factor-beta 1 (TGF-beta 1) is a potent inhibitor of hematopoietic cell growth. Here we report that TGF-beta 1 signals inhibition of IL-3-dependent 32D-123 murine myeloid cell growth by modulating the activities of cyclin E and cyclin-dependent kinase 2 (cdk2) proteins and their complex formation in the G(1) phase of the cell cycle. Whereas the cyclin E protein was hyperphosphorylated in TGF-beta 1-treated cells, TGF-beta 1 decreased both the phosphorylation of cdk2 and the kinase activity of the cyclin E-cdk2 complex. Decreased cyclin E-cdk2 kinase activity correlated with decreased phosphorylation of the retinoblastoma-related protein p107. In support of these observations, transient overexpression of p107 inhibited the proliferation of the myeloid cells, and expression of antisense oligo deoxynucleotides to p107 mRNA blocked TGF-beta 1 inhibition of myeloid cell growth. Furthermore, as reported previously, in 32D-123 TGF-beta 1-treated cells, c-Myc protein expression was decreased. TGF-beta 1 increased the binding of p107 to the transcription factor E2F, leading to decreased c-Myc protein levels, p107 inhibited E2F transactivation activity and was also found to bind the c-Myc protein, suggesting p107 negative regulation of c-Myc protein function. These studies demonstrate the modulation of p107 function by TGF-beta 1 and suggest a novel mechanism by which TGF-beta 1 blocks cell cycle progression in myeloid cells.	NCI,CHEMOPREVENT LAB,NIH,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP CANC CTR,MOLEC ONCOL LAB,BOSTON,MA 02129; NCI,BIOL CARCINOGENESIS & DEV PROGRAM,SAIC FREDERICK,NIH,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702; NCI,LAB LEUKOCYTE BIOL,DIV BASIC SCI,NIH,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702; NCI,DIV CANC TREATMENT,NIH,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								AYUSAWA D, 1983, J BIOL CHEM, V258, P2448; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BIRCHENALLROBERTS MC, 1991, J BIOL CHEM, V266, P9617; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHAMBARD JC, 1988, J CELL PHYSIOL, V135, P101, DOI 10.1002/jcp.1041350114; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DIMITRIS K, 1995, EXP CELL RES, V217, P477; DON QP, 1994, J BIOL CHEM, V269, P1306; DOU QP, 1993, CANCER RES, V53, P1493; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; EBLEN ST, 1994, CELL GROWTH DIFFER, V5, P109; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FURUKAWA Y, 1992, J BIOL CHEM, V267, P17121; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KELLER JR, 1988, J EXP MED, V168, P737, DOI 10.1084/jem.168.2.737; KITAGAWA M, 1992, ONCOGENE, V7, P1067; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; NEVINS JR, 1992, SCIENCE, V258, P424; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REDDY GPV, 1994, J CELL BIOCHEM, V54, P379, DOI 10.1002/jcb.240540404; RICHON VM, 1992, CELL GROWTH DIFFER, V3, P413; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROBERTS AB, 1990, TRANSFORMING GROWTH; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH PJ, 1983, BIOCHIM BIOPHYS ACTA, V739, P17, DOI 10.1016/0167-4781(83)90039-8; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; TSAI LH, 1993, ONCOGENE, V8, P1593; VILLAMORUZZI E, 1992, FEBS LETT, V304, P211, DOI 10.1016/0014-5793(92)80621-M; WARNER GL, 1992, CELL GROWTH DIFFER, V3, P175; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; YAMASHITA M, 1991, DEV GROWTH DIFFER, V33, P617; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	73	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7811	7819		10.1074/jbc.271.13.7811	http://dx.doi.org/10.1074/jbc.271.13.7811			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631825	hybrid			2022-12-27	WOS:A1996UC77400093
J	Kojima, K; Yamamoto, K; Irimura, T; Osawa, T; Ogawa, H; Matsumoto, I				Kojima, K; Yamamoto, K; Irimura, T; Osawa, T; Ogawa, H; Matsumoto, I			Characterization of carbohydrate-binding protein p33/41 - Relation with annexin IV, molecular basis of the doublet forms (p33 and p41), and modulation for the carbohydrate binding activity phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTICOAGULANT PROTEIN; PHOSPHATIDYLSERINE EXPOSURE; LIPOCORTIN FAMILY; CALPACTIN FAMILY; CELL-ADHESION; BOVINE KIDNEY; CALCIUM; GLUCOCORTICOIDS; SEQUENCES; MEMBRANES	A protein, p33/41, expressed in bovine kidney and many other tissues was identified as a lectin which binds to sialoglycoproteins and glycosaminoglycans in a calcium-dependent manner. Partial amino acid sequences of p33/41 are highly homologous to those of a calcium/phospholipid-binding annexin protein, annexin IV (endonexin), p33/41 exhibited similar calcium-dependent phospholipid binding activity (Kojima, K., Ogawa, H., Seno, N., Yamamoto, K., Irimura, T., Osawa, T., and Matsumoto, I. (1992) J. Biol. Chem. 267, 20536-20539). To further characterize p33/41, we cloned the p33/41 cDNA and characterized the recombinant protein encoded by this cDNA. Oligonucleotide probes were synthesized based on partial amino acid sequences of p33/41 and used for screening. A p33/41 cDNA clone was isolated encoding a protein of 319 amino acids with a calculated molecular mass of 35,769 Da, The deduced amino acid sequence was identical to that of bovine annexin IV except for one amino acid substitution. The recombinant protein gave two 33-kDa (p33) and 41-kDa (p41) bands on SDS-polyacrylamide gel electrophoresis under non-reducing conditions, and only one 33-kDa band under reducing conditions, as did the native protein, Mass spectrometric analysis combined with site-directed mutagenesis of each of the four cysteine residues of the recombinant protein revealed that p41 is a dimer of p33 cross-linked at Cys-198 via a disulfide bond, The recombinant protein bound to columns of heparin and fetuin glycopeptides in a calcium dependent manner and to phospholipid vesicles composed of phosphatidylserine (PS)/phosphatidylcholine (PC), phosphatidylethanolamine (PE)/PC or phosphatidylinositol (PI)/PC, Furthermore, concurrent binding assays showed that the binding of the recombinant protein to phospholipid vesicles was not affected by heparin, whereas that to heparin was influenced by the phospholipid composition of the vesicles; the highest binding was observed with vesicles composed of PE/PC. These results suggest that p53/41 binds two types of ligands via different sites and that phospholipids modulate the carbohydrate binding activity of p33/41.	UNIV TOKYO,FAC PHARMACEUT SCI,DIV CANC BIOL & MOLEC IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo	Kojima, K (corresponding author), OCHANOMIZU UNIV,FAC SCI,DEPT CHEM,BUNKYO KU,2-1-1 OTSUKA,TOKYO 112,JAPAN.							ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BARONDES SH, 1981, ANNU REV BIOCHEM, V50, P207, DOI 10.1146/annurev.bi.50.070181.001231; BECKER T, 1990, EMBO J, V9, P4207, DOI 10.1002/j.1460-2075.1990.tb07868.x; BIANCHI R, 1992, FEBS LETT, V296, P158, DOI 10.1016/0014-5793(92)80369-R; BLACKWELL GJ, 1980, NATURE, V287, P147, DOI 10.1038/287147a0; BLACKWELL GJ, 1982, BRIT J PHARMACOL, V76, P185, DOI 10.1111/j.1476-5381.1982.tb09205.x; BRISSON A, 1991, J MOL BIOL, V220, P199, DOI 10.1016/0022-2836(91)90002-N; CHAN HC, 1994, J BIOL CHEM, V269, P32464; CHEN JM, 1993, J BIOMOL STRUCT DYN, V10, P1067, DOI 10.1080/07391102.1993.10508696; CHRISTMAS P, 1991, J BIOL CHEM, V266, P2499; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; CRUETZ CE, 1992, SCIENCE, V258, P924; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; FLAHERTY MJ, 1990, J LAB CLIN MED, V115, P174; GENGE BR, 1991, J BIOL CHEM, V266, P10678; GEOFFROY JS, 1989, J CELL BIOL, V109, P2463, DOI 10.1083/jcb.109.5.2463; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GOULDING NJ, 1992, ARTHRITIS RHEUM, V35, P1395, DOI 10.1002/art.1780351126; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HAMMAN HC, 1988, BIOCHEM BIOPH RES CO, V156, P660, DOI 10.1016/S0006-291X(88)80893-3; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; IKEDA K, 1987, J BIOL CHEM, V262, P7451; KANAMORI A, 1986, J CHROMATOGR, V363, P231, DOI 10.1016/S0021-9673(01)83742-0; KITAGAKIOGAWA H, 1990, BIOCHIM BIOPHYS ACTA, V1033, P49, DOI 10.1016/0304-4165(90)90193-Z; KOJIMA K, 1992, J CHROMATOGR, V597, P323, DOI 10.1016/0021-9673(92)80127-G; KOJIMA K, 1992, J BIOL CHEM, V267, P20536; KOJIMA K, 1994, FEBS LETT, V342, P313, DOI 10.1016/0014-5793(94)80523-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARMONTH MP, 1992, BIOCHIM BIOPHYS ACTA, V1160, P76, DOI 10.1016/0167-4838(92)90040-K; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MATSUMOTO L, 1980, J BIOCHEM-TOKYO, V85, P1091; OTTO M, 1994, FEBS LETT, V356, P125, DOI 10.1016/0014-5793(94)01241-5; PFAFFLE M, 1988, EMBO J, V7, P2335, DOI 10.1002/j.1460-2075.1988.tb03077.x; RAO LVM, 1992, THROMB RES, V67, P517, DOI 10.1016/0049-3848(92)90013-Z; RAVANAT C, 1992, BIOCHEM J, V282, P7, DOI 10.1042/bj2820007; ROJAS E, 1990, J BIOL CHEM, V265, P21207; ROSS TS, 1990, SCIENCE, V248, P605, DOI 10.1126/science.2159184; TAIT JF, 1989, J BIOL CHEM, V264, P7944; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; TRESSLER RJ, 1993, J CELL BIOCHEM, V53, P265, DOI 10.1002/jcb.240530311; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; WRIGHT JF, 1994, BIOCHEM BIOPH RES CO, V198, P983, DOI 10.1006/bbrc.1994.1140; YEATMAN TJ, 1993, CLIN EXP METASTAS, V11, P37, DOI 10.1007/BF00880064	45	40	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7679	7685		10.1074/jbc.271.13.7679	http://dx.doi.org/10.1074/jbc.271.13.7679			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631806	hybrid			2022-12-27	WOS:A1996UC77400074
J	Leno, GH; Mills, AD; Philpott, A; Laskey, RA				Leno, GH; Mills, AD; Philpott, A; Laskey, RA			Hyperphosphorylation of nucleoplasmin facilitates Xenopus sperm decondensation at fertilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACIDIC PROTEIN; EGG CYTOPLASM; NUCLEI; OOCYTES; LAEVIS; PHOSPHORYLATION; REPLICATION; CHROMATIN; EXTRACTS	Previous studies showed that the nuclear phosphoprotein nucleoplasmin performs the first stage of chromatin decondensation of Xenopus sperm at fertilization. It binds and removes sperm basic proteins replacing them with histones. We now show that this activity depends upon the massive hyperphosphorylation of nucleoplasmin that occurs when oocytes mature into eggs. Egg extracts or purified hyperphosphorylated egg nucleoplasmin decondense sperm chromatin and re move sperm basic proteins much faster than oocyte extracts or hypophosphorylated oocyte nucleoplasmin. Furthermore, dephosphorylation of egg nucleoplasmin slows sperm decondensation and prevents basic protein removal from sperm chromatin. We conclude that hyperphosphorylation of nucleoplasmin is used to modulate the rapid changes in chromatin structure that accompany early development in Xenopus.	WELLCOME CANC RES CTR INST CANC & DEV BIOL,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1QR,ENGLAND	University of Cambridge	Leno, GH (corresponding author), UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,2500 N STATE ST,JACKSON,MS 39216, USA.			Philpott, Anna/0000-0003-3789-2463	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARRY JM, 1972, EXP CELL RES, V71, P90, DOI 10.1016/0014-4827(72)90267-4; BURGLIN TR, 1987, GENE DEV, V1, P190; COTTEN M, 1986, BIOCHEMISTRY-US, V25, P5063, DOI 10.1021/bi00366a014; COX LS, 1990, J CELL SCI, V97, P177; DIMITROV S, 1994, J CELL BIOL, V126, P591, DOI 10.1083/jcb.126.3.591; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; KROHNE G, 1980, P NATL ACAD SCI-BIOL, V77, P1034, DOI 10.1073/pnas.77.2.1034; KROHNE G, 1980, EXP CELL RES, V129, P167, DOI 10.1016/0014-4827(80)90341-9; LASKEY RA, 1983, PHILOS T ROY SOC B, V302, P143, DOI 10.1098/rstb.1983.0047; LENO GH, 1993, JOHN INN S, P135; LOHKA MJ, 1983, EXP CELL RES, V148, P481, DOI 10.1016/0014-4827(83)90169-6; MANN M, 1982, J EXP ZOOL, V222, P173, DOI 10.1002/jez.1402220209; MILLS AD, 1980, J MOL BIOL, V139, P561, DOI 10.1016/0022-2836(80)90148-5; OHSUMI K, 1991, DEV BIOL, V147, P110, DOI 10.1016/S0012-1606(05)80011-9; PHILPOTT A, 1992, CELL, V69, P759, DOI 10.1016/0092-8674(92)90288-N; PHILPOTT A, 1991, CELL, V65, P569, DOI 10.1016/0092-8674(91)90089-H; RISLEY MS, 1981, DEV BIOL, V84, P79, DOI 10.1016/0012-1606(81)90372-9; SEALY L, 1986, BIOCHEMISTRY-US, V25, P3064, DOI 10.1021/bi00358a049; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1	19	78	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7253	7256		10.1074/jbc.271.13.7253	http://dx.doi.org/10.1074/jbc.271.13.7253			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631735	hybrid			2022-12-27	WOS:A1996UC77400003
J	Rankin, S; HooshmandRad, R; ClaessonWelsh, L; Rozengurt, E				Rankin, S; HooshmandRad, R; ClaessonWelsh, L; Rozengurt, E			Requirement for phosphatidylinositol 3'-kinase activity in platelet-derived growth factor-stimulated tyrosine phosphorylation of p125 focal adhesion kinase and paxillin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; PHOSPHOLIPASE-C-GAMMA; PDGF BETA-RECEPTOR; SIGNALING COMPLEX; SRC FAMILY; ASSOCIATION; BINDING; VASOPRESSIN; BOMBESIN; 3-KINASE	The role of phosphatidylinositol 3'-kinase (PI 3'-kinase) activity in platelet-derived growth factor (PDGF)-stimulated tyrosine phosphorylation of focal adhesion kinase (p125(FAK)) paxillin has been examined. The tyrosine phosphorylation of p125(FAK) and paxillin in response to PDGF was markedly inhibited by wortmannin in a dose-dependent manner. PDGF-stimulated PI 3'-kinase activity, membrane ruffle formation, and tyrosine phosphorylation of p125(FAK) and paxillin were all inhibited by the same low concentrations of wortmannin (>90% inhibition at 40 nM). In contrast, tyrosine phosphorylation of p125(FAK) and paxillin in response to bombesin, endothelin, and phorbol 12,13-dibutyrate was not inhibited by wortmannin in these cells. Furthermore, LY294002, an inhibitor of PI 3'-kinase structurally unrelated to wortmannin, also inhibited PDGF-stimulated p125(FAK) tyrosine phosphorylation. PDGF was shown to stimulate the tyrosine phosphorylation of p125(FAK) in porcine aortic endothelial (PAE) cells transfected with the wild type PDGF-beta receptors, but not in PAE cells transfected with PDGF-beta receptors in which the PI 3'-kinase binding sites (Tyr-740/751) were replaced by phenylalanine. PDGF-stimulated, PI 3'-kinase-dependent tyrosine phosphorylation of p125(FAK) was not inhibited by rapamycin, and thus it was dissociated from the activation of p70 S6 kinase, previously identified as a molecular downstream target of PI 3'-kinase. Thus, we have identified a PI 3'-kinase-dependent signal transduction pathway in the action of PDGF, which leads to the phosphorylation of p125(FAK) and paxillin.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; LUDWIG INST CANC RES,UPPSALA BRANCH,S-75124 UPPSALA,SWEDEN	Cancer Research UK; Ludwig Institute for Cancer Research								ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LLIC D, 1995, NATURE, V377, P539; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NOBES CD, 1995, J CELL SCI, V108, P225; OKADA T, 1994, J BIOL CHEM, V269, P3563; POWIS G, 1994, CANCER RES, V54, P2419; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; ROZENGURT E, 1995, CANCER SURV, V24, P81; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; YANO H, 1993, J BIOL CHEM, V268, P25846; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	67	95	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7829	7834		10.1074/jbc.271.13.7829	http://dx.doi.org/10.1074/jbc.271.13.7829			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631827	hybrid			2022-12-27	WOS:A1996UC77400095
J	Tan, RY; Mabuchi, Y; Grabarek, Z				Tan, RY; Mabuchi, Y; Grabarek, Z			Blocking the Ca2+-induced conformational transitions in calmodulin with disulfide bonds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPONIN-C; PEPTIDE COMPLEX; MUSCLE; SITE; MUTAGENESIS; CALCINEURIN; RECOGNITION; RESOLUTION; MODEL	Calcium dependent regulation of intracellular processes is mediated by proteins that on binding Ca2+ assume a new conformation, which enables them to bind to their specific target proteins and to modulate their function. Calmodulin (CaM) and troponin C, the two best characterized Ca2+-regulatory proteins, are members of the family of Ca2+-binding proteins utilizing the helix-loop-helix structural motif (EF-hand), Herzberg, Moult, and James (Herzberg, O., Moult, J., and James, M. N. G. (1986) J. Biol. Chem. 261, 2638-2644) proposed that the Ca2+-induced conformational transition in troponin C involves opening of the interface between the a helical segments in the N-terminal domain of this protein. Here we have tested the hypothesis that a similar transition is the key Ca2+-induced regulatory event in calmodulin. Using site-directed mutagenesis we have substituted cysteine residues for Gln(41) and Lys(75) (CaM41/ 75) or Ile(85) and Leu(112) (CaM85/112) in the N-terminal and C-terminal domains, respectively, of human liver calmodulin. Based on molecular modeling, cysteines at these positions were expected to form intramolecular disulfide bonds in the Ca2+-free conformation of the protein, thus blocking the putative Ca2+-induced transition. We found that intramolecular disulfide bonds are readily formed in both mutants causing a decrease in affinity for Ca2+ and the loss of ability to activate target enzymes, phosphodiesterase and calcineurin, The regulatory activity is fully recovered in CaM41/75 and partially recovered in CaM85/112 upon reduction of the disulfide bonds with dithiotreitol and blocking the Cys residues by carboxyamidomethylation or cyanylation. These results indicate that the Ca2+-induced opening of the interfaces between helical segments in both domains of CaM is critical for its regulatory properties consistent with the Herzberg-Moult-James model.	BOSTON BIOMED RES INST, MUSCLE RES GRP, BOSTON, MA 02114 USA	Boston Biomedical Research Institute				Grabarek, Zenon/0000-0002-3636-5701	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL005949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37-HL-05949] Funding Source: Medline; NIAMS NIH HHS [P01-AR41637, AR-41156] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; CLORE GM, 1993, CURR OPIN STRUC BIOL, V3, P838, DOI 10.1016/0959-440X(93)90146-C; FINN BE, 1995, NAT STRUCT BIOL, V2, P777, DOI 10.1038/nsb0995-777; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GRABAREK Z, 1990, NATURE, V345, P132, DOI 10.1038/345132a0; GRABAREK Z, 1992, J MUSCLE RES CELL M, V13, P383, DOI 10.1007/BF01738034; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KLEE CB, 1983, METHOD ENZYMOL, V102, P227; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; NEWTON DL, 1984, J BIOL CHEM, V259, P4419; PALLEN CJ, 1983, J BIOL CHEM, V258, P8550; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; PERSECHINI A, 1988, J CARDIOVASC PHARM, V12, pS1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sillen L, 1964, STABILITY CONSTANTS; SKELTON NJ, 1994, NAT STRUCT BIOL, V1, P239, DOI 10.1038/nsb0494-239; SOWDHAMINI R, 1989, PROTEIN ENG, V3, P95, DOI 10.1093/protein/3.2.95; Strynadka N. C. J., 1995, Biophysical Journal, V68, pA359; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; WALLACE RW, 1983, METHOD ENZYMOL, V102, P39; WAWRZYNCZAK EJ, 1984, BIOCHEM INT, V9, P177; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758	29	56	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7479	7483		10.1074/jbc.271.13.7479	http://dx.doi.org/10.1074/jbc.271.13.7479			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631777	hybrid			2022-12-27	WOS:A1996UC77400045
J	Abell, A; Liu, XB; Segaloff, DL				Abell, A; Liu, XB; Segaloff, DL			Deletions of portions of the extracellular loops of the lutropin choriogonadotropin receptor decrease the binding affinity for ovine luteinizing hormone, but not human choriogonadotropin, by preventing the formation of mature cell surface receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORIONIC-GONADOTROPIN RECEPTOR; BETA-ADRENERGIC-RECEPTOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; PROTEIN-COUPLED RECEPTORS; PLASMA-MEMBRANE; LIGAND-BINDING; GLYCOSYLATION SITES; INTRACELLULAR LOOP; OVERLAP EXTENSION; EXPRESSION	The rat lutropin/choriogonadotropin receptor (rLHR) is a G protein-coupled receptor which binds either human choriogonadotropin (hCG) or lutropin (luteinizing hormone, LH) and, therefore, plays a central role in reproductive physiology. In addition to the seven transmembrane helices, three extracellular loops, three intracellular loops, and a cytoplasmic tail characteristic of all G protein-coupled receptors, the rLHR also contains a relatively large N-terminal extracellular domain. Since high affinity hormone binding occurs to this N-terminal extracellular domain and since G proteins are activated by intracellular regions of the receptor, it has been hypothesized that upon hormone binding a portion of the hormone or the receptor's extracellular domain might interact with the receptor's extracellular loops and/or transmembrane helices, thus evoking an intracellular conformational change. To explore this possibility, we prepared and characterized several mutants of the rLHR in which portions of the extracellular loops were deleted. Ultimately, it was not possible to examine the signal transduction properties of the mutants because all but one mutant were retained intracellularly. Although the intracellularly retained mutants must be somewhat misfolded, all were found to bind hCG with high affinity if the cells were first solubilized in detergent. However, the binding of oLH to the detergent solubilized mutants was altered. Thus, whereas the wild-type rLHR bound oLH with two apparent affinities, the solubilized deletion mutants bound oLH with only one apparent affinity. Although these data could be interpreted to suggest that an ovine LH (oLH) binding site on the extracellular loops of the rLHR was deleted, data shown argue against this hypothesis. Rather, the results presented suggest that the two apparent affinities of the wild-type rLHR for oLH represent the binding affinities of two populations of rLHR where the mature, cell surface form binds oLH with a higher affinity than the immature, intracellular form, Furthermore, we show that mutations of the rLHR which cause intracellular retention of the receptor result in a decrease from two to one apparent binding sites for oLH due to the absence of the high affinity oLH binding component contributed by the mature cell surface receptor. Therefore, whereas hCG cannot discriminate between the mature cell surface wild-type receptor and an intracellularly retained rLHR mutant, oLH can make this discrimination, thus suggesting a conformational difference between the two forms of the receptor.	UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD022196] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K04HD000968, R01HD022196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NICHD NIH HHS [HD00968, HD22196] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMOWITZ J, 1982, ENDOCRINOLOGY, V110, P336, DOI 10.1210/endo-110-2-336; AMIRZALTSMAN Y, 1980, ENDOCRINOLOGY, V106, P1166, DOI 10.1210/endo-106-4-1166; ASCOLI M, 1978, P NATL ACAD SCI USA, V75, P99, DOI 10.1073/pnas.75.1.99; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAVIS D, 1995, MOL ENDOCRINOL, V9, P159, DOI 10.1210/me.9.2.159; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; DOHLMAN HG, 1988, BIOCHEMISTRY-US, V27, P1813, DOI 10.1021/bi00406a002; FLANAGAN CA, 1994, J BIOL CHEM, V269, P22636; FONG TM, 1992, J BIOL CHEM, V267, P25664; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HIPKIN RW, 1992, MOL ENDOCRINOL, V6, P2210, DOI 10.1210/me.6.12.2210; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JI L, 1991, J BIOL CHEM, V266, P13076; JI L, 1991, ENDOCRINOLOGY, V128, P2648; LABARBERA AR, 1980, ARCH BIOCHEM BIOPHYS, V200, P177, DOI 10.1016/0003-9861(80)90344-6; LEONG SR, 1994, J BIOL CHEM, V269, P19343; LIMBIRD LE, 1981, BIOCHEM J, V195, P1; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MACHAMER CE, 1988, J BIOL CHEM, V263, P5948; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MCILROY PJ, 1981, J CYCLIC NUCLEOTIDE, V6, P379; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; QUINTANA J, 1993, MOL ENDOCRINOL, V7, P767, DOI 10.1210/me.7.6.767; RAO CV, 1975, MOL CELL ENDOCRINOL, V3, P255, DOI 10.1016/0303-7207(75)90008-8; ROCHE PC, 1985, ENDOCRINOLOGY, V117, P790, DOI 10.1210/endo-117-2-790; ROCHE PC, 1992, ENDOCRINOLOGY, V131, P268, DOI 10.1210/en.131.1.268; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; RODRIGUEZ MC, 1990, ENDOCRINOLOGY, V127, P674, DOI 10.1210/endo-127-2-674; ROSEMBLIT N, 1988, ENDOCRINOLOGY, V123, P2284, DOI 10.1210/endo-123-5-2284; ROZELL TG, 1995, MOL ENDOCRINOL, V9, P1727; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SHI YF, 1993, THYROID, V3, P129, DOI 10.1089/thy.1993.3.129; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; THOMAS DM, 1994, ENDOCRINOLOGY, V135, P1902, DOI 10.1210/en.135.5.1902; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; VUHAILUUTHI MT, 1992, BIOCHEMISTRY-US, V31, P8377, DOI 10.1021/bi00150a035; WANG HY, 1993, MOL ENDOCRINOL, V7, P1437, DOI 10.1210/me.7.11.1437; WANG HY, 1989, J BIOL CHEM, V264, P14424; WANG Z, 1993, MOL ENDOCRINOL, V7, P85, DOI 10.1210/me.7.1.85; XIE YB, 1990, J BIOL CHEM, V265, P21411; ZHU HY, 1995, MOL ENDOCRINOL, V9, P141, DOI 10.1210/me.9.2.141	48	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4518	4527						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626807				2022-12-27	WOS:A1996TW96000085
J	Duan, CM; Hawes, SB; Prevette, T; Clemmons, DR				Duan, CM; Hawes, SB; Prevette, T; Clemmons, DR			Insulin-like growth factor-I (IGF-I) regulates IGF-binding protein-5 synthesis through transcriptional activation of the gene in aortic smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOBLAST DIFFERENTIATION; RETINOBLASTOMA PROTEIN; BALLOON DENUDATION; MOLECULAR-CLONING; MESSENGER-RNA; RAT AORTA; EXPRESSION; IDENTIFICATION; FIBROBLASTS; SECRETION	Previous studies have shown that porcine aortic smooth muscle cells (SMCs) secrete two insulin-like growth factor-binding proteins (IGFBP), IGFBP-2 and -4, and that these IGFBPs modulate IGF-I-stimulated SMC proliferation and migration. In this study we demonstrate that porcine SMCs express IGFBP-5 mRNA and synthesize and secrete the protein, In this cell type, the biosynthesis of IGFBP-5 is up-regulated by IGF-I. This increase in IGFBP-5 synthesis is accompanied by an increase in the steady-state mRNA levels. The induction of IGFBP-5 mRNA by IGF-I is time- and dose-dependent and requires de novo protein synthesis, IGF-II and insulin also increase IGFBP-5 mRNA levels at high doses. An IGF-I analog with normal affinity for the IGF-I receptor but reduced affinity for IGFBPs evokes a similar increase. Another analog that binds to IGFBPs but not to the receptor has no effect, indicating that this effect of IGF-I is mediated through the IGF-I receptor. The IGF-I-induced IGFBP-5 gene expression is cell type-specific because IGF-I had no such effect in other cell types examined. Nuclear run-on assays revealed that IGF-I increased transcription rate of the IGFBP-5 gene, while IGF-I did not change the IGFBP-5 mRNA stability. Furthermore, the IGFBP-5 promoter was 3.5-fold more active in directing expression of the luciferase reporter gene in IGF-I-treated aortic SMCs as compared to control cells, whereas the luciferase activity remained the same in control- and IGF-I-treated fibroblasts. These results suggest that IGF-I up-regulates IGFBP-5 synthesis by transcriptionally activating the IGFBP-5 gene in aortic SMCs.			Duan, CM (corresponding author), UNIV N CAROLINA, DEPT MED, DIV ENDOCRINOL, CB 7170, CHAPEL HILL, NC 27599 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL026309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG002331, R37AG002331] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-26309] Funding Source: Medline; NIA NIH HHS [AG02331] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADASHI EY, 1994, MOL CELL ENDOCRINOL, V99, P279, DOI 10.1016/0303-7207(94)90018-3; ALEMANY J, 1990, P NATL ACAD SCI USA, V87, P3353, DOI 10.1073/pnas.87.9.3353; ALLANDER SV, 1994, J BIOL CHEM, V269, P10891; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARAI T, 1994, ENDOCRINOLOGY, V135, P2358, DOI 10.1210/en.135.6.2358; BACKELJAUW PF, 1993, ENDOCRINOLOGY, V132, P1677, DOI 10.1210/en.132.4.1677; BANSKOTA NK, 1989, DIABETES, V38, P123, DOI 10.2337/diabetes.38.1.123; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; BORNFELDT KE, 1990, J ENDOCRINOL, V125, P381, DOI 10.1677/joe.0.1250381; BOURNER MJ, 1992, J CELL BIOCHEM, V48, P215; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CANALIS E, 1995, J BIOL CHEM, V270, P10771, DOI 10.1074/jbc.270.18.10771; CERCEK B, 1990, CIRC RES, V66, P1755, DOI 10.1161/01.RES.66.6.1755; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CLEMMONS DR, 1985, CIRC RES, V56, P418, DOI 10.1161/01.RES.56.3.418; CLEMMONS DR, 1985, ENDOCRINOLOGY, V117, P77, DOI 10.1210/endo-117-1-77; COHICK WS, 1993, J CELL PHYSIOL, V157, P52, DOI 10.1002/jcp.1041570107; COHICK WS, 1995, J CELL PHYSIOL, V164, P187, DOI 10.1002/jcp.1041640123; CONOVER CA, 1995, ENDOCRINOLOGY, V136, P1403, DOI 10.1210/en.136.4.1403; CONOVER CA, 1993, ENDOCRINOLOGY, V132, P2525, DOI 10.1210/en.132.6.2525; CONOVER CA, 1993, J CLIN ENDOCR METAB, V76, P1153, DOI 10.1210/jc.76.5.1153; DELAFONTAINE P, 1991, HYPERTENSION, V18, P742, DOI 10.1161/01.HYP.18.6.742; DONG Y, 1995, ENDOCRINOLOGY, V136, P2000, DOI 10.1210/en.136.5.2000; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DU J, 1995, CIRC RES, V76, P963, DOI 10.1161/01.RES.76.6.963; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; EPSTEIN SE, 1991, CIRCULATION, V84, P778, DOI 10.1161/01.CIR.84.2.778; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FIELDER PJ, 1993, ENDOCRINOLOGY, V133, P415, DOI 10.1210/en.133.1.415; FURLANETTO RW, 1994, MOL ENDOCRINOL, V8, P510, DOI 10.1210/me.8.4.510; GOCKERMAN A, 1995, CIRC RES, V76, P514, DOI 10.1161/01.RES.76.4.514; GOCKERMAN A, 1995, ENDOCRINOLOGY, V136, P4168, DOI 10.1210/en.136.10.4168; GRANT MB, 1994, CIRCULATION, V89, P1511, DOI 10.1161/01.CIR.89.4.1511; GREENBERG ME, 1994, CURRENT PROTOCOLS MO, V1; JAMES PL, 1993, J BIOL CHEM, V268, P22305; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KHORSANDI MJ, 1992, J CLIN INVEST, V90, P1926, DOI 10.1172/JCI116070; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; KOU K, 1995, DNA CELL BIOL, V14, P241, DOI 10.1089/dna.1995.14.241; KOU K, 1994, GENOMICS, V20, P412, DOI 10.1006/geno.1994.1195; MARTIN JL, 1988, ENDOCRINOLOGY, V123, P1907, DOI 10.1210/endo-123-4-1907; MCCUSKER RH, 1988, J CELL PHYSIOL, V137, P505, DOI 10.1002/jcp.1041370316; MONNIER D, 1994, MOL CELL ENDOCRINOL, V104, P139, DOI 10.1016/0303-7207(94)90116-3; PARKER A, 1995, ENDOCRINOLOGY, V136, P2470, DOI 10.1210/en.136.6.2470; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; ROTWEIN P, 1995, MOL ENDOCRINOL, V9, P913, DOI 10.1210/me.9.7.913; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; SHEIKH MS, 1992, BIOCHEM BIOPH RES CO, V188, P1122, DOI 10.1016/0006-291X(92)91348-T; SHEMER J, 1993, J CLIN ENDOCR METAB, V77, P1246, DOI 10.1210/jc.77.5.1246; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SIMMONS JG, 1995, MOL ENDOCRINOL, V9, P1157, DOI 10.1210/me.9.9.1157; SKAR R, 1994, MOL CELL ENDOCRINOL, V106, P213, DOI 10.1016/0303-7207(94)90205-4; TAMAROGLIO TA, 1994, EXP CELL RES, V215, P338, DOI 10.1006/excr.1994.1350; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; URBAN RJ, 1994, J BIOL CHEM, V269, P25761; WOLFE BL, 1993, J BIOL CHEM, V268, P12418; YAMASHITA S, 1987, J CLIN INVEST, V79, P449, DOI 10.1172/JCI112832; ZHU X, 1993, BIOCHEM BIOPH RES CO, V190, P1045, DOI 10.1006/bbrc.1993.1154	62	78	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4280	4288						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626775				2022-12-27	WOS:A1996TW96000053
J	Davis, BH; Chen, AP; Beno, DWA				Davis, BH; Chen, AP; Beno, DWA			Raf and mitogen-activated protein kinase regulate stellate cell collagen gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; RETINOIC ACID; PROMOTER	Hepatic stellate cells become activated into myofibroblast-like cells during the early stages of hepatic injury associated with fibrogenesis. The subsequent dysregulation of hepatic stellate cell collagen gene expression is a central pathogenetic step during the development of cirrhosis. The cytoplasmic Raf and mitogen-activated protein (MAPK) kinases were found to differentially regulate alpha I(I) collagen gene expression in activated stellate cells. This suggests an unappreciated branch point exists between Raf and MAPK. A MAPK-stimulatory signal was mapped to the most proximal NF-1 and Sp-1 binding domains of the 5'-untranslated region of the collagen gene. A Raf-inhibitory signal was mapped to a further upstream binding domain involving a novel 60-kDa DNA-binding protein (p60). The cell-specific expression and induction of p60 in stellate cells during the early stages of hepatic fibrogenesis in vivo suggest a central role for this pathway during liver injury and stellate cell activation.			Davis, BH (corresponding author), UNIV CHICAGO,MED CTR,DEPT MED,GASTROENTEROL SECT,MC 4076,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.				NIDDK NIH HHS [DK 42086, DK40223, DK 02022] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002022, P30DK042086, R29DK040223] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARWAL S, 1995, ONCOGENE, V11, P427; ARMENDARIZBORUNDA J, 1994, BIOCHEM J, V304, P817, DOI 10.1042/bj3040817; ATFI A, 1995, P NATL ACAD SCI USA, V92, P1210; BENO DWA, 1995, AM J PHYSIOL-CELL PH, V268, pC604, DOI 10.1152/ajpcell.1995.268.3.C604; BENO DWA, 1995, J BIOL CHEM, V270, P3642, DOI 10.1074/jbc.270.8.3642; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRENNER DA, 1989, NUCLEIC ACIDS RES, V17, P6055, DOI 10.1093/nar/17.15.6055; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS BH, 1991, BIOCHEM J, V278, P43, DOI 10.1042/bj2780043; DAVIS BH, 1990, J CLIN INVEST, V86, P2062, DOI 10.1172/JCI114943; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FRIEDMAN SL, 1994, J BIOL CHEM, V269, P10551; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOUGLUM K, 1995, J CLIN INVEST, V96, P2269, DOI 10.1172/JCI118282; HOWE PH, 1993, J BIOL CHEM, V268, P21448; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATAI H, 1992, MOL CELL BIOCHEM, V118, P119; LASKIN DL, 1990, SEMIN LIVER DIS, V10, P293, DOI 10.1055/s-2008-1040485; LISKA DJ, 1994, J CELL BIOL, V125, P695, DOI 10.1083/jcb.125.3.695; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; RIPPE RA, 1995, HEPATOLOGY, V22, P241, DOI 10.1016/0270-9139(95)90378-X; RITZENTHALER JD, 1993, J BIOL CHEM, V268, P13625; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; SLACK JL, 1992, MOL CELL BIOL, V12, P4714, DOI 10.1128/MCB.12.10.4714; SLACK JL, 1991, MOL CELL BIOL, V11, P2066, DOI 10.1128/MCB.11.4.2066; WONG L, 1994, J CLIN INVEST, V94, P1563, DOI 10.1172/JCI117497; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	30	77	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11039	11042		10.1074/jbc.271.19.11039	http://dx.doi.org/10.1074/jbc.271.19.11039			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626642	hybrid			2022-12-27	WOS:A1996UJ94400002
J	Gilbert, GE; Arena, AA				Gilbert, GE; Arena, AA			Activation of the factor VIIIa-factor IXa enzyme complex of blood coagulation by membranes containing phosphatidyl-L-serine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-X; PHOSPHOLIPID-VESICLES; HUMAN-PLATELETS; FACTOR-VA; BINDING; PROTHROMBINASE	Factor IXa, a serine protease of blood coagulation, functions at least 100,000 times more efficiently when bound to factor VIIIa on a phospholipid membrane than when free in solution. We have utilized the catalytic activity of the factor VIIIa-factor IXa complex to report the effect of phospholipid membranes on binding of factor IXa to factor VIIIa and on enzymatic cleavage of the product. The apparent affinity of factor IXa for factor VIIIa was 10-fold lower in the absence of phospholipid membranes with a K-D of 46 nM versus 4.3 nM with phospholipid membranes. The K-m for activation of factor X by the factor VIIIa-factor IXa complex was 1700 nM in solution, 70-fold higher than the value of 28 nM when bound to membranes containing phosphatidyl-L-serine, phosphatidylethanolamine, and phosphatidylcholine at a ratio of 4:20:76. The largest effect of phosphatidyl-L-serine-containing membranes on the factor VIIIa-factor IXa complex was the accelerated rate of peptide bond cleavage, with the k(cat) increased by 1,500-fold from 0.022 to 33 min(-1). Membranes in which phosphatidyl-L-serine was replaced by phosphatidyl-D-serine, phosphatidic acid, or phosphatidylglycerol were at least 10-fold less effective for enhancing the k(cat). Thus, while membranes containing phosphatidyl-L-serine enhance condensation of the enzyme with its cofactor and substrate, their largest effect is activation of the assembled factor VIIIa-factor IXa enzyme complex.	BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02132; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02132	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Gilbert, GE (corresponding author), BROCKTON W ROXBURY VET AFFAIRS MED CTR,DEPT MED,1400 VFW PKWY,BOSTON,MA 02132, USA.				NHLBI NIH HHS [P01 HL42443I] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042443] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEALS JM, 1986, BIOCHEM J, V236, P861, DOI 10.1042/bj2360861; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; COMFURIUS P, 1990, J LIPID RES, V31, P1719; COMFURIUS P, 1977, BIOCHIM BIOPHYS ACTA, V488, P36, DOI 10.1016/0005-2760(77)90120-5; CURTIS JE, 1994, J BIOL CHEM, V269, P6246; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; GILBERT GE, 1993, BIOCHEMISTRY-US, V32, P9577, DOI 10.1021/bi00088a009; GILBERT GE, 1995, J BIOL CHEM, V270, P18500, DOI 10.1074/jbc.270.31.18500; GILBERT GE, 1992, J BIOL CHEM, V267, P15861; GILBERT GE, 1990, J BIOL CHEM, V265, P815; GILBERT GE, 1991, J BIOL CHEM, V266, P17261; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; KRISHNASWAMY S, 1994, BIOCHEMISTRY-US, V33, P7897, DOI 10.1021/bi00191a017; KUNG C, 1994, J BIOL CHEM, V269, P25838; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; MANN KG, 1990, BLOOD, V76, P1; MERTENS K, 1984, BIOCHEM J, V223, P599, DOI 10.1042/bj2230599; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4172, DOI 10.1021/bi00638a006; NESHEIM ME, 1988, J BIOL CHEM, V263, P16467; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; RAWALASHEIKH R, 1990, BIOCHEMISTRY-US, V29, P2606, DOI 10.1021/bi00462a025; ROSING J, 1980, J BIOL CHEM, V255, P274; SANDBERG H, 1985, THROMB RES, V39, P63, DOI 10.1016/0049-3848(85)90122-7; SIMS PJ, 1986, BLOOD, V68, P556; SKOGEN WF, 1984, J BIOL CHEM, V259, P2306; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; WOLF P, 1967, BRIT J HAEMATOL, V13, P269, DOI 10.1111/j.1365-2141.1967.tb08741.x	31	80	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11120	11125		10.1074/jbc.271.19.11120	http://dx.doi.org/10.1074/jbc.271.19.11120			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626656	hybrid			2022-12-27	WOS:A1996UJ94400016
J	Mandriota, SJ; Menoud, PA; Pepper, MS				Mandriota, SJ; Menoud, PA; Pepper, MS			Transforming growth factor beta 1 down-regulates vascular endothelial growth factor receptor 2/flk-1 expression in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; TYROSINE KINASE; ANGIOGENESIS; ACTIVATION; FACTOR-BETA-1; IDENTIFICATION; INHIBITION; PERICYTES; SEQUENCE; PLASMIN	Although the importance of the vascular endothelial growth factor (VEGF)/VEGF tyrosine kinase receptor (VEGFR) system in angiogenesis is well established, very little is known about the regulation of VEGFR expression in vascular endothelial cells. We have cloned partial cDNAs encoding bovine VEGFR-1 (flt) and -2 (flk-1) and used them to study VEGFR expression by bovine microvascular- and large vessel-derived endothelial cells. Both cell lines express flk-1, but not flt. Transforming growth factor beta 1 (TGF-beta 1) reduced the high affinity I-125-VEGF binding capacity of both cell types in a dose-dependent manner, with a 2.0-2.7-fold decrease at 1-10 ng/ml. Cross-linking experiments revealed a decrease in I-125-VEGF binding to a cell surface monomeric protein corresponding to Flk-1 on the basis of its affinity for VEGF, molecular mass (185-190 kDa), and apparent internalization after VEGF binding. Immunoprecipitation and Western blot experiments demonstrated a decrease in Flk-1 protein expression, and TGF-beta 1 reduced flk-1 mRNA levels in a dose-dependent manner. These results imply that TGF-beta 1 is a major regulator of the VEGF/Flk-1 signal transduction pathway in endothelial cells.	UNIV GENEVA,MED CTR,DEPT MORPHOL,CH-1211 GENEVA 4,SWITZERLAND; UNIV GENEVA,MED CTR,DIV ONCOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva; University of Geneva			Pepper, Michael S./M-6143-2014	Pepper, Michael S./0000-0001-6406-2380				AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; AUSPRUNK D, 1977, MICROVASC RES, V14, P52; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FINNERTY H, 1993, ONCOGENE, V8, P2293; FLAUMENHAFT R, 1992, J CELL BIOL, V118, P901, DOI 10.1083/jcb.118.4.901; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FURIE MB, 1984, J CELL BIOL, V98, P1033, DOI 10.1083/jcb.98.3.1033; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; ISACCHI A, 1990, NUCLEIC ACIDS RES, V18, P1906, DOI 10.1093/nar/18.7.1906; Joukov V, 1996, EMBO J, V15, P290; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MACFARLANE DE, 1993, NATURE, V362, P186, DOI 10.1038/362186a0; MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; PAKU S, 1991, LAB INVEST, V65, P334; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PEPPER MS, 1992, AM J PHYSIOL, V262, pC1246, DOI 10.1152/ajpcell.1992.262.5.C1246; PEPPER MS, 1995, J CELL SCI, V108, P73; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; PEPPER MS, 1996, IN PRESS CURR TOP MI, V2; PEPPER MS, 1996, IN PRESS ENZYME PROT; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VASSALLI JD, 1984, J EXP MED, V159, P1653, DOI 10.1084/jem.159.6.1653; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; YAMANE A, 1994, ONCOGENE, V9, P2683	47	138	144	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11500	11505		10.1074/jbc.271.19.11500	http://dx.doi.org/10.1074/jbc.271.19.11500			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626709	hybrid			2022-12-27	WOS:A1996UJ94400069
J	Ridky, TW; BizubBender, D; Cameron, CE; Weber, IT; Wlodawer, A; Copeland, T; Skalka, AM; Leis, J				Ridky, TW; BizubBender, D; Cameron, CE; Weber, IT; Wlodawer, A; Copeland, T; Skalka, AM; Leis, J			Programming the rous sarcoma virus protease to cleave new substrate sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The Rous sarcoma virus protease displays a high degree of specificity and catalyzes the cleavage of only a limited number of amino acid sequences. This specificity is governed by interactions between side chains of eight substrate amino acids and eight corresponding subsite pockets within the homodimeric enzyme, We have examined these complex interactions in order to learn how to introduce changes into the retroviral protease (PR) that direct it to cleave new substrates. Mutant enzymes with altered substrate specificity and wild-type or greater catalytic rates have been constructed previously by substituting single key amino acids in each of the eight enzyme subsites with those residues found in structurally related positions of human immunodeficiency virus (HIV)-1 PR. These individual amino acid substitutions have now been combined into one enzyme, resulting in a highly active mutant Rous sarcoma virus (RSV) protease that displays many characteristics associated with the HIV-1 enzyme, The hybrid protease is capable of catalyzing the cleavage of a set of HIV-1 viral polyprotein substrates that are not recognized by the wild-type RSV enzyme. Additionally, the modified PR is inhibited completely by the HIV-1 PR-specific inhibitor KNI-272 at concentrations where wild-type RSV PR is unaffected, These results indicate that the major determinants that dictate RSV and HIV-1 PR substrate specificity have been identified, Since the viral protease is a homodimer, the rational design of enzymes with altered specificity also requires a thorough understanding of the importance of enzyme symmetry in substrate selection, We demonstrate here that the enzyme homodimer acts symmetrically in substrate selection with each enzyme subunit being capable of recognizing both halves of a peptide substrate equally.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; NCI,FREDERICK CANC RES & DEV CTR,MACROMOL STRUCT LAB,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	Case Western Reserve University; Fox Chase Cancer Center; Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [CA52047, CA06937, CA58166] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052047, R01CA058166] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER F, 1987, J VIROL, V61, P534, DOI 10.1128/JVI.61.2.534-542.1987; BIZUB D, 1991, J BIOL CHEM, V266, P4951; CAMERON CE, 1994, J BIOL CHEM, V269, P11170; CAMERON CE, 1993, J BIOL CHEM, V268, P11711; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; FITZGERALD P, 1991, J BIOL CHEM, V265, P14209; GRINDE B, 1992, J BIOL CHEM, V267, P9481; GRINDE B, 1992, J BIOL CHEM, V267, P9491; GULNIK SV, 1995, BIOCHEMISTRY-US, V34, P9282, DOI 10.1021/bi00029a002; JASKOLSKI M, 1990, BIOCHEMISTRY-US, V29, P5889, DOI 10.1021/bi00477a002; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; RIDKY T, 1995, J BIOL CHEM, V270, P29621, DOI 10.1074/jbc.270.50.29621; Ridky TW, 1996, J BIOL CHEM, V271, P4709, DOI 10.1074/jbc.271.9.4709; SEDLACEK J, 1993, VIROLOGY, V192, P667, DOI 10.1006/viro.1993.1085; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279	15	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10538	10544		10.1074/jbc.271.18.10538	http://dx.doi.org/10.1074/jbc.271.18.10538			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631853	Green Submitted, hybrid			2022-12-27	WOS:A1996UJ34200021
J	Roll, B; Amons, R; deJong, WW				Roll, B; Amons, R; deJong, WW			Vitamin A(2) bound to cellular retinol-binding protein as ultraviolet filter in the eye lens of the gecko Lygodactylus picturatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VISUAL PIGMENTS; CRYSTALLINS; EXPRESSION; EVOLUTION; TISSUE	The yellow eye lenses of the diurnal gecko Lygodactylus picturatus contain, in addition to the usual crystallins, a monomeric protein with a molecular mass of 16 kDa., It comprises 6-8% of the total water-soluble lens proteins. We here identify it as a novel type of crystallin, most closely related with cellular retinol-binding protein I (CRBP I), Because of its tiny size, we designate it as L-crystallin. The typical endogenous ligand of CRBP is all-trans-retinol. In the gecko lens, however, the ligand of L-crystallin turns out to be 3-dehydroretinol (vitamin A(2)), which causes the yellow color of this lens, The L-crystallin . 3-dehydroretinol complex absorbs shortwave radiation, supposedly improving the optical quality of the dioptric apparatus and protecting the retina against ultraviolet damage, Whereas other crystallins have been recruited from stress proteins and metabolic enzymes, L-crystallin represents a completely new class of taxon-specific lens proteins, Also, its ligand 3-dehydroretinol represents a novel type of lens pigment.	LEIDEN UNIV,DEPT BIOCHEM MED,2300 RA LEIDEN,NETHERLANDS; UNIV NIJMEGEN,DEPT BIOCHEM,6500 HB NIJMEGEN,NETHERLANDS; UNIV AMSTERDAM,INST SYSTEMAT & POPULAT BIOL,1090 GT AMSTERDAM,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Radboud University Nijmegen; University of Amsterdam	Roll, B (corresponding author), RUHR UNIV BOCHUM,FAK BIOL,LEHRSTUHL TIERPHYSIOL,D-44780 BOCHUM,GERMANY.							BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BECKER RS, 1988, PHOTOCHEM PHOTOBIOL, V48, P369, DOI 10.1111/j.1751-1097.1988.tb02836.x; CHIOU SH, 1987, FEBS LETT, V221, P134, DOI 10.1016/0014-5793(87)80367-8; COLLIER R, 1987, DEGENERATIVE RETINAL, P571; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DEJONG WW, 1994, PROG RETIN EYE RES, V13, P391, DOI 10.1016/1350-9462(94)90018-3; JAWORSKI CJ, 1994, INVEST OPHTH VIS SCI, V35, P1706; JIMENEZASENSIO J, 1995, BIOCHEM BIOPH RES CO, V209, P796, DOI 10.1006/bbrc.1995.1570; KUCHLING H, 1979, TASCHENBUCH PHYSIK; LI E, 1986, P NATL ACAD SCI USA, V83, P5779, DOI 10.1073/pnas.83.16.5779; MACDONALD PN, 1987, J BIOL CHEM, V262, P10550; NEWCOMER ME, 1995, FASEB J, V9, P229, DOI 10.1096/fasebj.9.2.7781925; ONG DE, 1978, J BIOL CHEM, V253, P828; PIATIGORSKY J, 1991, SCIENCE, V252, P1078, DOI 10.1126/science.252.5009.1078; PROVENCIO I, 1992, VISION RES, V32, P2201, DOI 10.1016/0042-6989(92)90084-V; RAJAN N, 1990, J LIPID RES, V31, P821; Roll B, 1995, BIOCHEM BIOPH RES CO, V217, P452, DOI 10.1006/bbrc.1995.2797; ROLL B, 1995, HERPETOL J, V5, P298; ROLL B, 1990, THESIS RUHR U BOCHUM; Roll Beate, 1994, Sauria, V16, P307; Saari J.C., 1990, Progress in Retinal Research, V9, P363, DOI 10.1016/0278-4327(90)90011-6; THORPE A, 1993, VISION RES, V33, P289, DOI 10.1016/0042-6989(93)90085-B; UNDERWOOD G, 1970, BIOLOGY REPTILIA, V2, P1; VEERKAMP JH, 1995, PROG LIPID RES, V34, P17, DOI 10.1016/0163-7827(94)00005-7; WALLS G. L, 1934, AM J OPHTHALMOL, V17, P892, DOI DOI 10.1016/S0002-9394(34)93309-2; WALLS GL, 1942, VERTEBRATE EYE ITS A, P622; Wistow G, 1995, MOL BIOL EVOLUTION C; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; YU NT, 1991, EXP EYE RES, V52, P475, DOI 10.1016/0014-4835(91)90045-G; ZIGLER JS, 1991, FASEB J, V5, P223, DOI 10.1096/fasebj.5.2.2004667; ZIGMAN S, 1988, EXP EYE RES, V47, P819, DOI 10.1016/0014-4835(88)90065-6	31	27	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10437	10440						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631836				2022-12-27	WOS:A1996UJ34200004
J	Ohnuma, SI; Nakazawa, T; Hemmi, H; Hallberg, AM; Koyama, T; Ogura, K; Nishino, T				Ohnuma, SI; Nakazawa, T; Hemmi, H; Hallberg, AM; Koyama, T; Ogura, K; Nishino, T			Conversion from farnesyl diphosphate synthase to geranylgeranyl diphosphate synthase by random chemical mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLANESYL PYROPHOSPHATE SYNTHETASE; VARIABLE PRODUCT SPECIFICITY; SITE-DIRECTED MUTAGENESIS; MOLECULAR-CLONING; SUBSTRATE-SPECIFICITY; ARTIFICIAL SUBSTRATE; BIOSYNTHETIC-PATHWAY; CONSERVED ASPARTATE; SECONDARY-STRUCTURE; DOLICHYL PHOSPHATE	Prenyltransferases catalyze the consecutive condensation of isopentenyl diphosphate (IPP) with allylic diphosphates to produce prenyl diphosphates whose chain lengths are absolutely determined by each enzyme. In order to investigate the mechanisms of the consecutive reaction and of the determination of ultimate chain length, a random mutational approach was planned. The farnesyl diphosphate (FPP) synthase gene of Bacillus stearothermophilus was subjected to random mutagenesis by NaNO2 treatment to construct libraries of mutated FPP synthase genes on a high-copy plasmid. From the libraries, the mutants that showed the activity of geranylgeranyl diphosphate (GGPP) synthase were selected by the red-white screening method (Ohnuma, S.-i., Suzuki, M., and Nishino, T. (1994) J. Biol. Chem. 268, 14792-14797), which utilized carotenoid synthetic genes, phytoene synthase, and phytoene desaturase, to visualize the formation of GGPP in vivo. Eleven red positive clones were identified from about 24,300 mutants, and four (mutant 1, 2, 3, and 4) of them were analyzed for the enzyme activities. Results of in vitro assays demonstrated that all these mutants produced (all-E)-GGPP although the amounts were different. Each mutant was found to contain a few amino acid substitutions: mutant 1, Y81H and L275S; mutant 2, L34V and R59Q; mutant 3, V157A and H182Y; mutant 4, Y81H, P239R, and A265T. Site-directed mutagenesis showed that Y81H, L34V, or V157A was essential for the expression of the activity of GGPP synthase. Especially, the replacement of tyrosine 81 by histidine is the most effective because the production ratios of GGPP to FPP in mutant 1 and 4 are the largest. Based on prediction of the secondary structure, it is revealed that the tyrosine 81 situates on a point 11 similar to 12 Angstrom apart from the first DDXXD motif, whose distance is similar to the length of hydrocarbon moiety of FPP. These data might suggest that the aromatic ring of tyrosine 81 blocks the chain elongation longer than FPP. Comparisons of kinetic parameters of the mutated and wild type enzymes revealed several phenomena that may relate with the change of the ultimate chain length. They are a decrease of the total reaction rate, increase of K-m for dimethylallyl diphosphate, decrease of V-max for dimethylallyl diphosphate, and allylic substrate dependence of K-m for IPP.	TOHOKU UNIV,INST CHEM REACT SCI,SENDAI,MIYAGI 980,JAPAN	Tohoku University	Ohnuma, SI (corresponding author), TOHOKU UNIV,DEPT BIOCHEM & ENGN,AOBA KU,SENDAI,MIYAGI 98077,JAPAN.		Hemmi, Hisashi/I-6868-2014	Hemmi, Hisashi/0000-0002-9538-809X; Ohnuma, Shin-ichi/0000-0002-3305-5126				ANDERSON MS, 1989, J BIOL CHEM, V264, P19176; ASAI K, 1994, BIOCHEM BIOPH RES CO, V202, P340, DOI 10.1006/bbrc.1994.1933; ASHBY MN, 1990, J BIOL CHEM, V265, P1357; BABA T, 1978, BIOCHEMISTRY-US, V17, P5598, DOI 10.1021/bi00619a003; CARATTOLI A, 1991, J BIOL CHEM, V266, P5854; CHEN AJ, 1993, J BIOL CHEM, V268, P11002; CHEN AJ, 1994, PROTEIN SCI, V3, P600; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; CRICK DC, 1989, BIOCHIM BIOPHYS ACTA, V1004, P180, DOI 10.1016/0005-2760(89)90266-X; EGGENS I, 1983, BIOCHIM BIOPHYS ACTA, V751, P355, DOI 10.1016/0005-2760(83)90294-1; ERICSSON J, 1992, J BIOL CHEM, V267, P19730; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; FUJII H, 1980, BIOCHEM BIOPH RES CO, V96, P1648, DOI 10.1016/0006-291X(80)91363-7; FUJII H, 1982, J BIOL CHEM, V257, P4610; FUJISAKI S, 1990, J BIOCHEM-TOKYO, V108, P995, DOI 10.1093/oxfordjournals.jbchem.a123327; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; JOLY A, 1993, J BIOL CHEM, V268, P26983; KOIKETAKESHITA A, 1995, J BIOL CHEM, V270, P18396, DOI 10.1074/jbc.270.31.18396; KOYAMA T, 1988, TETRAHEDRON LETT, V29, P3807, DOI 10.1016/S0040-4039(00)82120-6; KOYAMA T, 1994, CAN J CHEM, V72, P75, DOI 10.1139/v94-012; KOYAMA T, 1993, J BIOCHEM-TOKYO, V113, P355, DOI 10.1093/oxfordjournals.jbchem.a124051; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASKOVICS FM, 1981, BIOCHEMISTRY-US, V20, P1893, DOI 10.1021/bi00510a027; LASKOVICS FM, 1979, J BIOL CHEM, V254, P9458; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; MATH SK, 1992, P NATL ACAD SCI USA, V89, P6761, DOI 10.1073/pnas.89.15.6761; MATSUOKA S, 1991, J BIOL CHEM, V266, P3464; MISAWA N, 1990, J BACTERIOL, V172, P6704, DOI 10.1128/jb.172.12.6704-6712.1990; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; OHNUMA S, 1992, J BIOCHEM-TOKYO, V112, P743, DOI 10.1093/oxfordjournals.jbchem.a123969; OHNUMA S, 1989, TETRAHEDRON, V45, P6145, DOI 10.1016/S0040-4020(01)85127-9; OHNUMA S, 1994, J BIOL CHEM, V269, P14792; OHNUMA SI, 1989, FEBS LETT, P71; POULTER CD, 1982, BIOSYNTHESIS ISOPREN, P161; REED BC, 1976, BIOCHEMISTRY-US, V15, P3739, DOI 10.1021/bi00662a015; SAGAMI H, 1977, BIOCHEMISTRY-US, V16, P4616, DOI 10.1021/bi00640a014; SAKAKIHARA Y, 1985, J NEUROCHEM, V44, P1535, DOI 10.1111/j.1471-4159.1985.tb08792.x; Sambrook J., 2002, MOL CLONING LAB MANU; SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; WILKIN DJ, 1990, J BIOL CHEM, V265, P4607	42	124	132	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10087	10095		10.1074/jbc.271.17.10087	http://dx.doi.org/10.1074/jbc.271.17.10087			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626566	hybrid			2022-12-27	WOS:A1996UG25700038
J	Wang, JP; Needleman, DH; Seryshev, AB; Aghdasi, B; Slavik, KJ; Liu, SQ; Pedersen, SE; Hamilton, SL				Wang, JP; Needleman, DH; Seryshev, AB; Aghdasi, B; Slavik, KJ; Liu, SQ; Pedersen, SE; Hamilton, SL			Interaction between ryanodine and neomycin binding sites on Ca2+ release channel from skeletal muscle sarcoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+ RELEASE; H-3 RYANODINE; PURIFICATION; RECEPTOR; RECONSTITUTION; MEMBRANES	Neomycin is a potent inhibitor of skeletal muscle sarcoplasmic reticulum (SR) calcium release. To elucidate the mechanism of inhibition, the effects of neomycin on the binding of [H-3]ryanodine to the Ca2+ release channel and on its channel activity when reconstituted into planar lipid bilayer were examined. Equilibrium binding of [H-3]ryanodine was partially inhibited by neomycin. Inhibition was incomplete at high neomycin concentrations, indicating noncompetitive inhibition rather than direct competitive inhibition. Neomycin and [H-3]ryanodine can bind to the channel simultaneously and, if [H-3]ryanodine is bound first, the addition of neomycin will slow the dissociation of [H-3]ryanodine from the high affinity site. Neomycin also slows the association of [H-3]ryanodine with the high affinity binding site. The neomycin binding site, therefore, appears to be distinct from the ryanodine binding site. Dissociation of [H-3]ryanodine from trypsin-treated membranes or from a solubilized 14 S complex is also slowed by neomycin. This complex is composed of polypeptides derived from the carboxyl terminus of the Ca2+ release channel after Arg-4475 (Callaway, C., Seryshev, A. Wang, J. P., Slavik, K. Needleman, D. H., Cantu, C., Wu, Y., Jayaraman, T., Marks, A. R., and Hamilton, S. L. (1994) J. Biol. Chem. 269, 15876-15884). The proteolytic 14 S complex isolated with ryanodine bound produces a channel upon reconstitution into planar lipid bilayers, and its activity is inhibited by neomycin. Our data are consistent with a model in which the ryanodine binding sites, the neomycin binding sites, and the channel-forming portion of the Ca2+ release channel are located between Arg-4475 and the carboxyl terminus.	BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine				Hamilton, Susan/0000-0003-0241-9369; Pedersen, Steen E./0000-0001-8755-8899	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K04NS001618] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41801] Funding Source: Medline; NINDS NIH HHS [NS01618] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BROWN EM, 1991, ENDOCRINOLOGY, V128, P3047, DOI 10.1210/endo-128-6-3047; CALLAWAY C, 1994, J BIOL CHEM, V269, P15876; CALVIELLO G, 1989, BIOCHEMISTRY-US, V28, P1301, DOI 10.1021/bi00429a053; HAMILTON SL, 1989, ANAL BIOCHEM, V183, P31, DOI 10.1016/0003-2697(89)90167-X; HAMILTON SL, 1991, CELLULAR CALCIUM, P313; HAWKES MJ, 1989, MEMBRANE BIOCHEM, V8, P133, DOI 10.3109/09687688909025827; HAWKES MJ, 1992, J BIOL CHEM, V267, P6702; INUI M, 1987, J BIOL CHEM, V262, P1740; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACK MM, 1992, J PHARMACOL EXP THER, V262, P1028; MARTONOSI AN, 1984, PHYSIOL REV, V64, P1240, DOI 10.1152/physrev.1984.64.4.1240; MEISSNER G, 1989, J BIOL CHEM, V264, P1715; PESSAH IN, 1991, MOL PHARMACOL, V39, P679; ROSEMBLATT M, 1981, J BIOL CHEM, V256, P8140; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; WYSKOVSKY W, 1990, EUR J BIOCHEM, V194, P549, DOI 10.1111/j.1432-1033.1990.tb15651.x; ZIMANYI I, 1991, J PHARMACOL EXP THER, V256, P938	18	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8387	8393		10.1074/jbc.271.14.8387	http://dx.doi.org/10.1074/jbc.271.14.8387			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626537	hybrid			2022-12-27	WOS:A1996UD60000077
J	Blanck, O; Iobst, ST; Gabel, C; Drickamer, K				Blanck, O; Iobst, ST; Gabel, C; Drickamer, K			Introduction of selectin-like binding specificity into a homologous mannose-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAIN; CELL-ADHESION; P-SELECTIN; RESIDUES; LIGAND; RAT	The structures of the ligand-binding C-type carbohydrate-recognition domains of selectin cell adhesion molecules and of mannose-binding proteins (MBPs) are similar to each other even though these proteins bind very different carbohydrate ligands. Our current understanding of ligand binding by E-selectin is based on structural studies of unliganded E-selectin and of MBP-carbohydrate complexes, combined with results from mutagenesis of E-selectin. Five regions of E-selectin that differ in sequence from the corresponding regions of MBP have been introduced into the carbohydrate-recognition domain of MBP. Four of the changes have little effect on ligand binding. Insertion of one stretch of positively charged amino acids alters the sugar binding selectivity of the domain so that it now binds HL-60 cells and serum albumin derivatized with sialyl-Lewis(x) tetrasaccharide, thus mimicking the properties of E-selectin.	COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; PFIZER INC,CENT RES,DEPT CANC IMMUNOL & INFECT DIS,GROTON,CT 06340	Columbia University; Pfizer								ANOSTARIO M, 1995, J BIOL CHEM, V270, P8138, DOI 10.1074/jbc.270.14.8138; BAJORATH J, 1994, BIOCHEMISTRY-US, V33, P1332, DOI 10.1021/bi00172a007; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DRICKAMER K, 1908, J BIOL CHEM, V261, P1034; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HOLLENBAUGH D, 1995, BIOCHEMISTRY-US, V34, P5678, DOI 10.1021/bi00016a044; HOLLENBAUGH D, 1993, BIOCHEMISTRY-US, V32, P2960, DOI 10.1021/bi00063a006; Iobst ST, 1996, J BIOL CHEM, V271, P6686, DOI 10.1074/jbc.271.12.6686; IOBST ST, 1994, J BIOL CHEM, V269, P15505; KOGAN TP, 1995, J BIOL CHEM, V270, P14047, DOI 10.1074/jbc.270.23.14047; Kolatkar AR, 1996, J BIOL CHEM, V271, P6679, DOI 10.1074/jbc.271.12.6679; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Maniatis T., 1982, MOL CLONING; MCEVER RP, 1994, CURR OPIN IMMUNOL, V6, P75, DOI 10.1016/0952-7915(94)90037-X; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; WEIS WI, 1996, IN PRESS ANN REV BIO, V65; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677	28	23	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7289	7292		10.1074/jbc.271.13.7289	http://dx.doi.org/10.1074/jbc.271.13.7289			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631744	hybrid			2022-12-27	WOS:A1996UC77400012
J	Chamberlain, LH; Burgoyne, RD				Chamberlain, LH; Burgoyne, RD			Identification of a novel cysteine string protein variant and expression of cysteine string proteins in non-neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESYNAPTIC CALCIUM-CHANNEL; SUPPRESSION CLONING; CDNA	Cysteine string proteins (Csps) are synaptic vesicle proteins thought to be involved in calcium-dependent neurotransmitter release at nerve endings. Here, we report the cloning of two Csp variants, termed Csp1 and Csp2, from bovine adrenal medullary chromaffin cells. The bovine Csp1 appears to be the homologue of rat brain Csp, sharing 95% identity at the amino acid level. The nucleotide sequence of csp2 is identical with that of csp1 except for a 72-base insert which introduces a stop codon into the coding sequence, which would be predicted to result in a truncated protein 3.3 kDa smaller than Csp1, Furthermore, polymerase chain reaction analysis detected homologues of Csp1 and Csp2 in rat kidney, liver, pancreas, spleen, lung, and adrenal gland. Expression of Csps in non-neuronal tissues was confirmed by Northern blotting and by immunoblotting with anti-Csp1 antiserum which also demonstrated expression of both full-length and truncated Csps in spleen, The widespread tissue distribution is inconsistent with a role for Csps as specific regulators of presynaptic calcium channels as previously proposed. We suggest that Csps may have a more general role in membrane traffic in non-neuronal as well as neuronal cells.	UNIV LIVERPOOL, PHYSIOL LAB, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND	University of Liverpool			Burgoyne, Robert/C-6706-2008; Burgoyne, Robert D/P-6641-2019	Burgoyne, Robert/0000-0002-9219-0387; Burgoyne, Robert D/0000-0002-9219-0387	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BRAUN JEA, 1995, NEUROPHARMACOLOGY, V34, P1361, DOI 10.1016/0028-3908(95)00114-L; BURGOYNE RD, 1994, ANN NY ACAD SCI, V710, P333, DOI 10.1111/j.1749-6632.1994.tb26640.x; BURGOYNE RD, 1992, NEUROMETHODS, V20, P433; GUNDERSEN CB, 1992, NEURON, V9, P527, DOI 10.1016/0896-6273(92)90190-O; GUNDERSEN CB, 1995, J THEOR BIOL, V172, P269, DOI 10.1006/jtbi.1995.0023; GUNDERSEN CB, 1994, J BIOL CHEM, V269, P19197; KOHAN SA, 1995, J NEUROSCI, V15, P6230; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; MASTROGIACOMO A, 1994, SCIENCE, V263, P981, DOI 10.1126/science.7906056; MASTROGIACOMO A, 1994, J NEUROCHEM, V62, P873; MASTROGIACOMO A, 1995, MOL BRAIN RES, V28, P12, DOI 10.1016/0169-328X(94)00172-B; OHKI R, 1992, J BIOL CHEM, V267, P13180; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; UMBACH JA, 1991, ANN NY ACAD SCI, V635, P443, DOI 10.1111/j.1749-6632.1991.tb36522.x; UMBACH JA, 1994, NEURON, V13, P899, DOI 10.1016/0896-6273(94)90255-0; ZINSMAIER KE, 1994, SCIENCE, V263, P977, DOI 10.1126/science.8310297; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150	18	75	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7320	7323		10.1074/jbc.271.13.7320	http://dx.doi.org/10.1074/jbc.271.13.7320			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631751	hybrid			2022-12-27	WOS:A1996UC77400019
J	Diehl, AM; Johns, DC; Yang, SQ; Lin, HZ; Yin, M; Matelis, LA; Lawrence, JH				Diehl, AM; Johns, DC; Yang, SQ; Lin, HZ; Yin, M; Matelis, LA; Lawrence, JH			Adenovirus-mediated transfer of CCAAT/enhancer-binding protein-alpha identifies a dominant antiproliferative role for this isoform in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTIONAL ACTIVATOR; 3 C/EBP ISOFORMS; ADULT-RAT HEPATOCYTES; ACUTE-PHASE RESPONSE; GENE-EXPRESSION; NUCLEAR-PROTEIN; 3T3-L1 PREADIPOCYTES; MESSENGER-RNA; ADIPOCYTE DIFFERENTIATION; REGENERATING LIVER	CCAAT/enhancer-binding protein (C/EBP) isoforms are thought to be important regulators of the hepatocyte phenotype, However, the specific physiological roles of different isoforms are poorly understood because hepatocytes express multiple C/EBPs, and various isoforms have overlapping functions, To identify the functions of C/EBP alpha in mature hepatocytes, replication-defective adenovirus vectors were used to efficiently and homogeneously overexpress the mouse C/EBP alpha gene in a SV40 virus conditionally transformed rat hepatocyte line that can be induced to express C/EBP beta and C/EBP delta but that has little endogenous C/EBP alpha expression, Hepatocytes were infected with a recombinant adenovirus vector carrying the cDNA for C/EBP alpha driven by Rous sarcoma virus promoter elements (AdCEBP alpha) or a similar vector carrying the Escherichia coli lacZ gene (Ad beta gal). Staining for beta-galactosidase demonstrated an infection efficiency of 100% at a multiplicity of infection of 25 plaque-forming units/cell and persistence of foreign gene expression for at least 9 days. Cultures infected with AdCEBP alpha had 50-fold higher levels of C/EBP alpha mRNA and protein than those infected with Ad beta gal, but similar expression of C/EBP beta, Infection with AdCEBP alpha inhibited proliferation in cells expressing little C/EBP beta, even when proliferation was driven by the SV40 transforming antigen, and also blunted mitogenic induction of the c-myc proto-oncogene in nontransformed cells with high levels of C/EBP beta, Although overexpression of C/EBP alpha consistently increased C/EBP alpha DNA binding activity, it was not sufficient for albumin expression, Infection with AdCEBP alpha only increased albumin mRNA levels in nontransformed cells that also expressed relatively high levels of C/EBP beta. Thus, in hepatocytes, C/EBP alpha has a dominant antiproliferative function, but must interact with other factors to regulate hepatocyte-specific gene expression.	JOHNS HOPKINS UNIV,DEPT PEDIAT,BALTIMORE,MD 21205	Johns Hopkins University	Diehl, AM (corresponding author), JOHNS HOPKINS UNIV,DEPT MED,ROSS 912,720 RUTLAND ST,BALTIMORE,MD 21205, USA.				NIAAA NIH HHS [R01 AA 09347, R01 AA 10154, K02 AA 00173] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K02AA000173, R01AA009347, R01AA010154] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; BETT AJ, 1993, J VIROL, V67, P5911, DOI 10.1128/JVI.67.10.5911-5921.1993; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU JY, 1983, MOL CELL BIOL, V3, P1013, DOI 10.1128/MCB.3.6.1013; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIEHL AM, 1994, HEPATOLOGY, V19, P447; DIEHL AM, 1994, AM J PHYSIOL-GASTR L, V267, pG552, DOI 10.1152/ajpgi.1994.267.4.G552; DIEHL AM, 1995, HEPATOLOGY, V22, P252, DOI 10.1016/0270-9139(95)90379-8; DIEHL AM, 1992, J CLIN INVEST, V89, P1706, DOI 10.1172/JCI115771; FLODBY P, 1993, EXP CELL RES, V208, P248, DOI 10.1006/excr.1993.1244; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; HAYWARD SW, 1995, IN VITRO CELL DEV-AN, V31, P14; HERBST RS, 1989, P NATL ACAD SCI USA, V86, P1553, DOI 10.1073/pnas.86.5.1553; HERBST RS, 1991, NEW BIOL, V3, P289; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; ISSHIKI H, 1991, NEW BIOL, V3, P63; JARNAGIN WR, 1992, NUCLEIC ACIDS RES, V20, P4205, DOI 10.1093/nar/20.16.4205; JOHNS DC, 1995, J CLIN INVEST, V96, P1152, DOI 10.1172/JCI118103; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KUO CF, 1990, DEVELOPMENT, V109, P473; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE LA, 1995, J CLIN INVEST, V95, P900, DOI 10.1172/JCI117741; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; LIU JK, 1988, GENE DEV, V2, P528, DOI 10.1101/gad.2.5.528; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; PASCO DS, 1989, DNA-J MOLEC CELL BIO, V8, P535, DOI 10.1089/dna.1.1989.8.535; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; RIPPE RA, 1990, MOL CELL BIOL, V10, P689, DOI 10.1128/MCB.10.2.689; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; SCOTT LM, 1992, BLOOD, V80, P1725; SHALABY F, 1990, P NATL ACAD SCI USA, V87, P2652, DOI 10.1073/pnas.87.7.2652; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VASSEUR-COGNET M, 1993, P NATL ACAD SCI USA, V90, P7312, DOI 10.1073/pnas.90.15.7312; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; Wang N., 1994, Molecular Biology of the Cell, V5, p336A; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; ZARET KS, 1988, P NATL ACAD SCI USA, V85, P9076, DOI 10.1073/pnas.85.23.9076	61	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7343	7350		10.1074/jbc.271.13.7343	http://dx.doi.org/10.1074/jbc.271.13.7343			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631755	hybrid			2022-12-27	WOS:A1996UC77400023
J	Prepens, U; Just, I; vonEichelStreiber, C; Aktories, K				Prepens, U; Just, I; vonEichelStreiber, C; Aktories, K			Inhibition of Fc epsilon RI-mediated activation of rat basophilic leukemia cells by Clostridium difficile toxin B (monoglucosyltransferase)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; BOTULINUM ADP-RIBOSYLTRANSFERASE; RHO GENE-PRODUCT; MAST-CELLS; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; HISTAMINE-SECRETION; PERTUSSIS TOXIN; RBL-2H3 CELLS	Treatment of rat basophilic leukemia (RBL) 2H3-hm1 cells with Clostridium difficile toxin B (2 ng/ml), which reportedly depolymerizes the actin cytoskeleton, blocked [H-3]serotonin release induced by 2,4-dinitrophenyl-bovine serum albumin, carbachol, mastoparan, and reduced ionophore A23187-stimulated degranulation by about 55-60%. In lysates of RBL cells, toxin B C-14-glucosylated two major and one minor protein, By using two-dimensional gel electrophoresis and immunoblotting, RhoA and Cdc42 were identified as protein substrates of toxin B. In contrast to toxin B, Clostridium botulinum transferase C3 that selectively inactivates RhoA by ADP-ribosylation did not inhibit degranulation up to a concentration of 150 mu g/ml. Antigen-stimulated tyrosine phosphorylation of a 110-kDa protein was inhibited by toxin B as well as by the phosphatidylinositol 3-kinase inhibitor wortmannin. Depolymerization of the microfilament cytoskeleton of RBL cells by C. botulinum C2 toxin or cytochalasin D resulted in an increased [H-3]serotonin release induced by antigen, carbachol, mastoparan, or by calcium ionophore A23187, but without affecting toxin B-induced inhibition of degranulation, The data indicate that toxin B inhibits activation of RBL cells by glucosylation of low molecular mass GTP-binding proteins of the Rho subfamily (most likely Cdc42) by a mechanism not involving the actin cytoskeleton.	UNIV FREIBURG, INST PHARMAKOL & TOXIKOL, D-79104 FREIBURG, GERMANY; UNIV MAINZ, INST MED MIKROBIOL & HYG, D-55101 MAINZ, GERMANY	University of Freiburg; Johannes Gutenberg University of Mainz			Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				AKTORIES K, 1995, METHOD ENZYMOL, V256, P184; AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; AKTORIES K, 1994, MOL CELL BIOCHEM, V138, P167, DOI 10.1007/BF00928459; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; AKTORIES K, 1989, J CELL BIOL, V109, P1385, DOI 10.1083/jcb.109.4.1385; AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P97; ALI H, 1989, J IMMUNOL, V143, P2626; ATKINSON TP, 1992, J IMMUNOL, V148, P2194; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BONGAERTS GPA, 1994, MICROB PATHOGENESIS, V17, P1, DOI 10.1006/mpat.1994.1047; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DEANIN GG, 1991, BIOCHEM BIOPH RES CO, V179, P551, DOI 10.1016/0006-291X(91)91406-3; EISEMAN E, 1992, NATURE, V355, P78; GARCIAGIL M, 1986, J IMMUNOL, V136, P259; GOMPERTS BD, 1994, ANN NY ACAD SCI, V710, P217, DOI 10.1111/j.1749-6632.1994.tb26630.x; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; JUST I, 1995, J CLIN INVEST, V95, P1026, DOI 10.1172/JCI117747; JUST I, 1992, J BIOL CHEM, V267, P10274; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KAWAKAMI T, 1992, J IMMUNOL, V148, P3513; KOFFER A, 1990, J CELL BIOL, V111, P919, DOI 10.1083/jcb.111.3.919; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LILLIE THW, 1993, BIOCHEM J, V290, P389, DOI 10.1042/bj2900389; LIN PY, 1991, J IMMUNOL, V146, P1609; MAEYAMA K, 1988, J IMMUNOL, V140, P3919; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MINOGUCHI K, 1994, J BIOL CHEM, V269, P16902; NAKAMURA T, 1985, J BIOL CHEM, V260, P3584; NAKATANI Y, 1994, J IMMUNOL, V153, P796; NARASIMHAN V, 1990, BIOCHEM BIOPH RES CO, V171, P222, DOI 10.1016/0006-291X(90)91380-B; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; OHISHI I, 1980, INFECT IMMUN, V30, P668; OTTLINGER ME, 1988, EXP CELL RES, V174, P215, DOI 10.1016/0014-4827(88)90156-5; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PRICE LS, 1995, CURR BIOL, V5, P68, DOI 10.1016/S0960-9822(95)00018-2; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAITO H, 1987, J IMMUNOL, V138, P3927; SEAGRAVE J, 1991, J CELL PHYSIOL, V148, P139, DOI 10.1002/jcp.1041480117; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHOSHAN MC, 1993, J CELL BIOCHEM, V52, P107, DOI 10.1002/jcb.240520114; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; VONEICHELSTREIBER C, 1987, MICROB PATHOGENESIS, V2, P307, DOI 10.1016/0882-4010(87)90073-8; WIEGERS W, 1991, EUR J CELL BIOL, V54, P237; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	58	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7324	7329		10.1074/jbc.271.13.7324	http://dx.doi.org/10.1074/jbc.271.13.7324			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631752	hybrid			2022-12-27	WOS:A1996UC77400020
J	Xiao, J; Messinger, Y; Jin, JZ; Myers, DE; Bolen, JB; Uckun, FM				Xiao, J; Messinger, Y; Jin, JZ; Myers, DE; Bolen, JB; Uckun, FM			Signal transduction through the beta 1 integrin family surface adhesion molecules VLA-4 and VLA-5 of human B-cell precursors activates CD19 receptor-associated protein-tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISCRETE DEVELOPMENTAL STAGES; LYMPHOBLASTIC-LEUKEMIA CELLS; BONE-MARROW FIBROBLASTS; STROMAL CELLS; ALPHA-4-BETA-1 INTEGRIN; PHOSPHORYLATION; FIBRONECTIN; VCAM-1; ENDOTHELIUM; STIMULATION	We demonstrate that the CD19 receptor associates with the beta 1 family integrin receptors on human B-cell precursors as well as mature B-lymphocytes, and engagement of the beta 1 family integrin receptors with monoclonal antibody homoconjugates leads to rapid activation of the CD19-associated protein-tyrosine kinases (PTK) and results in hyperphosphorylation of CD19 on tyrosine residues, Our findings prompt the hypothesis that homoconjugate-induced integrin clustering may effect the approximation and, by intermolecular cross-phosphorylation, activation of the CD19-associated PTK and subsequent tyrosine phosphorylation of the CD19 receptor, The ability of the beta 1 family integrin receptors to transmit a biochemical signal triggering the CD19-linked multifunctional PTK pathway provides a possible explanation for the pleiotropic biologic responses generated through adhesive VLA-4- and VLA-6-mediated contacts.	UNIV MINNESOTA,BIOTHERAPY PROGRAM,SIGNAL TRANSDUCT LAB,ROSEVILLE,MN 55113; UNIV MINNESOTA,CHILDRENS CANC GRP,LEUKEMIA BIOL REFERENCE LAB,ROSEVILLE,MN 55113; DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT CELL SIGNALING,PALO ALTO,CA 94304	University of Minnesota System; University of Minnesota System; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.				Uckun, Fatih M./0000-0001-9334-183X	NCI NIH HHS [R01-CA42633, R01-CA51425, R01-CA44114] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044114, R01CA051425, R01CA042633] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNARDI P, 1987, J CELL BIOL, V105, P489, DOI 10.1083/jcb.105.1.489; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BRADSTOCK K, 1993, BLOOD, V82, P3437; BRADSTOCK KF, 1995, LEUKEMIA LYMPHOMA, V18, P1, DOI 10.3109/10428199509064917; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DITTEL BN, 1993, BLOOD, V81, P2272; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FARGNOLI J, 1995, J BIOL CHEM, V270, P26533, DOI 10.1074/jbc.270.44.26533; FREEDMAN AS, 1993, J IMMUNOL, V150, P1645; GARCIAPARDO A, 1990, J IMMUNOL, V144, P3361; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JUNEJA HS, 1992, EXP HEMATOL, V20, P1263; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MAKRYNIKOLA V, 1993, LEUKEMIA, V7, P86; MANABE A, 1994, BLOOD, V83, P758; MIYAKE K, 1992, J CELL BIOL, V119, P653, DOI 10.1083/jcb.119.3.653; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; MOULD AP, 1991, J BIOL CHEM, V266, P3579; MYERS DE, 1991, J IMMUNOL METHODS, V36, P221; MYERS DE, 1995, P NATL ACAD SCI USA, V92, P1; NOJIMA Y, 1992, J EXP MED, V175, P1045, DOI 10.1084/jem.175.4.1045; PAPAYANNOPOULOU T, 1993, P NATL ACAD SCI USA, V90, P9374, DOI 10.1073/pnas.90.20.9374; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RYAN DH, 1991, J CLIN INVEST, V88, P995, DOI 10.1172/JCI115403; RYAN DH, 1992, J IMMUNOL, V149, P3759; SANCHEZMATEOS P, 1993, J IMMUNOL, V151, P3817; SIMMONS PJ, 1994, LEUKEMIA LYMPHOMA, V12, P353, DOI 10.3109/10428199409073776; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TANG JH, 1993, BLOOD, V82, P3415; TEDDER TE, 1994, IMMUNOL TODAY, V15, P437, DOI 10.1016/0167-5699(94)90274-7; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; UCKUN FM, 1991, J BIOL CHEM, V266, P17478; UCKUN FM, 1993, J BIOL CHEM, V268, P21172	44	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7659	7664		10.1074/jbc.271.13.7659	http://dx.doi.org/10.1074/jbc.271.13.7659			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631803				2022-12-27	WOS:A1996UC77400071
J	Stewart, CEH; Rotwein, P				Stewart, CEH; Rotwein, P			Insulin-like growth factor-II is an autocrine survival factor for differentiating myoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-CELL DIFFERENTIATION; IGF-I; SKELETAL-MUSCLE; EXPRESSION; IDENTIFICATION; RECEPTOR; BINDING; GENE; ACTIVATION; APOPTOSIS	Recent studies indicate that insulin-like growth factor-II (IGF-II) acts as an autocrine differentiation factor for skeletal myoblasts in culture. IGF-II mRNA and protein are induced as early events in muscle differentiation, and the rate and extent of IGF-II secretion correlate with both biochemical and morphological differentiation. Here we show that IGF-II also functions as an essential survival factor during the transition from proliferating to differentiating myoblasts. Stably transfected C2 muscle cell lines were established in which a mouse IGF-II cDNA was expressed in the antisense orientation relative to the constitutively active Moloney sarcoma virus promoter. IGF-II antisense cells proliferated normally in growth medium containing 20% serum but underwent rapid death when placed in low serum differentiation medium. Death was accompanied by characteristic markers of apoptosis with more than 90% of cells showing DNA fragmentation within 12-16 h. Myoblast death was prevented by IGF-I, des [1-3] IGF-I, IGF-II, and insulin with a dose potency consistent with activation of the IGF-I receptor; death also could be blocked by the protein synthesis inhibitor, cycloheximide. Exogenous IGFs additionally stimulated passage through a single cell cycle and subsequently induced terminal differentiation. Cell survival and cell cycle progression also were enhanced by fibroblast growth factor-2 and platelet-derived growth factor-bb, but these peptides did not promote differentiation. Our results define a novel system for studying apoptotic cell death and its prevention by growth factors, underscore the importance of IGF action in minimizing inappropriate cell death, and indicate that shared signal transduction pathways may mediate myoblast survival in vitro.	WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)			Rotwein, Peter/R-5783-2019; Stewart, Claire E/I-3177-2013	Rotwein, Peter/0000-0002-9505-1817; Stewart, Claire/0000-0002-8104-4819	NIDDK NIH HHS [R01 DK042748, 5 RO1-DK42748, DK20579] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579, P30DK020579, R01DK042748] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAXTER RC, 1993, TRENDS ENDOCRIN MET, V4, P91, DOI 10.1016/1043-2760(93)90085-S; BREIER BH, 1991, J ENDOCRINOL, V128, P347, DOI 10.1677/joe.0.1280347; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DAUGHADAY WH, 1987, METHOD ENZYMOL, V146, P248; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EWTON DZ, 1994, J CELL PHYSIOL, V161, P277, DOI 10.1002/jcp.1041610212; FLORINI JR, 1986, AM J PHYSIOL, V250, pC771, DOI 10.1152/ajpcell.1986.250.5.C771; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; Florini JR, 1995, DIABETES REV, V3, P73; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; JAMES PL, 1993, J BIOL CHEM, V268, P22305; JENNISCHE E, 1987, ACTA PHYSIOL SCAND, V129, P9, DOI 10.1111/j.1748-1716.1987.tb08034.x; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KIESS W, 1987, J BIOL CHEM, V262, P12745; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KOU K, 1993, MOL ENDOCRINOL, V7, P291, DOI 10.1210/me.7.2.291; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LEVINOVITZ A, 1992, MOL ENDOCRINOL, V6, P1227, DOI 10.1210/me.6.8.1227; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Montarras Didier, 1993, Comptes Rendus de l'Academie des Sciences Serie III Sciences de la Vie, V316, P1025; Nissley P, 1991, Growth Factors, V5, P29, DOI 10.3109/08977199109000269; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; QUINN LS, 1994, J CELL PHYSIOL, V159, P387, DOI 10.1002/jcp.1041590302; RESNICOFF M, 1995, CANCER RES, V55, P3739; RESNICOFF M, 1995, CANCER RES, V55, P2463; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; ROSEN KM, 1993, ENDOCRINOLOGY, V133, P474, DOI 10.1210/en.133.2.474; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; ROSENTHAL SM, 1991, J CLIN INVEST, V87, P1212, DOI 10.1172/JCI115121; ROSENTHAL SM, 1995, P NATL ACAD SCI USA, V92, P10307, DOI 10.1073/pnas.92.22.10307; SCHMID C, 1983, FEBS LETT, V161, P117, DOI 10.1016/0014-5793(83)80742-X; SELL C, 1995, CANCER RES, V55, P303; SMITH J, 1995, CELL DEATH DIFFER, V2, P243; TANAKA H, 1989, ENDOCRINOLOGY, V124, P870, DOI 10.1210/endo-124-2-870; TOLLEFSEN SE, 1989, P NATL ACAD SCI USA, V86, P1543, DOI 10.1073/pnas.86.5.1543; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VANDENBURGH HH, 1991, AM J PHYSIOL, V260, pC475, DOI 10.1152/ajpcell.1991.260.3.C475; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	52	187	193	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11330	11338		10.1074/jbc.271.19.11330	http://dx.doi.org/10.1074/jbc.271.19.11330			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626686	hybrid			2022-12-27	WOS:A1996UJ94400046
J	Warren, BS; Kusk, P; Wolford, RG; Hager, GL				Warren, BS; Kusk, P; Wolford, RG; Hager, GL			Purification and stabilization of transcriptionally active glucocorticoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; PROTEIN; DNA; ACTIVATION; COMPLEXES; INVITRO; INVIVO	A major obstacle to the purification of glucocorticoid receptor (GR) is the very high nonspecific surface adsorption of this protein. This phenomenon is a property of the GR itself and does not reflect overall protein concentration or buffer conditions. We have observed that the zwitterionic detergent 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid (CHAPS) is unique in its ability to stabilize the receptor and largely eliminate loss to nonspecific adsorption. We have coupled this observation with a two-step purification method that allows efficient purification and stabilization of transcriptionally active glucocorticoid receptor. For this procedure, the GR first undergoes a major purifica tion by anion exchange chromatography following hormone binding and on-column receptor transformation. Second, the GR is resolved to homogeneity utilizing a hydrophobic interaction chromatography step which consists of a 2.5 M to 0 M NaCl gradient elution of contaminating proteins followed by displacement of GR by CHAPS. GR at both stages of purification was able to activate transcription from the glucocorticoid response element containing the promoter region of the long terminal repeat of the mouse mammary tumor virus. This simple and efficient methodology should be of a considerable advantage for studies of the biology of the active, full-length GR.	NCI, MOLEC VIROL LAB, HORMONE ACT & ONCOGENESIS SECT, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BANIAHMAD C, 1994, BIOTECHNIQUES, V16, P194; BERGLUND H, 1992, BIOCHEMISTRY-US, V31, P12001, DOI 10.1021/bi00163a007; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLSTEDTDUKE J, 1990, RECEPTOR PURIFICATIO, P37; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DeFranco DB, 1995, VITAM HORM, V51, P315, DOI 10.1016/S0083-6729(08)61043-2; DENIS M, 1990, J CHROMATOGR, V508, P97, DOI 10.1016/S0021-9673(00)91243-3; FORMSTECHER P, 1987, RECENT ADV STEROID H, P499; GRANDICS P, 1984, J BIOL CHEM, V259, P3173; HASSANAIN HH, 1993, ANAL BIOCHEM, V213, P162, DOI 10.1006/abio.1993.1400; HAYNES RC, 1985, GOODMAN GILMANS PHAR, P1459; HTUN H, 1996, IN PRESS P NATL ACAD; ING NH, 1992, J BIOL CHEM, V267, P17617; KUSK P, 1995, MOL ENDOCRINOL, V6, P1180; LITWACK G, 1990, RECEPTOR PURIFICATIO, V2; MILLER PA, 1984, BIOCHEMISTRY-US, V23, P6883, DOI 10.1021/bi00321a093; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; NEUGEBAUER J, 1988, GUIDE PROPERTIES USE, P25; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; THOMAS TC, 1990, METHOD ENZYMOL, V182, P499; TSAI SY, 1990, J BIOL CHEM, V265, P17055; WESTPHAL HM, 1984, EMBO J, V3, P1493, DOI 10.1002/j.1460-2075.1984.tb02001.x; WRANGE O, 1984, J BIOL CHEM, V259, P4534; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3	28	20	20	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11434	11440		10.1074/jbc.271.19.11434	http://dx.doi.org/10.1074/jbc.271.19.11434			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626700	hybrid			2022-12-27	WOS:A1996UJ94400060
J	Ma, L; Brosius, MA; Burgess, BK				Ma, L; Brosius, MA; Burgess, BK			Construction of a form of the MoFe protein of nitrogenase that accepts electrons from the Fe protein but does not reduce substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM COFACTOR; AZOTOBACTER-VINELANDII; PARAMAGNETIC RESONANCE; CLOSTRIDIUM-PASTEURIANUM; KLEBSIELLA-PNEUMONIAE; CRYSTALLOGRAPHIC STRUCTURE; DINITROGENASE REDUCTASE; APODINITROGENASE; PURIFICATION; RESOLUTION	The direction of electron flow through nitrogenase is generally believed to be from the Fe protein to the P-clusters to the FeMo cofactor and then to substrate, In order to examine oxidation states of the P-clusters that might be involved in this pathway, we have constructed a form of the MoFe protein that contains a species called the MoFe cluster (Gavini, N., Ma, L., Watt, G., and Burgess, B. K. (1995) Biochemistry 33, 11842-11849) in place of FeMo cofactor, This MoFe cluster-containing protein was purified, and the presence of the cluster was con firmed by reisolation of the MoFe cluster followed by EPR spectroscopy, The protein does not reduce protons or acetylene, however, upon the addition of the Fe protein and MgATP, MgATP hydrolysis occurs at a rate 28% of the wild-type protein, As isolated in the presence of excess dithionite the MoFe cluster-containing protein is EPR silent, Upon addition of the Fe protein and MgATP ag = 1.94 EPR signal develops that integrates to about 1 spin per P-cluster, This signal only develops when both the Fe protein and MgATP are added and it arises from the P-clusters.	UNIV CALIF IRVINE, DEPT MOLEC BIOL & BIOCHEM, IRVINE, CA 92717 USA	University of California System; University of California Irvine					NIGMS NIH HHS [R01-GM-43144] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043144] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1993, J BIOL CHEM, V268, P23670; BOLIN JT, 1993, P NATL ACAD SCI USA, V90, P1078, DOI 10.1073/pnas.90.3.1078; BOLIN JT, 1993, ACS SYM SER, V535, P169; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; CLARK LJ, 1955, ANAL CHEM, V27, P2000, DOI 10.1021/ac60108a046; Dean D.R., 1992, BIOL NITROGEN FIXATI, P763; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; FISKE CH, 1952, J BIOL CHEM, V66, P325; GAVINI N, 1994, BIOCHEMISTRY-US, V33, P11842, DOI 10.1021/bi00205a021; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HALES BJ, 1989, J AM CHEM SOC, V111, P8519, DOI 10.1021/ja00204a035; HAWKES TR, 1983, BIOCHEM J, V209, P43, DOI 10.1042/bj2090043; HOMER MJ, 1993, J BACTERIOL, V175, P4907, DOI 10.1128/JB.175.15.4907-4910.1993; KIM CH, 1995, BIOCHEMISTRY-US, V34, P2798, DOI 10.1021/bi00009a008; KIM J, 1993, BIOCHEMISTRY-US, V32, P7104, DOI 10.1021/bi00079a006; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; MA L, 1994, J BIOL CHEM, V269, P18007; MORNINGSTAR JE, 1987, J AM CHEM SOC, V109, P6854, DOI 10.1021/ja00256a051; MORTENSON LE, 1973, BIOCHIM BIOPHYS ACTA, V292, P422, DOI 10.1016/0005-2728(73)90048-0; Newton WE, 1992, BIOL NITROGEN FIXATI, P877; ORMEJOHNSON WH, 1972, P NATL ACAD SCI USA, V69, P3142, DOI 10.1073/pnas.69.11.3142; ORMEJOHNSON WH, 1980, MOLYBDENUM MOLYBDENU, P427; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; ROBINSON AC, 1986, J BACTERIOL, V166, P180, DOI 10.1128/jb.166.1.180-186.1986; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; SHAH VK, 1981, P NATL ACAD SCI-BIOL, V78, P3438, DOI 10.1073/pnas.78.6.3438; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; SMITH BE, 1973, BIOCHEM J, V135, P331, DOI 10.1042/bj1350331; TAL S, 1991, J BIOL CHEM, V266, P10654; Thorneley R. N. F., 1985, MOLYBDENUM ENZYMES, P221; VANDEBOGART M, 1967, ANAL BIOCHEM, V20, P325, DOI 10.1016/0003-2697(67)90038-3; YATES MG, 1993, BIOL NITROGEN FIXATI, P685; ZUMFT WG, 1973, EUR J BIOCHEM, V35, P401, DOI 10.1111/j.1432-1033.1973.tb02852.x	37	24	24	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10528	10532		10.1074/jbc.271.18.10528	http://dx.doi.org/10.1074/jbc.271.18.10528			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631851	hybrid			2022-12-27	WOS:A1996UJ34200019
J	Popoff, MR; ChavesOlarte, E; Lemichez, E; vonEichelStreiber, C; Thelestam, M; Chardin, P; Cussac, D; Antonny, B; Chavrier, P; Flatau, G; Giry, M; deGunzburg, J; Boquet, P				Popoff, MR; ChavesOlarte, E; Lemichez, E; vonEichelStreiber, C; Thelestam, M; Chardin, P; Cussac, D; Antonny, B; Chavrier, P; Flatau, G; Giry, M; deGunzburg, J; Boquet, P			Ras, Rap, and Rac small GTP-binding proteins are targets for Clostridium sordellii lethal toxin glucosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFICILE; HYDROLYSIS; P21	Lethal toxin (LT) from Clostridium sordellii is one of the high molecular mass clostridial cytotoxins. On cultured cells, it causes a rounding of cell bodies and a disruption of actin stress fibers. We demonstrate that LT is a glucosyltransferase that uses UDP-Glc as a cofactor to covalently modify 21-kDa proteins both in vitro and in vivo. LT glucosylates Ras, Rap, and Rac. In Ras, threonine at position 35 was identified as the target amino acid glucosylated by LT. Other related members of the Ras GTPase superfamily, including RhoA, Cdc42, and Rab6, were not modified by LT. Incubation of serum-starved Swiss 3T3 cells with LT prevents the epidermal growth factor-induced phosphorylation of mitogen-activated protein kinases ERK1 and ERK2, indicating that the toxin blocks Ras function in vivo. We also demonstrate that LT acts inside the cell and that the glucosylation reaction is required to observe its dramatic effect on cell morphology. LT is thus a powerful tool to inhibit Ras function in vivo.	INST PASTEUR, UNITE TOXINES MICROBIENNES, F-75724 PARIS 15, FRANCE; KAROLINSKA INST, MICROBIOL & TUMORBIOL CTR, S-17177 STOCKHOLM, SWEDEN; CNRS, INST PHARMACOL MOLEC & CELLULAIRE, F-06560 VALBONNE, FRANCE; FAC MED NICE, INSERM, U452, F-06107 NICE 2, FRANCE; CTR IMMUNOL MARSEILLES LUMINY, F-13286 MARSEILLE, FRANCE; UNIV MAINZ, INST MED MIKROBIOL & HYG VERFUGUNGSGEBAUDE FORSCH, D-55101 MAINZ, GERMANY; INSERM, U248, F-75010 PARIS, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Karolinska Institutet; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); Johannes Gutenberg University of Mainz; Institut National de la Sante et de la Recherche Medicale (Inserm)			Antonny, Bruno/ABH-7434-2020; CHAVRIER, Philippe/AAG-2645-2020; CHAVRIER, Philippe/B-4707-2010; Lemichez, Emmanuel/G-3559-2013	Antonny, Bruno/0000-0002-9166-8668; CHAVRIER, Philippe/0000-0002-7351-733X; CHAVRIER, Philippe/0000-0002-7351-733X; Lemichez, Emmanuel/0000-0001-9080-7761				ANTONNY B, 1991, BIOCHEMISTRY-US, V30, P8287, DOI 10.1021/bi00098a002; ARSECULERATNE SN, 1969, J MED MICROBIOL, V2, P37, DOI 10.1099/00222615-2-1-37; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BETTE P, 1991, TOXICON, V29, P877, DOI 10.1016/0041-0101(91)90224-F; BRETSCHER A, 1981, P NATL ACAD SCI-BIOL, V78, P6849, DOI 10.1073/pnas.78.11.6849; ChavesOlarte E, 1996, J BIOL CHEM, V271, P6925, DOI 10.1074/jbc.271.12.6925; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FLORIN I, 1991, MICROB PATHOGENESIS, V11, P337, DOI 10.1016/0882-4010(91)90019-7; GIRY M, 1995, INFECT IMMUN, V63, P4063, DOI 10.1128/IAI.63.10.4063-4071.1995; GREEN GA, 1995, GENE, V161, P57, DOI 10.1016/0378-1119(95)00263-6; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; JIMENEZ B, 1991, INT J CANCER, V49, P471, DOI 10.1002/ijc.2910490327; JOHN J, 1993, J BIOL CHEM, V268, P923; JUST I, 1995, J CLIN INVEST, V95, P1026, DOI 10.1172/JCI117747; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LYERLY D M, 1988, Clinical Microbiology Reviews, V1, P1; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MARTINEZ RD, 1992, J MED MICROBIOL, V36, P30, DOI 10.1099/00222615-36-1-30; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POPOFF MR, 1987, INFECT IMMUN, V55, P35, DOI 10.1128/IAI.55.1.35-43.1987; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SANDVIG K, 1992, BIOCHEM SOC T, V20, P724, DOI 10.1042/bst0200724; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	29	177	180	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10217	10224		10.1074/jbc.271.17.10217	http://dx.doi.org/10.1074/jbc.271.17.10217			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626586	hybrid			2022-12-27	WOS:A1996UG25700058
J	Wu, XJ; Zhou, MY; Huang, LS; Wetterau, J; Ginsberg, HN				Wu, XJ; Zhou, MY; Huang, LS; Wetterau, J; Ginsberg, HN			Demonstration of a physical interaction between microsomal triglyceride transfer protein and apolipoprotein B during the assembly of ApoB-containing lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HEP G2 CELLS; INTRACELLULAR DEGRADATION; COMBINED HYPERLIPIDEMIA; OLEIC-ACID; SECRETION; LIVER; OLEATE; ABETALIPOPROTEINEMIA; STIMULATION	Microsomal triglyceride (TG) transfer protein (MTP) is an endoplasmic reticulum lumenal protein consisting of a 97-kDa subunit and protein disulfide isomerase. It is believed that MTP delivers TG to nascent apoB molecules during the assembly of lipoprotein particles in the secretory pathway. Although in vitro studies have established the mechanism of TG transfer between donor and acceptor membranes, the mechanism of action of MTP in vivo remains unknown. The present studies were undertaken to examine whether or not the transfer of TG to nascent apoB in the endoplasmic reticulum involves the physical interaction between MTP and apoB. HepG2 cells were labeled with [H-3]leucine, lysed in a nondenaturing homogenizing buffer, and immunoprecipitated with anti-MTP antiserum. We found that labeled apoB and protein disulfide isomerase were co-immunoprecipitated by this procedure. In addition, we were able to detect the 97-kDa subunit of MTP in these immunoprecipitates by immunoblot. The association of MTP and apoB, as assessed in pulse-labeled cells by co-immunoprecipitation, was transient; apoB was prominent on fluorography at 10 min of chase but minimal thereafter. Oleic acid treatment, which protects apoB from rapid intracellular degradation by increasing TG availability, increased both the degree and the duration of association between MTP and apoB dramatically. Inhibition of TG synthesis by Triacsin D, on the other hand, significantly decreased the MTP-apoB binding. N-Acetyl-leucyl-leucyl-norleucinal, a cysteine protease inhibitor, which directly protects apoB from rapid intracellular degradation but does not affect TG synthesis, increased the interaction between MTP and apoB only slightly, although it did prolong it. Our results suggest that direct interaction between MTP and apoB occurs during the assembly of apoB-containing lipoproteins in HepG2 cells.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,PRINCETON,NJ 08543	Columbia University; Bristol-Myers Squibb					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036000, P50HL021006] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36000, HL21006] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; ARAD Y, 1990, J LIPID RES, V31, P567; ATZEL A, 1993, BIOCHEMISTRY-US, V32, P10444, DOI 10.1021/bi00090a021; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; DASHTI N, 1989, J LIPID RES, V30, P1365; DIXON JL, 1991, J BIOL CHEM, V266, P5080; ELOVSON J, 1994, CIRCULATION, V90, P185; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; JANUS ED, 1980, EUR J CLIN INVEST, V10, P161, DOI 10.1111/j.1365-2362.1980.tb02076.x; Kane J.B., 1989, METABOLIC BASIS INHE, P1139; KISSEBAH AH, 1981, METABOLISM, V30, P856, DOI 10.1016/0026-0495(81)90064-0; KROON PA, 1986, P NATL ACAD SCI USA, V83, P5071, DOI 10.1073/pnas.83.14.5071; KUSWAHA RS, 1991, J LIPID RES, V32, P1929; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; LIN MCM, 1995, J LIPID RES, V36, P1073; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; OMURA S, 1986, J ANTIBIOT, V39, P1211, DOI 10.7164/antibiotics.39.1211; PULLINGER CR, 1989, J LIPID RES, V30, P1065; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SORCITHOMAS M, 1989, J BIOL CHEM, V264, P9039; TENG B, 1986, J CLIN INVEST, V77, P663, DOI 10.1172/JCI112360; THRIFT RN, 1986, J LIPID RES, V27, P236; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1984, J BIOL CHEM, V259, P863; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WU XJ, 1994, J LIPID RES, V35, P1200; WU XJ, 1994, J BIOL CHEM, V269, P12375	31	125	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10277	10281		10.1074/jbc.271.17.10277	http://dx.doi.org/10.1074/jbc.271.17.10277			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626595				2022-12-27	WOS:A1996UG25700067
J	Leone, G; Coffey, MC; Gilmore, R; Duncan, R; Maybaum, L; Lee, PWK				Leone, G; Coffey, MC; Gilmore, R; Duncan, R; Maybaum, L; Lee, PWK			C-terminal trimerization, but not N-terminal trimerization, of the reovirus cell attachment protein is a posttranslational and Hsp70/ATP-dependent process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPTAD REPEAT REGION; HEAT-SHOCK PROTEINS; FUNCTIONAL DOMAINS; SIGMA-1; PROTEIN-SIGMA-1; TRANSLOCATION; HEMAGGLUTININ; SEQUENCE; INVITRO; PORTION	The C-terminal globular head of the lollipop-shaped sigma 1 protein of reovirus is responsible for interaction with the host cell receptor. Like the N-terminal fibrous tail, it has its own trimerization domain, Whereas N-terminal trimerization (formation of a triple alpha-helical coiled coil) occurs at the level of polysomes (i.e. cotranslationally) and is ATP-independent, C-terminal trimerization is a posttranslational event that requires ATP. Coprecipitation experiments using anti-Hsp70 antibodies and truncated sigma 1 proteins synthesized in vitro revealed that only regions downstream of the N-terminal alpha-helical coiled coil were associated with Hsp70. Hsp70 was also found to be associated with nascent al chains on polysomes as well as with immature postribosomal sigma 1 trimers (hydralike intermediates with assembled N termini and unassembled C termini). These latter structures were true intermediates in the al biogenetic pathway since they could be chased into mature al trimers with the release of Hsp70. Thus, unlike N-terminal trimerization, C-terminal trimerization is Hsp70- and ATP-dependent. The involvement of two mechanistically distinct oligomerization events for the same molecule, one cotranslational and one posttranslational, may represent a common approach to the generation of oligomeric proteins in the cytosol.	UNIV CALGARY,HLTH SCI CTR,DEPT MICROBIOL & INFECT DIS,CALGARY,AB T2N 4N1,CANADA	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba			Giuseppe Leone, Full Professor/I-9166-2019	Giuseppe Leone, Full Professor/0000-0002-7812-5300; Duncan, Roy/0000-0002-5162-5081				BANERJEA AC, 1988, VIROLOGY, V167, P601, DOI 10.1016/0042-6822(88)90123-7; BANERJEA AC, 1990, VIROLOGY, V179, P460, DOI 10.1016/0042-6822(90)90315-I; BARDWELL JCA, 1988, J BACTERIOL, V170, P2977, DOI 10.1128/jb.170.7.2977-2983.1988; BASSELDUBY R, 1985, NATURE, V315, P421, DOI 10.1038/315421a0; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; BURSTIN SJ, 1982, VIROLOGY, V117, P146, DOI 10.1016/0042-6822(82)90514-1; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DUNCAN R, 1991, VIROLOGY, V182, P810, DOI 10.1016/0042-6822(91)90622-I; DUNCAN R, 1994, VIROLOGY, V203, P149, DOI 10.1006/viro.1994.1465; ELLIS RJ, 1994, CURR OPIN STRUC BIOL, V4, P117, DOI 10.1016/S0959-440X(94)90069-8; FERNANDES J, 1994, J BIOL CHEM, V269, P17043; FRASER RDB, 1990, J VIROL, V64, P2990, DOI 10.1128/JVI.64.6.2990-3000.1990; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; FURLONG DB, 1988, J VIROL, V62, P246, DOI 10.1128/JVI.62.1.246-256.1988; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEE PWK, 1981, VIROLOGY, V108, P156, DOI 10.1016/0042-6822(81)90535-3; LEONE G, 1991, VIROLOGY, V182, P346, DOI 10.1016/0042-6822(91)90678-5; LEONE G, 1991, VIROLOGY, V182, P336, DOI 10.1016/0042-6822(91)90677-4; LEONE G, 1992, CELL, V71, P479, DOI 10.1016/0092-8674(92)90516-F; LEONE G, 1991, VIROLOGY, V184, P758, DOI 10.1016/0042-6822(91)90447-J; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MAH DCW, 1990, VIROLOGY, V179, P95, DOI 10.1016/0042-6822(90)90278-Y; NAGATA L, 1987, VIROLOGY, V160, P162, DOI 10.1016/0042-6822(87)90056-0; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; NIBERT ML, 1990, J VIROL, V64, P2976, DOI 10.1128/JVI.64.6.2976-2989.1990; SOLL J, 1993, PHYSIOL PLANTARUM, V87, P433, DOI 10.1111/j.1399-3054.1993.tb01752.x; STRONG JE, 1991, VIROLOGY, V184, P23, DOI 10.1016/0042-6822(91)90818-V; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; TISSIERES A, 1974, J MOL BIOL, V84, P389, DOI 10.1016/0022-2836(74)90447-1; TURNER DL, 1992, VIROLOGY, V186, P219, DOI 10.1016/0042-6822(92)90076-2; YEUNG MC, 1989, VIROLOGY, V170, P62, DOI 10.1016/0042-6822(89)90352-8; YEUNG MC, 1987, VIROLOGY, V156, P377, DOI 10.1016/0042-6822(87)90417-X	44	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8466	8471		10.1074/jbc.271.14.8466	http://dx.doi.org/10.1074/jbc.271.14.8466			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626547	hybrid			2022-12-27	WOS:A1996UD60000087
J	Garrett, RM; Rajagopalan, KV				Garrett, RM; Rajagopalan, KV			Site-directed mutagenesis of recombinant sulfite oxidase - Identification of cysteine 207 as a ligand of molybdenum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODING NITRATE REDUCTASE; XANTHINE DEHYDROGENASE; NUCLEOTIDE-SEQUENCE; CDNA CLONING; GENE; PROTEIN; DOMAINS; LIVER	Each of the four cysteines in rat sulfite oxidase was altered by site directed mutagenesis to serine, and the mutant proteins were expressed in Escherichia coli. Three of the replacements proved to be silent mutations, while a single cysteine, Cys-207, was found to be essential for enzyme activity. The C207S mutation was also generated in cloned human sulfite oxidase. The mutant human enzyme also displayed severely attenuated activity but was expressed at higher levels allowing purifica tion and spectroscopic analysis. The absorption spectrum of the isolated molybdenum domain of the human C207S mutant displayed marked attenuation of the peak at 350 nm and a lesser decrease in absorbance from 450-600 nm as compared with the native human molybdenum domain. The molybdenum and molybdopterin contents of the two samples were comparable. These data suggest that the major features in the absorption spectrum of the native molybdenum domain arise from the binding of Cys-207 to the molybdenum and indicate that this residue functions as a ligand of the metal.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007031] Funding Source: NIH RePORTER; NIEHS NIH HHS [T32 ES07031] Funding Source: Medline; NIGMS NIH HHS [GM00091, GM 44283] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANKS GR, 1993, GENE, V131, P69, DOI 10.1016/0378-1119(93)90670-X; BARBER MJ, 1990, J BIOL CHEM, V265, P20912; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; COHEN HJ, 1971, J BIOL CHEM, V246, P359; CRAMER SP, 1981, J AM CHEM SOC, V103, P7721, DOI 10.1021/ja00416a005; CRAMER SP, 1979, J AM CHEM SOC, V101, P2772, DOI 10.1021/ja00504a067; CRAWFORD NM, 1988, P NATL ACAD SCI USA, V85, P5006, DOI 10.1073/pnas.85.14.5006; CRAWFORD NM, 1986, P NATL ACAD SCI USA, V83, P8073, DOI 10.1073/pnas.83.21.8073; DANIELVEDELE F, 1989, GENE, V85, P371, DOI 10.1016/0378-1119(89)90430-7; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FRIEMANN A, 1991, MOL GEN GENET, V227, P97, DOI 10.1007/BF00260713; GARDE J, 1995, J BIOL CHEM, V270, P6644, DOI 10.1074/jbc.270.12.6644; GARRETT RM, 1994, J BIOL CHEM, V269, P272; GARRETT RM, 1995, BBA-GENE STRUCT EXPR, V1262, P147, DOI 10.1016/0167-4781(95)00068-R; ICHIDA K, 1993, GENE, V133, P279; JOHNSON JL, 1988, METHOD ENZYMOL, V158, P371, DOI 10.1016/0076-6879(88)58069-2; JOHNSON JL, 1977, J BIOL CHEM, V252, P2017; JOHNSON JL, 1976, J CLIN INVEST, V58, P543, DOI 10.1172/JCI108499; JOHNSTONE IL, 1990, GENE, V90, P181, DOI 10.1016/0378-1119(90)90178-T; OKAMOTO PM, 1991, MOL GEN GENET, V227, P213, DOI 10.1007/BF00259673; PROSSER IM, 1990, PLANT MOL BIOL, V15, P187, DOI 10.1007/BF00017743; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; WRIGHT RM, 1993, P NATL ACAD SCI USA, V90, P10690, DOI 10.1073/pnas.90.22.10690	24	107	107	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7387	7391		10.1074/jbc.271.13.7387	http://dx.doi.org/10.1074/jbc.271.13.7387			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631762	hybrid			2022-12-27	WOS:A1996UC77400030
J	Kitamura, K; Singer, WD; Star, RA; Muallem, S; Miller, RT				Kitamura, K; Singer, WD; Star, RA; Muallem, S; Miller, RT			Induction of inducible nitric-oxide synthase by the heterotrimeric G protein G alpha(13)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT	While the functions of several G protein alpha subunits such as alpha(s) and alpha(q) are relatively well understood, the action of others such as alpha(13) remain largely undefined. Because of recent interest in regulation of nitric-oxide synthase (NOS) by G protein-coupled signaling systems and findings that receptors for two proinflammatory substances, thrombin and thromboxane couple to alpha(13), we studied the effect of alpha(13) on NOS activity in a renal epithelial cell line. We found that stable overexpression of alpha(13) or its GTPase-deficient mutant, alpha(13Q226L), in a continuous renal epithelial cell line (MCT) increased NOS activity. The increased NOS activity was due to increased expression of the macrophage-inducible form of NOS (iNOS). iNOS protein and activity were not increased in similar cells expressing an activated alpha(s) (alpha(sQ227L)) or were minimally increased in cells expressing activated alpha(i1) (alpha(i1Q204L)) and alpha(q) (alpha(qQ209L)), members of the three other G protein alpha chain families. Transient coexpression of alpha(13) or (alpha(13Q226L)) increased the activity of an iNOS promoter-CAT construct demonstrating that alpha(13) increases iNOS expression through transcription. Consequently, alpha(13) induces iNOS through a novel mechanism that is distinct from that of other G protein a chains and that may mediate the actions of G protein-dependent proinflammatory agents.	UNIV FLORIDA,J HILLIS MILLER HLTH CTR,DEPT MED,GAINESVILLE,FL 32610; UNIV FLORIDA,J HILLIS MILLER HLTH CTR,DEPT PHARMACOL,GAINESVILLE,FL 32610; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK39298, R29DK41726] Funding Source: Medline; NIGMS NIH HHS [F32-GM15359] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039298, R37DK039298, R29DK041726] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015359] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BROWN AM, 1988, AM J PHYSIOL, V254, pH401, DOI 10.1152/ajpheart.1988.254.3.H401; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAVERTY TP, 1988, J CELL BIOL, V107, P1359, DOI 10.1083/jcb.107.4.1359; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KITAMURA K, 1994, J CLIN INVEST, V94, P328, DOI 10.1172/JCI117325; KITAMURA K, 1995, AM J PHYSIOL, V268, P101; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MORRIS SM, 1994, AM J PHYSIOL, V266, pE829, DOI 10.1152/ajpendo.1994.266.6.E829; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; OFFERMANNS S, 1994, MOL CELL ENDOCRINOL, V100, P71, DOI 10.1016/0303-7207(94)90281-X; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Sambrook J., 2002, MOL CLONING LAB MANU; SINGER WD, 1994, J BIOL CHEM, V269, P19796; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; XU X, 1995, J BIOL CHEM, V270, P29169, DOI 10.1074/jbc.270.49.29169	27	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7412	7415		10.1074/jbc.271.13.7412	http://dx.doi.org/10.1074/jbc.271.13.7412			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631766	hybrid			2022-12-27	WOS:A1996UC77400034
J	Raju, TS; Stanley, P				Raju, TS; Stanley, P			LEC14, a dominant Chinese hamster ovary glycosylation mutant expresses complex N-glycans with a new N-acetylglucosamine residue in the core region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; HONEYBEE VENOM PHOSPHOLIPASE-A2; MAGNETIC-RESONANCE SPECTROSCOPY; CARBOHYDRATE CHAINS; ANIMAL GLYCOPROTEIN; GDP-FUCOSE; LYMNAEA-STAGNALIS; LECTIN; XYLOSE; CELLS	The Chinese hamster ovary cell (CHO) glycosylation mutant, LEC14, was previously selected for resistance to pea lectin (Pisum sativum agglutinin) and shown to behave dominantly. The lectin resistance properties of LEC14 cells are related to, but distinct from, those of LEC18, a dominant Chinese hamster ovary mutant that synthesizes complex N-glycans with a novel O-6-linked GlcNAc residue in the core region (Raju, T. S., Ray, M., and Stanley, P. (1995) J. Biol. Chem. 270, 30294-30302). Detailed structural studies of a complex N-glycan fraction from LEC14 cells have revealed yet another novel modification of the core region, [H-3]Glc-labeled LEC14 cellular glycopeptides were desialylated, and the fraction that did not bind to concanavalin A-Sepharose was found to have an increased proportion of species that bound to tomato-agarose, and to ricin-agarose, H-1 NMR spectroscopy and methylation linkage analysis of the tomato and ricin-bound fractions purified from similar to 10(10) LEC14 cells showed they were complex N-glycans containing a 2,3,6-trisubstituted core Man residue. To examine the core region more closely, these N-glycans were digested with mixtures of beta-D-galactosidases and N-acetyl-beta-D-glucosaminidases to obtain core glycopeptides. The latter were largely unbound by concanavalin A-Sepharose or pea lectin-agarose. H-1 NMR spectroscopy and electrospray ionization-mass spectrometry showed that the LEC14 core glycopeptides contain a new GlcNAc residue that substitutes the core beta(1,4)-Man residue at O-2 to give the following novel, N-linked core structure.	ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,NEW YORK,NY 10461	Yeshiva University				Stanley, Pamela/0000-0001-5704-3747	NATIONAL CANCER INSTITUTE [R01CA036434] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36434] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHFORD D, 1987, EUR J BIOCHEM, V166, P311, DOI 10.1111/j.1432-1033.1987.tb13516.x; BAENZIGER JU, 1979, J BIOL CHEM, V254, P2400; BOUWSTRA JB, 1990, EUR J BIOCHEM, V190, P113, DOI 10.1111/j.1432-1033.1990.tb15553.x; CAMPBELL C, 1984, J BIOL CHEM, V259, P3370; CAMPBELL C, 1984, J BIOL CHEM, V259, P1208; DANDREA G, 1988, GLYCOCONJUGATE J, V5, P151, DOI 10.1007/BF01061204; EDGE CJ, 1992, P NATL ACAD SCI USA, V89, P6338, DOI 10.1073/pnas.89.14.6338; FOURNET B, 1987, EUR J BIOCHEM, V166, P321, DOI 10.1111/j.1432-1033.1987.tb13517.x; GREEN ED, 1987, J BIOL CHEM, V262, P12030; GREY AA, 1982, CAN J BIOCHEM CELL B, V60, P1123, DOI 10.1139/o82-144; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HARDY MR, 1994, METHOD ENZYMOL, V230, P208; HASLAM SM, 1994, GLYCOBIOLOGY, V4, P105, DOI 10.1093/glycob/4.2.105; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; KAMERLING JP, 1991, PURE APPL CHEM, V63, P465, DOI 10.1351/pac199163040465; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; KOBATA A, 1979, ANAL BIOCHEM, V100, P1, DOI 10.1016/0003-2697(79)90102-7; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; LAMMERSE JPM, 1994, THESIS UTRECHT U; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; POTVIN B, 1991, CELL REGUL, V2, P989, DOI 10.1091/mbc.2.12.989; Raju TS, 1995, J BIOL CHEM, V270, P30294, DOI 10.1074/jbc.270.51.30294; REINHOLD VN, 1995, ANAL CHEM, V67, P1772, DOI 10.1021/ac00107a005; RIPKA J, 1986, SOMAT CELL MOLEC GEN, V12, P51, DOI 10.1007/BF01560727; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; STANLEY P, 1991, Glycobiology, V1, P307, DOI 10.1093/glycob/1.3.307; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; Stanley P, 1977, Adv Exp Med Biol, V84, P265; STANLEY P, 1983, METHOD ENZYMOL, V96, P157; STAUDACHER E, 1991, EUR J BIOCHEM, V199, P745, DOI 10.1111/j.1432-1033.1991.tb16179.x; STAUDACHER E, 1992, GLYCOCONJUGATE J, V9, P82, DOI 10.1007/BF00731703; STRECKER G, 1989, GLYCOCONJUGATE J, V6, P67, DOI 10.1007/BF01047891; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; VANKUIK JA, 1985, J BIOL CHEM, V260, P3984; VANKUIK JA, 1986, EUR J BIOCHEM, V160, P621; VANKUIK JA, 1987, EUR J BIOCHEM, V169, P399; VANKUIK JA, 1993, TRENDS FOOD SCI TECH, V4, P73; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; YORK WS, 1984, METHOD ENZYMOL, V118, P3	42	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7484	7493		10.1074/jbc.271.13.7484	http://dx.doi.org/10.1074/jbc.271.13.7484			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631778	hybrid			2022-12-27	WOS:A1996UC77400046
J	Sanna, MG; Simon, MI				Sanna, MG; Simon, MI			Isolation and in vitro characterization of CheZ suppressors for the Escherichia coli chemotactic response regulator mutant CheYN23D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CHEMOTAXIS; PROTEIN-PHOSPHORYLATION; SIGNAL-TRANSDUCTION; FLAGELLAR SWITCH	The phosphorylated form of the response regulator CheY promotes the tumble signal in Escherichia coli chemotaxis, Phospho-CheY is thought to interact with the switch at the base of the flagellar motor and cause reversal of flagellar rotation from counterclockwise to clockwise changing the swimming direction, Thus the level of phospho-CheY controls the direction of flagellar rotation, The decay of the tumble signal is caused by dephosphorylation of CheY. CheY has an intrinsic autophosphatase activity; however, this reaction is greatly accelerated by the presence of the CheZ protein, We have shown previously that mutations at residues Asn-23 and Lys-26 in CheY confer resistance to the dephosphorylation activity of CheZ (Sanna, M. G., Swanson, R. V., Bourret, R. B., and Simon, M. I. (1995) Mol. Microbiol. 15, 1069-1079). Here we show that mutant CheY(N23D) is impaired in binding to CheZ, which provides a possible explanation for its resistance to the dephosphorylation activity of CheZ, Moreover, we isolated CheZ second-site suppressors of CheY(N23D), which restore both dephosphorylation and binding activity in a CheY(N23D) background, When the CheZ suppressor mutations are mapped, they are found in two clusters at the N and C termini of the CheZ protein which could define two regions of interaction with CheY, Furthermore, these regions may generate a surface in the folded three-dimensional structure of CheZ required for interaction with CheY.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA	California Institute of Technology					NIAID NIH HHS [AI19296] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019296] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; BARAK R, 1992, BIOCHEMISTRY-US, V31, P1821, DOI 10.1021/bi00121a034; BLAT Y, 1994, BIOCHEMISTRY-US, V33, P902, DOI 10.1021/bi00170a008; Blat Y, 1996, J BIOL CHEM, V271, P1226, DOI 10.1074/jbc.271.2.1226; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BURKOVICH KA, 1990, CELL, V63, P1339; CADWELL RC, 1994, PCR METH APPL, V3, pS136; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1988, COLD SPRING HARB SYM, V53, P41, DOI 10.1101/SQB.1988.053.01.008; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; HESS JF, 1991, METHOD ENZYMOL, V200, P188; HUANG CX, 1993, BIOCHIM BIOPHYS ACTA, V1202, P297, DOI 10.1016/0167-4838(93)90019-N; KUO SC, 1987, J BACTERIOL, V169, P1307, DOI 10.1128/jb.169.3.1307-1314.1987; Leung DW, 1989, TECHNIQUE, V1, P11; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; ROMAN SJ, 1992, J BACTERIOL, V174, P6247, DOI 10.1128/JB.174.19.6247-6255.1992; SANNA MG, 1995, MOL MICROBIOL, V15, P1069, DOI 10.1111/j.1365-2958.1995.tb02282.x; SOCKETT H, 1992, J BACTERIOL, V174, P743; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6	23	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7357	7361		10.1074/jbc.271.13.7357	http://dx.doi.org/10.1074/jbc.271.13.7357			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631757	Green Accepted, hybrid			2022-12-27	WOS:A1996UC77400025
J	Siddhanta, U; Wu, CQ; AbuSoud, HM; Zhang, JL; Ghosh, DK; Stuehr, DJ				Siddhanta, U; Wu, CQ; AbuSoud, HM; Zhang, JL; Ghosh, DK; Stuehr, DJ			Heme iron reduction and catalysis by a nitric oxide synthase heterodimer containing one reductase and two oxygenase domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Inducible nitric oxide (NO) synthase (iNOS) is comprised of an oxygenase domain containing heme, tetrahydrobiopterin, the substrate binding site, and a reductase domain containing FAD, FMN, calmodulin, and the NADPH binding site, Enzyme activity requires a dimeric interaction between two oxygenase domains with the reductase domains attached as monomeric extensions, To understand how dimerization activates iNOS, we synthesized an iNOS heterodimer comprised of one full-length subunit and one histidine-tagged subunit that was missing its reductase domain, The heterodimer was purified using nickel-Sepharose and 2',5'-ADP affinity chromatography, The heterodimer catalyzed NADPH-dependent NO synthesis from L-arginine at a rate of 52 +/- 6 nmol of NO/min/nmol of heme, which is half the rate of purified iNOS homodimer, Heterodimer NO synthesis was associated with reduction of only half of its heme iron by NADPH, in contrast with near complete heme iron reduction in an iNOS homodimer, Full-length MOS monomer preparations could not synthesize NO nor catalyze NADPH-dependent heme iron reduction. Thus, dimerization activates NO synthesis by enabling electrons to transfer between the reductase and oxygenase domains. Although a single reductase domain can reduce only one of two hemes in a dimer, this supports NO synthesis from L-arginine.	CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Case Western Reserve University	Siddhanta, U (corresponding author), CLEVELAND CLIN RES INST,DEPT IMMUNOL,CLEVELAND,OH 44195, USA.				NATIONAL CANCER INSTITUTE [R01CA053914, R29CA053914] Funding Source: NIH RePORTER; NCI NIH HHS [CA53914] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; FISHER MT, 1985, J AM CHEM SOC, V107, P5018, DOI 10.1021/ja00303a045; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; GHOSH HM, 1995, BIOCHEMISTRY-US, V34, P11316; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; KERWIN JF, 1995, J MED CHEM, V38, P4343, DOI 10.1021/jm00022a001; KLATT P, 1994, J BIOL CHEM, V269, P1674; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; KLATT P, 1993, J BIOL CHEM, V268, P1481; KRONCKE KD, 1995, BIOL CHEM H-S, V376, P327; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SHETA EA, 1994, J BIOL CHEM, V269, P15147; SLIGAR SG, 1986, CYTOCHROME P450 STRU, P429; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; WANG JL, 1993, J BIOL CHEM, V268, P22255; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P7160	30	78	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7309	7312		10.1074/jbc.271.13.7309	http://dx.doi.org/10.1074/jbc.271.13.7309			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631749	hybrid			2022-12-27	WOS:A1996UC77400017
J	Goldman, PS; Schlador, ML; Shapiro, RA; Nathanson, NM				Goldman, PS; Schlador, ML; Shapiro, RA; Nathanson, NM			Identification of a region required for subtype-specific agonist-induced sequestration of the m2 muscarinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3RD CYTOPLASMIC LOOP; G-PROTEIN; CHOLINERGIC RECEPTORS; CELLS; M1; DOMAIN; EXPRESSION; BINDING; M3-MUSCARINIC-RECEPTOR; DESENSITIZATION	When the m1 and m2 muscarinic acetylcholine receptors are transiently expressed in JEG-3 cells, the m2, but not the mi, receptor undergoes agonist-induced sequestration. Both receptors exhibit internalization when expressed in Y1 cells. These results suggest that the m1 and m2 receptors use distinct cellular mechanisms or pathways for agonist-induced internalization and that JEG-3 cells are deficient in the mechanism or pathway used by the m1 receptor. Transfection experiments with chimeric receptors indicate that the specificity for agonist-induced internalization for the m2 receptor lies in the carboxyl-terminal fifth of the receptor. The intracellular carboxyl-terminal tail of the m2 receptor is neither sufficient nor required for the m2-specific sequestration. Site-directed mutagenesis demonstrates that two amino acids in the carboxyl-terminal end of the third cytoplasmic loop of the m2 receptor are required for sequestration in JEG-3 cells. In addition, the sixth transmembrane domain, which is adjacent to this cytoplasmic domain, is also required. Thus, m2-specific agonist-induced sequestration requires sequences both in the carboxyl-terminal end of the third cytoplasmic loop and the adjacent transmembrane domain.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44948] Funding Source: Medline; NIGMS NIH HHS [GM07270, GM07750] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; BLUML K, 1994, P NATL ACAD SCI USA, V91, P7980, DOI 10.1073/pnas.91.17.7980; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BURKE J, 1992, J BIOL CHEM, V267, P24433; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUERSON K, 1993, FEBS LETT, V324, P103, DOI 10.1016/0014-5793(93)81541-7; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FEIGENBAUM P, 1985, J PHARMACOL EXP THER, V233, P134; GALPER JB, 1982, J BIOL CHEM, V257, P344; GOLDMAN PS, 1994, J BIOL CHEM, V269, P15640; GOLDMAN PS, 1992, SOC NEUR ABSTR, V18, P387; HARDEN TK, 1985, J BIOL CHEM, V260, P3060; HUNTER DD, 1984, P NATL ACAD SCI-BIOL, V81, P3582, DOI 10.1073/pnas.81.11.3582; KEEFER JR, 1994, J BIOL CHEM, V269, P16425; KLEIN WL, 1979, BIOCHEM BIOPH RES CO, V90, P506, DOI 10.1016/0006-291X(79)91264-6; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LEE NH, 1993, J BIOL CHEM, V268, P7949; MACHAMER CE, 1993, MOL BIOL CELL, V4, P695, DOI 10.1091/mbc.4.7.695; MALOTEAUX JM, 1983, FEBS LETT, V156, P103, DOI 10.1016/0014-5793(83)80257-9; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4871; MIGEON JC, 1995, J BIOL CHEM, V270, P16070, DOI 10.1074/jbc.270.27.16070; MIGEON JC, 1994, J BIOL CHEM, V269, P9767; MORO O, 1994, J BIOL CHEM, V269, P6651; MORO O, 1993, J BIOL CHEM, V268, P6862; NAKATA H, 1994, EUR J BIOCHEM, V220, P29, DOI 10.1111/j.1432-1033.1994.tb18595.x; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; SCHERER NM, 1990, BIOCHEMISTRY-US, V29, P8475, DOI 10.1021/bi00488a039; SHAPIRO RA, 1993, J BIOL CHEM, V268, P21734; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; TAYLOR JE, 1979, LIFE SCI, V25, P2181, DOI 10.1016/0024-3205(79)90090-0; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; TRAUB LM, 1991, J BIOL CHEM, V266, P24642; TSUGA H, 1994, J BIOL CHEM, V269, P32522; WESS J, 1992, J BIOL CHEM, V267, P19313; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; WESS J, 1991, EMBO J, V10, P3629; YASAMURA Y, 1966, CANCER RES, V26, P529	43	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4215	4222						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626765				2022-12-27	WOS:A1996TW96000043
J	Li, XQ; Stebbins, B; Hoffman, L; Pratt, G; Rechsteiner, M; Coffino, P				Li, XQ; Stebbins, B; Hoffman, L; Pratt, G; Rechsteiner, M; Coffino, P			The N terminus of antizyme promotes degradation of heterologous proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE DECARBOXYLASE ANTIZYME; INTRACELLULAR DEGRADATION; DEPENDENT PROTEASES; RETICULOCYTE LYSATE; INHIBITORY PROTEIN; TRYPANOSOMA-BRUCEI; MESSENGER-RNA; RAT-LIVER; PURIFICATION; PROTEOLYSIS	Regulated degradation of ornithine decarboxylase (ODC) is mediated by its association with the inducible protein antizyme. The N terminus of antizyme (NAZ), although unneeded for the interaction with ODC, must be present to induce degradation. We report here that covalently grafting NAZ to ODC confers lability that normally results from the non-covalent association of native antizyme and ODC. To determine whether NAZ could act similarly as a modular functional domain when grafted to other proteins, we fused it to a region of cyclin B (amino acids 13-90) capable of undergoing degradation or to cyclin B (amino acids 13-59), which is not subject to degradation. The association with NAZ made both NAZ-cyclin B13-90 and NAZ-cyclin B13-59 unstable. Furthermore, NAZ and cyclin B 13-59 were together able to induce in vitro degradation of Trypanosoma brucei ODC, a stable protein. The ODC-antizyme complex bound to the 26 S protease but not the 20 S proteasome, consistent with the observation that ODC degradation is mediated by the 26 S protease. The association was shown to be independent of NAZ, suggesting that NAZ does not act as a recognition signal.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84132	University of California System; University of California San Francisco; Utah System of Higher Education; University of Utah	Li, XQ (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143, USA.			Coffino, Philip/0000-0003-0344-5083	NCI NIH HHS [CA 09043] Funding Source: Medline; NIGMS NIH HHS [R01 GM45335, R01 GM37009] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009043] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037009, R01GM045335] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASS KE, 1992, J BIOL CHEM, V267, P11034; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FONG WF, 1976, BIOCHIM BIOPHYS ACTA, V428, P456, DOI 10.1016/0304-4165(76)90054-4; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1992, MOL CELL BIOL, V12, P2178, DOI 10.1128/MCB.12.5.2178; GHODA L, 1990, J BIOL CHEM, V265, P11823; GLASS JR, 1987, J CELL PHYSIOL, V130, P133, DOI 10.1002/jcp.1041300119; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HELLER JS, 1976, P NATL ACAD SCI USA, V73, P1858, DOI 10.1073/pnas.73.6.1858; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; KITANI T, 1984, J BIOL CHEM, V259, P36; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; Li XQ, 1996, J BIOL CHEM, V271, P4447; MAMROUDKIDRON E, 1994, EUR J BIOCHEM, V226, P547, DOI 10.1111/j.1432-1033.1994.tb20079.x; MATSUFUJI S, 1990, J BIOCHEM-TOKYO, V108, P365, DOI 10.1093/oxfordjournals.jbchem.a123207; MIYAZAKI Y, 1992, GENE, V113, P191, DOI 10.1016/0378-1119(92)90395-6; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1985, BIOCHEM J, V226, P893, DOI 10.1042/bj2260893; MURAKAMI Y, 1992, BIOCHEM J, V283, P661, DOI 10.1042/bj2830661; PHILLIPS MA, 1987, J BIOL CHEM, V262, P8721; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8	30	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4441	4446						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626796				2022-12-27	WOS:A1996TW96000074
J	Rokaw, MD; Benos, DJ; Palevsky, PM; Cunningham, SA; West, ME; Johnson, JP				Rokaw, MD; Benos, DJ; Palevsky, PM; Cunningham, SA; West, ME; Johnson, JP			Regulation of a sodium channel-associated G-protein by aldosterone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LLC-PK1 RENAL-CELLS; APICAL MEMBRANE; ALPHA-SUBUNITS; GENE PROMOTER; NA+ CHANNELS; METHYLATION; MECHANISMS; TRANSPORT; INCREASES	The action of aldosterone to increase apical membrane permeability in responsive epithelia is thought to be due to activation of sodium channels. This channel is regulated, in part, by G-proteins, but it is not known if this mechanism is regulated by aldosterone. We report that aldosterone stimulates the expression of the 41-kDa alpha(i3) subunit of the heterotrimeric GTP-binding proteins in A-6 cells. Both mRNA and the total amount of this protein are increased by aldosterone. The G-protein is palmitoylated in response to the steroid, and the newly synthesized subunit is found to co-localize with the sodium channel. Aldosterone stimulation of sodium transport is significantly inhibited by inhibition of palmitoylation. These results suggest that aldosterone regulates sodium channel activity in epithelia through stimulation of the expression and post-translational targeting of a channel regulatory G-protein subunit.	UNIV PITTSBURGH, SCH MED, RENAL ELECTROLYTE DIV, LAB EPITHELIAL CELL BIOL, PITTSBURGH, PA 15213 USA; UNIV ALABAMA, DEPT PHYSIOL & BIOPHYS, BIRMINGHAM, AL 35292 USA; VET AFFAIRS MED CTR, RENAL SECT, PITTSBURGH, PA 15240 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Palevsky, Paul M./Q-1491-2019	Palevsky, Paul M./0000-0002-7334-5400	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK037206, R01DK037206, R01DK047874] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-47874, DK-37206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHER C, 1988, P NATL ACAD SCI USA, V85, P7413, DOI 10.1073/pnas.85.19.7413; AUSIELLO DA, 1992, J BIOL CHEM, V267, P4759; BENOS DJ, 1986, P NATL ACAD SCI USA, V83, P8525, DOI 10.1073/pnas.83.22.8525; CANTIELLO HF, 1990, J BIOL CHEM, V265, P21624; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DUCHATELLE P, 1992, MOL CELL BIOCHEM, V114, P27; HOLTZMAN EJ, 1991, J BIOL CHEM, V266, P1763; HOLTZMAN EJ, 1993, J BIOL CHEM, V268, P3964; ISMAILOV II, 1994, J BIOL CHEM, V269, P22193; JOHNSON JP, 1992, PHARMACOL THERAPEUT, V53, P1, DOI 10.1016/0163-7258(92)90042-X; KENNEDY AE, 1990, FASEB J, V4, pA445; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEN EL, 1975, BIOCHEMISTRY-US, V14, P2749, DOI 10.1021/bi00683a030; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; ROKAW MD, 1994, CLIN RES, V42, pA319; Sambrook J, 1989, MOL CLONING LABORATO; SARIBANSOHRABY S, 1993, J BIOL CHEM, V268, P26613; SARIBANSOHRABY S, 1984, SCIENCE, V225, P745, DOI 10.1126/science.6463652; SCHAFER JA, 1992, KIDNEY INT, V41, P255, DOI 10.1038/ki.1992.37; SCOTT WN, 1979, J BIOL CHEM, V254, P4957; SOLTYSIAK RM, 1984, BIOCHIM BIOPHYS ACTA, V792, P214, DOI 10.1016/0005-2760(84)90225-X; SPIEGEL AM, 1991, TRENDS BIOCHEM SCI, V338, P341; STEELE RE, 1992, J TISSUE CULTURE MET, V14, P259; STEELE RE, 1986, AM J PHYSIOL, V251, pC186; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WIESMANN WP, 1985, AM J PHYSIOL, V248, pF43, DOI 10.1152/ajprenal.1985.248.1.F43; WILLIAMSON BM, 1985, EMBO J, V3, P2581; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999; YOUNGSUK OH, 1993, AM J PHYSIOL, V265, pC85	33	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4491	4496						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626803				2022-12-27	WOS:A1996TW96000081
J	Cunningham, JG; Meyer, SC; Fox, JEB				Cunningham, JG; Meyer, SC; Fox, JEB			The cytoplasmic domain of the alpha-subunit of glycoprotein (GP) Ib mediates attachment of the entire GP Ib-IX complex to the cytoskeleton and regulates von Willebrand factor-induced changes in cell morphology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN; THROMBIN-STIMULATED PLATELETS; VONWILLEBRAND-FACTOR BINDING; LEUCINE-RICH GLYCOPROTEINS; IIB-IIIA; MEMBRANE SKELETON; FACTOR-VIII; E-CADHERIN; ADHESION; AGGREGATION	The glycoprotein (GP) Ib-IX complex is one of the major platelet membrane glycoproteins. Its extracellular domain binds von Willebrand factor at a site of injury, an interaction that leads to activation of intracellular pathways. Its intracellular domain associates tightly with the platelet cytoskeleton through actin-binding protein. The goal of the present study was to investigate the role of the cytoplasmic domain of the GP Ib-IX complex and its interaction with the cytoskeleton. Cultured cells were transfected with the cDNAs coding for GP Ib(beta), GP IX, and full-length or truncated forms of GP Ib(alpha). Western blots of detergent-insoluble fractions of Triton X-100-lysed cells showed that deletion of amino acids Trp-570 to Ser-590 from the cytoplasmic domain of GP Ib(alpha) abolished the interaction of the entire GP Ib-IX complex with the cytoskeleton. Truncated GP Ib(alpha) that was unable to associate with the cytoskeleton retained its ability to associate with GP Ib(beta), to be inserted into the membrane, and to bind von Willebrand factor. Cells expressing GP Ib(alpha) changed their shape following adhesion to immobilized von Willebrand factor. Cells expressing truncated GP Ib(alpha) also changed their shape following adhesion but showed a very different morphology as compared to cells expressing full-length GP Ib(alpha). These results show that GP Ib-IX-von Willebrand factor interactions lead to cytoskeletal reorganizations, that the cytoplasmic domain of GP Ib(alpha) regulates these reorganizations, and that the cytoplasmic domain of GP Ib(alpha) is absolutely required for attachment of the GP Ib-IX complex to the cytoskeleton.	CLEVELAND CLIN FDN,CTR THROMBOSIS & VASC RES FF20,CLEVELAND,OH 44195; CHILDRENS HOSP,OAKLAND RES INST,OAKLAND,CA 94609; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST CARDIOVASC RES,SAN FRANCISCO,CA 94143	Cleveland Clinic Foundation; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL030657, R37HL030657, R01HL030657, F32HL008605] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30657, 7 F32 HL08605] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AAKHUS AM, 1989, ELECTROPHORESIS, V10, P758, DOI 10.1002/elps.1150101105; ANDREWS RK, 1991, J BIOL CHEM, V266, P7144; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8317, DOI 10.1021/bi00447a009; ANDREWS RK, 1992, J BIOL CHEM, V267, P18605; BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; BRINKHOUS KM, 1980, BLOOD, V55, P517; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; DEMARCO L, 1985, J CLIN INVEST, V75, P1198, DOI 10.1172/JCI111816; DU XP, 1994, J BIOL CHEM, V269, P18287; DU XP, 1987, BLOOD, V69, P1524; EZZELL RM, 1988, J BIOL CHEM, V263, P13303; FOX JEB, 1988, J BIOL CHEM, V263, P4882; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1985, J BIOL CHEM, V260, P1970; FOX JEB, 1989, J BIOL CHEM, V264, P9520; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1987, THROMB DIATH HAEMO, P175; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; JAFFE SH, 1990, P NATL ACAD SCI USA, V87, P3589, DOI 10.1073/pnas.87.9.3589; KAO KJ, 1979, J CLIN INVEST, V63, P656, DOI 10.1172/JCI109348; KOUNS WC, 1991, J BIOL CHEM, V266, P13891; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JB, 1987, J LAB CLIN MED, V109, P495; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; LOPEZ JA, 1994, J BIOL CHEM, V269, P23716; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; MEYER S, 1993, J BIOL CHEM, V268, P20555; MEYER SC, 1995, J BIOL CHEM, V270, P14693, DOI 10.1074/jbc.270.24.14693; MURATA M, 1991, J BIOL CHEM, V266, P15474; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; OKITA JR, 1985, J CELL BIOL, V100, P317, DOI 10.1083/jcb.100.1.317; ROTH GJ, 1991, BLOOD, V77, P5; RUGGERI ZM, 1993, THROMB HAEMOSTASIS, V70, P119; SAKARIASSEN KS, 1986, BRIT J HAEMATOL, V63, P681, DOI 10.1111/j.1365-2141.1986.tb07552.x; SOLUM NO, 1983, BIOCHIM BIOPHYS ACTA, V729, P53, DOI 10.1016/0005-2736(83)90455-8; SOLUM NO, 1984, BIOCHIM BIOPHYS ACTA, V799, P209, DOI 10.1016/0304-4165(84)90263-0; TOBELEM G, 1976, NATURE, V263, P427, DOI 10.1038/263427a0; TORTI M, 1994, P NATL ACAD SCI USA, V91, P4239, DOI 10.1073/pnas.91.10.4239; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARDELL MR, 1989, J BIOL CHEM, V264, P15656; WEISS HJ, 1973, J CLIN INVEST, V52, P2697, DOI 10.1172/JCI107464; WEISS HJ, 1986, BLOOD, V67, P322; ZHANG J, 1992, J BIOL CHEM, V267, P4686	55	76	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11581	11587		10.1074/jbc.271.19.11581	http://dx.doi.org/10.1074/jbc.271.19.11581			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626721	hybrid			2022-12-27	WOS:A1996UJ94400081
J	Dauterive, R; Laroux, S; Bunn, RC; Chaisson, A; Sanson, T; Reed, BC				Dauterive, R; Laroux, S; Bunn, RC; Chaisson, A; Sanson, T; Reed, BC			C-terminal mutations that alter the turnover number for 3-O-methylglucose transport by GLUT1 and GLUT4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER; PLASMA-MEMBRANE; XENOPUS OOCYTES; KINETIC-PARAMETERS; SUGAR TRANSPORTER; 3T3-L1 CELLS; INSULIN; ADIPOCYTES; TRANSLOCATION; EXPRESSION	Turnover numbers for 3-O-methylglucose transport by the homologous glucose transporters GLUT1 and GLUT4 were compared to those for truncated and chimeric transporters expressed in Xenopus oocytes to assess potential regulatory properties of the C-terminal domain. The ability of high intracellular sugar concentrations to increase the turnover number for sugar entry (''accelerated exchange'') by GLUT1 and not by GLUT4 was maintained in oocytes. Replacing the GLUT1 C terminus with that of GLUT4 stimulated turnover 1.6-fold, but abolished accelerated exchange. Thus, the GLUT1 C terminus permits accelerated exchange by GLUT1, but in doing so must interact with other GLUT1 specific sequences since the GLUT4ctrm1 chimera did not exhibit this kinetic property. Removal of 38 C-terminal amino acids from GLUT4 reduced its turnover number by 40%, whereas removing only 20 residues or replacing its C terminus with that of GLUT1 increased its turnover number 3.5-3.9 fold. Therefore, using mechanisms independent of those which alter transporter targeting to the plasma membrane, C-terminal mutations in either GLUT1 or GLUT4 can activate transport normally restricted by the native C-terminal domain. These results implicate the C termini as targets of physiological factors, which through covalent modification or direct binding might alter C-terminal interactions to regulate intrinsic GLUT1 and GLUT4 transporter activity.	LOUISIANA STATE UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,SHREVEPORT,LA 71130	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport					NIDDK NIH HHS [DK42647, DK29717] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042647, R01DK029717] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURBAUM JJ, 1989, BIOCHEMISTRY-US, V28, P9293, DOI 10.1021/bi00450a009; CARRUTHERS A, 1989, BIOCHEMISTRY-US, V28, P8337, DOI 10.1021/bi00447a011; CARRUTHERS A, 1986, J BIOL CHEM, V261, P1028; COLEMAN A, 1987, TRANSCRIPTION TRANSL, P271; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; DIAMOND DL, 1993, J BIOL CHEM, V268, P6437; DUE AD, 1995, BIOCHEMISTRY-US, V34, P5462, DOI 10.1021/bi00016a017; Eilam Y., 1974, METHODS MEMBRANE BIO, V2, P283; FISCHBARG J, 1993, P NATL ACAD SCI USA, V90, P11658, DOI 10.1073/pnas.90.24.11658; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; GOULD GW, 1989, BIOCHEMISTRY-US, V28, P9447, DOI 10.1021/bi00450a030; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; Harlow E., 1988, ANTIBODIES LAB MANUA; HARRISON SA, 1991, P NATL ACAD SCI USA, V88, P7839, DOI 10.1073/pnas.88.17.7839; HRESKO RC, 1994, J BIOL CHEM, V269, P32110; KELLER K, 1989, J BIOL CHEM, V264, P18884; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LIN JL, 1992, BIOCHEM BIOPH RES CO, V184, P865, DOI 10.1016/0006-291X(92)90670-G; LOWE AG, 1986, BIOCHIM BIOPHYS ACTA, V857, P146, DOI 10.1016/0005-2736(86)90342-1; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; NISHIMURA H, 1993, J BIOL CHEM, P854; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; OKA Y, 1988, J BIOL CHEM, V263, P13432; PALFREYMAN RW, 1992, BIOCHEM J, V284, P275, DOI 10.1042/bj2840275; PILCH PF, 1993, J CLIN ENDOCR METAB, V77, P286, DOI 10.1210/jc.77.1.286; PIPER RC, 1993, J BIOL CHEM, V268, P16557; PIPER RC, 1992, J CELL BIOL, V117, P729, DOI 10.1083/jcb.117.4.729; REED BC, 1990, ARCH BIOCHEM BIOPHYS, V279, P261, DOI 10.1016/0003-9861(90)90490-P; REGEN DM, 1974, BIOCHIM BIOPHYS ACTA, V339, P218, DOI 10.1016/0005-2736(74)90320-4; Sambrook J., 2002, MOL CLONING LAB MANU; SHETTY M, 1993, J BIOL CHEM, V268, P17225; SHI YW, 1995, J BIOL CHEM, V270, P21772, DOI 10.1074/jbc.270.37.21772; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAYLOR LP, 1981, BIOCHIM BIOPHYS ACTA, V642, P325, DOI 10.1016/0005-2736(81)90449-1; VANNUCCI SJ, 1992, BIOCHEM J, V288, P325, DOI 10.1042/bj2880325; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; WALMSLEY AR, 1988, TRENDS BIOCHEM SCI, V13, P226, DOI 10.1016/0968-0004(88)90089-8; WHEELER TJ, 1994, BBA-BIOMEMBRANES, V1190, P345, DOI 10.1016/0005-2736(94)90093-0; WHEELER TJ, 1985, ANNU REV PHYSIOL, V47, P503, DOI 10.1146/annurev.ph.47.030185.002443; WHITESELL RR, 1977, ARCH BIOCHEM BIOPHYS, V181, P596, DOI 10.1016/0003-9861(77)90266-1; WHITESELL RR, 1989, BIOCHEMISTRY-US, V28, P5618, DOI 10.1021/bi00439a042; YANG J, 1993, J BIOL CHEM, V268, P4600	47	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11414	11421		10.1074/jbc.271.19.11414	http://dx.doi.org/10.1074/jbc.271.19.11414			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626697	hybrid			2022-12-27	WOS:A1996UJ94400057
J	Kundu, GC; Ji, IH; McCormick, DJ; Ji, TH				Kundu, GC; Ji, IH; McCormick, DJ; Ji, TH			Photoaffinity labeling of the lutropin receptor with synthetic peptide for carboxyl terminus of the human choriogonadotropin alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; HORMONE; SEQUENCE; BINDING; ACID	Human choriogonadotropin (hCG) consists of an alpha subunit and a beta subunit. The existing evidence from various studies using truncation, substitution, synthetic hormone peptides, and hCG crystals suggests that the C-terminal region of the alpha subunit contacts the luteinizing hormone/choriogonoadotropin (LH/CG) receptor and is involved in receptor activation. Despite a deluge of the speculation and the important role of the alpha C-terminal region, direct evidence for its interaction with the receptor has been elusive. Because of the significant biological activity, it is imperative to prove the interaction of the alpha C-terminal region. For this purpose, decamer peptides corresponding to the alpha subunit sequence from His(83) to Ser(92) (alpha(83-92)) were derivatized with the N-hydroxysuccinimide ester of 4-azidobenzoylglycine (ABG) and radioiodinated. The resulting ABG-I-125-alpha(83-92) was capable of binding and activating the LH/CG receptor. Furthermore, UV-sensitive ABG-I-125-alpha(83-92) exclusively photoaffinity-labeled an similar to 86-kDa molecule. This labeled molecule was shown to be the LH/CG receptor by various methods including immunoprecipitation by anti-LH/CG receptor antiserum. In addition, evidence is presented that the amino group of alpha Lys(91) of alpha(83-92) is in such close proximity to a carboxyl group of the receptor that this pair is cross-linked to form an amide, a zero length cross-link. This low affinity contact of alpha(83-92) and the receptor is sufficient for receptor activation and is crucial for the full understanding of the mechanistics of the receptor activation steps.	UNIV WYOMING,DEPT MOLEC BIOL,LARAMIE,WY 82071; MAYO CLIN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905	University of Wyoming; Mayo Clinic			Kundu, Gopal C./ABA-9897-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-18702] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CHAN KW, 1973, J BIOL CHEM, V248, P7930; CHARLESWORTH M, 1987, J BIOL CHEM, V270, P13409; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; JI I, 1981, P NATL ACAD SCI-BIOL, V78, P5465, DOI 10.1073/pnas.78.9.5465; JI IH, 1993, J BIOL CHEM, V268, P22971; JI IH, 1985, J BIOL CHEM, V260, P2815; JI L, 1980, P NATL ACAD SCI USA, V77, P7167; JI TH, 1983, METHOD ENZYMOL, V91, P580; KEUTMANN HT, 1989, MOL ENDOCRINOL, V3, P526, DOI 10.1210/mend-3-3-526; KIEHM DJ, 1977, J BIOL CHEM, V252, P8524; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; MEANS GE, 1971, CHEM MODIFICATION PR, P144; MORGAN FJ, 1975, J BIOL CHEM, V250, P5247; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; YOO J, 1991, J BIOL CHEM, V266, P17741; YOO JK, 1993, J BIOL CHEM, V268, P13034; ZHU HY, 1995, MOL ENDOCRINOL, V9, P141, DOI 10.1210/me.9.2.141	17	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11063	11066		10.1074/jbc.271.19.11063	http://dx.doi.org/10.1074/jbc.271.19.11063			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626648	hybrid			2022-12-27	WOS:A1996UJ94400008
J	Lu, HS; Jones, MD; Shieh, JH; Mendiaz, EA; Feng, D; Watler, P; Narhi, LO; Langley, KE				Lu, HS; Jones, MD; Shieh, JH; Mendiaz, EA; Feng, D; Watler, P; Narhi, LO; Langley, KE			Isolation and characterization of a disulfide-linked human stem cell factor dimer - Biochemical, biophysical, and biological comparison to the noncovalently held dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR CSF-1; HAMSTER OVARY CELLS; GROWTH-FACTOR; C-KIT; TYROSINE KINASE; SIGNAL TRANSDUCTION; CONDITIONED MEDIUM; GENE-PRODUCT; SI-LOCUS; LIGAND	Distinct from the noncovalently linked recombinant human stem cell factor (rhSCF) dimer, we report here the isolation and identification of an SDS-nondissociable dimer produced during folding/oxidation of rhSCF. Experimental evidence using various cleavage strategies and analyses shows that the isolated dimer is composed of two rhSCF monomers covalently linked by four disulfide bonds. The cysteines are paired as in the noncovalently associated dimer except that all pairings are intermolecular rather than intramolecular. Other structural models, involving intertwining of intramolecular disulfide loops, are ruled out. The molecule behaves similarly to the noncovalently associated dimer during ion-exchange or gel permeation chromatography. However, the disulfide-linked dimer exhibits increased hydrophobicity in reverse-phase columns and in the native state does not undergo spontaneous dimer dissociation-association as seen for the noncovalent dimer. Spectroscopic analyses indicate that the disulfide-linked and noncovalently associated rhSCF dimers have grossly similar secondary and tertiary structures. In vitro, the disulfide-linked dimer exhibits approximately 3-fold higher biological activity in supporting growth of a hematopoietic cell line and stimulating hematopoietic cell colony formation from enriched human CD34(+) cells. The molecule binds to the rhSCF receptor, Kit, with an efficiency only half that of the noncovalently associated dimer. Formation of intermolecular disulfides in the disulfide-linked dimer with retention of biological activity has implications for the three-dimensional structure of noncovalently held dimer and disulfide-linked dimer.			Lu, HS (corresponding author), AMGEN INC, AMGEN CTR, THOUSAND OAKS, CA 91320 USA.			Jones, Michael/0000-0001-7541-7634				ARAKAWA T, 1991, J BIOL CHEM, V266, P18942; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BRADLEY TR, 1978, J CELL PHYSIOL, V97, P517, DOI 10.1002/jcp.1040970327; Briddell R, 1995, BLOOD, V86, P918; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DAS SK, 1982, J BIOL CHEM, V257, P13679; DOVER GA, 1991, CELL, V65, P9, DOI 10.1016/0092-8674(91)90401-J; FAUSSET PR, 1991, ELECTROPHORESIS, V12, P22, DOI 10.1002/elps.1150120106; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GLOCKER MO, 1993, BIOCHEMISTRY-US, V32, P482, DOI 10.1021/bi00053a012; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; JOHNSSON A, 1982, BIOCHEM BIOPH RES CO, V104, P66, DOI 10.1016/0006-291X(82)91941-6; JONES MD, 1996, J BIOL CHEM, V271; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLEY KE, 1992, ARCH BIOCHEM BIOPHYS, V295, P21, DOI 10.1016/0003-9861(92)90482-C; LANGLEY KE, 1993, BLOOD, V81, P656; LEV S, 1992, J BIOL CHEM, V267, P15970; LU HS, 1995, BIOCHEM J, V305, P563, DOI 10.1042/bj3050563; LU HS, 1992, ARCH BIOCHEM BIOPHYS, V298, P150, DOI 10.1016/0003-9861(92)90106-7; LU HS, 1991, J BIOL CHEM, V266, P8102; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; RETTENMIER CW, 1989, CURR TOP MICROBIOL, V149, P129; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; SMITH KA, 1992, CURRENT PROTOCOLS IM; TOKSOZ D, 1992, P NATL ACAD SCI USA, V89, P7350, DOI 10.1073/pnas.89.16.7350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	34	11	11	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11309	11316		10.1074/jbc.271.19.11309	http://dx.doi.org/10.1074/jbc.271.19.11309			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626683	hybrid			2022-12-27	WOS:A1996UJ94400043
J	Pret, AM; Fiszman, MY				Pret, AM; Fiszman, MY			Sequence divergence associated with species-specific splicing of the nonmuscle beta-tropomyosin alternative exon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR RNAS; SITE SELECTION; BRANCH POINT; U6 SNRNA; MUSCLE TROPOMYOSIN; INTRON SEQUENCES; SINGLE GENE; U1 SNRNA; ELEMENTS	Alternative splicing of vertebrate beta-tropomyosin transcripts ensures mutually exclusive expression of internal exons 6A and 6B in nonmuscle and skeletal muscle cells, respectively. Recently, we reported that this splicing regulation requires species-specific elements, since the splicing profile for the chicken, rat, and Xenopus beta-tropomyosin alternative exons is not reproduced in transfection experiments when heterologous myogenic cells are used. By analyzing the splicing pattern of hybrid chicken/rat beta-TM constructions transfected into both quail and mouse cell lines, we demonstrate that chicken beta-tropomyosin exon 6A is flanked by stronger splicing signals than rat exon 6A, thus leading to the misregulation of splicing in heterologous cells. We have characterized three splicing signals that contribute to this difference: 1) nonconsensus nucleotide differences at positions +4 and +6 in the donor site downstream of exon 6A, 2) differences in the pyrimidine composition between the branch site and acceptor site upstream of exon 6A, and 3) a pyrimidine-rich intronic exon 6A splicing enhancer present upstream of exon 6A only in the chicken beta-TM gene. The functional divergence between splicing signals in two homologous vertebrate genes reveals species-specific strategies for proper modulation of splicing of alternative exons.	INST PASTEUR, DEPT BIOL MOLEC, F-75724 PARIS 15, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								BALVAY L, 1992, NUCLEIC ACIDS RES, V20, P3987, DOI 10.1093/nar/20.15.3987; BALVAY L, 1994, J BIOL CHEM, V269, P19675; BLACK DL, 1992, CELL, V69, P795, DOI 10.1016/0092-8674(92)90291-J; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JB, 1993, MOL CELL BIOL, V13, P2666, DOI 10.1128/MCB.13.5.2666; CSANK C, 1990, NUCLEIC ACIDS RES, V18, P5133, DOI 10.1093/nar/18.17.5133; DELGATTO F, 1995, MOL CELL BIOL, V15, P4825; DOMINSKI Z, 1994, MOL CELL BIOL, V14, P7445, DOI 10.1128/MCB.14.11.7445; DOMINSKI Z, 1994, J BIOL CHEM, V269, P23590; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; GALLEGO ME, 1992, MOL CELL BIOL, V12, P5415, DOI 10.1128/MCB.12.12.5415; GOUXPELLETAN M, 1990, EMBO J, V9, P241, DOI 10.1002/j.1460-2075.1990.tb08101.x; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUO W, 1993, NUCLEIC ACIDS RES, V21, P4762, DOI 10.1093/nar/21.20.4762; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; HELFMAN DM, 1989, NUCLEIC ACIDS RES, V17, P5633, DOI 10.1093/nar/17.14.5633; HELFMAN DM, 1986, MOL CELL BIOL, V6, P3582, DOI 10.1128/MCB.6.11.3582; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUH GS, 1994, GENE DEV, V8, P1561, DOI 10.1101/gad.8.13.1561; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; KISTER L, 1993, J BIOL CHEM, V268, P21955; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; LIBRI D, 1989, J BIOL CHEM, V264, P2935; LIBRI D, 1990, MOL CELL BIOL, V10, P5036, DOI 10.1128/MCB.10.10.5036; LIBRI D, 1992, MOL CELL BIOL, V12, P3204, DOI 10.1128/MCB.12.7.3204; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; LIBRI D, 1989, NUCLEIC ACIDS RES, V17, P6449; LO PCH, 1994, GENETICS, V138, P365; MCCULLOUGH AJ, 1993, MOL CELL BIOL, V13, P7689, DOI 10.1128/MCB.13.12.7689; MING G, 1993, MOL CELL BIOL, V13, P1104, DOI 10.1128/MCB.13.2.1104; Moore M., 1993, RNA WORLD, P303; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; ROSCIGNO RF, 1993, J BIOL CHEM, V268, P11222; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; STAMM S, 1994, NUCLEIC ACIDS RES, V22, P1515, DOI 10.1093/nar/22.9.1515; TALERICO M, 1994, MOL CELL BIOL, V14, P3434, DOI 10.1128/MCB.14.5.3434; TSUKAHARA T, 1994, NUCLEIC ACIDS RES, V22, P2318, DOI 10.1093/nar/22.12.2318; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	50	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11511	11517		10.1074/jbc.271.19.11511	http://dx.doi.org/10.1074/jbc.271.19.11511			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626711	hybrid			2022-12-27	WOS:A1996UJ94400071
J	Glaasker, E; Konings, WN; Poolman, B				Glaasker, E; Konings, WN; Poolman, B			Glycine betaine fluxes in Lactobacillus plantarum during osmostasis and hyper- and hypo-osmotic shock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MECHANICAL-PROPERTIES; MEMBRANE-VESICLES; ION CHANNELS; TRANSPORT; BACTERIA; EFFLUX; CELLS; GADOLINIUM; CHOLINE	Bacteria respond to changes in medium osmolarity by varying the concentrations of specific solutes in order to maintain constant turgor. The primary response of Lactobacillus plantarum to an osmotic upshock involves the accumulation of compatible solutes such as glycine betaine, proline, and glutamate. We have studied the osmotic regulation of glycine betaine transport in L. plantarum by measuring the overall and unidirectional rates of glycine betaine uptake and exit at osmostasis, and under conditions of osmotic upshock and downshock. At steady state conditions, a basal flux of glycine betaine (but no net uptake or efflux) is observed that amounts to about 20% of the rate of ''activated'' uptake (uptake at high osmolarity). No direct exchange of C-14-labeled glycine betaine in the medium for unlabeled glycine betaine in the cytoplasm was observed in glucose metabolizing and resting cells, indicating that a separate glycine betaine efflux system is responsible for the exit of glycine betaine. Upon osmotic upshock, the uptake system for glycine betaine is rapidly activated (within seconds), whereas the basal efflux is inhibited. These two responses account for a rapid accumulation of glycine betaine until osmostasis is reached. Upon osmotic downshock, glycine betaine is rapidly released by the cells in a process that has two kinetic components, i.e. one with a half-life of less than 2 s which is unaffected by the metabolic status of the cells, the other with a half-life of 4-5 min in glucose-metabolizing cells which is dependent on internal pH or a related parameter. We speculate that the former activity corresponds to a stretch-activated channel, whereas the latter may be facilitated by a carrier protein. Glycine betaine uptake is strongly inhibited immediately after an osmotic downshock, but slowly recovers in time. These studies demonstrate that in L. plantarum osmostasis is maintained through positive and negative regulation of both glycine betaine uptake and efflux, of which activation of uptake upon osmotic upshock and activation of a ''channel-like'' activity upon osmotic downshock are quantitatively most important.	UNIV GRONINGEN,GRONINGEN BIOMOL SCI & BIOTECHNOL INST,DEPT MICROBIOL,9751 NN HAREN,NETHERLANDS	University of Groningen			Konings, Wilhelmus N./C-7063-2013					BERRIER C, 1992, EUR J BIOCHEM, V206, P559, DOI 10.1111/j.1432-1033.1992.tb16960.x; BOCH J, 1994, J BACTERIOL, V176, P5364; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; DE MAN J. C., 1960, JOUR APPL BACT, V23, P130, DOI 10.1111/j.1365-2672.1960.tb00188.x; DRIESSEN AJM, 1993, METHOD ENZYMOL, V221, P394, DOI 10.1016/0076-6879(93)21032-4; EPSTEIN W, 1986, FEMS MICROBIOL LETT, V39, P73; ERTEL A, 1993, BIOPHYS J, V64, P426, DOI 10.1016/S0006-3495(93)81383-3; FOUCAUD C, 1992, J BIOL CHEM, V267, P22087; Glaasker E, 1996, J BACTERIOL, V178, P575, DOI 10.1128/jb.178.3.575-582.1996; GLAZER AN, 1992, NATURE, V359, P859, DOI 10.1038/359859a0; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; HALLETT FR, 1993, BIOPHYS J, V64, P435, DOI 10.1016/S0006-3495(93)81384-5; HASE CC, 1995, J BIOL CHEM, V270, P18329, DOI 10.1074/jbc.270.31.18329; KANESHIRO ES, 1993, J MICROBIOL METH, V17, P1, DOI 10.1016/S0167-7012(93)80010-4; KOO SP, 1991, J GEN MICROBIOL, V137, P2617, DOI 10.1099/00221287-137-11-2617; LAMARK T, 1992, FEMS MICROBIOL LETT, V96, P149; LANDFALD B, 1986, J BACTERIOL, V165, P849, DOI 10.1128/jb.165.3.849-855.1986; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCHT JM, 1994, FEMS MICROBIOL REV, V14, P3, DOI 10.1016/0168-6445(94)90008-6; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; MCFEETERS R F, 1986, Food Microbiology (London), V3, P73, DOI 10.1016/S0740-0020(86)80029-6; MCLAUGHLIN S, 1982, MEMBRANES TRANSPORT, V1, P51; MEURY J, 1985, EUR J BIOCHEM, V151, P613, DOI 10.1111/j.1432-1033.1985.tb09148.x; MILNER JL, 1988, J BIOL CHEM, V263, P14900; OTTO R, 1982, J BACTERIOL, V149, P733, DOI 10.1128/JB.149.2.733-738.1982; POOLMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1183, P5, DOI 10.1016/0005-2728(93)90003-X; SCHLEYER M, 1993, ARCH MICROBIOL, V160, P424, DOI 10.1007/BF00245302; SMALL DL, 1995, BRIT J PHARMACOL, V114, P180, DOI 10.1111/j.1476-5381.1995.tb14923.x; SPEED D, 1968, J CHROMATOGR, V35, P497, DOI 10.1016/S0021-9673(01)82415-8; SUGIURA A, 1994, MOL MICROBIOL, V14, P929, DOI 10.1111/j.1365-2958.1994.tb01328.x; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333; ZORATTI M, 1988, FEBS LETT, V240, P105, DOI 10.1016/0014-5793(88)80348-X	34	61	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10060	10065		10.1074/jbc.271.17.10060	http://dx.doi.org/10.1074/jbc.271.17.10060			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626562	hybrid, Green Published			2022-12-27	WOS:A1996UG25700034
J	Just, I; Selzer, J; Hofmann, F; Green, GA; Aktories, K				Just, I; Selzer, J; Hofmann, F; Green, GA; Aktories, K			Inactivation of Ras by Clostridium sordellii lethal toxin-catalyzed glucosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AERUGINOSA EXOENZYME-S; TRIPHOSPHATE CONFORMATION; CROSS-REACTIVITY; DIFFICILE; PROTEINS; PURIFICATION; P21	The lethal toxin (LT) from Clostridium sordellii belongs to the family of large clostridial cytotoxins causing morphological alterations in cultured cell lines accompanied by destruction of the actin cytoskeleton. C. sordellii LT exhibits 90% homology to Clostridium difficile toxin B, which has been recently identified as a monoglucosyltransferase (Just, I., Seizer, J., Wilm, M., von Eichel-Streiber, C., Mann, M., and Aktories, K. (1995) Nature 375, 500-503). We report here that LT too is a glucosyltransferase, which uses UDP-glucose as cosubstrate to modify low molecular mass GTPases. LT selectively modifies Rac and Ras, whereas the substrate specificity of toxin B is confined to the Rho subfamily proteins Rho, Rac, and Cdc42, which participate in the regulation of the actin cytoskeleton. In Rac, both toxin B and LT share the same acceptor amino acid, threonine 35. Glucosylation of Ras by LT results in inhibition of the epidermal growth factor stimulated p42/p44 MAP-kinase signal pathway. LT is the first bacterial toxin to inactivate Ras in intact cells.	UNIV STRASBOURG 1, FAC MED, LAB TOXINOL BACTERIENNE, F-67000 STRASBOURG, FRANCE	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Just, I (corresponding author), UNIV FREIBURG, INST PHARMAKOL & TOXIKOL, HERMANN HERDER STR 5, D-79104 FREIBURG, GERMANY.		Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BALDACINI O, 1992, TOXICON, V30, P129, DOI 10.1016/0041-0101(92)90466-I; BALDACINI O, 1990, J CHROMATOGR-BIOMED, V528, P357, DOI 10.1016/S0378-4347(00)82394-4; BETTE P, 1991, TOXICON, V29, P877, DOI 10.1016/0041-0101(91)90224-F; CIESIELSKITRESKA J, 1991, EUR J CELL BIOL, V56, P68; COBURN J, 1989, J BIOL CHEM, V264, P9004; COBURN J, 1992, CURR TOP MICROBIOL, V175, P133; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; GIRY M, 1995, INFECT IMMUN, V63, P4063, DOI 10.1128/IAI.63.10.4063-4071.1995; GREEN GA, 1995, GENE, V161, P57, DOI 10.1016/0378-1119(95)00263-6; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HATHEWAY CL, 1990, CLIN MICROBIOL REV, V3, P66, DOI 10.1128/CMR.3.1.66-98.1990; HENDRICKSON TL, 1995, BIOCHEMISTRY-US, V34, P9444, DOI 10.1021/bi00029a020; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOFMANN F, 1995, MOL GEN GENET, V247, P670, DOI 10.1007/BF00290398; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTINEZ RD, 1992, J MED MICROBIOL, V36, P30, DOI 10.1099/00222615-36-1-30; MARTINEZ RD, 1988, INFECT IMMUN, V56, P1215, DOI 10.1128/IAI.56.5.1215-1221.1988; MCGREGOR JA, 1989, AM J OBSTET GYNECOL, V161, P987, DOI 10.1016/0002-9378(89)90768-0; MERELLO S, 1995, J BIOL CHEM, V270, P7281, DOI 10.1074/jbc.270.13.7281; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PARKER CG, 1995, EMBO J, V14, P1294, DOI 10.1002/j.1460-2075.1995.tb07115.x; POPOFF MR, 1987, INFECT IMMUN, V55, P35, DOI 10.1128/IAI.55.1.35-43.1987; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SELF AJ, 1993, ONCOGENE, V8, P655; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONEICHELSTREIBER C, 1990, GENE, V96, P107, DOI 10.1016/0378-1119(90)90348-U; VONEICHELSTREIBER C, 1987, MICROB PATHOGENESIS, V2, P307, DOI 10.1016/0882-4010(87)90073-8; VONEICHELSTREIBER C, 1992, MOL GEN GENET, V233, P260, DOI 10.1007/BF00587587	39	158	163	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10149	10153		10.1074/jbc.271.17.10149	http://dx.doi.org/10.1074/jbc.271.17.10149			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626575	hybrid			2022-12-27	WOS:A1996UG25700047
J	Nomanbhoy, TK; Cerione, RA				Nomanbhoy, TK; Cerione, RA			Characterization of the interaction between RhoGDI and Cdc42Hs using fluorescence spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; GTP-BINDING PROTEIN; BOVINE BRAIN CYTOSOL; ACTIVATING PROTEIN; SUBSEQUENT BINDING; RAS P21; IDENTIFICATION; PURIFICATION; HYDROLYSIS; CLONING	The GDP-dissociation-inhibitor (GDI) for Rho-like GTP-binding proteins is capable of three different biochemical activities. These are the inhibition of GDP dissociation, the inhibition of GTP hydrolysis, and the stimulation of the release of GTP-binding proteins from membranes, In order to better understand how GDI interactions with Rho-like proteins mediate these different effects, we have set out to develop a direct fluorescence spectroscopic assay for the binding of the GDI to the Rho-like protein, Cdc42Hs. We show here that when the GDI interacts with Cdc42Hs that contains bound N-methylanthraniloyl GDP (Mant-GDP), there is an similar to 20% quenching of the Mant fluorescence. The GDI-induced quenching is only observed when Mant-GDP is bound to Spodoptera frugiperda-expressed Cdc42Hs and is not detected when the Mant nucleotide is bound to Escherichia coli-expressed Cdc42Hs and thus shows the same requirement for isoprenylated GTP-binding protein as that observed when assaying GDI activity. A truncated Cdc42Hs mutant that lacks 8 amino acids from the carboxyl terminus and is insensitive to GDI regulation also does not show changes in the fluorescence of its bound Mant-GDP upon GDI addition. Thus, the GDI-induced quenching of Mant-GDP provides a direct read out for the binding of the GDI to Cdc42Hs. Titration profiles of the GDI-induced quenching of the Mant-GDP fluorescence are saturable and are well fit to a simple 1:1 binding model for Cdc42Hs-GDI interactions with an apparent K-d value of 30 nM. A very similar K-d value (28 nM) is measured when titrating the GDI-induced quenching of the fluorescence of Mant-guanylyl imidotriphosphate, bound to Cdc42Hs. These results suggest that the GDI can bind to the GDP-bound and GTP-bound forms of Cdc42Hs equally well. Ne also have used the fluorescence assay for GDI interactions to demonstrate that the differences in functional potency observed ed between the GDI molecule and a related human leukemic protein, designated LD4, are due to differences in their binding affinities for Cdc42Hs. This, together with the results from studies using GDI/LD4 chimeras, allow us to conclude that a limit region within the carboxyl-terminal domain of the GDI molecule is responsible for its ability to bind with higher affinity (compared with LD4) to Cdc42Hs.	CORNELL UNIV,DEPT BIOCHEM MOLEC & CELL BIOL,ITHACA,NY 14853; CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853	Cornell University; Cornell University					NATIONAL EYE INSTITUTE [R01EY006429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER; NEI NIH HHS [EY06429] Funding Source: Medline; NIGMS NIH HHS [GM47458] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADRA CN, 1993, GENE CHROMOSOME CANC, V8, P253, DOI 10.1002/gcc.2870080408; ANTONNY B, 1991, BIOCHEMISTRY-US, V30, P8287, DOI 10.1021/bi00098a002; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HART MJ, 1991, J BIOL CHEM, V266, P20840; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LEONARD D, 1992, J BIOL CHEM, V267, P22860; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOORE KJM, 1993, BIOCHEMISTRY-US, V32, P7451, DOI 10.1021/bi00080a016; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOMANBHOY TK, 1996, IN PRESS BIOCHEMISTR; PLATKO JV, 1995, P NATL ACAD SCI USA, V92, P2974, DOI 10.1073/pnas.92.7.2974; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; UEDA T, 1990, J BIOL CHEM, V265, P9373; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	27	105	105	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10004	10009		10.1074/jbc.271.17.10004	http://dx.doi.org/10.1074/jbc.271.17.10004			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626553	hybrid			2022-12-27	WOS:A1996UG25700025
J	Reedquist, KA; Fukazawa, T; Panchamoorthy, G; Langdon, WY; Shoelson, SE; Druker, BJ; Band, H				Reedquist, KA; Fukazawa, T; Panchamoorthy, G; Langdon, WY; Shoelson, SE; Druker, BJ; Band, H			Stimulation through the T cell receptor induces Cbl association with Crk proteins and the guanine nucleotide exchange protein C3G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; ZETA-CHAIN; LEUCINE ZIPPER; V-CBL; ONCOGENE; BINDING; DOMAIN; IDENTIFICATION; CD4	We and others have recently identified Cbl, the protein product of the c-cbl protooncogene, as an early tyrosine kinase substrate upon T cell activation and have shown that Cbl forms in vivo complexes with Src family tyrosine kinases, Grb2 adaptor protein, and the p85 subunit of PI-3 kinase. Here we show that Cbl associates with all three forms of the human Crk protein, predominantly CrkL, following T cell receptor activation of Jurkat T cells. Association between Cbl and Crk proteins was confirmed in normal human peripheral blood-derived T cells. In vitro, Cbl was able to interact with the Crk SH2 domain but not the SH3 domain. A phosphopeptide corresponding to a potential Crk SH2 domain-binding motif in Cbl (pYDVP) specifically inhibited binding between Cbl and Crk SH2 domain. Anti-Cbl antibody completely immunodepleted the CrkL-associated 120-kDa phosphotyrosyl polypeptide, suggesting that the recently described p130(cas)-related Crk-associated p116 of T cells may be Cbl. Consistent with this possibility, the 4F4 antibody used to characterize the p116 polypeptide cross-reacted with Cbl protein when it was resolved on one- or two-dimensional gels. CrkL was constitutively associated with a substantial amount of the guanine nucleotide exchange protein C3G, and a fraction of the C3G protein was coimmunoprecipitated with Cbl in activated Jurkat T cells. These results suggest the possibility that Cbl may participate in a signaling pathway that regulates guanine nucleotide exchange on small G-proteins in T cells.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,LYMPHOCYTE BIOL SECT, DIV RHEUMATOL & IMMUNOL,DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,JOSLIN DIABET CTR, DEPT MED, BOSTON, MA 02115 USA; UNIV WESTERN AUSTRALIA, QUEEN ELIZABETH II MED CTR, DEPT PATHOL, NEDLANDS, WA 6009, AUSTRALIA; OREGON HLTH SCI UNIV, DIV HEMATOL & MED ONCOL, PORTLAND, OR 97201 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Joslin Diabetes Center, Inc.; University of Western Australia; Oregon Health & Science University			Fukazawa, Takuya/GLR-7099-2022	Druker, Brian/0000-0001-8331-8206	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR36308] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BLAKE TJ, 1991, ONCOGENE, V6, P653; BUDAY L, 1994, J BIOL CHEM, V269, P9019; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DOMCHEK SM, 1992, BIOCHEMISTRY-US, V31, P9865, DOI 10.1021/bi00156a002; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; ODA T, 1994, J BIOL CHEM, V269, P22925; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; OSMAN N, 1995, J BIOL CHEM, V270, P13981, DOI 10.1074/jbc.270.23.13981; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPITS H, 1983, HYBRIDOMA, V2, P423, DOI 10.1089/hyb.1983.2.423; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	57	168	172	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8435	8442		10.1074/jbc.271.14.8435	http://dx.doi.org/10.1074/jbc.271.14.8435			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626543	hybrid			2022-12-27	WOS:A1996UD60000083
J	Cichowski, K; Brugge, JS; Brass, LF				Cichowski, K; Brugge, JS; Brass, LF			Thrombin receptor activation and integrin engagement stimulate tyrosine phosphorylation of the proto-oncogene product, p95(vav), in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VAV PROTOONCOGENE PRODUCT; GUANINE-NUCLEOTIDE EXCHANGE; GLYCOPROTEIN-IIB-IIIA; HUMAN-BLOOD-PLATELETS; HEMATOPOIETIC-CELLS; MONOCLONAL-ANTIBODIES; KINASE INHIBITORS; ALPHA-THROMBIN; COLLAGEN; LIGAND	The vav proto-oncogene product, p95(vav) or Vav, is primarily expressed in hematopoietic cells and has been shown to be a substrate for tyrosine kinases. Although its function is unknown, Vav shares a region of homology with DBL, an exchange factor for the Rho family of GTP-binding proteins. The presence of this domain and the observation that cells transformed with Vav display prominent stress fibers and focal adhesions similar to those that are observed in RhoA transformed cells suggests that Vav may play a role in regulating the actin cytoskeleton. We have, therefore, examined Vav phosphorylation in platelets, which undergo dramatic cytoskeletal reorganization in response to agonists. Two potent platelet agonists, thrombin (via its G protein-coupled receptor) and collagen (via its interaction with the alpha(2) beta(1), integrin), caused Vav to become phosphorylated on tyrosine. Weaker platelet agonists, including ADP, epinephrine and the thromboxane A(2) analog, U46619, did not. The phosphorylation of Vav in response to thrombin was maximal within 15 s and was unaffected by aspirin, inhibitors of aggregation, or the presence of the ADP scavenger, apyrase. Vav phosphorylation was also observed when platelets became adherent to immobilized collagen (via integrin alpha(2) beta(1)), fibronectin (via integrin alpha(5) beta(1)), and fibrinogen (via integrin alpha(IIb)beta(3)). These results show that Vav phosphorylation by tyrosine kinases 1) occurs during platelet activation by potent agonists, 2) also occurs when platelets adhere to biologically relevant matrix proteins, 3) requires neither platelet aggregation nor the release of secondary agonists such as ADP and TxA(2), and 4) can be initiated by at least some members of two additional classes of receptors, G protein-coupled receptors and integrins, providing further evidence that both of these can couple to tyrosine kinases.	UNIV PENN,DIV HEMATOL ONCOL,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19104; ARIAD PHARMACEUT INC,CAMBRIDGE,MA 02139	University of Pennsylvania; University of Pennsylvania; Takeda Pharmaceutical Company Ltd; Takeda Oncology					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007439, P01HL040387] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL40387, T32 HL07439] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CHRZANOWSKAWODNICKA M, 1994, J CELL SCI, V107, P3643; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; CLARK EA, 1994, J BIOL CHEM, V269, P28859; COLLER BS, 1989, CIRCULATION, V80, P1766, DOI 10.1161/01.CIR.80.6.1766; DARBY C, 1994, J IMMUNOL, V152, P5429; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HALL S, 1994, DIAGN CYTOPATHOL, V10, P3, DOI 10.1002/dc.2840100103; HARGREAVES PG, 1994, THROMB HAEMOSTASIS, V72, P634; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HOLLENBERG MD, 1994, TRENDS PHARMACOL SCI, V15, P108, DOI 10.1016/0165-6147(94)90046-9; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MACKAY C, 1995, CURR BIOL, V5, P733, DOI 10.1016/S0960-9822(95)00147-3; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MORII N, 1992, J BIOL CHEM, V267, P20921; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; PELLETIER AJ, 1995, J BIOL CHEM, V270, P18133, DOI 10.1074/jbc.270.30.18133; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; PUIL L, 1992, Current Biology, V2, P275, DOI 10.1016/0960-9822(92)90396-R; RAMESMORALES F, 1994, ONCOGENE, V9, P1917; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; RASMUSSEN UB, 1993, J BIOL CHEM, V268, P14322; RENDU F, 1992, BIOCHEM PHARMACOL, V44, P881, DOI 10.1016/0006-2952(92)90119-4; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; RODRIGUEZLINARES B, 1994, FEBS LETT, V352, P335, DOI 10.1016/0014-5793(94)00983-X; SAITO Y, 1986, J BIOL CHEM, V261, P1355; SARGEANT P, 1993, FEBS LETT, V315, P242, DOI 10.1016/0014-5793(93)81172-V; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; UDDIN S, 1995, J BIOL CHEM, V270, P7712, DOI 10.1074/jbc.270.13.7712; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WENG WK, 1994, J BIOL CHEM, V269, P32514; WONG S, 1992, ONCOGENE, V7, P2407; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	68	78	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7544	7550		10.1074/jbc.271.13.7544	http://dx.doi.org/10.1074/jbc.271.13.7544			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631786				2022-12-27	WOS:A1996UC77400054
J	Aguanno, A; Afar, R; Albert, VR				Aguanno, A; Afar, R; Albert, VR			Tissue-specific expression of the nonneuronal promoter of the aromatic L-amino acid decarboxylase gene is regulated by hepatocyte nuclear factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATECHOLAMINE-SYNTHESIZING ENZYMES; PARALLEL UP-REGULATION; DOPA DECARBOXYLASE; TRANSCRIPTIONAL INTERFERENCE; RAT-BRAIN; FACTOR-I; PHEOCHROMOCYTOMA CELLS; MOLECULAR-CLONING; MONOAMINE-OXIDASE; MESSENGER-RNAS	The rat aromatic L-amino acid decarboxylase (AADC) gene contains alternative promoters which direct expression of neuronal and nonneuronal mRNAs that differ only in their 5'-untranslated regions (UTRs). We have analyzed the expression of the nonneuronal promoter of the rat AADC gene in the kidney epithelial cell line LLC-PK1 and in cells which do not express the nonneuronal form of AADC by transient transfection. These studies revealed that the first 1.1 kilobases of the nonneuronal promoter, including the nonneuronal-specific 5'-UTR (Exon 1), contains sufficient information to direct tissue-specific expression. Serial deletions of this promoter localized the cis-active element to a region between -52 and -28 base pairs upstream of the nonneuronal transcription start site. An APT-rich sequence, within this region which we have termed KL-1, was found to bind a kidney and liver-specific factor by DNase footprint analysis and was capable of directing tissue-specific expression from a heterologous promoter. Moreover, when the KL-1 sequence was mutated in the context of the entire promoter sequence, all transcriptional activity was abolished. DNA sequence comparison revealed that the KL-1 fragment is highly homologous to the binding site for hepatocyte nuclear factor-1 (HNF-1). Mobility shift studies utilizing an antibody to HNF-1 demonstrated binding of HNF-1 to the KL-1 fragment and cotransfection of HNF-1 cDNA into cells which do not express the nonneuronal form of AADC resulted in activation of transfected AADC nonneuronal promoter constructs. These results strongly suggest that the transcription factor which regulates the tissue-specific expression of the nonneuronal form of AADC mRNA is HNF-1.	ROCHE INST MOLEC BIOL,NUTLEY,NJ 07110									ADAM WR, 1986, CLIN EXP PHARMACOL P, V13, P47, DOI 10.1111/j.1440-1681.1986.tb00314.x; AFAR R, 1995, IN PRESS MOL BRAIN R; AGUANNO A, 1995, J NEUROCHEM, V65, P1944; ALBERT VR, 1992, P NATL ACAD SCI USA, V89, P12053, DOI 10.1073/pnas.89.24.12053; APERIA A, 1990, AM J HYPERTENS, V3, pS11, DOI 10.1093/ajh/3.6.11S; AUSEBEL FM, 1989, CURRENT PROTOCOLS MO; BARTKOWSKI S, 1993, MOL CELL BIOL, V13, P421, DOI 10.1128/MCB.13.1.421; BAUMHUETER S, 1988, EMBO J, V7, P2485, DOI 10.1002/j.1460-2075.1988.tb03095.x; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BLUMENFELD M, 1991, DEVELOPMENT, V113, P589; BUCKLAND PR, 1992, PSYCHOPHARMACOLOGY, V108, P98, DOI 10.1007/BF02245292; CEREGHINI S, 1990, EMBO J, V9, P2257, DOI 10.1002/j.1460-2075.1990.tb07396.x; CHIREUX M, 1994, J PHYSIOLOGY-PARIS, V88, P215, DOI 10.1016/0928-4257(94)90084-1; CHRISTENSON JG, 1972, P NATL ACAD SCI USA, V69, P343, DOI 10.1073/pnas.69.2.343; CORBIN V, 1989, NATURE, V337, P279, DOI 10.1038/337279a0; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DAWSON R, 1994, RENAL PHYSIOL BIOCH, V17, P85; DAWSON R, 1990, EUR J PHARM-MOLEC PH, V189, P423, DOI 10.1016/0922-4106(90)90041-U; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GOLDSTEIN M, 1972, PHARMACOL REV, V24, P293; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAHN SL, 1993, J NEUROCHEM, V60, P1058, DOI 10.1111/j.1471-4159.1993.tb03254.x; HAYASHI M, 1990, AM J PHYSIOL, V258, pF28, DOI 10.1152/ajprenal.1990.258.1.F28; HAYASHI M, 1991, AM J PHYSIOL, V260, pE657; ICHINOSE H, 1989, BIOCHEM BIOPH RES CO, V164, P1024, DOI 10.1016/0006-291X(89)91772-5; ICHINOSE H, 1992, BIOCHEMISTRY-US, V31, P11546, DOI 10.1021/bi00161a036; Jaeger CB, 1984, HDB CHEM NEUROANAT 1, V2, P387; KADESCH T, 1986, MOL CELL BIOL, V6, P2593, DOI 10.1128/MCB.6.7.2593; KIM KT, 1993, J NEUROCHEM, V60, P946, DOI 10.1111/j.1471-4159.1993.tb03241.x; KRIEGER M, 1991, P NATL ACAD SCI USA, V88, P2161, DOI 10.1073/pnas.88.6.2161; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; LEE MR, 1993, CLIN SCI, V84, P357, DOI 10.1042/cs0840357; LEVANTHAI A, 1993, MOL BRAIN RES, V17, P227, DOI 10.1016/0169-328X(93)90006-B; LI XM, 1993, NEUROCHEM RES, V18, P915, DOI 10.1007/BF00998277; LI XM, 1992, J NEUROCHEM, V59, P1172, DOI 10.1111/j.1471-4159.1992.tb08363.x; LI XM, 1992, J NEUROCHEM, V59, P2324; LI XM, 1994, NEUROCHEM RES, V19, P591, DOI 10.1007/BF00971335; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LOVENBERG W, 1962, J BIOL CHEM, V237, P89; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MUSZYNSKI M, 1983, J BIOL CHEM, V258, P1678; NICOSIA A, 1990, CELL, V61, P1225, DOI 10.1016/0092-8674(90)90687-A; PROUDFOOT NJ, 1986, NATURE, V322, P562, DOI 10.1038/322562a0; RAHMAN MK, 1981, BIOCHEM PHARMACOL, V30, P645, DOI 10.1016/0006-2952(81)90139-8; ROUET P, 1995, NUCLEIC ACIDS RES, V23, P395, DOI 10.1093/nar/23.3.395; ROWLANDS T, 1994, SCIENCE, V264, P1326, DOI 10.1126/science.8191287; SCHIBLER U, 1987, ANNU REV GENET, V21, P237, DOI 10.1146/annurev.ge.21.120187.001321; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SOARESDASILVA P, 1990, J AUTON PHARMACOL, V10, pS25, DOI 10.1111/j.1474-8673.1990.tb00224.x; SUMIICHINOSE C, 1995, J NEUROCHEM, V64, P514; SUZUKI H, 1984, AM J PHYSIOL, V247, pE258; TANAKA T, 1989, P NATL ACAD SCI USA, V86, P8142, DOI 10.1073/pnas.86.20.8142; VALLI VV, 1985, J NEUROSCI RES, V13, P481, DOI 10.1002/jnr.490130402; WESSEL TC, 1992, MOL BRAIN RES, V15, P349, DOI 10.1016/0169-328X(92)90128-X; WU GD, 1994, J BIOL CHEM, V269, P17080; WU J, 1990, MOL CELL BIOL, V10, P1209, DOI 10.1128/MCB.10.3.1209; YANUKAKASHLES O, 1994, MOL CELL BIOL, V14, P7124, DOI 10.1128/MCB.14.11.7124; ZIMLICHMAN R, 1988, CLIN SCI, V75, P515, DOI 10.1042/cs0750515	63	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4528	4538						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626808				2022-12-27	WOS:A1996TW96000086
J	Kim, S; Dallmann, HG; McHenry, CS; Marians, KJ				Kim, S; Dallmann, HG; McHenry, CS; Marians, KJ			tau Protects beta in the leading-strand polymerase complex at the replication fork	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OKAZAKI FRAGMENT SIZE; ESCHERICHIA-COLI; III HOLOENZYME; DNA; PURIFICATION; SUBUNIT; PROTEINS; IDENTIFICATION; MECHANISM; TEMPLATE	Replication forks formed in the absence of the tau subunit of the DNA polymerase III holoenzyme produce shorter leading and lagging strands than when tau is present. We show that one reason for this is that in the absence of tau, but in the presence of the gamma-complex, leading-strand synthesis is no longer highly processive. In the absence of tau, the size of the leading strand becomes proportional to the concentration of beta and inversely proportional to the concentration of the gamma-complex. In addition, the beta in the leading-strand complex is no longer resistant to challenge by either anti-beta antibodies or poly(dA):oligo(dT). Thus, tau is required to cement a processive leading-strand complex, presumably by preventing removal of beta catalyzed by the gamma-complex.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,GRAD PROGRAM MOLEC BIOL,DENVER,CO 80262; MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Memorial Sloan Kettering Cancer Center	Kim, S (corresponding author), CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOL BIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM34557, GM36255] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034557, R01GM036255, R01GM034557] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; ENGSTROM J, 1985, GENETICS, V113, P449; FAY PJ, 1981, J BIOL CHEM, V256, P976; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; JOHANSON KO, 1982, J BIOL CHEM, V257, P2310; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MODEL P, 1974, J MOL BIOL, V83, P231, DOI 10.1016/0022-2836(74)90389-1; MOK M, 1987, J BIOL CHEM, V262, P16644; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; SAKABE K, 1966, BIOCHIM BIOPHYS ACTA, V129, P652; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	25	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4315	4318						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626779				2022-12-27	WOS:A1996TW96000057
J	Henly, DC; Phillips, JW; Berry, MN				Henly, DC; Phillips, JW; Berry, MN			Suppression of glycolysis is associated with an increase in glucose cycling in hepatocytes from diabetic rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; CARBOHYDRATE-METABOLISM; HEPATIC GLUCONEOGENESIS; INDUCED THERMOGENESIS; INSULIN RESISTANCE; LIVER; MELLITUS; GLUCOSE-6-PHOSPHATASE; PHOSPHORYLATION; GLUCOKINASE	Rates of cycling between glucose and glucose 6-phosphhate and between glucose and pyruvate, and the effects of these cycles on glucose metabolism, were compared in hepatocytes isolated from fasted normal or streptozotocin-induced diabetic rats. In diabetic hepatocytes the rate of glucose phosphorylation was 30% lower than that in normal hepatocytes, and there was a doubling of the rate of glucose/glucose 6-phosphate cycling. In addition, the rate of glycolysis was 60% fewer in diabetic hepatocytes. This inhibition of glycolysis and stimulation of glucose/glucose 6-phosphate cycling appeared to be a consequence of the elevated rates of endogenous fatty acid oxidation observed in diabetic hepatocytes. The proportion of glycolytically derived pyruvate that was recycled to glucose was more than doubled in hepatocytes from diabetic rats compared with normal animals. This increase also appeared to be linked to the high rates of endogenous fatty acid oxidation in diabetic cells. As a consequence of the increased rates of both these cycles, 85% of all glucose molecules taken up by diabetic hepatocytes were recycled to glucose, compared with only 50% in normal hepatocytes. Glucose cycling is therefore likely to make a substantial contribution to the hyperglycemia of diabetes.			Henly, DC (corresponding author), FLINDERS UNIV S AUSTRALIA, SCH MED, DEPT MED BIOCHEM, GPO 2100, ADELAIDE, SA 5001, AUSTRALIA.							BARZILAI N, 1993, J BIOL CHEM, V268, P25019; BERGMEYER HU, 1983, METHODS ENZYMATIC AN; BERRY MN, 1990, NATO ADV SCI I A-LIF, V190, P343; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BERRY MN, 1993, FEBS LETT, V319, P26, DOI 10.1016/0014-5793(93)80030-X; BERRY MN, 1991, ISOLATED HEPATOCYTES, P15, DOI DOI 10.1016/S0075-7535(08)70023-8; BERRY MN, 1991, REGULATION HEPATIC F, P179; BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; CHEN RF, 1967, J BIOL CHEM, V242, P173; CLARK D, 1975, BIOCHEM BIOPH RES CO, V67, P212, DOI 10.1016/0006-291X(75)90304-6; CLARK DG, 1973, BIOCHEM BIOPH RES CO, V54, P1141, DOI 10.1016/0006-291X(73)90811-5; CLARK DG, 1979, BIOCHEM J, V184, P501, DOI 10.1042/bj1840501; DAVIDSON MB, 1981, METABOLISM, V30, P279, DOI 10.1016/0026-0495(81)90152-9; DECLERCQ PE, 1987, J BIOL CHEM, V262, P9812; EFENDIC S, 1988, J CLIN INVEST, V81, P1953, DOI 10.1172/JCI113543; EFENDIC S, 1985, P NATL ACAD SCI USA, V82, P2965, DOI 10.1073/pnas.82.9.2965; GIL J, 1986, BIOCHEM BIOPH RES CO, V136, P498, DOI 10.1016/0006-291X(86)90468-7; GOLAY A, 1991, INT J OBESITY, V15, P601; GONZALEZMANCHON C, 1992, ARCH BIOCHEM BIOPHYS, V292, P95, DOI 10.1016/0003-9861(92)90055-2; Gregory RB, 1996, METABOLISM, V45, P101, DOI 10.1016/S0026-0495(96)90206-1; GUMBINER B, 1991, J CLIN ENDOCR METAB, V72, P801, DOI 10.1210/jcem-72-4-801; HALESTRAP AP, 1978, BIOCHEM J, V172, P377, DOI 10.1042/bj1720377; HEIMBERG M, 1967, BIOCHIM BIOPHYS ACTA, V137, P435, DOI 10.1016/0005-2760(67)90125-7; HENLY DC, 1995, BBA-GEN SUBJECTS, V1244, P92, DOI 10.1016/0304-4165(94)00200-H; Hue L, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P247; KATZ J, 1978, J BIOL CHEM, V253, P4530; LEHTELA JT, 1990, AM J PHYSIOL, V259, pE389; LICKLEY HLA, 1987, DIABETOLOGIA, V30, P175, DOI 10.1007/BF00274224; MARETTE A, 1991, AM J PHYSIOL, V261, pE204, DOI 10.1152/ajpendo.1991.261.2.E204; MCGARRY JD, 1994, J CELL BIOCHEM, V55, P29, DOI 10.1002/jcb.240550005; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Newsholme E A, 1976, Biochem Soc Symp, P61; NEWSHOLME EA, 1984, TRENDS BIOCHEM SCI, V9, P277, DOI 10.1016/0968-0004(84)90165-8; PATEL TB, 1984, J BIOL CHEM, V259, P7525; PHILLIPS JW, 1995, EUR J BIOCHEM, V227, P352, DOI 10.1111/j.1432-1033.1995.tb20396.x; RANDLE PJ, 1994, DIABETOLOGIA, V37, pS155, DOI 10.1007/BF00400839; ROONEY DP, 1993, DIABETOLOGIA, V36, P106, DOI 10.1007/BF00400689; SEYDOUX J, 1983, ENDOCRINOLOGY, V113, P604, DOI 10.1210/endo-113-2-604; SHIBATA H, 1987, CAN J PHYSIOL PHARM, V65, P152, DOI 10.1139/y87-030; TUTWILER GF, 1979, J BIOL CHEM, V254, P2935; WEINBERG MB, 1980, BIOCHEM J, V188, P601, DOI 10.1042/bj1880601	41	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11268	11271		10.1074/jbc.271.19.11268	http://dx.doi.org/10.1074/jbc.271.19.11268			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626677	hybrid			2022-12-27	WOS:A1996UJ94400037
J	Lee, MJ; Evans, M; Hla, T				Lee, MJ; Evans, M; Hla, T			The inducible G protein-coupled receptor edg-1 signals via the G(i)/nitrogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; GTP-BINDING PROTEIN; MAP KINASE; CANNABINOID RECEPTOR; ALPHA SUBUNIT; MITOGEN; CDNA; ANGIOGENESIS; PURIFICATION; EXPRESSION	The edg-1 gene encodes an inducible G protein-coupled receptor (GPR) homologue that is induced during the in vitro differentiation of human endothelial cells. The aim of this study was to investigate the G protein-coupling and -signaling properties of the edg-1 polypeptide. The third cytosolic loop (i(3)) of edg-1 associates with G(i alpha) and G(o alpha) polypeptides in a guanosine 5'-O-(thiotriphosphate)-sensitive manner. Immunoprecipitation of the edg-1 polypeptide in transfected cells results in the co-precipitation of G(i alpha 1) and G(i alpha 3) polypeptides. These data strongly suggest that edg-1 is capable of coupling to the G(i) pathway. Overexpression of the edg-1 GPR in human embryonic kidney 293 cells results in the sustained activation of the MAP kinase activity that is blocked by pertussis toxin treatment. Moreover, NIH3T3 cells permanently transfected with edg-1 exhibit enhanced MAP kinase and phospholipase A(2) activities. These data suggest that the G(i)/mitogen-activated protein kinase pathway is a major signaling pathway regulated by the orphan receptor edg-1.	AMER RED CROSS, JEROME H HOLLAND LAB, DEPT BIOL MOLEC, ROCKVILLE, MD 20855 USA	American Red Cross			Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065	NHLBI NIH HHS [HL 49094] Funding Source: Medline; NIDDK NIH HHS [DK 45659] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045659] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BURSTEIN ES, 1995, FEBS LETT, V363, P261, DOI 10.1016/0014-5793(95)00323-2; CLARK KL, 1993, MOL CELL BIOL, V13, P1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CODINA J, 1987, SCIENCE, V236, P442, DOI 10.1126/science.2436299; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; CONN G, 1990, P NATL ACAD SCI USA, V87, P1323, DOI 10.1073/pnas.87.4.1323; CORVEN EJ, 1989, CELL, V59, P45; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; CUI Z, 1991, J BIOL CHEM, V266, P20276; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DOCTROW SR, 1987, J CELL BIOL, V104, P679, DOI 10.1083/jcb.104.3.679; EGGERICKX D, 1995, BIOCHEM J, V309, P837, DOI 10.1042/bj3090837; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HLA T, 1995, BBA-GENE STRUCT EXPR, V1260, P227, DOI 10.1016/0167-4781(94)00219-S; HLA T, 1990, J BIOL CHEM, V265, P9308; HLA T, 1990, BIOCHEM BIOPH RES CO, V167, P637, DOI 10.1016/0006-291X(90)92072-8; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HOWE LR, 1993, J BIOL CHEM, V268, P20717; IKEZU T, 1992, FEBS LETT, V311, P29, DOI 10.1016/0014-5793(92)81359-T; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KIM S, 1988, P NATL ACAD SCI USA, V85, P4153, DOI 10.1073/pnas.85.12.4153; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; LADO DC, 1994, GENE, V149, P331, DOI 10.1016/0378-1119(94)90171-6; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; LAW SF, 1991, J BIOL CHEM, V266, P17885; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MACIAG T, 1982, J CELL BIOL, V94, P511, DOI 10.1083/jcb.94.3.511; MACIAG T, 1981, J CELL BIOL, V91, P420, DOI 10.1083/jcb.91.2.420; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MCKENZIE FR, 1992, SIGNAL TRANSDUCTION, P45; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MONTESANO R, 1987, J CELL PHYSIOL, V130, P284, DOI 10.1002/jcp.1041300215; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MORO O, 1993, J BIOL CHEM, V268, P22273; NICOSIA RF, 1987, AM J PATHOL, V128, P78; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; ROSE MD, 1990, METHODS YEAST GENETI, P122; SA G, 1994, J BIOL CHEM, V269, P3219; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	61	145	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11272	11279		10.1074/jbc.271.19.11272	http://dx.doi.org/10.1074/jbc.271.19.11272			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626678	hybrid			2022-12-27	WOS:A1996UJ94400038
J	Marty, L; Fort, P				Marty, L; Fort, P			A delayed-early response nuclear gene encoding MRPL12, the mitochondrial homologue to the bacterial translational regulator L7/L12 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED MOUSE CELLS; ESCHERICHIA-COLI; GROWTH-FACTOR; RIBOSOMAL-PROTEINS; MOLECULAR-CLONING; NUCLEOTIDE-SEQUENCE; CROSS-LINKING; DNA-SYNTHESIS; CDNA CLONES; EXPRESSION	We have characterized a new delayed-early response mRNA encoding a 21-kDa product (MRPL12) that accumulates during the G(1) phase of growth-stimulated cells. MRPL12 is the mammalian homologue to chloroplastic and bacterial L12 ribosomal proteins. Immunofluorescence microscopy and cell fractionation indicate a predominant mitochondrial localization in various mammalian cell lines. The NH2-terminal 49 amino acids are necessary and sufficient to target the protein within the mitochondria and are probably cleaved off during import. MRPL12 proteins associate in vitro and cofractionate with ribosomal structures, as is the case for prokaryotic L12 proteins. Expression of a dominant inhibitory truncated protein leads to a severe reduction in cell growth by inhibiting mitochondrial ATP production. MRPL12 is the first mammalian mitochondrial ribosomal protein to be characterized.	UNIV MONTPELLIER 1,CNRS,INST MOLEC GENET,UMR5535,F-34033 MONTPELLIER,FRANCE; UNIV MONTPELLIER 2,CNRS,INST MOLEC GENET,F-34033 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier			Fort, Philippe/M-9498-2015	Fort, Philippe/0000-0001-5997-8722				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BATTINI R, 1987, J BIOL CHEM, V262, P4355; BETTINI E, 1992, J NEUROCHEM, V58, P1923, DOI 10.1111/j.1471-4159.1992.tb10070.x; BLATTNER FR, 1993, NUCLEIC ACIDS RES, V21, P5408; BONNE G, 1993, EUR J BIOCHEM, V217, P1099, DOI 10.1111/j.1432-1033.1993.tb18342.x; BRAVO R, 1988, COLD SPRING HARB SYM, V53, P901, DOI 10.1101/SQB.1988.053.01.103; CHAMBARD JC, 1986, EXP CELL RES, V164, P282, DOI 10.1016/0014-4827(86)90029-7; CHU W, 1993, NUCLEIC ACIDS RES, V21, P749, DOI 10.1093/nar/21.3.749; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DOUCETBRUTIN S, 1995, EXP CELL RES, V220, P152, DOI 10.1006/excr.1995.1301; ELBARADI TTAL, 1987, J MOL BIOL, V195, P909, DOI 10.1016/0022-2836(87)90494-3; ELHAG GA, 1992, NUCLEIC ACIDS RES, V20, P689, DOI 10.1093/nar/20.4.689; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GARLAND WG, 1987, FEBS LETT, V220, P43, DOI 10.1016/0014-5793(87)80872-4; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GIESE K, 1989, BIOCHEMISTRY-US, V28, P3525, DOI 10.1021/bi00434a056; GLAICHENHAUS N, 1986, EMBO J, V5, P1261, DOI 10.1002/j.1460-2075.1986.tb04355.x; GOPALAKRISHNAN L, 1994, J BIOL CHEM, V269, P105; GREGOIRE F, 1991, EXP CELL RES, V196, P270, DOI 10.1016/0014-4827(91)90261-R; GUERRA C, 1994, BIOCHEM BIOPH RES CO, V201, P813, DOI 10.1006/bbrc.1994.1773; HEIN J, 1989, MOL BIOL EVOL, V6, P669; HEMMERICH P, 1993, NUCLEIC ACIDS RES, V21, P223, DOI 10.1093/nar/21.2.223; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIRSCHHORN RR, 1984, P NATL ACAD SCI-BIOL, V81, P6004, DOI 10.1073/pnas.81.19.6004; HOU EW, 1993, GENE, V130, P287, DOI 10.1016/0378-1119(93)90433-4; KHO CJ, 1992, P NATL ACAD SCI USA, V89, P2200, DOI 10.1073/pnas.89.6.2200; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KLEIN BY, 1993, J CELL BIOCHEM, V53, P190, DOI 10.1002/jcb.240530303; KOPKE AKE, 1992, J BIOL CHEM, V267, P1382; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; LEIJONMARCK M, 1987, J MOL BIOL, V195, P555, DOI 10.1016/0022-2836(87)90183-5; LI YQ, 1992, FEBS LETT, V300, P199, DOI 10.1016/0014-5793(92)80845-8; LU X, 1992, BIOCHEM BIOPH RES CO, V186, P371; LUFT R, 1994, P NATL ACAD SCI USA, V91, P8731, DOI 10.1073/pnas.91.19.8731; MAGNALDO I, 1989, FEBS LETT, V245, P65, DOI 10.1016/0014-5793(89)80193-0; NIKAIDO T, 1991, EXP CELL RES, V192, P102, DOI 10.1016/0014-4827(91)90163-O; OJALA D, 1972, J MOL BIOL, V65, P273, DOI 10.1016/0022-2836(72)90282-3; OLEINIKOV AV, 1993, J BIOL CHEM, V268, P917; PETTERSSON I, 1979, FEBS LETT, V98, P139, DOI 10.1016/0014-5793(79)80170-2; POUYSSEGUR J, 1988, PHILOS T ROY SOC B, V320, P427, DOI 10.1098/rstb.1988.0086; POUYSSEGUR J, 1990, GROWTH FACTORS GENE, P80; RAIKHINSTEIN M, 1994, J STEROID BIOCHEM, V49, P257, DOI 10.1016/0960-0760(94)90266-6; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SIBOLD C, 1990, BIOCHIM BIOPHYS ACTA, V1050, P61, DOI 10.1016/0167-4781(90)90142-O; SUZUKI K, 1990, BIOCHEM BIOPH RES CO, V172, P35, DOI 10.1016/S0006-291X(05)80169-X; UCHIUMI T, 1986, J BIOL CHEM, V261, P9668; UCHIUMI T, 1986, EUR J BIOCHEM, V156, P37, DOI 10.1111/j.1432-1033.1986.tb09545.x; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; VINCENT S, 1993, NUCLEIC ACIDS RES, V21, P1498, DOI 10.1093/nar/21.6.1498; VINCENT S, 1993, ONCOGENE, V8, P1603; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WEGLOHNER W, 1994, J BIOL CHEM, V269, P7330; WICK M, 1994, J CELL SCI, V107, P227; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; YANG HC, 1986, J CELL PHYSIOL, V127, P410, DOI 10.1002/jcp.1041270309; YET SF, 1993, BIOCHEMISTRY-US, V32, P9486, DOI 10.1021/bi00087a029; ZHYVOLOUP AN, 1990, NUCLEIC ACIDS RES, V18, P4620, DOI 10.1093/nar/18.15.4620	65	29	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11468	11476		10.1074/jbc.271.19.11468	http://dx.doi.org/10.1074/jbc.271.19.11468			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626705	Green Published, hybrid			2022-12-27	WOS:A1996UJ94400065
J	Michael, WM; Dreyfuss, G				Michael, WM; Dreyfuss, G			Distinct domains in ribosomal protein L5 mediate 5 S rRNA binding and nucleolar localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING; XENOPUS-OOCYTES; SEQUENCE; EXPRESSION; COMPLEX	Ribosomal protein L5, a 34-kDa large ribosomal subunit protein, binds to 5 S rRNA and has been implicated in the intracellular transport of 5 S rRNA. By immunofluorescence microscopy, L5 is detected mostly in the nucleolus with a fainter signal in the nucleoplasm, and it is known to also be a component of large ribosomal subunits in the cytoplasm. 5 S rRNA is transcribed in the nucleoplasm, and L5 is thought to play an important role in delivering 5 S rRNA to the nucleolus. Using RNA-binding assays and transfection experiments, we have delineated the domains within L5 that confer its 5 S rRNA binding activity and that localize it to the nucleolus. We found that the amino-terminal 93 amino acids are necessary and sufficient to bind 5 S rRNA in vitro, while the carboxyl-terminal half of the protein, comprising amino acids 151-296, serves to localize the protein to the nucleolus. L5, therefore, has a modular domain structure reminiscent of other RNA transport proteins where one region of the molecule serves to bind RNA while another determines subcellular localization.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania			Dreyfuss, Gideon/D-1218-2013; McDermott, Michael Francis/GZM-5330-2022	Dreyfuss, Gideon/0000-0001-8129-8774; 				ALLISON LA, 1991, DEV BIOL, V144, P129, DOI 10.1016/0012-1606(91)90485-L; ALLISON LA, 1995, DEV BIOL, V168, P284, DOI 10.1006/dbio.1995.1080; ALLISON LA, 1993, MOL CELL BIOL, V13, P6819, DOI 10.1128/MCB.13.11.6819; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CARMOFONSECA M, 1993, J CELL BIOL, V120, P841, DOI 10.1083/jcb.120.4.841; CHAN YL, 1987, J BIOL CHEM, V262, P12879; FRANKE WW, 1988, EUR J CELL BIOL, V47, P145; GERBI SA, 1990, RIBOSOME STRUCTURE F, V1, P452; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; JAHN O, 1991, BIOCHIMIE, V73, P669, DOI 10.1016/0300-9084(91)90046-4; KENMOCHI N, 1991, BIOCHIM BIOPHYS ACTA, V1088, P445, DOI 10.1016/0167-4781(91)90142-9; KIM JK, 1993, PLANT MOL BIOL, V23, P409, DOI 10.1007/BF00029016; KNIGHT E, 1967, J MOL BIOL, V28, P491, DOI 10.1016/S0022-2836(67)80099-8; LITTLE RD, 1989, GENOMICS, V4, P376, DOI 10.1016/0888-7543(89)90345-5; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; MICHAEL WM, 1995, CELL, V83, P415; PECULIS BA, 1992, J CELL BIOL, V116, P1, DOI 10.1083/jcb.116.1.1; PHILLIPS WF, 1976, J BIOL CHEM, V251, P2876; SCHEER U, 1994, CURR OPIN CELL BIOL, V6, P354, DOI 10.1016/0955-0674(94)90026-4; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; SOLLNERWEBB B, 1991, TRENDS BIOCHEM SCI, V16, P58, DOI 10.1016/0968-0004(91)90025-Q; STEFFENSEN DM, 1974, NATURE, V252, P741, DOI 10.1038/252741a0; STEITZ JA, 1988, J CELL BIOL, V106, P545, DOI 10.1083/jcb.106.3.545; Tafuri Sherrie R., 1993, Trends in Cell Biology, V3, P94, DOI 10.1016/0962-8924(93)90080-K; TANG BZ, 1991, J BIOL CHEM, V266, P6120; Warner JR, 1990, CURR OPIN CELL BIOL, V2, P521, DOI 10.1016/0955-0674(90)90137-4; WORMINGTON WM, 1989, MOL CELL BIOL, V9, P5281, DOI 10.1128/MCB.9.12.5281; YAN C, 1993, J CELL BIOL, V123, P1081, DOI 10.1083/jcb.123.5.1081	32	56	60	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11571	11574		10.1074/jbc.271.19.11571	http://dx.doi.org/10.1074/jbc.271.19.11571			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626719	hybrid			2022-12-27	WOS:A1996UJ94400079
J	Beauparlant, P; Lin, RT; Hiscott, J				Beauparlant, P; Lin, RT; Hiscott, J			The role of the C-terminal domain of I kappa B alpha in protein degradation and stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; REL-ASSOCIATED PP40; DNA-BINDING; TRANSCRIPTION FACTOR; MYELOMONOBLASTIC CELLS; INHIBITOR; ACTIVATION; PRECURSOR; P105; PHOSPHORYLATION	In the present study, the role of the I kappa B alpha C terminus in NF-kappa B/I kappa B alpha regulation was examined in NIH 3T3 cells engineered to inducibly express wild type or mutated human I kappa B alpha proteins under the control of the tetracycline responsive promoter. Deletion studies demonstrated that the last C-terminal 30 amino acids (amino acids (aa) 288 to aa 317, deleted in I kappa B alpha Delta 3), including most of the PEST domain, were dispensible for I kappa B alpha function. However, deletions from aa 261 to 317 or aa 269 to 317 (I kappa B alpha Delta 1 and I kappa B alpha Delta 2 respectively), lacked the ability to dissociate NF-kappa B/DNA complexes in vitro and were unable to inhibit NF-kappa B dependent transcription. Moreover, I kappa B alpha Delta 1 and I kappa B alpha Delta 2 mutants were resistant to inducer-mediated degradation, Analysis of I kappa B alpha deletions in the presence of protein synthesis inhibitors revealed that, independently of stimulation, I kappa B alpha Delta 1 and I kappa B alpha Delta 2 had a half-life four times shorter than wild type I kappa B alpha and the interaction of I kappa B alpha Delta 1 and I kappa B alpha Delta 2 with p65 was dramatically decreased in vivo as measured by co-immunoprecipitation. Interestingly, protease inhibitors which block inducer-mediated degradation of I kappa B alpha also stabilized the turnover of I kappa B alpha Delta 1 and I kappa B alpha Delta 2. Based on these studies, we propose that in the absence of stimulation, the C-terminal domain between aa 269 and 287 may Play a role to protect I kappa B alpha from a constitutive protease activity.	SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST MED RES,TERRY FOX MOL ONCOL GRP,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT MICROBIOL,MONTREAL,PQ H3T 1E2,CANADA	Lady Davis Institute; McGill University; McGill University; McGill University			Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CRESSMAN DE, 1993, ONCOGENE, V8, P2567; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; ERNST MK, 1995, MOL CELL BIOL, V15, P872; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GERONDAKIS S, 1993, CELL GROWTH DIFFER, V4, P617; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LIN RT, 1994, J BIOL CHEM, V269, P17542; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; Lin RT, 1996, MOL CELL BIOL, V16, P1401; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; LINK E, 1992, J BIOL CHEM, V267, P239; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NAUMANN M, 1993, ONCOGENE, V8, P2275; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PEPIN N, 1994, VIROLOGY, V204, P706, DOI 10.1006/viro.1994.1586; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROULSTON A, 1992, J EXP MED, V175, P751, DOI 10.1084/jem.175.3.751; ROULSTON A, 1993, J VIROL, V67, P5235, DOI 10.1128/JVI.67.9.5235-5246.1993; SACHDEV S, 1995, ONCOGENE, V11, P811; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZEICHNER SL, 1992, J VIROL, V66, P2268, DOI 10.1128/JVI.66.4.2268-2273.1992	55	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10690	10696		10.1074/jbc.271.18.10690	http://dx.doi.org/10.1074/jbc.271.18.10690			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631876	hybrid			2022-12-27	WOS:A1996UJ34200044
J	Ouyang, LH; Jacob, KK; Stanley, FM				Ouyang, LH; Jacob, KK; Stanley, FM			GABP mediates insulin-increased prolactin gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; THYROID-HORMONE; STIMULATION; EXPRESSION; ACTIVATION; RECEPTORS; ELEMENT; COMPLEX	The insulin-response element from the prolactin gene is identical to the Ets-binding site, and dominant-negative Ets protein inhibits insulin-increased prolactin gene expression. Immunoblotting identified the Ets-related transcription factor GABP in nuclear extracts from GH cells. Expression of GABP alpha and GABP beta 1 squelches insulin-increased prolactin gene expression. GABP alpha and GABP beta 1 bind the insulin-response element of the prolactin promoter, and anti-GABP alpha and anti-GABP beta 1 antibodies supershift a species seen with nuclear extracts from GH cells. GABP alpha immunoprecipitated from insulin-treated, P-32 labeled GH cells was phosphorylated 3-fold more than GABP alpha from control cells. There was no increase in phosphorylation of GABP beta in response to insulin. Mitogen-activated protein (MAP) kinase activity is increased 10-fold in insulin-treated GH4 cells. MAP kinase immunoprecipitated from control cells does not phosphorylate GABP alpha while MAP kinase immunoprecipitated from insulin-treated cells shows substantial phosphorylation of GABP alpha. These studies suggest that GABP mediates insulin-increased transcription of the prolactin gene. GABP may be regulated by MAP kinase phosphorylation.	NYU,MED CTR,DEPT MED,NEW YORK,NY 10016; NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University; New York University				Stanley, Frederick/0000-0002-3684-2168	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043365] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43365] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; JACOB KK, 1995, MOL CELL ENDOCRINOL, V109, P175, DOI 10.1016/0303-7207(95)03500-7; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; JACOB KK, 1994, J BIOL CHEM, V269, P25515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STANLEY F, 1988, J BIOL CHEM, V263, P13444; STANLEY F, 1989, MOL ENDOCRINOL, V3, P1627, DOI 10.1210/mend-3-10-1627; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TRIESENBERG S, 1988, GENE DEV, V2, P720; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WHITE MF, 1994, J BIOL CHEM, V269, P1	18	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10425	10428		10.1074/jbc.271.18.10425	http://dx.doi.org/10.1074/jbc.271.18.10425			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631833	hybrid			2022-12-27	WOS:A1996UJ34200001
J	Befort, K; Tabbara, L; Kling, D; Maigret, B; Kieffer, BL				Befort, K; Tabbara, L; Kling, D; Maigret, B; Kieffer, BL			Role of aromatic transmembrane residues of the delta-opioid receptor in ligand recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ACETYLCHOLINE-BINDING; EXPRESSION; ACTIVATION; CLONING; M3-MUSCARINIC-RECEPTOR; DOPAMINE	In the present study we examine the role of transmembrane aromatic residues of the delta-opioid receptor in ligand recognition. Three-dimensional computer modeling of the receptor allowed to identify an aromatic pocket within the helices bundle which spans transmembrane domains (Tms) III to VII and consists of tyrosine, phenylalanine, and tryptophan residues. Their contribution to opioid binding was assessed by single amino acid replacement: Y129F and Y129A (Tm III), W173A (Tm IV), F218A and F222A (Tm V), W274A (Tm VI), and Y308F (Tm VII). Scatchard analysis shows that mutant receptors, transfected into COS cells, are expressed at levels comparable with that of the wild-type receptor. Binding properties of a set of representative opioids were examined. Mutations at position 129 most dramatically affected the binding of all tested ligands (up to 430-fold decrease of deltorphin II binding at Y129A), with distinct implication of the hydroxyl group and the aromatic ring, depending on the ligand under study. Affinity of most ligands was also reduced at Y308F mutant (up to 10-fold). Tryptophan residues seemed implicated in the recognition of specific ligand classes, with reduced binding for endogenous peptides at W173A mutant (up to 40-fold) and for nonselective alkaloids at W274A mutant (up to 65-fold). Phenylalanine residues in Tm V appeared poorly involved in opioid binding as compared with other aromatic amino acids examined. Generally, the binding of highly selective delta ligands (TIPP psi naltrindole, and BW373U86) was weakly modified by these mutations. Noticeably, TIPP psi binding was enhanced at W274A receptor by 5-fold. Conclusions from our study are: (i) aromatic amino acid residues identified by the model contribute to ligand recognition, with a preponderant role of Y129; (ii) these residues, which are conserved across opioid receptor subtypes, may be part of a general opioid binding domain; (iii) each ligand-receptor interaction is unique, as demonstrated by the specific binding pattern observed for each tested opioid compound.	UNIV NANCY 1,FAC SCI,CHIM THEOR LAB,F-54506 VANDOEUVRE NANCY,FRANCE	Universite de Lorraine	Befort, K (corresponding author), ECOLE SUPER BIOTECHNOL STRASBOURG,CNRS,UPR 9050,LAB RECEPTEURS & PROT MEMBRANNAIRES,F-67400 ILLKIRCH GRAFFENS,FRANCE.							BARNARD EA, 1993, CURR BIOL, V3, P211, DOI 10.1016/0960-9822(93)90335-L; Befort K, 1996, MOL PHARMACOL, V49, P216; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FONG TM, 1993, NATURE, V362, P350; FUKUDA K, 1995, J BIOL CHEM, V270, P6702, DOI 10.1074/jbc.270.12.6702; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; HJORTH SA, 1995, MOL PHARMACOL, V47, P1089; JOSEPH MP, 1995, J PROTEIN CHEM, V14, P381, DOI 10.1007/BF01886795; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KONG HY, 1994, P NATL ACAD SCI USA, V91, P8042, DOI 10.1073/pnas.91.17.8042; KONG HY, 1993, J BIOL CHEM, V268, P23055; MENG F, 1995, J BIOL CHEM, V270, P12730, DOI 10.1074/jbc.270.21.12730; MINAMI M, 1995, FEBS LETT, V364, P23, DOI 10.1016/0014-5793(95)00340-F; NAKAYAMA TA, 1991, J BIOL CHEM, V266, P4269; OLAH ME, 1992, J BIOL CHEM, V267, P10764; ONOGI T, 1995, FEBS LETT, V357, P93, DOI 10.1016/0014-5793(94)01341-W; PERLMAN JH, 1994, J BIOL CHEM, V269, P1610; POLLOCK NJ, 1992, J BIOL CHEM, V267, P17780; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REES DC, 1990, OPIOID RECEPTORS, P805; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG JB, 1994, J BIOL CHEM, V269, P25966; WESS J, 1992, J BIOL CHEM, V267, P19313; WESS J, 1993, EMBO J, V12, P331, DOI 10.1002/j.1460-2075.1993.tb05661.x; XUE JC, 1995, J BIOL CHEM, V270, P12977; XUE JC, 1994, J BIOL CHEM, V269, P30195; YAMANO Y, 1995, J BIOL CHEM, V270, P14024, DOI 10.1074/jbc.270.23.14024	35	151	155	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10161	10168		10.1074/jbc.271.17.10161	http://dx.doi.org/10.1074/jbc.271.17.10161			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626577	hybrid			2022-12-27	WOS:A1996UG25700049
J	HellerHarrison, RA; Morin, M; Guilherme, A; Czech, MP				HellerHarrison, RA; Morin, M; Guilherme, A; Czech, MP			Insulin-mediated targeting of phosphatidylinositol 3-kinase to GLUT4-containing vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATABLE GLUCOSE TRANSPORTER; ISOLATED RAT ADIPOCYTES; PLASMA-MEMBRANE; GLUT4; TRANSLOCATION; PROTEIN; STIMULATION; CELLS; INTERNALIZATION; LOCALIZATION	Phosphatidylinositol (PI) 3-kinase is hypothesized to be a signaling element in the acute redistribution of intracellular GLUT4 glucose transporters to the plasma membrane in response to insulin. However, some receptors activate PI 3-kinase without causing GLUT4 translocation, suggesting specific cellular localization may be critical to this PI 3-kinase function. Consistent with this idea, complexes containing PI 3-kinase bound to insulin receptor substrate 1 (IRS-1) in 3T3-L1 adipocytes are associated with intracellular membranes (Heller-Harrison, R., Morin, M. and Czech, M. (1995) J. Biol. Chem. 270, 24442-24450). We report here that in response to insulin, activated complexes of IRS-1-PI 3-kinase can be immunoprecipitated with anti-IRS-1 antibody from detergent extracts of immunoadsorbed GLUT4-containing vesicles prepared from 3T3-L1 adipocytes. The targeting of PI 3-kinase to rat adipocyte GLUT4-containing vesicles using vesicles prepared by sucrose velocity gradient ultracentrifugation was also demonstrated, Insulin treatment caused a 2.3-fold increase in immunoreactive p85 protein in these GLUT4-containing vesicles while anti-p85 immunoprecipitates of PI 3-kinase activity in GLUT4-containing vesicle extracts increased to a similar extent. HPLC analysis of the GLUT4 vesicle-associated PI 3-kinase activity showed insulin-mediated increases in PI 3-P, PI 3,4-P-2, and PI 3,4,5-P-3 when PI, PI 4-P, and PI 4,5-P-2 were used as substrates. Our data demonstrate that insulin directs the association of PI 3-kinase with GLUT4-containing vesicles in 3T3-L1 and rat adipocytes, consistent with the hypothesis that PI 3-kinase is involved in the insulin-regulated movement of GLUT4 to the plasma membrane.	UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	HellerHarrison, RA (corresponding author), UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA.				NIDDK NIH HHS [DK30898] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030898, R01DK030898] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; CZECH MP, 1993, J BIOL CHEM, V268, P9187; CZECH MP, 1995, ANNU REV NUTR, V15, P441, DOI 10.1146/annurev.nu.15.070195.002301; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; HERMAN GA, 1994, P NATL ACAD SCI USA, V91, P12750, DOI 10.1073/pnas.91.26.12750; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; ISAOFF S, 1995, P NATL ACAD SCI USA, V92, P10247; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KANAI F, 1993, J BIOL CHEM, V268, P14523; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; OKA Y, 1984, J BIOL CHEM, V259, P8125; OKADA T, 1994, J BIOL CHEM, V269, P3568; QUON MJ, 1994, TRENDS ENDOCRIN MET, V5, P369, DOI 10.1016/1043-2760(94)90104-X; QUON MJ, 1994, J BIOL CHEM, V269, P27920; QUON MJ, 1994, P NATL ACAD SCI USA, V91, P5587, DOI 10.1073/pnas.91.12.5587; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; WHITE MF, 1994, J BIOL CHEM, V269, P1; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	40	122	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10200	10204		10.1074/jbc.271.17.10200	http://dx.doi.org/10.1074/jbc.271.17.10200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626583	hybrid			2022-12-27	WOS:A1996UG25700055
J	Maillet, I; Lagniel, G; Perrot, M; Boucherie, H; Labarre, J				Maillet, I; Lagniel, G; Perrot, M; Boucherie, H; Labarre, J			Rapid identification of yeast proteins on two-dimensional gels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-COMPOSITION; SACCHAROMYCES-CEREVISIAE; 2-DIMENSIONAL ELECTROPHORESIS; SEQUENCE DATABASES; POLYPEPTIDES	This work describes a rapid and sensitive technique for the identification of Saccharomyces cerevisiae proteins on two-dimensional gels based on the determination of their amino acid ratios. Specific double labeling with H-3 and C-14 or S-35-labeled amino acids, chosen among those that are specifically incorporated into proteins without interconversion, allowed an accurate measurement of different amino acid ratios for 200 proteins. A computer program was developed to screen a yeast data base containing 1700 protein sequences and to identify proteins matching the measured M(r), pI, and amino acid ratios. The method, tested with 45 reference proteins, allowed 79 new identifications corresponding to abundant proteins belonging to a few functional families. Some protein spots correspond to homologs of mammalian proteins or to uncharacterized open reading frames. Remarkably, among identified proteins of similar abundance, the organellar proteins have a markedly lower codon usage bias than the cytosolic ones. The double labeling technique is particularly suited to the analysis, on a single two dimensional gel, of the influence of physiological or genetic changes on yeast protein content.	CEA SACLAY,SERV BIOCHIM & GENET MOL,F-91191 GIF SUR YVETTE,FRANCE; INST BIOCHIM & GENET CELLULAIRES,CNRS,UPR 9026,F-33077 BORDEAUX,FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS)								BATAILLE N, 1988, ELECTROPHORESIS, V9, P774, DOI 10.1002/elps.1150091113; BATAILLE N, 1987, YEAST, V3, P11, DOI 10.1002/yea.320030104; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BOUCHERIE H, 1995, YEAST, V11, P601, DOI 10.1002/yea.320110702; ECKERSKORN C, 1988, ELECTROPHORESIS, V9, P830, DOI 10.1002/elps.1150091208; GARRELS JI, 1994, ELECTROPHORESIS, V15, P1466, DOI 10.1002/elps.11501501210; GODEL H, 1984, J CHROMATOGR, V297, P49, DOI 10.1016/S0021-9673(01)89028-2; GRENSON M, 1983, EUR J BIOCHEM, V133, P135, DOI 10.1111/j.1432-1033.1983.tb07438.x; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; HOBOHM U, 1994, ANAL BIOCHEM, V222, P202, DOI 10.1006/abio.1994.1474; HU YM, 1995, MOL CELL BIOL, V15, P52, DOI 10.1128/MCB.15.1.52; Jones E. W., 1982, MOL BIOL YEAST SACCH, P181; JUNGBLUT P, 1992, J PROTEIN CHEM, V11, P603, DOI 10.1007/BF01024960; KLIER H, 1992, ELECTROPHORESIS, V13, P732, DOI 10.1002/elps.11501301157; LATTER GI, 1984, CLIN CHEM, V30, P1925; LUDWIG JR, 1982, MOL CELL BIOL, V2, P117, DOI 10.1128/MCB.2.2.117; LUTCKE H, 1995, EUR J BIOCHEM, V228, P531, DOI 10.1111/j.1432-1033.1995.0531m.x; MESSENGUY F, 1980, EUR J BIOCHEM, V108, P439, DOI 10.1111/j.1432-1033.1980.tb04740.x; MORTIMER RK, 1986, GENETICS, V113, P35; NEIDHARDT FC, 1989, ELECTROPHORESIS, V10, P116, DOI 10.1002/elps.1150100206; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; NORBECK J, 1995, ELECTROPHORESIS, V16, P149, DOI 10.1002/elps.1150160124; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; SANCHEZ Y, 1993, J BACTERIOL, V175, P6484, DOI 10.1128/jb.175.20.6484-6491.1993; SHAW G, 1993, P NATL ACAD SCI USA, V90, P5138, DOI 10.1073/pnas.90.11.5138; SIBBALD PR, 1991, ANAL BIOCHEM, V198, P330, DOI 10.1016/0003-2697(91)90434-U	27	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10263	10270		10.1074/jbc.271.17.10263	http://dx.doi.org/10.1074/jbc.271.17.10263			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626593	hybrid			2022-12-27	WOS:A1996UG25700065
J	Wang, TF; Guidotti, G				Wang, TF; Guidotti, G			CD39 is an ecto-(Ca2+,Mg2+)-apyrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR ATP; MOUSE LYMPHOCYTES; PLASMA-MEMBRANE; EXPRESSION; RESPONSES; RESISTANT	CD39, a 70- to 100-kDa molecule expressed primarily on activated lymphoid cells, was previously identified as a surface marker of Epstein Barr virus (EBV)-transformed B cells. In this report, we show that an ecto-(Ca2+,Mg2+)-apyrase activity is present on EBV-transformed B cells, but not on B or T lymphomas. The coincidence between CD39 expression and ecto-apyrase activity on immune cells suggests that CD39 may be an ecto-apyrase. This supposition is supported by the observation that the amino acid sequence of CD39 is significantly homologous to those of several newly identified nucleotide triphosphatases. Finally, we show that CD39 indeed has ecto-apyrase activity by expression in COS-7 cells.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University			Wang, Ting-Fang/ABI-3818-2020	Wang, Ting-Fang/0000-0001-6306-9505	NHLBI NIH HHS [HL08893] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; ASAI T, 1995, J BIOL CHEM, V270, P11391, DOI 10.1074/jbc.270.19.11391; BARANKIEWICZ J, 1988, J BIOL CHEM, V263, P7094; BARANKIEWICZ J, 1990, ANN NY ACAD SCI, V603, P380; BERMUDES D, 1994, J BIOL CHEM, V269, P29252; CHEN JH, 1989, SCIENCE, V243, P657, DOI 10.1126/science.2464852; CHEN M, 1992, J BIOL CHEM, V267, P9684; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENNSING S, 1994, BLOOD, V83, P3826; DIVIRGILIO F, 1989, J IMMUNOL, V143, P1955; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; DIVIRGILIO F, 1993, CELL TISSUE CULTUR B, V5; DOMBROWSKI KE, 1993, BIOCHEMISTRY-US, V32, P6515, DOI 10.1021/bi00077a004; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; FILLIPINI A, 1990, J BIOL CHEM, V267, P16081; Handa M, 1996, BIOCHEM BIOPH RES CO, V218, P916, DOI 10.1006/bbrc.1996.0162; IKEWAKI N, 1992, TISSUE ANTIGENS, V39, P174, DOI 10.1111/j.1399-0039.1992.tb01933.x; KANSAS GS, 1991, J IMMUNOL, V146, P2235; LIN SH, 1989, J BIOL CHEM, V264, P14403; LIN SH, 1985, J BIOL CHEM, V260, P976; LIN SH, 1989, CELL CALCIUM METABOL, P13; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574; OLAH ME, 1995, ANN REV PHARM TOXICO, V35, P518; PIZZO P, 1992, J IMMUNOL, V149, P3372; PLESNER L, 1995, INT REV CYTOL, V158, P1; REDDY NB, 1978, BIOCHIM BIOPHYS ACTA, V540, P371, DOI 10.1016/0304-4165(78)90167-8; ROWE M, 1982, INT J CANCER, V29, P373, DOI 10.1002/ijc.2910290403; Sambrook J., 2002, MOL CLONING LAB MANU; STOUT JG, 1994, J BIOCHEM BIOPH METH, V29, P61, DOI 10.1016/0165-022X(94)90057-4; ZANOVELLO P, 1990, J IMMUNOL, V145, P1545; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	34	249	266	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9898	9901		10.1074/jbc.271.17.9898	http://dx.doi.org/10.1074/jbc.271.17.9898			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626624	hybrid			2022-12-27	WOS:A1996UG25700008
J	Erlich, R; Gleeson, PA; Campbell, P; Dietzsch, E; Toh, BH				Erlich, R; Gleeson, PA; Campbell, P; Dietzsch, E; Toh, BH			Molecular characterization of trans-Golgi p230 - A human peripheral membrane protein encoded by a gene on chromosome 6p12-22 contains extensive coiled-coil alpha-helical domains and a granin motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SECONDARY-STRUCTURE; GLOBULAR PROTEINS; LEUCINE-ZIPPER; PREDICTION; COMPLEX; CONFORMATION; TRANSLATION; EXPRESSION; PATTERNS	Using autoantibodies from a Sjogren's syndrome patient, we have previously identified a 230-kDa peripheral membrane protein associated with the cytosolic face of the trans-Golgi (Kooy, J., Toh, B. H., Pettitt, J. M., Erlich, R. and Gleeson, P. A. (1992) J. Biol. Chem. 267, 20255-20263), Here we report the molecular cloning and sequence analysis of human p230 and the localization of its gene to chromosome 6p12-22, Partial cDNA clones, isolated from a HeLa cell cDNA library using autoantibodies, were used to obtain additional cDNAs, which together span 7695 base pairs (bp), The p230 mRNA is similar to 7.7 kilobases. Two alternatively spliced mRNAs for p230 were detected, These differed by 21- and 63-bp insertions in the 3'-sequence, resulting in differences in amino acid sequence at the carboxyl terminus, The predicted 261-kDa protein is highly hydrophilic with 17-20% homology with many proteins containing coiled-coil domains, Apart from two proline-rich regions (amino acids 1-117 and 239-270), p230 contains a very high frequency of heptad repeats, characteristic of alpha-helices that form dimeric coiled-coil structures, p230 also includes the sequence ESLALEELEL (amino acids 538-546), a motif found in the granin family of acidic proteins present in secretory granules of neuroendocrine cells, This is the first report of a cytosolic Golgi protein containing a granin motif. The structural characteristics of p230 indicate that it may play a role in vesicular transport from the trans-Golgi.	MONASH UNIV,SCH MED,DEPT PATHOL & IMMUNOL,MELBOURNE,VIC 3181,AUSTRALIA; FLINDERS MED CTR,DEPT CLIN IMMUNOL,BEDFORD PK,SA,AUSTRALIA; UNIV CAPE TOWN,SCH MED,DEPT BIOCHEM MED,CAPE TOWN 7925,SOUTH AFRICA	Monash University; Flinders Medical Centre; University of Cape Town				Gleeson, Paul/0000-0002-5336-6503				ALDERUCCIO F, 1993, J EXP MED, V178, P419, DOI 10.1084/jem.178.2.419; BRESSAN GM, 1987, NUCLEIC ACIDS RES, V15, P10056, DOI 10.1093/nar/15.23.10056; CHOMCZYNSKI P, 1992, NUCLEIC ACIDS RES, V20, P3791, DOI 10.1093/nar/20.14.3791; CHOO KH, 1991, PROTOCOLS HUMAN MOL, V7, P233; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENDOW SA, 1994, J CELL SCI, V107, P859; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FRITZLER MJ, 1993, J EXP MED, V178, P49, DOI 10.1084/jem.178.1.49; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; HUTTNER WB, 1995, CURR BIOL, V5, P242, DOI 10.1016/S0960-9822(95)00049-2; JONES SM, 1993, J CELL BIOL, V122, P775, DOI 10.1083/jcb.122.4.775; KNIGHT AE, 1993, J MOL BIOL, V231, P148, DOI 10.1006/jmbi.1993.1266; KOOY J, 1992, J BIOL CHEM, V267, P20255; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUBALEK EW, 1992, MOL BIOL CELL, V3, P1455, DOI 10.1091/mbc.3.12.1455; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; NARULA A, 1995, P NATL ACAD SCI USA, V92, P2874; OAS TG, 1994, TRENDS BIOCHEM SCI, V19, P51, DOI 10.1016/0968-0004(94)90030-2; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RIOS RM, 1994, J CELL BIOL, V125, P997, DOI 10.1083/jcb.125.5.997; ROBSON B, 1976, J MOL BIOL, V107, P327, DOI 10.1016/S0022-2836(76)80008-3; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SALAMA NR, 1995, CURR OPIN CELL BIOL, V7, P536, DOI 10.1016/0955-0674(95)80011-5; Sambrook J., 2002, MOL CLONING LAB MANU; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SEELIG HP, 1994, J AUTOIMMUN, V7, P67, DOI 10.1006/jaut.1994.1006; SEOG DH, 1994, J BIOCHEM-TOKYO, V116, P1341, DOI 10.1093/oxfordjournals.jbchem.a124685; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; SOHDA M, 1994, BIOCHEM BIOPH RES CO, V205, P1399, DOI 10.1006/bbrc.1994.2821; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; WEBBER LM, 1983, PATHOLOGY, V15, P112; WEBBER LM, 1983, CANCER GENET CYTOGEN, V8, P123, DOI 10.1016/0165-4608(83)90044-4; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; YOO SH, 1994, J BIOL CHEM, V269, P12001; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8816, DOI 10.1021/bi00085a012	55	86	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8328	8337		10.1074/jbc.271.14.8328	http://dx.doi.org/10.1074/jbc.271.14.8328			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626529	hybrid			2022-12-27	WOS:A1996UD60000069
J	Kitaura, M; Nakajima, T; Imai, T; Harada, S; Combadiere, C; Tiffany, HL; Murphy, PM; Yoshie, O				Kitaura, M; Nakajima, T; Imai, T; Harada, S; Combadiere, C; Tiffany, HL; Murphy, PM; Yoshie, O			Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; FUNCTIONAL EXPRESSION; RANTES; CYTOKINE; 1-ALPHA; GENE; CDNA	The CC chemokine eotaxin is a selective chemoattractant for guinea pig eosinophils, first purified from bronchoalveolar lavage fluid in a guinea pig model of allergic airway inflammation. We have now isolated the gene and cDNA for a human counterpart of eotaxin. The gene maps to chromosome 17 and is expressed constitutively at high levels in small intestine and colon, and at lower levels in various other tissues. The deduced mature protein sequence is 66% identical to human monocyte chemoattractant protein-1, and 60% identical to guinea pig eotaxin. Recombinant human eotaxin produced in insect cells induced a calcium flux response in normal human eosinophils, but not in neutrophils or monocytes. The response could not be desensitized by pretreatment of eosinophils with other CC chemokines, suggesting a unique receptor. In this regard, we show that human eotaxin is a potent and highly specific agonist for CC chemokine receptor 3, a G protein-coupled receptor selectively expressed in human eosinophils. Thus eotaxin and CC chemokine receptor 3 may be host factors highly specialized for eosinophil recruitment in inflammation, and may be good targets for the development of selective drugs for inflammatory diseases where eosinophils contribute to pathogenesis, such as asthma.	NIAID,HOST DEF LAB,NIH,BETHESDA,MD 20892; SHIONOGI INST MED SCI,SETTSU,OSAKA 566,JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Shionogi & Company Limited			Combadiere, Christophe/I-5639-2013	Combadiere, Christophe/0000-0002-1755-4531; Yoshie, Osamu/0000-0003-4353-5809				BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; BLACKSHAW AJ, 1986, J CLIN PATHOL, V39, P1, DOI 10.1136/jcp.39.1.1; Chang H C, 1989, Int Immunol, V1, P388, DOI 10.1093/intimm/1.4.388; CHARO IF, 1994, P NATL ACAD SCI USA, V270, P30235; COMBADIERE C, 1995, DNA CELL BIOL, V14, P673, DOI 10.1089/dna.1995.14.673; COMBADIERE C, 1995, J BIOL CHEM, V270, P30235; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; FRANCI C, 1995, J IMMUNOL, V154, P6511; FURUTANI Y, 1989, BIOCHEM BIOPH RES CO, V159, P249, DOI 10.1016/0006-291X(89)92430-3; GAO JL, 1995, J BIOL CHEM, V270, P17494, DOI 10.1074/jbc.270.29.17494; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GAO JL, 1994, J BIOL CHEM, V269, P28539; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; HEINRICH JN, 1993, MOL CELL BIOL, V13, P2020, DOI 10.1128/MCB.13.4.2020; JOSE PJ, 1994, BIOCHEM BIOPH RES CO, V205, P788, DOI 10.1006/bbrc.1994.2734; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LOETSCHER P, 1994, FASEB J, V8, P1055, DOI 10.1096/fasebj.8.13.7926371; MEURER R, 1993, J EXP MED, V178, P1913, DOI 10.1084/jem.178.6.1913; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; TIFFANY HL, 1995, J LEUKOCYTE BIOL, V58, P49; UGUCCIONI M, 1995, EUR J IMMUNOL, V25, P64, DOI 10.1002/eji.1830250113; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; VANRIPER G, 1994, J IMMUNOL, V152, P4055; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; YOSHIDA T, 1995, FEBS LETT, V360, P155, DOI 10.1016/0014-5793(95)00093-O; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3	37	361	394	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7725	7730		10.1074/jbc.271.13.7725	http://dx.doi.org/10.1074/jbc.271.13.7725			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631813	hybrid			2022-12-27	WOS:A1996UC77400081
J	Nagalla, SR; Barry, BJ; Falick, AM; Gibson, BW; Taylor, JE; Dong, JZ; Spindel, ER				Nagalla, SR; Barry, BJ; Falick, AM; Gibson, BW; Taylor, JE; Dong, JZ; Spindel, ER			There are three distinct forms of bombesin - Identification of [Leu(13)]bombesin, [Phe(13)]bombesin, and [Ser(3),Arg(10),Phe(13)]bombesin in the frog Bombina orientalis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIN-RELEASING PEPTIDE; LUNG-CARCINOMA CELLS; SWISS 3T3 CELLS; MOLECULAR-CLONING; NEUROMEDIN-B; LASER-DESORPTION; MAMMALIAN BOMBESIN; AMPHIBIAN BOMBESIN; MASS-SPECTROMETRY; MESSENGER-RNAS	Amphibian bombesin is the prototypic peptide that defines the bombesin-like peptide family. In this paper we show that in the frog Bombina orientalis, there are actually 3 distinct forms of bombesin, and each of these peptides is an agonist with differing affinities for the known bombesin receptors. Oligonucleotides complementary to the 5'- and 3'-untranslated regions of the bombesin mRNA were used to amplify bombesin-related cDNAs from the skin, brain, and gut of B. orientalis. Three classes of cDNAs were found. One class encoded the previously characterized form of bombesin which has a Leu at position 13 ([Leu(13)]bombesin). The other two classes, respectively, encoded new bombesin-like peptides which we have designated as [Phe(13)]bombesin and [Ser(3),Arg(10),Phe(13)]bombesin ([SAP]bombesin). The existence of [SAP]bombesin in skin was confirmed by tandem mass spectrometry. Polymerase chain reaction analysis of genomic DNA showed the mRNAs for [Leu(13)]bombesin, [Phe(13)]bombesin, and [SAP]bombesin most likely arise from separate genes. Polymerase chain reaction analysis showed different patterns of tissue-specific expression for each form. [Leu(13)]Bombesin and [SAP]bombesin were predominantly expressed in skin, brain, and gut; [Phe(13)]bombesin was expressed only in brain, and [Leu(13)]bombesin predominated in oocytes, [SAP]Bombesin contained a cleavage site between residues 4 and 5, which if used would yield the peptide [SAP]bombesin(5-14) which has the sequence [Gln(3),Arg(6)]neuromedin B. Thus a frog homolog of NMB could derive from the [SAP]bombesin prohormone. [Phe(13)]Bombesin, [SAP]bombesin, and [SAP]bombesin(5-14) were synthesized and their affinities for the mammalian bombesin-like peptide (GRP and NMB) receptors determined. These peptides acted as agonists for the GRP and NMB receptors, with relative potencies for the GRP receptor of [Leu(13)]bombesin > [Phe(13)]bombesin > [SAP]bombesin(5-14) > [SAP]bombesin and for the NMB receptor of [Phe(13)]bombesin > [SAP]bombesin(5-14) > [Leu(13)]bombesin > [SAP]bombesin. None of these peptides demonstrated high affinity binding for the BRS-3 receptor. The different receptor affinities and tissue distribution of these peptides suggests distinct physiologic roles and raises the possibility of as yet uncharacterized mammalian homologs of these new amphibian peptides.	OREGON REG PRIMATE RES CTR,DIV NEUROSCI,BEAVERTON,OR 97006; PERSEPT BIOSYST,S SAN FRANCISCO,CA 94080; UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; BIOMEASURE INC,MILFORD,MA 01757	Oregon Health & Science University; Oregon National Primate Research Center; University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [R23CA039237, R01CA039237] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614, P51RR000163] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39237] Funding Source: Medline; NCRR NIH HHS [RR01614, RR00163] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AGUAYO SM, 1994, AM J RESP CELL MOL, V10, P635, DOI 10.1165/ajrcmb.10.6.8003340; ANASTASI A, 1975, EXPERIENTIA, V31, P510, DOI 10.1007/BF01932427; ANASTASI A, 1971, EXPERIENTIA, V27, P166, DOI 10.1007/BF02145873; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; BROWN M, 1978, LIFE SCI, V23, P2721, DOI 10.1016/0024-3205(78)90652-5; BROWN M, 1977, SCIENCE, V196, P998, DOI 10.1126/science.860130; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; FALICK AM, 1993, J AM SOC MASS SPECTR, V4, P882, DOI 10.1016/1044-0305(93)87006-X; FATHI Z, 1993, J BIOL CHEM, V268, P5979; GIBSON BW, 1991, J BIOL CHEM, V266, P23103; GORBULEV V, 1992, EUR J BIOCHEM, V208, P405, DOI 10.1111/j.1432-1033.1992.tb17201.x; HUDSON P, 1981, NATURE, V291, P127, DOI 10.1038/291127a0; KARAS M, 1987, INT J MASS SPECTROM, V78, P53, DOI 10.1016/0168-1176(87)87041-6; KAUFMANN R, 1993, RAPID COMMUN MASS SP, V7, P902, DOI 10.1002/rcm.1290071010; KING KA, 1995, P NATL ACAD SCI USA, V92, P4357, DOI 10.1073/pnas.92.10.4357; KING KA, 1993, J CLIN INVEST, V91, P1969, DOI 10.1172/JCI116417; KRANE IM, 1988, J BIOL CHEM, V263, P13317; LEBACQVERHEYDEN AM, 1988, MOL ENDOCRINOL, V2, P556, DOI 10.1210/mend-2-6-556; LEBACQVERHEYDEN AM, 1991, PEPTIDE GROWTH FACTO, V2, P71; LI K, 1994, J CLIN INVEST, V94, P1605, DOI 10.1172/JCI117502; MASUI A, 1993, EUR J PHARMACOL, V238, P297, DOI 10.1016/0014-2999(93)90860-K; MCDONALD TJ, 1979, BIOCHEM BIOPH RES CO, V90, P227, DOI 10.1016/0006-291X(79)91614-0; MINAMINO N, 1983, BIOCHEM BIOPH RES CO, V114, P541, DOI 10.1016/0006-291X(83)90814-8; NAGALLA SR, 1992, J BIOL CHEM, V267, P6916; NAGALLA SR, 1994, MOL ENDOCRINOL, V8, P943, DOI 10.1210/me.8.8.943; NAGALLA SR, 1995, P NATL ACAD SCI USA, V92, P6205, DOI 10.1073/pnas.92.13.6205; NAKAJIMA T, 1970, Federation Proceedings, V29, P282; PONTIROLI AE, 1986, HORM RES, V23, P129, DOI 10.1159/000180307; RICHTER K, 1990, FEBS LETT, V262, P353, DOI 10.1016/0014-5793(90)80227-A; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SPENGLER B, 1992, RAPID COMMUN MASS SP, V6, P105, DOI 10.1002/rcm.1290060207; SPINDEL E, 1986, TRENDS NEUROSCI, V9, P130, DOI 10.1016/0166-2236(86)90042-1; SPINDEL ER, 1987, MOL ENDOCRINOL, V1, P224, DOI 10.1210/mend-1-3-224; SPINDEL ER, 1990, P NATL ACAD SCI USA, V87, P9813, DOI 10.1073/pnas.87.24.9813; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; SPINDEL ER, 1984, P NATL ACAD SCI-BIOL, V81, P5699, DOI 10.1073/pnas.81.18.5699; SPINDEL ER, 1993, RECENT PROG HORM RES, V48, P365; STEEL JH, 1992, ENDOCRINOLOGY, V130, P2587, DOI 10.1210/en.130.5.2587; TACHE Y, 1982, TRENDS NEUROSCI, V5, P431, DOI 10.1016/0166-2236(82)90234-X; VONSCHRENCK T, 1989, AM J PHYSIOL, V256, pG747, DOI 10.1152/ajpgi.1989.256.4.G747; WADA E, 1990, J NEUROSCI, V10, P2917; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4; WALLS FC, 1990, BIOLOGICAL MASS SPECTROMETRY /, P197; WALSH JH, 1979, FED PROC, V38, P2315; WANG LH, 1990, BIOCHEMISTRY-US, V29, P616, DOI 10.1021/bi00455a004; Watson S., 1994, G PROTEIN LINKED REC; WATSON S, 1995, TRENDS PHARM SCI S, V16, P16; WECHSELBERGER C, 1992, P NATL ACAD SCI USA, V89, P9819, DOI 10.1073/pnas.89.20.9819; WHARTON J, 1978, NATURE, V273, P769, DOI 10.1038/273769a0; YASUHARA T, 1983, BIOMED RES-TOKYO, V4, P407	52	60	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7731	7737		10.1074/jbc.271.13.7731	http://dx.doi.org/10.1074/jbc.271.13.7731			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631814	hybrid			2022-12-27	WOS:A1996UC77400082
J	Coleman, BA; Taylor, P				Coleman, BA; Taylor, P			Regulation of acetylcholinesterase expression during neuronal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; EMBRYONAL CARCINOMA-CELLS; MOLECULAR-FORMS; MAMMALIAN ACETYLCHOLINESTERASE; CAUDATE-NUCLEUS; BRAIN; GENE; MATURATION; PHENOTYPE; CORTEX	We have examined the developmental expression of acetylcholinesterase (AChE) during the process of neuronal differentiation from a pluripotent stem cell, P19 embryonic carcinoma cells form embryoid bodies, which, when cultured with retinoic acid, are induced to differentiate into neurons and glia. No AChE activity is present in the undifferentiated stem cells, and mRNA protection analyses do not detect AChE mRNA. Commitment to a neuronal differentiation pathway results in increased levels of AChE mRNA, production of a tetrameric form of the enzyme, and secretion of AChE into the culture medium. Concomitant with subsequent morphological differentiation into neurons, enzyme secretion diminishes and AChE becomes largely tethered to the neuronal cell membranes. The enzyme is attached to the cell surface as a globular tetramer. Its hydrodynamic properties are consistent with association through a noncatalytic hydrophobic subunit rather than anchorage by a glycophospholipid tail. No change in the rate of transcription of the Ache gene was detected during the course of differentiation, suggesting that the gene is actively transcribed at very early stages of development. Results suggest that stabilization of a labile mRNA governs the increase in AChE mRNA and gene product. The studies presented indicate that an early event in neuronal differentiation is the stabilization of the mRNA leading to expression of a secreted form of AChE. A subsequent step associated with neurite outgrowth results in a transition from secretion of the tetrameric enzyme to its localization on the cell membrane.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360, R01GM018360] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18360, GM24437] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSELMET A, 1994, J NEUROCHEM, V62, P2158; BEAR MF, 1985, J COMP NEUROL, V237, P519, DOI 10.1002/cne.902370408; BOSCHETTI N, 1994, NEUROCHEM RES, V19, P359, DOI 10.1007/BF00971586; BRIMIJOIN S, 1983, PROG NEUROBIOL, V21, P291, DOI 10.1016/0301-0082(83)90015-1; CHEUN JE, 1991, INT J DEV NEUROSCI, V9, P391, DOI 10.1016/0736-5748(91)90061-P; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Denis-Donini S, 1980, Curr Top Dev Biol, V16, P323; DIMPFEL W, 1977, J NEUROCHEM, V29, P329, DOI 10.1111/j.1471-4159.1977.tb09626.x; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FUENTES ME, 1993, NEURON, V10, P679, DOI 10.1016/0896-6273(93)90169-R; GENNARI K, 1987, J NEUROCHEM, V49, P12, DOI 10.1111/j.1471-4159.1987.tb03386.x; GREENBERG ME, 1987, CURRENT PROTOCOLS MO; GREENE LA, 1981, J BIOL CHEM, V256, P6363; HAMMOND P, 1994, P NATL ACAD SCI USA, V91, P10933, DOI 10.1073/pnas.91.23.10933; HOWE JG, 1986, P NATL ACAD SCI USA, V83, P9006, DOI 10.1073/pnas.83.23.9006; INESTROSA NC, 1987, J BIOL CHEM, V262, P4441; INESTROSA NC, 1994, NEUROSCI LETT, V173, P155, DOI 10.1016/0304-3940(94)90172-4; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; KARPEL R, 1994, EXP CELL RES, V210, P268, DOI 10.1006/excr.1994.1039; LAYER PG, 1995, PROG HISTOCHEM CYTOC, V29, P1; LAZAR M, 1980, J NEUROCHEM, V35, P1067, DOI 10.1111/j.1471-4159.1980.tb07860.x; LEVINE AJ, 1974, J CELL PHYSIOL, V84, P311, DOI 10.1002/jcp.1040840217; LI Y, 1993, J BIOL CHEM, V268, P5790; LI Y, 1991, J BIOL CHEM, V266, P23083; LIAO J, 1993, J NEUROCHEM, V61, P1127, DOI 10.1111/j.1471-4159.1993.tb03629.x; LUO ZG, 1994, J BIOL CHEM, V269, P27216; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; RIEGER F, 1976, J NEUROCHEM, V27, P121, DOI 10.1111/j.1471-4159.1976.tb01553.x; ROBERTSON RT, 1985, DEV BRAIN RES, V21, P203, DOI 10.1016/0165-3806(85)90209-3; ROBERTSON RT, 1993, NEWS PHYSIOL SCI, V8, P266; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SHARMA S, 1988, DEV BIOL, V125, P246, DOI 10.1016/0012-1606(88)90208-4; STAINES WA, 1994, NEUROSCIENCE, V58, P735, DOI 10.1016/0306-4522(94)90451-0; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; TERESKY AK, 1974, J CELL PHYSIOL, V84, P319, DOI 10.1002/jcp.1040840218; WADE PD, 1980, DEV NEUROSCI-BASEL, V3, P101, DOI 10.1159/000112383	39	88	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4410	4416						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626792				2022-12-27	WOS:A1996TW96000070
J	Deissler, H; BehnKrappa, A; Doerfler, W				Deissler, H; BehnKrappa, A; Doerfler, W			Purification of nuclear proteins from human HeLa cells that bind specifically to the unstable tandem repeat (CGG), in the human FMR1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRAGILE-X-SYNDROME; DNA METHYLATION; CPG ISLAND; HUMAN-DISEASE; PATTERNS; TRANSCRIPTION; SEQUENCES; SITES; IDENTIFICATION; EXPRESSION	Autonomous expansions of trinucleotide repeats with the general structure 5'-d(CNG)(n)-3' are associated with several human genetic diseases. We have characterized nuclear proteins binding to the unstable 5'-d(CGG)(n)-3' repeat. Its expansion in the human FMR1 gene leads to the fragile X syndrome, one of the most frequent causes of mental retardation in human males. Electrophoretic mobility shift assays using nuclear extracts from several human and other mammalian cell lines and from primary human cells demonstrated specific binding to double-stranded DNA fragments containing only a 5'-d(CGG)(17)-3' repeat or the repeat and flanking genomic sequences of the human FMR1 gene. Protein binding was inhibited by complete methylation of the trinucleotide repeat. The complex formed with crude nuclear extract apparently did not contain the human transcription factor Sp1 that binds to a characteristic GC-rich sequence. A 20-kDa protein involved in specific binding to the double-stranded 5'-d(CGG)(17)-3' repeat was purified from HeLa nuclear extracts by DNA affinity chromatography.	UNIV COLOGNE, INST GENET, D-50931 COLOGNE, GERMANY	University of Cologne				Deissler, Heidrun/0000-0003-0086-7811				BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BARRETT P, 1987, NUCLEIC ACIDS RES, V15, P2719, DOI 10.1093/nar/15.6.2719; BEHNKRAPPA A, 1994, HUM MUTAT, V3, P19, DOI 10.1002/humu.1380030104; BEHNKRAPPA A, 1991, GENOMICS, V11, P1, DOI 10.1016/0888-7543(91)90095-V; BINGHAM PM, 1995, NAT GENET, V9, P191, DOI 10.1038/ng0295-191; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; CHAMBERLIN M, 1962, P NATL ACAD SCI USA, V48, P81, DOI 10.1073/pnas.48.1.81; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOERFLER W, 1991, BIOL CHEM H-S, V372, P557; EICK D, 1980, J VIROL, V36, P41, DOI 10.1128/JVI.36.1.41-49.1980; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HANSEN RS, 1992, HUM MOL GENET, V1, P571, DOI 10.1093/hmg/1.8.571; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; HORNSTRA IK, 1993, HUM MOL GENET, V2, P1659; JONES C, 1995, NATURE, V376, P145, DOI 10.1038/376145a0; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; KORNBERG A, 1964, P NATL ACAD SCI USA, V51, P315, DOI 10.1073/pnas.51.2.315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MITCHELL JE, 1995, NUCLEIC ACIDS RES, V23, P1876, DOI 10.1093/nar/23.11.1876; NANCARROW JK, 1995, HUM MOL GENET, V4, P367, DOI 10.1093/hmg/4.3.367; NANCARROW JK, 1994, SCIENCE, V264, P1938, DOI 10.1126/science.8009225; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PARRISH JE, 1994, NAT GENET, V8, P229, DOI 10.1038/ng1194-229; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RICHARDS RI, 1993, HUM MOL GENET, V2, P1429, DOI 10.1093/hmg/2.9.1429; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; RIGGINS GJ, 1992, NAT GENET, V2, P186, DOI 10.1038/ng1192-186; SCHETTER C, 1993, J VIROL, V67, P6973, DOI 10.1128/JVI.67.12.6973-6978.1993; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; SUTHERLAND GR, 1979, AM J HUM GENET, V31, P125; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; WHITTAKER JL, 1984, MOL CELL BIOL, V4, P110, DOI 10.1128/MCB.4.1.110	43	40	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4327	4334						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626781				2022-12-27	WOS:A1996TW96000059
J	Fujita, M; Kiyono, T; Hayashi, Y; Ishibashi, M				Fujita, M; Kiyono, T; Hayashi, Y; Ishibashi, M			hCDC47, a human member of the MCM family - Dissociation of the nucleus-bound form during S phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; DNA-REPLICATION; SUBCELLULAR-LOCALIZATION; YEAST; PROTEINS; MAINTENANCE; MUTANTS; ANTIGEN; GENES	hCDC47 is a putative human homologue of yeast CDC47 and a member of the MCM protein family, which has been implicated in the regulatory machinery causing DNA to replicate only once in the S phase. In the present study, we performed an initial characterization of hCDC47. We found that hCDC47 protein was present in the nucleus of cultured human cells in two different forms; one extractable by a non-ionic detergent and the other resistant to such extraction and tightly associated with the nucleus. The levels of the nucleus-bound form gradually diminished during S phase progression, although the total amount of nuclear hCDC47 protein remained relatively constant, suggesting that the nucleus-bound form becomes dissociated from the nuclear structure during DNA replication. This behavior of hCDC47 protein is very similar to that of other mammalian MCM proteins reported recently. We also found that expression of hCDC47 mRNA was repressed in quiescent cells but was induced at the late G(1) to S phase by growth factor stimulation. Together, these findings indicate that hCDC47 protein together with other MCM proteins participates in the regulation of mammalian DNA replication.	AICHI CANC CTR,RES INST,LAB VIRAL ONCOL,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Aichi Cancer Center			Kiyono, Tohru/H-5834-2011	Fujita, Masatoshi/0000-0001-6617-2452				BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; CHEN YR, 1992, P NATL ACAD SCI USA, V89, P10459, DOI 10.1073/pnas.89.21.10459; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COXON A, 1992, NUCLEIC ACIDS RES, V20, P5571, DOI 10.1093/nar/20.21.5571; DALTON S, 1995, P NATL ACAD SCI USA, V92, P2514, DOI 10.1073/pnas.92.7.2514; FUJITA M, 1995, ONCOGENE, V11, P15; GIBSON S, 1987, UCLA S MOL CELL BIOL, V47, P341; GIBSON SI, 1990, MOL CELL BIOL, V10, P5707, DOI 10.1128/MCB.10.11.5707; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HU B, 1993, NUCLEIC ACIDS RES, V21, P5289, DOI 10.1093/nar/21.23.5289-a; KIMURA H, 1995, NUCLEIC ACIDS RES, V23, P2097, DOI 10.1093/nar/23.12.2097; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MAINE GT, 1984, GENETICS, V106, P365; MERRILL GF, 1992, BIOESSAYS, V14, P823, DOI 10.1002/bies.950141206; MUSAHL C, 1995, EUR J BIOCHEM, V230, P1096, DOI 10.1111/j.1432-1033.1995.tb20660.x; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHULTE D, 1995, J CELL SCI, V108, P1381; SPRINGER PS, 1995, SCIENCE, V268, P877, DOI 10.1126/science.7754372; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; TODOROV IT, 1994, J CELL SCI, V107, P253; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149	31	68	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4349	4354						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626784				2022-12-27	WOS:A1996TW96000062
J	Krebsbach, PH; Nakata, K; Bernier, SM; Hatano, O; Miyashita, T; Rhodes, CS; Yamada, Y				Krebsbach, PH; Nakata, K; Bernier, SM; Hatano, O; Miyashita, T; Rhodes, CS; Yamada, Y			Identification of a minimum enhancer sequence for the type II collagen gene reveals several core sequence motifs in common with the link protein gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORAMPHENICOL ACETYLTRANSFERASE; PROCOLLAGEN GENE; MAMMALIAN-CELLS; CULTURED-CELLS; 1ST INTRON; EXPRESSION; TRANSCRIPTION; PROMOTER; DOMAIN; CARTILAGE	The type II collagen gene (Col2a1) is expressed primarily in chondrocytes. Transcription of Col2a1 is mediated by cell-specific regulatory elements located within the promoter and first intron. Here, we map a minimal enhancer and identify elements that determine cartilage-specific Col2a1 expression by analyzing the activity of a series of chimeric genes consisting of rat Col2a1 first intron deletion mutants ligated to the chloramphenicol acetyltransferase reporter gene. We show that a 100-base pair (bp) segment within the first intron is the minimum size necessary for high level, cell type-specific expression of Col2a1. Sequence analysis of this 100-bp Col2a1 enhancer revealed several sequence motifs similar to motifs present within the regulatory region of the link protein gene, another cartilage gene. These motifs include an AT-rich element, a C1 motif and a C3 motif. Deletion of any of these elements reduced Col2a1 enhancer activity in chick embryo chondrocytes. We also tested enhancer-mediated activity in CFK2 cells which differentiate to a chondrogenic phenotype and begin to express type II collagen mRNA after extended culture. In stably transfected CFK2 cells, constructs containing the 100-bp enhancer were activated during the transition from prechondrogenic to chondrogenic cell populations and deletions within the enhancer strongly down-regulated activity. Chondrocyte-specific DNA-protein complexes were identified using nuclear extracts prepared from chick embryo chondrocytes and P-32-labeled oligonucleotides from these regions of the first intron. These results suggest that interaction of chondrocyte specific nuclear factors with multiple core elements from a small region within the first intron are important for cell-type specific Col2a1 enhancer activity.	NIDR,DEV BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Krebsbach, Paul H./AAC-4765-2021	rhodes, craig/0000-0001-5440-587X				AHMAD NN, 1991, P NATL ACAD SCI USA, V88, P6624, DOI 10.1073/pnas.88.15.6624; ALAKOKKO L, 1990, P NATL ACAD SCI USA, V87, P6565, DOI 10.1073/pnas.87.17.6565; BERNIER SM, 1993, J BONE MINER RES, V8, P475; BERNIER SM, 1990, J CELL PHYSIOL, V145, P274, DOI 10.1002/jcp.1041450212; BOGAERT R, 1994, AM J HUM GENET, V55, P1128; BORNSTEIN P, 1980, ANNU REV BIOCHEM, V49, P957, DOI 10.1146/annurev.bi.49.070180.004521; BRADHAM DM, 1994, J CELL PHYSIOL, V158, P61, DOI 10.1002/jcp.1041580109; CASTAGNOLA P, 1988, J CELL BIOL, V106, P461, DOI 10.1083/jcb.106.2.461; CASTRILLO JL, 1989, SCIENCE, V243, P814, DOI 10.1126/science.2563596; CHANDRASEKHAR S, 1990, EXP CELL RES, V191, P105, DOI 10.1016/0014-4827(90)90042-9; CHEAH KSE, 1991, DEVELOPMENT, V111, P945; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DENTE L, 1988, GENE DEV, V2, P259, DOI 10.1101/gad.2.2.259; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1991, CELL, V10, P2513; GERSTENFELD LC, 1989, J BIOL CHEM, V264, P5112; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; KREBSBACH PH, 1993, MOL CELL BIOL, V13, P5168, DOI 10.1128/MCB.13.9.5168; LINSENMAYER TF, 1973, BIOCHEM BIOPH RES CO, V53, P39, DOI 10.1016/0006-291X(73)91397-1; METSARANTA M, 1991, J BIOL CHEM, V266, P16862; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; POOLE AR, 1988, J CLIN INVEST, V81, P579, DOI 10.1172/JCI113356; RHODES C, 1995, NUCLEIC ACIDS RES, V23, P2305, DOI 10.1093/nar/23.12.2305; RYAN MC, 1990, GENOMICS, V8, P41, DOI 10.1016/0888-7543(90)90224-I; SAVAGNER P, 1995, DNA CELL BIOL, V14, P501, DOI 10.1089/dna.1995.14.501; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; TILLER GE, 1995, AM J HUM GENET, V56, P388; VISSING H, 1989, J BIOL CHEM, V264, P18265; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WANG LQ, 1991, J BIOL CHEM, V266, P19878; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; WOOD A, 1991, DEVELOPMENT, V111, P955	35	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4298	4303						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626777	hybrid			2022-12-27	WOS:A1996TW96000055
J	Petanceska, S; Canoll, P; Devi, LA				Petanceska, S; Canoll, P; Devi, LA			Expression of rat cathepsin S in phagocytic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENTATE GYRUS; CYSTEINE PROTEINASES; ALZHEIMERS-DISEASE; HEPARAN-SULFATE; BRAIN; CLONING; PROTEOGLYCAN; DEGRADATION; PLASTICITY; ACTIVATION	Cysteine lysosomal proteases are essential for turnover of intracellular and extracellular proteins. These enzymes are strongly implicated in normal and pathological processes involving tissue remodeling. Among the cysteine proteases, cathepsin S seems to be best suited for such a process since it retains most of its enzymatic activity at neutral pH. In situ hybridization analyses of the adult rat brain, spleen, and lung reveal that cathepsin S mRNA is preferentially expressed in cells of mononuclear-phagocytic origin. After entorhinal cortex lesion of adult rat brain (a paradigm for neuronal degeneration and reactive synaptogenesis), cathepsin S mRNA is dramatically increased in activated microglia in the deafferented dentate gyrus and in macrophages at the wound site, suggesting a role in lesion-induced tissue remodeling. This possibility is further supported by the finding that cathepsin S degrades a number of extracellular matrix molecules at neutral pH and by the finding that inflammatory mediators stimulate its secretion from the microglia and macrophages. These data suggest that cathepsin S is an important player in degenerative disorders associated with the cells of the mononuclear phagocytic system.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University			Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026880, R29NS026880, K04NS001788] Funding Source: NIH RePORTER; NINDS NIH HHS [NS K04 1788, NS 26880] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS DO, 1984, ANNU REV IMMUNOL, V2, P283, DOI 10.1146/annurev.immunol.2.1.283; AHMED NK, 1992, BIOCHEM PHARMACOL, V44, P1201, DOI 10.1016/0006-2952(92)90385-V; AMARAL DG, 1980, J COMP NEUROL, V194, P171, DOI 10.1002/cne.901940109; BROMME D, 1993, J BIOL CHEM, V268, P4832; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; CANOLL PD, 1993, DEV BRAIN RES, V75, P293, DOI 10.1016/0165-3806(93)90035-9; CARBONETTO S, 1984, TRENDS NEUROSCI, V7, P382, DOI 10.1016/S0166-2236(84)80061-2; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; FEDOROFF S, 1984, J NEUROSCI RES, V12, P15, DOI 10.1002/jnr.490120103; FONG D, 1991, BIOMED BIOCHIM ACTA, V50, P595; GEHRMANN J, 1991, ACTA NEUROPATHOL, V82, P442, DOI 10.1007/BF00293378; GRUMET M, 1994, J BIOL CHEM, V269, P12142; KATUNUMA N, 1989, INTRACELLULAR PROTEO; KIRSCHKE H, 1986, BIOCHEM J, V240, P455, DOI 10.1042/bj2400455; LAH TT, 1992, BIOL CHEM H-S, V373, P594; LEMERE CA, 1995, AM J PATHOL, V146, P848; LETOURNEAU PC, 1994, J NEUROSCI, V14, P915, DOI 10.1523/JNEUROSCI.14-03-00915.1994; LIESI P, 1984, EMBO J, V3, P683, DOI 10.1002/j.1460-2075.1984.tb01867.x; MACIEWICZ RA, 1990, FEBS LETT, V269, P189, DOI 10.1016/0014-5793(90)81151-D; MATTHEWS DA, 1976, BRAIN RES, V115, P1, DOI 10.1016/0006-8993(76)90819-2; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; NAKAJIMA K, 1992, J NEUROCHEM, V58, P1401, DOI 10.1111/j.1471-4159.1992.tb11356.x; PERRY HV, 1988, TRENDS NEUROSCI, V11, P85; PETANCESKA S, 1992, J BIOL CHEM, V267, P26038; PETANCESKA S, 1994, NEUROSCIENCE, V59, P729, DOI 10.1016/0306-4522(94)90190-2; QIAN F, 1991, BIOMED BIOCHIM ACTA, V50, P531; RAUCH U, 1992, J BIOL CHEM, V267, P19536; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; SACERDOTE P, 1993, GLIA, V9, P305, DOI 10.1002/glia.440090408; Sambrook J, 1989, MOL CLONING LABORATO; SHAFFER LM, 1993, 24 ANN M SOC NEUR, V19, P1008; SHI GP, 1992, J BIOL CHEM, V267, P7258; SHI GP, 1994, J BIOL CHEM, V269, P11530; Sloane B F, 1990, Semin Cancer Biol, V1, P137; SNOW AD, 1990, AM J PATHOL, V137, P1253; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; SU JH, 1992, NEUROSCIENCE, V51, P801, DOI 10.1016/0306-4522(92)90521-3; THOMAS EW, 1992, BRAIN RES REV, V9, P61; WIEDERANDERS B, 1992, J BIOL CHEM, V267, P13708; XIN XQ, 1992, ARCH BIOCHEM BIOPHYS, V299, P334, DOI 10.1016/0003-9861(92)90283-3	41	116	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4403	4409						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626791				2022-12-27	WOS:A1996TW96000069
J	Houseknecht, KL; Zhu, AX; Gnudi, L; Hamann, A; Zierath, JR; Tozzo, E; Flier, JS; Kahn, BB				Houseknecht, KL; Zhu, AX; Gnudi, L; Hamann, A; Zierath, JR; Tozzo, E; Flier, JS; Kahn, BB			Overexpression of Ha-ras selectively in adipose tissue of transgenic mice - Evidence for enhanced sensitivity to insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER; GENE-EXPRESSION; 3T3-L1 CELLS; ADIPOCYTES; STIMULATION; GLUT4; TRANSLOCATION; ACTIVATION; DISPOSAL; PROTEINS	To determine the role of Ras-dependent signaling pathways in adipocyte function, we created transgenic mice that overexpress Ha-ras in adipocytes using the aP2 fatty acid-binding protein promoter/enhancer ligated to the human genomic ras sequence. ras mRNA was increased 8-17-fold and Ras protein 4-5-fold in white and brown fat, with no overexpression in other tissues. The subcellular distribution of overexpressed Ras paralleled that of endogenous Ras. [U-C-14]Glucose uptake into isolated adipocytes was increased similar to 2-fold in the absence of insulin, and the ED(50) for insulin was reduced 70%, with minimal effect on maximally stimulated glucose transport. Expression of Glut4 protein was unaltered in transgenic adipocytes, but photoaffinity labeling of transporters in intact cells with [H-3]2-N-[4-(1-azi-Z,Z,Z-trifluoroethyl)benzoyl]-1,3-bis-(D-mannos-4-yloxy)-2-propylamine revealed 1.7-2.6-fold more cell-surface Glut4 in the absence of insulin and at half-maximal insulin concentration (0.3 nM) compared with nontransgenic adipocytes. With maximal insulin concentration (80 nM), cell-surface Glut4 in nontransgenic and transgenic adipocytes was similar. Glut1 expression and basal cell-surface Glut1 were increased 2-2.9-fold in adipocytes of transgenic mice. However, Glut1 was much less abundant than Glut4, making its contribution to transport negligible. These in vitro changes were accompanied by in vivo alterations including increased glucose tolerance, decreased plasma insulin levels, and decreased adipose mass. We conclude that ras overexpression in adipocytes leads to a partial translocation of Glut4 in the absence of insulin and enhanced Glut4 translocation at physiological insulin concentration, but no effect with maximally stimulating insulin concentrations.	BETH ISRAEL HOSP,DIABET UNIT,BOSTON,MA 02215; HARVARD UNIV,SCH MED,HARVARD THORNDIKE RES LAB,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Flier, jeffrey/AAG-6223-2019	gnudi, luigi/0000-0002-6353-630X; Zierath, Juleen/0000-0001-6891-7497	NIDDK NIH HHS [R37 DK-28082, R01 DK-43051, P30 DK-46200, R01 DK043051] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200, R01DK043051, R37DK028082] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK AE, 1990, BIOCHEM J, V269, P615, DOI 10.1042/bj2690615; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CUSHMAN SW, 1978, J LIPID RES, V19, P269; CUSHMAN SW, 1970, J CELL BIOL, V46, P326, DOI 10.1083/jcb.46.2.326; CZECH MP, 1976, J CLIN INVEST, V57, P1523, DOI 10.1172/JCI108422; DALLNER G, 1966, J CELL BIOL, V30, P97, DOI 10.1083/jcb.30.1.97; DECLUE JE, 1991, CANCER RES, V51, P712; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; DOHM GL, 1988, J CLIN INVEST, V82, P486, DOI 10.1172/JCI113622; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; FINGAR DC, 1994, J BIOL CHEM, V269, P10127; FOLEY JE, 1980, DIABETOLOGIA, V19, P234, DOI 10.1007/BF00275275; FOLEY JE, 1986, METHODS DIABETES RES, P211; GETTYS TW, 1991, J BIOL CHEM, V266, P15949; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GNUDI L, 1995, DIABETES, V44, pA20; GOULD GW, 1994, J BIOL CHEM, V269, P26622; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; HANSEN PA, 1994, J APPL PHYSIOL, V76, P979, DOI 10.1152/jappl.1994.76.2.979; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21391; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KASHIWAGI A, 1983, J CLIN INVEST, V72, P1246, DOI 10.1172/JCI111080; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; MANCHESTER J, 1994, P NATL ACAD SCI USA, V91, P4644, DOI 10.1073/pnas.91.11.4644; MCGUIRE TF, 1994, BIOCHEM BIOPH RES CO, V204, P399, DOI 10.1006/bbrc.1994.2472; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; OKADA T, 1994, J BIOL CHEM, V269, P3568; OSTEROP APRM, 1992, J BIOL CHEM, V267, P14647; PALFREYMAN RW, 1992, BIOCHEM J, V284, P275, DOI 10.1042/bj2840275; PEDERSEN O, 1992, J CLIN INVEST, V89, P1964, DOI 10.1172/JCI115804; PORRAS A, 1992, J BIOL CHEM, V267, P21124; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; REUSCH JEB, 1995, J BIOL CHEM, V270, P2036, DOI 10.1074/jbc.270.5.2036; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; VANDENBERGHE N, 1994, MOL CELL BIOL, V14, P2372, DOI 10.1128/MCB.14.4.2372; WALLBERGHENRIKSSON H, 1987, J BIOL CHEM, V262, P7665; WEISE RJ, 1995, J BIOL CHEM, V270, P3442; WHITE MF, 1994, J BIOL CHEM, V269, P1; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	56	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11347	11355		10.1074/jbc.271.19.11347	http://dx.doi.org/10.1074/jbc.271.19.11347			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626688	hybrid			2022-12-27	WOS:A1996UJ94400048
J	Quilliam, LA; Hisaka, MM; Zhong, S; Lowry, A; Mosteller, RD; Han, JW; Drugan, JK; Broek, D; Campbell, SL; Der, CJ				Quilliam, LA; Hisaka, MM; Zhong, S; Lowry, A; Mosteller, RD; Han, JW; Drugan, JK; Broek, D; Campbell, SL; Der, CJ			Involvement of the switch 2 domain of Ras in its interaction with guanine nucleotide exchange factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; CATALYTIC DOMAIN; GTP HYDROLYSIS; P21; PROTEIN; MUTANTS; RESIDUES; GAP; IDENTIFICATION; CEREVISIAE	While Ras proteins are activated by stimulated GDP release, which enables acquisition of the active GTP-bound state, little is known about how guanine nucleotide exchange factors (GEFs) interact with Ras to promote this exchange reaction. Here we report that mutations within the switch 2 domain of Ras (residues 62-69) inhibit activation of Ras by the mammalian GEFs, Sos1, and GRF/CDC25(Mm). While mutations in the 62-69 region blocked upstream activation of Ras, they did not disrupt Ras effector functions, including transcriptional activation and transformation of NIH 3T3 cells. Biochemical analysis indicated that the loss of GEF responsiveness of a Ras(69N) mutant was due to a loss of GEF binding, with no change in intrinsic nucleotide exchange activity. Furthermore, structural analysis of Ras(69N) using NMR spectroscopy indicated that mutation of residue 69 had a very localized effect on Ras structure that was limited to alpha-helix 2 of the switch 2 domain. Together, these results suggest that the switch 2 domain of Ras forms a direct interaction with GEFs.	INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV SO CALIF,DEPT BIOCHEM,NORRIS CANC CTR,LOS ANGELES,CA 90033	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Southern California	Quilliam, LA (corresponding author), INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,635 BARNHILL DR,MS 410,INDIANAPOLIS,IN 46202, USA.		Quilliam, Lawrence/Q-4987-2019; Quilliam, Lawrence/B-6447-2015	campbell, sharon/0000-0003-0311-409X; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA050261, R29CA063139, R29CA064569] Funding Source: NIH RePORTER; NCI NIH HHS [CA64569, CA50261, CA63139] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CARLIER MF, 1987, BIOCHEMISTRY-US, V26, P4428, DOI 10.1021/bi00388a036; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHEN SY, 1994, ONCOGENE, V9, P2691; DELOSKEY RJ, 1994, ARCH BIOCHEM BIOPHYS, V311, P72, DOI 10.1006/abbi.1994.1210; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FASANO O, 1988, EMBO J, V7, P3375, DOI 10.1002/j.1460-2075.1988.tb03210.x; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HAUBRUCK H, 1991, BIOCHIM BIOPHYS ACTA, V1072, P215, DOI 10.1016/0304-419X(91)90015-D; HOWE LR, 1993, ONCOGENE, V8, P2583; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOODIE SA, 1995, ONCOGENE, V11, P447; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; PARK WM, 1994, MOL CELL BIOL, V14, P8117, DOI 10.1128/MCB.14.12.8117; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; QUILLIAM LA, 1995, P NATL ACAD SCI USA, V92, P1272, DOI 10.1073/pnas.92.5.1272; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; REINSTEIN J, 1991, J BIOL CHEM, V266, P17700; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; STOUTEN PFW, 1993, FEBS LETT, V320, P1, DOI 10.1016/0014-5793(93)81644-F; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	44	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11076	11082		10.1074/jbc.271.19.11076	http://dx.doi.org/10.1074/jbc.271.19.11076			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626650	hybrid			2022-12-27	WOS:A1996UJ94400010
J	Richieri, GV; Ogata, RT; Kleinfeld, AM				Richieri, GV; Ogata, RT; Kleinfeld, AM			Kinetics of fatty acid interactions with fatty acid binding proteins from adipocyte, heart, and intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BOUND PALMITATE; MEMBRANES; LIVER; REFINEMENT; RESOLUTION; APOPROTEIN; DIVERSITY; MECHANISM	Rate constants for the interaction of fatty acids (FA) with fatty acid binding proteins (FABP) from adipocyte (A-FABP), heart (H-FABP), and intestine (I-FABP) were determined by using stopped-flow fluorometry and ADI-FAB, the fluorescent probe of free fatty acids (FFA), or a new FFA probe, ADIFAB2, constructed by derivatizing with acrylodan the Leu(72) --> Ala mutant of I-FABP. ADI-FAB2, because its binding affinities are about 10-fold greater than ADIFAB, was found to be more accurate for monitoring the kinetics of the higher affinity reactions. On- (k(on)) and off- (k(off)) rate constants were determined as a function of temperature. Our results reveal that in all cases the FA-FABP equilibrium is achieved within 2 s at 37 degrees C and within 20 s at 10 degrees C. Off-rate constants varied by about 10-fold among the different underivatized FABPs; k(off) values were smallest for H-FABP and largest for A-FABP, while k(on) values for these proteins generally varied by less than 2-fold. The results show that the previously reported larger affinities of I- and H-FABPs as compared to A-FABP are primarily a reflection of larger k(on) values for I-FABP and smaller k(off) values for H-FABP. Eyring transition state theory was used to evaluate the activation thermodynamic parameters for both on- and off-reactions and the results show that in virtually all cases the rate-limiting steps are predominately enthalpic. Activation free energies for binding to ADIFAB are generally composed of about 8 kcal/mol unfavorable enthalpy and about a 1 kcal/mol favorable entropic contribution. For the underivatized FABPs the activation free energies are all about 7 +/- 0.3 kcal/mol, suggesting that the transition state for entering or leaving the binding site involves a common protein structural change. We suggest that entering or leaving the FABP binding cavity involves similar mechanisms for all 3 FABPs and may involve amino acid residues located within the portal regions of these proteins.	MED BIOL INST,LA JOLLA,CA 92037						NIGMS NIH HHS [GM46931] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046931] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPERS DH, 1984, P NATL ACAD SCI-BIOL, V81, P313, DOI 10.1073/pnas.81.2.313; ANEL A, 1993, BIOCHEMISTRY-US, V32, P530, DOI 10.1021/bi00053a018; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; Bevington PR., 2002, DATA REDUCTION ERROR; EISENBERG D, 1979, PHYSICAL CHEM APPL L; FINKELSTEIN AV, 1989, PROTEIN ENG, V3, P1, DOI 10.1093/protein/3.1.1; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAUNERLAND NH, 1994, BIOCHEMISTRY-US, V33, P12378, DOI 10.1021/bi00207a004; INOUYE S, 1987, SYNTHESIS APPL DNA R, P187; JAKOBY MG, 1993, BIOCHEMISTRY-US, V32, P872, DOI 10.1021/bi00054a019; KIM HK, 1992, J BIOL CHEM, V267, P20051; LALONDE JM, 1994, J BIOL CHEM, V269, P25339; LOWE JB, 1987, J BIOL CHEM, V262, P5931; MISHKIN S, 1975, AM J PHYSIOL, V228, P1634, DOI 10.1152/ajplegacy.1975.228.6.1634; NAGHIBI H, 1995, P NATL ACAD SCI USA, V92, P5597, DOI 10.1073/pnas.92.12.5597; OCKNER RK, 1972, SCIENCE, V177, P56, DOI 10.1126/science.177.4043.56; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; RICHIERI GV, 1995, J BIOL CHEM, V270, P15076, DOI 10.1074/jbc.270.25.15076; RICHIERI GV, 1995, J LIPID RES, V36, P229; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1992, J BIOL CHEM, V267, P23534; SACCHETTINI JC, 1993, J BIOL CHEM, V268, P18399; SHA RS, 1993, J BIOL CHEM, V268, P7885; STORCH J, 1993, MOL CELL BIOCHEM, V123, P45, DOI 10.1007/BF01076474; STORCH J, 1990, J BIOL CHEM, V265, P7827; STORCH J, 1989, J BIOL CHEM, V264, P8706; VEERKAMP JH, 1992, BIOCHEM SOC T, V20, P801, DOI 10.1042/bst0200801; VEERKAMP JH, 1991, BIOCHIM BIOPHYS ACTA, V1081, P1, DOI 10.1016/0005-2760(91)90244-C; WEBER G, 1995, J PHYS CHEM-US, V99, P1052, DOI 10.1021/j100003a031; WEBER G, 1952, BIOCHEM J, V51, P145, DOI 10.1042/bj0510145; WOOTAN MG, 1993, BIOCHEMISTRY-US, V32, P8622, DOI 10.1021/bi00084a033; WOOTAN MG, 1994, J BIOL CHEM, V269, P10517; WOOTAN MG, 1990, BIOCHEMISTRY-US, V29, P9305, DOI 10.1021/bi00492a001; XU ZH, 1993, J BIOL CHEM, V268, P7874; ZANOTTI G, 1992, J BIOL CHEM, V267, P18541	37	68	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11291	11300		10.1074/jbc.271.19.11291	http://dx.doi.org/10.1074/jbc.271.19.11291			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626681	hybrid			2022-12-27	WOS:A1996UJ94400041
J	RodriguezCrespo, I; Gerber, NC; deMontellano, PRO				RodriguezCrespo, I; Gerber, NC; deMontellano, PRO			Endothelial nitric-oxide synthase - Expression in Escherichia coli, spectroscopic characterization, and role of tetrahydrobiopterin in dimer formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; NITROGEN-OXIDES; PURIFICATION; COFACTOR; ENZYME; FLAVIN; BRAIN; MYRISTOYLATION; IDENTIFICATION; FLAVOPROTEIN	Bovine endothelial nitric-oxide synthase (eNOS) expressed in Escherichia coli does not have the post-translational modifications found in the native enzyme and is free of tetrahydrobiopterin (BH4). In the presence of BH4, eNOS has an absorption maximum at 400 nm that shifts to 395 ma when the substrate L-arginine is added. The low-spin component of the spectrum of the BH4-free protein is decreased by the addition of BH4 without a corresponding increase in the high-spin component. Addition of BH4 decreases the low-spin population of eNOS even in the presence of excess L-arginine. These results indicate that BH4 directly modulates the heme environment, BH4-free eNOS is completely inactive, but catalytic activity is recovered when BH4 (EC(50) similar to 200 nM) is added. The spectroscopically determined binding constants for L-arginine are similar to 1.9 mu M in the presence and similar to>4.0 mu M in the absence of BH4. The BH4-supplemented enzyme has an activity of 90-120 nmol of citrulline min(-1) mg(-1) and K-m values of 3 and 14 mu M for L-arginine and N-hydroxy-L-arginine, respectively. Of particular interest is the finding by SDS-polyacrylamide gel electrophoresis that BH4-free eNOS exists in a monomer-dimer equilibrium very similar to that observed with the BH4-reconstituted protein, Addition of BH4 increases the percent of the dimer by only similar to 5%. The results establish that BH4, influences the heme environment and stabilizes the protein with respect to heme loss but is not required for dimer formation.	UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco			Rodriguez-Crespo, J. Ignacio/M-1966-2018	Rodriguez-Crespo, J. Ignacio/0000-0002-2582-129X	NIDDK NIH HHS [5 P30 DK26743] Funding Source: Medline; NIGMS NIH HHS [GM25515] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025515, R37GM025515] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSCONI L, 1995, MOL PHARMACOL, V47, P655; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; CHEN PF, 1994, J BIOL CHEM, V269, P25062; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; GERBER NC, 1995, J BIOL CHEM, V270, P17791, DOI 10.1074/jbc.270.30.17791; GONZALEZ FJ, 1995, ANNU REV PHARMACOL, V35, P369, DOI 10.1146/annurev.pa.35.040195.002101; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HEVEL JM, 1994, METHOD ENZYMOL, V233, P250; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KWON NS, 1989, J BIOL CHEM, V264, P20496; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LIU JW, 1995, BIOCHEMISTRY-US, V34, P12333, DOI 10.1021/bi00038a029; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NAKANE M, 1995, BIOCHEM BIOPH RES CO, V206, P511, DOI 10.1006/bbrc.1995.1073; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; RENAUD JP, 1993, BIOCHEM BIOPH RES CO, V192, P53, DOI 10.1006/bbrc.1993.1380; RIVEROSMORENO V, 1995, EUR J BIOCHEM, V230, P52; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; SAKAI N, 1993, MOL PHARMACOL, V43, P6; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SEO HG, 1995, BIOCHEM BIOPH RES CO, V208, P10, DOI 10.1006/bbrc.1995.1298; SESSA WC, 1993, CIRC RES, V72, P921, DOI 10.1161/01.RES.72.4.921; SESSA WC, 1992, J BIOL CHEM, V267, P15274; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; THONY B, 1992, BIOCHEM BIOPH RES CO, V189, P1437, DOI 10.1016/0006-291X(92)90235-D; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WOLFF DJ, 1994, ARCH BIOCHEM BIOPHYS, V314, P360, DOI 10.1006/abbi.1994.1454	49	180	182	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11462	11467		10.1074/jbc.271.19.11462	http://dx.doi.org/10.1074/jbc.271.19.11462			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626704	hybrid			2022-12-27	WOS:A1996UJ94400064
J	Waldmann, R; Champigny, G; Voilley, N; Lauritzen, I; Lazdunski, M				Waldmann, R; Champigny, G; Voilley, N; Lauritzen, I; Lazdunski, M			The mammalian degenerin MDEG, an amiloride-sensitive cation channel activated by mutations causing neurodegeneration in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION	Mutations of the degenerins (deg-1, mec-4, mec-10) are the major known causes of hereditary neurodegeneration in the nematode Caenorhabditis elegans, We cloned a neuronal degenerin (MDEG) from human and rat brain, MDEG is an amiloride sensitive cation channel permeable for Na+, K+, and Li+. This channel is activated by the same mutations which cause neurodegeneration in C. elegans, Like the hyperactive C. elegans degenerin mutants, constitutively active mutants of MDEG cause cell death, suggesting that gain of function of this novel neuronal ion channel might be involved in human forms of neurodegeneration.	INST PHARMACOL MOLEC & CELLULAIRE,UPR411 CNRS,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS)			Lauritzen, Inger/AFF-7261-2022; Lauritzen, Inger/AAE-9927-2022; Waldmann, Rainer/Q-2108-2016	Waldmann, Rainer/0000-0002-4599-2926; lauritzen, inger/0000-0002-2011-1387				BARGMANN CI, 1994, CELL, V78, P729; BARINAGA M, 1995, SCIENCE, V269, P917, DOI 10.1126/science.7638610; BARINAGA M, 1994, SCIENCE, V263, P756; BOOHER J, 1972, Neurobiology (Copenhagen), V2, P97; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; GARCIAANOVEROS J, 1995, CURR BIOL, V5, P441, DOI 10.1016/S0960-9822(95)00085-6; GARTY H, 1994, FASEB J, V8, P523; GOSLIN K, 1991, CULTURING NERVE CELL, P252; GUILLEMARE E, 1992, BIOCHEMISTRY-US, V31, P12463, DOI 10.1021/bi00164a024; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HENGARTNER MO, 1995, SCIENCE, V270, P931, DOI 10.1126/science.270.5238.931; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; JENTSCH TJ, 1994, NATURE, V367, P412, DOI 10.1038/367412a0; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; MARX J, 1993, SCIENCE, V262, P986; PRICE DA, 1977, SCIENCE, V197, P670, DOI 10.1126/science.877582; RENARD S, 1994, J BIOL CHEM, V269, P12981; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Van Broeckhoven C, 1995, NAT GENET, V11, P230; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757	33	272	290	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10433	10436		10.1074/jbc.271.18.10433	http://dx.doi.org/10.1074/jbc.271.18.10433			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631835	hybrid			2022-12-27	WOS:A1996UJ34200003
J	Charbit, A; Reizer, J; Saier, MH				Charbit, A; Reizer, J; Saier, MH			Function of the duplicated IIB domain and oligomeric structure of the fructose permease of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR PHOSPHOTRANSFERASE SYSTEM; BACTERIAL PHOSPHOENOLPYRUVATE; SALMONELLA-TYPHIMURIUM; NUCLEOTIDE-SEQUENCE; ENZYME-II; RHODOBACTER-CAPSULATUS; PHOSPHORYLATION; PROTEINS; MUTANTS; GENE	The fructose permease of Escherichia coli, the fructose-specific Enzyme II of the phosphoenolpyruvate-dependent phosphotransferase system (PTS), contains a duplicated IIB domain, The protein therefore consists of three distinct domains, B', B, and C (N-terminal to C-terminal), joined by flexible linkers and is thus designated FruB'BC. The N-terminal B' domain was removed using molecular genetic techniques, and the truncated Enzyme II (FruBC) was characterized relative to the wild-type enzyme both in vivo and in vitro. In vivo, FruBC exhibited depressed fermentation characteristics at low fructose concentrations. [C-14]Fructose uptake measurements revealed reduced rates only when the permease was rate-limiting for transport. In vitro, FruBC exhibited a 10-fold lower affinity for its phosphoryl donating protein, the ILA-FPr diphosphoryl transfer protein (DTP), than was observed with the mild-type enzyme, and the maximal velocity of fructose phosphorylation was 7-fold depressed, Because the fructose-1-phosphate:[C-14]fructose transphosphorylation reaction appeared normal, we conclude that the loss of the B' domain primarily affected phosphoryl transfer between the IIA and IIB domains of the permease, A mutant FruBC derivative with cysteine 112 replaced by serine (C112S FruBC) was inactive as a phosphoryl carrier and a sugar transport protein, Expression of the plasmid-encoded mutant protein inhibited the in vivo activity of the chromosomally encoded wild-type fructose permease, but it did not observably affect the activities of the mannitol or glucitol PTS permeases or of non-PTS sugar permeases, Further, the presence of the detergent extracted mutant protein inhibited the activity of the detergent solubilized wild-type or FruBC enzyme, In contrast, the wild-type FruB'BC permease was apparently epistatic over the truncated FruBC permease in vivo, The experiments reported 1) show that the B' domain of the fructose permease functions to facilitate phosphoryl transfer between DTP and the permease, 2) establish the essentiality of cysteine 112 in the B domain of the permease, 3) provide evidence that a functional fructose permease consists of an oligomer in which both IIB domains must be active for the enzyme to catalyze normal rates of phosphoryl transfer and transport, 4) suggest that a single B' domain in the oligomeric Enzyme II is sufficient to allow high efficiency phosphoryl transfer between the IIA domain of DTP and the IIB domain of the permease, and 5) show that the B' domain is not important for oligomerization.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego				charbit, alain/0000-0001-5243-4861	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021702] Funding Source: NIH RePORTER; NIAID NIH HHS [WRO1 AI4176, 5RO1 AI21702] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOER H, 1994, J BIOL CHEM, V269, P17863; BUHR A, 1994, J BIOL CHEM, V269, P23437; CHIN AM, 1989, J BACTERIOL, V171, P2424, DOI 10.1128/jb.171.5.2424-2434.1989; DECRECYLAGARD V, 1991, J BIOL CHEM, V266, P18154; ERNI B, 1986, BIOCHEMISTRY-US, V25, P305, DOI 10.1021/bi00350a004; GACHELIN G, 1969, BIOCHEM BIOPH RES CO, V34, P382, DOI 10.1016/0006-291X(69)90392-1; GEERSE RH, 1989, MOL GEN GENET, V216, P517, DOI 10.1007/BF00334399; JACOBSON GR, 1983, J BIOL CHEM, V258, P748; LENGELER JW, 1994, BBA-BIOENERGETICS, V1188, P1, DOI 10.1016/0005-2728(94)90017-5; LEONARD JE, 1983, J BIOL CHEM, V258, P757; LOLKEMA JS, 1992, NEW COMPR BIOCH, V21, P135; MEINS M, 1993, J BIOL CHEM, V268, P11604; MITCHELL WJ, 1993, J BACTERIOL, V175, P2756; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; POWELL BS, 1995, J BIOL CHEM, V270, P4822, DOI 10.1074/jbc.270.9.4822; PRIOR TI, 1988, J GEN MICROBIOL, V134, P2757; REIZER J, 1992, J BIOL CHEM, V267, P9158; REIZER J, 1995, MICROBIOL-UK, V141, P961, DOI 10.1099/13500872-141-4-961; REIZER J, 1989, EMBO J, V8, P2111, DOI 10.1002/j.1460-2075.1989.tb03620.x; REIZER J, 1994, FEMS MICROBIOL LETT, V118, P159, DOI 10.1111/j.1574-6968.1994.tb06819.x; REIZER J, 1994, PROTEIN SCI, V3, P440; ROBILLARD GT, 1988, BIOCHIM BIOPHYS ACTA, V947, P493, DOI 10.1016/0304-4157(88)90005-6; Romano A. H., 1992, EVOLUTION METABOLIC, P143; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SAIER MH, 1994, MOL MICROBIOL, V13, P755; SAIER MH, 1977, J BIOL CHEM, V252, P8899; SAIER MH, 1977, J BACTERIOL, V131, P716, DOI 10.1128/JB.131.2.716-718.1977; SAIER MH, 1982, J CELL BIOCHEM, V18, P231, DOI 10.1002/jcb.1982.240180210; SAIER MH, 1985, J CELL BIOCHEM, V27, P43, DOI 10.1002/jcb.240270106; SAIER MH, 1970, J BIOL CHEM, V245, P5870; SAIER MH, 1977, BACTERIOL REV, V41, P856, DOI 10.1128/MMBR.41.4.856-871.1977; Sambrook J., 2002, MOL CLONING LAB MANU; SEGAL IH, 1975, ENZYME KINETICS BEHA, P684; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; TITGEMEYER F, 1994, RES MICROBIOL, V145, P89, DOI 10.1016/0923-2508(94)90001-9; TITGEMEYER F, 1995, MICROBIOL-SGM, V141, P51, DOI 10.1099/00221287-141-1-51; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P1768, DOI 10.1021/bi00221a006; WU LF, 1990, J MOL BIOL, V213, P687, DOI 10.1016/S0022-2836(05)80256-6; WU LF, 1990, J BACTERIOL, V172, P7167, DOI 10.1128/jb.172.12.7167-7178.1990; WU LF, 1990, MOL MICROBIOL, V4, P1219, DOI 10.1111/j.1365-2958.1990.tb00698.x	40	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9997	10003		10.1074/jbc.271.17.9997	http://dx.doi.org/10.1074/jbc.271.17.9997			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626640	hybrid			2022-12-27	WOS:A1996UG25700024
J	Heidenreich, KA; Kummer, JL				Heidenreich, KA; Kummer, JL			Inhibition of p38 mitogen-activated protein kinase by insulin in cultured fetal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; NEURITE FORMATION; FACTOR-II; RAS; SURVIVAL; P21	Insulin supports the survival and differentiation of many types of fetal neurons. To determine if mitogen-activated protein (MAP) kinases play a role in mediating the neurotrophic actions of insulin, we identified the MAP kinases present in fetal chick forebrain neurons and examined their regulation by insulin. Cell extracts were fractionated on Mono Q columns, and phosphotransferase activity was measured using myelin basic protein as the substrate. In control neurons, four peaks of MAP kinase activity were resolved, Peaks I, II, and IV were identified by immunoblotting as c-Jun N-terminal kinase (JNK), extracellular signal-related kinase (ERK), and p38 MAP kinase, respectively. Neurons treated with insulin showed a dramatic decrease, 80-90%, in p38 MAP kinase activity without significant changes in the other MAP kinase activities. Insulin decreased the phosphotyrosine content of p38 MAP kinase with maximal effects observed within 5 min. Pretreatment of neurons with sodium orthovanadate blocked the ability of insulin to inhibit the tyrosine phosphorylation and activity of p38 MAP kinase, suggesting that activation of a tyrosine or dual specific phosphatase is necessary for the inhibition of p38 MAP kinase by insulin. Since p38 MAP kinase has been recently implicated in neuronal cell apoptosis, negative regulation of this kinase by insulin may be critical for the neurotrophic actions of insulin.	VET AFFAIRS MED CTR,DENVER,CO 80220	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Heidenreich, KA (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL C236,4200 E 9TH AVE,DENVER,CO 80262, USA.							AIZENMAN Y, 1987, BRAIN RES, V406, P32, DOI 10.1016/0006-8993(87)90766-9; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HEIDENREICH KA, 1989, ENDOCRINOLOGY, V125, P1451, DOI 10.1210/endo-125-3-1451; HEIDENREICH KA, 1988, J NEUROCHEM, V51, P878, DOI 10.1111/j.1471-4159.1988.tb01824.x; HEIDENREICH KA, 1993, J BIOL CHEM, V268, P663; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; MILL JF, 1985, P NATL ACAD SCI USA, V82, P7126, DOI 10.1073/pnas.82.20.7126; PORRAS A, 1992, J BIOL CHEM, V267, P21124; RECIOPINTO E, 1986, J NEUROSCI, V6, P1211; ROBINSON LJ, 1994, ENDOCRINOLOGY, V135, P2568, DOI 10.1210/en.135.6.2568; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; WHITE MF, 1994, J BIOL CHEM, V269, P1; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	22	95	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9891	9894		10.1074/jbc.271.17.9891	http://dx.doi.org/10.1074/jbc.271.17.9891			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626622	hybrid			2022-12-27	WOS:A1996UG25700006
J	Murata, T; Takase, K; Yamato, I; Igarashi, K; Kakinuma, Y				Murata, T; Takase, K; Yamato, I; Igarashi, K; Kakinuma, Y			The ntpJ gene in the Enterococcus hirae ntp operon encodes a component of KtrII potassium transport system functionally independent of vacuolar Na+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; STREPTOCOCCUS-FAECALIS; ESCHERICHIA-COLI; ION-TRANSPORT; ALKALINE PH; BACTERIA; CLONING; SUBUNIT; AMPLIFICATION; ANTIPORTER	The ntpJ gene, the tail end in the vacuolar type Na+-ATPase (ntp) operon of Enterococcus hirae, encodes a putative 49-kDa hydrophobic protein resembling K+ transporter protein in Saccharomyces cerevisiae (Takase, K., Kakinuma, S., Yamato, I., Konishi, K., Igarashi, K., and Kakinuma, Y. (1994) J. Biol. Chem. 269, 11037-11044). Northern blotting experiment revealed that the ntpJ gene was transcribed as a cistron in the ntp operon. We constructed an Enterococcus strain in which the ntpJ gene was disrupted by cassette mutagenesis with erythromycin resistance gene. The growth of this mutant was normal at low pH. However, the mutant did not grow at high pH in K+-limited medium (less than 1 mM), while the wild type strain grew well; the internal K+ concentration of this mutant was as low as 7% of that of the wild type strain, suggesting that the K+ accumulation at high pH was inactivated by disruption of the ntpJ gene. Potassium uptake activity via the KtrII system, which had been proposed as the proton potential-independent, Na+-ATPase-coupled system working at high pH (Kakinuma, Y., and Harold, F. M. (1985) J. Biol. Chem. 260, 2086-2091), was missing in this mutant strain. However this mutant retained as high activities of Na+-ATPase and Na+ pumping as the wild type strain. From these results, we conclude that the NtpJ is a membraneous component of the KtrII K+ uptake system but not a functional subunit of vacuolar Na+-ATPase complex; the interplay between the KtrII system and the Na+-ATPase was discussed.	CHIBA UNIV,FAC PHARMACEUT SCI,INAGE KU,CHIBA 263,JAPAN; SCI UNIV TOKYO,DEPT BIOL SCI & TECHNOL,NODA,CHIBA 278,JAPAN	Chiba University; Tokyo University of Science			Murata, Takeshi/F-6114-2011; Murata, Takeshi/J-6181-2017	Murata, Takeshi/0000-0002-5748-4670; Igarashi, Kazuei/0000-0003-3751-3187				ABRAMS A, 1985, ENZYMES BIOL MEMBR, V4, P177; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BAKKER EP, 1980, J BIOL CHEM, V255, P433; BERTL A, 1995, P NATL ACAD SCI USA, V92, P2701, DOI 10.1073/pnas.92.7.2701; DIMROTH P, 1987, MICROBIOL REV, V51, P320, DOI 10.1128/MMBR.51.3.320-340.1987; DIMROTH P, 1992, ANN NY ACAD SCI, V671, P310, DOI 10.1111/j.1749-6632.1992.tb43805.x; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; HAROLD FM, 1985, ANN NY ACAD SCI, V456, P375, DOI 10.1111/j.1749-6632.1985.tb14888.x; HEEFNER DL, 1982, MOL CELL BIOCHEM, V44, P81; HEEFNER DL, 1982, P NATL ACAD SCI-BIOL, V79, P2798, DOI 10.1073/pnas.79.9.2798; IMAE Y, 1989, J BIOENERG BIOMEMBR, V21, P705, DOI 10.1007/BF00762688; KAKINUMA Y, 1991, FEBS LETT, V292, P64, DOI 10.1016/0014-5793(91)80835-Q; KAKINUMA Y, 1990, FEBS LETT, V261, P135, DOI 10.1016/0014-5793(90)80654-2; KAKINUMA Y, 1990, J BACTERIOL, V172, P1732, DOI 10.1128/jb.172.4.1732-1735.1990; KAKINUMA Y, 1989, J BIOENERG BIOMEMBR, V21, P679, DOI 10.1007/BF00762686; KAKINUMA Y, 1987, J BACTERIOL, V169, P3886, DOI 10.1128/jb.169.9.3886-3890.1987; KAKINUMA Y, 1985, J BIOL CHEM, V260, P2086; KAKINUMA Y, 1995, FEBS LETT, V359, P255, DOI 10.1016/0014-5793(95)00056-F; KAKINUMA Y, 1994, J BIOCHEM-TOKYO, V116, P1302, DOI 10.1093/oxfordjournals.jbchem.a124679; KAKINUMA Y, 1990, FEBS LETT, V271, P97, DOI 10.1016/0014-5793(90)80381-R; KAKINUMA Y, 1990, FEBS LETT, V271, P102, DOI 10.1016/0014-5793(90)80382-S; KAKINUMA Y, 1993, BIOCHEM BIOPH RES CO, V195, P1063, DOI 10.1006/bbrc.1993.2152; KAKINUMA Y, 1988, J BIOL CHEM, V263, P14166; KAKINUMA Y, 1993, ALKALI CATION TRANSP, P277; KOBAYASHI H, 1982, J BACTERIOL, V150, P506, DOI 10.1128/JB.150.2.506-511.1982; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACRINA FL, 1982, GENE, V19, P345, DOI 10.1016/0378-1119(82)90025-7; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; PADAN E, 1994, BBA-BIOENERGETICS, V1185, P129, DOI 10.1016/0005-2728(94)90204-6; PADAN E, 1993, ALKALI CATION TRANSP, P3; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; ROSEN BP, 1986, ANNU REV MICROBIOL, V40, P263, DOI 10.1146/annurev.mi.40.100186.001403; SKULACHEV VP, 1988, MEMBRANE BIOENERGETI, P293; SOLIOZ M, 1990, BIOCHIMIE, V72, P279, DOI 10.1016/0300-9084(90)90084-T; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; TAKASE K, 1993, J BIOL CHEM, V268, P11610; TAKASE K, 1994, J BIOL CHEM, V269, P11037; TOKUDA H, 1985, MICROBIOL SCI, V2, P65; WASER M, 1992, J BIOL CHEM, V267, P5396; Yamato I., 1993, ALKALI CATION TRANSP, P53	43	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10042	10047		10.1074/jbc.271.17.10042	http://dx.doi.org/10.1074/jbc.271.17.10042			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626559	hybrid			2022-12-27	WOS:A1996UG25700031
J	Lee, RJ; Huang, L				Lee, RJ; Huang, L			Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; MAMMALIAN-CELLS; OVARIAN-CANCER; DELIVERY; ENDOCYTOSIS; EXPRESSION; EFFICIENT	We have developed a lipidic gene transfer vector, LP-DII, where DNA was first complexed to polylysine at a ratio of 1:0.75 (w/w) and then entrapped into folate-targeted pH-sensitive anionic liposomes composed of dioleoyl phosphatidylethanolamine (DOPE)/cholesteryl hemisuccinate/folate-polyethlene glycol-DOPE (6:4:0.01 mol/mol) via charge interaction. LPDII transfection of KB cells, a cell line overexpressing the tumor marker folate receptor, was affected by both the lipid to DNA ratio and the lipid composition. At low lipid to DNA ratios (e.g. 4 and 6), LPDII particles were positively charged; transfection and cellular uptake levels were independent of the folate receptor and did not require a pH-sensitive lipid composition. Meanwhile, transfection and uptake of negatively charged LPDII particles, Le. those with high lipid to DNA ratios (e.g. 10 and 12), were folate receptor-dependent and required a pH-sensitive lipid composition. The transfection activity of LPDII was lost when the inverted cone-shaped DOPE was replaced by dioleoyl phosphatidylcholine. LPDII particles with lipid to DNA ratios of 4, 6, 10, and 12 were similar to 20-30 times more active than DNA . 3-beta-[N-(N',N'-dimethylethane)carbamoyl]cholesterol cationic liposome complexes in KB cells and were much less cytotoxic. On the sucrose gradient, LPDII particles had a migration rate in between those of the free DNA and the DNA polylysine complex. An electron micrograph of LPDII showed a structure of spherical particles with a positively stained core enclosed in a lipidic envelope with a mean diameter of 74 +/- 14 nm. This novel gene transfer vector may potentially be useful in gene therapy for tumor-specific delivery.	UNIV PITTSBURGH,SCH MED,DEPT PHARMACOL,LAB DRUG TARGETING,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CANCER INSTITUTE [P01CA059327] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050256] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044935] Funding Source: NIH RePORTER; NCI NIH HHS [CA59327] Funding Source: Medline; NHLBI NIH HHS [HL50256] Funding Source: Medline; NIDDK NIH HHS [DK44935] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAMPBELL IG, 1991, CANCER RES, V51, P5329; CONEY LR, 1991, CANCER RES, V51, P6125; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ENGELHARDT JF, 1994, P NATL ACAD SCI USA, V91, P6196, DOI 10.1073/pnas.91.13.6196; FELGNER PL, 1991, NATURE, V349, P351, DOI 10.1038/349351a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GARINCHESA P, 1993, AM J PATHOL, V142, P557; GOTTSCHALK S, 1994, GENE THER, V1, P185; KANE MA, 1986, J BIOL CHEM, V261, P5625; KOTIN RM, 1994, HUM GENE THER, V5, P793, DOI 10.1089/hum.1994.5.7-793; LEAMON CP, 1991, P NATL ACAD SCI USA, V88, P5572, DOI 10.1073/pnas.88.13.5572; LEE RJ, 1994, J BIOL CHEM, V269, P3198; LEE RJ, 1995, BBA-BIOMEMBRANES, V1233, P134, DOI 10.1016/0005-2736(94)00235-H; MATHIAS CJ, 1996, IN PRESS J NUCL MED; MILLER AD, 1990, HUM GENE THER, V1, P5, DOI 10.1089/hum.1990.1.1-5; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; PLANK C, 1992, BIOCONJUGATE CHEM, V3, P533, DOI 10.1021/bc00018a012; Prensky W, 1976, Methods Cell Biol, V13, P121, DOI 10.1016/S0091-679X(08)61800-2; REMY JS, 1995, P NATL ACAD SCI USA, V92, P1744, DOI 10.1073/pnas.92.5.1744; Sambrook J., 2002, MOL CLONING LAB MANU; WANG CY, 1987, P NATL ACAD SCI USA, V84, P7851, DOI 10.1073/pnas.84.22.7851; WANG S, 1995, P NATL ACAD SCI USA, V92, P3318, DOI 10.1073/pnas.92.8.3318; WU GY, 1987, J BIOL CHEM, V262, P4429; Zhou X, 1992, J LIPOSOME RES, V2, P125	27	354	399	1	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8481	8487		10.1074/jbc.271.14.8481	http://dx.doi.org/10.1074/jbc.271.14.8481			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626549	hybrid			2022-12-27	WOS:A1996UD60000089
J	Cougnon, M; Planelles, G; Crowson, MS; Shull, GE; Rossier, BC; Jaisser, F				Cougnon, M; Planelles, G; Crowson, MS; Shull, GE; Rossier, BC; Jaisser, F			The rat distal colon P-ATPase alpha subunit encodes a ouabain-sensitive H+,K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-K+-ATPASE; FUNCTIONAL EXPRESSION; GASTRIC H+,K+-ATPASE; POTASSIUM-DEPLETION; BETA-SUBUNIT; COLLECTING DUCT; KIDNEY; CELLS; NA,K-ATPASE; BINDING	The functional properties and the pharmacological profile of the recently cloned cDNA colonic P-ATPase alpha subunit (Crowson, M. S., and Shull, G. E. (1992) J. Biol. Chem. 267, 13740-13748) were investigated by using the Xenopus oocyte expression system, Xenopus oocytes were injected with alpha subunit cRNAs from Bufo marinus bladder or rat distal colon and/or with beta subunit cRNA from B. marinus bladder, Two days after injection, K+ uptake was measured by using Rb-86(+) as a K+ surrogate, and pH measurements were performed by means of ion-selective microelectrodes. Co-injection of alpha and beta subunit cRNAs lead to a large increase in Rb-86(+) uptake, an intracellular alkalinization, and an extracellular medium acidification, as compared to alpha or beta injection alone, These results indicate that the colonic P-ATPase alpha subunit, like the bladder alpha subunit, acts as a functional H+,K+-ATPase, and that co-expression of alpha and beta subunits is required for the function, External K+ activation of the Rb-86(+) uptake had a K-1/2 similar to 440 mu M for the bladder isoform (consistent with the previously reported value (Jaisser, F., Horisberger, J. D., Geering, K., and Rossier, B. C. (1933) J. Cell Biol. 123, 1421-1431)) and a K-1/2 similar to 730 mu M for the colonic isoform, Sch28080 was ineffective to reduce Rb-86(+) uptake whereas ouabain inhibited the activity expressed from rat colon alpha subunit with a K-i of 970 mu M when measured at the V-max of the enzyme, We conclude that, when expressed in Xenopus oocytes, the rat colon P-ATPase alpha subunit encodes a ouabain-sensitive H+,K+-ATPase.	UNIV PARIS 05,FAC MED NECKER,INSERM U323,F-75015 PARIS,FRANCE; UNIV CINCINNATI,COLL MED,CINCINNATI,OH 45267; INST PHARMACOL & TOXICOL,CH-1005 LAUSANNE,SWITZERLAND; INST CURIE,UMR144,F-75005 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Cincinnati; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite			Planelles, Gabrielle/F-9603-2013	Planelles, Gabrielle/0000-0002-7314-8837				AGARWAL R, 1994, GASTROENTEROLOGY, V107, P548, DOI 10.1016/0016-5085(94)90184-8; ANAGNOSTOPOULOS T, 1987, J PHYSIOL-LONDON, V393, P73, DOI 10.1113/jphysiol.1987.sp016811; BLANCO G, 1995, BIOCHEMISTRY-US, V34, P319, DOI 10.1021/bi00001a039; BLANCO G, 1994, J BIOL CHEM, V269, P23420; BLANCO G, 1993, P NATL ACAD SCI USA, V90, P1824, DOI 10.1073/pnas.90.5.1824; CALLAGHAN JM, 1995, AM J PHYSIOL-RENAL, V268, pF363, DOI 10.1152/ajprenal.1995.268.3.F363; CHEVAL L, 1991, AM J PHYSIOL, V260, pF800, DOI 10.1152/ajprenal.1991.260.6.F800; CHOW DC, 1993, AM J PHYSIOL, V265, pC1562, DOI 10.1152/ajpcell.1993.265.6.C1562; CHOW DC, 1992, AM J PHYSIOL, V263, pC39, DOI 10.1152/ajpcell.1992.263.1.C39; CORTAS N, 1971, BIOCHIM BIOPHYS ACTA, V249, P181, DOI 10.1016/0005-2736(71)90095-2; CROWSON MS, 1992, J BIOL CHEM, V267, P13740; DELCASTILLO JR, 1991, AM J PHYSIOL, V261, pG1005, DOI 10.1152/ajpgi.1991.261.6.G1005; DETOMASO AW, 1994, J CELL BIOL, V127, P55, DOI 10.1083/jcb.127.1.55; DOUCET A, 1987, AM J PHYSIOL, V253, pF418, DOI 10.1152/ajprenal.1987.253.3.F418; DUARTE CG, 1971, AM J PHYSIOL, V221, P632, DOI 10.1152/ajplegacy.1971.221.2.632; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; FORBUSH B, 1983, CURR TOP MEMBR TRANS, V19, P167; GIFFORD JD, 1992, AM J PHYSIOL, V262, pF692, DOI 10.1152/ajprenal.1992.262.4.F692; HAYASHI M, 1987, AM J PHYSIOL, V252, pF447, DOI 10.1152/ajprenal.1987.252.3.F447; HAYASHI M, 1987, AM J PHYSIOL, V252, pF437, DOI 10.1152/ajprenal.1987.252.3.F437; HORISBERGER JD, 1991, P NATL ACAD SCI USA, V88, P8397, DOI 10.1073/pnas.88.19.8397; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAISSER F, 1993, AM J PHYSIOL, V265, pC1080, DOI 10.1152/ajpcell.1993.265.4.C1080; JAISSER F, 1993, PFLUG ARCH EUR J PHY, V425, P446, DOI 10.1007/BF00374871; JAISSER F, 1993, J CELL BIOL, V123, P1421, DOI 10.1083/jcb.123.6.1421; JAISSER F, 1996, IN PRESS AM J PHYSL; KLAASSEN CHW, 1993, FEBS LETT, V329, P277, DOI 10.1016/0014-5793(93)80237-O; KRAUT JA, 1995, AM J PHYSIOL-RENAL, V268, pF581, DOI 10.1152/ajprenal.1995.268.4.F581; MARXER A, 1989, J CELL BIOL, V109, P1057, DOI 10.1083/jcb.109.3.1057; MATTHEWS PM, 1995, AM J PHYSIOL, V268, pC1207; RABON EC, 1990, ANNU REV PHYSIOL, V52, P321; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; STRIEDER N, 1974, PFLUG ARCH EUR J PHY, V349, P91, DOI 10.1007/BF00586621; SWEIRY JH, 1990, J PHYSIOL-LONDON, V423, P155, DOI 10.1113/jphysiol.1990.sp018016; TABUCHI Y, 1992, JPN J PHYSIOL, V42, P577, DOI 10.2170/jjphysiol.42.577; Wright FS, 1992, KIDNEY PHYSL PATHOPH, P2209; ZHOU XM, 1992, AM J PHYSIOL, V263, pF43, DOI 10.1152/ajprenal.1992.263.1.F43	38	104	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7277	7280		10.1074/jbc.271.13.7277	http://dx.doi.org/10.1074/jbc.271.13.7277			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631741	hybrid			2022-12-27	WOS:A1996UC77400009
J	Cunillera, N; Arro, M; Delourme, D; Karst, F; Boronat, A; Ferrer, A				Cunillera, N; Arro, M; Delourme, D; Karst, F; Boronat, A; Ferrer, A			Arabidopsis thaliana contains two differentially expressed farnesyl-diphosphate synthase genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; COENZYME-A REDUCTASE; SACCHAROMYCES-CEREVISIAE; ISOPRENOID BIOSYNTHESIS; COORDINATE REGULATION; CONSERVED ASPARTATE; MESSENGER-RNAS; PLANTS; SEQUENCE; PRENYLTRANSFERASE	The enzyme farnesyl-diphosphate synthase (FPS; EC 2.5.1.1/EC 2.5.1.10) catalyzes the synthesis of farnesyl diphosphate (FPP) from isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP). This reaction is considered to be a rate-limiting step in isoprenoid biosynthesis. Southern blot analysis indicates that Arabidopsis thaliana contains at least 2 genes (FPS1 and FPS2) encoding FPS. The FPS1 and FPS2 genes have been cloned and characterized. The two genes have a very similar organization with regard to intron positions and exon sizes and share a high level of sequence similarity, not only in the coding region but also in the intronic sequences. Northern blot analysis showed that FPS1 and FPS2 have a different pattern of expression. FPS1 mRNA accumulates preferentially in roots and inflorescences, whereas FPS2 mRNA is predominantly expressed in inflorescences. The cDNA corresponding to the FPS1 gene was isolated by functional complementation of a mutant yeast strain deffective in FPS activity (Delourme, D., Lacroute, F., and Karst, F. (1994) Plant Mol. Biol. 26, 1867-1873). By using a reverse transcription-polymerase chain reaction strategy we have cloned the cDNA corresponding to the FPS2 gene. Analysis of the FPS2 cDNA sequence revealed an open reading frame encoding a protein of 342 amino acid residues with a predicted molecular mass of 39,825 Da. FPS1 and FPS2 isoforms share an overall amino acid identity of 90.6%. Arabidopsis FPS2 was able to rescue the lethal phenotype of an ERG20-disrupted yeast strain. We demonstrate that FPS2 catalyzes the two successive condensations of IPP with both DMAPP and geranyl diphosphate leading to FPP. The significance of the occurrence of different FPS isoforms in plants is discussed in the context of the complex organization of the plant isoprenoid pathway.	UNIV BARCELONA,FAC FARM,UNITAT BIOQUIM,E-08028 BARCELONA,SPAIN; UNIV POITIERS,INST BIOL MOL & INGN GENET,LAB GENET PHYSIOL & MOL,F-86022 POITIERS,FRANCE; UNIV BARCELONA,FAC QUIM,DEPT BIOQUIM & BIOL MOLEC,E-08028 BARCELONA,SPAIN	University of Barcelona; Universite de Poitiers; University of Barcelona			Ferrer, Albert/AAI-4595-2021	Ferrer, Albert/0000-0002-0741-2388; ARRO PLANS, MONTSERRAT/0000-0002-7118-7402				ATTUCCI S, 1995, ARCH BIOCHEM BIOPHYS, V321, P493, DOI 10.1006/abbi.1995.1422; ATTUCCI S, 1995, PLANT PHYSIOL, V108, P835, DOI 10.1104/pp.108.2.835; Bach T.J., 1991, PHYSL BIOCH STEROLS, P29; BACH TJ, 1987, PLANT PHYSIOL BIOCH, V25, P163; BACH TJ, 1995, LIPIDS, V30, P191, DOI 10.1007/BF02537822; BACH TJ, 1991, LIPIDS, V26, P637, DOI 10.1007/BF02536429; BACK K, 1995, J BIOL CHEM, V270, P7375, DOI 10.1074/jbc.270.13.7375; BARTLEY GE, 1995, PLANT CELL, V7, P1027, DOI 10.1105/tpc.7.7.1027; BHATTACHARYYA MK, 1995, PLANT MOL BIOL, V28, P1, DOI 10.1007/BF00042033; BLANCHARD L, 1993, GENE, V125, P185, DOI 10.1016/0378-1119(93)90326-X; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREATHNACH R, 1981, ANN REV BIOCH, V50, P19176; CAELLES C, 1989, PLANT MOL BIOL, V13, P627, DOI 10.1007/BF00016018; CASEY PJ, 1992, J LIPID RES, V33, P1731; CHAMBON C, 1990, CURR GENET, V18, P41, DOI 10.1007/BF00321113; CHAPPELL J, 1995, PLANT PHYSIOL, V107, P1, DOI 10.1145/224057.224059; CHAPPELL J, 1995, ANNU REV PLANT PHYS, V46, P521, DOI 10.1146/annurev.pp.46.060195.002513; CHEN AJ, 1994, PROTEIN SCI, V3, P600; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DEAN C, 1985, EMBO J, V5, P3055; Dellaporta S.L., 1984, MOL BIOL PLANTS LABO, P36; DELOURME D, 1994, PLANT MOL BIOL, V26, P1867, DOI 10.1007/BF00019499; ENJUTO M, 1994, P NATL ACAD SCI USA, V91, P927, DOI 10.1073/pnas.91.3.927; ERICSSON J, 1992, J BIOL CHEM, V267, P18707; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GERLACH WL, 1979, NUCLEIC ACIDS RES, V7, P1869, DOI 10.1093/nar/7.7.1869; GERSHENZON J, 1990, RECENT ADV PHYTOCHEM, V24, P99; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRAY JC, 1987, ADV BOT RES, V14, P25; HUGUENEY P, 1990, FEBS LETT, V273, P235, DOI 10.1016/0014-5793(90)81093-4; JOLY A, 1993, J BIOL CHEM, V268, P26983; KLEINIG H, 1989, ANNU REV PLANT PHYS, V40, P39, DOI 10.1146/annurev.pp.40.060189.000351; KOIKETAKESHITA A, 1995, J BIOL CHEM, V270, P18396, DOI 10.1074/jbc.270.31.18396; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; MINET M, 1992, PLANT J, V2, P417; MUEHLBACHER M, 1988, BIOCHEMISTRY-US, V27, P7315, DOI 10.1021/bi00419a021; POULTER CD, 1981, BIOSYNTHESIS ISOPREN, P161; ROSSER DSE, 1989, J BIOL CHEM, V264, P12653; RUNQUIST M, 1994, J BIOL CHEM, V269, P5804; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Somerville C.R., 1982, METHODS CHLOROPLAST, P129; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; STERMER BA, 1994, J LIPID RES, V35, P1133; SULLIVAN ML, 1993, PLANT MOL BIOL, V23, P1091, DOI 10.1007/BF00042344; von Heijne G, 1992, Genet Eng (N Y), V14, P1; WEISSENBORN DL, 1995, PHYSIOL PLANTARUM, V93, P393, DOI 10.1111/j.1399-3054.1995.tb02244.x; WILKIN DJ, 1990, J BIOL CHEM, V265, P4607	51	138	162	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7774	7780		10.1074/jbc.271.13.7774	http://dx.doi.org/10.1074/jbc.271.13.7774			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631820	hybrid			2022-12-27	WOS:A1996UC77400088
J	deKruif, J; Logtenberg, T				deKruif, J; Logtenberg, T			Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FRAGMENTS; MINIANTIBODIES; AVIDITY	This report describes the construction of leucine zipper-based dimerization cassettes for the conversion of recombinant monomeric scFv antibody fragments to bivalent and bispecific dimers. A truncated murine IgG3 hinge region and a Fos or Jun leucine zipper were cloned into four scFv fragments previously isolated from a synthetic antibody phage display library, Cysteine residues flanking the zipper region were introduced to covalently link dimerized scFv fragments. The secreted fusion proteins were shown to spontaneously and efficiently form stable Fos . Fos or Jun . Jun homodimers in the Escherichia coli periplasm at levels comparable to their monovalent counterparts. The bivalent (scFv)(2) fragments performed well in enzyme-linked immunosorbent assay, flowcytometric, and immunohistochemical analysis. Fos and Jun homodimer (scFv)(2) antibodies with different specificities could be reduced, reshuffled, and reoxidized to form preparations of functional bispecific (scFv)(2) Fos . Jun heterodimers. These Fos and Jun fusion protein cassettes provide a universal basis for the construction of dimeric scFv antibodies with enhanced avidity or dual specificity.			deKruif, J (corresponding author), UNIV UTRECHT, DEPT IMMUNOL, HP F03821, POB 85500, 3508 GA UTRECHT, NETHERLANDS.							BURTON DR, 1994, ADV IMMUNOL, V57, P189; CRAMERI R, 1993, GENE, V137, P69, DOI 10.1016/0378-1119(93)90253-Y; DEKRUIF J, 1995, P NATL ACAD SCI USA, V92, P3938, DOI 10.1073/pnas.92.9.3938; DERKUIF J, 1995, J MOL BIOL, V248, P97; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; Holliger Philipp, 1993, Current Opinion in Biotechnology, V4, P446, DOI 10.1016/0958-1669(93)90010-T; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HOOGENBOOM HR, 1992, J MOL BIOL, V227, P381, DOI 10.1016/0022-2836(92)90894-P; HUSTON JS, 1991, METHOD ENZYMOL, V203, P46; KOSTELNY SA, 1992, J IMMUNOL, V148, P1547; KURUCZ I, 1995, J IMMUNOL, V154, P4576; MACK M, 1995, P NATL ACAD SCI USA, V92, P7021, DOI 10.1073/pnas.92.15.7021; MALLENDER WD, 1994, J BIOL CHEM, V269, P199; MEERMAN HJ, 1994, BIO-TECHNOL, V12, P1107, DOI 10.1038/nbt1194-1107; NERI D, 1995, J MOL BIOL, V246, P367, DOI 10.1006/jmbi.1994.0091; NEUBERGER MS, 1984, NATURE, V312, P604, DOI 10.1038/312604a0; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PACK P, 1993, BIO-TECHNOL, V11, P1271; PACK P, 1995, J MOL BIOL, V246, P28, DOI 10.1006/jmbi.1994.0062; PACK P, 1992, BIOCHEMISTRY-US, V31, P1579, DOI 10.1021/bi00121a001; PLUCKTHUN A, 1992, IMMUNOL REV, V130, P151, DOI 10.1111/j.1600-065X.1992.tb01525.x; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245	23	75	154	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7630	7634		10.1074/jbc.271.13.7630	http://dx.doi.org/10.1074/jbc.271.13.7630			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631798	hybrid			2022-12-27	WOS:A1996UC77400066
J	Dvir, A; Garrett, KP; Chalut, C; Egly, JM; Conaway, JW; Conaway, RC				Dvir, A; Garrett, KP; Chalut, C; Egly, JM; Conaway, JW; Conaway, RC			A role for ATP and TFIIH in activation of the RNA polymerase II preinitiation complex prior to transcription initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL-DOMAIN KINASE; MAJOR LATE PROMOTER; FACTOR-DELTA; RAT-LIVER; ABORTIVE INITIATION; RUNOFF TRANSCRIPTS; FACTOR-EPSILON; REQUIREMENT; INVITRO; MECHANISM	A requirement for an ATP cofactor in synthesis of the first 8-10 bonds of promoter-specific transcripts by RNA polymerase II is well established. Whether ATP is required for synthesis of the first phosphodiester bond or at a slightly later stage in synthesis of nascent transcripts, however, remains controversial. Goodrich and Tjian (Goodrich, J. A., and Tjian, R, (1994) Cell 77, 145-156) recently proposed that synthesis of the first phosphodiester bond of promoter-specific transcripts by RNA polymerase II is independent of ATP and general transcription factors TFIIE and TFIIH. Here we investigate this model, Taken together, our findings indicate that ATP, TFIIE, and TFIIH can have a profound effect on the efficiency of transcription initiation, First, we observe that synthesis of the first phosphodiester bond of transcripts initiated at the adenovirus 2 major late promoter depends strongly on ATP, TFIIE, and TFIIH in a transcription system reconstituted with RNA polymerase II, TFIIH, and recombinant TBP, TFIIB, TFIIE, and TFIIF. Second, we demonstrate that, in this enzyme system, ATP-dependent activation of transcription initiation can occur immediately prior to synthesis of the first phosphodiester bond of nascent transcripts, Finally, we demonstrate that the activated initiation complex is unstable and decays rapidly to an inactive state in the presence of the inhibitor ATP gamma S (adenosine 5'-O-(thio)triphosphate), even during reiterative synthesis of abortive transcripts.	OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,OKLAHOMA CITY,OK 73104; CNRS,INSERM U184,F-67404 ILLKIRCH GRAFFENS,FRANCE	Oklahoma Medical Research Foundation; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)				Chalut, Christian/0000-0002-4849-1369; Conaway, Joan/0000-0002-2786-0663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041628, R37GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; ERNST H, 1983, MOL CELL BIOL, V3, P2172, DOI 10.1128/MCB.3.12.2172; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FLORES O, 1992, J BIOL CHEM, V267, P2786; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; JACOB GA, 1994, J BIOL CHEM, V269, P3655; JACOB GA, 1991, J BIOL CHEM, V266, P22537; JIANG Y, 1995, J BIOL CHEM, V270, P27332, DOI 10.1074/jbc.270.45.27332; JIANG Y, 1993, J BIOL CHEM, V268, P6535; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LUSE DS, 1987, J BIOL CHEM, V262, P14990; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; PARVIN JD, 1994, J BIOL CHEM, V269, P18414; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON MG, 1991, NATURE, V354, P369; SAMUELS M, 1984, J BIOL CHEM, V259, P2517; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; TAN SY, 1994, BIOTECHNIQUES, V16, P824; TANTIN D, 1994, J BIOL CHEM, V269, P17397; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361	35	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7245	7248		10.1074/jbc.271.13.7245	http://dx.doi.org/10.1074/jbc.271.13.7245			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631733				2022-12-27	WOS:A1996UC77400001
J	Fujita, Y; Sasaki, T; Fukui, K; Kotani, H; Kimura, T; Hata, Y; Sudhof, TC; Scheller, RH; Takai, Y				Fujita, Y; Sasaki, T; Fukui, K; Kotani, H; Kimura, T; Hata, Y; Sudhof, TC; Scheller, RH; Takai, Y			Phosphorylation of Munc-18/n-Sec1/rbSec1 by protein kinase C - Its implication in regulating the interaction of Munc-18/n-Sec1/rbSec1 with syntaxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; MAST-CELLS; RAT-BRAIN; CALCIUM; ACTIVATION; PURIFICATION; EXOCYTOSIS; CHROMATOGRAPHY; SYNAPTOTAGMIN; PHOSPHOLIPIDS	Munc-18/n-Sec1/rbSec1 interacts with syntaxin and this interaction inhibits the association of vesicle-associated membrane protein (VAMP)/synaptobrevin and synaptosomal-associated protein of 25 kDa (SNAP-25) with syntaxin. Syntaxin, VAMP, and SNAP-25 serve as soluble N-ethylmaleimide-sensitive fusion protein attachment protein (SNAP) receptors essential for docking and/or fusion of synaptic vesicles with the presynaptic plasma membrane. Genetic analyses in yeast, Caenorhabditis elegans, and Drosophila suggest that Munc-18 is essential for vesicle transport. On the other hand, protein kinase C (PKC) stimulates Ca2+-dependent exocytosis in various types of secretory cells. However, the modes of action of Munc-18 and PKC in vesicle transport have not been clarified. Here, we show that recombinant Munc-18 is phosphorylated by conventional PKC in a Ca2+- and phospholipid-dependent manner in a cell-free system. About 1 mol of phosphate is maximally incorporated into 1 mol of Munc-18. The major phosphorylation sites are Ser(306) and Ser(313). The Munc-18 complexed with syntaxin is not phosphorylated. The PKC-catalyzed phosphorylation of Munc-18 inhibits its interaction with syntaxin. These results suggest that the PKC-catalyzed phosphorylation of Munc-18 plays an important role in regulating the interaction of Munc-18 with syntaxin and thereby the docking and/or the fusion of synaptic vesicles with the presynaptic plasma membrane.	OSAKA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, SUITA, OSAKA 565, JAPAN; NATL INST PHYSIOL SCI, DEPT CELL PHYSIOL, OKAZAKI, AICHI 444, JAPAN; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DEPT MOLEC GENET, DALLAS, TX 75235 USA; STANFORD UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT CELLULAR & MOLEC PHYSIOL, STANFORD, CA 94305 USA	Osaka University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; Stanford University			Fujita, Yasuyuki/A-4324-2012					AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; AKAGAWA K, 1986, BRAIN RES, V383, P110, DOI 10.1016/0006-8993(86)90012-0; BAJJALIEH SM, 1995, J BIOL CHEM, V270, P1971, DOI 10.1074/jbc.270.5.1971; BECHTEL PJ, 1977, J BIOL CHEM, V252, P2691; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGOYNE RD, 1988, FEBS LETT, V238, P151, DOI 10.1016/0014-5793(88)80246-1; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; HUANG KP, 1988, J BIOL CHEM, V263, P14839; INOUE A, 1992, J BIOL CHEM, V267, P10613; KAIBUCHI K, 1983, J BIOL CHEM, V258, P6701; KATAKAMI Y, 1984, BIOCHEM BIOPH RES CO, V121, P573, DOI 10.1016/0006-291X(84)90220-1; KATO M, 1994, BIOCHEM BIOPH RES CO, V205, P1776, DOI 10.1006/bbrc.1994.2875; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIKKAWA U, 1986, BIOCHEM BIOPH RES CO, V135, P636, DOI 10.1016/0006-291X(86)90040-9; KNIGHT DE, 1983, FEBS LETT, V160, P98, DOI 10.1016/0014-5793(83)80944-2; KOOPMANN WR, 1990, BIOCHEM J, V265, P365, DOI 10.1042/bj2650365; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PELHAM HRB, 1993, NATURE, V364, P582, DOI 10.1038/364582a0; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; POCOTTE SL, 1985, P NATL ACAD SCI USA, V82, P930, DOI 10.1073/pnas.82.3.930; ROTHMAN JE, 1994, NATURE, V372, P56; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; SEKIGUCHI K, 1988, J BIOCHEM-TOKYO, V103, P759, DOI 10.1093/oxfordjournals.jbchem.a122343; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TAKAI Y, 1984, ADV CYCLIC NUCL PROT, V18, P119; TAKAI Y, 1977, J BIOL CHEM, V252, P7603; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TAKAI Y, 1979, BIOCHEM BIOPH RES CO, V91, P1218, DOI 10.1016/0006-291X(79)91197-5; YAMAUCHI T, 1983, EUR J BIOCHEM, V132, P15, DOI 10.1111/j.1432-1033.1983.tb07319.x; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	41	224	230	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7265	7268		10.1074/jbc.271.13.7265	http://dx.doi.org/10.1074/jbc.271.13.7265			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631738	hybrid			2022-12-27	WOS:A1996UC77400006
J	Ma, JJ; Tasch, JE; Tao, T; Zhao, JY; Xie, JX; Drumm, ML; Davis, PB				Ma, JJ; Tasch, JE; Tao, T; Zhao, JY; Xie, JX; Drumm, ML; Davis, PB			Phosphorylation-dependent block of cystic fibrosis transmembrane conductance regulator chloride channel by exogenous R domain protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CL CHANNEL; CFTR; GENE; INACTIVATION; CELLS	The cystic fibrosis transmembrane conductance regulator (CFTR) constitutes a linear conductance chloride channel, which is regulated by cAMP-dependent protein kinase phosphorylation at multiple sites located in the intracellular regulatory (R) domain, Studies in a lipid bilayer system, reported here, provide evidence for the control of CFTR chloride channel by its R domain, The exogenous R domain protein (encoded by exon 13 plus 85 base pairs of exon 14) interacted specifically with the CFTR molecule and inhibited the chloride conductance in a phosphorylation-dependent manner. Only the unphosphorylated R domain protein blocked the CFTR channel, Such functional interaction suggests that the putative gating particle of the CFTR chloride channel resides in the R domain.	CASE WESTERN RESERVE UNIV,DEPT PEDIAT,SCH MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOPHYS,SCH MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT MOLEC BIOL & MICROBIOL,SCH MED,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045965, P30DK027651] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK45965, R01DK/HL49003, P30DK27651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ARMSTRONG CM, 1973, J GEN PHYSIOL, V62, P375, DOI 10.1085/jgp.62.4.375; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DULHANTY AM, 1994, BIOCHEMISTRY-US, V33, P4072, DOI 10.1021/bi00179a036; GABRIEL SE, 1992, AM J PHYSIOL, V263, pC708, DOI 10.1152/ajpcell.1992.263.3.C708; GADSBY DC, 1994, TRENDS BIOCHEM SCI, V19, P513, DOI 10.1016/0968-0004(94)90141-4; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIORDAN JR, 1989, SCIENCE, V245, P1066; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; Tao T, 1996, BIOPHYS J, V70, P743, DOI 10.1016/S0006-3495(96)79614-5; TILLY BC, 1992, J BIOL CHEM, V267, P9470; XIE JX, 1995, J BIOL CHEM, V270, P28084; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	20	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7351	7356		10.1074/jbc.271.13.7351	http://dx.doi.org/10.1074/jbc.271.13.7351			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631756	hybrid			2022-12-27	WOS:A1996UC77400024
J	Bodovitz, S; Klein, WL				Bodovitz, S; Klein, WL			Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E POLYMORPHISM; ALZHEIMERS-DISEASE; PARENTERAL USE; SEQUENCE; CELLS; HYDROXYPROPYLCYCLODEXTRINS; PHOSPHORYLATION; IDENTIFICATION; MEMBRANES; TRANSPORT	Amyloid precursor protein (APP) and cholesterol metabolism are genetically linked to Alzheimer's disease, the latter through apolipoprotein E, a lipid and cholesterol transport protein. We have examined the hypothesis that the processing of APP is disrupted by elevated cholesterol, which is known to modulate the activity of several transmembrane proteins. In the current study, cholesterol, solubilized by methyl-beta-cyclodextrin or ethanol, was added to the culture media of APP 751 stably transfected HEK 293 cells. Radiolabeled APP and APP(sol) (the soluble N-terminal derivative following alpha-secretase cleavage) were precipitated from lysates and conditioned media of stably transfected HEK 293 cells; the relative levels were determined by quantitative densitometry following separation by SDS-polyacrylamide gel electrophoresis. The data show that cholesterol, solubilized by methyl-beta-cyclodextrin, greatly reduced the levels of APP(sol). Low doses of ethanol-solubilized cholesterol similarly caused a dramatic reduction of APP(sol). By contrast, levels of APP holoprotein remained the same or increased. The large decrease seen in APP(sol) production was not due to nonspecific inhibition of secretion because several secreted proteins increased in level. Cholesterol, which impedes membrane fluidity, may lower APP(sol) production by impeding the interaction of the substrate with its protease(s). If APP(sol) were to function trophically, as suggested by other studies, the current conclusion suggests that changes in cellular cholesterol levels in Alzheimer's disease could contribute to neuronal degeneration by decreasing the production of APP(sol).	NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,EVANSTON,IL 60208	Northwestern University					NIA NIH HHS [AG10481] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG010481] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JP, 1992, J NEUROCHEM, V59, P2328; ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; ARAKI W, 1991, BIOCHEM BIOPH RES CO, V181, P265, DOI 10.1016/S0006-291X(05)81412-3; BODOVITZ S, 1995, J NEUROCHEM, V64, P307; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CRAIDO M, 1982, BIOCHEMISTRY-US, V21, P3622; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; DECAPRIO J, 1992, J LIPID RES, V33, P441; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FERREIRA A, 1993, J NEUROSCI, V13, P3112; FONG TM, 1986, BIOCHEMISTRY-US, V25, P830, DOI 10.1021/bi00352a015; GILLESPIE SL, 1992, BIOCHEM BIOPH RES CO, V187, P1285, DOI 10.1016/0006-291X(92)90442-N; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GREENBERG SM, 1994, P NATL ACAD SCI USA, V91, P7104, DOI 10.1073/pnas.91.15.7104; GRUNZE M, 1980, BIOCHIM BIOPHYS ACTA, V600, P860, DOI 10.1016/0005-2736(80)90489-7; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HERON DS, 1980, P NATL ACAD SCI-BIOL, V77, P7463, DOI 10.1073/pnas.77.12.7463; IRIE T, 1992, J PHARM SCI-US, V81, P524, DOI 10.1002/jps.2600810610; IRIE T, 1992, J PHARM SCI, V81, P521, DOI 10.1002/jps.2600810609; JAFFE AB, 1994, J BIOL CHEM, V269, P13065; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LASA M, 1991, ENDOCRINOLOGY, V132, P1701; LEBLANC AC, 1992, J NEUROSCI RES, V31, P635, DOI 10.1002/jnr.490310407; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MITCHELL DC, 1990, BIOCHEMISTRY-US, V29, P9143, DOI 10.1021/bi00491a007; NINOMIYA H, 1993, J CELL BIOL, V121, P879, DOI 10.1083/jcb.121.4.879; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; NITSCH RM, 1993, P NATL ACAD SCI USA, V90, P5191, DOI 10.1073/pnas.90.11.5191; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; PIRTILIA T, 1995, J NEUROL SCI, V127, P90; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUBERT D, 1989, BIOCHEM BIOPH RES CO, V162, P83, DOI 10.1016/0006-291X(89)91965-7; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SING CF, 1985, AM J HUM GENET, V37, P268; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SPARKS DL, 1993, J NEUROPATH EXP NEUR, V52, P135, DOI 10.1097/00005072-199303000-00006; SPARKS DL, 1990, NEUROBIOL AGING, V11, P601, DOI 10.1016/0197-4580(90)90024-T; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; USAMI M, 1993, J NEUROCHEM, V61, P239, DOI 10.1111/j.1471-4159.1993.tb03560.x; UTERMANN G, 1994, CURR BIOL, V4, P362, DOI 10.1016/S0960-9822(00)00081-6; WANG R, 1991, J BIOL CHEM, V266, P16960; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; YEAGLE PL, 1991, BIOCHIMIE, V73, P1303, DOI 10.1016/0300-9084(91)90093-G	50	398	414	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4436	4440						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626795				2022-12-27	WOS:A1996TW96000073
J	Kuang, YN; Wu, YP; Jiang, HP; Wu, DQ				Kuang, YN; Wu, YP; Jiang, HP; Wu, DQ			Selective G protein coupling by C-C chemokine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; PHOSPHOLIPASE-C; ALPHA-SUBUNITS; FUNCTIONAL EXPRESSION; SIGNAL-TRANSDUCTION; COMPLEMENTARY-DNA; BETA-GAMMA; ACTIVATION; FAMILY; CELLS	The C-C chemokines are major mediators of chemotaxis of monocytes and some T cells in inflammatory reactions. The pathways by which the C-C chemokine receptors activate phospholipase C (PLC) were investigated in cotransfected COS-7 cells. The C-C chemokine receptor-1 (CKR-1), the MCP-1 receptor-A (MCP-1Ra), and MCP-1Rb can reconstitute ligand-induced accumulation of inositol phosphates with PLC beta 2 in a pertussis toxin-sensitive manner, presumably through G beta gamma released from the G(i) proteins. However, these three receptors demonstrated different specificity in coupling to the alpha subunits of the G(q) class. While none of the receptors can couple to G alpha q/11, MCP-1Rb can couple to both G alpha 14 and G alpha 16, but its splicing variant, MCP-1Rb, cannot. Since MCP-1Ra and -b differ only in their C-terminal intracellular domains, the C-terminal ends of MCP-1Rs determine G protein coupling specificity. CKR-1 can couple to G alpha 14 but not to G alpha 16, suggesting some of the C-C chemokine receptors, unlike the C-X-C chemokine receptors, discriminate against G alpha 16, a hematopoietic-specific G alpha subunit. The intriguing specificity in coupling of the G(q) class of G proteins implies that the chemokines may be involved in some distinct functions in vivo. The commonality of the chemokine receptors in coupling to the G(i)-G beta gamma-PLC beta 2 pathway provides a potential target for developing broad spectrum anti-inflammatory drugs.	UNIV ROCHESTER, DEPT PHARMACOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, DEPT PHYSIOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, DEPT BIOCHEM, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, DEPT ONCOL, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester					NIGMS NIH HHS [GM53162429] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; FRANCI C, 1995, J IMMUNOL, V154, P6511; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; JIANG HP, 1994, J BIOL CHEM, V269, P7593; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KRIZ R, 1990, CIBA F SYMP, V150, P112; LEE CH, 1992, J BIOL CHEM, V267, P16044; MURPHY PM, 1987, FEBS LETT, V221, P81, DOI 10.1016/0014-5793(87)80356-3; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SCHALL TJ, 1994, CYTOKINE HDB, P419; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; UEDA N, 1994, J BIOL CHEM, V269, P4388; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1995, J BIOL CHEM, V270, P16008, DOI 10.1074/jbc.270.27.16008; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; WU DQ, 1995, J BIOL CHEM, V270, P9828, DOI 10.1074/jbc.270.17.9828; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811	31	163	166	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					3975	3978						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626727				2022-12-27	WOS:A1996TW96000005
J	Parnet, P; Garka, KE; Bonnert, TP; Dower, SK; Sims, JE				Parnet, P; Garka, KE; Bonnert, TP; Dower, SK; Sims, JE			IL-1Rrp is a novel receptor-like molecule similar to the type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; GENE	A novel member of the interleukin-1 receptor family has been cloned by polymerase chain reaction using degenerate oligonucleotide primers derived from regions of sequence conservation, using as template a yeast artificial chromosome known to contain both interleukin-1 (IL-1) receptors and T1/ST2. The new receptor, called IL-1 receptor-related protein or IL-1Rrp, fails to bind any of the known IL-1 ligands. A chimeric receptor, in which the IL-1Rrp cytoplasmic domain is fused to the extracellular and transmembrane regions of the IL-1 receptor, responds to IL-1 following transfection into COS cells by activation of NF kappa B and induction of IL-8 promoter function.	IMMUNEX RES & DEV CORP,SEATTLE,WA 98101; INSERM,U394,F-33077 BORDEAUX,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Parnet, Patricia/AAW-5064-2021; Parnet, Patricia/GOH-1209-2022	dower, steve/0000-0002-4675-4225; Sims, John/0000-0002-5667-9185				AREND WP, 1994, J IMMUNOL, V153, P4766; BAUM PR, 1994, EMBO J, V13, P3992, DOI 10.1002/j.1460-2075.1994.tb06715.x; BAYLE MA, 1996, IN PRESS J BIOL CHEM, V271; BERGERS G, 1994, EMBO J, V13, P1176, DOI 10.1002/j.1460-2075.1994.tb06367.x; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; LORD KA, 1990, ONCOGENE, V5, P1095; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MITCHAM JL, 1996, IN PRESS J BIOL CHEM, V271; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; SIMS JE, 1995, CYTOKINE, V7, P483, DOI 10.1006/cyto.1995.0066; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; YANAGISAWA K, 1993, FEBS LETT, V318, P83, DOI 10.1016/0014-5793(93)81333-U; 1994, PROGRAM MANUAL GCG P	14	212	252	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					3967	3970						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626725				2022-12-27	WOS:A1996TW96000003
J	Wang, YS; Macke, JP; Abella, BS; Andreasson, K; Worley, P; Gilbert, DJ; Copeland, NG; Jenkins, NA; Nathans, J				Wang, YS; Macke, JP; Abella, BS; Andreasson, K; Worley, P; Gilbert, DJ; Copeland, NG; Jenkins, NA; Nathans, J			A large family of putative transmembrane receptors homologous to the product of the Drosophila tissue polarity gene frizzled	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MESSENGER-RNAS; MOLECULAR-CLONING; RAT-BRAIN; PROTEIN; MOUSE; ORGANIZATION; SEQUENCES; ALIGNMENT; WINGLESS; ENCODES	In Drosophila melanogaster, the frizzled gene plays an essential role in the development of tissue polarity as assessed by the orientation of cuticular structures. Through a combination of random cDNA sequencing, degenerate polymerase chain reaction amplification, and low stringency hybridization we have identified six novel frizzled homologues from mammals, at least 11 from zebrafish, several from chicken and sea urchin, and one from Caenorhabditis elegans. The complete deduced amino acid sequences of the mammalian and nematode homologues share with the Drosophila frizzled protein a conserved amino-terminal cysteine-rich domain and seven putative transmembrane segments. Each of the mammalian homologues is expressed in a distinctive set of tissues in the adult, and at least three are expressed during embryogenesis. As hypothesized for the Drosophila frizzled protein, the frizzled homologues are likely to act as transmembrane receptors for as yet unidentified ligands. These observations predict the existence of a family of signal transduction pathways that are homologous to the pathway that determines tissue polarity in Drosophila.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT OPHTHALMOL,BALTIMORE,MD 21205; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Howard Hughes Medical Institute; Johns Hopkins University	Wang, YS (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.		Abella, Benjamin/G-3579-2010	Nathans, Jeremy/0000-0001-8106-5460; Abella, Benjamin/0000-0003-2521-0891				ADLER PN, 1990, GENETICS, V126, P401; ADLER PN, 1987, DEV GENET, V8, P99, DOI 10.1002/dvg.1020080206; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BORJIGIN J, 1994, J BIOL CHEM, V269, P14715; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BUCHBERG AM, 1989, GENETICS, V122, P153; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; COLE AJ, 1990, J NEUROCHEM, V55, P1920, DOI 10.1111/j.1471-4159.1990.tb05777.x; CONLON RA, 1995, DEVELOPMENT, V121, P1533; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Green EL, 1981, GENETICS PROBABILITY, P77; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; JENKINS NA, 1995, GENOMICS, V28, P333, DOI 10.1006/geno.1995.1150; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PARK WJ, 1994, MECH DEVELOP, V45, P127, DOI 10.1016/0925-4773(94)90026-4; PATHAK BG, 1996, IN PRESS GENOMICS; PRITCHARD MA, 1991, GENOMICS, V10, P801, DOI 10.1016/0888-7543(91)90466-R; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REHN M, 1995, J BIOL CHEM, V270, P4705, DOI 10.1074/jbc.270.9.4705; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; Sambrook J, 1989, MOL CLONING LABORATO; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SPRING J, 1994, GENOMICS, V21, P597, DOI 10.1006/geno.1994.1319; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WILKIE TM, 1993, GENOMICS, V18, P175, DOI 10.1006/geno.1993.1452; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; ZHOU ZY, 1995, GENOMICS, V27, P370	43	316	379	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4468	4476						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626800				2022-12-27	WOS:A1996TW96000078
J	Arribas, J; Coodly, L; Vollmer, P; Kishimoto, TK; RoseJohn, S; Massague, J				Arribas, J; Coodly, L; Vollmer, P; Kishimoto, TK; RoseJohn, S; Massague, J			Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ANCHORED GROWTH-FACTORS; TGF-ALPHA; MEMBRANE; CLEAVAGE; RECEPTOR; LIGAND; MECHANISMS; RELEASE; DISEASE	The extracellular domains of a diverse group of membrane proteins are shed in response to protein kinase C activators such as phorbol 12-myristate 13-acetate (PMA). The lack of sequence similarity in the cleavage sites suggests the involvement-of many proteases of diverse specificity in this process. However, a mutant Chinese hamster ovary cell line recently isolated for being defective in PMA-activated shedding of the membrane-anchored growth factor transforming growth factor alpha precursor (proTGF-alpha) is concomitantly defective in the shedding of many other unrelated membrane proteins. Here we show that independent mutagenesis and selection experiments yield shedding mutants having the same recessive phenotype and belonging to the same genetic complementation group. Furthermore, two structurally distinct agents, TAPI-2 and 1,10-phenanthroline, which are known to inhibit metalloproteases, block PMA-activated shedding of proTGF-alpha, cell adhesion receptor L-selectin, interleukin 6 receptor alpha subunit, beta-amyloid precursor protein, and an entire set of anonymous Chinese hamster ovary cell surface proteins. Certain serine protease inhibitors prevent release of these proteins by interfering with their maturation and transport to the cell surface but do not inhibit ectodomain shedding hom the cell surface. The results suggest the existence of a common system for membrane protein ectodomain shedding involving one or several proteolytic activities sensitive to metalloprotease inhibitors, whose ability to act can be disrupted by recessive mutations in a single gene.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; UNIV MAINZ,FAK MED,MED KLIN 1,D-55101 MAINZ,GERMANY; BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT IMMUNOL,RIDGEFIELD,CT 06877	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Johannes Gutenberg University of Mainz; Boehringer Ingelheim			Arribas, Joaquin/M-4482-2014; Rose-John, Stefan/A-7998-2010	Arribas, Joaquin/0000-0002-0504-0664; Rose-John, Stefan/0000-0002-7519-3279; Massague, Joan/0000-0001-9324-8408	NCI NIH HHS [CA53559] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053559] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; BAZIL V, 1994, J IMMUNOL, V152, P1314; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; DINARELLO CA, 1995, CURR BIOL, V5, P587, DOI 10.1016/S0960-9822(95)00116-3; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; IGNOTZ RA, 1986, P NATL ACAD SCI USA, V83, P6307, DOI 10.1073/pnas.83.17.6307; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; LECA G, 1995, J IMMUNOL, V154, P1069; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MULLBERG J, 1994, J IMMUNOL, V152, P4958; MULLBERG J, 1992, BIOCHEM BIOPH RES CO, V189, P794, DOI 10.1016/0006-291X(92)92272-Y; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PORTEU F, 1991, J BIOL CHEM, V266, P18846; Powers J.C., 1986, PROTEINASE INHIBITOR, P219; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SERRAPAGES C, 1994, J BIOL CHEM, V269, P23632; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; STEIN J, 1991, ONCOGENE, V6, P601; STOYAN T, 1993, EUR J BIOCHEM, V216, P239, DOI 10.1111/j.1432-1033.1993.tb18138.x; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	36	361	369	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11376	11382		10.1074/jbc.271.19.11376	http://dx.doi.org/10.1074/jbc.271.19.11376			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626692	hybrid			2022-12-27	WOS:A1996UJ94400052
J	Ozer, J; Bolden, AH; Lieberman, PM				Ozer, J; Bolden, AH; Lieberman, PM			Transcription factor IIA mutations show activator-specific defects and reveal a IIA function distinct from stimulation of TBP-DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TFIID COMPLEX; BASIC REPEAT; SUBUNITS; DOMAIN; YEAST; PROTEIN; IDENTIFICATION; COACTIVATORS; INITIATION	The general transcription factor IIA (TFIIA) binds to the TATA binding protein (TBP) and mediates transcriptional activation by distinct classes of activators. To elucidate the function of TFIIA in transcriptional activation, point mutants were created in the human TFIIA-gamma subunit at positions conserved with the yeast homologue. We have identified a class of TFIIA mutants that stimulate TBP-DNA binding (T-A complex) but fail to support transcriptional activation by several different activators, suggesting that these mutants are defective in their ability to facilitate an activation step subsequent to TBP promoter binding, Point mutations of the hydrophobic core of conserved residues from 65 to 74 resulted in various activation-defective phenotypes. These residues were found to be important for TFIIA gamma-gamma interactions, suggesting that gamma-gamma interactions are critical for TFIIA function as a coactivator. A subset of these TFIIA-gamma mutations disrupted transcriptional activation by all activators tested, except for the Epstein-Barr virus encoded Zta protein. The gamma Y65F, gamma W72A, and gamma W72F mutants mediate Zta activation, but not GAL4-AH, AP-1, GAL4-CTF, or GAL4-VP16 activation. The gamma W72A mutant failed to stimulate TFIID-DNA binding (D-A complex) but was able to form a complex with TFIID and DNA in the presence of Zta (Z-D-A complex). Thus, the ability of Zta to activate transcription with gamma W72A appears to result fi om a unique ability to form the stable Z-D-A complex with this mutant. Our results show that different activators utilize the general factor TFIIA in unique ways and that TFIIA contributes transcription activation functions in addition to the facilitation of TBP-DNA binding.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; ROCHE INST MOLEC BIOL,NUTLEY,NJ 07110	The Wistar Institute								ARNDT KM, 1995, EMBO J, V14, P1490, DOI 10.1002/j.1460-2075.1995.tb07135.x; ASO T, 1994, EMBO J, V13, P435, DOI 10.1002/j.1460-2075.1994.tb06278.x; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BERNSTEIN R, 1994, J BIOL CHEM, V269, P24361; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAREY M, 1992, J VIROL, V66, P4803, DOI 10.1128/JVI.66.8.4803-4813.1992; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHI TH, 1993, MOL CELL BIOL, V13, P7045, DOI 10.1128/MCB.13.11.7045; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; DEJONG J, 1995, P NATL ACAD SCI USA, V92, P3313, DOI 10.1073/pnas.92.8.3313; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; INOSTROZA JA, 1992, CELL, V70, P477; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM TK, 1993, J BIOL CHEM, V268, P20866; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE M, 1995, MOL CELL BIOL, V15, P5461; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN P, 1994, MOL CELL BIOL, V14, P8365, DOI 10.1128/MCB.14.12.8365; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; OHKUMA Y, 1995, MOL CELL BIOL, V15, P4856; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; PUGH BF, 1992, J BIOL CHEM, V267, P679; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; RANISH JA, 1991, J BIOL CHEM, V266, P19320; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUN XQ, 1994, GENE DEV, V8, P2336, DOI 10.1101/gad.8.19.2336; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	67	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11182	11190		10.1074/jbc.271.19.11182	http://dx.doi.org/10.1074/jbc.271.19.11182			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626665	hybrid			2022-12-27	WOS:A1996UJ94400025
J	Rovere, C; Barbero, P; Kitabgi, P				Rovere, C; Barbero, P; Kitabgi, P			Evidence that PC2 is the endogenous pro-neurotensin convertase in rMTC 6-23 cells and that PC1- and PC2-transfected PC12 cells differentially process pro-neurotensin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROMEDIN-N-PRECURSOR; ENDOPROTEASE FAMILY; SUBTILISIN FAMILY; BASIC RESIDUES; GENE; IDENTIFICATION; KEX2; RAT; ENDOPEPTIDASE; EXPRESSION	The neuropeptide precursor proneurotensin/neuromedin N (pro-NT/NN) is mainly expressed and differentially processed in the brain and in the small intestine. We showed previously that rMTC 6-23 cells process pro-NT/NN with a pattern similar to brain tissue and increase pro-NT/NN expression in response to dexamethasone, and that PC12 cells also produce pro-NT/NN but are virtually unable 60 process it. In addition, PC12 cells were reported to be devoid of the prohormone convertases PC1 and PC2. The present study was designed to identify the proprotein convertase(s) (PC) involved in pro-NT/NN processing in rMTC 6-23 cells and to compare PC1- and PC2-transfected PC12 cells for their ability to process pro-NT/NN. rMTC 6-23 cells were devoid of PC1, PC4, and PC5 but expressed furin and PC2. Stable expression of antisense PC2 RNA in rMTC 6-23 cells led to a 90% decrease in PC2 protein levels that correlated with a >80% reduction of pro-NT/NN processing. PC2 expression was stimulated by dexamethasone in a time- and concentration-dependent manner. Stable PC12/PC2 transfectants processed pro-NT/NN with a pattern similar to that observed in the brain and in rMTC 6-23 cells. In contrast, stable PC12/PC1 transfectants reproduced the pro-NT/NN processing pattern seen in the gut. We conclude that (i) PC2 is the major pro-NT/NN convertase in rMTC 6-23 cells; (ii) its expression is coregulated with that of pro-NT/NN in this cell line; and (iii) PC2 and PC1 differentially process pro-NT/NN with brain and intestinal phenotype, respectively.	UNIV NICE, CNRS, INST PHARMACOL MOLEC & CELLULAIRE, F-06560 VALBONNE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Rovere-Jovene, Carole/O-4557-2016	Rovere-Jovene, Carole/0000-0001-9400-7972				BAILYES EM, 1992, BIOCHEM J, V285, P391, DOI 10.1042/bj2850391; Basak A, 1995, J Pept Sci, V1, P385, DOI 10.1002/psc.310010606; BENJANNET S, 1995, J NEUROCHEM, V64, P2303; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BIDARD JN, 1993, BIOCHEM J, V291, P225, DOI 10.1042/bj2910225; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; CARRAWAY RE, 1990, J BIOL CHEM, V265, P8627; CARRAWAY RE, 1993, PEPTIDES, V14, P991, DOI 10.1016/0196-9781(93)90076-S; CARRAWAY RE, 1992, ANN NY ACAD SCI, V668, P1, DOI 10.1111/j.1749-6632.1992.tb27335.x; CARRAWAY RE, 1991, BIOCHEM BIOPH RES CO, V179, P301, DOI 10.1016/0006-291X(91)91369-N; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DENADAI F, 1994, NEUROSCIENCE, V60, P159, DOI 10.1016/0306-4522(94)90211-9; DENADAI F, 1993, ENDOCRINOLOGY, V132, P1614, DOI 10.1210/en.132.4.1614; DITTIE AS, 1995, BIOCHEM J, V310, P777, DOI 10.1042/bj3100777; DOBNER PR, 1988, J BIOL CHEM, V263, P13983; DOBNER PR, 1987, P NATL ACAD SCI USA, V84, P3516, DOI 10.1073/pnas.84.10.3516; GAUDRIAULT G, 1994, J NEUROCHEM, V62, P361; HALBAN PA, 1994, BIOCHEM J, V299, P1; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KISLAUSKIS E, 1990, NEURON, V4, P783, DOI 10.1016/0896-6273(90)90205-T; KISLAUSKIS E, 1988, J BIOL CHEM, V263, P4963; LINDBERG I, 1994, MOL CELL NEUROSCI, V5, P614, DOI 10.1006/mcne.1994.1075; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; NICOT A, 1995, NEUROREPORT, V6, P2158, DOI 10.1097/00001756-199511000-00015; RHODES CJ, 1992, J BIOL CHEM, V267, P22719; ROTHENBERG ME, 1995, J BIOL CHEM, V270, P10136, DOI 10.1074/jbc.270.17.10136; ROUILLE Y, 1994, P NATL ACAD SCI USA, V91, P3242, DOI 10.1073/pnas.91.8.3242; ROUILLE Y, 1995, J BIOL CHEM, V270, P26488, DOI 10.1074/jbc.270.44.26488; ROVERE C, 1993, PEPTIDES, V14, P983, DOI 10.1016/0196-9781(93)90075-R; SCARCERIAUX V, 1995, ENDOCRINOLOGY, V136, P2554, DOI 10.1210/en.136.6.2554; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHAW C, 1990, PEPTIDES, V11, P227, DOI 10.1016/0196-9781(90)90075-G; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; STEINER DF, 1992, J BIOL CHEM, V267, P23435; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VANDEVEN WJM, 1991, ENZYME, V45, P257, DOI 10.1159/000468900; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; ZEYTINOGLU FN, 1980, P NATL ACAD SCI-BIOL, V77, P3741, DOI 10.1073/pnas.77.6.3741; ZHOU A, 1994, J BIOL CHEM, V269, P17440; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHOU Y, 1995, J BIOL CHEM, V270, P24702, DOI 10.1074/jbc.270.42.24702; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	55	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11368	11375		10.1074/jbc.271.19.11368	http://dx.doi.org/10.1074/jbc.271.19.11368			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626691	hybrid			2022-12-27	WOS:A1996UJ94400051
J	Boss, V; Talpade, DJ; Murphy, TJ				Boss, V; Talpade, DJ; Murphy, TJ			Induction of NFAT-mediated transcription by G(q)-coupled receptors in lymphoid and non-lymphoid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOSPORINE-A; NUCLEAR FACTOR; MUSCARINIC RECEPTOR; ACTIVATION; CALCINEURIN; IDENTIFICATION; SPECIFICITY; COMPLEX; PROTEIN; BINDING	The nuclear factor of activated T cells (NFAT) was discovered as an inducible transcription factor activated by antigen stimulation of the T cell receptor in lymphocytes. Stimulation of NFAT-mediated transcription is now reported in both lymphoid and non-lymphoid cells following activation of a neurotransmitter receptor. Carbachol induces robust luciferase responses in Jurkat and pheochromocytoma PC12 cells expressing an NFAT-luciferase reporter construct and a G(q)-coupled m3 muscarinic receptor. Cyclosporin blocks this response in PC12 cells, as in Jurkat cells. In PC12 cells expressing a G(i)-coupled m2 muscarinic receptor, carbachol induces NFAT-mediated luciferase activity that is strictly dependent upon co-expression of a chimeric G alpha(q)/alpha(i) subunit which confers G(q)-effector coupling on G(i)-linked receptors/ These findings suggest that neurotransmitters, autacoids, or hormones acting on G(q)-protein-coupled receptors may serve as physiological stimulators of NFAT in lymphoid and non lymphoid cells.	EMORY UNIV,SCH MED,DEPT PHARMACOL,ATLANTA,GA 30322	Emory University					NHLBI NIH HHS [HL48252, HL52810] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL048252, R01HL052810] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKERILL GW, 1995, BLOOD, V86, P2689; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; DESAI DM, 1990, NATURE, V348, P66, DOI 10.1038/348066a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GOLDSMITH MA, 1989, J BIOL CHEM, V264, P17190; HO AM, 1994, J BIOL CHEM, V269, P28181; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MURPHY TJ, 1993, MOL PHARMACOL, V44, P1; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PINKASKRAMARSKI R, 1990, NEUROSCI LETT, V108, P335, DOI 10.1016/0304-3940(90)90663-T; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SZAMEL M, 1995, EUR J BIOCHEM, V228, P1; TAKEUCHI K, 1993, CIRC RES, V73, P612, DOI 10.1161/01.RES.73.4.612; VENTAKARAMAN L, 1994, IMMUNITY, V1, P189; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Weiss DL, 1996, MOL CELL BIOL, V16, P228; WU J, 1995, MOL CELL BIOL, V15, P4337; YASEEN NR, 1993, J BIOL CHEM, V268, P14285	28	58	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10429	10432		10.1074/jbc.271.18.10429	http://dx.doi.org/10.1074/jbc.271.18.10429			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631834	hybrid			2022-12-27	WOS:A1996UJ34200002
J	Gamby, C; Waage, MC; Allen, RG; Baizer, L				Gamby, C; Waage, MC; Allen, RG; Baizer, L			Growth-associated protein-43 (GAP-43) facilitates peptide hormone secretion in mouse anterior pituitary AtT-20 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING-PROTEIN; KINASE-C SUBSTRATE; AXONALLY TRANSPORTED PROTEINS; RETINAL GANGLION-CELLS; B-50 GAP-43; NORADRENALINE RELEASE; NEUROTRANSMITTER RELEASE; SUBCELLULAR FRACTION; PHOSPHORYLATION-SITE; SYNAPTIC PLASTICITY	The neuronal growth-associated protein (GAP)-43 (neuromodulin, B-50, F1), which is concentrated in the growth cones of elongating axons during neuronal development and in nerve terminals in restricted regions of the adult nervous system, has been implicated in the release of neurotransmitter. To study the role of GAP-43 in evoked secretion, we transfected mouse anterior pituitary AtT-20 cells with the rat GAP-43 cDNA and derived stably transfected cell lines. Depolarization-mediated beta-endorphin secretion was greatly enhanced in the GAP-43-expressing AtT-20 cells without a significant change in Ca2+ influx; in contrast, expression of GAP-43 did not alter corticotropin releasing factor-evoked hormone secretion. The transfected cells also displayed a flattened morphology and extended processes when plated on laminin-coated substrates. These results suggest that AtT-20 cells are a useful model system for further investigations on the precise biological function(s) of GAP-43.	GOOD SAMARITAN HOSP, RS DOW NEUROL SCI INST, PORTLAND, OR 97209 USA; OREGON HLTH SCI UNIV, DEPT DEV & CELL BIOL, PORTLAND, OR 97209 USA; OREGON HLTH SCI UNIV, CTR RES OCCUPAT & ENVIRONM TOXICOL, PORTLAND, OR 97209 USA	Oregon Health & Science University; Oregon Health & Science University					NINDS NIH HHS [NS26806] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS026806] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; ALOYO VJ, 1983, J NEUROCHEM, V41, P649, DOI 10.1111/j.1471-4159.1983.tb04790.x; ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4615, DOI 10.1021/bi00289a001; AXELROD J, 1984, SCIENCE, V224, P452, DOI 10.1126/science.6143403; Baetge E E, 1992, Perspect Dev Neurobiol, V1, P21; BAETGE EE, 1991, NEURON, V6, P21, DOI 10.1016/0896-6273(91)90118-J; BASI GS, 1987, CELL, V49, P785, DOI 10.1016/0092-8674(87)90616-7; BENOWITZ LI, 1989, J NEUROSCI, V9, P990; BENOWITZ LI, 1987, TRENDS NEUROSCI, V10, P527, DOI 10.1016/0166-2236(87)90135-4; BENOWITZ LI, 1988, J NEUROSCI, V8, P339; BENOWITZ LI, 1983, J NEUROSCI, V3, P2153; BENOWITZ LI, 1987, J NEUROCHEM, V48, P1640, DOI 10.1111/j.1471-4159.1987.tb05713.x; BIFFO S, 1990, EUR J NEUROSCI, V2, P487, DOI 10.1111/j.1460-9568.1990.tb00440.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUONASSISI V, 1962, P NATL ACAD SCI USA, V48, P1184, DOI 10.1073/pnas.48.7.1184; CHAN SY, 1986, J NEUROSCI, V6, P3618; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIMLER BM, 1985, J BIOL CHEM, V260, P784; CIMLER BM, 1987, J BIOL CHEM, V262, P12158; COGGINS PJ, 1991, J NEUROCHEM, V56, P1095, DOI 10.1111/j.1471-4159.1991.tb11398.x; COGGINS PJ, 1989, J NEUROCHEM, V53, P1895, DOI 10.1111/j.1471-4159.1989.tb09259.x; DEGRAAN PNE, 1990, J NEUROCHEM, V55, P2139; DEKKER LV, 1989, J NEUROCHEM, V52, P24, DOI 10.1111/j.1471-4159.1989.tb10893.x; DEKKER LV, 1991, J NEUROCHEM, V56, P1146, DOI 10.1111/j.1471-4159.1991.tb11404.x; DEKKER LV, 1989, NATURE, V342, P74, DOI 10.1038/342074a0; DEKKER LV, 1991, PROG BRAIN RES, V89, P209; DELAMONTE SM, 1989, DEV BRAIN RES, V46, P161, DOI 10.1016/0165-3806(89)90279-4; DOSTER SK, 1991, NEURON, V6, P635, DOI 10.1016/0896-6273(91)90066-9; EIPPER BA, 1978, J BIOL CHEM, V253, P5732; FITZGERALD M, 1991, NEUROSCIENCE, V41, P187, DOI 10.1016/0306-4522(91)90209-7; GIANOTTI C, 1992, NEURON, V8, P843, DOI 10.1016/0896-6273(92)90198-M; GISPEN WH, 1991, MOL NEUROBIOL, V5, P61, DOI 10.1007/BF02935540; GORDONWEEKS PR, 1989, TRENDS NEUROSCI, V12, P363, DOI 10.1016/0166-2236(89)90073-8; GORGELS TGMF, 1989, J NEUROSCI, V9, P3861; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GOSLIN K, 1988, NATURE, V336, P672, DOI 10.1038/336672a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUILD S, 1987, J PHARMACOL EXP THER, V241, P126; HATFIELD JM, 1988, DEV BIOL, V126, P164, DOI 10.1016/0012-1606(88)90250-3; HENS JJH, 1995, J NEUROCHEM, V64, P1127; HENS JJH, 1993, J NEUROCHEM, V60, P1264, DOI 10.1111/j.1471-4159.1993.tb03286.x; IVINS KJ, 1993, J NEUROCHEM, V60, P626, DOI 10.1111/j.1471-4159.1993.tb03194.x; KARNS LR, 1987, SCIENCE, V236, P597, DOI 10.1126/science.2437653; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KRISTJANSSON GI, 1982, J NEUROCHEM, V39, P371, DOI 10.1111/j.1471-4159.1982.tb03958.x; LIU YC, 1991, NEURON, V6, P411, DOI 10.1016/0896-6273(91)90249-Y; LIU YC, 1993, BIOCHEMISTRY-US, V32, P10714, DOI 10.1021/bi00091a023; LIU YC, 1994, J NEUROSCI, V14, P5807; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LOVINGER DM, 1985, BRAIN RES, V343, P137, DOI 10.1016/0006-8993(85)91167-9; LUINI A, 1985, P NATL ACAD SCI USA, V82, P8034, DOI 10.1073/pnas.82.23.8034; MAINS RE, 1981, J CELL BIOL, V89, P21, DOI 10.1083/jcb.89.1.21; MEIRI KF, 1986, P NATL ACAD SCI USA, V83, P3537, DOI 10.1073/pnas.83.10.3537; MEIRI KF, 1990, J NEUROSCI, V10, P256; MORTON AJ, 1992, EUR J NEUROSCI, V4, P910, DOI 10.1111/j.1460-9568.1992.tb00117.x; MOSS DJ, 1990, J NEUROCHEM, V54, P729, DOI 10.1111/j.1471-4159.1990.tb02312.x; NELSON RB, 1985, EXP NEUROL, V89, P213, DOI 10.1016/0014-4886(85)90277-8; NEVE RL, 1988, P NATL ACAD SCI USA, V85, P3638, DOI 10.1073/pnas.85.10.3638; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; PADEN CM, 1994, ENDOCRINOLOGY, V134, P503, DOI 10.1210/en.134.1.503; PERRONEBIZZOZERO NI, 1987, J NEUROCHEM, V48, P644, DOI 10.1111/j.1471-4159.1987.tb04141.x; ROSENTHAL A, 1987, EMBO J, V6, P3641, DOI 10.1002/j.1460-2075.1987.tb02696.x; SABOL SL, 1980, ARCH BIOCHEM BIOPHYS, V203, P37, DOI 10.1016/0003-9861(80)90151-4; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHEA TB, 1991, J NEUROSCI, V11, P1685; SKENE JHP, 1986, SCIENCE, V233, P783, DOI 10.1126/science.3738509; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SKENE JHP, 1981, J NEUROSCI, V1, P419; SKENE JHP, 1981, J CELL BIOL, V89, P86, DOI 10.1083/jcb.89.1.86; SKENE JHP, 1981, J CELL BIOL, V89, P96, DOI 10.1083/jcb.89.1.96; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STRITTMATTER SM, 1994, J CELL SCI, V107, P195; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; STRITTMATTER SM, 1993, P NATL ACAD SCI USA, V90, P5327, DOI 10.1073/pnas.90.11.5327; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; VANDERNEUT R, 1990, NEUROSCI LETT, V109, P36, DOI 10.1016/0304-3940(90)90534-G; VANDERZEE CEEM, 1989, J NEUROSCI, V9, P3505; VITALE N, 1994, J BIOL CHEM, V269, P30293; WIDMER F, 1993, J CELL BIOL, V120, P503, DOI 10.1083/jcb.120.2.503; YANKNER BA, 1990, MOL BRAIN RES, V7, P39, DOI 10.1016/0169-328X(90)90071-K; ZUBER MX, 1989, SCIENCE, V244, P1193, DOI 10.1126/science.2658062	84	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10023	10028		10.1074/jbc.271.17.10023	http://dx.doi.org/10.1074/jbc.271.17.10023			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626556	hybrid			2022-12-27	WOS:A1996UG25700028
J	Liu, YP; Wang, Z; Rana, TM				Liu, YP; Wang, Z; Rana, TM			Visualizing a specific contact in the HIV-1 Tat protein fragment and trans-activation responsive region RNA complex by photocross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; MUTATIONAL ANALYSIS; MESSENGER-RNA; MAJOR GROOVE; CROSS-LINKING; GENE-PRODUCT; BASIC DOMAIN; RECOGNITION; TYPE-1	Replication of human immunodeficiency virus type 1 (HIV-1) requires specific interactions of Tat protein with the trans-activation responsive region (TAR) RNA, a stem-loop structure containing two helical stem regions separated by a trinucleotide bulge. The Tat protein contains a basic RNA-binding region (amino acids 49-57) located in the carboxyl-terminal half of the protein, and peptides containing this basic domain of Tat protein can bind TAR RNA with high affinities. We synthesized a 31-amino acid Tat fragment (amino acids 42-72) containing the basic region and part of flanking regulatory core domain that formed a specific complex with TAR RNA. Upon UV irradiation (254 nm), this Tat fragment cross-linked covalently with TAR RNA. Sites of cross-links were determined on both the TAR RNA and Tat protein fragment by RNA and protein sequencing, respectively. These results revealed that guanosine 26 of TAR RNA was cross-linked with tyrosine 47 of the Tat peptide. Our results provide the first physical evidence for a direct amino acid-base contact in Tat-TAR complex. Recently, orientation of the Tat-(42-72) was deter mined in our laboratory by psoralen Tat-(42-72) conjugate (Wang, Z., and Rana, T. M. (1995) J. Am. Chem. Soc. 117, 5438-5444). On the basis of our findings, we suggest a model in which Tat binds to TAR RNA by inserting the basic recognition sequence into the major groove with an orientation where lysine 41 in the core domain of Tat contacts the lower stem and Tyr(47) is close to G(26) of TAR RNA. The knowledge of the orientation of Tat and details of other interactions with TAR RNA in Tat-TAR complex has significant implications for understanding gene regulation in HIV-1.	RUTGERS STATE UNIV, UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT PHARMACOL, PISCATAWAY, NJ 08854 USA; RUTGERS STATE UNIV, BIOCHEM & MOL BIOL GRAD PROGRAM, PISCATAWAY, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick			Wang, Ting-Fang/ABI-3818-2020	Wang, Ting-Fang/0000-0001-6306-9505	NIAID NIH HHS [AI 34785] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034785] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555; BASILION JP, 1994, P NATL ACAD SCI USA, V91, P574, DOI 10.1073/pnas.91.2.574; BAUDIN F, 1989, NUCLEIC ACIDS RES, V17, P2043, DOI 10.1093/nar/17.5.2043; BERKHOUT B, 1991, NUCLEIC ACIDS RES, V19, P6169, DOI 10.1093/nar/19.22.6169; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BLATTER EE, 1992, NATURE, V359, P650, DOI 10.1038/359650a0; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CHOW CS, 1992, BIOCHEMISTRY-US, V31, P972, DOI 10.1021/bi00119a005; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DELLING U, 1991, P NATL ACAD SCI USA, V88, P6234, DOI 10.1073/pnas.88.14.6234; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; ELANGOVAN B, 1992, J VIROL, V66, P2031, DOI 10.1128/JVI.66.4.2031-2036.1992; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; GOTT JM, 1991, BIOCHEMISTRY-US, V30, P6290, DOI 10.1021/bi00239a030; GREENBERG JR, 1979, NUCLEIC ACIDS RES, V6, P715, DOI 10.1093/nar/6.2.715; HAMY F, 1993, J MOL BIOL, V230, P111, DOI 10.1006/jmbi.1993.1129; HAUBER J, 1988, J VIROL, V62, P673, DOI 10.1128/JVI.62.3.673-679.1988; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; HOWE PWA, 1994, EMBO J, V13, P3873, DOI 10.1002/j.1460-2075.1994.tb06698.x; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2555, DOI 10.1128/MCB.8.6.2555; JEANG KT, 1993, J BIOL CHEM, V268, P24940; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KUCHINO Y, 1989, METHOD ENZYMOL, V180, P154; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; MUSIERFORSYTH K, 1991, SCIENCE, V253, P784, DOI 10.1126/science.1876835; NEENHOLD HR, 1995, BIOCHEMISTRY-US, V34, P6303, DOI 10.1021/bi00019a007; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; PINOLROMA S, 1989, METHOD ENZYMOL, V180, P410; PUGLISI JD, 1993, P NATL ACAD SCI USA, V90, P3680, DOI 10.1073/pnas.90.8.3680; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; PUGLISI JD, 1992, SCIENCE, V90, P3680; RICE AP, 1990, J VIROL, V64, P1864, DOI 10.1128/JVI.64.4.1864-1868.1990; RICE AP, 1988, NATURE, V332, P551, DOI 10.1038/332551a0; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SELBY MJ, 1989, GENE DEV, V3, P547, DOI 10.1101/gad.3.4.547; SHARP PA, 1989, CELL, V59, P229, DOI 10.1016/0092-8674(89)90279-1; Smith K. C., 1976, PHOTOCHEM PHOTOBIOL, V2, P187; SUMNERSMITH M, 1991, J VIROL, V65, P5196, DOI 10.1128/JVI.65.10.5196-5202.1991; Tinoco I. Jr., 1990, Nucleic Acids and Molecular Biology, V4, P205; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; WANG ZY, 1995, J AM CHEM SOC, V117, P5438, DOI 10.1021/ja00125a002; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WEEKS KM, 1993, SCIENCE, V261, P1574, DOI 10.1126/science.7690496; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WU HN, 1987, BIOCHEMISTRY-US, V26, P8221, DOI 10.1021/bi00399a030; WYATT JR, 1989, BIOESSAYS, V11, P100, DOI 10.1002/bies.950110406	64	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10391	10396		10.1074/jbc.271.17.10391	http://dx.doi.org/10.1074/jbc.271.17.10391			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626612	hybrid			2022-12-27	WOS:A1996UG25700084
J	Pinkoski, MJ; Winkler, U; Hudig, D; Bleackley, RC				Pinkoski, MJ; Winkler, U; Hudig, D; Bleackley, RC			Binding of granzyme B in the nucleus of target cells - Recognition of an 80-kilodalton protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIC LYMPHOCYTES-T; DNA FRAGMENTATION; SERINE PROTEASES; NUCLEOLUS; SPECIFICITY; CYTOLYSIS; APOPTOSIS; KINETICS; GENES; C23	Granzyme B (cytotoxic cell proteinase 1) is a serine proteinase that has been implicated in cytotoxic T lymphocyte-induced apoptosis, In order to understand how granzyme B is involved in mechanisms of target cell destruction, characterization and identification of substrates are required. We have developed an in situ binding assay using permeabilized cells and recombinant granzyme B that allows us to visualize potential substrates after immunostaining with anti granzyme B antiserum. Confocal laser scanning microscopy and immunoelectron microscopic analyses demonstrate that granzyme B recognizes a nuclear substrate. The labeling pattern observed corresponds with regions of positive staining with uranyl acetate which binds to heterochromatin in the nucleus. Positive labeling of target cells with granzyme B is dependent on the presence of a catalytically active proteinase, since an inactive proenzyme form of granzyme B fails to give rise to any binding in the target cells. Far-Western blotting and immunoprecipitation of subcellular fractions of target cells have shown that the putative substrate of catalytically active granzyme B is an 80-kDa nuclear protein. Minor cytosolic bands of 50 and 94 kDa are also observed. A cytoplasmic band of 69 kDa is detected by both active and zymogen forms of granzyme B.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA; UNIV NEVADA,DEPT MICROBIOL,RENO,NV 89557; UNIV NEVADA,CELL & MOL BIOL GRAD PROGRAM,RENO,NV 89557	University of Alberta; Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno								BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; BIGGIOGERA M, 1990, DEVELOPMENT, V110, P1263; BIGGIOGERA M, 1989, J HISTOCHEM CYTOCHEM, V37, P1371, DOI 10.1177/37.9.2768807; Bollag D.M., 1991, PROTEIN METHODS; CAPUTO A, 1993, J BIOL CHEM, V268, P17672; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; FAKAN S, 1986, BIOL CELL, V56, P189, DOI 10.1111/j.1768-322X.1986.tb00452.x; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LISCHWE MA, 1982, J BIOL CHEM, V257, P4600; LOBE CG, 1986, SCIENCE, V232, P858, DOI 10.1126/science.3518058; MUELLER C, 1988, J EXP MED, V167, P1124, DOI 10.1084/jem.167.3.1124; MURPHY MEP, 1988, PROTEINS, V4, P190, DOI 10.1002/prot.340040306; PASTERNACK MS, 1991, J BIOL CHEM, V266, P14703; PEREZ P, 1985, J IMMUNOL, V134, P478; PODACK ER, 1991, ANNU REV IMMUNOL, V9, P129, DOI 10.1146/annurev.iy.09.040191.001021; POE M, 1991, J BIOL CHEM, V266, P98; PRENDERGAST JA, 1992, J BIOL CHEM, V267, P5090; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SCHEER U, 1994, CURR OPIN CELL BIOL, V6, P354, DOI 10.1016/0955-0674(94)90026-4; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VANDELAER M, 1993, EXP CELL RES, V205, P430, DOI 10.1006/excr.1993.1110; WEIMER R, 1992, HUM GENET, V88, P673, DOI 10.1007/BF02265296; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0	27	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10225	10229		10.1074/jbc.271.17.10225	http://dx.doi.org/10.1074/jbc.271.17.10225			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626587	hybrid			2022-12-27	WOS:A1996UG25700059
J	Sakamoto, H; Kawasaki, M; Uchida, S; Sasaki, S; Marumo, F				Sakamoto, H; Kawasaki, M; Uchida, S; Sasaki, S; Marumo, F			Identification of a new outwardly rectifying Cl- channel that belongs to a subfamily of the CIC Cl- channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CYSTIC-FIBROSIS GENE; RAT-KIDNEY CORTEX; CHLORIDE CHANNELS; EPITHELIAL-CELL; NONEPITHELIAL CELLS; MAMMALIAN-CELLS; MESSENGER-RNAS; EXPRESSION; CLONING	A new outwardly rectifying Cl- channels (ORCC) that belongs 60 ClC Cl- channel family has been identified from rat kidney and designated as ClC-5. ClC-5 cDNA encodes a polypeptide of 746 amino acids, which is indicated by hydrophobicity analysis to have structural features that are common of the ClC family. However, the amino acid sequence was weakly homologous to those of other ClC Cl- channels except for ClC-3, which we recently identified as a Ca2+-sensitive ORCC. Northern blot analysis of rat tissues showed that ClC-5 mRNA was predominantly expressed in the kidney and colon. To characterize the functional properties of ClC-5 by whole cell patch-clamp technique, we established the stably transfected CHO-K1 cell line using intranuclear microinjection technique. The transfected cells induced outwardly rectifying and 4,4'-diisothiocyanostilbene-2,2'disulfonic acid-sensitive Cl- currents on whole cell configuration. Following the identification of two highly homologous ORCCs, ClC-3 and ClC-5, a new subfamily encoding ORCC has emerged in the ClC family. Furthermore, ClC-5 was almost identical to a partial sequence of human cDNA that is related to Dent's disease. The molecular structure and functional properties of ClC-5 will provide an important insight into ORCCs and the pathogenesis of Dent's disease.			Sakamoto, H (corresponding author), TOKYO MED & DENT UNIV,DEPT INTERNAL MED 2,BUNKYO KU,1-5-45 YUSHIMA,TOKYO 113,JAPAN.							ADACHI S, 1994, J BIOL CHEM, V269, P17677; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BROWN D, 1989, AM J PHYSIOL, V256, pF1, DOI 10.1152/ajprenal.1989.256.1.F1; CAPECCHI MR, 1980, CELL, V22, P479, DOI 10.1016/0092-8674(80)90358-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLIFF WH, 1992, AM J PHYSIOL, V262, pC1154, DOI 10.1152/ajpcell.1992.262.5.C1154; DENT CE, 1964, ARCH DIS CHILD, V39, P240, DOI 10.1136/adc.39.205.240; DIAMOND JM, 1969, ANNU REV PHYSIOL, V31, P581, DOI 10.1146/annurev.ph.31.030169.003053; EDWIN S, 1990, NATURE, V348, P545; FISHER SE, 1994, HUM MOL GENET, V3, P2053; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; FRIZZELL RA, 1994, CURR TOP MEMBR, V42, P173, DOI 10.1016/S0070-2161(08)60823-0; GABRIEL SE, 1992, AM J PHYSIOL, V263, pC708, DOI 10.1152/ajpcell.1992.263.3.C708; HALM DR, 1992, J GEN PHYSIOL, V99, P339, DOI 10.1085/jgp.99.3.339; HALM DR, 1990, CURR TOP MEMBR TRANS, V37, P247; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; JENTSCH TJ, 1995, J PHYSIOL-LONDON, V482P, pS19; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KAWASAKI M, 1995, NEURON, V14, P1285, DOI 10.1016/0896-6273(95)90275-9; KAWASAKI M, 1994, NEURON, V12, P597, DOI 10.1016/0896-6273(94)90215-1; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KEOWN WA, 1990, METHOD ENZYMOL, V185, P527, DOI 10.1016/0076-6879(90)85043-N; KIEFERLE S, 1994, P NATL ACAD SCI USA, V91, P6943, DOI 10.1073/pnas.91.15.6943; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8123; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MILEDI R, 1982, PROC R SOC SER B-BIO, V215, P491, DOI 10.1098/rspb.1982.0056; MORIYAMA T, 1990, AM J PHYSIOL, V258, pF1470, DOI 10.1152/ajprenal.1990.258.5.F1470; PUSCH M, 1994, PHYSIOL REV, V74, P813, DOI 10.1152/physrev.1994.74.4.813; REEVES WB, 1992, ANNU REV PHYSIOL, V54, P29, DOI 10.1146/annurev.physiol.54.1.29; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SABOLIC I, 1985, AM J PHYSIOL, V248, pF835, DOI 10.1152/ajprenal.1985.248.6.F835; SCHMID A, 1989, J MEMBRANE BIOL, V111, P265, DOI 10.1007/BF01871011; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SCHWIEBERT EM, 1994, CURR TOP MEMBR, V42, P265; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; UCHIDA S, 1993, J BIOL CHEM, V268, P3821; VANDYKE RW, 1988, J BIOL CHEM, V263, P2603; VANSLEGTENHORST MA, 1994, HUM MOL GENET, V3, P547; WELSH MJ, 1986, NATURE, V322, P467, DOI 10.1038/322467a0; WONG OM, 1992, NEPHROCALCINOSIS, P1882; WONG OM, 1994, Q J MED, V87, P473	49	53	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10210	10216		10.1074/jbc.271.17.10210	http://dx.doi.org/10.1074/jbc.271.17.10210			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626585	hybrid			2022-12-27	WOS:A1996UG25700057
J	Schieffer, B; Paxton, WG; Chai, Q; Marrero, MB; Bernstein, KE				Schieffer, B; Paxton, WG; Chai, Q; Marrero, MB; Bernstein, KE			Angiotensin II controls p21(ras) activity via pp60(c-src)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AORTIC SMOOTH-MUSCLE; GAP-ASSOCIATED PROTEINS; TYROSINE KINASES; CELLS; RAS; PHOSPHORYLATION; HYPERTROPHY; ACTIVATION; RECEPTOR; P190	Angiotensin II is the major effector peptide of the renin-angiotensin system, and it exerts its physiologic functions via a G protein-coupled cell surface receptor called AT(1). We found that in rat aortic smooth muscle cells, angiotensin II stimulated the formation of Ras-GTP, Ras-Raf-1 complex formation, and the tyrosine phosphorylation of two important has GTPase activating proteins (GAPs), p120 Ras-GAP and p190 Rho-GAP. Electroporation of anti-pp60(c-src) antibody into cultured, adherent smooth muscle cells blocked the angiotensin II stimulation of Ras-GAP and Rho-GAP tyrosine phosphorylation. In contrast electroporation of antibodies against c-Yes or c-Fyn had no effect. Anti-pp60(c-src) antibody also blocked angiotensin II-stimulated Ras activation and Ras Raf-1 complex formation. These data strongly suggest that a G protein-coupled receptor such as the AT(1) receptor can activate the Ras protein cascade via the tyrosine kinase pp60(c-src).	EMORY UNIV,DEPT PATHOL,ATLANTA,GA 30322; EMORY UNIV,CTR MOL & CELLULAR SIGNALLING,ATLANTA,GA 30322	Emory University; Emory University				Bernstein, Kenneth/0000-0001-8097-3272	NIDDK NIH HHS [DK45215, DK44280, DK39777] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044280, R37DK039777, P50DK045215, R01DK039777] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER RW, 1985, HYPERTENSION, V7, P447, DOI 10.1161/01.HYP.7.3.447; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; CHANG JH, 1993, ONCOGENE, V8, P959; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIBBONS GH, 1990, CARDIOVASC DRUG THER, V4, P237, DOI 10.1007/BF01857638; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; ISHIDA Y, 1992, FEBS LETT, V310, P41, DOI 10.1016/0014-5793(92)81142-9; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; PEACH MJ, 1990, J CARDIOVASC PHARM S, V16, P25; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAAD MJA, 1995, BIOCHEM J, V310, P741, DOI 10.1042/bj3100741; SCHIEFFER B, 1994, CIRCULATION, V89, P2273, DOI 10.1161/01.CIR.89.5.2273; SCHIEFFER B, 1995, AM J PHYSIOL, V38, pH157; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; VAILLANCOURT RR, 1994, METHOD ENZYMOL, V238, P255	33	127	131	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10329	10333		10.1074/jbc.271.17.10329	http://dx.doi.org/10.1074/jbc.271.17.10329			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626602	hybrid			2022-12-27	WOS:A1996UG25700074
J	Nikolakaki, E; Simos, G; Spyros, D; Georgatos, SD; Giannakouros, T				Nikolakaki, E; Simos, G; Spyros, D; Georgatos, SD; Giannakouros, T			A nuclear envelope-associated kinase phosphorylates arginine-serine motifs and modulates interactions between the lamin B receptor and other nuclear proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; SENSITIVE METHOD; GENE ENCODES; DOMAINS; BINDING; CLONING; SITE	Previous studies have identified a subassembly of nuclear envelope proteins, termed ''the LBR complex'' This complex includes the lamin B receptor protein (LBR or p58), a kinase which phosphorylates LBR in a constitutive fashion (LBR kinase), the nuclear lamins A and B, an 18-kDa polypeptide (p18), and a 34-kDa protein (p34/p32). The latter polypeptide has been shown to interact with the HIV-1 proteins Rev and Tat and with the splicing factor 2 (SF2). Using recombinant proteins produced in bacteria and synthetic peptides representing different regions of LBR, we now show that the LBR kinase modifies specifically arginine-serine (RS) dipeptide motifs located at the nucleoplasmic, NH2-terminal domain of LBR and in members of the SR family of splicing factors. Furthermore, we show that the NH2-terminal domain of LBR binds to p34/p32, whereas a mutated domain lacking the RS region does not. Phosphorylation of LBR by the RS kinase completely abolishes binding of p34/p32, suggesting that this enzyme regulates interactions among the components of the LBR complex.	EUROPEAN MOLEC BIOL LAB, CELL BIOL PROGRAM, D-69117 HEIDELBERG, GERMANY; ARISTOTELIAN UNIV THESSALONIKI, BIOCHEM LAB, FAC CHEM, GR-54006 THESSALONIKI, GREECE; UNIV CRETE, FAC MED, DEPT BASIC SCI, GR-71110 IRAKLION, CRETE, GREECE	European Molecular Biology Laboratory (EMBL); Aristotle University of Thessaloniki; University of Crete			GIANNAKOUROS, THOMAS/R-3204-2019; Simos, George/AAH-2596-2021	Georgatos, Spyros/0000-0002-2078-7467; Simos, George/0000-0001-5453-3185				ANTONIOU M, 1993, J CELL BIOL, V123, P1055, DOI 10.1083/jcb.123.5.1055; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; CHEN WN, 1991, YEAST, V7, P305, DOI 10.1002/yea.320070313; COURVALIN JC, 1992, J BIOL CHEM, V267, P19035; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GEORGATOS SD, 1987, J CELL BIOL, V105, P117, DOI 10.1083/jcb.105.1.117; GEORGATOS SD, 1994, CURR OPIN CELL BIOL, V6, P347, DOI 10.1016/0955-0674(94)90025-6; GEORGATOS SD, 1987, J CELL BIOL, V105, P105, DOI 10.1083/jcb.105.1.105; Gerace Larry, 1994, Trends in Cell Biology, V4, P127, DOI 10.1016/0962-8924(94)90067-1; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; Harlow E., 1988, ANTIBODIES LAB MANUA; HONORE B, 1993, GENE, V134, P283, DOI 10.1016/0378-1119(93)90108-F; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORENZ RT, 1992, DNA CELL BIOL, V11, P685, DOI 10.1089/dna.1992.11.685; LUO KX, 1991, METHOD ENZYMOL, V201, P149; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; MAISON C, 1995, EMBO J, V14, P3311, DOI 10.1002/j.1460-2075.1995.tb07338.x; MEIER J, 1994, EMBO J, V13, P1888, DOI 10.1002/j.1460-2075.1994.tb06458.x; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHULER E, 1994, J BIOL CHEM, V269, P11312; SHIMANUKI M, 1992, MOL BIOL CELL, V3, P263, DOI 10.1091/mbc.3.3.263; SIMOS G, 1992, EMBO J, V11, P4027, DOI 10.1002/j.1460-2075.1992.tb05496.x; SIMOS G, 1994, FEBS LETT, V346, P225, DOI 10.1016/0014-5793(94)00479-X; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH S, 1994, P NATL ACAD SCI USA, V91, P10124, DOI 10.1073/pnas.91.21.10124; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; YE Q, 1994, J BIOL CHEM, V269, P11306; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	42	88	90	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8365	8372		10.1074/jbc.271.14.8365	http://dx.doi.org/10.1074/jbc.271.14.8365			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626534	hybrid			2022-12-27	WOS:A1996UD60000074
J	Armesilla, AL; Calvo, D; Vega, MA				Armesilla, AL; Calvo, D; Vega, MA			Structural and functional characterization of the human CD36 gene promoter - Identification of a proximal PEBP2/CBF site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-VIRUS ENHANCERS; DNA-BINDING PROTEINS; THROMBOSPONDIN RECEPTOR; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; GLYCOPROTEIN-IV; MELANOMA-CELLS; EXPRESS CD36; ERYTHROCYTES; MONOCYTES	CD36 is a cell surface glycoprotein composed of a single polypeptide chain, which interacts with thrombospondin, collagens type I and IV, oxidized low density lipoprotein, fatty acids, anionic phospholipids, and erythrocytes parasitized with Plasmodium falciparum. Its expression is restricted to a few cell types, including monocyte/macrophages. In these cells, CD36 is involved in phagocytosis of apoptotic cells, and foam cell formation by uptake of oxidized low density lipoprotein. To study the molecular mechanisms that control the transcription of the CD36 gene in monocytic cells we have isolated and analyzed the CD36 promoter. Transient expression experiments of 5'-deletion fragments of the CD36 promoter coupled to luciferase demonstrated that as few as 158 base pairs upstream from the transcription initiation site were sufficient to direct the monocyte-specific transcription of the reporter gene. Within the above region, the fragment spanning nucleotides -158 to -90 was required for optimal transcription in monocytic cells. Biochemical analysis of the region -158/-90 revealed a binding site for transcription factors of the polyomavirus enhancer-binding protein 2/core-binding factor (PEBP2/CBF) family at position -103. Disruption of the PEBP2/CBF site markedly diminished the CD36 promoter activity, indicating an essential role of the PEBP2/CBF factors in the constitutive transcription of the CD36 gene. The involvement of members of the PEBP2/CBF family in chromosome translocations associated with acute myeloid leukemia, and in the transcriptional regulation of the myeloid-specific genes encoding for myeloperoxidase, elastase, and the colony-stimulating factor receptor, highlights the relevance of the regulation of the CD36 gene promoter in monocytic cells by members of the PEBP2/CBF family.	CSIC,INST PARASITOL BIOMED LOPEZ NEYRA,E-18001 GRANADA,SPAIN; HOSP PRINCESA,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Hospital de La Princesa			Vega, Miguel A/M-1367-2016	Vega, Miguel A/0000-0001-6151-4193; Armesilla, Angel/0000-0003-3546-5580				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ARMESILLA AL, 1994, J BIOL CHEM, V269, P18985; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BAE SC, 1996, IN PRESS GENE AMST; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; CALVO D, 1995, GENOMICS, V25, P100, DOI 10.1016/0888-7543(95)80114-2; CALVO D, 1993, J BIOL CHEM, V268, P18929; CLEZARDIN P, 1985, BRIT J HAEMATOL, V60, P331, DOI 10.1111/j.1365-2141.1985.tb07419.x; EDELMAN P, 1986, BLOOD, V67, P56; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; GALSON DL, 1988, MOL CELL BIOL, V8, P381, DOI 10.1128/MCB.8.1.381; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOTTSCHALK LR, 1990, MOL CELL BIOL, V10, P5486, DOI 10.1128/MCB.10.10.5486; GREENWALT DE, 1995, J CLIN INVEST, V96, P1382, DOI 10.1172/JCI118173; GREENWALT DE, 1992, BLOOD, V80, P1105; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HUH HY, 1995, J BIOL CHEM, V270, P6267, DOI 10.1074/jbc.270.11.6267; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KIEFFER N, 1989, BIOCHEM J, V262, P835, DOI 10.1042/bj2620835; KONIG H, 1995, GENE DEV, V9, P1598, DOI 10.1101/gad.9.13.1598; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIN P, 1993, SCIENCE, V261, P1041; LU J, 1995, MOL CELL BIOL, V15, P1651; LUBBERT M, 1991, BLOOD, V77, P909; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PAHL HL, 1991, EXP HEMATOL, V19, P1038; PAHL HL, 1993, J BIOL CHEM, V268, P5014; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SILVERSTEIN RL, 1992, J BIOL CHEM, V267, P16607; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; SWERLICK RA, 1992, J IMMUNOL, V148, P78; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANDON NN, 1989, J BIOL CHEM, V264, P7576; VANSCHRAVENDIJK MR, 1992, BLOOD, V80, P2105; VEGA MA, 1991, J BIOL CHEM, V266, P16818; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	60	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7781	7787		10.1074/jbc.271.13.7781	http://dx.doi.org/10.1074/jbc.271.13.7781			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631821	hybrid			2022-12-27	WOS:A1996UC77400089
J	Brandish, PE; Burnham, MK; Lonsdale, JT; Southgate, R; Inukai, M; Bugg, TDH				Brandish, PE; Burnham, MK; Lonsdale, JT; Southgate, R; Inukai, M; Bugg, TDH			Slow binding inhibition of phospho-N-acetylmuramyl-pentapeptide-translocase (Escherichia coli) by mureidomycin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHEROPLAST FORMING ACTIVITY; CELL WALL PEPTIDOGLYCAN; PEPTIDYLNUCLEOSIDE ANTIBIOTICS; A-D; TRANSFERASE; RESISTANCE	Enzymes of the membrane cycle of reactions in bacterial peptidoglycan biosynthesis remain as unexploited potential targets for antibacterial agents, The first of these enzymes, phospho-N-acetylmuramyl-pentapeptide-translocase (EC 2.7.8.13), has been overexpressed in Escherichia cold and solubilized from particulate fractions, The work of W. A. Weppner and F. C. Neuhaus ((1977) J. Biol. Chem. 252, 2296-2303) has been extended to establish a usable routine fluorescence-based continuous assay for solubilized preparations, This assay has been used in the characterization of the natural product, mureidomycin A as a potent slow binding inhibitor of the enzyme with K-i and K-i* of 36 nM and 2 nM, respectively.	UNIV SOUTHAMPTON,DEPT CHEM,SOUTHAMPTON SO17 1BJ,HANTS,ENGLAND; SMITHKLINE BEECHAM PHARMACEUT,EPSOM KT18 5XQ,SURREY,ENGLAND; SMITHKLINE BEECHAM PHARMACEUT,BETCHWORTH RH3 7AJ,SURREY,ENGLAND; SANKYO CO LTD,BIOMED RES LABS,SHINAGAWA KU,TOKYO 140,JAPAN	University of Southampton; GlaxoSmithKline; GlaxoSmithKline; Daiichi Sankyo Company Limited								BANERJEE DK, 1989, J BIOL CHEM, V264, P2024; BUGG TDH, 1994, FEMS MICROBIOL LETT, V119, P255; BUGG TDH, 1992, NAT PROD REP, V9, P199, DOI 10.1039/np9920900199; DUNCAN K, 1988, BIOCHEMISTRY-US, V27, P3709, DOI 10.1021/bi00410a028; FLOURET B, 1981, ANAL BIOCHEM, V114, P59, DOI 10.1016/0003-2697(81)90451-6; HEYDANEK MG, 1970, BIOCHEMISTRY-US, V9, P3618, DOI 10.1021/bi00820a018; HEYDANEK MG, 1969, BIOCHEMISTRY-US, V8, P1474, DOI 10.1021/bi00832a024; HEYDANEK MG, 1969, BIOCHEMISTRY-US, V8, P1214, DOI 10.1021/bi00831a056; HIGASHI Y, 1967, P NATL ACAD SCI USA, V57, P1878, DOI 10.1073/pnas.57.6.1878; IKEDA M, 1991, J BACTERIOL, V173, P1021, DOI 10.1128/jb.173.3.1021-1026.1991; INUKAI M, 1993, ANTIMICROB AGENTS CH, V37, P980, DOI 10.1128/AAC.37.5.980; INUKAI M, 1989, J ANTIBIOT, V42, P662, DOI 10.7164/antibiotics.42.662; ISONO F, 1992, ANTIMICROB AGENTS CH, V36, P1024, DOI 10.1128/AAC.36.5.1024; ISONO F, 1989, J ANTIBIOT, V42, P674, DOI 10.7164/antibiotics.42.674; ISONO F, 1989, J ANTIBIOT, V42, P667, DOI 10.7164/antibiotics.42.667; KAUSHAL GP, 1985, J BIOL CHEM, V260, P6303; KIMURA K, 1989, AGR BIOL CHEM TOKYO, V53, P1811, DOI 10.1080/00021369.1989.10869560; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LUGTENBE.EJ, 1972, J BACTERIOL, V109, P326, DOI 10.1128/JB.109.1.326-335.1972; MORRISON JF, 1987, ADV ENZYMOL RELAT AR, V57, P201; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; Penefsky H S, 1979, Methods Enzymol, V56, P527; PLESS DD, 1973, J BIOL CHEM, V248, P1568; Segel I.H., 1993, ENZYME KINETICS, P606; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRUVE WG, 1966, BIOCHEMISTRY-US, V5, P82, DOI 10.1021/bi00865a012; SWARTZ MN, 1994, P NATL ACAD SCI USA, V91, P2420, DOI 10.1073/pnas.91.7.2420; TAMURA G, 1976, AGR BIOL CHEM TOKYO, V40, P447, DOI 10.1080/00021369.1976.10862071; TANAKA H, 1979, BIOCHEM BIOPH RES CO, V86, P906; UBUKATA M, 1988, J AM CHEM SOC, V110, P4416, DOI 10.1021/ja00221a052; VERMA AK, 1977, J BIOL CHEM, V252, P7235; WEPPNER WA, 1977, J BIOL CHEM, V252, P2296	32	97	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7609	7614		10.1074/jbc.271.13.7609	http://dx.doi.org/10.1074/jbc.271.13.7609			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631795	hybrid			2022-12-27	WOS:A1996UC77400063
J	Lee, JC; Turgeon, CL; Yeh, LCC				Lee, JC; Turgeon, CL; Yeh, LCC			The accessibility of yeast ribosomal protein l1 as probed by proteolysis and site-directed mutagenesis is different in intact 60 and 80 S ribosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOME; SACCHAROMYCES-CEREVISIAE RIBOSOMES; RNA-BINDING PROTEIN; INITIATION COMPLEX; CROSS-LINKING; SUBUNIT; CONFORMATION; DIGESTION; 5S-RNA	Accessible regions of protein L1 in intact 60 and 80 S ribosomes from Saccharomyces cervisiae were first detected by controlled proteolysis. The N-terminal region of L1 in either 60 S or 80 S particles, was inaccessible to proteases, but the central and C-terminal regions were accessible. The accessibility of the central region differed depending on the ribosome state. These regions were further examined by determination of the chemical reactivity of specific cysteine residues introduced into these regions by site-directed mutagenesis. All cysteine mutant proteins were capable of binding yeast 5 S rRNA in vitro and the ribosomes containing the mutant proteins were functional in vivo. Residues Cys-257 and Cys-275 were modified in both the 60 and 80 S ribosomes but the modification rates were different in the two ribosome states. Both residues Cys-62 and Cys-286 were inaccessible in 80 S or 60 S ribosomes. Taken together, the present study identified several accessible regions of L1 in intact ribosomes and further showed that the accessibility of some of the regions was altered upon ribosomal subunit association. The most likely interpretation of these results is that the conformation of the ribosomal protein L1 was altered upon ribosomal subunit association.			Lee, JC (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, SAN ANTONIO, TX 78284 USA.				NIGMS NIH HHS [GM-35851] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1991, DEV BIOL, V144, P129, DOI 10.1016/0012-1606(91)90485-L; ALLISON LA, 1993, MOL CELL BIOL, V13, P6819, DOI 10.1128/MCB.13.11.6819; ARPIN M, 1975, BIOCHIMIE, V57, P1177; BOUBLIK M, 1983, EUR J CELL BIOL, V32, P136; BRIMACOMBE R, 1990, BIOCHIM BIOPHYS ACTA, V1050, P8, DOI 10.1016/0167-4781(90)90133-M; CRICHTON RR, 1972, MOL GEN GENET, V114, P95, DOI 10.1007/BF00332780; DESHMUKH M, 1993, MOL CELL BIOL, V13, P2835, DOI 10.1128/MCB.13.5.2835; ERICSON G, 1989, J BIOL CHEM, V264, P540; GUDKOV AT, 1989, BIOCHIMIE, V71, P779, DOI 10.1016/0300-9084(89)90040-0; HENKEL B, 1974, ACTA BIOL MED GER, V33, P691; HOLMBERG L, 1994, NUCLEIC ACIDS RES, V22, P2776, DOI 10.1093/nar/22.14.2776; HOLMBERG L, 1992, J BIOL CHEM, V267, P21906; KENMOCHI N, 1989, BIOCHEM J, V259, P277, DOI 10.1042/bj2590277; KRUFT V, 1991, BIOCHEMISTRY-US, V30, P11781, DOI 10.1021/bi00115a007; LEE JC, 1985, ARCH BIOCHEM BIOPHYS, V237, P292, DOI 10.1016/0003-9861(85)90280-2; LEE JC, 1992, J BIOL CHEM, V267, P2502; LEE JC, 1983, ARCH BIOCHEM BIOPHYS, V224, P69, DOI 10.1016/0003-9861(83)90190-X; LEE JC, 1987, BIOCHIM BIOPHYS ACTA, V908, P109, DOI 10.1016/0167-4781(87)90049-2; LODMELL JS, 1993, BIOCHEMISTRY-US, V32, P4067, DOI 10.1021/bi00066a030; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOORE PB, 1986, STRUCTURE FUNCTION G, P87; NAZAR RN, 1979, EUR J BIOCHEM, V102, P573, DOI 10.1111/j.1432-1033.1979.tb04274.x; NEWBERRY V, 1978, NUCLEIC ACIDS RES, V5, P1753, DOI 10.1093/nar/5.6.1753; NOWOTNY V, 1986, STRUCTURE FUNCTION G, P101; NYGARD O, 1987, BIOCHIM BIOPHYS ACTA, V908, P46, DOI 10.1016/0167-4781(87)90020-0; NYGARD O, 1990, EUR J BIOCHEM, V191, P1, DOI 10.1111/j.1432-1033.1990.tb19087.x; OAKES MI, 1990, RIBOSOME, P180; PINARD R, 1993, FASEB J, V7, P173, DOI 10.1096/fasebj.7.1.7678560; ROMBY P, 1990, BIOCHIM BIOPHYS ACTA, V1050, P84, DOI 10.1016/0167-4781(90)90146-S; SERDYUK IN, 1986, STRUCTURE FUNCTION G, P425; STEITZ JA, 1988, J CELL BIOL, V106, P545, DOI 10.1083/jcb.106.3.545; STOFFLERMEILICKE M, 1990, RIBOSOME, P123; TAKAHASHI Y, 1985, EUR J BIOCHEM, V152, P279, DOI 10.1111/j.1432-1033.1985.tb09195.x; TERAO K, 1982, J BIOCHEM-TOKYO, V92, P1663, DOI 10.1093/oxfordjournals.jbchem.a134093; Traut R. R., 1980, RIBOSOMES STRUCTURE, P89; TSAY YF, 1990, THESIS CARNEGIE MELL; UCHIUMI T, 1986, J BIOL CHEM, V261, P9663; WELLER JW, 1992, BIOCHEMISTRY-US, V31, P2748, DOI 10.1021/bi00125a015; WESTERMANN P, 1983, BIOCHIM BIOPHYS ACTA, V741, P103, DOI 10.1016/0167-4781(83)90015-5; WILSON JE, 1991, METHOD BIOCHEM ANAL, V35, P207; YEH LCC, 1995, BIOCHIMIE, V77, P167, DOI 10.1016/0300-9084(96)88121-1; YEH LCC, 1995, J MOL BIOL, V246, P295, DOI 10.1006/jmbi.1994.0085; YEH LCC, 1990, ARCH BIOCHEM BIOPHYS, V276, P481, DOI 10.1016/0003-9861(90)90748-N	43	3	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7429	7434		10.1074/jbc.271.13.7429	http://dx.doi.org/10.1074/jbc.271.13.7429			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631769	hybrid			2022-12-27	WOS:A1996UC77400037
J	Stewart, L; Ireton, GC; Champoux, JJ				Stewart, L; Ireton, GC; Champoux, JJ			The domain organization of human topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; NUCLEOTIDE-SEQUENCE; CATALYTIC ACTIVITY; RECOGNITION SITES; CLEAVAGE INVITRO; BINDING SEQUENCE; SV40 DNA; CAMPTOTHECIN; SPECIFICITY; PREFERENCE	Using limited proteolysis, me show that the domain boundaries of human topoisomerase I closely parallel those predicted from sequence comparisons with other cellular Topo I enzymes. The enzyme is comprised of (i) an NH2-terminal domain (similar to 24 kDa), which is known to be dispensable for activity, (ii) the core domain (similar to 54 kDa), (iii) a linker region (similar to 3 kDa), and (iv) the COOH-terminal domain (similar to 10 kDa), which contains the active site tyrosine. The highly conserved core and COOH-terminal domains are resistant to proteolysis, while the unconserved NH2-terminal and linker domains are sensitive. Noncovalent binding of Topo I to plasmid DNA or to short duplex oligonucleotides decreases the sensitivity of the linker to proteolysis by approximately a factor of 10 but has no effect on proteolysis of the NH2-terminal domain, When the enzyme is covalently complexed to an 18 base pair single-stranded oligonucleotide, the linker region is sensitive to proteolysis whether or not duplex DNA is present. The net positive charge of the linker domain suggests that at a certain point in catalysis the linker may bind directly to DNA. Further, we show that limited subtilisin cleavage can generate a mixture of 60-kDa core and similar to 10-kDa COOH-terminal fragments, which retain a level. of topoisomerase activity that is nearly equal to undigested control samples, presumably because the two fragments remain associated after proteolytic cleavage, Thus, despite its potential role in DNA binding, the linker domain (in addition to the NH2-terminal domain) appears to be dispensable for topoisomerase activity, Finally, the limited proteolysis pattern of the human enzyme differs substantially from the limited proteolysis pattern of the vaccinia viral Topo I, indicating that the two enzymes belong to separate eukaryotic topoisomerase I subfamilies.	UNIV WASHINGTON,SCH MED,DEPT MICROBIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049156] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49156] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSNER J, 1992, J BIOL CHEM, V267, P12408; ANDERSEN AH, 1985, NUCLEIC ACIDS RES, V13, P1543, DOI 10.1093/nar/13.5.1543; BEDNAR J, 1994, J MOL BIOL, V235, P825, DOI 10.1006/jmbi.1994.1042; BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHRISTIANSEN K, 1993, J BIOL CHEM, V268, P9690; CHRISTIANSEN K, 1994, J BIOL CHEM, V269, P721; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; EDWARDS KA, 1982, NUCLEIC ACIDS RES, V10, P2565, DOI 10.1093/nar/10.8.2565; Harlow E., 1988, ANTIBODIES LAB MANUA; HERTZBERG RP, 1989, J MED CHEM, V32, P715, DOI 10.1021/jm00123a038; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; KIKUCHI A, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P121; KJELDSEN E, 1988, J MOL BIOL, V202, P333, DOI 10.1016/0022-2836(88)90462-7; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MADDEN KR, 1995, EMBO J, V14, P5399, DOI 10.1002/j.1460-2075.1995.tb00224.x; MADDEN KR, 1992, CANCER RES, V52, P525; PARKER LH, 1993, J MOL BIOL, V231, P6, DOI 10.1006/jmbi.1993.1252; PEREZSTABLE C, 1988, NUCLEIC ACIDS RES, V16, P7975, DOI 10.1093/nar/16.16.7975; PORTER SE, 1989, MOL CELL BIOL, V9, P541, DOI 10.1128/MCB.9.2.541; SEKIGUCHI J, 1995, J BIOL CHEM, V270, P11636, DOI 10.1074/jbc.270.19.11636; SHARMA A, 1994, STRUCTURE, V2, P767, DOI 10.1016/S0969-2126(94)00077-8; SHEN CC, 1990, J MOL BIOL, V212, P67, DOI 10.1016/0022-2836(90)90305-6; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; STEVNSNER T, 1989, J BIOL CHEM, V264, P10110; STEWART L, 1991, J VIROL, V65, P6218, DOI 10.1128/JVI.65.11.6218-6231.1991; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; SVEJSTRUP JQ, 1990, J BIOL CHEM, V265, P12529; TANIZAWA A, 1993, NUCLEIC ACIDS RES, V21, P5175; THOMSEN B, 1987, EMBO J, V6, P1817, DOI 10.1002/j.1460-2075.1987.tb02436.x; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	36	151	154	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7602	7608		10.1074/jbc.271.13.7602	http://dx.doi.org/10.1074/jbc.271.13.7602			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631794	hybrid			2022-12-27	WOS:A1996UC77400062
J	Gong, ZY; Ewart, KV; Hu, ZZ; Fletcher, GL; Hew, CL				Gong, ZY; Ewart, KV; Hu, ZZ; Fletcher, GL; Hew, CL			Skin antifreeze protein genes of the winter flounder, Pleuronectes americanus, encode distinct and active polypeptides without the secretory signal and prosequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT; FISH; PRECURSOR; SEQUENCE; DNA; ICE; RNA	Distinct antifreeze polypeptides (AFP) were isolated from the skin of the winter flounder, Pleuronectes americanus, by gel filtration and reverse phase high performance liquid chromatography. In parallel, several cDNA clones were isolated from a skin cDNA library using a liver AFP cDNA probe, Both protein and DNA sequence analyses indicate that flounder skin contains several distinct but homologous alanine-rich AFPs. Although the skin type AFPs contain 11 similar amino acid repeats found in the secretory liver type AFPs, the skin type AFPs are mature polypeptides lacking both the signal and prosequences, indicating that they may function intracellularly. The skin type AFP is significantly less active in thermal hysteretic activity than the liver type AFP. Genomic Southern analysis indicates that like the liver type AFP genes, there are multiple copies (30-40 copies) of skin type AFP. Although the liver type AFP genes are specifically expressed in the liver and to a lesser extent in intestine, the skin type AFP genes are expressed in all tissues examined including the liver and abundantly in exterior tissues, i.e. skin, scales, fin, and gills, suggesting an important protecting role in these exterior tissues.	UNIV TORONTO, DEPT CLIN BIOCHEM, TORONTO, ON M5G 1L5, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO, ON M5G 1L5, CANADA; HOSP SICK CHILDREN, RES INST, TORONTO, ON M5G 1L5, CANADA; NATL UNIV SINGAPORE, DEPT ZOOL, SINGAPORE 117548, SINGAPORE; MEM UNIV NEWFOUNDLAND, CTR OCEAN SCI, ST JOHNS, NF A1C 5S7, CANADA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); National University of Singapore; Memorial University Newfoundland			Hew, Choy Leong/I-1501-2012; Gong, Zhiyuan/H-8794-2012	Hew, Choy Leong/0000-0002-9441-0064; Gong, Zhiyuan/0000-0002-9660-5260				BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CHAKRABARTTY A, 1989, J BIOL CHEM, V264, P11313; CHAKRABARTTY A, 1988, CAN J ZOOL, V66, P403, DOI 10.1139/z88-057; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Davies Peter L., 1993, Biochemistry and Molecular Biology of Fishes, V2, P279; DAVIES PL, 1982, P NATL ACAD SCI-BIOL, V79, P335, DOI 10.1073/pnas.79.2.335; DAVIES PL, 1992, GENE, V112, P171, DOI 10.1016/0378-1119(92)90373-W; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; DEVRIES AL, 1983, ANNU REV PHYSIOL, V45, P245, DOI 10.1146/annurev.ph.45.030183.001333; Ewart K. Vanya, 1993, Molecular Marine Biology and Biotechnology, V2, P20; FLETCHER GL, 1989, FISH PHYSIOL BIOCHEM, V7, P387, DOI 10.1007/BF00004733; FOURNEY RM, 1984, CAN J ZOOL, V62, P28, DOI 10.1139/z84-006; GONG ZY, 1992, CAN J ZOOL, V70, P810, DOI 10.1139/z92-114; GONG ZY, 1995, BIOCHEM BIOPH RES CO, V206, P387, DOI 10.1006/bbrc.1995.1053; GRIFFITH M, 1995, BIOTECHNOL ADV, V13, P375, DOI 10.1016/0734-9750(95)02001-J; HEW CL, 1988, J BIOL CHEM, V263, P12049; HEW CL, 1986, EUR J BIOCHEM, V160, P267, DOI 10.1111/j.1432-1033.1986.tb09966.x; HEW CL, 1985, EUR J BIOCHEM, V151, P167, DOI 10.1111/j.1432-1033.1985.tb09081.x; KAO MH, 1986, CAN J ZOOL, V64, P578, DOI 10.1139/z86-085; KREIL G, 1994, CIBA F SYMP, V186, P77; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; PICKETT M, 1984, EUR J BIOCHEM, V143, P35, DOI 10.1111/j.1432-1033.1984.tb08335.x; PICKETT MH, 1983, BIOCHIM BIOPHYS ACTA, V739, P97, DOI 10.1016/0167-4781(83)90049-0; Sambrook J., 2002, MOL CLONING LAB MANU; SCOTT GK, 1985, P NATL ACAD SCI USA, V82, P2613, DOI 10.1073/pnas.82.9.2613; SCOTT GK, 1987, EUR J BIOCHEM, V168, P629, DOI 10.1111/j.1432-1033.1987.tb13462.x; SICHERI F, 1995, NATURE, V375, P427, DOI 10.1038/375427a0; VALERIO PF, 1992, J EXP BIOL, V164, P135; WEN DY, 1992, BIOPHYS J, V63, P1659, DOI 10.1016/S0006-3495(92)81750-2; WEN DY, 1992, J BIOL CHEM, V267, P14102	30	73	83	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4106	4112						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626748	hybrid			2022-12-27	WOS:A1996TW96000026
J	Penrose, JF; Spector, J; Baldasaro, M; Xu, KY; Boyce, J; Arm, JP; Austen, KF; Lam, BK				Penrose, JF; Spector, J; Baldasaro, M; Xu, KY; Boyce, J; Arm, JP; Austen, KF; Lam, BK			Molecular cloning of the gene for human leukotriene C-4 synthase - Organization, nucleotide sequence, and chromosomal localization to 5q35	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-LIPOXYGENASE-ACTIVATING PROTEIN; HUMAN EOSINOPHILS; HUMAN-LEUKOCYTES; CELL-CULTURES; MAST-CELLS; IDENTIFICATION; PURIFICATION; ASTHMA; INTERLEUKIN-5; BIOSYNTHESIS	Leukotriene C-4 (LTC(4)) synthase catalyzes the conjugation of LTA(4) with reduced GSH to form LTC(4), the parent of the receptor active cysteinyl leukotrienes implicated in the pathobiology of bronchial asthma. Previous cloning of the cDNA for human LTC(4) synthase demonstrated significant homology of its amino acid sequence to that of 5-lipoxygenase activating protein (FLAP) but none to that of the GSH S-transferase superfamily. Genomic cloning from a P1 library now reveals that the gene for LTC(4) synthase contains five exons (ranging from 71 to 257 nucleotides in length) and four introns, which in total span 2.52 kilobase pairs in length. The intron/exon junctions of LTC(4) synthase align identically with those of FLAP; however, the small size of the LTC(4) synthase gene contrasts with the >31-kilobase pair size reported for FLAP. Confirmation of the LTC(4) synthase gene size to ensure that no deletions had occurred during the cloning was obtained by two overlapping polymerase chain reactions from genomic DNA, which provided products of the predicted sizes. Primer extension analysis with poly(A)(+) RNA from culture-derived human eosinophilic granulocytes or the KG-1 myelogenous cell line revealed multiple transcriptional start sites with prominent signals at 66, 69, and 96 base pairs 5' of the ATG translation start site. The 5'-flanking region revealed a GC-rich promotor sequence consistent with an SP-1 site and consensus sequences for AP-1 and AP-2 enhancer elements, 24, 807, and 877 bp, respectively, 5' from the first transcription initiation site. Southern blot analysis of a genomic DNA (with full-length cDNA as well as 5' and 3' oligonucleotide probes) confirmed the size of the gene and indicated a single copy gene in normal human genomic DNA. Fluorescent in situ hybridization mapped LTC(4) synthase to chromosomal location 5q35, which is in close proximity 60 the cluster of genes for cytokines and receptors involved in the regulation of cells central to allergic inflammation and implicated in bronchial asthma.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV RHEUMATOL & IMMUNOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022531, R37AI022531, U01AI031599, U19AI031599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES006105] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22531, AI31599] Funding Source: Medline; NIEHS NIH HHS [ES06105] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BOYCE JA, 1995, J EXP MED, V182, P49, DOI 10.1084/jem.182.1.49; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHRISTIE PE, 1991, AM REV RESPIR DIS, V144, P957, DOI 10.1164/ajrccm/144.4.957; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; DAVIDSON AB, 1987, AM REV RESPIR DIS, V135, P333; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P863, DOI 10.1164/ajrccm/142.4.863; DVORAK AM, 1989, LAB INVEST, V61, P116; ERNST P, 1995, IMMUNITY, V2, P311, DOI 10.1016/1074-7613(95)90139-6; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; FUNK CD, 1992, P NATL ACAD SCI USA, V89, P3962, DOI 10.1073/pnas.89.9.3962; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; ISRAEL E, 1993, ANN INTERN MED, V119, P1059, DOI 10.7326/0003-4819-119-11-199312010-00001; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KENNEDY BP, 1991, J BIOL CHEM, V266, P8511; KERSANACH R, 1994, NATURE, V367, P387, DOI 10.1038/367387a0; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; LAM BK, 1989, J BIOL CHEM, V264, P12885; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; LEBMAN DA, 1988, J EXP MED, V168, P853, DOI 10.1084/jem.168.3.853; LEE CW, 1983, IMMUNOLOGY, V48, P27; LEVITT RC, 1995, CLIN EXP ALLERGY, V25, P119, DOI 10.1111/j.1365-2222.1995.tb00439.x; MACGLASHAN DW, 1986, J IMMUNOL, V136, P2231; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MCNISH RW, 1993, BIOCHEM BIOPH RES CO, V196, P147; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; MOSSMANN TR, 1989, ADV IMMUNOL, V46, P111; NICHOLSON DW, 1993, P NATL ACAD SCI USA, V90, P2015, DOI 10.1073/pnas.90.5.2015; NICHOLSON DW, 1992, J BIOL CHEM, V267, P17849; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; OWEN WF, 1989, J EXP MED, V170, P343, DOI 10.1084/jem.170.1.343; PENROSE JF, 1995, AM J RESP CRIT CARE, V152, P283, DOI 10.1164/ajrccm.152.1.7599836; PENROSE JF, 1992, P NATL ACAD SCI USA, V89, P11603, DOI 10.1073/pnas.89.23.11603; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; ROUZER CA, 1986, P NATL ACAD SCI USA, V83, P857, DOI 10.1073/pnas.83.4.857; ROUZER CA, 1985, P NATL ACAD SCI USA, V82, P6040, DOI 10.1073/pnas.82.18.6040; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMALE S.T., 1994, TRANSCRIPTION MECHAN, P63; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; SODERSTROM M, 1992, BIOCHEM BIOPH RES CO, V189, P1043, DOI 10.1016/0006-291X(92)92309-L; TATE SS, 1981, MOL CELL BIOCHEM, V39, P357, DOI 10.1007/BF00232585; TAYLOR GW, 1989, LANCET, V1, P584; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; VANLEEUWEN BH, 1989, BLOOD, V73, P1142; VICKERS PJ, 1992, MOL PHARMACOL, V42, P94; WASMUTH JJ, 1991, CYTOGENET CELL GENET, V58, P261, DOI 10.1159/000133165; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WELSCH DJ, 1994, P NATL ACAD SCI USA, V91, P9745, DOI 10.1073/pnas.91.21.9745; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935	62	90	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11356	11361		10.1074/jbc.271.19.11356	http://dx.doi.org/10.1074/jbc.271.19.11356			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626689	hybrid			2022-12-27	WOS:A1996UJ94400049
J	Sauma, S; Friedman, E				Sauma, S; Friedman, E			Increased expression of protein kinase C beta activates ERK3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; TYROSINE; AUTOPHOSPHORYLATION; DIFFERENTIATION; CARCINOGENESIS; SEQUENCES	In a prior study, we have shown that stable transfection of expression plasmids for protein kinase C beta 1 (PKC beta 1) or PKC beta 2 into differentiated colon cancer cells led to elevated levels of PKC beta 1 or PKC beta 2 protein and PKC beta kinase activities in the transfectants, without altering PKC alpha levels. PKC gamma is not found in these cells, so the major modulation was in PKC beta. PKC beta transfectant cells exhibited blocked differentiation, increased growth rate in athymic mice, and restoration of the basic fibroblast growth factor response pathway. In this study, we have extended the analysis of these PKC beta transfectants to the mitogen-activated protein kinase ERK3. Analysis of cell lysates on the mitogen-activated protein kinase substrate myelin basic protein by in gel kinase assay showed increased activity at 63 kDa, the size of ERK3, in each of two PKC beta 1 and each of two PKC beta 2 transfectants compared with the vector control transfectant. ERK3 was expressed at equal abundance in PRC beta 1, PKC beta 2, and control transfectant cells as demonstrated by Western blotting and by immunoprecipitation with anti-ERK3 monoclonal antibody. However, a >10-fold increase in ERK3 activity in each PKC beta transfectant was shown by immunoprecipitation with anti-ERK3 monoclonal antibody followed by either immune complex kinase assay or by in gel kinase assay. Thus, while overexpression of transfected PKC beta does not lead to overexpression of ERK3, it does lead to constitutive activation of ERK3. A causal link between PKC beta overexpression and ERK3 activation was established because 12-O-tetradecanoylphorbol-13-acetate treatment down-regulated both PKC and ERK3 activities in both PKC beta 1 transfectants. ERK3 activity was found in nuclear and membrane fractions in each PKC beta transfectant, in contrast to controls, perhaps accounting for constitutive activation of ERK3 in cells with elevated levels of PKC beta 1 or PKC beta 2.	MEM SLOAN KETTERING CANC CTR,LAB GASTROINTESTINAL TUMOR BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [R01CA045783, R01CA067405] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA45783, R01 CA67405] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CRAVEN PA, 1992, CANCER RES, V52, P2216; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOEI S, 1994, MOL CARCINOGEN, V11, P197; FRIEDMAN EA, 1981, CANCER RES, V41, P4588; GOLDSTEIN DR, 1995, CARCINOGENESIS, V16, P1121, DOI 10.1093/carcin/16.5.1121; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GUILLEM JG, 1988, CANCER RES, V48, P3964; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; KAHLRAINER P, 1994, CARCINOGENESIS, V15, P779, DOI 10.1093/carcin/15.4.779; KUBO K, 1987, FEBS LETT, V223, P138, DOI 10.1016/0014-5793(87)80524-0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE HS, 1993, J BIOL CHEM, V268, P5255; MURRAY NR, 1994, J BIOL CHEM, V269, P21385; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; OKA H, 1995, CANCER RES, V55, P4182; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RESKA A, 1995, P NATL ACAD SCI USA, V92, P8881; SAUMA S, 1996, IN PRESS CELL GROWTH, V7; SAXON ML, 1994, J CELL BIOL, V126, P747, DOI 10.1083/jcb.126.3.747; SCHWARTZ GK, 1993, J NATL CANCER I, V85, P402, DOI 10.1093/jnci/85.5.402; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; YAN ZF, 1994, J BIOL CHEM, V269, P13231; ZHO G, 1995, J BIOL CHEM, V270, P12664; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202	31	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11422	11426		10.1074/jbc.271.19.11422	http://dx.doi.org/10.1074/jbc.271.19.11422			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626698	hybrid			2022-12-27	WOS:A1996UJ94400058
J	Seiffert, D				Seiffert, D			Hydrolysis of platelet vitronectin by calpain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; S-PROTEIN; IDENTIFICATION; CLEAVAGE; DOMAIN; SITE; EXPRESSION; SEQUENCE; HEPARIN; COMPLEX	Vitronectin (Vn) is not only a major adhesive glycoprotein present in platelets but also regulates proteolytic enzyme cascades, including the blood coagulation, fibrinolytic, and complement systems. In human platelet lysates prepared by freeze-thawing or by the addition of nonionic detergent, the Vn antigen content was drastically reduced in comparison with lysates prepared in tire presence of SDS, suggesting that Vn is hydrolyzed by platelet-associated enzymes. Exogenously added purified human Vn and Vn present in plasma were also cleaved by these enzyme systems. Degradation was mediated by a nonsecreted or membrane-associated protease system that was inhibited by E-64, EDTA, and leu-peptin but not inhibitors of serine and aspartic proteases, suggesting an involvement of calcium-dependent cysteine proteases. Consistently, calpastatin inhibited the hydrolysis of Vn, suggesting that Vn is a substrate for calpain. This was confirmed in a purified system. Vn was cleaved by calpains I and II in a dose- and time-dependent manner, resulting in defined Vn fragments with similar electrophoretic mobility in comparison with those detected in platelet lysates. Functional characterization of the calpain-hydrolyzed Vn revealed that while the type 1 plasminogen activator inhibitor binding activity was unchanged, the heparin and cell binding functions were destroyed. These results suggest that calpains released upon platelet membrane damage or upon tissue injury and necrosis differentially regulate functional domains of the Vn molecule.			Seiffert, D (corresponding author), SCRIPPS RES INST, DEPT VASC BIOL VB3, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050704] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50704] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNES DW, 1983, P NATL ACAD SCI-BIOL, V80, P1362, DOI 10.1073/pnas.80.5.1362; CHAIN D, 1991, FEBS LETT, V285, P251, DOI 10.1016/0014-5793(91)80810-P; CHERNY RC, 1993, J BIOL CHEM, V268, P9725; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; GECHTMAN Z, 1993, FEBS LETT, V315, P293, DOI 10.1016/0014-5793(93)81181-X; Holmsen H., 1994, HEMOSTASIS THROMBOSI, P524; KAMBAYASHI J, 1989, METHOD ENZYMOL, V169, P442; KOST C, 1992, J BIOL CHEM, V267, P12098; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOSKUTOFF DJ, 1991, FIBRINOLYSIS, V5, P197, DOI 10.1016/0268-9499(91)90001-K; PARKER CJ, 1989, BRIT J HAEMATOL, V71, P245, DOI 10.1111/j.1365-2141.1989.tb04262.x; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PREISSNER KT, 1989, BLOOD, V74, P1989; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SCHMAIER AH, 1990, BLOOD, V75, P1273; SEIFFERT D, 1990, J CELL BIOL, V111, P1283, DOI 10.1083/jcb.111.3.1283; SEIFFERT D, 1991, P NATL ACAD SCI USA, V88, P9402, DOI 10.1073/pnas.88.21.9402; SEIFFERT D, 1995, FEBS LETT, V368, P155, DOI 10.1016/0014-5793(95)00630-R; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; SIGURDARDOTTIR O, 1994, BBA-PROTEIN STRUCT M, V1208, P104, DOI 10.1016/0167-4838(94)90166-X; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; TOMASINI BR, 1990, PROGR HEMOSTASIS THR, P269; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZHAO Y, 1993, BIOCHEM BIOPH RES CO, V192, P575, DOI 10.1006/bbrc.1993.1454	28	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11170	11176		10.1074/jbc.271.19.11170	http://dx.doi.org/10.1074/jbc.271.19.11170			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626663				2022-12-27	WOS:A1996UJ94400023
J	Winston, J; Dong, F; Pledger, WJ				Winston, J; Dong, F; Pledger, WJ			Differential modulation of G(1) cyclins and the Cdk inhibitor p27(kip1) by platelet-derived growth factor and plasma factors in density-arrested fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; CELL-CYCLE; MAMMALIAN-CELLS; DNA-REPLICATION; PROTEIN-KINASE; TGF-BETA; G1; G(1)-CYCLINS; TRANSITION; EXPRESSION	Stimulation of quiescent Balb/c 3T3 fibroblasts into S phase requires the synergistic action of platelet-derived growth factor (PDGF) and progression factors found in platelet-poor plasma (PPP). Traverse of the G(1)/S phase boundary and the initiation of DNA replication require functional cyclin E-cyclin-dependent kinase (Cdk) 2 and cyclin A-Cdk2 complexes; however, the mechanisms by which PDGF and PPP regulate Cdk2 activation are not known. Density-arrested fibroblasts contain low levels of cyclins E and A, and high levels of the Cdk inhibitor p27(kip1). Exposure to PDGF, which stimulates cell cycle entry but not progression through G(1), induces the formation of cyclin D-1-Cdk4 complexes that bind p27(kip1) and titrate the pool of Kip1 available to inhibit Cdk2. In addition, PDGF stimulates a moderate transient reduction in the abundance of p27(kip1) protein, However, limited expression of cyclin E and cyclin A is observed after PDGF treatment, and in the absence of PPP, p27 levels are sufficient to bind and inactivate existing cyclin-Cdk complexes. Although plasma does not significantly increase the proportion of Kip1 bound to cyclin D-1-Cdk4, stimulation of PDGF-treated cells with plasma does overcome the threshold inhibition of p27(kip1) by further increasing the expression of cyclins E and A and decreasing the amount of Kip1 over a prolonged time period. Our results indicate that the distinct mitogenic activities of PDGF and PPP differentially influence the activation of cyclin E- and cyclin A-associated kinases that ultimately regulate entry into S phase.	UNIV S FLORIDA,H LEE MOFFIT CANC CTR & RES INST,TAMPA,FL 33612; UNIV S FLORIDA,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33612; UNIV S FLORIDA,DEPT MED MICROBIOL,TAMPA,FL 33612; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Vanderbilt University					NATIONAL CANCER INSTITUTE [R01CA067360] Funding Source: NIH RePORTER; NCI NIH HHS [CA67360] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJCHENBAUM F, 1993, CELL, V75, P817; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LEOF EB, 1982, J CELL BIOCHEM, V19, P93, DOI 10.1002/jcb.240190108; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSAUBO M, 1993, SCIENCE, V259, P1980; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON PYC, 1995, MOL BIOL CELL, V6, P1197; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1993, ONCOGENE, V8, P1593; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910	35	71	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11253	11260		10.1074/jbc.271.19.11253	http://dx.doi.org/10.1074/jbc.271.19.11253			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626675	hybrid			2022-12-27	WOS:A1996UJ94400035
J	Baum, LG; Derbin, K; Perillo, NL; Wu, T; Pang, M; Uittenbogaart, C				Baum, LG; Derbin, K; Perillo, NL; Wu, T; Pang, M; Uittenbogaart, C			Characterization of terminal sialic acid linkages on human thymocytes - Correlation between lectin-binding phenotype and sialyltransferase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; HAMSTER OVARY CELLS; LINKED OLIGOSACCHARIDES; PEANUT AGGLUTININ; MOLECULAR-CLONING; GENE; GLYCOSYLATION; ALPHA-2,3-SIALYLTRANSFERASE; ANTIGEN; DIFFERENTIATION	T cell surface sialylation changes during maturation in the thymus, We have previously demonstrated increased expression of mRNA encoding the Gal beta 1, 3GalNAc alpha 2,3-sialyltransferase in mature medullary human thymocytes, compared with immature cortical thymocytes, For this enzyme, increased expression of transferase mRNA correlated with increased sialylation of O-glycans, We have now examined the pattern of expression in the human thymus of two additional sialyltransferases, the Gal beta 1,4GlcNAc alpha 2,6-sialyltransferase (ST6N) and the Gal beta 1,3/4GlcNAc alpha 2,3-sialyltransferase (ST3N), The patterns of mRNA expression were compared with the pattern of binding of two sialic acid-specific plant lectins, Sambucus nigra agglutinin and Maackia amurensis agglutinin, which preferentially recognize alpha 2,6- and alpha 2,3-linked sialic acids, respectively, on N-glycans, By in situ hybridization, mRNA encoding ST3N was detected uniformly throughout the thymus, All thymocytes bound M, amurensis agglutinin, demonstrating a direct correlation between the level of ST3N mRNA expression and cell-surface glycosylation, In contrast, mRNA encoding ST6N was also expressed uniformly throughout the thymus; however, only mature (CD3(hi)) medullary thymocytes bound S. nigra agglutinin, On mature thymocytes, S. nigra agglutinin appeared to bind primarily to the cell-surface glycoprotein CD45; since only the mature thymocytes expressed the CD45RA isoform, while both mature and immature populations expressed the CD45R0 isoform, CD45RA may be a preferred substrate for ST6N, These results demonstrate that glycoprotein sialylation is tightly regulated during T cell development and that the developmentally regulated expression of specific oligosaccharide structures on the cell surface may be influenced by expression of both the relevant glycosyltransferase and specific acceptor substrate.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Baum, LG (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL & LAB MED,10833 LECONTE AVE,LOS ANGELES,CA 90024, USA.				NCI NIH HHS [CA-16042] Funding Source: Medline; NIAID NIH HHS [AI-07126] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKASHI M, 1988, BLOOD, V72, P469; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BORREBAECK CAK, 1993, IMMUNOL TODAY, V14, P477, DOI 10.1016/0167-5699(93)90259-N; BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; Colin Hughes R., 1992, CURR OPIN STRUC BIOL, V2, P687, DOI 10.1016/0959-440X(92)90202-I; CUMMING D A, 1991, Glycobiology, V1, P115, DOI 10.1093/glycob/1.2.115; DAHMS NM, 1986, J BIOL CHEM, V261, P3186; DESPONT JP, 1975, CELL IMMUNOL, V17, P487, DOI 10.1016/S0008-8749(75)80052-9; DO KY, 1994, J BIOL CHEM, V269, P23456; FOX RI, 1983, J IMMUNOL, V131, P762; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; GILLESPIE W, 1993, J BIOL CHEM, V268, P3801; GOELZ S, 1994, J BIOL CHEM, V269, P1033; HANASAKI K, 1994, J BIOL CHEM, V269, P10637; IWAMORI M, 1989, J BIOCHEM-TOKYO, V105, P723, DOI 10.1093/oxfordjournals.jbchem.a122735; KANEKO Y, 1995, J HISTOCHEM CYTOCHEM, V43, P945, DOI 10.1177/43.9.7642967; KEPPLER OT, 1992, EUR J IMMUNOL, V22, P2777, DOI 10.1002/eji.1830221104; KIJIMOTOOCHIAI S, 1995, GLYCOBIOLOGY, V5, P443, DOI 10.1093/glycob/5.4.443; KITIGAWA H, 1994, J BIOL CHEM, V269, P17872; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LEE EU, 1989, J BIOL CHEM, V264, P13848; Lowe J B, 1991, Semin Cell Biol, V2, P289; LOWE JB, 1991, J BIOL CHEM, V266, P17467; OHANLON TP, 1989, J BIOL CHEM, V264, P17389; OHTA T, 1994, BIOCHEM BIOPH RES CO, V200, P1283, DOI 10.1006/bbrc.1994.1590; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; POWELL LD, 1994, J BIOL CHEM, V269, P10628; REISNER Y, 1976, CELL IMMUNOL, V25, P129, DOI 10.1016/0008-8749(76)90103-9; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SATO T, 1993, BIOCHEMISTRY-US, V32, P12694, DOI 10.1021/bi00210a019; SAWADA R, 1993, J BIOL CHEM, V268, P12675; SGROI D, 1994, SCAND J IMMUNOL, V39, P433, DOI 10.1111/j.1365-3083.1994.tb03397.x; SGROI D, 1995, P NATL ACAD SCI USA, V92, P4026, DOI 10.1073/pnas.92.9.4026; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; SMITH DF, 1990, J BIOL CHEM, V265, P6225; STANLEY P, 1992, GLYCOBIOLOGY, V2, P99, DOI 10.1093/glycob/2.2.99; TAATJES DJ, 1988, J BIOL CHEM, V263, P6302; TERSTAPPEN LWMM, 1992, BLOOD, V79, P666; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; UENO Y, 1989, CELL IMMUNOL, V124, P239, DOI 10.1016/0008-8749(89)90128-7; UITTENBOGAART C H, 1990, International Immunology, V2, P1179, DOI 10.1093/intimm/2.12.1179; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; VEROSTEK MF, 1995, GLYCOBIOLOGY, V5, P671, DOI 10.1093/glycob/5.7.671; VOLLGER LW, 1993, CYTOKINE, V5, P157, DOI 10.1016/1043-4666(93)90055-A; WANG WC, 1988, J BIOL CHEM, V263, P4576; WANG XC, 1993, J BIOL CHEM, V268, P4355; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEN DX, 1992, J BIOL CHEM, V267, P21011; WHITEHEART SW, 1990, CELL IMMUNOL, V125, P337, DOI 10.1016/0008-8749(90)90089-A	52	86	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10793	10799		10.1074/jbc.271.18.10793	http://dx.doi.org/10.1074/jbc.271.18.10793			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631891	hybrid			2022-12-27	WOS:A1996UJ34200059
J	Chacko, GW; Brandt, JT; Coggeshall, KM; Anderson, CL				Chacko, GW; Brandt, JT; Coggeshall, KM; Anderson, CL			Phosphoinositide 3-kinase and p72(syk) noncovalently associate with the low affinity Fc gamma receptor on human platelets through an immunoreceptor tyrosine-based activation motif - Reconstitution with synthetic phosphopeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; CELL-LINE; KINASE; THROMBIN; PHOSPHORYLATION; RII	Previously, we have demonstrated that the cytoplasmic tyrosine kinase p72(syk) is coupled to the platelet Fc receptor for IgG (Fc gamma RIIA) (Chacko, G. W., Duchemin, A. M., Coggeshall, K. M., Osborne, J. M., Brandt, J. T., and Anderson, C. L. (1994) J. Biol. Chem. 269, 32435-32440). Further analysis of the platelet activation by Fc gamma RIIA demonstrated that Fc gamma RIIA is also inducibly coupled to the serine/threonine and lipid kinase, phosphoinositide 3-kinase (PI 3-K), Activation of platelets with anti-Fc gamma RIIA. antibodies resulted in the noncovalent association of PI 3-K with Fc gamma RIIA as well as an increase in Fc gamma RIIA-associated PI 3-K activity, Binding of both p72(syk) and PI 3-K to Fc gamma RIIA was reconstituted with synthetic phosphopeptides corresponding to the sequence of the atypical immunoreceptor tyrosine-based activation motif (ITAM) in the cytoplasmic domain of Fc gamma RIIA, Our findings demonstrate that coupling of both p72(syk) and PI 3-K activities to Fc gamma RIIA is regulated by tyrosine phosphorylation of the ITAM, and we speculate that p72(syk) might act as an adapter to recruit PI 3-K to activated Fc gamma RIIA.	OHIO STATE UNIV,DEPT INTERNAL MED,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT PATHOL,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT MICROBIOL,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Chacko, George/I-4945-2014	Chacko, George/0000-0002-2127-1892	NCI NIH HHS [CA64268] Funding Source: Medline; NHLBI NIH HHS [R01-HL46652] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064268, R01CA064268] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046652] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGARWAL A, 1993, J BIOL CHEM, V268, P15900; ANDERSON CL, 1986, J BIOL CHEM, V261, P2856; ANDERSON CL, 1995, SEMIN THROMB HEMOST, V21, P1, DOI 10.1055/s-2007-1000374; BONNEMA JD, 1994, J EXP MED, V180, P1427, DOI 10.1084/jem.180.4.1427; BROOKS DG, 1989, J EXP MED, V170, P369; BUDDE P, 1994, EUR J CELL BIOL, V64, P45; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CASSEL DL, 1993, MOL IMMUNOL, V30, P451, DOI 10.1016/0161-5890(93)90113-P; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; CHACKO GW, 1996, HUMAN FC RECEPTORS; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; CLARK EA, 1994, J BIOL CHEM, V269, P28859; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; FRY MJ, 1993, PHILOS T ROY SOC B, V340, P337, DOI 10.1098/rstb.1993.0076; FUJII C, 1994, EUR J BIOCHEM, V226, P243, DOI 10.1111/j.1432-1033.1994.tb20047.x; GHAZIZADEH S, 1995, BIOCHEM J, V305, P669, DOI 10.1042/bj3050669; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HUANG MM, 1992, J BIOL CHEM, V267, P5467; Indik Z K, 1995, Semin Immunol, V7, P45, DOI 10.1016/1044-5323(95)90007-1; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KANAKARAJ P, 1994, J EXP MED, V179, P551, DOI 10.1084/jem.179.2.551; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KING M, 1992, EXP HEMATOL, V20, P576; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LAW CL, 1994, J BIOL CHEM, V269, P12310; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; MCINTYRE EA, 1988, J IMMUNOL, V141, P4333; MITCHELL MA, 1994, BLOOD, V84, P1753; MULLER B, 1994, IMMUNOGENETICS, V39, P359; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; NINOMIYA N, 1994, J BIOL CHEM, V269, P22732; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; REZAUL K, 1994, THROMB HAEMOSTASIS, V72, P937; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TING AT, 1995, J BIOL CHEM, V270, P16415, DOI 10.1074/jbc.270.27.16415; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; VANDENHERIKOUDIJK IE, 1995, BLOOD, V86, P3302, DOI 10.1182/blood.V86.9.3302.bloodjournal8693302; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAGI S, 1994, BIOCHEM BIOPH RES CO, V200, P28, DOI 10.1006/bbrc.1994.1409; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471; YANAGI S, 1994, EUR J BIOCHEM, V224, P329, DOI 10.1111/j.1432-1033.1994.00329.x; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHANG J, 1995, J BIOL CHEM, V270, P22807, DOI 10.1074/jbc.270.39.22807; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHANG J, 1993, J BIOL CHEM, V268, P22251	59	96	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10775	10781		10.1074/jbc.271.18.10775	http://dx.doi.org/10.1074/jbc.271.18.10775			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631888	hybrid			2022-12-27	WOS:A1996UJ34200056
J	Andersson, M; Holmgren, A; Spyrou, G				Andersson, M; Holmgren, A; Spyrou, G			NK-lysin, a disulfide-containing effector peptide of T-lymphocytes, is reduced and inactivated by human thioredoxin reductase - Implication for a protective mechanism against NK-lysin cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; ANTIMICROBIAL PEPTIDE; ANTIBIOTIC PEPTIDES; GROWTH-FACTOR; PANETH CELLS; HOST DEFENSE; FACTOR ADF; RECEPTOR; IMMUNITY; INVITRO	The cytotoxic and antibacterial polypeptide NK-lysin has a molecular mass of approximately 9 kDa and contains three disulfide bonds. The activity was highly dependent on intact disulfides, because the bactericidal effect on Escherichia coli and the cytolytic effect on human 3B6 lymphocytes was inhibited when NK-lysin was treated with dithiothreitol prior to incubation with the cells. NK-lysin was a direct substrate for human or calf thymus thioredoxin reductase and preincubation of the peptide with mammalian thioredoxin reductase, and NADPH abolished its antibacterial and cytolytic activities. The addition of human thioredoxin further enhanced the inhibitory effect of thioredoxin reductase and NADPH. In contrast, E. coli thioredoxin reductase showed no direct disulfide reductase activity with NK-lysin in agreement with previous data showing large differences in structure and substrate specificity between the mammalian and E. coli enzymes. NK-lysin is the first identified macromolecular disulfide substrate for human thioredoxin reductase apart from human thioredoxin. When 3B6 cells were incubated with NADPH, thioredoxin, and thioredoxin reductase prior to addition of NK-lysin, cytotoxicity was markedly reduced. These data suggest that thioredoxin reductase inactivates NK-lysin and provides a mechanism by which the cytotoxic activity of NK-lysin is regulated.	KAROLINSKA INST, NOVUM, DEPT BIOSCI, S-14157 HUDDINGE, SWEDEN	Karolinska Institutet	Andersson, M (corresponding author), KAROLINSKA INST, DEPT MED BIOCHEM & BIOPHYS, MED NOBEL INST, S-17177 STOCKHOLM, SWEDEN.		Andersson, Mats/A-2903-2008; Andersson, Mats L/M-9124-2014	Andersson, Mats L/0000-0001-7582-8791				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANDERSSON M, 1995, EMBO J, V14, P1615, DOI 10.1002/j.1460-2075.1995.tb07150.x; ANDERSSON M, 1995, FEBS LETT, V362, P328, DOI 10.1016/0014-5793(95)00268-E; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOMAN HG, 1994, CIBA F S, V186; CORFT LR, 1980, HDB PROTEIN SEQUENCE, P422; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; ERICSON ML, 1992, LYMPHOKINE CYTOK RES, V11, P201; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; GRIPPO JF, 1985, J BIOL CHEM, V260, P93; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; HOFFMANN JA, 1992, IMMUNOL TODAY, V13, P411, DOI 10.1016/0167-5699(92)90092-L; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HOLMGREN A, 1980, P NATL ACAD SCI-BIOL, V77, P5149, DOI 10.1073/pnas.77.9.5149; HOLMGREN A, 1977, J BIOL CHEM, V252, P4600; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOLMGREN A, 1981, TRENDS BIOCHEM SCI, V6, P26, DOI 10.1016/0968-0004(81)90010-4; HULTMARK D, 1983, EMBO J, V2, P571, DOI 10.1002/j.1460-2075.1983.tb01465.x; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; KUDRYASHOV BA, 1990, B EXP BIOL MED+, V109, P513, DOI 10.1007/BF00840056; KUMAR S, 1992, EUR J BIOCHEM, V207, P435, DOI 10.1111/j.1432-1033.1992.tb17068.x; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; LEIPPE M, 1992, EMBO J, V11, P3501, DOI 10.1002/j.1460-2075.1992.tb05432.x; LICHTENSTEIN A, 1986, BLOOD, V68, P1407; LOZANO RM, 1994, ARCH BIOCHEM BIOPHYS, V309, P356, DOI 10.1006/abbi.1994.1124; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; LUNDSTROMLJUNG J, 1995, FEBS LETT, V357, P305, DOI 10.1016/0014-5793(94)01386-F; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MATSUDA M, 1991, J IMMUNOL, V147, P3837; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MOUSLI M, 1990, TRENDS PHARMACOL SCI, V11, P358, DOI 10.1016/0165-6147(90)90179-C; NAKABAYASHI H, 1990, FEBS LETT, V267, P135, DOI 10.1016/0014-5793(90)80307-5; RADERMACHER SW, 1993, J NEUROSCI RES, V36, P657, DOI 10.1002/jnr.490360606; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; ROSEN A, 1995, INT IMMUNOL, V7, P625, DOI 10.1093/intimm/7.4.625; ROZELL B, 1985, EUR J CELL BIOL, V38, P79; SCHALLREUTER KU, 1991, INT J CANCER, V48, P15; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TERRITO MC, 1989, J CLIN INVEST, V84, P2017, DOI 10.1172/JCI114394; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; TTRAPANI GD, 1991, HUM REPROD, V6, P450; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WAKASUGI H, 1987, P NATL ACAD SCI USA, V84, P804, DOI 10.1073/pnas.84.3.804; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; WAKSMAN G, 1994, J MOL BIOL, V236, P800, DOI 10.1006/jmbi.1994.1190; WIEGAND M, 1989, J STEROID BIOCHEM, V32, P53, DOI 10.1016/0022-4731(89)90013-7; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; WIMLEY WC, 1994, PROTEIN SCI, V3, P1362, DOI 10.1002/pro.5560030902; YAMASHITA T, 1995, BBA-GEN SUBJECTS, V1243, P295, DOI 10.1016/0304-4165(94)00139-O; YAMAUCHI A, 1992, MOL IMMUNOL, V29, P263; ZASLOFF M, 1992, CURR OPIN IMMUNOL, V4, P3, DOI 10.1016/0952-7915(92)90115-U	59	95	97	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10116	10120		10.1074/jbc.271.17.10116	http://dx.doi.org/10.1074/jbc.271.17.10116			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626570	hybrid			2022-12-27	WOS:A1996UG25700042
J	Ostlund, RE; Seemayer, R; Gupta, S; Kimmel, R; Ostlund, EL; Sherman, WR				Ostlund, RE; Seemayer, R; Gupta, S; Kimmel, R; Ostlund, EL; Sherman, WR			A stereospecific myo-inositol D-chiro-inositol transporter in HepG2 liver cells - Identification with D-chiro-[3-H-3]inositol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOINOSITOL UPTAKE; LIQUID-CHROMATOGRAPHY; DIABETES-MELLITUS; HEPATOCYTES; METABOLISM; PROTEIN	D-chiro-Inositol is an epimer of myo-inositol that is found in certain mammalian glycosylphosphatidylinositol protein anchors and inositol phosphoglycans possessing insulin-like bioactivity. In order to generate a probe for metabolic studies, D-chiro-[3-H-3]inositol was synthesized by selective reduction of D-chiro-3-inosose at pH 6.5 with sodium borotritide. D-chiro-[3-H-3]Inositol was taken up by HepG2 human liver cells through a saturable and stereospecific pathway in which D-chiro-inositol and myo-inositol competed equally but L-chiro-inositol was not recognized. D-Glucose, but not L-glucose, competed for D-chiro-[3-H-3]inositol uptake over glucose concentrations of 4-28 mM. Maximum transport capacity was 717 pmol/mg cell protein/3 h with a K-m value of 348 mu M. Uptake was reduced by 76% when sodium was eliminated from the medium and by 94% when the experiment was performed at 0 degrees C. The new myo/D-chiro-inositol transporter is distinct from the sodium-myo-inositol co-transporter found in many tissues and accounts for all of the saturable D-chiro-inositol uptake and for a portion of the saturable low affinity myo-inositol uptake in HepG2 cells. It may allow D-chiro-inositol to be used by cells in the presence of a relatively large amount of competing myo-inositol.	WASHINGTON UNIV,SCH MED,DIV METAB,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT PSYCHIAT,ST LOUIS,MO 63110; GENENCOR INT INC,S SAN FRANCISCO,CA 94080; AMER RADIOLABELED CHEM INC,ST LOUIS,MO 63146	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579, P30DK020579] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00954] Funding Source: Medline; NIDDK NIH HHS [DK 20579] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN CP, 1979, J PHARM SCI, V68, P1022, DOI 10.1002/jps.2600680827; GHIASUDDIN M, 1981, J CHROMATOGR, V211, P295, DOI 10.1016/S0021-9673(00)88050-4; GREENE DA, 1982, J CLIN INVEST, V70, P1009, DOI 10.1172/JCI110688; KENNINGTON AS, 1990, NEW ENGL J MED, V323, P373, DOI 10.1056/NEJM199008093230603; KWON HM, 1992, J BIOL CHEM, V267, P6297; LARNER J, 1988, BIOCHEM BIOPH RES CO, V151, P1416, DOI 10.1016/S0006-291X(88)80520-5; LOW MG, 1987, BIOCHEM J, V241, P615, DOI 10.1042/bj2410615; MANDEL M, 1993, J ORG CHEM, V58, P2331, DOI 10.1021/jo00060a061; MATO JM, 1987, BIOCHEM BIOPH RES CO, V146, P764, DOI 10.1016/0006-291X(87)90595-X; NAKANISHI T, 1989, P NATL ACAD SCI USA, V86, P6002, DOI 10.1073/pnas.86.15.6002; OLGEMOLLER B, 1990, BIOCHIM BIOPHYS ACTA, V1052, P47, DOI 10.1016/0167-4889(90)90056-J; OSTLUND RE, 1993, P NATL ACAD SCI USA, V90, P9988, DOI 10.1073/pnas.90.21.9988; OSTLUND RE, 1995, DIABETES CARE, V18, P1074, DOI 10.2337/diacare.18.7.1074b; PHILLIPS DV, 1982, J AGR FOOD CHEM, V30, P456, DOI 10.1021/jf00111a011; PRPIC V, 1982, J BIOL CHEM, V257, P1315; SASAKI K, 1988, CARBOHYD RES, V183, P1, DOI 10.1016/0008-6215(88)80040-5; SIGAL SH, 1993, METABOLISM, V42, P395, DOI 10.1016/0026-0495(93)90093-4; WAKISAKA M, 1995, DIABETOLOGIA, V38, P291; WALTER EI, 1990, J IMMUNOL, V144, P1030; WANG WT, 1990, ANAL BIOCHEM, V188, P432, DOI 10.1016/0003-2697(90)90632-J; YOREK MA, 1986, ARCH BIOCHEM BIOPHYS, V246, P801, DOI 10.1016/0003-9861(86)90336-X	22	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10073	10078		10.1074/jbc.271.17.10073	http://dx.doi.org/10.1074/jbc.271.17.10073			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626564	hybrid			2022-12-27	WOS:A1996UG25700036
J	Tange, TO; Jensen, TH; Kjems, J				Tange, TO; Jensen, TH; Kjems, J			In vitro interaction between human immunodeficiency virus type 1 rev protein and splicing factor ASF/SF2-associated protein, p32	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL MESSENGER-RNA; HIV-1 REV; BINDING SITE; EXPRESSION; REGION; OLIGOMERIZATION; PURIFICATION; SEQUENCE; PEPTIDE; ELEMENT	Continuous replication of human immunodeficiency virus type 1 requires the expression of the regulatory protein Rev, which binds to the Rev response element (RRE) and up-regulates the cytoplasmic appearance of singly spliced and unspliced mRNA species. It has been demonstrated that the murine protein YL2 interacts with Rev in vivo and modulates the activity of Rev (Luo, Y., Yu, H., and Peterlin, B. M. (1994) J. Virol. 68, 3850-3856). Here we show that the YL2 human homologue, the p32 protein, which co-purifies with alternative splicing factor ASF/SF2, interacts directly with the basic domain of Rev in vitro and that the Rev-p32 complex is resistant to high concentrations of salt or nonionic detergent. Protein footprinting data suggest that Rev interacts specifically with amino acids within the 196-208 region of p32. An analysis of the ternary complex, formed among p32, Rev, and RRE RNA, shows that Rev can bridge the association of p32 and RRE. Furthermore, we demonstrate that exogenously added p32 specifically relieves the inhibition of splicing in vitro exerted by the basic domain of Rev. Our data are consistent with a model in which p32 functions as a link between Rev and the cellular splicing apparatus.	AARHUS UNIV,DEPT MOLEC BIOL,DK-8000 AARHUS C,DENMARK	Aarhus University			Jensen, Torben H/G-2954-2017; Kjems, Jorgen/I-3490-2016	Kjems, Jorgen/0000-0003-4128-9317				BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; COCHRANE AW, 1989, VIROLOGY, V173, P335, DOI 10.1016/0042-6822(89)90252-3; COLE JL, 1993, BIOCHEMISTRY-US, V32, P11769, DOI 10.1021/bi00095a004; COOK KS, 1991, NUCLEIC ACIDS RES, V19, P1577, DOI 10.1093/nar/19.7.1577; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; GAIT MJ, 1993, TRENDS BIOCHEM SCI, V18, P255, DOI 10.1016/0968-0004(93)90176-N; HADZOPOULOUCLADARAS M, 1989, J VIROL, V63, P1265, DOI 10.1128/JVI.63.3.1265-1274.1989; HAMMARSKJOLD ML, 1994, J VIROL, V68, P951; HEAPHY S, 1991, P NATL ACAD SCI USA, V88, P7366, DOI 10.1073/pnas.88.16.7366; HONORE B, 1993, GENE, V134, P283, DOI 10.1016/0378-1119(93)90108-F; HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787; HOPE TJ, 1992, J VIROL, V66, P1849, DOI 10.1128/JVI.66.4.1849-1855.1992; HUANG ZM, 1995, MOL CELL BIOL, V15, P3864; Jeang K T, 1991, AIDS, V5 Suppl 2, pS3, DOI 10.1097/00002030-199101001-00002; JENSEN TH, 1995, GENE, V162, P235, DOI 10.1016/0378-1119(95)00328-4; JENSEN TH, 1995, J BIOL CHEM, V270, P13777, DOI 10.1074/jbc.270.23.13777; KJEMS J, 1993, J VIROL, V67, P4769, DOI 10.1128/JVI.67.8.4769-4776.1993; KJEMS J, 1991, CELL, V67, P169, DOI 10.1016/0092-8674(91)90580-R; KJEMS J, 1992, EMBO J, V11, P1119, DOI 10.1002/j.1460-2075.1992.tb05152.x; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; KONFORTI BB, 1993, CELL, V75, P863, DOI 10.1016/0092-8674(93)90531-T; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LU XB, 1990, P NATL ACAD SCI USA, V87, P7598, DOI 10.1073/pnas.87.19.7598; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MCDONALD D, 1992, J VIROL, V66, P7232, DOI 10.1128/JVI.66.12.7232-7238.1992; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; NAKANO H, 1994, NUCLEIC ACIDS RES, V22, P543, DOI 10.1093/nar/22.3.543; NALIN CM, 1990, P NATL ACAD SCI USA, V87, P7593, DOI 10.1073/pnas.87.19.7593; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; STUTZ F, 1994, EMBO J, V13, P4096, DOI 10.1002/j.1460-2075.1994.tb06727.x; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; SZILVAY AM, 1995, J VIROL, V69, P3315, DOI 10.1128/JVI.69.6.3315-3323.1995; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758; VENKATESAN S, 1992, J VIROL, V66, P7469, DOI 10.1128/JVI.66.12.7469-7480.1992; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; YU L, 1995, J VIROL, V69, P3007, DOI 10.1128/JVI.69.5.3007-3016.1995; YU L, 1995, J VIROL, V69, P3017, DOI 10.1128/JVI.69.5.3017-3023.1995; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734	46	74	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10066	10072		10.1074/jbc.271.17.10066	http://dx.doi.org/10.1074/jbc.271.17.10066			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626563	hybrid			2022-12-27	WOS:A1996UG25700035
J	Tomashek, JJ; Sonnenburg, JL; Artimovich, JM; Klionsky, DJ				Tomashek, JJ; Sonnenburg, JL; Artimovich, JM; Klionsky, DJ			Resolution of subunit interactions and cytoplasmic subcomplexes of the yeast vacuolar proton-translocating ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; SACCHAROMYCES-CEREVISIAE; ADENOSINE-TRIPHOSPHATASE; TRIFLUOPERAZINE RESISTANCE; MUTATIONAL ANALYSIS; CATALYTIC SUBUNIT; GENE ENCODES; MEMBRANE; MUTANTS; ACIDIFICATION	The vacuolar proton-translocating ATPase is the principal energization mechanism that enables the yeast vacuole to perform most of its physiological functions. We have undertaken an examination of subunit-subunit interactions and assembly states of this enzyme. Yeast two-hybrid data indicate that Vma1p and Vma2p interact with each other and that Vma4p interacts with itself. Three-hybrid data indicate that the Vma4p self-interaction is stabilized by both Vma1p and Vma2p. Native gel electrophoresis reveals numerous partial complexes not previously described. In addition to a large stable cytoplasmic complex seen in wild-type, Delta vma3 and Delta vma5 strains, we see partial complexes in the Delta vma4 and Delta vma7 strains. All larger complexes are lost in the Delta vma1, Delta vma2, and Delta vma8 strains. We designate the large complex seen in wild-type cells containing at least subunits Vma1p, Vma2p, Vma4p, Vma7p, and Vma8p as the definitive V-1 complex.	UNIV CALIF DAVIS,MICROBIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053396] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53396] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARAI H, 1988, J BIOL CHEM, V263, P8796; BACHHAWAT AK, 1993, YEAST, V9, P175, DOI 10.1002/yea.320090208; BARTEL PL, 1993, BIOTECHNIQUES, V214, P920; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BOWMAN EJ, 1995, BBA-BIOMEMBRANES, V1237, P95, DOI 10.1016/0005-2736(95)00108-F; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOURY F, 1990, J BIOL CHEM, V265, P18554; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; GRAHAM LA, 1995, J BIOL CHEM, V270, P15037, DOI 10.1074/jbc.270.25.15037; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; GROMETELHANAN Z, 1992, J BIOENERG BIOMEMBR, V24, P447, DOI 10.1007/BF00762361; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; HARVEY WR, 1992, J EXP BIOL, V172, P1; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HILL KJ, 1995, J BIOL CHEM, V270, P22329, DOI 10.1074/jbc.270.38.22329; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; HIRATA R, 1993, J BIOL CHEM, V268, P961; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KLIONSKY DJ, 1992, J BIOL CHEM, V267, P3416; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MARTINYBARON G, 1992, PLANT PHYSIOL, V99, P1635, DOI 10.1104/pp.99.4.1635; Miller J. H, 1972, EXPT MOL GENETICS; MORANO KA, 1994, J CELL SCI, V107, P2813; MYERS M, 1993, J BIOL CHEM, V268, P9184; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON M, 1989, MOL CELL BIOL, V9, P384, DOI 10.1128/MCB.9.2.384; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; PRESTON RA, 1992, GENETICS, V131, P551; PRESTON RA, 1989, P NATL ACAD SCI USA, V86, P7027, DOI 10.1073/pnas.86.18.7027; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; SHIH CK, 1990, MOL CELL BIOL, V10, P3397, DOI 10.1128/MCB.10.7.3397; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; UCHIDA E, 1988, J BIOL CHEM, V263, P45; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; YAVER DS, 1993, J BIOL CHEM, V268, P10564	54	58	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10397	10404		10.1074/jbc.271.17.10397	http://dx.doi.org/10.1074/jbc.271.17.10397			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626613	hybrid			2022-12-27	WOS:A1996UG25700085
J	Du, XP; Fox, JE; Pei, S				Du, XP; Fox, JE; Pei, S			Identification of a finding sequence for the 14-3-3 protein within the cytoplasmic domain of the adhesion receptor, platelet glycoprotein Ib alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR BINDING; CALCIUM-DEPENDENT EXOCYTOSIS; KINASE-C; SHEAR-STRESS; MEMBRANE; AGGREGATION; COMPLEX; PURIFICATION; ACTIVATION; THROMBIN	The zeta-form 14-3-3 protein (14-3-3 zeta) regulates protein kinases and interacts with several signaling molecules. We reported previously that a platelet adhesion receptor, glycoprotein (GP) Ib-IX, was associated with a 29-kDa protein with partial sequences identical to 14-3-3 zeta. In this study, the interaction between GPIb-IX and recombinant 14-3-3 zeta is reconstituted. Further, we show that the 14-3-3 zeta binding site in GPIb is within a 15 residue sequence at the C terminus of GPIb alpha, as indicated by antibody inhibition and direct binding of 14-3-3 zeta to synthetic GPIb alpha cytoplasmic domain peptides. The 14-3-3 zeta binds to recombinant wild type GPIb-IX but not to the GPIb alpha mutants lacking C-terminal 5 or more residues, suggesting that the C-terminal 5 residues of GPIb alpha are critical. Similarity between the GPIb alpha C-terminal sequence and the serine-rich regions of Raf and Bcr kinases suggests a possible serine-rich recognition motif for the 14-3-3 protein.	CLEVELAND CLIN FDN, CTR THROMBOSIS & VASC BIOL, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation	Du, XP (corresponding author), SCRIPPS RES INST, DEPT VASC BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NHLBI NIH HHS [HL30657, HL52547] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030657, R01HL030657, R29HL052547, R23HL030657] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; ANDREWS RK, 1992, J BIOL CHEM, V267, P18605; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; CHOW TW, 1992, BLOOD, V80, P113; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; DEMARCO L, 1985, P NATL ACAD SCI USA, V82, P7424; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DU XP, 1994, J BIOL CHEM, V269, P18287; DU XP, 1987, BLOOD, V69, P1524; DU XP, 1993, J BIOL CHEM, V268, P23087; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FOX JEB, 1988, J BIOL CHEM, V263, P4882; FOX JEB, 1985, J BIOL CHEM, V260, P1970; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; GRALNICK HR, 1989, BRIT J HAEMATOL, V71, P253, DOI 10.1111/j.1365-2141.1989.tb04263.x; HARMON JT, 1986, J BIOL CHEM, V261, P3224; IKEDA Y, 1993, THROMB HAEMOSTASIS, V69, P496; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; ISOBE T, 1992, FEBS LETT, V308, P121, DOI 10.1016/0014-5793(92)81257-M; ISOBE T, 1991, J MOL BIOL, V217, P125, DOI 10.1016/0022-2836(91)90616-E; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; KROLL MH, 1993, J BIOL CHEM, V268, P3520; KUPAN LA, 1992, J BIOL CHEM, V267, P8707; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LOEB LA, 1986, J BIOL CHEM, V261, P467; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; MEYER SC, 1995, J BIOL CHEM, V270, P14693, DOI 10.1074/jbc.270.24.14693; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; ROBINSON K, 1994, BIOCHEM J, V299, P853, DOI 10.1042/bj2990853; ROTH D, 1994, BIOCHEM J, V301, P305, DOI 10.1042/bj3010305; ROTH GJ, 1991, BLOOD, V77, P5; RUGGERI ZM, 1994, ANN NY ACAD SCI, V714, P200, DOI 10.1111/j.1749-6632.1994.tb12045.x; TANJI M, 1994, J NEUROCHEM, V63, P1908; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; YAMAMOTO N, 1985, THROMB RES, V39, P751, DOI 10.1016/0049-3848(85)90259-2; YAMAUCHI T, 1981, J BIOL CHEM, V256, P5404; YOSHIDA N, 1983, J BIOL CHEM, V258, P7168	50	131	135	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7362	7367		10.1074/jbc.271.13.7362	http://dx.doi.org/10.1074/jbc.271.13.7362			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631758	hybrid			2022-12-27	WOS:A1996UC77400026
J	Kobayashi, M; Habuchi, H; Habuchi, O; Saito, M; Kimata, K				Kobayashi, M; Habuchi, H; Habuchi, O; Saito, M; Kimata, K			Purification and characterization of heparan sulfate 2-sulfotransferase from cultured Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; CHICK-EMBRYO CHONDROCYTES; FACTOR BINDING DOMAINS; RAT-LIVER; CHONDROITIN 6-SULFOTRANSFERASE; N-SULFOTRANSFERASE; MOLECULAR-CLONING; O-SULFATION; BIOSYNTHESIS; EXPRESSION	Heparan sulfate 2-sulfotransferase, which catalyzes the transfer of sulfate from adenosine 3'-phosphate 5'-phosphosulfate to position 2 of L-iduronic acid residue in heparan sulfate, was purified 51,700-fold to apparent homogeneity with a 6% yield from cultured Chinese hamster ovary cells, The isolation procedure included a combination of affinity chromatography on heparin Sepharose CL-6B and 3',5'-ADP-agarose, which was repeated twice for each, and finally gel chromatography on Superose 12, Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the purified enzyme showed two protein bands with molecular masses of 47 and 44 kDa, Both proteins appeared to be glycoproteins, because their molecular masses decreased after N-glycanase digestion, When completely desulfated and N-resulfated heparin and mouse ngelbreth-Holm-Swarm tumor heparan sulfate were used as accepters, the purified enzyme transferred sulfate to position 2 of L-iduronic acid residue but did not transfer sulfate to the amino group of glucosamine residue or to position 6 of N-sulfoglucosamine residue, Heparan sulfates from pig aorta and bovine liver, however, were poor accepters, The enzyme showed no activities toward chondroitin, chondroitin sulfate, dermatan sulfate, and keratan sulfate, The optimal pH for the enzyme activity was around 5.5. The enzyme activity was minimally affected by dithiothreitol and was stimulated strongly by protamine. The K-m value for adenosine 5'-phosphate 5'-phosphosulfate was 0.20 mu M.	AICHI MED UNIV,INST MOLEC SCI MED,NAGAKUTE,AICHI 48011,JAPAN; AICHI UNIV EDUC,DEPT LIFE SCI,KARIYA,AICHI 448,JAPAN; HOKKAIDO UNIV,SCH MED,INST CANC,DIV BIOCHEM,SAPPORO,HOKKAIDO 060,JAPAN	Aichi Medical University; Aichi University Education; Hokkaido University								AVIEZER D, 1994, J BIOL CHEM, V269, P114; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; DELFERT DM, 1985, ANAL BIOCHEM, V148, P303, DOI 10.1016/0003-2697(85)90233-7; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; GOHLER D, 1984, EUR J BIOCHEM, V138, P301, DOI 10.1111/j.1432-1033.1984.tb07915.x; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HABUCHI O, 1980, BIOCHIM BIOPHYS ACTA, V616, P208, DOI 10.1016/0005-2744(80)90139-4; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; HABUCHI O, 1991, BIOCHIM BIOPHYS ACTA, V1133, P9; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; INOUE H, 1986, J BIOL CHEM, V261, P4460; ISHIHARA M, 1993, GLYCOBIOLOGY, V3, P83, DOI 10.1093/glycob/3.1.83; ISHIHARA M, 1993, J BIOL CHEM, V268, P20091; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KUSCHE M, 1988, J BIOL CHEM, V263, P15474; KUSCHE M, 1991, J BIOL CHEM, V266, P7400; KUSCHE M, 1990, J BIOL CHEM, V265, P15403; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS G, 1989, BIOCHEM J, V261, P389, DOI 10.1042/bj2610389; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; Lindahl U., 1989, HEPARIN, P159; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MANDON E, 1994, J BIOL CHEM, V269, P11729; MANDON EC, 1994, P NATL ACAD SCI USA, V91, P10707, DOI 10.1073/pnas.91.22.10707; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; STROMINGER JL, 1959, J BIOL CHEM, V234, P3263; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WLAD H, 1994, J BIOL CHEM, V269, P24538	43	67	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7645	7653		10.1074/jbc.271.13.7645	http://dx.doi.org/10.1074/jbc.271.13.7645			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631801	hybrid			2022-12-27	WOS:A1996UC77400069
J	Monera, OD; Zhou, NE; Lavigne, P; Kay, CM; Hodges, RS				Monera, OD; Zhou, NE; Lavigne, P; Kay, CM; Hodges, RS			Formation of parallel and antiparallel coiled-coils controlled by the relative positions of alanine residues in the hydrophobic core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-HELIX; PROTEIN; TROPOMYOSIN; STABILITY; BUNDLE; DESIGN	The orientation of alpha-helical chains in two-stranded coiled-coils has been shown to be determined by the presence of favorable interchain electrostatic interactions. In this study, we used de novo designed 35-residue peptides to show that when interchain electrostatic interactions are not a factor in coiled-coil formation, the relative positions of Ala residues in the middle heptad can control the parallel or antiparallel orientation of alpha-helical chains in coiled-coils. The peptides formed four-stranded coiled-coils where the helices are either all-parallel or all-antiparallel with respect to their nearest neighbor. The common structural element in these four-stranded coiled-coils is an alternating pair of Ala and Leu residues (Ala-Leu-Ala-Leu) in each of the two planes in the middle heptad. These results indicate that both the relative positions of the Ala residues in the hydrophobic core and the interchain electrostatic interactions between charged residues in the e and g positions should be considered in designing coiled-coils with the desired number of strands in the multiple-stranded assembly. These design elements are also important in orienting functional groups or domains attached to the terminals ends of a coiled-coil carrier.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA; UNIV ALBERTA,PROT ENGN NETWORK CTR EXCELLENCE,EDMONTON,AB T6G 2H7,CANADA	University of Alberta; University of Alberta								Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; BABUL J, 1969, ANAL BIOCHEM, V28, P216, DOI 10.1016/0003-2697(69)90172-9; CHOU KC, 1988, P NATL ACAD SCI USA, V85, P4295, DOI 10.1073/pnas.85.12.4295; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COOPER TM, 1990, BIOPOLYMERS, V30, P657, DOI 10.1002/bip.360300703; DEGRADO WF, 1989, SCIENCE, V243, P622, DOI 10.1126/science.2464850; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HODGES R S, 1992, Current Biology, V2, P122, DOI 10.1016/0960-9822(92)90241-2; Hodges R. S., 1972, COLD SPRING HARB SYM, V37, P299; HOL WGJ, 1981, NATURE, V294, P532, DOI 10.1038/294532a0; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; KAY LE, 1991, BIOCHEMISTRY-US, V30, P4323, DOI 10.1021/bi00231a031; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LAVIGNE P, 1995, J MOL BIOL, V254, P505, DOI 10.1006/jmbi.1995.0634; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; MUNSON M, 1994, PROTEIN SCI, V3, P2015, DOI 10.1002/pro.5560031114; RASHIN AA, 1984, J MOL BIOL, V173, P515, DOI 10.1016/0022-2836(84)90394-2; RICHMOND TJ, 1984, J MOL BIOL, V178, P63, DOI 10.1016/0022-2836(84)90231-6; SODEK J, 1972, P NATL ACAD SCI USA, V69, P3800, DOI 10.1073/pnas.69.12.3800; STONE D, 1974, P 9 FED EUR BIOCH SO, P125; WISHART DS, 1994, COMPREHENSIVE PROGRA; ZHOU NE, 1992, J BIOL CHEM, V267, P2664; ZHOU NE, 1993, BIOCHEMISTRY-US, V32, P3178, DOI 10.1021/bi00063a033; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250; ZHOU NE, 1994, PROTEIN PEPTIDE LETT, V1, P114; ZHU BY, 1993, PROTEIN SCI, V2, P383	29	71	75	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					3995	4001						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626731				2022-12-27	WOS:A1996TW96000009
J	Walker, D; Chaddock, AM; Chaddock, JA; Roberts, LM; Lord, JM; Robinson, C				Walker, D; Chaddock, AM; Chaddock, JA; Roberts, LM; Lord, JM; Robinson, C			Ricin A chain fused to a chloroplast-targeting signal is unfolded on the chloroplast surface prior to import across the envelope membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-CHAIN; PRECURSOR PROTEINS; BINDING; TRANSLOCATION; ATP	The initial stages of chloroplast protein import involve the binding of precursor proteins to surface-bound receptors prior to translocation across the envelope membranes in a partially folded conformation, We have analyzed the unfolding process by examining the conformation of a construct, comprising the presequence of a chloroplast protein linked to ricin A chain, before and after binding to the chloroplast surface, We show that the presequence is highly susceptible to proteolysis in solution, probably reflecting a lack of tertiary structure, whereas the A chain passenger protein is resistant to extremely high concentrations of protease, unless deliberately unfolded using denaturant, The A chain moiety is furthermore active, indicating that the presence of the presequence does not prevent formation of a tightly folded, native state, In contrast, receptor-bound p33KRA (fusion protein comprising the 33-kDa presequence plus 22 residues of mature protein, linked to the A chain of ricin) is quantitatively digested by protease concentrations that have little effect on the A chain in solution, We conclude that protein unfolding can take place on the chloroplast surface in the absence of translocation and without the aid of soluble factors.	UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	University of Warwick				Walker, Denise/0000-0003-1534-1679				AMERICA T, 1994, PLANT MOL BIOL, V24, P283, DOI 10.1007/BF00020168; CHADDOCK JA, 1993, PROTEIN ENG, V6, P425, DOI 10.1093/protein/6.4.425; CREIGHTON AM, 1995, J BIOL CHEM, V270, P1663, DOI 10.1074/jbc.270.4.1663; DELLACIOPPA G, 1986, P NATL ACAD SCI USA, V83, P6873, DOI 10.1073/pnas.83.18.6873; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; GRAY JC, 1995, TRENDS CELL BIOL, V5, P243, DOI 10.1016/S0962-8924(00)89018-2; GUERA A, 1993, PLANT MOL BIOL, V23, P309, DOI 10.1007/BF00029007; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; KATZIN BJ, 1991, PROTEINS, V10, P251, DOI 10.1002/prot.340100309; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PELHAM H R B, 1992, Trends in Cell Biology, V2, P183, DOI 10.1016/0962-8924(92)90230-K; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; PILON M, 1992, J BIOL CHEM, V267, P19907; ROBERTS LM, 1991, FEBS LETT, V293, P134, DOI 10.1016/0014-5793(91)81169-9; ROBINSON C, 1994, PLANT MOL BIOL, V26, P15, DOI 10.1007/BF00039516; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SCHNELL DJ, 1994, SCIENCE, V266, P1035; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; SIMPSON JC, 1995, J BIOL CHEM, V270, P20078, DOI 10.1074/jbc.270.34.20078; THEG SM, 1992, BIOCHEMISTRY-US, V31, P5053, DOI 10.1021/bi00136a018; THEG SM, 1989, J BIOL CHEM, V264, P6730; WU CB, 1994, J BIOL CHEM, V269, P32264	23	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4082	4085						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626744				2022-12-27	WOS:A1996TW96000022
J	Greene, EA; Spiegelman, GB				Greene, EA; Spiegelman, GB			The Spo0A protein of Bacillus subtilis inhibits transcription of the abrB gene without preventing binding of the polymerase to the promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RNA-POLYMERASE; LAC REPRESSOR; SPORULATION; INITIATION; EXPRESSION; PHOSPHORELAY; MECHANISM; CONTACTS; PRODUCT	Repression of transcription of the abrB gene is essential to expression of many of the postexponential genes in Bacillus. The repression is due to the activity of the response regulator protein Spo0A. We have used in vitro transcription and DNase I and hydroxyl radical footprinting to explore the mechanism of transcription inhibition. Spo0A binds to specific DNA sequences (0A boxes), and two such boxes are found downstream of the tandem promoters for the abrB gene. The data indicate that both RNA polymerase and Spo0A bind simultaneously to a DNA fragment containing the promoters and the 0A boxes. The Spo0A prevents the polymerase from inducing DNA strand denaturation at the promoter for the abrB gene.	UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER,BC V6T 1Z3,CANADA; UNIV BRITISH COLUMBIA,DEPT MICROBIOL & IMMUNOL,VANCOUVER,BC V6T 1Z3,CANADA	University of British Columbia; University of British Columbia								BIRD TH, 1993, MOL MICROBIOL, V9, P741, DOI 10.1111/j.1365-2958.1993.tb01734.x; BIRD TH, 1995, THESIS U BRIT COLUMB; BRODOLIN KL, 1993, NUCLEIC ACIDS RES, V21, P5748, DOI 10.1093/nar/21.24.5748; BROWN DP, 1994, MOL MICROBIOL, V14, P411, DOI 10.1111/j.1365-2958.1994.tb02176.x; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; CRAIG ML, 1995, BIOCHEMISTRY-US, V34, P15624, DOI 10.1021/bi00048a004; DOBINSON KF, 1985, J BIOL CHEM, V260, P5950; ERRINGTON J, 1993, MICROBIOL REV, V57, P1; FERRARI E, 1988, J BACTERIOL, V170, P289, DOI 10.1128/JB.170.1.289-295.1988; FERRARI FA, 1985, P NATL ACAD SCI USA, V82, P2647, DOI 10.1073/pnas.82.9.2647; Greenberg M. T., 1991, ROCHESTER S DEV PSYC, P21; GROMSLEY JK, 1994, J BIOL CHEM, V269, P16977; HOCH JA, 1993, ANNU REV MICROBIOL, V47, P441, DOI 10.1146/annurev.micro.47.1.441; HOCHSCHILD A, 1983, CELL, V32, P319, DOI 10.1016/0092-8674(83)90451-8; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; LEE JY, 1991, CELL, V66, P793, DOI 10.1016/0092-8674(91)90122-F; MARAHIEL MA, 1987, J BACTERIOL, V169, P2215, DOI 10.1128/jb.169.5.2215-2222.1987; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; OHLSEN KL, 1994, P NATL ACAD SCI USA, V91, P1756, DOI 10.1073/pnas.91.5.1756; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PEREGO M, 1988, MOL MICROBIOL, V2, P689, DOI 10.1111/j.1365-2958.1988.tb00079.x; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; PEREGO M, 1991, J BACTERIOL, V173, P2514, DOI 10.1128/jb.173.8.2514-2520.1991; PTASHNE M, 1992, GENETIC SWITCH, P20; Sambrook J., 2002, MOL CLONING LAB MANU; SCHICKOR P, 1990, EMBO J, V9, P2215, DOI 10.1002/j.1460-2075.1990.tb07391.x; SCHLAX PJ, 1995, J MOL BIOL, V245, P331, DOI 10.1006/jmbi.1994.0028; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SQUIRES CL, 1975, J MOL BIOL, V11, P747; STRANEY DC, 1987, J MOL BIOL, V193, P267, DOI 10.1016/0022-2836(87)90218-X; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; STRAUCH M, 1990, P NATL ACAD SCI USA, V87, P1801, DOI 10.1073/pnas.87.5.1801; STRAUCH MA, 1993, MOL MICROBIOL, V7, P337, DOI 10.1111/j.1365-2958.1993.tb01125.x; STRAUCH MA, 1991, BIOL BACILLI, P105; STRAUCH MA, 1992, BACILLUS SUBTILIS MO, P767; TRACH K, 1991, RES MICROBIOL, V142, P815, DOI 10.1016/0923-2508(91)90060-N; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; WHIPPLE FW, 1992, J MOL BIOL, V223, P399, DOI 10.1016/0022-2836(92)90660-C; ZUBER P, 1987, J BACTERIOL, V169, P2223, DOI 10.1128/jb.169.5.2223-2230.1987	41	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11455	11461		10.1074/jbc.271.19.11455	http://dx.doi.org/10.1074/jbc.271.19.11455			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626703	hybrid			2022-12-27	WOS:A1996UJ94400063
J	Donahue, BA; Fuchs, RPP; Reines, D; Hanawalt, PC				Donahue, BA; Fuchs, RPP; Reines, D; Hanawalt, PC			Effects of aminofluorene and acetylaminofluorene DNA adducts on transcriptional elongation by RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; EXCISION REPAIR; MUTATION SPECTRUM; MAMMALIAN-CELLS; INVITRO; STRAND; CARCINOGEN; GENE; TERMINATION; N-ACETOXY-N-2-ACETYLAMINOFLUORENE	A prominent model for the mechanism of transcription-coupled DNA repair proposes that an arrested RNA polymerase directs the nucleotide excision repair complex to the transcription-blocking lesion,The specific role for RNA polymerase II in this mechanism can be examined by comparing the extent of polymerase arrest with the extent of transcription-coupled repair for a specific DNA lesion, Previously we reported that a cyclobutane pyrimidine dimer that is repaired preferentially in transcribed genes is a strong block to transcript elongation by RNA pol II (Donahue, B. A., Yin, S.,Taylor, J.-S., Reines, D., and Hanawalt, P. C. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 8502-8506), Here we report the extent of RNA polymerase II arrest by the C-8 guanine DNA adduct formed by N-2-aminofluorene, a lesion that does not appear to be preferentially repaired, Templates for an in vitro transcription assay were constructed with either an N-2-aminofluorene adduct or the helix-distorting N-2-acetylaminofluorene adduct situated at a specific site downstream from the major late promoter of adenovirus, Consistent with the model for transcription-coupled repair, an aminofluorene adduct located on the transcribed strand was a weak pause site for RNA polymerase II, An acetylaminofluorene adduct located on the transcribed strand was an absolute block to transcriptional elongation, Either adduct located on the nontranscribed strand enhanced polymerase arrest at a nearby sequence specific pause site.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305; ECOLE SUPER BIOTECHNOL STRASBOURG,CNRS,UPR 9003,F-67400 ILLKIRCH GRAFFENS,FRANCE; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Stanford University; Centre National de la Recherche Scientifique (CNRS); Emory University			excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243	NCI NIH HHS [CA 44349] Funding Source: Medline; NIGMS NIH HHS [R01 GM046331] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BICHARA M, 1985, J MOL BIOL, V183, P341, DOI 10.1016/0022-2836(85)90005-1; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; CHEN YH, 1993, J BIOL CHEM, V268, P5849; CHEN YH, 1991, P NATL ACAD SCI USA, V88, P9583, DOI 10.1073/pnas.88.21.9583; DAUNE MP, 1981, JNCI-J NATL CANCER I, V58, P201; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; FUCHS R, 1972, BIOCHEMISTRY-US, V11, P2659, DOI 10.1021/bi00764a017; FUCHS RPP, 1981, NATURE, V294, P657, DOI 10.1038/294657a0; FUCHS RPP, 1976, BIOCHEMISTRY-US, V15, P3347, DOI 10.1021/bi00660a027; FUCHS RPP, 1984, EMBO J, V3, P757, DOI 10.1002/j.1460-2075.1984.tb01880.x; GAO SW, 1994, SCIENCE, V263, P1438, DOI 10.1126/science.8128226; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU WG, 1993, J BIOL CHEM, V268, P25604; HANAWALT P, 1993, CURR BIOL, V3, P67, DOI 10.1016/0960-9822(93)90156-I; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KOFFELSCHWARTZ N, 1984, J MOL BIOL, V177, P33, DOI 10.1016/0022-2836(84)90056-1; LINDSLEY JE, 1994, BIOCHEMISTRY-US, V33, P764, DOI 10.1021/bi00169a018; MAH MCM, 1991, P NATL ACAD SCI USA, V88, P10193, DOI 10.1073/pnas.88.22.10193; MAHER VM, 1975, J NATL CANCER I, V54, P1287, DOI 10.1093/jnci/54.6.1287; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MICHAELS ML, 1987, J BIOL CHEM, V262, P14648; OCONNOR D, 1985, P NATL ACAD SCI USA, V82, P2325, DOI 10.1073/pnas.82.8.2325; OGAWA HI, 1993, CARCINOGENESIS, V14, P2245, DOI 10.1093/carcin/14.11.2245; OHANDLEY SF, 1993, BIOCHEMISTRY-US, V32, P2481, DOI 10.1021/bi00061a005; POIRIER MC, 1980, MOL PHARMACOL, V18, P581; REINES D, 1991, J BIOL CHEM, V266, P10510; REINES D, 1994, TRANSCRIPTION MECHAN, P263; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SHIBUTANI S, 1993, J BIOL CHEM, V268, P11703; STRAUSS BS, 1990, CARCINOGENESIS, V11, P2103, DOI 10.1093/carcin/11.12.2103; TANG MS, 1989, J BIOL CHEM, V264, P14455; TANG MS, 1982, NATURE, V299, P646, DOI 10.1038/299646a0; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; TROELSTRA C, 1990, MOL CELL BIOL, V10, P5806, DOI 10.1128/MCB.10.11.5806; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VONHIPPEL PH, 1991, P NATL ACAD SCI USA, V88, P2307, DOI 10.1073/pnas.88.6.2307; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; ZHOU W, 1995, CELL, V82, P577, DOI 10.1016/0092-8674(95)90030-6	42	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10588	10594		10.1074/jbc.271.18.10588	http://dx.doi.org/10.1074/jbc.271.18.10588			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631860	hybrid, Green Accepted			2022-12-27	WOS:A1996UJ34200028
J	Gelman, MS; Prives, JM				Gelman, MS; Prives, JM			Arrest of subunit folding and assembly of nicotinic acetylcholine receptors in cultured muscle cells by dithiothreitol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; GONADOTROPIN-BETA SUBUNIT; ENDOPLASMIC-RETICULUM; MEMBRANE GLYCOPROTEIN; BINDING-SITE; PROTEINS; OLIGOMERIZATION; HEMAGGLUTININ; KINETICS; PATHWAY	In this study we have used cultured muscle cells to investigate the role of disulfide bond formation in the sequence of molecular events leading to nicotinic acetylcholine receptor (AChR) assembly and surface expression, We have observed that disulfide bond formation in newly synthesized AChR alpha-subunits occurs 5-20 min after translation and that this modification can be blocked by dithiothreitol (DTT), a membrane-permeant thiol-reducing agent, DTT treatment was found to arrest AChR alpha-subunit conformational maturation, assembly, and appearance on the cell surface, showing that these events are dependent on prior formation of disulfide bonds, Subunits prevented from maturation by the reducing agent do not irreversibly misfold or aggregate, since upon removal of DTT, AChR alpha-subunits undergo formation of disulfide bonds and resume folding, oligomerization, and surface expression, We have previously found that nascent alpha-subunits form transient complexes with the molecular chaperone calnexin immediately after subunit synthesis (Gelman, M, S,, Chang, W,, Thomas, D. Y,, Bergeron, J, J, M,, and Prives, J, M, (1995) J, Biol, Chem, 270, 15085-15092) and have now observed that both the formation and the subsequent dissociation of these complexes are unaffected by DTT treatment, Thus, alpha-subunits appear to dissociate from calnexin independently of their undergoing disulfide bond formation and achieving conformational maturation, This finding together with the absence of irreversible misfolding of DTT arrested alpha-subunits suggests that calnexin may act to prevent misfolding by aiding in the initial folding events and is not an essential participant in the late stages of alpha-subunit maturation.	SUNY STONY BROOK,HLTH SCI CTR,DEPT PHARMACOL SCI,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NIGMS NIH HHS [GMO7518] Funding Source: Medline; NINDS NIH HHS [NS25945] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025945] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON DJ, 1981, P NATL ACAD SCI-BIOL, V78, P5598, DOI 10.1073/pnas.78.9.5598; ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204; DEVREOTES PN, 1977, CELL, V10, P365, DOI 10.1016/0092-8674(77)90023-X; FORSAYETH JR, 1992, J CELL BIOL, V117, P841, DOI 10.1083/jcb.117.4.841; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; Gaut JR, 1993, CURR OPIN CELL BIOL, V5, P589, DOI 10.1016/0955-0674(93)90127-C; GELMAN MS, 1995, J BIOL CHEM, V270, P15085, DOI 10.1074/jbc.270.25.15085; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HUTH JR, 1992, J BIOL CHEM, V267, P21396; HUTH JR, 1992, J BIOL CHEM, V267, P8870; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; KAO PN, 1986, J BIOL CHEM, V261, P8085; KARLIN A, 1991, HARVEY LECT, V85, P71; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; KARLIN A, 1966, BIOCHIM BIOPHYS ACTA, V126, P525, DOI 10.1016/0926-6585(66)90010-0; KARLIN A, 1969, J GEN PHYSIOL, V54, pS245; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE AQ, 1994, J BIOL CHEM, V269, P7514; LODISH HF, 1993, J BIOL CHEM, V268, P20598; MERLIE JP, 1986, J MEMBRANE BIOL, V91, P1, DOI 10.1007/BF01870209; MERLIE JP, 1981, J BIOL CHEM, V256, P3605; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; ONEILL MC, 1972, J CELL BIOL, V52, P52, DOI 10.1083/jcb.52.1.52; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PRIVES J, 1982, J CELL BIOL, V92, P231, DOI 10.1083/jcb.92.1.231; PRIVES JM, 1976, SURFACE MEMBRANE REC, P363; ROSS AF, 1987, J BIOL CHEM, V262, P14640; SEGAL MS, 1992, J CELL BIOL, V118, P227, DOI 10.1083/jcb.118.2.227; SMITH MM, 1987, J BIOL CHEM, V262, P4367; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001; SUMIKAWA K, 1991, J BIOL CHEM, V267, P6286; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; TATU U, 1995, EMBO J, V14, P1340, DOI 10.1002/j.1460-2075.1995.tb07120.x; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; WADA I, 1994, J BIOL CHEM, V269, P7464; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	48	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10709	10714		10.1074/jbc.271.18.10709	http://dx.doi.org/10.1074/jbc.271.18.10709			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631879	hybrid			2022-12-27	WOS:A1996UJ34200047
J	Chestukhin, A; Litovchick, L; Schourov, D; Cox, S; Taylor, SS; Shaltiel, S				Chestukhin, A; Litovchick, L; Schourov, D; Cox, S; Taylor, SS; Shaltiel, S			Functional malleability of the carboxyl-terminal tail in protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLITTING MEMBRANAL PROTEINASE; CIRCULAR DICHROIC EVIDENCE; CATALYTIC SUBUNIT; INHIBITOR PROTEIN; PEPTIDE INHIBITOR; CRYSTAL-STRUCTURE; SUBSTRATE-SPECIFICITY; MAGNETIC-RESONANCE; ESCHERICHIA-COLI; BASIC RESIDUES	The catalytic (C) subunit of protein kinase A (PKA) is regarded as a framework for the protein kinase family. Its sequence is composed of a conserved core (residues 40-300) between two segments at the amino and carboxyl termini of the protein. Since the various protein kinases differ in their specificity, it seems reasonable to assume that these nonhomologous segments may be involved in endowing each kinase with its individual specificity. Here we present data to show that the cluster of acidic amino acids ((328)DDYEEEE(334)) at the carboxyl-terminal ''tail'' of the C subunit, specifically Tyr(330), contributes to its substrate recognition. This is based on three complementary lines of evidence: (i) on a conformation-sensitive cleavage of the C subunit by a kinase-splitting membranal proteinase that specifically recognizes this cluster, to demonstrate the occurrence in solution of ''open'' (cleavable) and ''closed'' (noncleavable) conformations of the C subunit; (ii) on analysis of the three-dimensional structures of the open and closed conformations of the C subunit, showing an similar to 7-Angstrom movement of the phenolic hydroxyl of Tyr(330) to reach (in the closed conformation) an similar to 3-Angstrom distance from the nitrogen atoms of the Arg residue at position p-3 of the PKA consensus sequence; and (iii) on single-site mutations of the C subunit (e.g. Y330A) that show a significant contribution of Tyr(330) to the K-m of PKA for its substrates/inhibitors and to its catalytic efficacy (V-max/K-m).	WEIZMANN INST SCI, DEPT REGULAT BIOL, IL-76100 REHOVOT, ISRAEL; UNIV CALIF SAN DIEGO, DEPT CHEM, SAN DIEGO, CA 92093 USA	Weizmann Institute of Science; University of California System; University of California San Diego				Litovchick, Larisa/0000-0002-9540-597X				ALHANATY E, 1979, BIOCHEM BIOPH RES CO, V89, P323, DOI 10.1016/0006-291X(79)90633-8; ALHANATY E, 1981, P NATL ACAD SCI-BIOL, V78, P3492, DOI 10.1073/pnas.78.6.3492; ALHANATY E, 1985, CURR TOP CELL REGUL, V27, P267; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BUECHLER JA, 1990, BIOCHEMISTRY-US, V29, P1937, DOI 10.1021/bi00459a039; CHENG HC, 1985, BIOCHEM J, V231, P655, DOI 10.1042/bj2310655; Cleland W. W, 1970, ENZYMES, V2, P1; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; EGAN JJ, 1988, ANAL BIOCHEM, V175, P552, DOI 10.1016/0003-2697(88)90583-0; EVERS C, 1978, MEMBRANE BIOCHEM, V1, P203, DOI 10.3109/09687687809063848; FERAMISCO JR, 1980, J BIOL CHEM, V255, P4240; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GRANOT J, 1980, BIOCHEMISTRY-US, V19, P3537, DOI 10.1021/bi00556a019; GRANOT J, 1981, BIOCHEMISTRY-US, V20, P602, DOI 10.1021/bi00506a024; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERBERG FW, 1993, PROTEIN ENG, V6, P771, DOI 10.1093/protein/6.7.771; JIMENEZ JS, 1981, FEBS LETT, V130, P127, DOI 10.1016/0014-5793(81)80680-1; JIMENEZ JS, 1982, BIOCHEMISTRY-US, V21, P1623, DOI 10.1021/bi00536a024; JOHNSON EM, 1975, BIOCHEMISTRY-US, V14, P3873, DOI 10.1021/bi00688a022; KARLSSON R, 1993, ACTA CRYSTALLOGR D, V49, P381, DOI 10.1107/S0907444993002306; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KINZEL V, 1987, ARCH BIOCHEM BIOPHYS, V253, P341, DOI 10.1016/0003-9861(87)90187-1; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1993, ACTA CRYSTALLOGR D, V49, P357, DOI 10.1107/S0907444993000502; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KREBS EG, 1985, BIOCHEM SOC T, V13, P813, DOI 10.1042/bst0130813; Krebs EG, 1986, ENZYMES, V17, P3, DOI 10.1016/S1874-6047(08)60426-6; KUPFER A, 1980, BIOCHEM BIOPH RES CO, V96, P77, DOI 10.1016/0006-291X(80)91183-3; KUPFER A, 1982, BIOCHEMISTRY-US, V21, P1631, DOI 10.1021/bi00536a025; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OLAH GA, 1993, BIOCHEMISTRY-US, V32, P3649, DOI 10.1021/bi00065a018; ORELLANA SA, 1993, J BIOL CHEM, V268, P6843; POMERANTZ AH, 1977, P NATL ACAD SCI USA, V74, P4261, DOI 10.1073/pnas.74.10.4261; REED J, 1984, BIOCHEMISTRY-US, V23, P968, DOI 10.1021/bi00300a026; REED J, 1985, BIOCHEMISTRY-US, V24, P2967, DOI 10.1021/bi00333a024; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; SEGER R, 1989, EMBO J, V8, P435, DOI 10.1002/j.1460-2075.1989.tb03395.x; SEGER R, 1988, J BIOL CHEM, V263, P3496; SEGER R, 1993, INNOVATION PROTEASES, P231; SHALTIEL S, 1988, ROOTS OF MODERN BIOCHEMISTRY, P781; SHALTIEL S, 1989, INTRACELLULAR PROTEO, P188; SHOJI S, 1981, P NATL ACAD SCI-BIOL, V78, P848, DOI 10.1073/pnas.78.2.848; SLICE LW, 1989, J BIOL CHEM, V264, P20940; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; VANPATTEN SM, 1986, J BIOL CHEM, V261, P5514; VERON M, 1993, P NATL ACAD SCI USA, V90, P10618, DOI 10.1073/pnas.90.22.10618; WALSH D A, 1992, Current Opinion in Cell Biology, V4, P241, DOI 10.1016/0955-0674(92)90039-F; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; YONEMOTO WM, 1991, METHOD ENZYMOL, V200, P581; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	60	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10175	10182		10.1074/jbc.271.17.10175	http://dx.doi.org/10.1074/jbc.271.17.10175			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626579	hybrid			2022-12-27	WOS:A1996UG25700051
J	Massillon, D; Barzilai, N; Chen, W; Hu, MZ; Rossetti, L				Massillon, D; Barzilai, N; Chen, W; Hu, MZ; Rossetti, L			Glucose regulates in vivo glucose-6-phosphatase gene expression in the liver of diabetic rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN; INHIBITION; NIDDM	Overproduction of glucose by the liver is the major cause of fasting hyperglycemia in both insulin-dependent and non-insulin-dependent diabetes mellitus. The distal enzymatic step in the process of glucose output is catalyzed by the glucose-6-phosphatase complex. We show here that 90% partially pancreatectomized diabetic rats have a >5-fold increase in the messenger RNA and a 3-4-fold increase in the protein level of the catalytic subunit of glucose-6-phosphatase in the liver. Normalization of the plasma glucose concentration in diabetic rats with either insulin or the glycosuric agent phlorizin normalized the hepatic glucose-6-phosphatase messenger RNA and protein within similar to 8 h. Conversely, phlorizin failed to decrease hepatic glucose-6-phosphatase gene expression in diabetic rats when the fall in the plasma glucose concentration was prevented by glucose infusion, These data indicate that in vivo gene expression of glucose-6-phosphatase in the diabetic liver is regulated by glucose independently from insulin, and thus prolonged hyperglycemia may result in overproduction of glucose via increased expression of this protein.	ALBERT EINSTEIN COLL MED,CTR DIABET RES & TRAINING,BRONX,NY 10461; ALBERT EINSTEIN COLL MED,DIV ENDOCRINOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NIDDK NIH HHS [DK 20541, DK 45024, DK 48321] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045024, R37DK048321, P30DK020541, R01DK048321, R29DK045024, P60DK020541] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHMORE J, 1954, P NATL ACAD SCI USA, V40, P673, DOI 10.1073/pnas.40.8.673; BARZILAI N, 1993, J BIOL CHEM, V268, P25019; BELL PM, 1986, J CLIN INVEST, V78, P1479, DOI 10.1172/JCI112739; BODE AM, 1992, J BIOL CHEM, V267, P2860; BONNERWEIR S, 1983, J CLIN INVEST, V71, P1544, DOI 10.1172/JCI110910; BURCHELL A, 1990, FASEB J, V4, P2978, DOI 10.1096/fasebj.4.12.2168325; CHAN TM, 1975, AM J PHYSIOL, V229, P1702, DOI 10.1152/ajplegacy.1975.229.6.1702; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DIAMOND MP, 1988, METABOLISM, V37, P28, DOI 10.1016/0026-0495(88)90025-X; Foglia Virgilio G., 1944, REV SOC ARGENTINA BIOL, V20, P21; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; FULCERI R, 1995, BIOCHEM J, V307, P391, DOI 10.1042/bj3070391; GARDNER LB, 1993, DIABETES, V42, P1614, DOI 10.2337/diabetes.42.11.1614; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; HANSON TL, 1970, BIOCHIM BIOPHYS ACTA, V198, P66, DOI 10.1016/0005-2744(70)90033-1; JAHOOR F, 1990, AM J PHYSIOL, V258, pE288, DOI 10.1152/ajpendo.1990.258.2.E288; JENNSEN T, 1990, J CLIN INVEST, V86, P489; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; LANGE AJ, 1986, J BIOL CHEM, V261, P101; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; LIU ZQ, 1994, BIOCHEM BIOPH RES CO, V205, P680, DOI 10.1006/bbrc.1994.2719; MINASSIAN C, 1994, J BIOL CHEM, V269, P16585; MULLER S, 1995, J BACTERIOL, V177, P4517; PRIPBUUS C, 1995, EUR J BIOCHEM, V230, P309, DOI 10.1111/j.1432-1033.1995.tb20564.x; PUHAKAINEN I, 1991, DIABETES, V40, P1319, DOI 10.2337/diabetes.40.10.1319; ROSSETTI L, 1993, J CLIN INVEST, V92, P1126, DOI 10.1172/JCI116681; ROSSETTI L, 1990, J CLIN INVEST, V85, P1785, DOI 10.1172/JCI114636; ROSSETTI L, 1987, J CLIN INVEST, V79, P1610; SHELLY LL, 1993, J BIOL CHEM, V268, P482; WOLFE RB, 1986, J PARENTER ENTERAL N, V11, P109	31	148	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9871	9874		10.1074/jbc.271.17.9871	http://dx.doi.org/10.1074/jbc.271.17.9871			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626617	hybrid			2022-12-27	WOS:A1996UG25700001
J	Darke, PL; Cole, JL; Waxman, L; Hall, DL; Sardana, MK; Kuo, LC				Darke, PL; Cole, JL; Waxman, L; Hall, DL; Sardana, MK; Kuo, LC			Active human cytomegalovirus protease is a dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; GENE	The quaternary state of the human cytomegalovirus (hCMV) protease has been analyzed in relation to its catalysis of peptide hydrolysis. Based on results obtained from steady state kinetics, size exclusion chromatography, and velocity sedimentation, the hCMV protease exists in a monomer-dimer equilibrium. Dimerization of the protease is enhanced by the presence of glycerol and high concentrations of enzyme. Isolation of monomeric and dimeric species eluted from a size exclusion column, followed by immediate assay, identifies the dimer as the active species. Activity measurements conducted with a range of enzyme concentrations are also consistent with a kinetic model in which only the dimeric hCMV protease is active. Using this model, the dissociation constant of the protease is 6.6 mu M in 10% glycerol and 0.55 mu M in 20% glycerol at 30 degrees C and pH 7.5.	MERCK SHARP & DOHME RES LABS,DEPT BIOL CHEM,W POINT,PA 19486	Merck & Company	Darke, PL (corresponding author), MERCK SHARP & DOHME RES LABS,DEPT ANTIVIRAL RES,W POINT,PA 19486, USA.		Cole, James/G-2586-2011					BAUM EZ, 1993, J VIROL, V67, P497, DOI 10.1128/JVI.67.1.497-506.1993; BURCK PJ, 1994, J VIROL, V68, P2937, DOI 10.1128/JVI.68.5.2937-2946.1994; Cohn E., 1943, PROTEINS AMINO ACIDS, P157; COX AG, 1995, J VIROL, V69, P4524; GAO M, 1994, J VIROL, V68, P3702, DOI 10.1128/JVI.68.6.3702-3712.1994; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4667, DOI 10.1021/bi00519a023; HOLSKIN BP, 1995, ANAL BIOCHEM, V227, P148, DOI 10.1006/abio.1995.1264; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; MATUSICKKUMAR L, 1995, J VIROL, V69, P7113, DOI 10.1128/JVI.69.11.7113-7121.1995; PHILO JS, 1994, MODERN ANAL ULTRACEN, P159; PINKO C, 1995, J BIOL CHEM, V270, P23634, DOI 10.1074/jbc.270.40.23634; PRESTON VG, 1983, J VIROL, V45, P1056, DOI 10.1128/JVI.45.3.1056-1064.1983; SARDANA VV, 1994, J BIOL CHEM, V269, P14337; STEVENS JT, 1994, EUR J BIOCHEM, V226, P361, DOI 10.1111/j.1432-1033.1994.tb20060.x; WELCH AR, 1991, P NATL ACAD SCI USA, V88, P10792, DOI 10.1073/pnas.88.23.10792	15	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7445	7449		10.1074/jbc.271.13.7445	http://dx.doi.org/10.1074/jbc.271.13.7445			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631772	hybrid			2022-12-27	WOS:A1996UC77400040
J	Hamman, BD; Oleinikov, AV; Jokhadze, GG; Bochkariov, DE; Traut, RR; Jameson, DM				Hamman, BD; Oleinikov, AV; Jokhadze, GG; Bochkariov, DE; Traut, RR; Jameson, DM			Tetramethylrhodamine dimer formation as a spectroscopic probe of the conformation of Escherichia coli ribosomal protein L7/L12 dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; NUCLEAR MAGNETIC-RESONANCE; CROSS-LINKING; SUBUNIT; FLUORESCENCE; REGION; L7-L12; L12	The fluorescent probe tetramethylrhodamine iodoacetamide was attached to cysteine residues substituted at various specific locations in full-length and deletion variants of the homodimeric Escherichia coli ribosomal protein L7/L12, Ground-state tetramethylrhodamine dimers form between the two subunits of L7/L12 depending upon the location of the probe, The formation of tetramethylrhodamine dimers caused the appearance of a new absorption band at 518 nm that was used to estimate the extent of interaction of the probes in the different protein variants, Intersubunit tetramethylrhodamine dimers form when tetramethylrhodamine acetamide is attached to two different sites in the N-terminal domain of the L7/L12 dimer (residues 12 or 33), but not when attached to sites in the C-terminal domain (residues 63, 89, or 99), The tetramethylrhodamine dimers do form at sites in the C-terminal domain in L7/L12 variants that contain deletions of 11 or 18 residues within the putative flexible hinge that separates the N- and C-terminal domains, The tetramethylrhodamine dimers disappear rapidly (within 5 s) upon addition of excess unlabeled wild-type L7/L12, It appears that singly labeled L7/L12 dimers are formed by exchange with wild-type dimers, Binding of L7/L12:tetramethylrhodamine cysteine 33 or cysteine 12 dimers either to L7/L12-depleted ribosomal core particles, or to ribosomal protein L10 alone, results in disappearance of the 518-nm absorption band, This result implies a conformational change in the N-terminal domain of L7/L12 upon its binding to the ribosome, or to L10.	UNIV HAWAII,DEPT BIOCHEM & BIOPHYS,HONOLULU,HI 96822; UNIV CALIF DAVIS,DEPT BIOL CHEM,SCH MED,DAVIS,CA 95616	University of Hawaii System; University of California System; University of California Davis					NIGMS NIH HHS [GM17924] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017924, R37GM017924] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AJTAI K, 1992, BIOCHEMISTRY-US, V31, P12431, DOI 10.1021/bi00164a019; ALLEN G, 1981, SEQUENCING PROTEINS, P58; ARBELOA IL, 1982, CHEM PHYS LETT, V87, P556, DOI 10.1016/0009-2614(82)83177-1; BUSHUEV VN, 1989, J BIOL CHEM, V264, P4498; CALDWELL P, 1978, P NATL ACAD SCI USA, V75, P5349, DOI 10.1073/pnas.75.11.5349; CASIANO C, 1990, J BIOL CHEM, V265, P18757; CORRIE JET, 1994, J CHEM SOC PERK T 1, P2967, DOI 10.1039/p19940002967; COWGILL CA, 1984, J BIOL CHEM, V259, P5257; DEMAS JN, 1971, J PHYS CHEM-US, V75, P991, DOI 10.1021/j100678a001; EDMUNDSON AB, 1984, MOL IMMUNOL, V21, P561, DOI 10.1016/0161-5890(84)90041-5; ERIJMAN L, 1993, PHOTOCHEM PHOTOBIOL, V57, P411, DOI 10.1111/j.1751-1097.1993.tb02310.x; ERIJMAN L, 1991, BIOCHEMISTRY-US, V30, P1595, DOI 10.1021/bi00220a022; FEKKES T, 1995, BIOCHEMISTRY-US, V34, P10078; FORSTER T, 1957, Z ELEKTROCHEM, V61, P344; GUDKOV AT, 1978, EUR J BIOCHEM, V90, P309, DOI 10.1111/j.1432-1033.1978.tb12605.x; HAMMAN BD, 1993, BIOPHYS J, V64, pA53; HAMMAN BD, THESIS ANN ARBOR; LEIJONMARCK M, 1987, J MOL BIOL, V195, P555, DOI 10.1016/0022-2836(87)90183-5; MAKAROV EM, 1993, BIOCHIMIE, V75, P963, DOI 10.1016/0300-9084(93)90146-J; MOLLER W, 1983, J MOL BIOL, V163, P553, DOI 10.1016/0022-2836(83)90112-2; OLEINIKOV AV, 1993, J BIOL CHEM, V268, P917; OLEINIKOV AV, 1993, P NATL ACAD SCI USA, V90, P9828, DOI 10.1073/pnas.90.21.9828; Schaffer F. P., 1973, DYE LASERS; SELWYN JE, 1972, J PHYS CHEM-US, V76, P762, DOI 10.1021/j100649a026; TOKIMATSU H, 1981, J MOL BIOL, V152, P397, DOI 10.1016/0022-2836(81)90250-3; TRAUT RR, 1993, TRANSLATIONAL APPARATUS, P521; TRITTON TR, 1978, BIOCHEMISTRY-US, V17, P3959, DOI 10.1021/bi00612a013; VERSCHOOR A, 1986, J ULTRASTRUCT RES, V92, P180; Weber G., 1992, PROTEIN INTERACTIONS; ZECHERLE GN, 1992, J BIOL CHEM, V267, P5889; ZECHERLE GN, 1992, BIOCHEMISTRY-US, V31, P9526, DOI 10.1021/bi00155a003	31	55	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7568	7573		10.1074/jbc.271.13.7568	http://dx.doi.org/10.1074/jbc.271.13.7568			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631789	hybrid			2022-12-27	WOS:A1996UC77400057
J	Peppard, JV; Loo, P; Sills, MA; Munster, D; Pomponi, SA; Wright, AE				Peppard, JV; Loo, P; Sills, MA; Munster, D; Pomponi, SA; Wright, AE			Characterization of an interleukin 6 cytokine family antagonist protein from a marine sponge, Callyspongia sp.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-6 SIGNAL TRANSDUCER; ONCOSTATIN-M; RECEPTOR; GP130; IMMUNE; LIF	An inhibitor of IL-6 binding to the human hepatoma line HepG2 and myeloma cell line U266 was identified in a saline extract of the marine sponge, Callyspongia sp. Functional activity, measured through the increase in haptoglobin production by HepG2 cells stimulated with IL-6, could be strongly inhibited by the extract. Similarly, IL-6-induced production of IgM by the B cell line SKW6.4 was substantially reduced, In neither cell line was there evidence of toxicity produced by the extract. Other sponges of the Callyspongia species were found to contain analogous activity. The activity was destroyed by trypsin treatment or boiling of the extract, suggesting that the inhibition is due to a protein, When the binding of IL-6 to its receptor complex was dissected in. vitro, inhibition of binding of IL-6 to soluble receptor by the extract was not detected, but binding of the IL-6 . sIL-6R complex to soluble gp130 was inhibited in a dose-dependent fashion. This was borne out in cellular assays since the extract inhibited activation of HepG2 cells stimulated with oncostatin M or leukemia inhibitory factor, cytokines which also use gp130 for signal transduction. These results suggest that the Callyspongia extract contains a protein which blocks the interaction of the IL-6 family of cytokines with their signal transduction moiety, gp130, Elucidation of the structure and mode of action of such a protein would be helpful in designing gp130 antagonists to inhibit the functions of this cytokine family, overproduction of which has been associated with cancer and pathologies of autoimmune disease and AIDS.	HARBOR BRANCH OCEANOG INST INC,FT PIERCE,FL 34946	Harbor Branch Oceanographic Institute Foundation	Peppard, JV (corresponding author), CIBA GEIGY CORP,DIV PHARMACEUT,RES DEPT,556 MORRIS AVE,SUMMIT,NJ 07901, USA.							BAUMANN H, 1987, J IMMUNOL, V139, P4122; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEWEERDT WH, 1986, ZOOLOGISCHE VERHANDE, V225, P1; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Patterson P H, 1992, Curr Opin Neurobiol, V2, P94, DOI 10.1016/0959-4388(92)90169-L; PEPPARD JV, 1994, CELL IMMUNOL, V155, P253, DOI 10.1006/cimm.1994.1118; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TAGA T, 1992, CRIT REV IMMUNOL, V11, P265; van Soest RWM, 1980, STUD FAUNA CURACAO, V62, P1; YAMAMORI T, 1992, NEUROSCI RES, V15, P151, DOI 10.1016/0168-0102(92)90001-S	15	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7281	7284		10.1074/jbc.271.13.7281	http://dx.doi.org/10.1074/jbc.271.13.7281			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631742	hybrid			2022-12-27	WOS:A1996UC77400010
J	Sanchez, A; Alvarez, AM; Benito, M; Fabregat, I				Sanchez, A; Alvarez, AM; Benito, M; Fabregat, I			Apoptosis induced by transforming growth factor-beta in fetal hepatocyte primary cultures - Involvement of reactive oxygen intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; C-FOS EXPRESSION; PROLIFERATIVE CONDITIONS; GLUTATHIONE-REDUCTASE; REGRESSING LIVER; RAT HEPATOCYTES; FACTOR-BETA-1; HORMONES; GENE; GROWTH-FACTOR-BETA-1	Transforming growth factor-beta (TGF-beta), a growth regulator of fetal hepatocytes in primary culture, also regulates death of these cells. Dose-response analysis showed that the TGF-beta concentration needed to induce hepatocyte death (2.5 ng/ml) was 5 times that needed to inhibit growth in these cells (0.5 ng/ml). In response to TGF-beta, hepatocytes induced DNA fragmentation and the appearance of nuclei with a DNA content lower than 2C (diploid content), typical of a programmed cell death model. TGF-beta-induced apoptosis in fetal hepatocytes was preceded by an induction of reactive oxygen species production and a decrease in the glutathione intracellular content, indicating that this factor induces oxidative stress in fetal hepatocytes. Studies performed to analyze levels of c-fos mRNA, a gene whose expression is modulated by redox state, demonstrated that only high, apoptotic concentrations of TGF-beta (2.5 ng/ml) produced an increase in the mRNA Levels of this gene, the level of induction being similar to that found when cells were incubated in the presence of tert-butyl hydroperoxide. Gel mobility shift assays showed that the c-fos-induced expression was coincident with an increase in AP-1 activity. Finally, cell death induced by TGF-beta in fetal hepatocytes was partially blocked by radical scavengers, which decreased the percentage of apoptotic cells, whereas these agents did not modify the growth-inhibitory effect elicited by TGF-beta in these cells. In summary, the results presented in this paper provide evidence for the involvement of an oxidative process in the apoptosis elicited by TGF-beta in fetal hepatocytes.	UNIV COMPLUTENSE MADRID,DEPT BIOQUIM & BIOL MOLEC,INST BIOQUIM,CONSEJO SUPER INVEST CIENT,E-28040 MADRID,SPAIN; UNIV COMPLUTENSE MADRID,FAC FARM,CTR CITOMETRIA FLUJO,E-28040 MADRID,SPAIN	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Complutense University of Madrid			Sánchez, Aránzazu/H-7810-2015; Benito, Manuel/J-5637-2014; Alvarez-Barrientos, Alberto/L-9299-2014; Fabregat, Isabel/H-7038-2015	Sánchez, Aránzazu/0000-0001-9145-6633; Benito, Manuel/0000-0002-7218-406X; Alvarez-Barrientos, Alberto/0000-0003-4761-0212; Fabregat, Isabel/0000-0003-0136-8440				ABDELRAZZAK Z, 1994, MOL PHARMACOL, V46, P1100; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BANKS MF, 1994, J NUTR, V124, P378, DOI 10.1093/jn/124.3.378; BARKER CW, 1994, J BIOL CHEM, V269, P3985; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYANT PJ, 1988, DEV BIOL, V128, P386, DOI 10.1016/0012-1606(88)90300-4; BUROW S, 1987, EUR J CELL BIOL, V43, P128; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEAN RT, 1993, TRENDS BIOCHEM SCI, V18, P437, DOI 10.1016/0968-0004(93)90145-D; DEJUAN C, 1992, EXP CELL RES, V202, P495, DOI 10.1016/0014-4827(92)90104-G; DEJUAN C, 1994, BIOCHEM BIOPH RES CO, V204, P1364, DOI 10.1006/bbrc.1994.2614; DEJUAN C, 1992, J CELL PHYSIOL, V152, P95, DOI 10.1002/jcp.1041520113; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DRYSDALE BE, 1983, J IMMUNOL, V131, P2362; EKLOW L, 1984, EUR J BIOCHEM, V138, P459, DOI 10.1111/j.1432-1033.1984.tb07938.x; FABREGAT I, 1992, BIOCHEM BIOPH RES CO, V189, P684, DOI 10.1016/0006-291X(92)92255-V; FABREGAT I, 1985, ARCH BIOCHEM BIOPHYS, V236, P110, DOI 10.1016/0003-9861(85)90610-1; FUKUDA K, 1993, HEPATOLOGY, V18, P945, DOI 10.1002/hep.1840180428; GARCIARUIZ C, 1995, HEPATOLOGY, V21, P207, DOI 10.1016/0270-9139(95)90430-1; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JAGODZINSKI LL, 1981, P NATL ACAD SCI-BIOL, V78, P3521, DOI 10.1073/pnas.78.6.3521; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; KORSMEYER SJ, 1992, BLOOD, V80, P879; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; LACAL JC, 1984, P NATL ACAD SCI USA, V81, P6305; LYONS AB, 1992, CYTOMETRY, V13, P809; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MEYER M, 1994, CHEM-BIOL INTERACT, V91, P91, DOI 10.1016/0009-2797(94)90029-9; MOLERO C, 1993, J CELL PHYSIOL, V155, P197, DOI 10.1002/jcp.1041550125; MOLERO C, 1992, EXP CELL RES, V200, P295, DOI 10.1016/0014-4827(92)90175-8; MOULTON BC, 1994, ENDOCRINOLOGY, V134, P1055, DOI 10.1210/en.134.3.1055; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; OBERHAMMER F, 1991, CANCER RES, V51, P2478; OBERHAMMER F, 1993, HEPATOLOGY, V18, P1238; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; RONCERO C, 1989, BIOCHIM BIOPHYS ACTA, V1012, P320, DOI 10.1016/0167-4889(89)90115-8; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; SANCHEZ A, 1995, J CELL PHYSIOL, V165, P398, DOI 10.1002/jcp.1041650221; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STEINMAN HM, 1995, J BIOL CHEM, V270, P3487; THANNICKAL VJ, 1993, AM J PHYSIOL, V265, pL622, DOI 10.1152/ajplung.1993.265.6.L622; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; WEN P, 1994, MOL CELL BIOL, V14, P6616, DOI 10.1128/MCB.14.10.6616; WHITE E, 1993, GENE DEV, V7, P2277, DOI 10.1101/gad.7.12a.2277; YANAGIHARA K, 1992, CANCER RES, V52, P4042	53	246	251	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7416	7422		10.1074/jbc.271.13.7416	http://dx.doi.org/10.1074/jbc.271.13.7416			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631767	Green Published, hybrid			2022-12-27	WOS:A1996UC77400035
J	Genuario, RR; Perry, RP				Genuario, RR; Perry, RP			The GA-binding protein can serve as both an activator and repressor of ribosomal protein gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE ELEMENTS; PROMOTER; EXPRESSION; SUBUNITS; MOTIFS	The GA-binding protein (GABP), a heterodimeric transcription factor with widespread tissue distribution, has been found to be a strong positive regulator of several ribosomal protein (rp)-encoding genes. In such genes, e.g. the mouse rpL30 gene, the GABP-binding sites are located 40-80 base pairs upstream of the transcriptional start point. Potential GABP-binding sites are present in the promoters of numerous other rp genes, not only in upstream regions, but also in the immediate vicinity of the transcriptional start point. The mouse rpS16 gene is an example of the latter type. We demonstrate here that GABP binds to the rpS16 initiation region, and in so doing down-regulates rpS16 transcription both in vivo and in vitro. Supplementation of cell-free extracts with GABP inhibits transcription on rpS16 templates while concomitantly stimulating transcription on rpL30 templates. The repressive and stimulatory effects, which were proportional to the amount of GABP added, required both the GABP cu subunit and either a beta(1) or beta(2) subunit. Mutations of the rpS16 GABP-binding sites that abolish binding increased rpS16 promoter activity in vivo and in vitro, whereas mutations that strengthen GABP binding caused a reduction in promoter activity. The binding of GABP to the rpS16 initiation region does not significantly affect the positioning of the transcriptional start points. Taken together with earlier studies, these new findings indicate that GABP can have a dual role as repressor or activator of rp gene transcription.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017330] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09035, CA-06927] Funding Source: Medline; NIAID NIH HHS [AI-17330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1994, J BIOL CHEM, V269, P4381; CHUNG S, 1991, GENE, V100, P173, DOI 10.1016/0378-1119(91)90363-G; DELABROUSSE FC, 1994, GENE DEV, V8, P1853, DOI 10.1101/gad.8.15.1853; Genuario R. Robert, 1993, Gene Expression, V3, P279; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; HARIHARAN N, 1989, NUCLEIC ACIDS RES, V17, P5323, DOI 10.1093/nar/17.13.5323; HARIHARAN N, 1990, P NATL ACAD SCI USA, V87, P1526, DOI 10.1073/pnas.87.4.1526; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; MARCHIONI M, 1993, MOL CELL BIOL, V13, P6479, DOI 10.1128/MCB.13.10.6479; ROBERTS SGE, 1995, NATURE, V375, P105, DOI 10.1038/375105a0; SAFRANY G, 1995, EUR J BIOCHEM, V230, P1066, DOI 10.1111/j.1432-1033.1995.tb20657.x; SAWADA J, 1994, EMBO J, V13, P1396, DOI 10.1002/j.1460-2075.1994.tb06393.x; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380	23	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4388	4395						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626789				2022-12-27	WOS:A1996TW96000067
J	Doherty, AJ; Ashford, SR; Subramanya, HS; Wigley, DB				Doherty, AJ; Ashford, SR; Subramanya, HS; Wigley, DB			Bacteriophage T7 DNA ligase - Overexpression, purification, crystallization, and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC ACID LIGASE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; PHYSICAL CHARACTERIZATION; FUNCTIONAL EXPRESSION; POLYNUCLEOTIDE LIGASE; CATALYTIC DOMAIN; END LIGATION; BLUNT-END; ENZYME	The bacteriophage T7 DNA ligase gene was amplified using polymerase chain reaction-based methods and cloned into a T7 promoter-based expression vector. The protein was overexpressed to greater than 15% of total soluble protein and purified to homogeneity, yielding 60-70 mg of protein per liter of bacterial culture. An initial physical and biochemical characterization of the enzyme reveals that it exists as a monomer and can ligate nicked, cohesive, and blunt-ended DNA fragments. Inhibition of the enzyme activity by a nonhydrolyzable ATP analogue was also investigated. The enzyme has been crystallized from methoxypolyethylene glycol. The crystals are of the orthorhombic space group P2(1)2(1)2 and diffract to 2.6 Angstrom. The unit cell dimensions are a 66.1 Angstrom, b = 87.6 Angstrom, and c = 78.6 Angstrom with one monomer in the asymmetric unit (V-m = 2.77 Angstrom(3)/Da). This is the first member of the DNA ligase family of enzymes to be crystallized.	UNIV OXFORD,MOLEC BIOPHYS LAB,OXFORD OX1 3QU,ENGLAND	University of Oxford				Doherty, Aidan/0000-0002-6370-1109	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARANY F, 1991, GENE, V109, P1, DOI 10.1016/0378-1119(91)90582-V; BARNES DE, 1990, P NATL ACAD SCI USA, V87, P6679, DOI 10.1073/pnas.87.17.6679; BNAKS GR, 1986, BIOCHIM BIOPHYS ACTA, V826, P180; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; DERMODY JJ, 1979, J BACTERIOL, V139, P701, DOI 10.1128/JB.139.2.701-704.1979; DOHARTY AJ, 1995, NUCLEIC ACIDS RES, V23, P2074; DUNN JJ, 1981, J MOL BIOL, V148, P308; Engler M.J., 1982, ENZYMES, V15, P3, DOI [10.1016/S1874-6047(08)60273-5, DOI 10.1016/S1874-6047(08)60273-5]; FAREED GC, 1971, J BIOL CHEM, V246, P925; HARVEY CL, 1971, J BIOL CHEM, V246, P4523; HEAPHY S, 1987, BIOCHEMISTRY-US, V26, P1688, DOI 10.1021/bi00380a030; HINKLE DC, 1975, J BIOL CHEM, V250, P5523; ISHINO Y, 1986, MOL GEN GENET, V204, P1, DOI 10.1007/BF00330179; KLETZIN A, 1992, NUCLEIC ACIDS RES, V20, P5389, DOI 10.1093/nar/20.20.5389; KODAMA K, 1991, NUCLEIC ACIDS RES, V19, P6093, DOI 10.1093/nar/19.22.6093; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUER G, 1991, J BACTERIOL, V173, P5047, DOI 10.1128/jb.173.16.5047-5053.1991; LEHMAN IR, 1974, SCIENCE, V186, P790; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; LITTLE JW, 1967, P NATL ACAD SCI USA, V58, P2004, DOI 10.1073/pnas.58.5.2004; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MODRICH P, 1973, J BIOL CHEM, V248, P7495; MODRICH P, 1973, J BIOL CHEM, V248, P7502; OLIVERA BM, 1968, P NATL ACAD SCI USA, V61, P237, DOI 10.1073/pnas.61.1.237; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PANET A, 1973, BIOCHEMISTRY-US, V12, P5045, DOI 10.1021/bi00749a003; PHEIFFER BH, 1983, NUCLEIC ACIDS RES, V11, P7853, DOI 10.1093/nar/11.22.7853; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWER B, 1994, P NATL ACAD SCI USA, V91, P4328, DOI 10.1073/pnas.91.10.4328; SGARAMEL.V, 1970, P NATL ACAD SCI USA, V67, P1468, DOI 10.1073/pnas.67.3.1468; SHELDRICK G, 1982, CRYSTALLOGRAPHIC COM, P145; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; TOMKINSON AE, 1991, P NATL ACAD SCI USA, V88, P400, DOI 10.1073/pnas.88.2.400; WEISS B, 1968, J BIOL CHEM, V243, P4556; WOOD WB, 1966, J MOL BIOL, V16, P118, DOI 10.1016/S0022-2836(66)80267-X; YANG SW, 1992, J BIOL CHEM, V267, P8117; YANG SW, 1992, J BIOL CHEM, V267, P2345; ZIMMERMAN SB, 1983, P NATL ACAD SCI-BIOL, V80, P5852, DOI 10.1073/pnas.80.19.5852	43	38	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11083	11089		10.1074/jbc.271.19.11083	http://dx.doi.org/10.1074/jbc.271.19.11083			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626651	hybrid			2022-12-27	WOS:A1996UJ94400011
J	Kontush, A; Meyer, S; Finckh, B; Kohlschutter, A; Beisiegel, U				Kontush, A; Meyer, S; Finckh, B; Kohlschutter, A; Beisiegel, U			alpha-Tocopherol as a reductant for Cu(II) in human lipoproteins - Triggering role in the initiation of lipoprotein oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; LIPID-PEROXIDATION; VITAMIN-E; PLASMA-LIPOPROTEINS; COPPER; PROOXIDANT; ANTIOXIDANT; BINDING; INVITRO; IRON	Initiation of lipid peroxidation by Cu(II) requires reduction of Cu(II) to Cu(I) as a first step. It is unclear, however, whether this reaction occurs in the course of lipoprotein oxidation. It is also unknown which reductant, if any, can drive the reduction of Cu(II) in this case. We found that Cu(II) was rapidly reduced to Cu(I) by all major human lipoproteins (high, low and very low density lipoproteins (HDL, LDL, and VLDL), and chylomicrons). Cu(II)-reducing activity was associated with a lipid moiety of the lipoproteins. The rates of Cu(II) reduction by different lipoproteins were similar when the lipoproteins were adjusted to similar alpha-tocopherol concentrations, Enriching lipoproteins with alpha-tocopherol considerably increased the rate of Cu(II) reduction. Cu(II) reduction by alpha-tocopherol-deficient LDL isolated from a patient with familial inherited vitamin E deficiency was found to occur much slower in comparison with LDL isolated from a donor with a normal plasma level of alpha-tocopherol. Initial rate of Cu(II) reduction by alpha-tocopherol-deficient LDL was found to be zero. Enriching LDL with ubiquinol-10 to concentrations close to those of alpha-tocopherol did not influence the reaction rate. When LDL was treated with ebselen to eliminate preformed lipid hydroperoxides, the reaction rate was also not changed significantly, Cu(II) reduction was accompanied by a consumption of lipoprotein alpha-tocopherol and accumulation of conjugated dienes in the samples. Increasing alpha-tocopherol content in lipoproteins slightly decreased the rate of conjugated diene accumulation in LDL and HDL and considerably increased it in VLDL. The results suggest that alpha-tocopherol plays a triggering role in the lipoprotein oxidation by Cu(II), providing its initial step as follows: alpha TocH + Cu(II) --> alpha Toc(.) + Cu(I) + H+. This reaction appears to diminish or totally eliminate the antioxidative activity of alpha-tocopherol in the course of lipoprotein oxidation.	UNIV HAMBURG, KRANKENHAUS EPPENDORF, MED KLIN, D-20246 HAMBURG, GERMANY; UNIV HAMBURG, KRANKENHAUS EPPENDORF, KINDERKLIN, D-20246 HAMBURG, GERMANY	University of Hamburg; University of Hamburg			Kohlschütter, Alfried/ABE-3495-2021; Kontush, Anatol/J-2198-2016; Kohlschütter, Alfried/ABH-5710-2020	Kohlschütter, Alfried/0000-0002-2700-0401; 				AVIRAM M, 1993, ATHEROSCLEROSIS, V98, P1, DOI 10.1016/0021-9150(93)90217-I; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BOWRY VW, 1993, J AM CHEM SOC, V115, P6029, DOI 10.1021/ja00067a019; BOWRY VW, 1992, BIOCHEM J, V288, P341, DOI 10.1042/bj2880341; Bruckdorfer K. Richard, 1993, Current Opinion in Lipidology, V4, P238, DOI 10.1097/00041433-199306000-00010; CHAPMAN MJ, 1986, METHOD ENZYMOL, V128, P70; COMINACINI L, 1991, CLIN CHIM ACTA, V204, P57, DOI 10.1016/0009-8981(91)90217-Z; CROFT KD, 1995, BBA-LIPID LIPID MET, V1254, P250, DOI 10.1016/0005-2760(94)00166-V; DIEBERROTHENEDER M, 1991, J LIPID RES, V32, P1325; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; ESTERBAUER H, 1991, AM J CLIN NUTR, V53, pS314, DOI 10.1093/ajcn/53.1.314S; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; Finckh B, 1995, ANAL BIOCHEM, V232, P210, DOI 10.1006/abio.1995.0009; Frei Balz B., 1993, P131; FUKUZAWA K, 1988, ARCH BIOCHEM BIOPHYS, V260, P153, DOI 10.1016/0003-9861(88)90436-5; FUKUZAWA K, 1993, J NUTR SCI VITAMINOL, V39, pS9, DOI 10.3177/jnsv.39.Supplement_S9; HALLIWELL B, 1995, AM J CLIN NUTR, V61, p670S, DOI 10.1093/ajcn/61.3.670S; Hochstein P, 1980, Ann N Y Acad Sci, V355, P240, DOI 10.1111/j.1749-6632.1980.tb21342.x; JESSUP W, 1993, BIOCHEM SOC T, V21, P321, DOI 10.1042/bst0210321; KLEINVELD HA, 1993, FREE RADICAL BIO MED, V15, P273, DOI 10.1016/0891-5849(93)90074-5; KOHLSCHUTTER A, 1988, J INHERIT METAB DIS, V11, P149, DOI 10.1007/BF01804221; Kontush A, 1996, FREE RADICAL RES, V24, P135, DOI 10.3109/10715769609088009; KONTUSH A, 1994, FEBS LETT, V341, P69, DOI 10.1016/0014-5793(94)80242-4; KONTUSH A, 1995, BBA-LIPID LIPID MET, V1258, P177, DOI 10.1016/0005-2760(95)00115-S; KUZUYA M, 1992, BIOCHIM BIOPHYS ACTA, V1123, P334, DOI 10.1016/0005-2760(92)90015-N; LENAZ G, 1992, BIOCHEM CELL BIOL, V70, P504, DOI 10.1139/o92-078; LEPAGE G, 1986, J LIPID RES, V27, P114; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNCH SM, 1995, J BIOL CHEM, V270, P5158, DOI 10.1074/jbc.270.10.5158; MAIORINO M, 1993, FEBS LETT, V330, P174, DOI 10.1016/0014-5793(93)80267-X; MAIORINO M, 1995, FREE RADICAL BIO MED, V18, P67, DOI 10.1016/0891-5849(94)00103-Q; NIKI E, 1984, J BIOL CHEM, V259, P4177; OBRIEN PJ, 1969, CAN J BIOCHEM CELL B, V47, P485, DOI 10.1139/o69-076; OUAHCHI K, 1995, NAT GENET, V9, P141, DOI 10.1038/ng0295-141; PIFAT G, 1992, CHEM PHYS LIPIDS, V63, P159, DOI 10.1016/0009-3084(92)90032-K; PRINCEN HMG, 1992, ARTERIOSCLER THROMB, V12, P554, DOI 10.1161/01.ATV.12.5.554; RAHMAN A, 1989, CARCINOGENESIS, V10, P1833, DOI 10.1093/carcin/10.10.1833; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; SATTLER W, 1994, ARCH BIOCHEM BIOPHYS, V309, P214, DOI 10.1006/abbi.1994.1105; SPARROW CP, 1993, J LIPID RES, V34, P1219; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; THOMAS CE, 1991, J PHARMACOL EXP THER, V256, P1182; THOMAS JP, 1994, ARCH BIOCHEM BIOPHYS, V315, P244, DOI 10.1006/abbi.1994.1496; VOSSEN RCRM, 1993, LIPIDS, V28, P857, DOI 10.1007/BF02536243; WITZTUM JL, 1993, BRIT HEART J, V69, pS12; WOOD JL, 1995, FEBS LETT, V366, P75, DOI 10.1016/0014-5793(95)00494-T; YAMAMOTO K, 1988, BIOCHIM BIOPHYS ACTA, V958, P19, DOI 10.1016/0005-2760(88)90241-X; YOSHIDA Y, 1994, BBA-GEN SUBJECTS, V1200, P85, DOI 10.1016/0304-4165(94)90121-X	50	106	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11106	11112		10.1074/jbc.271.19.11106	http://dx.doi.org/10.1074/jbc.271.19.11106			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626654	hybrid			2022-12-27	WOS:A1996UJ94400014
J	Rahn, T; Ronnstrand, L; Leroy, MJ; Wernstedt, C; Tornqvist, H; Manganiello, VC; Belfrage, P; Degerman, E				Rahn, T; Ronnstrand, L; Leroy, MJ; Wernstedt, C; Tornqvist, H; Manganiello, VC; Belfrage, P; Degerman, E			Identification of the site in the cGMP-inhibited phosphodiesterase phosphorylated in adipocytes in response to insulin and isoproterenol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; KM CAMP PHOSPHODIESTERASE; RAT ADIPOCYTES; FAT-CELLS; AMP PHOSPHODIESTERASE; GEL-ELECTROPHORESIS; ACTIVATION; LIPOLYSIS; STIMULATION	Stimulation of rat adipocytes with insulin and isoproterenol results in serine phosphorylation and activation of the adipocyte cGMP-inhibited phosphodiesterase (cGI PDE), events believed to be important in the antilipolytic action of insulin (Degerman, E., Smith, C. J., Tornqvist, H., Vasta, V., Manganiello, V. C., and Belfrage, P. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 533-537). Here we demonstrate, by two-dimensional phosphopeptide mapping, that the major phosphopeptide generated by trypsin, or trypsin followed by Asp-N protease digestion of [P-32]cGI PDE phosphorylated in adipocytes in response to isoproterenol and/or insulin, in each case co-migrates with the phosphopeptide released by the same treatment of M(297)FRRPS((P) under bar)LPCISREQ(310). This peptide was synthesized based on the deduced sequence of the cloned rat adipocyte cGI PDE and phosphorylated by cAMP-dependent protein kinase (protein kinase A). Radiosequencing of authentic and synthetic tryptic P-32-peptides showed that a single site in cGI PDE (Ser(302)) was phosphorylated in adipocytes incubated with isoproterenol and/or insulin. The more than additive phosphorylation and activation of cGI PDE in response to the two hormones found in this report and previously (Smith, C. J., Vasta, V., Degerman, E., Belfrage, P., and Manganiello, V. C. (1991) J. Biol. Chem. 266, 13385-13390) is proposed to reflect cross-talk between their respective signal transduction pathways at the level of the cGI PDE serine protein kinase or upstream regulatory component(s).	LUND UNIV, DEPT MOLEC & CELL BIOL, MOLEC SIGNALLING LAB, S-22100 LUND, SWEDEN; UNIV LUND HOSP, DEPT PEDIAT, S-22100 LUND, SWEDEN; CTR BIOMED, LUDWIG INST CANC RES, S-75185 UPPSALA, SWEDEN; NHLBI, NIH, BETHESDA, MD 20892 USA	Lund University; Lund University; Skane University Hospital; Ludwig Institute for Cancer Research; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Leroy-Zamia, Marie-Josèphe/M-3367-2017; Ronnstrand, Lars/A-2429-2011	Ronnstrand, Lars/0000-0003-1275-5809				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BEEBE SJ, 1985, J BIOL CHEM, V260, P5781; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CAMA A, 1992, J BIOL CHEM, V267, P8383; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DEGERMAN E, 1990, P NATL ACAD SCI USA, V87, P533, DOI 10.1073/pnas.87.2.533; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; ELKS ML, 1985, ENDOCRINOLOGY, V116, P2119, DOI 10.1210/endo-116-5-2119; ERIKSSON H, 1995, BBA-MOL CELL RES, V1266, P101, DOI 10.1016/0167-4889(94)00237-9; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GETTYS TW, 1988, J BIOL CHEM, V263, P10359; GRANT PG, 1988, P NATL ACAD SCI USA, V85, P9071, DOI 10.1073/pnas.85.23.9071; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HONNOR RC, 1985, J BIOL CHEM, V260, P5122; HOPKIRK TJ, 1986, BIOCHIM BIOPHYS ACTA, V885, P195, DOI 10.1016/0167-4889(86)90089-3; JONGKYEONG C, 1994, NATURE, V370, P71; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KILGOUR E, 1989, BIOCHEM J, V260, P27, DOI 10.1042/bj2600027; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONDOS C, 1985, J BIOL CHEM, V260, P5139; LOPEZAPARICIO P, 1993, BIOCHEM BIOPH RES CO, V193, P1137, DOI 10.1006/bbrc.1993.1744; MACPHEE CH, 1986, J CYCLIC NUCL PROT, V11, P487; MANGANIELLO VC, 1995, CELL SIGNAL, V7, P445, DOI 10.1016/0898-6568(95)00017-J; MANGANIELLO VC, 1971, J BIOL CHEM, V246, P2195; NILSSON NO, 1980, FEBS LETT, V111, P125, DOI 10.1016/0014-5793(80)80776-9; RAHN T, 1994, FEBS LETT, V350, P314, DOI 10.1016/0014-5793(94)00797-7; RASCON A, 1994, J BIOL CHEM, V269, P11962; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMITZPEIFFER C, 1992, CELL SIGNAL, V4, P37, DOI 10.1016/0898-6568(92)90006-T; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SHIBATA H, 1990, BIOCHEM BIOPH RES CO, V167, P614, DOI 10.1016/0006-291X(90)92069-C; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH CJ, 1989, MOL PHARMACOL, V35, P381; SMITH CJ, 1991, J BIOL CHEM, V266, P13385; TAIRA M, 1993, J BIOL CHEM, V268, P18573; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; WHITE MF, 1994, J BIOL CHEM, V269, P1; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	43	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11575	11580		10.1074/jbc.271.19.11575	http://dx.doi.org/10.1074/jbc.271.19.11575			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626720	hybrid			2022-12-27	WOS:A1996UJ94400080
J	Sugimoto, K; Honda, S; Yamamoto, T; Ueki, T; Monden, M; Kaji, A; Matsumoto, K; Nakamura, T				Sugimoto, K; Honda, S; Yamamoto, T; Ueki, T; Monden, M; Kaji, A; Matsumoto, K; Nakamura, T			Molecular cloning and characterization of a newly identified member of the cadherin family, PB-cadherin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; HEPATOCYTE GROWTH-FACTOR; DESMOSOMAL GLYCOPROTEIN; CYTOPLASMIC DOMAIN; SEQUENCE-ANALYSIS; NERVOUS-SYSTEM; GENE FAMILY; EXPRESSION; UVOMORULIN; CDNA	We have isolated cDNA clones encoding novel proteins belonging to the cadherin family. These novel proteins are encoded by two distinct mRNA species generated by alternative splicing from a single gene, and based on preferential expression in the pituitary gland and brain, we named it PB-cadherin. One mRNA species encodes long type PB-cadherin composed of 803 amino acid residues with a longer cytoplasmic domain, whereas the other species encodes short type PB-cadherin composed of 694 amino acid residues with a shorter cytoplasmic domain. Both long and short type PB-cadherin contain five repeats of a cadherin motif in the extracellular domain, the transmembrane domain, and the cytoplasmic domain, and the deduced amino acid sequences have a 30% homology to those of E-, N-, and P-cadherins. Although the primary structure of N-terminal amino acids is identical between long and short type PB-cadherin, the following structures in the cytoplasmic regions are completely different. The long type PB-cadherin but not the short type contains the putative catenin-binding domain. When these two distinct forms of PB-cadherins were stably expressed in L cells, L cells expressing long type PB-cadherin or short type PB-cadherin both acquired a Ca2+-dependent cell adhesion property, thereby indicating that both types of PB-cadherin are responsible for Ca2+-dependent cell adhesion. Persistent expression of PB-cadherin mRNA was found in the brain of rat embryos at least from embryonic day 15 to the postnatal period. In situ localization of PB-cadherin mRNA in the adult rat brain indicated that PB-cadherin mRNA is expressed in the inner granular layer of the olfactory bulb, Purkinje cell layer of the cerebellum, and in the pineal gland. PB-cadherin may play an important role in morphogenesis and tissue formation in neural and non-neural cells for the development and maintenance of the brain and neuroendocrine organs by regulating cell-cell adhesion.	OSAKA UNIV,SCH MED,BIOMED RES CTR,DIV BIOCHEM,SUITA,OSAKA 565,JAPAN; TSUMURA CO LTD,AMI,IBARAKI 30011,JAPAN; OSAKA UNIV,SCH MED,DEPT SURG 2,SUITA,OSAKA 565,JAPAN; UNIV PENN,SCH MED,DEPT MICROBIOL,PHILADELPHIA,PA 19104	Osaka University; Tsumura & Company; Osaka University; University of Pennsylvania			MATSUMOTO, Kunio/D-8441-2015	MATSUMOTO, Kunio/0000-0002-6532-4482				AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; COLLINS JE, 1991, J CELL BIOL, V113, P381, DOI 10.1083/jcb.113.2.381; DEGEN SJF, 1991, BIOCHEMISTRY-US, V30, P9781, DOI 10.1021/bi00104a030; GALLIN WJ, 1987, P NATL ACAD SCI USA, V84, P2808, DOI 10.1073/pnas.84.9.2808; GOODWIN L, 1990, BIOCHEM BIOPH RES CO, V173, P1224, DOI 10.1016/S0006-291X(05)80917-9; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HONDA S, 1995, MOL BRAIN RES, V32, P197, DOI 10.1016/0169-328X(95)00075-4; INUZUKA H, 1991, NEURON, V7, P69, DOI 10.1016/0896-6273(91)90075-B; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; MATSUNAGA M, 1988, NEURON, V1, P289, DOI 10.1016/0896-6273(88)90077-3; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAKAGAWA S, 1995, DEVELOPMENT, V121, P1321; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAPOLITANO EW, 1991, J CELL BIOL, V113, P893, DOI 10.1083/jcb.113.4.893; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; NOSE A, 1987, EMBO J, V6, P3655, DOI 10.1002/j.1460-2075.1987.tb02698.x; OKAZAKI M, 1994, J BIOL CHEM, V269, P12092; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; OZAWA M, 1990, J CELL BIOL, V111, P1645, DOI 10.1083/jcb.111.4.1645; PARKER AE, 1991, J BIOL CHEM, V266, P10438; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; REDIES C, 1993, DEV DYNAM, V197, P26, DOI 10.1002/aja.1001970104; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; SHIMOYAMA Y, 1989, CANCER RES, V49, P2128; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; SUZUKI S, 1991, CELL REGUL, V2, P261, DOI 10.1091/mbc.2.4.261; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; YANAGITA K, 1993, J BIOL CHEM, V268, P21212	42	52	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11548	11556		10.1074/jbc.271.19.11548	http://dx.doi.org/10.1074/jbc.271.19.11548			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626716	hybrid			2022-12-27	WOS:A1996UJ94400076
J	Gum, R; Lengyel, E; Juarez, J; Chen, JH; Sato, H; Seiki, M; Boyd, D				Gum, R; Lengyel, E; Juarez, J; Chen, JH; Sato, H; Seiki, M; Boyd, D			Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGENASE GENE; INFLAMMATORY CYTOKINES; MAP KINASE; C-JUN; EXPRESSION; CELLS; ENHANCER; FIBROBLASTS; INDUCTION; ONCOGENE	The 92-kDa type IV collagenase (92-kDa gelatinase B also referred to as MMP-9), which plays a critical role in extracellular matrix degradation, is regulated by growth factors that mediate their effects through the ras proto oncogene. The current study was undertaken to determine the transcriptional requirements for the induction of 92-kDa gelatinase B expression by an activated ras oncogene. Transfection of OVCAR-3 cells with an expression vector encoding an activated Ha-ras increased 92-kDa gelatinolytic activity and stimulated (over 10-fold) the activity of a CAT reporter driven by 670 nucleotides of 5' flanking sequence of the 92-kDa gelatinase B gene. Transient assays using a CAT reporter driven by 5' deleted fragments of the 92-kDa gelatinase B promoter indicated that a region spanning -634 to -531 was required for optimal induction of the promoter. The individual deletion, or mutation, of a PEA3/ets (-540) motif, AP-1 sites (-533, -79), a NF-kappa B (-600) consensus sequence, and a GT box (-52) substantially reduced the activation of the promoter by ras. An expression vector encoding the PEA3 transcription factor caused a 3-fold stimulation of the wild type but not the PEA3/ets-deleted 92-kDa gelatinase B promoter. Coexpression of a dominant negative c-jun antagonized the ras-dependent stimulation of the 92-kDa gelatinase B promoter-driven CAT reporter. The signaling pathway mediating the induction of 92-kDa gelatinase B promoter activity by ras was examined. The expression of a phosphatase (CL100) which inactivates multiple mitogen-activated protein kinase members abrogated the stimulation of 92-kDa gelatinase B promoter activity by ras, However, the expression of a kinase deficient mitogen-activated protein kinase kinase 1 (MEK1) did not prevent the activation of the 92-kDa gelatinase B promoter by ras and a constitutively activated c-raf expression vector was insufficient for 92-kDa gelatinase B promoter activation. Thus, the stimulation of the 92-kDa gelatinase B promoter by ras requires multiple elements including closely spaced PEA3/ets and AP-1 sites and is MEK1-independent.	MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; TECH UNIV MUNICH,DEPT OBSTET & GYNECOL,D-81675 MUNICH,GERMANY; TZU CHI COLL MED,INST MED RES,DEPT MOLEC BIOL,HUALIEN 970,TAIWAN; KANAZAWA UNIV,CANC RES INST,DEPT MOL VIROL & ONCOL,KANAZAWA,ISHIKAWA 920,JAPAN	University of Texas System; UTMD Anderson Cancer Center; Technical University of Munich; Tzu Chi University; Kanazawa University			Seiki, Motoharu/K-9443-2015; SATO, Hiroshi/D-8454-2015; Lengyel, Ernst/D-9220-2014	Lengyel, Ernst/0000-0001-8624-1507	NCI NIH HHS [R01CA58311] Funding Source: Medline; NIDCR NIH HHS [R01DE10845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; ALESSI DR, 1993, ONCOGENE, V8, P2015; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENG T, 1995, NATURE, V371, P171; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRIDMAN R, 1995, CANCER RES, V55, P2548; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; HURWITZ A, 1993, ENDOCRINOLOGY, V132, P2709, DOI 10.1210/en.132.6.2709; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KRAMER B, 1995, J BIOL CHEM, V270, P6577; LENGYEL E, 1995, CANCER RES, V55, P963; LENGYEL E, 1995, J BIOL CHEM, V270, P23007, DOI 10.1074/jbc.270.39.23007; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; LYONS JG, 1993, J BIOL CHEM, V268, P19143; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NICOLSON GL, 1990, ONCOGENE, V5, P747; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; PYKE C, 1992, CANCER RES, V52, P1336; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1993, ONCOGENE, V8, P395; SOUDANT N, 1994, NUCLEIC ACIDS RES, V22, P3871, DOI 10.1093/nar/22.19.3871; STACEY DW, 1991, ONCOGENE, V6, P2297; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; TREMBLE P, 1995, J CELL BIOL, V129, P1707, DOI 10.1083/jcb.129.6.1707; UNEMORI EN, 1991, J CLIN INVEST, V88, P1656, DOI 10.1172/JCI115480; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; WASYLYK C, 1994, ONCOGENE, V9, P3665; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; XIN J, 1995, GENE DEV, V6, P481	61	322	339	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10672	10680		10.1074/jbc.271.18.10672	http://dx.doi.org/10.1074/jbc.271.18.10672			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631874	hybrid			2022-12-27	WOS:A1996UJ34200042
J	Sarno, S; Vaglio, P; Meggio, F; Issinger, OG; Pinna, LA				Sarno, S; Vaglio, P; Meggio, F; Issinger, OG; Pinna, LA			Protein kinase CK2 mutants defective in substrate recognition - Purification and kinetic analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CYTOSOL; CASEIN KINASE-2; CONSENSUS SEQUENCES; BETA-SUBUNIT; CELLULAR-REGULATION; CATALYTIC SUBUNIT; SITE SPECIFICITY; PHOSPHORYLATION; IDENTIFICATION; MECHANISM	Five mutants of protein kinase CK2 alpha subunit in which altogether 14 basic residues were singly to quadruply replaced by alanines (K74A,K75A,K764,K77A; K79A, R80A,K83A; R191A/R195A,K198A; R228A; and R278A, K279AR280A) have been purified to near homogeneity either as such or after addition of the recombinant beta subunit, By this latter procedure five mutated tetrameric holoenzymes were obtained as judged from their subunit composition, sedimentation coefficient on sucrose gradient ultracentrifugation, and increased activity toward a specific peptide substrate as compared with the isolated alpha subunits, The kinetic constants and the phosphorylation efficiencies (V-max/K-m) of all the mutants with the parent peptide RRRADDSDDDDD and a series of derivatives, in which individual aspartic acids were replaced by alanines, have been determined, Three mutants, namely K74A,K75A,K76A,K77A; K79A,R80A, K83A; and R191A,R195A,K198A display dramatically lower phosphorylation efficiency and 8-50-fold higher K-m values with the parent peptide, symptomatic of reduced attitude to bind the peptide substrate as compared with CK2 wild type, Such differences either disappear or are attenuated if the mutants R191A,R195A, K198A; K79A,R80A,K83A; and K74A,K75A,K76A,K77A are assayed with the peptides RRRADDSADDDD, RRRADDSDDADD, and RRRADDSDDDAA, respectively, In contrast, the phosphorylation efficiencies of the other substituted peptides decrease more markedly with these mutants than with CK2 wild type, These data show that one or more of the basic residues clustered in the 191-198, 79-83, and 74-77 sequences are implicated in the recognition of the acidic determinants at positions +1, +3, and +4/+5, respectively, and that if these residues are mutated, the relevance of the other acidic residues surrounding serine is increased, In contrast the other two mutants, namely R228A and R278A,K279A, R280A, display with all the peptides V-max values higher than CK2 wild type, counterbalanced however by somewhat higher K-m values, It can be concluded from these data that all the five mutations performed are compatible with the reconstitution of tetrameric holoenzyme, but all of them influence the enzymatic efficiency of CK2 to different extents, Although the basic residues mutated in the 74-77, 79-83, and 191-198 sequences are clearly implicated in substrate recognition by interacting with acidic determinants at variable positions downstream from serine, the other basic residues seem to play a more elusive and/or indirect role in catalysis.	UNIV PADUA, DIPARTIMENTO CHIM BIOL, I-351321 PADUA, ITALY; CNR, CTR STUDIO FISIOL MITOCONDRIALE, I-351321 PADUA, ITALY; ODENSE UNIV, BIOKEMISK INST, DK-5230 ODENSE, DENMARK	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Southern Denmark				Vaglio, Philippe/0000-0003-2900-5596				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BOLDYREFF B, 1992, BIOCHEM BIOPH RES CO, V188, P228, DOI 10.1016/0006-291X(92)92374-7; BOLDYREFF B, 1993, BIOCHEMISTRY-US, V32, P12672, DOI 10.1021/bi00210a016; BOSSEMEYER D, 1995, FEBS LETT, V369, P57, DOI 10.1016/0014-5793(95)00580-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DOBROWOLSKA G, 1994, FEBS LETT, V355, P237, DOI 10.1016/0014-5793(94)01190-7; FERRARI S, 1987, EUR J BIOCHEM, V163, P481, DOI 10.1111/j.1432-1033.1987.tb10894.x; GALLAGHER PJ, 1993, J BIOL CHEM, V268, P26578; GATICA M, 1994, FEBS LETT, V339, P93, DOI 10.1016/0014-5793(94)80392-7; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GIBBS CS, 1991, BIOCHEMISTRY-US, V30, P5329, DOI 10.1021/bi00236a001; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HRUBEY TW, 1990, BIOCHEM BIOPH RES CO, V172, P190, DOI 10.1016/S0006-291X(05)80192-5; HU E, 1990, J BIOL CHEM, V265, P20609; HUANG CYF, 1995, J BIOL CHEM, V270, P7183, DOI 10.1074/jbc.270.13.7183; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MARIN O, 1992, FEBS LETT, V301, P111, DOI 10.1016/0014-5793(92)80221-2; MARIN O, 1994, BIOCHEM BIOPH RES CO, V198, P898, DOI 10.1006/bbrc.1994.1128; MARIN O, 1995, FEBS LETT, V363, P111, DOI 10.1016/0014-5793(95)00295-K; MEGGIO F, 1984, EUR J BIOCHEM, V145, P593, DOI 10.1111/j.1432-1033.1984.tb08598.x; MEGGIO F, 1989, BIOCHIM BIOPHYS ACTA, V1010, P128, DOI 10.1016/0167-4889(89)90193-6; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; PERICH JW, 1992, BIOCHEMISTRY-US, V31, P5893, DOI 10.1021/bi00140a027; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; SARNO S, 1995, BIOCHEM BIOPH RES CO, V206, P171, DOI 10.1006/bbrc.1995.1024; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TOMODA T, 1993, BIOCHIM BIOPHYS ACTA, V1175, P333, DOI 10.1016/0167-4889(93)90226-F; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; Vaglio P, 1996, FEBS LETT, V380, P25, DOI 10.1016/0014-5793(95)01542-6	42	111	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10595	10601		10.1074/jbc.271.18.10595	http://dx.doi.org/10.1074/jbc.271.18.10595			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631861	hybrid			2022-12-27	WOS:A1996UJ34200029
J	Katoh, T; Morita, F				Katoh, T; Morita, F			Roles of light chains in the activity and conformation of smooth muscle myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT INTERACTIONS; GIZZARD MYOSIN; HEAVY-CHAIN; BINDING; ACTIN; PHOSPHORYLATION; SUBFRAGMENT-1; PROTEIN; ALKALI; ATP	The 20-kDa regulatory (LC20) and 17-kDa essential (LC17) light chain subunits could be removed from porcine aorta smooth muscle myosin by the use of trifluoperazine and ammonium chloride. The isolated heavy chain rebound both light chains, resulting in the restoration of native properties. Experiments on reconstitution of the isolated heavy chain with LC17 and/or LC20 showed that both light chains were required for folding into the 10 S conformation and thus for the phosphorylation dependent filament format-ion of smooth muscle myosin. However, LC17 was not essential for the phosphorylation-dependent regulation of actin-activated ATPase activity and superprecipitation but was required for full regulation. LC17 and phosphorylated LC20 were found to act as activators, and dephosphorylated LC20 was found to act as a repressor of the motor activities of smooth muscle myosin.			Katoh, T (corresponding author), HOKKAIDO UNIV,GRAD SCH SCI,DIV CHEM,SAPPORO,HOKKAIDO 060,JAPAN.							ASHIBA G, 1985, BIOCHEMISTRY-US, V24, P6618, DOI 10.1021/bi00344a048; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; COLE DG, 1992, BIOCHEMISTRY-US, V31, P6186, DOI 10.1021/bi00142a003; GONZALEZROMO P, 1992, ANAL BIOCHEM, V200, P235, DOI 10.1016/0003-2697(92)90458-J; GRAND RJA, 1983, BIOCHEM J, V211, P267, DOI 10.1042/bj2110267; HASEGAWA Y, 1990, J BIOCHEM-TOKYO, V108, P909, DOI 10.1093/oxfordjournals.jbchem.a123313; HASEGAWA Y, 1988, J BIOCHEM-TOKYO, V103, P15, DOI 10.1093/oxfordjournals.jbchem.a122222; IKEBE M, 1994, J BIOL CHEM, V269, P28173; KATOH T, 1995, EUR J BIOCHEM, V227, P459, DOI 10.1111/j.1432-1033.1995.tb20410.x; KATOH T, 1995, EUR J BIOCHEM, V233, P123, DOI 10.1111/j.1432-1033.1995.123_1.x; KATOH T, 1995, J BIOCHEM-TOKYO, V118, P428, DOI 10.1093/oxfordjournals.jbchem.a124925; KATOH T, 1993, J BIOL CHEM, V268, P2380; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; LOWEY S, 1995, BIOPHYS J S, V68, P120; PASTRALANDIS SC, 1986, J BIOL CHEM, V261, P4811; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Trybus KM, 1991, CURR OPIN CELL BIOL, V3, P105, DOI 10.1016/0955-0674(91)90172-U; TRYBUS KM, 1988, J BIOL CHEM, V263, P16485; TRYBUS KM, 1987, J CELL BIOL, V105, P3007, DOI 10.1083/jcb.105.6.3007; TRYBUS KM, 1994, J CELL BIOL, V124, P963, DOI 10.1083/jcb.124.6.963; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; WAGNER PD, 1981, NATURE, V292, P560, DOI 10.1038/292560a0; WALLER GS, 1995, J BIOL CHEM, V270, P15348, DOI 10.1074/jbc.270.25.15348; WALLER GS, 1985, J BIOL CHEM, V260, P4368; WINKELMANN DA, 1983, CELL, V34, P295, DOI 10.1016/0092-8674(83)90160-5; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; YOSHIDA M, 1988, J BIOCHEM-TOKYO, V103, P380, DOI 10.1093/oxfordjournals.jbchem.a122278	33	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9992	9996		10.1074/jbc.271.17.9992	http://dx.doi.org/10.1074/jbc.271.17.9992			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626639	hybrid			2022-12-27	WOS:A1996UG25700023
J	Mary, J; Redeker, V; LeCaer, JP; Rossier, J; Schmitter, JM				Mary, J; Redeker, V; LeCaer, JP; Rossier, J; Schmitter, JM			Posttranslational modifications in the C-terminal tail of axonemal tubulin from sea urchin sperm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TUBULIN; BETA-TUBULIN; BRAIN; ISOTYPE; IDENTIFICATION; EXPRESSION	After proteolytic digestion of sperm tubulin from sea urchin Paracentrotus lividus, C-terminal peptides were isolated by chromatographic separations. The peptides mere analyzed by Edman degradation and matrix-assisted laser desorption/ionization-time of flight mass spectrometry. About 70% of the isolated C-terminal peptides were unmodified. The remaining modified peptides have undergone a combination of numerous posttranslational modifications generating significant heterogeneity of sperm tubulin, alpha-Tubulin is modified by detyrosylation, release of the penultimate glutamate, polyglutamylation, and polyglycylation. Glycylation and glutamylation can coexist within one alpha-tubulin isoform, beta-Tubulin undergoes polyglycylation but was not observed to be polyglutamylated. The number of units posttranslationally added reaches 11 and 12 glycyl units on beta- and alpha-tubulin, respectively. This is different from the polyglycylation of axonemal tubulin in Paramecium cilia where up to 40 added glycyl units were observed both on alpha- and beta-tubulin.	ECOLE POLYTECH,CNRS,URA 1970,BIOCHIM LAB,F-91128 PALAISEAU,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris	Mary, J (corresponding author), ECOLE SUPER PHYS & CHIM IND VILLE PARIS,CNRS,URA 2054,LAB NEUROBIOL DIVERSITE CELLULAIRE,F-75231 PARIS 5,FRANCE.		Mary, Jean/H-2344-2011; Redeker, Virginie/L-8929-2018	Mary, Jean/0000-0002-2438-8383; Redeker, Virginie/0000-0003-2694-8388				ALEXANDER JE, 1991, P NATL ACAD SCI USA, V88, P4685, DOI 10.1073/pnas.88.11.4685; BARRA HS, 1973, J NEUROCHEM, V20, P97, DOI 10.1111/j.1471-4159.1973.tb12108.x; BRE MH, 1996, IN PRESS J CELL SCI; COWAN NJ, 1988, CYTOSKELETON CELL DI, P157; DIAZNIDO J, 1990, J BIOL CHEM, V265, P13949; DIBARNARDO MG, 1989, NUCLEIC ACIDS RES, V17, P5851; EDDE B, 1992, BIOCHEMISTRY-US, V31, P403, DOI 10.1021/bi00117a014; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; Gagnon C, 1995, J CELL BIOCH B S, V19B, P112; GEUENS G, 1989, J CELL BIOL, V108, P939, DOI 10.1083/jcb.108.3.939; GIANGUZZA F, 1989, Molecular Reproduction and Development, V1, P170, DOI 10.1002/mrd.1080010305; GIANGUZZA F, 1990, NUCLEIC ACIDS RES, V18, P4915, DOI 10.1093/nar/18.16.4915; HUITOREL P, 1995, J CELL BIOCH B, V19, P1080; LEDIZET M, 1987, P NATL ACAD SCI USA, V84, P5720, DOI 10.1073/pnas.84.16.5720; LUDUENA RF, 1988, FEBS LETT, V230, P142, DOI 10.1016/0014-5793(88)80658-6; MARY J, 1994, FEBS LETT, V353, P89, DOI 10.1016/0014-5793(94)01018-8; PATURLELAFANECHERE L, 1994, J CELL SCI, V107, P1529; PATURLELAFANECHERE L, 1991, BIOCHEMISTRY-US, V30, P10523, DOI 10.1021/bi00107a022; REDEKER V, 1992, FEBS LETT, V313, P185, DOI 10.1016/0014-5793(92)81441-N; REDEKER V, 1994, SCIENCE, V266, P1688, DOI 10.1126/science.7992051; RUDIGER M, 1992, FEBS LETT, V308, P101, DOI 10.1016/0014-5793(92)81061-P; RUDIGER M, 1995, FEBS LETT, V364, P147, DOI 10.1016/0014-5793(95)00373-H; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; ZHU NZ, 1992, MOL BIOL CELL, V3, P50	24	54	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9928	9933		10.1074/jbc.271.17.9928	http://dx.doi.org/10.1074/jbc.271.17.9928			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626629	hybrid			2022-12-27	WOS:A1996UG25700013
J	Wenstrup, RJ; Fowlkes, JL; Witte, DP; Florer, JB				Wenstrup, RJ; Fowlkes, JL; Witte, DP; Florer, JB			Discordant expression of osteoblast markers in MC3T3-E1 cells that synthesize a high turnover matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOGENESIS IMPERFECTA; BONE SIALOPROTEIN; OSTEOCALCIN GENE; I PROCOLLAGEN; DELETED GENE; COLLAGEN; PHENOTYPE; DIFFERENTIATION; MOUSE; LINE	To examine the autocrine effects that an organizing extracellular matrix has on osteoblast precursors, we created MC3T3-E1 cell lines that stably expressed pro-alpha 1(I) collagen chains with a truncated triple helical domain. Cells that had incorporated the pro-alpha 1(I) expression plasmid (pMG155) expressed shortened pro-alpha 1(I) transcripts at high levels and efficiently secreted the expression gene products into culture media. Those cells lost over 30% of newly deposited collagenous matrix compared with virtually no loss in control cultures, and media from the abnormal cells had qualitative differences in matrix metalloprotinase production. Electron micrographs strongly suggested that type I collagen molecules containing the truncated pro-alpha 1(I) chains dramatically interfered with collagen fibrillogenesis in newly forming osteoblast matrix. Abnormal collagen fibrillogenesis was also associated with altered characteristics of cellular differentiation in that abnormal cells displayed a delayed and attenuated increase in alkaline phosphatase activity. Surprisingly, synthesis of osteocalcin was more than 5-fold higher than control cultures. These findings demonstrate that osteoblasts require a normally structured collagenous matrix for up-regulation of alkaline phosphatase activity. However, in the presence of rapid turnover of osteoblast matrix, osteocalcin gene expression may be up-regulated in response to local signals by an unknown mechanism.	CINCINNATI CHILDRENS HOSP, DIV PATHOL, CINCINNATI, OH 45229 USA; DUKE UNIV, MED CTR, DEPT PEDIAT, DURHAM, NC 27710 USA	Cincinnati Children's Hospital Medical Center; Duke University	Wenstrup, RJ (corresponding author), CINCINNATI CHILDRENS HOSP, DIV HUMAN GENET, TCHRF ROOM 1033, 3333 BURNET AVE, CINCINNATI, OH 45229 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002276] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40586] Funding Source: Medline; NIDDK NIH HHS [DK02276] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONOW MA, 1990, J CELL PHYSIOL, V143, P213, DOI 10.1002/jcp.1041430203; BARON R, 1983, PEDIATR RES, V17, P204, DOI 10.1203/00006450-198303000-00007; BERG RA, 1982, METHOD ENZYMOL, V82, P372; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BONADIO J, 1985, J BIOL CHEM, V260, P1734; CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESBOIS C, 1995, J BONE MINER RES, V10, pS139; DOTY SB, 1971, CLIN ORTHOP RELAT R, P191, DOI 10.1097/00003086-197110000-00027; FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235; FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843; FUJISAWA R, 1992, CALCIFIED TISSUE INT, V51, P438; GERSTENFELD LC, 1988, J CELL BIOL, V106, P979, DOI 10.1083/jcb.106.3.979; GERSTENFELD LC, 1987, DEV BIOL, V122, P49, DOI 10.1016/0012-1606(87)90331-9; GLOWACKI J, 1989, CONNECT TISSUE RES, V20, P121, DOI 10.3109/03008208909023880; GLOWACKI J, 1987, CELL DIFFER DEV, V21, P247, DOI 10.1016/0045-6039(87)90479-9; GRONOWICZ G, 1989, J BONE MINER RES, V4, P313; HELMINEN HJ, 1993, J CLIN INVEST, V92, P582, DOI 10.1172/JCI116625; IKEDA K, 1993, J CELL PHYSIOL, V156, P130, DOI 10.1002/jcp.1041560118; LEBOY PS, 1989, J BIOL CHEM, V264, P17281; LIAN JB, 1992, CRIT REV ORAL BIOL M, V3, P269, DOI 10.1177/10454411920030030501; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; OLDBERG A, 1988, J BIOL CHEM, V263, P19430; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; OLSEN AS, 1991, J BIOL CHEM, V266, P1117; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; OWEN TA, 1993, P NATL ACAD SCI USA, V90, P1503, DOI 10.1073/pnas.90.4.1503; PEREIRA R, 1993, J CLIN INVEST, V91, P709, DOI 10.1172/JCI116252; QUARLES LD, 1992, J BONE MINER RES, V7, P683; QUARLES LD, 1991, ENDOCRINOLOGY, V128, P3144, DOI 10.1210/endo-128-6-3144; ROBEY PG, 1993, J BONE MINER RES, V8, pS483; STEMARIE LG, 1984, J CLIN PATHOL, V37, P1081, DOI 10.1136/jcp.37.10.1081; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TAKEUCHI Y, 1994, J BONE MINER RES, V9, pS126; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; TERMINE JD, 1984, P NATL ACAD SCI-BIOL, V81, P2213, DOI 10.1073/pnas.81.7.2213; UITTO J, 1975, COLLAGEN METABOLISM, P139; VETTER U, 1991, J BONE MINER RES, V6, P501; WU LNY, 1989, J BIOL CHEM, V264, P21346	41	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10271	10276		10.1074/jbc.271.17.10271	http://dx.doi.org/10.1074/jbc.271.17.10271			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626594				2022-12-27	WOS:A1996UG25700066
J	Kim, DH; Iijima, H; Goto, K; Sakai, J; Ishii, H; Kim, HJ; Suzuki, H; Kondo, H; Saeki, S; Yamamoto, T				Kim, DH; Iijima, H; Goto, K; Sakai, J; Ishii, H; Kim, HJ; Suzuki, H; Kondo, H; Saeki, S; Yamamoto, T			Human apolipoprotein E receptor 2 - A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LDL-RECEPTOR; MESSENGER-RNA; MEDIATED ENDOCYTOSIS; NERVOUS-SYSTEM; SEQUENCE; PROTEIN; DNA; SURFACE; RABBIT; CELLS	Isolation and characterization of a human cDNA demonstrated a novel lipoprotein receptor designated apolipoprotein E receptor 2 (apoER2). The new receptor consists of five functional domains resembling the low density lipoprotein (LDL) and very low density lipoprotein (VLDL) receptors. LDL receptor deficient Chinese hamster ovary cells expressing human apoER2 bound apoE rich beta-migrating VLDL with high affinity and internalized. LDL was bound with much lower affinity to these cells. The 4.5- and 8.5-kb mRNAs for the receptor were most highly expressed in human brain and placenta. In rabbit tissues, multiple species of the mRNA with 4, 4.5, 5.5, 8.5, and 11 kb were detected most intensely in brain and testis and, to a much lesser extent, in ovary, but were undetectable in other tissues. In rat adrenal pheochromocytoma PC12 cells, the receptor mRNA was induced by treatment of the cells with nerve growth factor. The receptor transcripts were detectable most intensely in the cerebellar cortex, choroid plexus, ependyma, hippocampus, olfactory bulb and, to a much lesser extent, in the cerebral cortex as revealed by in situ hybridization histochemistry. In the cerebellar cortex, the receptor transcripts were densely deposited in Purkinje cell somata.	TOHOKU UNIV,CTR GENE RES,SENDAI,MIYAGI 981,JAPAN; TOHOKU UNIV,SCH MED,DEPT ANAT,SENDAI,MIYAGI 980,JAPAN	Tohoku University; Tohoku University				Sakai, Juro/0000-0003-4043-1035				BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; DAVIS CG, 1987, NATURE, V326, P760, DOI 10.1038/326760a0; Dhopeshwarkar G A, 1973, Adv Lipid Res, V11, P109; DOBBING J, 1963, J NEUROCHEM, V10, P739, DOI 10.1111/j.1471-4159.1963.tb08930.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAFVELS ME, 1994, ENDOCRINOLOGY, V135, P387, DOI 10.1210/en.135.1.387; GAFVELS ME, 1993, SOMAT CELL MOLEC GEN, V19, P557, DOI 10.1007/BF01233382; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HOFMANN SL, 1987, P NATL ACAD SCI USA, V84, P6312, DOI 10.1073/pnas.84.17.6312; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; Kabara J J, 1973, Prog Brain Res, V40, P363; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1396, DOI 10.1073/pnas.78.3.1396; LEE LY, 1989, NUCLEIC ACIDS RES, V17, P1259, DOI 10.1093/nar/17.3.1259; MEHTA KD, 1991, J BIOL CHEM, V266, P10406; NIMPF J, 1989, J BIOL CHEM, V264, P1393; OKA K, 1994, EUR J BIOCHEM, V224, P975, DOI 10.1111/j.1432-1033.1994.00975.x; OKA K, 1994, GENOMICS, V20, P298, DOI 10.1006/geno.1994.1171; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SAKAI J, 1994, J BIOL CHEM, V269, P2173; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASTRY PS, 1985, PROG LIPID RES, V24, P69, DOI 10.1016/0163-7827(85)90011-6; SCHONBAUM CP, 1995, P NATL ACAD SCI USA, V92, P1485, DOI 10.1073/pnas.92.5.1485; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SWANSON LW, 1988, P NATL ACAD SCI USA, V85, P9821, DOI 10.1073/pnas.85.24.9821; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; WEBB JC, 1994, HUM MOL GENET, V3, P531, DOI 10.1093/hmg/3.4.531; YAMAMOTO T, 1993, TRENDS CARDIOVAS MED, V3, P144, DOI 10.1016/1050-1738(93)90015-X; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YOCHEM J, 1993, P NATL ACAD SCI USA, V90, P4572, DOI 10.1073/pnas.90.10.4572; YOKODE M, 1992, J CELL BIOL, V117, P39, DOI 10.1083/jcb.117.1.39	45	346	356	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8373	8380		10.1074/jbc.271.14.8373	http://dx.doi.org/10.1074/jbc.271.14.8373			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626535	hybrid			2022-12-27	WOS:A1996UD60000075
J	Bouillot, C; Prochiantz, A; Rougon, G; Allinquant, B				Bouillot, C; Prochiantz, A; Rougon, G; Allinquant, B			Axonal amyloid precursor protein expressed by neurons in vitro is present in a membrane fraction with caveolae-like properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES NEURITE OUTGROWTH; EPITHELIAL-CELLS; MDCK CELLS; DIFFERENTIATION; TRANSPORT; ISOFORMS; ADHESION; SIGNAL; FORM; LINE	In cortical neurons differentiating in vitro, transmembrane amyloid precursor protein (APP) is distributed in two pools. Whereas the first pool is present in all cell compartments, the second pool is highly enriched in the axon and cell body. In an earlier study we demonstrated that this second pool, referred to as axonal-APP (Ax-APP), is present in the vicinity of the plasma membrane and colocalizes only partially with clathrin (Allinquant, B., Moya, K. L., Bouillot, C., and Prochiantz, A. (1994) J. Neurosci. 14, 6842-6854). In this report, using immunocytochemical and fractionation techniques we demonstrate that Ax-APP is present in microdomains enriched in the glypiated glycoprotein F3. The F3/Ax-APP microdomains are resistant to nonionic detergents and sediment at low density on a sucrose gradient. The two latter properties are reminiscent of those of caveolae, a type of plasmalemmal vesicle found in several cell types, but not previously described in the nervous system due to the absence of caveolin in neurons. The presence of Ax-APP in caveolae-like vesicles raises the possibility that APP serves as a transmembrane signaling molecule for GPI-linked glycoproteins. In addition, our data support new hypotheses on the endocytic pathways leading to the production of the amyloidogenic beta A4 peptide.	ECOLE NORMALE SUPER,CNRS,URA 1414,F-75230 PARIS 05,FRANCE; UNIV LUMINY,CNRS,UPR 9943,F-13288 MARSEILLE 09,FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)			ROUGON, Genevieve/G-2578-2013	ROUGON, Genevieve/0000-0003-1316-8200				ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919; ALLINQUANT B, 1994, J NEUROSCI, V14, P6842; AMARATUNGA A, 1995, J BIOL CHEM, V270, P17268, DOI 10.1074/jbc.270.29.17268; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BRABET P, 1990, J NEUROCHEM, V54, P1310, DOI 10.1111/j.1471-4159.1990.tb01964.x; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; DOHERTY P, 1989, J CELL BIOL, V109, P789, DOI 10.1083/jcb.109.2.789; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; DURBEC P, 1992, J CELL BIOL, V117, P877, DOI 10.1083/jcb.117.4.877; FERREIRA A, 1993, J NEUROSCI, V13, P3112; FRA AM, 1994, J BIOL CHEM, V269, P30745; GENNARINI G, 1989, J CELL BIOL, V109, P775, DOI 10.1083/jcb.109.2.775; GENNARINI G, 1991, NEURON, V6, P595, DOI 10.1016/0896-6273(91)90062-5; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HUNG AY, 1992, P NATL ACAD SCI USA, V89, P9439, DOI 10.1073/pnas.89.20.9439; JIN LW, 1994, J NEUROSCI, V14, P5461; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; KOO EH, 1994, J BIOL CHEM, V269, P17386; KURZCHALIA TV, 1994, FEBS LETT, V346, P88, DOI 10.1016/0014-5793(94)00466-8; LAFONT F, 1992, DEVELOPMENT, V114, P17; LAFONT F, 1994, PERSPECT DEV NEUROBI, V2, P259; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MORIN PJ, 1993, J NEUROCHEM, V61, P464; MOYA KL, 1994, DEV BIOL, V161, P597, DOI 10.1006/dbio.1994.1055; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; OLIVE S, 1995, J NEUROCHEM, V65, P2307; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHYNG SL, 1994, J CELL BIOL, V125, P1239, DOI 10.1083/jcb.125.6.1239; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SMALL DH, 1994, J NEUROSCI, V14, P2117; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; TIVERON MC, 1992, NATURE, V355, P745, DOI 10.1038/355745a0; TUREK JJ, 1993, J CELL SCI, V106, P423; VIOLETTE SM, 1992, P NATL ACAD SCI USA, V89, P3805, DOI 10.1073/pnas.89.9.3805	46	126	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7640	7644		10.1074/jbc.271.13.7640	http://dx.doi.org/10.1074/jbc.271.13.7640			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631800	hybrid			2022-12-27	WOS:A1996UC77400068
J	Hidalgo, E; Demple, B				Hidalgo, E; Demple, B			Activation of SoxR-dependent transcription in vitro by noncatalytic or NifS-mediated assembly of [2Fe-2S] clusters into Apo-SoxR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROXY-ACID DEHYDRATASE; IRON-SULFUR CLUSTER; FE-S CLUSTER; ESCHERICHIA-COLI; STRESS REGULON; SUPEROXIDE; BIOSYNTHESIS; INACTIVATION; PROTEIN; ENZYME	SoxR is a transcriptional activator that senses superoxide and nitric oxide stress in Escherichia coli. The active protein isolated from E. coli contains a pair of [2Fe-2S] clusters per SoxR dimer. Ne previously demonstrated that the iron-free protein (apo-SoxR), isolated during purification in thiol-containing buffers, binds soxS promoter DNA with an affinity equal to that of the metalloprotein (Fe-SoxR), but lacks significant ability to activate transcription in vitro, Here we demonstrate the reversibility of this process: the full transcriptional activity of SoxR can be restored by in vitro assembly of iron-sulfur clusters into the apoprotein. Two methods were used to synthesize the metallocenters of SoxR: (i) nonenzymatic, in which apo-SoxR, incubated in the presence of iron, inorganic sulfide, and a reducing agent, regained full transcriptional activity in 5-6 h; (ii) enzymatic, in which NifS protein of Azotobacter vinelandii regenerated active Fe-SoxR in as little as 2 min. Analysis by electron paramagnetic resonance spectroscopy indicated that binuclear [2Fe-2S] clusters were restored by both the enzymatic and nonenzymatic reconstitutions. A mutant SoxR protein missing one of its four cysteine residues failed to undergo either transcriptional activation or the formation of [2Fe-2S] centers, even in the presence of NifS. Thus, only the presence of an iron-sulfur center is required to restore transcriptional activity to apo-SoxR. Moreover, the catalytic generation of [2Fe-2S] centers extends the known specificity of this enzyme beyond that already shown for [4Fe-4S] centers. Catalytic generation of [2Fe-2S]-containing SoxR could allow for rapid activation of this transcription factor in vivo.	HARVARD UNIV, SCH PUBL HLTH, DEPT MOL & CELLULAR TOXICOL, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health			Hidalgo, Elena/K-2919-2014	Hidalgo, Elena/0000-0002-3768-6785	NCI NIH HHS [CA37831] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037831] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMABILECUEVAS CF, 1991, NUCLEIC ACIDS RES, V19, P4479, DOI 10.1093/nar/19.16.4479; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; BERNLOHR DA, 1981, BIOCHEMISTRY-US, V20, P5675, DOI 10.1021/bi00523a006; CHOU JH, 1993, J BACTERIOL, V175, P1026, DOI 10.1128/JB.175.4.1026-1031.1993; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; FLINT DH, 1993, J BIOL CHEM, V268, P25547; FLINT DH, 1993, J BIOL CHEM, V268, P14732; FLINT DH, 1993, J BIOL CHEM, V268, P22369; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GRANDONI JA, 1989, J BIOL CHEM, V264, P6058; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; HIDALGO E, 1995, J BIOL CHEM, V270, P20908, DOI 10.1074/jbc.270.36.20908; HIDALGO E, 1995, IN PRESS REGULATION; JOHNSON MK, 1994, ENCY INORGANIC CHEM, V4, P1896; KENNEDY C, 1992, MOL GEN GENET, V231, P494, DOI 10.1007/BF00292722; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LI ZY, 1994, J BIOL CHEM, V269, P18371; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; Ma D, 1996, MOL MICROBIOL, V19, P101, DOI 10.1046/j.1365-2958.1996.357881.x; NUNOSHIBA T, 1992, J BACTERIOL, V174, P6054, DOI 10.1128/JB.174.19.6054-6060.1992; NUNOSHIBA T, 1993, CANCER RES, V53, P3250; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9998; SANYAL I, 1994, BIOCHEMISTRY-US, V33, P3625, DOI 10.1021/bi00178a020; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; WU J, 1992, J BACTERIOL, V174, P3915, DOI 10.1128/jb.174.12.3915-3920.1992; WU J, 1995, J BIOL CHEM, V270, P10323, DOI 10.1074/jbc.270.17.10323; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031	30	73	78	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7269	7272		10.1074/jbc.271.13.7269	http://dx.doi.org/10.1074/jbc.271.13.7269			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631739	hybrid			2022-12-27	WOS:A1996UC77400007
J	Ma, JY; Colley, KJ				Ma, JY; Colley, KJ			A disulfide-bonded dimer of the Golgi beta-galactoside alpha 2,6-sialyltransferase is catalytically inactive yet still retains the ability to bind galactose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-MANNOSIDASE-II; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; SECRETORY PATHWAY; MEMBRANE-PROTEIN; RAT-LIVER; APPARATUS; RETENTION; CELLS; GLYCOSYLATION	The alpha 2,6-sialyltransferase is a terminal glycosyltransferase localized in the trans Golgi and trans Golgi network. Here we show that 30% of the total rat liver Golgi alpha 2,6-sialyltransferase forms a disulfide-bonded 100-kDa species that can be converted to the 50-kDa monomer form of the enzyme upon reduction. Limited proteolysis of both enzyme forms demonstrates that the 100-kDa species is a disulfide-bonded homodimer of the alpha 2,6-sialyltransferase. The alpha 2,6-sialyltransferase disulfide-bonded dimer is found in bovine liver Golgi membranes and in Golgi membranes prepared and solubilized in the presence of 100 mM iodoacetamide, suggesting that it is not unique to rat liver or formed aberrantly upon membrane lysis. The dimer form of the enzyme possesses no significant catalytic activity and has a much lower affinity for CDP-hexanolamine-agarose compared with the monomer form. In contrast, both the alpha 2,6-sialyltransferase monomer and the disulfide-bonded dimer bind strongly to galactose and galactose-terminated substrates. These results suggest that the alpha 2,6-sialyltransferase disulfide-bonded dimer lacks catalytic activity due to a weak affinity for its sugar nucleotide donor, CMP-NeuAc, and that this catalytically inactive form of the enzyme may act as a galactose-specific lectin in the Golgi.	UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NIGMS NIH HHS [GM48134] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048134, R01GM048134] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADA GL, 1961, J GEN MICROBIOL, V24, P409, DOI 10.1099/00221287-24-3-409; AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; BOSSHART H, 1992, EUR J BIOCHEM, V208, P341, DOI 10.1111/j.1432-1033.1992.tb17192.x; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BURKE J, 1994, J BIOL CHEM, V269, P12049; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; COLLEY KJ, 1992, J BIOL CHEM, V267, P245; DAHDAL RY, 1993, J BIOL CHEM, V286, P26310; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; FAST DG, 1993, BIOCHIM BIOPHYS ACTA, V1202, P325, DOI 10.1016/0167-4838(93)90023-K; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; FLEISCHER B, 1993, BIOCHEMISTRY-US, V32, P2076, DOI 10.1021/bi00059a027; Fleischer S, 1974, Methods Enzymol, V31, P6; HAKAMORI S, 1984, ANNU REV IMMUNOL, V2, P103; HAMMOND C, 1993, CURR BIOL, V3, P884, DOI 10.1016/0960-9822(93)90226-E; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT JM, 1978, BIOCHEMISTRY-US, V17, P5406, DOI 10.1021/bi00618a014; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; LODISH HF, 1993, J BIOL CHEM, V268, P20598; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NAVARATNAM N, 1988, EUR J BIOCHEM, V171, P623, DOI 10.1111/j.1432-1033.1988.tb13833.x; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; PAULSON JC, 1977, J BIOL CHEM, V252, P2356; PAULSON JC, 1978, J BIOL CHEM, V253, P5617; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SHAPER NL, 1994, J BIOL CHEM, V269, P25165; SVENSSON EC, 1992, J BIOL CHEM, V267, P3466; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WANG XC, 1993, J BIOL CHEM, V268, P4355; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245	52	68	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7758	7766		10.1074/jbc.271.13.7758	http://dx.doi.org/10.1074/jbc.271.13.7758			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631818	hybrid			2022-12-27	WOS:A1996UC77400086
J	Marta, M; Patamia, M; Lupi, A; Antenucci, M; DiIorio, M; Romeo, S; Petruzzelli, R; Pomponi, M; Giardina, B				Marta, M; Patamia, M; Lupi, A; Antenucci, M; DiIorio, M; Romeo, S; Petruzzelli, R; Pomponi, M; Giardina, B			Bovine hemoglobin cross-linked through the beta chains - Functional and structural aspects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPHOSPHATE-BINDING-SITE; 2-NOR-2-FORMYLPYRIDOXAL 5'-PHOSPHATE; HUMAN DEOXYHEMOGLOBIN; 2,3-DIPHOSPHOGLYCERATE; PROTEINS	2-Nor-2-formylpyridoxal (NFPLP) has been synthesized and coupled to bovine Hb according to the procedure developed by Benesch and Benesch (1). The reaction of bovine Db with NFPLP leads to a cross-linkage between the beta subunits, which greatly stabilizes the low affinity T state of the molecule and simultaneously abolishes the tendency of the tetramer to dissociate into alpha beta dimers. The functional properties, examined from both the equilibrium and kinetic points of view, indicate that the chemical modification affects the O-2 affinity, abolishes cooperativity, and induces a slight decrease of the Bohr effect. From modeling studies we are confronted with two different structural alternatives; the cross-link of beta chains may be formed between lysine 82 of beta(2) and the N terminus of methionine 2 of beta(1) or between the two lysine 82 residues of both beta(2) chains. Digestion of modified beta globin chains and isolation of the cross-linked peptide have showed that NFPLP cross-links Met-beta 2 and Lys-beta 82. This allowed discussion in some detail of the molecular basis of the Bohr effect of the modified bovine hemoglobin. On the whole, NFPLP-modified bovine Hb could be considered as a first step toward the synthesis of a potential blood substitute.	UNIV CATTOLICA SACRO CUORE, FAC MED, IST CHIM & CHIM CLIN, I-00168 ROME, ITALY; CNR, CTR STUDIO CHIM RECETTORI & MOLEC BIOL ATT, I-00168 ROME, ITALY; UNIV MILAN, FAC FARM, IST CHIM FARMACEUT & TOSSICOL, I-20131 MILAN, ITALY; UNIV CHIETI, IST SCI BIOCHIM, DIPARTIMENTO BIOL, I-66100 CHIETI, ITALY	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Consiglio Nazionale delle Ricerche (CNR); University of Milan; G d'Annunzio University of Chieti-Pescara			Lupi, Alessandro/N-6114-2019; Lupi, Alessandro/AAH-8299-2020; Romeo, Sergio/B-4478-2009	Lupi, Alessandro/0000-0003-3644-0449; Lupi, Alessandro/0000-0003-3644-0449; Romeo, Sergio/0000-0003-4692-7314; Marta, Maurizio/0000-0002-8872-3304; Patamia, Maria/0000-0003-2655-8056				ARNONE A, 1972, NATURE, V237, P146, DOI 10.1038/237146a0; ARNONE A, 1977, J MOL BIOL, V115, P627, DOI 10.1016/0022-2836(77)90107-3; Ascoli F, 1981, Methods Enzymol, V76, P72; BELLELLI A, 1987, J BIOL CHEM, V262, P2624; BENESCH R, 1984, P NATL ACAD SCI-BIOL, V81, P2941, DOI 10.1073/pnas.81.9.2941; BENESCH R, 1975, BIOCHEM BIOPH RES CO, V63, P1123, DOI 10.1016/0006-291X(75)90685-3; Benesch R, 1981, Methods Enzymol, V76, P147; BUNN HF, 1971, SCIENCE, V172, P1049, DOI 10.1126/science.172.3987.1049; DAVINO R, 1989, EUR J BIOCHEM, V179, P699, DOI 10.1111/j.1432-1033.1989.tb14603.x; FANELLI AR, 1964, ADV PROTEIN CHEM, V19, P73, DOI 10.1016/S0065-3233(08)60189-8; FEOLA M, 1983, SURG GYNECOL OBSTET, V157, P399; FRONTICELLI C, 1990, EUR J BIOCHEM, V193, P331, DOI 10.1111/j.1432-1033.1990.tb19342.x; FRONTICELLI C, 1986, BIOCHIM BIOPHYS ACTA, V874, P76, DOI 10.1016/0167-4838(86)90104-4; Giardina B, 1981, Methods Enzymol, V76, P417; GIBSON QH, 1959, PROG BIOPHYS MOL BIO, V9, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NIGEN AM, 1980, J BIOL CHEM, V255, P5525; PERUTZ MF, 1980, J MOL BIOL, V136, P183, DOI 10.1016/0022-2836(80)90312-5; PERUTZ MF, 1993, J MOL BIOL, V233, P536, DOI 10.1006/jmbi.1993.1530; PERUTZ MF, 1980, J MOL BIOL, V138, P649, DOI 10.1016/S0022-2836(80)80022-2; POCKER A, 1973, J ORG CHEM, V38, P4295, DOI 10.1021/jo00964a019; SHELTON JB, 1981, J LIQ CHROMATOGR, V4, P1381, DOI 10.1080/01483918108059615; SLOVITER HA, 1982, FED PROC, V41, P652; VANDERPLAS J, 1987, TRANSFUSION, V27, P425	25	13	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7473	7478		10.1074/jbc.271.13.7473	http://dx.doi.org/10.1074/jbc.271.13.7473			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631776	hybrid			2022-12-27	WOS:A1996UC77400044
J	Roff, M; Thompson, J; Rodriguez, MS; Jacque, JM; Baleux, F; ArenzanaSeisdedos, F; Hay, RT				Roff, M; Thompson, J; Rodriguez, MS; Jacque, JM; Baleux, F; ArenzanaSeisdedos, F; Hay, RT			Role of I kappa B alpha ubiquitination in signal-induced activation of NF-kappa B in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN EBP1; DNA-BINDING; CYTOPLASMIC RETENTION; TRANSCRIPTION FACTOR; P50 PRECURSOR; P65 SUBUNIT; C-REL; INHIBITOR; P105; CLONING	In unstimulated cells, the transcript-ion factor NF-kappa B is held in the cytoplasm in an inactive state by the inhibitor protein I kappa B alpha. Stimulation of cells results in rapid phosphorylation and degradation of I kappa B alpha, thus releasing NF-kappa B, which translocates to the nucleus and activates transcription of responsive genes. Here we demonstrate that in cells where proteasomal degradation is inhibited, signal induction by tumor necrosis factor alpha results in the rapid accumulation of higher molecular weight forms of I kappa B alpha that dissociate from NF-kappa B and are consistent with ubiquitin conjugation. Removal of the high molecular weight forms of I kappa B alpha by a recombinant ubiquitin carboxyl-terminal hydrolase and reactivity of the immunopurified material with a monoclonal antibody specific for ubiquitin indicated that I kappa B alpha was conjugated to multiple copies of ubiquitin. Western blot analysis of immunopurified I kappa B alpha from cells expressing epitope-tagged versions of I kappa B alpha and ubiquitin revealed the presence of multiple copies of covalently bound tagged ubiquitin. An S32A/S36A mutant of I kappa B alpha that is neither phosphorylated nor degraded in response to signal induction fails to undergo inducible ubiquitination in vivo. Thus signal-induced activation of NF-kappa B involves phosphorylation-dependent ubiquitination of I kappa B alpha, which targets the protein for rapid degradation by the proteasome and releases NF-kappa B for translocation to the nucleus.	UNIV ST ANDREWS,SCH BIOL & MED SCI,ST ANDREWS KY16 9AL,FIFE,SCOTLAND; INST PASTEUR,UNITE IMMUNOL VIRALE,F-75015 PARIS,FRANCE; INST PASTEUR,UNITE CHIM ORGAN,F-75015 PARIS,FRANCE	University of St Andrews; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Arenzana-Seisdedos, Fernando/E-5835-2016; Jacque, Jean-Marc/B-6875-2008; Hay, Ronald/S-3233-2019; Hay, Ronald T/F-9338-2011	Hay, Ronald/0000-0001-7113-9024; Hay, Ronald T/0000-0001-7113-9024				ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CLARK L, 1989, J MOL BIOL, V206, P615, DOI 10.1016/0022-2836(89)90570-6; CLARK L, 1989, NUCLEIC ACIDS RES, V17, P499, DOI 10.1093/nar/17.2.499; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FEHRENTZ JA, 1985, INT J PEPT PROT RES, V26, P236; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GUARINO LA, 1995, CELL, V80, P301, DOI 10.1016/0092-8674(95)90413-1; HANKE T, 1992, J GEN VIROL, V73, P653, DOI 10.1099/0022-1317-73-3-653; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HAY RT, 1993, BIOCHEM SOC T, V21, P926, DOI 10.1042/bst0210926; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LASZLO L, 1990, FEBS LETT, V261, P365, DOI 10.1016/0014-5793(90)80593-8; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; LION HC, 1993, CURR OPIN CELL BIOL, V5, P477; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MATTHEWS JR, 1993, NUCLEIC ACIDS RES, V21, P1727, DOI 10.1093/nar/21.8.1727; MATTHEWS JR, 1993, NUCLEIC ACIDS RES, V21, P4516, DOI 10.1093/nar/21.19.4516; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; ZHANG N, 1993, DEV BIOL, V157, P214, DOI 10.1006/dbio.1993.1125	69	205	210	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7844	7850		10.1074/jbc.271.13.7844	http://dx.doi.org/10.1074/jbc.271.13.7844			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631829	hybrid			2022-12-27	WOS:A1996UC77400097
J	Serra, D; Fillat, C; Matas, R; Bosch, F; Hegardt, FG				Serra, D; Fillat, C; Matas, R; Bosch, F; Hegardt, FG			Tissue-specific expression and dietary regulation of chimeric mitochondrial 3-hydroxy-3-methylglutaryl coenzyme a synthase human growth hormone gene in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MITOCHONDRIAL; GUT EPITHELIUM; FUSION GENES; LIVER; ELEMENTS; KETOGENESIS; INTESTINE; PATTERNS	We have studied the role of the mitochondrial 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) synthase gene in regulating ketogenesis. The gene exhibits expression in various tissues and it is regulated in a tissue-specific manner. To investigate the underlying mechanisms of this expression, we linked a 1148-base-pair portion of the mitochondrial HMG-CoA synthase promoter to the human growth hormone (hGH) gene and analyzed the expression of the hGH reporter gene in transgenic mice, mRNA levels for hGH were observed in liver, testis, ovary, stomach, colon, cecum, brown adipose tissue, spleen, adrenal glands, and mammary glands from adult mice, and also in liver and stomach, duodenum, jejunum, brown adipose tissue, and heart of suckling mice. There was no expression either in kidney or in any other nonketogenic tissue. The comparison between these data and those of the endogenous mitochondrial HMG-CoA synthase gene suggests that the 1148 base pairs of the promoter contain the elements necessary for expression in liver and testis, but an enhancer is necessary for full expression in intestine of suckling animals and that a silencer prevents expression in stomach, brown adipose tissue, spleen, adrenal glands, and mammary glands in wild type adult mice. In starvation, transgenic mice showed higher expression in liver than did wild type. Both refeeding and insulin injection reduced the expression. Fat diets, composed in each case of different fatty acids, produced similar expression levels, respectively, to those found in wild type animals, suggesting that long-, medium-, and short-chain fatty acids may exert a positive influence on the transcription rate in this 1148-base-pair portion of the promoter. The ketogenic capacity of liver and the blood ketone body levels were equal in transgenic mice and in nontransgenic mice.	UNIV BARCELONA,SCH PHARM,BIOCHEM UNIT,E-08028 BARCELONA,SPAIN; SCH VET MED,DEPT BIOCHEM & MOLEC BIOL,BARCELONA,SPAIN	University of Barcelona			Fillat, Cristina/ABH-1674-2020; Serra, Dolors/L-3657-2014	Serra, Dolors/0000-0002-4936-4206; BOSCH, FATIMA/0000-0002-7705-5515; Fillat, Cristina/0000-0002-0801-3338				AYTE J, 1990, P NATL ACAD SCI USA, V87, P3874, DOI 10.1073/pnas.87.10.3874; BEKESI A, 1990, BIOL NEONATE, V58, P160, DOI 10.1159/000243256; BERNIRSCHKE K, 1978, PATHOLOGY LAB ANIMAL, V2, P1194; CASALS N, 1992, BIOCHEM J, V283, P261, DOI 10.1042/bj2830261; Cecim M., 1994, TRANSGENICS, V1, P431; DECAUX JF, 1988, FEBS LETT, V232, P156, DOI 10.1016/0014-5793(88)80407-1; GILGOMEZ G, 1993, EUR J BIOCHEM, V213, P773, DOI 10.1111/j.1432-1033.1993.tb17819.x; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HOGAN B, 1986, MANIPULATING MOUSE E, P81; JETTON TL, 1994, J BIOL CHEM, V269, P3641; KUHARASIRI MH, 1985, J BIOL CHEM, V260, P14529; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; QUANT PA, 1987, BIOCHEM SOC T, V15, P1068, DOI 10.1042/bst0151068; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; ROTTMAN JN, 1993, J BIOL CHEM, V268, P11994; ROYO T, 1993, J LIPID RES, V34, P867; Sambrook J., 2002, MOL CLONING LAB MANU; SARGENT TD, 1979, P NATL ACAD SCI USA, V76, P3256, DOI 10.1073/pnas.76.7.3256; SERRA D, 1993, ARCH BIOCHEM BIOPHYS, V301, P445, DOI 10.1006/abbi.1993.1169; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; SIMON TC, 1993, J BIOL CHEM, V268, P18345; THUMELIN S, 1993, BIOCHEM J, V292, P493, DOI 10.1042/bj2920493; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; WILLIAMSON DH, 1962, BIOCHEM J, V82, P90, DOI 10.1042/bj0820090; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x	25	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7529	7534		10.1074/jbc.271.13.7529	http://dx.doi.org/10.1074/jbc.271.13.7529			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631784	hybrid			2022-12-27	WOS:A1996UC77400052
J	Zha, HB; AimeSempe, C; Sato, T; Reed, JC				Zha, HB; AimeSempe, C; Sato, T; Reed, JC			Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BN3) distinct from BH1 and BH2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Most members of the Bcl-2 protein family of apoptosis regulating proteins contain two evolutionarily conserved domains, termed BH1 and BH2. Both BH1 and BH2 in the Bcl-2 protein are required for its function as an inhibitor of cell death and for heterodimerization with the proapoptotic protein Bax. In this report, we mapped the region in Bax required for heterodimerization with Bcl-2 and homodimerization with Bax, using yeast two-hybrid and in vitro protein-protein interaction assays. Neither the BH1 nor the BH2 domain of Bax was required for binding to the wild-type Bcl-2 and Bax proteins. Moreover, Bax (Delta BH1) and Bax (Delta BH2) mutant proteins bound efficiently to themselves and each other, further confirming the lack of requirement for BH1 and BH2 for Bax/Bax homodimerization. Bax/Bax homodimerization was not dependent on the inclusion of the NH2-terminal 58 amino acids of the Bax protein in each dimerization partner, unlike Bcl-2/Bcl-2 homodimers which involve head-to-tail interactions between the region of Bcl-2 where BH1 and BH2 resides, and an NH2-terminal domain in Bcl-2 that contains another domain BH4 which is conserved among antiapoptotic members of the Bcl-2 family. Similarly, heterodimerization with Bcl-2 occurred without the NH2-terminal domain of either Bax or Bcl-2, suggesting a tail-to-tail interaction. The essential region in Bax required for both homodimerization with Bax and heterodimerization with Bcl-2 was mapped to residues 59-101. This region in Bax contains a stretch of 15 amino acids that is highly homologous in several members of the Bcl-2 protein family, suggesting the existence of a novel functional domain which we have termed BH3. Deletion of this 15-amino acid region abolished the ability of Bax to dimerize with itself and to heterodimerize with Bcl-2. The findings suggest that the structural features of Bax and Bcl-2 that allow them to participate in homo- and heterodimerization phenomena are markedly different, despite their amino-acid sequence similarity.	LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute				Sempe, Christine/0000-0001-6903-1575				APTE SS, 1995, GENOMICS, V26, P592, DOI 10.1016/0888-7543(95)80180-T; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; BOYD JM, 1995, ONCOGENE, V11, P1921; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SATO T, 1994, GENE, V140, P291, DOI 10.1016/0378-1119(94)90561-4; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TANAKA S, 1993, J BIOL CHEM, V268, P10920; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	21	393	414	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7440	7444		10.1074/jbc.271.13.7440	http://dx.doi.org/10.1074/jbc.271.13.7440			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631771	hybrid			2022-12-27	WOS:A1996UC77400039
J	Lesage, F; Guillemare, E; Fink, M; Duprat, F; Lazdunski, M; Romey, G; Barhanin, J				Lesage, F; Guillemare, E; Fink, M; Duprat, F; Lazdunski, M; Romey, G; Barhanin, J			A pH-sensitive yeast outward rectifier K+ channel with two pore domains and novel gating properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; PLASMA-MEMBRANE; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL EXPRESSION; GUARD-CELLS; TRANSPORT; CLONING	YORK is a newly cloned K+ channel from yeast. Unlike all other cloned K+ channels, it has two pore domains instead of one. It displays eight transmembrane segments arranged like a covalent assembly of a Shaker-type voltage-dependent K+ channel (without S4 transmembrane segments) with an inward rectifier K+ channel, When expressed in Xenopus oocytes, YORK does not pass inward currents; it conducts only K+-selective outward currents, However, the mechanism responsible for this strict outward rectification is unusual. Like inward rectifiers, its activation potential threshold closely follows the K+ equilibrium potential. Unlike inward rectifiers, the rectification is not due to a voltage-dependent Mg2+ block, The blocking element is probably intrinsic to the YORK protein itself, YORK activity is decreased at acidic internal pH, with a pK(alpha) of 6.5. Pharmacological and regulation properties were analyzed. Ba2+ ions and quinine block YORK currents through high and low affinity sites, while tetraethylammonium displays only one affinity for blocking. Activation of protein kinase C indirectly produces an increase of the current, while protein kinase A activation has no effect.	CNRS,INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS)			Lesage, Florian/P-9780-2019; Lesage, Florian/D-5097-2011; Duprat, Fabrice/D-1221-2013	Lesage, Florian/0000-0002-4406-7106; Lesage, Florian/0000-0002-4406-7106; Duprat, Fabrice/0000-0001-8774-1220				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; ATTALI B, 1992, FEBS LETT, V303, P229, DOI 10.1016/0014-5793(92)80526-M; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; BERTL A, 1993, J MEMBRANE BIOL, V132, P183; BLATT MR, 1993, PLANTA, V191, P330, DOI 10.1007/BF00195690; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CHAMBARD JC, 1990, NUCLEIC ACIDS RES, V18, P5282, DOI 10.1093/nar/18.17.5282; CHANDY KG, 1995, CRC HDB RECEPTORS CH; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; DUPRAT F, 1995, BIOCHEM BIOPH RES CO, V212, P657, DOI 10.1006/bbrc.1995.2019; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; GUSTIN MC, 1986, SCIENCE, V233, P1195, DOI 10.1126/science.2426783; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Hille B., 1992, IONIC CHANNELS EXCIT; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; JEGLA T, 1995, RECEPTOR CHANNEL, V3, P51; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; MATSUDA H, 1991, ANNU REV PHYSIOL, V53, P289, DOI 10.1146/annurev.ph.53.030191.001445; MILKMAN R, 1994, P NATL ACAD SCI USA, V91, P3510, DOI 10.1073/pnas.91.9.3510; MIOSGA T, 1994, YEAST, V10, P965, DOI 10.1002/yea.320100712; NICHOLS CG, 1994, J PHYSIOL-LONDON, V476, P399, DOI 10.1113/jphysiol.1994.sp020141; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; PONGS O, 1993, J MEMBRANE BIOL, V136, P1; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SCHROEDER JI, 1988, J GEN PHYSIOL, V92, P667, DOI 10.1085/jgp.92.5.667; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; SERRANO R, 1977, EUR J BIOCHEM, V80, P97, DOI 10.1111/j.1432-1033.1977.tb11861.x; SIGEL E, 1990, J MEMBRANE BIOL, V117, P201, DOI 10.1007/BF01868451; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; VANDEMORTEL JBJ, 1988, BIOCHIM BIOPHYS ACTA, V936, P421, DOI 10.1016/0005-2728(88)90019-9	37	91	95	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4183	4187						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626760				2022-12-27	WOS:A1996TW96000038
J	Hallier, M; Tavitian, A; MoreauGachelin, F				Hallier, M; Tavitian, A; MoreauGachelin, F			The transcription factor Spi-1/PU.1 binds RNA and interferes with the RNA-binding protein p54(nrb)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICING FACTOR; POLYMERASE-II; FUSION; TRANSLOCATION; LIPOSARCOMA; ONCOGENE; INVITRO; CLONING; DOMAIN; FAMILY	The protooncogene for Spi-1/PU.1 is an Ets-related transcription factor overexpressed during Friend erythroleukemia. The molecular basis by which Spi-1/PU.1 is involved in the erythroleukemic process remains to be elucidated. By using an immobilized protein binding assay, we have identified a 55-kDa protein as a putative partner of Spi-1/PU.1 protein. Microsequence analysis revealed that this 55-kDa protein was p54(nrb) (nuclear RNA-binding protein, 54 kDa) a RNA-binding protein highly similar to the splicing factor PSF (polypyrimidine tract-binding protein-associated splicing factor). In this paper, we show that Spi-1/PU.1 impedes the binding of p54(nrb) to RNA and alters the splicing process in vitro. Moreover, we present evidence that the transcriptional factor Spi-1/PU.1, unlike other Ets proteins, is able to bind RNA. Altogether, these results raise the intriguing possibility that the functional interference observed between Spi-1/PU.1 and RNA-binding proteins might represent a novel mechanism in malignant erythropoiesis.	INST CURIE,INSERM,U248,F-75231 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Hallier, Marc/L-2031-2015					BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DELGADO MD, 1994, ONCOGENE, V9, P1723; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONG BH, 1993, NUCLEIC ACIDS RES, V21, P4085, DOI 10.1093/nar/21.17.4085; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; ICHIKAWA H, 1994, CANCER RES, V54, P2865; JIMENEZ B, 1991, INT J CANCER, V49, P471, DOI 10.1002/ijc.2910490327; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1996, MOL CELL BIOL, V16; OHNO T, 1994, ONCOGENE, V9, P3087; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	25	72	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11177	11181		10.1074/jbc.271.19.11177	http://dx.doi.org/10.1074/jbc.271.19.11177			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626664	hybrid			2022-12-27	WOS:A1996UJ94400024
J	Bateman, A; MacLeod, RJ; Lembessis, P; Hu, J; Esch, F; Solomon, S				Bateman, A; MacLeod, RJ; Lembessis, P; Hu, J; Esch, F; Solomon, S			The isolation and characterization of a novel corticostatin/defensin-like peptide from the kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDES; HUMAN-NEUTROPHILS; BIOLOGICAL-ACTIVITY; APICAL MEMBRANE; CA-2+ CHANNELS; MESSENGER-RNA; HOST DEFENSE; PANETH CELLS; BONE-MARROW; PURIFICATION	We report the isolation and characterization of RK-1, a novel peptide found in the kidney. RK-1 is related to the corticostatin/defensins and has the sequence MPC SCKKYCDPWEVIDGSCGLFNSKYICCREK but differs from the very cationic corticostatins/defensins in having only one arginine and a calculated charge at pH 7 of +1. Like some myeloid corticostatin/defensins RK-1 inhibits the growth of Escherichia coli. Since corticostatin/defensins effect ion flux in responsive epithelia we used volume changes in villus enterocytes as a model system to study the effects of RK-1 on ion channels in epithelial cells. At concentrations greater than or equal to 10(-9) M RK-1 decreased enterocyte volume in a dose-dependent manner through a pathway that requires extracellular calcium and is inhibited by niguldipine, a dihydropyridine-sensitive ''L''-type Ca2+-channel blocker. In other assay systems for corticostatin/defensins, such as the inhibition of adrenocorticotropin-stimulated steroidogenesis, or cell lysis, RK-1 was inactive or only weakly active. These results demonstrate the existence of a novel system of biologically active peptides in the kidney represented by RK-1 which is antimicrobial and can activate epithelial ion channels in vitro.	MCGILL UNIV, MONTREAL CHILDRENS HOSP, RES INST, DEPT PEDIAT, MONTREAL, PQ H3H 1P3, CANADA; UCL, EISAI LONDON RES LABS, LONDON WC1E 6BT, ENGLAND	McGill University; Eisai Co Ltd; University of London; University College London	Bateman, A (corresponding author), MCGILL UNIV, ROYAL VICTORIA HOSP,DEPT MED,ENDOCRINE LAB, RM L 2 05, 687 PINE AVE W, MONTREAL, PQ H3A 1A1, CANADA.			Bateman, Andrew/0000-0003-0597-769X; Lembessis, Panagiotis/0000-0001-8972-3499				BACSKAI BJ, 1990, NATURE, V347, P388, DOI 10.1038/347388a0; BATEMAN A, 1992, PEPTIDES, V13, P133, DOI 10.1016/0196-9781(92)90152-S; BATEMAN A, 1991, REGUL PEPTIDES, V35, P135, DOI 10.1016/0167-0115(91)90476-W; BELCOURT D, 1992, REGUL PEPTIDES, V40, P87, DOI 10.1016/0167-0115(92)90086-A; BOER R, 1989, EUR J PHARM-MOLEC PH, V172, P131, DOI 10.1016/0922-4106(89)90004-7; DESAUVAGE FJ, 1992, P NATL ACAD SCI USA, V89, P9089, DOI 10.1073/pnas.89.19.9089; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; EISENHAUER PB, 1989, INFECT IMMUN, V57, P2021, DOI 10.1128/IAI.57.7.2021-2027.1989; FRINDT G, 1987, AM J PHYSIOL, V252, pF458, DOI 10.1152/ajprenal.1987.252.3.F458; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; GATTI RG, 1992, ARCH GERONTOL GERIAT, V3, P159; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; HU J, 1991, BIOCHEM BIOPH RES CO, V180, P558; HUNTER M, 1986, AM J PHYSIOL, V251, pF725, DOI 10.1152/ajprenal.1986.251.4.F725; HUTTNER KM, 1994, GENOMICS, V19, P448, DOI 10.1006/geno.1994.1093; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; LEHRER RI, 1983, INFECT IMMUN, V42, P10, DOI 10.1128/IAI.42.1.10-14.1983; LEHRER RI, 1990, BLOOD, V76, P2169; MACLEOD RJ, 1992, J MEMBRANE BIOL, V130, P23; MACLEOD RJ, 1990, AM J PHYSIOL, V258, pG665, DOI 10.1152/ajpgi.1990.258.5.G665; MACLEOD RJ, 1991, P NATL ACAD SCI USA, V88, P552, DOI 10.1073/pnas.88.2.552; MCCARTY NA, 1990, AM J PHYSIOL, V259, pF950, DOI 10.1152/ajprenal.1990.259.6.F950; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; SELSTED ME, 1985, J BIOL CHEM, V260, P4579; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SINGH A, 1988, BIOCHEM BIOPH RES CO, V155, P524, DOI 10.1016/S0006-291X(88)81118-5; STEINHAUSEN M, 1989, PROG APPL MICROCIRC, V14, P25; SUSSMAN M, 1979, RENAL DISEASE, P400; TANIGUCHI J, 1989, AM J PHYSIOL, V257, pF347, DOI 10.1152/ajprenal.1989.257.3.F347; TATEMOTO K, 1978, P NATL ACAD SCI USA, V75, P4115, DOI 10.1073/pnas.75.9.4115; TERRITO MC, 1989, J CLIN INVEST, V84, P2017, DOI 10.1172/JCI114394; TOMINAGA T, 1990, J ENDOCRINOL, V125, P287, DOI 10.1677/joe.0.1250287; WILDE CG, 1989, J BIOL CHEM, V264, P11200; YAMASHITA T, 1989, INFECT IMMUN, V57, P2405, DOI 10.1128/IAI.57.8.2405-2409.1989; YU ASL, 1992, P NATL ACAD SCI USA, V89, P10494, DOI 10.1073/pnas.89.21.10494; YU YM, 1989, AM J PHYSIOL, V257, pF1094, DOI 10.1152/ajprenal.1989.257.6.F1094; ZHU QH, 1988, P NATL ACAD SCI USA, V85, P592, DOI 10.1073/pnas.85.2.592; ZHU QZ, 1992, ENDOCRINOLOGY, V130, P1413, DOI 10.1210/en.130.3.1413	43	39	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10654	10659		10.1074/jbc.271.18.10654	http://dx.doi.org/10.1074/jbc.271.18.10654			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631871	hybrid			2022-12-27	WOS:A1996UJ34200039
J	Judelson, C; Privalsky, ML				Judelson, C; Privalsky, ML			DNA recognition by normal and oncogenic thyroid hormone receptors - Unexpected diversity in half-site specificity controlled by non-zinc-finger determinants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; RESPONSE ELEMENTS; AMINO-ACIDS; GLUCOCORTICOID RECEPTOR; NUCLEAR RECEPTORS; ESTROGEN-RECEPTOR; GENE-EXPRESSION; HIGH-AFFINITY; C-ERBA; BINDING	The nuclear hormone receptors regulate target gene expression in response to hormones of extracellular origin. The DNA binding specificity of these receptors therefore plays the critical role of defining the precise repertoire of target genes that respond to a given hormone. We report here an analysis of the DNA binding specificity of the thyroid hormone receptor (c-ErbA protein) and that of an oncogenic derivative, the v-ErbA protein. These otherwise closely similar proteins exhibit quite divergent DNA sequence specificities at multiple positions within the DNA binding site. The thyroid hormone receptor (c-ErbA protein) exhibits a particularly broad DNA specificity, whereas the v-ErbA protein is comparatively quite specific. Intriguingly, these differences in DNA recognition largely map to an N-terminal receptor domain not traditionally implicated in DNA binding, and are further influenced by heterodimer formation with retinoid X receptors. We propose that the N terminus of nuclear hormone receptors plays an critical role in DNA recognition by altering the conformation of the receptor domains that make the actual base-specific contacts.	UNIV CALIF DAVIS,DIV BIOL SCI,MICROBIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis					NCI NIH HHS [CA53394] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053394, R01CA053394] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; CARLSONJURICA MA, 1990, ENDOCR REV, V11, P201; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; CHEN HW, 1995, P NATL ACAD SCI USA, V92, P422, DOI 10.1073/pnas.92.2.422; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GEWIRTH DT, 1995, STRUCT BIOL, V2, P386; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; IKEDA M, 1994, ENDOCRINOLOGY, V135, P1628, DOI 10.1210/en.135.4.1628; KATZ RW, 1995, J BIOL CHEM, V270, P5238, DOI 10.1074/jbc.270.10.5238; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KIM HS, 1992, MOL ENDOCRINOL, V6, P1489, DOI 10.1210/me.6.9.1489; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MANGELSDORF DJ, 1993, RECENT PROG HORM RES, V48, P99; MCBROOM LDB, 1995, MOL CELL BIOL, V15, P796; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NELSON CC, 1995, J BIOL CHEM, V270, P16981, DOI 10.1074/jbc.270.28.16981; NELSON CC, 1995, J BIOL CHEM, V270, P16988, DOI 10.1074/jbc.270.28.16988; NELSON CC, 1994, MOL ENDOCRINOL, V8, P829, DOI 10.1210/me.8.7.829; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SANDE S, 1993, J VIROL, V67, P1067, DOI 10.1128/JVI.67.2.1067-1074.1993; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SCHROEDER C, 1992, ONCOGENE, V7, P217; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1995, STRUCTURE, V3, P201, DOI 10.1016/S0969-2126(01)00150-2; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SMITMCBRIDE Z, 1994, MOL ENDOCRINOL, V8, P819, DOI 10.1210/me.8.7.819; SUBAUSTE JS, 1995, J BIOL CHEM, V270, P7957, DOI 10.1074/jbc.270.14.7957; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WONG CW, 1995, MOL ENDOCRINOL, V9, P551, DOI 10.1210/me.9.5.551; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZHANG XK, 1993, RECEPTOR, V3, P183	47	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10800	10805		10.1074/jbc.271.18.10800	http://dx.doi.org/10.1074/jbc.271.18.10800			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631892	hybrid			2022-12-27	WOS:A1996UJ34200060
J	Chiang, HL; Schekman, R; Hamamoto, S				Chiang, HL; Schekman, R; Hamamoto, S			Selective uptake of cytosolic, peroxisomal, and plasma membrane proteins into the yeast lysosome for degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CATABOLITE INACTIVATION; AUTOPHAGIC VACUOLE; RAT-LIVER; PEPTIDE SEQUENCES; MUTANTS; PROTEOLYSIS; SYSTEM; MECHANISMS; ENZYME	When glucose-starved cells are replenished with glucose, the key gluconeogenic enzyme, fructose-1,6-bisphosphatase (FBPase), is selectively targeted from the cytosol to the yeast lysosome (vacuole) for degradation, The glucose-induced targeting of FBPase to the vacuole for degradation occurs in cells grown under a variety of metabolic conditions. Immunoelectron microscopic studies demonstrate that the uptake of FBPase by the vacuole is mediated in part by an autophagic process, FBPase can be found on the vacuolar membrane and also at the sites of membrane invaginations, Furthermore, FBPase is associated with different forms of vesicles, which are induced to accumulate inside the vacuole, We have identified peroxisomes as the organelles that are delivered to the vacuole for degradation when cells are replenished with glucose, Ultrastructural studies indicate that peroxisomes are engulfed by the vacuole by an autophagic process, leading to the destruction of whole organelles in the vacuole. Furthermore, the galactose transporter (Gal2p) is also delivered from the plasma membrane to the vacuole for degradation in response to glucose. Gal2p is delivered to the vacuole through the endocytic pathway, as mutants defective in receptor-mediated endocytosis fail to degrade Gal2p in response to glucose.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley	Chiang, HL (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049267] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM 49267] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLBERG J, 1982, LAB INVEST, V47, P523; AHLBERG J, 1982, EXP CELL RES, V142, P373, DOI 10.1016/0014-4827(82)90379-2; BORMANN C, 1978, ARCH MICROBIOL, V117, P67, DOI 10.1007/BF00689353; BUSTURIA A, 1985, BIOCHIM BIOPHYS ACTA, V820, P324, DOI 10.1016/0005-2736(85)90128-2; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CHIANG HL, 1994, NATURE, V369, P284, DOI 10.1038/369284a0; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CHVATCHKO Y, 1986, CELL, V46, P355, DOI 10.1016/0092-8674(86)90656-2; CUERVO AM, 1994, J BIOL CHEM, V269, P26374; DELAGUERRA R, 1988, FEBS LETT, V242, P149, DOI 10.1016/0014-5793(88)81004-4; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DULIC V, 1989, EMBO J, V8, P1349, DOI 10.1002/j.1460-2075.1989.tb03515.x; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; FERGUSON JJ, 1967, EUR J BIOCHEM, V1, P21, DOI 10.1111/j.1432-1033.1967.tb00037.x; FINLEY D, 1985, TRENDS BIOCHEM SCI, V10, P343, DOI 10.1016/0968-0004(85)90108-2; FRANCOIS J, 1991, YEAST, V7, P575, DOI 10.1002/yea.320070605; FUNAGUMA T, 1985, BIOCHEM BIOPH RES CO, V130, P467, DOI 10.1016/0006-291X(85)90440-1; FUNAYAMA S, 1980, EUR J BIOCHEM, V109, P61, DOI 10.1111/j.1432-1033.1980.tb04767.x; GANCEDO C, 1971, J BACTERIOL, V107, P401, DOI 10.1128/JB.107.2.401-405.1971; HASILIK A, 1978, EUR J BIOCHEM, V85, P599, DOI 10.1111/j.1432-1033.1978.tb12275.x; HEMMINGS BA, 1981, P NATL ACAD SCI-BIOL, V78, P435, DOI 10.1073/pnas.78.1.435; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, P193; JONES EW, 1991, J BIOL CHEM, V266, P7963; JONES EW, 1977, GENETICS, V85, P23; KOMINAMI E, 1983, J BIOL CHEM, V258, P6093; KOPITZ J, 1990, J CELL BIOL, V111, P841; LATTERICH M, 1991, MOL MICROBIOL, V5, P2417, DOI 10.1111/j.1365-2958.1991.tb02087.x; MATERN H, 1977, J BIOL CHEM, V252, P6399; MORTIMORE GE, 1981, J BIOL CHEM, V256, P7659; MULLER M, 1981, J BIOL CHEM, V256, P723; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; RAMOS J, 1988, J BACTERIOL, V170, P3575; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; SCHORK SM, 1994, FEBS LETT, V349, P270, DOI 10.1016/0014-5793(94)00668-7; Seglen P O, 1990, Semin Cell Biol, V1, P441; SURMACZ CA, 1987, BIOCHEM J, V242, P453, DOI 10.1042/bj2420453; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; TUTTLE DL, 1995, J CELL SCI, V108, P25; VEENHUIS M, 1983, ARCH MICROBIOL, V134, P193, DOI 10.1007/BF00407757	44	88	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9934	9941		10.1074/jbc.271.17.9934	http://dx.doi.org/10.1074/jbc.271.17.9934			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626630	hybrid			2022-12-27	WOS:A1996UG25700014
J	Ghosh, S; Toth, C; Peterlin, BM; Seto, E				Ghosh, S; Toth, C; Peterlin, BM; Seto, E			Synergistic activation of transcription by the mutant and wild-type minimal transcriptional activation domain of VP16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS REGULATORY PROTEIN; GENE-EXPRESSION; FACTOR-TFIIB; AMINO-ACIDS; BINDING; VMW65; TAT; SEQUENCE	VP16 activates transcription by stimulating initiation, and for this function the aromatic residue at position 442 within its activation domain is critical. Recent studies have suggested that VP16 also stimulates transcriptional elongation. It has been shown that VP16 can activate transcription tethered downstream of the transcription start site to RNA. Here, we analyze the synergistic activation features of hybrid VP16 fusion proteins when tethered simultaneously to RNA downstream of the start site and to DNA upstream of a promoter in order to investigate its role in postinitiation control of transcription. Upon targeting the VP16 activation domain simultaneously to both DNA and RNA, high levels of transcriptional synergism is observed. Importantly, a transcription-defective VP16 minimal activation domain (amino acids 413-453) mutated at critical residue 442 (phenylalanine --> proline) maintained synergism, when bound to RNA, with the DNA-bound wild-type VP16 minimal activation domain. Targeting of this ''functionally defective'' VP16 minimal activation domain via RNA and an intact activation domain via DNA allowed us to uncover a postinitiation activity for VP16 not previously detected in DNA targeting studies. We suggest that, in addition to stimulating initiation, VP16 also acts at a postinitiation step involving residues other than the critical residue at position 442 within the same 41-amino acid minimal activation domain (amino acids 413-453) required for initiation.	UNIV TEXAS,HLTH SCI CTR,CTR MOLEC MED,SAN ANTONIO,TX 78245; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of Texas System; University of Texas Health San Antonio; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Ghosh, S (corresponding author), UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,15355 LAMBDA DR,SAN ANTONIO,TX 78245, USA.							CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; EICK D, 1994, TRENDS GENET, V10, P292, DOI 10.1016/0168-9525(90)90013-V; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GHOSH S, 1993, J MOL BIOL, V234, P610, DOI 10.1006/jmbi.1993.1615; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GREAVES R, 1989, J VIROL, V63, P1641, DOI 10.1128/JVI.63.4.1641-1650.1989; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JIANG Y, 1994, J BIOL CHEM, V269, P5505; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; TILEY LS, 1992, GENE DEV, V6, P2077, DOI 10.1101/gad.6.11.2077; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; WALKER S, 1993, MOL CELL BIOL, V13, P5233, DOI 10.1128/MCB.13.9.5233; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x	34	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9911	9918		10.1074/jbc.271.17.9911	http://dx.doi.org/10.1074/jbc.271.17.9911			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626627	hybrid			2022-12-27	WOS:A1996UG25700011
J	Jain, MK; Fujita, KP; Hsieh, CM; Endege, WO; Sibinga, NES; Yet, SF; Kashiki, S; Lee, WS; Perrella, MA; Haber, E; Lee, ME				Jain, MK; Fujita, KP; Hsieh, CM; Endege, WO; Sibinga, NES; Yet, SF; Kashiki, S; Lee, WS; Perrella, MA; Haber, E; Lee, ME			Molecular cloning and characterization of SmLIM, a developmentally regulated LIM protein preferentially expressed in aortic smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH PROTEIN; GENE; HOMEODOMAIN; FAMILY; DOMAIN; ATHEROSCLEROSIS; ATHEROGENESIS; PATHOGENESIS; BINDING; ELEGANS	Differentiated, quiescent vascular smooth muscle cells assume a dedifferentiated, proliferative phenotype in response to injury, one of the hallmarks of arteriosclerosis. Members of the LIM family of zinc-finger proteins are important in the differentiation of various cells including striated muscle. We describe here the molecular cloning and characterization of a developmentally regulated smooth muscle LIM protein, SmLIM, that is expressed preferentially in the rat aorta. This 194-amino acid protein has two LIM domains, and comparisons of rat SmLIM with its mouse and human homologues reveal high levels of amino acid sequence conservation (100 and 99%, respectively). SmLIM is a nuclear protein and maps to human chromosome 3. SmLIM mRNA expression was high in aorta but not in striated muscle and low in other smooth muscle tissues such as intestine and uterus. In contrast with arterial tissue, SmLIM mRNA was barely detectable in venous tissue. The presence of SmLIM expression within aortic smooth muscle cells was confirmed by in situ hybridization. In vitro, SmLIM mRNA levels decreased by 80% in response to platelet-derived growth factor-BB in rat aortic smooth muscle cells. In vivo, SmLIM mRNA decreased by 60% in response to vessel wall injury during periods of maximal smooth muscle cell proliferation. The down-regulation of SmLIM by phenotypic change in vascular smooth muscle cells suggests that it may be involved in their growth and differentiation.	HARVARD UNIV, SCH PUBL HLTH, CARDIOVASC BIOL LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DIV CARDIOVASC, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DIV PULM, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital			Yet, Shaw-Fang/O-8583-2019; Yet, Shaw-Fang/B-1067-2010; Sibinga, Nicholas/GOJ-8544-2022	Sibinga, Nicholas/0000-0003-4838-910X; Yet, Shaw-Fang/0000-0001-9097-3962	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003194, K08HL003274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER; NHLBI NIH HHS [KO8 HL03274, KO8 HL03194] Funding Source: Medline; NIGMS NIH HHS [R01 GM53249] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BUCKINGHAM ME, 1994, CURR OPIN GENET DEV, V4, P745, DOI 10.1016/0959-437X(94)90142-P; CLOWES AW, 1983, LAB INVEST, V49, P327; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GORSKI DH, 1993, MOL CELL BIOL, V13, P3722, DOI 10.1128/MCB.13.6.3722; GORSKI DH, 1995, CARDIOVASC RES, V30, P585; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; Hogan B. L., 1994, MANIPULATING MOUSE E, P24; HOLT CM, 1993, ANN THORAC SURG, V55, P1522, DOI 10.1016/0003-4975(93)91103-T; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; Kaufman M. H., 1992, ATLAS MOUSE DEV, P38; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEE WS, 1993, ENDOCRINOLOGY, V132, P2136, DOI 10.1210/en.132.5.2136; LIBBY P, 1991, LAB INVEST, V64, P5; MCLAUGHLIN CR, 1994, NUCLEIC ACIDS RES, V22, P5477, DOI 10.1093/nar/22.24.5477; MILLER VM, 1989, AM J PHYSIOL, V257, pH1127, DOI 10.1152/ajpheart.1989.257.4.H1127; MIZUNO K, 1994, ONCOGENE, V9, P1605; MUNRO JM, 1988, LAB INVEST, V58, P249; NUNOUE K, 1995, ONCOGENE, V11, P701; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OWENS GK, 1995, PHYSIOL REV, V75, P487; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; TAN MS, 1994, KIDNEY INT, V46, P690, DOI 10.1038/ki.1994.322; THORINTRESCASES N, 1995, AM J PHYSIOL-HEART C, V268, pH1122, DOI 10.1152/ajpheart.1995.268.3.H1122; Tsai JC, 1996, J CLIN INVEST, V97, P146, DOI 10.1172/JCI118383; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; WANG XK, 1992, GENOMICS, V14, P391, DOI 10.1016/S0888-7543(05)80231-9; WANG XK, 1992, J BIOL CHEM, V267, P9176; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WEIR L, 1995, J BIOL CHEM, V270, P5457, DOI 10.1074/jbc.270.10.5457; WEISKIRCHEN R, 1995, J BIOL CHEM, V270, P28946, DOI 10.1074/jbc.270.48.28946; WEISKIRCHEN R, 1993, ONCOGENE, V8, P2317; YANG ZH, 1993, J CARDIOVASC PHARM, V22, pS17, DOI 10.1097/00005344-199322005-00004; YOSHIZUMI M, 1995, J CLIN INVEST, V95, P2275, DOI 10.1172/JCI117918	54	79	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10194	10199		10.1074/jbc.271.17.10194	http://dx.doi.org/10.1074/jbc.271.17.10194			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626582				2022-12-27	WOS:A1996UG25700054
J	Pritchard, AE; Dallmann, HG; McHenry, CS				Pritchard, AE; Dallmann, HG; McHenry, CS			In vivo assembly of the tau-complex of the DNA polymerase III holoenzyme expressed from a five-gene artificial operon - Cleavage of the tau-complex to form a mixed gamma-tau-complex by the ompT protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SUBUNIT; PURIFICATION; IDENTIFICATION; OVEREXPRESSION; COMPONENTS	A plasmid was constructed that encodes all five subunits of the Escherichia coli tau-complex on a single artificially constructed operon under the control of an inducible promoter. The proteins tau, delta, delta', chi, and psi overproduced from this artificial operon assemble efficiently in vivo, providing an efficient source of homogeneous tau-complex. The gamma subunit is a truncated form of tau that is produced by a translational frameshift. When protein expression was induced in bacterial strains containing the outer membrane protein T (OmpT) protease, tau was proteolyzed after lysis to a gamma-like protein, gamma(P), and a peptide, C-tau, corresponding to the C terminus of tau. N-terminal sequencing of C-tau revealed a cleavage site between two lysines at positions 429 and 430 of tau. The deduced sequence of gamma(P) is, therefore, only two amino acids shorter than natural gamma. The proteolysis by OmpT was also shown directly by using purified OmpT and tau-complex in an in vitro reaction. A gamma(P)-complex and a mixed tau-gamma(P)-complex were purified from ompT(+) cells. When the tau-complex proteins were overexpressed in ompT(-) bacteria, intact tau-complex lacking gamma(P) could be purified.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,GRAD PROGRAM MOL BIOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NIGMS NIH HHS [GM35695] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035695] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V167, P711, DOI 10.1016/0006-291X(90)92083-C; BLINKOVA A, 1993, J BACTERIOL, V175, P6018, DOI 10.1128/JB.175.18.6018-6027.1993; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; CARTER JR, 1993, J BACTERIOL, V175, P5604, DOI 10.1128/JB.175.17.5604-5610.1993; CARTER JR, 1992, J BACTERIOL, V174, P7013, DOI 10.1128/JB.174.21.7013-7025.1992; CARTER JR, 1993, J BACTERIOL, V175, P3812, DOI 10.1128/JB.175.12.3812-3822.1993; Cull MG, 1995, METHOD ENZYMOL, V262, P22; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HAWKER JR, 1987, J BIOL CHEM, V262, P12722; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; LANZER M, 1988, P NATL ACAD SCI USA, V85, P8973, DOI 10.1073/pnas.85.23.8973; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MCHENRY CS, 1989, MOL MECH DNA REPLICA, P115; MCHENRY CS, 1986, MECHANISMS DNA REPLI, P47; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; SUGIMURA K, 1988, J BACTERIOL, V170, P5625, DOI 10.1128/jb.170.12.5625-5632.1988; SUGIMURA K, 1988, J BACTERIOL, V170, P3650, DOI 10.1128/jb.170.8.3650-3654.1988; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WHITE CB, 1995, J BIOL CHEM, V270, P12990, DOI 10.1074/jbc.270.22.12990; XIAO H, 1995, J BIOL CHEM, V270, P13378, DOI 10.1074/jbc.270.22.13378	28	29	30	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10291	10298		10.1074/jbc.271.17.10291	http://dx.doi.org/10.1074/jbc.271.17.10291			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626597	hybrid			2022-12-27	WOS:A1996UG25700069
J	Schwemmle, M; Kaspers, B; Irion, A; Staeheli, P; Schultz, U				Schwemmle, M; Kaspers, B; Irion, A; Staeheli, P; Schultz, U			Chicken guanylate-binding protein - Conservation of GTPase activity and induction by cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON; ESTABLISHMENT; SEQUENCE; GAMMA	To gain further insights into the cytokine network of birds, we used polymerase chain reaction technology to clone a cDNA that codes for a chicken homolog of the interferon-induced guanylate-binding proteins (GBPs). In its N-terminal moiety, the 64-kDa chicken GBP contains two sequence blocks of 100 and 19 amino acids, respectively, that are about 70% identical to mammalian GBPs. The first region includes two motifs of the canonical GTP-binding consensus element. The other parts of chicken GBP are poorly conserved, except for a CAAX motif at the extreme C terminus which might signal isoprenylation. Like mammalian GBPs, recombinant chicken GBP specifically bound to agarose-immobilized guanine nucleotides and hydrolyzed GTP to both GDP and GMP. Regulation by interferons was also conserved: chicken GBP RNA was barely detectable in uninduced chicken cells. Low GBP RNA levels were found in cells treated with type I interferon, whereas very high levels were observed in cells treated with supernatant of a chicken T cell line that secretes a gamma-interferon-like activity. Together with recent phylogenetic studies of interferon genes, these results suggest that in spite of low sequence conservation, the various components of the avian interferon system are functionally well conserved.	UNIV FREIBURG,DEPT VIROL,INST MED MIKROBIOL & HYG,ABT VIROL,D-79008 FREIBURG,GERMANY; UNIV MUNICH,INST TIERPHYSIOL,MUNICH,GERMANY	University of Freiburg; University of Munich								BERNASCONI D, 1995, J INTERF CYTOK RES, V15, P47, DOI 10.1089/jir.1995.15.47; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; CHENG YSE, 1985, J BIOL CHEM, V260, P5834; CHENG YSE, 1991, MOL CELL BIOL, V11, P4717, DOI 10.1128/MCB.11.9.4717; CHENG YSE, 1983, J BIOL CHEM, V258, P7746; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEMAYER EM, 1988, INTERFERONS OTHER RE; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DIJKMANS R, 1990, VET IMMUNOL IMMUNOP, V26, P319, DOI 10.1016/0165-2427(90)90116-A; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; JUNGWIRTH C, 1995, P NATL ACAD SCI USA, V92, P3105, DOI 10.1073/pnas.92.8.3105; KAADEN OR, 1982, IN VITRO CELL DEV B, V18, P827, DOI 10.1007/BF02796323; KAWAGUCHI T, 1987, CANCER RES, V47, P4460; MARMOR MD, 1993, J EXP MED, V177, P647, DOI 10.1084/jem.177.3.647; PANABIERES F, 1984, BIOCHEM BIOPH RES CO, V118, P767, DOI 10.1016/0006-291X(84)91461-X; RICHTER MF, 1995, J BIOL CHEM, V270, P13512, DOI 10.1074/jbc.270.22.13512; SCHULTZ U, 1995, EUR J IMMUNOL, V25, P847, DOI 10.1002/eji.1830250332; SCHULTZ U, 1995, EUR J BIOCHEM, V229, P73, DOI 10.1111/j.1432-1033.1995.tb20439.x; SCHWEMMLE M, 1994, J BIOL CHEM, V269, P11299; SCHWEMMLE M, 1994, VIROLOGY, V206, P545; SEKELLICK MJ, 1994, J INTERFERON RES, V14, P71, DOI 10.1089/jir.1994.14.71; STAEHELI P, 1984, VIROLOGY, V137, P135, DOI 10.1016/0042-6822(84)90016-3; Staeheli P, 1987, Interferon, V8, P1	24	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10304	10308		10.1074/jbc.271.17.10304	http://dx.doi.org/10.1074/jbc.271.17.10304			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626599	hybrid			2022-12-27	WOS:A1996UG25700071
J	Whitelock, JM; Murdoch, AD; Iozzo, RV; Underwood, PA				Whitelock, JM; Murdoch, AD; Iozzo, RV; Underwood, PA			The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBENDOTHELIAL EXTRACELLULAR-MATRIX; DENSITY-LIPOPROTEIN RECEPTOR; BIOLOGICAL-ACTIVITIES; SULFATE PROTEOGLYCAN; SUBSTRATE-SPECIFICITY; ADHESION MOLECULES; FACTOR BINDING; HEPARIN; PURIFICATION; DOMAINS	Perlecan is a modular heparan sulfate proteoglycan that is localized to cell surfaces and within basement membranes. Its ability to interact with basic fibroblast growth factor (bFGF) suggests a central role in angiogenesis during development, wound healing, and tumor invasion. In the present study we investigated, using domain specific anti-perlecan monoclonal antibodies, the binding site of bFGF on human endothelial perlecan and its cleavage by proteolytic and glycolytic enzymes. The heparan sulfate was removed from perlecan by heparitinase treatment, and the similar to 450-kDa protein core was digested with various proteases. Plasmin digestion resulted in a large fragment of similar to 300 kDa, whereas stromelysin and rat collagenase cleaved the protein core into smaller fragments. All three proteases removed immunoreactivity toward the anti-domain I antibody. We showed also that perlecan bound bFGF specifically by the heparan sulfate chains located on the amino-terminal domain I. Once bound, the growth factor was released very efficiently by stromelysin, rat collagenase, plasmin, heparitinase I, platelet extract, and heparin. Interestingly, heparinase I, an enzyme with a substrate specificity for regions of heparan sulfate similar to those that bind bFGF, released only small amounts of bFGF. Our findings provide direct evidence that bFGF binds to heparan sulfate sequences attached to domain I and support the hypothesis that perlecan represents a major storage site for this growth factor in the blood vessel wall. Moreover, the concerted action of proteases that degrade the protein core and heparanases that remove the heparan sulfate may modulate the bioavailability of the growth factor.	THOMAS JEFFERSON UNIV,DEPT PATHOL ANAT & CELL BIOL,PHILADELPHIA,PA 19107	Jefferson University	Whitelock, JM (corresponding author), CSIRO,DIV BIOMOLEC ENGN,POB 184,SYDNEY,NSW 2114,AUSTRALIA.		Iozzo, Renato/AAS-1980-2020	Whitelock, John/0000-0003-1835-802X; Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [R01 CA-47282, R01 CA-39481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047282, R01CA039481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BAIRD A, 1987, BIOCHEM BIOPH RES CO, V142, P428, DOI 10.1016/0006-291X(87)90292-0; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BENEZRA M, 1993, BLOOD, V81, P3324; BENEZRA M, 1992, EXP CELL RES, V201, P208, DOI 10.1016/0014-4827(92)90365-F; COUCHMAN JR, 1993, CELL SURFACE EXTRACE, P33; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GOSPODAROWICZ D, 1981, J CELL PHYSIOL, V109, P69, DOI 10.1002/jcp.1041090109; Graham LD, 1995, BIOCHEM MOL BIOL INT, V37, P239; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBLOM A, 1990, GLYCOCONJUGATE J, V7, P545, DOI 10.1007/BF01189076; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LYONS JG, 1989, MATRIX, V9, P7, DOI 10.1016/S0934-8832(89)80012-5; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; MENASHI S, 1995, FEBS LETT, V361, P61, DOI 10.1016/0014-5793(95)00125-S; MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NADER HB, 1990, J BIOL CHEM, V265, P16807; NETHERY A, 1986, ANAL BIOCHEM, V159, P390, DOI 10.1016/0003-2697(86)90358-1; NUGENT MA, 1993, CIRC RES, V73, P1051, DOI 10.1161/01.RES.73.6.1051; OOSTA GM, 1982, J BIOL CHEM, V257, P1249; RUOSLAHTI E, 1982, METHOD ENZYMOL, V82, P803; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHMIDT A, 1992, J BIOL CHEM, V267, P19242; SELLERS A, 1978, BIOCHEM J, V171, P493, DOI 10.1042/bj1710493; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; UNDERWOOD PA, 1983, J IMMUNOL METHODS, V60, P33, DOI 10.1016/0022-1759(83)90332-0; UNDERWOOD PA, 1989, J CELL SCI, V93, P641; UNDERWOOD PA, 1992, J CELL SCI, V102, P833; VIGNY M, 1988, J CELL PHYSIOL, V137, P321, DOI 10.1002/jcp.1041370216; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VLODAVSKY I, 1993, MOL CELLULAR ASPECTS, P327; WALKER A, 1994, J BIOL CHEM, V269, P931; WEIS JR, 1991, THROMB RES, V61, P171, DOI 10.1016/0049-3848(91)90245-R; [No title captured]	43	483	509	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10079	10086		10.1074/jbc.271.17.10079	http://dx.doi.org/10.1074/jbc.271.17.10079			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626565	hybrid			2022-12-27	WOS:A1996UG25700037
J	Pande, A; Tremmel, KD; DeMaria, CT; Blaxall, BC; Minobe, WA; Sherman, JA; Bisognano, JD; Bristow, MR; Brewer, G; Port, JD				Pande, A; Tremmel, KD; DeMaria, CT; Blaxall, BC; Minobe, WA; Sherman, JA; Bisognano, JD; Bristow, MR; Brewer, G; Port, JD			Regulation of the mRNA-binding protein AUF1 by activation of the beta-adrenergic receptor signal transduction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; FAILING HUMAN HEART; HUMAN VENTRICULAR MYOCARDIUM; 3' UNTRANSLATED REGION; BETA-2-ADRENERGIC RECEPTORS; CROSS-REGULATION; GENE-EXPRESSION; RICH DOMAINS; C-PROTEINS; GM-CSF	In both cell culture based model systems and in the failing human heart, beta-adrenergic receptors (beta-AR) undergo agonist-mediated down-regulation. This decrease correlates closely with down-regulation of its mRNA, an effect regulated in part by changes in mRNA stability. Regulation of mRNA stability has been associated with mRNA-binding proteins that recognize A + U-rich elements within the 3'-untranslated regions of many mRNAs encoding proto-oncogene and cytokine mRNAs. We demonstrate here that the mRNA-binding protein, AUF1, is present in both human heart and in hamster DDT1-MF2 smooth muscle cells and that its abundance is regulated by beta-AR agonist stimulation. In human heart, AUF1 mRNA and protein was significantly increased in individuals with myocardial failure, a condition associated with increases in the beta-adrenergic receptor agonist norepinephrine. In the same hearts, there was a significant decrease (similar to 50%) in the abundance of beta(1)-AR mRNA and protein. In DDT1-MFB cells, where agonist-mediated destabilization of beta(2)-AR mRNA was first described, exposure to beta-AR agonist resulted in a significant increase in AUF1 mRNA and protein (similar to 100%). Conversely, agonist exposure significantly decreased (similar to 40%) beta(2)-adrenergic receptor mRNA abundance. Last, we demonstrate that AUF1 can be immunoprecipitated from polysome-derived proteins following UV cross-linking to the 3'-untranslated region of the human beta(1)-AR mRNA and that purified, recombinant p37(AUF1) protein also binds to beta(1)-AR 3'-untranslated region mRNA.	UNIV COLORADO,HLTH SCI CTR,DIV CARDIOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT IMMUNOL & MICROBIOL,WINSTON SALEM,NC 27157	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Wake Forest University; Wake Forest Baptist Medical Center			bristow, michael r/G-7850-2011; Blaxall, Burns/ABD-8289-2021		NHLBI NIH HHS [HL51239, R01 HL051239, HL48013] Funding Source: Medline; NIAID NIH HHS [T32-AI07401] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048013, R01HL051239, R29HL051239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007401] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAHOUTH SW, 1992, MOL PHARMACOL, V42, P971; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BINDER R, 1989, J BIOL CHEM, V264, P16910; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1990, METHOD ENZYMOL, V181, P202; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; BRISTOW MR, 1992, J CLIN INVEST, V89, P803, DOI 10.1172/JCI115659; BRISTOW MR, 1990, CIRCULATION, V82, P12; BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297; BRISTOW MR, 1993, J CLIN INVEST, V92, P2737, DOI 10.1172/JCI116891; BRODDE OE, 1986, J CARDIOVASC PHARM, V8, P1235, DOI 10.1097/00005344-198611000-00021; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1988, TRENDS BIOCHEM SCI, V13, P339, DOI 10.1016/0968-0004(88)90103-X; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; COLLINS S, 1991, ANNU REV PHYSIOL, V53, P497, DOI 10.1146/annurev.physiol.53.1.497; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; EHRENMAN K, 1994, GENE, V149, P315, DOI 10.1016/0378-1119(94)90168-6; FELDMAN AM, 1991, CIRCULATION, V83, P1866, DOI 10.1161/01.CIR.83.6.1866; FERRY RC, 1994, J BIOL CHEM, V269, P31850; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; HADCOCK JR, 1991, J BIOL CHEM, V266, P11915; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HENICS T, 1994, J BIOL CHEM, V269, P5377; HUANG LY, 1993, J BIOL CHEM, V268, P25769; IZZO NJ, 1994, J BIOL CHEM, V269, P1705; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LANGECARTER CA, 1991, J BIOL CHEM, V266, P22529; LEE NH, 1994, J BIOL CHEM, V269, P4291; LOGANZO F, 1993, MOL ENDOCRINOL, V7, P434, DOI 10.1210/me.7.3.434; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MORRIS GM, 1991, J BIOL CHEM, V266, P2233; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PORT JD, 1992, J BIOL CHEM, V267, P24103; RAGHOW R, 1987, TRENDS BIOCHEM SCI, V12, P358, DOI 10.1016/0968-0004(87)90165-4; RATNASABAPATHY R, 1990, J BIOL CHEM, V265, P14050; RUBIN SA, 1994, CIRCULATION, V90, P145; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SAKAUE M, 1991, J BIOL CHEM, V266, P5743; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95, DOI 10.1016/0304-419X(92)90009-N; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; THOLANIKUNNEL BG, 1995, J BIOL CHEM, V270, P12787, DOI 10.1074/jbc.270.21.12787; TREMMEL KD, 1996, KEYSTONE S MOL BIOL, P47; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VRIZ S, 1989, FEBS LETT, V251, P201, DOI 10.1016/0014-5793(89)81455-3; WINSTALL E, 1995, MOL CELL BIOL, V15, P3796; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WRESCHNER DH, 1988, EUR J BIOCHEM, V172, P333, DOI 10.1111/j.1432-1033.1988.tb13891.x; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	67	137	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8493	8501		10.1074/jbc.271.14.8493	http://dx.doi.org/10.1074/jbc.271.14.8493			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626551	hybrid			2022-12-27	WOS:A1996UD60000091
J	Delwel, GO; Hogervorst, F; Sonnenberg, A				Delwel, GO; Hogervorst, F; Sonnenberg, A			Cleavage of the alpha 6A subunit is essential for activation of the alpha 6A beta 1 integrin by phorbol 12-myristate 13-acetate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; T-CELLS; DEPENDENT ADHESION; CHAIN; VLA; MODULATION; AFFINITY; RECEPTOR; LAMININ; PHOSPHORYLATION	The alpha 6 integrin subunit is proteolytically cleaved during biosynthesis in a covalently associated heavy and light chain, To examine the importance of cleavage for the function of the alpha 6 subunit, we introduced mutations in the cDNA encoding the RKKR (876-879) sequence, the presumed cleavage site, in which either one or two basic residues were replaced by glycine. Wild-type and mutant alpha 6A cDNAs (alpha 6(GKKR), alpha 6(RKKG) and alpha 6(RGGR)) were transfected into K562 cells. The mutant alpha 6A integrin subunits were expressed in association with endogenous beta 1, at levels comparable to that of the wild-type alpha 6A beta 1. A single alpha 6A polypeptide chain (150 kDa) was precipitated from surface-labeled alpha 6(GKKR), alpha 6(RKKG), and alpha 6(RGGR) transfectants, while the separate heavy (120 kDa) and light chains (31 or 30 kDa) were precipitated from the wild-type alpha 6(RKKR) transfectant. Thus, a change in the RKKR sequence prevents cleavage of alpha 6. After activation by the anti-beta 1 stimulatory mAb TS2/16 both cleaved and uncleaved alpha 6A beta 1 integrins bound and spread on laminin-1. Remarkably, the phorbol ester phorbol 12-myristate 13-acetate, which activates wild-type alpha 6A beta 1 to bind to laminin-1, did not activate uncleaved alpha 6A beta 1. We conclude that uncleaved alpha 6A beta 1 is capable of ligand binding and transducing outside/in signals, like wild type alpha 6A beta 1. However, inside/out signaling is affected. It appears that cleavage of alpha 6 is required to generate the proper conformation in alpha 6 that enables affinity modulation of the alpha 6A beta 1 receptor by phorbol 12-myristate 13-acetate.	NETHERLANDS CANC INST,DIV CELL BIOL,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute								AMIOT M, 1986, SCAND J IMMUNOL, V23, P109, DOI 10.1111/j.1365-3083.1986.tb01948.x; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; ARROYO AG, 1993, J BIOL CHEM, V268, P9863; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DELWEL GO, 1993, J BIOL CHEM, V268, P25865; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; DETMERS PA, 1987, J CELL BIOL, V105, P1137, DOI 10.1083/jcb.105.3.1137; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GIMOND C, 1995, EXP CELL RES, V216, P232, DOI 10.1006/excr.1995.1029; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1994, INTEGRINS BIOL PROBL, P2; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOGERVORST F, 1991, EUR J BIOCHEM, V199, P425, DOI 10.1111/j.1432-1033.1991.tb16140.x; HOGERVORST F, 1993, J BIOL CHEM, V268, P18427; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KOLODZIEJ MA, 1991, J BIOL CHEM, V266, P23499; MASUMOTO A, 1993, J BIOL CHEM, V263, P12927; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SONNENBERG A, 1990, J CELL SCI, V96, P207; Sonnenberg A, 1993, Curr Top Microbiol Immunol, V184, P7; SONNENBERG A, 1987, J BIOL CHEM, V262, P10376; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TAMURA RN, 1991, P NATL ACAD SCI USA, V88, P10183, DOI 10.1073/pnas.88.22.10183; TEIXIDO J, 1992, J BIOL CHEM, V267, P1786; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; VANKOOYK Y, 1994, J CELL BIOL, V124, P1061, DOI 10.1083/jcb.124.6.1061; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0	38	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7293	7296		10.1074/jbc.271.13.7293	http://dx.doi.org/10.1074/jbc.271.13.7293			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631745	hybrid			2022-12-27	WOS:A1996UC77400013
J	Guler, S; Seeliger, A; Hartel, H; Renger, G; Benning, C				Guler, S; Seeliger, A; Hartel, H; Renger, G; Benning, C			A null mutant of Synechococcus sp PCC7942 deficient in the sulfolipid sulfoquinovosyl diacylglycerol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOBACTER-SPHAEROIDES; CYANOBACTERIUM; COMPLEMENTATION; POLYPEPTIDE; COMPLEX	The sulfolipid 6-sulfo-alpha-D-quinovosyldiacylglycerol is associated with the thylakoid membranes of many photosynthetic organisms. Previously, genes involved in sulfolipid biosynthesis have been characterized only in the purple bacterium Rhodobacter sphaeroides, Unlike plants and cyanobacteria, photosynthesis in this bacterium is anoxygenic due to the lack of a water splitting photosystem II. To test the function of sulfolipid in an organism with oxygenic photosynthesis, we isolated and inactivated a sulfolipid gene of the cyanobacterium Synechococcus sp, PCC7942. Extensive analysis of the sulfolipid-deficient null mutant revealed subtle changes in photosynthesis related biochemistry of O-2. In addition, a slight increase in the variable room temperature chlorophyll fluorescence yield was observed. Regardless of these changes, it seems unlikely that sulfolipid is an essential constituent of a functional competent water oxidase or the core antenna complex of photosystem II. However, reduced growth of the mutant under phosphate-limiting conditions supports the hypothesis that sulfolipid acts as a surrogate for anionic phospholipids under phosphate-limiting growth conditions.	INST GENBIOL FORSCH BERLIN GMBH, D-14195 BERLIN, GERMANY; TECH UNIV BERLIN, MAX VOLMER INST BIOPHYS & PHYS CHEM, D-10623 BERLIN, GERMANY; HUMBOLDT UNIV BERLIN, INST BIOL PFLANZENPHYSIOL, D-10115 BERLIN, GERMANY	Technical University of Berlin; Humboldt University of Berlin			Benning, Christoph/Y-2528-2019	Benning, Christoph/0000-0001-8585-3667				BARBER J, 1986, PHOTOSYNTH RES, V9, P239, DOI 10.1007/BF00029747; BENNING C, 1992, J BACTERIOL, V174, P6479, DOI 10.1128/JB.174.20.6479-6487.1992; BENNING C, 1993, P NATL ACAD SCI USA, V90, P1561, DOI 10.1073/pnas.90.4.1561; BENNING C, 1992, J BACTERIOL, V174, P2352, DOI 10.1128/JB.174.7.2352-2360.1992; BENNING C, 1995, ARCH BIOCHEM BIOPHYS, V317, P103, DOI 10.1006/abbi.1995.1141; BENSON AA, 1963, ADV LIPID RES, V1, P387; CASTENHOLZ RW, 1988, METHOD ENZYMOL, V167, P68; CEDERGREN RA, 1994, J LIPID RES, V35, P1452; CLARKE AK, 1993, P NATL ACAD SCI USA, V90, P11985, DOI 10.1073/pnas.90.24.11985; COLLIER JL, 1992, J BACTERIOL, V174, P4718, DOI 10.1128/JB.174.14.4718-4726.1992; GLEITER HM, 1995, BIOCHEMISTRY-US, V34, P6847, DOI 10.1021/bi00020a031; GLEITER HM, 1994, BIOCHEMISTRY-US, V33, P12603; GOLBECK JH, 1992, ANNU REV PLANT PHYS, V43, P293, DOI 10.1146/annurev.pp.43.060192.001453; GOLBECK JH, 1993, P NATL ACAD SCI USA, V90, P1642, DOI 10.1073/pnas.90.5.1642; GOUNARIS K, 1985, FEBS LETT, V188, P68, DOI 10.1016/0014-5793(85)80876-0; Harwood J. L., 1980, The biochemistry of plants. A comprehensive treatise. Volume 4. Lipids: structure and function., P301; HERDMAN M, 1979, J GEN MICROBIOL, V111, P63, DOI 10.1099/00221287-111-1-63; IMHOFF JF, 1982, J BACTERIOL, V150, P1192, DOI 10.1128/JB.150.3.1192-1201.1982; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; MESSINGER J, 1993, BIOCHEMISTRY-US, V32, P9379, DOI 10.1021/bi00087a017; NAKATANI HY, 1984, BIOCHIM BIOPHYS ACTA, V765, P347, DOI 10.1016/0005-2728(84)90175-0; OKA A, 1981, J MOL BIOL, V147, P217, DOI 10.1016/0022-2836(81)90438-1; PICK U, 1987, BIOCHIM BIOPHYS ACTA, V891, P28, DOI 10.1016/0005-2728(87)90080-6; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RENGER G, 1993, PHOTOSYNTH RES, V38, P229, DOI 10.1007/BF00046749; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATO N, 1995, EUR J BIOCHEM, V230, P987, DOI 10.1111/j.1432-1033.1995.tb20646.x; SIGRIST M, 1988, PLANT SCI, V58, P15, DOI 10.1016/0168-9452(88)90149-5; VERMAAS W, 1993, ANNU REV PLANT PHYS, V44, P457, DOI 10.1146/annurev.pp.44.060193.002325; VERMAAS WFJ, 1994, FEBS LETT, V337, P103, DOI 10.1016/0014-5793(94)80638-1; VERMAAS WFJ, 1986, P NATL ACAD SCI USA, V83, P9474, DOI 10.1073/pnas.83.24.9474; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WADA H, 1990, NATURE, V347, P200, DOI 10.1038/347200a0; WILDE A, 1995, PLANT CELL, V7, P649, DOI 10.1105/tpc.7.5.649; WOLK CP, 1988, J BACTERIOL, V170, P1239, DOI 10.1128/jb.170.3.1239-1244.1988; ZHANG LL, 1994, J BIOL CHEM, V269, P5036	36	133	142	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7501	7507						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631780				2022-12-27	WOS:A1996UC77400048
J	KochNolte, F; Petersen, D; Balasubramanian, S; Haag, F; Kahlke, D; Willer, T; Kastelein, R; Bazan, F; Thiele, HG				KochNolte, F; Petersen, D; Balasubramanian, S; Haag, F; Kahlke, D; Willer, T; Kastelein, R; Bazan, F; Thiele, HG			Mouse T cell membrane proteins Rt6-1 and Rt6-2 are arginine protein mono(ADPribosyl)transferases and share secondary structure motifs with ADP-ribosylating bacterial toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; DIPHTHERIA-TOXIN; SKELETAL-MUSCLE; CRYSTAL-STRUCTURE; PERTUSSIS TOXIN; LYMPHOCYTES-T; BINDING-SITE; RIBOSYLTRANSFERASE; RAT; NAD	Mono ADP-ribosylation is a posttranslational protein modification that has been implicated in the regulation of key biological functions in bacteria as well as in animals, Recently, the first cDNAs for eucaryotic mono(ADPribosyl)transferases were cloned and found to exhibit significant sequence similarity only to one other known protein, the T cell differentiation antigen Rt6, In this paper we describe secondary structure analyses of Rt6 and related proteins and show conserved structure motifs and amino acid residues consistent with a common ancestry of these eucaryotic proteins and bacterial ADP-ribosyltransferases. Moreover, we have expressed soluble mouse Rt6-1 and Rt6-2 gene products in which C-terminal tags (FLAG-His(6)) replace the native glycosylphosphatidylinositol anchor signal sequences. Purified recombinant Rt6-2, but not Rt6-1, shows NAD(+) glycohydrolase activity, which is inhibited by the arginine analogue agmatine. Immunoprecipitation of recombinant Rt6-1 and Rt6-2 with anti-FLAG M2 antibody followed by incubation with [P-32]NAD(+) leads to rapid and covalent incorporation of radioactivity into the light chain of the M2 antibody, The bound label is resistant to treatment with HgCl2 but sensitive to NH2OH, characteristic of arginine-linked ADP-ribosylation. These results demonstrate that Rt6-1 and Rt6-2 possess the enzymatic activities typical for NAD(+)-dependent arginine/protein mono(ADPribosyl)transferases (EC 2.4.2.31), They are the first such enzymes to be molecularly characterized in the immune system.	UNIV HAMBURG HOSP, DEPT IMMUNOL, MED CLIN, D-20246 HAMBURG, GERMANY; DNAX RES INST MOLEC & CELLULAR BIOL INC, PALO ALTO, CA 94304 USA	University of Hamburg; University Medical Center Hamburg-Eppendorf; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Bazan, J. Fernando/B-4562-2010	Koch-Nolte, Friedrich/0000-0003-1730-6674				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; ANTOINE R, 1993, J BIOL CHEM, V268, P24149; BARBIERI JT, 1989, INFECT IMMUN, V57, P3549, DOI 10.1128/IAI.57.11.3549-3554.1989; BLANKE SR, 1994, BIOCHEMISTRY-US, V33, P5155, DOI 10.1021/bi00183a019; BURNETTE WN, 1988, SCIENCE, V242, P72, DOI 10.1126/science.2459776; BUTCHER GW, 1977, RAT NEWS LETT, V1, P12; CARROLL SF, 1984, P NATL ACAD SCI-BIOL, V81, P3307, DOI 10.1073/pnas.81.11.3307; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; DOMENIGHINI M, 1994, MOL MICROBIOL, V14, P41, DOI 10.1111/j.1365-2958.1994.tb01265.x; DONG C, 1994, INT IMMUNOL, V6, P1353, DOI 10.1093/intimm/6.9.1353; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; FANGMANN J, 1991, EUR J IMMUNOL, V21, P753, DOI 10.1002/eji.1830210331; Fishman P.H., 1990, ADP RIBOSYLATING TOX, P127; GODEAU F, 1984, ANAL BIOCHEM, V137, P287, DOI 10.1016/0003-2697(84)90087-3; GREINER DL, 1987, J EXP MED, V166, P461, DOI 10.1084/jem.166.2.461; GRIMALDI JC, 1995, J IMMUNOL, V155, P811; HAAG F, 1995, EUR J IMMUNOL, V25, P2355, DOI 10.1002/eji.1830250835; HAAG F, 1990, NUCLEIC ACIDS RES, V18, P1047, DOI 10.1093/nar/18.4.1047; HOPP TP, 1988, BIOTECHNOLOGY, V6, P205; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JACOBSON MK, 1989, ADP RIBOSE TRANSFER; KAISHO T, 1994, P NATL ACAD SCI USA, V91, P5325, DOI 10.1073/pnas.91.12.5325; KASHAN A, 1989, IMMUNOL LETT, V23, P133, DOI 10.1016/0165-2478(89)90125-9; KLEBL BM, 1994, FEBS LETT, V342, P66, DOI 10.1016/0014-5793(94)80586-5; KOCH F, 1990, P NATL ACAD SCI USA, V87, P964, DOI 10.1073/pnas.87.3.964; KOCH F, 1986, J EXP MED, V164, P1338, DOI 10.1084/jem.164.4.1338; KOCHNOLTE F, 1995, INT IMMUNOL, V7, P883, DOI 10.1093/intimm/7.5.883; KOCHNOLTE F, IN PRESS MOL IMMUNOL; MAEHAMA T, 1991, J BIOL CHEM, V266, P10062; MAEHAMA T, 1995, J BIOL CHEM, V270, P22747, DOI 10.1074/jbc.270.39.22747; MCMAHON KK, 1993, BIOCHEM J, V293, P789, DOI 10.1042/bj2930789; MEYER T, 1988, BIOL CHEM H-S, V369, P579, DOI 10.1515/bchm3.1988.369.2.579; PAPINI E, 1989, J BIOL CHEM, V264, P12385; PAYNE DM, 1985, BIOCHEMISTRY-US, V24, P7540, DOI 10.1021/bi00347a006; PETERSON JE, 1990, J BIOL CHEM, V265, P17062; QUIST EE, 1994, J MOL CELL CARDIOL, V26, P251, DOI 10.1006/jmcc.1994.1028; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; SANDER C, 1994, NUCLEIC ACIDS RES, V22, P3597; SCHUMAN EM, 1994, P NATL ACAD SCI USA, V91, P11958, DOI 10.1073/pnas.91.25.11958; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SOMAN G, 1991, BIOCHEM BIOPH RES CO, V176, P301, DOI 10.1016/0006-291X(91)90924-V; STEIN PE, 1994, STRUCTURE, V2, P45, DOI 10.1016/S0969-2126(00)00007-1; TAKADA T, 1994, J BIOL CHEM, V269, P9420; TAKADA T, 1995, J BIOL CHEM, V270, P541, DOI 10.1074/jbc.270.2.541; THIELE HG, 1987, TRANSPLANT P, V19, P3157; TSUCHIYA M, 1994, J BIOL CHEM, V269, P27451; TWETEN RK, 1985, J BIOL CHEM, V260, P392; WANG J, 1994, J IMMUNOL, V153, P4048; WEISS MS, 1995, BIOCHEMISTRY-US, V34, P773, DOI 10.1021/bi00003a010; WONIGEIT K, 1987, TRANSPLANT P, V19, P296; YANG XD, 1994, P NATL ACAD SCI USA, V91, P12604, DOI 10.1073/pnas.91.26.12604; YOST DA, 1983, J BIOL CHEM, V258, P4926; ZOLKIEWSKA A, 1993, J BIOL CHEM, V268, P25273; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	54	99	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7686	7693		10.1074/jbc.271.13.7686	http://dx.doi.org/10.1074/jbc.271.13.7686			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631807	hybrid			2022-12-27	WOS:A1996UC77400075
J	Montserat, J; Chen, L; Lawrence, DS; Zhang, ZY				Montserat, J; Chen, L; Lawrence, DS; Zhang, ZY			Potent low molecular weight substrates for protein-tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART; PHOSPHORYLATION; PHOSPHOPROTEIN; INHIBITOR; DARPP-32	The ability of protein-tyrosine phosphatases (PTPases) to catalyze the hydrolysis of simple aromatic phosphates has been recognized for some time. However, these compounds are significantly poorer substrates than their peptide-based counterparts containing phosphotyrosine. Consequently, the effort to create potent PTPase substrates has predominately focused on the use of peptidic carriers to deliver the phosphotyrosine moiety to the enzyme active site. We now report the synthesis and evaluation of several low molecular weight aromatic phosphates that serve as robust substrates for the rat PTPase, PTP1. We initially surveyed the ability of PTP1 to catalyze the hydrolysis of a variety of phenyl phosphate structural variants. Sterically demanding substituents positioned ortho and (to a lesser extent) meta to the phosphate group severely compromise the ability of these species to serve as phosphatase substrates. However, both benzylic and negatively charged substituents para to the hydrolyzable phosphate dramatically promote hydrolytic efficiency, which appears to be augmented through a dramatic enhancement in the affinity of the substrate for PTP1. The best substrate examined in this study exhibits a K-m of 16 +/- 3 mu M. In addition, it serves as an inhibitor of the PTP1-catalyzed hydrolysis of p-nitrophenyl phosphate with a K-i of 4.9 +/- 0.7 mu M. The extraordinary structural simplicity of this compound, as well as those of several others described herein, provides a promising starting point for the design of potent PTPase inhibitors.	ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461; SUNY BUFFALO,DEPT CHEM,BUFFALO,NY 14260	Yeshiva University; Albert Einstein College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								BLACK MJ, 1983, ANAL BIOCHEM, V135, P233, DOI 10.1016/0003-2697(83)90756-X; BORN TL, 1995, J BIOL CHEM, V270, P25651, DOI 10.1074/jbc.270.43.25651; BURKE TR, 1994, BIOCHEM BIOPH RES CO, V204, P129, DOI 10.1006/bbrc.1994.2435; CHATTERJEE S, 1992, PEPTIDES CHEM BIOL, P553; CHEN L, 1995, BIOCHEM BIOPH RES CO, V216, P976, DOI 10.1006/bbrc.1995.2716; DESMARAIS S, 1995, FASEB J, V9, pA1347; Dunn D, 1996, J BIOL CHEM, V271, P168, DOI 10.1074/jbc.271.1.168; FASTREZ J, 1973, BIOCHEMISTRY-US, V12, P1067, DOI 10.1021/bi00730a008; FERSHT A, 1985, ENZYME STRUCTURE MEC, P109; HEMMINGS HC, 1990, J BIOL CHEM, V265, P20369; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HENGGE AC, 1995, BIOCHEMISTRY-US, V34, P13982, DOI 10.1021/bi00043a003; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KWON YG, 1995, 9 INT C 2 MESS PHOSP; MARTIN B, 1985, J BIOL CHEM, V260, P4932; PERRY JW, 1988, SYNTHESIS-STUTTGART, P142; ZHANG ZY, 1990, ARCH BIOCHEM BIOPHYS, V282, P39, DOI 10.1016/0003-9861(90)90084-C; ZHANG ZY, 1991, BIOCHEMISTRY-US, V30, P8954, DOI 10.1021/bi00101a006; ZHANG ZY, 1995, J BIOL CHEM, V270, P16052; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16088, DOI 10.1021/bi00049a024; ZHANG ZY, 1994, ADV ENZYMOL RAMB, V68, P1; ZHANG ZY, 1995, J BIOL CHEM, V270, P11199, DOI 10.1074/jbc.270.19.11199; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516	24	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7868	7872		10.1074/jbc.271.13.7868	http://dx.doi.org/10.1074/jbc.271.13.7868			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631832	hybrid			2022-12-27	WOS:A1996UC77400100
J	Olsen, DB; Benseler, F; Cole, JL; Stahlhut, MW; Dempski, RE; Darke, PL; Kuo, LC				Olsen, DB; Benseler, F; Cole, JL; Stahlhut, MW; Dempski, RE; Darke, PL; Kuo, LC			Elucidation of basic mechanistic and kinetic properties of influenza endonuclease using chemically synthesized RNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL COMPLEMENTARY RNA; TRANSCRIPTION INVITRO; HAMMERHEAD RIBOZYME; MESSENGER-RNA; P-PROTEINS; CAP; PRIMERS; VIRUS	Influenza virus utilizes a unique mechanism for initiating the transcription of viral mRNA. The viral transcriptase ribonucleoprotein complex hydrolyzes host cell transcripts containing the cap 1 structure (m(7)GpppG(2'-OMe)-) to generate a capped primer for viral mRNA transcription. Basic aspects of this viral endonuclease reaction are elucidated in this study through the use of synthetic, radiolabeled RNA substrates and substrate analogs containing the cap 1 structure. Unlike most ribonucleases, this viral endonuclease is shown to catalyze the hydrolysis of the scissile phosphodiester, resulting in 5'-phosphate- and 3'-hydroxyl-containing fragments. Nevertheless, the 2'-OH adjacent to the released ribosyl 3'-OH is shown to be important for catalysis. In addition, while the endonuclease steady-state turnover rate is measured to be 2 h(-1), phosphodiester bond hydrolysis is not rate-limiting. The direct generation of a free 3'-OH and the subsequent slow release of this product are consistent with the viral need for efficient use of the capped primer in subsequent reactions of the influenza transcriptase complex.	NAPS GMBH, INST BIOANALYT, D-37079 GOTTINGEN, GERMANY		Olsen, DB (corresponding author), MERCK SHARP & DOHME RES LABS, DEPT BIOL CHEM, W POINT, PA 19486 USA.		Cole, James/G-2586-2011	olsen, david/0000-0001-5521-0206				BEIJER B, 1990, NUCLEIC ACIDS RES, V18, P5143, DOI 10.1093/nar/18.17.5143; BLAAS D, 1982, VIROLOGY, V116, P339, DOI 10.1016/0042-6822(82)90425-1; BOULOY M, 1979, J VIROL, V32, P895, DOI 10.1128/JVI.32.3.895-904.1979; BOULOY M, 1978, P NATL ACAD SCI USA, V75, P4886, DOI 10.1073/pnas.75.10.4886; BRAAM J, 1983, CELL, V34, P609; BROWNLEE GG, 1995, NUCLEIC ACIDS RES, V23, P2641, DOI 10.1093/nar/23.14.2641; CHUNG TDY, 1994, P NATL ACAD SCI USA, V91, P2372, DOI 10.1073/pnas.91.6.2372; CIANCI C, 1995, J VIROL, V69, P3995, DOI 10.1128/JVI.69.7.3995-3999.1995; COLE JL, 1995, ANAL BIOCHEM, V231, P309, DOI 10.1006/abio.1995.9994; FURUICHI Y, 1989, METHOD ENZYMOL, V180, P164; HEIDENREICH O, 1994, J BIOL CHEM, V269, P2131; LUDWIG J, 1989, J ORG CHEM, V54, P631, DOI 10.1021/jo00264a024; OLSEN DB, 1991, BIOCHEMISTRY-US, V30, P9735, DOI 10.1021/bi00104a024; PLOTCH SJ, 1981, CELL, V23, P847, DOI 10.1016/0092-8674(81)90449-9; PLOTCH SJ, 1979, P NATL ACAD SCI USA, V76, P1618, DOI 10.1073/pnas.76.4.1618; Sambrook KJ, 1989, MOL CLONING LAB MANU; SEGEL IH, 1975, ENZYME KINETICS BEHA, P471; SHATKIN A, 1976, PAABS REV, V5, P425; SHI LC, 1995, VIROLOGY, V208, P38, DOI 10.1006/viro.1995.1127; THOMPSON JE, 1994, BIOCHEMISTRY-US, V33, P7408, DOI 10.1021/bi00189a047; TUSCHL T, 1993, BIOCHEMISTRY-US, V32, P11658, DOI 10.1021/bi00094a023; UCHIYAMA Y, 1994, J MOL BIOL, V243, P782, DOI 10.1016/0022-2836(94)90047-7; ULMANEN I, 1981, P NATL ACAD SCI-BIOL, V78, P7355, DOI 10.1073/pnas.78.12.7355; ULMANEN I, 1983, J VIROL, V45, P27, DOI 10.1128/JVI.45.1.27-35.1983; ZHIRNOV OP, 1992, VIROLOGY, V186, P324, DOI 10.1016/0042-6822(92)90090-C	25	16	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7435	7439		10.1074/jbc.271.13.7435	http://dx.doi.org/10.1074/jbc.271.13.7435			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631770	hybrid			2022-12-27	WOS:A1996UC77400038
J	Turner, JR; Lencer, WI; Carlson, S; Madara, JL				Turner, JR; Lencer, WI; Carlson, S; Madara, JL			Carboxyl-terminal vesicular stomatitis virus G protein-tagged intestinal Na+-dependent glucose cotransporter (SGLT1) - Maintenance of surface expression and global transport function with selective perturbation of transport kinetics and polarized expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE PROTEINS; CELL-LINE CACO-2; IN-VITRO MODEL; BRUSH-BORDER; CYTOPLASMIC DOMAIN; NA+/GLUCOSE COTRANSPORTER; ESCHERICHIA-COLI; LOCALIZATION; CYTOSKELETON; SUBSTRATE	The Na+-dependent glucose transporter (SGLT1) mediates absorption of luminal glucose by the intestine. However, available intestinal cell Lines that recapitulate a monolayer phenotype only express SGLT1 at low levels. Thus, to facilitate studies of the biology of SGLT1 function in epithelial monolayers, we engineered an epitope-tagged construct containing the YTDIEMNRLGK sequence (from the vesicular stomatitis virus G protein). The tag was placed at the carboxyl terminus since this is the least conserved portion of SGLT1. Transiently transfected COS-1 cells demonstrated surface expression of the immunoreactive protein and enhanced Na+-dependent glucose uptake that was phloridzin-sensitive (a specific competitive inhibitor of SGLT1). However, subsequent detailed analyses of epitope-tagged SGLT1 using stably transfected clones derived from the Caco-2 human intestinal epithelial cell line revealed substantial effects of the epitope on critical functions of SGLT1. When compared with native SGLT1 transfectants, the apparent K-m for sugar transport was increased 23-fold (313 mu M to 7.37 mM for native versus epitope-tagged SGLT1). In contrast, the apparent K-Na for epitope-tagged SGLT1 was similar to that for native SGLT1. Permeabilization studies indicated that the C-terminal epitope tag was intracellular and thus could not directly disrupt extracellular ligand-binding sites. Immunolocalization and functional assays designed to detect polarized surface expression indicated that epitope tagging resulted in loss of apical targeting and enrichment of basolateral expression. Functional isolation of the small apical pool of epitope-tagged SGLT1 (by selective inhibition of basolateral epitope-tagged SGLT1) revealed that, despite the documented kinetic alterations in sugar transport, epitope-tagged SGLT1 could promote absorptive Na+ currents. These data show that 1) the C terminus of SGLT1 is intracellular; 2) disruption of protein structure by addition of a C-terminal tag leads to selective modifications of SGLT1 function; 3) the kinetics of sugar transport can be altered independently of influences on the Na+-binding site of SGLT1; and 4) the weak basolateral targeting sequence present within the epitope tag is dominant over endogenous SGLT1 apical targeting information and can direct polytopic membrane protein localization. The data also caution that subtle effects of foreign sequences must be considered when epitope tagging polytopic membrane proteins.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; CHILDRENS HOSP,COMBINED PROGRAM PEDIAT GASTROENTEROL & NUTR,BOSTON,MA 02115; HARVARD UNIV,CTR DIGEST DIS,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University	Turner, JR (corresponding author), BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV GASTROINTESTINAL PATHOL,75 FRANCIS ST,BOSTON,MA 02115, USA.		Turner, Jerrold R/A-6895-2009	Turner, Jerrold R/0000-0003-0627-9455; Lencer, Wayne/0000-0001-7346-2730	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035932] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL0 7627] Funding Source: Medline; NIDDK NIH HHS [R01 DK35932, R01 DK41086] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROTLAROCHE E, 1987, BIOCHIM BIOPHYS ACTA, V904, P71, DOI 10.1016/0005-2736(87)90088-5; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; GELI V, 1988, P NATL ACAD SCI USA, V85, P689, DOI 10.1073/pnas.85.3.689; HANADA K, 1992, BIOCHIM BIOPHYS ACTA, V1105, P61, DOI 10.1016/0005-2736(92)90162-F; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1994, PHYSIOL REV, V74, P993, DOI 10.1152/physrev.1994.74.4.993; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; IKEDA TS, 1989, J MEMBRANE BIOL, V110, P87, DOI 10.1007/BF01870995; KIMMICH GA, 1981, AM J PHYSIOL, V241, pC227, DOI 10.1152/ajpcell.1981.241.5.C227; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LEE WS, 1994, J BIOL CHEM, V269, P12032; MACDONALD RS, 1993, J RECEPTOR RES, V13, P1093, DOI 10.3109/10799899309063266; MADARA JL, 1989, J CLIN INVEST, V83, P724, DOI 10.1172/JCI113938; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MEICHSNER M, 1993, NEUROSCIENCE, V54, P873, DOI 10.1016/0306-4522(93)90581-Y; MONLAUZEUR L, 1995, J BIOL CHEM, V270, P12219, DOI 10.1074/jbc.270.20.12219; OHSAWA M, 1988, J BACTERIOL, V170, P5185, DOI 10.1128/jb.170.11.5185-5191.1988; PETERSON MD, 1993, J CELL SCI, V105, P461; PETERSON MD, 1992, J CELL SCI, V102, P581; PETERSON MD, 1993, J CELL SCI, V105, P445; PINTO M, 1983, BIOL CELL, V47, P323; RILEY SA, 1991, BIOCHIM BIOPHYS ACTA, V1066, P175, DOI 10.1016/0005-2736(91)90184-A; TAKATA K, 1992, CELL TISSUE RES, V267, P3, DOI 10.1007/BF00318685; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; TOGGENBURGER G, 1982, BIOCHIM BIOPHYS ACTA, V688, P557, DOI 10.1016/0005-2736(82)90367-4; TURK E, 1994, J BIOL CHEM, V269, P15204; TURK E, 1991, NATURE, V350, P354, DOI 10.1038/350354a0; WADZINSKI BE, 1992, J BIOL CHEM, V267, P16883; WEISZ OA, 1992, J BIOL CHEM, V267, P22282; WRIGHT EM, 1993, ANNU REV PHYSIOL, V55, P575, DOI 10.1146/annurev.ph.55.030193.003043; WRIGHT EM, 1994, J EXP BIOL, V196, P197; YAMATO I, 1990, J BIOL CHEM, V262, P2450	36	52	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7738	7744		10.1074/jbc.271.13.7738	http://dx.doi.org/10.1074/jbc.271.13.7738			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631815	hybrid, Green Published			2022-12-27	WOS:A1996UC77400083
J	Mallow, EB; Harris, A; Salzman, N; Russell, JP; Deberardinis, RJ; Ruchelli, E; Bevins, CL				Mallow, EB; Harris, A; Salzman, N; Russell, JP; Deberardinis, RJ; Ruchelli, E; Bevins, CL			Human enteric defensins - Gene structure and developmental expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDE GENE; CYSTIC-FIBROSIS GENE; PANETH CELLS; SMALL-INTESTINE; ANTIBACTERIAL PEPTIDES; NECROTIZING ENTEROCOLITIS; ANTIBIOTIC PEPTIDES; EPITHELIAL-CELLS; XENOPUS-LAEVIS; MESSENGER-RNA	Paneth cells, secretory epithelial cells of the small intestinal crypts, are proposed to contribute to local host defense, Both mouse and human Paneth cells express a collection of antimicrobial proteins, including members of a family of antimicrobial peptides named defensins, In this study, data from an anchored polymerase chain reaction (PCR) strategy suggest that only two defensin mRNA isoforms are expressed in the human small intestine, far fewer than the number expressed in the mouse, The two isoforms detected by this PCR approach were human defensin family members, HD-5 and HD-6, The gene encoding HD-6 was cloned and characterized, HD-6 has a genomic organization similar to HD-5, and the two genes have a striking pattern of sequence similarity localized chiefly in their proximal 5'-flanking regions, Analysis of human fetal RNA by reverse transcriptase-PCR detected enteric defensin HD-5 mRNA at 13.5 weeks of gestation in the small intestine and the colon, but by 17 weeks HD-5 was restricted to the small intestine, HD-6 mRNA was detectable at 13.5-17 weeks of gestation in the small intestine but not in the colon, This pattern of expression coincides with the previously described appearance of Paneth cells as determined by ultrastructural approaches, Northern analysis of total RNA from small intestine revealed quantifiable enteric defensin mRNA in five samples from 19-24 weeks of gestation at levels approximately 40-250-fold less than those observed in the adult, with HD-5 mRNA levels greater than those of HD-6 in all samples, In situ hybridization analysis localized expression of enteric defensin mRNA to Paneth cells at 24 weeks of gestation, as is seen in the newborn term infant and the adult, Consistent with earlier morphological studies, the ratio of Paneth cell number per crypt was reduced in samples at 24 weeks of gestation compared with the adult, and this lower cell number partially accounts for the lower defensin mRNA levels as determined by Northern analysis, Low levels of enteric defensin expression in the fetus may be characteristic of an immaturity of local defense, which is thought to predispose infants born prematurely to infection from intestinal microorganisms.	CHILDRENS HOSP, DEPT PEDIAT, DIV HUMAN GENET & MOLEC BIOL, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP, DIV NEONATOL, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP, DIV PATHOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PEDIAT, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT GENET, PHILADELPHIA, PA 19104 USA; UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, OXFORD OX3 9DU, ENGLAND	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Oxford			Bevins, Charles L/P-4438-2015	Bevins, Charles L/0000-0003-2725-2622; Salzman, Nita/0000-0003-0939-6139	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI032234, R37AI032738, R01AI032738, R01AI032234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046589] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32234, AI32738] Funding Source: Medline; NIDDK NIH HHS [DK46589] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGERBERTH B, 1991, EUR J BIOCHEM, V202, P849, DOI 10.1111/j.1432-1033.1991.tb16442.x; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALEY SB, 1994, INFECT IMMUN, V62, P5397, DOI 10.1128/IAI.62.12.5397-5403.1994; BJERKNES M, 1981, AM J ANAT, V160, P51, DOI 10.1002/aja.1001600105; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; Borson N D, 1992, PCR Methods Appl, V2, P144; BRY L, 1994, P NATL ACAD SCI USA, V91, P10335, DOI 10.1073/pnas.91.22.10335; CHAMBERS JA, 1993, J CELL SCI, V105, P417; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIAMOND G, 1993, P NATL ACAD SCI USA, V90, P4596, DOI 10.1073/pnas.90.10.4596; DIAMOND G, 1994, CHEST, V105, pS51, DOI 10.1378/chest.105.3_Supplement.51S; EISENHAUER PB, 1992, INFECT IMMUN, V60, P3556, DOI 10.1128/IAI.60.9.3556-3565.1992; ELMES ME, 1976, J PATHOL, V118, P183, DOI 10.1002/path.1711180308; ERLANDSEN SL, 1974, J HISTOCHEM CYTOCHEM, V22, P401, DOI 10.1177/22.6.401; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GANZ T, 1989, J IMMUNOL, V143, P1358; GANZ T, 1990, EUR J HAEMATOL, V44, P1; GILMAN M, 1987, CURRENT PROTOCOLS MO; HARRIS A, 1991, DEVELOPMENT, V113, P305; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; Henning Susan J., 1994, P571; Hertzog AJ, 1937, AM J PATHOL, V13, P351; HUTTNER KM, 1994, GENOMICS, V19, P448, DOI 10.1006/geno.1994.1093; JOINER KA, 1989, J CELL BIOL, V109, P2771, DOI 10.1083/jcb.109.6.2771; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; JONES DE, 1993, THESIS U PENNSYLVANI; KINNEY JS, 1994, CLIN PERINATOL, V21, P317, DOI 10.1016/S0095-5108(18)30348-8; KIYOHARA H, 1992, J HISTOCHEM CYTOCHEM, V40, P1659, DOI 10.1177/40.11.1431054; KLIEGMAN RM, 1993, PEDIATR RES, V34, P701, DOI 10.1203/00006450-199312000-00001; KLIEGMAN RM, 1984, NEW ENGL J MED, V310, P1093, DOI 10.1056/NEJM198404263101707; KLOCKARS M, 1975, J HISTOCHEM CYTOCHEM, V23, P932, DOI 10.1177/23.12.1104708; LEE JY, 1989, P NATL ACAD SCI USA, V86, P9159, DOI 10.1073/pnas.86.23.9159; LEHRER RI, 1992, CIBA F SYMP, V171, P276; LEWIN K, 1969, Annals of the Royal College of Surgeons of England, V44, P23; LINZMEIER R, 1993, FEBS LETT, V321, P267, DOI 10.1016/0014-5793(93)80122-B; LUBBERT M, 1991, BLOOD, V77, P909; MATHAN M, 1987, HISTOCHEMISTRY, V87, P91, DOI 10.1007/BF00518730; MIZRAHI A, 1965, J PEDIATR-US, V66, P697, DOI 10.1016/S0022-3476(65)80003-8; MOORE KS, 1991, J BIOL CHEM, V266, P19851; MOXEY PC, 1978, ANAT RECORD, V191, P269, DOI 10.1002/ar.1091910302; NAGAOKA I, 1992, FEBS LETT, V303, P31, DOI 10.1016/0014-5793(92)80471-R; OUELLETTE AJ, 1992, FEBS LETT, V304, P146, DOI 10.1016/0014-5793(92)80606-H; OUELLETTE AJ, 1994, INFECT IMMUN, V62, P5040, DOI 10.1128/IAI.62.11.5040-5047.1994; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; OUELLETTE AJ, 1990, J BIOL CHEM, V265, P9831; PEETERS T, 1975, GUT, V16, P553, DOI 10.1136/gut.16.7.553; PONDER BAJ, 1985, NATURE, V313, P689, DOI 10.1038/313689a0; REILLY DS, 1994, J HISTOCHEM CYTOCHEM, V42, P697, DOI 10.1177/42.6.8189032; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; SENEGASBALAS F, 1984, HISTOCHEMISTRY, V81, P581, DOI 10.1007/BF00489538; TRIER JS, 1963, J CELL BIOL, V18, P599, DOI 10.1083/jcb.18.3.599; WINNING RS, 1991, NUCLEIC ACIDS RES, V19, P3709, DOI 10.1093/nar/19.13.3709; ZASLOFF M, 1992, CURR OPIN IMMUNOL, V4, P3, DOI 10.1016/0952-7915(92)90115-U	56	238	248	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4038	4045						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626737				2022-12-27	WOS:A1996TW96000015
J	Chen, JCR; Zhang, JP; Stephens, RS				Chen, JCR; Zhang, JP; Stephens, RS			Structural requirements of heparin binding to Chlamydia trachomatis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; SULFATE PROTEOGLYCANS; HUMAN CYTOMEGALOVIRUS; HOST-CELLS; SURFACE; INFECTION; ADHESION; SEQUENCE	Heparin is a functional and structural analog of the Chlamydia trachomatis heparan sulfate-like attachment ligand that mediates infectivity by bridging chlamydiae to eukaryotic cells. The binding of heparin to the Chlamydia organism's surface was characterized by a direct binding assay, Although for two C. trachomatis biovars the binding by heparin was saturable, trachoma biovar organisms bound twice the amount of heparin than lymphogranuloma venereum biovar organisms. To probe the structural nature of the heparan sulfate-like ligand interactions, a range of heparin-derived oligosaccharides and sulfation-modified species of heparin were compared for their ability to compete with [H-3]heparin for binding to chlamydial organisms and for inhibition of chlamydial attachment and infection of eukaryotic host cells. The assays revealed that a decasaccharide was the minimal chain length required to effectively bind C. trachomatis organisms, compete with the host cell receptor and rescue infectivity. In addition, a moderately sulfated adhesin analog, N-desulfated, N-acetylated heparin, was able to compete with chlamydial organisms for host cell receptors, whereas this derivative could not compete with [H-3]heparin for binding to chlamydial organisms. These results indicate that the specificity of the eukaryotic cell receptor and the chlamydial surface acceptor differ in their fine-structure requirements of ligand binding, and that the size and sulfation density of the heparan sulfate-like Ligand each contribute to its ability to bind and bridge chlamydiae to eukaryotic cells.	UNIV CALIF BERKELEY, PROGRAM INFECT DIS, BERKELEY, CA 94720 USA; UNIV SAN FRANCISCO, DEPT LAB MED, SAN FRANCISCO, CA 94143 USA; UNIV SAN FRANCISCO, FRANCIS I PROCTOR FDN, SAN FRANCISCO, CA 94143 USA	University of California System; University of California Berkeley; University of San Francisco; University of San Francisco					NATIONAL EYE INSTITUTE [R01EY007757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032943] Funding Source: NIH RePORTER; NEI NIH HHS [EY07757] Funding Source: Medline; NIAID NIH HHS [AI32943] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAE JH, 1994, BIOCHEM J, V301, P121, DOI 10.1042/bj3010121; CARDIN AD, 1991, METHOD ENZYMOL, V203, P556; CHEN JCR, 1994, MOL MICROBIOL, V11, P501, DOI 10.1111/j.1365-2958.1994.tb00331.x; COMPTON T, 1993, VIROLOGY, V193, P834, DOI 10.1006/viro.1993.1192; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOEHLER JE, 1990, J BIOL CHEM, V265, P13206; KOLIAKOS GG, 1989, J BIOL CHEM, V264, P2313; KUO CC, 1976, INFECT IMMUN, V13, P1103, DOI 10.1128/IAI.13.4.1103-1109.1976; LINDAHL U, 1991, THROMB HAEMOSTASIS, V66, P44; LOVE DC, 1993, J CELL BIOL, V123, P759, DOI 10.1083/jcb.123.3.759; LYCKE E, 1991, J GEN VIROL, V72, P1131, DOI 10.1099/0022-1317-72-5-1131; MENOZZI FD, 1991, FEMS MICROBIOL LETT, V78, P59; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; MUKHOPADHYAY NK, 1989, BIOCHEM J, V264, P517, DOI 10.1042/bj2640517; NEYTS J, 1992, VIROLOGY, V189, P48, DOI 10.1016/0042-6822(92)90680-N; ORTEGABARRIA E, 1991, CELL, V67, P411, DOI 10.1016/0092-8674(91)90192-2; OSCARSSON LG, 1989, J BIOL CHEM, V264, P296; PATEL M, 1993, AIDS RES HUM RETROV, V9, P167, DOI 10.1089/aid.1993.9.167; SCHACHTER J, 1990, WESTERN J MED, V153, P523; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; SODERLUND G, 1982, INFECT IMMUN, V36, P893; VARELAS JB, 1991, ANAL BIOCHEM, V197, P396, DOI 10.1016/0003-2697(91)90410-U; ZHANG JP, 1992, CELL, V69, P861, DOI 10.1016/0092-8674(92)90296-O; ZHU ZL, 1995, P NATL ACAD SCI USA, V92, P3546, DOI 10.1073/pnas.92.8.3546	28	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11134	11140		10.1074/jbc.271.19.11134	http://dx.doi.org/10.1074/jbc.271.19.11134			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626658	hybrid			2022-12-27	WOS:A1996UJ94400018
J	Dietrich, J; Hou, XH; Wegener, AMK; Pedersen, LO; Odum, N; Geisler, C				Dietrich, J; Hou, XH; Wegener, AMK; Pedersen, LO; Odum, N; Geisler, C			Molecular characterization of the di-leucine-based internalization motif of the T cell receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN LYMPHOCYTES-T; FACTOR-II RECEPTOR; ANTIGEN RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; SUBSTRATE-SPECIFICITY; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; CYTOPLASMIC TAIL; SYNTHETIC PEPTIDES	Several cell surface receptors including the T cell receptor (TCR) are phosphorylated and down-regulated following activation of protein kinases. We have recently shown that both phosphorylation of Ser-126 and the presence of the di-leucine sequence Leu-131 and Leu-132 in CD3 gamma are required for protein kinase C (PKC)-mediated TCR down-regulation. To identify additional residues required for PKC-mediated phosphorylation of CD3 gamma and for TCR down-regulation, an alanine scanning of CD3 gamma was done. Mutations of Arg-124, Ser-126, Lys-128, and Gln-129 inhibited both phosphorylation and TCR down-regulation, whereas mutation of Asp-127 only inhibited down-regulation. Further analyses demonstrated a discrepancy between the ability to be phosphorylated on CD3 gamma and to down-regulate the TCR in several transfectants. Phosphorylation was not as strictly dependent on the nature and position of the phosphoacceptor group and basic residues as were the subsequent steps involved in TCR down-regulation. Our results suggest that PKC-mediated TCR down-regulation may be regarded as a two-step process. 1) Recognition and phosphorylation of CD3 gamma by PKC. In this process Arg-124, Ser-126, Lys-128, and Gln-129 are important. 2) Recognition of phosphorylated CD3 gamma by molecules involved in receptor internalization. In this process Ser(P)-126, Asp-127, Leu-131, and Leu-132 are important.	UNIV COPENHAGEN, PANUM INST, INST MED MICROBIOL & IMMUNOL, DK-2200 COPENHAGEN, DENMARK	University of Copenhagen			Geisler, Carsten/A-7056-2012	Geisler, Carsten/0000-0002-8472-0771				ABRAHAM RT, 1992, TRENDS BIOCHEM SCI, V17, P434, DOI 10.1016/0968-0004(92)90015-2; AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; ALEXANDER DR, 1992, BIOCHEM J, V288, P69, DOI 10.1042/bj2880069; ANDO I, 1985, EUR J IMMUNOL, V15, P196, DOI 10.1002/eji.1830150217; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BOYER C, 1991, EUR J IMMUNOL, V21, P1623, DOI 10.1002/eji.1830210707; BREMNES B, 1994, J CELL SCI, V107, P2021; CANTRELL D, 1987, NATURE, V325, P540, DOI 10.1038/325540a0; CANTRELL DA, 1989, J IMMUNOL, V142, P1626; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DAVIES AA, 1987, J BIOL CHEM, V262, P10918; DEMBIC Z, 1986, NATURE, V320, P232, DOI 10.1038/320232a0; Dietrich J, 1996, J CELL BIOL, V132, P299, DOI 10.1083/jcb.132.3.299; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; FERRARI S, 1985, FEBS LETT, V184, P72, DOI 10.1016/0014-5793(85)80656-6; FINKENZELLER G, 1990, NUCLEIC ACIDS RES, V18, P2183, DOI 10.1093/nar/18.8.2183; GEISLER C, 1992, J IMMUNOL, V148, P2437; GEISLER C, 1988, SCAND J IMMUNOL, V27, P685, DOI 10.1111/j.1365-3083.1988.tb02402.x; GEISLER C, 1992, J IMMUNOL, V148, P3469; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; HOU XH, 1994, EUR J IMMUNOL, V24, P1228, DOI 10.1002/eji.1830240534; HOUSE C, 1987, J BIOL CHEM, V262, P772; HSIEH JC, 1993, J BIOL CHEM, V268, P15118; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KONING F, 1990, EUR J IMMUNOL, V20, P299, DOI 10.1002/eji.1830200211; KRANGEL MS, 1987, J EXP MED, V165, P1141, DOI 10.1084/jem.165.4.1141; KRISSANSEN GW, 1986, EMBO J, V5, P1799, DOI 10.1002/j.1460-2075.1986.tb04429.x; KUBO K, 1987, FEBS LETT, V223, P138, DOI 10.1016/0014-5793(87)80524-0; KUHLMANN J, 1993, SCAND J IMMUNOL, V37, P271, DOI 10.1111/j.1365-3083.1993.tb01766.x; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MALISSEN B, 1993, CURR OPIN IMMUNOL, V5, P324, DOI 10.1016/0952-7915(93)90049-X; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; MARAIS RM, 1990, FEBS LETT, V277, P151, DOI 10.1016/0014-5793(90)80831-3; MINAMI Y, 1987, J BIOL CHEM, V262, P13342; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OBRIAN CA, 1984, BIOCHEM BIOPH RES CO, V124, P296, DOI 10.1016/0006-291X(84)90951-3; ORR JW, 1994, J BIOL CHEM, V269, P8383; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PIETERS J, 1993, J CELL SCI, V106, P831; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; REINHERZ EL, 1982, CELL, V30, P735, DOI 10.1016/0092-8674(82)90278-1; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SHIN JY, 1991, J BIOL CHEM, V266, P10658; TELERMAN A, 1987, EUR J IMMUNOL, V17, P991, DOI 10.1002/eji.1830170715; TURNER RS, 1985, J BIOL CHEM, V260, P1503; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; VEGA MA, 1991, J BIOL CHEM, V266, P16269; WEGENER AMK, 1995, J BIOL CHEM, V270, P4675, DOI 10.1074/jbc.270.9.4675; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; ZANDERS ED, 1983, NATURE, V303, P625, DOI 10.1038/303625a0	64	55	55	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11441	11448		10.1074/jbc.271.19.11441	http://dx.doi.org/10.1074/jbc.271.19.11441			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626701	hybrid			2022-12-27	WOS:A1996UJ94400061
J	Pfefferkorn, LC; Swink, SL				Pfefferkorn, LC; Swink, SL			Intracluster restriction of Fc receptor gamma-chain tyrosine phosphorylation subverted by a protein-tyrosine phosphatase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH OXIDASE ACTIVITY; TRANSIENT ACTIVATION; RAT ADIPOCYTES; VANADATE; CELLS; H2O2; DEPHOSPHORYLATION; BINDING; KINASE; RI	This study shows that aggregation of U937 cell high affinity IgG Fc receptor (Fc gamma RI) results in the transient tyrosine phosphorylation of Fc gamma RI gamma-chain but not the phosphorylation of gamma-chains associated with nonaggregated IgA Fc receptors (Fc alpha R) on the same cells. Thus, normally, tyrosine phosphorylation of gamma-chains is limited to FcR in aggregates, In contrast, aggregation of Fc gamma RI in the presence of vanadate induced the sustained tyrosine phosphorylation of Fc gamma RI gamma-chains and the rapid and extensive phosphorylation of nonaggregated Fc alpha R gamma-chains and low affinity IgG Fc receptors (Fc gamma RII). This global phosphorylation of motifs on nonaggregated FcR was also detected upon aggregation of Fc alpha R or Fc gamma RII, which induced the phosphorylation of nonaggregated Fc gamma RI gamma-chains. Vanadate prevented dephosphorylation of proteins and increased kinase activity in stimulated cells, Evidence failed to support alternative explanations such as acquisition of phospho-gamma through subunit exchange or a coalescence of nonaggregated with aggregated FcR, It is likely, therefore, that activated kinases interacted with nonaggregated FcR in stimulated cells. Pervanadate induced the tyrosine phosphorylation of gamma-chains in the absence of FcR crosslinking, indicating that the kinases could be activated by phosphatase inhibition and could react with nonaggregated substrates. We conclude that under normal conditions there is a vanadate-sensitive mechanism that prevents tyrosine phosphorylation of nonaggregated FcR gamma-chain motifs in activated cells, restricting their phosphorylation to aggregates.			Pfefferkorn, LC (corresponding author), DARTMOUTH COLL SCH MED, DEPT MICROBIOL BORWELL, HANOVER, NH 03756 USA.				NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI029455] Funding Source: NIH RePORTER; NCI NIH HHS [CA23108] Funding Source: Medline; NIAID NIH HHS [AI29455] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DUCHEMIN AM, 1994, J BIOL CHEM, V269, P12111; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; GORTER A, 1987, IMMUNOLOGY, V61, P303; GUYRE PM, 1983, J CLIN INVEST, V72, P393, DOI 10.1172/JCI110980; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HUANG MM, 1992, J BIOL CHEM, V267, P5467; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KADOTA S, 1987, J BIOL CHEM, V262, P8252; KENT UM, 1994, P NATL ACAD SCI USA, V91, P3087, DOI 10.1073/pnas.91.8.3087; METZGER H, 1992, J IMMUNOL, V149, P1477; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; PAOLINI R, 1992, P NATL ACAD SCI USA, V89, P10733, DOI 10.1073/pnas.89.22.10733; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PFEFFERKORN LC, 1994, J IMMUNOL, V153, P3228; PFEFFERKORN LC, 1990, MOL IMMUNOL, V27, P263, DOI 10.1016/0161-5890(90)90139-Q; PFEFFERKORN LC, 1989, J BIOL CHEM, V264, P14112; PFEFFERKORN LC, 1989, J IMMUNOL, V143, P2640; PFEFFERKORN LC, 1995, J BIOL CHEM, V270, P8164, DOI 10.1074/jbc.270.14.8164; PFEFFERKORN LC, 1995, 9 INT C IMM SAN FRAN, pA68; PRIBLUDA VS, 1992, P NATL ACAD SCI USA, V89, P11446, DOI 10.1073/pnas.89.23.11446; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SHEN L, 1989, J IMMUNOL, V143, P4117; SWIETER M, 1995, J IMMUNOL, V155, P5330; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; VANDEWINKEL JGJ, 1991, J LEUKOCYTE BIOL, V49, P511, DOI 10.1002/jlb.49.5.511; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; WOFSY C, 1995, J BIOL CHEM, V270, P20264, DOI 10.1074/jbc.270.35.20264; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013	34	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11099	11105		10.1074/jbc.271.19.11099	http://dx.doi.org/10.1074/jbc.271.19.11099			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626653	hybrid			2022-12-27	WOS:A1996UJ94400013
J	Xie, Z; Price, DH				Xie, Z; Price, DH			Purification of an RNA polymerase II transcript release factor from Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION COMPLEXES; TERMINATION FACTOR; HUMAN MITOCHONDRIA; GENE-EXPRESSION; PROTEIN; INVITRO; RHO	Factor 2 was previously identified in Drosophila K-c cell nuclear extract (KcN) as an activity suppressing the appearance of long transcripts (Price, D. H., Sluder, A. E., and Greenleaf, A. L. (1987) J. Biol. Chem. 262, 3244-3255). A 154-kDa protein with factor 2 activity was purified to apparent homogeneity from KcN. An immobilized template assay indicated that factor 2 caused the release of transcripts by RNA polymerase II in an ATP-dependent manner. Some early elongation complexes were resistant to factor 2 action but became sensitive after treatment with 1 M KCl. In the absence of factor 2, transcription complexes still exhibited a low degree of processivity suggesting that factor 2 was only partially responsible for abortive elongation.			Xie, Z (corresponding author), UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242, USA.		Price, David H/F-6173-2010	Price, David/0000-0002-5597-385X	NIGMS NIH HHS [R01-GM35500] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTSCH I, 1988, MOL CELL BIOL, V8, P3891, DOI 10.1128/MCB.8.9.3891; COPPOLA JA, 1983, P NATL ACAD SCI-BIOL, V80, P1251, DOI 10.1073/pnas.80.5.1251; DAGA A, 1993, J BIOL CHEM, V268, P8123; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; HAGLER J, 1994, J BIOL CHEM, V269, P10050; KEPHART DD, 1992, MOL CELL BIOL, V12, P2067, DOI 10.1128/MCB.12.5.2067; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2; KUHN A, 1990, NATURE, V344, P559, DOI 10.1038/344559a0; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; PRICE DH, 1987, J BIOL CHEM, V262, P3244; RICHARDSON JP, 1980, BIOCHEMISTRY-US, V19, P4293, DOI 10.1021/bi00559a022; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; SELBY CP, 1995, J BIOL CHEM, V270, P4890, DOI 10.1074/jbc.270.9.4890; SELBY CP, 1995, J BIOL CHEM, V270, P4882, DOI 10.1074/jbc.270.9.4882; SLUDER AE, 1988, J BIOL CHEM, V263, P9917; SPENCER CA, 1990, ONCOGENE, V5, P777; WRIGHT S, 1993, MOL BIOL CELL, V4, P661, DOI 10.1091/mbc.4.7.661; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241	21	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11043	11046		10.1074/jbc.271.19.11043	http://dx.doi.org/10.1074/jbc.271.19.11043			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626643	hybrid			2022-12-27	WOS:A1996UJ94400003
J	Benbow, U; Buttice, G; Nagase, H; Kurkinen, M				Benbow, U; Buttice, G; Nagase, H; Kurkinen, M			Characterization of the 46-kDa intermediates of matrix metalloproteinase 3 (stromelysin 1) obtained by site-directed mutation of phenylalanine 83	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHEUMATOID SYNOVIAL FIBROBLASTS; TISSUE INHIBITOR; CYSTEINE SWITCH; ACTIVATION; COLLAGENASE; MECHANISMS; PROCOLLAGENASE; PURIFICATION; EXPRESSION; PRECURSOR	The precursor of matrix metalloproteinase 3 (MMP-3/stromelysin 1) is activated in vitro by proteinases or mercurial compounds by stepwise processes which include the initial formation of short-lived intermediates and the subsequent intermolecular cleavage of the His(82)-Phe(83) bond to generate the fully activated mature MMP-3 (Nagase, H., Enghild, J. J., Suzuki, K., and Salvesen, G. (1990) Biochemistry 29, 5783-5789), To study the enzymatic properties of the intermediates we have mutated either His(82) or Phe(83) to Arg to obtain a stable MMP-3 intermediate, The mutant proteins were expressed in Chinese hamster ovary K-1 cells using a mammalian expression system. The proMMP-3(H82R) mutant was activated by chymotrypsin, elastase, and 4-aminophenylmercuric acetate to the 45-kDa MMP-3 with similar mechanism and kinetics as the wild-type. In contrast, the activation of the proMMP-3(F83R) mutant by proteinases or 4-aminophenylmercuric acetate resulted in 46-kDa forms, which retained 13, 14, or 15 amino acids of the pro-domain depending on the activators, The proteinase-activated MMP-3(F83R) intermediates exhibited little enzymatic activity, but they were partially active after treatment with SH-reacting reagents. These molecules could bind to the tissue inhibitor of metalloproteinases-1 and alpha(2)-macroglobulin. However, the SH group of Cys(75) of the intermediates was not modified by SH-reagents, indicating that the enzymatic activity generated by SH-reagents resulted from molecular perturbation of the enzyme rather than their interaction with Cys(75). When gelatin and transferrin were digested with the 46-kDa intermediates the products were different from those generated by the wild-type MMP-3, suggesting an alteration in substrate specificity, The treatment of proMMP-3 with trypsin resulted in the formation of a 45-kDa MMP-3 with an NH2-terminal Thr(85), whose activity and substrate specificity were similar to those of the 46-kDa MMP-3(F83R) obtained from the proMMP-3(F83R) mutant. These observations indicate that the correct processing at the His(82)-Phe(83) bond is critical for expression of the full activity and the specificity of MMP-3.	UNIV KANSAS,MED CTR,DEPT BIOCHEM,KANSAS CITY,KS 66160; UNIV KANSAS,MED CTR,DEPT MOLEC BIOL,KANSAS CITY,KS 66160; WAYNE STATE UNIV,SCH MED,CTR MOL MED & GENET,DETROIT,MI 48202	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; Wayne State University				Buttice', Giovanna/0000-0001-6550-5585	NIAMS NIH HHS [AR39189, AR40994] Funding Source: Medline; NICHD NIH HHS [HD24442] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024442] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039189, R01AR040994] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CHEN LC, 1993, BIOCHEMISTRY-US, V32, P10289, DOI 10.1021/bi00090a003; COCKETT MI, 1990, BIO-TECHNOL, V8, P662, DOI 10.1038/nbt0790-662; CRABBE T, 1992, BIOCHEMISTRY-US, V31, P8500, DOI 10.1021/bi00151a017; DAVIS GE, 1990, CANCER RES, V50, P1113; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; FIRESTEIN GS, 1991, ARTHRITIS RHEUM, V34, P1094, DOI 10.1002/art.1780340905; GRAVALLESE EM, 1991, ARTHRITIS RHEUM-US, V34, P1076, DOI 10.1002/art.1780340903; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ITO A, 1988, ARCH BIOCHEM BIOPHYS, V267, P211, DOI 10.1016/0003-9861(88)90025-2; KNAUPER V, 1993, BIOCHEM J, V295, P581; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCACHREN SS, 1991, ARTHRITIS RHEUM-US, V34, P1085; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; NAGASE H, 1995, METHOD ENZYMOL, V248, P449; NAGASE H, 1994, J BIOL CHEM, V269, P20952; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NIEDZWIECKI L, 1992, BIOCHEMISTRY-US, V31, P12618, DOI 10.1021/bi00165a011; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKADA Y, 1988, BIOCHEM J, V254, P731, DOI 10.1042/bj2540731; OKADA Y, 1992, LAB INVEST, V66, P680; OKADA Y, 1989, ANN RHEUM DIS, V48, P645, DOI 10.1136/ard.48.8.645; OKADA Y, 1986, J BIOL CHEM, V261, P14245; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; SAARINEN J, 1994, J BIOL CHEM, V269, P18134; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUS J, 1988, J BIOL CHEM, V263, P6742; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; SIRI A, 1995, J BIOL CHEM, V270, P8650, DOI 10.1074/jbc.270.15.8650; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; SUZUKI K, 1995, BIOCHEM J, V305, P301, DOI 10.1042/bj3050301; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WALAKOVITS LA, 1992, ARTHRITIS RHEUM, V35, P35, DOI 10.1002/art.1780350106; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WU JJ, 1991, J BIOL CHEM, V266, P5625	45	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10715	10722		10.1074/jbc.271.18.10715	http://dx.doi.org/10.1074/jbc.271.18.10715			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631880	hybrid			2022-12-27	WOS:A1996UJ34200048
J	Yamamoto, F; McNeill, PD				Yamamoto, F; McNeill, PD			Amino acid residue at codon 268 determines both activity and nucleotide-sugar donor substrate specificity of human histo-blood group A and B transferases - In vitro mutagenesis study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR GENETIC-ANALYSIS; GROUP SYSTEM; GROUP-A; ABO; DNA; CLONING; ALLELES	Histo-blood group A transferase produces A antigens and transfers GalNAc to the acceptor substrate, H structures of glycolipids and glycoproteins, B transferase transfers galactose in place of GalNAc to the same acceptor substrate to synthesize B antigens. We have previously identified four amino acid substitutions between human A and B transferases. Out of these four, substitutions at the last two positions (codons 266 and 268) were found to be crucial for the different donor nucleotide-sugar specificities between A and B transferases as analyzed by gene transfer of chimeric A-B transferase genes. In the present study, we have in vitro mutagenized codon 268 of these two transferase cDNA expression constructs (glycine and alanine in A and B transferases, respectively) and produced substitution constructs with every possible amino acid residue at this position, We examined the activity and specificity of each construct by gene transfer followed by immunodetection of A and B antigens and in vitro enzymatic assay, Amino acid substitution constructs on the A transferase backbone with alanine, serine, and cysteine expressed enzymes with A and B transferase activities. Weak A activity was detected with histidine and phenylalanine constructs while weak B activity was detected with asparagine and threonine constructs, All the other amino acid substitutions at codon 268 on the A transferase backbone showed neither A nor B activity, The glycine construct on the B transferase backbone expressed both A and B transferase activities, Some substitution constructs on the B transferase backbone maintained B activity while some other substitutions abolished the activity. These results show that the side chain of the amino acid residue at 268 of the human A and B transferases is responsible for determining both activity and nucleotide-sugar donor substrate specificity and strongly suggest its direct involvement in the recognition of and binding to the sugar moiety of the nucleotide-sugars.	UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT PATHOBIOL,SEATTLE,WA 98195; BIOMEMBRANE INST,SEATTLE,WA 98119	University of Washington; University of Washington Seattle	Yamamoto, F (corresponding author), LA JOLLA CANC RES FDN,BURNHAM INST,10901 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Yamamoto, Fumiichiro/F-1478-2016	Yamamoto, Fumiichiro/0000-0001-9690-7034				Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; CHANG JG, 1992, BLOOD, V79, P2176, DOI 10.1182/blood.V79.8.2176.bloodjournal7982176; CROUSE C, 1995, BIOTECHNIQUES, V18, P478; GREENWELL P, 1986, CARBOHYD RES, V149, P149, DOI 10.1016/S0008-6215(00)90375-6; GRUNNET N, 1994, VOX SANG, V67, P210, DOI 10.1111/j.1423-0410.1994.tb01662.x; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; HAWLEY-NELSON P, 1993, FOCUS MADISON, V15, P73; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KOMINATO Y, 1992, BIOCHEM BIOPH RES CO, V189, P154, DOI 10.1016/0006-291X(92)91538-2; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LIM K, 1989, BIOTECHNIQUES, V7, P576; STRONCEK DF, 1995, TRANSFUSION, V35, P231, DOI 10.1046/j.1537-2995.1995.35395184280.x; Stroup M, 1987, SCI FORUM BLOOD GROU; UGOZZOLI L, 1992, GENOMICS, V12, P670, DOI 10.1016/0888-7543(92)90292-Z; Watkins W M, 1980, Adv Hum Genet, V10, P1; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMAMOTO F, 1993, VOX SANG, V64, P171, DOI 10.1111/j.1423-0410.1993.tb05157.x; YAMAMOTO F, 1995, VOX SANG, V69, P1, DOI 10.1111/j.1423-0410.1995.tb00339.x; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146; YAMAMOTO F, 1992, BIOCHEM BIOPH RES CO, V187, P366, DOI 10.1016/S0006-291X(05)81502-5; YAMAMOTO F, 1993, VOX SANG, V64, P175, DOI 10.1111/j.1423-0410.1993.tb05158.x; YAMAMOTO FI, 1993, VOX SANG, V64, P120, DOI 10.1111/j.1423-0410.1993.tb02529.x; YAMAMOTO FI, 1993, VOX SANG, V64, P116, DOI 10.1111/j.1423-0410.1993.tb02528.x	24	78	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10515	10520		10.1074/jbc.271.18.10515	http://dx.doi.org/10.1074/jbc.271.18.10515			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631849	hybrid			2022-12-27	WOS:A1996UJ34200017
J	Wieprecht, M; Wieder, T; Paul, C; Geilen, CC; Orfanos, CE				Wieprecht, M; Wieder, T; Paul, C; Geilen, CC; Orfanos, CE			Evidence for phosphorylation of CTP:phosphocholine cytidylyltransferase by multiple proline-directed protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CTP; HELA-CELLS; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; INDUCED INHIBITION; OKADAIC ACID; HEPATOCYTES; DIACYLGLYCEROL; TRANSLOCATION; EXPRESSION; CYTIDYLTRANSFERASE	Reversible phosphorylation of CTP:phosphocholine cytidylyltransferase, the rate-limiting enzyme of phosphatidylcholine biosynthesis, is thought to play a role in regulating its activity. In the present study, the hypothesis that proline-directed kinases play a major role in phosphorylating cytidylyltransferase is substantiated using a c-Ha-ras-transfected clone of the human keratinocyte cell line HaCaT. Cellular extracts from epidermal growth factor-stimulated HaCaT cells and from ras-transfected HaCaT cells phosphorylated cytidylyltransferase much stronger as compared with extracts from quiescent HaCaT cells, The tryptic phosphopeptide pattern of cytidylyltransferase phosphorylated by cell-free extracts from ras-transfected HaCaT cells was similar compared with the patterns of cytidylyltransferase phosphorylated by p44(mpk) mitogen-activated protein kinase and p34(cdc2) kinase in vitro, whereas in the case of casein kinase II the pattern was different, Furthermore, in c-Ha-ras-transfected HaCaT cells the in. vivo phosphorylation state of cytidylyltransferase was 2-fold higher as compared with untransfected HaCaT cells, This higher phosphorylation of cytidylyltransferase in the ras-transfected clone was reduced to a level below the phosphorylation of cytidylyltransferase in untransfected cells, using olomoucine, a specific inhibitor of proline-directed kinases. The reduced phosphorylation of cytidylyltransferase in olomoucine-treated cells correlated with an enhanced stimulation of enzyme activity by oleic acid.	FREE UNIV BERLIN, UNIV MED CTR BENJAMIN FRANKLIN, DEPT DERMATOL, D-12200 BERLIN, GERMANY; FREE UNIV BERLIN, UNIV MED CTR BENJAMIN FRANKLIN, INST BIOCHEM & MOLEC BIOL, D-12200 BERLIN, GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin								BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOUKAMP P, 1990, CANCER RES, V50, P2840; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P26, DOI 10.1016/0005-2760(87)90214-1; DUBOIS MF, 1993, FEBS LETT, V324, P191, DOI 10.1016/0014-5793(93)81391-C; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GEILEN CC, 1992, J BIOL CHEM, V267, P6719; GROBLEWSKI GE, 1995, J BIOL CHEM, V270, P1437, DOI 10.1074/jbc.270.3.1437; HATCH GM, 1992, J BIOL CHEM, V267, P15751; HATCH GM, 1990, BIOCHIM BIOPHYS ACTA, V1042, P374, DOI 10.1016/0005-2760(90)90167-V; HOUWELING M, 1994, J BIOL CHEM, V269, P7544; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; JAMIL H, 1993, BIOCHEM J, V291, P419, DOI 10.1042/bj2910419; JAMIL H, 1992, J BIOL CHEM, V267, P1752; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCHE MM, 1993, ARCH BIOCHEM BIOPHYS, V301, P114, DOI 10.1006/abbi.1993.1122; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; PELECH SL, 1982, J BIOL CHEM, V257, P4198; SANGHERA JS, 1989, J BIOL CHEM, V264, P1215; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOHAL PS, 1990, J BIOL CHEM, V265, P11746; SWEITZER TD, 1994, ARCH BIOCHEM BIOPHYS, V311, P107, DOI 10.1006/abbi.1994.1215; TRONCHERE H, 1994, BBA-LIPID LIPID MET, V1212, P137, DOI 10.1016/0005-2760(94)90248-8; UTAL AK, 1991, J BIOL CHEM, V266, P24084; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WANG YL, 1993, J BIOL CHEM, V268, P5512; WATKINS JD, 1992, ARCH BIOCHEM BIOPHYS, V292, P360, DOI 10.1016/0003-9861(92)90003-F; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WIEDER T, 1994, FEBS LETT, V345, P207, DOI 10.1016/0014-5793(94)00433-1; WIEPRECHT M, 1994, BIOCHEM J, V297, P241, DOI 10.1042/bj2970241; WIEPRECHT M, 1994, FEBS LETT, V353, P221, DOI 10.1016/0014-5793(94)01040-4; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503	35	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9955	9961		10.1074/jbc.271.17.9955	http://dx.doi.org/10.1074/jbc.271.17.9955			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626633	hybrid			2022-12-27	WOS:A1996UG25700017
J	Ishii, H; Kizaki, K; Horie, S; Kazama, M				Ishii, H; Kizaki, K; Horie, S; Kazama, M			Oxidized low density lipoprotein reduces thrombomodulin transcription in cultured human endothelial cells through degradation of the lipoprotein in lysosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-C ACTIVATION; TISSUE-FACTOR; NATURAL ANTICOAGULANT; HEMOSTATIC PROPERTIES; COFACTOR ACTIVITY; RETINOIC ACID; CYCLIC-AMP; EXPRESSION; SURFACE	Oxidized low density lipoprotein (LDL), a potent atherogenic lipoprotein, has been shown to cause the alteration of various endothelial functions. We have examined the effect of oxidized LDL on the cofactor activity for thrombin-dependent protein C activation and expression of thrombomodulin (TM), a cell surface antithrombotic glycoprotein, on cultured human umbilical vein endothelial cells. Oxidized LDL prepared by irradiation of LDL with 254-nm ultraviolet light did not directly affect the cofactor activity of isolated TM. Exposure of the cells to oxidized LDL (25-200 mu g/ml), but not native LDL and acetylated LDL, reduced TM cofactor activity in parallel with its antigen levels on the cell surface in an oxidation-, concentration- and time dependent manner. TM mRNA levels were reduced prior to decrease in TM antigen levels and were 50% of the control levels at 3.0 h after treatment of the cells with oxidized LDL. The apparent half-life time (t(1/2) = 2.8 h) of TM mRNA in the oxidized LDL-treated cells, however, did not significantly differ from that (t(1/2) = 2.6 h) in the control cells when the cells were coincubated with 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole, a transcriptional inhibitor. Treatment of the cells with bafilomycin A1, an inhibitor for the proton pump of the lysosomes, inhibited intracellular degradation of the LDL and prevented down-regulations of the mRNA and the cell surface TM antigen levels caused by oxidized LDL. The inhibitor molecule in oxidized LDL was shown to be a lipid; organic solvent extracts (300 mg/ml cholesterol, an equivalent concentration with lipids in 200 mu g/ml oxidized LDL) of oxidized LDL inhibited expression of TM antigen to nearly the same extent as the oxidized LDL, although water extracts did not affect TM expression on the cells. These results suggested that down-regulation of TM on endothelial cells exposed to oxidized LDL resulted from inhibition of its transcription mediated by lysosomal degradation of oxidized LDL and that a lipid component in the LDL could be an active species. A decrease in TM expression on the surface of endothelial cells may contribute to promote thrombosis in atherosclerotic lesions.			Ishii, H (corresponding author), TEIKYO UNIV,FAC PHARMACEUT SCI,DEPT CLIN BIOCHEM,1091-1 SUARASHI,SAGAMIKO,KANAGAWA 19901,JAPAN.							ACTON SL, 1994, J BIOL CHEM, V269, P21003; ARCHIPOFF G, 1991, BIOCHEM J, V273, P679, DOI 10.1042/bj2730679; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Buege J A, 1978, Methods Enzymol, V52, P302; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONWAY EM, 1988, MOL CELL BIOL, V8, P5588, DOI 10.1128/MCB.8.12.5588; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; DERIJKE YB, 1994, BIOCHEM J, V304, P69, DOI 10.1042/bj3040069; DITTMAN WA, 1990, BLOOD, V75, P329; DOUSSET N, 1990, BIOCHIM BIOPHYS ACTA, V1045, P219, DOI 10.1016/0005-2760(90)90123-F; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; FEI H, 1993, ARTERIOSCLER THROMB, V138, P601; GARCIAMALDONADO M, 1991, TRANSPLANTATION, V51, P701, DOI 10.1097/00007890-199103000-00030; Gimbrone M., 1986, VASCULAR ENDOTHELIUM, P1; GLASER CB, 1992, J CLIN INVEST, V90, P2565, DOI 10.1172/JCI116151; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GREENWALT DE, 1992, BLOOD, V80, P1105; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; HASHIMOTO N, 1985, J BIOCHEM, V97, P1347, DOI 10.1093/oxfordjournals.jbchem.a135187; HAYASHI T, 1992, BLOOD, V79, P2930; HIROKAWA K, 1991, J CELL PHYSIOL, V147, P157, DOI 10.1002/jcp.1041470120; HORIE S, 1992, BIOCHEM J, V281, P149, DOI 10.1042/bj2810149; ISHII H, 1990, THROMB RES, V59, P841, DOI 10.1016/0049-3848(90)90397-U; ISHII H, 1992, BLOOD, V80, P2556; ISHII H, 1990, THROMB HAEMOSTASIS, V63, P157; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KIZAKI K, 1994, THROMB HAEMOSTASIS, V72, P573; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KOSUGI K, 1987, J CELL PHYSIOL, V130, P311, DOI 10.1002/jcp.1041300302; KUGIYAMA K, 1993, CIRC RES, V73, P335, DOI 10.1161/01.RES.73.2.335; KUME N, 1991, BIOCHIM BIOPHYS ACTA, V1091, P63, DOI 10.1016/0167-4889(91)90223-K; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; LENTZ SR, 1991, BLOOD, V77, P542; LENTZ SR, 1994, THROMBIN THROMBOMODU, P91; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOORE KL, 1989, BLOOD, V73, P159; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; NAGANUMA S, 1992, BIOCHIM BIOPHYS ACTA, V1126, P41, DOI 10.1016/0005-2760(92)90214-G; NAITO M, 1991, AM J PATHOL, V139, P1411; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; NAWROTH PP, 1986, P NATL ACAD SCI USA, V83, P3460, DOI 10.1073/pnas.83.10.3460; NEMERSON Y, 1988, BLOOD, V71, P1; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; REES MM, 1993, THROMB RES, V71, P337, DOI 10.1016/0049-3848(93)90160-P; RODGERS GM, 1988, FASEB J, V2, P116, DOI 10.1096/fasebj.2.2.3277885; SALEM HH, 1984, J BIOL CHEM, V259, P2246; SCARPATI EM, 1989, J BIOL CHEM, V264, P20705; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; WEIS JR, 1991, FASEB J, V5, P2459, DOI 10.1096/fasebj.5.10.2065893; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; XIE JF, 1994, J IMMUNOL, V153, P378; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	57	53	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8458	8465		10.1074/jbc.271.14.8458	http://dx.doi.org/10.1074/jbc.271.14.8458			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626546	hybrid			2022-12-27	WOS:A1996UD60000086
J	Wada, H; Ivester, CT; Carabello, BA; Cooper, G; McDermott, PJ				Wada, H; Ivester, CT; Carabello, BA; Cooper, G; McDermott, PJ			Translational initiation factor eIF-4E - A link between cardiac load and protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AORTIC PERFUSION-PRESSURE; ADULT FELINE CARDIOCYTES; HYPERTROPHY; DEFORMATION; DETERMINANT	To define the coupling mechanism between cardiac load and the rate of protein synthesis, changes in the extent of eIF-4E phosphorylation were measured after imposition of a load. Electrically stimulated contraction of adult feline cardiocytes increased eIF-4E phosphorylation to 34% after 4 h, as compared with 8% phosphorylation in quiescent controls. However, eIF-4E phosphorylation did not increase upon electrical stimulation in the presence of 7.5 mM 2,3-butanedione monoxime, an inhibitor of actin-myosin cross-bridge cycling and active tension development. Treatment of adult cardiocytes with either 0.1 mu M insulin or 0.1 mu M phorbol 12-myristate 13-acetate increased eIF-4E phosphorylation to 23 and 64%, respectively, but these increases were not blocked by 2,3-butanedione monoxime. In canine models of acute hemodynamic overload in vivo, eIF-4E phosphorylation increased to 23% in response to left ventricular pressure overload as compared with 7% phosphorylation in controls. Acute volume overload had no effect on eIF-4E phosphorylation. These changes in eIF-4E phosphorylation account for differences in anabolic responses to acute pressure versus acute volume overload. These data suggest that eIF-4E phosphorylation is a mechanism by which increased cardiac load is coupled to accelerated rates of protein synthesis.	VET ADM MED CTR,CARDIOL SECT,CHARLESTON,SC 29401; GAZES CARDIAC RES INST,DEPT MED,CHARLESTON,SC 29401; GAZES CARDIAC RES INST,DEPT PHYSIOL,CHARLESTON,SC 29401; GAZES CARDIAC RES INST,DEPT CELL BIOL & ANAT,CHARLESTON,SC 29401	US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048788] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL-48788] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACKX PH, 1994, J PHYSIOL-LONDON, V476, P487, DOI 10.1113/jphysiol.1994.sp020149; CLERK A, 1994, J BIOL CHEM, V269, P32848; COOPER G, 1987, ANNU REV PHYSIOL, V49, P501, DOI 10.1146/annurev.ph.49.030187.002441; DELCAYRE C, 1992, AM J PHYSIOL, V263, pH1537, DOI 10.1152/ajpheart.1992.263.5.H1537; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HESKETH JE, 1991, BIOCHEM J, V277, P1; IMAMURA T, 1994, CIRC RES, V75, P418, DOI 10.1161/01.RES.75.3.418; INGBER DE, 1994, INT REV CYTOL, V150, P173; IVESTER CT, 1995, J BIOL CHEM, V270, P21950, DOI 10.1074/jbc.270.37.21950; IVESTER CT, 1993, AM J PHYSIOL, V265, pH666; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; KATO S, 1995, AM J PHYSIOL-HEART C, V268, pH2495; KENT RL, 1989, CIRC RES, V64, P74, DOI 10.1161/01.RES.64.1.74; KIMBALL SR, 1990, J BIOL CHEM, V265, P16794; KIRA Y, 1984, AM J PHYSIOL, V246, pC247, DOI 10.1152/ajpcell.1984.246.3.C247; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; MADER S, 1995, BIOCHIMIE, V77, P40, DOI 10.1016/0300-9084(96)88102-8; MAKKINJE A, 1995, J BIOL CHEM, V270, P14824, DOI 10.1074/jbc.270.24.14824; MANN DL, 1989, CIRC RES, V64, P1079, DOI 10.1161/01.RES.64.6.1079; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MORGAN HE, 1987, ANNU REV PHYSIOL, V49, P533; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; MORLEY SJ, 1994, MOL BIOL REP, V19, P221, DOI 10.1007/BF00986964; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RHOADS RE, 1993, PROG NUCLEIC ACID RE, V46, P183, DOI 10.1016/S0079-6603(08)61022-3; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; STERN BD, 1993, PROTEIN EXPRES PURIF, V4, P320, DOI 10.1006/prep.1993.1041	28	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8359	8364		10.1074/jbc.271.14.8359	http://dx.doi.org/10.1074/jbc.271.14.8359			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626533	hybrid			2022-12-27	WOS:A1996UD60000073
J	Bougeret, C; Delaunay, T; Romero, F; Jullien, P; Sabe, H; Hanafusa, H; Benarous, R; Fischer, S				Bougeret, C; Delaunay, T; Romero, F; Jullien, P; Sabe, H; Hanafusa, H; Benarous, R; Fischer, S			Detection of a physical and functional interaction between Csk and Lck which involves the SH2 domain of Csk and is mediated by autophosphorylation of Lck on tyrosine 394	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; NEGATIVE REGULATORY SITE; TERMINAL SRC KINASE; C-SRC; PROTEIN-KINASE; PHOSPHORYLATED PEPTIDES; ESCHERICHIA-COLI; FAMILY KINASES; P56(LCK); ACTIVATION	The COOH-terminal Src kinase (Csk) is responsible for the phosphorylation of the conserved, negative regulatory, carboxyl-terminal tyrosine of most of the Src family protein tyrosine kinases. Up to now, no stable binding of Csk to Src kinases has been detected. We therefore decided to analyze this interaction using two systems which allow detection of transient interaction. We produced and purified recombinant proteins in the glutathione S transferase prokaryotic expression system. First, using real-time biospecific interaction analysis (BIAcore(TM)), we detected in vitro a specific interaction between Csk and one of its substrates Lck, a lymphocyte-specific member of the Src family. This interaction requires the autophosphorylation of Lck: on tyrosine 394 (the phosphorylation of which is correlated with an increase of the kinase activity) and involves a functional Csk SH2 domain, Second, using the yeast two-hybrid system, we confirmed in vivo the physical interaction between Csk and Lck. Furthermore, in vitro we showed that autophosphorylation of Lck on tyrosine 394 enhances the phosphorylation of Lck by Csk on the negative regulatory site, tyrosine 505, suggesting that activated Lck serves preferentially as substrate for Csk. These findings might explain the mechanism(s) by which Csk interacts with most of Src kinases to downregulate their kinase activity.	UNIV PARIS 05, INSERM, U332, INST COCHIN GENET MOLEC, F-75014 PARIS, FRANCE; INRA, LAB VIROL & IMMUNOL MOL, F-78352 JOUY EN JOSAS, FRANCE; UNIV PARIS 05, INSERM, U363, INST COCHIN GENET MOLEC, F-75014 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Bougeret, C (corresponding author), ROCKEFELLER UNIV, MOLEC ONCOL LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.		Sabe, Hisataka/A-4066-2012; Sabe, Hisataka/GPF-4385-2022; Romero, Francisco/K-2101-2014	Romero, Francisco/0000-0002-9588-6881	NCI NIH HHS [CA44 356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; AMREIN KE, 1993, P NATL ACAD SCI USA, V90, P10285, DOI 10.1073/pnas.90.21.10285; AVRAHAM S, 1995, J BIOL CHEM, V270, P1833, DOI 10.1074/jbc.270.4.1833; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BENNETT BD, 1994, J BIOL CHEM, V269, P1068; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; BOUGERET C, 1993, ONCOGENE, V8, P1241; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BRUNATI AM, 1993, EUR J BIOCHEM, V216, P323, DOI 10.1111/j.1432-1033.1993.tb18149.x; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CHOW LML, 1994, P NATL ACAD SCI USA, V91, P4975, DOI 10.1073/pnas.91.11.4975; CLOUTIER JF, 1995, MOL CELL BIOL, V15, P5937; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GERVAIS FG, 1993, MOL CELL BIOL, V13, P7112, DOI 10.1128/MCB.13.11.7112; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HATA A, 1994, MOL CELL BIOL, V14, P7306, DOI 10.1128/MCB.14.11.7306; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; JULLIEN P, 1994, EUR J BIOCHEM, V224, P589, DOI 10.1111/j.1432-1033.1994.00589.x; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; LOFAS S, 1990, J CHEM SOC CHEM COMM, P1526, DOI 10.1039/c39900001526; MACAULEY A, 1993, ONCOGENE, V8, P117; MCVICAR DW, 1994, ONCOGENE, V9, P2037; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MUSTELIN T, 1994, SRC FAMILY TYROSINE, P8; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEET K, 1995, MOL CELL BIOL, V15, P4908; OKADA M, 1993, J BIOL CHEM, V268, P18070; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; RUZZENE M, 1994, J BIOL CHEM, V269, P15885; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SAKANO S, 1994, ONCOGENE, V9, P1155; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; Sherman F., 1986, METHODS YEAST GENETI; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SOULA M, 1993, J BIOL CHEM, V268, P27420; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOTJEK AB, 1993, CELL, V74, P205; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	59	33	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7465	7472		10.1074/jbc.271.13.7465	http://dx.doi.org/10.1074/jbc.271.13.7465			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631775	hybrid			2022-12-27	WOS:A1996UC77400043
J	Itoh, T; Muto, A; Watanabe, S; Miyajima, A; Yokota, T; Arai, K				Itoh, T; Muto, A; Watanabe, S; Miyajima, A; Yokota, T; Arai, K			Granulocyte-macrophage colony-stimulating factor provokes RAS activation and transcription of c-fos through different modes of signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON BETA-SUBUNIT; GM-CSF RECEPTOR; PROTEIN-TYROSINE KINASE; PHOSPHOTYROSINE PHOSPHATASE; INTERLEUKIN-3; PHOSPHORYLATION; TRANSDUCTION; GROWTH; SH2; RECONSTITUTION	Granulocyte-macrophage colony-stimulating factor (GM-CSF) provokes a proliferative response and induction of early-response genes such as c-fos in target cells, It also induces rapid tyrosine phosphorylation of cellular proteins, including the beta subunit (beta c) of its functional receptor. However, locations and functions of phosphorylated tyrosine residues within the beta c are unclear, To elucidate the mechanism of the human GMCSF receptor signal transduction, mutational analyses were made of the cytoplasmic domain of the beta c, using murine BA/F3 cells. Deletion of the conserved box 1 motif resulted in loss of tyrosine phosphorylation of the beta c, thereby indicating an essential role for this motif in activating the tyrosine kinase which phosphorylates beta c. A C-terminal truncated mutant at position 589 activated the c-fos promoter, and this activation was diminished by a substitution at tyrosine 577 (Tyr(577)). However, the same substitution in the full-length beta c did not completely abrogate the c-fos promoter activation, hence, redundant signaling pathways probably exist, When we analyzed signaling molecules functioning downstream of the beta c we found that Tyr(577) is essential for Shc phosphorylation, while tyrosine phosphorylation of PTP1D was mediated through Tyr(577) as well as through other site(s). We suggest that GM-CSF stimulates at least two modes of signals leading to has activation, an event which ultimately gives rise to promoter activation of c-fos.	UNIV TOKYO, INST MED SCI, DEPT MOLEC & DEV BIOL, MINATO KU, TOKYO 108, JAPAN; UNIV TOKYO, INST MED SCI, DEPT STEM CELL REGULATION, MINATO KU, TOKYO 108, JAPAN; UNIV TOKYO, INST MOLEC & CELLULAR BIOSCI, LAB CELLULAIR BIOXYNTH, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo; University of Tokyo; University of Tokyo			Itoh, Tohru/GYQ-8698-2022; Muto, Akihiko/O-1199-2016; Yokota, Takashi/J-8483-2015	Itoh, Tohru/0000-0002-6579-1638; 				BALDWIN GC, 1992, DEV BIOL, V151, P352, DOI 10.1016/0012-1606(92)90175-G; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; CORMACK B, 1991, CURRENT PROTOCOLS MO; DURONIO V, 1992, J BIOL CHEM, V267, P21856; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOLDSMITH MA, 1994, J BIOL CHEM, V269, P14698; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCOLL SR, 1991, BLOOD, V78, P1842; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIYAJIMA A, 1987, GENE, V58, P273, DOI 10.1016/0378-1119(87)90382-9; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TORIGOE T, 1992, BLOOD, V80, P617; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; WATANABE S, 1993, MOL BIOL CELL, V4, P983, DOI 10.1091/mbc.4.10.983; WATANABE Y, 1992, BLOOD, V80, P2215; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	38	81	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7587	7592		10.1074/jbc.271.13.7587	http://dx.doi.org/10.1074/jbc.271.13.7587			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631792	hybrid			2022-12-27	WOS:A1996UC77400060
J	Keyt, BA; Berleau, LT; Nguyen, HV; Chen, H; Heinsohn, H; Vandlen, R; Ferrara, N				Keyt, BA; Berleau, LT; Nguyen, HV; Chen, H; Heinsohn, H; Vandlen, R; Ferrara, N			The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR FAMILY; ANGIOGENESIS; PROTEINS; BINDING; CELLS; FORMS; COMPARTMENTALIZATION; DIFFERENTIATION; EXPRESSION; MEMBRANE	Vascular endothelial growth factor (VEGF) is a potent and specific mitogen for endothelial cells. VEGF is synthesized and secreted by many differentiated cells in response to a variety of stimuli including hypoxia. VEGF is expressed in a variety of tissues as multiple homodimeric forms (121, 165, 189, and 206 amino acids/monomer) resulting from alternative RNA splicing. VEGF(121) is a soluble mitogen that does not bind heparin; the longer forms of VEGF bind heparin with progressively higher affinity. The higher molecular weight forms of VEGF can be cleaved by plasmin to release a diffusible form(s) of VEGF. We characterized the proteolysis of VEGF by plasmin and other proteases. Thrombin, elastase, and collagenase did not cleave VEGF, whereas trypsin generated a series of smaller fragments. The isolated plasmin fragments of VEGF were compared with respect to heparin binding, interaction with soluble VEGF receptors, and ability to promote endothelial cell mitogenesis. Plasmin yields two fragments of VEGF as indicated by reverse phase high performance liquid chromatography and SDS-polyacrylamide gel electrophoresis: an amino-terminal homodimeric protein containing receptor binding determinants and a carboxyl-terminal polypeptide which bound heparin. Amino-terminal sequencing of the carboxyl-terminal peptide identified the plasmin cleavage site as Arg(110)-Ala(111). A heterodimeric form of VEGF(165/110), was isolated from partial plasmin digests of VEGF(165). The carboxyl-terminal polypeptide (111-165) displayed no affinity for soluble kinase domain region (KDR) or Fms-like tyrosine kinase (FLT-1) receptors. The various isoforms of VEGF (165, 165/110, 110, and 121) bound soluble kinase domain region receptor with similar affinity (approximately 30 pM). In contrast, soluble FLT-1 receptor differentiated VEGF isoforms (165, 165/110, 110, and 121) with apparent affinities of 10, 30, 120, and 200 pM, respectively. Endothelial cell mitogenic potencies of VEGF(110) and VEGF(121) were decreased more than 100-fold compared to that of VEGF(165). The present findings indicate that removal of the carboxyl-terminal domain, whether it is due to alternative splicing of mRNA or to proteolysis, is associated with a significant loss in bioactivity.	GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PROC SCI,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech	Keyt, BA (corresponding author), GENENTECH INC,DEPT CARDIOVASC RES,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.							ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; BREIER G, 1992, DEVELOPMENT, V114, P521; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1993, J CLIN INVEST, V91, P160, DOI 10.1172/JCI116166; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; MIGNATTI P, 1989, J CELL BIOL, V108, P671, DOI 10.1083/jcb.108.2.671; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PARK JE, 1994, J BIOL CHEM, V269, P25646; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RATHJEN PD, 1990, CELL, V62, P1105, DOI 10.1016/0092-8674(90)90387-T; SASISEKHARAN R, 1994, P NATL ACAD SCI USA, V91, P1524, DOI 10.1073/pnas.91.4.1524; SOKER S, 1994, BIOCHEM BIOPH RES CO, V203, P1339, DOI 10.1006/bbrc.1994.2329; TESSLER S, 1994, J BIOL CHEM, V269, P12456; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988	35	508	549	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7788	7795		10.1074/jbc.271.13.7788	http://dx.doi.org/10.1074/jbc.271.13.7788			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631822				2022-12-27	WOS:A1996UC77400090
J	Ohguchi, K; Banno, Y; Nakashima, S; Nozawa, Y				Ohguchi, K; Banno, Y; Nakashima, S; Nozawa, Y			Regulation of membrane-bound phospholipase D by protein kinase C in HL60 cells - Synergistic action of small GTP-binding protein RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D ACTIVATION; STREPTOLYSIN-O; HL-60 CELLS; BRAIN; PHOSPHORYLATION; OVEREXPRESSION; HYDROLYSIS; INHIBITION; PLATELETS; CYTOSOL	In HL60 cells, the membrane-bound phospholipase D (PLD) was stimulated by 4 beta-phorbol 12-myristate 13-acetate (PMA) in the presence of the cytosolic fraction from HL60 cells or rat brain. The cytosolic factor for this PMA-induced PLD activation was subjected to purification from rat brain by sequential chromatographies. The PLD stimulating activity was found in protein kinase C (PKC) fraction containing alpha, beta I, beta II, and gamma isozymes. PKC isozymes were further separated by hydroxylapatite chromatography. PKC alpha and -beta, but not gamma, isozymes were found to activate membrane-bound PLD. PKC alpha was much more effective than PKC beta for PLD activation. Millimolar concentrations of MgATP were required for the PKC-mediated PLD activation in HL60 membranes. MgATP is utilized to maintain the levels of phosphatidylinositol 4,5-bisphosphate (PIP2) under these assay conditions. The PKC-mediated PLD activation was completely inhibited by neomycin, a high affinity ligand for PIP2, and this suppression was recovered by the addition of exogenous PIP2(.) Thus, these results suggest that PIP2 is supposed to play a key role in PKC-mediated PLD activity in HL60 membranes. Furthermore, PKC alpha-mediated PLD activation was potentiated by the addition of recombinant RhoA protein in the presence of guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S). The results obtained here indicate that PKC alpha and RhoA (GTP form) exert a synergistic action in the membrane-bound PLD activation in HL60 cells.	GIFU UNIV,SCH MED,DEPT BIOCHEM,GIFU 500,JAPAN	Gifu University								ALAM MS, 1995, BIOCHEM BIOPH RES CO, V207, P460, DOI 10.1006/bbrc.1995.1210; BANNO Y, 1995, J BIOL CHEM, V270, P4318, DOI 10.1074/jbc.270.9.4318; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRISCOE CP, 1995, BIOCHEM J, V306, P115, DOI 10.1042/bj3060115; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHAUHAN VPS, 1990, FEBS LETT, V272, P99, DOI 10.1016/0014-5793(90)80457-T; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1994, FEBS LETT, V342, P149, DOI 10.1016/0014-5793(94)80490-7; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; COORSSEN JR, 1993, FEBS LETT, V316, P170, DOI 10.1016/0014-5793(93)81209-I; ELDAR H, 1993, J BIOL CHEM, V268, P12560; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GENY B, 1995, EUR J BIOCHEM, V231, P31, DOI 10.1111/j.1432-1033.1995.tb20666.x; GENY B, 1993, EUR J BIOCHEM, V215, P389, DOI 10.1111/j.1432-1033.1993.tb18045.x; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; INOUE H, 1995, BIOCHEM BIOPH RES CO, V210, P542, DOI 10.1006/bbrc.1995.1694; KANOH H, 1993, NEUROSCI LETT, V151, P146, DOI 10.1016/0304-3940(93)90007-8; KISS Z, 1990, J BIOL CHEM, V265, P7345; KUSNER DJ, 1994, BIOCHEM J, V304, P485, DOI 10.1042/bj3040485; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LISCOVITCH M, 1991, CELL REGUL, V2, P1011, DOI 10.1091/mbc.2.12.1011; LIU B, 1994, J BIOCHEM-TOKYO, V116, P882, DOI 10.1093/oxfordjournals.jbchem.a124611; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; OHGUCHI K, 1995, BIOCHEM BIOPH RES CO, V211, P306, DOI 10.1006/bbrc.1995.1811; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; QIAN Z, 1989, J BIOL CHEM, V264, P21720; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; SMITH CD, 1989, J BIOL CHEM, V264, P3206; SUZUKI T, 1994, PLATELETS, V5, P336, DOI 10.3109/09537109409006443; TETTENBORN CS, 1988, BIOCHEM BIOPH RES CO, V155, P249, DOI 10.1016/S0006-291X(88)81076-3; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERMEULEN J, 1990, BIOCHEM J, V271, P693, DOI 10.1042/bj2710693; WHATMORE J, 1994, FEBS LETT, V352, P113, DOI 10.1016/0014-5793(94)00930-9; XIE MS, 1991, BIOCHEM J, V278, P81, DOI 10.1042/bj2780081; YANG SF, 1967, J BIOL CHEM, V242, P477; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z	49	105	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4366	4372						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626786				2022-12-27	WOS:A1996TW96000064
J	Stancato, LF; David, M; CarterSu, C; Larner, AC; Pratt, WB				Stancato, LF; David, M; CarterSu, C; Larner, AC; Pratt, WB			Preassociation of STAT1 with STATE and STAT3 in separate signalling complexes prior to cytokine stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; INTERFERON-ALPHA; TRANSCRIPTIONAL ACTIVATOR; GLUCOCORTICOID RECEPTOR; PROTEINS; ISGF-3	A variety of cytokines and growth factors act through an induction of gene expression mediated by a family of latent transcription factors called STAT (signal transducers and activators of transcription) proteins. Ligand-induced tyrosine phosphorylation of the STATs promotes their homodimer and heterodimer formation and subsequent nuclear translocation. We demonstrate here that STAT protein heterocomplexes exist prior to cytokine treatment, When unstimulated HeLa cells are ruptured in hypotonic buffer without salt or detergent, immunoadsorption of either STAT1 or STAT2 from the resulting cytosol yields coimmunoadsorption of the other STAT protein, Similarly, STAT1-STAT3 heterocomplexes are coimmunoadsorbed from hypotonic cytosol, STAT1 and STAT2 or STAT1 and STAT3 translated in reticulocyte lysate spontaneously form heterocomplexes when the translation lysates are mixed at 0 degrees C, Our data suggest that interferon-alpha/beta-induced tyrosine phosphorylation increases the stability of a preexisting, latent, STAT1-STAT2 signaling complex. Newly translated STAT1 binds in equilibrium fashion to STAT2 and STAT3, but we show that STAT2 and STAT3 exist in separate heterocomplexes with STAT1, consistent with a model in which STAT1 contains a common binding site for other STAT proteins.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; US FDA,DIV CYTOKINE BIOL,BETHESDA,MD 20892	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Food & Drug Administration (FDA)					NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034171, R01DK034171] Funding Source: NIH RePORTER; NCI NIH HHS [CA28010, R01 CA028010] Funding Source: Medline; NIDDK NIH HHS [DK34171, R01 DK034171] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CAMPBELL GS, 1995, P NATL ACAD SCI USA, V270, P3974; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DAVID M, 1992, SCIENCE, V257, P813, DOI 10.1126/science.1496402; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; IHLE JN, 1994, TRENDS ENDOCRIN MET, V5, P137, DOI 10.1016/1043-2760(94)90096-5; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; PRATT WB, 1993, J BIOL CHEM, V268, P21455; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1994, CURR OPIN CELL BIOL, V6, P253, DOI 10.1016/0955-0674(94)90144-9; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STANCATO LF, 1993, J BIOL CHEM, V268, P21711	21	111	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4134	4137						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626752				2022-12-27	WOS:A1996TW96000030
J	Kunapuli, SP; Bradford, HN; Jameson, BA; DeLaCadena, RA; Rick, L; Wassell, RP; Colman, RW				Kunapuli, SP; Bradford, HN; Jameson, BA; DeLaCadena, RA; Rick, L; Wassell, RP; Colman, RW			Thrombin-induced platelet aggregation is inhibited by the heptapeptide Leu(271)-ALa(277) of domain 3 in the heavy chain of high molecular weight kininogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; CYSTEINE PROTEINASES; COAGULANT ACTIVITY; BINDING-SITE; ACTIVATION; RECEPTOR; CALPAIN; IDENTIFICATION; CYSTATIN; CONTAINS	The ability of kininogens to modulate thrombin-induced aggregation of human platelets has been assigned to domain 3 (D3) in the common heavy chain coded for by exons 7, 8, and 9 of kininogen gene. We expressed each of the exons 7, 8, and 9, and various combinations as glutathione S-transferase fusion proteins in Escherichia coli. Each of the exon products 7 (Lys(236)-Gln(292)), 8 (Va1(293)-Gly(328)), and 9 (Gln(329)-Met(357)), and their combinations were evaluated for the ability to inhibit thrombin induced platelet aggregation. Only products containing exon 7 inhibited platelet aggregation induced by thrombin with an IC50 of >20 mu M. A deletion mutant of exon 7 product, polypeptide 7A product (Lys(236)-Lys(270)) did not block thrombin-induced platelet aggregation, while 7B product (Thr-(255)-Gln(292)) and 7C product (Leu(271)-Gln(292)) inhibited aggregation. These findings indicated that the inhibitory activity is localized to residues Leu(271)-Gln(292). Peptides Phe(279)-Ile(283) and Phe(281)-Gln(292) did not block thrombin, and Asn(275)-Phe(279) had only minimal inhibitory activity. A heptapeptide Leu(271)-Ala(277) inhibited thrombin-induced aggregation of platelets with an IC50 of 65 mu M. The effect is specific for the. activation of platelets by thrombin but not ADP or collagen. No evidence for a thrombin-kininogen complex was found, and neither HK nor its derivatives directly inhibited thrombin activity. Knowledge of the critical sequence of kininogen should allow design of compounds that can modulate thrombin activation of platelets.	TEMPLE UNIV, SCH MED, SOL SHERRY THROMBOSIS RES CTR, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, DEPT MED, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, DEPT PATHOL, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, DEPT PHYSIOL, PHILADELPHIA, PA 19140 USA; ARES ADV TECHNOL, RANDOLPH, MA 02368 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University				Bradford, Harlan/0000-0001-5582-278X	NHLBI NIH HHS [HL45486] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL045486] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BRADFORD HN, 1990, BIOCHEM J, V270, P83, DOI 10.1042/bj2700083; BRADFORD HN, 1993, J BIOL CHEM, V268, P26546; COLMAN RW, 1984, J CLIN INVEST, V73, P1249, DOI 10.1172/JCI111326; COLMAN RW, 1970, J BIOL CHEM, V245, P5941; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; DANIEL JL, 1984, J BIOL CHEM, V259, P9826; DELACADENA RA, 1994, THROMB HAEMOSTASIS, V72, P125; DELACADENA RA, 1993, THROMB HAEMOSTASIS, V69, P781; DELACADENA RA, 1994, HEMOSTASIS THROMBOSI, P224; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GASH AK, 1986, AM J CARDIOL, V57, P175, DOI 10.1016/0002-9149(86)90975-6; GUSTAFSON EJ, 1986, J CLIN INVEST, V78, P310, DOI 10.1172/JCI112567; GUSTAFSON EJ, 1989, J CLIN INVEST, V84, P28, DOI 10.1172/JCI114151; HANSON SR, 1988, J CLIN INVEST, V81, P149, DOI 10.1172/JCI113286; HASAN AAK, 1995, BLOOD, V85, P3134, DOI 10.1182/blood.V85.11.3134.bloodjournal85113134; HERAS M, 1989, CIRCULATION, V79, P657, DOI 10.1161/01.CIR.79.3.657; HERWALD H, 1995, J BIOL CHEM, V270, P14634; Holmsen H., 1994, HEMOSTASIS THROMBOSI, P524; HUMPHRIES JE, 1994, FIBRINOLYSIS, V8, P245, DOI 10.1016/0268-9499(94)90050-7; ISHIGURO H, 1987, BIOCHEMISTRY-US, V26, P7021, DOI 10.1021/bi00396a025; JAMIESON GA, 1978, J CLIN INVEST, V61, P861, DOI 10.1172/JCI109000; JIANG YP, 1992, J BIOL CHEM, V267, P3712; KERBIRIOUNABIAS DM, 1984, BRIT J HAEMATOL, V56, P273, DOI 10.1111/j.1365-2141.1984.tb03955.x; KIKUMOTO R, 1984, BIOCHEMISTRY-US, V23, P85, DOI 10.1021/bi00296a014; KITAMURA N, 1985, J BIOL CHEM, V260, P8610; KUNAPULI SP, 1993, J BIOL CHEM, V268, P2486; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARKWARDT F, 1991, THROMB HAEMOSTASIS, V66, P141; MELONI FJ, 1991, J BIOL CHEM, V266, P6786; NURDEN AT, 1974, BRIT J HAEMATOL, V28, P253, DOI 10.1111/j.1365-2141.1974.tb06660.x; PAGE JD, 1994, ARCH BIOCHEM BIOPHYS, V314, P159, DOI 10.1006/abbi.1994.1424; PARKER RC, 1962, METHODS TISSUE CULTU; PHILLIPS DR, 1975, NATURE, V257, P599, DOI 10.1038/257599a0; PURI RN, 1993, BLOOD COAGUL FIBRIN, V4, P495; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMAIER AH, 1986, J CLIN INVEST, V77, P1565, DOI 10.1172/JCI112472; SCHMAIER AH, 1987, J BIOL CHEM, V262, P1405; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; SCOTT CF, 1985, J BIOL CHEM, V260, P856; SCOTT CF, 1984, J CLIN INVEST, V73, P954, DOI 10.1172/JCI111319; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAIT JF, 1987, J BIOL CHEM, V262, P11651; TAKAGAKI Y, 1985, J BIOL CHEM, V260, P8601; TAKAMATSU J, 1986, J CLIN INVEST, V77, P362, DOI 10.1172/JCI112313; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WACHTFOGEL YT, 1994, J BIOL CHEM, V269, P19307	50	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11228	11235		10.1074/jbc.271.19.11228	http://dx.doi.org/10.1074/jbc.271.19.11228			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626672	hybrid			2022-12-27	WOS:A1996UJ94400032
J	Matsunaga, T; Park, CH; Bessho, T; Mu, D; Sancar, A				Matsunaga, T; Park, CH; Bessho, T; Mu, D; Sancar, A			Replication protein A confers structure-specific endonuclease activities to the XPF-ERCC1 and XPG subunits of human DNA repair excision nucleases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								XPF-ERCC1 and XPG proteins are nucleases that are involved in human nucleotide excision repair. In this study, we characterized the structure-specific junction-cutting activities of both nucleases using DNA substrates containing a bubble or loop structure. We found that the junction-cutting activities of XPF-ERCC1 and XPG were greatly stimulated by human replication protein A (RPA), while heterologous single-stranded DNA-binding proteins could not substitute for human RPA. To test for specific interaction between RPA and XPF-ERCC1 as is known to occur between RPA and XPG, we employed a pull-down assay with immobilized ''bubble'' substrate. We found that the binding of XPF-ERCC1 complex to the bubble substrate was enhanced by RPA, suggesting a possible mechanism for RPA in the excision nuclease system, that is the targeting of the nuclease subunits to their specific sites of action. Furthermore, the RPA-promoted junction cutting by XPF-ERCC1 and XPG nucleases was observed with ''loop'' substrates as well, raising the possibility that XPF-ERCC1, XPG, and RPA may function in removing loop structures from DNA, independent of the other subunits of the human excinuclease.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Mu, David/E-8933-2011	Mu, David/0000-0002-7762-0182	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; FRIEDBERG EC, 1995, DNA REPAIR; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; HABRAKEN Y, 1994, NUCLEIC ACIDS RES, V22, P3312, DOI 10.1093/nar/22.16.3312; HABRAKEN Y, 1994, J BIOL CHEM, V269, P31342; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI L, 1995, MOL CELL BIOL, V15, P5396; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NAGAI A, 1995, BIOCHEM BIOPH RES CO, V211, P960, DOI 10.1006/bbrc.1995.1905; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; PARK CH, 1993, NUCLEIC ACIDS RES, V21, P5110, DOI 10.1093/nar/21.22.5110; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637	27	160	163	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11047	11050		10.1074/jbc.271.19.11047	http://dx.doi.org/10.1074/jbc.271.19.11047			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626644	Green Published, hybrid			2022-12-27	WOS:A1996UJ94400004
J	Meikrantz, W; Schlegel, R				Meikrantz, W; Schlegel, R			Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; GENE-EXPRESSION; C-MYC; DNA-REPLICATION; DISTINCT ROLES; ACTIVATION; CDC2; INDUCTION; SURVIVAL; LINES	In many cell types, position in the cell cycle appears to play a role in determining susceptibility to apoptosis (programmed cell death), and expression of various cyclins and activation of cyclin-dependent kinases (CDKs) have been shown to correlate with the onset of apoptosis in a number of experimental systems. To assess the role of CDK-mediated cell cycle events in apoptosis, we have expressed CDK dominant negative mutants in human HeLa cells. Dominant negative mutants of CDC2, CDK2, and CDK3 each suppressed apoptosis induced by both staurosporine and tumor necrosis factor alpha, whereas a dominant negative mutant of CDK5 was without effect. Like CDC2 and CDK2, CDK3 was shown to form a complex with cyclin A in vivo. CDK5 did not bind cyclin A to any detectable extent. Overexpression of wild type CDC2, CDK2, CDK3, or cyclin A (but not cyclin B) markedly elevated the incidence of apoptosis in BCL-2(+) cells, which otherwise fail to respond to these agents, These results help identify cell cycle events that are also important for efficient apoptosis.	HARVARD UNIV,SCH PUBL HLTH,DEPT MOL & CELLULAR TOXICOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health					NCI NIH HHS [CA61626] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA061626] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BELIZARIO JE, 1991, CANCER RES, V51, P2379; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOEHME SA, 1993, EUR J IMMUNOL, V23, P1552, DOI 10.1002/eji.1830230724; BUCHOU T, 1993, ONCOGENE, V8, P1765; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CHEN G, 1995, J EXP MED, V181, P2295, DOI 10.1084/jem.181.6.2295; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FANG F, 1993, J CELL SCI, V106, P983; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOWARD MK, 1993, J NEUROCHEM, V60, P1783, DOI 10.1111/j.1471-4159.1993.tb13404.x; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KERR JFR, 1991, APOPTOSIS MOL BASIS, P5; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KULL FC, 1981, CANCER RES, V41, P4885; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; MARTI A, 1994, ONCOGENE, V9, P1213; MEIKRANTZ W, 1990, P NATL ACAD SCI USA, V87, P9600, DOI 10.1073/pnas.87.24.9600; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MYERSON M, 1992, EMBO J, V11, P2909; NISHIOKA WK, 1992, J EXP MED, V175, P23, DOI 10.1084/jem.175.1.23; NISHIOKA WK, 1994, J EXP MED, V179, P769, DOI 10.1084/jem.179.2.769; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; SCOTT DW, 1986, J EXP MED, V164, P156, DOI 10.1084/jem.164.1.156; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; STEINMANN KE, 1994, ONCOGENE, V9, P387; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALLACH D, 1984, J IMMUNOL, V132, P2464; WESSELBORG S, 1993, J IMMUNOL, V150, P4338; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	53	185	189	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10205	10209		10.1074/jbc.271.17.10205	http://dx.doi.org/10.1074/jbc.271.17.10205			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626584	hybrid			2022-12-27	WOS:A1996UG25700056
J	Peng, M; Huang, L; Xie, Z; Huang, WH; Askari, A				Peng, M; Huang, L; Xie, Z; Huang, WH; Askari, A			Partial inhibition of Na+/K+-ATPase by ouabain induces the Ca2+-dependent expressions of early-response genes in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MYOCARDIAL-CELLS; SIGNAL-TRANSDUCTION PATHWAYS; SODIUM-PUMP INHIBITION; CHICK HEART-CELLS; C-FOS; PARACRINE MECHANISM; 5'-FLANKING REGION; PROTEIN-SYNTHESIS; CATION-TRANSPORT; 2ND MESSENGERS	Exposure of neonatal rat cardiac myocytes to ouabain concentrations that caused partial inhibition of Na+/K+-ATPase but no loss of viability, increased c-fos and c-jun mRNAs and the transcription factor AP-1. The increased mRNAs were proportional to the extent of inhibition of Na+/K+-ATPase and the resulting rise in steady state intracellular Ca2+ concentration. The rapid and sustained increase of c-fos mRNA was shown to be due to increased transcriptional rate. Induction of c-fos by ouabain was prevented when either extracellular or intracellular Ca2' was lowered and was attenuated by pretreatment of myocytes with a phorbol ester under conditions known to down-regulate protein kinase C. Exposure to ouabain for 24-48 h also increased total transcriptional activity and protein content of myocytes. The findings suggest that the same signal responsible for the positive inotropic action of ouabain, i.e, net influx of Ca2+ caused by partial inhibition of Na+/K+-ATPase, also initiates the rapid protein kinase C-dependent inductions of the early-response genes, the subsequent regulations of other cardiac genes by the resulting transcription factors, and stimulation of myocyte growth. Whether these hitherto unrecognized effects of cardiac glycosides are obtained in the intact heart and their relevance to the therapeutic uses of these drugs remain to be determined.	MED COLL OHIO,DEPT PHARMACOL,TOLEDO,OH 43699						NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36573] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKERA T, 1991, LIFE SCI, V48, P97, DOI 10.1016/0024-3205(91)90402-W; ALLO SN, 1992, AM J PHYSIOL, V263, pC319, DOI 10.1152/ajpcell.1992.263.2.C319; ARYSTARKHOVA E, 1994, SODIUM PUMP, P230; BARRY WH, 1985, CIRC RES, V56, P231, DOI 10.1161/01.RES.56.2.231; BIEDERT S, 1979, J GEN PHYSIOL, V74, P479, DOI 10.1085/jgp.74.4.479; BISHOPRIC NH, 1992, MOL CELL BIOL, V12, P292; BLAUSTEIN MP, 1993, AM J PHYSIOL, V264, pC1367, DOI 10.1152/ajpcell.1993.264.6.C1367; BROWN JH, 1992, TRENDS CARDIOVAS MED, V2, P209, DOI 10.1016/1050-1738(92)90026-O; CAYANIS E, 1992, J MEMBRANE BIOL, V125, P163; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; EISNER DA, 1992, HEART CARDIOVASCULAR, V1, P863; GOLOMB E, 1994, AM J HYPERTENS, V7, P69, DOI 10.1093/ajh/7.1.69; GOSWAMI SK, 1992, CELL MOL BIOL, V38, P49; GOTOH H, 1993, BIOCHEM BIOPH RES CO, V194, P72, DOI 10.1006/bbrc.1993.1786; HELLER M, 1988, BIOCHIM BIOPHYS ACTA, V939, P595, DOI 10.1016/0005-2736(88)90107-1; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1981; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KAPLAN JG, 1978, ANNU REV PHYSIOL, V40, P19, DOI 10.1146/annurev.ph.40.030178.000315; KATZ AM, 1994, ANN INTERN MED, V121, P363, DOI 10.7326/0003-4819-121-5-199409010-00009; KENT RL, 1989, CIRC RES, V64, P74, DOI 10.1161/01.RES.64.1.74; KIM D, 1984, CIRC RES, V55, P39, DOI 10.1161/01.RES.55.1.39; KIM D, 1987, CIRC RES, V60, P185, DOI 10.1161/01.RES.60.2.185; KIRTANE A, 1994, J MEMBRANE BIOL, V137, P9; KOVACICMILIVOJEVIC B, 1992, MOL CELL BIOL, V12, P292, DOI 10.1128/MCB.12.1.292; LACHANT NA, 1995, AM J HEMATOL, V49, P56, DOI 10.1002/ajh.2830490110; LEE G, 1994, MOL CELL BIOL, V14, P4579, DOI 10.1128/MCB.14.7.4579; LEE HR, 1988, J BIOL CHEM, V263, P7352; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCALL D, 1979, AM J PHYSIOL, V236, pC87, DOI 10.1152/ajpcell.1979.236.1.C87; MCDERMOTT PJ, 1989, CIRC RES, V64, P542, DOI 10.1161/01.RES.64.3.542; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; NAKAGAWA Y, 1992, J BIOL CHEM, V267, P8785; NG YC, 1987, AM J PHYSIOL, V252, pH1016; ORLOWSKI J, 1990, J BIOL CHEM, V265, P3462; OTANI H, 1989, MOL CELL BIOCHEM, V90, P111; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PENG M, 1995, CELL MOL BIOL RES, V41, P189; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PUCEAT M, 1991, BIOCHEM J, V274, P55, DOI 10.1042/bj2740055; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SCHUNKERT H, 1995, CIRC RES, V76, P489, DOI 10.1161/01.RES.76.3.489; Schwartz A, 1988, Prog Clin Biol Res, V268B, P321; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SHULL MM, 1990, GENOMICS, V6, P451, DOI 10.1016/0888-7543(90)90475-A; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SIMPSON PC, 1991, MOL CELL BIOCHEM, V104, P35; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; VANBILSEN M, 1993, CARDIOVASC RES, V27, P1140; VEMURI R, 1989, AM J PHYSIOL, V256, pC1273, DOI 10.1152/ajpcell.1989.256.6.C1273; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; XIE ZJ, 1989, ANAL BIOCHEM, V183, P215, DOI 10.1016/0003-2697(89)90470-3; YAGAWA Y, 1990, BIOCHIM BIOPHYS ACTA, V1049, P286, DOI 10.1016/0167-4781(90)90099-N; ZHENG JS, 1994, CIRC RES, V74, P1034, DOI 10.1161/01.RES.74.6.1034	59	170	175	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10372	10378		10.1074/jbc.271.17.10372	http://dx.doi.org/10.1074/jbc.271.17.10372			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626609	hybrid			2022-12-27	WOS:A1996UG25700081
J	Tzameli, I; Zannis, VI				Tzameli, I; Zannis, VI			Binding specificity and modulation of the ApoA-I promoter activity by homo- and heterodimers of nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; 9-CIS RETINOIC ACID; HORMONE RESPONSE ELEMENT; THYROID-HORMONE; PLASMA-LEVELS; GENE; TRANSCRIPTION; EXPRESSION; RXR; SUPERFAMILY	Three proximal regulatory elements, AIB, AIC, and AID, of the apoA-I gene are necessary and sufficient for its hepatic expression in vivo and in vitro. DNA binding and competition assays showed that elements AIB and AID contain hormone response elements composed of imperfect direct repeats that support the binding of the hepatic nuclear factor-4, other nuclear orphan receptors, and the ligand-dependent nuclear receptors retinoic X receptor (RXR alpha), RXR alpha/RAR alpha, and RXR alpha/T(3)R beta. Substitution mutations on repeats 1 and 2 in the hormone response sites of elements AIB and AID, respectively, abolished the binding of all nuclear receptors and reduced promoter activity to background levels, indicating the importance of both hormone response elements for the hepatic expression of the apoA-I gene. Cotransfection experiments in HepG2 cells with normal and mutated promoter constructs and plasmids expressing nuclear hormone receptors showed that RXR alpha homodimers transactivated the wild type promoter 150% of control, in the presence of 9-cis-retinoic acid (RA), whereas RXR alpha/T(3)R beta heterodimers repressed transcription to 60% of control, in the presence of T-3. RXR alpha/RAR alpha and hepatic nuclear factor-4 did not affect the transcription, driven by the proximal apoA-I promoter. Potassium permanganate and dimethyl sulfate interference experiments showed that RXR alpha homodimers, RXR alpha/RAR alpha, and RXR alpha/T(3)R beta heterodimers participate in protein-DNA interactions with 12, 13, and 11 out of the 14 nucleotides, respectively, that span repeats 1 and 2 and the spacer region separating them on the hormone response element of element AID. The binding of RXR alpha homodimers and RXR alpha/T(3)R beta heterodimers is associated with ligand-dependent activation by 9-cis-RA or repression by T-3. Upon deletion or mutation of repeat 1, homodimeric binding of RXR alpha is lost whereas heterodimeric binding is retained. This heterodimeric binding to the mutated element AID is mediated solely by interactions with repeat 2 and one adjacent nucleotide and is confined to a heptameric core recognition motif. The interactions of the RXR alpha heterodimers with repeat 2 are associated with low levels of ligand independent transcriptional activity. The findings suggest that the specific types of homo- and heterodimers of nuclear hormone receptors occupying the hormone response elements of apoA-I and the availability of the ligand may play an important role in the transcriptional regulation of the human apoA-I gene.	BOSTON UNIV,MOLEC GENET SECT,CTR ADV BIOMED RES,CARDIOVASC INST,BOSTON,MA 02118; BOSTON UNIV,MED CTR,DEPT MED,BOSTON,MA 02118; BOSTON UNIV,MED CTR,DEPT BIOCHEM,BOSTON,MA 02118	Boston University; Boston University; Boston University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048739, R01HL033952] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-33952, HL-48739] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CASTELLI WP, 1977, CIRCULATION, V55, P767, DOI 10.1161/01.CIR.55.5.767; CHEN HW, 1995, P NATL ACAD SCI USA, V92, P422, DOI 10.1073/pnas.92.2.422; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GILLER T, 1995, J LIPID RES, V36, P1021; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LENG XH, 1994, J BIOL CHEM, V269, P31436; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MAKRIDES SC, 1988, EUR J BIOCHEM, V173, P465, DOI 10.1111/j.1432-1033.1988.tb14022.x; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1994, RETINOIDS BIOL CHEM, V8, P319; MEITUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRUSS M, 1990, P NATL ACAD SCI USA, V87, P7180, DOI 10.1073/pnas.87.18.7180; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VUDAC N, 1994, J BIOL CHEM, V269, P31012; WALSH A, 1989, J BIOL CHEM, V264, P6488; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	46	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8402	8415		10.1074/jbc.271.14.8402	http://dx.doi.org/10.1074/jbc.271.14.8402			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626539				2022-12-27	WOS:A1996UD60000079
J	Belan, PV; Gerasimenko, OV; Tepikin, AV; Petersen, OH				Belan, PV; Gerasimenko, OV; Tepikin, AV; Petersen, OH			Localization of Ca2+ extrusion sites in pancreatic acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOCRINE PANCREAS; INOSITOL TRISPHOSPHATE; PLASMA-MEMBRANE; CALCIUM; SECRETION; OSCILLATIONS; RELEASE; PUMP	We have investigated the localization of Ca2+ extrusion sites in mouse pancreatic acinar cells, Employing a new technique, in which high resolution localization of cellular Ca2+ exit is achieved by confocal microscopy and a Ca2+-sensitive fluorescent probe coupled to heavy dextran to slow down diffusion of extracellular Ca2+, it is shown directly that the secretory pole (secretory granule area) is the major site for Ca2+ extrusion following agonist stimulation, This Ca2+ extrusion appears not to be a consequence of exocytosis, as assessment of secretion under our experimental conditions (low external Ca2+ concentration, room temperature) using the technique of monitoring quinacrine fluorescence shows little loss of secretory granules in spite of sustained Ca2+ exit. We conclude that Ca2+ is primarily extruded by Ca2+ pumps from the secretory pole and propose that this process is useful for maintaining a high Ca2+ concentration in the acinar lumen, which is necessary for promotion of endocytosis.	UNIV LIVERPOOL,MRC,SECRETORY CONTROL RES GRP,PHYSIOL LAB,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool			Gerasimenko, Oleg/A-6622-2010; Belan, Pavel/AAV-3522-2021; Petersen, Ole H/E-8708-2010	Gerasimenko, Oleg/0000-0003-2573-8258; Belan, Pavel/0000-0001-5429-3716; Petersen, Ole/0000-0002-6998-0380; Tepikin, Alexei/0000-0002-8172-7513	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; BOLENDER RP, 1974, J CELL BIOL, V61, P269, DOI 10.1083/jcb.61.2.269; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CHANG A, 1989, HDB PHYSL GASTROINTE, V3, P531; ENYEDI A, 1994, J BIOL CHEM, V269, P41; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; Humbert JP, 1996, J BIOL CHEM, V271, P478, DOI 10.1074/jbc.271.1.478; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; MARUYAMA Y, 1993, EMBO J, V12, P3017, DOI 10.1002/j.1460-2075.1993.tb05970.x; MARUYAMA Y, 1989, PFLUG ARCH EUR J PHY, V413, P438, DOI 10.1007/BF00584496; MUALLEM S, 1989, ANNU REV PHYSIOL, V51, P83; NICAISE G, 1992, BIOL CELL, V75, P89, DOI 10.1016/0248-4900(92)90128-N; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; TEPIKIN AV, 1992, J BIOL CHEM, V267, P14073; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; TOESCU EC, 1995, J BIOL CHEM, V270, P8528, DOI 10.1074/jbc.270.15.8528; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; UEDA N, 1977, PFLUG ARCH EUR J PHY, V370, P179, DOI 10.1007/BF00581692; YOO SH, 1990, J BIOL CHEM, V265, P13446; ZHANG BX, 1992, J BIOL CHEM, V267, P15419	25	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7615	7619		10.1074/jbc.271.13.7615	http://dx.doi.org/10.1074/jbc.271.13.7615			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631796				2022-12-27	WOS:A1996UC77400064
J	Cartier, GE; Yoshikami, DJ; Gray, WR; Luo, SQ; Olivera, BM; McIntosh, JM				Cartier, GE; Yoshikami, DJ; Gray, WR; Luo, SQ; Olivera, BM; McIntosh, JM			A new alpha-conotoxin which targets alpha 3 beta 2 nicotinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT; LOPHOTOXIN; EXPRESSION; DIVERSITY; PEPTIDES; TOXINS; PROBES; BRAIN; VENOM	We have isolated a 16-amino acid peptide from the venom of the marine snail Conus magus which potently blocks nicotinic acetylcholine receptors (nAChRs) composed of alpha 3 beta 2 subunits. This peptide, named alpha-conotoxin MII, was identified by electrophysiologically screening venom fractions against cloned nicotinic receptors expressed in Xenopus oocytes. The peptide's structure, which has been confirmed by mass spectrometry and total chemical synthesis, differs significantly from those of all previously isolated alpha-conotoxins. Disulfide bridging, however, is conserved. The toxin blocks the response to acetylcholine in oocytes expressing alpha 3 beta 2 nAChRs with an IC50 of 0.5 nM and is 2-4 orders of magnitude less potent on other nAChR subunit combinations. We have recently reported the isolation and characterization of alpha-conotoxin ImI, which selectively targets homomeric alpha 7 neuronal nAChRs. Yet other alpha-conotoxins selectively block the muscle subtype of nAChR. Thus, it is increasingly apparent that alpha-conotoxins represent a significant resource for ligands with which to probe structure-function relationships of various nAChR subtypes.	UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT PSYCHIAT, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					PHS HHS [P01 48677] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; ABRAMSON SN, 1988, J BIOL CHEM, V263, P18568; Arneric Stephen P., 1995, P95; BOULTER J, 1986, NATURE, V319, P368, DOI 10.1038/319368a0; CHANGEUX JP, 1993, SCI AM, V269, P58, DOI 10.1038/scientificamerican1193-58; CHIAPPINELLI VA, 1993, NATURAL SYNTHETIC NE, P66; CRUZ LJ, 1985, J TOXICOL-TOXIN REV, V4, P107, DOI 10.3109/15569548509014416; DENERIS ES, 1988, NEURON, V1, P45, DOI 10.1016/0896-6273(88)90208-5; DUVOISIN RM, 1989, NEURON, V3, P487, DOI 10.1016/0896-6273(89)90207-9; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; FAINZILBER M, 1994, BIOCHEMISTRY-US, V33, P9523, DOI 10.1021/bi00198a018; FENICAL W, 1981, SCIENCE, V212, P1512, DOI 10.1126/science.6112796; FIORDALISI JJ, 1994, BIOCHEMISTRY-US, V33, P12962, DOI 10.1021/bi00248a004; GERZANICH V, 1994, MOL PHARMACOL, V45, P212; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; GOLDMAN D, 1987, CELL, V48, P965, DOI 10.1016/0092-8674(87)90705-7; GRAY WR, 1983, J BIOL CHEM, V258, P2247; GRAY WR, 1981, J BIOL CHEM, V256, P4734; GRAY WR, 1995, J NEUR ABSTR, V21, P10; GROEBE DR, 1995, MOL PHARMACOL, V48, P105; HANN RM, 1994, BIOCHEMISTRY-US, V33, P14058, DOI 10.1021/bi00251a014; HOPKINS C, 1995, J BIOL CHEM, V270, P22361, DOI 10.1074/jbc.270.38.22361; JOHNSON DS, 1995, MOL PHARMACOL, V48, P194; KOSUGE T, 1981, TETRAHEDRON LETT, V22, P3417, DOI 10.1016/S0040-4039(01)81920-1; KREIENKAMP HJ, 1994, J BIOL CHEM, V269, P8108; LUETJE CW, 1990, J NEUROCHEM, V55, P632, DOI 10.1111/j.1471-4159.1990.tb04180.x; MARTINEZ JS, 1995, BIOCHEMISTRY-US, V34, P14519, DOI 10.1021/bi00044a030; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; MCINTOSH M, 1982, ARCH BIOCHEM BIOPHYS, V218, P329, DOI 10.1016/0003-9861(82)90351-4; MYERS RA, 1991, BIOCHEMISTRY-US, V30, P9370, DOI 10.1021/bi00102a034; MYERS RA, 1993, CHEM REV, V93, P1923, DOI 10.1021/cr00021a013; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PATRICK J, 1987, ANN NY ACAD SCI, V505, P194, DOI 10.1111/j.1749-6632.1987.tb51292.x; RAMILO CA, 1992, BIOCHEMISTRY-US, V31, P9919, DOI 10.1021/bi00156a009; SEGUELA P, 1993, J NEUROSCI, V13, P596; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; Taylor P., 1990, PHARMACOL BASIS THER, P166; WADA K, 1988, SCIENCE, V240, P330, DOI 10.1126/science.2832952; WARD JM, 1990, FEBS LETT, V270, P45, DOI 10.1016/0014-5793(90)81231-C; ZAFARALLA GC, 1988, BIOCHEMISTRY-US, V27, P7102, DOI 10.1021/bi00418a065	40	440	458	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7522	7528		10.1074/jbc.271.13.7522	http://dx.doi.org/10.1074/jbc.271.13.7522			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631783				2022-12-27	WOS:A1996UC77400051
J	Everett, SA; Dennis, MF; Patel, KB; Maddix, S; Kundu, SC; Willson, RL				Everett, SA; Dennis, MF; Patel, KB; Maddix, S; Kundu, SC; Willson, RL			Scavenging of nitrogen dioxide, thiyl, and sulfonyl free radicals by the nutritional antioxidant beta-carotene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; ELECTRON-TRANSFER-REACTIONS; LOW-DENSITY-LIPOPROTEIN; PULSE-RADIOLYSIS; LIPID-PEROXIDATION; ABSORPTION-SPECTRA; SINGLET OXYGEN; OXIDATION; CYSTEINE; ALCOHOLS	Mechanisms of free radical scavenging by the nutritional antioxidant beta-carotene have been investigated by pulse radiolysis. Free radicals, which can initiate the chain of lipid peroxidation, including nitrogen dioxide (NO2.), thiyl (RS(.)), and sulfonyl (RSO(2)(.)) radicals, are rapidly scavenged by beta-carotene, Absolute rate constant k[NO2. + beta-carotene] = (1.1 +/- 0.1) x 10(8) M(-1) s(-1) and for the glutathione thiyl radical k[GS(.) + beta-carotene] = (2.2 +/- 0.1) x 10(8) M(-1) s(-1) have been determined, The mechanisms however are mutually exclusive, the former involving electron transfer to generate the radical-cation [beta-carotene](sic) and the latter by radical-addition to generate an adduct-radical [RS ...beta-carotene](.). Rate constants for thiyl radical-addition reactions vary from 10(6) to 10(9) M(-1) s(-1) and correlate with the lipophilicity of the thiyl radical under study, Sulfonyl radicals undergo both electron abstraction, [beta-carotene](sic) and radical-addition, [RSO(2) ...beta-carotene](.) in an approximate 3:1 ratio, The beta-carotene radical-cation and adduct-radicals are highly resonance stabilized and undergo slow bimolecular decay to non-radical products, These carotenoid-derived radicals react differently with oxygen, a factor which is expected to influence the antioxidant activity of beta-carotene within tissues of varying oxygen tension in vivo.	BRUNEL UNIV, DEPT BIOL & BIOCHEM, UXBRIDGE UB8 3PH, MIDDX, ENGLAND	Brunel University	Everett, SA (corresponding author), MT VERNON HOSP, GRAY LAB, POB 100, NORTHWOOD HA6 2JR, MIDDX, ENGLAND.		Kundu, Subhas C/AAC-1317-2020	Kundu, Subhas C/0000-0002-7170-2291				ADAMS GE, 1968, T FARADAY SOC, V64, P902, DOI 10.1039/tf9686400902; Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; [Anonymous], 1994, Ann Epidemiol, V4, P1, DOI 10.1016/1047-2797(94)90036-1; Asmus, 1990, SULFUR CTR REACTIVE; ASMUS KD, 1984, METHOD ENZYMOL, V105, P167; BENAZIZ A, 1971, PHYTOCHEMISTRY, V10, P1445, DOI 10.1016/0031-9422(71)85006-9; BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156; CHATGILIALOGLU C, 1987, J PHYS CHEM-US, V91, P3747, DOI 10.1021/j100298a007; CHAUVET JP, 1983, J PHYS CHEM-US, V87, P592, DOI 10.1021/j100227a016; CHEESEMAN KH, 1993, FREE RADICALS MED; CHUGAHUJA JK, 1993, J AM DIET ASSOC, V93, P318, DOI 10.1016/0002-8223(93)91559-9; CONN PF, 1991, J PHOTOCH PHOTOBIO B, V11, P41, DOI 10.1016/1011-1344(91)80266-K; CONN PF, 1992, FREE RADICAL RES COM, V16, P401, DOI 10.3109/10715769209049190; DAWE EA, 1975, J CHEM SOC FARAD T 1, V71, P2162, DOI 10.1039/f19757102162; DIPLOCK A, 1995, BIOCHEMIST, V17, P16; DIPLOCK AT, 1991, AM J CLIN NUTR, V20, P123; DIX TA, 1993, CHEM RES TOXICOL, V6, P2, DOI 10.1021/tx00031a001; EVERETT SA, 1995, BIOCHEM SOC T, V23, pS230, DOI 10.1042/bst023230s; FOOTE CS, 1968, J AM CHEM SOC, V90, P6233, DOI 10.1021/ja01024a061; FORNI LG, 1986, J CHEM SOC PERK T 2, P1, DOI 10.1039/p29860000001; FUNGARD U, 1995, IN PRESS EUR J CANC; GEY KF, 1993, BRIT MED BULL, V49, P679, DOI 10.1093/oxfordjournals.bmb.a072640; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HARMAN LS, 1984, J BIOL CHEM, V259, P5606; HILL TJ, 1995, J AM CHEM SOC, V117, P8322, DOI 10.1021/ja00137a004; HUIE RE, 1994, TOXICOLOGY, V89, P193, DOI 10.1016/0300-483X(94)90098-1; HUSTON P, 1992, J AM CHEM SOC, V114, P9510, DOI 10.1021/ja00050a033; JIALAL I, 1991, BIOCHIM BIOPHYS ACTA, V1086, P134, DOI 10.1016/0005-2760(91)90164-D; Karmann W., 1969, INT J RADIAT PHYS CH, V1, P395; KENNEDY TA, 1991, CHEM RES TOXICOL, V4, P290, DOI 10.1021/tx00021a005; KENNEDY TA, 1992, J BIOL CHEM, V267, P4658; KIKUGAWA K, 1994, FREE RADICAL RES, V21, P399, DOI 10.3109/10715769409056592; KRINSKY NI, 1989, FREE RADICAL BIO MED, V7, P617, DOI 10.1016/0891-5849(89)90143-3; KRINSKY NI, 1995, ATHEROSCLEROSIS, V112, P187; KUNDU SC, 1995, METHOD ENZYMOL, V251, P69, DOI 10.1016/0076-6879(95)51111-3; MILLER KW, 1985, ANAL BIOCHEM, V145, P21, DOI 10.1016/0003-2697(85)90321-5; PACKER JE, 1981, BIOCHEM BIOPH RES CO, V98, P901, DOI 10.1016/0006-291X(81)91196-7; PALOZZA P, 1992, METHOD ENZYMOL, V213, P403; PETO R, 1981, NATURE, V290, P201, DOI 10.1038/290201a0; PRINCEN HMG, 1992, ARTERIOSCLER THROMB, V12, P554, DOI 10.1161/01.ATV.12.5.554; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; PRYOR WA, 1981, SCIENCE, V214, P435, DOI 10.1126/science.214.4519.435; REAVEN PD, 1994, ARTERIOSCLER THROMB, V14, P1162, DOI 10.1161/01.ATV.14.7.1162; RICHTERS A, 1988, J TOXICOL ENV HEALTH, V25, P383, DOI 10.1080/15287398809531217; ROMERO FJ, 1992, J BIOL CHEM, V267, P1680; SANTAMARIA L, 1992, J NUTR SCI VITAMINOL, V67, P563; SCHONEICH C, 1989, BIOCHEM BIOPH RES CO, V161, P113, DOI 10.1016/0006-291X(89)91568-4; SCHONEICH C, 1992, ARCH BIOCHEM BIOPHYS, V292, P456, DOI 10.1016/0003-9861(92)90016-P; SCHONEICH C, 1989, FREE RADICAL RES COM, V6, P393, DOI 10.3109/10715768909087923; SCHONEICH C, 1990, RADIAT ENVIRON BIOPH, V29, P263, DOI 10.1007/BF01210407; SCHULER RH, 1981, J PHYS CHEM-US, V85, P192, DOI 10.1021/j150602a017; SCHWARTZ JL, 1993, ANN NY ACAD SCI, V686, P262, DOI 10.1111/j.1749-6632.1993.tb39185.x; SEHESTED K, 1968, J PHYS CHEM-US, V72, P626, DOI 10.1021/j100848a040; SEVILLA MD, 1990, INT J RADIAT BIOL, V57, P65, DOI 10.1080/09553009014550351; Spinks J. W. T., 1990, INTRO RAD CHEM, P364; Stanbury D. M., 1989, ADV INORG CHEM RA, V33, P69, DOI 10.1016/S0898-8838(08)60194-4; SUNDQUIST AR, 1994, METHOD ENZYMOL, V234, P384; TAMBA M, 1986, INT J RADIAT BIOL, V50, P595, DOI 10.1080/09553008614550991; TINKLER JH, 1995, NAT MED, V1, P98; TINKLER JH, 1994, J PHOTOCH PHOTOBIO B, V26, P283, DOI 10.1016/1011-1344(94)07049-0; TRUSCOTT TG, 1973, PHOTOCHEM PHOTOBIOL, V17, P43, DOI 10.1111/j.1751-1097.1973.tb06329.x; VANPOPPEL G, 1993, EUR J CANCER, V56, P211; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; WARD JF, 1984, INT J RADIAT ONCOL, V10, P1533, DOI 10.1016/0360-3016(84)90497-8; Ward Paul, 1995, P1; WARDMAN P, 1989, J PHYS CHEM REF DATA, V18, P1637, DOI 10.1063/1.555843; WARDMAN P, 1994, INT J RADIAT BIOL, V65, P35, DOI 10.1080/09553009414550051; WARDMAN P, 1995, METHOD ENZYMOL, V251, P31, DOI 10.1016/0076-6879(95)51108-3; WILLSON RL, 1983, BIOL VITAMIN E, P19; WINTERBOURN CC, 1994, ARCH BIOCHEM BIOPHYS, V314, P284, DOI 10.1006/abbi.1994.1444; WOLFENDEN BS, 1982, J CHEM SOC PERK T 2, P805, DOI 10.1039/p29820000805; YIM MB, 1994, J BIOL CHEM, V269, P1621; ZIEGLER RG, 1993, ANN NY ACAD SCI, V691, P110, DOI 10.1111/j.1749-6632.1993.tb26162.x	73	160	168	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					3988	3994						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626730	hybrid			2022-12-27	WOS:A1996TW96000008
J	Luo, CM; Tang, W; Mekeel, KL; DeFrank, JS; Anne, RP; Powell, SN				Luo, CM; Tang, W; Mekeel, KL; DeFrank, JS; Anne, RP; Powell, SN			High frequency and error-prone DNA recombination in ataxia telangiectasia cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; IONIZING-RADIATION; V(D)J RECOMBINATION; HOMOLOGOUS RECOMBINATION; SCID MUTATION; UV; IRRADIATION; DEFECTS; P53; INSTABILITY	The only specific DNA repair defect found in ataxia telangiectasia (A-T) cells is mis-repair of cleaved DNA In this report we measured DNA recombination, given its role in DNA repair and genetic instability. Using plasmids containing selectable reporter genes, we found a higher frequency of both chromosomal recombination (>100 times) and extra-chromosomal recombination (27 times) in SV40-transformed A-T cell lines compared with in an SV40-transformed normal fibroblast cell line. Southern analysis of single A-T colonies exhibiting postintegration recombination revealed that 24/27 had undergone aberrant rearrangements; recombination in normal fibroblast colonies was achieved by gene conversion in 8/11 clones and 10/11 clones showed unchanged copies of the plasmid. Using co-transfection of two integrating plasmids, each containing a separate deletion in the xgprt reporter gene, the 27 times difference in extrachromosomal recombination was found when the plasmids were cleaved at a distance from the reporter gene. When the plasmids were cleaved within the reporter gene, the co-transfection frequency was reduced in A-T, but was increased in normal cells. We conclude that A-T cell lines have not only a high frequency chromosomal and extra-chromosomal recombination, but also exhibit error-prone recombination of cleaved DNA.	HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT RADIAT ONCOL, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital					NCI NIH HHS [CA58985] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058985] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; COLE J, 1976, MUTAT RES, V41, P377, DOI 10.1016/0027-5107(76)90110-X; COX R, 1984, BRIT J CANCER, V49, P67; DASGUPTA UB, 1980, MOL GEN GENET, V178, P617, DOI 10.1007/BF00337869; DEBENHAM PG, 1987, J CELL SCI, P177; EDWARDS MJ, 1980, NATURE, V287, P745, DOI 10.1038/287745a0; GATTI RA, 1994, INT J RADIAT BIOL, V66, pS57, DOI 10.1080/09553009414551861; HAMILTON AA, 1987, MOL CELL BIOL, V7, P1409, DOI 10.1128/MCB.7.4.1409; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; HSIEH CL, 1993, J BIOL CHEM, V268, P20105; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; LIPKOWITZ S, 1992, P NATL ACAD SCI USA, V89, P5301, DOI 10.1073/pnas.89.12.5301; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MEYN MS, 1994, INT J RADIAT BIOL, V66, pS141; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; NASRIN N, 1994, CANCER GENET CYTOGEN, V77, P14, DOI 10.1016/0165-4608(94)90142-2; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; POWELL S, 1993, MUTAT RES, V294, P9, DOI 10.1016/0921-8777(93)90053-J; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TAYLOR AMR, 1976, NATURE, V260, P441, DOI 10.1038/260441a0; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; TAYLOR AMR, 1994, INT J RADIAT BIOL, V65, P65, DOI 10.1080/09553009414550091; TAYLOR AMR, 1978, MUTAT RES, V50, P407, DOI 10.1016/0027-5107(78)90045-3; THACKER J, 1994, INT J RADIAT BIOL, V66, pS87; THACKER J, 1989, MUTAT RES, V220, P187, DOI 10.1016/0165-1110(89)90024-9; TIMME TL, 1989, PLASMID, V22, P1, DOI 10.1016/0147-619X(89)90030-9; TSUJIMURA T, 1990, P NATL ACAD SCI USA, V87, P1566, DOI 10.1073/pnas.87.4.1566; WAHLS WP, 1990, SOMAT CELL MOLEC GEN, V16, P321, DOI 10.1007/BF01232460	33	68	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4497	4503						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626804				2022-12-27	WOS:A1996TW96000082
J	Shin, WS; Hong, YH; Peng, HB; DeCaterina, R; Libby, P; Liao, JK				Shin, WS; Hong, YH; Peng, HB; DeCaterina, R; Libby, P; Liao, JK			Nitric oxide attenuates vascular smooth muscle cell activation by interferon-gamma - The role of constitutive NF-kappa B activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE-1 VCAM-1; TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; GENE-EXPRESSION; NUCLEAR FACTOR; ATHEROSCLEROTIC PLAQUES; BALLOON INJURY; MACROPHAGES; MECHANISM; ATHEROGENESIS	Atherogenesis involves cellular immune responses and altered vascular smooth muscle cell (SMC) function. Cytokines such as interleukin (IL)-1 alpha and interferon-gamma (TFN-gamma) may contribute to this process by activating SMC. To determine whether the anti-atherogenic mediator, nitric oxide ((NO)-N-.), can modulate cytokine-induced SMC activation, we investigated the effects of various (NO)-N-.-generating compounds on the expression of intercellular and vascular cell adhesion molecules (ICAM-1 and VCAM-1). Induction of ICAM-1 expression by IL-1 alpha and VCAM-1 expression by IFN-gamma was attenuated by (NO)-N-. donors but not by cGMP analogues. Nuclear run-on assays and transfection studies using various VCAM-1 promoter constructs linked to the chloramphenicol acetyltransferase reporter gene showed that (NO)-N-. repressed IFN-gamma-induced VCAM-1 gene transcription, in part, through inhibition of nuclear factor-kappa B (NF-kappa B). Electrophoretic mobility shift assay revealed that SMC possess basal constitutive NF-kappa B activity, which was augmented by treatment with IL-1 alpha. In contrast, IFN-gamma induced and activated interferon regulatory factor (IRF)-1 but had little effect on basal constitutive NF-kappa B activity. (NO)-N-. donors had no inhibitory effect on IRF-1 activation but did inhibit basal and IL-1 alpha-stimulated NF-kappa B activation. These findings suggest that the induction of ICAM-1 and VCAM-1 expression requires NF-kappa B activation and that (NO)-N-. attenuates IFN-gamma-induced VCAM-1 expression primarily by inhibiting basal constitutive NF-kappa B activity in SMC.	BRIGHAM & WOMENS HOSP, DIV CARDIOVASC, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Libby, Peter/AAY-6404-2021; De Caterina, Raffaele/K-3857-2016	Libby, Peter/0000-0002-1502-502X; De Caterina, Raffaele/0000-0003-1637-574X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052233] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-05280, HL-52233] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BELLAS RE, 1995, J CLIN INVEST, V96, P2521, DOI 10.1172/JCI118313; BENNETT MR, 1994, CIRC RES, V74, P525, DOI 10.1161/01.RES.74.3.525; BRUNE B, 1989, J BIOL CHEM, V264, P8455; COLLINS T, 1993, LAB INVEST, V68, P499; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FREYSCHUSS A, 1993, J CLIN INVEST, V91, P1282, DOI 10.1172/JCI116326; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GARG UC, 1991, J BIOL CHEM, V266, P9; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; IGNARRO LJ, 1991, BLOOD VESSELS, V28, P67; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LAWRENCE R, 1994, J BIOL CHEM, V269, P28913; LI HM, 1993, AM J PATHOL, V143, P1551; LIBBY P, 1983, J CELL PHYSIOL, V115, P217, DOI 10.1002/jcp.1041150217; LIBBY P, 1992, CIRCULATION, V86, P47; LIBBY P, 1991, LAB INVEST, V64, P5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NAKAKI T, 1990, EUR J PHARM-MOLEC PH, V189, P347, DOI 10.1016/0922-4106(90)90031-R; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; OBRIEN KD, 1993, J CLIN INVEST, V92, P945, DOI 10.1172/JCI116670; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; PENG HB, 1995, J BIOL CHEM, V270, P17050, DOI 10.1074/jbc.270.28.17050; POSTON RN, 1992, AM J PATHOL, V140, P665; PRINTSEVA OY, 1992, AM J PATHOL, V140, P889; RADOMSKI MW, 1992, BRIT J PHARMACOL, V107, P745, DOI 10.1111/j.1476-5381.1992.tb14517.x; RASBAND W, 1993, NIH IMAGE VERSION 1; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA H, 1993, CIRCULATION, V88, P1788, DOI 10.1161/01.CIR.88.4.1788; TIPPING PG, 1993, AM J PATHOL, V142, P1721; TSAO PS, 1994, CIRCULATION, V89, P2176, DOI 10.1161/01.CIR.89.5.2176; VONDERLEYEN HE, 1995, P NATL ACAD SCI USA, V92, P1137, DOI 10.1073/pnas.92.4.1137; WARNER SJC, 1989, ARTERIOSCLEROSIS, V9, P279, DOI 10.1161/01.ATV.9.3.279; WARNER SJC, 1989, J CLIN INVEST, V83, P1174, DOI 10.1172/JCI113998	49	131	135	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11317	11324		10.1074/jbc.271.19.11317	http://dx.doi.org/10.1074/jbc.271.19.11317			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626684	hybrid			2022-12-27	WOS:A1996UJ94400044
J	Yang, XY; Mackins, JY; Li, QJ; Antony, AC				Yang, XY; Mackins, JY; Li, QJ; Antony, AC			Isolation and characterization of a folate receptor-directed metalloprotease from human placenta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEINS; MEMBRANE-PROTEINS; HUMAN-MILK; KB CELLS; IDENTIFICATION; CONVERSION; PROTEASE; INVITRO	Glycosyl-phosphatidylinositol-anchored hydrophobic placental folate receptors (PFRs), which have an important functional role in maternal-to-fetal transplacental folate transport, can be converted to soluble hydrophilic forms by a placental metalloprotease. Using a Triton X-114 temperature-induced phase separation assay to monitor enzyme-mediated conversion of radiolabeled hydrophobic PFR into hydrophilic PFR, a metalloenzyme was isolated to apparent homogeneity from Triton X-114-solubilized human placenta using concanavalin A-Sepharose and reverse-phase high performance liquid chromatography (HPLC) as major purification steps. The purified hydrophobic enzyme eluted as a single protein peak on reverse-phase HPLC and SDS-polyacrylamide gel electrophoresis revealed a single 63,000 M(r) species, which was reduced to 58,000 M(r) following de glycosylation, findings comparable with amino acid analysis (M(r) similar to 59,000). The metalloenzyme was activated by Mg2+, Zn2+, Mn2+, and Ca2+, optimally at physiologic pH; it also exhibited EDTA-sensitive endoproteolytic cleavage of [H-3]leucine-labeled full-length nascent PFR polypeptide generated in vitro in the absence of microsomes. Rabbit polyclonal anti-metalloprotease antiserum specifically immunoprecipitated I-125-metalloprotease and recognized cross-reacting moieties on plasma membranes of normal human hematopoietic progenitor cells and human cervical carcinoma cells, both of which also express FR.	INDIANA UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL CANCER INSTITUTE [R01CA058919] Funding Source: NIH RePORTER; NCI NIH HHS [CA58919] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONY AC, 1992, BLOOD, V79, P2807; ANTONY AC, 1987, J CLIN INVEST, V80, P711, DOI 10.1172/JCI113126; ANTONY AC, 1994, BIOCHEM J, V298, P9, DOI 10.1042/bj2980009; ANTONY AC, 1991, J CLIN INVEST, V87, P313, DOI 10.1172/JCI114989; ANTONY AC, 1982, J BIOL CHEM, V257, P81; ANTONY AC, 1987, J CLIN INVEST, V80, P1618, DOI 10.1172/JCI113249; ANTONY AC, 1989, J BIOL CHEM, V264, P1911; ANTONY AC, 1987, ANAL BIOCHEM, V162, P224, DOI 10.1016/0003-2697(87)90031-5; ANTONY AC, 1981, J BIOL CHEM, V256, P9684; BORDIER C, 1981, J BIOL CHEM, V256, P1604; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; ELWOOD PC, 1991, J BIOL CHEM, V266, P2346; ELWOOD PC, 1986, J BIOL CHEM, V261, P10081; GRANDA JL, 1990, CONNECT TISSUE RES, V24, P249, DOI 10.3109/03008209009152153; HANSEN SI, 1992, BIOSCIENCE REP, V12, P87, DOI 10.1007/BF02351212; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; HENDERSON GI, 1995, J LAB CLIN MED, V126, P184; KANE MA, 1988, J CLIN INVEST, V81, P1398, DOI 10.1172/JCI113469; LALA PK, 1990, CANCER METAST REV, V9, P369, DOI 10.1007/BF00049525; LEE HC, 1992, BIOCHEMISTRY-US, V31, P3236, DOI 10.1021/bi00127a027; LUHRS CA, 1989, J BIOL CHEM, V264, P21446; LUHRS CA, 1987, P NATL ACAD SCI USA, V84, P6546, DOI 10.1073/pnas.84.18.6546; MOORE S, 1963, METHOD ENZYMOL, V6, P819, DOI 10.1016/0076-6879(63)06257-1; Sambrook J., 2002, MOL CLONING LAB MANU; SUN XL, 1995, J CLIN INVEST, V96, P1535, DOI 10.1172/JCI118192; TZINIA AK, 1991, MOL BIOCHEM PARASIT, V47, P83, DOI 10.1016/0166-6851(91)90150-5; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VERMA RS, 1991, J BIOL CHEM, V266, P12522; VERMA RS, 1992, J BIOL CHEM, V267, P4119; ZHOU N E, 1990, Peptide Research, V3, P8; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10791	32	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11493	11499		10.1074/jbc.271.19.11493	http://dx.doi.org/10.1074/jbc.271.19.11493			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626708	hybrid			2022-12-27	WOS:A1996UJ94400068
J	Kayo, T; Sawada, Y; Suzuki, Y; Suda, M; Tanaka, S; Konda, Y; Miyazaki, J; Takeuchi, T				Kayo, T; Sawada, Y; Suzuki, Y; Suda, M; Tanaka, S; Konda, Y; Miyazaki, J; Takeuchi, T			Proprotein-processing endoprotease furin decreases regulated secretory pathway-specific proteins in the pancreatic beta cell line MIN6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN-SECRETION; PROHORMONE CONVERTASES; PROINSULIN; EXPRESSION; CLEAVAGE; GLUCOSE; BIOSYNTHESIS; CALCIUM; SITE; PC2	Prohormone convertases PC2 and PC3, yeast Kex2-family endoproteases specific to the regulated secretory pathway, cleave proinsulin to insulin in the secretory granules of pancreatic beta cells. The well-differentiated beta cell line MIN6 expresses PC2 and PC3 and another regulated secretory pathway-specific protein chromogranin A. Furin, another yeast Kex2 endoprotease, exists in the trans-Golgi networks of many cell types, The beta cell line RINm5F (a cell line that is less differentiated than the MIN6 cell line) does not express the regulated pathway-specific proteins, but strongly expresses furin. We suspected that furin expression may cause the decrement of regulated secretory pathway-specific proteins, To test this hypothesis, we expressed a furin cDNA with a metallothionein promoter in MIN6 cells. With Zn2+ stimulation of furin expression, the messages of PC2, PC3, and chromogranin A decreased, and the processing of proinsulin to mature insulin became less efficient. The furin-expressing MIN6 cells exhibited less insulin content and weakened insulin secretion in response to a high glucose concentration. The conditioned medium from furin-expressing MIN6 cells also exerted a decrease of PC2 and PC3 expression in unaltered MIN6 cells. Thus, proteins cleaved by furin inside the cells or by truncated furin shed into the culture medium appear to cause decreased PC2 and PC3 expression, insulin content, and glucose-responsive insulin secretion in MIN6 cells.	GUNMA UNIV,INST MOL & CELLULAR REGULAT,DEPT MOLEC MED,MAEBASHI,GUMMA 371,JAPAN; GUNMA UNIV,INST MOL & CELLULAR REGULAT,DEPT CELL BIOL,MAEBASHI,GUMMA 371,JAPAN; TOHOKU UNIV,INST DEV AGING & CANC,SENDAI,MIYAGI 980,JAPAN	Gunma University; Gunma University; Tohoku University			Miyazaki, Jun-ichi/N-1976-2015	Miyazaki, Jun-ichi/0000-0003-2475-589X				BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CLARK SA, 1990, ENDOCRINOLOGY, V127, P2779, DOI 10.1210/endo-127-6-2779; DAVIDSON HW, 1987, BIOCHEM J, V245, P575, DOI 10.1042/bj2450575; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; GAZDAR AF, 1980, P NATL ACAD SCI-BIOL, V77, P3519, DOI 10.1073/pnas.77.6.3519; GOLD G, 1984, DIABETES, V33, P556, DOI 10.2337/diabetes.33.6.556; HALBAN PA, 1990, TRENDS ENDOCRIN MET, V1, P261, DOI 10.1016/1043-2760(90)90007-P; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; IRMINGER JC, 1994, J BIOL CHEM, V269, P1756; ISHIHARA H, 1994, J BIOL CHEM, V269, P3081; LEVY JC, 1993, DIABETES, V42, P162, DOI 10.2337/diabetes.42.1.162; LING ZD, 1994, ENDOCRINOLOGY, V134, P2614, DOI 10.1210/en.134.6.2614; MALAISSE WJ, 1990, PEPTIDE HORMONE SECR, P211; MATSUUCHI L, 1991, J CELL BIOL, V112, P843, DOI 10.1083/jcb.112.5.843; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MIZUNO K, 1987, BIOCHEM BIOPH RES CO, V144, P807, DOI 10.1016/S0006-291X(87)80036-0; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; NAGAMUNE H, 1995, ENDOCRINOLOGY, V136, P357, DOI 10.1210/en.136.1.357; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; OTONKOSKI T, 1994, DIABETES, V43, P1164, DOI 10.2337/diabetes.43.9.1164; OUAFIK H, 1987, P NATL ACAD SCI USA, V84, P261; PARMER RJ, 1989, HYPERTENSION, V14, P435, DOI 10.1161/01.HYP.14.4.435; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCAMMELL JG, 1993, TRENDS ENDOCRIN MET, V4, P14, DOI 10.1016/1043-2760(93)90058-M; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHEN FS, 1993, J BIOL CHEM, V268, P24910; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; SMEEKENS SP, 1993, BIO-TECHNOL, V11, P182, DOI 10.1038/nbt0293-182; TSUJI A, 1994, BIOCHEM BIOPH RES CO, V200, P943, DOI 10.1006/bbrc.1994.1541; WANG JL, 1993, J BIOL CHEM, V268, P7785; YANAGITA M, 1993, ENDOCRINOLOGY, V133, P639, DOI 10.1210/en.133.2.639; ZHANG HJ, 1989, DIABETES, V38, P44, DOI 10.2337/diabetes.38.1.44	45	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10731	10737		10.1074/jbc.271.18.10731	http://dx.doi.org/10.1074/jbc.271.18.10731			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631882	hybrid			2022-12-27	WOS:A1996UJ34200050
J	Kharat, I; Saatcioglu, F				Kharat, I; Saatcioglu, F			Antiestrogenic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin are mediated by direct transcriptional interference with the liganded estrogen receptor - Cross-talk between aryl hydrocarbon- and estrogen-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; AH-RECEPTOR; GLUCOCORTICOID RECEPTOR; POSSIBLE MECHANISM; CIGARETTE-SMOKING; BINDING ACTIVITY; DNA-SEQUENCE; MCF-7 CELLS; FEMALE RAT; GENE	Aryl hydrocarbon receptor (AhR) ligands have diverse biological effects including striking antiestrogenic activity. We have investigated at the molecular level the antiestrogenic activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). We show that the previously documented TCDD-mediated decrease in estradiol-inducible gene products such as cathepsin D (cat D) is due to a sharp decline in mRNA accumulation despite any change in estrogen receptor (ER) mRNA levels. The decline in cat D mRNA level is most likely due to a decrease in transcription of the cat D gene since TCDD blocks the ability of ER to transactivate from an estrogen response element. AhR is required for this activity as TCDD is no longer antiestrogenic in a mutant cell line that is deficient in functional AhR. We provide evidence that the loss of transactivation potential by ER in the presence of TCDD is due to a sharp decrease in its ability to bind to an estrogen response element. Reciprocally, estradiol treatment blocked TCDD-induced accumulation of CYP1A1 mRNA and AhR-mediated activation of the CYP1A1 promoter. This is due to the ability of liganded ER to interfere with the binding of AhR to the xenobiotic response element. These results provide a molecular mechanism for the antiestrogenic effects of TCDD and demonstrate the presence of a two-way crosstalk between the intracellular signaling pathways involving estrogens and aryl hydrocarbons.	UNIV CALIF SAN DIEGO, SCH MED, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; MAHARISHI INT UNIV, MOLEC BIOL LAB, FAIRFIELD, IA 52557 USA	University of California System; University of California San Diego					NCI NIH HHS [R01-CA-38655] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038655] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ALEXANDERBRIDGES M, 1992, ADV ENZYME REGUL, V32, P149; ASTROFF B, 1990, BIOCHEM PHARMACOL, V39, P485, DOI 10.1016/0006-2952(90)90054-O; ASTROFF B, 1990, MOL CELL ENDOCRINOL, V72, P247, DOI 10.1016/0303-7207(90)90149-3; ASTROFF B, 1988, TOXICOL APPL PHARM, V95, P435, DOI 10.1016/0041-008X(88)90361-4; BIEGEL L, 1990, J STEROID BIOCHEM, V37, P725, DOI 10.1016/0960-0760(90)90357-Q; BJELDANES LF, 1991, P NATL ACAD SCI USA, V88, P9543, DOI 10.1073/pnas.88.21.9543; BRESNICK E, 1990, CARCINOGENESIS, V11, P1159, DOI 10.1093/carcin/11.7.1159; BRINTON LA, 1993, AM J EPIDEMIOL, V137, P281, DOI 10.1093/oxfordjournals.aje.a116675; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CAVAILLES V, 1993, P NATL ACAD SCI USA, V90, P203, DOI 10.1073/pnas.90.1.203; CLARK AR, 1993, BIOCHEM J, V296, P521, DOI 10.1042/bj2960521; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; GALLO MA, 1986, TOXICOL LETT, V32, P123, DOI 10.1016/0378-4274(86)90058-5; GIERTHY JF, 1988, BREAST CANCER RES TR, V12, P227, DOI 10.1007/BF01805943; GIERTHY JF, 1987, CANCER RES, V47, P6198; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; GUENGERICH FP, 1989, ANNU REV PHARMACOL, V29, P241; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HANKINSON O, 1985, J BIOL CHEM, V260, P1790; HARRIS M, 1990, CANCER RES, V50, P3579; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LANIGAN TM, 1993, MOL CELL BIOL, V13, P6079, DOI 10.1128/MCB.13.10.6079; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; MICHNOVICZ JJ, 1986, NEW ENGL J MED, V315, P1305, DOI 10.1056/NEJM198611203152101; MUTO H, 1989, ARCH ENVIRON HEALTH, V44, P171, DOI 10.1080/00039896.1989.9935882; *NAT TOX PROGR, 1982, BIOASS 2 3 7 8 TETR; PASCO DS, 1993, J BIOL CHEM, V268, P1053; PELKONEN O, 1982, PHARMACOL REV, V34, P189; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PYYKKO K, 1989, CYTOCHROME P-450 : BIOCHEMISTRY AND BIOPHYSICS /, P528; REICK M, 1994, MOL CELL BIOL, V14, P5653, DOI 10.1128/MCB.14.9.5653; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; ROMKES M, 1987, TOXICOL APPL PHARM, V87, P306, DOI 10.1016/0041-008X(87)90292-4; ROMKES M, 1988, TOXICOL APPL PHARM, V92, P368, DOI 10.1016/0041-008X(88)90177-9; SAATCIOGLU F, 1990, J BIOL CHEM, V265, P9251; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SAATCIOGLU F, 1990, MOL CELL BIOL, V10, P6408, DOI 10.1128/MCB.10.12.6408; SPINK DC, 1990, P NATL ACAD SCI USA, V87, P6917, DOI 10.1073/pnas.87.17.6917; SPINK DC, 1992, ARCH BIOCHEM BIOPHYS, V293, P342, DOI 10.1016/0003-9861(92)90404-K; STAUBER C, 1992, NEW BIOL, V4, P527; Tourmaa TE, 1995, NUTR HLTH, V10, P105; VESSEY M, 1983, BRIT J CANCER, V47, P455, DOI 10.1038/bjc.1983.74; WANG X, 1993, MOL CELL ENDOCRINOL, V96, P159, DOI 10.1016/0303-7207(93)90106-T; WHITE TEK, 1993, BIOCHEM BIOPH RES CO, V193, P956, DOI 10.1006/bbrc.1993.1718; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; ZACHAREWSKI T, 1992, TOXICOL APPL PHARM, V113, P311, DOI 10.1016/0041-008X(92)90130-K; ZACHAREWSKI T, 1991, BIOCHEM PHARMACOL, V41, P1931, DOI 10.1016/0006-2952(91)90133-P	52	175	183	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10533	10537		10.1074/jbc.271.18.10533	http://dx.doi.org/10.1074/jbc.271.18.10533			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631852	hybrid			2022-12-27	WOS:A1996UJ34200020
J	May, JM; Qu, ZC; Morrow, JD				May, JM; Qu, ZC; Morrow, JD			Interaction of ascorbate and alpha-tocopherol in resealed human erythrocyte ghosts - Transmembrane electron transfer and protection from lipid peroxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED BLOOD-CELLS; VITAMIN-E; ACCEPTOR OXIDOREDUCTASE; MEMBRANE DAMAGE; LIPOSOMES; ANTIOXIDANT; REDUCTION; PLASMA; NADH; ACID	A role for ascorbate-derived electrons in protection against oxidative damage to membrane lipids was investigated in resealed human erythrocyte ghosts, Incubation of resealed ghosts with the membrane-impermeant oxidant ferricyanide doubled the ghost membrane concentration of F-2-isoprostanes, a sensitive marker of lipid peroxidation, Incorporation of ascorbate into ghosts during resealing largely prevented F-2-isoprostane formation due to extravesicular ferricyanide. This protection was associated with a rapid transmembrane oxidation of intravesicular ascorbate by extravesicular ferricyanide. Transmembrane electron transfer, which was measured indirectly as ascorbate-dependent ferricyanide reduction, correlated with the content of alpha-tocopherol in the ghost membrane in several respects, First, ascorbate resealed within ghosts protected against ferricyanide-induced oxidation of endogenous alpha-tocopherol in the ghost membrane, Second, when exogenous alpha-tocopherol was incorporated into the ghost membrane during the resealing step, subsequent ferricyanide reduction was enhanced, Last, incubation of intact erythrocytes with soybean phospholipid liposomes, followed by resealed ghost preparation, caused a proportional decrease in both the membrane content of alpha-tocopherol and in ferricyanide reduction, Incorporation of exogenous alpha-tocopherol during resealing of ghosts prepared from liposome-treated cells completely restored the ferricyanide-reducing capacity of the ghosts. These results suggest that the transmembrane transfer of ascorbate-derived electrons in erythrocyte ghosts is dependent in part on alpha-tocopherol and that such transfer may help to protect the erythrocyte membrane against oxidant stress originating outside the cell.			May, JM (corresponding author), VANDERBILT UNIV,SCH MED,DEPT MED,715 MED RES BLDG 2,NASHVILLE,TN 37232, USA.				NIDDK NIH HHS [DK 26657, DK 50435, DK 48831] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026657, R01DK050435, R01DK048831] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGAR NS, 1986, J CLIN INVEST, V77, P319, DOI 10.1172/JCI112294; Agutter PS, 1979, BIOCHEM SOC T, V7, P710, DOI 10.1042/bst0070710; AVRON M, 1963, ANAL BIOCHEM, V6, P549, DOI 10.1016/0003-2697(63)90149-0; BIERI JG, 1976, VITAM HORM, V34, P31, DOI 10.1016/S0083-6729(08)60072-2; CLEMENS MR, 1987, CHEM PHYS LIPIDS, V45, P251, DOI 10.1016/0009-3084(87)90068-5; CRANE FL, 1985, ENZYMES BIOL MEMBR, P465; DOBA T, 1985, BIOCHIM BIOPHYS ACTA, V835, P298, DOI 10.1016/0005-2760(85)90285-1; FEE JA, 1972, BIOCHEM BIOPH RES CO, V49, P150, DOI 10.1016/0006-291X(72)90022-8; FREI B, 1990, P NATL ACAD SCI USA, V87, P4879, DOI 10.1073/pnas.87.12.4879; GREBING C, 1984, J BIOENERG BIOMEMBR, V16, P517, DOI 10.1007/BF00743243; HATAM LJ, 1979, J LIPID RES, V20, P639; HODGSON LL, 1995, J CELL PHYSIOL, V162, P181, DOI 10.1002/jcp.1041620204; HUGHES RE, 1968, BRIT J HAEMATOL, V14, P247, DOI 10.1111/j.1365-2141.1968.tb01494.x; IHEANACHO EN, 1995, FREE RADICAL BIO MED, V18, P543, DOI 10.1016/0891-5849(94)00182-J; ILANI A, 1987, BIOPHYS J, V51, P161, DOI 10.1016/S0006-3495(87)83321-0; JAIN SK, 1989, J BIOL CHEM, V264, P21340; KAGAN VE, 1990, ARCH BIOCHEM BIOPHYS, V280, P147, DOI 10.1016/0003-9861(90)90529-8; KAGAN VE, 1990, METHOD ENZYMOL, V186, P355; KAYDEN HJ, 1973, J LIPID RES, V14, P533; KITABCHI AE, 1982, BIOCHIM BIOPHYS ACTA, V684, P200, DOI 10.1016/0005-2736(82)90006-2; KITAJIMA S, 1981, ARCH BIOCHEM BIOPHYS, V210, P330, DOI 10.1016/0003-9861(81)90196-X; KOBAYASHI T, 1985, BIOCHIM BIOPHYS ACTA, V814, P170, DOI 10.1016/0005-2736(85)90433-X; KOJIMA N, 1979, J BIOL CHEM, V254, P8847; LANG JK, 1986, ANAL BIOCHEM, V157, P106, DOI 10.1016/0003-2697(86)90203-4; LEUNG HW, 1981, BIOCHIM BIOPHYS ACTA, V664, P266; LEVINE M, 1986, NEW ENGL J MED, V314, P892, DOI 10.1056/NEJM198604033141407; LITTLE C, 1968, BIOCHEM BIOPH RES CO, V31, P145, DOI 10.1016/0006-291X(68)90721-3; LONGMIRE AW, 1994, BIOCHEM PHARMACOL, V47, P1173, DOI 10.1016/0006-2952(94)90389-1; LYNCH SM, 1994, J CLIN INVEST, V93, P998, DOI 10.1172/JCI117107; MAY JM, 1995, BBA-BIOMEMBRANES, V1238, P127, DOI 10.1016/0005-2736(95)00120-R; MAYU JM, 1995, BIOCHEMISTRY-US, V34, P12721; MCGOWN EL, 1990, BIOCHIM BIOPHYS ACTA, V1036, P202, DOI 10.1016/0304-4165(90)90035-U; MEISTER A, 1994, J BIOL CHEM, V269, P9397; MISHRA RK, 1969, J MEMBRANE BIOL, V1, P214, DOI 10.1007/BF01869782; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; MORROW JD, 1994, METHOD ENZYMOL, V233, P163; NIKI E, 1987, CHEM PHYS LIPIDS, V44, P227, DOI 10.1016/0009-3084(87)90052-1; NIKI E, 1988, J BIOL CHEM, V263, P19809; OKAMURA M, 1979, J NUTR SCI VITAMINOL, V25, P269, DOI 10.3177/jnsv.25.269; ORRINGER EP, 1979, J CLIN INVEST, V63, P53, DOI 10.1172/JCI109277; Pachla L A, 1979, Methods Enzymol, V62, P15, DOI 10.1016/0076-6879(79)62183-3; PACKER JE, 1979, NATURE, V278, P737, DOI 10.1038/278737a0; SCHIPFER W, 1985, INT J BIOCHEM, V17, P819, DOI 10.1016/0020-711X(85)90270-8; SNYDER LM, 1988, BIOCHIM BIOPHYS ACTA, V937, P229, DOI 10.1016/0005-2736(88)90245-3; Steck T L, 1974, Methods Enzymol, V31, P172; STOCKER R, 1986, BIOCHIM BIOPHYS ACTA, V876, P294, DOI 10.1016/0005-2760(86)90287-0; SUN IL, 1992, P NATL ACAD SCI USA, V89, P11126, DOI 10.1073/pnas.89.23.11126; SZEKELY M, 1952, ACTA PHYSIOL HUNG, V3, P571; TOMODA A, 1980, EXPERIENTIA, V36, P1345, DOI 10.1007/BF01960088; URSINI F, 1982, BIOCHIM BIOPHYS ACTA, V710, P197, DOI 10.1016/0005-2760(82)90150-3; VANDENBERG JJM, 1990, CHEM PHYS LIPIDS, V53, P309, DOI 10.1016/0009-3084(90)90028-P; WANG CS, 1978, J SUPRAMOL STR CELL, V9, P1, DOI 10.1002/jss.400090102; WOLFF SP, 1994, METHOD ENZYMOL, V233, P182	53	55	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10577	10582		10.1074/jbc.271.18.10577	http://dx.doi.org/10.1074/jbc.271.18.10577			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631858	hybrid			2022-12-27	WOS:A1996UJ34200026
J	Mora, C; Chillaron, J; Calonge, MJ; Forgo, J; Testar, X; Nunes, V; Murer, H; Zorzano, A; Palacin, M				Mora, C; Chillaron, J; Calonge, MJ; Forgo, J; Testar, X; Nunes, V; Murer, H; Zorzano, A; Palacin, M			The rBAT gene is responsible for L-cystine uptake via the b(0,+)-like amino acid transport system in a ''renal proximal tubular'' cell line (OK cells)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; XENOPUS-LAEVIS OOCYTES; RABBIT KIDNEY CORTEX; EXPRESSION CLONING; RAT-KIDNEY; STRAIGHT TUBULES; HIGH-AFFINITY; HEAVY-CHAIN; CDNA; LYSINE	Several studies have shown that the cRNA of human, rabbit, or rat rBAT induces in Xenopus oocytes sodium-independent, high affinity uptake of L-cystine via a system b(0,+)-like amino acid exchanger. We have shown that mutations in rBAT cause type I cystinuria (Calonge, M. J., Gasparini, P., Chillaron, J., Chillon, M., Gallucci, M., Rousaud, F., Zelante, L., Testar, X., Dallapiccola, B., Di Silverio, F., Barcelo, P., Estivill, X., Zorzano, A., Nunes, V., and Palacin, M. (1994) Nat. Genet. 6, 420-425; Calonge, M. J., Volipini, V., Bisceglia, L., Rousaud, F., De Sanctis, L., Beccia, E., Zelante, L., Testar, X., Zorzano, A., Estivill, X., Gasparini, P., Nunes, V., and Palacin, M. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9667-9671). Apart from oocytes, no other expression system has been used for transfection of functional rBAT activity. Furthermore, the b(0,+)-like transport activity has not been clearly described in the kidney or intestine. Here, we report that a ''proximal tubular-like'' cell line derived from opossum kidney (OR cells) expresses an rBAT transcript. Poly(A)(+) RNA from OK cells induced system b(0,+)-like transport activity in oocytes. This was hybrid-depleted by human rBAT antisense oligonucleotides. A polymerase chain reaction amplified cDNA fragment (similar to 700 base pairs) from OK cell RNA corresponds to an rBAT protein fragment 65-69% identical to those from human, rabbit and rat kidneys. We have also examined transport of L-cystine in OK cells and found characteristics very similar to the amino acid exchanger activity induced by rBAT cRNA in oocytes. Uptake of L-cystine was of high affinity, sodium-independent and shared with L-arginine and L-leucine. It was trans-stimulated by amino acids with the same specificity as rBAT-induced transport activity in oocytes. Furthermore, it was localized to the apical pole of confluent OK cells. To demonstrate that the rBAT protein is functionally related to this transport activity, we have transfected OK cells with human rBAT antisense and sense sequences. Transfection with rBAT antisense, but not with rBAT sense, resulted in the specific reduction of rBAT mRNA expression and b(0,+)-like transport activity. These results demonstrate that rBAT is functionally related to the L-cystine uptake via system b(0,+)-like in the apical pole of the renal OK cell line.	UNIV BARCELONA,FAC BIOL,DEPT BIOCHEM & MOLEC BIOL,E-08028 BARCELONA,SPAIN; UNIV ZURICH,DEPT PHYSIOL,CH-8057 ZURICH,SWITZERLAND; INST RECERCA ONCOL,DEPT MOLEC GENET,E-08907 LHOSPITALET LLOBR,BARCELONA,SPAIN	University of Barcelona; University of Zurich			Mora, Conchi/A-8280-2010; Nunes, Virginia/D-4356-2014; Chillaron, Josep/ABF-7663-2021; Zorzano, Antonio/R-5479-2018; Nunes, Virginia/AAD-1014-2019; Palacín, Manuel/G-9786-2015	Mora, Conchi/0000-0002-5644-0537; Nunes, Virginia/0000-0002-5747-9310; Chillaron, Josep/0000-0003-3068-7598; Nunes, Virginia/0000-0002-5747-9310; Palacin, Manuel/0000-0002-8670-293X				AHMED A, 1995, J BIOL CHEM, V270, P8482, DOI 10.1074/jbc.270.15.8482; BERTRAN J, 1993, J BIOL CHEM, V268, P14842; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; BERTRAN J, 1992, BIOCHEM J, V281, P717, DOI 10.1042/bj2810717; BIBER J, 1985, AM J PHYSIOL, V249, pC430, DOI 10.1152/ajpcell.1985.249.5.C430; BOVEE KC, 1984, METABOLISM, V33, P602, DOI 10.1016/0026-0495(84)90056-8; BUSCH AE, 1994, J BIOL CHEM, V269, P25581; CALONGE MJ, 1995, P NATL ACAD SCI USA, V92, P9667, DOI 10.1073/pnas.92.21.9667; CALONGE MT, 1994, NAT GENET, V6, P420, DOI 10.1038/ng0494-420; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COADY MJ, 1994, FEBS LETT, V356, P174, DOI 10.1016/0014-5793(94)01262-8; COICADAN L, 1980, PEDIATR RES, V14, P109, DOI 10.1203/00006450-198002000-00008; DEVES R, 1992, J PHYSIOL-LONDON, V454, P491, DOI 10.1113/jphysiol.1992.sp019275; FOREMAN JW, 1980, METABOLISM, V29, P53, DOI 10.1016/0026-0495(80)90098-0; FURLONG TJ, 1990, AM J PHYSIOL, V258, pF321, DOI 10.1152/ajprenal.1990.258.2.F321; FURRIOLS M, 1993, J BIOL CHEM, V268, P27060; GASPARINI P, 1995, AM J HUM GENET, V57, P781; KOYAMA H, 1978, IN VITRO CELL DEV B, V14, P239; LEE WS, 1993, J CLIN INVEST, V91, P1959, DOI 10.1172/JCI116415; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCKUSICK VA, 1990, MENDELIAN INHERITANC, P1128; MCNAMARA PD, 1992, BIOCHIM BIOPHYS ACTA, V1103, P101, DOI 10.1016/0005-2736(92)90062-Q; MCNAMARA PD, 1981, BIOCHEM J, V194, P443, DOI 10.1042/bj1940443; MOSCKOVITZ R, 1993, P NATL ACAD SCI USA, V90, P4022, DOI 10.1073/pnas.90.9.4022; MOSCKOVITZ R, 1994, FASEB J, V8, P1069, DOI 10.1096/fasebj.8.13.7926373; OZEGOVIC B, 1982, BIOSCIENCE REP, V2, P913, DOI 10.1007/BF01114898; PALACIN M, 1994, J EXP BIOL, V196, P123; PICKEL VM, 1993, P NATL ACAD SCI USA, V90, P7779, DOI 10.1073/pnas.90.16.7779; PRAS E, 1995, AM J HUM GENET, V56, P1297; PRAS E, 1994, NAT GENET, V6, P415, DOI 10.1038/ng0494-415; ROSENBERG LE, 1965, NEW ENGL J MED, V273, P1239, DOI 10.1056/NEJM196512022732303; ROSENBERG LE, 1966, J CLIN INVEST, V45, P365, DOI 10.1172/JCI105351; SCHAFER JA, 1984, PFLUG ARCH EUR J PHY, V401, P143, DOI 10.1007/BF00583874; SEGAL S, 1968, P NATL ACAD SCI USA, V59, P231, DOI 10.1073/pnas.59.1.231; SEGAL S, 1977, SCIENCE, V197, P169, DOI 10.1126/science.877548; SEGAL S, 1995, METABOLIC MOL BASES, V3, P3581; SILBERNAGL S, 1988, PHYSIOL REV, V68, P911, DOI 10.1152/physrev.1988.68.3.911; STATES B, 1990, J CELL PHYSIOL, V143, P555, DOI 10.1002/jcp.1041430321; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; TEIXEIRA S, 1987, J BIOL CHEM, V262, P9574; THIER S, 1964, SCIENCE, V143, P482, DOI 10.1126/science.143.3605.482; VOLKL H, 1982, PFLUG ARCH EUR J PHY, V395, P190, DOI 10.1007/BF00584808; WANG Y, 1995, FEBS LETT, V368, P389, DOI 10.1016/0014-5793(95)00685-3; WEBBER WA, 1961, AM J PHYSIOL, V200, P380, DOI 10.1152/ajplegacy.1961.200.2.380; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; WRIGHT EM, 1994, NAT GENET, V6, P328, DOI 10.1038/ng0494-328	47	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10569	10576		10.1074/jbc.271.18.10569	http://dx.doi.org/10.1074/jbc.271.18.10569			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631857	hybrid, Green Accepted, Green Published			2022-12-27	WOS:A1996UJ34200025
J	Sun, XJ; Pons, S; Asano, T; Myers, MG; Glasheen, E; White, MF				Sun, XJ; Pons, S; Asano, T; Myers, MG; Glasheen, E; White, MF			The fyn tyrosine kinase binds Irs-1 and forms a distinct signaling complex during insulin stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-SRC ACTIVITY; HEMATOPOIETIC-CELLS; CATALYTIC ACTIVITY; SH3 DOMAINS; MUTANT MICE; RECEPTOR; PROTEIN; PHOSPHORYLATION; ASSOCIATION; EXPRESSION	Irs-proteins link the receptors for insulin/IGF-1, growth hormones, and several interleukins and interferons to signaling proteins that contain Src homology-2 (SH2). To identify new Irs-1-binding proteins, we screened a mouse embryo expression library with recombinant [P-32]Irs-1, which revealed a specific association between p59(fyn) and Irs-1. The SH2 domain in p59(fyn) bound to phosphorylated Tyr(895) and Tyr(1172), which are located in YXX(L/I) motifs. Mutation of p59(fyn) at the COOH-terminal tyrosine phosphorylation site (Tyr(531)) enhanced its binding to Irs-1 during insulin stimulation. Binding experiments with various SH2 proteins revealed that Grb-2 was largely excluded from Irs-1 complexes containing p59(fyn), whereas Grb-2 and p85 occurred in the same Irs-1 complex, By comparison with the insulin receptor, p59(fyn) kinase phosphorylated a unique cohort of tyrosine residues in Irs-1. These results outline a role for p59(fyn) or other related Src-kinases during insulin and cytokine signaling.	JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,PROGRAM CELL & DEV BIOL,BOSTON,MA 02215	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Pons, Sebastian/K-7794-2014	Pons, Sebastian/0000-0003-1027-0621	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK038712, R01DK038712, R01DK043808, R29DK038712] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38712, DK 43808] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1991, CELL GROWTH DIFFER, V2, P483; FEENER EP, 1993, J BIOL CHEM, V268, P11256; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; KEEGAN AD, 1993, RES IMMUNOL, V144, P590, DOI 10.1016/S0923-2494(05)80008-2; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MYERS MG, 1995, TRENDS ENDOCRIN MET, V6, P209, DOI 10.1016/1043-2760(95)00092-V; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; PONS S, 1995, MOL CELL BIOL, V15, P4453; RUBINFELD B, 1992, MOL CELL BIOL, V12, P4634, DOI 10.1128/MCB.12.10.4634; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; VEILLETTE A, 1992, ONCOGENE, V7, P971; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; Zhou-Li Fei, 1995, Molecular and Cellular Biology, V15, P4232	47	110	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10583	10587		10.1074/jbc.271.18.10583	http://dx.doi.org/10.1074/jbc.271.18.10583			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631859	hybrid			2022-12-27	WOS:A1996UJ34200027
J	BarreraHernandez, G; Wanke, IE; Wong, NCW				BarreraHernandez, G; Wanke, IE; Wong, NCW			Effects of diabetes mellitus on hepatocyte nuclear factor 1 decrease albumin gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-1-ANTITRYPSIN GENE; LIVER-SPECIFIC TRANSCRIPTION; EUKARYOTIC PROTEIN-SYNTHESIS; CELL-SPECIFIC EXPRESSION; FACTOR-I; INVITRO TRANSCRIPTION; PHOSPHOENOLPYRUVATE CARBOXYKINASE; MESSENGER-RNA; PROMOTER; RATS	We have previously reported that albumin gene transcription is reduced in diabetes mellitus (DM), The present study explored the mechanism by which albumin gene transcription is down-regulated in DM. Deletional studies and displacement of factors binding to site B of the albumin promoter indicated that the repressive effects of DM are mediated by nuclear factors binding to this site. Since hepatocyte nuclear factor 1 (HNF1) activates albumin promoter activity and is the predominant factor binding to site B, we examined HNF1. The abundance and binding activity of HNF1 were reduced in hepatonuclear extracts from diabetic compared to control rats, However, HNF1 mRNA levels were unchanged, suggesting that the effect of DM on HNF1 is at the posttranscriptional level. Extracts from diabetic animals also contained another protein, distinct from HNF1 and vHNF1, which bound to site B in gel retardation studies, In summary, our studies demonstrate that the reduced abundance and binding activity of HNF1 correlates with decreased albumin gene transcription in DM.	UNIV CALGARY,DEPT MED,CALGARY,AB T2N 4N1,CANADA; UNIV CALGARY,DEPT MED BIOCHEM,CALGARY,AB T2N 4N1,CANADA	University of Calgary; University of Calgary								BAUMHUETER S, 1988, EMBO J, V7, P2485, DOI 10.1002/j.1460-2075.1988.tb03095.x; BEALE EG, 1992, FASEB J, V6, P3330, DOI 10.1096/fasebj.6.15.1281456; BERNIER D, 1993, MOL CELL BIOL, V13, P1619, DOI 10.1128/MCB.13.3.1619; BOSCH F, 1995, DIABETES, V44, P267, DOI 10.2337/diabetes.44.3.267; BRETHERTONWATT D, 1989, DIABETOLOGIA, V32, P881, DOI 10.1007/BF00297454; BURKE PA, 1994, SURGERY, V116, P285; CARMASSI F, 1992, THROMB RES, V67, P643, DOI 10.1016/0049-3848(92)90068-L; CEREGHINI S, 1992, DEVELOPMENT, V116, P783; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CEREGHINI S, 1990, EMBO J, V9, P2257, DOI 10.1002/j.1460-2075.1990.tb07396.x; CHAN J, 1993, NUCLEIC ACIDS RES, V21, P1205, DOI 10.1093/nar/21.5.1205; CHAN L, 1995, BIOCHIMIE, V77, P75, DOI 10.1016/0300-9084(96)88107-7; CIMBALA MA, 1982, J BIOL CHEM, V257, P7629; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; DILLMANN WH, 1988, DIABETES METAB REV, V4, P789, DOI 10.1002/dmr.5610040807; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; FELDMAN ST, 1992, INVEST OPHTH VIS SCI, V33, P3307; FINOTTI P, 1992, DIABETES RES CLIN PR, V18, P35, DOI 10.1016/0168-8227(92)90053-T; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HERBST RS, 1991, NEW BIOL, V3, P289; ICHIKAWA K, 1991, J MOL ENDOCRINOL, V7, P123, DOI 10.1677/jme.0.0070123; IZBAN MG, 1989, J BIOL CHEM, V264, P9171; JOHNSON PF, 1990, CELL GROWTH DIFFER, V1, P47; JOHNSON TR, 1991, P NATL ACAD SCI USA, V88, P5287, DOI 10.1073/pnas.88.12.5287; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; KUO CJ, 1991, EMBO J, V10, P2231, DOI 10.1002/j.1460-2075.1991.tb07759.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI Y, 1988, MOL CELL BIOL, V8, P4362, DOI 10.1128/MCB.8.10.4362; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MURTY CVR, 1986, BIOCHEMISTRY-US, V25, P4376, DOI 10.1021/bi00363a030; NAHON JL, 1987, BIOCHIMIE, V69, P445, DOI 10.1016/0300-9084(87)90082-4; NAKABAYASHI H, 1991, MOL CELL BIOL, V11, P5885, DOI 10.1128/MCB.11.12.5885; NGUYEN V, 1994, EXP EYE RES, V59, P335, DOI 10.1006/exer.1994.1115; PATEL YM, 1994, J BIOL CHEM, V269, P5619; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PIETRANGELO A, 1994, P NATL ACAD SCI USA, V91, P182, DOI 10.1073/pnas.91.1.182; RECKELHOFF JF, 1993, DIABETES, V42, P1425, DOI 10.2337/diabetes.42.10.1425; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RINGEISEN F, 1993, J BIOL CHEM, V268, P25706; ROMNEY JS, 1992, THESIS U CALGARY CAL; ROY S, 1990, P NATL ACAD SCI USA, V87, P404, DOI 10.1073/pnas.87.1.404; ROY S, 1994, J BIOL CHEM, V269, P691; Sambrook J., 2002, MOL CLONING LAB MANU; SCHORPP M, 1988, J MOL BIOL, V202, P307, DOI 10.1016/0022-2836(88)90460-3; SHEN RF, 1987, NUCLEIC ACIDS RES, V15, P8399, DOI 10.1093/nar/15.20.8399; SPARKS JD, 1992, J CLIN INVEST, V89, P1418, DOI 10.1172/JCI115731; STAUBER WT, 1985, HISTOCHEM J, V17, P613, DOI 10.1007/BF01003201; THORNGATE FE, 1994, P NATL ACAD SCI USA, V91, P5392, DOI 10.1073/pnas.91.12.5392; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; TRONCHE F, 1989, MOL CELL BIOL, V9, P4759, DOI 10.1128/MCB.9.11.4759; TRONCHE F, 1990, MOL BIOL MED, V7, P173; VALERA A, 1993, J CLIN INVEST, V92, P4, DOI 10.1172/JCI116580; WANKE IE, 1991, J BIOL CHEM, V266, P6068; WHITE JD, 1990, ENDOCRINOLOGY, V126, P765, DOI 10.1210/endo-126-2-765; WUARIN J, 1990, J MOL BIOL, V214, P865, DOI 10.1016/0022-2836(90)90341-I; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807	67	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9969	9975		10.1074/jbc.271.17.9969	http://dx.doi.org/10.1074/jbc.271.17.9969			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626635	hybrid			2022-12-27	WOS:A1996UG25700019
J	Gohlke, M; Baude, G; Nuck, R; Grunow, D; Kannicht, C; Bringmann, P; Donner, P; Reutter, W				Gohlke, M; Baude, G; Nuck, R; Grunow, D; Kannicht, C; Bringmann, P; Donner, P; Reutter, W			O-linked L-fucose is present in Desmodus rotundus salivary plasminogen activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-HYDROXYASPARTIC ACID; GROWTH-FACTOR DOMAIN; HUMAN FACTOR-IX; K-DEPENDENT PROTEINS; HUMAN FACTOR-VII; BLOOD-COAGULATION; VAMPIRE BAT; SERINE RESIDUE; HUMAN-PLASMA; IDENTIFICATION	DSPA alpha 1 (Desmodus rotundus salivary plasminogen activator), a plasminogen activator from the saliva of the vampire bat Desmodus rotundus, is an effective thrombolytic agent. An unusual type of posttranslational modification, in which L-fucose is O-glycosidically linked to threonine 61 in the epidermal growth factor domain was found for natural DSPA alpha 1 and its recombinant form isolated from Chinese hamster ovary cells. In the present study a combination of carbohydrate and amino acid composition analysis, amino acid sequencing, and mass spectrometry revealed that the L-fucose is bound to residues 56-68 of DSPA alpha 1. The amino acid sequence of this glycosylation site agreed with the suggested consensus sequence Cys-Xaa-Xaa-Gly-Gly-Ser/Thr-Cys described for other proteins, A new strategy for the identification of the modified amino acid was established. Direct evidence for the occurrence of fucosyl-threonine was obtained by mass spectrometry after digestion of the glycopeptide with a mixture of peptidases. On the basis of these results, DSPA alpha 1 is a suitable model for studying the influence of O-fucosylation on clearance rates, particularly in comparative studies with the identically fucosylated and structurally related tissue plasminogen activator.	FREE UNIV BERLIN,INST MOLEK BIOL & BIOCHEM,D-14195 BERLIN,GERMANY; SCHERING AG,RES LABS,W-1000 BERLIN,GERMANY	Free University of Berlin; Schering AG								ALLEN GA, 1989, LAB TECHNIQUES BIOCH, P53; BACHMANN F, 1987, THROMB DIATH HAEMO, P227; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BJOERN S, 1991, J BIOL CHEM, V266, P11051; Bornstein P, 1977, Methods Enzymol, V47, P132; BUKO AM, 1991, P NATL ACAD SCI USA, V88, P3992, DOI 10.1073/pnas.88.9.3992; CARTWRIGHT T, 1974, BLOOD, V43, P317, DOI 10.1182/blood.V43.3.317.317; CUMMINGS RD, 1992, BIOESSAYS, V14, P849, DOI 10.1002/bies.950141210; DRAKENBERG T, 1983, P NATL ACAD SCI-BIOL, V80, P1802, DOI 10.1073/pnas.80.7.1802; FEARS R, 1989, BIOCHEM J, V261, P313, DOI 10.1042/bj2610313; FERNLUND P, 1983, J BIOL CHEM, V258, P2509; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GEILEN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P108, DOI 10.1016/0003-9861(92)90551-7; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; HAJJAR KA, 1994, J CLIN INVEST, V93, P703, DOI 10.1172/JCI117023; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; HARRIS RJ, 1993, BIOCHEMISTRY-US, V32, P6539, DOI 10.1021/bi00077a007; HARRIS RJ, 1992, J BIOL CHEM, V267, P5102; HARRIS RJ, 1991, BIOCHEMISTRY-US, V30, P2311, DOI 10.1021/bi00223a004; HASE S, 1990, J BIOL CHEM, V265, P1858; HASE S, 1988, J BIOCHEM-TOKYO, V104, P867, DOI 10.1093/oxfordjournals.jbchem.a122571; HAWKEY C, 1966, NATURE, V211, P434, DOI 10.1038/211434c0; HIGGINS DL, 1990, ANNU REV PHARMACOL, V30, P91; KASAI S, 1985, J BIOL CHEM, V260, P2382; KEILDLOUHA V, 1971, FEBS LETT, V16, P291, DOI 10.1016/0014-5793(71)80373-3; KENTZER EJ, 1990, BIOCHEM BIOPH RES CO, V171, P401, DOI 10.1016/0006-291X(90)91407-J; KRATZSCHMAR J, 1992, GENE, V116, P281, DOI 10.1016/0378-1119(92)90526-U; KRATZSCHMAR J, 1991, GENE, V105, P229, DOI 10.1016/0378-1119(91)90155-5; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; MCMULLEN BA, 1985, J BIOL CHEM, V260, P5328; MCMULLEN BA, 1983, BIOCHEM BIOPH RES CO, V115, P8, DOI 10.1016/0006-291X(83)90961-0; NISHIMURA H, 1989, J BIOL CHEM, V264, P20320; NISHIMURA H, 1992, J BIOCHEM-TOKYO, V111, P460, DOI 10.1093/oxfordjournals.jbchem.a123780; NISHIMURA H, 1992, J BIOL CHEM, V267, P17520; OTTER M, 1991, J BIOL CHEM, V266, P13931; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; PETRI T, 1995, J BIOTECHNOL, V39, P75, DOI 10.1016/0168-1656(94)00146-4; PRZYSIECKI CT, 1987, P NATL ACAD SCI USA, V84, P7856, DOI 10.1073/pnas.84.22.7856; SCHLEUNING WD, 1992, ANN NY ACAD SCI, V667, P395, DOI 10.1111/j.1749-6632.1992.tb51639.x; SMITH DL, 1990, METHOD ENZYMOL, V193, P374, DOI 10.1016/0076-6879(90)93428-N; STENFLO J, 1988, J BIOL CHEM, V263, P21; STENFLO J, 1987, P NATL ACAD SCI USA, V84, P368, DOI 10.1073/pnas.84.2.368; STULTS NL, 1993, GLYCOBIOLOGY, V3, P589, DOI 10.1093/glycob/3.6.589; TAKEYA H, 1988, J BIOL CHEM, V263, P14868; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WAXDAL MJ, 1968, BIOCHEMISTRY-US, V7, P1959, DOI 10.1021/bi00845a046; WITT W, 1994, CIRCULATION, V90, P421, DOI 10.1161/01.CIR.90.1.421; WUN TC, 1985, J BIOL CHEM, V260, P5061	49	26	28	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7381	7386		10.1074/jbc.271.13.7381	http://dx.doi.org/10.1074/jbc.271.13.7381			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631761	hybrid			2022-12-27	WOS:A1996UC77400029
J	Kwast, KE; Hand, SC				Kwast, KE; Hand, SC			Acute depression of mitochondrial protein synthesis during anoxia - Contributions of oxygen sensing, matrix acidification, and redox state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; ARTEMIA EMBRYOS; GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; HEART-MITOCHONDRIA; INTRACELLULAR PH; ANAEROBIC DORMANCY; KINETIC-PROPERTIES; MESSENGER-RNA; OXIDATION	Mitochondrial protein synthesis is acutely depressed during anoxia-induced quiescence in embryos of Artemia franciscana. Oxygen deprivation is accompanied in vivo by a dramatic drop in extramitochondrial pH, and both of these alterations strongly inhibit protein synthesis in isolated mitochondria. Here we show that the oxygen dependence is not explained simply by blockage of the electron transport chain or by the increased redox state. Whereas oxygen deprivation substantially depressed protein synthesis within 5 min and resulted in a 77% reduction after 1 h, aerobic incubations with saturating concentrations of cyanide or antimycin A had little effect during the first 20 min and only a modest effect after 1 h (36 and 20% reductions, respectively). Yet the mitochondrial NAD(P)H pools were fully reduced after 2-3 min with all three treatments, This cyanide- and antimycin-insensitive but hypoxia-sensitive pattern of protein synthesis depression suggests the presence of a molecular oxygen sensor within the mitochondrion. Second, we show for the first time that acidification of extramitochondrial pH exerts inhibition on protein synthesis specifically through changes in matrix pH, Matrix pH was 8.2 during protein synthesis assays performed at the extramitochondrial pH optimum of 7.5, When this proton gradient was abolished with nigericin, the extramitochondrial pH optimum for protein synthesis displayed an alkaline shift of similar to 0.7 pH unit, These data suggest the presence of proton-sensitive translational components within the mitochondrion.	UNIV COLORADO,DEPT ENVIRONM POPULAT & ORGANISM BIOL,BOULDER,CO 80309; UNIV COLORADO,GRAD PROGRAM MOL BIOPHYS,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder								ACKER H, 1994, RESP PHYSL, V9, P1; ANDERSSON BS, 1987, AM J PHYSIOL, V252, pC349, DOI 10.1152/ajpcell.1987.252.4.C349; AW TY, 1989, AM J PHYSIOL, V257, pC435, DOI 10.1152/ajpcell.1989.257.3.C435; BATES TE, 1995, BIOCHEM BIOPH RES CO, V213, P896, DOI 10.1006/bbrc.1995.2213; BAYSAL K, 1991, ARCH BIOCHEM BIOPHYS, V268, P383; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BRIERLEY GP, 1989, BIOCHEMISTRY-US, V28, P4347, DOI 10.1021/bi00436a034; BUSA WB, 1982, ARCH BIOCHEM BIOPHYS, V216, P711, DOI 10.1016/0003-9861(82)90261-2; BUSA WB, 1983, SCIENCE, V221, P366, DOI 10.1126/science.221.4608.366; CARPENTER JF, 1986, J COMP PHYSIOL B, V156, P451, DOI 10.1007/BF00691030; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CLEGG JS, 1994, J EXP ZOOL, V270, P332, DOI 10.1002/jez.1402700312; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; DAWSON RMC, 1986, DATA BIOCH RES, P302; DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531; FOX TD, 1993, PROTEIN SYNTHESIS TA, P157; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GONZALEZFLECHA B, 1995, J BIOL CHEM, V270, P13681, DOI 10.1074/jbc.270.23.13681; GORLACH A, 1993, BIOCHEM J, V290, P771; GROOT GSP, 1975, NATURE, V255, P238, DOI 10.1038/255238a0; Hand S.C., 1991, Advances in Comparative and Environmental Physiology, V8, P1; HAND SC, 1988, SCIENCE, V239, P1425, DOI 10.1126/science.239.4846.1425; Hand SC, 1996, ANNU REV PHYSIOL, V58, P539, DOI 10.1146/annurev.ph.58.030196.002543; HAND SC, 1993, SURVIVING HYPOXIA ME, P171; HARDEWIG I, 1996, IN PRESS CELL MOL BI; HARMON PA, 1994, BIOCHEMISTRY-US, V33, P699, DOI 10.1021/bi00169a011; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; HIDALGO E, 1995, J BIOL CHEM, V270, P20908, DOI 10.1074/jbc.270.36.20908; HOFMANN GE, 1990, AM J PHYSIOL, V258, pR1184, DOI 10.1152/ajpregu.1990.258.5.R1184; HOFMANN GE, 1992, J EXP BIOL, V164, P103; HOFMANN GE, 1994, P NATL ACAD SCI USA, V91, P3492; HUTSON SM, 1987, J BIOL CHEM, V262, P9629; ISFORT RJ, 1993, EUR J BIOCHEM, V213, P349, DOI 10.1111/j.1432-1033.1993.tb17768.x; IUCHI S, 1993, MOL MICROBIOL, V9, P9, DOI 10.1111/j.1365-2958.1993.tb01664.x; JUNG DW, 1989, ANAL BIOCHEM, V178, P348, DOI 10.1016/0003-2697(89)90651-9; KOBZIK L, 1995, BIOCHEM BIOPH RES CO, V211, P375, DOI 10.1006/bbrc.1995.1824; KWAST KE, 1993, AM J PHYSIOL, V265, pR1238, DOI 10.1152/ajpregu.1993.265.6.R1238; KWAST KE, 1995, BBA-BIOENERGETICS, V1232, P5, DOI 10.1016/0005-2728(95)00090-9; Kwast KE, 1996, BIOCHEM J, V313, P207, DOI 10.1042/bj3130207; LATIPAA PM, 1986, BIOCHIM BIOPHYS ACTA, V875, P293, DOI 10.1016/0005-2760(86)90179-7; MCKEE EE, 1984, J BIOL CHEM, V259, P9320; MCKEE EE, 1990, AM J PHYSIOL, V258, pE492, DOI 10.1152/ajpendo.1990.258.3.E492; MILLS NC, 1984, ANAL BIOCHEM, V138, P164, DOI 10.1016/0003-2697(84)90785-1; NICHOLLS DG, 1992, BIOENERGETICS, V2, P30; NUMOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993; PADMANABAN G, 1989, TRENDS BIOCHEM SCI, V14, P492, DOI 10.1016/0968-0004(89)90182-5; PINKHAM JL, 1992, METAL IONS FUNGI, P455; POYTON RO, 1996, IN PRESS ANN REV BIO, V65; REES BB, 1989, J BIOL CHEM, V264, P15410; RHOADS RE, 1983, BIOCHEMISTRY-US, V23, P6084; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TAN CC, 1991, AM J PHYSIOL, V261, pF982, DOI 10.1152/ajprenal.1991.261.6.F982; TISCHLER ME, 1977, ARCH BIOCHEM BIOPHYS, V184, P222, DOI 10.1016/0003-9861(77)90346-0; TOLEDANO MB, 1994, CELL, V78, P897, DOI 10.1016/S0092-8674(94)90702-1; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WINKLER M, 1988, BIOESSAYS, V8, P157, DOI 10.1002/bies.950080507; WOODROW G, 1979, J BIOL CHEM, V254, P6088; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	61	58	64	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7313	7319		10.1074/jbc.271.13.7313	http://dx.doi.org/10.1074/jbc.271.13.7313			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631750	hybrid			2022-12-27	WOS:A1996UC77400018
J	Prieve, MG; Guttridge, KL; Munguia, JE; Waterman, ML				Prieve, MG; Guttridge, KL; Munguia, JE; Waterman, ML			The nuclear localization signal of lymphoid enhancer factor-1 is recognized by two differentially expressed Srp1-nuclear localization sequence receptor proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ENHANCER; HMG DOMAIN; SACCHAROMYCES-CEREVISIAE; BINDING; TRANSLOCATION; IMPORT; STEPS; LEF-1; DNA	Proteins are directed to the nucleus by their nuclear localization sequences (NLSs) in a multistep process, The first step, which is to dock the NLS-containing protein to the nuclear pore, is carried out in part by a recently identified NLS receptor named Srp1/importin-alpha. Using the high mobility group (HMG) DNA binding domain of human lymphoid enhancer factor-1 (hLEF-1) as bait in a yeast two-hybrid screen, we have identified two different mouse Srp1 proteins (pendulin/importin-alpha and mSrp1) that each bind to a 9-amino acid sequence in hLEF-1 called the B box, We show that the B box of hLEF-1, a region essential for high affinity DNA binding, is also necessary and sufficient for nuclear localization, lending support to the model that NLSs can function both in nuclear transport and DNA binding, Pendulin and mSrp1 are the mouse homologues of hRch1/hSrp1 alpha/importin-alpha and hSrp1/karyopherin alpha/NPI-1, respectively, and show considerable sequence divergence from each other. We find a surprising and significant difference in the expression pattern of pendulin and mSrp1 mRNA, suggesting that these two Srp1 proteins are distinguishable in function as well as sequence.	UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine					NCI NIH HHS [CA-62079] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062079] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; AZUMA Y, 1995, IN PRESS P NATL ACAD; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; KUSSEL P, 1995, J CELL BIOL, V129, P1491, DOI 10.1083/jcb.129.6.1491; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; OSBORNE MA, 1993, ANNU REV BIOCHEM, V62, P219; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; TOROK I, 1995, J CELL BIOL, V129, P1473, DOI 10.1083/jcb.129.6.1473; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANHOUTE L, 1993, J BIOL CHEM, V268, P18083; VIRCA GD, 1990, BIOTECHNIQUES, V8, P370; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; YANO R, 1994, P NATL ACAD SCI USA, V91, P6880, DOI 10.1073/pnas.91.15.6880; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	30	91	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7654	7658		10.1074/jbc.271.13.7654	http://dx.doi.org/10.1074/jbc.271.13.7654			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631802	hybrid			2022-12-27	WOS:A1996UC77400070
J	Qu, BH; Thomas, PJ				Qu, BH; Thomas, PJ			Alteration of the cystic fibrosis transmembrane conductance regulator folding pathway - Effects of the Delta F508 mutation on the thermodynamic stability and folding yield of NBD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING FOLD; ESCHERICHIA-COLI; MOLECULAR-BASIS; PROTEIN; PURIFICATION; CHANNEL; GENE; IDENTIFICATION; LOCALIZATION; EPITHELIA	The cellular phenotype of the most common cystic fibrosis-causing mutation, deletion of phenylalanine 508 (Delta F508) in the amino-terminal nucleotide binding domain (NBD1) of the cystic fibrosis transmembrane conductance regulator (CFTR), is the inability of the mutant protein to fold and transit to the apical membrane of affected epithelial cells. Expressed NBD1s were purified and folded in vitro into soluble monomers capable of binding nucleotide. Here we report that the Delta F508 mutation has little effect on the thermodynamic stability of the folded NBD1. The Delta G(D,GdnHCl)(0) is 15.5 kJ/mol for the wild type NBD1 and 14.4 kJ/mol for NBD1 Delta F. In contrast, the mutation significantly reduces the folding yield at a variety of temperatures, indicating that Phe-508 makes crucial contacts during the folding process, but plays little role in stabilization of the native state. Under conditions that approximate the efficiency of maturation in vivo, the rate off-pathway is significantly increased by the disease causing mutation. These results establish a molecular mechanism for most cases of cystic fibrosis and provide insight into the complex processes by which primary sequence encodes the three-dimensional structure.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Thomas, Philip J/F-7115-2012					ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ARISPE N, 1992, P NATL ACAD SCI USA, V89, P1539, DOI 10.1073/pnas.89.5.1539; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CUTTING GR, 1993, J BIOENERG BIOMEMBR, V25, P7, DOI 10.1007/BF00768062; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DANNER M, 1993, PROTEIN SCI, V2, P1869, DOI 10.1002/pro.5560021109; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DORK T, 1991, HUM GENET, V87, P441; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KO YH, 1993, J BIOL CHEM, V268, P24330; KO YH, 1995, J BIOL CHEM, V270, P22093, DOI 10.1074/jbc.270.38.22093; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STOYAN T, 1993, EUR J BIOCHEM, V216, P239, DOI 10.1111/j.1432-1033.1993.tb18138.x; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; THOMAS PJ, 1992, FEBS LETT, V312, P7, DOI 10.1016/0014-5793(92)81399-7; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6	32	120	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7261	7264		10.1074/jbc.271.13.7261	http://dx.doi.org/10.1074/jbc.271.13.7261			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631737				2022-12-27	WOS:A1996UC77400005
J	Ribon, V; Saltiel, AR				Ribon, V; Saltiel, AR			Nerve growth factor stimulates the tyrosine phosphorylation of endogenous Crk-II and augments its association with p130(Cas) in PC-12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; SH3 DOMAINS; NEURONAL DIFFERENTIATION; ONCOGENE PRODUCT; PHOSPHOLIPASE-C; V-CRK; RECEPTOR; BINDING; IDENTIFICATION; PAXILLIN	The cellular homologs of the v-Crk oncogene product consist primarily of Src homology region 2 (SH2)(1) and 3 (SH3) domains, v-Crk overexpression causes cell trans formation and elevation of tyrosine phosphorylation in fibroblasts and accelerates differentiation of PC-12 cells in response to nerve growth factor (NGF), To further explore the role of Crk in NGF-induced PC-12 cell differentiation, we found that both NGF and epidermal growth factor stimulate the tyrosine phosphorylation of endogenous Crk II. Moreover, hormone stimulation enhanced the specific association of Crk proteins with the tyrosine-phosphorylated p130(Cas), the major phosphotyrosine-containing protein in cells transformed with v-Crk. This interaction is mediated by the SH2 domain of Crk and can be inhibited with a phosphopeptide containing the Crk-SH2 binding motif. Furthermore, the Crk-SH2 domain binds tyrosine-phosphorylated paxillin, a cytoskeletal protein, following treatment of PC-12 cells with NGF or epidermal growth factor. These data suggest that Crk functions in a number of signaling processes in PC-12 cells.	WARNER LAMBERT PARKE DAVIS, PHARMACEUT RES DIV, DEPT SIGNAL TRANSDUCT, ANN ARBOR, MI 48105 USA; UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA	Pfizer; University of Michigan System; University of Michigan			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; HU Q, 1995, MOL CELL BIOL, V14, P1964; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCNAMARA DJ, 1993, INT J PEPT PROT RES, V42, P240; MOCHAMMADI M, 1992, NATURE, V358, P681; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; RIBON V, 1994, MOL CELL NEUROSCI, V5, P277, DOI 10.1006/mcne.1994.1032; ROSEN MK, 1995, SCIENCE, V374, P477; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALTIEL AR, 1994, BIOESSAYS, V16, P405, DOI 10.1002/bies.950160608; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	47	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7375	7380		10.1074/jbc.271.13.7375	http://dx.doi.org/10.1074/jbc.271.13.7375			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631760	hybrid			2022-12-27	WOS:A1996UC77400028
J	Sick, C; Schultz, U; Staeheli, P				Sick, C; Schultz, U; Staeheli, P			A family of genes coding for two serologically distinct chicken interferons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE ACTIVATION; GAMMA	Southern blot analysis and screening of a genomic lambda phage library with the previously cloned chicken interferon (IFN) cDNA indicated that the chicken genome contains at least 10 IFN genes, A particularly strongly hybridizing phage clone that we analyzed in more detail carried a head to tail arrangement of three intron-less IFN genes that differed from each other and from the cloned chicken IFN cDNA by only a few base changes, The primary translation products of these three IFN genes consist of 193 amino acids, and the mature proteins are composed of 162 amino acids. All three genes of this IFN family, designated IFN1, yielded active chicken IFN when expressed individually in transfected COS7 cells. A weakly hybridizing phage clone contained an additional intron-less chicken IFN gene, designated IFN2, whose product was 57% identical to chicken IFN1. Southern blot analysis suggested that the chicken genome contains a single IFN2 gene, The primary translation product of IFN2 consists of 203 amino acids, and the mature protein is composed of 176 amino acids, Purified recombinant chicken IFN2 from Escherichia coli had a specific antiviral activity of about 10(6) units/mg, which was about 20-fold lower than that of chicken IFN1 purified in parallel, The antiviral activity of chicken IFN2 from E. coli or from transfected COS7 cells could not be neutralized by antiserum to recombinant chicken IFN1, Thus, like mammals, the chicken has a large number of type I IFN genes that code for at least two serologically distinct antiviral activities.	UNIV FREIBURG,DEPT VIROL,INST MED MIKROBIOL & HYG,D-79008 FREIBURG,GERMANY	University of Freiburg								ADOLF GR, 1987, J GEN VIROL, V68, P1669, DOI 10.1099/0022-1317-68-6-1669; BURT DW, 1995, TRENDS GENET, V11, P190, DOI 10.1016/S0168-9525(00)89042-3; DEMAYER EM, 1988, INTERFERONS OTHER RE; DIJKMANS R, 1988, CURR OPIN IMMUNOL, V1, P269, DOI 10.1016/0952-7915(88)90013-1; DIJKMANS R, 1990, VET IMMUNOL IMMUNOP, V26, P319, DOI 10.1016/0165-2427(90)90116-A; IJZERMANS JNM, 1989, IMMUNOBIOLOGY, V179, P456, DOI 10.1016/S0171-2985(89)80049-X; IMAKAWA K, 1987, NATURE, V330, P377, DOI 10.1038/330377a0; PACE JL, 1983, P NATL ACAD SCI-BIOL, V80, P3782, DOI 10.1073/pnas.80.12.3782; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; SCHULTZ U, 1995, VIROLOGY, V212, P641, DOI 10.1006/viro.1995.1522; SCHULTZ U, 1995, EUR J IMMUNOL, V25, P847, DOI 10.1002/eji.1830250332; SCHULTZ U, 1995, EUR J BIOCHEM, V229, P73, DOI 10.1111/j.1432-1033.1995.tb20439.x; SEKELLICK MJ, 1994, J INTERFERON RES, V14, P71, DOI 10.1089/jir.1994.14.71; SHAW GD, 1983, NUCLEIC ACIDS RES, V11, P555, DOI 10.1093/nar/11.3.555; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4; WHALEY AE, 1994, J BIOL CHEM, V269, P10864	16	89	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7635	7639		10.1074/jbc.271.13.7635	http://dx.doi.org/10.1074/jbc.271.13.7635			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631799	hybrid			2022-12-27	WOS:A1996UC77400067
J	Guyton, KZ; Liu, YS; Gorospe, M; Xu, QB; Holbrook, NJ				Guyton, KZ; Liu, YS; Gorospe, M; Xu, QB; Holbrook, NJ			Activation of mitogen-activated protein kinase by H2O2 - Role in cell survival following oxidant injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; GENE-PRODUCT; PHOSPHORYLATION; CARCINOGENESIS; EXPRESSION; PATHWAY; RAS	The mitogen-activated protein kinase (MAPK) family is comprised of key regulatory proteins that control the cellular response to both proliferation and stress signals. In this study we investigated the factors controlling MAPK activation by H2O2 and explored the impact of altering the pathways to kinase activation on cell survival following H2O2 exposure. Potent activation (10-20-fold) of extracellular signal-regulated protein kinase (ERK2) occurred within 10 min of H2O2 treatment, whereupon rapid inactivation ensued, H2O2 activated ERK2 in several cell types and also moderately activated (3-5-fold) both c-Jun N-terminal kinase and p38/RK/CSBP, Additionally, H2O2 increased the mRNA expression of MAPK-dependent genes c-jun, c-fos, and MAPK phosphatase-1. Suramin pretreatment completely inhibited H2O2 stimulation of ERK2, highlighting a role for growth factor receptors in this activation, Further, ERK2 activation by H2O2 was blocked by pretreatment with either N-acetyl-cysteine, o-phenanthroline, or mannitol, indicating that metal-catalyzed free radical formation mediates the initiation of signal transduction by H2O2. H2O2-stimulated activation of ERK2 was abolished in PC12 cells by inducible or constitutive expression of the dominant negative Ras-N-17 allele. Interestingly, PC12/Ras-N-17 cells were more sensitive than wild-type PC12 cells to H2O2 toxicity. Moreover, NIH 3T3 cells expressing constitutively active MAPK kinase (MEK, the immediate upstream regulator of ERK) were more resistant to H2O2 toxicity, while those expressing kinase-defective MEK were more sensitive, than cells expressing wild-type MEK. Taken together, these studies provide insight into mechanisms of MAPK regulation by H2O2 and suggest that ERK plays a critical role in cell survival following oxidant injury.	NIA,GERONTOL RES CTR,GENE EXPRESS & AGING SECT,NIH,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)			Liu, Yusen/E-3527-2011	Liu, Yusen/0000-0002-0994-0109				ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; BOULIKAS T, 1995, INT J ONCOL, V6, P271; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CERUTTI PA, 1989, ENVIRON HEALTH PERSP, V81, P39, DOI 10.2307/3430802; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GUYTON KZ, 1993, BRIT MED BULL, V49, P523, DOI 10.1093/oxfordjournals.bmb.a072628; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KEHRER JP, 1993, CRIT REV TOXICOL, V23, P21, DOI 10.3109/10408449309104073; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEWIS T, 1995, J CELL SCI, V108, P2885; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; LOS M, 1995, EUR J IMMUNOL, V25, P159, DOI 10.1002/eji.1830250127; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; NAKASHIMA I, 1994, J IMMUNOL, V152, P1064; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; OKA H, 1995, CANCER RES, V55, P4182; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; Ross R., 1980, HDB PHYSL CARDIOVA 2, P69; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHIEVEN GL, 1993, J BIOL CHEM, V268, P16688; SCHIEVEN GL, 1994, TRENDS ENDOCRIN MET, V5, P383, DOI 10.1016/1043-2760(94)90106-6; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHIBANUMA M, 1988, ONCOGENE, V3, P17; STAAL FJT, 1994, P NATL ACAD SCI USA, V91, P3619, DOI 10.1073/pnas.91.9.3619; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SZEBERENYI J, 1992, ONCOGENE, V7, P2105; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324	42	1112	1139	2	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4138	4142		10.1074/jbc.271.7.3604	http://dx.doi.org/10.1074/jbc.271.7.3604			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626753	hybrid			2022-12-27	WOS:A1996TW96000031
J	Trapani, JA; Browne, KA; Smyth, MJ; Jans, DA				Trapani, JA; Browne, KA; Smyth, MJ; Jans, DA			Localization of granzyme B in the nucleus - A putative role in the mechanism of cytotoxic lymphocyte-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SV40 T-ANTIGEN; NATURAL-KILLER-CELLS; SERINE ESTERASE GENE; MOLECULAR-CLONING; LYTIC GRANULES; PROTEIN-TRANSPORT; SEQUENCES; IDENTIFICATION; PROTEASES; RECEPTOR	One mechanism used by cytotoxic T cells and natural killer cells to kill target cells involves synergy between the pore-forming protein, perforin, and a serine protease termed granzyme B, both constituents of the cytoplasmic granules of cytolytic lymphocytes, Exposing susceptible cells to perforin and granzyme B results in apoptosis, the morphological consequences of which are most clearly seen in the nucleus, It is conventionally accepted that perforin acts by perforating the target cell membrane; however, the site and mode of action of granzyme B are unknown, We have addressed this issue using Western blotting, proteolytic assays, and confocal laser scanning microscopy to demonstrate that purified human granzyme B can be taken up in large amounts and bound within nuclei, By contrast, perforin and non-granzyme serine proteases did not undergo nuclear uptake, Both unglycosylated human granzyme B (26 kDa) and that bearing high mannose glycosylation (32 kDa) were internalized and bound within nuclei, but forms greater than 32 kDa with complex carbohydrate addition were excluded, The uptake of granzymes was not dependent on net charge, as nuclei absorbed similar quantities of granzyme B at neutral pH and through a range of basic pHs but did not take up other very basic serine proteases such as the mouse mast cell protease 5, Confocal laser scanning microscopy indicated nuclear and nucleolar accumulation of fluoresceinated granzyme B by isolated nuclei, Measurement of the kinetics of nuclear import using an in vitro nuclear transport assay indicated maximal levels of nuclear accumulation of granzyme about 2.5-fold above those in the cytoplasm and nucleolar accumulation a further 3-4-fold higher, Nuclear and nucleolar accumulation were exceedingly rapid, reaching half-maximal levels within 3.3 and 7.5 min, respectively, implying that nuclear accumulation probably occurs prior to transport to the nucleolus, Our observations may provide a mechanism explaining how aspartate-specific cell death proteases access the nuclear substrate poly(ADP-ribose) polymerase, the cleavage of which is an early event in apoptosis.	JOHN CURTIN SCH MED RES,DIV BIOCHEM & MOLEC BIOL,NUCL TARGETING LAB,CANBERRA,ACT 2600,AUSTRALIA	Australian National University; John Curtin School of Medical Research	Trapani, JA (corresponding author), AUSTIN RES INST,CELLULAR CYTOTOX LAB,STUDLEY RD,HEIDELBERG,VIC 3084,AUSTRALIA.		Smyth, Mark J/H-8709-2014	Smyth, Mark J/0000-0001-7098-7240; Trapani, Joseph/0000-0003-0983-1532				BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BURKHARDT JK, 1990, J CELL BIOL, V111, P2327, DOI 10.1083/jcb.111.6.2327; CHANG TW, 1980, J IMMUNOL, V124, P870; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DUKE RC, 1988, J IMMUNOL, V141, P2191; DUKE RC, 1989, J EXP MED, V170, P145; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; FEILOTTER H, 1992, BIOCHEM CELL BIOL, V70, P954, DOI 10.1139/o92-140; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GEISBERG M, 1991, TISSUE ANTIGENS, V35, P229; GREEN GDJ, 1979, ANAL BIOCHEM, V93, P223, DOI 10.1016/S0003-2697(79)80070-6; GRIFFITHS GM, 1993, J CELL BIOL, V120, P885, DOI 10.1083/jcb.120.4.885; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HUANG RY, 1991, EUR J IMMUNOL, V21, P1611, DOI 10.1002/eji.1830210706; HUDIG D, 1991, J IMMUNOL, V147, P1360; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JANS DA, 1994, ONCOGENE, V9, P2961; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; JANS DA, 1995, IN PRESS J BIOL CHEM; JANS DA, 1995, IN PRESS SCI INT; JANS DA, 1995, IN PRESS BIOCH J; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KAUFMANN SH, 1993, CANCER RES, V53, P3976; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LIU CC, 1986, J EXP MED, V164, P2061, DOI 10.1084/jem.164.6.2061; LIU CC, 1989, J EXP MED, V170, P2105, DOI 10.1084/jem.170.6.2105; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; MILLER M, 1991, PHYSIOL REV, V71, P909, DOI 10.1152/physrev.1991.71.3.909; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NAKAJIMA H, 1994, J IMMUNOL, V152, P1057; NAKAJIMA H, 1995, J EXP MED, V181, P1905, DOI 10.1084/jem.181.5.1905; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NORTHEMANN W, 1985, J BIOL CHEM, V260, P6200; OJCIUS DM, 1991, J IMMUNOL, V146, P4427; PASTERNACK MS, 1991, J BIOL CHEM, V266, P14703; PODACK ER, 1985, IMMUNOL TODAY, V6, P21, DOI 10.1016/0167-5699(85)90164-1; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SALI A, 1993, J BIOL CHEM, V268, P9023; SHI L, 1994, SCIENCE, V243, P1443; SHI L, 1991, J EXP MED, V175, P553; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; SMYTH MJ, 1992, J BIOL CHEM, V267, P24418; SMYTH MJ, 1995, IMMUNOL TODAY, V16, P202, DOI 10.1016/0167-5699(95)80122-7; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TRAPANI JA, 1994, J BIOL CHEM, V269, P18359; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; TRAPANI JA, 1988, P NATL ACAD SCI USA, V85, P6924, DOI 10.1073/pnas.85.18.6924; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WARREN G, 1987, NATURE, V327, P17, DOI 10.1038/327017a0; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; XUE ZX, 1993, EUR J CELL BIOL, V62, P13; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YOUNG JD, 1986, CELL, V46, P641, DOI 10.1016/0092-8674(86)90336-3; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YURT RW, 1977, J BIOL CHEM, V252, P518	60	100	105	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4127	4133						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626751				2022-12-27	WOS:A1996TW96000029
J	Werlen, C; Kohler, HPE; vanderMeer, JR				Werlen, C; Kohler, HPE; vanderMeer, JR			The broad substrate chlorobenzene dioxygenase and cis-chlorobenzene dihydrodiol dehydrogenase of Pseudomonas sp strain P51 are linked evolutionarily to the enzymes for benzene and toluene degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODING NAPHTHALENE DIOXYGENASE; NUCLEOTIDE-SEQUENCE; PUTIDA F1; PSEUDOALCALIGENES KF707; ESCHERICHIA-COLI; DEGRADING STRAIN; BPH OPERON; GENES; OXIDATION; METABOLISM	The chlorobenzene degradation pathway of Pseudomonas sp, strain P51 is an evolutionary novelty, The first enzymes of the pathway, the chlorobenzene dioxygenase and the cis-chlorobenzene dihydrodiol dehydrogenase, are encoded on a plasmid-located transposon Tn5280. Chlorobenzene dioxygenase is a four-protein complex, formed by the gene products of tcbAa for the large subunit of the terminal oxygenase, tcbAb for the small subunit, tcbAc for the ferredoxin, and tcbAd for the NADH reductase, Directly downstream of tcbAd is the gene for the cis-chlorobenzene dihydrodiol dehydrogenase, tcbB, Homology comparisons indicated that these genes and gene products are most closely related to those for toluene (todC1C2BAD) and benzene degradation (bedC1C2BA and bnzABCD) and distantly to those for biphenyl, naphthalene, and benzoate degradation, Similar to the tod-encoded enzymes, chlorobenzene dioxygenase and cis-chlorobenzene dihydrodiol dehydrogenase were capable of oxidizing 1,2-dichlorobenzene, toluene, naphthalene, and biphenyl, but not benzoate, to the corresponding dihydrodiol and dihydroxy intermediates, These data strongly suggest that the chlorobenzene dioxygenase and dehydrogenase originated from a toluene or benzene degradation pathway, probably by horizontal gene transfer, This evolutionary event left its traces as short gene fragments directly outside the tcbAB coding regions.	SWISS FED INST ENVIRONM SCI & TECHNOL,DEPT MICROBIOL,CH-8600 DUBENDORF,SWITZERLAND	Swiss Federal Institutes of Technology Domain; Swiss Federal Institute of Aquatic Science & Technology (EAWAG)			Kohler, Hans-Peter/C-1456-2015; van der Meer, Jan Roelof/G-6610-2012	Kohler, Hans-Peter/0000-0001-7667-0762; van der Meer, Jan Roelof/0000-0003-1485-3082				ASTURIAS JA, 1995, GENE, V156, P11, DOI 10.1016/0378-1119(94)00530-6; Brenner Vladimir, 1994, Biodegradation, V5, P359, DOI 10.1007/BF00696470; DENOME SA, 1993, J BACTERIOL, V175, P6890, DOI 10.1128/jb.175.21.6890-6901.1993; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENSLEY BD, 1983, SCIENCE, V222, P167, DOI 10.1126/science.6353574; ERICKSON BD, 1992, J BACTERIOL, V174, P2903, DOI 10.1128/JB.174.9.2903-2912.1992; FUKUDA M, 1994, BIOCHEM BIOPH RES CO, V202, P850, DOI 10.1006/bbrc.1994.2008; FURUKAWA K, 1993, J BACTERIOL, V175, P5224, DOI 10.1128/JB.175.16.5224-5232.1993; GIBSON DT, 1990, PSEUDOMONAS : BIOTRANSFORMATIONS, PATHOGENESIS, AND EVOLVING BIOTECHNOLOGY, P121; GIBSON DT, 1973, BIOCHEM BIOPH RES CO, V50, P211, DOI 10.1016/0006-291X(73)90828-0; GIBSON DT, 1970, BIOCHEMISTRY-US, V9, P1626, DOI 10.1021/bi00809a023; GIBSON DT, 1993, J BACTERIOL, V175, P4561, DOI 10.1128/JB.175.14.4561-4564.1993; HARAYAMA S, 1992, MET IONS BIOL SYST, V28, P99; HARAYAMA S, 1992, ANNU REV MICROBIOL, V46, P565, DOI 10.1146/annurev.mi.46.100192.003025; HARAYAMA S, 1991, J BACTERIOL, V173, P7540, DOI 10.1128/jb.173.23.7540-7548.1991; HIROSE J, 1994, GENE, V138, P27; HOFER B, 1994, GENE, V144, P9, DOI 10.1016/0378-1119(94)90196-1; IRIE S, 1987, J BACTERIOL, V169, P5174, DOI 10.1128/jb.169.11.5174-5179.1987; JEFFREY AM, 1975, BIOCHEMISTRY-US, V14, P575, DOI 10.1021/bi00674a018; KIKUCHI Y, 1994, J BACTERIOL, V176, P1689, DOI 10.1128/jb.176.6.1689-1694.1994; KOHLER HPE, 1993, J BACTERIOL, V175, P1621, DOI 10.1128/JB.175.6.1621-1628.1993; KUHM AE, 1991, J BACTERIOL, V173, P3795, DOI 10.1128/JB.173.12.3795-3802.1991; KURKELA S, 1988, GENE, V73, P355, DOI 10.1016/0378-1119(88)90500-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASAI E, 1995, APPL ENVIRON MICROB, V61, P2079, DOI 10.1128/AEM.61.6.2079-2085.1995; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; MENN FM, 1991, GENE, V104, P91, DOI 10.1016/0378-1119(91)90470-V; NEIDLE EL, 1991, J BACTERIOL, V173, P5385, DOI 10.1128/jb.173.17.5385-5395.1991; PATEL TR, 1974, J BACTERIOL, V119, P879, DOI 10.1128/JB.119.3.879-888.1974; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROJO F, 1987, SCIENCE, V238, P1395, DOI 10.1126/science.3479842; Sambrook J., 2002, MOL CLONING LAB MANU; SAYLER GS, 1990, MICROBIAL ECOL, V19, P1, DOI 10.1007/BF02015050; SIMON MJ, 1993, GENE, V127, P31, DOI 10.1016/0378-1119(93)90613-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAIRA K, 1992, J BIOL CHEM, V267, P4844; TAIRA K, 1988, BIOCHEMISTRY-US, V27, P3990, DOI 10.1021/bi00411a015; TAKIZAWA N, 1994, J BACTERIOL, V176, P2444, DOI 10.1128/JB.176.8.2444-2449.1994; TAN HM, 1993, GENE, V130, P33, DOI 10.1016/0378-1119(93)90343-2; TAN HM, 1994, J BACTERIOL, V176, P2507, DOI 10.1128/JB.176.9.2507-2512.1994; TEBBE CC, 1992, APPL MICROBIOL BIOT, V37, P818, DOI 10.1007/BF00174852; TIMMIS KN, 1990, ADV AP BIOT, V4, P61; VANDERMEER JR, 1991, J BACTERIOL, V173, P3700, DOI 10.1128/JB.173.12.3700-3708.1991; VANDERMEER JR, 1991, J BACTERIOL, V173, P2425, DOI 10.1128/jb.173.8.2425-2434.1991; VANDERMEER JR, 1991, J BACTERIOL, V173, P6, DOI 10.1128/JB.173.1.6-15.1991; VANDERMEER JR, 1992, MICROBIOL REV, V56, P677, DOI 10.1128/MMBR.56.4.677-694.1992; VANDERMEER JR, 1991, J BACTERIOL, V173, P7077, DOI 10.1128/jb.173.22.7077-7083.1991; WACKETT LP, 1988, APPL ENVIRON MICROB, V54, P1703, DOI 10.1128/AEM.54.7.1703-1708.1988; WASSERFALLEN A, 1991, BIO-TECHNOL, V9, P296, DOI 10.1038/nbt0391-296; ZYLSTRA GJ, 1989, J BIOL CHEM, V264, P14940	50	96	104	4	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4009	4016						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626733				2022-12-27	WOS:A1996TW96000011
J	McGinnity, DF; Devreese, B; Prazeres, S; VanBeeumen, J; Moura, I; Moura, JJG; Pettigrew, GW				McGinnity, DF; Devreese, B; Prazeres, S; VanBeeumen, J; Moura, I; Moura, JJG; Pettigrew, GW			A single histidine is required for activity of cytochrome c peroxidase from Paracoccus denitrificans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; RESIDUES; DEHYDROGENASE; PREDICTION; MECHANISM; ALGORITHM; PROTEINS	The diheme cytochrome c peroxidase from Paracoccus denitrificans was modified with the histidine-specific reagent diethyl pyrocarbonate. At low excess of reagent, 1 mol of histidine was modified in the oxidized enzyme, and modification was associated with loss of the ability to form the active state. With time, the modification reversed, and the ability to form the active state was recovered, The agreement between the spectrophotometric measurement of histidine modification and radioactive incorporation using a radiolabeled reagent indicated Little modification of other amino acids. However, the reversal of histidine modification observed spectrophotometrically was not matched by loss of radioactivity, and we propose a slow transfer of the ethoxyformyl group to an unidentified amino acid. The presence of CN- bound to the active peroxidatic site of the enzyme led to complete protection of the essential histidine from modification. Limited subtilisin treatment of the native enzyme followed by tryptic digest of the C-terminal fragment (residues 251-338) showed that radioactivity was located in a peptide containing a single histidine at position 275. We propose that this conserved residue, in a highly conserved region, is central to the function of the active mixed-valence state.	UNIV EDINBURGH,ROYAL DICK SCH VET STUDIES,DEPT PRECLIN VET SCI,EDINBURGH EH9 1QH,MIDLOTHIAN,SCOTLAND; DEPT BIOCHEM PHYSIOL & MICROBIOL,B-9000 GHENT,BELGIUM; UNIV NOVA LISBOA,FAC CIENCIAS & TECNOL,DEPT QUIM,P-2825 MONTE DE CAPARICA,PORTUGAL	University of Edinburgh; Universidade Nova de Lisboa			Moura, José J G/D-6426-2013; Moura, Isabel/D-6339-2013; Devreese, Bart/B-2011-2009; Devreese, Bart/K-2841-2019	Moura, José J G/0000-0002-4726-2388; Moura, Isabel/0000-0003-0971-4977; Devreese, Bart/0000-0002-9764-2581; Devreese, Bart/0000-0002-9764-2581	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BHATTACHARYYA DK, 1992, J BIOL CHEM, V267, P9800; BOSSHARD HR, 1984, J BIOL CHEM, V259, P5683; BURSTEIN Y, 1974, BIOCHEMISTRY-US, V13, P205, DOI 10.1021/bi00698a030; COULSON AFW, 1971, J BIOL CHEM, V246, P917; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; ELLFOLK N, 1991, BIOCHIM BIOPHYS ACTA, V1080, P68, DOI 10.1016/0167-4838(91)90113-E; ELLFOLK N, 1983, BIOCHIM BIOPHYS ACTA, V743, P23, DOI 10.1016/0167-4838(83)90413-2; ELLFOLK N, 1984, BIOCHIM BIOPHYS ACTA, V784, P62, DOI 10.1016/0167-4838(84)90173-0; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FOOTE N, 1984, BIOCHEM J, V223, P369, DOI 10.1042/bj2230369; FOOTE N, 1985, BIOCHEM J, V230, P227, DOI 10.1042/bj2300227; FUKUYAMA K, 1995, J BIOL CHEM, V270, P21884, DOI 10.1074/jbc.270.37.21884; FULOP V, 1995, STRUCTURE, V3, P1225, DOI 10.1016/S0969-2126(01)00258-1; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GILMOUR R, 1994, BIOCHEM J, V300, P907, DOI 10.1042/bj3000907; Gilmour R, 1995, EUR J BIOCHEM, V234, P878, DOI 10.1111/j.1432-1033.1995.878_a.x; GILMOUR R, 1993, BIOCHEM J, V294, P745, DOI 10.1042/bj2940745; GOODHEW CF, 1990, BIOCHEM J, V271, P707, DOI 10.1042/bj2710707; HEGYI G, 1974, EUR J BIOCHEM, V44, P7, DOI 10.1111/j.1432-1033.1974.tb03452.x; HOLBROOK JJ, 1973, BIOCHEM J, V131, P729, DOI 10.1042/bj1310729; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; MILES EDW, 1972, METHOD ENZYMOL, V25, P44; MORE C, 1990, J MAGN RESON, V90, P486, DOI 10.1016/0022-2364(90)90053-C; OVADI J, 1969, ACTA BIOCHIM BIOPHYS, V4, P265; PETTIGREW GW, 1982, BIOCHEM J, V201, P9, DOI 10.1042/bj2010009; POULOS TL, 1993, J BIOL CHEM, V268, P4429; PRAZERES S, 1995, J BIOL CHEM, V270, P24264, DOI 10.1074/jbc.270.41.24264; RIDOUT CJ, 1995, FEBS LETT, V365, P152, DOI 10.1016/0014-5793(95)00461-H; RONNBERG M, 1981, ARCH BIOCHEM BIOPHYS, V207, P197, DOI 10.1016/0003-9861(81)90025-4; TUDBALL N, 1972, BIOCHEM J, V129, P419, DOI 10.1042/bj1290419	32	16	16	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11126	11133		10.1074/jbc.271.19.11126	http://dx.doi.org/10.1074/jbc.271.19.11126			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626657	hybrid			2022-12-27	WOS:A1996UJ94400017
J	Shearwin, KE; Egan, JB				Shearwin, KE; Egan, JB			Purification and self-association equilibria of the lysis-lysogeny switch proteins of coliphage 186	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMBDA CI-REPRESSOR; GENE-EXPRESSION; TEMPERATE COLIPHAGE-186; BACTERIOPHAGE-MU; DNA; BINDING; NER; SEQUENCE	The CI repressor protein, responsible for maintenance of the lysogenic state, and the Apl protein, required for efficient prophage induction, are the two control proteins of the lysis-lysogeny transcriptional switch of coliphage 186. These proteins have been overexpressed, purified, and their self-association behavior examined by sedimentation equilibrium. Phage 186 CI dimers self-associate in solution through tetramers to octamers in a concerted process. The Apl protein of 186 is an unusual example of a helix-turn-helix protein which is monomeric in solution.	UNIV ADELAIDE,DEPT BIOCHEM,ADELAIDE,SA 5005,AUSTRALIA	University of Adelaide			Shearwin, Keith/AAS-1247-2021	Shearwin, Keith/0000-0002-7736-2742				ABBOTT J, 1993, BIOCHEMISTRY-US, V32, P9649, DOI 10.1021/bi00088a017; ALLET B, 1988, GENE, V65, P259, DOI 10.1016/0378-1119(88)90462-3; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BURZ DS, 1994, BIOCHEMISTRY-US, V33, P8406, DOI 10.1021/bi00194a004; DIBBENS JA, 1992, MOL MICROBIOL, V6, P2643, DOI 10.1111/j.1365-2958.1992.tb01441.x; Dodd IB, 1996, J BIOL CHEM, V271, P11532, DOI 10.1074/jbc.271.19.11532; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; DODD IB, 1993, MOL MICROBIOL, V10, P1139, DOI 10.1111/j.1365-2958.1993.tb00983.x; DODD IB, 1990, J MOL BIOL, V214, P27, DOI 10.1016/0022-2836(90)90144-B; ESPOSITO D, 1994, MOL MICROBIOL, V13, P685, DOI 10.1111/j.1365-2958.1994.tb00462.x; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; GOOSEN N, 1986, J BACTERIOL, V167, P503, DOI 10.1128/jb.167.2.503-507.1986; HARRISON SC, 1992, TRANSCRIPTIONAL REGU; HEXNER PE, 1961, P NATL ACAD SCI USA, V47, P1848, DOI 10.1073/pnas.47.11.1848; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KALIONIS B, 1986, J MOL BIOL, V191, P199, DOI 10.1016/0022-2836(86)90257-3; KUKOLJ G, 1992, J BIOL CHEM, V267, P17827; KUKOLJ G, 1989, EMBO J, V8, P3141, DOI 10.1002/j.1460-2075.1989.tb08467.x; LAMONT I, 1989, P NATL ACAD SCI USA, V86, P5492, DOI 10.1073/pnas.86.14.5492; LAUE TM, 1993, BIOCHEMISTRY-US, V32, P2469, DOI 10.1021/bi00061a003; McKnight S.L., 1992, TRANSCRIPTIONAL REGU; PTASHNE M, 1992, GENETIC SWITCH GENE; RICHARDSON H, 1989, J MOL BIOL, V206, P59, DOI 10.1016/0022-2836(89)90523-8; SENEAR DF, 1993, BIOCHEMISTRY-US, V32, P6179, DOI 10.1021/bi00075a010; STRZELECKA TE, 1995, BIOCHEMISTRY-US, V34, P2946, DOI 10.1021/bi00009a026; STUDIER RW, 1990, METHOD ENZYMOL, V185, P60; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045	28	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11525	11531		10.1074/jbc.271.19.11525	http://dx.doi.org/10.1074/jbc.271.19.11525			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626713	hybrid			2022-12-27	WOS:A1996UJ94400073
J	Wheeler, LJ; Ray, NB; Ungermann, C; Hendricks, SP; Bernard, MA; Hanson, ES; Mathews, CK				Wheeler, LJ; Ray, NB; Ungermann, C; Hendricks, SP; Bernard, MA; Hanson, ES; Mathews, CK			T4 phage gene 32 protein as a candidate organizing factor for the Deoxyribonucleoside triphosphate synthetase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DEOXYCYTIDYLATE HYDROXYMETHYLASE; BACTERIOPHAGE-T4 PROTEINS; THYMIDYLATE SYNTHASE; DNA-REPLICATION; PURIFICATION; CLONING; OVERPRODUCTION; RECOMBINATION; EXPRESSION	After T4 bacteriophage infection of Escherichia coli, the enzymes of deoxyribonucleoside triphosphate biosynthesis form a multienzyme complex that we call T4 deoxyribonucleoside triphosphate (dNTP) synthetase, At least eight phage-coded enzymes and two enzymes of host origin are found in this 1.5-mDa complex. The complex may shuttle dNTPs to DNA replication sites, because replication draws from small pools, which are probably highly localized. Several specific protein-protein contacts within the complex are described in this paper. We have studied protein-protein interactions in the complex by immobilizing individual enzymes and identifying radiolabeled T4 proteins that are retained by columns of these respective affinity ligands. Elsewhere we have described interactions involving three T4 enzymes found in the complex. In this paper we describe similar analysis of five more proteins: dihydrofolate reductase, dCTPase-dUTPase, deoxyribonucleoside monophosphokinase, ribonucleotide reductase, and E. coli nucleoside diphosphokinase,. All eight proteins analyzed to date retain single-strand DNA-binding protein (gp32), the product of T4 gene 32. At least one T4 protein, thymidylate synthase, binds directly to gp32, as shown by affinity chromatographic analysis of the two purified proteins. Among its several roles, gp32 stabilizes single-strand template DNA ahead of a replicating DNA polymerase, Our data suggest a model in which dNTP synthetase complexes, probably more than one per growing DNA chain, are drawn to replication forks via their affinity for gp32 and hence are localized so as to produce dNTPs at their sites of utilization, immediately ahead of growing DNA 3' termini.	OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331	Oregon State University				Bernard, Mark/0000-0001-7141-2975				ALLEN JR, 1983, J BIOL CHEM, V258, P5746; BELFORT M, 1983, J BIOL CHEM, V258, P2045; BRUSH GS, 1990, J BACTERIOL, V172, P2935, DOI 10.1128/jb.172.6.2935-2939.1990; CHIU CS, 1982, J BIOL CHEM, V257, P5087; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; GARY TP, 1992, THESIS VANDERBILT U; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HANSON E, 1994, J BIOL CHEM, V269, P30999; HANSOU ES, 1994, THESIS OREGON STATE; HOFFMANN HJ, 1992, P NATL ACAD SCI USA, V89, P12108, DOI 10.1073/pnas.89.24.12108; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; JI JP, 1993, MUTAT RES, V294, P247, DOI 10.1016/0921-8777(93)90007-4; Karpel R.L., 1990, BIOL NONSPECIFIC DNA, P103; KERNBERG A, 1992, DNA REPLICATION, P324; KRASSA KB, 1991, P NATL ACAD SCI USA, V88, P4010, DOI 10.1073/pnas.88.9.4010; KREUZER KN, 1994, MOL BIOL BACTERIOPHA, P28; LOHMAN TM, 1984, BIOCHEMISTRY-US, V23, P4665, DOI 10.1021/bi00315a023; MATHEWS CK, 1993, PROG NUCLEIC ACID RE, V44, P167, DOI 10.1016/S0079-6603(08)60220-2; MATHEWS CK, 1993, J BACTERIOL, V175, P6377, DOI 10.1128/jb.175.20.6377-6381.1993; MILLER RC, 1972, J VIROL, V10, P920, DOI 10.1128/JVI.10.5.920-924.1972; Moen L K, 1988, J Mol Recognit, V1, P48, DOI 10.1002/jmr.300010109; PUROHIT S, 1984, J BIOL CHEM, V259, P6261; RAY NB, 1992, THESIS OREGON STATE; REDDY GPV, 1978, J BIOL CHEM, V253, P3461; RICHEY B, 1987, J BIOL CHEM, V262, P7157; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SHAMOO Y, 1986, P NATL ACAD SCI USA, V83, P8844, DOI 10.1073/pnas.83.23.8844; TSENG MJ, 1992, J BACTERIOL, V174, P5740, DOI 10.1128/JB.174.17.5740-5744.1992; UNGERMANN C, 1993, THESIS OREGON STATE; WARNER HR, 1966, P NATL ACAD SCI USA, V56, P1233, DOI 10.1073/pnas.56.4.1233; WERNER R, 1968, J MOL BIOL, V33, P679, DOI 10.1016/0022-2836(68)90313-6; WHEELER L, 1992, J BIOL CHEM, V267, P7664; YONESAKI T, 1985, EUR J BIOCHEM, V148, P127, DOI 10.1111/j.1432-1033.1985.tb08816.x; YOUNG JP, 1992, J BIOL CHEM, V267, P10786	34	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11156	11162		10.1074/jbc.271.19.11156	http://dx.doi.org/10.1074/jbc.271.19.11156			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626661				2022-12-27	WOS:A1996UJ94400021
J	Golabek, AA; Soto, C; Vogel, T; Wisniewski, T				Golabek, AA; Soto, C; Vogel, T; Wisniewski, T			The interaction between apolipoprotein E and Alzheimer's amyloid beta-peptide is dependent on beta-peptide conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBROSPINAL-FLUID; FIBRIL FORMATION; TYPE-4 ALLELE; DISEASE; PROTEIN; AGGREGATION; DEPOSITS; BINDING; GENE; PRECURSOR	An important feature of Alzheimer's disease (AD) is the cerebral deposition of amyloid. The main component of the amyloid is a 39-44-amino acid residue protein called amyloid beta (A beta), which also exists as a normal protein in biological fluids, known as soluble A beta. A major risk factor for late-onset AD is the inheritance of the apolipoprotein (ape) E4 isotype of apoE. How apoE is involved in the pathogenesis of AD is unclear; however, evidence exists for a direct apoE/A beta interaction. We and others have shown that apoE copurifies with A beta from AD amyloid plaques and that under certain in vitro conditions apoE promotes a beta-sheet structure in A beta peptides. Currently we document the high affinity binding of A beta peptides to both human recombinant apoE3 and -E4 with a K-D of 20 nM. This interaction is greatly influenced by the conformational state of the A beta peptide used. Furthermore, we show that the fibril modulating effect of apoE is also influenced by the initial secondary structure of the A beta peptide. The preferential binding of apoE to A beta peptides with a beta-sheet conformation can in part explain the copurification of A beta and apoE from AD amyloid plaques.	NYU, MED CTR, DEPT NEUROL, NEW YORK, NY 10016 USA; BIOTECHNOL GEN LTD, REHOVOT, ISRAEL; POLISH ACAD SCI, MED RES CTR, DEPT NEUROPATHOL, WARSAW, POLAND	New York University; Polish Academy of Sciences			Wisniewski, Thomas/Q-6525-2019	Wisniewski, Thomas/0000-0002-3379-8966	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005891, K08AG000542, R37AG005891] Funding Source: NIH RePORTER; NIA NIH HHS [AG00542, AG05891] Funding Source: Medline; NINDS NIH HHS [NS30455] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGGERBECK LP, 1988, J MOL BIOL, V202, P179, DOI 10.1016/0022-2836(88)90531-1; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BURDICK D, 1992, J BIOL CHEM, V267, P546; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; CASTANO EM, 1995, J BIOL CHEM, V270, P17610, DOI 10.1074/jbc.270.29.17610; CASTANO EM, 1995, BIOCHEM J, V306, P599, DOI 10.1042/bj3060599; CASTANO EM, 1986, BIOCHEM BIOPH RES CO, V141, P782, DOI 10.1016/S0006-291X(86)80241-8; CLEMENTS A, 1993, NEUROSCI LETT, V161, P17, DOI 10.1016/0304-3940(93)90129-9; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; EXLEY C, 1993, FEBS LETT, V324, P293, DOI 10.1016/0014-5793(93)80137-J; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLABEK A, 1995, NEUROSCI LETT, V191, P79, DOI 10.1016/0304-3940(95)11565-7; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KAMINO K, 1992, AM J HUM GENET, V51, P998; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LADU MJ, 1995, J BIOL CHEM, V270, P9039, DOI 10.1074/jbc.270.16.9039; LEE JP, 1995, BIOCHEMISTRY-US, V34, P5191, DOI 10.1021/bi00015a033; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LUNDKATZ S, 1993, J BIOL CHEM, V268, P23008; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Mahley Robert W., 1995, Current Opinion in Lipidology, V6, P86, DOI 10.1097/00041433-199504000-00005; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAK K, 1994, BRAIN RES, V667, P138, DOI 10.1016/0006-8993(94)91725-6; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATSUBARA E, 1995, J BIOL CHEM, V270, P7563, DOI 10.1074/jbc.270.13.7563; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MURPHY GM, 1994, AM J PATHOL, V144, P1082; NAIKI H, 1993, LAB INVEST, V68, P332; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NASLUND J, 1995, NEURON, V15, P219, DOI 10.1016/0896-6273(95)90079-9; NATHAN BP, 1995, J BIOL CHEM, V270, P19791, DOI 10.1074/jbc.270.34.19791; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J NEUROCHEM, V61, P1916, DOI 10.1111/j.1471-4159.1993.tb09834.x; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SATO C, 1995, NEUROSCI LETT, V200, P105, DOI 10.1016/0304-3940(95)12089-M; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SHURAEV VV, 1996, IN PRESS FEBS LETT; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; Soto C, 1996, BIOCHEM J, V314, P701, DOI 10.1042/bj3140701; SOTO C, 1995, FEBS LETT, V371, P110, DOI 10.1016/0014-5793(95)00863-5; SOTO C, 1995, NEUROSCI LETT, V186, P115, DOI 10.1016/0304-3940(95)11299-C; SOTO C, 1996, IN PRESS NEUROREPORT; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TABATON M, 1994, BIOCHEM BIOPH RES CO, V200, P1598, DOI 10.1006/bbrc.1994.1634; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; VOGEL T, 1985, P NATL ACAD SCI USA, V82, P8696, DOI 10.1073/pnas.82.24.8696; WISNIEWSKI T, 1995, LANCET, V345, P956, DOI 10.1016/S0140-6736(95)90701-7; WISNIEWSKI T, 1995, AM J PATHOL, V147, P238; Wisniewski T, 1996, BIOCHEM J, V313, P575, DOI 10.1042/bj3130575; WISNIEWSKI T, 1993, ANN NEUROL, V34, P631, DOI 10.1002/ana.410340422; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WISNIEWSKI T, 1993, BIOCHEM BIOPH RES CO, V192, P359, DOI 10.1006/bbrc.1993.1423; WISNIEWSKI T, 1994, ANN NEUROL, V35, P245, DOI 10.1002/ana.410350223; YANG FS, 1994, NEUROREPORT, V5, P2117, DOI 10.1097/00001756-199410270-00032; YOUNKIN SG, 1995, ANN NEUROL, V37, P287, DOI 10.1002/ana.410370303	73	115	126	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10602	10606		10.1074/jbc.271.18.10602	http://dx.doi.org/10.1074/jbc.271.18.10602			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631862				2022-12-27	WOS:A1996UJ34200030
J	Sugahara, T; Sato, A; Kudo, M; BenMenahem, D; Pixley, MR; Hsueh, AJW; Boime, I				Sugahara, T; Sato, A; Kudo, M; BenMenahem, D; Pixley, MR; Hsueh, AJW; Boime, I			Expression of biologically active fusion genes encoding the common alpha subunit and the follicle-stimulating hormone beta subunit - Role of a linker sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; GLYCOPROTEIN HORMONES; MONOCLONAL-ANTIBODIES; LUTEINIZING-HORMONE; ESCHERICHIA-COLI; GRANULOSA-CELLS; FOLLITROPIN; RECEPTOR; PROTEIN; BINDING	The gonadotropin/thyrotropin hormone family is characterized by a heterodimeric structure composed of a common alpha subunit noncovalently linked to a hormone-specific beta subunit, The conformation of the heterodimer is essential for controlling secretion, hormone-specific post-translational modifications, and signal transduction. Structure function studies of follicle-stimulating hormone (FSH) and the other glycoprotein hormones are often hampered by mutagenesis-induced defects in subunit combination, Thus, the ability to overcome the limitation of subunit assembly would expand the range of structure-activity relationships that can be performed on these hormones, Here we converted the FSH heterodimer to a single chain by genetically fusing the carboxyl end of the FSH beta subunit to the amino end of the alpha subunit in the presence or absence of a linker sequence, In the absence of the CTP linker, the secretion rate was decreased over 3-fold. Unexpectedly, however, receptor binding/signal transduction was unaffected by the absence of the linker, These data show that the single-chain FSH was secreted efficiently and is biologically active and that the conformation determinants required for secretion and biologic activity are not the same.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)				Ben-Menahem, David/0000-0002-8985-0591	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD092922] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD92922] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARGOS P, 1990, J MOL BIOL, V211, P943, DOI 10.1016/0022-2836(90)90085-Z; ARORA N, 1994, J BIOL CHEM, V269, P26165; BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BENKIRANE MM, 1987, ENDOCRINOLOGY, V12, P1171; BENMENAHEM D, 1996, IN PRESS TRENDS ENDO; BIELINSKA M, 1994, MOL ENDOCRINOL, V8, P919, DOI 10.1210/me.8.7.919; BIELINSKA M, 1996, J CELL BIOL, V111, P330; BIELINSKA M, 1995, GLYCOPROTEINS A, V29, P565; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; CORLESS CL, 1987, J CELL BIOL, V104, P1173, DOI 10.1083/jcb.104.5.1173; DAVOREN JB, 1985, BIOL REPROD, V33, P37, DOI 10.1095/biolreprod33.1.37; EHRLICH PH, 1985, AM J REPROD IM MIC, V8, P48; FARES FA, 1992, P NATL ACAD SCI USA, V89, P4303; FURUHASHI M, 1994, J BIOL CHEM, V269, P25543; FURUHASHI M, 1995, MOL ENDOCRINOL, V9, P56; HALLEWELL RA, 1989, J BIOL CHEM, V264, P5260; HARIKRISHNA JA, 1993, DNA CELL BIOL, V12, P371, DOI 10.1089/dna.1993.12.371; HOJO H, 1985, ENDOCRINOLOGY, V117, P2428, DOI 10.1210/endo-117-6-2428; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; HUTH JR, 1992, J BIOL CHEM, V267, P8870; JIA XC, 1991, MOL ENDOCRINOL, V5, P759, DOI 10.1210/mend-5-6-759; KEENE JL, 1989, J BIOL CHEM, V264, P4769; LAPTHORN A, 1994, NATURE, P455; MATZUK MM, 1990, ENDOCRINOLOGY, V126, P376, DOI 10.1210/endo-126-1-376; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; POMERANTZ JL, 1995, SCIENCE, V267, P93, DOI 10.1126/science.7809612; RAO MC, 1977, ENDOCRINOLOGY, V101, P512, DOI 10.1210/endo-101-2-512; SANO T, 1992, P NATL ACAD SCI USA, V89, P1534, DOI 10.1073/pnas.89.5.1534; SCHIMMEL P, 1992, PROTEIN SCI, V1, P1387, DOI 10.1002/pro.5560011018; SOMOZA JR, 1993, J MOL BIOL, V234, P390, DOI 10.1006/jmbi.1993.1594; STRICKLAND TW, 1982, ENDOCRINOLOGY, V111, P95, DOI 10.1210/endo-111-1-95; SUGAHARA T, 1995, P NATL ACAD SCI USA, V92, P2041, DOI 10.1073/pnas.92.6.2041; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; TILLY JL, 1992, ENDOCRINOLOGY, V131, P799, DOI 10.1210/en.131.2.799; TOTH MJ, 1986, J BIOL CHEM, V261, P6643; WHITLOW M, 1991, Methods (Orlando), V2, P97, DOI 10.1016/S1046-2023(05)80209-9; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; YEH P, 1992, P NATL ACAD SCI USA, V89, P1904, DOI 10.1073/pnas.89.5.1904; YOO JK, 1993, J BIOL CHEM, V268, P13034	40	64	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10445	10448		10.1074/jbc.271.18.10445	http://dx.doi.org/10.1074/jbc.271.18.10445			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631838	hybrid			2022-12-27	WOS:A1996UJ34200006
J	Yablonski, MJ; Pasek, DA; Han, BD; Jones, ME; Traut, TW				Yablonski, MJ; Pasek, DA; Han, BD; Jones, ME; Traut, TW			Intrinsic activity and stability of bifunctional human UMP synthase and its two separate catalytic domains, orotate phosphoribosyltransferasee and orotidine-5'-phosphate decarboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URIDINE 5'-PHOSPHATE SYNTHASE; AFFINITY-CHROMATOGRAPHY; CONFORMATION STATES; KINETIC MECHANISM; PURIFICATION; YEAST; 5'-MONOPHOSPHATE; PROTEIN; AGGREGATION; DEPENDENCE	Human UMP synthase is a bifunctional protein containing two separate catalytic domains, orotate phosphoribosyltransferase (EC 2.4.2.10) and orotidine-5'-phosphate decarboxylase (EC 4.1.1.23), These studies address the question of why the last two reactions in pyrimidine nucleotide synthesis are catalyzed by a bi-functional enzyme in mammalian cells, but by two separate enzymes in microorganisms, From existing data on subunit associations of the respective enzymes and calculations showing the molar concentration of enzyme to be far lower in mammalian cells than in microorganisms, we hypothesize that the covalent union in UMP synthase stabilizes the domains containing the respective catalytic centers, Evidence supporting this hypothesis comes from studies of stability of enzyme activity in vitro, at physiological concentrations, of UMP synthase, the two isolated catalytic domains prepared by site-directed mutagenesis of UMP synthase, and the yeast ODCase, The two engineered domains have activities very similar to the native UMP synthase, but unlike the bifunctional protein, the domains are quite unstable under conditions promoting the dissociated monomer.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill								BELL JB, 1991, J BIOL CHEM, V266, P12662; BHATIA MB, 1990, BIOCHEMISTRY-US, V29, P10480, DOI 10.1021/bi00498a009; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODY RS, 1979, J BIOL CHEM, V254, P4238; CREASEY WA, 1961, J BIOL CHEM, V236, P2058; DONOVAN WP, 1983, J BACTERIOL, V156, P620, DOI 10.1128/JB.156.2.620-624.1983; FLOYD EE, 1985, J BIOL CHEM, V260, P9443; HAN BD, 1995, BIOCHEMISTRY-US, V34, P10835, DOI 10.1021/bi00034a016; Jones M E, 1978, Methods Enzymol, V51, P155; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIVINGSTONE LR, 1987, J BIOL CHEM, V262, P15726; MCCLARD RW, 1980, BIOCHEMISTRY-US, V19, P4699, DOI 10.1021/bi00561a024; PETERS GJ, 1979, INT J BIOCHEM, V10, P885, DOI 10.1016/0020-711X(79)90118-6; POTVIN BW, 1978, BIOCHEM PHARMACOL, V27, P655, DOI 10.1016/0006-2952(78)90501-4; REYES P, 1975, J BIOL CHEM, V250, P5097; SHIMOSAKA M, 1985, J BIOCHEM, V98, P1689, DOI 10.1093/oxfordjournals.jbchem.a135440; SMILEY JA, 1992, BIOCHEMISTRY-US, V31, P12162, DOI 10.1021/bi00163a027; SWANSON JA, 1991, J CELL BIOL, V115, P941, DOI 10.1083/jcb.115.4.941; TIPOE GL, 1992, J ANAT, V181, P189; TRAUT TW, 1980, BIOCHEMISTRY-US, V19, P6068, DOI 10.1021/bi00567a019; Traut TW, 1996, PROG NUCLEIC ACID RE, V53, P1, DOI 10.1016/S0079-6603(08)60142-7; TRAUT TW, 1994, CRIT REV BIOCHEM MOL, V29, P125, DOI 10.3109/10409239409086799; TRAUT TW, 1977, J BIOL CHEM, V252, P8374; TRAUT TW, 1980, BIOCHEMISTRY-US, V19, P6062, DOI 10.1021/bi00567a018; TRAUT TW, 1989, ARCH BIOCHEM BIOPHYS, V268, P108, DOI 10.1016/0003-9861(89)90570-5; TRAUT TW, 1979, J BIOL CHEM, V254, P1143; UMEZU K, 1971, J BIOCHEM, V70, P249, DOI 10.1093/oxfordjournals.jbchem.a129637; VICTOR J, 1979, J BIOL CHEM, V254, P2647; Walenta S, 1989, Adv Exp Med Biol, V248, P847; 1991, J THEOR BIOL, V152, P1	30	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10704	10708		10.1074/jbc.271.18.10704	http://dx.doi.org/10.1074/jbc.271.18.10704			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631878	hybrid, Green Published			2022-12-27	WOS:A1996UJ34200046
J	August, A; Dupont, B				August, A; Dupont, B			Association between mitogen-activated protein kinase and the zeta chain of the T cell receptor (TcR) with the SH2,3 domain of p56(lck) - Differential regulation by TcR cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; COMPLEX; PHOSPHORYLATION; STIMULATION; P56LCK; RAF-1; CD4	A number of protein-tyrosine kinases have been shown to be important in T cell activation. One such kinase, Lck, has been demonstrated genetically to be essential for T cell receptor (TcR) signaling, and the SH2 and SH3 (src homology 2 and 3) domains of Lck have been shown to be indispensable for T cell activation. We have sought substrates with which the SH2,3 domain mould interact following T cell activation using fusion proteins containing the Lck SH2 and SH3 domains linked to glutathione S-transferase. We demonstrate that the SH2,3 region interacts specifically and directly with numerous tyrosine-phosphorylated molecules following TcR cross-linking, including constitutively with mitogen-activated protein kinase (MAPK)/extracellular-regulated kinase and inducibly with the zeta chain of the TcR. The interaction with MAPK/extracellular-regulated kinase was via the SH3 domain. The interaction with the tyrosine-phosphorylated zeta chain, while phosphotyrosine-dependent, required both the SH3 and SH2 domains. These interactions were specific as molecules known to be tyrosine-phosphorylated following TcR cross-linking, phospholipase C-gamma 1 and Fyn, were not bound. Thus, we suggest that during TcR signaling, Lck interacts with numerous molecules, including MAPK and TcR-zeta, via its SH2,3 domain. The interaction with MAPK mould place Lck in a position to be involved in the complex resulting in the activation of MAPK. In addition, the binding of Lck to the tyrosine-phosphorylated zeta chain of the TcR would serve to strengthen the interaction of the associated CD4 and the TcR complex, leading to increased avidity for the antigen-major histocompatibility protein complex.	SLOAN KETTERING INST CANC RES,PROGRAM IMMUNOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [P01CA022507, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [CA22507, CA08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMREIN KE, 1993, P NATL ACAD SCI USA, V90, P10285, DOI 10.1073/pnas.90.21.10285; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; CHAREST DL, 1993, MOL CELL BIOL, V13, P4679, DOI 10.1128/MCB.13.8.4679; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; COLLINS TL, 1992, J IMMUNOL, V148, P2159; COLLINS TL, 1993, P NATL ACAD SCI USA, V90, P11885, DOI 10.1073/pnas.90.24.11885; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; DASGUPTA JD, 1992, J EXP MED, V175, P285, DOI 10.1084/jem.175.1.285; DONG ZY, 1993, J EXP MED, V177, P1071, DOI 10.1084/jem.177.4.1071; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; GOLD MR, 1994, J IMMUNOL, V153, P2369; HOWE LR, 1995, TRENDS BIOCHEM SCI, V20, P59, DOI 10.1016/S0968-0004(00)88958-6; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PERI KG, 1993, ONCOGENE, V8, P2765; PRASAD KVS, 1992, MOL CELL BIOL, V12, P5260, DOI 10.1128/MCB.12.11.5260; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; THOME M, 1995, J EXP MED, V181, P1997, DOI 10.1084/jem.181.6.1997; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VOGEL LB, 1993, MOL CELL BIOL, V13, P7408, DOI 10.1128/MCB.13.12.7408; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WENG ZG, 1993, J BIOL CHEM, V268, P14956; XU H, 1993, CELL, V74, P638	34	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10054	10059						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626561				2022-12-27	WOS:A1996UG25700033
J	Gattoni, M; Boffi, A; Sarti, P; Chiancone, E				Gattoni, M; Boffi, A; Sarti, P; Chiancone, E			Stability of the heme-globin linkage in alpha beta dimers and isolated chains of human hemoglobin - A study of the heme transfer reaction from the immobilized proteins to albumin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELF-ASSOCIATING PROTEINS; MUTANT	The stability of the heme-globin linkage in alpha beta dimers and in the isolated chains of human hemoglobin has been probed by studying the transfer of heme from the proteins immobilized onto CNBr-activated Sepharose 4B to human albumin. The kinetic and equilibrium features of the reaction have been measured spectrophotometrically given the stability of the heme donors and the ease with which heme donor and acceptor can be separated. Isolated alpha and beta chains transfer heme to albumin at similar rates (1-6 x 10(-2) s(-1) at pH 9.0 and 20 degrees C) in the ferrous CO-bound and in the ferric state. In alpha beta dimers the heme-globin linkage is strengthened considerably, albeit to a different extent in the ferrous CO-bound and ferric met-aquo derivatives. Only in the latter heme is lost at a measurable rate, 0.065 +/- 0.011 x 10(-2) s(-1) for alpha heme and 2.8 +/- 0.6 x 10(-2) s(-1) for beta heme at pH 9.0 and 20 degrees C, which is very close to the rate measured with soluble met-aquo-hemoglobin at micromolar concentrations. These results indicate that in human hemoglobin the heme-globin linkage in the alpha chains is stabilized by interactions between unlike chains at the alpha(1) beta(2) interface, whereas heme binding to the beta chains is stabilized by interactions at the alpha(1) beta(2) interface. These long range factors have to be taken into account in addition to the local factors at the heme pocket when evaluating the effect of point mutation and chemical modification.	UNIV ROMA LA SAPIENZA, DEPT BIOCHEM SCI A ROSSI FANELLI, CNR, CTR MOLEC BIOL, I-00185 ROME, ITALY; UNIV CAGLIARI, INST BIOL CHEM, I-09100 CAGLIARI, ITALY	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; University of Cagliari			Sarti, Paolo/D-2946-2009	Sarti, Paolo/0000-0002-8219-4827				ANTONINI E, 1977, ANNU REV BIOPHYS BIO, V6, P239, DOI 10.1146/annurev.bb.06.060177.001323; ANTONINI E, 1975, PROTEIN LIGAND INTER, P45; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P127; BEAVEN GH, 1974, EUR J BIOCHEM, V41, P539, DOI 10.1111/j.1432-1033.1974.tb03295.x; BENESCH RE, 1995, J BIOL CHEM, V270, P13785, DOI 10.1074/jbc.270.23.13785; BENESCH RE, 1990, J BIOL CHEM, V265, P14881; BERGER RL, 1973, ANAL LETT, V6, P125; BROWN SB, 1970, BIOCHEM J, V117, P733, DOI 10.1042/bj1170733; BUNN HF, 1968, J BIOL CHEM, V243, P465; CHIANCONE E, 1986, ANAL BIOCHEM, V158, P211, DOI 10.1016/0003-2697(86)90611-1; CHIANCONE E, 1968, J BIOL CHEM, V243, P1212; CHIANCONE E, 1987, METHOD ENZYMOL, V135, P484; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DILORIO EE, 1991, BIOPHYS J, V59, P742, DOI 10.1016/S0006-3495(91)82287-1; FANELLI MRR, 1978, EUROPEAN J BIOCH, V92, P253; GERACI G, 1969, J BIOL CHEM, V244, P4664; Gilbert L M, 1973, Methods Enzymol, V27, P273; HARGROVE MS, 1994, J BIOL CHEM, V269, P4207; IDE GJ, 1976, J AM CHEM SOC, V98, P1595, DOI 10.1021/ja00422a060; ROSENFELD M, 1950, J BIOL CHEM, V183, P663; SMITH ML, 1984, FEBS LETT, V169, P147, DOI 10.1016/0014-5793(84)80307-5; TURNER GJ, 1992, PROTEINS, V14, P333, DOI 10.1002/prot.340140303	22	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10130	10136		10.1074/jbc.271.17.10130	http://dx.doi.org/10.1074/jbc.271.17.10130			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626572	hybrid			2022-12-27	WOS:A1996UG25700044
J	Kamai, Y; Mikawa, S; Endo, K; Sakai, H; Komano, T				Kamai, Y; Mikawa, S; Endo, K; Sakai, H; Komano, T			Regulation of insulin-like growth factor-I expression in mouse preadipocyte Ob1771 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE CONVERSION; GENE-EXPRESSION; 3T3 CELLS; GLYCEROPHOSPHATE DEHYDROGENASE; RECEPTOR-BINDING; HUMAN-SERUM; HORMONE; DIFFERENTIATION; SEQUENCE; FIBROBLASTS	In mouse preadipocyte Ob1771 cells, transcription of the insulin-libe growth factor-I (IGF-I) gene was stimulated by growth hormone (GH), and IGF-I protein combined with GH in medium was required for their differentiation to adipocytes. During induction of the differentiation, the intracellular expression of each class of IGF-I mRNA was analyzed by reverse transcriptase-polymerase chain reaction, When the cells were cultured in the presence of GH, the class 1del. IGF-I mRNA was a major molecular species among IGF-I mRNAs, In the presence of both GH and IGF-I, the splicing pattern of IGF-I mRNA changed from class 1del. to class 1. Moreover, as detected by Western blotting, the IGF-I protein was present in cells and in the medium only when the cells were cultured in the presence of both GH and IGF-I, We found that IGF-I secreted from Ob1771 cells could act in an autocrine/paracrine fashion and induce the differentiation of other Ob1771 cells, It was demonstrated that the translation efficiency of class 1 mRNA was higher than that of class 1del. mRNA in vitro. These results suggested that stimulation with exogenous IGF-I in the presence of GH was required for the production of class 1 IGF-I mRNA and that the production of the IGF-I protein was activated by increasing the translation efficiency through shifting the splicing pattern of IGF-I mRNA from class 1del. to class 1. Exogenous IGF-I triggered the differentiation by initiating the synthesis of endogenous IGF-I.	KYOTO UNIV,DEPT AGR CHEM,BIOCHEM LAB,FAC AGR,KYOTO 60601,JAPAN	Kyoto University								ADAMO ML, 1991, BIOCHEM BIOPH RES CO, V176, P887, DOI 10.1016/S0006-291X(05)80269-4; AMRI EZ, 1986, BIOCHEM J, V238, P115, DOI 10.1042/bj2380115; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BLUNDELL TL, 1978, P NATL ACAD SCI USA, V75, P180, DOI 10.1073/pnas.75.1.180; BUCCI C, 1989, NUCLEIC ACIDS RES, V17, P3596, DOI 10.1093/nar/17.9.3596; CASELLA SJ, 1987, DNA-J MOLEC CELL BIO, V6, P325, DOI 10.1089/dna.1987.6.325; CHALFANT CE, 1995, J BIOL CHEM, V270, P13326, DOI 10.1074/jbc.270.22.13326; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIAMOND RH, 1993, J BIOL CHEM, V268, P15185; DOGLIO A, 1986, BIOCHEM J, V238, P123, DOI 10.1042/bj2380123; DOGLIO A, 1987, EMBO J, V6, P4011, DOI 10.1002/j.1460-2075.1987.tb02744.x; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; FOYT HL, 1991, J BIOL CHEM, V266, P7300; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; HAUNER H, 1986, INT J OBESITY, V10, P323; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; ISAKSSON OGP, 1982, SCIENCE, V216, P1237, DOI 10.1126/science.7079756; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KOZAK LP, 1974, J BIOL CHEM, V249, P7775; KURIHARCUCH W, 1978, CELL, V14, P53, DOI 10.1016/0092-8674(78)90300-8; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; MORIKAWA M, 1982, CELL, V29, P783, DOI 10.1016/0092-8674(82)90440-8; NIXON T, 1984, ENDOCRINOLOGY, V114, P527, DOI 10.1210/endo-114-2-527; PAIRAULT J, 1979, P NATL ACAD SCI USA, V76, P5138, DOI 10.1073/pnas.76.10.5138; PRADINESFIGUERES A, 1990, J LIPID RES, V31, P1283; ROBERTS CT, 1987, MOL ENDOCRINOL, V1, P243, DOI 10.1210/mend-1-3-243; ROBERTS CT, 1987, BIOCHEM BIOPH RES CO, V146, P1154, DOI 10.1016/0006-291X(87)90768-6; SCHMIDT W, 1990, J BIOL CHEM, V265, P15489; SCHOENLE E, 1982, NATURE, V296, P252, DOI 10.1038/296252a0; SELL SM, 1994, J BIOL CHEM, V269, P30769; SHIMATSU A, 1987, NUCLEIC ACIDS RES, V15, P7196, DOI 10.1093/nar/15.17.7196; SHIMATSU A, 1987, J BIOL CHEM, V262, P7894; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WISE LS, 1979, J BIOL CHEM, V254, P273; ZAPF J, 1978, EUR J BIOCHEM, V87, P285, DOI 10.1111/j.1432-1033.1978.tb12377.x; ZEZULAK KM, 1986, SCIENCE, V233, P551, DOI 10.1126/science.3726546	36	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9883	9886		10.1074/jbc.271.17.9883	http://dx.doi.org/10.1074/jbc.271.17.9883			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626620	hybrid			2022-12-27	WOS:A1996UG25700004
J	Liu, PS; Ying, YS; Ko, YG; Anderson, RGW				Liu, PS; Ying, YS; Ko, YG; Anderson, RGW			Localization of platelet-derived growth factor-stimulated phosphorylation cascade to caveolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED-CELLS; RECEPTOR; INTERNALIZATION; MOLECULES; PDGF	Previously we showed that interleukin 1 beta stimulates the conversion of sphingomyelin to ceramide in the caveolae fraction of normal human fibroblasts. The ceramide, in turn, blocked platelet-derived growth factor (PDGF) stimulated DNA synthesis. We now present evidence that the PDGF receptor initiates signal transduction from caveolae. Cell fractionation and immunocytochemistry show caveolae to be the principal location of PDGF receptors at the cell surface. Multiple caveolae proteins acquire phosphotyrosine when PDGF binds to its receptor, but the hormone appears to have little effect on the tyrosine phosphorylation of non-caveolae membrane proteins. Five proteins known to interact with the phosphorylated receptor were found to be highly enriched in caveolae membrane. PDGF caused the concentration of three of these proteins to significantly increase in the caveolae fraction. Finally, PDGF stimulated the association of a 190-kDa phosphoprotein with the caveolae marker protein, caveolin. Therefore, ceramide may modulate PDGF receptor function directly in caveolae.	UNIV TEXAS, SW MED CTR, DEPT CELL BIOL & NEUROSCI, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Liu, Pingsheng/B-7124-2012		NHLBI NIH HHS [HL 20948] Funding Source: Medline; NIGMS NIH HHS [GM 43169, GM 52016] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043169, R01GM052016] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; PALADE GE, 1953, J APPL PHYS, V24, P1424; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; SANAN DA, 1991, J HISTOCHEM CYTOCHEM, V39, P1017, DOI 10.1177/39.8.1906908; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; SMART EJ, 1995, IN PRESS COLD SPRING; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	27	335	339	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10299	10303		10.1074/jbc.271.17.10299	http://dx.doi.org/10.1074/jbc.271.17.10299			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626598				2022-12-27	WOS:A1996UG25700070
J	Robinson, AS; Bockhaus, JA; Voegler, AC; Wittrup, KD				Robinson, AS; Bockhaus, JA; Voegler, AC; Wittrup, KD			Reduction of BiP levels decreases heterologous protein secretion in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEINS; IMMUNOGLOBULIN HEAVY-CHAIN; HAMSTER OVARY CELLS; ENDOPLASMIC-RETICULUM; BINDING-PROTEIN; GRP78-BIP GENE; CHAPERONE BIP; YEAST; TRANSLOCATION; EXPRESSION	Increased levels of the endoplasmic reticulum-resident protein folding chaperone BiP would be expected to either increase protein secretory capacity by improved solubilization of folding precursors or decrease secretory capacity by binding and retaining misfolded proteins. To address this question, the relationship between BiP levels and heterologous secretion in yeast was determined. A yeast strain was constructed in which BiP expression is tunable from 5 to 250% of wild-type levels, and this strain was used to explore the effect of varying BiP level on overall secretion of three heterologous proteins: human granulocyte colony-stimulating factor, Schizosaccharomyces pombe acid phosphatase, and bovine pancreatic trypsin inhibitor. For all three proteins examined, reduction in BiP expression below wild-type level diminished overall secretion, whereas 5-fold BiP overexpression from a constitutive glycolytic promoter did not substantially increase or decrease secretion titers. These results are consistent with a positive role for BiP in promoting membrane translocation and solubilization of folding precursors but are inconsistent with a negative role in proofreading and improper retention of heterologous secreted proteins.	UNIV ILLINOIS, DEPT CHEM ENGN, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign			Robinson, Anne Skaja/H-7894-2012	Robinson, Anne Skaja/0000-0001-7235-1481				BITTER GA, 1987, METHOD ENZYMOL, V153, P516; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BUTT TR, 1987, MICROBIOL REV, V51, P351, DOI 10.1128/MMBR.51.3.351-364.1987; CHON Q, 1992, NUCLEIC ACIDS RES, V20, P1717; DORNER AJ, 1994, BIOLOGICALS, V22, P103, DOI 10.1006/biol.1994.1016; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GUNTHER R, 1993, J BIOL CHEM, V268, P7728; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; HODGSON J, 1993, BIO-TECHNOL, V11, P887, DOI 10.1038/nbt0893-887; HSU TA, 1994, PROTEIN EXPRES PURIF, V5, P595, DOI 10.1006/prep.1994.1082; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; NG DTW, 1992, MOL BIOL CELL, V3, P143, DOI 10.1091/mbc.3.2.143; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; ROBINSON AS, 1993, ACS SYM SER, V526, P121; ROBINSON AS, 1995, BIOTECHNOL PROGR, V11, P171, DOI 10.1021/bp00032a009; ROBINSON AS, 1994, BIO-TECHNOL, V12, P381, DOI 10.1038/nbt0494-381; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHULTZ LD, 1994, ANN NY ACAD SCI, V721, P148, DOI 10.1111/j.1749-6632.1994.tb47387.x; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; Shuster J R, 1991, Curr Opin Biotechnol, V2, P685, DOI 10.1016/0958-1669(91)90035-4; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; TOKUNAGA M, 1992, J BIOL CHEM, V267, P17553; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; VOORBERG J, 1993, EMBO J, V12, P749, DOI 10.1002/j.1460-2075.1993.tb05709.x; WATOWICH SS, 1991, J VIROL, V65, P3590, DOI 10.1128/JVI.65.7.3590-3597.1991; WITTRUP KD, 1994, BIOTECHNOL TECH, V8, P161, DOI 10.1007/BF00161582; WITTRUP KD, 1995, ANN NY ACAD SCI, V745, P321	55	74	83	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10017	10022		10.1074/jbc.271.17.10017	http://dx.doi.org/10.1074/jbc.271.17.10017			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626555	hybrid			2022-12-27	WOS:A1996UG25700027
J	Tazi, A; LeBras, S; Lamghitnia, HO; Vincent, JD; Czernichow, P; Scharfmann, R				Tazi, A; LeBras, S; Lamghitnia, HO; Vincent, JD; Czernichow, P; Scharfmann, R			Neurotrophin-3 increases intracellular calcium in a rat insulin-secreting cell line through its action on a functional TrkC receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ENDOCRINE-CELLS; KINASE; EXPRESSION; NEURONS; BDNF; IDENTIFICATION; ESTABLISHMENT; FAMILY; CA-2+	Pancreatic beta cells and neuronal cells show a large number of similarities. For example, functional receptors for nerve growth factor are present in beta cells. Here we investigate whether TrkC, a neuronal high affinity receptor for neurotrophin-3, is expressed in the insulin-secreting cell line INS-1. We demonstrate the expression in INS-1 cells of mRNAs coding for TrkC identical in size to those found in the brain. As in neuronal cells, different alternatively spliced forms of TrkC mRNA differing by the insertion of an alternative exon in their kinase domain, were expressed in INS-1 cells. TrkC protein is also expressed in INS-1 cells and is functional. Indeed, when INS-1 cells were treated with neurotrophin-3, TrkC became phosphorylated on tyrosine residues, and the expression of early response genes was induced. This activation of the receptor was paralleled by a rapid and transient increase in cytosolic free calcium due to an influx of extracellular calcium. Functional receptors for NT-3 are thus expressed in INS-1 cells. This cell line provides a new model for the study of NT-3 signal transduction and should be useful in the understanding of the role of neurotrophins in insulin-secreting cells.	HOP ROBERT DEBRE,INSERM,CJF 9313,F-75019 PARIS,FRANCE; CNRS,INST ALFRED FESSARD,F-91198 GIF SUR YVETTE,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			scharfmann, raphael/L-3296-2017	Scharfmann, Raphael/0000-0001-7619-337X; Tazi, Abdelali/0000-0002-0258-3794				ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; ARENAS E, 1994, NATURE, V367, P368, DOI 10.1038/367368a0; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARRES BA, 1994, NATURE, V367, P371, DOI 10.1038/367371a0; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; BERGGREN PO, 1994, BIOCHEM SOC T, V22, P12, DOI 10.1042/bst0220012; BERNINGER B, 1993, NEUROREPORT, V4, P1303, DOI 10.1097/00001756-199309150-00004; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARY DO, 1994, P NATL ACAD SCI USA, V91, P11133, DOI 10.1073/pnas.91.23.11133; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DAVIES AM, 1995, EMBO J, V14, P4482, DOI 10.1002/j.1460-2075.1995.tb00127.x; DURBEEJ M, 1993, DEVELOPMENT, V119, P977; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; KALCHEIM C, 1992, P NATL ACAD SCI USA, V89, P1661, DOI 10.1073/pnas.89.5.1661; KANAKAGANTENBEIN C, 1995, ENDOCRINOLOGY, V136, P761, DOI 10.1210/en.136.2.761; KIM HG, 1994, P NATL ACAD SCI USA, V91, P12341, DOI 10.1073/pnas.91.25.12341; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; PHILIPSON LH, 1993, DIABETES, V42, P1372, DOI 10.2337/diabetes.42.9.1372; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; SCHARFMANN R, 1993, DIABETES, V42, P1829, DOI 10.2337/diabetes.42.12.1829; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; TAPLEY P, 1992, ONCOGENE, V7, P371; TAZI A, 1995, J NEUROENDOCRINOL, V7, P29, DOI 10.1111/j.1365-2826.1995.tb00664.x; TEITELMAN G, 1990, DEV BIOL, V142, P368, DOI 10.1016/0012-1606(90)90357-O; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; TURQUE N, 1994, MOL ENDOCRINOL, V8, P929, DOI 10.1210/me.8.7.929; URFER R, 1994, EMBO J, V13, P5896, DOI 10.1002/j.1460-2075.1994.tb06935.x; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; YAAR M, 1994, J CLIN INVEST, V94, P1550, DOI 10.1172/JCI117496	44	24	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10154	10160		10.1074/jbc.271.17.10154	http://dx.doi.org/10.1074/jbc.271.17.10154			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626576	hybrid			2022-12-27	WOS:A1996UG25700048
J	Henseler, M; Klein, A; Glombitza, GJ; Suzuki, K; Sandhoff, K				Henseler, M; Klein, A; Glombitza, GJ; Suzuki, K; Sandhoff, K			Expression of the three alternative forms of the sphingolipid activator protein precursor in baby hamster kidney cells and functional assays in a cell culture system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBROSIDE SULFATE ACTIVATOR; METACHROMATIC LEUKODYSTROPHY; BETA-GLUCOSIDASE; MESSENGER-RNA; SAPOSIN-A; DEFICIENCY; PROSAPOSIN; DISEASE; ACID; GENE	Sphingolipid activator proteins (SAPs) are non-enzymatic glycoproteins required for lysosomal degradation of various sphingolipids with short oligosaccharide chains by their respective exohydrolases. Four of these (SAP-A to SAP-D or saposins A to D) are derived from a common precursor by proteolytic processing. Alternative splicing of the SAP-precursor gene results in insertion of additional 6 or 9 bases of exon 8' or 8, respectively, into the SAP-B coding region of the transcribed mRNAs. To examine the features of the three different SAP-precursor proteins (prosaposins), the respective cDNAs were stably expressed in baby hamster kidney cells. Pulse-chase experiments with transfected cells and endocytosis studies on human fibroblasts showed that synthesis, transport, and maturation of all SAP-precursor led to formation of the four mature SAPs (SAP-A to SAP-D). In order to determine the biological function of the three different SAP-B isoforms, SAP-precursor-deficient human fibroblasts were loaded with recombinant SAP-precursor proteins with or without 2- and 3-amino acid insertions, respectively, purified from the medium of the baby hamster kidney cells. They were found to stimulate at nanomolar concentrations the turnover of biosynthetically labeled ceramide, glucosylceramide, and lactosylceramide. Since the physiological function of SAP-B is to stimulate the degradation of sulfatide by arylsulfatase A (EC 3.1.6.1) and globotriaosylceramide by beta-galactosidase (EC 3.2.1.23) loading studies with the respective exogenously labeled lipids on SAP precursor-deficient fibroblasts were performed. Addition of different purified SAP-precursors to the medium of the lipid-loaded fibroblasts showed positive stimulation of the lipid degradation by all three SAP-B isoforms derived from the SAP-precursors. These findings establish that all three forms of the SAP-B can function as sulfatide/ globotriaosylceramide activator.	UNIV BONN,INST ORGAN CHEM & BIOCHEM,D-53121 BONN,GERMANY; UNIV N CAROLINA,SCH MED,BRAIN & DEV RES CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT NEUROL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT PSYCHIAT,CHAPEL HILL,NC 27599	University of Bonn; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NICHD NIH HHS [P30-HD03110] Funding Source: Medline; NINDS NIH HHS [NS24289] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD003110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024289] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BRADOVA V, 1993, HUM GENET, V92, P143, DOI 10.1007/BF00219682; CHRISTOMANOU H, 1986, BIOL CHEM H-S, V367, P879, DOI 10.1515/bchm3.1986.367.2.879; FLUHARTY AL, 1995, TRENDS GLYCOSCI GLYC, V7, P167, DOI 10.4052/tigg.7.167; FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P5339; FURST W, 1990, EUR J BIOCHEM, V192, P709, DOI 10.1111/j.1432-1033.1990.tb19280.x; FURST W, 1988, BIOL CHEM H-S, V369, P317, DOI 10.1515/bchm3.1988.369.1.317; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; HARZER K, 1989, EUR J PEDIATR, V149, P31, DOI 10.1007/BF02024331; Henseler M, 1996, AM J HUM GENET, V58, P65; HIRAIWA M, 1993, ARCH BIOCHEM BIOPHYS, V304, P110, DOI 10.1006/abbi.1993.1328; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; HOLTSCHMIDT H, 1991, J BIOL CHEM, V266, P7556; HOLTSCHMIDT H, 1991, FEBS LETT, V280, P267, DOI 10.1016/0014-5793(91)80308-P; ISIDORO C, 1991, BIOCHEM J, V273, P363, DOI 10.1042/bj2730363; ITO K, 1993, EUR J BIOCHEM, V215, P171, DOI 10.1111/j.1432-1033.1993.tb18020.x; KAO FT, 1987, SOMAT CELL MOLEC GEN, V13, P685, DOI 10.1007/BF01534489; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1440, DOI 10.1006/bbrc.1994.1612; KONDOH K, 1991, BIOCHEM BIOPH RES CO, V181, P286, DOI 10.1016/S0006-291X(05)81415-9; KUDOH T, 1982, J CLIN INVEST, V70, P89, DOI 10.1172/JCI110607; KUHN A, 1994, EMBO J, V13, P416, DOI 10.1002/j.1460-2075.1994.tb06276.x; KYRKLUND T, 1987, LIPIDS, V22, P274, DOI 10.1007/BF02533991; LAMONTAGNE S, 1994, J BIOL CHEM, V269, P20528; MORIMOTO S, 1989, P NATL ACAD SCI USA, V86, P3389, DOI 10.1073/pnas.86.9.3389; MUNFORD RS, 1995, J LIPID RES, V36, P1653; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; OBRIEN JS, 1995, FASEB J, V9, P681, DOI 10.1096/fasebj.9.8.7768361; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; OBRIEN JS, 1994, P NATL ACAD SCI USA, V91, P9593, DOI 10.1073/pnas.91.20.9593; PATON BC, 1992, BIOCHEM J, V285, P481, DOI 10.1042/bj2850481; POTIER M, 1988, BIOCHEM BIOPH RES CO, V155, P32, DOI 10.1016/S0006-291X(88)81045-3; SANDHOFF K, 1995, METABOLIC MOL BASES, P2427; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO A, 1988, J BIOL CHEM, V263, P19597; SANO A, 1994, BIOCHEM BIOPH RES CO, V204, P994, DOI 10.1006/bbrc.1994.2558; SCHLOTE W, 1991, EUR J PEDIATR, V150, P584, DOI 10.1007/BF02072213; SCHNABEL D, 1992, J BIOL CHEM, V267, P3312; SCHWARZMANN G, 1978, BIOCHIM BIOPHYS ACTA, V529, P106, DOI 10.1016/0005-2760(78)90108-X; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEVENS RL, 1993, BIOCHEMISTRY-US, V32, P4051, DOI 10.1021/bi00066a028; SUZUKI Y, 1972, J LIPID RES, V13, P680; SYLVESTER SR, 1984, BIOL REPROD, V31, P1087, DOI 10.1095/biolreprod31.5.1087; TAYAMA M, 1993, BIOCHEM J, V290, P401, DOI 10.1042/bj2900401; TSUDA M, 1992, BIOCHEM BIOPH RES CO, V184, P1266, DOI 10.1016/S0006-291X(05)80019-1; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; WEITZ G, 1983, HOPPESEYLERS Z PHYSL, V364, P862; WIRTH M, 1988, GENE, V73, P419, DOI 10.1016/0378-1119(88)90506-9; YAMASHITA K, 1990, BIOCHEMISTRY-US, V29, P3030, DOI 10.1021/bi00464a020; ZHANG XL, 1991, HUM GENET, V87, P211, DOI 10.1007/BF00204185; ZHANG XL, 1990, P NATL ACAD SCI USA, V87, P1426, DOI 10.1073/pnas.87.4.1426	51	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8416	8423		10.1074/jbc.271.14.8416	http://dx.doi.org/10.1074/jbc.271.14.8416			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626540	hybrid, Green Published			2022-12-27	WOS:A1996UD60000080
J	Holt, KH; Waters, SB; Okada, S; Yamauchi, K; Decker, SJ; Saltiel, AR; Motto, DG; Koretzky, GA; Pessin, JE				Holt, KH; Waters, SB; Okada, S; Yamauchi, K; Decker, SJ; Saltiel, AR; Motto, DG; Koretzky, GA; Pessin, JE			Epidermal growth factor receptor targeting prevents uncoupling of the Grb2-SOS complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; GTPASE ACTIVATING PROTEIN; SIGNAL TRANSDUCTION; TYROSINE KINASES; INSULIN-RECEPTOR; SH3 DOMAIN; RAS; RAF-1; PHOSPHORYLATION; INTERACTS	Insulin stimulates the Ras/Raf/MEK/ERK pathway leading to feedback phosphorylation of the Ras guanylnucleotide exchange protein SOS and dissociation of Grb2 from SOS. Even though epidermal growth factor (EGF) also stimulates ERK activity and phosphorylation of SOS similar to insulin, EGF induces a dissociation of the Grb2 SOS complex from She. To determine the molecular basis for this difference, we examined the signaling properties of a mutant EGF receptor lacking the five major autophosphorylation sites, Although EGF stimulation of the mutant EGF receptor activates ERK and phosphorylation of both She and SOS, it fails to directly associate with either She or Grb2. However, under these conditions EGF induces a dissociation of the Grb2-SOS complex suggesting a role for receptor and/or plasma membrane targeting in the stabilization of Grb2-SOS interaction, Consistent with this hypothesis, expression of an SHc domain Grb2 mutant which is unable to mediate plasma membrane targeting of the Grb2-SOS complex results in both insulin- and EGF-stimulated uncoupling of Grb2 from SOS. Furthermore, a plasma membrane bound Grb2 fusion protein remains constitutively associated with SOS. Together, these data demonstrate that EGF stimulation prevents the feedback uncoupling of Grb2 from SOS by inducing a persistent plasma membrane receptor targeting of the Grb2-SOS complex.	UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242; WARNER LAMBERT PARKE DAVIS,PHARMACEUT RES DIV,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105	University of Iowa; University of Iowa; Pfizer			Saltiel, Alan/L-3632-2019; Koretzky, Gary/AAU-5381-2021	Saltiel, Alan/0000-0002-9726-9828				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUDAY L, 1995, ONCOGENE, V11, P1327; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KLARLUND JK, 1995, J BIOL CHEM, V270, P23421, DOI 10.1074/jbc.270.40.23421; LANGLOIS WJ, 1994, ENDOCRINOLOGY, V135, P2412, DOI 10.1210/en.135.6.2412; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALTIEL AR, 1994, FASEB J, V8, P1034, DOI 10.1096/fasebj.8.13.7926368; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SERTH J, 1992, BIOCHEMISTRY-US, V31, P6361, DOI 10.1021/bi00143a001; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	53	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8300	8306		10.1074/jbc.271.14.8300	http://dx.doi.org/10.1074/jbc.271.14.8300			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626525	hybrid			2022-12-27	WOS:A1996UD60000065
J	McLaughlin, MM; Kumar, S; McDonnell, PC; VanHorn, S; Lee, JC; Livi, GP; Young, PR				McLaughlin, MM; Kumar, S; McDonnell, PC; VanHorn, S; Lee, JC; Livi, GP; Young, PR			Identification of mitogen-activated protein (MAP) kinase-activated protein kinase-3, a novel substrate of CSBP p38 MAP kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-HYBRID SYSTEM; MUTATIONS; YEAST; P53	CSBP p38 is a mitogen-activated protein kinase that is activated in response to stress, endotoxin, interleukin 1, and tumor necrosis factor. Using a catalytically inactive mutant (D168A) of human CSBP2 as the bait in a yeast two-hybrid screen, we have identified and cloned a novel kinase which shares similar to 70% amino acid identity to mitogen-activated protein kinase-activated protein kinase (MAPKAP kinase)-2, and thus was designated MAPKAP kinase-3. The binding of CSBP to MAPKAP kinase-3 was confirmed in vitro by the precipitation of epitope-tagged CSBP1, CSBP2, and CSBP2(D168A) and endogenous CSBP from mammalian cells by a bacterially expressed GST-MAPKAP kinase-3 fusion protein and in vivo by co-precipitation of the epitope-tagged proteins co expressed in HeLa cells. MAPKAP kinase-3 was phosphorylated by both CSBP1 and CSBP2 and was then able to phosphorylate HSP27 in vitro. Treatment of HeLa cells with sorbitol or TNF resulted in activation of CSBP and MAPKAP kinase-3 and activation of MAPKAP kinase-3 could be blocked by preincubation of cells with SB203580, a specific inhibitor of CSBP kinase activity. These data suggest that MAPKAP kinase-3 is activated by stress and cytokines and is a novel substrate of CSBP both in vitro and in vivo.	SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC IMMUNOL UE0548,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT GENE EXPRESS SCI,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC GENET,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT CELLULAR BIOCHEM,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline								AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; IWABUCHI K, 1993, ONCOGENE, V8, P1693; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUMAR S, 1995, J BIOL CHEM, V270, P29043, DOI 10.1074/jbc.270.49.29043; KUMAR S, 1995, J BIOL CHEM, V270, P27905, DOI 10.1074/jbc.270.46.27905; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LI B, 1993, FASEB J, V7, P957, DOI 10.1096/fasebj.7.10.8344494; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAO VN, 1994, ONCOGENE, V9, P1855; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; VOLONTE C, 1993, J BIOL CHEM, V268, P21410; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x; ZU YL, 1994, BIOCHEM BIOPH RES CO, V200, P1118, DOI 10.1006/bbrc.1994.1566	35	306	321	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8488	8492		10.1074/jbc.271.14.8488	http://dx.doi.org/10.1074/jbc.271.14.8488			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626550	hybrid			2022-12-27	WOS:A1996UD60000090
J	Dulubova, IE; Krasnoperov, VG; Khvotchev, MV; Pluzhnikov, KA; Volkova, TM; Grishin, EV; Vais, H; Bell, DR; Usherwood, PNR				Dulubova, IE; Krasnoperov, VG; Khvotchev, MV; Pluzhnikov, KA; Volkova, TM; Grishin, EV; Vais, H; Bell, DR; Usherwood, PNR			Cloning and structure of delta-latroinsectotoxin, a novel insect-specific member of the latrotoxin family - Functional expression requires C-terminal truncation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WIDOW SPIDER VENOM; BACTERIOPHAGE-T7 RNA-POLYMERASE; MOLECULAR-WEIGHT PROTEIN; ANKYRIN-LIKE REPEATS; ALPHA-LATROTOXIN; RECEPTOR; CDNA; NEUROTOXIN; SEQUENCE; GENES	The venom of the black widow spider (BWSV) (Latrodectus mactans tredecimguttatus) contains several potent, high molecular mass (>110 kDa) neurotoxins that cause neurotransmitter release in a phylum-specific manner. The molecular mechanism of action of these proteins is poorly understood because their structures are largely unknown, and they have not been functionally expressed, This study reports on the primary structure of delta-latroinsectotoxin (delta-LIT), a novel insect-specific toxin from BWSV, that contains 1214 amino acids, delta-LIT comprises four structural domains: a signal peptide followed by an N-terminal domain that exhibits the highest degree of identity with other latrotoxins, a central region composed of 15 ankyrin-like repeats, and a C-terminal domain, The domain organization of delta-LIT is similar to that of other latrotoxins, suggesting that these toxins are a family of related proteins, The predicted molecular mass and apparent mobility of the protein (similar to 130 kDa) encoded in the delta-LIT gene differs from that of native delta-LIT purified from BWSV (similar to 110 kDa), suggesting that the toxin is produced by proteolytic processing of a precursor. MALDI-MS of purified native delta-LIT revealed a molecular ion with m/z+ of 110916 +/- 100, indicating that the native delta-LIT is 991 amino acids in length, When the full-length delta-LIT cDNA was expressed in bacteria the protein product was inactive, but expression of a C-terminally truncated protein containing 991 residues produced a protein that caused massive neurotransmitter release at the locust neuromuscular junction at nanomolar concentrations, Channels formed in locust muscle membrane and artificial lipid bilayers by the native delta-LIT have a high Ca2+ permeability, whereas those formed by truncated, recombinant protein do not.	RUSSIAN ACAD SCI, SHEMYAKIN & OVCHINNIKOV INST BIOORGAN CHEM, MOSCOW 117871, RUSSIA; UNIV NOTTINGHAM, DEPT LIFE SCI, NOTTINGHAM NG7 2RD, ENGLAND	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; University of Nottingham			Khvotchev, Mikhail/G-5411-2013	Khvotchev, Mikhail/0000-0001-9328-8549	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENNETT V, 1992, J BIOL CHEM, V267, P8703; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; CORRONADO R, 1983, BIOPHYS J, V43, P231; CULLCANDY SG, 1973, NATURE, V241, P353, DOI 10.1038/241353a0; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; DINIZ MRV, 1993, J BIOL CHEM, V268, P15340; FILIPPOV AK, 1994, NEUROSCIENCE, V61, P179, DOI 10.1016/0306-4522(94)90070-1; FRITZ LC, 1980, NATURE, V283, P486, DOI 10.1038/283486a0; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GRASSO A, 1988, E H S BIOT, P67; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HODGKISS JP, 1978, J PHYSIOL-LONDON, V285, P113, DOI 10.1113/jphysiol.1978.sp012561; HOYLE G, 1995, P ROY SOC LOND B BIO, V243, P343; HUDDIE PL, 1986, J PHYSL, V378, pP608; KIYATKIN N, 1992, TOXICON, V30, P771, DOI 10.1016/0041-0101(92)90012-T; KIYATKIN N, 1993, EUR J BIOCHEM, V213, P121, DOI 10.1111/j.1432-1033.1993.tb17741.x; KIYATKIN NI, 1995, EUR J BIOCHEM, V230, P854, DOI 10.1111/j.1432-1033.1995.tb20628.x; KIYATKIN NI, 1990, FEBS LETT, V270, P127, DOI 10.1016/0014-5793(90)81250-R; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRASNOPEROV VG, 1992, J NAT TOXINS, V1, P17; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONGENEC.HE, 1970, NATURE, V225, P701, DOI 10.1038/225701a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNEV AV, 1991, BIOORG KHIM+, V17, P1021; MAGAZANIK LG, 1992, NEUROSCIENCE, V46, P181, DOI 10.1016/0306-4522(92)90017-V; MELDOLESI J, 1984, P NATL ACAD SCI-BIOL, V81, P620, DOI 10.1073/pnas.81.2.620; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; PESCATORI M, 1995, EUR J BIOCHEM, V230, P322, DOI 10.1111/j.1432-1033.1995.0322i.x; PETRENKO AG, 1993, J BIOL CHEM, V268, P1860; PETRENKO AG, 1990, EMBO J, V9, P2023, DOI 10.1002/j.1460-2075.1990.tb08331.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEER H, 1985, EMBO J, V4, P323, DOI 10.1002/j.1460-2075.1985.tb03632.x; SHATURSKY OY, 1995, BBA-BIOMEMBRANES, V1233, P14, DOI 10.1016/0005-2736(94)00226-F; STAHL B, 1994, J BIOL CHEM, V269, P24770; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USHERWOOD PNR, 1973, J PHYSL, V285, P113; USHERWOOD PNR, 1963, NATURE, V191, P814; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VOLKOVA TM, 1991, BIOORG KHIM+, V17, P437; VOLKOVA TM, 1995, TOXICON, V33, P483, DOI 10.1016/0041-0101(94)00166-6; YUUKI T, 1991, AGR BIOL CHEM TOKYO, V55, P1233, DOI 10.1080/00021369.1991.10870757	44	58	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7535	7543		10.1074/jbc.271.13.7535	http://dx.doi.org/10.1074/jbc.271.13.7535			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631785	hybrid			2022-12-27	WOS:A1996UC77400053
J	Guy, CT; Cardiff, RD; Muller, WJ				Guy, CT; Cardiff, RD; Muller, WJ			Activated neu induces rapid tumor progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; TRANSGENIC MICE; GROWTH-FACTOR; METASTATIC DISEASE; MAMMARY-TUMORS; HA-RAS; ONCOGENE; EXPRESSION; GENE; PROTOONCOGENE	Expression of the activated neu oncogene in transgenic mice has been associated with both the synchronous (single-step) and the stochastic (multistep) transformation of the mammary epithelium, To determine the basis for these conflicting observations, additional strains of transgenic mice carrying the activated neu oncogene under the transcriptional control of the mouse mammary tumor virus promoter/enhancer were produced. Activated neu transgene expression, as measured by in situ hybridization and ribonuclease protection assays, resulted in rapid conversion of the normal mammary epithelium to malignant phenotype in three independent strains of mice. Expression of the transgene in male mice led to epithelial hyperplasia of the epididymis and male infertility but not malignancy. These results indicate that tissue context is an important parameter in malignant progression and that expression of appropriate levels of activated neu is sufficient for rapid production of mammary tumors in transgenic mice.	MCMASTER UNIV,INST MOLEC BIOL & BIOTECHNOL,HAMILTON,ON L8S 4K1,CANADA; UNIV CALIF DAVIS,SCH MED,DEPT PATHOL,DAVIS,CA 95616	McMaster University; University of California System; University of California Davis					NCI NIH HHS [R01 CAS4285] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALI IU, 1988, SCIENCE, V240, P1795, DOI 10.1126/science.3289120; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARNES DM, 1988, BRIT J CANCER, V58, P448, DOI 10.1038/bjc.1988.238; BORG A, 1990, CANCER RES, V50, P4332; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HAFEN E, 1983, EMBO J, V2, P617, DOI 10.1002/j.1460-2075.1983.tb01472.x; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; LEMOINE NR, 1990, ONCOGENE, V5, P237; LEVEBRE, 1991, MOL CELL BIOL, V11, P2529; LUCCHINI F, 1992, CANCER LETT, V64, P203, DOI 10.1016/0304-3835(92)90044-V; MELTON DA, 1984, NUCLEIC ACIDS RES, V5, P919; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; QUINN P, 1982, J REPROD FERTIL, V66, P161; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; ZELLER R, 1983, CELL, V32, P425, DOI 10.1016/0092-8674(83)90462-2; ZELLER R, 1987, GENE DEV, V1, P693, DOI 10.1101/gad.1.7.693	35	122	126	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7673	7678		10.1074/jbc.271.13.7673	http://dx.doi.org/10.1074/jbc.271.13.7673			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631805	hybrid			2022-12-27	WOS:A1996UC77400073
J	Kang, SH; Brown, DA; Kitajima, I; Xu, X; Heidenreich, O; Gryaznov, S; Nerenberg, M				Kang, SH; Brown, DA; Kitajima, I; Xu, X; Heidenreich, O; Gryaznov, S; Nerenberg, M			Binding and functional effects of transcriptional factor Sp1 on the murine interleukin-8 promotor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; 3 C/EBP ISOFORMS; GENE-EXPRESSION; DNA-BINDING; HUMAN-FIBROBLASTS; NUCLEAR PROTEINS; SV40 ENHANCER; VIRUS TYPE-1; IL-6 GENE; NF-IL6	The NF-kappa B and NF-IL6 elements have previously been shown to play an important role in regulation of both the mouse and human interleukin-6 gene. Between these two elements lies a G/C-rich sequence, which contains three repeats of the element CCACC, protein binding to which has not been previously characterized. In this study we demonstrate that the transcription factor Sp1 binds to these repeats and plays an important role in basal and in inducible expression of the murine interleukin-6 gene.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; LYNX THERAPEUT, HAYWARD, CA 94545 USA	Scripps Research Institute			Heidenreich, Olaf/AAP-5045-2021	Heidenreich, Olaf/0000-0001-5404-6483				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, SEMIN CANCER BIOL, V1, P17; ALAM T, 1992, J BIOL CHEM, V267, P5021; BETTS JC, 1993, J BIOL CHEM, V268, P25624; BIDWELL JP, 1993, P NATL ACAD SCI USA, V90, P3162, DOI 10.1073/pnas.90.8.3162; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN DA, 1994, J BIOL CHEM, V269, P26801; BROWN DA, 1994, TRANSGENICS, V1, P377; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; DAILEY L, 1988, GENE DEV, V2, P1700, DOI 10.1101/gad.2.12b.1700; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; ELIAS JA, 1990, J IMMUNOL, V145, P161; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; HAEGEMAN G, 1986, EUR J BIOCHEM, V159, P625, DOI 10.1111/j.1432-1033.1986.tb09931.x; HSU W, 1993, MOL CELL BIOL, V13, P2515, DOI 10.1128/MCB.13.4.2515; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; KANG SH, 1995, NUCLEIC ACIDS RES, V23, P2344, DOI 10.1093/nar/23.12.2344; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KITAJIMA I, 1992, J BIOL CHEM, V267, P25881; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LUST JA, 1994, MAYO CLIN PROC, V69, P691, DOI 10.1016/S0025-6196(12)61351-2; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MERCURIO F, 1989, EMBO J, V8, P1455, DOI 10.1002/j.1460-2075.1989.tb03528.x; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NAUMANN M, 1993, ONCOGENE, V8, P2275; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; ROSALES R, 1987, EMBO J, V6, P3015, DOI 10.1002/j.1460-2075.1987.tb02607.x; SEHGAL PB, 1990, P SOC EXP BIOL MED, V195, P183; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TANABE O, 1988, J IMMUNOL, V141, P3875; TANIMURA A, 1993, J VIROL, V67, P5375, DOI 10.1128/JVI.67.9.5375-5382.1993; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; VANWIJNEN AJ, 1993, BIOCHEMISTRY-US, V32, P8397, DOI 10.1021/bi00084a003; WALTHER Z, 1988, J IMMUNOL, V140, P974; WANG YK, 1993, MOL CELL BIOL, V13, P5691, DOI 10.1128/MCB.13.9.5691; XU X, 1995, J CLIN INVEST, V96, P1548, DOI 10.1172/JCI118193; XU X, 1994, MOL CELL BIOL, V14, P5371, DOI 10.1128/MCB.14.8.5371; Xu X, 1996, BIOTECHNIQUES, V20, P44; YAMAGUCHI Y, 1994, J BIOL CHEM, V269, P19410; YANG J, 1994, J IMMUNOL, V152, P943; YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x; ZILBERSTEIN A, 1986, EMBO J, V5, P2529, DOI 10.1002/j.1460-2075.1986.tb04531.x	55	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7330	7335		10.1074/jbc.271.13.7330	http://dx.doi.org/10.1074/jbc.271.13.7330			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631753				2022-12-27	WOS:A1996UC77400021
J	Lee, KD; Oh, YK; Portnoy, DA; Swanson, JA				Lee, KD; Oh, YK; Portnoy, DA; Swanson, JA			Delivery of macromolecules into cytosol using liposomes containing hemolysin from Listeria monocytogenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PH-SENSITIVE LIPOSOMES; BACILLUS-SUBTILIS; TUBULAR LYSOSOMES; MHC PRESENTATION; MAMMALIAN-CELLS; ENDOCYTOSIS; MACROPHAGES; ANTIGENS; BINDING; GROWTH	The cytosolic space of cells is an important but relatively inaccessible target for the delivery of therapeutic macromolecules. Here we describe the efficient delivery of macromolecules into the cytosolic space of macrophages from liposomes that contain listeriolysin O (LLO), the hemolytic protein of Listeria monocytogenes that normally mediates bacterial passage from phagosomes into cytosol, LLO was purified and encapsulated inside pH-sensitive liposomes, along with other molecules to be delivered, When internalized by bone marrow-derived macrophages, these liposomes rapidly released encapsulated fluorescent dye, first into endosomes and then into the cytosol, without measurably harming the cells. Furthermore, these liposomes efficiently delivered encapsulated ovalbumin to the cytosolic pathway of antigen processing and presentation, as measured by the major histocompatibility complex (MHC) class I-restricted presentation of peptides derived from ovalbumin. Delivery was significantly better than that obtained by other currently available liposome formulations, LLO-containing liposomes should therefore provide an efficient vehicle for delivery of antigens or therapeutic molecules in vivo.	UNIV PENN,DEPT MICROBIOL,PHILADELPHIA,PA 19104	University of Pennsylvania	Lee, KD (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,220 LONGWOOD AVE,BOSTON,MA 02115, USA.		Swanson, Joel A/P-4362-2014; Oh, Yu Kyoung/G-8754-2013	Swanson, Joel A/0000-0003-0900-8212; 				BIELECKI J, 1990, NATURE, V345, P175, DOI 10.1038/345175a0; CAMILLI A, 1991, J EXP MED, V173, P751, DOI 10.1084/jem.173.3.751; CHU CJ, 1990, PHARM RES-DORDR, V7, P824, DOI 10.1023/A:1015908831507; DALEKE DL, 1990, BIOCHIM BIOPHYS ACTA, V1024, P352, DOI 10.1016/0005-2736(90)90365-U; GAILLARD JL, 1986, INFECT IMMUN, V52, P50, DOI 10.1128/IAI.52.1.50-55.1986; GEOFFROY C, 1987, INFECT IMMUN, V55, P1641, DOI 10.1128/IAI.55.7.1641-1646.1987; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GOLDFINE H, 1995, P NATL ACAD SCI USA, V92, P2979, DOI 10.1073/pnas.92.7.2979; Gregoriadis G, 1993, LIPOSOME TECHNOLOGY; HARDING CV, 1991, J IMMUNOL, V147, P2860; HARDING CV, 1994, METHOD CELL BIOL, V45, P313; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; JONES S, 1994, INFECT IMMUN, V62, P5608, DOI 10.1128/IAI.62.12.5608-5613.1994; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; LASIC DD, 1995, SCIENCE, V267, P1275, DOI 10.1126/science.7871422; LEE KD, 1992, BIOCHIM BIOPHYS ACTA, V1103, P185, DOI 10.1016/0005-2736(92)90086-2; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; OLSON F, 1979, BIOCHIM BIOPHYS ACTA, V557, P9, DOI 10.1016/0005-2736(79)90085-3; PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; PORTNOY DA, 1992, INFECT IMMUN, V60, P2710, DOI 10.1128/IAI.60.7.2710-2717.1992; PORTNOY DA, 1994, ANN NY ACAD SCI, V730, P15, DOI 10.1111/j.1749-6632.1994.tb44235.x; RACOOSIN EL, 1993, J CELL BIOL, V121, P1011, DOI 10.1083/jcb.121.5.1011; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SMITH GA, 1995, INFECT IMMUN, V63, P4231, DOI 10.1128/IAI.63.11.4231-4237.1995; STRAUBINGER RM, 1983, CELL, V32, P1069, DOI 10.1016/0092-8674(83)90291-X; STRAUBINGER RM, 1993, METHOD ENZYMOL, V221, P361, DOI 10.1016/0076-6879(93)21030-C; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149	31	93	113	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7249	7252		10.1074/jbc.271.13.7249	http://dx.doi.org/10.1074/jbc.271.13.7249			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631734	hybrid			2022-12-27	WOS:A1996UC77400002
J	Ridge, KD; Lee, SSJ; Abdulaev, NG				Ridge, KD; Lee, SSJ; Abdulaev, NG			Examining rhodopsin folding and assembly through expression of polypeptide fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT RETINITIS-PIGMENTOSA; BOVINE RHODOPSIN; MONOCLONAL-ANTIBODIES; TRANSGENIC MICE; SIGNAL SEQUENCE; PROTEINS; GENE; MUTATIONS; MEMBRANES; CHAIN	Previous work on the expression of bovine opsin fragments separated in the cytoplasmic region has allowed the identification of specific polypeptide segments that contain sufficient information to fold independently, insert into a membrane, and assemble to form a functional photoreceptor. To further examine the contributions of these and other polypeptide segments to the mechanism of opsin folding and assembly, we have constructed 20 additional opsin gene fragments where the points of separation occur in the intradiscal, transmembrane, and cytoplasmic regions. Nineteen of these fragments were stably expressed in COS-1 cells. A five-helix fragment was stably produced only after coexpression with its complementary two-helix fragment. Two fragments composed of the amino-terminal region and the first transmembrane helix were not N-glycosylated and were only partially membrane integrated. One of the singly expressed fragments, which is truncated after the retinal attachment site, bound 11-cis-retinal. Of the coexpressed complementary fragments, only those separated in the second intradiscal and third cytoplasmic regions formed noncovalently linked rhodopsins. Both of these pigments showed reduced transducin activation. Therefore, while many opsin fragments contain enough information to fold and insert into a membrane, only those separated at specific locations assemble to a retinal-binding opsin.	UNIV MARYLAND, MARYLAND BIOTECHNOL INST, ROCKVILLE, MD 20850 USA		Ridge, KD (corresponding author), NATL INST STAND & TECHNOL, CTR ADV RES BIOTECHNOL, BOULDER, CO 80303 USA.				NEI NIH HHS [EY 11112] Funding Source: Medline; NATIONAL EYE INSTITUTE [R29EY011112, R55EY011112] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; ANUKANTH A, 1994, J BIOL CHEM, V269, P19738; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; BERTOLAET BL, 1995, BIOCHEMISTRY-US, V34, P5736, DOI 10.1021/bi00017a005; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BORJIGIN J, 1994, J BIOL CHEM, V269, P14715; CHABRE M, 1979, VISION RES, V19, P1005, DOI 10.1016/0042-6989(79)90226-8; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; FUKUDA MN, 1979, J BIOL CHEM, V254, P8201; HARGRAVE PA, 1992, INT REV CYTOL, V137B, P49; HARGRAVE PA, 1983, BIOPHYS STRUCT MECH, V9, P235, DOI 10.1007/BF00535659; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KURADA P, 1995, NEURON, V14, P571, DOI 10.1016/0896-6273(95)90313-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD DW, 1987, P MEMBRANE PROTEIN S, P45; LI TS, 1995, P NATL ACAD SCI USA, V92, P3551, DOI 10.1073/pnas.92.8.3551; MACKE JP, 1993, AM J HUM GENET, V53, P80; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIN KC, 1993, J BIOL CHEM, V268, P9400; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; NAASH MI, 1993, P NATL ACAD SCI USA, V90, P5499, DOI 10.1073/pnas.90.12.5499; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; OVCHINNIKOV YA, 1982, BIOORG KHIM+, V8, P1011; OVCHINNIKOV YA, 1982, FEBS LETT, V148, P179, DOI 10.1016/0014-5793(82)80805-3; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P3261, DOI 10.1021/bi00010a016; RIDGE KD, 1995, P NATL ACAD SCI USA, V92, P3204, DOI 10.1073/pnas.92.8.3204; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; ROSENFELD PJ, 1992, NAT GENET, V1, P209, DOI 10.1038/ng0692-209; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1993, J BIOL CHEM, V268, P26645; SUNG CH, 1994, J NEUROSCI, V14, P5818; TSUNASAWA S, 1980, BIOCHIM BIOPHYS ACTA, V624, P218, DOI 10.1016/0005-2795(80)90241-X; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WANG JK, 1980, BIOCHEMISTRY-US, V19, P5111, DOI 10.1021/bi00563a027; WASHBURN T, 1989, J BIOL CHEM, V264, P15464; WEISS ER, 1994, BIOCHEMISTRY-US, V33, P7587, DOI 10.1021/bi00190a011; WRUBEL W, 1990, J BACTERIOL, V172, P5374, DOI 10.1128/jb.172.9.5374-5381.1990; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002; ZEN KH, 1994, BIOCHEMISTRY-US, V33, P8198, DOI 10.1021/bi00193a005	61	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7860	7867		10.1074/jbc.271.13.7860	http://dx.doi.org/10.1074/jbc.271.13.7860			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631831	hybrid			2022-12-27	WOS:A1996UC77400099
J	Hoeg, JM; Vaisman, BL; Demosky, SJ; Meyn, SM; Talley, GD; Hoyt, RF; Feldman, S; Berard, AM; Sakai, N; Wood, D; Brousseau, ME; Marcovina, S; Brewer, HB; SantamarinaFojo, S				Hoeg, JM; Vaisman, BL; Demosky, SJ; Meyn, SM; Talley, GD; Hoyt, RF; Feldman, S; Berard, AM; Sakai, N; Wood, D; Brousseau, ME; Marcovina, S; Brewer, HB; SantamarinaFojo, S			Lecithin:cholesterol acyltransferase overexpression generates hyperalpha-lipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENT ALLELIC MUTATIONS; LIPID TRANSFER PROTEINS; FISH EYE SYNDROME; PLASMA; GENE; LCAT; EXPRESSION	Cholesterol esterification within plasma lipoprotein particles is catalyzed by lecithin:cholesterol acyltransferase (LCAT). The impact of the overexpression of this enzyme on plasma concentrations of the different plasma lipoproteins in an animal model expressing cholesteryl ester transfer protein was evaluated by generating rabbits expressing human LCAT. A 6.2-kilobase human genomic DNA construct was injected into the pronuclei of rabbit embryos. Of the 1002 embryos that were injected, 3 founder rabbits were characterized that expressed the human LCAT gene. As in mice and humans, the principal sites of mRNA expression in these rabbits is in the liver and brain, indicating that the regulatory elements required for tissue-specific expression among these species are similar. The alpha-LCAT activity correlated with the number of copies of LCAT that integrated into the rabbit DNA. Compared with controls, the high expressor LCAT-transgenic rabbits total and high density lipoprotein (HDL) cholesterol concentrations were increased 1.5-2.5-fold with a 3.1-fold increase in the plasma cholesterol esterification rate. Analysis of the plasma lipoproteins by fast protein liquid chromatography indicates that these changes reflected an increased concentration of apolipoprotein E-enriched, HDL(1)-sized particles, whereas atherogenic apolipoprotein B particles disappeared from the plasma. The concentrations of plasma HDL cholesterol were highly correlated with both human LCAT mass (r = 0.93; p = 0.001) and the log LCAT activity (r = 0.94; p < 0.001) in the transgenic rabbits. These results indicate that overexpression of LCAT in the presence of cholesteryl ester transfer protein leads to both hyperalphalipoproteinemia and reduced concentrations of atherogenic lipoproteins.	NHLBI, LAB ANIM MED & SURG, NIH, BETHESDA, MD 20892 USA; UNIV WASHINGTON, SCH MED, DEPT MED, NW LIPID RES LABS, SEATTLE, WA 98195 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Washington; University of Washington Seattle	Hoeg, JM (corresponding author), NHLBI, MOLEC DIS BRANCH,NIH,BLDG 10,RM 7N115, 10 CTR DR MSC 1666, BETHESDA, MD 20892 USA.		Feldman, Sanford/AAH-7070-2021; Vaisman, Boris L/B-3453-2008	Meyn, Susan/0000-0002-0894-0721				ALBERS JJ, 1982, ATHEROSCLEROSIS, V43, P369, DOI 10.1016/0021-9150(82)90036-3; ALBERS JJ, 1984, ARTERIOSCLEROSIS, V4, P49, DOI 10.1161/01.ATV.4.1.49; ALBERS JJ, 1981, J CLIN INVEST, V67, P141, DOI 10.1172/JCI110006; Anitschkow N., 1913, ZENTRALBL ALLG PATHO, V24, P1; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; BOLIN DJ, 1994, J BIOL CHEM, V269, P7429; BORRESEN AL, 1978, J IMMUNOGENET, V5, P5; BRINTON EA, 1994, ARTERIOSCLER THROMB, V14, P707, DOI 10.1161/01.ATV.14.5.707; CHAPMAN MJ, 1980, J LIPID RES, V21, P789; COHN JS, 1988, J LIPID RES, V29, P925; FIELDING CJ, 1972, BIOCHIM BIOPHYS ACTA, V270, P513, DOI 10.1016/0005-2760(72)90116-6; FRANCONE OL, 1995, J CLIN INVEST, V96, P1440, DOI 10.1172/JCI118180; Glomset J.A., 1995, METABOLIC MOL BASES, Vseventh, P1933; GLOMSET JA, 1966, J LIPID RES, V7, P638; HA YC, 1982, COMP BIOCHEM PHYS B, V71, P265, DOI 10.1016/0305-0491(82)90252-8; HOEG JM, 1990, J LIPID RES, V31, P1761; IKEWAKI K, 1993, J LIPID RES, V34, P2207; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P205, DOI 10.1016/0005-2760(91)90062-M; KLEIN HG, 1992, J CLIN INVEST, V89, P499, DOI 10.1172/JCI115612; KLEIN HG, 1993, J LIPID RES, V34, P49; KLEIN HG, 1993, J CLIN INVEST, V92, P479, DOI 10.1172/JCI116591; LUSIS AJ, 1992, CURR OPIN LIPIDOL, V3, P143; MATZ CE, 1982, J BIOL CHEM, V257, P4541; MCLEAN J, 1986, NUCLEIC ACIDS RES, V14, P9397, DOI 10.1093/nar/14.23.9397; MEIJER GW, 1993, BIOCHEM J, V293, P729, DOI 10.1042/bj2930729; NORUM KR, 1967, SCAND J CLIN LAB INV, V20, P231, DOI 10.3109/00365516709076948; Overturf ML, 1992, CURR OPIN LIPIDOL, V3, P179, DOI DOI 10.1097/00041433-199206000-00004; PERK K, 1972, Laboratory Animals (London), V6, P315, DOI 10.1258/002367772781006130; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; ROUIS M, 1990, EUR J BIOCHEM, V189, P447, DOI 10.1111/j.1432-1033.1990.tb15509.x; SHENG J, 1990, METABOLISM, V39, P155, DOI 10.1016/0026-0495(90)90069-O; SKINNER MP, 1995, NAT MED, V1, P69, DOI 10.1038/nm0195-69; Sperry WM, 1935, J BIOL CHEM, V111, P467; STOKKE KT, 1971, SCAND J CLIN LAB INV, V27, P21, DOI 10.3109/00365517109080184; TALL AR, 1993, J LIPID RES, V34, P1255; VAISMAN BL, 1995, J BIOL CHEM, V270, P12269, DOI 10.1074/jbc.270.20.12269; WARNICK GR, 1982, CLIN CHEM, V28, P1379	37	92	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4396	4402						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626790				2022-12-27	WOS:A1996TW96000068
J	Langland, JO; Langland, LA; Browning, KS; Roth, DA				Langland, JO; Langland, LA; Browning, KS; Roth, DA			Phosphorylation of plant eukaryotic initiation factor-2 by the plant-encoded double-stranded RNA-dependent protein kinase, pPKR, and inhibition of protein synthesis in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHEAT-GERM; FACTOR-II; TRANSLATIONAL CONTROL; MONOCLONAL-ANTIBODIES; RABBIT RETICULOCYTES; EIF-2-ALPHA KINASE; MESSENGER-RNA; ALPHA-SUBUNIT; HUMAN-CELLS; INTERFERON	Regulation of protein synthesis by eukaryotic initiation factor-2 alpha (eIF-2 alpha) phosphorylation is a highly conserved phenomenon in eukaryotes that occurs in response to various stress conditions. Protein kinases capable of phosphorylating eIF-2 alpha have been characterized from mammals and yeast. However, the phenomenon of eIF2-alpha-mediated regulation of protein synthesis and the presence of an elF-2 alpha kinase has not been demonstrated in higher plants. We show that plant eIF-2 alpha (peIF-2 alpha) and mammalian eIF-2 alpha (meIF-2 alpha) are phosphorylated similarly by both the double-stranded RNA-binding kinase, pPKR, present in plant ribosome salt wash fractions and the meIF-2 alpha kinase, PHR. By several criteria, phosphorylation of peIF-2 alpha is directly correlated with pPKR. protein and autophosphorylation levels. Significantly, pPKR is capable of specifically phosphorylating Ser(51) in a synthetic eIF-2 alpha peptide, a key characteristic of the eIF-2 alpha kinase family. Taken together, these data support the concept that pPKR is a member of the eIF-2 alpha kinase family. In addition, the inhibition of brome mosaic virus RNA in vitro translation in wheat germ lysates by the addition of double-stranded RNA, phosphorylated peIF-2 alpha; meIF-2 alpha, or activated human PKR suggests that plant protein synthesis may be regulated via phosphorylation of eIF-2 alpha.	UNIV WYOMING,DEPT PLANT SOIL & INSECT SCI,LARAMIE,WY 82071; UNIV TEXAS,DEPT CHEM & BIOCHEM,AUSTIN,TX 78712	University of Wyoming; University of Texas System; University of Texas Austin								BENNE R, 1980, EUR J BIOCHEM, V104, P109, DOI 10.1111/j.1432-1033.1980.tb04406.x; BROWNING KS, 1985, PLANT PHYSIOL, V77, P370, DOI 10.1104/pp.77.2.370; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CLARKE RD, 1987, MOL CELL BIOCHEM, V74, P129; CRUM CJ, 1988, J BIOL CHEM, V263, P13440; DAVIES MV, 1992, J VIROL, V66, P1943, DOI 10.1128/JVI.66.4.1943-1950.1992; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DEZOETEN GA, 1989, VIROLOGY, V172, P213, DOI 10.1016/0042-6822(89)90123-2; ERNST H, 1987, J BIOL CHEM, V262, P1206; HE X, 1994, PROG MOL SUBCELL BIO, V14, P28; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HIDDINGA HJ, 1988, SCIENCE, V241, P451, DOI 10.1126/science.3393910; HINNEBUSCH AG, 1990, TRENDS BIOCHEM SCI, V15, P148, DOI 10.1016/0968-0004(90)90215-W; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; HU J, 1991, BIOCHEM BIOPH RES CO, V179, P229, DOI 10.1016/0006-291X(91)91359-K; LANGLAND JO, 1992, J BIOL CHEM, V267, P10729; LANGLAND JO, 1995, PROTEIN EXPRES PURIF, V6, P25, DOI 10.1006/prep.1995.1004; LANGLAND JO, 1995, PLANT PHYSIOL, V108, P1259, DOI 10.1104/pp.108.3.1259; LAURENT AG, 1985, P NATL ACAD SCI USA, V82, P4341, DOI 10.1073/pnas.82.13.4341; LAX SR, 1986, METHOD ENZYMOL, V118, P109; LAX SR, 1986, J BIOL CHEM, V261, P5632; MEHTA HB, 1986, J BIOL CHEM, V261, P6705; MELLOR H, 1991, BIOCHEM BIOPH RES CO, V178, P430, DOI 10.1016/0006-291X(91)90125-Q; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; PAL JK, 1991, BIOCHEMISTRY-US, V30, P2555, DOI 10.1021/bi00223a037; RANU RS, 1980, BIOCHEM BIOPH RES CO, V97, P1124, DOI 10.1016/0006-291X(80)91492-8; RAY MK, 1992, P NATL ACAD SCI USA, V89, P539, DOI 10.1073/pnas.89.2.539; REIJNDERS L, 1975, BIOCHIM BIOPHYS ACTA, V390, P69, DOI 10.1016/0005-2787(75)90009-X; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SAMUEL CE, 1992, PHARMACOL THERAPEUT, V54, P307, DOI 10.1016/0163-7258(92)90005-K; SAMUEL CE, 1986, METHOD ENZYMOL, V119, P499; SARRE TF, 1989, BIOSYSTEMS, V22, P311, DOI 10.1016/0303-2647(89)90053-1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; SEAL SN, 1983, J BIOL CHEM, V258, P573; SHAIKHIN SM, 1992, BIOCHIMIE, V74, P447, DOI 10.1016/0300-9084(92)90085-S; SPREMULLI LL, 1979, J BIOL CHEM, V254, P143; THOMIS DC, 1992, VIROLOGY, V188, P33, DOI 10.1016/0042-6822(92)90732-5; Treadwell B V, 1979, Methods Enzymol, V60, P181; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579	42	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4539	4544						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626809				2022-12-27	WOS:A1996TW96000087
J	RodriguezLopez, JN; Smith, AT; Thorneley, RNF				RodriguezLopez, JN; Smith, AT; Thorneley, RNF			Role of Arginine 38 in horseradish peroxidase a critical, residue for substrate binding and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; COMPOUND-I; ACTIVE-SITE; HYDROGEN-PEROXIDE; ELEMENTARY STEPS; ESCHERICHIA-COLI; AROMATIC DONOR; HEME; OXIDATION; THERMODYNAMICS	The observed pseudo-first order rate constant for the reaction between a horseradish peroxidase (HRP) variant (R38L)HRPC* and hydrogen peroxide saturates at high peroxide concentrations (K-m = 11.8 mM), The data are consistent with a two-step mechanism involving the formation of an HRP-H2O2 intermediate (k = 1.1 x 10(4) M(-1) s(-1)) whose conversion to compound I is rate-limiting (k = 142 s(-1)) suggesting that Arg-38 is not only involved in the cleavage of the O-O bond of peroxide but also has an important role in facilitating the rapid binding of H2O2 to HRP. Rapid-scan spectrophotometry revealed the presence of a transient intermediate with a spectrum consistent with a ferric-hydroperoxy complex. At high peroxide concentrations (>500 mu M), compound I is converted to compound III without the accumulation of compound II. Spectrophotometric titrations show that arginine 38 is also involved in modulating the apparent affinity of HRPC for reducing substrates such as guaiacol and p-cresol. The spectrum of the complex formed when these substrates bind to the ferric form of the mutant enzyme differs from that observed when they bind to the wild-type ferric enzyme. At neutral and alkaline pH compound I of (R38L)HRPC* was stable and reduced to ferric enzyme without apparent formation of compound II upon titration with p-cresol or ascorbic acid, suggesting a change in the rate-limiting step in the peroxidase cycle. Steady-state kinetic analyses carried out at pH 7.0 showed significant increases in the apparent K-m for guaiacol, p-cresol, and 2,2'-azinobis(3-ethylbenzothiazolinesulfonic acid) (ABTS). The high stability of the oxyferryl form of (R38L)HRPC* and its low catalytic constant for reducing substrates also shows that arginine 38 modulates the reactivity of HRP compound I.	JOHN INNES CTR PLANT SCI RES,NITROGEN FIXAT LAB,NORWICH NR4 7UH,NORFOLK,ENGLAND; UNIV SUSSEX,DEPT BIOCHEM,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Sussex			Neptuno, Jose/F-5012-2016	Rodriguez-Lopez, Jose Neptuno/0000-0001-6863-1173; Smith, Andrew/0000-0002-0926-1878				ARASASINGHAM RD, 1989, J AM CHEM SOC, V111, P7800, DOI 10.1021/ja00202a021; BABCOCK GT, 1993, J BIOENERG BIOMEMBR, V25, P71, DOI 10.1007/BF00762849; BAEK HK, 1989, BIOCHEMISTRY-US, V28, P5714, DOI 10.1021/bi00440a003; BAEK HK, 1992, J AM CHEM SOC, V114, P718, DOI 10.1021/ja00028a046; BALNY C, 1987, EUR BIOPHYS J BIOPHY, V14, P375; Bernasconi C. F., 1976, RELAXATION KINETICS; BHATTACHARYYA DK, 1993, J BIOL CHEM, V268, P22292; BURSTYN JN, 1988, J AM CHEM SOC, V110, P1382, DOI 10.1021/ja00213a009; CHANG CS, 1993, BIOCHEMISTRY-US, V32, P923, DOI 10.1021/bi00054a025; COTTON ML, 1973, CAN J CHEM, V51, P582, DOI 10.1139/v73-088; CRITCHLOW JE, 1972, J BIOL CHEM, V247, P3714; DEMONTELLANO PRO, 1992, ANNU REV PHARMACOL, V32, P89, DOI 10.1146/annurev.pharmtox.32.1.89; DRAPER NR, 1981, APPLIED REGRESSION A; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; ERMAN JE, 1992, J AM CHEM SOC, V114, P6592, DOI 10.1021/ja00042a068; FARHANGRAZI ZS, 1994, BIOCHEMISTRY-US, V33, P5647, DOI 10.1021/bi00184a038; Furhop J., 1975, PORPHYRINS METALLOPO, P757; GEORGE P, 1953, ARCH BIOCHEM BIOPHYS, V41, P416; GOODIN DB, 1987, J BIOL CHEM, V262, P7719; HARRIS RZ, 1993, J BIOL CHEM, V268, P1637; HOSOYA T, 1989, BIOCHEMISTRY-US, V28, P2639, DOI 10.1021/bi00432a042; KREMER AB, 1980, J BIOL CHEM, V255, P2405; LEIGH JS, 1975, FEBS LETT, V51, P304, DOI 10.1016/0014-5793(75)80913-6; MAURO JM, 1988, BIOCHEMISTRY-US, V27, P6256; MEUNIER B, 1995, BIOCHEMISTRY-US, V34, P14687, DOI 10.1021/bi00045a009; MILLER MA, 1994, NAT STRUCT BIOL, V1, P524, DOI 10.1038/nsb0894-524; MIMS MP, 1983, J BIOL CHEM, V258, P4219; MODI S, 1989, J BIOL CHEM, V264, P19677; POULOS TL, 1980, J BIOL CHEM, V255, P8199; RIORDAN JF, 1977, SCIENCE, V195, P884, DOI 10.1126/science.190679; SAUNDERS SE, 1990, NUCLEIC ACIDS RES, V18, P4948, DOI 10.1093/nar/18.16.4948; SCHEJTER A, 1976, ARCH BIOCHEM BIOPHYS, V174, P36, DOI 10.1016/0003-9861(76)90321-0; SCHONBAUM GR, 1972, J BIOL CHEM, V247, P3353; SHIRO Y, 1986, J BIOL CHEM, V261, P9382; SMITH AT, 1992, EUR J BIOCHEM, V207, P507, DOI 10.1111/j.1432-1033.1992.tb17077.x; SMITH AT, 1990, J BIOL CHEM, V265, P13335; SMITH AT, 1993, PLANT PEROXIDASES BI, P159; SMULEVICH G, 1994, BIOCHEMISTRY-US, V33, P7398, DOI 10.1021/bi00189a046; VEITCH NC, 1990, EUR J BIOCHEM, V189, P351, DOI 10.1111/j.1432-1033.1990.tb15496.x; VEITCH NC, 1995, BIOCHEM SOC T, V23, P232, DOI 10.1042/bst0230232; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036; VLAHOS CJ, 1985, J BIOL CHEM, V260, P5480; WANG JS, 1991, BIOCHEM BIOPH RES CO, V179, P1320, DOI 10.1016/0006-291X(91)91717-Q; WELINDER KG, 1985, EUR J BIOCHEM, V151, P497, DOI 10.1111/j.1432-1033.1985.tb09129.x; WELINDER KG, 1979, EUR J BIOCHEM, V96, P483, DOI 10.1111/j.1432-1033.1979.tb13061.x; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; YONETANI T, 1967, J BIOL CHEM, V242, P1974; YONETANI T, 1987, J BIOL CHEM, V262, P9547; [No title captured]	50	178	183	3	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4023	4030						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626735				2022-12-27	WOS:A1996TW96000013
J	Gill, DJ; Low, BC; Grigor, MR				Gill, DJ; Low, BC; Grigor, MR			Interleukin-1 beta and tumor necrosis factor-alpha stimulate the cat-2 gene of the L-arginine transporter in cultured vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; CATIONIC AMINO-ACIDS; RELAXING FACTOR; ANGIOTENSIN-II; RECEPTOR; RAT; MACROPHAGES; EXPRESSION; INDUCTION; MEMBRANE	The production of nitric oxide (NO) from L-arginine by nitric oxide synthase (NOS) in cytokine-stimulated vascular smooth muscle cells (VSMC) is thought to play an important role in the pathophysiology of several vascular disease states including septic shock. This study examines the relationship between cytokine-stimulated NO production and L-arginine transport in cultured VSMC. Cultured VSMC from rat aorta were stimulated with interleukin-1 beta, tumor necrosis factor-alpha, and/or angiotensin II (Ang II); and the accumulation of nitrite, a stable product of NO metabolism, in the culture media and the rates of net L-arginine uptake were measured. Interleukin-1 beta and tumor necrosis factor-alpha, alone or in combination, stimulated both the uptake of L-arginine and the accumulation of nitrite in the culture media in a dose-dependent manner. Inhibition of NOS activity by substituted analogues of L-arginine had no effect on cytokine-stimulated L-arginine transport. Ang II in the presence of cytokines up-regulated L-arginine transport while inhibiting nitrite accumulation. Two forms of the L-arginine transporter, cat-1b and cat-2, are expressed in VSMC. Northern analysis revealed that the cytokine-stimulated increase in L-arginine transport coincided with increased levels of cat-2 mRNA. In contrast, cat-1b does not appear to be regulated by cytokines at the mRNA level, although significant increases in response to Ang II were observed. These results show that, while cytokines can stimulate both NOS activity and L-arginine uptake, NO production is not required to signal the increase in L-arginine transport. Furthermore, Ang II and cytokine stimulation of L-arginine uptake involves the differential regulation of the cationic amino acid transporter (cat) genes.	UNIV OTAGO,DEPT BIOCHEM,DUNEDIN 9001,NEW ZEALAND; UNIV OTAGO,CTR GENE RES,DUNEDIN 9001,NEW ZEALAND	University of Otago; University of Otago			Low, Boon Chuan/AAU-7685-2021; Low, Boon Chuan/H-8049-2012	Low, Boon Chuan/0000-0003-0756-096X; Low, Boon Chuan/0000-0003-0756-096X; Gill, Denzil/0000-0001-5826-4103				ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BAYDOUN AR, 1993, BRIT J PHARMACOL, V110, P1401, DOI 10.1111/j.1476-5381.1993.tb13976.x; BEASLEY D, 1994, AM J PHYSIOL, V266, pR1197, DOI 10.1152/ajpregu.1994.266.4.R1197; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BOGLE RG, 1992, BIOCHEM J, V284, P15, DOI 10.1042/bj2840015; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; DURANTE W, 1995, AM J PHYSIOL-HEART C, V268, pH1158; FINLEY KD, 1995, P NATL ACAD SCI USA, V92, P9378, DOI 10.1073/pnas.92.20.9378; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; HARRIS EL, 1990, BIOCHEM BIOPH RES CO, V170, P1249, DOI 10.1016/0006-291X(90)90528-U; HATTORI Y, 1994, J BIOL CHEM, V269, P9405; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Kakuda DK, 1993, TRANSGENE, V1, P91; KILBERG MS, 1993, ANN REV NUTR, V13, P136; KOIDE M, 1993, FEBS LETT, V318, P213, DOI 10.1016/0014-5793(93)80514-U; LOW BC, 1992, J BIOL CHEM, V267, P20740; LOW BC, 1995, J BIOL CHEM, V270, P27577, DOI 10.1074/jbc.270.46.27577; LOW BC, 1993, J CELL PHYSIOL, V156, P626, DOI 10.1002/jcp.1041560323; LOW BC, 1994, J BIOL CHEM, V269, P32098; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MACLEOD CL, 1994, J EXP BIOL, V196, P109; NAKAYAMA I, 1994, J BIOL CHEM, V269, P11628; PETROS A, 1994, CARDIOVASC RES, V28, P34, DOI 10.1093/cvr/28.1.34; SATO H, 1991, BIOCHIM BIOPHYS ACTA, V1069, P46, DOI 10.1016/0005-2736(91)90102-E; SCHINI VB, 1993, EUR HEART J, V14, P16; SCHINI VB, 1991, BIOCHEM BIOPH RES CO, V176, P114, DOI 10.1016/0006-291X(91)90897-G; SIRSJO A, 1994, FEBS LETT, V338, P191, DOI 10.1016/0014-5793(94)80363-3; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; VANWINKLE LJ, 1995, BBA-BIOMEMBRANES, V1233, P213, DOI 10.1016/0005-2736(94)00303-7; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WANG WW, 1995, BIOCHEM BIOPH RES CO, V210, P1009, DOI 10.1006/bbrc.1995.1757; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WU JY, 1994, J VIROL, V68, P1615, DOI 10.1128/JVI.68.3.1615-1623.1994; ZAR JH, 1974, BIOSTAT ANAL, P151	37	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11280	11283		10.1074/jbc.271.19.11280	http://dx.doi.org/10.1074/jbc.271.19.11280			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626679	hybrid			2022-12-27	WOS:A1996UJ94400039
J	Spiro, RG; Zhu, Q; Bhoyroo, V; Soling, HD				Spiro, RG; Zhu, Q; Bhoyroo, V; Soling, HD			Definition of the lectin-like properties of the molecular chaperone, calreticulin, and demonstration of its copurification with endomannosidase from rat liver Golgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; ALPHA-D-MANNOSIDASE; ENDOPLASMIC-RETICULUM; GLYCOPROTEIN-BIOSYNTHESIS; BINDING-PROTEIN; GLUCOSE; COMPLEX; CELLS; GLYCOSYLATION; MATURATION	Calreticulin was identified by immunochemical and sequence analyses to be the higher molecular mass (60 kDa) component of the polypeptide doublet previously observed in a rat liver Golgi endomannosidase preparation obtained by chromatography on a Glc alpha 1-->3Man-containing matrix. The affinity for this saccharide ligand, which paralleled that of endomannosidase and was also observed with purified rat liver calreticulin, suggested that this chaperone has lectin-like binding properties. Studies carried out with immobilized calreticulin and a series of radiolabeled oligosaccharides derived from N-linked carbohydrate units revealed that interactions with this protein were limited to monoglucosylated polymannose components. Although optimal binding occurred with Glc(1)Man(9)GlcNAc, substantial interaction with calreticulin was retained after sequential trimming of the polymannose portion down to the Glc(1)Man(5)GlcNAc stage. The alpha 1-->6-mannose branch point of the oligosaccharide core, however, appeared to be essential for recognition as Glc(1)Man(4)GlcNAc did not interact with the calreticulin. The carbohydrate-peptide linkage region had no discernible influence on binding as monoglucosylated oligosaccharides in N-glycosidic linkage interacted with the chaperone to the same extent as in their unconjugated state. The immobilized calreticulin proved to be a highly effective tool for sorting out monoglucosylated polymannose oligosaccharides or glycopeptides from complex mixtures of processing intermediates. The copurification of calreticulin and endomannosidase from a Golgi fraction in comparable amounts and the strikingly similar saccharide specificities of the chaperone and the processing enzyme have suggested a tentative model for the dissociation through glucose removal of calreticulin-glycoprotein complexes in a post-endoplasmic reticulum locale; in this scheme, deglucosylation would be brought about by the action of endomannosidase rather than glucosidase II.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02215 USA; UNIV GOTTINGEN, ZENTRUM INNERE MED, BIOCHEM ABT, D-3400 GOTTINGEN, GERMANY	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Gottingen	Spiro, RG (corresponding author), JOSLIN DIABET CTR, ELLIOTT P JOSLIN RES LAB, 1 JOSLIN PL, BOSTON, MA 02215 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017477, R01DK017325] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 17325, DK 17477] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANUMULA KR, 1983, J BIOL CHEM, V258, P5274; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Burns K, 1994, Trends Cell Biol, V4, P152; DePierre J., 1976, BIOCH ANAL MEMBRANES, P79; DUPUIS M, 1993, J EXP MED, V177, P1, DOI 10.1084/jem.177.1.1; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; GODELAINE D, 1981, J BIOL CHEM, V256, P161; Goldstein I., 1986, LECTINS, DOI DOI 10.1016/B978-0-12-449945-4.50007-5; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HIRAIZUMI S, 1994, J BIOL CHEM, V269, P4697; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MOHAN PS, 1986, J BIOL CHEM, V261, P4328; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; MOORE SEH, 1993, J BIOL CHEM, V268, P3809; MOORE SEH, 1994, J BIOL CHEM, V269, P12715; MOOS M, 1988, J BIOL CHEM, V263, P6005; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; NAKAMURA M, 1993, EXP CELL RES, V205, P101, DOI 10.1006/excr.1993.1063; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PETER F, 1992, J BIOL CHEM, V267, P10631; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; RABOUILLE C, 1992, J BIOL CHEM, V267, P11573; SASAK VW, 1985, BIOCHEM J, V232, P759, DOI 10.1042/bj2320759; SPIRO MJ, 1985, J BIOL CHEM, V260, P5808; SPIRO MJ, 1979, J BIOL CHEM, V254, P7668; SPIRO MJ, 1976, J BIOL CHEM, V251, P6400; SPIRO RG, 1983, J BIOL CHEM, V258, P9469; STROUS GJ, 1987, J BIOL CHEM, V262, P3620; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227; TURCO SJ, 1977, P NATL ACAD SCI USA, V74, P4411, DOI 10.1073/pnas.74.10.4411; VAN PN, 1989, J BIOL CHEM, V264, P17494; WADA I, 1995, J BIOL CHEM, V270, P20298, DOI 10.1074/jbc.270.35.20298; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Weng SA, 1996, ARCH BIOCHEM BIOPHYS, V325, P113, DOI 10.1006/abbi.1996.0014; WENG SA, 1993, J BIOL CHEM, V268, P25656; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; WIEST DL, 1995, EMBO J, V14, P3425, DOI 10.1002/j.1460-2075.1995.tb07348.x; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	51	245	252	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11588	11594		10.1074/jbc.271.19.11588	http://dx.doi.org/10.1074/jbc.271.19.11588			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626722	hybrid			2022-12-27	WOS:A1996UJ94400082
J	Hallenbeck, PL; Minucci, S; Lippoldt, P; Phyillaier, M; Horn, V; Ozato, K; Nikodem, VM				Hallenbeck, PL; Minucci, S; Lippoldt, P; Phyillaier, M; Horn, V; Ozato, K; Nikodem, VM			Differential 9-cis-retinoic acid-dependent transcriptional activation by murine retinoid X receptor alpha (RXR alpha) and RXR beta - Role of cell type and RXR domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; DIRECT REPEAT; DNA-BINDING; GENE; RAR; HETERODIMERIZATION; PROTEIN	The 9-cis-retinoic acid (9cRA)-inducible enhancer of the rat cellular retinol-binding protein type II gene (CRBP II) was shown to be differentially regulated by the murine retinoid X receptor alpha (RXR alpha) as compared with RXR beta. Transient transfection assays performed in NIH 3T3 fibroblast cells demonstrated that RXR alpha yielded a high level of 9cRA-dependent transcription of a reporter gene linked to the CRBP II enhancer, when compared with RXR beta. This effect was cell type-dependent, since both receptors elicited comparable transcriptional activation of the same reporter in P19 embryonal carcinoma cells, To further explore the structural determinants responsible for the differences between these two receptors, a series of chimeric receptor constructs mere made, Co-transfection assays utilizing these chimeras demonstrated that both the N terminus and the hinge region connecting the DNA binding domain with the ligand binding domain of RXR alpha were responsible for the high level of 9cRA-dependent transcription observed in MH 3T3 cells, Furthermore, the hinge region of RXR alpha was shown to be necessary to repress, in the absence of hormone, the transcriptional activation function located in the N-terminal domain of RXR alpha. These results stress the importance of functional links between different RXR domains and suggest an RXR subtype and cell type dependent specificity in the control of the 9cRA response.	NIDDK,GENET & BIOCHEM BRANCH,BETHESDA,MD 20892; NICHHD,LAB MOL GROWTH REGULAT,NIH,BETHESDA,MD 20892; DEPT VET AFFAIRS MED CTR,ORAL PATHOL RES LAB,WASHINGTON,DC 20422	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Minucci, Saverio/J-9669-2012					BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN HW, 1995, P NATL ACAD SCI USA, V92, P422, DOI 10.1073/pnas.92.2.422; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HALLENBECK PL, 1993, J BIOL CHEM, V268, P3825; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; KEAVENEY M, 1995, INDUCIBLE GENE EXPRE, V2, P182; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEE M, 1994, SCIENCE, V260, P1117; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MEDIN JA, 1994, MOL CELL ENDOCRINOL, V105, P27, DOI 10.1016/0303-7207(94)90032-9; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	25	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10503	10507		10.1074/jbc.271.18.10503	http://dx.doi.org/10.1074/jbc.271.18.10503			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631847	hybrid			2022-12-27	WOS:A1996UJ34200015
J	Jiang, YH; Yu, VC; Buchholz, F; OConnell, S; Rhodes, SJ; Candeloro, C; Xia, YR; Lusis, AJ; Rosenfeld, MG				Jiang, YH; Yu, VC; Buchholz, F; OConnell, S; Rhodes, SJ; Candeloro, C; Xia, YR; Lusis, AJ; Rosenfeld, MG			A novel family of Cys-Cys, His-Cys zinc finger transcription factors expressed in developing nervous system and pituitary gland	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTOR; THYROID-HORMONE; BINDING-PROTEIN; MAMMALIAN-CELLS; X-RECEPTOR; RXR-BETA; GENE; DNA; SEQUENCE; PURIFICATION	A screen designed to identify proteins that specifically bind to retinoic acid response elements resulted in the identification of a rat cDNA encoding a novel protein containing six Cys-Cys, His-Cys zinc fingers, This gene is expressed in a restricted fashion exhibiting distinct temporal and spatial patterns in the developing nervous system, primarily brain, spinal cord, sensory ganglia, retina, and nasal epithelia, as well as in the pituitary, and is referred to as neural zinc finger factor 1 (NZF-1), NZF-1 binds specifically to a cis-regulatory element of the beta-retinoic acid receptor (RAR beta) gene, as well as to other related DNA elements, including two in the upstream enhancer region of the mouse Pit-1 gene. In heterologous cells, NZF-1 activates transcription from promoters containing specific binding sequences and can synergize with other factors, such as Pit-1, to regulate gene expression, These results suggest that NZF-1 may exert regulatory roles in the developing and mature nervous system and in the pituitary gland, Identification of a second mouse gene highly homologous to NZF-1, encoded by a distinct genomic locus, reveals a dispersed gene family encoding proteins containing Cys-Cys, His-Cys motifs.	UNIV CALIF SAN DIEGO,SCH MED,HOWARD HUGHES MED INST,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Buchholz, Frank/B-4700-2017; Yu, Victor/A-7899-2015	Buchholz, Frank/0000-0002-4577-3344; Yu, Victor/0000-0003-3270-4734				BERG JM, 1990, J BIOL CHEM, V265, P6513; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HENDERSON LE, 1981, J BIOL CHEM, V256, P8400; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KIM JG, 1992, MOL CELL BIOL, V12, P5632, DOI 10.1128/MCB.12.12.5632; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MILLER J, 1985, EMBO J, V4, P2961; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; WARDEN CH, 1993, GENOMICS, V18, P295, DOI 10.1006/geno.1993.1469; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	30	57	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10723	10730		10.1074/jbc.271.18.10723	http://dx.doi.org/10.1074/jbc.271.18.10723			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631881	hybrid			2022-12-27	WOS:A1996UJ34200049
J	Tozzo, E; Kahn, BB; Pilch, PF; Kandror, KV				Tozzo, E; Kahn, BB; Pilch, PF; Kandror, KV			Glut4 is targeted to specific vesicles in adipocytes of transgenic mice overexpressing Glut4 selectively in adipose tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-STIMULATED TRANSLOCATION; REGULATABLE GLUCOSE TRANSPORTER; ISOLATED RAT ADIPOCYTES; INTRACELLULAR SEQUESTRATION; SUBCELLULAR TRAFFICKING; NH2 TERMINUS; 3T3-L1 CELLS; PROTEINS; IDENTIFICATION; LOCALIZATION	Adipocytes of transgenic mice overexpressing Glut4 selectively in adipose tissue (Shepherd, P. R., Gnudi, L., Tozzo, E., Yang, H., Leach, F., and Kahn, B. B. (1993) J. Biol. Chem, 268, 22243-22246) have 15-20-fold more Glut4 than normal adipocytes. To study compartmentalization of intracellular Glut4 in these cells, we fractionated light microsomes prepared from transgenic and normal adipocytes in velocity and density sucrose gradients, Glut4-containing intracellular membranes from both cell types have a specific and narrow distribution in these gradients, i.e. behave as homogeneous vesicles with identical sedimentation coefficients and different buoyant densities, Immunoadsorption of Glut4-containing vesicles with covalently immobilized monoclonal anti-transporter antibody demonstrated that the total polypeptide composition of these vesicles from transgenic and normal cells was identical, with the exception of Glut4 itself, which was much more abundant in the transgenic cells. Both preparations also had comparable levels of secretory carrier membrane proteins and of aminopeptidase activity (gp160). Glut4-containing vesicles from both normal and transgenic adipocytes excluded Glut1, which in both cell types formed a different vesicle population, Thus, even under conditions of high level overexpression, Glut4 is still specifically targeted to the same unique type of structurally defined insulin sensitive vesicles as in normal cells.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,DIABET UNIT,BOSTON,MA 02215	Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School				Pilch, Paul/0000-0003-1997-0499; Kandror, Konstantin/0000-0002-8601-9313	NIDDK NIH HHS [P30 DK-46200, DK-30425, R01 DK043051, DK-43051] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030425, R01DK043051, P30DK046200, R37DK043051] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASANO T, 1992, J BIOL CHEM, V267, P19636; BELL GI, 1993, J BIOL CHEM, V268, P19161; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; CZECH MP, 1993, J BIOL CHEM, V268, P9187; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; JAMES DE, 1994, J CELL BIOL, V126, P1123, DOI 10.1083/jcb.126.5.1123; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1995, J CELL BIOL, V129, P999, DOI 10.1083/jcb.129.4.999; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Little G H, 1976, Methods Enzymol, V45, P495; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; PIPER RC, 1992, J CELL BIOL, V117, P729, DOI 10.1083/jcb.117.4.729; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; SATOH S, 1993, J BIOL CHEM, V268, P17820; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; THOIDIS G, 1993, J BIOL CHEM, V268, P11691; TOZZO E, 1995, AM J PHYSIOL-ENDOC M, V268, pE956, DOI 10.1152/ajpendo.1995.268.5.E956; VERHEY KJ, 1993, J CELL BIOL, V123, P137, DOI 10.1083/jcb.123.1.137; YANG J, 1993, J BIOL CHEM, V268, P4600; YANG J, 1992, J BIOL CHEM, V267, P10393; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	36	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10490	10494		10.1074/jbc.271.18.10490	http://dx.doi.org/10.1074/jbc.271.18.10490			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631845	hybrid			2022-12-27	WOS:A1996UJ34200013
J	Bouziane, M; Cherny, DI; Mouscadet, JF; Auclair, C				Bouziane, M; Cherny, DI; Mouscadet, JF; Auclair, C			Alternate strand DNA triple helix-mediated inhibition of HIV-1 U5 long terminal repeat integration in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; INVITRO ASSAY; DUPLEX DNA; RECOGNITION; PROTEIN; OLIGONUCLEOTIDES; OXAZOLOPYRIDOCARBAZOLE; ANALOGS; BINDING	Integration of the human immunodeficiency virus (HIV) DNA into the host genome is an obligatory process in the replicative life cycle of the virus. This event is mediated in vitro by integrase, a viral protein which binds to specific sequences located on both extremities of the DNA long terminal repeats (LTRs). These sites are highly conserved in all HIV genomes and thus provide potential targets for the selective inhibition of integration. The integrase-binding site located on the HIV-1 U5 LTR end contains two adjacent purine tracts on opposite strands, 5'... GGAAAATCTCT-3'/3'-CCTTTTA- GAGA.,,5', in parallel orientations. A single strand oligonucleotide 5'-GGTTTTTGTGT-3' was designed to associate with these tracts via its ability to form a continuous alternate strand DNA tripler. Under neutral pH and physiological temperature, the oligonucleotide, tagged with an intercalator chromophore oxazolopyridocarbazole, formed a stable tripler with the target DNA. The occurrence of this unusual tripler was demonstrated by both DNase I footprinting and electron microscopy. The tripler inhibits the two steps of the integrase-mediated reactions, namely, the endonucleolytic cleavage of the dinucleotide 5'-GT-3' from the 3' end of the integration substrate and the integration of the substrate into the heterologous target DNA. The midpoints for both inhibition reactions were observed at oligonucleotide concentrations of 50-100 nM. We believe that these results open new possibilities for the specific targeting of viral DNA LTR ends with the view of inhibiting integration under physiological conditions.	INST GUSTAVE ROUSSY, LAB PHYSICOCHIM & PHARMACOL MACROMOL BIOL, CNRS URA 147, F-94805 VILLEJUIF, FRANCE	UNICANCER; Gustave Roussy								AUCLAIR C, 1984, J MED CHEM, V27, P1161, DOI 10.1021/jm00375a013; BEAL PA, 1992, J AM CHEM SOC, V114, P4979; BROWN PO, 1990, CURR TOP MICROBIOL, V157, P19; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; CARTEAU S, 1993, ARCH BIOCHEM BIOPHYS, V300, P756, DOI 10.1006/abbi.1993.1105; CARTEAU S, 1994, BIOCHEM PHARMACOL, V47, P1821, DOI 10.1016/0006-2952(94)90311-5; CARTEAU S, 1993, ARCH BIOCHEM BIOPHYS, V305, P606, DOI 10.1006/abbi.1993.1468; CARTEAU S, 1993, BIOCHEM BIOPH RES CO, V192, P1409, DOI 10.1006/bbrc.1993.1573; CAZENAVE C, 1991, ANTISENSE NUCLEIC AC, P47; Cherney Dmitry I., 1994, Journal of Molecular Recognition, V7, P171, DOI 10.1002/jmr.300070304; CHERNY DI, 1993, J MOL BIOL, V230, P379, DOI 10.1006/jmbi.1993.1154; CRAIGIE R, 1991, NUCLEIC ACIDS RES, V19, P2729, DOI 10.1093/nar/19.10.2729; CUSHMAN M, 1992, BIOCHEM BIOPH RES CO, V185, P85, DOI 10.1016/S0006-291X(05)80958-1; CUSHMAN M, 1995, J MED CHEM, V38, P443, DOI 10.1021/jm00003a007; DELAIN E, 1992, MICROSC MICROANAL M, V3, P175, DOI 10.1051/mmm:0199200302-3017500; Delain E, 1995, VISUALIZATION NUCL A, P35; DEMIDOV VV, 1994, NUCLEIC ACIDS RES, V22, P5218, DOI 10.1093/nar/22.24.5218; DUBOCHET J, 1971, J ULTRA MOL STRUCT R, V35, P147, DOI 10.1016/S0022-5320(71)80148-X; FESEN MR, 1993, P NATL ACAD SCI USA, V90, P2399, DOI 10.1073/pnas.90.6.2399; GAUTIER C, 1987, NUCLEIC ACIDS RES, V15, P6625, DOI 10.1093/nar/15.16.6625; HORNE DA, 1990, J AM CHEM SOC, V112, P2435, DOI 10.1021/ja00162a063; JAYASENA SD, 1993, BIOCHEMISTRY-US, V32, P2800, DOI 10.1021/bi00062a010; JAYASENA SD, 1992, NUCLEIC ACIDS RES, V20, P5279, DOI 10.1093/nar/20.20.5279; JAYASENA SD, 1992, BIOCHEMISTRY-US, V31, P320, DOI 10.1021/bi00117a002; LAFEMINA RL, 1995, ANTIMICROB AGENTS CH, V39, P320, DOI 10.1128/AAC.39.2.320; MAZUMDER A, 1995, AIDS RES HUM RETROV, V11, P115, DOI 10.1089/aid.1995.11.115; MOUSCADET JF, 1994, J BIOL CHEM, V269, P21635; MOUSCADET JF, 1994, BIOCHEMISTRY-US, V33, P4187, DOI 10.1021/bi00180a011; OLIVAS WM, 1994, BIOCHEMISTRY-US, V33, P983, DOI 10.1021/bi00170a017; ONO A, 1991, BIOCHEMISTRY-US, V30, P9914, DOI 10.1021/bi00105a015; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; SHERMAN PA, 1992, J VIROL, V66, P3593, DOI 10.1128/JVI.66.6.3593-3601.1992; SUBRA F, 1993, BIOCHEM PHARMACOL, V45, P93, DOI 10.1016/0006-2952(93)90381-6; SUN JS, 1991, CR ACAD SCI III-VIE, V313, P585; SUN JS, 1995, JERUS SYM Q, V27, P267; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; TSO POP, 1992, ANN NY ACAD SCI, V660, P159; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; WASHBROOK E, 1994, NUCLEIC ACIDS RES, V22, P3977, DOI 10.1093/nar/22.19.3977; WASHBROOK E, 1994, BIOCHEM J, V301, P569, DOI 10.1042/bj3010569; WILLIAMSON JR, 1990, NUCLEIC ACIDS RES, V18, P379, DOI 10.1093/nar/18.2.379	41	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10359	10364		10.1074/jbc.271.17.10359	http://dx.doi.org/10.1074/jbc.271.17.10359			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626607	hybrid			2022-12-27	WOS:A1996UG25700079
J	Tang, W; Bunting, M; Zimmerman, GA; McIntyre, TM; Prescott, SM				Tang, W; Bunting, M; Zimmerman, GA; McIntyre, TM; Prescott, SM			Molecular cloning of a novel human diacylglycerol kinase highly selective for arachidonate-containing substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; ENDOTHELIAL-CELLS; GROWTH-FACTOR; ZINC-FINGER; ACID; EXPRESSION; METABOLISM; SEQUENCE; MOTIFS	Diacylglycerol (DAG) is a second messenger that activates protein kinase C and also occupies a central role in phospholipid biosynthesis. Conversion of DAG to phosphatidic acid by DAG kinase regulates the amount of DAG and the route it takes. We used degenerate primers to amplify polymerase chain reaction products from cDNA derived from human endothelial cells. A product with a novel sequence was identified and used to clone a 2,6-kilobase cDNA from an endothelial cell library. When transfected with a truncated version of this cDNA, COS-7 cells had a marked increase in DAG kinase activity, which demonstrated clear selectivity for arachidonoyl-containing species of diacylglycerol. The open reading frame of this clone has 567 residues with a predicted protein of 64 kDa. This enzyme, which we designated DGK epsilon, has two distinctive zinc finger-like structures in its N-terminal region, but does not contain the E-F hand motifs found in several other mammalian DGKs. The catalytic domain of DGK epsilon, which is related to other DGKs, contains two ATP-binding motifs. Northern blotting demonstrated that DGK epsilon is expressed predominantly in testis. This unique diacylglycerol kinase may terminate signals transmitted through arachidonoyl-DAG or may contribute to the synthesis of phospholipids with defined fatty acid composition.	UNIV UTAH, PROGRAM HUMAN MOL BIOL & GENET, NORA ECCLES HARRISON CARDIOVASC RES & TRAINING IN, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT INTERNAL MED, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT PATHOL, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT BIOCHEM, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NATIONAL CANCER INSTITUTE [R01CA059548] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL050153] Funding Source: NIH RePORTER; NCI NIH HHS [CA59548] Funding Source: Medline; NHLBI NIH HHS [HL50153] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMED S, 1993, J BIOL CHEM, V268, P10709; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; Holub B J, 1978, Adv Lipid Res, V16, P1; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KATO M, 1987, J BIOL CHEM, V262, P5696; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MACDONALD ML, 1988, J BIOL CHEM, V263, P1584; MACDONALD ML, 1988, J BIOL CHEM, V263, P1575; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; PREISS J, 1986, J BIOL CHEM, V261, P8597; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; SEVERSON DL, 1986, BIOCHEM CELL BIOL, V64, P976, DOI 10.1139/o86-130; WALSH JP, 1994, J BIOL CHEM, V269, P21155; WHATLEY RE, 1993, J BIOL CHEM, V268, P16130; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; ZIMMERMAN GA, 1990, METHOD ENZYMOL, V187, P520	25	147	154	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10237	10241		10.1074/jbc.271.17.10237	http://dx.doi.org/10.1074/jbc.271.17.10237			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626589	hybrid			2022-12-27	WOS:A1996UG25700061
J	Post, GR; Goldstein, D; Thuerauf, DJ; Glembotski, CC; Brown, JH				Post, GR; Goldstein, D; Thuerauf, DJ; Glembotski, CC; Brown, JH			Dissociation of p44 and p42 mitogen-activated protein kinase activation from receptor-induced hypertrophy in neonatal rat ventricular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN LIGHT CHAIN-2; MYOCARDIAL-CELL HYPERTROPHY; ATRIAL-NATRIURETIC-FACTOR; CARDIAC GENE-EXPRESSION; ADRENERGIC-STIMULATION; SIGNAL-TRANSDUCTION; GROWTH-FACTORS; MAP KINASE; PARACRINE MECHANISM; PATHWAYS	In response to hormones and mechanical stretch, neonatal rat ventricular myocytes exhibit a hypertrophic response that is characterized by induction of cardiac-specific genes and increased myocardial cell size. Hypertrophic stimuli also activate mitogen-activated protein kinase (MAPK), an enzyme thought to play a central role in the regulation of cell growth and differentiation. To determine if MAPK activation is sufficient for acquisition of the molecular and morphological features of cardiac hypertrophy we compared four agonists that stimulate G protein-coupled receptors. Whereas phenylephrine and endothelin transactivate cardiac-specific promoter/luciferase reporter genes, increase atrial natriuretic factor (ANF) expression, and promote myofilament organization, neither carbachol nor ATP induces these responses. Interestingly, all four agonists activate both the p42 and the p44 isoforms of MAPK. Furthermore, the kinetics of MAPK activation are not different for the hypertrophic agonist phenylephrine and the nonhypertrophic agonist carbachol. Transient transfection of myocytes with dominant-interfering mutants of p42 and p44 MAPK failed to block phenylephrine-induced ANF expression, although Ras-induced gene expression was inhibited by expression of the mutant MAPK constructs. Moreover, PD 098059, an inhibitor of MAPK kinase, blocked phenylephrine-stimulated MAPK activity but not ANF reporter gene expression. Thus, MAPK activation is not sufficient for G protein receptor-mediated induction of cardiac cell growth and gene expression and is apparently not required for transcriptional activation of the ANF gene.	UNIV CALIF SAN DIEGO, SCH MED, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; SAN DIEGO STATE UNIV, INST MOLEC BIOL, SAN DIEGO, CA 92182 USA; SAN DIEGO STATE UNIV, DEPT BIOL, SAN DIEGO, CA 92182 USA	University of California System; University of California San Diego; California State University System; San Diego State University; California State University System; San Diego State University					NHLBI NIH HHS [HL28143, HL46345] Funding Source: Medline; NINDS NIH HHS [NS 25037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028143, R37HL028143, P01HL046345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BROWN JH, 1992, TRENDS CARDIOVAS MED, V2, P209, DOI 10.1016/1050-1738(92)90026-O; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CLERK A, 1994, J BIOL CHEM, V269, P32848; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EDWARDS DR, 1994, TRENDS PHARMACOL SCI, V15, P239, DOI 10.1016/0165-6147(94)90318-2; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KAMESHITA I, 1989, LIFE SCI, V52, P521; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LEE HR, 1988, J BIOL CHEM, V263, P7352; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCDONOUGH PM, 1993, AM J PHYSIOL, V264, pH625, DOI 10.1152/ajpheart.1993.264.2.H625; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAMIREZ MT, 1995, J BIOL CHEM, V270, P8446, DOI 10.1074/jbc.270.15.8446; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SADOSHIMA J, 1995, CIRC RES, V76, P1; SCHNEIDER MD, 1990, CIRCULATION, V81, P1443, DOI 10.1161/01.CIR.81.5.1443; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; STEINBERG SF, 1989, J PHARMACOL EXP THER, V250, P1141; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069; ZHENG JS, 1994, CIRC RES, V74, P1034, DOI 10.1161/01.RES.74.6.1034	42	155	157	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8452	8457		10.1074/jbc.271.14.8452	http://dx.doi.org/10.1074/jbc.271.14.8452			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626545	hybrid			2022-12-27	WOS:A1996UD60000085
J	Mikusova, K; Mikus, M; Besra, GS; Hancock, I; Brennan, PJ				Mikusova, K; Mikus, M; Besra, GS; Hancock, I; Brennan, PJ			Biosynthesis of the linkage region of the mycobacterial cell wall	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEICHOIC-ACID; STRUCTURAL FEATURES; PEPTIDOGLYCAN; TUBERCULOSIS; ARABINOGALACTAN; SMEGMATIS; ANTIGENICITY; TUNICAMYCIN; INHIBITION; NOCARDIA	The ''core'' structure of the cell wall of Mycobacterium and related genera is unique among prokaryotes, consisting of a covalently linked complex of mycolic acids, D-arabinan and D-galactan (mycolylarabinogalactan, mAG), which, in turn, is linked to peptidoglycan via a special linkage unit, -alpha-L-Rhap(1-->3)-D-GlcNAc-P-. Little is known of the biosynthesis of this complex, although it is the site of action of several common anti-tuberculosis drugs. Isolated cell membranes of Mycobacterium smegmatis catalyzed the incorporation of [C-14]GlcNAc from UDP-[C-14]GlcNAc into two glycolipids (1 and 2) and of [C-14]Rha from TDP-[C-14]Rha into glycolipid 2. These products were characterized as polyprenol-P-P-GlcNAc (glycolipid 1) and polyprenol-P-P-GlcNAc-Rha (glycolipid 2) based on sensitivity of synthesis to tunicamycin, chromatographic characterization of the products of mild acid hydrolysis, and mass spectral analysis of the glycosyl and polyprenyl units. Glycolipids 1 and 2 were shown to be precursors of the linkage unit in polymerized cell wall. The inclusion in the assays of UDP-[C-14]Galp and a preparation of cell walls allowed the incorporation of [C-14]Gal into two further glycolipids (3 and 4). Preliminary evidence indicates a precursor-product relationship among glycolipids 1, 2, 3, and 4. Thus, the first steps in the biosynthesis of the mycobacterial cell wall involve synthesis of the linkage disaccharide on a polyprenyl-P-P carrier followed by growth of the galactan unit. Assays are thus defined for the screening of new anti-tuberculosis drugs active against cell wall synthesis.	COLORADO STATE UNIV, DEPT MICROBIOL, FT COLLINS, CO 80523 USA; UNIV NEWCASTLE UPON TYNE, DEPT MICROBIOL, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND	Colorado State University; Newcastle University - UK			Mikusova, Katarina/I-3622-2014	Besra, Gurdyal/0000-0002-5605-0395	NIAID NIH HHS [AI 30189, AI 18357] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI018357, R01AI018357, U01AI030189, R37AI018357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Archibald A. R., 1993, P381; Aspinall GO, 1995, ADV CARBOHYD CHEM BI, V51, P169, DOI 10.1016/S0065-2318(08)60194-8; Ballou C, 1976, Adv Microb Physiol, V14, P93, DOI 10.1016/S0065-2911(08)60227-1; BESRA GS, 1995, BIOCHEMISTRY-US, V34, P4257, DOI 10.1021/bi00013a015; BESRA GS, 1994, P NATL ACAD SCI USA, V91, P12735, DOI 10.1073/pnas.91.26.12735; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; COLEY J, 1978, FEBS LETT, V88, P1, DOI 10.1016/0014-5793(78)80594-8; DAFFE M, 1990, J BIOL CHEM, V265, P6734; DAFFE M, 1993, CARBOHYD RES, V249, P383, DOI 10.1016/0008-6215(93)84102-C; DAWSON RMC, 1959, DATA BIOCH RES, P470; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; DITTMER JC, 1964, J LIPID RES, V5, P126; DUNPHY PJ, 1966, CHEM IND-LONDON, P1549; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUJIOKA M, 1985, J GEN MICROBIOL, V131, P1323; HANCOCK IC, 1976, FEBS LETT, V69, P75, DOI 10.1016/0014-5793(76)80657-6; HIRSCHFIELD GR, 1990, J BACTERIOL, V172, P1005, DOI 10.1128/jb.172.2.1005-1013.1990; KANETSUNA F, 1970, BIOCHIM BIOPHYS ACTA, V208, P434; KNO SC, 1974, BIOCHEM BIOPH RES CO, V58, P287; KOJIMA N, 1983, J BIOL CHEM, V258, P9043; KOJIMA N, 1985, J BACTERIOL, V161, P299, DOI 10.1128/JB.161.1.299-306.1985; LEHLE L, 1980, EUR J BIOCHEM, V109, P589, DOI 10.1111/j.1432-1033.1980.tb04832.x; LIU TY, 1967, J BIOL CHEM, V242, P471; LUNDBLAD A, 1975, BIOMED MASS SPECTROM, V2, P285, DOI 10.1002/bms.1200020602; MCARTHUR HAI, 1980, FEBS LETT, V111, P317, DOI 10.1016/0014-5793(80)80818-0; MCNEIL M, 1990, J BIOL CHEM, V265, P18200; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; MCNEIL M, 1987, J BIOL CHEM, V262, P2630; MCNEIL M, 1989, METHOD ENZYMOL, V179, P215; MCNEIL MR, 1991, RES MICROBIOL, V142, P451, DOI 10.1016/0923-2508(91)90120-Y; MIKUSOVA K, 1995, ANTIMICROB AGENTS CH, V39, P2484, DOI 10.1128/AAC.39.11.2484; OKAZAKI R, 1962, J BIOL CHEM, V237, P3014; SARVAS M, 1971, J BACTERIOL, V105, P1063, DOI 10.1128/JB.105.3.1063-1072.1971; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SCHULTZ J, 1974, ARCH BIOCHEM BIOPHYS, V160, P311, DOI 10.1016/S0003-9861(74)80039-1; SCHULTZ JC, 1975, BIOCHIM BIOPHYS ACTA, V381, P175, DOI 10.1016/0304-4165(75)90199-3; STEVENSON G, 1994, J BACTERIOL, V176, P4144, DOI 10.1128/JB.176.13.4144-4156.1994; TAKATSUKI A, 1975, AGR BIOL CHEM TOKYO, V39, P2089, DOI 10.1080/00021369.1975.10861914; TAKAYAMA K, 1973, BIOCHIM BIOPHYS ACTA, V316, P212, DOI 10.1016/0005-2760(73)90011-8; TAKAYAMA K, 1970, J BIOL CHEM, V245, P6251; TAKAYAMA K, 1975, J LIPID RES, V16, P308; TREJO AG, 1970, BIOCHEM J, V117, P637, DOI 10.1042/bj1170637; WARD JB, 1977, FEBS LETT, V78, P151, DOI 10.1016/0014-5793(77)80294-9; WHEELER PR, 1993, BIOCHIM BIOPHYS ACTA, V1167, P182, DOI 10.1016/0005-2760(93)90160-B; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328; YAMAMORI S, 1978, J BIOL CHEM, V254, P6516	48	130	137	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7820	7828		10.1074/jbc.271.13.7820	http://dx.doi.org/10.1074/jbc.271.13.7820			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631826	hybrid			2022-12-27	WOS:A1996UC77400094
J	Ramotar, D; Demple, B				Ramotar, D; Demple, B			Functional expression of Escherichia coli endonuclease IV in apurinic endonuclease-deficient yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPAIR ENZYME; APYRIMIDINIC ENDONUCLEASE; EXONUCLEASE-III; IONIZING-RADIATION; HOMOLOGY; DAMAGE; CDNA; GENE; APN1; SEQUENCE	Saccharomyces cerevisiae Apn1 and Escherichia coli endonuclease IV are homologous enzymes that initiate the repair of abasic (AP) sites or oxidative DNA strand breaks. Yeast lacking Apn1 (apn1(-)) are hypersensitive to simple alkylating agents (which produce many AP sites) and to oxidants and display an elevated spontaneous mutation rate due to endogenous damages. We explored whether the prokaryotic repair enzyme could substitute for its yeast counterpart. Plasmid constructs were generated that expressed endonuclease IV at 1/20 to 10-fold the AP endonuclease activity of wild-type yeast; some of these plasmids expressed hybrid forms of endonuclease IV equipped with the C-terminal nuclear localization signal of Apn1. Although hybrid endonuclease IV-Apn1 (but not native endonuclease IV) was selectively localized to the yeast nucleus, expression of this chimeric protein at 25% of the normal Apn1 level did not restore alkylation or oxidant resistance to apn1(-) yeast, but it did partially counteract the mutator phenotype of apn1(-) yeast. Expression of either the hybrid protein or native endonuclease IV at similar to 10 times wild-type Apn1 levels restored wild-type resistance to methyl methanesulfonate and near-wild-type H2O2 resistance. High level expression of native endonuclease IV also restored the normal spontaneous mutation rate to apn1(-) yeast. These data place limits on the amounts of AP endonuclease activity necessary for repair of DNA damages caused by both endogenous and environmental agents and point to a direct role of spontaneous AP sites as potentially mutagenic lesions.	HARVARD UNIV, SCH PUBL HLTH, DEPT MOLEC & CELLULAR TOXICOL, BOSTON, MA 02115 USA; CHUL, Ste Foy, PQ G1V 4G2, CANADA	Harvard University; Harvard T.H. Chan School of Public Health; Laval University								BABIYCHUK E, 1994, P NATL ACAD SCI USA, V91, P3299, DOI 10.1073/pnas.91.8.3299; BERNELOTMOENS C, 1989, NUCLEIC ACIDS RES, V17, P587, DOI 10.1093/nar/17.2.587; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; DEMPLE B, 1986, P NATL ACAD SCI USA, V83, P7731, DOI 10.1073/pnas.83.20.7731; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GERSHONI JM, 1983, ANAL BIOCHEM, V131, P1, DOI 10.1016/0003-2697(83)90128-8; HARING M, 1994, NUCLEIC ACIDS RES, V22, P2010, DOI 10.1093/nar/22.11.2010; HENNER WD, 1983, J BIOL CHEM, V258, P5198; HONORE N, 1993, MOL MICROBIOL, V7, P207, DOI 10.1111/j.1365-2958.1993.tb01112.x; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; IDE H, 1994, BIOCHEMISTRY-US, V33, P7842, DOI 10.1021/bi00191a011; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; JOHNSON AW, 1988, J BIOL CHEM, V263, P18017; JOHNSON AW, J BIOL CHEM, V263, P18006; KUNZ BA, 1994, P NATL ACAD SCI USA, V91, P8165, DOI 10.1073/pnas.91.17.8165; LEVIN JD, 1988, J BIOL CHEM, V263, P8066; LEVIN JD, 1990, NUCLEIC ACIDS RES, V18, P5069, DOI 10.1093/nar/18.17.5069; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; PUYET A, 1989, J BACTERIOL, V171, P2278, DOI 10.1128/jb.171.5.2278-2286.1989; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; RAMOTAR D, 1993, J BIOL CHEM, V268, P20533; RAMOTAR D, 1991, MOL MICROBIOL, V5, P149, DOI 10.1111/j.1365-2958.1991.tb01835.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P1087, DOI 10.1093/nar/19.5.1087; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANDER M, 1991, NUCLEIC ACIDS RES, V19, P4523, DOI 10.1093/nar/19.16.4523; SEKI S, 1991, J BIOL CHEM, V266, P20797; Sherman F., 1983, METHODS YEAST GENETI; Von Borstel R C, 1978, Methods Cell Biol, V20, P1, DOI 10.1016/S0091-679X(08)62005-1; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; WARNER HR, 1980, P NATL ACAD SCI-BIOL, V77, P4602, DOI 10.1073/pnas.77.8.4602; WEI X, 1993, P NATL ACAD SCI USA, V90, P2117, DOI 10.1073/pnas.90.6.2117; Wilson DM, 1995, NUCLEIC ACIDS RES, V23, P5027	40	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7368	7374		10.1074/jbc.271.13.7368	http://dx.doi.org/10.1074/jbc.271.13.7368			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631759	hybrid			2022-12-27	WOS:A1996UC77400027
J	Hellqvist, M; Mahlapuu, M; Samuelsson, L; Enerback, S; Carlsson, P				Hellqvist, M; Mahlapuu, M; Samuelsson, L; Enerback, S; Carlsson, P			Differential activation of lung-specific genes by two forkhead proteins, FREAC-1 and FREAC-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING MOTIF; TRANSCRIPTION FACTORS; HEAD DOMAIN; ALVEOLAR RHABDOMYOSARCOMA; CELL LINE; CC10 GENE; EXPRESSION; FAMILY; ELEMENTS; IDENTIFICATION	We describe the cDNA sequences for two human transcription factors, Forkhead RElated ACtivator (FREAC)-1 and -2, that belong to the forkhead family of eukaryotic DNA binding proteins, EREAC-1 and -2 are encoded by distinct genes, are almost identical within their DNA binding domains and in the COOH termini, but are otherwise divergent. Cotransfections with a reporter carrying FREAC binding sites showed that both proteins are transcriptional activators, and deletions located the activation domains to the COOH-terminal side of the forkhead domains. Expression of FREAC-1 and FREAC-2 is restricted to lung and placenta. We show that the promoters of genes for lung-specific proteins such as pulmonary surfactant proteins A, B, and C (SPA, SPB, and SPC) and the Clara cell 10-kDa protein (CC10) contain potential binding sites for FREAC-1 and FREAC-2, DNaseI footprinting verified that FREAC proteins bind to the predicted sites in the CC10 and SPB promoters. While an SPB promoter construct could be transactivated by both FREAC-1 and EREAC-2, CC10 was only activated by FREAC-1. Efficient activation of CC10 by FREAC-1 is shown to be specific for a lung cell line with Clara cell characteristics (H441) and to involve a region of the FREAC-1 protein unable to activate in other cell types.	GOTHENBURG UNIV,LUNDBERG LAB,DEPT MOLEC BIOL,S-41390 GOTHENBURG,SWEDEN	University of Gothenburg			Carlsson, Peter/B-5551-2008	Carlsson, Peter/0000-0001-6535-5927; Mahlapuu, Margit/0000-0001-8740-8874				ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; AVRAHAM KB, 1995, GENOMICS, V25, P388, DOI 10.1016/0888-7543(95)80038-N; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BINGLE CD, 1995, BIOCHEM J, V308, P197, DOI 10.1042/bj3080197; BINGLE CD, 1993, BIOCHEM J, V295, P227, DOI 10.1042/bj2950227; BOHINSKI RJ, 1993, J BIOL CHEM, V268, P11160; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BORK P, 1992, PROTEIN SCI, V1, P1677, DOI 10.1002/pro.5560011216; BRENNAN RG, 1993, CELL, V74, P773, DOI 10.1016/0092-8674(93)90456-Z; CARLSSON P, 1989, GENE, V77, P113, DOI 10.1016/0378-1119(89)90365-X; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEVIDENCE DE, 1994, DEV BIOL, V166, P195, DOI 10.1006/dbio.1994.1307; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; COSTA RH, 1994, LIVER GENE TRANSCRIP, P183; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GROSSNIKLAUS U, 1992, GENE DEV, V6, P1030, DOI 10.1101/gad.6.6.1030; HACKER U, 1992, P NATL ACAD SCI USA, V89, P8754, DOI 10.1073/pnas.89.18.8754; HACKETT BP, 1995, P NATL ACAD SCI USA, V92, P4249, DOI 10.1073/pnas.92.10.4249; KAESTNER KH, 1993, P NATL ACAD SCI USA, V90, P7628, DOI 10.1073/pnas.90.16.7628; KAUFMANN E, 1995, J MOL BIOL, V248, P239, DOI 10.1006/jmbi.1995.0218; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; Larsson C, 1995, GENOMICS, V30, P464, DOI 10.1006/geno.1995.1266; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NICHOLS WW, 1977, SCIENCE, V196, P60, DOI 10.1126/science.841339; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; PIERROU S, 1995, ANAL BIOCHEM, V229, P99, DOI 10.1006/abio.1995.1384; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; SAWAYA PL, 1993, MOL CELL BIOL, V13, P3860, DOI 10.1128/MCB.13.7.3860; SAWAYA PL, 1994, J BIOL CHEM, V269, P22211; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SHAPIRO DN, 1993, CANCER RES, V53, P5108; STRAHLE U, 1993, GENE DEV, V7, P1436, DOI 10.1101/gad.7.7b.1436; STRIPP BR, 1992, J BIOL CHEM, V267, P14703; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7	47	74	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4482	4490						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626802				2022-12-27	WOS:A1996TW96000080
J	Lee, JH; Jang, SI; Yang, JM; Markova, NG; Steinert, PM				Lee, JH; Jang, SI; Yang, JM; Markova, NG; Steinert, PM			The proximal promoter of the human transglutaminase 3 gene - Stratified squamous epithelial-specific expression in cultured cells is mediated by binding of Sp1 and ets transcription factors to a proximal promoter element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL TRANSGLUTAMINASE; HAIR FOLLICLE TRANSGLUTAMINASES; AMINO-ACID-SEQUENCE; KERATINOCYTE TRANSGLUTAMINASE; TRANSGENIC MICE; RETINOIC ACID; GUINEA-PIG; PROTRANSGLUTAMINASE-E; ENVELOPE PRECURSOR; HUMAN LORICRIN	The transglutaminase 3 enzyme is expressed during the late stages of the terminal differentiation of the epidermis and in certain cell types of the hair follicle. The enzyme is thought to be critically involved in the crosslinking of structural proteins and in the formation of the cornified cell envelope, thereby contributing to rigid structures that play vital roles in shape determination and/or barrier functions. To explore the mechanisms regulating the expression of the transglutaminase 3 gene (TGM3), 3.0 kilobase pairs of sequences upstream from the transcription start site were assessed for their ability to control the expression of a chloramphenicol acetyltransferase reporter gene. Deletion analyses in transiently transfected epidermal keratinocytes defined sequences between -126 and -91 as the proximal promoter region of the gene, and which can confer epithelial-specific expression to the TGM3 gene in vitro. Mutation and DNA-protein binding analyses indicated that a complex interaction between adjacent Sp1- and ets-like recognition motifs with their cognate binding factors is required for the function of the TGM3 promoter. As these TGM3 sequences can confer promoter/enhancer activity to reporter genes at a level comparable to the powerful SV40 promoter, they may be useful for gene therapy in keratinocytes.	NIAMS, NIH, SKIN BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)								ANSIEAU S, 1993, GENOMICS, V18, P537, DOI 10.1016/S0888-7543(11)80010-8; AUBER L., 1952, TRANS ROY SOC EDINBURGH, V62, P191; Ausubel FM, 1991, CURRENT PROTOCOLS MO; BIRBECK MSC, 1957, J BIOPHYS BIOCHEM CY, V3, P203, DOI 10.1083/jcb.3.2.203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; CANDI E, 1995, J BIOL CHEM, V270, P26382, DOI 10.1074/jbc.270.44.26382; CARDINALI M, 1990, CANCER RES, V50, P8010; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; CHANG SK, 1986, J BIOL CHEM, V261, P8112; CHUNG SI, 1972, ANN NY ACAD SCI, V202, P240, DOI 10.1111/j.1749-6632.1972.tb16338.x; CHUNG SI, 1972, P NATL ACAD SCI USA, V69, P303, DOI 10.1073/pnas.69.2.303; CURTIS CG, 1974, BIOCHEMISTRY-US, V13, P3257, DOI 10.1021/bi00713a012; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; DITTMER J, 1994, J BIOL CHEM, V269, P21428; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; FIETZ MJ, 1993, J CELL BIOL, V121, P855, DOI 10.1083/jcb.121.4.855; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GENTILE V, 1991, J BIOL CHEM, V266, P478; GENTILE V, 1992, J CELL BIOL, V56, P170; GRECO MA, 1995, J INVEST DERMATOL, V104, P204, DOI 10.1111/1523-1747.ep12612759; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; JANG SI, 1995, J INVEST DERMATOL, V104, P676; JETTEN AM, 1986, J BIOL CHEM, V261, P5097; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM IG, 1993, J BIOL CHEM, V268, P12682; KIM IG, 1992, J BIOL CHEM, V267, P7710; KIM IG, 1994, J INVEST DERMATOL, V103, P137, DOI 10.1111/1523-1747.ep12392470; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; LEE SC, 1993, J BIOL CHEM, V268, P12164; LICHTI U, 1988, CANCER RES, V48, P74; LICHTI U, 1991, ANN NY ACAD SCI, V642, P82; LICHTI U, 1985, J BIOL CHEM, V260, P1422; LIEW FM, 1992, EXP CELL RES, V202, P310, DOI 10.1016/0014-4827(92)90080-R; LU S, 1995, J BIOL CHEM, V270, P9748, DOI 10.1074/jbc.270.17.9748; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARKOVA NG, 1993, MOL CELL BIOL, V13, P613, DOI 10.1128/MCB.13.1.613; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; NEGI M, 1985, J INVEST DERMATOL, V85, P75, DOI 10.1111/1523-1747.ep12275357; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OGAWA H, 1976, J BIOL CHEM, V251, P7281; Ohtsuki Mamitaro, 1993, Gene Expression, V3, P201; PETERSON LL, 1984, MOL CELL BIOCHEM, V58, P99, DOI 10.1007/BF00240609; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PHILLIPS MA, 1992, J BIOL CHEM, V267, P2282; POLAKOWSKA RR, 1992, P NATL ACAD SCI USA, V89, P4476, DOI 10.1073/pnas.89.10.4476; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; Reichert Uwe, 1993, P107; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; ROOP D, 1995, SCIENCE, V267, P474, DOI 10.1126/science.7529942; ROTHNAGEL JA, 1986, J CELL BIOL, V102, P1419, DOI 10.1083/jcb.102.4.1419; RUSSELL LJ, 1994, AM J HUM GENET, V55, P1146; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT R, 1988, J INVEST DERMATOL, V90, P475, DOI 10.1111/1523-1747.ep12460936; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Steinert P M, 1995, Cell Death Differ, V2, P33; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; STEINERT PM, 1971, J INVEST DERMATOL, V56, P49, DOI 10.1111/1523-1747.ep12291902; STEVEN AC, 1994, J CELL SCI, V107, P693; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; VASYLYK B, 1993, EUR J BIOCHEM, V211, P7; WANG M, 1994, GENOMICS, V23, P721, DOI 10.1006/geno.1994.1571; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; YAMADA K, 1994, BIOCHEM MOL BIOL INT, V34, P827; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858; YONEDA K, 1992, J BIOL CHEM, V267, P18060; YONEDA K, 1993, P NATL ACAD SCI USA, V90, P10754, DOI 10.1073/pnas.90.22.10754; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022	75	90	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4561	4568						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626812				2022-12-27	WOS:A1996TW96000090
J	Li, XQ; Coffino, P				Li, XQ; Coffino, P			Identification of a region of p53 that confers lability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; CELLULAR TUMOR-ANTIGEN; ORNITHINE DECARBOXYLASE; INTRACELLULAR DEGRADATION; E6 ONCOPROTEIN; INHIBITORY PROTEIN; CELLS; UBIQUITINATION; ASSOCIATION; PROTEOLYSIS	Degradation provides one means for controlling the cellular level of the p53 tumor suppressor. Here we have determined a structural element of p53 required for degradation. To create a substrate amenable to in vitro analysis of proteolysis, we appended to p53 the N terminus of antizyme, a protein that binds to and induces degradation of mammalian ornithine decarboxylase (ODC). We found using deletion analysis that an element within amino acids 100-150 is required for degradation of the fusion protein. A monoclonal antibody (PAb246) that binds close to this region prevents the degradation induced by human papillomavirus 16 E6 protein. Furthermore, we found that amino acids 100-150 of p53 can function as an independent domain to induce Trypanosoma brucei ODC, a stable protein, to be degraded in vivo or, by cooperating with an antizyme binding domain of ODC, to confer polyamine-dependent regulation.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Li, XQ (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143, USA.			Coffino, Philip/0000-0003-0344-5083	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045335] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM45335] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FONG WF, 1976, BIOCHIM BIOPHYS ACTA, V428, P456, DOI 10.1016/0304-4165(76)90054-4; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1992, MOL CELL BIOL, V12, P2178, DOI 10.1128/MCB.12.5.2178; GHODA L, 1990, J BIOL CHEM, V265, P11823; GLASS JR, 1987, J CELL PHYSIOL, V130, P133, DOI 10.1002/jcp.1041300119; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HELLER JS, 1976, P NATL ACAD SCI USA, V73, P1858, DOI 10.1073/pnas.73.6.1858; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI X, 1990, MOL CELL BIOL, V12, P3556; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; Li XQ, 1996, J BIOL CHEM, V271, P4441; LOETSCHER P, 1991, J BIOL CHEM, V266, P11213; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1992, BIOCHEM J, V283, P661, DOI 10.1042/bj2830661; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; RUSSNAK R, 1990, GENE DEV, V4, P764, DOI 10.1101/gad.4.5.764; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SEELY JE, 1983, J BIOL CHEM, V258, P2496; STEGLICH C, 1982, J BIOL CHEM, V257, P4603; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	41	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4447	4451						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626797				2022-12-27	WOS:A1996TW96000075
J	Regan, LM; OBrien, LM; Beattie, TL; Sudhakar, K; Walker, FJ; Fay, PJ				Regan, LM; OBrien, LM; Beattie, TL; Sudhakar, K; Walker, FJ; Fay, PJ			Activated protein C-catalyzed proteolysis of factor VIIIa alters its interactions within factor xase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; FACTOR-VA; FACTOR-IXA; BLOOD-COAGULATION; A1/A3-C1-C2 DIMER; LIGHT-CHAIN; A2 SUBUNIT; INACTIVATION; THROMBIN; BINDING	Factor VIIIa, the cofactor for the factor IXa-dependent conversion of factor X to factor Xa, is proteolytically inactivated by activated protein C (APC), APC cleaves at two sites in factor VIIIa, Arg(336), near the C terminus of the A1 subunit; and Arg(562), bisecting the A2 subunit (Fay, P., Smudzin, T., and Walker, F. (1991) J. Biol. Chem. 266, 20139-20145), Factor VIIIa increased the fluorescence anisotropy of fluorescein-Phe Phe Arg factor IXa (Fl-FFR-FIXa; K-d = 42.4 nM), whereas cleavage of factor VIIIa by APC eliminated this property, Isolation of the APC-cleaved A1/A3-C1-C2 dimer (A1(336)/A3-C1-C2), and the fragments derived from cleaved A2 subunit (A2(N)/A2(C)), permitted dissection of the roles of individual cleavages in cofactor inactivation, Intact A1/A3-C1-C2 dimer increased Fl-FFR-FIXa anisotropy and bound factor X in a solid phase assay, while these activities were absent in the A1(336)/A3-C1-C2. However, the residues removed by this cleavage, Met(337)-Arg(372), did not directly participate in these functions since neither a synthetic peptide to this sequence nor an anti-peptide polyclonal antibody blocked these activities using intact dimer, CD spectral analysis of the intact and truncated dimers indicated reduced alpha and/or beta content in the latter, The A1/A3-C1-C2 dimer plus A2 subunit reconstitutes cofactor activity and produced a factor VIIIa-like effect on the anisotropy of Fl-FFR-FIXa, However, when A2 was replaced by the A2(N)/A2(C) fragments, the resulting fluorescence signal was equivalent to that observed with the dimer alone, These results indicate that APC inactivates the cofactor at two levels within the intrinsic factor Xase complex, Cleavage of either subunit modulates the factor IXa active site, suggesting an essential synergy of interactive sites in factor VIIIa, Furthermore, cleavage of the A1 site alters the conformation of a factor X binding site within that subunit, thereby reducing the affinity of cofactor for substrate.	UNIV ROCHESTER,MED CTR,SCH MED,DEPT MED,HEMATOL UNIT,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV CONNECTICUT,HLTH SCI CTR,AMER RED CROSS,BLOOD SERV,FARMINGTON,CT 06032; UNIV CONNECTICUT,HLTH SCI CTR,DEPT MED,FARMINGTON,CT 06032; UNIV CONNECTICUT,HLTH SCI CTR,DEPT LAB MED,FARMINGTON,CT 06032	University of Rochester; University of Rochester; American Red Cross; University of Connecticut; University of Connecticut; University of Connecticut					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030616, R01HL038199] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30616, HL 07152, HL 38199] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; BERTINA RM, 1984, BIOCHEM BIOPH RES CO, V125, P177, DOI 10.1016/S0006-291X(84)80351-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASILLAS G, 1971, COAGULATION, V4, P107; CURTIS JE, 1994, J BIOL CHEM, V269, P6246; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1993, J BIOL CHEM, V268, P17861; FAY PJ, 1994, J BIOL CHEM, V269, P20522; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1989, BIOCHIM BIOPHYS ACTA, V294, P142; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; KALAFATIS M, 1995, J BIOL CHEM, V270, P4053, DOI 10.1074/jbc.270.8.4053; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1994, J CLIN INVEST, V93, P2497, DOI 10.1172/JCI117259; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; MESTERS RM, 1993, BIOCHEMISTRY-US, V32, P12656, DOI 10.1021/bi00210a014; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; NESHEIM ME, 1982, J BIOL CHEM, V257, P1443; OBRIEN LM, 1995, J BIOL CHEM, V270, P27087, DOI 10.1074/jbc.270.45.27087; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; PITTMAN DD, 1992, BLOOD, V79, P389; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; REGAN LM, 1994, J BIOL CHEM, V269, P9445; SCANDELLA D, 1993, BLOOD, V82, P1767; TOOLE JJ, 1984, NATURE, V312, P334; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1990, J BIOL CHEM, V265, P1484; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	43	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					3982	3987						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626729				2022-12-27	WOS:A1996TW96000007
J	Revelle, BM; Scott, D; Kogan, TP; Zheng, JH; Beck, PJ				Revelle, BM; Scott, D; Kogan, TP; Zheng, JH; Beck, PJ			Structure-function analysis of P-selectin-sialyl Lewis(x) binding interactions - Mutagenic alteration of ligand binding specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; LEUKOCYTE ADHESION MOLECULE-1; GRANULE MEMBRANE-PROTEIN; CELL-ADHESION; GMP-140; ENDOTHELIUM; NEUTROPHILS; ELAM-1; LEX; OLIGOSACCHARIDES	P-selectin is a vascular cell adhesion molecule that is expressed on the surface of platelets and endothelial cells in response to inflammatory stimuli. It is believed to aid in the binding and recruitment of leukocytes to inflamed tissue. P-selectin adhesion to leukocytes is mediated by the amino-terminal lectin domain that binds the sialyl Lewis(X) (sLe(X)) carbohydrate (Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc). Neither the three-dimensional structure of P-selectin nor the protein-carbohydrate interactions that mediate the binding of P-selectin to the sLe(X) carbohydrate have been determined. The most closely related protein for which a ligand-bound three-dimensional structure has been resolved is the rat mannose-binding protein (Weis, W. L., Drickamer, K., and Hendrickson, W. A. (1992) Nature 360, 127-134). Using the known binding interactions that occur between the rat mannose-binding protein and its ligand (oligomannose) as a template, we have used site-directed mutagenesis to substitute Ala-77 with lysine. This substitution changed P-selectin-carbohydrate binding specificity from sLe(X) to oligomannose. Further substitution altered the binding preference from mannose to galactose in a predictable manner. These results indicate that P-selectin binds sLe(X) in a shallow cleft that is similar to the mannose-binding protein saccharide-binding cleft. Additionally, we present an extensive mutagenic analysis of P-selectin Lys-113, a residue that has previously been implicated in P-selectin binding to both sLe(X) and 3-sulfated galactosylceramide (sulfatide). Our analysis demonstrates that Lys-113 is probably not involved in P-selectin binding to either sulfatide or sLe(X). Functionally, it appears that P-selectin has retained a conserved carbohydrate and calcium coordination site that enables it to bind carbohydrate in a manner that is quite similar to that which has been determined for the rat mannose-binding protein.	TEXAS BIOTECHNOL CORP,DEPT MOLEC BIOL,HOUSTON,TX 77030; TEXAS BIOTECHNOL CORP,DEPT MED CHEM,HOUSTON,TX 77030; UNIV TEXAS,SCH MED,DEPT INTERNAL MED,HOUSTON,TX 77030	University of Texas System								ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; BAJORATH J, 1994, BIOCHEMISTRY-US, V33, P1332, DOI 10.1021/bi00172a007; BECK PJ, 1990, MOL CELL BIOL, V10, P4612, DOI 10.1128/MCB.10.9.4612; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; BJERCKE RJ, 1986, J IMMUNOL METHODS, V90, P203, DOI 10.1016/0022-1759(86)90077-3; CECCONI O, 1994, J BIOL CHEM, V269, P15060; CORRAL L, 1990, BIOCHEM BIOPH RES CO, V172, P1349, DOI 10.1016/0006-291X(90)91598-M; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; Harlow E., 1988, ANTIBODIES LAB MANUA; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HOLLENBAUGH D, 1993, BIOCHEMISTRY-US, V32, P2960, DOI 10.1021/bi00063a006; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KOGAN TP, 1995, J BIOL CHEM, V270, P14047, DOI 10.1074/jbc.270.23.14047; KUNZENDORF U, 1994, CANCER RES, V54, P1109; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MILLS A, 1993, FEBS LETT, V319, P5, DOI 10.1016/0014-5793(93)80026-Q; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; NELSON RM, 1993, BLOOD, V82, P3253; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; ROSSITER H, 1994, EUR J IMMUNOL, V24, P205, DOI 10.1002/eji.1830240132; Sambrook J., 2002, MOL CLONING LAB MANU; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WEIS WI, 1994, STRUCTURE, V2, P147, DOI 10.1016/S0969-2126(00)00016-2; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0	40	35	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4289	4297						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626776				2022-12-27	WOS:A1996TW96000054
J	Shipley, JM; Doyle, GAR; Fliszar, CJ; Ye, QZ; Johnson, LL; Shapiro, SD; Welgus, HG; Senior, RM				Shipley, JM; Doyle, GAR; Fliszar, CJ; Ye, QZ; Johnson, LL; Shapiro, SD; Welgus, HG; Senior, RM			The structural basis for the elastolytic activity of the 92-kDa and 72-kDa gelatinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL COLLAGENASE; STROMELYSIN CATALYTIC DOMAIN; HUMAN ALVEOLAR MACROPHAGES; SUBSTRATE-SPECIFICITY; MATRIX METALLOPROTEINASES; IV COLLAGENASE; EXPRESSION; IDENTIFICATION; PURIFICATION; DEGRADATION	Several matrix metalloproteinases, including the 92-kDa and 72-kDa gelatinases, macrophage metalloelastase (MME), and matrilysin degrade insoluble elastin. Because elastolytically active MME and matrilysin consist only of a catalytic domain (CD), we speculated that the homologous CDs of the 92-kDa and 72-kDa gelatinases would confer their elastolytic activities. In contrast to the MME CD, the 92 and 72 CDs expressed in Escherichia coli (lacking the internal fibronectin type II-like repeats) had no elastase activity, although both were gelatinolytic and cleaved a thiopeptolide substrate at rates comparable to the full-length gelatinases. To test the role of the fibronectin type II-like repeats in elastolytic activity, we expressed the 92-kDa gelatinase CD with its fibronectin type II-Like repeats (92 CD/FN) in yeast. 92 CD/FN degraded insoluble elastin with activity comparable to full-length 92-kDa gelatinase. 92 and 72 CDs lacking the fibronectin type II-like repeats did not bind elastin, whereas the parent enzymes and 92 CD/FN did bind elastin. Furthermore, recombinant 92-kDa fibronectin type II-like repeats inhibited binding of the 92-kDa gelatinase to elastin. We conclude that the 92- and 72-kDa gelatinases require the fibronectin type II-like repeats for elastase activity.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT MED,RESP & CRIT CARE DIV,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT MED,DIV DERMATOL,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; WARNER LAMBERT PARKE DAVIS,DIV PHARMACEUT RES,DEPT BIOCHEM,ANN ARBOR,MI 48105	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Pfizer			Ye, Qizhuang/B-3147-2009		NHLBI NIH HHS [R0-1 HL47328, P0-1 HL29594] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047328, P01HL029594] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANDA MJ, 1981, METHODS STUDYING MON, P603; BANYAI L, 1994, BIOCHEM J, V298, P403, DOI 10.1042/bj2980403; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; CHAPMAN HA, 1994, AM J RESP CRIT CARE, V150, pS155, DOI 10.1164/ajrccm/150.6_Pt_2.S155; COLLIER IE, 1992, J BIOL CHEM, V267, P6776; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FRISCH SM, 1990, ONCOGENE, V5, P75; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; JANOFF A, 1985, AM REV RESPIR DIS, V132, P417; MARCY AI, 1991, BIOCHEMISTRY-US, V30, P6476, DOI 10.1021/bi00240a018; Mecham R.P., 1991, CELL BIOL EXTRACELLU, V2nd, P79; MURPHY G, 1994, J BIOL CHEM, V269, P6632; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHNIERER S, 1993, BIOCHEM BIOPH RES CO, V191, P319, DOI 10.1006/bbrc.1993.1220; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SENIOR RM, 1989, AM REV RESPIR DIS, V139, P1251, DOI 10.1164/ajrccm/139.5.1251; SHAPIRO SD, 1991, J CLIN INVEST, V87, P1828, DOI 10.1172/JCI115204; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; THOMPSON RW, 1995, J CLIN INVEST, V96, P318, DOI 10.1172/JCI118037; WEINGARTEN H, 1985, ANAL BIOCHEM, V147, P437, DOI 10.1016/0003-2697(85)90294-5; YE QZ, 1995, BIOCHEMISTRY-US, V34, P4702, DOI 10.1021/bi00014a026; YE QZ, 1992, BIOCHEMISTRY-US, V31, P11231, DOI 10.1021/bi00160a038	36	178	182	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4335	4341						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626782				2022-12-27	WOS:A1996TW96000060
J	Snedden, WA; Koutsia, N; Baum, G; Fromm, H				Snedden, WA; Koutsia, N; Baum, G; Fromm, H			Activation of a recombinant Petunia glutamate decarboxylase by calcium/calmodulin or by a monoclonal antibody which recognizes the calmodulin binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC ACID; LIGHT CHAIN KINASE; CYTOPLASMIC PH REGULATION; INTRACELLULAR PH; HEAT-SHOCK; CELLS; PROTEIN; MUSCLE; PURIFICATION; CALCIUM	To date, only plants have been shown to possess a form of glutamate decarboxylase (GAD) that binds calmodulin, In the present study, a recombinant calmodulin-binding 58-kDa petunia GAD produced in Escherichia coli was purified to homogeneity using calmodulin-affinity chromatography, and its responsiveness to calcium and calmodulin was examined in vitro, At pH 7.0-7.5, the purified recombinant enzyme was essentially inactive in the absence of calcium and calmodulin, but it could be stimulated to high levels of activity (V-max = 30 mu mol of CO2 min(-1) mg of protein(-1)) by the addition of exogenous calmodulin (K-0.5 = 15 nM) in the presence of calcium (K-0.5 = 0.8 mu M). Neither calcium nor calmodulin alone had any effect on GAD activity. Recombinant GAD displayed hyperbolic kinetics at pH 7.3 (K-m = 8.2 mM). A monoclonal antibody directed against the carboxyl-terminal region, which contains the calmodulin-binding domain of GAD, was able to fully activate GAD in a dose-dependent manner in the absence of calcium and calmodulin, whereas an antibody recognizing an epitope outside of this region was unable to activate GAD, This study provides the first evidence that the activity of the purified 58-kDa GAD polypeptide is essentially calcium/calmodulin-dependent at physiological pH. Furthermore, activation of GAD by two different proteins that interact with the calmodulin binding domain, a monoclonal antibody or calcium/ calmodulin, suggests that this domain plays a major role in the regulation of plant GAD activity.	WEIZMANN INST SCI,DEPT PLANT GENET,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science			FROMM, HILLEL/AAF-6783-2019	FROMM, HILLEL/0000-0003-1977-1211; Baum, Gideon/0000-0002-4167-0188				ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ARAKI Y, 1991, BIOCHEM J, V275, P679, DOI 10.1042/bj2750679; ARAZI T, 1995, PLANT PHYSIOL, V108, P551, DOI 10.1104/pp.108.2.551; AURISANO N, 1995, PHYTOCHEMISTRY, V38, P1147, DOI 10.1016/0031-9422(94)00774-N; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BAO J, 1995, J BIOL CHEM, V270, P6464, DOI 10.1074/jbc.270.12.6464; BAUM G, 1993, J BIOL CHEM, V268, P19610; BLUMENTHAL DK, 1982, BIOCHEMISTRY-US, V21, P2386, DOI 10.1021/bi00539a017; Bown A., 1989, BIOCH LIFE SCI ADV, V8, P21; BRAAM J, 1992, P NATL ACAD SCI USA, V89, P3213, DOI 10.1073/pnas.89.8.3213; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITKREUZ KE, 1995, PLANT PHYSIOL, V108, P99, DOI 10.1104/pp.108.1.99; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; CARROLL AD, 1994, PLANT PHYSIOL, V106, P513, DOI 10.1104/pp.106.2.513; CHEN YL, 1994, PLANT PHYSIOL, V106, P1381, DOI 10.1104/pp.106.4.1705; CHEN YR, 1987, J BIOL CHEM, V262, P10689; CRAWFORD LA, 1994, PLANT PHYSIOL, V104, P865, DOI 10.1104/pp.104.3.865; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; ERLANDER MG, 1991, NEUROCHEM RES, V16, P215, DOI 10.1007/BF00966084; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FONDA ML, 1985, METHOD ENZYMOL, V113, P11; GARVEY EP, 1994, ARCH BIOCHEM BIOPHYS, V311, P235, DOI 10.1006/abbi.1994.1232; GUERN J, 1986, PLANT PHYSIOL, V82, P840, DOI 10.1104/pp.82.3.840; HOFMANN F, 1994, J BIOL CHEM, V269, P24298; INATOMI K, 1975, BIOCHEM J, V147, P479, DOI 10.1042/bj1470479; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KEE SM, 1987, J BIOL CHEM, V262, P9448; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KNIGHT MR, 1992, P NATL ACAD SCI USA, V89, P4967, DOI 10.1073/pnas.89.11.4967; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; KURKDJIAN A, 1989, ANNU REV PLANT PHYS, V40, P271, DOI 10.1146/annurev.pp.40.060189.001415; LING V, 1994, PLANT CELL, V6, P1135, DOI 10.1105/tpc.6.8.1135; MARTIN DL, 1987, CELL MOL NEUROBIOL, V7, P237, DOI 10.1007/BF00711302; MATSUMOTO T, 1990, AGR BIOL CHEM TOKYO, V54, P3001, DOI 10.1080/00021369.1990.10870411; MAYER RR, 1990, PLANT PHYSIOL, V94, P796, DOI 10.1104/pp.94.2.796; NATHAN B, 1994, J BIOL CHEM, V269, P7249; NISHIKAWA M, 1985, J BIOL CHEM, V260, P8978; RHODES D, 1986, PLANT PHYSIOL, V82, P890, DOI 10.1104/pp.82.4.890; ROBERTS JKM, 1992, PLANT PHYSIOL, V98, P480, DOI 10.1104/pp.98.2.480; ROSENBERG GB, 1987, METHOD ENZYMOL, V139, P776; SATYANARAYAN V, 1985, EUR J BIOCHEM, V150, P53, DOI 10.1111/j.1432-1033.1985.tb08987.x; SATYANARAYAN V, 1990, PHYTOCHEMISTRY, V29, P367, DOI DOI 10.1016/0031-9422(90)85081-P; SATYANARAYAN V, 1986, PHYTOCHEMISTRY, V25, P997; SMITH MK, 1992, J BIOL CHEM, V267, P1761; SNEDDEN WA, 1995, PLANT PHYSIOL, V108, P543, DOI 10.1104/pp.108.2.543; SNEDDEN WA, 1992, PLANT PHYSIOL, V99, P665, DOI 10.1104/pp.99.2.665; SOLIMENA M, 1991, TRENDS NEUROSCI, V14, P452, DOI 10.1016/0166-2236(91)90044-U; STEWART AA, 1983, EUR J BIOCHEM, V132, P289, DOI 10.1111/j.1432-1033.1983.tb07361.x; STREETER JG, 1972, PLANT PHYSIOL, V49, P572, DOI 10.1104/pp.49.4.572; TSUSHIDA T, 1987, AGR BIOL CHEM TOKYO, V51, P2865; TZACHUK VA, 1981, BIOCHEMISTRY-MOSCOW, V46, P779; WALLACE W, 1984, PLANT PHYSIOL, V75, P170, DOI 10.1104/pp.75.1.170; WEINSTEIN H, 1994, ANNU REV PHYSIOL, V56, P213, DOI 10.1146/annurev.ph.56.030194.001241; WU JY, 1991, NEUROCHEM RES, V16, P227, DOI 10.1007/BF00966085; ZURINI M, 1984, J BIOL CHEM, V259, P618	55	121	132	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4148	4153						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626755				2022-12-27	WOS:A1996TW96000033
J	Katagiri, K; Yokoyama, KK; Yamamoto, T; Omura, S; Irie, S; Katagiri, T				Katagiri, K; Yokoyama, KK; Yamamoto, T; Omura, S; Irie, S; Katagiri, T			Lyn and Fgr protein-tyrosine kinases prevent apoptosis during retinoic acid-induced granulocytic differentiation of HL-80 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; HL-60 CELLS; MONOCYTIC DIFFERENTIATION; EXPRESSION; GENE; NEUTROPHILS; INDUCTION; LINE; VAV; PHOSPHORYLATION	The human promyelocytic leukemia cell line HL-60 can be induced to differentiate toward neutrophils and subsequently die via apoptosis in vitro. In this paper, we investigated the roles of protein-tyrosine kinases (PTKs) in retinoic acid (RA)-induced granulocytic differentiation of HL-60 cells. Accompanying the RA-induced differentiation, activities of src family PTKs Lyn and Fgr became detected and reached a plateau 2 days after the stimulation. The immunoblotting using anti-phosphotyrosine antibody (PY-20) showed that the proteins of 56 and 53 kDa were predominantly tyrosine-phosphorylated at day 2. Adsorption and immunoprecipitation of the cell lysate by specific antibodies evidenced that these phosphotyrosine-containing proteins are Lyn and Fgr PTKs. The degree of both activities and tyrosine phosphorylation of these PTKs was reduced to be minimal at day 5 when the HL-60 cells start to die by apoptosis. The inhibitors of PTKs, herbimycin A and genistein, were demonstrated to cause premature cell death of HL-60 cells in the presence of RA. The death was the consequence of an apoptotic process. The RA-treated HL-60 cells, when incubated with specific c-lyn or c-fgr antisense oligodeoxynucleotide, also underwent premature death at day 2. These data implicate that Lyn and Fgr PTKs prevent programmed cell death to promote granulocytic differentiation of HL-60 cells.	NIPPI INC,INST BIOMATRIX,ADACHI KU,TOKYO 120,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN; UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN; KITASATO INST,BIOL FUNCT RES CTR,MINATO KU,TOKYO 108,JAPAN	RIKEN; University of Tokyo	Katagiri, K (corresponding author), KITASATO INST,CTR BASIC RES,DEPT MOLEC IMMUNOL,MINATO KU,5-9-1 SHIROKANE,TOKYO 108,JAPAN.							AFFORD SC, 1992, J BIOL CHEM, V267, P21612; BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CASTAIGNE S, 1990, BLOOD, V76, P1704; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GRIGG JM, 1991, LANCET, V338, P720, DOI 10.1016/0140-6736(91)91443-X; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KATAGIRI K, 1992, CELL IMMUNOL, V140, P282, DOI 10.1016/0008-8749(92)90196-V; KATAGIRI K, 1994, BLOOD, V84, P1780; KATAGIRI K, 1991, J IMMUNOL, V146, P701; KATAGIRI K, 1993, J IMMUNOL, V150, P585; KATAGIRI T, 1989, P NATL ACAD SCI USA, V86, P10064, DOI 10.1073/pnas.86.24.10064; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; NAUMOVSKI L, 1994, BLOOD, V83, P2261; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; NUNEZ G, 1994, IMMUNOL TODAY, V15, P582, DOI 10.1016/0167-5699(94)90221-6; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; ORITANI K, 1992, BLOOD, V80, P2298; PORFIRI E, 1991, BLOOD, V78, P1069; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868	36	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11557	11562		10.1074/jbc.271.19.11557	http://dx.doi.org/10.1074/jbc.271.19.11557			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626717				2022-12-27	WOS:A1996UJ94400077
J	Krebs, J; Means, RL; Honegger, P				Krebs, J; Means, RL; Honegger, P			Induction of calmodulin kinase IV by the thyroid hormone during the development of rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CEREBELLAR GRANULE CELLS; BINDING PROTEIN; GENE-EXPRESSION; STIMULATION; GR; PHOSPHORYLATION; DIFFERENTIATION; GROWTH; FETAL	This communication reports the specific induction of calmodulin kinase IV by the thyroid hormone 3,3',5-triiodo-L-thyronine (T-3) in a time and concentration-dependent manner at a very early stage of brain differentiation using a fetal rat telencephalon primary cell culture system, which can grow and differentiate under chemically defined conditions. The induction of the enzyme that can be observed both on the mRNA and on the protein level is T-3-specific, i.e. it cannot be induced by retinoic acid or reverse T-3, and can be inhibited on both the transcriptional and the translational level by adding to the culture medium actinomycin D or cycloheximide, respectively. The earliest detection of calmodulin kinase IV in the fetal brain tissue of the rat is at days E16/E17, both on the mRNA as well as on the protein level. This is the first report in which a second messenger-dependent kinase involved in the control of cell regulatory processes is itself controlled by a primary messenger, the thyroid hormone.	DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; UNIV LAUSANNE,INST PHYSIOL,CH-1005 LAUSANNE,SWITZERLAND	Duke University; University of Lausanne	Krebs, J (corresponding author), ETH ZURICH,INST BIOCHEM,CH-8092 ZURICH,SWITZERLAND.		krebs, joachim/B-3023-2013; Krebs, Joachim/CAF-0460-2022		NICHD NIH HHS [HD-07503] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALMAZAN G, 1985, DEV NEUROSCI-BASEL, V7, P45, DOI 10.1159/000112275; BALAZS R, 1971, BRAIN RES, V25, P555, DOI 10.1016/0006-8993(71)90460-4; BLAND MM, 1994, GENE, V142, P191, DOI 10.1016/0378-1119(94)90260-7; CORTHESYTHEULAZ I, 1991, AM J PHYSIOL, V261, pC124, DOI 10.1152/ajpcell.1991.261.1.C124; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHER CL, 1991, J IMMUNOL, V146, P1743; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; GUERINI D, 1984, J BIOL CHEM, V259, P5172; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HANSONPL, 1992, ANN REV BIOCH, V61, P559; HONEGGER P, 1979, NATURE, V282, P305, DOI 10.1038/282305a0; HONEGGER P, 1982, DEV BRAIN RES, V3, P229, DOI 10.1016/0165-3806(82)90023-2; HONEGGER P, 1983, DEV BRAIN RES, V11, P245, DOI 10.1016/0165-3806(83)90222-5; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; JORGENSEN OS, 1986, INT J DEV NEUROSCI, V4, P519, DOI 10.1016/0736-5748(86)90004-3; KAWAOI A, 1985, ACTA ENDOCRINOL-COP, V108, P518, DOI 10.1530/acta.0.1080518; KREBS J, 1995, P 9 INT S CALC BIND, pGS8; KREBS J, 1992, P 8 INT S CALC BIND, pB35; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON CA, 1995, P 77 M END SOC WASH, P48; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; SAHYOUN N, 1991, P NATL ACAD SCI USA, V88, P2643, DOI 10.1073/pnas.88.7.2643; SAKAGAMI H, 1992, MOL BRAIN RES, V16, P20, DOI 10.1016/0169-328X(92)90189-I; SAKAGAMI H, 1993, MOL BRAIN RES, V19, P215, DOI 10.1016/0169-328X(93)90029-O; SCHMITT CA, 1988, J BIOL CHEM, V263, P17643; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SLAUGHTER GR, 1987, BIOL REPROD, V37, P1259, DOI 10.1095/biolreprod37.5.1259; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; TOKUMITSU H, 1994, J BIOL CHEM, V269, P15520; ZURINI M, 1984, J BIOL CHEM, V259, P618	44	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11055	11058		10.1074/jbc.271.19.11055	http://dx.doi.org/10.1074/jbc.271.19.11055			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626646				2022-12-27	WOS:A1996UJ94400006
J	Silvagno, F; Xia, HH; Bredt, DS				Silvagno, F; Xia, HH; Bredt, DS			Neuronal nitric-oxide synthase-mu, an alternatively spliced isoform expressed in differentiated skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEM; CELL; GENE	Nitric oxide (NO) functions as a molecular mediator in numerous processes in cellular development and physiology. Differential expression and regulation of a family of three NO synthase (NOS) gene products help achieve this diversity of action. Previous studies identify post- translational modification and interaction of NOS with specific protein targets as tissue-specific modes of regulation, Here, we show that alternative splicing specifically regulates neuronal NOS (nNOS, type I) in striated muscle. nNOS in skeletal muscle is slightly more massive than nNOS from brain owing to a 102-base pair (34-amino acid) alternatively spliced segment between exons 16 and 17. Following purification, this novel nNOS mu isoform has similar catalytic activity to that of nNOS expressed in cerebellum. nNOS mu appears to function exclusively in differentiated muscle as its expression occurs coincidentally with myotube fusion in culture. An isoform-specific antibody detects nNOS mu protein only in skeletal muscle and heart, This study identifies alternative splicing as a means for tissue-specific regulation of nNOS and reports the first additional protein sequence for a mammalian NOS since the original cloning of the gene family.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; BALON TW, 1994, J APPL PHYSIOL, V77, P2519, DOI 10.1152/jappl.1994.77.6.2519; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BREITBART RE, 1985, CELL, V41, P67, DOI 10.1016/0092-8674(85)90062-5; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; COOPER TA, 1985, J BIOL CHEM, V260, P1140; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HALL AV, 1994, J BIOL CHEM, V269, P33082; HAN X, 1994, J PHYSIOL-LONDON, V476, P309, DOI 10.1113/jphysiol.1994.sp020132; HARE JM, 1995, J CLIN INVEST, V95, P360, DOI 10.1172/JCI117664; HOFFMAN EP, 1988, NEURON, V1, P411, DOI 10.1016/0896-6273(88)90191-2; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; LEE KH, 1994, J BIOL CHEM, V269, P14371; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NATHAN C, 1994, J BIOL CHEM, V269, P13725; OGURA T, 1993, BIOCHEM BIOPH RES CO, V193, P1014, DOI 10.1006/bbrc.1993.1726; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; STERN MD, 1992, FASEB J, V6, P3092, DOI 10.1096/fasebj.6.12.1325933; WANG T, 1995, NATURE, V374, P262, DOI 10.1038/374262a0; WHALEN RG, 1981, NATURE, V292, P805, DOI 10.1038/292805a0; XIE JL, 1995, P NATL ACAD SCI USA, V92, P1242, DOI 10.1073/pnas.92.4.1242	28	288	295	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11204	11208		10.1074/jbc.271.19.11204	http://dx.doi.org/10.1074/jbc.271.19.11204			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626668				2022-12-27	WOS:A1996UJ94400028
J	Zhang, L; Yu, YK; Mackin, S; Weight, FF; Uhl, GR; Wang, JB				Zhang, L; Yu, YK; Mackin, S; Weight, FF; Uhl, GR; Wang, JB			Differential mu opiate receptor phosphorylation and desensitization induced by agonists and phorbol esters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPIOID RECEPTOR; RAT-BRAIN; EXPRESSION; CLONING	mu opiate receptors, the principal sites for opiate analgesia and reward, can display compensatory responses to opiate agonist drug administration. Agonist-induced K+ channel responses mediated by these receptors desensitize when examined in Xenopus oocyte expression systems. Mechanisms underlying such processes could include phosphorylation events similar to those re ported to desensitize other G protein-linked receptors. We used C-terminally directed anti-mu receptor antibodies to immunoprecipitate a phosphoprotein with size appropriate for the mu receptor from stably expressing Chinese hamster ovary cells. Phosphorylation of this mu opiate receptor protein was enhanced approximately 5-fold by treatment with the mu agonist morphine. The time course and dose-response relationships between mu receptor phosphorylation and agonist-induced desensitization display interesting parallels. Phosphorylation of mu opiate receptor protein is also enhanced similar to 5-fold by treatment with the protein kinase C activator phorbol 12-myristate 13-acetate. The protein kinase inhibitor staurosporine blocked the effect of phorbol 12-myristate 13-acetate on mu receptor phosphorylation. However, staurosporine failed to block morphine-induced phosphorylation. These observations suggest that several biochemical pathways can lead to mu receptor phosphorylation events that may include mechanisms involved in mu receptor desensitization.	UNIV MARYLAND,SCH PHARM,DEPT PHARMACEUT SCI,BALTIMORE,MD 21201; NIAAA,MOLEC & CELLULAR NEUROBIOL LAB,BETHESDA,MD 20892; NATL INST DRUG ABUSE,MOL NEUROBIOL BRANCH,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21224	University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Johns Hopkins University; Johns Hopkins University			Zhang, Li/W-2104-2019					ARDEN JR, 1995, J NEUROCHEM, V65, P1636; CHEN Y, 1994, J BIOL CHEM, V269, P7839; CHEN Y, 1993, MOL PHARMACOL, V44, P8; CHENG PY, 1995, ANALGESIA, V1, P363; CHILDERS SR, 1991, LIFE SCI, V48, P1191; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P6596, DOI 10.1073/pnas.90.14.6596; EPPLER CM, 1993, J BIOL CHEM, V268, P26447; FUKUDA K, 1993, FEBS LETT, V327, P311, DOI 10.1016/0014-5793(93)81011-N; HERZ A, 1993, OPIOIDS HDB EXPT PHA, V104; JOHNSON PS, 1994, REGUL PEPTIDES, V54, P139, DOI 10.1016/0167-0115(94)90429-4; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOVOOR A, 1995, J BIOL CHEM, V270, P589, DOI 10.1074/jbc.270.2.589; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; NORTH RA, 1987, P NATL ACAD SCI USA, V84, P5487, DOI 10.1073/pnas.84.15.5487; PEI G, 1995, MOL PHARMACOL, V48, P173; ROTHMAN RB, 1995, SYNAPSE, V21, P60, DOI 10.1002/syn.890210109; SMART D, 1994, J NEUROCHEM, V62, P1009; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; WALAAS SI, 1991, PHARMACOL REV, V43, P299; WANG JB, 1993, P NATL ACAD SCI USA, V90, P10230, DOI 10.1073/pnas.90.21.10230; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4	23	145	145	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11449	11454		10.1074/jbc.271.19.11449	http://dx.doi.org/10.1074/jbc.271.19.11449			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626702	hybrid			2022-12-27	WOS:A1996UJ94400062
J	Bayewitch, M; Rhee, RH; AvidorReiss, T; Breuer, A; Mechoulam, R; Vogel, Z				Bayewitch, M; Rhee, RH; AvidorReiss, T; Breuer, A; Mechoulam, R; Vogel, Z			(-)-Delta(9)-Tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; TETRAHYDROCANNABINOL; ANANDAMIDE; MODULATION; INVITRO; BRAIN	(-)-Delta(9)-Tetrahydrocannabinol ((-)-Delta(9)-THC) is the major active psychotropic component of the marijuana plant, Cannabis sativa. The membrane proteins that have been found to bind this material or its derivatives have been called the cannabinoid receptors. Two GTP-binding protein-coupled cannabinoid receptors have been cloned. CB1 or the neuronal cannabinoid receptor is found mostly in neuronal cells and tissues while CB2 or the peripheral cannabinoid receptor has been detected in spleen and in several cells of the immune system. It has previously been shown that activation of CB1 or CB2 receptors by cannabinoid agonists inhibits adenylyl cyclase activity. Utilizing Chinese hamster ovary cells and COS cells transfected with the cannabinoid receptors we report that (-)-Delta(9)-THC binds to both receptors with similar affinity. However, in contrast to its capacity to serve as an agonist for the CB1 receptor, (-)-Delta(9)-THC was only able to induce a very slight inhibition of adenylyl cyclase at the CB2 receptor. Morever, (-)-Delta(9)-THC antagonizes the agonist-induced inhibition of adenylyl cyclase mediated by CB2. Therefore, we conclude that (-)-Delta(9)-THC constitutes a weak antagonist for the CB2 receptor.	WEIZMANN INST SCI, DEPT NEUROBIOL, IL-76100 REHOVOT, ISRAEL; HEBREW UNIV JERUSALEM, FAC MED, DEPT NAT PROD, IL-91120 JERUSALEM, ISRAEL	Weizmann Institute of Science; Hebrew University of Jerusalem			Rhee, Man Hee/O-5705-2016; Avidor-Reiss, Tomer/AAK-6153-2020	Rhee, Man Hee/0000-0002-3088-1318; Avidor-Reiss, Tomer/0000-0003-0918-526X	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006265, R01DA006481] Funding Source: NIH RePORTER; NIDA NIH HHS [DA6481, DA6265] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BAYEWITCH M, 1995, FEBS LETT, V375, P143, DOI 10.1016/0014-5793(95)01207-U; BIDAUTRUSSELL M, 1990, J NEUROCHEM, V55, P21, DOI 10.1111/j.1471-4159.1990.tb08815.x; BUFORD NT, 1995, J PHARMACOL EXP THER, V274, P134; COMPTON DR, 1993, J PHARMACOL EXP THER, V265, P218; DELEAN A, 1988, USERS GUIDE ALLFIT, P97; DEROCQ JM, 1995, FEBS LETT, V369, P177, DOI 10.1016/0014-5793(95)00746-V; DEVANE WA, 1992, J MED CHEM, V35, P2065, DOI 10.1021/jm00089a018; DILL JA, 1988, J PHARMACOL EXP THER, V244, P1157; FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376; FELDER CC, 1995, MOL PHARMACOL, V48, P443; FELDER CC, 1992, MOL PHARMACOL, V42, P313; FRIDE E, 1995, J PHARMACOL EXP THER, V272, P699; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; HELDMAN E, 1996, IN PRESS EUR J PHARM; HOWLETT AC, 1988, MOL PHARMACOL, V33, P297; HOWLETT AC, 1984, MOL PHARMACOL, V26, P532; HOWLETT AC, 1986, MOL PHARM, V29, P161; KAMINSKI NE, 1992, MOL PHARMACOL, V42, P736; KAMINSKI NE, 1994, BIOCHEM PHARMACOL, V48, P1899, DOI 10.1016/0006-2952(94)90588-6; KEOWN WA, 1990, METHOD ENZYMOL, V185, P527, DOI 10.1016/0076-6879(90)85043-N; LEE M, 1995, J PHARMACOL EXP THER, V275, P529; LEVITZKI A, 1984, RECEPTORS QUANTITATI, P19; LOPEZCEPERO M, 1986, J LEUKOCYTE BIOL, V39, P679, DOI 10.1002/jlb.39.6.679; LYNN AB, 1994, J PHARMACOL EXP THER, V268, P1612; MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825; MACKIE K, 1993, MOL PHARMACOL, V44, P498; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1990, TETRAHEDRON-ASYMMETR, V1, P315, DOI 10.1016/S0957-4166(00)86322-3; MECHOULAM R, 1972, J AM CHEM SOC, V94, P6159, DOI 10.1021/ja00772a038; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SLIPETZ DM, 1995, MOL PHARMACOL, V48, P352; VOGEL Z, 1993, J NEUROCHEM, V61, P352, DOI 10.1111/j.1471-4159.1993.tb03576.x; WALLACH J, 1994, FEBS LETT, V338, P257, DOI 10.1016/0014-5793(94)80279-3	36	121	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9902	9905		10.1074/jbc.271.17.9902	http://dx.doi.org/10.1074/jbc.271.17.9902			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626625				2022-12-27	WOS:A1996UG25700009
J	Diggle, C; Quirk, PG; Bizouarn, T; Grimley, RL; Cotton, NPJ; Thomas, CM; Jackson, JB				Diggle, C; Quirk, PG; Bizouarn, T; Grimley, RL; Cotton, NPJ; Thomas, CM; Jackson, JB			Mutation of Tyr(235) in the NAD(H)-binding subunit of the proton-translocating nicotinamide nucleotide transhydrogenase of Rhodospirillum rubrum affects the conformational dynamics of a mobile loop and lowers the catalytic activity of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOBACTER-CAPSULATUS; H+-TRANSHYDROGENASE; ESCHERICHIA-COLI; BINDING SITES	The Tyr residue in the mobile loop region of the soluble, domain I polypeptide (called Th-s) of the proton-translocating transhydrogenase from Rhodospirillum rubrum has been substituted by Asn and by Phe. The recombinant proteins were expressed at high levels in Escherichia coli and purified to homogeneity. The two well defined resonances at 6.82 and 7.12ppm, observed in the one-dimensional proton NMR spectrum of wild-type protein, and previously attributed to the Tyr residue, were absent in both mutants. In the Tyr(235) --> Phe mutant Th-s, they were replaced by two new resonances at 7.26 and 7.33 ppm, characteristic of a Phe residue. In both mutants, narrow resonances attributable to Met residues (and in the Tyr(235) --> Phe mutant, resonances attributable to Ala residues) were shifted relative to the wild type, but other features in the NMR spectra were unaffected. The conformational dynamics of the mobile loop closure in response to nucleotide binding by the protein were altered in the two mutants. The fluorescence emission from Trp(72) was unaffected by both Tyr substitutions, and the fluorescence was still quenched by NADH. The mutant Th-s proteins bound to chromatophore membranes depleted of their native Th-s with undiminished affinity. In these reconstituted systems, the K-m values for thio-NADP(+) and NADH, during light-driven transhydrogenation, were similar to those of wild-type, but the k(cat) values were decreased about 2-fold. In reverse transhydrogenation, the K-m values for NADPH were slightly decreased in the mutants relative to wild-type, but those for acetyl pyridine adenine dinucleotide were increased about 10- and 13-fold, respectively, and the k(cat) values were decreased about 2- and 5-fold, respectively, in the Tyr(235) --> Phe and Tyr(235) --> Asn mutants. It is concluded that Tyr(235) may contribute to the process of nucleotide binding and that substitution of this residue prevents proper functioning of the mobile loop in catalysis.	UNIV BIRMINGHAM,SCH BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,SCH BIOL SCI,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham			Thomas, Christopher M/J-8258-2017; bizouarn, tania/W-6782-2019	Thomas, Christopher M/0000-0002-2810-0455; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BIZOUARN T, 1995, BBA-BIOENERGETICS, V1229, P49, DOI 10.1016/0005-2728(94)00186-9; Bizouarn T, 1996, J BIOL CHEM, V271, P10103, DOI 10.1074/jbc.271.17.10103; Bizouarn T, 1996, BBA-BIOENERGETICS, V1273, P4, DOI 10.1016/0005-2728(95)00125-5; CLAYTON RK, 1963, BIOCHIM BIOPHYS ACTA, V75, P312, DOI 10.1016/0006-3002(63)90618-8; COTTON NPJ, 1989, EUR J BIOCHEM, V182, P593, DOI 10.1111/j.1432-1033.1989.tb14868.x; CUNNINGHAM IJ, 1992, BIOCHIM BIOPHYS ACTA, V1100, P332, DOI 10.1016/0167-4838(92)90490-5; CUNNINGHAM IJ, 1992, BIOCHIM BIOPHYS ACTA, V1101, P345, DOI 10.1016/0167-4838(92)90562-R; DIGGLE C, 1995, EUR J BIOCHEM, V232, P315, DOI 10.1111/j.1432-1033.1995.tb20814.x; DIGGLE C, 1995, EUR J BIOCHEM, V228, P719, DOI 10.1111/j.1432-1033.1995.0719m.x; FISHER RR, 1969, FEBS LETT, V3, P27, DOI 10.1016/0014-5793(69)80087-6; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GLAVAS NA, 1995, BBA-BIOENERGETICS, V1231, P297, DOI 10.1016/0005-2728(95)00089-2; HUTTON M, 1994, EUR J BIOCHEM, V219, P1041, DOI 10.1111/j.1432-1033.1994.tb18587.x; LEVER TM, 1991, EUR J BIOCHEM, V197, P247, DOI 10.1111/j.1432-1033.1991.tb15905.x; MEJBAUMKATZENELLENBOGEN W, 1959, CLIN CHIM ACTA, V4, P515, DOI 10.1016/0009-8981(59)90158-5; OLAUSSON T, 1993, BIOCHEMISTRY-US, V32, P13237, DOI 10.1021/bi00211a036; PALMER T, 1992, BIOCHIM BIOPHYS ACTA, V1099, P157, DOI 10.1016/0304-4173(92)90022-7; Sambrook J., 2002, MOL CLONING LAB MANU; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; WAKABAYASHI S, 1987, BIOCHEM INT, V15, P915; WILLIAMS R, 1994, MICROBIOL-UK, V140, P1595, DOI 10.1099/13500872-140-7-1595; YAMAGUCHI M, 1994, J BIOENERG BIOMEMBR, V26, P435, DOI 10.1007/BF00762784	22	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10109	10115		10.1074/jbc.271.17.10109	http://dx.doi.org/10.1074/jbc.271.17.10109			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626569	hybrid			2022-12-27	WOS:A1996UG25700041
J	Fu, MX; Requena, JR; Jenkins, AJ; Lyons, TJ; Baynes, JW; Thorpe, SR				Fu, MX; Requena, JR; Jenkins, AJ; Lyons, TJ; Baynes, JW; Thorpe, SR			The advanced glycation end product, N-(epsilon)(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; ATHEROGENESIS; PROTEIN	N-epsilon-(Carboxymethyl)lysine (CML) is an advanced glycation end product formed on protein by combined nonenzymatic glycation and oxidation (glycoxidation) reactions, We now report that CML is also formed during metal-catalyzed oxidation of polyunsaturated fatty acids in the presence of protein. During copper-catalyzed oxidation in vitro, the CML content of low density lipoprotein increased in concert with conjugated dienes but was independent of the presence of the Amadori compound, fructoselysine, on the protein, CML was also formed in a time-dependent manner in RNase incubated under aerobic conditions in phosphate buffer containing arachidonate or linoleate; only trace amounts of CML were formed from oleate. After 6 days of incubation the yield of CML in RNase from arachidonate was similar to 0.7 mmol/mol lysine compared with only 0.03 mmol/mol lysine for protein incubated under the same conditions with glucose. Glyoxal, a known precursor of CML, was also formed during incubation of RNase with arachidonate. These results suggest that lipid peroxidation, as well as glycoxidation, may be an important source of CML in tissue proteins in vivo and that CML may be a general marker of oxidative stress and long term damage to protein in aging, atherosclerosis, and diabetes.	UNIV S CAROLINA,DEPT CHEM & BIOCHEM,COLUMBIA,SC 29208; UNIV S CAROLINA,SCH MED,COLUMBIA,SC 29208; MED UNIV S CAROLINA,DEPT MED,CHARLESTON,SC 29245	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Medical University of South Carolina				Lyons, Timothy/0000-0003-2106-1622; Jenkins, Alicia/0000-0003-0583-3717	NEI NIH HHS [5R29 EY 10697] Funding Source: Medline; NIA NIH HHS [AG-11471] Funding Source: Medline; NATIONAL EYE INSTITUTE [R29EY010697] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; BROWNLEE M, 1994, DIABETES, V43, P836, DOI 10.2337/diab.43.6.836; CHUNG BH, 1986, METHOD ENZYMOL, V128, P181; CURCIO F, 1992, IN VITRO CELL DEV-AN, V28A, P787; CURTISS LK, 1985, DIABETES, V34, P452, DOI 10.2337/diabetes.34.5.452; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; FOLCH J, 1957, J BIOL CHEM, V226, P497; FU MX, 1994, DIABETES, V43, P676, DOI 10.2337/diabetes.43.5.676; GIARDINO I, 1994, J CLIN INVEST, V94, P110, DOI 10.1172/JCI117296; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; KAWAMURA M, 1994, J CLIN INVEST, V94, P771, DOI 10.1172/JCI117396; KNECHT KJ, 1991, DIABETES, V40, P190, DOI 10.2337/diabetes.40.2.190; LOIDLSTAHLHOFEN A, 1994, BBA-LIPID LIPID MET, V1211, P156, DOI 10.1016/0005-2760(94)90264-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MLAKAR A, 1994, BBA-LIPID LIPID MET, V1214, P209; MULLARKEY CJ, 1990, BIOCHEM BIOPH RES CO, V173, P932, DOI 10.1016/S0006-291X(05)80875-7; NIYATISHIRKHODAEE F, 1993, J AGR FOOD CHEM, V41, P227, DOI 10.1021/jf00026a016; OSBORNE JC, 1986, METHOD ENZYMOL, V128, P213; PALINSKI W, 1995, ARTERIOSCL THROM VAS, V15, P571, DOI 10.1161/01.ATV.15.5.571; PHILISTSIMIKAS A, 1995, ARTERIOSCL THROM VAS, V15, P367, DOI 10.1161/01.ATV.15.3.367; PICARD S, 1992, P NATL ACAD SCI USA, V89, P6876, DOI 10.1073/pnas.89.15.6876; REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021; REQUENA JR, 1993, DIABETES RES, V20, P43; TSAI EC, 1994, DIABETES, V43, P1010, DOI 10.2337/diabetes.43.8.1010; VLASSARA H, 1994, LAB INVEST, V70, P138; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; WELLSKNECHT MC, 1995, BIOCHEMISTRY-US, V34, P15134, DOI 10.1021/bi00046a020; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499	30	680	706	0	58	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9982	9986		10.1074/jbc.271.17.9982	http://dx.doi.org/10.1074/jbc.271.17.9982			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626637	hybrid			2022-12-27	WOS:A1996UG25700021
J	Kanety, H; Hemi, P; Papa, MZ; Karasik, A				Kanety, H; Hemi, P; Papa, MZ; Karasik, A			Sphingomyelinase and ceramide suppress insulin-induced tyrosine phosphorylation of the insulin receptor substrate-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; CELLS	The sphingomyelin pathway is a newly described signal transduction pathway mediating the action of several cytokines including tumor necrosis factor-alpha (TNF), TNF was recently shown to interfere with insulin-induced tyrosine phosphorylation of the insulin receptor substrate-1 (IRS-1). In this work we examined the possible effect of direct activation of the sphingomyelin pathway on insulin-induced tyrosine phosphorylation of IRS-1. Incubation of the insulin-sensitive rat hepatoma Fao cells with bacterial sphingomyelinase (SMase) that causes membrane hydrolysis of sphingomyelin led to a time- and dose-dependent decrease in insulin-induced tyrosine phosphorylation of IRS-1, The effect was apparent after 10 min of incubation and with a dose of 10 milliunits/ml SMase, It was not associated with a decrease in insulin receptor autophosphorylation, In addition, SMase treatment interrupted the association of the 85-kDa catalytic subunit of phosphatidylinositol 3-kinase with IRS-1. A similar impact on IRS-1 tyrosine phosphorylation was observed after addition of cell-permeable ceramide analogs (C2 and C6). Comparable changes in IRS-1 tyrosine phosphorylation and electrophoretic mobility were found after exposure of cells to either TNF, SMase, or ceramide. Our findings suggest that TNF may utilize the sphingomyelin pathway in its effect on the insulin-stimulated tyrosine phosphorylation of IRS-1.	CHAIM SHEBA MED CTR,DEPT SURG,IL-52621 TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,INST ENDOCRINOL,IL-52621 TEL HASHOMER,ISRAEL	Chaim Sheba Medical Center; Chaim Sheba Medical Center								BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KANETY H, 1994, P NATL ACAD SCI USA, V91, P1853, DOI 10.1073/pnas.91.5.1853; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIU J, 1994, J BIOL CHEM, V269, P3047; MIRALPEIX M, 1992, BIOCHEMISTRY-US, V31, P9031, DOI 10.1021/bi00152a046; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; RAINES MA, 1993, J BIOL CHEM, V268, P14572; SALEEM A, 1995, J IMMUNOL, V154, P4150; SANTANA P, 1995, ENDOCRINOLOGY, V136, P2345, DOI 10.1210/en.136.5.2345; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WHITE MF, 1994, J BIOL CHEM, V269, P1; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; ZHANG YH, 1995, ENDOCRINOLOGY, V136, P4157, DOI 10.1210/en.136.10.4157	24	142	145	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9895	9897		10.1074/jbc.271.17.9895	http://dx.doi.org/10.1074/jbc.271.17.9895			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626623	hybrid			2022-12-27	WOS:A1996UG25700007
J	Khurana, S; Nath, SK; Levine, SA; Bowser, JM; Tse, CM; Cohen, ME; Donowitz, M				Khurana, S; Nath, SK; Levine, SA; Bowser, JM; Tse, CM; Cohen, ME; Donowitz, M			Brush border phosphatidylinositol 3-kinase mediates epidermal growth factor stimulation of intestinal NaCl absorption and Na+/H+ exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOINOSITIDE 3-KINASE; GLUCOSE-TRANSPORT; FACTOR RECEPTORS; SKELETAL-MUSCLE; F-ACTIN; MEMBRANE; CELL; PHOSPHORYLATION; TRANSLOCATION	In terminally differentiated ileal villus Na+-absorptive cells, epidermal growth factor (EGF) stimulates NaCl absorption and its component brush border Na+/H+ exchanger, acting via basolateral membrane receptors, and as we confirm here, a brush border tyrosine kinase, In the present study we show that brush border phosphatidylinositol 3-kinase (PI 3-kinase) is involved in EGF stimulation of NaCl absorption and brush border Na+/H+ exchange, In rabbit ileum studied with the Ussing chamber-voltage clamp technique, EGF stimulation of active NaCl absorption is inhibited by the selective PI 3-kinase inhibitor wortmannin, PI 3-kinase, a largely cytosolic enzyme, translocates specifically to the brush border of ileal absorptive cells following EGF treatment, This translocation occurs as early as 1 min after EGF treatment and remains increased at the brush border for at least 15 min, EGF also causes a rapid (1 min) and large (4-5-fold) increase in brush border PI 3-kinase activity, Involvement of PI S-kinase activity in intestinal Na+ absorption is established further by studies done in the human colon cancer cell line, Caco-2, stably transfected with the intestinal brush border isoform of the Na+/H+ exchanger, NHE3 (Caco-2/NHE3 cells), Brush border Na+/H+ exchange activity was measured using the pH-sensitive fluorescent dye 2'7'-bis(carboxyethyl)5-(6)-carboxyfluorescein EGF added to the basolateral surface but not apical surface of Caco-2n/NHE3 cells increased brush border Na+/H+ exchange activity, The EGF-induced increase in brush border Na+/H+ exchange activity was completely abolished in cells pretreated with wortmannin, EGF treatment caused increased tyrosine phosphorylation of PI 3-kinase in both ileal brush border membranes and Caco-2/NHE3 cells, suggesting that a tyrosine kinase upstream of the PI 3-kinase is involved in the EGF effects on Na+ absorption. In conclusion, the present study provides evidence in two separate intestinal models, the ileum and a human colon cancer cell line, that PI 3-kinase is an intermediate in EGF stimulation of intestinal Na+ absorption.	JOHNS HOPKINS UNIV HOSP,SCH MED,DIV GASTROINTESTINAL,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,SCH MED,DIV GASTROINTESTINAL,DEPT PHYSIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine				Khurana, Seema/0000-0002-6884-810X	NIDDK NIH HHS [R01 DK 266523, P01DK44484] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044484] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNARD RJ, 1992, FASEB J, V6, P3238, DOI 10.1096/fasebj.6.14.1426762; BISHOP WP, 1994, AM J PHYSIOL-GASTR L, V267, pG892, DOI 10.1152/ajpgi.1994.267.5.G892; CANNON C, 1985, NATURE, V314, P443, DOI 10.1038/314443a0; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593, DOI 10.1152/jappl.1991.70.4.1593; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COHEN ME, 1991, J CLIN INVEST, V88, P855, DOI 10.1172/JCI115387; COHEN ME, 1990, P NATL ACAD SCI USA, V87, P8990, DOI 10.1073/pnas.87.22.8990; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DONOWITZ M, 1987, AM J PHYSIOL, V252, pG723, DOI 10.1152/ajpgi.1987.252.6.G723; DONOWITZ M, 1994, AM J PHYSIOL, V266, pG647, DOI 10.1152/ajpgi.1994.266.4.G647; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; EBERLE M, 1990, J BIOL CHEM, V265, P16725; EMMER E, 1989, J MEMBRANE BIOL, V108, P207, DOI 10.1007/BF01871735; GROSS DAE, 1994, BIOCHEM J, V303, P21; HIRST BH, 1985, BIOCHEM J, V231, P641, DOI 10.1042/bj2310641; HOLMGREN K, 1992, AM J PHYSIOL, V262, pC672, DOI 10.1152/ajpcell.1992.262.3.C672; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KELLY KL, 1992, J BIOL CHEM, V267, P3423; Khurana S, 1996, BIOCHEM J, V313, P509, DOI 10.1042/bj3130509; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; MA YH, 1994, J BIOL CHEM, V269, P30734; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; OKADA T, 1994, J BIOL CHEM, V269, P3568; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; POWIS G, 1994, CANCER RES, V54, P2419; SCHEVING LA, 1989, J BIOL CHEM, V264, P1735; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; THOMPSON JF, 1993, AM J PHYSIOL, V265, pG63, DOI 10.1152/ajpgi.1993.265.1.G63; THOMPSON JF, 1994, GASTROENTEROLOGY, V107, P1278, DOI 10.1016/0016-5085(94)90528-2; TSE CM, 1993, P NATL ACAD SCI USA, V90, P9110, DOI 10.1073/pnas.90.19.9110; WANG Z, 1993, J BIOL CHEM, V268, P11925; WEISER MM, 1973, J BIOL CHEM, V248, P2536; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1; ZHANG J, 1992, J BIOL CHEM, V267, P4686	39	93	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9919	9927		10.1074/jbc.271.17.9919	http://dx.doi.org/10.1074/jbc.271.17.9919			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626628	hybrid			2022-12-27	WOS:A1996UG25700012
J	Fukuda, M; Kojima, T; Mikoshiba, K				Fukuda, M; Kojima, T; Mikoshiba, K			Phospholipid composition dependence of Ca2+-dependent phospholipid binding to the C2A domain of synaptotagmin IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTRANSMITTER RELEASE; EXOCYTOSIS; DROSOPHILA; MUTANTS; P65	Synaptotagmins I and II are Ca2+- and phospholipid-binding proteins of synaptic vesicles that may function as Ca2+ receptors for neurotransmitter release via their first C2 domains. Herein, we describe the phospholipid binding properties of C2A domains of multiple synaptotagmins (II-VI). We demonstrate that all synaptotagmins can bind negatively charged phospholipids (phosphatidylserine (PS) and phosphatidylinositol (PI)) in a Ca2+-dependent manner, although it was previously reported that synaptotagmins IV and VI do not bind phos pholipids. The Ca2+-dependent interaction of the C2A domain of synaptotagmin IV with PS was found to have two components with EC(50) values of approximately 5 and 120 mu M free Ca2+ and exhibited positive cooperativity (Hill coefficient of approximately 2 for both components). This value is lower than that of the C2A domain of synaptotagmin II (Hill coefficient of approximately 3). All other isoforms bound PS with high affinity (EC(50) of 0.3-1 mu M free Ca2+ Hill coefficient of 3-3.5). In addition, the C2A domain df synaptotagmin IV cannot bind liposomes consisting of PS (or PI) and phosphatidylcholine, PC (or phosphatidylethanolamine, PE) (1:1, w/w), indicating that the binding to negatively charged phospholipids is inhibited by the presence of PC or PE. In contrast, other isoforms bound all of the liposomes, which include either PS or PI, in a Ca2+-dependent manner. Mutational analysis indicated that this phospholipid composition-dependent Ca2+ binding of synaptotagmin IV results in the substitution of Asp for Ser at position 244. The cytoplasmic domain of synaptotagmin IV also shows this unique phospholipid binding. However, it binds PS with a positive cooperativity and an affinity similar to those of the C2A domains of other isoforms. Our results suggest that synaptotagmin IV is also a potential Ca2+ sensor for neurotransmitter release.	UNIV TOKYO,INST MED SCI,DEPT MOLEC NEUROBIOL,MINATO KU,TOKYO 108,JAPAN; EXPLORATORY RES ADV TECHNOL,CALCIOSIGNAL NET PROJECT,MEGURO KU,TOKYO 153,JAPAN	University of Tokyo	Fukuda, M (corresponding author), INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC NEUROBIOL LAB,3-1-1 KOYADAI,TSUKUBA,IBARAKI 305,JAPAN.		Fukuda, MItsunori/I-1511-2015; Mikoshiba, Katsuhiko/N-7943-2015	Fukuda, MItsunori/0000-0002-8620-5853; 				BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; CRAXTON M, 1995, FEBS LETT, V361, P196, DOI 10.1016/0014-5793(95)00176-A; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; MOCHIDA S, 1995, SAT S 15 ISN M JUN 2, P124; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OHARAIMAIZUMI M, 1995, SAT S 15 ISN M JUN 2, P125; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; ULLRICH B, 1994, NEURON, V13, P1281, DOI 10.1016/0896-6273(94)90415-4; VICIAN L, 1995, P NATL ACAD SCI USA, V92, P2164, DOI 10.1073/pnas.92.6.2164; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	28	93	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8430	8434		10.1074/jbc.271.14.8430	http://dx.doi.org/10.1074/jbc.271.14.8430			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626542	hybrid			2022-12-27	WOS:A1996UD60000082
J	Jenkins, TM; Engelman, A; Ghirlando, R; Craigie, R				Jenkins, TM; Engelman, A; Ghirlando, R; Craigie, R			A soluble active mutant of HIV-1 integrase - Involvement of both the core and carboxyl-terminal domains in multimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RETROVIRAL INTEGRATION; ESCHERICHIA-COLI; DNA INTEGRATION; PROTEIN INVITRO; RNA-POLYMERASE; IDENTIFICATION; MUTAGENESIS; REGION; TYPE-1	Structural studies of human immunodeficiency virus type 1 (HIV-1) integrase have been impeded by the low solubility of the protein. By systematic replacement of hydrophobic residues, we previously identified a single amino acid change (F185K) that dramatically improved the solubility of the catalytic domain of HIV-1 integrase and enabled the structure to be determined by x-ray crystallography. We have introduced the same mutation into full-length HIV-1 integrase. The resulting recombinant protein is soluble and fully active in vitro, whereas, HIV-1 carrying the mutation is replication-defective due to improper virus assembly. Analysis of the recombinant protein by gel filtration and sedimentation equilibrium demonstrate a dimer-tetramer self-association. We find that the regions involved in multimerization map to both the catalytic core and carboxyl-terminal domains. The dramatically improved solubility of this protein make it a good candidate for structural studies.	NIDDKD,MOLEC BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Ghirlando, Rodolfo/A-8880-2009					ANSARILARI MA, 1995, VIROLOGY, V211, P332, DOI 10.1006/viro.1995.1412; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; EIJKELENBOOM APAM, 1995, NAT STRUCT BIOL, V2, P807, DOI 10.1038/nsb0995-807; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1995, J VIROL, V69, P2729, DOI 10.1128/JVI.69.5.2729-2736.1995; ENGELMAN A, 1995, J VIROL, V69, P5908, DOI 10.1128/JVI.69.9.5908-5911.1995; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; GOFF SP, 1992, ANNU REV GENET, V26, P527, DOI 10.1146/annurev.ge.26.120192.002523; GRANDGENETT DP, 1978, VIROLOGY, V89, P119, DOI 10.1016/0042-6822(78)90046-6; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JENKINS TM, 1995, P NATL ACAD SCI USA, V92, P6057, DOI 10.1073/pnas.92.13.6057; JONES KS, 1992, J BIOL CHEM, V267, P16037; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAFEMINA RL, 1991, J VIROL, V65, P5624, DOI 10.1128/JVI.65.10.5624-5630.1991; LEAVITT AD, 1993, J BIOL CHEM, V268, P2113; LODI PJ, 1995, BIOCHEMISTRY-US, V34, P9826, DOI 10.1021/bi00031a002; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; POLARD P, 1995, MOL MICROBIOL, V15, P13, DOI 10.1111/j.1365-2958.1995.tb02217.x; ROARK DE, 1976, BIOPHYS CHEM, V5, P185, DOI 10.1016/0301-4622(76)80034-8; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSS EK, 1991, J VIROL, V65, P4350, DOI 10.1128/JVI.65.8.4350-4358.1991; ROWLAND SJ, 1990, MOL MICROBIOL, V4, P961, DOI 10.1111/j.1365-2958.1990.tb00669.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; SHIN CG, 1994, J VIROL, V68, P1633, DOI 10.1128/JVI.68.3.1633-1642.1994; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691; VINK C, 1993, TRENDS GENET, V9, P433, DOI 10.1016/0168-9525(93)90107-S; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; WHITCOMB JM, 1992, ANNU REV CELL BIOL, V8, P275, DOI 10.1146/annurev.cb.08.110192.001423; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988	42	260	271	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7712	7718		10.1074/jbc.271.13.7712	http://dx.doi.org/10.1074/jbc.271.13.7712			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631811	hybrid			2022-12-27	WOS:A1996UC77400079
J	Hammell, RL; HitchcockDeGregori, SE				Hammell, RL; HitchcockDeGregori, SE			Mapping the functional domains within the carboxyl terminus of alpha-tropomyosin encoded by the alternatively spliced ninth exon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTOMYOSIN SUBFRAGMENT-1 ATPASE; MUSCLE THIN-FILAMENTS; TROPONIN-T; SKELETAL-MUSCLE; F-ACTIN; NONPOLYMERIZABLE TROPOMYOSIN; LABELED TROPOMYOSIN; ESCHERICHIA-COLI; AMINO TERMINUS; BINDING-SITES	Tropomyosins are highly conserved, coiled-coil actin binding proteins found in most eukaryotic cells, Striated and smooth muscle alpha-tropomyosins differ by the regions encoded by exons 2 and 9, Unacetylated smooth tropomyosin expressed in Escherichia coli binds actin with high affinity, whereas unacetylated striated tropomyosin requires troponin, found only in striated muscle, for strong actin binding, The residues encoded by exon 9 cause these differences (Cho, Y.-J., and Hitchcock-DeGregori, S, E. (1991) Proc. Natl, Acad, Sci, U, S. A, 88, 10153-10157), We mapped the functional domains encoded by the alpha-tropomyosin exon 9a (striated muscle-specific) and 9d (constitutively expressed), by measuring actin binding and regulation of the actomyosin MgATPase by tropomyosin exon 9 chimeras and truncation mutants expressed in E. coli, We have shown that: 1) the carboxyl-terminal nine residues define the actin affinity of unacetylated tropomyosin; 2) in the presence of Ca2+, the entire exon 9a is required for troponin to promote fully high affinity actin binding; 3) the first 18 residues encoded by exon 9a are critical for the interaction of troponin with tropomyosin on the thin filament, even in the absence of Ca2+. The results give new insight into the structural requirements of tropomyosin for thin filament assembly and regulatory function.			Hammell, RL (corresponding author), ROBERT WOOD JOHNSON MED SCH, DEPT NEUROSCI & CELL BIOL, 675 HOES LANE, PISCATAWAY, NJ 08854 USA.				NHLBI NIH HHS [HL35726] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILEY K, 1948, BIOCHEM J, V43, P2791; BARTEGI A, 1990, EUR J BIOCHEM, V194, P845, DOI 10.1111/j.1432-1033.1990.tb19478.x; BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; CHO YJ, 1990, J BIOL CHEM, V265, P538; CHO YJ, 1991, P NATL ACAD SCI USA, V88, P10153, DOI 10.1073/pnas.88.22.10153; CHO YJ, 1991, THESIS RUTGERS; CHONG PCS, 1982, J BIOL CHEM, V257, P9152; DAHIYA R, 1994, J BIOL CHEM, V269, P29457; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FANNING AS, 1994, CELL MOTIL CYTOSKEL, V29, P29, DOI 10.1002/cm.970290104; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; GOA J, 1953, SCAND J CLIN LAB INV, V5, P218, DOI 10.3109/00365515309094189; Greenfield NJ, 1995, BIOCHEMISTRY-US, V34, P16797, DOI 10.1021/bi00051a030; Hammell R. L., 1994, Molecular Biology of the Cell, V5, p401A; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; HITCHCOCK SE, 1975, EUR J BIOCHEM, V52, P255, DOI 10.1111/j.1432-1033.1975.tb03993.x; HITCHCOCK SE, 1973, J MOL BIOL, V80, P825, DOI 10.1016/0022-2836(73)90212-X; HITCHCOCKDEGREGORI SE, 1982, J BIOL CHEM, V257, P2573; HITCHCOCKDEGREGORI SE, 1990, J MOL BIOL, V214, P885, DOI 10.1016/0022-2836(90)90343-K; HITCHCOCKDEGREGORI SE, 1994, ADV EXP MED BIOL, V358, P85; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; ISHII Y, 1991, J BIOL CHEM, V266, P6894; ISHII Y, 1990, BIOCHEMISTRY-US, V29, P1160, DOI 10.1021/bi00457a010; KLUWE L, 1995, J MUSCLE RES CELL M, V16, P103, DOI 10.1007/BF00122528; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LEESMILLER JP, 1990, MOL CELL BIOL, V10, P1729, DOI 10.1128/MCB.10.4.1729; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; LEHRER SS, 1984, J BIOL CHEM, V259, P2070; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; LEHRER SS, 1975, P NATL ACAD SCI USA, V72, P3377, DOI 10.1073/pnas.72.9.3377; LIN JJC, 1988, J CELL BIOL, V107, P563, DOI 10.1083/jcb.107.2.563; MAK AS, 1983, J BIOL CHEM, V258, P4330; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; NOVY RE, 1993, BIOCHIM BIOPHYS ACTA, V1162, P255, DOI 10.1016/0167-4838(93)90289-4; NOVY RE, 1993, CELL MOTIL CYTOSKEL, V26, P248, DOI 10.1002/cm.970260308; OBRIEN EJ, 1971, PHILOS T ROY SOC B, V261, P201, DOI 10.1098/rstb.1971.0051; PATO MD, 1981, J BIOL CHEM, V256, P602; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; PEARLSTONE JR, 1983, J BIOL CHEM, V258, P2534; PITTENGER MF, 1995, J CELL SCI, V108, P3253; PITTENGER MF, 1992, J CELL BIOL, V118, P841, DOI 10.1083/jcb.118.4.841; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; POTTER JD, 1974, BIOCHEMISTRY-US, V13, P2697, DOI 10.1021/bi00710a007; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; Sambrook J., 2002, MOL CLONING LAB MANU; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; TAO T, 1986, BIOCHEMISTRY-US, V25, P7633, DOI 10.1021/bi00371a054; URBANCIKOVA M, 1994, J BIOL CHEM, V269, P24310; WEGNER A, 1981, BIOCHEMISTRY-US, V20, P5633, DOI 10.1021/bi00522a043; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WIECZOREK DF, 1988, MOL CELL BIOL, V8, P679, DOI 10.1128/MCB.8.2.679; YANG YZ, 1979, J BIOL CHEM, V254, P7137; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535; [No title captured]	62	77	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4236	4242						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626768				2022-12-27	WOS:A1996TW96000046
J	Jezewska, MJ; Bujalowski, W				Jezewska, MJ; Bujalowski, W			Global conformational transitions in Escherichia coli primary replicative helicase DnaB protein induced by ATP, ADP, and single-stranded DNA binding - Multiple conformational, states of the helicase hexamer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMENSIONAL HOMOGENEOUS LATTICE; COOPERATIVE BINDING; THEORETICAL ASPECTS; LARGE LIGANDS; MECHANISM	The direct evidence of dramatic conformational changes of the DnaB hexamer, induced by nucleotide binding, and the presence of multiple conformational states of the enzyme have been obtained by using analytical sedimentation equilibrium, sedimentation velocity studies, and the rigorous fluorescence titration technique. Equilibrium sedimentation measurements show that in the presence of the ATP nonhydrolyzable analog, AMP-PNP, the DnaB helicase fully preserves its hexameric structure. However, in the presence of the saturating concentration of AMP-PNP, the sedimentation coefficient of the hexamer is s(20,w) = 11.9 +/- 0.2 compared to the sedimentation coefficient s(20,w) = 10.5 +/- 0.2 of the free DnaB helicase hexamer. This large sedimentation coefficient change indicates dramatic global conformational transitions of the hexamer, encompassing all six subunits, upon binding the ATP analog, In the presence of ADP, the sedimentation coefficient is s(20,w) = 11.4 +/- 0.2, indicating that the conformation of the ADP form of the hexamer is different from the ATP form. The sedimentation coefficient of the ternary complex DnaB-(AMP-PNP)-d epsilon G(p epsilon A)(19), s(20,w) = 12.4, suggests that the DnaB helicase undergoes further conformational changes upon binding single-stranded DNA (ssDNA). The large global structural changes correlate with the functional activities of the enzyme, In the absence of the ATP analog, the hexamer exists in a ''closed'' conformation which has extremely low affinity toward ssDNA. Upon binding the ATP analog, the DnaB hexamer transforms into a ''tense'' state which binds ssDNA with an affinity of similar to 4 orders of magnitude higher than in the absence of the nucleotide, In the presence of ADP, the DnaB hexamer assumes a ''relaxed'' conformation. The functional difference between these two conformations is reflected in the much weaker allosteric effect of ADP on the ssDNA binding with the affinity constant similar to 3 orders of magnitude weaker than in the presence of the ATP analog (tense state).	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston					NIGMS NIH HHS [GM-46679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1981, J BIOL CHEM, V256, P5253; BAKER TA, 1987, J BIOL CHEM, V262, P6877; BUJALOWSKI W, 1994, BIOCHEMISTRY-US, V33, P4682, DOI 10.1021/bi00181a028; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31359; BUJALOWSKI W, 1993, BIOCHEMISTRY-US, V32, P5888, DOI 10.1021/bi00073a023; BUJALOWSKI W, 1995, BIOCHEMISTRY-US, V34, P8513, DOI 10.1021/bi00027a001; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; BUJALOWSKI W, 1989, BIOPOLYMERS, V28, P1637, DOI 10.1002/bip.360280912; Cantor C. R, 1980, BIOPHYSICAL CHEM 2, P591; HILL TL, 1981, P NATL ACAD SCI-BIOL, V78, P4796, DOI 10.1073/pnas.78.8.4796; HOWLETT GJ, 1977, BIOCHEMISTRY-US, V16, P5077, DOI 10.1021/bi00642a021; KORNBERG A, 1992, DNA REPLICATION, P355; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MCMACKEN R, 1977, J BIOL CHEM, V253, P3313; PEARCE TC, 1978, J MOL BIOL, V105, P383; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4051; WICKNER S, 1973, P NATL ACAD SCI USA, V71, P783; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350	23	66	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4261	4265						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626772				2022-12-27	WOS:A1996TW96000050
J	Mohr, S; Stamler, JS; Brune, B				Mohr, S; Stamler, JS; Brune, B			Posttranslational modification of glyceraldehyde-3-phosphate dehydrogenase by S-nitrosylation and subsequent NADH attachment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDE-GENERATING AGENTS; NITRIC-OXIDE; ADP-RIBOSYLATION; PROTEIN; BINDING	Nitric oxide (NO)-related activity has been associated with an NAD(+)-dependent modification of the glycolytic enzyme, glyceraldehyde-3-phosphate dehydrogenase (GAPDH). However, the mechanism by which NO effects covalent attachment of nucleotide and its role in regulation of enzyme activity are controversial. Recent studies have shown that S-nitrosylation of GAPDH (Cys(149)) initiates subsequent modification by the pyridinium cofactor. Here we show that NADH rather than NAD(+) is the preferred substrate. Transnitrosation from active site S-nitrosothiol to the reduced nicotinamide ring system appears to facilitate protein thiolate attack on the enzyme-bound cofactor. This results in attachment of the intact NADH molecule. Moreover, we find that S-nitrosylation of GAPDH is responsible for reversible enzyme inhibition, whereas attachment of NADH accounts for irreversible enzyme inactivation. S-Nitrosylation may serve to protect GAPDH from oxidant inactivation in settings of cytokine overproduction and to regulate glycolysis. NADH attachment is more likely to be a pathophysiological event associated with inhibition of gluconeogenesis.	UNIV ERLANGEN NURNBERG,FAC MED,DEPT 4,EXPT DIV,D-91054 ERLANGEN,GERMANY; UNIV KONSTANZ,FAC BIOL,D-78434 CONSTANCE,GERMANY; DUKE UNIV,MED CTR,DIV PULM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DIV CARDIOVASC,DURHAM,NC 27710	University of Erlangen Nuremberg; University of Konstanz; Duke University; Duke University				Stamler, Jonathan/0000-0002-6866-1572	NHLBI NIH HHS [HLS2529, HLO2582] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002582] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; BARRIO JR, 1972, P NATL ACAD SCI USA, V69, P2039, DOI 10.1073/pnas.69.8.2039; BRUNE B, 1989, J BIOL CHEM, V264, P8455; BRUNE B, 1990, P NATL ACAD SCI USA, V87, P3304, DOI 10.1073/pnas.87.9.3304; BRUNE B, 1994, LIFE SCI, V54, P61, DOI 10.1016/0024-3205(94)00775-6; DEGROOTE MA, 1995, P NATL ACAD SCI USA, V92, P6399, DOI 10.1073/pnas.92.14.6399; DIMMELER S, 1992, J BIOL CHEM, V267, P16771; DIMMELER S, 1992, EUR J BIOCHEM, V210, P305, DOI 10.1111/j.1432-1033.1992.tb17422.x; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; HENDERSON SA, 1994, J BIOL CHEM, V269, P25239; HENRY Y, 1993, FASEB J, V7, P1124, DOI 10.1096/fasebj.7.12.8397130; HORTON RA, 1994, BIOCHEM J, V299, P735, DOI 10.1042/bj2990735; KLEPP J, 1989, J AM CHEM SOC, V111, P4440, DOI 10.1021/ja00194a045; KOTS AY, 1992, FEBS LETT, V300, P9, DOI 10.1016/0014-5793(92)80153-8; LIPTON SA, 1994, NEUROPHARMACOLOGY, V33, P1229, DOI 10.1016/0028-3908(94)90021-3; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; MEYER DJ, 1994, FEBS LETT, V345, P177, DOI 10.1016/0014-5793(94)00429-3; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; MORRIS SL, 1981, J BACTERIOL, V148, P465, DOI 10.1128/JB.148.2.465-471.1981; OAE S, 1983, ORG PREP PROCED INT, V15, P165, DOI 10.1080/00304948309355444; Oppenheimer N. J., 1987, PYRIDINE NUCLEOTIDE, P323; PANCHOLI V, 1993, P NATL ACAD SCI USA, V90, P8154, DOI 10.1073/pnas.90.17.8154; RACKER E, 1952, J BIOL CHEM, V198, P731; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TABUCHI A, 1994, FEBS LETT, V351, P123, DOI 10.1016/0014-5793(94)00839-6; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382	31	199	205	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4209	4214						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626764				2022-12-27	WOS:A1996TW96000042
J	Lim, AL; PowersLee, SG				Lim, AL; PowersLee, SG			Requirement for the carboxyl-terminal domain of Saccharomyces cerevisiae carbamoyl-phosphate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL PROTEIN CAD; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; CATALYTIC DOMAINS; SHUTTLE VECTORS; BINDING-SITES; LARGE SUBUNIT; LIVER; LOCATION; SEQUENCE	The arginine-specific carbamoyl phosphate synthetase of Saccharomyces cerevisiae is a heterodimeric enzyme, with a 45-kDa CPA1 subunit binding and cleaving glutamine, and a 124-kDa CPA2 subunit accepting the ammonia moiety cleaved from glutamine, binding all of the remaining substrates and carrying out all of the other catalytic events. CPA2 is composed of two apparently duplicated amino acid sequences involved in binding the two ATP molecules needed for carbamoyl phosphate synthesis and a carboxyl-terminal domain which appears to be less tightly folded than the remainder of the protein. Using deletion mutagenesis, we have established that essentially all of the carboxyl-terminal domain of CPA2 is required for catalytic function and that even small truncations lead to significant changes in the CPA2 conformation. In addition, we have demonstrated that the C-terminal region of CPA2 can be expressed as an autonomously folded unit which is stabilized by specific interactions with the remainder of CPA2. We also made the unexpected finding that, even when ammonia is used as the substrate and there is no catalytic role for CPA1, interaction with CPA1 led to an increase in the V-max of CPA2 in crude extracts.	NORTHEASTERN UNIV, DEPT BIOL, BOSTON, MA 02115 USA	Northeastern University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033460] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33460] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALBER T, 1987, BIOCHEMISTRY-US, V26, P3754, DOI 10.1021/bi00387a002; ANDERSON PM, 1995, NITROGEN METABOLISM, P33; BEIN K, 1991, J BIOL CHEM, V266, P3791; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUBECK P, 1993, NUCLEIC ACIDS RES, V21, P3601, DOI 10.1093/nar/21.15.3601; BUESO J, 1994, BIOCHEM BIOPH RES CO, V203, P1083, DOI 10.1006/bbrc.1994.2293; CERVERA J, 1993, J BIOL CHEM, V268, P12504; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EVANS DR, 1988, BIOCHIM BIOPHYS ACTA, V953, P185, DOI 10.1016/0167-4838(88)90023-4; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUILLOU F, 1992, BIOCHEMISTRY-US, V31, P1656, DOI 10.1021/bi00121a012; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; HELBING CC, 1994, J BIOL CHEM, V269, P11743; JONES EW, 1991, J BIOL CHEM, V266, P7963; KIM H, 1991, BIOCHEMISTRY-US, V30, P10322, DOI 10.1021/bi00106a033; KIM HS, 1992, J BIOL CHEM, V267, P7177; LACROUTE F, 1965, J GEN MICROBIOL, V40, P127, DOI 10.1099/00221287-40-1-127; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU X, 1994, J BIOL CHEM, V269, P27747; LUSTY CJ, 1982, P NATL ACAD SCI-BIOL, V79, P2240, DOI 10.1073/pnas.79.7.2240; LUSTY CJ, 1983, J BIOL CHEM, V258, P4466; MANCHESTER M, 1994, J BIOL CHEM, V269, P7689; MARSHALL M, 1988, ARCH BIOCHEM BIOPHYS, V262, P455, DOI 10.1016/0003-9861(88)90397-9; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; NYUNOYA H, 1984, J BIOL CHEM, V259, P9790; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PIERARD A, 1978, J BACTERIOL, V134, P167; POST LE, 1990, J BIOL CHEM, V265, P7742; POTTER MD, 1992, J BIOL CHEM, V267, P2023; POTTER MD, 1993, ARCH BIOCHEM BIOPHYS, V306, P377, DOI 10.1006/abbi.1993.1526; POWERSLEE SG, 1986, J BIOL CHEM, V261, P5349; POWERSLEE SG, 1987, J BIOL CHEM, V262, P9052; PRICE CW, 1978, J GEN MICROBIOL, V106, P145, DOI 10.1099/00221287-106-1-145; RODRIGUEZAPARICIO LB, 1989, BIOCHEMISTRY-US, V28, P3070, DOI 10.1021/bi00433a050; Rose MD., 1990, METHODS YEAST GENETI; RUBINO SD, 1987, J BIOL CHEM, V262, P4382; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; RUBIO V, 1991, BIOCHEMISTRY-US, V30, P1068, DOI 10.1021/bi00218a027; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TROTTA PP, 1974, J BIOL CHEM, V249, P492; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2	48	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11400	11409		10.1074/jbc.271.19.11400	http://dx.doi.org/10.1074/jbc.271.19.11400			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626695	hybrid			2022-12-27	WOS:A1996UJ94400055
J	Welsh, GI; Miyamoto, S; Price, NT; Safer, B; Proud, CG				Welsh, GI; Miyamoto, S; Price, NT; Safer, B; Proud, CG			T-cell activation leads to rapid stimulation of translation initiation factor eIF2B and inactivation of glycogen synthase kinase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; POLYPEPTIDE-CHAIN INITIATION; RABBIT RETICULOCYTE LYSATE; PROTEIN-SYNTHESIS; LYMPHOCYTE STIMULATION; FACTOR-II; PHOSPHORYLATION; PHYTOHEMAGGLUTININ; MECHANISM; INSULIN	Mitogenic stimulation of T-lymphocytes causes a rapid activation of protein synthesis, which reflects in part increased expression of many translation components. Their levels, however, rise more slowly than the rate of protein synthesis, indicating an enhancement of the efficiency of their utilization. Initiation factor eIF2B catalyzes a hey regulatory step in the initiation of translation, and we have therefore studied its activity following T-cell activation. eIF2B activity rises quickly, increasing as early as 5 min after cell stimulation. This initial phase is followed by an additional slow but substantial increase in eLF2B activity. The level of eIF2B subunits did not change over the initial rapid phase but did increase at later time points. Northern analysis revealed that levels of eIF2B mRNA only rose during the later phase. The rapid activation of eIF2B following mitogenic stimulation of T-cells is therefore mediated by factors other than its own concentration. The largest (epsilon) subunit of elF2B is a substrate for glycogen synthase kinase 3 (GSK-3), the activity of which rapidly decreases following T-cell activation. Since phosphorylation of eIF2B by GSK-3 appears to inhibit nucleotide exchange in vitro, this provides a potential mechanism by which eIF2B may be activated.	UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND; NHLBI,MOLEC HEMATOL BRANCH,NIH,BETHESDA,MD 20892	University of Bristol; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)				Welsh, Gavin Iain/0000-0002-2148-6658; Proud, Christopher/0000-0003-0704-6442	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHERN T, 1973, BIOCHIM BIOPHYS ACTA, V331, P91, DOI 10.1016/0005-2787(73)90422-X; AHERN T, 1974, NATURE, V248, P519, DOI 10.1038/248519a0; AHERN T, 1975, EXP CELL RES, V92, P513, DOI 10.1016/0014-4827(75)90410-3; ASHMAN RF, 1984, FUNDAMENTAL IMMUNOLO, P267; BOAL TR, 1993, BIOCHIM BIOPHYS ACTA, V1176, P257, DOI 10.1016/0167-4889(93)90053-R; CARTER CS, 1987, TRANSFUSION, V27, P362, DOI 10.1046/j.1537-2995.1987.27487264750.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN RB, 1990, EMBO J, V9, P3831, DOI 10.1002/j.1460-2075.1990.tb07601.x; COOPER HL, 1977, J CELL PHYSIOL, V93, P213, DOI 10.1002/jcp.1040930207; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DHOLAKIA JN, 1988, P NATL ACAD SCI USA, V85, P51, DOI 10.1073/pnas.85.1.51; DHOLAKIA JN, 1986, P NATL ACAD SCI USA, V83, P6746, DOI 10.1073/pnas.83.18.6746; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; GROSS M, 1988, J BIOL CHEM, V263, P12486; GROSS M, 1989, J BIOL CHEM, V264, P21879; HERSHEY JWB, 1990, ENZYME, V44, P17, DOI 10.1159/000468744; HERSHEY WB, 1991, ANNU REV BIOCHEM, V60, P717; HUGHES K, 1992, BIOCHEM J, V288, P309, DOI 10.1042/bj2880309; JEDLICKA P, 1991, J BIOL CHEM, V266, P15663; KAY JE, 1975, BIOCHIM BIOPHYS ACTA, V378, P241, DOI 10.1016/0005-2787(75)90112-4; KAY JE, 1971, BIOCHIM BIOPHYS ACTA, V247, P322, DOI 10.1016/0005-2787(71)90680-0; KIMBALL SR, 1995, BIOCHEM BIOPH RES CO, V212, P1074, DOI 10.1006/bbrc.1995.2079; MEHTA HB, 1983, J BIOL CHEM, V258, P3438; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MOULE SK, 1995, BIOCHEM J, V311, P595, DOI 10.1042/bj3110595; OLDFIELD S, 1992, EUR J BIOCHEM, V208, P73, DOI 10.1111/j.1432-1033.1992.tb17160.x; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; PRICE NT, 1989, BIOCHIM BIOPHYS ACTA, V1008, P177, DOI 10.1016/0167-4781(80)90005-6; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; REDPATH NT, 1992, ANAL BIOCHEM, V202, P340, DOI 10.1016/0003-2697(92)90115-N; REDPATH NT, 1994, BBA-MOL CELL RES, V1220, P147, DOI 10.1016/0167-4889(94)90130-9; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; SINGH LP, 1994, BIOCHEMISTRY-US, V33, P9152, DOI 10.1021/bi00197a018; SINGH LP, 1995, BIOCHEM BIOPH RES CO, V212, P1007, DOI 10.1006/bbrc.1995.2070; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; VANLINT J, 1993, ANAL BIOCHEM, V208, P132, DOI 10.1006/abio.1993.1018; WELSH GI, 1992, BIOCHEM J, V284, P19, DOI 10.1042/bj2840019; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WETTENHALL RE, 1974, BIOCHIM BIOPHYS ACTA, V349, P214, DOI 10.1016/0005-2787(74)90082-3	42	91	92	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11410	11413		10.1074/jbc.271.19.11410	http://dx.doi.org/10.1074/jbc.271.19.11410			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626696	hybrid			2022-12-27	WOS:A1996UJ94400056
J	Hutson, RA; Zhou, YT; Collins, MD; Johnson, EA; Hatheway, CL; Sugiyama, H				Hutson, RA; Zhou, YT; Collins, MD; Johnson, EA; Hatheway, CL; Sugiyama, H			Genetic characterization of Clostridium botulinum type A containing silent type B neurotoxin gene sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; PROGENITOR TOXIN; COMPONENT; CLONING	A recent study detected genes encoding type B botulinum neurotoxin in some type A strains of Clostridium botulinum that exhibit no type B toxin activity, In this study, we investigated the presence, structure, linkage, and organization of genes encoding botulinum neurotoxin (BoNT) and other components of the progenitor complex. Sequence analysis showed that the silent BoNT/B gene is highly related to that from authentic proteolytic type B C. botulinum, However, a stop signal and deletions were found within the sequence, A non-toxin nonhemagglutinin gene (NTNH) was mapped immediately upstream of both the BoNT/A and silent BoNT/B genes. Significantly the NTNH gene adjacent to the defective BoNT/B gene was ''chimeric,'' the 5'- and 3'-regions of the gene had high homology with corresponding regions of the type B NTNH gene, while the 471-amino acid sequence in the central region was identical to NTNH of type A. Hemagglutinin genes HA-33 and HA-II were not found adjacent to the NTNH/A gene, but instead there was an unidentified open reading frame previously reported in strains of C. botulinum types E and F. By contrast HA-II, HA-33, and NTNH genes were located immediately upstream of the silent BoNT/B gene, Pulsed field gel electrophoretic analysis of chromosomal DNA digests indicated the distance between type A and B gene clusters to be less than 40 kilobases.	CTR DIS CONTROL & PREVENT,NCID,DBMD,ATLANTA,GA 30333; BIOL & BIOTECH SCI RES COUNCIL,INST FOOD RES,READING LAB,READING RG6 6BZ,BERKS,ENGLAND; UNIV WISCONSIN,DEPT FOOD MICROBIOL & TOXICOL,MADISON,WI 53706; UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706	Centers for Disease Control & Prevention - USA; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								CORDOBA JJ, 1995, SYST APPL MICROBIOL, V18, P13, DOI 10.1016/S0723-2020(11)80443-1; EAST AK, 1994, SYST APPL MICROBIOL, V17, P306, DOI 10.1016/S0723-2020(11)80045-7; EAST AK, 1994, CURR MICROBIOL, V29, P69, DOI 10.1007/BF01575751; EAST AK, 1992, FEMS MICROBIOL LETT, V96, P225, DOI 10.1016/0378-1097(92)90408-G; FRANCIOSA G, 1994, J CLIN MICROBIOL, V32, P1911, DOI 10.1128/JCM.32.8.1911-1917.1994; FUJII N, 1993, J GEN MICROBIOL, V139, P79, DOI 10.1099/00221287-139-1-79; GIMENEZ DF, 1970, ZENTBL BAKTERIOLOG P, V215, P212; Hatheway C.L., 1993, CLOSTRIDIUM BOTULINU, P3; LIN WJ, 1995, APPL ENVIRON MICROB, V61, P4441, DOI 10.1128/AEM.61.12.4441-4447.1995; SOMERS E, 1991, J PROTEIN CHEM, V10, P415, DOI 10.1007/BF01025256; THOMPSON DE, 1990, EUR J BIOCHEM, V189, P73, DOI 10.1111/j.1432-1033.1990.tb15461.x; TSUZUKI K, 1992, BIOCHEM BIOPH RES CO, V183, P1273, DOI 10.1016/S0006-291X(05)80328-6; TSUZUKI K, 1990, INFECT IMMUN, V58, P3173, DOI 10.1128/IAI.58.10.3173-3177.1990; WHELAN SM, 1992, APPL ENVIRON MICROB, V58, P2345, DOI 10.1128/AEM.58.8.2345-2354.1992; ZHOU YT, 1995, INFECT IMMUN, V63, P2087, DOI 10.1128/IAI.63.5.2087-2091.1995	15	69	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10786	10792		10.1074/jbc.271.18.10786	http://dx.doi.org/10.1074/jbc.271.18.10786			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631890	hybrid			2022-12-27	WOS:A1996UJ34200058
J	Lin, JX; Mietz, J; Modi, WS; John, S; Leonard, WJ				Lin, JX; Mietz, J; Modi, WS; John, S; Leonard, WJ			Cloning of human Stat5B - Reconstitution of interleukin-2-induced Stat5A and Stat5B DNA binding activity in COS-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR GAMMA-CHAIN; IL-2 RECEPTOR; FUNCTIONAL COMPONENT; LINE; GENE	We have isolated a second human Stat5 cDNA, Stat5B, and demonstrated that the genes encoding both Stat5A and Stat5B are located at chromosome 17q11.2, Both genes were constitutively transcribed in peripheral blood lymphocytes. By using specific antisera, we demonstrated that both Stat5A and Stat5B are activated by interleukin-2 (IL-2) in peripheral blood lymphocytes, natural killer-like YT leukemia cells, and human T cell lymphotropic virus type I-transformed MT-2 T cells. In COS-7 cells, which constitutively express the Janus family tyrosine kinase Jak1, reconstitution of IL-2-induced Stat5A and Stat5B DNA binding activities was dependent on the coexpression of Jak3 along with the IL-2 receptor beta chain and the common cytokine receptor gamma-chain. This IL-2-induced Stat5 activation was dependent on the presence of either of two tyrosines (Tyr-392 or Tyr-510) in the IL-2 receptor beta chain, indicating that either of these two tyrosines can serve as a docking site, Moreover, we demonstrated that human Stat5 activation is also dependent on Tyr-694 in Stat5A and Tyr-699 in Stat5B, indicating that these tyrosines are required for dimerization. The COS-7 reconstitution system described herein provides a valuable assay for further elucidation of the IL-2-activated JAK-STAT pathway.	NHLBI,LAB MOL IMMUNOL,NIH,BETHESDA,MD 20892; NCI,FREDERICK CANC RES & DEV CTR,SCI APPLICAT INT CORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Leonard, Warren/AAA-1397-2022	John, Susan/0000-0002-5620-1982				AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GNARRA JR, 1990, P NATL ACAD SCI USA, V87, P3440, DOI 10.1073/pnas.87.9.3440; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IZQUIERDO M, 1993, EUR J IMMUNOL, V23, P131, DOI 10.1002/eji.1830230121; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KIMURA Y, 1995, INT IMMUNOL, V7, P115, DOI 10.1093/intimm/7.1.115; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; Leonard WJ, 1996, ANNU REV MED, V47, P229; LEONARD WJ, 1994, IMMUNOL REV, V138, P61, DOI 10.1111/j.1600-065X.1994.tb00847.x; LEONARD WJ, 1994, CURR OPIN IMMUNOL, V6, P631, DOI 10.1016/0952-7915(94)90152-X; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; RUI H, 1994, J BIOL CHEM, V269, P5364; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TORY K, 1992, GENOMICS, V13, P275, DOI 10.1016/0888-7543(92)90243-L; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YODOI J, 1985, J IMMUNOL, V134, P1623; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	51	185	191	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10738	10744		10.1074/jbc.271.18.10738	http://dx.doi.org/10.1074/jbc.271.18.10738			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631883	hybrid			2022-12-27	WOS:A1996UJ34200051
J	Bunting, M; Tang, W; Zimmerman, GA; McIntyre, TM; Prescott, SM				Bunting, M; Tang, W; Zimmerman, GA; McIntyre, TM; Prescott, SM			Molecular cloning and characterization of a novel human diacylglycerol kinase zeta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE CONTROL PROTEINS; CELL-CELL-INTERACTIONS; RETINAL DEGENERATION; SIGNAL TRANSDUCTION; TRANSFORMED FIBROBLASTS; ACTIVATING PROTEIN; ENDOTHELIAL-CELLS; BINDING-PROTEIN; PHOSPHOLIPASE-C; NERVOUS-SYSTEM	Diacylglycerol (DAG) occupies a central position in the synthesis of complex Lipids and also has important signaling roles. For example, DAG is an allosteric regulator of protein kinase C, and the cellular levels of DAG may influence a variety of processes including growth and differentiation. We previously demonstrated that human endothelial cells derived from umbilical vein express growth-dependent changes in their basal levels of diacylglycerol and diacylglycerol kinase activity (Whatley, R. E., Stroud, E. D., Bunting, M., Zimmerman, G. A., McIntyre, T. M., and Prescott, S. M. (1993) J. Biol. Chem. 268, 16130-16138). To further explore the role of diacylglycerol metabolism in endothelial responses, we used a degenerate reverse transcription-polymerase chain reaction method to identify diacylglycerol kinase isozymes expressed by human endothelial cells. We report the isolation of a 3.5-kilobase cDNA encoding a novel diacylglycerol kinase (hDGK zeta) with a predicted molecular mass of 103.9 kDa. Human DGK zeta contains two zinc fingers, an ATP binding site, and four ankyrin repeats near the carboxyl terminus, A unique feature, as compared with other diacylglycerol kinases, is the presence of a sequence homologous to the MARCKS phosphorylation site domain. From Northern blot analysis of multiple tissues, we observed that hDGK zeta mRNA is expressed at highest levels in brain, COS-7 cells transfected with the hDGK zeta cDNA express 117-kDa and 114-kDa proteins that react specifically with an antibody to a peptide derived from a unique sequence in hDGK zeta. The transfected cells also express increased diacylglycerol kinase activity, which is not altered in the presence of R59949, an inhibitor of human platelet DGK activity. The hDGK zeta displays stereoselectivity for 1,2-diacylglycerol species in comparison to 1,3-diacylglycerol, but does not exhibit any specificity for molecular species of long chain diacylglycerols.	UNIV UTAH, ECCLES PROGRAM HUMAN MOL BIOL & GENET, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT INTERNAL MED, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT PATHOL, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT BIOCHEM, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NATIONAL CANCER INSTITUTE [R01CA059548] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL050153] Funding Source: NIH RePORTER; NCI NIH HHS [CA59548] Funding Source: Medline; NHLBI NIH HHS [HL50153] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMED S, 1993, J BIOL CHEM, V268, P10709; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; Baenziger N L, 1974, Methods Enzymol, V31, P149; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECOURCELLES DD, 1989, J BIOL CHEM, V264, P3274; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; FU T, 1992, FEBS LETT, V307, P301, DOI 10.1016/0014-5793(92)80700-Q; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARDEN N, 1993, BIOCHEM J, V289, P439, DOI 10.1042/bj2890439; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HOTTA Y, 1970, P NATL ACAD SCI USA, V67, P1156, DOI 10.1073/pnas.67.3.1156; INOUE H, 1989, J BIOL CHEM, V264, P5996; ISHIKAWA F, 1986, JPN J CANCER RES, V77, P1183; JOHNSON MA, 1982, J INSECT PHYSIOL, V28, P233, DOI 10.1016/0022-1910(82)90082-8; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KATO H, 1988, BIOCHEM BIOPH RES CO, V154, P959, DOI 10.1016/0006-291X(88)90233-1; KATO M, 1987, J BIOL CHEM, V262, P5696; KATO M, 1989, FEBS LETT, V247, P247, DOI 10.1016/0014-5793(89)81345-6; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEUNG T, 1993, J BIOL CHEM, V268, P3813; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MAHONEY CW, 1994, PROTEIN KINASE C, P16; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MASAI I, 1992, P NATL ACAD SCI USA, V89, P6030, DOI 10.1073/pnas.89.13.6030; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; PREISS J, 1986, J BIOL CHEM, V261, P8597; PRESCOTT SM, 1983, J BIOL CHEM, V258, P764; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; QUEST AFG, 1994, J BIOL CHEM, V269, P2961; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; SCHMIDT SY, 1983, J NEUROCHEM, V40, P1630, DOI 10.1111/j.1471-4159.1983.tb08136.x; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TUFTY RM, 1975, SCIENCE, V187, P167, DOI 10.1126/science.1111094; WALSH JP, 1994, J BIOL CHEM, V269, P21155; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WHATLEY RE, 1993, J BIOL CHEM, V268, P16130; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; ZIMMERMAN GA, 1990, METHOD ENZYMOL, V187, P520	57	150	155	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10230	10236		10.1074/jbc.271.17.10230	http://dx.doi.org/10.1074/jbc.271.17.10230			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626588	hybrid			2022-12-27	WOS:A1996UG25700060
J	Itano, N; Kimata, K				Itano, N; Kimata, K			Expression cloning and molecular characterization of HAS protein, a eukaryotic hyaluronan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERICELLULAR MATRIX; CELLS; SEQUENCES; GENE	We developed a mammalian transient expression system to isolate cDNA clones that determine hyaluronan expression. HAS(-), a mouse mammary carcinoma mutant cell line, which is defective in hyaluronan synthase activity, was first established and used as a recipient for the expression cloning, One cloned cDNA that overcame the deficiency was isolated, The cDNA termed HAS contains an open reading frame of 1749 base pairs encoding a new protein of 583 amino acids, Homology analysis of the amino acid sequence suggests that HAS protein is related to streptococcal hyaluronan synthase and also to Xenopus laevis DG42 protein that was found to be homologous to bacterial hyaluronan synthase. Expression of HAS cDNA in HAS(-) cells complemented not only their mutant phenotypes such as deficient hyaluronan-matrix deposition but also hyaluronan synthase activity itself, Therefore, HAS cDNA is responsible for the activity of the hyaluronan synthase, a key enzyme of hyaluronan synthesis in eukaryotic cells.	AICHI MED UNIV, INST MOLEC SCI MED, NAGAKUTE, AICHI 48011, JAPAN	Aichi Medical University								ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1994, BIOCHEM BIOPH RES CO, V199, P1, DOI 10.1006/bbrc.1994.1184; DOUGHERTY BA, 1994, J BIOL CHEM, V269, P169; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HUANG L, 1993, J BIOL CHEM, V268, P26725; KIMATA K, 1983, CANCER RES, V43, P1347; KLEWES L, 1993, BIOCHEM J, V290, P791, DOI 10.1042/bj2900791; KNUDSON W, 1989, CIBA F SYMP, V143, P150; KNUDSON W, 1991, J CELL SCI, V99, P227; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; MIAN N, 1986, BIOCHEM J, V237, P343, DOI 10.1042/bj2370343; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NG KF, 1989, J BIOL CHEM, V264, P11776; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; SEMINO CE, 1995, P NATL ACAD SCI USA, V92, P3498, DOI 10.1073/pnas.92.8.3498; TENGBLAD A, 1979, BIOCHIM BIOPHYS ACTA, V578, P281, DOI 10.1016/0005-2795(79)90158-2; TENGBLAD A, 1980, BIOCHEM J, V185, P101, DOI 10.1042/bj1850101; Toole B.P., 1981, CELL BIOL EXTRACELLU, P259, DOI DOI 10.1007/978-1-4613-0881-2_10; TURLEY EA, 1989, CIBA F SYMP, V143, P121; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; YAMAGATA M, 1993, J CELL SCI, V106, P55; YASUDA H, 1991, CELL STRUCT FUNCT, V16, P105, DOI 10.1247/csf.16.105; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657	27	140	157	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9875	9878		10.1074/jbc.271.17.9875	http://dx.doi.org/10.1074/jbc.271.17.9875			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626618	hybrid			2022-12-27	WOS:A1996UG25700002
J	Shainskaya, A; Karlish, SJD				Shainskaya, A; Karlish, SJD			Chymotryptic digestion of the cytoplasmic domain of the beta subunit of Na/K-ATPase alters kinetics of occlusion of Rb+ ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE ALPHA-SUBUNIT; CATION OCCLUSION; OUABAIN BINDING; INTRACELLULAR-TRANSPORT; EXTRACELLULAR DOMAIN; NA+,K+-ATPASE; ECTODOMAIN; EXPRESSION; NA,K-PUMP; DELETIONS	This paper demonstrates that specific chymotryptic digestion of the cytoplasmic domain of the beta subunit of Na/K-ATPase leads to changes in the kinetics of occlusion of Rb+ ions. The experiments utilize extensively trypsinized Na/K-ATPase, ''19-kDa membranes,'' which lack cytoplasmic loops of the alpha subunit, whereas membrane-embedded fragments (a COOH-terminal 19 kDa and three fragments of 8.1-11.7 kDa) containing transmembrane segments and extracellular loops are intact. The beta subunit is partially split into NH2- and COOH-terminal fragments of 16 and approximate to 50 kDa, respectively. Cation occlusion and ouabain binding are preserved. The 19-kDa membranes were incubated, at 37 degrees C, with a selection of proteases, in the presence of Rb+ ions. In these conditions, only alpha-chymotrypsin destroyed the ability to occlude Rb+ ions. This process was associated with truncation of the 16-kDa fragment of the beta subunit in two stages. In the first stage, chymotrypsin removed 10 residues from the 16-kDa fragment to form a 15-kDa fragment (NH2-terminal Ile(15)) and 4 or 6 residues from the NH2 terminus of the alpha subunit fragment beginning at Asp(68). In these membranes Rb+ occlusion was still intact at 37 degrees C. Strikingly, however, deocclusion of two Rb+ ions, which is characteristically biphasic in 10-kDa membranes, displayed deocclusion kinetic with mainly one fast phase. These membranes also showed a much lower affinity for Rb+ ions compared with 19-kDa membranes; and, consistent with the lower Rb+ affinity, Rb+ ions, at nonsaturating concentrations, protected less well against thermal inactivation of Rb+ occlusion. In the second stage, the 15-kDa fragment was truncated further to a 14-kDa fragment (NH2-terminal Leu(24)), followed by thermal destabilization of Rb+ occlusion even at high concentrations of Rb+ ions. Eventually, the thermally inactivated complex of fragments of alpha and beta subunits was digested to the limit peptides. The results suggest that the cytoplasmic domain of the beta subunit interacts with that of the alpha subunit, possibly with residues leading into the first transmembrane segment, and controls access of Rb+ ions into or out of the occlusion sites.	WEIZMANN INST SCI, DEPT BIOCHEM, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								ANTOLOVIC R, 1995, EUR J BIOCHEM, V227, P61, DOI 10.1111/j.1432-1033.1995.tb20359.x; ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BEGGAH AT, 1993, BIOCHEMISTRY-US, V32, P14117, DOI 10.1021/bi00214a007; BLANCO G, 1995, BIOCHEMISTRY-US, V34, P319, DOI 10.1021/bi00001a039; BLANCO G, 1994, J BIOL CHEM, V269, P23420; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; CANESSA CM, 1993, J BIOL CHEM, V268, P17722; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CHOW DC, 1993, AM J PHYSIOL, V265, pC1562, DOI 10.1152/ajpcell.1993.265.6.C1562; CHOW DC, 1995, J EXP BIOL, V198, P1; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; EAKLE KA, 1995, J BIOL CHEM, V270, P13937, DOI 10.1074/jbc.270.23.13937; FAMBROUGH DM, 1994, AM J PHYSIOL, V266, pC579, DOI 10.1152/ajpcell.1994.266.3.C579; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; FORBUSH B, 1983, CURR TOP MEMBR TRANS, V19, P167; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; GEERING K, 1993, AM J PHYSIOL, V265, pC1169, DOI 10.1152/ajpcell.1993.265.4.C1169; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GLYNN IM, 1985, J PHYSIOL-LONDON, V368, P453, DOI 10.1113/jphysiol.1985.sp015868; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; HAMRICK M, 1993, J BIOL CHEM, V268, P24367; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAISSER F, 1996, IN PRESS AM J PHYSL; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; Jorgensen P L, 1974, Methods Enzymol, V32, P277; Karlish S J, 1991, Soc Gen Physiol Ser, V46, P129; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KIRLEY TL, 1990, J BIOL CHEM, V265, P4227; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LEMAS MV, 1992, J BIOL CHEM, V267, P20987; LINGREL JB, 1991, SOC GEN PHY, V46, P1; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; NOGUCHI S, 1994, FEBS LETT, V341, P233, DOI 10.1016/0014-5793(94)80463-X; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; OR E, 1993, J BIOL CHEM, V268, P16929; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; RENAUD KJ, 1991, J BIOL CHEM, V266, P20491; SACHS G, 1995, ANNU REV PHARMACOL, V35, P277, DOI 10.1146/annurev.pa.35.040195.001425; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SCHWAPPACH B, 1994, J BIOL CHEM, V269, P21620; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; SHANI M, 1987, BIOCHIM BIOPHYS ACTA, V904, P13, DOI 10.1016/0005-2736(87)90081-2; SHIN JM, 1994, J BIOL CHEM, V269, P8642	52	24	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10309	10316		10.1074/jbc.271.17.10309	http://dx.doi.org/10.1074/jbc.271.17.10309			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626600	hybrid			2022-12-27	WOS:A1996UG25700072
J	Suehiro, K; Smith, JW; Plow, EF				Suehiro, K; Smith, JW; Plow, EF			The ligand recognition specificity of beta 3 integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; ARG-GLY-ASP; DIVALENT-CATION REGULATION; VITRONECTIN RECEPTOR; GPIIB-IIIA; BINDING-SITES; CROSS-LINKING; MONOCLONAL-ANTIBODY; FIBRINOGEN BINDING; ADHESION RECEPTOR	alpha(IIb)beta(3) (platelet membrane glycoprotein IIb-IIa) and alpha(v) beta(3) are members of the beta(3) subfamily of integrin adhesion receptors. A cyclic peptide, KYGC(s-s)HarGDW-PC(s-s) (cHarGD), originally described by Scarborough et al. (Scarborough, R. M., Naughton, M. A., Teng, W., Rose, J. W., Phillips, D. R., Nannizzi, L., Arsten, A., Campbell, A. M., and Charo, I. F. (1993) J. Biol Chem. 268, 1066-1073) has been employed as a high affinity ligand for alpha(IIb)beta(3) to examine the specificity of the beta(3) integrins. cHarGD interacted with high affinity with purified alpha(IIb)beta(3) (K-d = 10 nm) or with platelets (K-d = 120 nM). While cHarGD was specific for alpha(IIb)beta(3)-specific, even in the presence of Mn2+. cHarGD became cross-linked to a site in beta(3) of alpha(IIb)beta(3), which is distinct from that of RGD peptides. These results allow identification of at lease four classes of beta(3) ligands: Class, I represented by RGD peptides and vitronectin, react similarly with alpha(IIb)beta(3) and alpha(v) beta(3); Class II, represented by cHarGD, gamma-chain peptides and fibrinogen, react with both receptors in the presence of Mn2+ but only with alpha(IIb)beta(3) in the presence of Ca2+; Class III, represented by barbourin, are alpha(IIb)beta(3)-specific under all cation conditions; Class IV, represented by osteopontin, bind primarily to alpha(v) beta(3).	CLEVELAND CLIN FDN, JOSEPH J JACOBS CTR THROMBOSIS & VASC RES FF20, DEPT MOL CARDIOL, CLEVELAND, OH 44195 USA; BURNHAM INST, LA JOLLA, CA 92037 USA	Cleveland Clinic Foundation; Sanford Burnham Prebys Medical Discovery Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038292, R01HL054924] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54924, HL-38292] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1991, J IMMUNOL, V147, P1891; BAJT ML, 1992, J BIOL CHEM, V267, P3789; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BARUTHIO F, 1988, CLIN CHEM, V34, P227; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; Brandt M, 1986, MANGANESE METABOLISM, P3; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CALVETE JJ, 1994, THROMB HAEMOSTASIS, V72, P1; CALVETE JJ, 1992, EUR J BIOCHEM, V206, P759, DOI 10.1111/j.1432-1033.1992.tb16982.x; CALVETE JJ, 1994, BIOCHEM BIOPH RES CO, V202, P135, DOI 10.1006/bbrc.1994.1903; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; DOBRINA A, 1991, J CLIN INVEST, V88, P20, DOI 10.1172/JCI115278; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DSOUZA SE, 1988, J BIOL CHEM, V263, P3943; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; LANZA F, 1992, J CLIN INVEST, V89, P1995, DOI 10.1172/JCI115808; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1553, DOI 10.1056/NEJM199506083322306; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LU XJ, 1994, BIOCHEM J, V304, P929, DOI 10.1042/bj3040929; LUSCINSKAS FW, 1994, FASEB J, V8, P929, DOI 10.1096/fasebj.8.12.7522194; MARCINKIEWICZ C, 1995, THROMB HAEMOSTASIS, V73, pA1123; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; MCLANE MA, 1994, BIOCHEM J, V301, P429, DOI 10.1042/bj3010429; PFAFF M, 1994, J BIOL CHEM, V269, P20233; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PLOW EF, 1985, BLOOD, V66, P724; PLOW EF, 1992, J LAB CLIN MED, V120, P198; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RAMSAMOOJ P, 1991, BIOCHEM J, V276, P725, DOI 10.1042/bj2760725; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; SHADLE PJ, 1984, J CELL BIOL, V99, P2056, DOI 10.1083/jcb.99.6.2056; SHATTIL SJ, 1995, THROMB HAEMOSTASIS, V74, P149; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SMITH JW, 1991, J BIOL CHEM, V266, P11429; SMITH JW, 1994, J BIOL CHEM, V269, P960; SMYTH SS, 1993, BLOOD, V81, P2827; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; THIAGARAJAN P, 1988, J BIOL CHEM, V263, P3035; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	65	70	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10365	10371		10.1074/jbc.271.17.10365	http://dx.doi.org/10.1074/jbc.271.17.10365			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626608	hybrid			2022-12-27	WOS:A1996UG25700080
J	Xia, Y; Khatchikian, G; Zweier, JL				Xia, Y; Khatchikian, G; Zweier, JL			Adenosine deaminase inhibition prevents free radical-mediated injury in the postischemic heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCARDIAL REPERFUSION INJURY; XANTHINE-OXIDASE INHIBITOR; INFARCT SIZE; PERFUSED HEART; ISCHEMIA; ALLOPURINOL; GENERATION; PROTECTION; DOGS; METABOLISM	In the presence of its substrates hypoxanthine and xanthine, xanthine oxidase generates oxygen free radicals that cause postischemic injury. Recently, it has been demonstrated that the burst of xanthine oxidase-mediated free radical generation in the reperfused heart is triggered by a large increase in substrate formation, which occurs secondary to the degradation of adenine nucleotides during ischemia. It is not known, however, whether blocking this substrate formation is sufficient to prevent radical generation and functional injury. Therefore, studies were performed in isolated rat hearts in which xanthine oxidase substrate formation was blocked with the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), and measurements of contractile function and free radical generation were performed. Chromatographic measurements of the intracellular adenine nucleotide pool showed that preischemic administration of EHNA blocked postischemic hypoxanthine, xanthine, and inosine formation. Electron paramagnetic resonance spin trapping measurements of free radical generation showed that inhibition of adenosine deaminase with EHNA blocked free radical generation and that it also increased the recovery of contractile function by more than 2-fold. Exogenous infusion of hypoxanthine and xanthine totally reversed the protective effects of EHNA. These results demonstrate that blockade of xanthine oxidase substrate formation by adenosine deaminase inhibition can prevent free radical generation and contractile dysfunction in the postischemic heart.	JOHNS HOPKINS BAYVIEW MED CTR, JOHNS HOPKINS MED INST, DEPT MED, DIV CARDIOL, BALTIMORE, MD 21224 USA; JOHNS HOPKINS BAYVIEW MED CTR, JOHNS HOPKINS MED INST, ELECTRON PARAMAGNET RESONANCE CTR, BALTIMORE, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine					NHLBI NIH HHS [HL-38324] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038324, R01HL038324] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELFATTAH AS, 1988, CIRCULATION, V78, P224; ABDELFATTAH AS, 1990, CIRCULATION, V82, P341; AKIZUKI S, 1985, CARDIOVASC RES, V19, P686, DOI 10.1093/cvr/19.11.686; ARROYO CM, 1987, FEBS LETT, V221, P101, DOI 10.1016/0014-5793(87)80360-5; BAK MI, 1994, J CLIN INVEST, V93, P40, DOI 10.1172/JCI116974; BERNE RM, 1980, CIRC RES, V47, P807, DOI 10.1161/01.RES.47.6.807; BOLLI R, 1991, CARDIOVASC DRUG THER, V5, P249, DOI 10.1007/BF00054747; BOLLING SF, 1992, J THORAC CARDIOV SUR, V103, P73; CERUTTI PA, 1988, OXYRADICALS MOL BIOL, P1; CHAMBERS DE, 1985, J MOL CELL CARDIOL, V17, P145, DOI 10.1016/S0022-2828(85)80017-1; CHAMBERS DJ, 1987, ANN THORAC SURG, V44, P291, DOI 10.1016/S0003-4975(10)62076-0; EDDY LJ, 1987, AM J PHYSIOL, V253, pH709, DOI 10.1152/ajpheart.1987.253.3.H709; GRUM CM, 1989, J MOL CELL CARDIOL, V21, P263, DOI 10.1016/0022-2828(89)90741-4; HULLRYDE EA, 1986, J CHROMATOGR, V377, P165, DOI 10.1016/S0378-4347(00)80771-9; JENNINGS RB, 1985, ANNU REV PHYSIOL, V47, P727, DOI 10.1146/annurev.ph.47.030185.003455; KRAUSE SM, 1992, J BIOL CHEM, V267, P2480; KUKREJA RC, 1992, CARDIOVASC RES, V26, P641, DOI 10.1093/cvr/26.7.641; KUPPUSAMY P, 1989, J BIOL CHEM, V264, P9880; LIU GS, 1991, CIRCULATION, V84, P350, DOI 10.1161/01.CIR.84.1.350; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNING AS, 1984, CIRC RES, V55, P545, DOI 10.1161/01.RES.55.4.545; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; OPIE LH, 1989, CIRCULATION, V80, P1049, DOI 10.1161/01.CIR.80.4.1049; PARKS DA, 1986, ACTA PHYSIOL SCAND, V126, P87; PORTER DJT, 1992, BIOCHEMISTRY-US, V31, P8216, DOI 10.1021/bi00150a014; PUETT DW, 1987, CIRCULATION, V76, P678, DOI 10.1161/01.CIR.76.3.678; REIMER KA, 1985, CIRCULATION, V71, P1069, DOI 10.1161/01.CIR.71.5.1069; RICHARD VJ, 1988, CIRCULATION, V78, P473, DOI 10.1161/01.CIR.78.2.473; Roy R.S., 1983, CELLULAR MED ASPECTS, VII, P145; SIMPSON PJ, 1987, J LAB CLIN MED, V110, P13; SWAIN JL, 1986, HEART CARDIOVASCULAR, P911; THOMPSONGORMAN SL, 1990, J BIOL CHEM, V265, P6656; VARGEESE C, 1994, J MED CHEM, V37, P3844, DOI 10.1021/jm00048a020; WERNS SW, 1986, CIRCULATION, V73, P518, DOI 10.1161/01.CIR.73.3.518; XIA Y, 1995, J BIOL CHEM, V270, P18797, DOI 10.1074/jbc.270.32.18797; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404; ZWEIER JL, 1987, J BIOL CHEM, V262, P8015; ZWEIER JL, 1988, J BIOL CHEM, V263, P1353; ZWEIER JL, 1994, AM J PHYSIOL, V266, pC700, DOI 10.1152/ajpcell.1994.266.3.C700; ZWEIER JL, 1994, J BIOL CHEM, V269, P24156; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	42	103	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10096	10102		10.1074/jbc.271.17.10096	http://dx.doi.org/10.1074/jbc.271.17.10096			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626567	hybrid			2022-12-27	WOS:A1996UG25700039
J	Sjoberg, ER; Kitagawa, H; Glushka, J; vanHalbeek, H; Paulson, JC				Sjoberg, ER; Kitagawa, H; Glushka, J; vanHalbeek, H; Paulson, JC			Molecular cloning of a developmentally regulated N-acetylgalactosamine alpha 2,6-sialyltransferase specific for sialylated glycoconjugates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYLTRANSFERASE GENE FAMILY; LINKED OLIGOSACCHARIDE CHAINS; HUMAN-MELANOMA CELLS; SIALIC ACIDS; GAL-BETA-1,3(4)GLCNAC ALPHA-2,3-SIALYLTRANSFERASE; ALPHA-2->6 SIALYLTRANSFERASE; COHERENCE TRANSFER; NMR-SPECTROSCOPY; ROTATING-FRAME; EXPRESSION	A cDNA encoding a novel sialyltransferase has been isolated employing the polymerase chain reaction using degenerate primers to conserved regions of the sialylmotif that is present in all eukaryotic members of the sialyltransferase gene family examined to date. The cDNA sequence revealed an open reading frame coding for 305 amino acids, making it the shortest sialyltransferase cloned to date. This open reading frame predicts all the characteristic structural features of other sialyltransferases including a type II membrane protein topology and both sialylmotifs, one centrally located and the second in the carboxyl-terminal portion of the cDNA. When compared with all other sialyltransferase cDNAs, the predicted amino acid sequence displays the lowest homology in the sialyltransferase gene family. Northern analysis shows this sialyltransferase to be developmentally regulated in brain with expression persisting through adulthood in spleen, kidney, and lung. Stable transfection of the full-length cDNA in the human kidney carcinoma eel line 293 produced an active sialyltransferase with marked specificity for the sialoside, Neu5Ac alpha 2,3Gal beta 1,3GalNAc and glycoconjugates carrying the same sequence such as G(M1b) and fetuin. The disialylated tetrasaccharide formed by reacting the sialyltransferase with the aforementioned sialoside was analyzed by one- and two-dimensional H-1 and C-13 NMR spectroscopy and was shown to be the Neu5Ac alpha 2,3Gal beta 1,3(Neu5Ac alpha 2,6)GalNAc sialoside. This indicates that the enzyme is a GalNAc alpha 2,6-sialyltransferase. Since two other ST6GalNAc sialyltransferase cDNAs have been isolated, this sialyltransferase has been designated ST6GalNAc III. Of these three, ST6GalNAc III displays the most restricted acceptor specificity and is the only sialyltransferase cloned to date capable of forming the developmentally regulated ganglioside G(D1 alpha) from G(M1b).	CYTEL CORP, SAN DIEGO, CA 92121 USA; Scripps Res Inst, DEPT CHEM, SAN DIEGO, CA 92121 USA; SCRIPPS RES INST, DEPT BIOL MOLEC, SAN DIEGO, CA 92121 USA; UNIV GEORGIA, COMPLEX CARBOHYDRATE RES CTR, ATHENS, GA 30602 USA; UNIV GEORGIA, DEPT BIOCHEM, ATHENS, GA 30602 USA	Scripps Research Institute; Scripps Research Institute; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia			Paulson, James/AAG-3565-2019; Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR005351] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027904] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR-05351] Funding Source: Medline; NIGMS NIH HHS [GM 27904] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMANO J, 1988, J BIOL CHEM, V263, P1157; BAUBICHONCORTAY H, 1986, CARBOHYD RES, V149, P209, DOI 10.1016/S0008-6215(00)90379-3; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BERGH MLE, 1983, J BIOL CHEM, V258, P7430; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Corfield A. P., 1982, CELL BIOL MONOGR, V10, P195; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; EBEL F, 1992, BIOCHEMISTRY-US, V31, P12190, DOI 10.1021/bi00163a031; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; FURUYA S, 1994, J BIOL CHEM, V269, P32418; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; GRIESINGER C, 1987, J MAGN RESON, V75, P261, DOI 10.1016/0022-2364(87)90035-7; GRUNDMANN U, 1990, NUCLEIC ACIDS RES, V18, P667, DOI 10.1093/nar/18.3.667; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; HAYES BK, 1993, J BIOL CHEM, V268, P16139; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; IRIE F, 1994, FEBS LETT, V351, P291, DOI 10.1016/0014-5793(94)00883-3; ISHIKAWA D, 1995, GLYCOCONJUGATE J, V12, P523; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUROSAWA N, 1994, J BIOL CHEM, V269, P19048; KUROSAWA N, 1994, J BIOL CHEM, V269, P1402; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEE YC, 1994, J BIOL CHEM, V269, P10028; LERNER L, 1986, J MAGN RESON, V69, P375, DOI 10.1016/0022-2364(86)90091-0; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MCEVER RP, 1994, CURR OPIN IMMUNOL, V6, P75, DOI 10.1016/0952-7915(94)90037-X; MORRIS GA, 1978, J MAGN RESON, V29, P433, DOI 10.1016/0022-2364(78)90003-3; NAKAMURA K, 1995, J BIOL CHEM, V270, P3876, DOI 10.1074/jbc.270.8.3876; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; RUCKER SP, 1989, MOL PHYS, V68, P509, DOI 10.1080/00268978900102331; SABESAN S, 1986, J AM CHEM SOC, V108, P2068, DOI 10.1021/ja00268a056; SASAKI K, 1994, J BIOL CHEM, V269, P15950; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; SJOBERG ER, 1993, J BIOL CHEM, V268, P10185; SJOBERG ER, 1992, J BIOL CHEM, V267, P16200; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; VANHALBEEK H, 1994, METHOD ENZYMOL, V230, P132; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEN DX, 1992, J BIOL CHEM, V267, P21011; WILLIAMS MA, 1995, GLYCOCONJUGATE J, V12, P755, DOI 10.1007/BF00731235; YEDNOCK TA, 1989, ADV IMMUNOL, V44, P313; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628; YOUNG WW, 1992, J BIOL CHEM, V267, P12011	68	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7450	7459		10.1074/jbc.271.13.7450	http://dx.doi.org/10.1074/jbc.271.13.7450			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631773				2022-12-27	WOS:A1996UC77400041
J	Tzagoloff, A; Jang, J; Glerum, DM; Wu, M				Tzagoloff, A; Jang, J; Glerum, DM; Wu, M			FLX1 codes for a carrier protein involved in maintaining a proper balance of flavin nucleotides in yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSPORT PROTEINS; MEMBRANE SYSTEM; TRANSFORMATION; PURIFICATION; SEQUENCE; MUTANTS; ATPASE	Respiratory defective mutants of Saccharomyces cerevisiae previously assigned to complementation group G178 are characterized by an abnormally low ratio of FAD/FMN in mitochondria. A nuclear gene, designated FLX1, was selected from a yeast genomic library, based on its ability to confer wild-type growth properties to a representative G178 mutant. Genetic evidence has con firmed that the flavin nucleotide imbalance of G178 mutants is caused by mutations in FLX1. The sequence of FLX1 is identical to a reading frame recently reported to be present on yeast chromosome IX (GenBank(TM) 247047). The sequence and tripartite repeat structure of the FLX1 product (Flx1p) indicate it is a member of a protein family consisting of mitochondrial substrate and nucleotide carriers. In yeast, FAD synthetase is present in the soluble cytoplasmic protein fraction but not in mitochondria. Riboflavin kinase, the preceding enzyme in flavin biosynthesis, is present in both subcellular fractions. The absence of FAD synthetase in mitochondria implies that FAD is imported from the cytoplasm. The lower concentration of mitochondrial FAD in flx1 mutants suggests that Flx1p is involved in flavin transport, a role that is also supported by biochemical evidence indicating more efficient flux of FAD across mitochondrial membrane vesicles prepared from wild-type strains than membrane vesicles from flx1 mutants.			Tzagoloff, A (corresponding author), COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA.		Glerum, Moira/AHD-3271-2022	Wu, Mian/0000-0002-2714-0500	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022174, R56HL022174, R37HL022174] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL022174, HL22174] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACHER A, 1990, CHEM BIOCH FLAVOENZY; BOTSTEIN D, 1982, MOL BIOL YEAST SACCH, P607; Dawson R. M. C., 1991, DATA BIOCH RES, V3rd, P363; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; KEARNEY EB, 1951, J BIOL CHEM, V193, P821; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Reed L.J., 1966, METHOD ENZYMOL, V9, P247; RICCIO P, 1975, FEBS LETT, V56, P133, DOI 10.1016/0014-5793(75)80127-X; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; ten Berge A M, 1974, Mol Gen Genet, V131, P113; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; WOHLRAB H, 1980, J BIOL CHEM, V255, P8170; WU M, 1995, MOL CELL BIOL, V15, P264, DOI 10.1128/MCB.15.1.264	26	113	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7392	7397		10.1074/jbc.271.13.7392	http://dx.doi.org/10.1074/jbc.271.13.7392			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631763	hybrid			2022-12-27	WOS:A1996UC77400031
J	VanNhieu, GT; Krukonis, ES; Reszka, AA; Horwitz, AF; Isberg, RR				VanNhieu, GT; Krukonis, ES; Reszka, AA; Horwitz, AF; Isberg, RR			Mutations in the cytoplasmic domain of the integrin beta(1) chain indicate a role for endocytosis factors in bacterial internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; COATED PIT FORMATION; DENSITY-LIPOPROTEIN RECEPTOR; LYSOSOMAL ACID-PHOSPHATASE; CULTURED ANIMAL-CELLS; FIBRONECTIN RECEPTOR; TYROSINE PHOSPHORYLATION; YERSINIA-ENTEROCOLITICA; TRANSMEMBRANE LINKAGE; TRANSFERRIN RECEPTOR	Mutations that result in defective beta(1)-integrin focal adhesion formation were analyzed for effects on bacterial internalization. Mutations in the cytoplasmic domain of the beta(1) chain that disrupt the sequence NPIY resulted in integrins deficient in bacterial uptake, Other mutations in the beta(1) chain that reduced cytoskeletal association showed enhanced bacterial uptake, Replacement of the NPIY sequence of the beta(1) subunit by the endocytosis internalization sequence PPGY resulted in integrin receptors highly proficient in bacterial internalization, yet severely defective in focal contact localization, Electron microscopy indicated that coated structures associated specifically with bacteria-binding beta(1)-integrins, with an apparent recruitment of coated pits from ventral cell surfaces to apical surfaces corresponding to nascent bacterial phagosomes. Clathrin inhibition studies indicated a role for the adaptor molecule AP2 as well as clathrin in integrin-mediated bacterial internalization. These results indicate that association of beta(1)-integrins with the cytoskeleton at focal contacts interferes with integrin-mediated bacterial internalization. Also, although actin polymerization is required for bacterial uptake, clathrin is probably involved in bacterial uptake promoted by beta(1)-integrins.	TUFTS UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MOLEC BIOL & MICROBIOL, BOSTON, MA 02111 USA; UNIV ILLINOIS, DEPT CELL & STRUCT BIOL, URBANA, IL 61801 USA	Howard Hughes Medical Institute; Tufts University; University of Illinois System; University of Illinois Urbana-Champaign			Van Nhieu, Guy Tran/Y-6359-2018	Van Nhieu, Guy Tran/0000-0002-3901-2186	NIAID NIH HHS [R01-AI23538] Funding Source: Medline; NIDDK NIH HHS [P30 DK34928] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGGELER J, 1982, J CELL BIOL, V94, P613, DOI 10.1083/jcb.94.3.613; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; AVNUR Z, 1981, CELL, V25, P121, DOI 10.1016/0092-8674(81)90236-1; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BRASAEMLE DL, 1988, BIOTECHNIQUES, V6, P418; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; BRODSKY FM, 1985, J CELL BIOL, V101, P2047, DOI 10.1083/jcb.101.6.2047; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHIN DJ, 1989, P NATL ACAD SCI USA, V86, P9289, DOI 10.1073/pnas.86.23.9289; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; CLARKE MSF, 1992, J CELL SCI, V102, P533; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; FINLAY BB, 1988, BIOCHIMIE, V70, P1089, DOI 10.1016/0300-9084(88)90271-4; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GREENBERG S, 1993, J EXP MED, V177, P529, DOI 10.1084/jem.177.2.529; GRINNELL F, 1986, J CELL BIOL, V103, P2697, DOI 10.1083/jcb.103.6.2697; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; ISBERG RR, 1985, NATURE, V317, P262, DOI 10.1038/317262a0; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LEE CA, 1992, P NATL ACAD SCI USA, V89, P1847, DOI 10.1073/pnas.89.5.1847; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; OKA JA, 1989, J BIOL CHEM, V264, P12016; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PITT A, 1992, J CLIN INVEST, V90, P1978, DOI 10.1172/JCI116077; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; RAUB TJ, 1989, EXP CELL RES, V184, P407, DOI 10.1016/0014-4827(89)90340-6; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROSENSHINE I, 1992, INFECT IMMUN, V60, P2211, DOI 10.1128/IAI.60.6.2211-2217.1992; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SMYTHE E, 1992, J CELL BIOL, V119, P1163, DOI 10.1083/jcb.119.5.1163; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; SUZUKI T, 1991, FASEB J, V5, P187, DOI 10.1096/fasebj.5.2.1706281; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TAPLEY P, 1989, ONCOGENE, V4, P325; VANNHIEU GT, 1993, EMBO J, V12, P1887, DOI 10.1002/j.1460-2075.1993.tb05837.x; VANNHIEU GT, 1993, IMMUNOMETHODS, V2, P71; VIGNOUD L, 1994, BIOCHEM BIOPH RES CO, V199, P603, DOI 10.1006/bbrc.1994.1271; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; WRIGHT SD, 1985, J LEUKOCYTE BIOL, V38, P327, DOI 10.1002/jlb.38.2.327; WRIGHT SD, 1983, J EXP MED, V158, P2016, DOI 10.1084/jem.158.6.2016; YOKOTA A, 1992, P NATL ACAD SCI USA, V89, P5030, DOI 10.1073/pnas.89.11.5030; YOUNG VB, 1992, J CELL BIOL, V116, P197, DOI 10.1083/jcb.116.1.197	62	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7665	7672		10.1074/jbc.271.13.7665	http://dx.doi.org/10.1074/jbc.271.13.7665			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631804				2022-12-27	WOS:A1996UC77400072
J	Blondelle, SE; Houghten, RA; PerezPaya, E				Blondelle, SE; Houghten, RA; PerezPaya, E			Identification of inhibitors of melittin using nonsupport-bound combinatorial libraries	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM; AQUEOUS MELITTIN; SELF-ASSOCIATION; GENERAL-METHOD; PEPTIDES; FLUORESCENCE; CALMODULIN; MEMBRANES	A strategy has been developed for the identification of inhibitors of toxins or regulatory proteins. This approach is based on blocking the access of such proteins to their biological targets during their solution transport. This approach uses the strength of nonsupport-bound synthetic combinatorial libraries (SCLs) for the study of acceptor-ligand interactions. A non-receptor assisted toxin, melittin, was selected for the present study to illustrate this application of the SCL approach. Hexapeptide SCLs were assayed for their ability to inhibit the cytolytic activity of melittin toward bacterial and erythrocyte cells. Over 20 inhibitory hexapeptides were identified following the screening and deconvolution processes from millions of sequences. The identified inhibitory peptides appeared to interact directly with melittin. These interactions appear to decrease melittin's ability to undergo lipid- and/or polysaccharide-induced conformational changes, and are demonstrated by fluorescence and circular dichroism spectroscopy.			Blondelle, SE (corresponding author), TORREY PINES INST MOLEC STUDIES, 3550 GEN ATOM CT, SAN DIEGO, CA 92121 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045583] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 45583] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLONDELLE SE, 1993, BIOCHIM BIOPHYS ACTA, V1202, P331, DOI 10.1016/0167-4838(93)90024-L; BLONDELLE SE, 1994, ANTIMICROB AGENTS CH, V38, P2280, DOI 10.1128/AAC.38.10.2280; BLONDELLE SE, 1995, TRAC-TREND ANAL CHEM, V14, P83, DOI 10.1016/0165-9936(95)91476-9; Cornut I., 1993, AMPHIPATHIC HELIX, P173; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; DOOLEY CT, 1993, P NATL ACAD SCI USA, V90, P10811, DOI 10.1073/pnas.90.22.10811; DOOLEY CT, 1994, SCIENCE, V266, P2019, DOI 10.1126/science.7801131; EICHLER J, 1993, BIOCHEMISTRY-US, V32, P11035, DOI 10.1021/bi00092a013; EICHLER J, 1994, PEPTIDE RES, V7, P300; FURKA A, 1991, INT J PEPT PROT RES, V37, P487, DOI 10.1111/j.1399-3011.1991.tb00765.x; GOTO Y, 1992, BIOCHEMISTRY-US, V31, P732, DOI 10.1021/bi00118a014; HABERMANN E, 1967, H-S Z PHYSIOL CHEM, V348, P37, DOI 10.1515/bchm2.1967.348.1.37; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HOUGHTEN RA, 1986, INT J PEPT PROT RES, V27, P673; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; ITAKURA M, 1992, J BIOCHEM, V112, P183, DOI 10.1093/oxfordjournals.jbchem.a123875; JOHN E, 1991, BIOPHYS J, V60, P319, DOI 10.1016/S0006-3495(91)82056-2; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; OSTRESH JM, 1994, P NATL ACAD SCI USA, V91, P11138, DOI 10.1073/pnas.91.23.11138; PAUDEL HK, 1993, BIOCHEMISTRY-US, V32, P11865, DOI 10.1021/bi00095a015; PEREZPAYA E, 1995, J BIOL CHEM, V270, P1048, DOI 10.1074/jbc.270.3.1048; PINILLA C, 1994, DRUG DEVELOP RES, V33, P133, DOI 10.1002/ddr.430330210; PINILLA C, 1994, BIOCHEM J, V301, P847, DOI 10.1042/bj3010847; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; PINILLA C, 1995, BIOPOLYMERS, V37, P221, DOI 10.1002/bip.360370306; PINILLA C, 1993, GENE, V128, P71, DOI 10.1016/0378-1119(93)90155-V; QUAY SC, 1983, BIOCHEMISTRY-US, V22, P695, DOI 10.1021/bi00272a026; QUAY SC, 1985, BIOCHIM BIOPHYS ACTA, V831, P22, DOI 10.1016/0167-4838(85)90144-X; STEINER RF, 1987, ARCH BIOCHEM BIOPHYS, V254, P342, DOI 10.1016/0003-9861(87)90110-X; TALBOT JC, 1979, FEBS LETT, V102, P191, DOI 10.1016/0014-5793(79)80957-6; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; TERWILLIGER TC, 1982, J BIOL CHEM, V257, P6016; TOSTESON MT, 1990, BIOPHYS J, V58, P1367, DOI 10.1016/S0006-3495(90)82483-8; WEAVER AJ, 1989, BIOCHEMISTRY-US, V28, P8614, DOI 10.1021/bi00447a052; WEBER P, 1993, RECENT ADV CHEMOTHER, P649; WILCOX W, 1992, PROTEIN SCI, V1, P641, DOI 10.1002/pro.5560010510	37	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4093	4099						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626746	hybrid			2022-12-27	WOS:A1996TW96000024
J	Isakoff, SJ; Yu, YP; Su, YC; Blaikie, P; Yajnik, V; Rose, E; Weidner, KM; Sachs, M; Margolis, B; Skolnik, EY				Isakoff, SJ; Yu, YP; Su, YC; Blaikie, P; Yajnik, V; Rose, E; Weidner, KM; Sachs, M; Margolis, B; Skolnik, EY			Interaction between the phosphotyrosine binding domain of Shc and the insulin receptor is required for Shc phosphorylation by insulin in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; GRB2	Stimulation of the insulin receptor (IR) results in tyrosine phosphorylation of the intermediate molecules insulin receptor substrate-1 (IRS-1), IRS-2, and Shc, which then couple the IR to downstream signaling pathways by serving as binding sites for signaling molecules with SH2 domains. It has been proposed that direct binding of IRS-1, IRS-2, and Shc to an NPX-Tyr(P) motif in the juxtamembrane region of the IR is required for tyrosine phosphorylation of these molecules by the LR. In this regard, Shc and IRS-1 contain domains that are distinct from SH2 domains, referred to as the phosphotyrosine binding (PTB) or phosphotyrosine interaction (PI) domains, which bind phosphotyrosine in the context of an NPX-Tyr(P) motif. To further clarify the role of the Shc PTB/PI domain, we identified a mutation in this domain that abrogated binding of Shc to the IR in vitro. Interestingly, this mutation completely abolished Shc phosphorylation by the IR in vivo whereas mutation of the arginine in the FLVRES motif of the Shc SH2 domain did not affect Shc phosphorylation by insulin. In addition, we identified specific amino acids on the IR that are required for the IR to stimulate Shc but not IRS-1 phosphorylation in vivo. As with the PTB/PI domain Shc mutant, the ability of these mutant receptors to phosphorylate Shc correlates with the binding of the PTB/PI domain of Shc to similar sequences in vitro. These findings support a model in which binding of the PTB/PI domain of Shc directly to the NPX-Tyr(P) motif on the LR mediates Shc phosphorylation by insulin.	NYU,MED CTR,DEPT PHARMACOL,SKIRBALL INST BIOMOL MED,NEW YORK,NY 10016; MAX DELBRUCK CTR MOLEC MED,D-13125 BERLIN,GERMANY; UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109	New York University; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Howard Hughes Medical Institute; University of Michigan System; University of Michigan			Isakoff, Steven/ABE-3566-2020					BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERNANDEZ R, 1995, EMBO J, V14, P3373, DOI 10.1002/j.1460-2075.1995.tb07343.x; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P12; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LI NX, 1994, ONCOGENE, V9, P3457; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TRUB T, 1995, J BIOL CHEM, V270, P18205; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VOYJTEK AB, 1993, CELL, V74, P205; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; Yajnik V, 1996, J BIOL CHEM, V271, P1813, DOI 10.1074/jbc.271.4.1813; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	38	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					3959	3962						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626723				2022-12-27	WOS:A1996TW96000001
J	Lahtinen, U; Hellman, U; Wernstedt, C; Saraste, J; Pettersson, RF				Lahtinen, U; Hellman, U; Wernstedt, C; Saraste, J; Pettersson, RF			Molecular cloning and expression of a 58-kDa cis-Golgi and intermediate compartment protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEINS; CELL-SURFACE; BETA-COP; TRANSPORT; ER; IDENTIFICATION; MEMBRANE; RETENTION; APPARATUS	An abundant 58-kDa (p58) homodimeric and hexameric microsomal membrane protein has been biochemically characterized and localized to tubulo-vesicular elements at the endoplasmic reticulum-Golgi interface and the cis-Golgi cisternae in pancreatic acinar cells (Lahtinen, U., Dahllof, B., and Saraste, J. (1992) J. Cell Sci. 103, 321-333). Here we report the purification of p58 by two-dimensional gel electrophoresis, and the cloning and sequencing of the rat and part of the Xenopus laevis cDNAs. The rat cDNA encodes a 517-amino acid protein having a putative signal sequence, a transmembrane domain close to the C terminus and a short cytoplasmic tail. The C-terminal tail contains a double-lysine motif (KKFF), known to mediate retrieval of proteins from the Golgi back to the endoplasmic reticulum. The rat p58 sequence was found to be 89% identical with those of ERGIC-53 and MR60, two previously identified human membrane proteins. Strong homology with the frog sequence was also observed indicating high evolutionary conservation. Overexpression of c-Myc-tagged p58 resulted in accumulation of the protein both in the endoplasmic reticulum and in an apparently enlarged Golgi complex, as well as its leakage to the plasma membrane. Immunolocalization using antibodies raised against a lumenal peptide stained the total cellular pool of p58, while anti-tail peptide antibodies detected p58 only in a restricted Golgi region. This suggests that the C-terminal tail of p58 located in the endoplasmic reticulum and transport intermediates is hidden, but becomes exposed when the protein reaches the Golgi complex.	LUDWIG INST CANC RES,UPPSALA BRANCH,S-75124 UPPSALA,SWEDEN; UNIV BERGEN,DEPT BIOCHEM & MOLEC BIOL,N-5009 BERGEN,NORWAY	Ludwig Institute for Cancer Research; University of Bergen	Lahtinen, U (corresponding author), LUDWIG INST CANC RES,STOCKHOLM BRANCH,BOX 240,S-17177 STOCKHOLM,SWEDEN.							AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ARAR C, 1995, J BIOL CHEM, V270, P3551, DOI 10.1074/jbc.270.8.3551; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HENDRICKS LC, 1991, J BIOL CHEM, V266, P17559; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; ITIN C, 1995, EMBO J, V14, P2250, DOI 10.1002/j.1460-2075.1995.tb07219.x; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KAPPELER F, 1994, J BIOL CHEM, V269, P6279; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHTINEN U, 1992, J CELL SCI, V103, P321; LETOURNEUR F, 1995, J CELL BIOL, V129, P971, DOI 10.1083/jcb.129.4.971; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PIMPANEAU V, 1991, CARBOHYD RES, V213, P95, DOI 10.1016/S0008-6215(00)90601-3; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SARASTE J, 1991, J CELL SCI, V100, P415; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; TOWNSLEY FM, 1994, EUR J CELL BIOL, V64, P211; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8	53	68	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4031	4037						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626736				2022-12-27	WOS:A1996TW96000014
J	Nitsch, RM; Deng, MH; Growdon, JH; Wurtman, RJ				Nitsch, RM; Deng, MH; Growdon, JH; Wurtman, RJ			Serotonin 5-HT2a and 5-HT2e receptors stimulate amyloid precursor protein ectodomain secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN; ALZHEIMERS-DISEASE; GROWTH-FACTOR; KINASE-C; PEPTIDE; ACTIVATION; RELEASE; CLEAVAGE; ALPHA; IDENTIFICATION	Alzheimer's disease amyloid consists of amyloid beta-peptides (A beta) derived from the larger precursor amyloid precursor protein (APP). Non-amyloidogenic APP processing involves regulated cleavage within the A beta domain followed by secretion of the ectodomain (APPs). APPs secretion can be stimulated by muscarinic acetylcholine receptors coupled to phospholipases and kinases. To determine whether other receptor classes can regulate APP processing, we examined the relation between serotonin receptors and APPs secretion. Serotonin increased APPs release 3-4 fold in 3T3 cells stably overexpressing 5-HT2aR or 5 HT2cR. The increase was dose-dependent and was blocked by serotoninergic antagonists. Phorbol esters also increased APPs secretion, but neither kinase inhibitors nor down-regulation of PKC blocked the serotonin-induced increase in APPs secretion. Thus PKC is not necessary to stimulate APPs secretion. Phospholipase A(2) (PLA(2)) inhibitors blocked the 5-HT2aR-mediated increase in APPs secretion, suggesting a role of PLA(2) in coupling 5-HT2aR to APP processing. In contrast, coupling of 5-HT2cR to APPs secretion involved both PKC and PLA(2). Serotonin also stimulated the release of the APLP2 ectodomain, suggesting that additional members of the APP multigene family are processed via similar regulated pathways. Inasmuch as generation of APPs precludes the formation of amyloidogenic derivatives, serotonin receptors provide a novel pharmacological target to reduce these derivatives in Alzheimer's disease.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02114	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Massachusetts General Hospital								ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919; BARGER SW, 1995, J NEUROCHEM, V64, P2087; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BUXBAUM JD, 1994, P NATL ACAD SCI USA, V91, P4489, DOI 10.1073/pnas.91.10.4489; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DYRKS T, 1994, FEBS LETT, V349, P210, DOI 10.1016/0014-5793(94)00671-7; EMMERLING MR, 1993, BIOCHEM BIOPH RES CO, V197, P292, DOI 10.1006/bbrc.1993.2474; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FARBER SA, 1995, J NEUROSCI, V15, P7442; GABUZDA D, 1993, J NEUROCHEM, V61, P2326, DOI 10.1111/j.1471-4159.1993.tb07479.x; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GREENBERG SM, 1994, P NATL ACAD SCI USA, V91, P7104, DOI 10.1073/pnas.91.15.7104; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HUNG AY, 1993, J BIOL CHEM, V268, P22959; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LEE RKK, 1995, P NATL ACAD SCI USA, V92, P8083, DOI 10.1073/pnas.92.17.8083; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; MUCKE L, 1995, J EXP MED, V181, P1551, DOI 10.1084/jem.181.4.1551; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; MUCKE L, 1996, IN PRESS ANN NY ACAD; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; NITSCH RM, 1993, P NATL ACAD SCI USA, V90, P5191, DOI 10.1073/pnas.90.11.5191; NITSCH RM, 1994, BIOCHEM PHARMACOL, V47, P1275, DOI 10.1016/0006-2952(94)90325-5; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SANDMANN J, 1991, J BIOL CHEM, V266, P6031; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SLACK BE, 1993, J BIOL CHEM, V268, P21097; SLACK BE, 1995, J BIOL CHEM, V270, P8337, DOI 10.1074/jbc.270.14.8337; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; STAM NJ, 1992, EUR J PHARM-MOLEC PH, V227, P153, DOI 10.1016/0922-4106(92)90123-D; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; VONDERKAMMER H, 1994, DNA CELL BIOL, V13, P1137, DOI 10.1089/dna.1994.13.1137; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WOLF BA, 1995, J BIOL CHEM, V270, P4916, DOI 10.1074/jbc.270.9.4916; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243	52	179	190	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4188	4194						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626761				2022-12-27	WOS:A1996TW96000039
J	Guo, Q; Penman, M; Trigatti, BL; Krieger, M				Guo, Q; Penman, M; Trigatti, BL; Krieger, M			A single point mutation in epsilon-COP results in temperature-sensitive, lethal defects in membrane transport in a Chinese hamster ovary cell mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; CLATHRIN-COATED VESICLES; BREFELDIN-A; GOLGI-COMPLEX; ENDOPLASMIC-RETICULUM; GROWTH-FACTOR; BETA-COP; PROTEINS; ACCUMULATION; SECRETION	At the nonpermissive temperature of 39.5 degrees C, the Chinese hamster ovary cell conditionally lethal, temperature-sensitive (ts) mutant IdlF exhibits the following defects: rapid degradation of low density lipoprotein receptors, disruption of ER-through-Golgi transport, and disintegration of the Golgi apparatus. All of these are corrected by transfection with an expression vector for wild-type epsilon-COP, a subunit of coatomers (Guo, Q., Vasile, E., and Krieger, M. (1994) J. Cell Biol. 125, 1213-1224). We now report the identification in IdlF cells of a point mutation in the epsilon-COP gene, Glu(251) to Lys(251), which prevents the corresponding cDNA from correcting the defects in transfected IdlF cells and the immunochemical analysis of the synthesis, structure, and stability of epsilon-COP. At the permissive temperature (34 degrees C), the steady state level of ts-epsilon-COP in IdlF cells was about half that of epsilon-COP in wild-type Chinese hamster ovary cells and the isoelectric point of ts-epsilon-COP was 0.14 pH units higher than that of the wild type protein. The stability but not the biosynthesis of ts-epsilon-COP was temperature-sensitive (t(1/2) > 6 h at 34 degrees C and similar to 1-2 h at 39.5 degrees C), and this accounts for the virtual absence of detectable ts-epsilon-COP protein in IdlF cells after incubation at 39.5 degrees C for > 6 h, The steady state levels in IdlF cells of another coatomer subunit, beta-COP, and the peripheral Golgi protein IdlCp were not temperature-sensitive. Thus, a mutation in epsilon-COP that causes instability at 39.5 degrees C is responsible for all of the temperature-sensitive defects in IdlF cells, and the stability of beta-COP is not linked directly to that of epsilon-COP. IdlF cells should be useful for the future analysis of the structure and function of epsilon-COP, the assembly of COPs into coatomers, and the participation of coatomers in intracellular membrane transport.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)				Trigatti, Bernardo (Dino) L./0000-0002-4556-119X	NHLBI NIH HHS [HL-08775, HL41484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008775, P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUDEN R, 1994, J BIOL CHEM, V269, P24486; Duden R, 1991, Trends Cell Biol, V1, P14, DOI 10.1016/0962-8924(91)90064-G; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; Harlow E., 1988, ANTIBODIES LAB MANUA; HOBBIE L, 1994, J BIOL CHEM, V269, P20958; KOZARSKY KF, 1986, J CELL BIOL, V102, P1567, DOI 10.1083/jcb.102.5.1567; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; KUGE O, 1993, J CELL BIOL, V123, P1727, DOI 10.1083/jcb.123.6.1727; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ORCI L, 1994, P NATL ACAD SCI USA, V91, P11924, DOI 10.1073/pnas.91.25.11924; ORCI L, 1991, CELL, V64, P1183; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PODOS SD, 1994, J CELL BIOL, V127, P679, DOI 10.1083/jcb.127.3.679; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; REDDY P, 1989, MOL CELL BIOL, V9, P4799, DOI 10.1128/MCB.9.11.4799; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J, 1989, MOL CLONIG LAB MANUA; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SHITE S, 1990, J BIOL CHEM, V265, P17385; SPIRO DJ, 1995, J BIOL CHEM, V270, P13693, DOI 10.1074/jbc.270.23.13693; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; TAKATSUKI A, 1985, AGR BIOL CHEM TOKYO, V49, P899, DOI 10.1080/00021369.1985.10866826; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARREN G, 1993, NATURE, V362, P297, DOI 10.1038/362297a0; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WHITNEY JA, 1995, CELL, V83, P703	41	68	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11191	11196		10.1074/jbc.271.19.11191	http://dx.doi.org/10.1074/jbc.271.19.11191			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626666	hybrid			2022-12-27	WOS:A1996UJ94400026
J	deVitry, C; Breyton, C; Pierre, Y; Popot, JL				deVitry, C; Breyton, C; Pierre, Y; Popot, JL			The 4-kDa nuclear-encoded PetM polypeptide of the chloroplast cytochrome b(6)f - Complex nucleic acid and protein sequences, targeting signals, transmembrane topology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII; MEMBRANE-PROTEINS; MOLECULAR-WEIGHT; TRANSIT PEPTIDES; GENES; SUBUNITS; MITOCHONDRIAL; EXPRESSION; SPINACH	The 4-kDa subunit of cytochrome b(6)f complex encoded by the nuclear PetM gene in Chlamydomonas reinhardtii has been characterized, 38 of the 39 residues of the mature protein have been established by Edman degradation, a cDNA clone encoding the complete precursor has been isolated and sequenced, and a 0.6-kb transcript detected, The deduced amino acid sequence of the precursor includes an N-terminal transit peptide of 60 amino acids with stromal targeting features. Examination of the sequence suggests that PetM spans the membrane as a single transmembrane alpha-helix, which is supported by its non-extractability following dissociating treatments, When PetM and PetG, another small subunit of the b(6)f complex, are folded into alpha-helices, an array of identical residues becomes apparent, Proteolysis data, charge distribution, and homology with PetG are consistent with a lumenal localization of the N terminus of PetM.			deVitry, C (corresponding author), INST BIOL PHYSICOCHIM,CNRS URA 1187,SERV PHOTOSYNTHESE,13 RUE PIERRE & MARIE CURIE,F-75005 PARIS,FRANCE.							ATTEIA A, 1992, J BIOL CHEM, V267, P226; BALD D, 1992, P 9 INT C PHOT, P629; BERTHOLD DA, 1995, J BIOL CHEM, V270, P29293, DOI 10.1074/jbc.270.49.29293; BREYTON C, 1994, J BIOL CHEM, V269, P7597; BUSCHLEN S, 1991, FEBS LETT, V284, P257, DOI 10.1016/0014-5793(91)80698-3; DALBEY RE, 1995, TRENDS CELL BIOL, V5, P380, DOI 10.1016/S0962-8924(00)89079-0; DELEPELAIRE P, 1979, P NATL ACAD SCI USA, V76, P111, DOI 10.1073/pnas.76.1.111; DEVITRY C, 1989, CR ACAD SCI III-VIE, V309, P709; DEVITRY C, 1994, J BIOL CHEM, V269, P7603; DEVITRY C, 1991, J BIOL CHEM, V266, P16614; DEVITRY C, 1989, J CELL BIOL, V109, P991, DOI 10.1083/jcb.109.3.991; deVitry C, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P595; DRAPIER D, 1992, PLANT CELL, V4, P283, DOI 10.2307/3869540; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FONG SE, 1992, CURR GENET, V21, P527, DOI 10.1007/BF00351664; FRANZEN LG, 1990, FEBS LETT, V260, P165, DOI 10.1016/0014-5793(90)80094-Y; GAVEL Y, 1991, FEBS LETT, V282, P41, DOI 10.1016/0014-5793(91)80440-E; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; GOLDSCHMIDTCLERMONT M, 1986, J MOL BIOL, V191, P421, DOI 10.1016/0022-2836(86)90137-3; HALEY J, 1989, P NATL ACAD SCI USA, V86, P1534, DOI 10.1073/pnas.86.5.1534; HERRMANN RG, 1993, FEBS LETT, V326, P192, DOI 10.1016/0014-5793(93)81789-3; HUANG D, 1994, BIOCHEMISTRY-US, V33, P4401, DOI 10.1021/bi00180a038; Joliot A, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P615; LEMAIRE C, 1986, BIOCHIM BIOPHYS ACTA, V851, P229, DOI 10.1016/0005-2728(86)90130-1; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; PIERRE Y, 1993, CR ACAD SCI III-VIE, V316, P1404; POPOT JL, 1990, ANNU REV BIOPHYS BIO, V19, P369; Popot JL, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P507; SCHMIDT CL, 1993, PHOTOSYNTH RES, V38, P73, DOI 10.1007/BF00015063; TAKAHASHI Y, 1996, IN PRESS EMBO J; Theg Steven M., 1993, Trends in Cell Biology, V3, P186, DOI 10.1016/0962-8924(93)90212-J; WYNN RM, 1988, BIOCHIM BIOPHYS ACTA, V935, P115, DOI 10.1016/0005-2728(88)90208-3	32	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10667	10671		10.1074/jbc.271.18.10667	http://dx.doi.org/10.1074/jbc.271.18.10667			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631873	hybrid			2022-12-27	WOS:A1996UJ34200041
J	LopezBeltran, EA; Mate, MJ; Cerdan, S				LopezBeltran, EA; Mate, MJ; Cerdan, S			Dynamics and environment of mitochondrial water as detected by H-1 NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; RED-BLOOD-CELLS; HUMAN-ERYTHROCYTES; DIFFUSION PERMEABILITY; TRANSPORT; GRADIENT; O-17	The dynamics and environment of water in suspensions of isolated rat liver mitochondria have been investigated by H-1 NMR, NMR longitudinal and transversal relaxation times (T-1 and T-2) were measured in the resuspension medium (2.65 s and 44.57 ms) and in mitochondrial suspensions (1.74 s and 23.14 ms), respectively, Results showed monoexponential relaxation in both cases, suggesting a fast water exchange across the inner mitochondrial membrane. Ferromagnetically induced shift of the extramitochondrial water with nonpermeant ferromagnetic particles revealed no detectable water signal from the intramitochondrial compartment, confirming the fast exchange case, Simulations on a two-compartment model indicated that the intramitochondrial water residence time has an upper limit of approximately 100 mu s. Calculated intramitochondrial relaxation times revealed that the intramitochondrial environment has an apparent viscosity 30 times larger than the resuspension medium and 15 times larger than the cytosol of erythrocytes. The higher apparent viscosity of the mitochondrial matrix could account for reductions of more than one order of magnitude in the diffusion coefficient of water and other substrates, limitations in the rate of enzymatic reactions which are diffusion controlled and a more favorable formation of multienzyme complexes.	CSIC, INST INVEST BIOMED, E-28029 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)				Cerdan, Sebastian/0000-0001-9965-0270				ANDRASKO J, 1976, BIOCHIM BIOPHYS ACTA, V428, P304, DOI 10.1016/0304-4165(76)90038-6; BENGA G, 1990, J BIOCHEM BIOPH METH, V21, P87, DOI 10.1016/0165-022X(90)90057-J; BENGA G, 1992, EUR J CELL BIOL, V59, P219; BENGA G, 1989, INT REV CYTOL, V114, P273; CHIEN DY, 1977, BIOCHIM BIOPHYS ACTA, V464, P45, DOI 10.1016/0005-2736(77)90369-8; CLEVELAND GG, 1976, BIOPHYS J, V16, P1043, DOI 10.1016/S0006-3495(76)85754-2; CONLON T, 1972, BIOCHIM BIOPHYS ACTA, V288, P354, DOI 10.1016/0005-2736(72)90256-8; COOKE R, 1974, ANNU REV BIOPHYS BIO, V3, P95, DOI 10.1146/annurev.bb.03.060174.000523; Darley-Usmar V.M., 1987, MITOCHONDRIA PRACTIC, P4; Dawson A., 1987, MITOCHONDRIA PRACTIC, P35; FEHRST A, 1977, ENZYME STRUCTURE MEC, P126; FOSTER MA, 1984, MAGNETIC RESONANCE M, P137; GADIAN DG, 1982, NUCL MAGNETIC RESONA, P125; GARLID KD, 1979, CELL ASS WATER, P293; GUNTER TE, 1972, BIOPHYS J, V12, P625, DOI 10.1016/S0006-3495(72)86108-3; HAINES TH, 1994, FEBS LETT, V346, P115, DOI 10.1016/0014-5793(94)00470-6; HERBST MD, 1989, AM J PHYSIOL, V256, pC1097, DOI 10.1152/ajpcell.1989.256.5.C1097; HUTSON SM, 1992, BIOCHEMISTRY-US, V31, P1322, DOI 10.1021/bi00120a007; Israelachvili J, 1996, NATURE, V379, P219, DOI 10.1038/379219a0; KOENIG SH, 1969, J BIOL CHEM, V244, P3283; KOENIG SH, 1975, P NATL ACAD SCI USA, V72, P2667, DOI 10.1073/pnas.72.7.2667; LANG RDA, 1987, MITOCHONDRIA PRACTIC, P17; LANOUE KF, 1984, J BIOL CHEM, V259, P4116; LATOUR LL, 1994, P NATL ACAD SCI USA, V91, P1229, DOI 10.1073/pnas.91.4.1229; MCCONNELL HM, 1958, J CHEM PHYS, V28, P430, DOI 10.1063/1.1744152; MOLDAY RS, 1982, J IMMUNOL METHODS, V52, P353, DOI 10.1016/0022-1759(82)90007-2; MOLDES M, 1994, NMR BIOMED, V7, P249, DOI 10.1002/nbm.1940070602; NEVILLE MC, 1974, SCIENCE, V184, P1072, DOI 10.1126/science.184.4141.1072; NIETO R, 1992, BIOCHIMIE, V74, P903, DOI 10.1016/0300-9084(92)90074-O; OVADI J, 1992, TRENDS BIOCHEM SCI, V17, P445, DOI 10.1016/0968-0004(92)90485-R; POXLEITNER M, 1993, Z NATURFORSCH C, V48, P654; PRICE WS, 1989, BIOPHYS CHEM, V33, P205, DOI 10.1016/0301-4622(89)80022-5; RENSHAW P F, 1986, Magnetic Resonance Imaging, V4, P351, DOI 10.1016/0730-725X(86)91045-3; SCARPA A, 1979, MEMBRANE TRANSPORT B, V2, P263; SHPORER M, 1975, BIOCHIM BIOPHYS ACTA, V385, P81, DOI 10.1016/0304-4165(75)90076-8; SOLOMON AK, 1989, METHOD ENZYMOL, V173, P192; Srere P A, 1987, Biochem Soc Symp, V54, P173; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; WANG JH, 1951, J AM CHEM SOC, V73, P510, DOI 10.1021/ja01146a002; WELCH GR, 1994, TRENDS BIOCHEM SCI, V19, P193; WELCH GR, 1986, S BIOL HUNG, V30, P217	42	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10648	10653		10.1074/jbc.271.18.10648	http://dx.doi.org/10.1074/jbc.271.18.10648			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631870	hybrid			2022-12-27	WOS:A1996UJ34200038
J	Pandey, A; Liu, X; Dixon, JE; DiFiore, PP; Dixit, VM				Pandey, A; Liu, X; Dixon, JE; DiFiore, PP; Dixit, VM			Direct association between the Ret receptor tyrosine kinase and the Src homology 2-containing adapter protein Grb7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; BINDING; DOMAINS; LINE	Adapter proteins containing Src homology 2 (SH2) domains link transmembrane receptor protein-tyrosine kinases to downstream signal transducing molecules, A family of SH2 containing adapter proteins including Grb7 and Grb10 has been recently identified, We had previously shown that Grb10 associates with Ret via its SH2 domain in an activation-dependent manner (Pandey, A., Duan, H., Di Fiore, P.P., and Dixit, V.M, (1995) J. Biol, Chem, 270, 21461-21463), We now demonstrate that the related adapter molecule Grb7 also associates with Ret in vitro and in vivo, and that the binding of the SH2 domain of Grb7 to Ret is direct, This binding is depend ent upon Ret autophosphorylation since Grb7 is incapable of binding a kinase-defective mutant of Ret, Thus two members of the Grb family, Grb7 and Grb10, likely relay signals emanating from Ret to other, as yet, unidentified targets within the cell.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT BIOCHEM,ANN ARBOR,MI 48109; EUROPEAN INST ONCOL,MILAN,ITALY	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; IRCCS European Institute of Oncology (IEO)			Pandey, Akhilesh/B-4127-2009; dixit, vishva m/A-4496-2012; Di Fiore, Pier Paolo/K-2130-2012	Pandey, Akhilesh/0000-0001-9943-6127; dixit, vishva m/0000-0001-6983-0326; Di Fiore, Pier Paolo/0000-0002-2252-0950	NIDDK NIH HHS [DK 39255] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039255] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASAI N, 1995, MOL CELL BIOL, V15, P1613; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HU HM, 1994, J BIOL CHEM, V269, P30069; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; MARGOLIS B, 1994, PROG BIOPHYS MOL BIO, V62, P223, DOI 10.1016/0079-6107(94)90013-2; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; OOI J, 1995, ONCOGENE, V10, P1621; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; ROMANO A, 1994, ONCOGENE, V9, P2923; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; ZHU GC, 1992, P NATL ACAD SCI USA, V89, P9559, DOI 10.1073/pnas.89.20.9559	21	71	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10607	10610		10.1074/jbc.271.18.10607	http://dx.doi.org/10.1074/jbc.271.18.10607			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631863	hybrid			2022-12-27	WOS:A1996UJ34200031
J	Tsuda, H; Yamada, SH; Yamane, Y; Yoshida, K; Hopwood, JJ; Sugahara, K				Tsuda, H; Yamada, SH; Yamane, Y; Yoshida, K; Hopwood, JJ; Sugahara, K			Structures of five sulfated hexasaccharides prepared from porcine intestinal heparin using bacterial heparinase - Structural variants with apparent biosynthetic precursor-product relationships for the antithrombin III-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; HUMAN-ENDOTHELIAL CELLS; 2 SERIES; OLIGOSACCHARIDES; DEPOLYMERIZATION; TETRASACCHARIDES; PURIFICATION; AFFINITY; SEQUENCE; IDENTIFICATION	Porcine intestinal heparin was extensively digested with Flavobacterium heparinase and size-fractionated by gel chromatography. Subfractionation of the hexasaccharide fraction by anion exchange high pressure liquid chromatography yielded 10 fractions. Six contained oligosaccharides derived from the repeating disaccharide region, whereas four contained glycoserines from the glycosaminoglycan-protein linkage region. The latter structures were reported recently (Sugahara, K., Tsuda, H., Yoshida, K., Yamada, S., de Beer, T., and Vliegenthart, J. F. G. (1995) J. Biol. Chem. 270, 22914-22923). In this study, the structures of one tetra- and five hexasaccharides from the repeat region were determined by chemical and enzymatic analyses as well as 500-MHz H-1 NMR spectroscopy. The tetrasaccharide has the hexasulfated structure typical of heparin. The five hexa- or heptasulfated hexasaccharides share the common core pentasulfated structure Delta HexA(2S)alpha 1-4GlcN(NS,6S)alpha 1-4IdoA alpha/GlcA beta 1-4GlcN(6S)alpha 1-4GlcA beta 1-4GlcN(NS) with one or two additional sulfate groups (Delta HexA, GlcN, IdoA, and GlcA represent 4-deoxy-alpha-L-threo-hex-4-enepyranosyluronic acid, D-glucosamine, L-iduronic acid, and D-glucuronic acid, whereas 2S, 6S, and NS stand for 2-O-, 6-O-, and 2-N-sulfate, respectively). Three components have the following hitherto unreported structures: Delta HexeA(2S)alpha 1-4GlcN(NS,6S)alpha 1-4GlcA beta 1-4GlcN(NS,GS)alpha 1-4GlcA beta 1-4GlcN(NS,6S), Delta HexA(2S)alpha 1-4GlcN(NS,6S)alpha 1-4IdoA alpha 1-4GlcNAc(6S)alpha 1-4GlcA beta 1-4GlcN(NS,3S), and Delta HexA(2S)alpha 1-4GlcN(NS,6S)alpha 1-41doA(2S) alpha 1-4GlcNAc(6S)alpha 1-4GlcA beta 1-4GlcN(NS,6S). Two of the five hexasaccharides are structural variants derived from the antithrombin III-binding sites containing 3-O-sulfated GlcN at the reducing termini with or without a 6-O-sulfate group on the reducing N,3-disulfated GlcN residue. Another contains the structure identical to that of the above heptasulfated antithrombin III binding site fragment but lacks the 3-O-sulfate group and therefore is a pro-form for the binding site. Another has an extra sulfate group on the internal IdoA residue of this pro-form and therefore can be considered to have diverged from the binding site in the biosynthetic pathway. Thus, the isolated hexasaccharides in this study include the three overlapping pairs of structural variants with an apparent biosynthetic precursor-product relationship, which may reflect biosynthetic regulatory mechanisms of the binding site.	KOBE PHARMACEUT UNIV,DEPT BIOCHEM,HIGASHINADA KU,KOBE 658,JAPAN; SEIKAGAKU CORP,TOKYO RES INST,HIGASHIYAMATO,TOKYO 207,JAPAN; ADELAIDE CHILDRENS HOSP INC,DEPT CHEM PATHOL,LYSOSOMAL DIS RES UNIT,ADELAIDE,SA 5006,AUSTRALIA	Kobe Pharmaceutical University; Seikagaku Corporation								BARZU T, 1989, J CELL PHYSIOL, V140, P538, DOI 10.1002/jcp.1041400320; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; FOLKMAN J, 1989, HEPARIN, P317; FREEMAN C, 1992, BIOCHEM J, V282, P899, DOI 10.1042/bj2820899; GALLAGHER JT, 1989, HEPARIN, P135; GILAT D, 1995, J EXP MED, V181, P1929, DOI 10.1084/jem.181.5.1929; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HOOGEWERF AJ, 1995, J BIOL CHEM, V270, P3268, DOI 10.1074/jbc.270.7.3268; HORNE A, 1992, CARBOHYD RES, V225, P43, DOI 10.1016/0008-6215(92)80038-3; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P817, DOI 10.1093/glycob/4.6.817; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; KUSCHE M, 1988, J BIOL CHEM, V263, P15474; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LINDAHL U, 1965, J BIOL CHEM, V240, P2821; Lindahl U., 1989, HEPARIN, P159; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; LINKER A, 1984, CARBOHYD RES, V127, P75, DOI 10.1016/0008-6215(84)85107-1; LYON M, 1994, J BIOL CHEM, V269, P11216; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; MARCUM JA, 1989, HEPARIN, P275; MCLEAN MW, 1984, EUR J BIOCHEM, V145, P607, DOI 10.1111/j.1432-1033.1984.tb08600.x; MERCHANT ZM, 1985, BIOCHEM J, V229, P369, DOI 10.1042/bj2290369; MORITA T, 1977, J BIOCHEM-TOKYO, V82, P1495, DOI 10.1093/oxfordjournals.jbchem.a131840; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; RAZI N, 1995, J BIOL CHEM, V270, P11267, DOI 10.1074/jbc.270.19.11267; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; SUGAHARA K, 1995, J BIOL CHEM, V270, P22914, DOI 10.1074/jbc.270.39.22914; SUGAHARA K, 1992, J BIOL CHEM, V267, P1528; SUGAHARA K, 1987, ARCH BIOCHEM BIOPHYS, V258, P391, DOI 10.1016/0003-9861(87)90360-2; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; TSUKADA T, 1987, COMP BIOCHEM PHYS B, V86, P565, DOI 10.1016/0305-0491(87)90449-4; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; YAMADA S, 1992, J BIOCHEM-TOKYO, V112, P440, DOI 10.1093/oxfordjournals.jbchem.a123919; YAMADA S, 1995, J BIOL CHEM, V270, P8696; YAMADA S, 1994, GLYCOBIOLOGY, V4, P69, DOI 10.1093/glycob/4.1.69; YAMADA SH, 1993, J BIOL CHEM, V268, P4780; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YOSHIDA K, 1989, 10TH P INT S GLYC JE, P330	51	24	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10495	10502		10.1074/jbc.271.18.10495	http://dx.doi.org/10.1074/jbc.271.18.10495			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631846	hybrid			2022-12-27	WOS:A1996UJ34200014
J	Zhou, J; Mulshine, JL; Unsworth, EJ; Scott, FR; Avis, IM; Vos, MD; Treston, AM				Zhou, J; Mulshine, JL; Unsworth, EJ; Scott, FR; Avis, IM; Vos, MD; Treston, AM			Purification and characterization of a protein that permits early detection of lung cancer - Identification of heterogeneous nuclear ribonucleoprotein-A2/B1 as the antigen for monoclonal antibody 703D4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING-PROTEINS; GENE-EXPRESSION; SEQUENCE; SENSITIVITY; CELLS	We have reported that a mouse monoclonal antibody, 703D4, detects lung cancer 2 years earlier than routine chest x-ray or cytomorphology, We purified the 703D4 antigen to elucidate its role in early lung cancer biology, using Western blot detection after SDS-polyacrylamide gel electrophoresis. Purification steps included anion exchange chromatography, preparative isoelectric focusing, polymer-based C-18-like, and analytical C-4 reverse phase high performance liquid chromatography. After 25-50,000-fold purification, the principal immunostaining protein was >95% pure by Coomassie staining, The NH2 terminus was blocked, so CNBr digestion was used to generate internal peptides, Three sequences, including one across a site of alternate exon splicing, all identified a single protein, heterogeneous nuclear ribonucleoprotein-A2 (hnRNP-A2), A minor co-purifying immunoreactive protein resolved at the final C-4 high performance liquid chromatography step is the splice variant hnRNP-B1, Northern analysis of RNA from primary normal bronchial epithelial cells demonstrated a low level of hnRNP-A2/B1 expression, consistent with immunohistochemical staining of clinical samples, and increased hnRNP-A2/B1 expression was found in lung cancer cells, hnRNP-A2/B1 expression is under proliferation-dependent control in normal bronchial epithelial cell primary cultures, but not in SV40-transformed bronchial epithelial cells or tumor cell lines, With our clinical data, this information suggests that hnRNP-A2/B1 is an early marker of lung epithelial transformation and carcinogenesis.	NCI, BIOMARKERS & PREVENT RES BRANCH, DCS, ROCKVILLE, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BEVERLEY PCL, 1991, BRIT J CANCER, V63, P10; BIAMONTI G, 1993, J MOL BIOL, V230, P77, DOI 10.1006/jmbi.1993.1127; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BOSSER R, 1995, MOL CELL BIOL, V15, P661; BRODER CC, 1994, P NATL ACAD SCI USA, V91, P11699, DOI 10.1073/pnas.91.24.11699; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; DAVIS LG, 1986, BASIC METHODS MOL BI, P129; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FROST JK, 1984, AM REV RESPIR DIS, V130, P549; GANJU RK, 1994, J CLIN INVEST, V94, P1784, DOI 10.1172/JCI117526; GROSS E, 1974, BIOCHEM BIOPH RES CO, V59, P1145, DOI 10.1016/S0006-291X(74)80098-7; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KUMAR A, 1986, J BIOL CHEM, V261, P1266; KYOGASHIMA M, 1989, ARCH BIOCHEM BIOPHYS, V275, P309, DOI 10.1016/0003-9861(89)90378-0; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P6461, DOI 10.1093/nar/20.24.6461; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; MULSHINE JL, 1983, J IMMUNOL, V131, P497; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; PERTON FG, 1995, BIOL CHEM H-S, V376, P243; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; PLANCK SR, 1988, NUCLEIC ACIDS RES, V16, P11663, DOI 10.1093/nar/16.24.11663; PRASAD S, 1994, BIOCHEM BIOPH RES CO, V204, P772, DOI 10.1006/bbrc.1994.2526; RAJPUROHIT R, 1994, J BIOL CHEM, V269, P1075; RISIO M, 1992, J CELL BIOCHEM, P79; SACCOMANNO G, 1970, ACTA CYTOL, V14, P377; SOULARD M, 1993, NUCLEIC ACIDS RES, V21, P4210, DOI 10.1093/nar/21.18.4210; TOCKMAN MS, 1988, J CLIN ONCOL, V6, P1685, DOI 10.1200/JCO.1988.6.11.1685; WILLIAMS KR, 1985, P NATL ACAD SCI USA, V82, P5666, DOI 10.1073/pnas.82.17.5666; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313; ZHOU J, 1996, IN PRESS LUNG CANC	32	113	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10760	10766		10.1074/jbc.271.18.10760	http://dx.doi.org/10.1074/jbc.271.18.10760			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631886				2022-12-27	WOS:A1996UJ34200054
J	Bizouarn, T; Diggle, C; Quirk, PG; Grimley, RL; Cotton, NPJ; Thomas, CM; Jackson, JB				Bizouarn, T; Diggle, C; Quirk, PG; Grimley, RL; Cotton, NPJ; Thomas, CM; Jackson, JB			Interaction of nucleotides with the NAD(H)-binding domain of the proton-translocating transhydrogenase of Rhodospirillum rubrum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NICOTINAMIDE; MITOCHONDRIA; KINETICS; ENZYME	Transhydrogenase catalyzes the reduction of NADP(+) by NADH coupled to the translocation of protons across a membrane. The polypeptide composition of the enzyme in Rhodospirillum rubrum is unique in that the NAD(H)-binding domain (called Th-s) exists as a separate polypeptide. Th-s was expressed in Escherichia coli and purified. The binding of nucleotide substrates and analogues to Th-s was examined by one dimensional proton nuclear magnetic resonance (NMR) spectroscopy and by measuring the quenching of fluorescence of its lone Trp residue. NADH and reduced acetylpyridine adenine dinucleotide bound tightly to Th-s, whereas NAD(+), oxidized acetylpyridine adenine dinucleotide, deamino-NADH, 5'-AMP and adenosine bound less tightly. Reduced nicotinamide mononucleotide, NADPH and 2'-AMP bound only very weakly to Th-s. The difference in the binding affinity between NADH and NAD(+) indicates that there may be an energy requirement for the transfer of reducing equivalents into this site in the complete enzyme under physiological conditions. Earlier results had revealed a mobile loop at the surface of Th-s (Diggle, C., Cotton, N. P. J., Grimley, R. L., Quirk, P. G., Thomas, C. M., and Jackson, J. B. (1995) Eur. J. Biochem. 232, 315-326); the loop loses mobility when Th-s binds nucleotide; the reaction involves two steps. This was more clearly evident, even for tight-binding nucleotides, when experiments were carried out at higher temperatures (37 degrees C), where the resonances of the mobile loop were substantially narrower. The binding of adenosine was sufficient to initiate loop closure; the presence of a reduced nicotinamide moiety in the dinucleotide apparently serves to tighten the binding. Two-dimensional 1(H) NMR spectroscopy of the Th-s-5'-AMP complex revealed nuclear Overhauser effect interactions between protons of amino acid residues in the mobile loop (including those in a Tyr residue) and the nucleotide. This suggests that, in the complex, the loop has closed down to within 0.5 nm of the nucleotide.	UNIV BIRMINGHAM,SCH BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,SCH BIOL SCI,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham			Thomas, Christopher M/J-8258-2017; bizouarn, tania/W-6782-2019	Thomas, Christopher M/0000-0002-2810-0455; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BIZOUARN T, 1995, BBA-BIOENERGETICS, V1229, P49, DOI 10.1016/0005-2728(94)00186-9; BIZOUARN T, 1996, IN PRESS BIOCH BIOPH; CUNNINGHAM IJ, 1992, BIOCHIM BIOPHYS ACTA, V1100, P332, DOI 10.1016/0167-4838(92)90490-5; DIGGLE C, 1995, EUR J BIOCHEM, V232, P315, DOI 10.1111/j.1432-1033.1995.tb20814.x; DIGGLE C, 1995, EUR J BIOCHEM, V228, P719, DOI 10.1111/j.1432-1033.1995.0719m.x; Diggle C, 1996, J BIOL CHEM, V271, P10109, DOI 10.1074/jbc.271.17.10109; ENANDER K, 1982, J BIOL CHEM, V257, P4760; FISHER RR, 1971, J BIOL CHEM, V246, P4679; FJELLSTROM O, 1995, PROTEINS, V21, P91, DOI 10.1002/prot.340210203; GALANTE YM, 1980, J BIOL CHEM, V255, P9641; GRAU UM, 1981, J MOL BIOL, V151, P289, DOI 10.1016/0022-2836(81)90516-7; HANSON RL, 1979, J BIOL CHEM, V254, P888; HATEFI Y, 1992, MOL MECHANISMS BIOEN, P265; HOMYK M, 1979, BIOCHIM BIOPHYS ACTA, V571, P201, DOI 10.1016/0005-2744(79)90091-3; HU X, 1995, BBA-BIOENERGETICS, V1229, P64, DOI 10.1016/0005-2728(94)00187-A; HUTTON M, 1994, EUR J BIOCHEM, V219, P1041, DOI 10.1111/j.1432-1033.1994.tb18587.x; JACKSON JB, 1991, J BIOENERG BIOMEMBR, V23, P715, DOI 10.1007/BF00785998; LEVER TM, 1991, EUR J BIOCHEM, V197, P247, DOI 10.1111/j.1432-1033.1991.tb15905.x; MEJBAUMKATZENELLENBOGEN W, 1959, CLIN CHIM ACTA, V4, P515, DOI 10.1016/0009-8981(59)90158-5; OLAUSSON T, 1995, BBA-BIOENERGETICS, V1231, P1, DOI 10.1016/0005-2728(95)00058-Q; RYDSTROM J, 1977, BIOCHIM BIOPHYS ACTA, V463, P155, DOI 10.1016/0304-4173(77)90007-6; SAZANOV LA, 1994, FEBS LETT, V344, P109, DOI 10.1016/0014-5793(94)00370-X; SAZANOV LA, 1995, BBA-BIOENERGETICS, V1231, P304; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; WILLIAMS R, 1994, MICROBIOL-UK, V140, P1595, DOI 10.1099/13500872-140-7-1595; Woenckhaus C., 1987, PYRIDINE NUCLEOTID A, P449; YAMAGUCHI M, 1993, J BIOL CHEM, V268, P17871; YAMAGUCHI M, 1994, J BIOENERG BIOMEMBR, V26, P435, DOI 10.1007/BF00762784	28	31	31	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10103	10108		10.1074/jbc.271.17.10103	http://dx.doi.org/10.1074/jbc.271.17.10103			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626568	hybrid			2022-12-27	WOS:A1996UG25700040
J	DeSmedt, F; Boom, A; Pesesse, X; Schiffmann, SN; Erneux, C				DeSmedt, F; Boom, A; Pesesse, X; Schiffmann, SN; Erneux, C			Post-translational modification of human brain type I inositol-1,4,5-trisphosphate 5-phosphatase by farnesylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; INOSITOL 1,4,5-TRISPHOSPHATE 3-KINASE; RAT-BRAIN; HUMAN-PLATELETS; TRISPHOSPHATE; MEMBRANE; PURIFICATION; EXPRESSION; POLYPHOSPHATE-5-PHOSPHATASE; TETRAKISPHOSPHATE	In brain, type I inositol-1,4,5-trisphosphate 5-phosphatase (InsP(3) 5-phosphatase) is the major isoenzyme hydrolyzing the calcium-mobilizing second messenger InsP. Activity of this enzyme could be measured in both soluble and particulate fractions of tissue homogenates. The protein sequence showed a putative C-terminal isoprenylation site (CVVQ). In this study, two mutants have been generated. The first mutant (C409S) has a serine replacing a cysteine at position 409 of the wild-type enzyme. The second mutant (K407D1) is a deletion mutant that lacks the last five C-terminal amino acids. These constructs were individually expressed by transfection in COS-7 cells. Western blot analysis of wild-type transfected cells indicated that both soluble and particulate fractions had a 43-kDa immunoreactive band, with a higher proportion of the original homogenate associated with the particulate part. On the contrary, when the two mutated constructs were transfected in COS-7 cells, the phosphatase was predominantly soluble. Confocal immunofluorescence studies showed the wild-type enzyme to be present on the cell surface of transfected COS-7 cells and in subcellular compartments around the nucleus. This was not observed for the two mutants, where uniform immunofluorescence labeling was observed throughout the cytosol. Recombinant type I InsP(3) 5-phosphatase expressed in Escherichia coli was a substrate of purified farnesyltransferase. Altogether, the data therefore suggest a direct participation of Cys-409 in a C-terminally anchored InsP(3) 5-phosphatase by farnesylation.	FREE UNIV BRUSSELS, INTERDISCIPLINARY RES INST, B-1070 BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, NEUROPATHOL & NEUROPEPTIDE RES LAB, BRAIN RES INST, B-1070 BRUSSELS, BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel				Schiffmann, Serge/0000-0002-0118-9816				ADAMSON P, 1992, J BIOL CHEM, V267, P20033; ARMSTRONG SA, 1995, J BIOL CHEM, V270, P7864, DOI 10.1074/jbc.270.14.7864; ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CONNOLLY TM, 1987, J BIOL CHEM, V262, P2146; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; COX AD, 1995, METHOD ENZYMOL, V250, P105; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DESMEDT F, 1994, FEBS LETT, V347, P69, DOI 10.1016/0014-5793(94)00509-5; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; ERNEUX C, 1989, EUR J BIOCHEM, V181, P317, DOI 10.1111/j.1432-1033.1989.tb14726.x; ERNEUX C, 1986, BIOCHEM BIOPH RES CO, V134, P351, DOI 10.1016/0006-291X(86)90570-X; ERNEUX C, 1995, EUR J BIOCHEM, V234, P598, DOI 10.1111/j.1432-1033.1995.598_b.x; Gottesman M M, 1987, Methods Enzymol, V151, P3, DOI 10.1016/S0076-6879(87)51004-7; HANSBRO PM, 1994, ARCH BIOCHEM BIOPHYS, V311, P47, DOI 10.1006/abbi.1994.1207; HANSEN CA, 1987, J BIOL CHEM, V262, P17319; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; JOLY C, 1995, J NEUROSCI, V15, P3970; KING WG, 1989, J BIOL CHEM, V264, P6070; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAXMINARAYAN KM, 1993, J BIOL CHEM, V268, P4968; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; LU CY, 1989, J MEMBRANE BIOL, V109, P85, DOI 10.1007/BF01870793; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHGURO H, 1991, EMBO J, V10, P3669, DOI 10.1002/j.1460-2075.1991.tb04934.x; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RUBIERA C, 1990, BIOCHEM J, V269, P353, DOI 10.1042/bj2690353; SHEARS SB, 1988, BIOCHEM J, V256, P363, DOI 10.1042/bj2560363; TAKAZAWA K, 1990, BIOCHEM J, V272, P107, DOI 10.1042/bj2720107; TAKAZAWA K, 1991, BIOCHEM J, V278, P883, DOI 10.1042/bj2780883; TAKIMOTO K, 1989, J BIOCHEM-TOKYO, V106, P684, DOI 10.1093/oxfordjournals.jbchem.a122917; VERJANS B, 1994, BIOCHEM J, V300, P85, DOI 10.1042/bj3000085; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145; WILCOX RA, 1994, SIGNAL ACTIVATED PHO, P190; ZHANG FL, 1994, J BIOL CHEM, V269, P23465; ZHANG FL, 1996, IN PRESS ANN REV BIO, V65; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853	48	66	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10419	10424		10.1074/jbc.271.17.10419	http://dx.doi.org/10.1074/jbc.271.17.10419			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626616	hybrid			2022-12-27	WOS:A1996UG25700088
J	Smith, AN; Barth, ML; McDowell, TL; Moulin, S; Nuthall, HN; Hollingsworth, MA; Harris, A				Smith, AN; Barth, ML; McDowell, TL; Moulin, S; Nuthall, HN; Hollingsworth, MA; Harris, A			A regulatory element in intron 1 of the cystic fibrosis transmembrane conductance regulator gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE; EPITHELIAL-CELLS; PROMOTER REGION; CFTR EXPRESSION; IDENTIFICATION; CHROMATIN; DIFFERENTIATION; LOCALIZATION; SEQUENCES; INDUCTION	The cystic fibrosis transmembrane conductance regulator (CFTR) gene exhibits a tightly regulated pattern of expression in human epithelial cells. The mechanism of this regulation is complex and is likely to involve a number of genetic elements that effect temporal and spatial expression, To date none of the elements that have been identified in the CFTR promoter regulate tissue-specific expression. We have identified a putative regulatory element within the first intron of the CFTR gene at 181 + 10kb, The region containing this element was first identified as a DNase I hypersensitive site that was present in cells that express the CFTR gene but absent from cells not transcribing CFTR, In vitro analysis of binding of proteins to this region of DNA sequence by gel mobility shift assays and DNase I footprinting revealed that some proteins that are only present in CFTR-expressing cells bound to specific elements, and other proteins that bound to adjacent elements were present in all epithelial cells irrespective of their CFTR expression status. When assayed in transient expression systems in a cell line expressing CFTR endogenously, this DNA sequence augmented reporter gene expression through activation of the CFTR promoter but had no effect in nonexpressing cells.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND; UNIV NEBRASKA,MED CTR,EPPLEY INST,OMAHA,NE 68198	University of Oxford; University of Nebraska System; University of Nebraska Medical Center			Saraiva-Pereira, Maria Luiza/H-6302-2013	Saraiva-Pereira, Maria Luiza/0000-0003-3905-9563	NIDDK NIH HHS [DK46589] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046589] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHOU JL, 1991, J BIOL CHEM, V266, P24471; COLEMAN L, 1991, J CELL SCI, V98, P85; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; FOGH J, 1977, J NATL CANCER I, V58, P209, DOI 10.1093/jnci/58.2.209; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; GRIESENBACH U, 1994, PAED PULMONOL S, V10, P199; HARRIS A, 1989, J CELL SCI, V92, P687; HARRIS A, 1991, DEVELOPMENT, V113, P305; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; HINES RN, 1988, CARCINOGENESIS, V9, P1599, DOI 10.1093/carcin/9.9.1599; HOLLINGSWORTH MA, 1994, NUCLEIC ACIDS RES, V22, P1138, DOI 10.1093/nar/22.7.1138; HUET C, 1987, J CELL BIOL, V105, P345, DOI 10.1083/jcb.105.1.345; JENUWEIN T, 1993, GENE DEV, V7, P2016, DOI 10.1101/gad.7.10.2016; KIM YW, 1989, PANCREAS, V4, P353, DOI 10.1097/00006676-198906000-00013; KOH J, 1993, J BIOL CHEM, V268, P15912; KOZENS AL, 1994, AM J RESPIR CELL MOL, V10, P38; MA YG, 1992, DEV BIOL, V154, P45, DOI 10.1016/0012-1606(92)90046-J; MCDONALD CD, 1994, GENE, V150, P267, DOI 10.1016/0378-1119(94)90436-7; MCDONALD RA, 1995, P NATL ACAD SCI USA, V92, P7560, DOI 10.1073/pnas.92.16.7560; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROCHWERGER L, 1994, J CELL SCI, V107, P2439; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SIDDIQUI AH, 1988, MOL CELL BIOL, V8, P4634, DOI 10.1128/MCB.8.11.4634; SMITH AN, 1995, BIOCHEM BIOPH RES CO, V211, P274, DOI 10.1006/bbrc.1995.1807; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; TREZISE AEO, 1993, HUM MOL GENET, V2, P213, DOI 10.1093/hmg/2.3.213; VYAS P, 1992, CELL, V69, P781, DOI 10.1016/0092-8674(92)90290-S; YOSHIMURA K, 1991, NUCLEIC ACIDS RES, V19, P5417, DOI 10.1093/nar/19.19.5417; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140	34	76	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9947	9954		10.1074/jbc.271.17.9947	http://dx.doi.org/10.1074/jbc.271.17.9947			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626632	hybrid			2022-12-27	WOS:A1996UG25700016
J	Teichmann, U; vanDyck, L; Guiard, B; Fischer, H; Glockshuber, R; Neupert, W; Langer, T				Teichmann, U; vanDyck, L; Guiard, B; Fischer, H; Glockshuber, R; Neupert, W; Langer, T			Substitution of PIM1 protease in mitochondria by Escherichia coli Lon protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; PRECURSOR PROTEIN; LA; BACTERIAL; IMPORT; PROTEOLYSIS; HYDROLYSIS; GENE; DEGRADATION; PRODUCT	PIM1 protease in mitochondria belongs to a conserved family of ATP-dependent proteases, which includes the Escherichia coli Lon protease. Yeast cells lacking PIM1 are largely defective in degrading misfolded proteins in the mitochondrial matrix, are respiratory deficient, and lose integrity of mitochondrial DNA. In order to analyze whether E. coli Lon protease is functionally equivalent to mitochondrial PIM1 protease, yeast cells lacking the PIM1 gene were transformed with a construct consisting of a mitochondrial targeting sequence fused onto the Lon protease. In these cells, the fusion protein was expressed and imported into mitochondria, and the targeting sequence was removed. In the absence of PIM1 protease, the E. coli Lon protease mediated the degradation of misfolded proteins in the matrix space in cooperation with the mitochondrial hsp70 system. These cells maintained the integrity of the mitochondrial genome and the respiratory function at 30 degrees C but not at 37 degrees C. Stabilization of mitochondrial DNA in Delta pim1 cells depended on protein degradation by the E. coli Lon protease, as a proteolytically inactive Lon variant was not capable of substituting for a loss of PIM1 protease. These results demonstrate functional conservation of Lon-like proteases from prokaryotes to eukaryotes and shed new light on the role of Lon-like proteases in mitochondrial biogenesis.	UNIV MUNICH, INST PHYSIOL CHEM, D-80336 MUNICH, GERMANY; UNIV PARIS 06, CTR GENET MOLEC, CNRS, F-91190 GIF SUR YVETTE, FRANCE; ETH HONGGERBERG, INST MOLEK BIOL & BIOPHYS, CH-8093 ZURICH, SWITZERLAND	University of Munich; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Swiss Federal Institutes of Technology Domain; ETH Zurich				Langer, Thomas/0000-0003-1250-1462				AMERIK AY, 1994, FEBS LETT, V340, P25, DOI 10.1016/0014-5793(94)80166-5; AMERIK AY, 1991, FEBS LETT, V287, P211, DOI 10.1016/0014-5793(91)80053-6; Ausubel FM, 1992, CURRENT PROTOCOLS MO; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CHARETTE MF, 1981, P NATL ACAD SCI-BIOL, V78, P4728, DOI 10.1073/pnas.78.8.4728; CHUNG CH, 1981, P NATL ACAD SCI-BIOL, V78, P4931, DOI 10.1073/pnas.78.8.4931; DESAUTELS M, 1982, P NATL ACAD SCI-BIOL, V79, P1869, DOI 10.1073/pnas.79.6.1869; FISCHER H, 1993, J BIOL CHEM, V268, P22502; FISCHER H, 1994, FEBS LETT, V356, P101, DOI 10.1016/0014-5793(94)01244-X; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOFF SA, 1987, J BIOL CHEM, V262, P4508; GOLDBERG AL, 1985, J BIOL CHEM, V260, P2029; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HERRMANN JM, 1994, CELL BIOL LAB HDB; KOL H, 1991, THESIS U MUNCHEN; KUTEJOVA E, 1993, FEBS LETT, V329, P47, DOI 10.1016/0014-5793(93)80190-6; NICHOLSON DW, 1987, EUR J BIOCHEM, V164, P147, DOI 10.1111/j.1432-1033.1987.tb11006.x; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; ROSE MD, 1993, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIESTL RH, 1993, METHODS, V5, P78; SCHMITT M, 1995, EMBO J, V14, P3434, DOI 10.1002/j.1460-2075.1995.tb07349.x; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VANDYCK L, 1994, J BIOL CHEM, V269, P238; VANHEUSDEN GPH, 1992, FEBS LETT, V302, P145, DOI 10.1016/0014-5793(92)80426-H; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VESTWEBER D, 1988, EMBO J, V7, P1147, DOI 10.1002/j.1460-2075.1988.tb02924.x; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; WANG N, 1994, J BIOL CHEM, V269, P29308; WATABE S, 1985, J BIOL CHEM, V260, P4498; WAXMAN L, 1986, SCIENCE, V232, P500, DOI 10.1126/science.2938257	36	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10137	10142		10.1074/jbc.271.17.10137	http://dx.doi.org/10.1074/jbc.271.17.10137			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626573	hybrid			2022-12-27	WOS:A1996UG25700045
J	Zhao, WN; McAlisterHenn, L				Zhao, WN; McAlisterHenn, L			Assembly and function of a cytosolic form of NADH-specific isocitrate dehydrogenase in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL MALATE-DEHYDROGENASE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; GENE; DISRUPTION; BINDING; PHOSPHORYLATION; EXPRESSION; PROTEINS; CLONING	Mitochondrial NAD-dependent isocitrate dehydrogenase catalyzes a rate-limiting step in the tricarboxylic acid cycle. Yeast isocitrate dehydrogenase is an octomer composed of two subunits (IDH1 and IDH2) encoded by different genes and possessing independent mitochondrial targeting presequences. Oligonucleotide-directed mutagenesis was used to remove the presequences from each gene and from both genes carried on centromere-based expression plasmids. Effects on cellular localization were examined in a yeast strain containing chromosomal disruptions of IDH1 and IDH2 loci. Each subunit was found to be dependent upon its prese quence for mitochondrial localization, and the subunits are independently imported into mitochondria under most growth conditions. Furthermore, an active holoenzyme can be assembled in the cytosol and this ''cytosolic'' form of isocitrate dehydrogenase can reverse the acetate(-) growth phenotype characteristic of the Delta IDH1/Delta IDH2 disruption strain, indicating functional replacement of the mitochondrial enzyme. However, transformants containing plasmids lacking either the IDH1 or IDH2 presequence coding regions were unexpectedly found to be capable of growth on acetate medium. Further investigation demonstrated that cellular localization of the IDH1 subunit can be biased by this stringent growth pressure.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NIGMS NIH HHS [GM51265] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051265] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNES LD, 1971, BIOCHEMISTRY-US, V10, P3939, DOI 10.1021/bi00797a022; BEDWELL DM, 1987, MOL CELL BIOL, V7, P294; BOTSTEIN D, 1979, GENE, V8, P12; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CUPP JR, 1992, J BIOL CHEM, V267, P16417; CUPP JR, 1993, BIOCHEMISTRY-US, V32, P9323, DOI 10.1021/bi00087a010; CUPP JR, 1991, J BIOL CHEM, V266, P22199; DAUM G, 1982, J BIOL CHEM, V257, P3028; DOUGLAS MG, 1986, MICROBIOL REV, V50, P166, DOI 10.1128/MMBR.50.2.166-178.1986; ELZINGA SDJ, 1993, NUCLEIC ACIDS RES, V21, P5328, DOI 10.1093/nar/21.23.5328; HASELBECK RJ, 1993, J BIOL CHEM, V268, P12116; HASELBECK RJ, 1991, J BIOL CHEM, V266, P2339; HATHAWAY JA, 1963, J BIOL CHEM, V238, P2875; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KEYS DA, 1990, J BACTERIOL, V172, P4200; KIM KS, 1986, MOL CELL BIOL, V6, P1936, DOI 10.1128/MCB.6.6.1936; LOFTUS TM, 1994, BIOCHEMISTRY-US, V33, P9661, DOI 10.1021/bi00198a035; MCALISTERHENN L, 1987, J BACTERIOL, V169, P5157, DOI 10.1128/jb.169.11.5157-5166.1987; MINARD KI, 1991, MOL CELL BIOL, V11, P370, DOI 10.1128/MCB.11.1.370; OHNISHI T, 1966, J BIOL CHEM, V241, P1797; RALEIGH EA, 1988, NUCLEIC ACIDS RES, V16, P1563, DOI 10.1093/nar/16.4.1563; ROISE D, 1988, J BIOL CHEM, V263, P4509; Sambrook J., 2002, MOL CLONING LAB MANU; SIKORSKI RS, 1989, GENETICS, V122, P19; STEIN I, 1994, MOL CELL BIOL, V14, P4770, DOI 10.1128/MCB.14.7.4770; THOMPSON LM, 1989, J BIOL CHEM, V264, P12091; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K	30	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10347	10352		10.1074/jbc.271.17.10347	http://dx.doi.org/10.1074/jbc.271.17.10347			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626605	hybrid			2022-12-27	WOS:A1996UG25700077
J	Dick, LR; Cruikshank, AA; Grenier, L; Melandri, FD; Nunes, SL; Stein, RL				Dick, LR; Cruikshank, AA; Grenier, L; Melandri, FD; Nunes, SL; Stein, RL			Mechanistic studies on the inactivation of the proteasome by lactacystin A central role for clasto-lactacystin beta-lactone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Lactacystin is a Streptomyces metabolite that inhibits cell cycle progression and induces differentiation in a murine neuroblastoma cell line, The cellular target of lactacystin is the 20 S proteasome, also known as the multicatalytic proteinase complex, an essential component of the ubiquitin-proteasome pathway for intracellular protein degradation, In aqueous solution at pH 8, lactacystin undergoes spontaneous hydrolysis to yield N-acetyl-L-cysteine and the inactive lactacystin analog, clasto-lactacystin dihydroxy acid, We have studied the mechanism of lactacystin hydrolysis under these conditions and found that it proceeds exclusively through the intermediacy of the active lactacystin analog, clasto-lactacystin beta-lactone, Conditions that stabilize lactacystin (and thus prevent the transient accumulation of the intermediate beta-lactone) negate the ability of lactacystin to inactivate the proteasome. Together these findings suggest that lactacystin acts as a precursor for clasto-lactacystin beta-lactone and that the latter is the sole species that interacts with the proteasome.			Dick, LR (corresponding author), PROSCRIPT INC,38 SIDNEY ST,CAMBRIDGE,MA 02139, USA.		Dick, Lawrence/ABA-8831-2021	Dick, Larry/0000-0002-6880-0405				CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COREY EJ, 1992, J AM CHEM SOC, V114, P10677, DOI 10.1021/ja00052a096; COREY EJ, 1993, TETRAHEDRON LETT, V34, P6977, DOI 10.1016/S0040-4039(00)61575-7; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GANOTH D, 1988, J BIOL CHEM, V263, P12412; GOLDBERG AL, 1995, CHEM BIOL, V2, P503, DOI 10.1016/1074-5521(95)90182-5; HOUGH R, 1987, J BIOL CHEM, V262, P8303; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; RIVETT AJ, 1993, BIOCHEM J, V291, P1; RUBIN D, 1995, CURR BIOL, V3, P854; TANAKA K, 1995, MOL BIOL REP, V21, P21, DOI 10.1007/BF00990966; WILK S, 1993, ENZYME PROTEIN, V47, P187, DOI 10.1159/000468677	15	338	349	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7273	7276		10.1074/jbc.271.13.7273	http://dx.doi.org/10.1074/jbc.271.13.7273			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631740				2022-12-27	WOS:A1996UC77400008
J	Bose, S; Komorowski, R; Seetharam, S; Gilfix, B; Rosenblatt, DS; Seetharam, B				Bose, S; Komorowski, R; Seetharam, S; Gilfix, B; Rosenblatt, DS; Seetharam, B			In vitro and in vivo inactivation of transcobalamin II receptor by its antiserum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSIC FACTOR-COBALAMIN; BRUSH-BORDER MEMBRANE; VITAMIN-B12 METABOLISM; BINDING; KIDNEY; CELLS; RAT; EXPRESSION; PROTEINS; SERUM	Rabbits injected with pure human placental transcobalamin II-receptor (TC II-R) failed to thrive with no apparent tissue or organ damage, but a 2-fold elevation of the metabolites, homocysteine, methylmalonic acid, and the ligand, transcobalamin II, in their plasma, Exogenously added transcobalamin II-[Co-57]cyanocobalamin bound very poorly (2-5%) to the affected rabbit Liver, kidney, and intestinal total or intestinal basolateral membrane extracts relative to the binding by membrane extracts from normal rabbit tissues, The activity was restored to normal values following a wash of affected rabbit tissue membranes with pH 3 buffer containing 200 mM potassium thiocyanate, Immunoblot analysis of normal and affected rabbit kidney and liver total membranes revealed similar amounts of 124-kDa TC II-R dimer protein, The neutralized and dialyzed extract from the affected rabbit membranes inhibited the binding of the ligand to pure TC II-R and the harvested affected rabbit serum inhibited the uptake of TC II-[Co-57]cobalamin (Cbl) from the basolateral side of human intestinal epithelial (Caco-2) cells and decreased the utilization of [Co-57]Cbl as coenzymes by the Cbl-dependent enzymes, The loss of exogenously added ligand binding or the binding of I-126-protein A occurred with the intestinal basolateral, but not the apical membranes. Based on these results, we suggest that circulatory antibodies to TC II-R cause its in vivo functional inactivation, suppress Cbl uptake by multiple tissues, and thus cause severe Cbl deficiency and the noted failure to thrive.	MED COLL WISCONSIN,MACC RES CTR,DEPT BIOCHEM,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT PATHOL,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT MED,MILWAUKEE,WI 53226; MCGILL UNIV,DEPT MED,DIV MED GENET,MONTREAL,PQ H3A 1A1,CANADA; VET ADM MED CTR,MILWAUKEE,WI 53226	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; McGill University; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Gilfix, Brian/AFT-0832-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026638] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-26638] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOSE S, 1995, BIOCHEM J, V310, P923, DOI 10.1042/bj3100923; BOSE S, 1995, J BIOL CHEM, V270, P8152, DOI 10.1074/jbc.270.14.8152; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COOPER BA, 1987, ANNU REV NUTR, V7, P291, DOI 10.1146/annurev.nu.07.070187.001451; DEAIZPURUA HJ, 1983, NEW ENGL J MED, V309, P625, DOI 10.1056/NEJM198309153091102; FENTON WA, 1989, METABOLIC BASIS INHE, P2065; FULLER S, 1984, CELL, V38, P65, DOI 10.1016/0092-8674(84)90527-0; GOTTLIEB C, 1965, BLOOD-J HEMATOL, V25, P875, DOI 10.1182/blood.V25.6.875.875; HALL CA, 1990, EUR J HAEMATOL, V45, P143, DOI 10.1111/j.1600-0609.1990.tb00441.x; LINDEMANS J, 1986, J EXP CELL RES, V184, P449; LINDENBAUM J, 1990, AM J HEMATOL, V34, P90; MALATHI P, 1979, BIOCHIM BIOPHYS ACTA, V554, P259, DOI 10.1016/0005-2736(79)90023-3; MAMER OA, 1994, 42 ANN C AM SOC MASS, P1158; MOLITORIS BA, 1985, J MEMBRANE BIOL, V83, P207, DOI 10.1007/BF01868695; RAMANUJAM KS, 1991, AM J PHYSIOL, V260, pG416, DOI 10.1152/ajpgi.1991.260.3.G416; RAMANUJAM KS, 1991, BIOCHEM BIOPH RES CO, V179, P543, DOI 10.1016/0006-291X(91)91405-2; RAMANUJAM KS, 1990, BIOCHIM BIOPHYS ACTA, V1030, P157, DOI 10.1016/0005-2736(90)90251-I; ROSENBLATT DS, 1985, SCIENCE, V228, P1319, DOI 10.1126/science.4001945; SEETHARAM B, 1981, J BIOL CHEM, V256, P3785; SEETHARAM B, 1983, BIOCHEM BIOPH RES CO, V115, P238, DOI 10.1016/0006-291X(83)90995-6; SEETHARAM B, 1985, NUTR REV, V43, P97, DOI 10.1111/j.1753-4887.1985.tb06875.x; SEETHARAM B, 1988, J BIOL CHEM, V263, P4443; Seetharam Bellur, 1994, P1997; SEETHARAM S, 1992, J BIOL CHEM, V267, P7421; SELIGMAN PA, 1978, J BIOL CHEM, V253, P1766; YOUNGDAHLTURNER P, 1978, J CLIN INVEST, V61, P133, DOI 10.1172/JCI108911	26	24	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4195	4200						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626762				2022-12-27	WOS:A1996TW96000040
J	Potterf, SB; Muller, J; Bernardini, I; Tietze, F; Kobayashi, T; Hearing, VJ; Gahl, WA				Potterf, SB; Muller, J; Bernardini, I; Tietze, F; Kobayashi, T; Hearing, VJ; Gahl, WA			Characterization of a melanosomal transport system in murine melanocytes mediating entry of the melanogenic substrate tyrosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE GRANULAR FRACTIONS; LYSOSOMAL MEMBRANE-TRANSPORT; HUMAN FIBROBLAST LYSOSOMES; RAT-THYROID CELLS; CYSTINE TRANSPORT; AMINO-ACIDS; STIMULATION; NUTRITION; MELANOMA; DISEASE	In this study, we identify a transport system for tyrosine, the initial precursor of melanin synthesis, in the melanosomes of murine melanocytes. Melanosomes preloaded with tyrosine demonstrated countertransport of 10 mu M [H-3]tyrosine, indicating carrier-mediated transport. Melanosomal tyrosine transport was saturable, with an apparent K-m for tyrosine transport of 54 mu M and a maximal velocity of 15 pmol of tyrosine/unit of hexosaminidase/min. Transport was temperature-dependent (E(alpha) = 7.5 kcal/mol) and showed stereospecificity for the L-isomer of tyrosine. Aromatic, neutral hydrophobic compounds (such as tryptophan and phenylalanine), as well as the small, bulky neutral amino acids (such as leucine, isoleucine, and methionine) competed for tyrosine transport. Tyrosine transport was inhibited by the classical system L analogue, 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid and by monoiodotyrosine, but not by cystine, lysine, glutamic acid, or 2-(methylamino)isobutyric acid. Tyrosine transport showed no dependence on Na+ or K+, and did not require an acidic environment or the availability of free thiols. These results demonstrate the existence of a neutral amino acid carrier in murine melanocyte melanosomes which resembles the rat thyroid FRTL-5 lysosomal system h. This transport system is critical to the function of the melanosome since tyrosine is the essential substrate required for the synthesis of the pigment melanin.	NICHHD,SECT HUMAN BIOCHEM GENET,HERITABLE DISORDERS BRANCH,BETHESDA,MD 20892; NCI,CELL BIOL LAB,BETHESDA,MD 20892; US FDA,DIV VIRAL PROD,CTR BIOL EVALUAT & RES,ROCKVILLE,MD 20852; NIDDK,MOL & CELLULAR BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Kobayashi, Takeshi/0000-0002-4372-5285				ANDERSSON HC, 1990, J BIOL CHEM, V265, P10950; AROCA P, 1993, J BIOL CHEM, V268, P25650; BENNETT DC, 1989, DEVELOPMENT, V105, P379; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BERNAR J, 1986, J BIOL CHEM, V261, P7107; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; COLLARINI EJ, 1989, BIOCHIM BIOPHYS ACTA, V987, P139, DOI 10.1016/0005-2736(89)90536-1; DIMENT S, 1995, J BIOL CHEM, V270, P4213, DOI 10.1074/jbc.270.9.4213; GAHL WA, 1989, ANNU REV NUTR, V9, P39, DOI 10.1146/annurev.nu.09.070189.000351; GAHL WA, 1983, BIOCHEM J, V216, P393, DOI 10.1042/bj2160393; GAHL WA, 1985, BIOCHEM J, V228, P263, DOI 10.1042/bj2280263; GAHL WA, 1996, IN PRESS PIGMENT CEL; GREENE AA, 1990, J BIOL CHEM, V265, P9888; HARPER GS, 1988, J BIOL CHEM, V263, P9320; HATTA S, 1988, J INVEST DERMATOL, V91, P181, DOI 10.1111/1523-1747.ep12464454; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; ITO S, 1993, PIGMENTATION PIGMENT; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; KOBAYASHI T, 1994, J BIOL CHEM, V269, P29198; MENON IA, 1976, UNIQUE PROPERTIES ME; NAKAGAWA H, 1984, J INVEST DERMATOL, V83, P140, DOI 10.1111/1523-1747.ep12263344; OETTING WS, 1994, J INVEST DERMATOL, V103, pS131, DOI 10.1111/1523-1747.ep12399447; OHKURA T, 1984, ARCH BIOCHEM BIOPHYS, V235, P63, DOI 10.1016/0003-9861(84)90255-8; ORLOW SJ, 1995, J INVEST DERMATOL, V105, P3, DOI 10.1111/1523-1747.ep12312291; ORLOW SJ, 1993, J INVEST DERMATOL, V100, P55, DOI 10.1111/1523-1747.ep12354138; PISONI RL, 1991, BIOCHIM BIOPHYS ACTA, V1071, P351, DOI 10.1016/0304-4157(91)90002-E; PISONI RL, 1990, J CELL BIOL, V110, P327, DOI 10.1083/jcb.110.2.327; PISONI RL, 1995, J BIOL CHEM, V270, P1179, DOI 10.1074/jbc.270.3.1179; RENLUND M, 1986, SCIENCE, V232, P759, DOI 10.1126/science.3961501; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; SMIT NPM, 1993, BIOCHIM BIOPHYS ACTA, V1181, P1, DOI 10.1016/0925-4439(93)90082-C; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TIETZE F, 1989, J BIOL CHEM, V264, P15316; WILBRANDT W, 1961, PHARMACOL REV, V13, P109; ZHOU BK, 1994, P NATL ACAD SCI USA, V91, P7076, DOI 10.1073/pnas.91.15.7076	35	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4002	4008						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626732				2022-12-27	WOS:A1996TW96000010
J	Wondrak, EM; Nashed, NT; Haber, MT; Jerina, DM; Louis, JM				Wondrak, EM; Nashed, NT; Haber, MT; Jerina, DM; Louis, JM			A transient precursor of the HTV-1 protease - Isolation, characterization, and kinetics of maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 PROTEASE; ESCHERICHIA-COLI; PROTEINASES; INHIBITION; PARTICLES; FUSION; SALT; GAG	Recently, the mechanism of autoprocessing of the protease (PR) of the human immunodeficiency virus type 1 from the model polyprotein, MBP-Delta TF-PR-Delta Pol, which contains the protease linked to short native flanking sequences (Delta TF and Delta Pol) fused to the maltose binding protein (MBP) of Escherichia coli, was reported (Louis, J. M., Nashed, N. T., Parris, G. D., Kimmel, A. R., and Jerina, D. M. (1994) Proc, Natl Acad Sci. U.S.A. 91, 7970-7974). According to this mechanism, intramolecular cleavage of the N-terminal strands of the dimeric MBP-Delta TF-PR-Delta Pol protein leads to the formation of the PR-Delta Pol intermediate, which is subsequently converted to the mature protease by cleavage of the C-terminal strands. We now report the purification and characterization of the PR-Delta Pol intermediate and the kinetics of its processing to the mature protease. Unlike the MBP-Delta TF-PR-Delta Pol precursor, PR-Delta Pol has proteolytic activity similar to that of the mature enzyme at pH 5.0. The pH rate profile for k(cat)/K-m is similar to that of the mature protease above pH 4.0. Although the PR-Delta Pol is more sensitive than the mature protease toward denaturing reagents, both the enzymatic activity and the intrinsic fluorescence of PR-Delta Pol are linearly dependent on the protein concentration, indicating that the protein is largely in its dimeric form above 10 nM. In contrast to the first-order kinetics observed for the proteolytic reaction at the N terminus of the protease, the proteolytic reaction at the C terminus of the protease is second order in protein concentration. These results are discussed in terms of a mechanism in which the C-terminally located Delta Pol peptide chains are cleaved intermolecularly to release the mature protease.	NIDDK, MOL MECHANISMS DEV SECT, CELLULAR & DEV BIOL LAB, NIH, BETHESDA, MD 20892 USA; NIDDK, SECT OXIDAT MECHANISMS, BIOORGAN CHEM LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Louis, John M/0000-0002-0052-1899				BOUTELJE J, 1990, ARCH BIOCHEM BIOPHYS, V283, P141, DOI 10.1016/0003-9861(90)90624-8; CO E, 1994, BIOCHEMISTRY-US, V33, P1248, DOI 10.1021/bi00171a027; Creighton T. E., 1993, PROTEINS STRUCTURES; ERICKSON J, 1991, ADV EXP MED BIOL, V306, P191; GROBELNY D, 1990, BIOCHEM BIOPH RES CO, V169, P1111, DOI 10.1016/0006-291X(90)92010-W; HATFIELD DL, 1992, ADV VIRUS RES, V41, P193, DOI 10.1016/S0065-3527(08)60037-8; KAPLAN AH, 1994, J VIROL, V68, P6782, DOI 10.1128/JVI.68.10.6782-6786.1994; KAPLAN AH, 1993, J VIROL, V67, P4050, DOI 10.1128/JVI.67.7.4050-4055.1993; KARACOSTAS V, 1993, VIROLOGY, V193, P661, DOI 10.1006/viro.1993.1174; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KAY J, 1990, BIOCHIM BIOPHYS ACTA, V1048, P1, DOI 10.1016/0167-4781(90)90015-T; KRAUSSLICH HG, 1991, P NATL ACAD SCI USA, V88, P3213, DOI 10.1073/pnas.88.8.3213; LOUIS JM, 1991, EUR J BIOCHEM, V199, P361, DOI 10.1111/j.1432-1033.1991.tb16132.x; LOUIS JM, 1991, ADV EXP MED BIOL, V306, P499; LOUIS JM, 1994, P NATL ACAD SCI USA, V91, P7970, DOI 10.1073/pnas.91.17.7970; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; POLGAR L, 1994, BIOCHEMISTRY-US, V33, P9351, DOI 10.1021/bi00197a040; TOZSER J, 1991, FEBS LETT, V281, P77, DOI 10.1016/0014-5793(91)80362-7; TROPEA JE, 1992, BIOORG CHEM, V20, P67, DOI 10.1016/0045-2068(92)90027-Z; WEBER IT, 1990, J BIOL CHEM, V265, P10492; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551; WONDRAK EM, 1991, FEBS LETT, V280, P344, DOI 10.1016/0014-5793(91)80327-Y	23	54	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4477	4481						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626801				2022-12-27	WOS:A1996TW96000079
J	Demianova, M; Formosa, TG; Ellis, SR				Demianova, M; Formosa, TG; Ellis, SR			Yeast proteins related to the p40/laminin receptor precursor are essential components of the 40 S ribosomal subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY LAMININ RECEPTOR; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; EMBRYONIC RETINA; CELLS; SEQUENCE; BINDING; GENE; DNA; POLYPEPTIDE	We report here the isolation of two genes from the yeast, Saccharomyces cerevisiae, that encode proteins closely related to mammalian p40/laminin receptor precursors (LRPs). The yeast genes, designated YST1 and YST2, encode proteins with over 95% amino acid sequence identity with one another and over 60% identity with the human p40/laminin receptor precursor. The Yst/p40/37-LRP proteins are also more distantly related to the S2 family of ribosomal proteins. Analysis of the distribution of Yst1 tagged with the c-myc epitope revealed that the Yst proteins are components of the 40 S ribosomal subunit. Disruption of either YST1 or YST2 causes a significant reduction in growth rate, while disruption of both genes is lethal. Compared to wild type, polysome profiles in strains lacking either YST1 or YST2 show a pronounced shift from larger to smaller polysomes. This shift is accompanied by a substantial increase in free 60 S subunits and reduced levels of 40 S subunits. We conclude that the Yst proteins are required for translation and contribute to the assembly and/or stability of the 40 S ribosomal subunit.	UNIV LOUISVILLE, DEPT BIOCHEM, LOUISVILLE, KY 40292 USA; UNIV UTAH, DEPT BIOCHEM, SALT LAKE CITY, UT 84132 USA	University of Louisville; Utah System of Higher Education; University of Utah				Formosa, Tim/0000-0002-8477-2483	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040632] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40632] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOVICH N, 1985, MOL CELL BIOL, V5, P3429, DOI 10.1128/MCB.5.12.3429; AUTH D, 1992, P NATL ACAD SCI USA, V89, P4368, DOI 10.1073/pnas.89.10.4368; BAIM SB, 1985, MOL CELL BIOL, V5, P1839, DOI 10.1128/MCB.5.8.1839; BRADFORD MM, 1976, J BIOL CHEM, V266, P20440; CASTRONOVO V, 1991, J BIOL CHEM, V266, P20440; DAVIS SC, 1992, J BIOL CHEM, V267, P5508; DONOVAN DM, 1990, MOL CELL BIOL, V10, P6097, DOI 10.1128/MCB.10.11.6097; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; FOLLEY LS, 1994, GENETICS, V137, P369; GARCIAHERNANDEZ M, 1994, J BIOL CHEM, V269, P20744; GARRELS JI, 1994, ELECTROPHORESIS, V15, P1466, DOI 10.1002/elps.11501501210; GUO NH, 1992, J BIOL CHEM, V267, P17743; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; INFANTE AA, 1971, BIOCHIM BIOPHYS ACTA, V246, P81, DOI 10.1016/0005-2787(71)90074-8; KEPPEL E, 1991, J CELL SCI, V100, P789; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALJAS A, 1990, RIBOSOME STRUCTURE F, P309; LOPEZRIBOT JL, 1994, INFECT IMMUN, V62, P742; MAKRIDES S, 1988, NUCLEIC ACIDS RES, V16, P2349, DOI 10.1093/nar/16.5.2349; MCCAFFERY P, 1990, P NATL ACAD SCI USA, V87, P8570, DOI 10.1073/pnas.87.21.8570; MELNICK MB, 1993, GENETICS, V135, P553; NARASIMHAN S, 1994, P NATL ACAD SCI USA, V91, P7440, DOI 10.1073/pnas.91.16.7440; OUZOUNIS C, 1995, NUCLEIC ACIDS RES, V23, P565, DOI 10.1093/nar/23.4.565; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RABACCHI SA, 1990, DEVELOPMENT, V109, P521; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; REMACHA M, 1992, J BIOL CHEM, V267, P12061; ROSENTHAL ET, 1995, J CELL SCI, V108, P245; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; RYMOND BC, 1992, MOL CELLULAR BIOL YE, P143; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS C, 1994, J BIOL CHEM, V269, P15689; SHERMAN F, 1991, METHOD ENZYMOL, V194, P1; SIKORSKI RS, 1989, GENETICS, V122, P19; TOHGO A, 1994, FEBS LETT, V340, P133, DOI 10.1016/0014-5793(94)80188-6; TOONE WM, 1991, J BACTERIOL, V173, P3291, DOI 10.1128/jb.173.11.3291-3302.1991; WEWER UM, 1986, P NATL ACAD SCI USA, V83, P7137, DOI 10.1073/pnas.83.19.7137; WITTMANNLIEBOLD B, 1990, RIBOSOME, P598; WOOLFORD JL, 1991, MOL CELLULAR BIOL YE, V1, P587; YANG G, 1992, J NEUROBIOL, V23, P491, DOI 10.1002/neu.480230505; YENOFSKY R, 1982, P NATL ACAD SCI-BIOL, V79, P5876, DOI 10.1073/pnas.79.19.5876	43	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11383	11391		10.1074/jbc.271.19.11383	http://dx.doi.org/10.1074/jbc.271.19.11383			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626693				2022-12-27	WOS:A1996UJ94400053
J	Ma, J; Saito, H; Oka, T; Vijay, IK				Ma, J; Saito, H; Oka, T; Vijay, IK			Negative regulatory element involved in the hormonal regulation of GlcNAc-1-P transferase gene in mouse mammary gland	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE N-ACETYLGLUCOSAMINE-1-PHOSPHATE TRANSFERASE; ASPARAGINE-LINKED GLYCOPROTEINS; ACETYL-D-GLUCOSAMINE; BETA-CASEIN; TRANSCRIPTIONAL REPRESSION; RESPONSE ELEMENTS; THYROID-HORMONE; NUCLEAR FACTOR; RETINOIC ACID; PROMOTER	The gene encoding UDP-GlcNAc:dolichol phosphate N-acetylglucosamine-1-phosphate transferase (GPT), the enzyme that initiates the pathway for the biosynthesis of asparagine-linked glycoproteins, is ubiquitously expressed in eukaryotic cells. However, its expression in the mammary gland is developmentally and hormonally regulated; transcription of the mouse mammary GPT gene is stimulated by the lactogenic hormones, insulin, glucocorticoid, and prolactin. The involvement of cis-acting elements in regulating the expression of the mouse GPT (mGPT) gene was investigated by transient transfections of various GPT promoter/luciferase (Luc) constructs into primary mouse mammary epithelial cells. A series of 5'-deletions of the GPT promoter identified a distal negative regulatory region (base pairs -1057 to -968) and deletion of this region results in enhanced hormonal induction (similar to 7-fold) with no effect on basal promoter activity. Electrophoretic mobility shift assays (EMSA) performed with nuclear extracts from different developmental stages of mouse mammary gland demonstrated that the binding activity of the nuclear proteins to the distal negative regulatory region was predominant in virgin stage as compared with pregnant and lactating stages. EMSA performed with nuclear extracts from virgin explants showed that the binding activity was markedly decreased after cultivation with the combination of the three lactogenic hormones. DNase I footprinting analysis identified two pentamer direct repeat motifs, AGGAA and GAAAC, within the negative regulatory region. EMSA competition experiments showed that mutations within the direct repeats failed to compete for binding of the nuclear proteins to labeled wild type oligonucleotide. Transcription from the promoter containing the mutated direct repeats was increased greatly, consistent with the conclusion that these motifs functions in vivo to repress GPT gene expression. These data suggest the importance of the negative regulatory region in hormonal control of mGPT gene expression in mammary gland.	UNIV MARYLAND, DEPT ANIM SCI, COLLEGE PK, MD 20742 USA; NIDDK, CELLULAR & MOLEC BIOL LAB, NIH, BETHESDA, MD 20892 USA	University System of Maryland; University of Maryland College Park; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)					NIDDK NIH HHS [DK19682] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019682] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABEIJON C, 1990, J BIOL CHEM, V265, P14691; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; GARLATTI M, 1993, J BIOL CHEM, V268, P6567; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; KEAN EL, 1991, J BIOL CHEM, V266, P942; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LIU X, 1992, MOL CELL BIOL, V12, P4112, DOI 10.1128/MCB.12.9.4112; Maxam A M, 1980, Methods Enzymol, V65, P499; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAJPUT B, 1994, J BIOL CHEM, V269, P9590; RAJPUT B, 1994, J BIOL CHEM, V269, P16054; RAJPUT B, 1992, BIOCHEM J, V285, P985, DOI 10.1042/bj2850985; RAJPUT B, 1995, GLYCOCONJUGATE J, V12, P476; RINE J, 1983, P NATL ACAD SCI-BIOL, V80, P6750, DOI 10.1073/pnas.80.22.6750; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SCOCCA JR, 1990, J BIOL CHEM, V265, P20621; SHAILUBHAI K, 1988, J BIOL CHEM, V263, P15964; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VIJAY IK, 1986, EUR J BIOCHEM, V154, P57, DOI 10.1111/j.1432-1033.1986.tb09358.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG XC, 1993, J BIOL CHEM, V268, P4355; WATSON CJ, 1991, NUCLEIC ACIDS RES, V19, P6603, DOI 10.1093/nar/19.23.6603; YANG J, 1994, GLYCOBIOLOGY, V4, P703, DOI 10.1093/glycob/4.5.703; YOSHIMURA M, 1990, P NATL ACAD SCI USA, V87, P3670, DOI 10.1073/pnas.87.10.3670; YOSHIMURA M, 1990, ENDOCRINOLOGY, V126, P427, DOI 10.1210/endo-126-1-427; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; Zhou Ming-Dong, 1992, Gene Expression, V2, P127; ZHU XY, 1990, J BIOL CHEM, V265, P14250	41	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11197	11203		10.1074/jbc.271.19.11197	http://dx.doi.org/10.1074/jbc.271.19.11197			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626667				2022-12-27	WOS:A1996UJ94400027
J	Na, SQ; Chuang, TH; Cunningham, A; Turi, TG; Hanke, JH; Bokoch, GM; Danley, DE				Na, SQ; Chuang, TH; Cunningham, A; Turi, TG; Hanke, JH; Bokoch, GM; Danley, DE			D4-GDI, a substrate of CPP32, is proteolyzed during Fas-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; GTP-BINDING PROTEIN; DEATH GENE CED-3; LYMPHOCYTES; INDUCTION; ENZYME; CELLS	Apoptosis (programmed cell death) is a fundamental process for normal development of multicellular organisms, and is involved in the regulation of the immune system, normal morphogenesis, and maintenance of homeostasis. ICE/CED-3 family cysteine proteases have been implicated directly in apoptosis, but relatively few of the substrates through which their action is mediated have been identified. Here we report that D4-GDI, an abundant hematopoietic cell GDP dissociation inhibitor for the Ras-related Rho family GTPases, is a substrate of the apoptosis protease CPP32/Yama/Apopain. D4-GDI was rapidly truncated to a 23-kDa fragment in Jurkat cells with kinetics that parallel the onset of apoptosis following Fas cross-linking with agonistic antibody or treatment with staurosporine. Fas- and staurosporine-induced apoptosis as well as cleavage of D4-GDI were inhibited by the ICE inhibitor, YVAD-cmk. D4-GDI was cleaved in vitro by recombinant CPP32 expressed in Escherichia coli to form a 23-kDa fragment. The CPP32-mediated cleavage of D4-GDI was completely inhibited by 1 mu M DEVD-CHO, a reported selective inhibitor of CPP32. In contrast, the ICE-selective inhibitors, YVAD-CHO or YVAD-cmk, did not inhibit CPP32-mediated D4-GDI cleavage at concentrations up to 50 mu M. N-terminal sequencing of the 23-kDa D4-GDI fragment demonstrated that D4-GDI was cleaved between Asp(19) and Ser(20) of the poly(ADP-ribose) polymerase-like cleavage sequence DELD(19)S. These data suggest that regulation by D4-GDI of Rho family GTPases may be disrupted during apoptosis by CPP32-mediated cleavage of the GDI protein.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; PFIZER INC, DIV CENT RES, DEPT MOLEC SCI, GROTON, CT 06340 USA	Scripps Research Institute; Scripps Research Institute; Pfizer			Chuang, Tsung-Hsien/F-9679-2010		NIGMS NIH HHS [GM44428, GM39434] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434, R01GM044428] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANEL A, 1994, EUR J IMMUNOL, V24, P2469, DOI 10.1002/eji.1830241032; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; CHUANG TH, 1993, J BIOL CHEM, V268, P775; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CRITCHFIELD JM, 1994, SCIENCE, V263, P1139, DOI 10.1126/science.7509084; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GILLETTEFERGUSON I, 1994, EUR J IMMUNOL, V24, P1181, DOI 10.1002/eji.1830240526; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LARRICK JW, 1992, TRENDS BIOTECHNOL, V10, P146, DOI 10.1016/0167-7799(92)90202-7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RUSSELL JH, 1991, P NATL ACAD SCI USA, V88, P2151, DOI 10.1073/pnas.88.6.2151; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VIGNAUX F, 1995, J EXP MED, V181, P781, DOI 10.1084/jem.181.2.781; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	43	197	203	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11209	11213		10.1074/jbc.271.19.11209	http://dx.doi.org/10.1074/jbc.271.19.11209			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626669	hybrid			2022-12-27	WOS:A1996UJ94400029
J	Stein, B; Brady, H; Yang, MX; Young, DB; Barbosa, MS				Stein, B; Brady, H; Yang, MX; Young, DB; Barbosa, MS			Cloning and characterization of MEK6, a novel member of the mitogen-activated protein kinase kinase cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; SIGNAL-REGULATED KINASES; MAP KINASE; PHOSPHORYLATION; IDENTIFICATION; ERKS; TRANSCRIPTION; TYROSINE; INSULIN; FAMILY	Mitogen-activated protein kinases are members of a conserved cascade of kinases involved in many signal transduction pathways. They stimulate phosphorylation of transcription factors in response to extracellular signals such as growth factors, cytokines, ultraviolet light, and stress-inducing agents. A novel mitogen-activated protein kinase kinase, MEK6, was cloned and characterized. The complete MEK6 cDNA was isolated by polymerase chain reaction. It encodes a 334-amino acid protein with 82% identity to MKK3. MEK6 is highly expressed in skeletal muscle like many other members of this family, but in contrast to MKK3 its expression in leukocytes is very low. MEK6 is a member of the p38 kinase cascade and efficiently phosphorylates p38 but not c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) family members in direct kinase assays. Coupled kinase assays demonstrated that MEK6 induces phosphorylation of ATF2 by p38 but does not phosphorylate ATF2 directly. MEK6 is strongly activated by UV, anisomycin, and osmotic shock but not by phorbol esters, nerve growth factor, and epidermal growth factor. This separates MEK6 from the ERK subgroup of protein kinases. MEK6 is only a poor substrate for MEKK, a mitogen-activated protein kinase kinase kinase that efficiently phosphorylates the related family member JNKK.			Stein, B (corresponding author), SIGNAL PHARMACEUT INC,5555 OBERLIN DR,SAN DIEGO,CA 92121, USA.							BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHOI KY, 1994, CELL, V78, P499; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOPER JA, 1994, CURR BIOL, V4, P1118, DOI 10.1016/S0960-9822(00)00251-7; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STURGILL TW, 1986, BIOCHEM BIOPH RES CO, V134, P565, DOI 10.1016/S0006-291X(86)80457-0; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; YAN MH, 1994, NATURE, V372, P798; ZHOU G, 1995, J BIOL CHEM, V270, P12664; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	40	158	163	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11427	11433		10.1074/jbc.271.19.11427	http://dx.doi.org/10.1074/jbc.271.19.11427			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626699	hybrid			2022-12-27	WOS:A1996UJ94400059
J	Bhunia, AK; Han, H; Snowden, A; Chatterjee, S				Bhunia, AK; Han, H; Snowden, A; Chatterjee, S			Lactosylceramide stimulates Ras-GTP loading, kinases (MEK, Raf), p44 mitogen-activated protein kinase, and c-fos expression in human aortic smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; PROLIFERATION; MODULATION; COMPLEX; DOMAIN; MYC; JUN	Previously, our laboratory has shown that lactosylceramide (LacCer) can serve as a mitogenic agent in the proliferation of aortic smooth muscle cells ''a hallmark in the pathogenesis of atherosclerosis'' (Chatterjee, S. (1991) Biochem. Biophys. Res. Commun. 181, 554-561). Here we report a novel aspect of LacCer-mediated signal transduction. We demonstrate that LacCer (10 mu M) can stimulate the phosphorylation of mitogen-activated protein (MAP) kinase p44(MAPK) to phosphorylated p44(MAPK) in aortic smooth muscle cells from rabbit or human origin. Western immunoblot assays and direct measurement of activity in immunoprecipitated MAP kinase revealed that within 5 min of incubation of cells with LacCer there was a 3.5-fold increase in the activity of p44(MAPK). This continued up to 10 min of incubation; thereafter, the MAP kinase activity decreased in these cells. Phosphoamino acid analysis revealed that the tyrosine and threonine moieties of p44(MAPK) was phosphorylated by LacCer. Incubation of cells with ceramide and glucosylceramide did not significantly stimulate p44(MAPK) activity. Preincubation with tyrphostin (20 mu M; a potent and specific inhibitor of tyrosine kinase) markedly inhibited the LacCer mediated stimulation in p44(MAPK) activity. Next we investigated the upstream and downstream parameters in MAP kinase signaling pathways. We found that lactosylceramide stimulated (7-fold) the loading of GTP on Ras. Concomitantly, Lac-Cer stimulated the phosphorylation of MAP kinase kinases (MEK) and Raf within 2.5 min. Lactosylceramide specifically induced c-fos mRNA expression (3-fold) in these cells as compared to control. In summary, one of the biochemical mechanisms in LacCer mediated induction in the proliferation of aortic smooth muscle cells may involve Ras-GTP loading activation of the kinase cascade (MEK, Raf, p44(MAPK)), and c-fos expression.	JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, LIPID RES UNIT, BALTIMORE, MD 21287 USA	Johns Hopkins University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL047212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031722] Funding Source: NIH RePORTER; NHLBI NIH HHS [1-P50 HL47212] Funding Source: Medline; NIDDK NIH HHS [R01-DK31722] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BREMER EG, 1986, J BIOL CHEM, V261, P2434; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHATTERJEE S, 1991, BIOCHEM BIOPH RES CO, V181, P554, DOI 10.1016/0006-291X(91)91225-2; CHATTERJEE S, 1989, J BIOL CHEM, V264, P12554; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DEUG T, 1994, NATURE, V371, P171; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAIRD AD, 1995, J BIOL CHEM, V270, P26742, DOI 10.1074/jbc.270.45.26742; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; NISHIDA E, 1992, INT REV CYTOL, V138, P211, DOI 10.1016/S0074-7696(08)61589-2; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; RAO GN, 1994, J BIOL CHEM, V269, P32586; RAO GN, 1995, J CLIN INVEST, V96, P842, DOI 10.1172/JCI118130; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SENGUPTA A, 1988, P NATL ACAD SCI USA, V85, P8062, DOI 10.1073/pnas.85.21.8062; SETH A, 1991, J BIOL CHEM, V266, P23521; SETH A, 1992, J BIOL CHEM, V267, P24796; SHAYMAN JA, 1991, J BIOL CHEM, V266, P22968; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WINSTON BW, 1995, J BIOL CHEM, V270, P27391, DOI 10.1074/jbc.270.46.27391	50	67	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10660	10666		10.1074/jbc.271.18.10660	http://dx.doi.org/10.1074/jbc.271.18.10660			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631872	hybrid			2022-12-27	WOS:A1996UJ34200040
J	Kawasaki, T; Fujimura, Y; Usami, Y; Suzuki, M; Miura, S; Sakurai, Y; Makita, K; Taniuchi, Y; Hirano, K; Titani, K				Kawasaki, T; Fujimura, Y; Usami, Y; Suzuki, M; Miura, S; Sakurai, Y; Makita, K; Taniuchi, Y; Hirano, K; Titani, K			Complete amino acid sequence and identification of the platelet glycoprotein Ib-binding site of jararaca GPIb-BP, a snake venom protein isolated from Bothrops jararaca	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; VONWILLEBRAND-FACTOR; ALBOAGGREGIN-B; BOTROCETIN; PEPTIDE	Jararaca GPIb-BP, a snake venom protein composed of alpha and beta subunits purified from Bothrops jararaca, binds to platelet glycoprotein (GP)Ib and functions as a receptor blocker for von Willebrand factor binding to GPIb (Fujimura, Y., Ikeda, Y., Miura, S., Yoshida, E., Shima, H., Nishida, S., Suzuki, M., Titani, K., Taniuchi, Y., and Kawasaki, T. (1995) Thromb. Haemostasis 74, 743-750). We present here the entire 142- and 123-residue amino acid sequences of the respective alpha and beta subunits and also demonstrate that the platelet GPIb-binding site resides on the beta and not on the alpha subunit based on an enzyme-linked immunosorbent assay using biotin-labeled jararaca GPIb-BP and competing ligands. Sequences of the alpha and beta subunits were determined by analysis of the intact S-pyridylethylated proteins and their peptides generated by digestion with Achromobacter protease I, Staphyloccocus aureus V8 protease, pepsin, endoproteinase Asp-N, or L-1-tosylamino-2-phenylethyl chloromethyl ketone-trypsin. A 38-39% identity of amino acid sequence between the alpha and beta subunits of jararaca GPIb-BP was observed, as well as a high degree of sequence identities (38-64%) with the respective subunits of botrocetin (Usami, Y., Fujimura, Y., Suzuki, M., Ozeki, Y., Nishio, K., Fukui, H., and Titani, K (1993) Pr oc. Natl. Acad. Sci. U.S. A. 90, 928-932) and the beta-chain of echicetin (Peng, M., Holt, J. C., and Niewiarowski, S. (1994) Biochem. Biophys. Res. Commun. 205, 68-72).	NARA MED UNIV,DEPT BLOOD TRANSFUS,KASHIHARA,NARA 634,JAPAN; GIFU PHARMACEUT UNIV,DEPT PHARMACEUT,GIFU 502,JAPAN; FUJITA HLTH UNIV,SCH MED,INST COMPREHENS MED SCI,DIV BIOMED POLYMER SCI,TOYOAKE,AICHI 40711,JAPAN	Nara Medical University; Gifu Pharmaceutical University; Fujita Health University	Kawasaki, T (corresponding author), YAMANOUCHI PHARMACEUT CO LTD,INST DRUG DISCOVERY RES,CARDIOVASC & ATHEROSCLEROSIS RES LABS,TSUKUBA,IBARAKI 305,JAPAN.		Sakurai, Yoshihiko/C-5622-2011	Sakurai, Yoshihiko/0000-0002-1773-5535				BRUINS AP, 1987, ANAL CHEM, V59, P2642, DOI 10.1021/ac00149a003; CHEN YL, 1995, BIOCHEM BIOPH RES CO, V210, P472, DOI 10.1006/bbrc.1995.1684; FUJIMURA Y, 1991, BIOCHEMISTRY-US, V30, P1957, DOI 10.1021/bi00221a032; FUJIMURA Y, 1995, THROMB HAEMOSTASIS, V74, P743; HERMODSON MA, 1973, BIOCHEMISTRY-US, V12, P3136; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HIGGINS RC, 1979, ANAL BIOCHEM, V93, P257, DOI 10.1016/S0003-2697(79)80077-9; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P486; KAWASAKI T, 1995, BIOCHEM J, V308, P947, DOI 10.1042/bj3080947; KNECHT R, 1986, ANAL CHEM, V58, P2375, DOI 10.1021/ac00125a006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHONEY WC, 1980, J BIOL CHEM, V255, P1199; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P44, DOI 10.1016/0005-2744(81)90106-6; OZEKI Y, 1994, ARCH BIOCHEM BIOPHYS, V308, P306, DOI 10.1006/abbi.1994.1043; PENG ML, 1991, BIOCHEMISTRY-US, V30, P11529, DOI 10.1021/bi00113a007; PENG ML, 1994, BIOCHEM BIOPH RES CO, V205, P68, DOI 10.1006/bbrc.1994.2630; PENG ML, 1993, BLOOD, V81, P2321; Ruegg U T, 1977, Methods Enzymol, V47, P111; SAKARIASSEN KS, 1979, NATURE, V279, P636, DOI 10.1038/279636a0; TANIUCHI Y, 1995, BBA-GEN SUBJECTS, V1244, P331, DOI 10.1016/0304-4165(95)00052-D; USAMI Y, 1993, P NATL ACAD SCI USA, V90, P928, DOI 10.1073/pnas.90.3.928; YOSHIDA E, 1995, BRIT J HAEMATOL, V89, P861; YOSHIDA E, 1993, BIOCHEM BIOPH RES CO, V191, P1386, DOI 10.1006/bbrc.1993.1371	23	68	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10635	10639		10.1074/jbc.271.18.10635	http://dx.doi.org/10.1074/jbc.271.18.10635			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631868				2022-12-27	WOS:A1996UJ34200036
J	Otto, JC; Smith, WL				Otto, JC; Smith, WL			Photolabeling of prostaglandin endoperoxide H synthase-1 with 3-trifluoro-3-(m-[I-125]iodophenyl)diazirine as a probe of membrane association and the cyclooxygenase active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; SUBCELLULAR-LOCALIZATION; MESSENGER-RNA; SYNTHETASE; SHEEP; PURIFICATION; CELLS; DRUGS; ACID	Previous studies of the crystal structure of the ovine prostaglandin endoperoxide ET synthase-1 (PGHS-1)/S-flurbiprofen complex (Picot, D., Loll, P. J,, and Garavito, R. M. (1994) Nature 367, 243-249) suggest that the enzyme is associated with membranes through a series of four amphipathic helices located between residues 70 and 117. We have used the photoactivatable, hydrophobic reagent 3-trifluoro-3-(m-[I-125]iodophenyl)diazirine ([I-125]TID) which partitions into membranes and other hydrophobic domains to determine which domains of microsomal PGHS-1 are subject to photolabeling. After incubation of ovine vesicular gland microsomes with [I-125]TID, ovine PGHS-1 was one of the major photolabeled proteins. Proteolytic cleavage of labeled PGHS-1 at Arg(277) with trypsin established that [I-125]TID was incorporated into both the 33-kDa tryptic peptide containing the amino terminus and the 38-kDa tryptic peptide containing the carboxyl terminus. This pattern of photolabeling was not affected by the presence of 20 mM glutathione, indicating that the photolabeling observed for PGHS-1 was not due to the presence of [I-125]TID in the aqueous phase, However, nonradioactive TID as well as two inhibitors, ibuprofen and sulindac sulfide, which bind the cyclooxygenase active site of PGHS-1, prevented the labeling of the 38-kDa carboxyl-terminal tryptic peptide. These results suggest that [I-125]TID can label both the cyclooxygenase active site in the tryptic 38-kDa fragment and a membrane binding domain located in the 33-kDa fragment. Cleavage of photolabeled PGHS-1 with endoproteinase Lys-C yielded a peptide containing residues 25-166 which was labeled with [I-125]TID. This peptide contains the putative membrane binding domain of ovine PGHS-1. Our results provide biochemical support for the concept developed from the crystal structure that PGHS-1 binds to membranes via four amphipathic helices located near the NH2 terminus of the protein.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042509, R01DK022042, R37DK022042] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07404] Funding Source: Medline; NIDDK NIH HHS [DK42509, DK22042] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BHATTACHARYYA DK, 1995, ARCH BIOCHEM BIOPHYS, V317, P19, DOI 10.1006/abbi.1995.1130; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNNER J, 1981, BIOCHEMISTRY-US, V20, P7174, DOI 10.1021/bi00528a019; CHEN YNP, 1987, J BIOL CHEM, V262, P16892; DEWITT DL, 1981, J BIOL CHEM, V256, P375; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1212; FUTAKI N, 1993, GEN PHARMACOL, V24, P105, DOI 10.1016/0306-3623(93)90018-S; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P502, DOI 10.1016/0003-9861(89)90317-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MIZUNO K, 1982, PROSTAGLANDINS, V23, P743; MUTSAERS JHGM, 1985, EUR J BIOCHEM, V147, P569; OTTO JC, 1994, J BIOL CHEM, V269, P19868; PICOT D, 1994, FEBS LETT, V346, P21, DOI 10.1016/0014-5793(94)00314-9; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; ROLLINS TE, 1980, J BIOL CHEM, V255, P4872; SILVIA WJ, 1994, MOL ANDROL, V6, P197; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; SMITH WL, 1994, EICOSANOIDS THEIR IN, P1; STRITTMATTER P, 1982, J BIOL CHEM, V257, P1883; VANDEROUDERAA FJ, 1980, EUR J BIOCHEM, V109, P1; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; WHITE BH, 1988, BIOCHEMISTRY-US, V27, P8741, DOI 10.1021/bi00424a009; WHITE BH, 1992, J BIOL CHEM, V267, P15770; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0	35	30	30	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9906	9910		10.1074/jbc.271.17.9906	http://dx.doi.org/10.1074/jbc.271.17.9906			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626626				2022-12-27	WOS:A1996UG25700010
J	Whitley, P; Grahn, E; Kutay, U; Rapoport, TA; vonHeijne, G				Whitley, P; Grahn, E; Kutay, U; Rapoport, TA; vonHeijne, G			A 12-residue-long polyleucine tail is sufficient to anchor synaptobrevin to the endoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE; MUTAGENESIS; SEQUENCES; PROTEINS; SIGNAL	Synaptobrevin is a tail-anchored protein with a hydrophobic C-terminal transmembrane segment that inserts into the endoplasmic reticulum membrane independently of the SRP/Sec61p pathway. Here, we show that idealized hydrophobic segments composed of 11-17 leucines and 1 valine function as insertion signals in vitro, whereas shorter segments do not. These results suggest that there are no specific requirements beyond overall hydrophobicity for C-terminal endoplasmic reticulum insertion signals.	UNIV STOCKHOLM,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Stockholm University; Harvard University; Harvard Medical School			von Heijne, Gunnar/AAH-9389-2019; Grahn, Elin/G-5634-2011; von Heijne, Gunnar/F-5576-2011	von Heijne, Gunnar/0000-0002-4490-8569				BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2247, DOI 10.1093/nar/19.suppl.2247; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; Erickson B. W., 1976, PROTEINS, VII, P255; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; JANIAK F, 1994, J BIOL CHEM, V269, P9842; JANIAK F, 1994, BIOCHEM J, V300, P191, DOI 10.1042/bj3000191; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; LILJESTROM P, 1991, J VIROL, V65, P147; MITOMA JY, 1992, EMBO J, V11, P4197, DOI 10.1002/j.1460-2075.1992.tb05513.x; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; NILSSON I, 1993, J BIOL CHEM, V268, P5798; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SAKAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P16, DOI 10.1073/pnas.89.1.16; SIDMAN KE, 1988, NUCLEIC ACIDS RES, V16, P1869, DOI 10.1093/nar/16.5.1869; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; YAMASAKI S, 1994, P NATL ACAD SCI USA, V91, P4688, DOI 10.1073/pnas.91.11.4688	24	63	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7583	7586		10.1074/jbc.271.13.7583	http://dx.doi.org/10.1074/jbc.271.13.7583			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631791	hybrid, Green Published			2022-12-27	WOS:A1996UC77400059
J	Bartell, JG; Davis, T; Kremer, EJ; Dewey, MJ; Kistler, WS				Bartell, JG; Davis, T; Kremer, EJ; Dewey, MJ; Kistler, WS			Expression of the rat testis-specific histone hit gene in transgenic mice - One kilobase of 5'-flanking sequence mediates correct expression of a lacZ fusion gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC VARIANT; H1T GENE; NUCLEAR PROTEINS; BINDING-PROTEIN; PROMOTER; MOUSE; SPERMATOGENESIS; TRANSCRIPTION; H-1; ELEMENT	H1t is synthesized in mid to late pachytene spermatocytes of the male germ line and is the only tissue-specific member of the mammalian H1 histone family, As a step toward identifying DNA sequences that confer its tissue-specific expression, we have produced transgenic mice containing the intact rat H1t gene as well as a H1t-lacZ fusion gene, Transgenic mice carrying a 6.8-kilobase fragment of rat genomic DNA encompassing the H1t gene expressed rat H1t at high levels in the testis and in no other organ examined. H1t fragments truncated to within 141 base pairs (bp) of the gene in the 5' direction or within 837 bp in the 3' direction retained testis specificity, Expression of rat H1t protein was also evident in the testes of the transgenic mice, and in some lines the level of rat H1t exceeded that of the mouse protein, The stage of spermatogenesis of transgene expression was assessed by following appearance of transgenic mRNA in developing mice and by immunohistochemistry using an antiserum to rat H1t. In lines from three different constructs, expression was restricted to germinal cells, although in two strongly expressing lines the transgenes were expressed somewhat prematurely in preleptotene spermatocytes, An H1t(-948/+71)-lacZ fusion was also expressed specifically in the spermatocytes and round spermatids of a transgenic line, confirming that sequences sufficient for correct tissue and developmental expression lie within this 1,019-bp segment of the gene.	UNIV S CAROLINA, SCH MED, DEPT CHEM & BIOCHEM, COLUMBIA, SC 29208 USA; UNIV S CAROLINA, DEPT BIOL SCI, COLUMBIA, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia			Kremer, Eric J/D-3734-2013	Kremer, EJ/0000-0001-6114-7530	NICHD NIH HHS [HD10793] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD010793] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEHRINGER RR, 1993, DEVELOPMENT, V117, P823; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BERK AJ, 1989, METHOD ENZYMOL, V180, P334; BREUER B, 1989, GENE, V81, P307, DOI 10.1016/0378-1119(89)90191-1; BREUER B, 1993, NUCLEIC ACIDS RES, V21, P927, DOI 10.1093/nar/21.4.927; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BROWN DT, 1993, J BIOL CHEM, V268, P713; BUCCI LR, 1982, EXP CELL RES, V140, P111, DOI 10.1016/0014-4827(82)90162-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE KD, 1986, J BIOL CHEM, V261, P7178; COLES LS, 1985, NUCLEIC ACIDS RES, V13, P585, DOI 10.1093/nar/13.2.585; DALTON S, 1988, MOL CELL BIOL, V8, P4576, DOI 10.1128/MCB.8.10.4576; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; DELUCIA F, 1994, BIOCHEM BIOPH RES CO, V198, P32, DOI 10.1006/bbrc.1994.1005; DRABENT B, 1991, GENE, V103, P263, DOI 10.1016/0378-1119(91)90284-I; GALCHEVAGARGOVA Z, 1993, MOL ENDOCRINOL, V7, P979, DOI 10.1210/me.7.8.979; GALLINARI P, 1989, MOL CELL BIOL, V9, P1566, DOI 10.1128/MCB.9.4.1566; GORDON JW, 1981, SCIENCE, V211, P1265, DOI 10.1126/science.6259727; GRIMES S, 1987, EXP CELL RES, V173, P534, DOI 10.1016/0014-4827(87)90293-X; GRIMES SR, 1990, J CELL BIOCHEM, V44, P1, DOI 10.1002/jcb.240440102; GRIMES SR, 1992, EXP CELL RES, V201, P216, DOI 10.1016/0014-4827(92)90366-G; GRIMES SR, 1992, ARCH BIOCHEM BIOPHYS, V296, P402, DOI 10.1016/0003-9861(92)90590-S; Hecht N. B., 1993, CELL MOL BIOL TESTIS, P400; HEINTZ N, 1991, BIOCHIM BIOPHYS ACTA, V1088, P327, DOI 10.1016/0167-4781(91)90122-3; HOGAN B, 1986, MANIPULATING MOUSE E, P174; HUH NE, 1991, NUCLEIC ACIDS RES, V19, P93, DOI 10.1093/nar/19.1.93; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; KHOCHBIN S, 1994, NUCLEIC ACIDS RES, V22, P2887, DOI 10.1093/nar/22.15.2887; KIM YJ, 1987, DEV BIOL, V124, P23, DOI 10.1016/0012-1606(87)90455-6; KISTLER WS, 1989, HISTONES OTHER BASIC, P331; KREMER EJ, 1991, EXP CELL RES, V197, P330, DOI 10.1016/0014-4827(91)90442-W; KREMER EJ, 1992, GENE, V110, P167, DOI 10.1016/0378-1119(92)90644-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGFORD KG, 1991, J BIOL CHEM, V266, P15559; LIM K, 1992, J BIOL CHEM, V267, P15271; MARTINELLI R, 1994, MOL CELL BIOL, V14, P8322, DOI 10.1128/MCB.14.12.8322; MEISTRICH ML, 1985, DEV BIOL, V112, P230, DOI 10.1016/0012-1606(85)90137-X; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; PESCHON JJ, 1987, P NATL ACAD SCI USA, V84, P5316, DOI 10.1073/pnas.84.15.5316; POCCIA D, 1986, INT REV CYTOL, V105, P1, DOI 10.1016/S0074-7696(08)61061-X; ROBINSON MO, 1989, P NATL ACAD SCI USA, V86, P8437, DOI 10.1073/pnas.86.21.8437; ROSENTHAL DS, 1991, CELL GROWTH DIFFER, V2, P107; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEARLE PF, 1984, MOL CELL BIOL, V4, P1221, DOI 10.1128/MCB.4.7.1221; SEYEDIN SM, 1980, J BIOL CHEM, V255, P5949; SHIRES A, 1976, J BIOL CHEM, V251, P4155; STEIN G S, 1992, Current Opinion in Cell Biology, V4, P166, DOI 10.1016/0955-0674(92)90028-B; STEWART TA, 1988, MOL CELL BIOL, V8, P1748, DOI 10.1128/MCB.8.4.1748; TROSTLEWEIGE PK, 1982, J BIOL CHEM, V257, P5560; TROSTLEWEIGE PK, 1984, J BIOL CHEM, V259, P8769; VANWERT JM, 1995, BIOCHEMISTRY-US, V34, P8733, DOI 10.1021/bi00027a024; VANWIJNEN AJ, 1988, BIOCHEMISTRY-US, V27, P6534, DOI 10.1021/bi00417a051; WOLFE SA, 1989, BIOCHIM BIOPHYS ACTA, V1007, P140, DOI 10.1016/0167-4781(89)90032-8; WOLFE SA, 1993, J CELL BIOCHEM, V53, P156, DOI 10.1002/jcb.240530208; WOLFFE A, 1992, CHROMATIN STRUCTURE; WOLGEMUTH DJ, 1991, MAMM GENOME, V1, P283, DOI 10.1007/BF00352340; ZAMBROWICZ BP, 1993, P NATL ACAD SCI USA, V90, P5071, DOI 10.1073/pnas.90.11.5071	58	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4046	4054						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626738	hybrid			2022-12-27	WOS:A1996TW96000016
J	Bonnet, F; Perin, JP; Charbonnier, F; Camuzat, A; Roussel, G; Nussbaum, JL; Alliel, PM				Bonnet, F; Perin, JP; Charbonnier, F; Camuzat, A; Roussel, G; Nussbaum, JL; Alliel, PM			Structure and cellular distribution of mouse brain testican - Association with the postsynaptic area of hippocampus pyramidal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCANS; AMINO-ACID-SEQUENCES; NEURITE OUTGROWTH; MOLECULAR-CLONING; MESSENGER-RNAS; CORE PROTEIN; RAT-BRAIN; SYSTEM; MODULATORS; INHIBITORS	The complete deduced primary structure of mouse brain testican has been established from cDNA cloning. The cDNA encodes a polypeptide of 442 amino acids belonging to the proteoglycan family. The mouse brain testican core protein is 95% identical to its human testicular counterpart. In situ hybridization investigations revealed that mouse testican mRNA is mainly present in a subpopulation of pyramidal neurons localized in the CA3 area of the hippocampus. An immunocytochemical approach, with antibodies directed against an overexpressed chimeric antigen, produced in bacterial systems, showed that testican is associated with the postsynaptic region of these pyramidal neurons. Testican includes several putative functional domains related to extracellular or pericellular proteins associated with binding and/or regulatory functions. On the basis of its structural organization and its occurrence in postsynaptic areas, this proteoglycan might contribute to various neuronal mechanisms in the central nervous system.	UNIV PARIS 05, CNRS URA 1188, F-75270 PARIS 06, FRANCE; UNIV STRASBOURG 1, CNRS ERS 110, F-67084 STRASBOURG, FRANCE	UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				CHARBONNIER, Francoise/0000-0002-4875-2506; Charbonnier, Frederic/0000-0003-4341-3246				ALLIEL PM, 1993, EUR J BIOCHEM, V214, P347, DOI 10.1111/j.1432-1033.1993.tb17930.x; APOSTOL I, 1993, J PROTEIN CHEM, V12, P419, DOI 10.1007/BF01025042; ARAI T, 1994, J BIOL CHEM, V269, P20388; ARAUJO DM, 1989, BRAIN RES, V484, P130, DOI 10.1016/0006-8993(89)90355-7; BIROC SL, 1993, DEV BRAIN RES, V75, P119, DOI 10.1016/0165-3806(93)90071-H; BONNET F, 1992, BIOCHEM J, V288, P565, DOI 10.1042/bj2880565; BOURDON MA, 1990, EXTRACELLULAR MATRIX, P157; BREESE CR, 1991, ADV EXP MED BIOL, V293, P449; BURG MA, 1994, J NEUROBIOL, V25, P1, DOI 10.1002/neu.480250102; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; COLE GJ, 1991, NEURON, V7, P1007, DOI 10.1016/0896-6273(91)90345-Z; DAMON DH, 1988, J CELL PHYSIOL, V135, P293, DOI 10.1002/jcp.1041350217; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FAYEIN NA, 1992, BIOL CELL, V76, P1, DOI 10.1016/0248-4900(92)90189-8; FERNS MJ, 1992, CELL, V70, P1, DOI 10.1016/0092-8674(92)90525-H; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; GERBER LD, 1992, J BIOL CHEM, V267, P12168; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; GRUMET M, 1994, J BIOL CHEM, V269, P12142; GUERMAH M, 1991, P NATL ACAD SCI USA, V88, P4503, DOI 10.1073/pnas.88.10.4503; HAMMATIBRIVANLO.A, 1994, CELL, V77, P283; HASHIMOTO M, 1992, J BIOL CHEM, V267, P7203; HUHTALA ML, 1986, BIOCHEM BIOPH RES CO, V141, P263, DOI 10.1016/S0006-291X(86)80363-1; IIJIMA N, 1991, J NEUROCHEM, V56, P706, DOI 10.1111/j.1471-4159.1991.tb08207.x; JOHNSTON IG, 1990, NEURON, V4, P165, DOI 10.1016/0896-6273(90)90452-L; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KARTHIKEYAN L, 1994, J CELL SCI, V107, P3213; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRUEGER RC, 1992, J BIOL CHEM, V267, P12149; LAFONT F, 1994, DEV BIOL, V165, P453, DOI 10.1006/dbio.1994.1267; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; MAEDA N, 1992, DEV BIOL, V151, P564, DOI 10.1016/0012-1606(92)90194-L; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MARGOLIS RK, 1989, NEUROBIOLOGY GLYCOCO, P85; MARKS JL, 1991, ADV EXP MED BIOL, V293, P459; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; OOHIRA A, 1991, J NEUROSCI, V11, P822; OOHIRA A, 1994, NEUROSCI RES, V20, P195, DOI 10.1016/0168-0102(94)90088-4; PERRIS R, 1990, DEV BIOL, V137, P1, DOI 10.1016/0012-1606(90)90002-Z; RAUCH U, 1992, J BIOL CHEM, V267, P19536; ROUSSEL G, 1987, J NEUROCYTOL, V16, P195, DOI 10.1007/BF01795303; ROUSSEL G, 1991, DEV NEUROSCI-BASEL, V13, P98, DOI 10.1159/000112146; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWCHENKO PE, 1988, NATURE, V334, P615, DOI 10.1038/334615a0; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P2951, DOI 10.1093/nar/10.9.2951; STIPP CS, 1994, J CELL BIOL, V124, P149, DOI 10.1083/jcb.124.1.149; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; YAMADA H, 1994, J BIOL CHEM, V269, P10119; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	56	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4373	4380						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626787				2022-12-27	WOS:A1996TW96000065
J	Girard, JP; Springer, TA				Girard, JP; Springer, TA			Modulation of endothelial cell adhesion by hevin, an acidic protein associated with high endothelial venules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; L-SELECTIN; VASCULAR ADDRESSIN; HUMAN TENASCIN; BINDING; THROMBOSPONDIN; SPARC; DIFFERENTIATION; MOLECULE; PEPTIDES	High endothelial venules (HEV) are specialized plump postcapillary venules in lymphoid tissues that support high levels of lymphocyte extravasation from the blood. We have recently identified a novel human transcript, expressed to high levels in HEV, that encodes a secreted, acidic protein closely related to the anti-adhesive extracellular matrix protein known as BM-40, osteonectin, and SPARC (secreted protein acidic and rich in cysteine). Here, we show that this protein, designated hevin, is associated with basal, lateral, and apical surfaces of HEV cells, and unlike MECA-79 antigen, is not expressed on the underlying basement membrane. In contrast to fibronectin or other adhesive extracellular matrix proteins, purified hevin does not support endothelial cell adhesion in vitro. Moreover, addition of soluble exogenous hevin inhibits attachment and spreading of endothelial cells on fibronectin substrates. Hevin-treated cells do not form focal adhesions and exhibit a rounded morphology. Together, these results suggest that hevin is an abundant extracellular protein that modulates high endothelial cell adhesion to the basement membrane.	HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; CNRS,LAB BIOL MOLEC EUCARYOTE,F-31062 TOULOUSE,FRANCE	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)			GIRARD, Jean-Philippe/F-5229-2010	GIRARD, Jean-Philippe/0000-0002-9154-1691	NCI NIH HHS [CA 31798] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA031798, R01CA031798] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDERUCCIO F, 1991, J EXP MED, V173, P941, DOI 10.1084/jem.173.4.941; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; Bebbington CR, 1987, DNA CLONING PRACTICA, VIII, P163; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; CARLEY WW, 1988, EXP CELL RES, V178, P426, DOI 10.1016/0014-4827(88)90411-9; DEJANA E, 1988, J CELL BIOL, V107, P1215, DOI 10.1083/jcb.107.3.1215; GASTINEL LN, 1992, P NATL ACAD SCI USA, V89, P638, DOI 10.1073/pnas.89.2.638; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; GIRARD JP, 1995, IMMUNITY, V2, P113, DOI 10.1016/1074-7613(95)90083-7; GOLDBLUM SE, 1994, P NATL ACAD SCI USA, V91, P3448, DOI 10.1073/pnas.91.8.3448; HARLOW E, 1988, ANTIBODIES LABORATOR; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; IMAI Y, 1993, NATURE, V361, P555; JOSHI P, 1993, J CELL SCI, V106, P389; LAHAV J, 1988, EXP CELL RES, V177, P199, DOI 10.1016/0014-4827(88)90037-7; LANE TF, 1990, J CELL BIOL, V111, P3065, DOI 10.1083/jcb.111.6.3065; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; MICHIE SA, 1993, AM J PATHOL, V143, P1688; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1995, J CELL BIOCHEM, V57, P341, DOI 10.1002/jcb.240570218; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; MURPHYULLRICH JE, 1993, J BIOL CHEM, V268, P26784; NORDGARDSUMNICH.KE, 1993, SCIENCE, V261, P480; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; POTTGIESSER J, 1994, J MOL BIOL, V238, P563, DOI 10.1006/jmbi.1994.1315; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341; SRIRAMARAO P, 1993, J CELL SCI, V105, P1001; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; TAKAHASHI K, 1990, IN VITRO CELL DEV, V25, P265; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; WATT FM, 1986, TRENDS BIOCHEM SCI, V11, P482, DOI 10.1016/0968-0004(86)90252-5; ZHU DZ, 1991, P NATL ACAD SCI USA, V88, P9568, DOI 10.1073/pnas.88.21.9568	37	109	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4511	4517						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626806				2022-12-27	WOS:A1996TW96000084
J	Robinson, KM; Lemire, BD				Robinson, KM; Lemire, BD			A requirement for matrix processing peptidase but not for mitochondrial chaperonin in the covalent attachment of FAD to the yeast succinate dehydrogenase flavoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C HEME LYASE; SACCHAROMYCES-CEREVISIAE; PRECURSOR PROTEINS; ESCHERICHIA-COLI; FUMARATE REDUCTASE; 6-HYDROXY-D-NICOTINE OXIDASE; MOLECULAR CHAPERONES; BOUND FLAVIN; CYTOCHROME-C; IMPORT	Succinate dehydrogenase (EC 1.3.99.1) in the yeast Saccharomyces cerevisiae is a mitochondrial heterotetramer containing a flavoprotein subunit with an 8 alpha-N(3)-histidyl-linked FAD cofactor. The covalent linkage of the FAD is necessary for activity. We have developed an in vitro assay that measures the flavinylation of the flavoprotein precursor in mitochondrial matrix fractions. Flavoprotein modification does not depend on translocation across a membrane, but it does require proteolytic processing by the mitochondrial processing peptidase prior to flavin attachment. Since ATP depletion, N-ethylmaleimide, or proteinase treatments of matrix fractions inhibit flavoprotein modification, at least one additional matrix protein component appears to be required. Having previously suggested that the flavoprotein begins folding before FAD attachment occurs, we tested whether the mitochondrial chaperonin, heat shock protein 60, might be necessary. Co-immunoprecipitation of the flavoprotein and the chaperonin demonstrate that the proteins do indeed interact. However, immunodepletion of the chaperonin from matrix fractions does not inhibit FAD attachment. Nonprotein components are also required for flavoprotein modification. In addition to ATP, effector molecules such as succinate, fumarate, or malate also stimulate modification. Together, these results suggest that FAD addition is an early event in succinate dehydrogenase assembly.	UNIV ALBERTA, DEPT BIOCHEM, MED RES COUNCIL CANADA, GRP MOL BIOL MEMBRANES, EDMONTON, AB T6G 2H7, CANADA	University of Alberta								Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ARRETZ M, 1991, BIOMED BIOCHIM ACTA, V50, P403; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BLAUT M, 1989, J BIOL CHEM, V264, P13599; BRANDSCH R, 1992, J BIOL CHEM, V267, P20844; BRANDSCH R, 1991, J BIOL CHEM, V266, P19056; BRANDSCH R, 1993, J BIOL CHEM, V268, P12724; BRANDSCH R, 1989, EUR J BIOCHEM, V182, P125, DOI 10.1111/j.1432-1033.1989.tb14808.x; BULLIS BL, 1994, J BIOL CHEM, V269, P6543; CHAPMAN KB, 1992, GENE, V118, P131, DOI 10.1016/0378-1119(92)90260-V; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; COLE ST, 1985, BIOCHIM BIOPHYS ACTA, V811, P381, DOI 10.1016/0304-4173(85)90008-4; DAIGNANFORNIER B, 1994, J BIOL CHEM, V269, P15469; DECKER KF, 1993, ANNU REV NUTR, V13, P17, DOI 10.1146/annurev.nu.13.070193.000313; DUMONT ME, 1991, MOL CELL BIOL, V11, P5487, DOI 10.1128/MCB.11.11.5487; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GLICK BS, 1992, TRENDS BIOCHEM SCI, V17, P453, DOI 10.1016/0968-0004(92)90487-T; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GLICK BS, 1991, METHOD CELL BIOL, V34, P389; GRAHAM LA, 1993, J BIOENERG BIOMEMBR, V25, P245, DOI 10.1007/BF00762586; GROSS NH, 1984, METHOD ENZYMOL, V107, P261; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; HALLBERG EM, 1993, MOL CELL BIOL, V13, P3050, DOI 10.1128/MCB.13.5.3050; HEDERSTEDT L, 1982, J BACTERIOL, V152, P157; HEDERSTEDT L, 1980, J BACTERIOL, V144, P941, DOI 10.1128/JB.144.3.941-951.1980; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; ISAYA G, 1994, MOL CELL BIOL, V14, P5603, DOI 10.1128/MCB.14.8.5603; JASCUR T, 1991, METHOD CELL BIOL, V34, P359; KIM JH, 1994, J BACTERIOL, V176, P6349, DOI 10.1128/jb.176.20.6349-6361.1994; LANG H, 1991, EUR J BIOCHEM, V198, P793, DOI 10.1111/j.1432-1033.1991.tb16083.x; LATOUR DJ, 1988, BIOCH CELL BIOL, V67, P251; LEMIRE BD, 1982, J BACTERIOL, V152, P1126; LOMBARDO A, 1990, J BIOL CHEM, V265, P10419; MURAKAMI K, 1988, J BIOL CHEM, V263, P18437; MURAKAMI K, 1990, EMBO J, V9, P3201, DOI 10.1002/j.1460-2075.1990.tb07518.x; MURAKAMI K, 1992, J BIOL CHEM, V267, P13119; NARGANG FE, 1988, J BIOL CHEM, V263, P9388; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PFANNER N, 1990, J BIOL CHEM, V265, P16324; Robinson KM, 1996, J BIOL CHEM, V271, P4055; Robinson KM, 1995, METHOD ENZYMOL, V260, P34, DOI 10.1016/0076-6879(95)60128-7; ROBINSON KM, 1991, J BIOL CHEM, V266, P21347; ROBINSON KM, 1994, EUR J BIOCHEM, V222, P983, DOI 10.1111/j.1432-1033.1994.tb18949.x; ROBINSON KM, 1992, J BIOL CHEM, V267, P10101; ROSPERT S, 1994, J BIOL CHEM, V269, P17279; SAIJO T, 1995, J BIOL CHEM, V270, P1899, DOI 10.1074/jbc.270.4.1899; SCHMIDT DM, 1992, BIOCHEMISTRY-US, V31, P8442, DOI 10.1021/bi00151a008; SCHMIDT U, 1969, ADV ENZYMOL RAMB, V32, P423; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; WEYLER W, 1990, BIOCHEM BIOPH RES CO, V173, P1205, DOI 10.1016/S0006-291X(05)80914-3	52	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4061	4067						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626740				2022-12-27	WOS:A1996TW96000018
J	Taipale, J; KeskiOja, J				Taipale, J; KeskiOja, J			Hepatocyte growth factor releases epithelial and endothelial cells from growth arrest induced by transforming growth factor-beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX GENE-EXPRESSION; TGF-BETA; EXTRACELLULAR-MATRIX; SCATTER FACTOR; II RECEPTOR; PERICELLULAR MATRIX; NEGATIVE REGULATION; DEPENDENT KINASE; INHIBITION; ACTIVATION	Human lung fibroblasts and Mv1Lu mink lung epithelial cells were used as a model to study the role of extracellular matrix in epithelial-mesenchymal interactions. Extracellular matrices of fibroblasts were found to contain growth promoting activity that reduced the sensitivity of Mv1Lu cells to the growth inhibitory effects of transforming growth factor-beta (TGF-beta). The majority of the activity was identified as hepatocyte growth factor/scatter factor (HGF) by inhibition with specific antibodies and by reconstitution of the effect by recombinant HGF. HGF induced cell proliferation when contact-inhibited Mv1Lu cells were trypsinized and plated in the presence of TGF-beta 1. The effect was valid also in assays where Madin-Darby canine kidney epithelial cells or bovine capillary endothelial cells were used. The multiplication of chronically TGF-beta 1 inhibited Mv1Lu cells was also induced by HGF. In addition, HGF induced anchorage independent growth of Mv1Lu cells that was refractory to TGF-beta 1 growth inhibition. Immunoprecipitation analysis indicated that HGF prevented the suppression of Cdk4 and Cdk2, but not the induction of p21, by TGF-beta 1. Since both TGF-beta 1 and HGF require proteolysis for activation, the results imply that proteolytic activity of epithelial and endothelial cells directs their responses to signals from mesenchymal-type extracellular matrices, and that during development, matrix-bound growth and invasion promoting and suppressing factors are activated in a coordinated manner.	HELSINKI UNIV, HAARTMAN INST, DEPT VIROL, SF-00014 HELSINKI, FINLAND; HELSINKI UNIV, DEPT DERMATOL, SF-00014 HELSINKI, FINLAND; HELSINKI UNIV, DEPT VENEREOL, SF-00014 HELSINKI, FINLAND	University of Helsinki; University of Helsinki; University of Helsinki								ASSOIAN RK, 1986, J CELL BIOL, V102, P1217, DOI 10.1083/jcb.102.4.1217; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; Brownh PD, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037500; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CZAJA MJ, 1989, J CELL BIOL, V108, P2477, DOI 10.1083/jcb.108.6.2477; DROZDOFF V, 1994, P NATL ACAD SCI USA, V91, P5528, DOI 10.1073/pnas.91.12.5528; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FALCONE DJ, 1993, J BIOL CHEM, V268, P11951; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; HAN EKH, 1993, J CELL BIOL, V122, P461, DOI 10.1083/jcb.122.2.461; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HEDMAN K, 1979, J CELL BIOL, V81, P83, DOI 10.1083/jcb.81.1.83; HEINE UI, 1990, DEVELOPMENT, V109, P29; HOWE PH, 1990, J CELL PHYSIOL, V142, P39, DOI 10.1002/jcp.1041420106; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; KAMALATI T, 1992, J CELL SCI, V101, P323; KATO J, 1993, GENE DEV, V7, P331; KAWAIDA K, 1994, P NATL ACAD SCI USA, V91, P4357, DOI 10.1073/pnas.91.10.4357; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAIHO M, 1987, J BIOL CHEM, V262, P17467; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIU YH, 1994, MOL CELL BIOL, V14, P7046, DOI 10.1128/MCB.14.11.7046; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUMOTO K, 1992, J BIOL CHEM, V267, P24917; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; MIZOI T, 1993, CANCER RES, V53, P183; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MOSES HL, 1985, CANCER CELL, V3, P65; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NEVINS JR, 1992, SCIENCE, V258, P424; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; PELTON RW, 1990, DEV BIOL, V141, P456, DOI 10.1016/0012-1606(90)90401-4; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; ROBERTS AB, 1980, P NATL ACAD SCI-BIOL, V77, P3494, DOI 10.1073/pnas.77.6.3494; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; SANTOS OFP, 1993, DEV BIOL, V160, P293, DOI 10.1006/dbio.1993.1308; SANTOS OFP, 1994, DEV BIOL, V163, P525, DOI 10.1006/dbio.1994.1169; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SERRA R, 1994, DEVELOPMENT, V120, P2153; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SILBERSTEIN GB, 1992, DEV BIOL, V152, P354, DOI 10.1016/0012-1606(92)90142-4; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SUN LZ, 1994, J BIOL CHEM, V269, P26449; SUN LZ, 1994, EXP CELL RES, V214, P215, DOI 10.1006/excr.1994.1251; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; TAIPALE J, 1994, CELL GROWTH DIFFER, V5, P1309; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; YANAGITA K, 1993, J BIOL CHEM, V268, P21212	81	54	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4342	4348						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626783				2022-12-27	WOS:A1996TW96000061
J	Wang, K; Knipfer, M; Huang, QQ; vanHeerden, A; Hsu, LCL; Gutierrez, G; Quian, XL; Stedman, H				Wang, K; Knipfer, M; Huang, QQ; vanHeerden, A; Hsu, LCL; Gutierrez, G; Quian, XL; Stedman, H			Human skeletal muscle nebulin sequence encodes a blueprint for thin filament architecture - Sequence motifs and affinity profiles of tandem repeats and terminal SH3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE; SARCOMERE MATRIX; MYOFIBRILLAR COMPONENTS; MONOCLONAL-ANTIBODIES; PHOSPHORYLATION SITES; ACTIN-FILAMENTS; STRIATED-MUSCLE; BINDING-SITE; KINASE-II; Z-LINE	Analysis of deduced protein sequence and structural motifs of similar to 5500 residues of human fetal skeletal muscle nebulin reveals the design principles of this giant multifunctional protein in the sarcomere. The bulk of the sequence is constructed of similar to 150 tandem copies of similar to 35-residue modules that can be classified into seven types. The majority of these modules form 20 super-repeats, with each super-repeat containing a 7-module set (one of each type in the same order). These super-repeats are further divided into eight segments: with six segments containing adjacent, highly homologous super-repeats, one single repeat segment consisting of 8 nebulin modules of the same type, and a non-repeat segment terminating with a SH3 domain at the C terminus. The interactions of actin, tropomyosin, troponin, and calmodulin with nebulin fragments consisting of either repeating modules or the SH3 domain support its role as a giant actin-binding cofilament of the composite thin filament. Such affinity profiles also suggest that nebulin may bind to tropomyosin and troponin to form a composite calcium-linked regulatory complex on the thin filament. The modular construction, super-repeat structure, and segmental organization of nebulin sequence appear to encode thin filament length, periodicity, insertion, and sarcomere proportion in the resting muscle.	UNIV TEXAS, CELL RES INST, AUSTIN, TX 78712 USA; UNIV PENN, SCH MED, INST HUMAN GENE THERAPY, DEPT SURG, PHILADELPHIA, PA 19104 USA	University of Texas System; University of Texas Austin; University of Pennsylvania	Wang, K (corresponding author), UNIV TEXAS, INST BIOCHEM, DEPT CHEM & BIOCHEM, AUSTIN, TX 78712 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043514, R37AR043514] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR43514] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BOGATCHEVA NV, 1993, BIOCHEM J, V290, P437, DOI 10.1042/bj2900437; CASELLA JF, 1987, J CELL BIOL, V105, P371, DOI 10.1083/jcb.105.1.371; CHEN JK, 1994, BIOORG MED CHEM LETT, V4, P1755, DOI 10.1016/S0960-894X(00)80375-3; CHEN MJG, 1993, J BIOL CHEM, V268, P20327; EBASHI S, 1967, J BIOCHEM-TOKYO, V61, P817; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FOWLER VM, 1993, J CELL BIOL, V120, P411, DOI 10.1083/jcb.120.2.411; FRANZINI-ARMSTRONG C, 1970, Tissue and Cell, V2, P327, DOI 10.1016/S0040-8166(70)80023-4; GOETINCK S, 1994, J CELL BIOL, V127, P79, DOI 10.1083/jcb.127.1.79; GOTTLIEB M, 1987, ANAL BIOCHEM, V165, P33, DOI 10.1016/0003-2697(87)90197-7; IKEBE M, 1990, J BIOL CHEM, V265, P17607; JIN JP, 1991, J BIOL CHEM, V266, P21215; JIN JP, 1991, FEBS LETT, V281, P93, DOI 10.1016/0014-5793(91)80366-B; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KRUGER M, 1991, J CELL BIOL, V115, P97, DOI 10.1083/jcb.115.1.97; LABEIT S, 1991, FEBS LETT, V282, P313, DOI 10.1016/0014-5793(91)80503-U; LABEIT S, 1995, J MOL BIOL, V248, P308, DOI 10.1016/S0022-2836(95)80052-2; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LIN JJC, 1981, P NATL ACAD SCI-BIOL, V78, P2335, DOI 10.1073/pnas.78.4.2335; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; LOCKER RH, 1986, J BIOCHEM, V99, P1473, DOI 10.1093/oxfordjournals.jbchem.a135617; MAK AS, 1991, J BIOL CHEM, V266, P19971; MAK AS, 1991, J BIOL CHEM, V266, P6678; MARSTON SB, 1991, BIOCHEM J, V279, P1; MARUYAMA K, 1989, J MUSCLE RES CELL M, V10, P350, DOI 10.1007/BF01758431; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MONCMAN CL, 1995, CELL MOTIL CYTOSKEL, V32, P205, DOI 10.1002/cm.970320305; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NAVE R, 1990, FEBS LETT, V269, P163, DOI 10.1016/0014-5793(90)81144-D; OHTSUKI I, 1974, J BIOCHEM-TOKYO, V75, P753, DOI 10.1093/oxfordjournals.jbchem.a130448; PFUHL M, 1994, EMBO J, V13, P1782, DOI 10.1002/j.1460-2075.1994.tb06446.x; PIEROBONBORMIOLI S, 1989, J MUSCLE RES CELL M, V10, P446, DOI 10.1007/BF01771820; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROOT DD, 1994, BIOCHEMISTRY-US, V33, P12581, DOI 10.1021/bi00208a008; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUURING E, 1992, ONCOGENE, V7, P355; SHIRINSKY VP, 1992, J BIOL CHEM, V267, P15886; SJOSTROM M, 1977, J MOL BIOL, V109, P49, DOI 10.1016/S0022-2836(77)80045-4; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOMERVILLE LL, 1988, ARCH BIOCHEM BIOPHYS, V262, P118, DOI 10.1016/0003-9861(88)90174-9; STEDMAN H, 1989, CELLULAR MOL BIOL MU, P181; Stedman H, 1988, GENOMICS, V2, P1, DOI 10.1016/0888-7543(88)90102-4; TATSUMI R, 1992, J BIOCHEM-TOKYO, V112, P780, DOI 10.1093/oxfordjournals.jbchem.a123975; VIBERT P, 1993, J CELL BIOL, V123, P313, DOI 10.1083/jcb.123.2.313; WANG K, 1993, BIOPHYS J, V64, P1161, DOI 10.1016/S0006-3495(93)81482-6; WANG K, 1979, P NATL ACAD SCI USA, V76, P3698, DOI 10.1073/pnas.76.8.3698; WANG K, 1988, J CELL BIOL, V107, P2199, DOI 10.1083/jcb.107.6.2199; WANG K, 1990, Journal of Cell Biology, V111, p428A; WILSON FJ, 1977, TISSUE CELL, V9, P273, DOI 10.1016/0040-8166(77)90021-0; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WRIGHT J, 1993, J MUSCLE RES CELL M, V14, P476, DOI 10.1007/BF00297210; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZEVIANI M, 1988, Genomics, V2, P249, DOI 10.1016/0888-7543(88)90009-2; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	59	120	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4304	4314						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626778				2022-12-27	WOS:A1996TW96000056
J	Witteveen, CFB; Giovanelli, J; Kaufman, S				Witteveen, CFB; Giovanelli, J; Kaufman, S			Reduction of quinonoid dihydrobiopterin to tetrahydrobiopterin by nitric oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; L-ARGININE; METHYLENETETRAHYDROFOLATE REDUCTASE; BIOCHEMICAL-CHARACTERIZATION; DIHYDROPTERIDINE REDUCTASE; MURINE MACROPHAGES; LIVER; PURIFICATION; COFACTOR; INHIBITION	Rat cerebellar nitric oxide synthase (NOS) purified from transfected human kidney cells catalyzes an NADPH-dependent reduction of quinonoid dihydrobiopterin (qBH(2)) to tetrahydrobiopterin (BH4). Reduction of qBH(2) at 25 mu M proceeds at a rate that is comparable with that of the overall reaction (citrulline synthesis) and requires calcium ions and calmodulin for optimal activity; NADH has only 10% of the activity of NADPH. The reduction rate with the quinonoid form of 6-methyldihydropterin is approximately twice that with qBH(2). 7,8-Dihydrobiopterin had negligible activity. Neither 7,8-dihydrobiopterin nor BH4 affected the rate of qBH(2) reduction. Reduction is inhibited by the flavoprotein inhibitor diphenyleneiodonium, whereas inhibitors of electron transfer through heme (7-nitroindazole and N-nitroarginine) stimulated the rate to a small extent, Methotrexate, which inhibits a variety of enzymes catalyzing dihydrobiopterin reduction, did not inhibit. These studies provide the first demonstration of the reduction of qBH(2) to BH4 by NOS and indicate that the reduction is catalyzed by the flavoprotein ''diaphorase'' activity of NOS. This activity is located on the reductase (C-terminal) domain, whereas the high affinity BH4 site involved in NOS activation is located on the oxygenase (N-terminal) domain. The possible significance of this reduction of qBH(2) to the essential role of BH4 in NOS is discussed.	NIMH,NEUROCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)								ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; ARCHER MC, 1970, CAN J BIOCHEM CELL B, V48, P278, DOI 10.1139/o70-049; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CAMPOS KL, 1995, J BIOL CHEM, V270, P1721, DOI 10.1074/jbc.270.4.1721; CAMPOS KL, 1992, BIOL NITRIC OXIDE, V2, P47; CHEN PF, 1994, J BIOL CHEM, V269, P25062; CITRON BA, 1992, PROTEIN EXPRES PURIF, V3, P93, DOI 10.1016/S1046-5928(05)80024-5; CRAINE JE, 1972, J BIOL CHEM, V247, P6082; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; HAAVIK J, 1983, J CHROMATOGR, V257, P361, DOI 10.1016/S0021-9673(01)88192-9; HEALES S, 1989, J CHROMATOGR-BIOMED, V494, P77, DOI 10.1016/S0378-4347(00)82658-4; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; KAUFMAN S, 1971, ADV ENZYMOL RAMB, V35, P245; KAUFMAN S, 1967, J BIOL CHEM, V242, P3934; KAUFMAN S, 1959, J BIOL CHEM, V234, P2683; KAUFMAN S, 1961, J BIOL CHEM, V236, P804; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; KLATT P, 1993, J BIOL CHEM, V268, P14781; KLATT P, 1992, J BIOL CHEM, V267, P11374; KOWLESSUR D, 1995, P NATL ACAD SCI USA, V92, P4743, DOI 10.1073/pnas.92.11.4743; KUTZBACH C, 1971, BIOCHIM BIOPHYS ACTA, V250, P459, DOI 10.1016/0005-2744(71)90247-6; KWON NS, 1989, J BIOL CHEM, V264, P20496; MANGUM JH, 1979, CHEM BIOL PTERIDINES, P453; MATSUURA S, 1986, P81; MATTHEWS RG, 1980, J BIOL CHEM, V255, P6014; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; NAKANISHI N, 1977, J BIOCHEM-TOKYO, V81, P681, DOI 10.1093/oxfordjournals.jbchem.a131504; NISHIMURA JS, 1995, BIOCHEM BIOPH RES CO, V210, P288, DOI 10.1006/bbrc.1995.1659; OSBORN MJ, 1958, P SOC EXP BIOL MED, V97, P429; PUFAHL RA, 1992, BIOCHEMISTRY-US, V31, P6822, DOI 10.1021/bi00144a024; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; TEW DG, 1993, BIOCHEMISTRY-US, V32, P10209, DOI 10.1021/bi00089a042; TURNER AJ, 1979, CHEM BIOL PTERIDINES, P501; UMANS JG, 1995, ANNU REV PHYSIOL, V57, P771, DOI 10.1146/annurev.ph.57.030195.004011; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; WOLFF DJ, 1994, ARCH BIOCHEM BIOPHYS, V311, P300, DOI 10.1006/abbi.1994.1241; ZHANG J, 1995, ANNU REV PHARMACOL, V35, P213	52	39	39	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4143	4147						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626754				2022-12-27	WOS:A1996TW96000032
J	Chung, SM; Jiang, L; Cheng, S; Furneaux, H				Chung, SM; Jiang, L; Cheng, S; Furneaux, H			Purification and properties of HuD, a neuronal RNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; DROSOPHILA-MELANOGASTER; UNTRANSLATED REGIONS; RICH DOMAINS; HELA-CELLS; IDENTIFICATION; RECOGNITION; SEQUENCE; ELAV; SPECIFICITY	HuD is a human neuronal specific RNA-binding protein. In this study we have purified HuD and examined its RNA binding properties in detail. HuD binds to mRNAs that contain an AU-rich element with high affinity. In the case of the c-fos AU-rich element, HuD binds to a 27-nucleotide core element comprising AUUUA, AUUUUA and AUUUUUA motifs. Mutation in any two of these motifs abrogates binding. HuD contains two tandem RNA recognition motifs (RRM), a basic domain, and a third RRM. Deletion analysis has shown that only the first and second RRMs are essential for RNA binding. Thus, these specific RNA binding properties support the idea that the HuD regulates gene expression at the post-transcriptional level.	MEM SLOAN KETTERING CANC CTR,MOLEC NEUROONCOL LAB,PROGRAM MOL PHARMACOL & THERAPEUT,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM CELLULAR BIOCHEM & BIOPHYS,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center				furneaux, henry/0000-0003-2212-1017	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029682] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA08748] Funding Source: Medline; NINDS NIH HHS [NS29682] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abe R, 1994, DNA Res, V1, P175, DOI 10.1093/dnares/1.4.175; ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; [Anonymous], 1995, NEUROSCIENTIST, DOI DOI 10.1177/107385849500100203; BARAMI K, 1995, J NEUROBIOL, V28, P82, DOI 10.1002/neu.480280108; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CAMPOS AR, 1985, J NEUROGENET, V2, P197, DOI 10.3109/01677068509100150; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; FURNEAUX HM, 1985, P NATL ACAD SCI USA, V82, P4351, DOI 10.1073/pnas.82.13.4351; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; HOMYK T, 1985, J NEUROGENET, V2, P309, DOI 10.3109/01677068509102326; HUANG LY, 1993, J BIOL CHEM, V268, P25769; JIMMINEZ F, 1979, NATURE, V282, P310; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIM YJ, 1993, J NEUROSCI, V13, P1045; KING PH, 1994, J NEUROSCI, V14, P1943; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; LIU J, 1995, NEUROLOGY, V45, P544, DOI 10.1212/WNL.45.3.544; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; NAKAGAWA J, 1995, P NATL ACAD SCI USA, V92, P2051, DOI 10.1073/pnas.92.6.2051; PERRON M, 1995, MECH DEVELOP, V51, P235, DOI 10.1016/0925-4773(95)00368-1; PRUZAN R, 1990, J BIOL CHEM, V265, P2804; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHAW J, 1988, J IMMUNOL, V140, P2243; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	43	152	153	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11518	11524		10.1074/jbc.271.19.11518	http://dx.doi.org/10.1074/jbc.271.19.11518			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626712	hybrid			2022-12-27	WOS:A1996UJ94400072
J	Mothe, I; VanObberghen, E				Mothe, I; VanObberghen, E			Phosphorylation of insulin receptor substrate-1 on multiple serine residues, 612, 632, 662, and 731, modulates insulin action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; OKADAIC ACID; TYROSINE PHOSPHORYLATION; PROTEIN IRS-1; CELLS; SIGNAL; ADIPOCYTES; PLASMID	Okadaic acid has been described previously as being a negative regulator of insulin signaling, as it inhibits insulin stimulation of glucose transport. In addition, this drug induces on insulin receptor substrate-1 (IRS-1) a decrease in tyrosine phosphorylation, concomitantly with an increase in serine/threonine phosphorylation. The present work was aimed at the identification of the serine/threonine residues that, upon phosphorylation, might be involved in modulating insulin signaling. To this end, we studied double-point mutants of IRS-1, in which serines 612/632 and 662/731 were replaced with alanine. These are four plausible sites of phosphorylation by mitogen-activated protein kinases and are in the immediate proximity of tyrosine residues, which are potential sites of interaction with the phosphatidylinositol 3-kinase Src homology 2 domains. Using transient expression in 293 EBNA cells, we demonstrate that serines 612, 632, 662, and 731 and mitogen-activated protein kinases are not involved in the okadaic acid effect on IRS-1. Rather, these serines appear to play a role in modulating basal and insulin-stimulated IRS-1 tyrosine phosphorylation, association of IRS-1 with p85, and phosphatidylinositol 3-kinase activity in the IRS-1 . p85 immune complex, since mutation of these sites enhances these events. Our findings suggest the existence of an IRS-1 desensitization mechanism resulting from serine/threonine phosphorylation, occurring at least on serines 612, 632, 662, and 731.			Mothe, I (corresponding author), FAC MED NICE,INSERM,U145,AVE VALLOMBROSE,F-06107 NICE 2,FRANCE.		MOTHE-SATNEY, ISABELLE/Q-6377-2016	MOTHE-SATNEY, ISABELLE/0000-0002-2693-8385				CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FREYCHET P, 1971, BIOCHEM BIOPH RES CO, V43, P400, DOI 10.1016/0006-291X(71)90767-4; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; JULLIEN D, 1993, J BIOL CHEM, V268, P15246; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1996, IN PRESS MOL CELL BI; PONS S, 1995, MOL CELL BIOL, V15, P4453; ROCCHI S, 1995, ENDOCRINOLOGY, V136, P5291, DOI 10.1210/en.136.12.5291; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; TANTI JF, 1994, J BIOL CHEM, V269, P6051; TANTI JF, 1993, AM J PHYSIOL, V264, pE868, DOI 10.1152/ajpendo.1993.264.6.E868; VANOBBERGHEN E, 1994, DIABETOLOGIA, V87, P125; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0	29	213	225	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11222	11227		10.1074/jbc.271.19.11222	http://dx.doi.org/10.1074/jbc.271.19.11222			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626671	hybrid			2022-12-27	WOS:A1996UJ94400031
J	Thomas, JG; Baneyx, F				Thomas, JG; Baneyx, F			Protein misfolding and inclusion body formation in recombinant Escherichia coli cells overexpressing heat-shock proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNAK; GROEL; CHAPERONINS; MUTATION	PreS2-S'-beta-galactosidase, a three-domain fusion protein that aggregates extensively in the cytoplasm of Escherichia coli, was used to systematically investigate the effects of heat-shock protein (hsp) overproduction on protein misfolding and inclusion body formation. While the co-overexpression of the DnaK and DnaJ molecular chaperones led to a 3-6-fold increase in the recovery of enzymatically active preS2-S'-beta-galactosidase over a wide range of growth temperatures (30-42 degrees C), an increase in the concentration of the GroEL and GroES chaperonins had a significant effect at 30 degrees C only, Coimmunoprecipitation experiments confirmed that preS2-S'-beta-galactosidase formed a stable complex with DnaK, but not with GroEL, at 42 degrees C, When the intracellular concentration of chromosomal heat-shock proteins was increased by overproduction of the heat-shock transcription factor sigma(32), or by addition of 3% ethanol (v/v) to the growth medium, a 2-3-fold higher recovery of active enzyme was observed at 30 and 42 degrees C, but not at 37 degrees C, The overexpression of all heat-shock proteins or specific chaperone operons did not significantly affect the synthesis rates or stability of preS2-S'-beta-galactosidase and did not lead to the disaggregation of preformed inclusion bodies. Rather, the improvements in the recovery of soluble and active fusion protein resulted primarily from facilitated folding and assembly. Our findings suggest that titration of the DnaK-DnaJ early folding factors leads to the formation of preS2-S'-beta-galactosidase inclusion bodies.	UNIV WASHINGTON,DEPT CHEM ENGN,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM088437] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; Ayling A, 1996, PROTEIN SCI, V5, P478; BANEYX F, 1992, J BIOL CHEM, V267, P11637; BANEYX F, 1994, ANN NY ACAD SCI, V745, P383; BLUM P, 1992, BIO-TECHNOL, V10, P301, DOI 10.1038/nbt0392-301; BROSS P, 1993, BIOCHIM BIOPHYS ACTA, V1182, P264, DOI 10.1016/0925-4439(93)90068-C; CASPERS P, 1994, CELL MOL BIOL, V40, P635; DALE GE, 1994, PROTEIN ENG, V7, P925, DOI 10.1093/protein/7.7.925; DUENAS M, 1994, BIOTECHNIQUES, V16, P476; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GATENBY AA, 1994, ANNU REV PLANT PHYS, V45, P469; GATENBY AA, 1992, PLANT MOL BIOL, V19, P677, DOI 10.1007/BF00026793; Georgiou G., 1990, RECOMBINANT DNA TECH, P333; GOLUBINOFF P, 1989, NATURE, V337, P44; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; GROSSMAN AD, 1987, GENE DEV, V1, P179, DOI 10.1101/gad.1.2.179; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HERMAN C, 1995, P NATL ACAD SCI USA, V92, P3516, DOI 10.1073/pnas.92.8.3516; HWANG DS, 1990, J BIOL CHEM, V265, P19244; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEE SC, 1992, J BIOL CHEM, V267, P2849; LEE SC, 1990, EUR J BIOCHEM, V187, P417, DOI 10.1111/j.1432-1033.1990.tb15320.x; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Miller J. H, 1972, EXPT MOL GENETICS; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, P1334; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PEREZPEREZ J, 1995, BIOCHEM BIOPH RES CO, V210, P524, DOI 10.1006/bbrc.1995.1691; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; Steczko J, 1991, Protein Expr Purif, V2, P221, DOI 10.1016/1046-5928(91)90075-T; THOMAS JG, 1996, IN PRESS ANN N Y ACA; TILLY K, 1989, J BACTERIOL, V171, P1585, DOI 10.1128/jb.171.3.1585-1589.1989; VANBOGELEN RA, 1987, J BACTERIOL, V169, P26, DOI 10.1128/jb.169.1.26-32.1987; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WYNN RM, 1992, J BIOL CHEM, V267, P12400; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YURA T, 1993, ANNU REV MICROBIOL, V47, P321, DOI 10.1146/annurev.mi.47.100193.001541	41	170	182	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11141	11147		10.1074/jbc.271.19.11141	http://dx.doi.org/10.1074/jbc.271.19.11141			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626659	hybrid			2022-12-27	WOS:A1996UJ94400019
J	Yang, WL; Bruno, MEC; Carman, GM				Yang, WL; Bruno, MEC; Carman, GM			Regulation of yeast CTP synthetase activity by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTIDINE 5'-TRIPHOSPHATE SYNTHETASE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; TRIPHOSPHATE SYNTHETASE; MUTATOR GENE; CELL-CYCLE; MUTANTS; PURIFICATION; PHOSPHORYLATION; BIOSYNTHESIS	CTP synthetase (EC 6.3.4.2, UTP:ammonia ligase (ADP-forming)) is an allosterically regulated enzyme in the yeast Saccharomyces cerevisiae. In this work we examined the regulation of CTP synthetase activity by S. cerevisiae protein kinase C (Pkc1p) phosphorylation. The results of labeling experiments with S. cerevisiae mutants expressing different levels of the PKC1 gene indicated that phosphorylation of CTP synthetase was mediated by Pkc1p in vivo. In vitro, Pkc1p phosphorylated purified CTP synthetase on serine and threonine residues, which resulted in the activation (3-fold) of enzyme activity. The mechanism of this activation involved an increase in the apparent V-max of the reaction and an increase in the enzyme's affinity for ATP. In vitro phosphorylated CTP synthetase also exhibited a decrease in its positive cooperative kinetic behavior with respect to UTP and ATP. Phosphorylation of CTP synthetase did not have a significant effect on the kinetic properties of the enzyme with respect to glutamine and GTP, Phosphorylation of CTP synthetase resulted in a decrease in the enzyme's sensitivity to product inhibition by CTP. Phosphorylation did not affect the mechanism by which CTP inhibits CTP synthetase activity.	RUTGERS STATE UNIV, COOK COLL, NEW JERSEY AGR EXPT STN, DEPT FOOD SCI, NEW BRUNSWICK, NJ 08903 USA	Rutgers State University New Brunswick					NIGMS NIH HHS [GM-50679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON PM, 1983, BIOCHEMISTRY-US, V22, P3285, DOI 10.1021/bi00282a038; ANTONSSON B, 1994, J BIOL CHEM, V269, P16821; ARONOW B, 1984, J BIOL CHEM, V259, P9035; BELL RM, 1991, J BIOL CHEM, V266, P4661; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNER MF, 1992, TRENDS BIOCHEM SCI, V17, P66, DOI 10.1016/0968-0004(92)90504-3; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CHOCK PB, 1980, ANNU REV BIOCHEM, V49, P813, DOI 10.1146/annurev.bi.49.070180.004121; CHU EHY, 1984, BIOCHEM GENET, V22, P701, DOI 10.1007/BF00485854; CULBERTSON MR, 1975, GENETICS, V80, P23; DESAINTVINCENT BR, 1980, BIOCHIM BIOPHYS ACTA, V610, P352; EXTON JH, 1990, J BIOL CHEM, V265, P1; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; HAID A, 1983, METHOD ENZYMOL, V96, P192; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; KAIBUCHI K, 1985, J BIOL CHEM, V260, P1366; KAMEMOTO ES, 1986, J BIOL CHEM, V261, P4346; KAUFMAN ER, 1986, MUTAT RES, V161, P19, DOI 10.1016/0027-5107(86)90096-5; KIZAKI H, 1980, CANCER RES, V40, P3921; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LEVITZKI A, 1969, P NATL ACAD SCI USA, V62, P1121, DOI 10.1073/pnas.62.4.1121; LEVITZKI A, 1971, BIOCHEMISTRY-US, V10, P3365, DOI 10.1021/bi00794a008; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P247, DOI 10.1021/bi00752a016; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P241, DOI 10.1021/bi00752a015; LEWIS DA, 1989, BIOCHEMISTRY-US, V28, P8454, DOI 10.1021/bi00447a027; LIEBERMAN I, 1956, J BIOL CHEM, V222, P765; LIN K, 1995, J BIOL CHEM, V270, P26833, DOI 10.1074/jbc.270.45.26833; LONG CW, 1967, J BIOL CHEM, V242, P4715; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MEUTH M, 1979, P NATL ACAD SCI USA, V76, P6505, DOI 10.1073/pnas.76.12.6505; MEUTH M, 1982, SOMAT CELL GENET, V8, P423, DOI 10.1007/BF01538705; NADKARNI AK, 1995, J BIOL CHEM, V270, P24982, DOI 10.1074/jbc.270.42.24982; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OZIERKALOGEROPOULOS O, 1991, MOL GEN GENET, V231, P7, DOI 10.1007/BF00293815; OZIERKALOGEROPOULOS O, 1994, MOL GEN GENET, V242, P431, DOI 10.1007/BF00281793; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; THOMAS PE, 1988, BIOCHIM BIOPHYS ACTA, V953, P334, DOI 10.1016/0167-4838(88)90042-8; TIPPLES G, 1995, J BIOL CHEM, V270, P7908, DOI 10.1074/jbc.270.14.7908; TRACH K, 1988, J BACTERIOL, V170, P4194, DOI 10.1128/jb.170.9.4194-4208.1988; TRUDEL M, 1984, J BIOL CHEM, V259, P2355; VANDENBERG AA, 1993, EUR J BIOCHEM, V216, P161; VONDERSAAL W, 1985, J BIOL CHEM, V260, P4993; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WATANABE M, 1994, J BIOL CHEM, V269, P16829; WEBER G, 1980, LIFE SCI, V27, P793, DOI 10.1016/0024-3205(80)90333-1; Weber G, 1978, Adv Enzyme Regul, V17, P1; WENG M, 1986, J BIOL CHEM, V261, P5568; WU WI, 1994, J BIOL CHEM, V269, P29495; YAMAUCHI M, 1990, EMBO J, V9, P2095, DOI 10.1002/j.1460-2075.1990.tb07377.x; YANG WL, 1994, BIOCHEMISTRY-US, V33, P10785, DOI 10.1021/bi00201a028; YANG WL, 1995, J BIOL CHEM, V270, P14983, DOI 10.1074/jbc.270.25.14983	60	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11113	11119		10.1074/jbc.271.19.11113	http://dx.doi.org/10.1074/jbc.271.19.11113			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626655	hybrid			2022-12-27	WOS:A1996UJ94400015
J	Bruck, I; Woodgate, R; McEntee, K; Goodman, MF				Bruck, I; Woodgate, R; McEntee, K; Goodman, MF			Purification of a soluble UmuD'C complex from Escherichia coli - Cooperative binding of UmuD'C to single-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECA PROTEIN; SOS MUTAGENESIS; POLYMERASE-III; CLEAVAGE; REPAIR; UMUC; GENE; UV; LEXA; OVERPRODUCTION	The Escherichia coli UmuD' and UmuC proteins play essential roles in SOS-induced mutagenesis, Previous studies investigating the molecular mechanisms of mutagenesis have been hindered by the lack of availability of a soluble UmuC protein, We report the extensive purification of a soluble UmuD'C complex and its interactions with DNA, The molecular mass of the complex is estimated to be 70 kDa, suggesting that the complex consists of one UmuC (46 kDa) and two UmuD' (12 kDa) molecules, In contrast to its inability to bind to double-stranded DNA, UmuD'C binds cooperatively to single-stranded DNA as measured by agarose gel electrophoresis and confirmed by steady-state fluorescence depolarization, A Hill coefficient, n = 3, characterizes the binding of UmuD'C to M13 DNA and to a 600 nucleotide DNA oligomer, suggesting that at least three protein complexes may interact cooperatively when binding to DNA, The apparent equilibrium binding constant of UmuD'C to single-stranded DNA is approximately 300 nM. Binding of the complex to a short, 80 nucleotide, DNA oligonucleotide was detectable by fluorescence depolarization, but it did not appear to be cooperative, Binding of UmuD'C to single stranded M13 DNA causes an acceleration of the protein-DNA complex, suggesting that the longer DNA may undergo compaction, The UmuD'C complex associates with RecA-coated DNA, and the UmuD'C complex remains bound to DNA in the presence of RecA.	NIH, SECT DNA REPLIACT REPAIR & MUTAGENESIS, BETHESDA, MD 20892 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	National Institutes of Health (NIH) - USA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Bruck, I (corresponding author), UNIV SO CALIF, DEPT BIOL SCI, HEDCO MOL BIOL LABS, LOS ANGELES, CA 90089 USA.			Woodgate, Roger/0000-0001-5581-4616	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021422, R01GM042554, R01GM021422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011398] Funding Source: NIH RePORTER; NIA NIH HHS [AG11398] Funding Source: Medline; NIGMS NIH HHS [GM42554, GM21422] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILONE A, 1991, BIOCHIMIE, V73, P479, DOI 10.1016/0300-9084(91)90115-H; BONNER CA, 1988, J BIOL CHEM, V263, P18946; BRIDGES BA, 1985, P NATL ACAD SCI USA, V82, P4193, DOI 10.1073/pnas.82.12.4193; BRIDGES BA, 1984, MOL GEN GENET, V196, P364, DOI 10.1007/BF00328073; BRIDGES BA, 1976, MOL GEN GENET, V144, P53, DOI 10.1007/BF00277304; BURCKHARDT SE, 1988, P NATL ACAD SCI USA, V85, P1811, DOI 10.1073/pnas.85.6.1811; CHABBERT M, 1987, BIOCHEMISTRY-US, V26, P2218, DOI 10.1021/bi00382a022; CHABBERT M, 1991, J BIOL CHEM, V266, P5395; ECHOLS H, 1990, MUTAT RES, V236, P301, DOI 10.1016/0921-8777(90)90013-U; FRANK EG, 1993, P NATL ACAD SCI USA, V90, P8169, DOI 10.1073/pnas.90.17.8169; FREITAG N, 1989, P NATL ACAD SCI USA, V86, P8363, DOI 10.1073/pnas.86.21.8363; FRIEDBERG EC, 1995, DNA REPAIR; HAGENSEE ME, 1987, P NATL ACAD SCI USA, V84, P4195, DOI 10.1073/pnas.84.12.4195; IWASAKI H, 1990, J BACTERIOL, V172, P6268, DOI 10.1128/jb.172.11.6268-6273.1990; KITAGAWA Y, 1985, P NATL ACAD SCI USA, V82, P4336, DOI 10.1073/pnas.82.13.4336; KOHWISHIGEMATSU T, 1978, P NATL ACAD SCI USA, V75, P4689, DOI 10.1073/pnas.75.10.4689; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P145; LAWRENCE CW, 1996, IN PRESS MOL GEN GEN; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; MARSH L, 1985, J BACTERIOL, V162, P155, DOI 10.1128/JB.162.1.155-161.1985; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MURLI S, 1993, CURR OPIN GENET DEV, V3, P719, DOI 10.1016/S0959-437X(05)80089-9; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; PERRY KL, 1985, P NATL ACAD SCI USA, V82, P4331, DOI 10.1073/pnas.82.13.4331; PETIT MA, 1994, J BIOL CHEM, V269, P23824; Radman M., 1975, MOL MECHANISMS REPAI, P355; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; ROSENBERG M, 1990, J BIOL CHEM, V265, P20641; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; SHINAGAWA H, 1988, P NATL ACAD SCI USA, V85, P1806, DOI 10.1073/pnas.85.6.1806; SILVER MS, 1982, BIOCHEMISTRY-US, V21, P6066, DOI 10.1021/bi00267a007; SOMMER S, 1993, MOL MICROBIOL, V10, P963, DOI 10.1111/j.1365-2958.1993.tb00968.x; SWEASY JB, 1990, J BACTERIOL, V172, P3030, DOI 10.1128/jb.172.6.3030-3036.1990; TESSMAN I, 1994, GENETICS, V136, P439; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WITKIN EM, 1976, BACTERIOL REV, V40, P869, DOI 10.1128/MMBR.40.4.869-907.1976; WOODGATE R, 1994, J BACTERIOL, V176, P5011, DOI 10.1128/jb.176.16.5011-5021.1994; WOODGATE R, 1991, MOL GEN GENET, V229, P10, DOI 10.1007/BF00264207; WOODGATE R, 1992, MOL MICROBIOL, V6, P2213, DOI 10.1111/j.1365-2958.1992.tb01397.x; WOODGATE R, 1989, P NATL ACAD SCI USA, V86, P7301, DOI 10.1073/pnas.86.19.7301; WOODGATE R, 1992, MUTAT RES, V281, P221, DOI 10.1016/0165-7992(92)90012-7; YUEN SW, 1989, BIOTECHNIQUES, V7, P74	47	95	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10767	10774		10.1074/jbc.271.18.10767	http://dx.doi.org/10.1074/jbc.271.18.10767			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631887				2022-12-27	WOS:A1996UJ34200055
J	Stephens, JM; Morrison, RF; Pilch, PF				Stephens, JM; Morrison, RF; Pilch, PF			The expression and regulation of STATs during 3T3-L1 adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; TRANSCRIPTIONAL REPRESSION; GENE-EXPRESSION; PREADIPOCYTES; COORDINATE; CELLS; GLUT4	STATs (Signal Transducers and Activators of Transcription) comprise a family of transcription factors that reside in the cytoplasm of resting cells, In response to a variety of stimuli, STATs become tyrosine-phosphorylated and translocate to the nucleus where they mediate transcriptional regulation, We have used the 3T3-L1 murine cell line to examine the expression of STAT proteins as a function of their differentiation into adipocytes, The expression of STATs 1, 3, and 5, but not of STAT 6, is markedly elevated in adipocytes as compared with their fibroblast precursors, Exposure of 3T3-L1 preadipocytes to tumor necrosis factor alpha (TNF alpha) blocks their differentiation into adipocytes, Therefore, we examined STAT expression as a function of differentiation in the presence of this cytokine, The expression of STATs 1 and 5 is markedly attenuated in the presence of TNF alpha, whereas STAT 3 expression is unaffected by this treatment, Only STAT 1 is down-regulated by TNF alpha in fully differentiated cells, Thus, although the expression of STATs 1, 3, and 5 is markedly enhanced upon differentiation, only STAT 5 expression is tightly correlated with the adipocyte phenotype, These data suggest that STAT 5, and possibly STAT 1, could be potential inducers of tissue-specific genes, which contribute to the development and maintenance of the adipocyte phenotype.	BOSTON UNIV,MED CTR,DEPT BIOCHEM,BOSTON,MA 02118	Boston University			Stephens, Jacqueline M/R-5217-2018	Pilch, Paul/0000-0003-1997-0499	NIDDK NIH HHS [DK44269, DK46200, DK30425] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200, R01DK030425, P01DK044269] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARAHMANDPOUR F, 1995, FEBS LETT, V360, P29, DOI 10.1016/0014-5793(95)00072-H; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; RODBELL M, 1964, J BIOL CHEM, V239, P375; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SMAS CM, 1995, BIOCHEM J, V309, P697, DOI 10.1042/bj3090697; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; STEPHENS JM, 1992, J BIOL CHEM, V267, P13580; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TORTI FM, 1989, J CELL BIOL, V108, P1105, DOI 10.1083/jcb.108.3.1105	21	98	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10441	10444		10.1074/jbc.271.18.10441	http://dx.doi.org/10.1074/jbc.271.18.10441			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631837	Green Published, hybrid			2022-12-27	WOS:A1996UJ34200005
J	EllisDavies, GCR; Kleyman, TR; Kaplan, JH				EllisDavies, GCR; Kleyman, TR; Kaplan, JH			Photolabile amiloride derivatives as cation site probes of the Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; OCCLUDED STATE; CDNA SEQUENCE; SODIUM-PUMP; BINDING; KIDNEY; OCCLUSION; CELLS; (NA+; (NA+,K+)-ATPASE	Treatment of purified canine renal Na,K-ATPase with a range of photoactivatable amiloride derivatives results in inhibition of ATPase activity prior to illumination. Inhibition by amiloride derivatives substituted on a guanidium N could not be prevented by the presence of either K or Na; however, these cations could protect the enzyme against inhibition by derivatives substituted on the 5-position of the pyrazine ring. In the case of 5-(N-ethyl-[2'-methoxy-4'-nitrobenzyl])amiloride (NENMBA), the presence of monovalent cations (Na, K, and Rb) protected the enzyme effectively against inhibition, with concentrations in the millimolar range. ATP did not prevent inhibition; furthermore, native and NENMBA-treated enzyme exhibited normal levels of high affinity [H-3]ADP (and hence ATP) binding. The rate of inhibition increased with increasing concentrations of NENMBA. Extensive washing of NENMBA-inhibited enzyme did not restore ATPase activity, showing that NENMBA has an extremely slow off-rate for dissociation from its inhibitory site. Partially inhibited enzyme could be rapidly pelleted and resuspended in NENMBA-free buffer and inhibition was observed to continue, albeit at a somewhat diminished rate, suggesting that NENMBA gains access to its inhibitory site after partitioning into the lipid phase rather than directly from the aqueous solution. Photolysis of NENMBA inhibited enzyme resulted in covalent incorporation of the reagent into the ar-subunit of the Na,K-ATPase, as observed by separation of labeled protein on a Laemmli gel and Western analysis using a polyclonal amiloride antibody. Almost all of the covalent labeling could be prevented by the presence of Rb in the incubation and labeling medium. These results suggest that NENMBA inhibits the Na,K-ATPase by disruption of the cation transport domain rather than the catalytic domain of the enzyme and that it promises to be a useful tool for cation site localization.	OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA; UNIV PENN, DEPT MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA; VET ADM MED CTR, PHILADELPHIA, PA 19104 USA	Oregon Health & Science University; University of Pennsylvania; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Kaplan, Jack/0000-0002-7048-6574	NIGMS NIH HHS [GM39500] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039500] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMLER E, 1988, BIOCHIM BIOPHYS ACTA, V945, P367, DOI 10.1016/0005-2736(88)90499-3; ARGUELLO JM, 1991, J BIOL CHEM, V266, P14627; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; BAXTERLOWE LA, 1989, FEBS LETT, V257, P181, DOI 10.1016/0014-5793(89)81816-2; BROTHERUS JR, 1981, BIOCHEM BIOPH RES CO, V100, P146, DOI 10.1016/S0006-291X(81)80075-7; DAVID P, 1993, BIOCHIM BIOPHYS ACTA, V1146, P59, DOI 10.1016/0005-2736(93)90338-Z; ELLISDAVIES GCR, 1990, J BIOL CHEM, V265, P20570; ELLISDAVIES GCR, 1993, BIOPHYS J, V64, pA332; FORBUSH B, 1987, J BIOL CHEM, V262, P11104; FORBUSH B, 1988, J BIOL CHEM, V263, P7979; GARVIN JL, 1985, J MEMBRANE BIOL, V87, P45, DOI 10.1007/BF01870698; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1985, J PHYSIOL-LONDON, V368, P453, DOI 10.1113/jphysiol.1985.sp015868; GLYNN IM, 1982, J PHYSIOL-LONDON, V330, P17, DOI 10.1113/jphysiol.1982.sp014326; JELENC PC, 1978, P NATL ACAD SCI USA, V75, P3564, DOI 10.1073/pnas.75.8.3564; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; KAPLAN JH, 1985, ANNU REV PHYSIOL, V47, P535, DOI 10.1146/annurev.ph.47.030185.002535; KAPLAN JH, 1989, RED BLOOD CELL MEMBR, P455; KAWAKAMI K, 1986, J BIOCHEM-TOKYO, V100, P389, DOI 10.1093/oxfordjournals.jbchem.a121726; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KLEYMAN TR, 1989, AM J PHYSIOL, V257, pC1135, DOI 10.1152/ajpcell.1989.257.6.C1135; KLEYMAN TR, 1989, J BIOL CHEM, V264, P11995; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; KRONENBERG ME, 1966, RECL TRAV CHIM PAY-B, V85, P56; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOVITZ RM, 1989, EMBO J, V8, P193, DOI 10.1002/j.1460-2075.1989.tb03364.x; LIANG SM, 1976, BIOCHIM BIOPHYS ACTA, V452, P552, DOI 10.1016/0005-2744(76)90207-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERCER RW, 1986, MOL CELL BIOL, V6, P3884, DOI 10.1128/MCB.6.11.3884; OR E, 1993, J BIOL CHEM, V268, P16929; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PEDEMONTE CH, 1986, J BIOL CHEM, V261, P3632; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; PEDEMONTE CH, 1986, J BIOL CHEM, V261, P6660; ROBINSON JD, 1985, FEBS LETT, V24, P6783; SCHONER W, 1969, FEBS LETT, V5, P285, DOI 10.1016/0014-5793(69)80369-8; SHANISEKLER M, 1988, J BIOL CHEM, V263, P19331; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SOLTOFF SP, 1983, SCIENCE, V220, P957, DOI 10.1126/science.6302840; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; VERREY F, 1989, AM J PHYSIOL, V256, pF1034, DOI 10.1152/ajprenal.1989.256.6.F1034; YAMAGUCHI M, 1983, CURR TOP MEMBR TRANS, V19, P203; ZHUANG YX, 1984, BIOCHEMISTRY-US, V23, P4481, DOI 10.1021/bi00314a038	44	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10353	10358		10.1074/jbc.271.17.10353	http://dx.doi.org/10.1074/jbc.271.17.10353			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626606	hybrid			2022-12-27	WOS:A1996UG25700078
J	Yang, X; Goncalves, J; Gabuzda, D				Yang, X; Goncalves, J; Gabuzda, D			Phosphorylation of Vif and its role in HIV-1 replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN-KINASE-C; GAG GENE-PRODUCTS; REV PROTEIN; ANTIRETROVIRAL ACTIVITY; INFECTED-CELLS; DNA-SYNTHESIS; VPU-PROTEIN; CEM CELLS; SOR GENE	Vif is a 23-kDa protein encoded by human immunodeficiency virus, type 1 (HIV-1) which is important for virion infectivity. Here, we describe the phosphorylation of HIV-1 Vif and its role in HIV-1 replication. In vivo studies demonstrated that Vif is highly phosphorylated on serine and threonine residues. To identify phosphorylation sites and characterize the Vif kinase(s), Vif was expressed in Escherichia coli and purified for use as a substrate in in vitro kinase assays. The purified Vif protein was phosphorylated in vitro on serine and threonine residues by a kinase(s) present in both cytosol and membrane fractions. Phosphorylation of Vif was stimulated by phorbol 12-myristate 13-acetate and inhibited by staurosporine and hypericin, a drug with potent anti-HIV activity. The Vif kinase(s) was resistant to inhibitors of protein kinase C, cAMP-dependent kinase, and cGMP-dependent kinase, suggesting that it is distinct from these enzymes. To identify the phosphorylation sites, P-32-labeled Vif was digested by V8 protease and the peptides were resolved by reverse-phase high performance liquid chromatography. Radioactive peptide sequencing identified three phosphorylation sites within the C terminus, Ser(144), Thr(155), and Thr(188). Two-dimensional tryptic phosphopeptide mapping indicated that these sites are also phosphorylated in vivo. Both Ser(144) and Thr(188) are contained in the recognition motifs (R/KXXS*/T* and R/KXXXS*/T*) used by serine/threonine protein kinases such as cGMP-dependent kinase and PKC. Ser(144) is present in the motif SLQXLA, which is the most highly conserved sequence among all lentivirus Vif proteins. Mutation of Ser(144) to alanine resulted in loss of Vif activity and >90% inhibition of HIV-1 replication. These studies suggest that phosphorylation of Vif by a serine/threonine protein kinase(s) plays an important role in regulating HIV-1 replication and infectivity.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DIV HUMAN RETROVIROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			iMed.ULisboa, M2B/B-5277-2014; Goncalves, Joao/B-2013-2008	iMed.ULisboa, M2B/0000-0002-1245-3715; Goncalves, Joao/0000-0002-1245-3715	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI033837, R01AI036186, P30AI028691] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36186, AI33837, AI28691] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANDRES JC, 1994, VIROLOGY, V201, P157, DOI 10.1006/viro.1994.1278; BLANC D, 1993, VIROLOGY, V193, P186, DOI 10.1006/viro.1993.1114; BORMAN AM, 1995, J VIROL, V69, P2058, DOI 10.1128/JVI.69.4.2058-2067.1995; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURNETTE B, 1993, J BIOL CHEM, V268, P8698; COCHRANE A, 1989, VIROLOGY, V171, P264, DOI 10.1016/0042-6822(89)90535-7; COCHRANE AW, 1989, VIROLOGY, V173, P335, DOI 10.1016/0042-6822(89)90252-3; COCHRANE AW, 1989, J VIROL, V63, P4438, DOI 10.1128/JVI.63.10.4438-4440.1989; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COURCOUL M, 1995, J VIROL, V69, P2068, DOI 10.1128/JVI.69.4.2068-2074.1995; DEGAR S, 1992, AIDS RES HUM RETROV, V8, P1929, DOI 10.1089/aid.1992.8.1929; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; FORD CE, 1994, J BIOL CHEM, V269, P30378; FRIBORG J, 1995, J ACQ IMMUN DEF SYND, V8, P10; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; GONCALVES J, 1995, J VIROL, V69, P7196, DOI 10.1128/JVI.69.11.7196-7204.1995; GONCALVES J, 1994, J VIROL, V68, P704, DOI 10.1128/JVI.68.2.704-712.1994; GUY B, 1991, J VIROL, V65, P1325, DOI 10.1128/JVI.65.3.1325-1331.1991; GUY B, 1990, VIROLOGY, V176, P413, DOI 10.1016/0042-6822(90)90011-F; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HAUBER J, 1988, J VIROL, V62, P4801, DOI 10.1128/JVI.62.12.4801-4804.1988; HAYASHI H, 1993, J BIOL CHEM, V268, P7107; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; HERRMANN CH, 1993, VIROLOGY, V197, P601, DOI 10.1006/viro.1993.1634; HOGLUND S, 1994, VIROLOGY, V201, P349, DOI 10.1006/viro.1994.1300; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAURENT AG, 1990, J GEN VIROL, V71, P2273, DOI 10.1099/0022-1317-71-10-2273; LAVIE G, 1989, P NATL ACAD SCI USA, V86, P5963, DOI 10.1073/pnas.86.15.5963; LENARD J, 1993, P NATL ACAD SCI USA, V90, P158, DOI 10.1073/pnas.90.1.158; LIU HM, 1995, J VIROL, V69, P7630, DOI 10.1128/JVI.69.12.7630-7638.1995; MERUELO D, 1988, P NATL ACAD SCI USA, V85, P5230, DOI 10.1073/pnas.85.14.5230; MERVIS RJ, 1988, J VIROL, V62, P3993, DOI 10.1128/JVI.62.11.3993-4002.1988; MICHAELS FH, 1993, AIDS RES HUM RETROV, V9, P1025, DOI 10.1089/aid.1993.9.1025; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; MYERS G, 1988, HUMAN RETROVIRUSES A; OBERSTE MS, 1992, VIRUS GENES, V6, P95, DOI 10.1007/BF01703760; OVERTON HA, 1989, VIROLOGY, V170, P107, DOI 10.1016/0042-6822(89)90357-7; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; SAKAI H, 1993, J VIROL, V67, P1663, DOI 10.1128/JVI.67.3.1663-1666.1993; SAWAI ET, 1994, P NATL ACAD SCI USA, V91, P1539, DOI 10.1073/pnas.91.4.1539; SCHUBERT U, 1992, EUR J BIOCHEM, V204, P875, DOI 10.1111/j.1432-1033.1992.tb16707.x; SIMM M, 1995, J VIROL, V69, P4582, DOI 10.1128/JVI.69.7.4582-4586.1995; SOVA P, 1993, J VIROL, V67, P6322, DOI 10.1128/JVI.67.10.6322-6326.1993; STREBEL K, 1989, J VIROL, V63, P3784, DOI 10.1128/JVI.63.9.3784-3791.1989; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; TAKAHASHI I, 1989, BIOCHEM BIOPH RES CO, V165, P1207, DOI 10.1016/0006-291X(89)92730-7; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; VERONESE FD, 1988, J VIROL, V62, P795, DOI 10.1128/JVI.62.3.795-801.1988; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; WETTENHALL REH, 1991, METHOD ENZYMOL, V201, P186; YU G, 1995, J BIOL CHEM, V270, P4792, DOI 10.1074/jbc.270.9.4792	55	97	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10121	10129		10.1074/jbc.271.17.10121	http://dx.doi.org/10.1074/jbc.271.17.10121			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626571	hybrid			2022-12-27	WOS:A1996UG25700043
J	Grahame, DA; DeMoll, E				Grahame, DA; DeMoll, E			Partial reactions catalyzed by protein components of the acetyl-CoA decarbonylase synthase enzyme complex from Methanosarcina barkeri	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE DEHYDROGENASE; METHANOTHRIX-SOEHNGENII; CLOSTRIDIUM-THERMOACETICUM; COENZYME-A; PURIFICATION; CLEAVAGE; THERMOPHILA; CENTERS	In methanogens, the acetyl-CoA decarbonylase synthase (ACDS) complex, which has five different subunits, catalyzes synthesis and cleavage of acetyl-CoA according to the reaction: CO2 + 2H(+) + 2e(-) + CH3-H4SPt + CoA reversible arrow acetyl-CoA + H4SPt + H2O, where H4SPt and CH3-H4SPt are tetrahydrosarcinapterin and N-5-methyl-tetrahydrosarcinapterin, respectively. We have dissociated the ACDS complex into three protein components by limited proteolytic digestion, Catalysis of acetyl-CoA synthesis was lost in parallel with the loss of the intact beta subunit; however, no decrease in activity was detected in any of three partial reactions found to be catalyzed by distinct protein components of the proteolyzed ACDS complex: (a) CO dehydrogenase, catalyzed by the alpha epsilon component, (b) CH3-H(4)pteridine:cob(I)amide-protein methyltransferase, catalyzed by the intact gamma subunit and fragments of the delta subunit, and (c) acetyltransferase, catalyzed by a truncated form of the beta subunit. The results indicated that the beta subunit is responsible for binding CoA and acetyl-CoA and suggested that acetylenzyme formation occurs on the beta subunit. A value of 5.5 x [H+](-1) M(-1) was determined for the equilibrium constant of the following reaction at pH 7.5 and 25 degrees C: CH3-H4SPt + cob(I)amide-protein + H+ reversible arrow H4SPt + CH3-cob(III)amide-protein.	UNIV KENTUCKY,ALBERT B CHANDLER MED CTR,DEPT MICROBIOL & IMMUNOL,LEXINGTON,KY 40536	University of Kentucky	Grahame, DA (corresponding author), UNIFORMED SERV UNIV HLTH SCI,DEPT BIOCHEM,BETHESDA,MD 20814, USA.							ABBANAT DR, 1991, P NATL ACAD SCI USA, V88, P3272, DOI 10.1073/pnas.88.8.3272; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEMOLL E, 1987, J BACTERIOL, V169, P3916, DOI 10.1128/jb.169.9.3916-3920.1987; EGGEN RIL, 1991, J BIOL CHEM, V266, P6883; GRAHAME DA, 1995, BIOCHEMISTRY-US, V34, P4617, DOI 10.1021/bi00014a015; GRAHAME DA, 1991, J BIOL CHEM, V266, P22227; GRAHAME DA, 1987, J BIOL CHEM, V262, P3706; GRAHAME DA, 1993, BIOCHEMISTRY-US, V32, P10786, DOI 10.1021/bi00091a033; HU SI, 1984, J BIOL CHEM, V259, P8892; JETTEN MSM, 1989, EUR J BIOCHEM, V181, P437, DOI 10.1111/j.1432-1033.1989.tb14744.x; JETTEN MSM, 1991, EUR J BIOCHEM, V202, P1291, DOI 10.1111/j.1432-1033.1991.tb16502.x; JETTEN MSM, 1991, EUR J BIOCHEM, V195, P385, DOI 10.1111/j.1432-1033.1991.tb15717.x; KRZYCKI JA, 1984, J BACTERIOL, V158, P231, DOI 10.1128/JB.158.1.231-237.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU WP, 1991, J BIOL CHEM, V266, P3554; PEZACKA E, 1986, J BIOL CHEM, V261, P1609; RAYBUCK SA, 1991, J BACTERIOL, V173, P929, DOI 10.1128/jb.173.2.929-932.1991; ROBERTS DL, 1994, J BACTERIOL, V176, P6127, DOI 10.1128/jb.176.19.6127-6130.1994; TERLESKY KC, 1986, J BACTERIOL, V168, P1053, DOI 10.1128/jb.168.3.1053-1058.1986; VANBEELEN P, 1984, EUR J BIOCHEM, V139, P359	20	57	64	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8352	8358		10.1074/jbc.271.14.8352	http://dx.doi.org/10.1074/jbc.271.14.8352			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626532	hybrid			2022-12-27	WOS:A1996UD60000072
J	Lepier, A; Graf, R; Azuma, M; Merzendorfer, H; Harvey, WR; Wieczorek, H				Lepier, A; Graf, R; Azuma, M; Merzendorfer, H; Harvey, WR; Wieczorek, H			The peripheral complex of the tobacco hornworm V-ATPase contains a novel 13-kDa subunit G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; VESICLE PROTON PUMP; TRANSPORTING PLASMA-MEMBRANES; MANDUCA-SEXTA MIDGUT; SECONDARY-STRUCTURE; NEUROSPORA-CRASSA; RECONSTITUTION; PURIFICATION; PREDICTION; EXPRESSION	A prominent 16-kDa protein copurifies with the V-ATPase isolated from both posterior midgut and Malpighian tubules of Manduca sexta larvae and thus was believed to represent a V-ATPase subunit. [C-14]N,N'-dicyclohexylcarbodiimide labeling and its position on SDS-electrophoresis gels revealed that this protein was different from the 17-kDa proteolipid. A cDNA clone encoding a highly hydrophilic protein with a calculated molecular mass of 13,692 Da was obtained by immunoscreening. Monospecific antibodies, affinity-purified to the 13-kDa recombinant protein expressed in Escherichia coli, specifically recognized the 16-kDa protein of the purified V-ATPase, confirming that a cDNA encoding this protein had been cloned. In vitro translation of the cRNA showed that the cloned 13-kDa subunit behaved like a 16-kDa protein on SDS-electrophoresis gels. The cloned protein showed 37% amino acid sequence identity to the 13-kDa V-ATPase subunit Vma10p recently cloned from yeast and some similarity to subunit b of bacterial F-ATPases. In contrast to the Vma10p protein, which behaved like a V-0 subunit, the M. serta 13-kDa protein behaved like a V-1 subunit, since it could be stripped from the membrane by treatment with the chaotropic salt KI and by cold inactivation. When KI dissociated V-ATPase subunits were reassociated by dialysis that removed the KI, a soluble, 450-kDa complex of the M. serta V-ATPase could be purified by gel chromatography. This V-1 complex consisted of subunits A, B, E, and the 13-kDa subunit, confirming that the cloned protein is a new V-ATPase subunit and a member of the peripheral V-1 complex of the V-ATPase. We designate this new V-1 component subunit G.	UNIV MUNICH,INST ZOOL,D-80021 MUNICH,GERMANY; TEMPLE UNIV,DEPT BIOL,PHILADELPHIA,PA 19122	University of Munich; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			/AAU-6215-2020		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022444] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 22444] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI I, 1990, J BIOL CHEM, V265, P960; ARAI H, 1988, J BIOL CHEM, V263, P8796; AZUMA M, 1995, FEBS LETT, V361, P153, DOI 10.1016/0014-5793(95)00146-Z; BELL RA, 1976, ANN ENTOMOL SOC AM, V69, P365, DOI 10.1093/aesa/69.2.365; BERTRAM G, 1991, J INSECT PHYSIOL, V37, P201, DOI 10.1016/0022-1910(91)90070-G; Booth A G, 1974, Biochem J, V142, P575; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1986, P NATL ACAD SCI USA, V83, P48, DOI 10.1073/pnas.83.1.48; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DECKERSHEBESTREIT G, 1992, J EXP BIOL, V172, P451; DOW JAT, 1992, GENE, V122, P355, DOI 10.1016/0378-1119(92)90226-F; FINBOW ME, 1993, J CELL SCI, V106, P463; GIORDANA B, 1994, J EXP BIOL, V196, P145; GLUCK S, 1987, J BIOL CHEM, V262, P15780; GLUCK SL, 1992, J EXP BIOL, V172, P219; GRAF R, 1994, J BIOL CHEM, V269, P3767; GRAF R, 1992, FEBS LETT, V300, P119, DOI 10.1016/0014-5793(92)80177-I; GRAF R, 1994, BBA-BIOMEMBRANES, V1190, P193, DOI 10.1016/0005-2736(94)90053-1; GRAF R, 1995, P GER ZOOL SOC, P103; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; GUO Y, 1996, IN PRESS GENE AMST; HARDY S, 1991, EUR J BIOCHEM, V202, P431, DOI 10.1111/j.1432-1033.1991.tb16392.x; HARVEY WR, 1992, J EXP BIOL, V172, P1; KATAYAMA C, 1990, STRATEGIES MOL BIOL, V4, P56; KLEIN U, 1991, J EXP BIOL, V161, P61; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUMHOLZ LR, 1989, NUCLEIC ACIDS RES, V17, P7993, DOI 10.1093/nar/17.19.7993; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEPIER A, 1994, J EXP BIOL, V196, P361; LION T, 1990, ANAL BIOCHEM, V188, P335, DOI 10.1016/0003-2697(90)90616-H; MARTIN FG, 1994, J EXP BIOL, V196, P77; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON N, 1992, J EXP BIOL, V172, P19; NICOLSON SW, 1993, J INSECT PHYSIOL, V39, P451, DOI 10.1016/0022-1910(93)90076-4; NISHIKAWA K, 1983, BIOCHIM BIOPHYS ACTA, V748, P285, DOI 10.1016/0167-4838(83)90306-0; NOEL J, 1993, BIOCHEM CELL BIOL, V71, P390, DOI 10.1139/o93-057; NOVAK FJS, 1992, BIOCHIM BIOPHYS ACTA, V1132, P67, DOI 10.1016/0167-4781(92)90053-3; ONKEN H, 1995, J EXP BIOL, V198, P767; PEREZCASTINEIRA JR, 1990, BIOCHEM J, V271, P127, DOI 10.1042/bj2710127; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; REA PA, 1987, BIOCHIM BIOPHYS ACTA, V904, P1, DOI 10.1016/0005-2736(87)90080-0; RUSSELL VEW, 1992, J EXP BIOL, V166, P131; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEIKL H, 1989, J BIOL CHEM, V264, P11136; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; VANKERKHOVE E, 1994, BELG J ZOOL, V124, P73; WARD JM, 1992, PLANT PHYSIOL, V99, P925, DOI 10.1104/pp.99.3.925; WIECZOREK H, 1991, J BIOL CHEM, V266, P15340; WIECZOREK H, 1992, J EXP BIOL, V172, P335; WIECZOREK H, 1986, BIOCHIM BIOPHYS ACTA, V857, P271, DOI 10.1016/0005-2736(86)90356-1; WIECZOREK H, 1990, METHOD ENZYMOL, V192, P608; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; XIE XS, 1988, J BIOL CHEM, V263, P9859	56	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8502	8508		10.1074/jbc.271.14.8502	http://dx.doi.org/10.1074/jbc.271.14.8502			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626552	hybrid			2022-12-27	WOS:A1996UD60000092
J	Blake, DJ; Nawrotzki, R; Peters, MF; Froehner, SC; Davies, KE				Blake, DJ; Nawrotzki, R; Peters, MF; Froehner, SC; Davies, KE			Isoform diversity of dystrobrevin, the murine 87-kDa postsynaptic protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-RELATED PROTEIN; ACETYLCHOLINE-RECEPTOR; SKELETAL-MUSCLE; TERMINAL DOMAIN; ELECTRIC TISSUE; ALPHA-ACTININ; AGRIN; TORPEDO; MEMBRANE; BINDING	Dystrophin-related and -associated proteins are important in the formation and maintenance of the mammalian neuromuscular junction. We have characterized mouse cDNA clones encoding isoforms of the dystrophin-homologous 87-kDa postsynaptic protein, dystrobrevin. In Torpedo, the 87-kDa protein is multiply phosphorylated and closely associated with proteins in the postsynaptic cytoskeleton, including the acetylcholine receptor. In contrast to Torpedo, where only a single transcript is seen, the mouse expresses several mRNAs encoding different isoforms. A 6.0-kilobase transcript in brain encodes a 78-kDa protein (dystrobrevin-1) that is very similar to the Torpedo sequence. A second transcript encodes a 59-kDa protein (dystrobrevin-2) that has a different C terminus, lacking the putative tyrosine kinase substrate domain. In skeletal and cardiac muscle, transcripts of 1.7 and 3.3/3.5 kilobases predominate and encode additional isoforms. Alternative splicing within the coding region and differential usage of untranslated regions produce additional variation. Multiple dystrobrevin-immunoreactive proteins copurify with syntrophin from mouse tissues. In skeletal muscle, dystrobrevin immunoreactivity is restricted to the neuromuscular junction and sarcolemma. The occurrence of many dystrobrevin isoforms is significant because alternative splicing and phosphorylation often have profound effects upon the biological activity of synaptic proteins.	JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC GENET GRP,OXFORD OX3 9DU,ENGLAND; UNIV N CAROLINA,DEPT PHYSIOL,CHAPEL HILL,NC 27599	University of Oxford; University of North Carolina; University of North Carolina Chapel Hill								ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1994, P NATL ACAD SCI USA, V91, P4446, DOI 10.1073/pnas.91.10.4446; AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; BEWICK GS, 1992, NEUROREPORT, V3, P857, DOI 10.1097/00001756-199210000-00009; Blake Derek J., 1992, Human Molecular Genetics, V1, P103, DOI 10.1093/hmg/1.2.103; BLAKE DJ, 1995, TRENDS BIOCHEM SCI, V20, P133, DOI 10.1016/S0968-0004(00)88986-0; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BUTLER MH, 1992, J BIOL CHEM, V267, P6213; BYERS TJ, 1991, J CELL BIOL, V115, P411, DOI 10.1083/jcb.115.2.411; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CARR C, 1989, J CELL BIOL, V109, P1753, DOI 10.1083/jcb.109.4.1753; CHANG HW, 1989, J BIOL CHEM, V264, P20831; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DWYER TM, 1995, FEBS LETT, V375, P91, DOI 10.1016/0014-5793(95)01176-F; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; HOCH W, 1993, NEURON, V11, P479, DOI 10.1016/0896-6273(93)90152-H; KRAMARCY NR, 1994, J BIOL CHEM, V269, P2870; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; NASTUK MA, 1991, NEURON, V7, P807, DOI 10.1016/0896-6273(91)90283-6; Nguyen T M, 1991, J Cell Biol, V115, P1695, DOI 10.1083/jcb.115.6.1695; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; PETERS MF, 1994, NEUROREPORT, V5, P1577, DOI 10.1097/00001756-199408150-00009; PHILLIPS WD, 1993, J CELL BIOL, V123, P729, DOI 10.1083/jcb.123.3.729; SEALOCK R, 1991, J CELL BIOL, V113, P1133, DOI 10.1083/jcb.113.5.1133; SHADIACK AM, 1991, J NEUROBIOL, V22, P617, DOI 10.1002/neu.480220607; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; SUZUKI A, 1992, FEBS LETT, V308, P154, DOI 10.1016/0014-5793(92)81265-N; SUZUKI A, 1995, J CELL BIOL, V128, P373, DOI 10.1083/jcb.128.3.373; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; TIMMUSK T, 1995, J CELL BIOL, V128, P185, DOI 10.1083/jcb.128.1.185; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; WAGNER KR, 1994, J NEUROCHEM, V62, P1947; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WALLACE BG, 1995, J CELL BIOL, V128, P1121, DOI 10.1083/jcb.128.6.1121; WALLACE BG, 1989, J NEUROSCI, V9, P1294; WAY M, 1992, FEBS LETT, V301, P243, DOI 10.1016/0014-5793(92)80249-G; YANG B, 1994, J BIOL CHEM, V269, P6040; YANG B, 1995, J BIOL CHEM, V270, P4975, DOI 10.1074/jbc.270.10.4975; YEADON JE, 1991, J CELL BIOL, V115, P1069, DOI 10.1083/jcb.115.4.1069; YOSHIDA M, 1995, FEBS LETT, V367, P311, DOI 10.1016/0014-5793(95)00574-S; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	51	145	146	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7802	7810		10.1074/jbc.271.13.7802	http://dx.doi.org/10.1074/jbc.271.13.7802			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631824	hybrid, Green Published			2022-12-27	WOS:A1996UC77400092
J	Ladner, RD; McNulty, DE; Carr, SA; Roberts, GD; Caradonna, SJ				Ladner, RD; McNulty, DE; Carr, SA; Roberts, GD; Caradonna, SJ			Characterization of distinct nuclear and mitochondrial forms of human deoxyuridine triphosphate nucleotidohydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URACIL-DNA GLYCOSYLASE; MASS-SPECTROMETRY; DUTP NUCLEOTIDOHYDROLASE; POLYACRYLAMIDE GELS; CELLS; INHIBITION; SEQUENCE; PROTEINS; ENZYME; PYROPHOSPHATASE	Deoxyuridine triphosphate nucleotidohydrolase (dUTPase; EC 3.6.1.23) was purified from HeLa cells by immunoaffinity chromatography. Based on SDS-polyacrylamide gel electrophoresis, two distinct forms of dUTPase were evident in the purified preparation. These proteins were further characterized by a combination of NH2-terminal protein sequencing, mass spectrometry, and mass spectrometry-based protein sequencing. These analyses indicate that the two forms of dUTPase are largely identical, differing only in a short region of their amino-terminal sequences. Despite the structural difference, both forms of dUTPase exhibited identical binding characteristics for dUTP. Each form of dUTPase has a distinct cellular localization. Cellular fractionation and isopycnic density centrifugation indicate that the lower molecular weight form of dUTPase (DUT-N) is associated with the nucleus, while the higher molecular weight species (DUT-M) fractionates with the mitochondria. The DUT-N isoform is approximately 30-fold more abundant in HeLa cells than DUT-M as determined by densitometry. The NH2-terminal protein sequence of both DUT-N and DUT-M did not match previous reports of the predicted amino-terminal sequence for human dUTPase (McIntosh, E. M., Ager, D. D., Gadsden, M. H., and Haynes, R. H. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 8020-8024; Strahler, J. R., Zhu X., Hora, N., Wang, Y. K., Andrews, P. C., Roseman, N. A., Neel, J. V., Turka, L., and Hanash, S. M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 4991-4995). A cDNA corresponding to the DUT-N isoform was isolated utilizing an oligonucleotide probe based on the determined NH2-terminal sequence. The cDNA contains a 164-amino acid open reading frame, encoding a protein of M(r) 17,748. The DUT-N cDNA sequence matches the previously cloned cDNAs with the exception of a few discrepancies in the 5' end. Our data indicate a 69-base pair addition to the 5' end of the previously reported open reading frame.	SMITHKLINE BEECHAM PHARMACEUT,DEPT PROT BIOCHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PHYS & STRUCT CHEM,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline	Ladner, RD (corresponding author), UNIV MED & DENT NEW JERSEY,SCH OSTEOPATH MED,DEPT BIOL MOLEC,2 MED CTR DR,STRATFORD,NJ 08084, USA.		Caradonna, Salvatore/AFU-8514-2022; Carr, Steven A./AAH-8366-2019	Caradonna, Salvatore/0000-0002-2104-581X; 	NCI NIH HHS [CA42605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042605] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; BILLECI TM, 1993, ANAL CHEM, V65, P1709, DOI 10.1021/ac00061a013; Bradbury NE, 1936, PHYS REV, V49, P0388, DOI 10.1103/PhysRev.49.388; BROYLES SS, 1993, VIROLOGY, V195, P863, DOI 10.1006/viro.1993.1446; CANMAN CE, 1994, CANCER RES, V54, P2296; CANMAN CE, 1992, P NATL ACAD SCI USA, V89, P10474, DOI 10.1073/pnas.89.21.10474; CARADONNA SJ, 1981, J BIOL CHEM, V256, P9834; CARADONNA SJ, 1984, J BIOL CHEM, V259, P5459; CARR SA, 1995, P 43 ASMS C MASS SPE, P620; CEDERGRENZEPPEZAUER ES, 1992, NATURE, V355, P740, DOI 10.1038/355740a0; CLAYTON DA, 1992, INT REV CYTOL, V141, P217, DOI 10.1016/S0074-7696(08)62067-7; CLIMIE S, 1994, PROTEIN EXPRES PURIF, V5, P252, DOI 10.1006/prep.1994.1038; CRAVATH AM, 1929, PHYS REV, V34, P605; CURTIN NJ, 1991, CANCER RES, V51, P2346; Darley-Usmar V.M., 1987, MITOCHONDRIA PRACTIC, P4; DELLANEGRA S, 1985, ANAL CHEM, V57, P2035, DOI 10.1021/ac00288a007; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOMENA JD, 1985, BIOCHEMISTRY-US, V24, P7320, DOI 10.1021/bi00346a045; ELDER JH, 1992, J VIROL, V66, P1791, DOI 10.1128/JVI.66.3.1791-1794.1992; ELHAJJ HH, 1988, J BACTERIOL, V170, P1069, DOI 10.1128/jb.170.3.1069-1075.1988; FISHER FB, 1986, VIROLOGY, V148, P190, DOI 10.1016/0042-6822(86)90414-9; FORD TC, 1991, INTRO CENTRIFUGATION, P79; GADSDEN MH, 1993, EMBO J, V12, P4425, DOI 10.1002/j.1460-2075.1993.tb06127.x; Harlow E., 1988, ANTIBODIES LAB MANUA; HEMLING ME, 1995, P 43 ASMS C MASS SPE, P492; INGRAHAM HA, 1986, BIOCHEMISTRY-US, V25, P3225, DOI 10.1021/bi00359a022; KAUFMANN R, 1994, INT J MASS SPECTROM, V131, P355, DOI 10.1016/0168-1176(93)03876-N; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; Ladner RD, 1996, J BIOL CHEM, V271, P7752, DOI 10.1074/jbc.271.13.7752; LICHTENSTEIN DL, 1995, J VIROL, V69, P2881, DOI 10.1128/JVI.69.5.2881-2888.1995; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LIRETTE R, 1990, J CELL BIOCHEM, V43, P339, DOI 10.1002/jcb.240430406; MCGEOCH DJ, 1990, NUCLEIC ACIDS RES, V18, P4105, DOI 10.1093/nar/18.14.4105; MCINTOSH EM, 1992, P NATL ACAD SCI USA, V89, P8020, DOI 10.1073/pnas.89.17.8020; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; PYLES RB, 1992, J VIROL, V66, P6706, DOI 10.1128/JVI.66.11.6706-6713.1992; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; ROISE D, 1988, J BIOL CHEM, V263, P4509; Sambrook J., 2002, MOL CLONING LAB MANU; SEDWICK WD, 1981, P NATL ACAD SCI-BIOL, V78, P917, DOI 10.1073/pnas.78.2.917; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SPENGLER B, 1992, J PHYS CHEM-US, V96, P9678, DOI 10.1021/j100203a022; STRAHLER JR, 1993, P NATL ACAD SCI USA, V90, P4991, DOI 10.1073/pnas.90.11.4991; TANG XJ, 1988, ANAL CHEM, V60, P1791, DOI 10.1021/ac00168a029; THREADGILL DS, 1993, J VIROL, V67, P2592, DOI 10.1128/JVI.67.5.2592-2600.1993; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YASUI A, 1992, MUTAT RES, V273, P231, DOI 10.1016/0921-8777(92)90084-G; YU W, 1993, ANAL CHEM, V65, P3015, DOI 10.1021/ac00069a014	48	69	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7745	7751		10.1074/jbc.271.13.7745	http://dx.doi.org/10.1074/jbc.271.13.7745			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631816				2022-12-27	WOS:A1996UC77400084
J	Orita, S; Sasaki, T; Komuro, R; Sakaguchi, G; Maeda, M; Igarashi, H; Takai, Y				Orita, S; Sasaki, T; Komuro, R; Sakaguchi, G; Maeda, M; Igarashi, H; Takai, Y			Doc2 enhances Ca2+-dependent exocytosis from PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; NEUROTRANSMITTER RELEASE; SYNAPTOTAGMIN P65; EXPRESSION; KINASE; TISSUE; DIACYLGLYCEROL; RABPHILIN-3A; ACTIVATION; MESSENGER	We previously isolated a new protein having two C2-like domains which interacted with Ca2+ and phospholipid and named Doc2 (Double C2). Because Doc2 was abundantly expressed in brain where it was highly concentrated on the synaptic vesicle fraction, we have examined here whether Doc2 is involved in Ca2+-dependent exocytosis from cultured PC12 cells. For this purpose, we took advantage of the growth hormone (GH) co-expression assay system of PC12 cells in which GH is stored in dense core vesicles and released in response to high K+ in an extracellular Ca2+-dependent manner. Northern and Western blot analyses indicated that Doc2 is present in PC12 cells. Overexpression of hemagglutinin-tagged Doc2 stimulated the Ca2+-dependent, high K+-induced release of co-expressed GH without affecting the basal release. in the PC12 cells transfected with a plasmid with the coding sequence of Doc2 in the antisense orientation, the high K+-induced release of co-expressed GH was inversely inhibited. The Doc2 mutant expressing an N-terminal fragment or a C-terminal fragment containing two C2-like domains inhibited the high K+-induced release of co-expressed GH. These results indicate that Doc2 enhances Ca2+-dependent exocytosis of dense core vesicles from PC12 cells.	OSAKA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,SUITA,OSAKA 565,JAPAN; SHIONOGI INST MED SCI,SETTSU 566,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Osaka University; Shionogi & Company Limited; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)								AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BORSE N, 1992, SCIENCE, V256, P1021; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GODA Y, 1994, P NATL ACAD SCI USA, V91, P12942, DOI 10.1073/pnas.91.26.12942; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LITTLETON JT, 1995, TRENDS NEUROSCI, V18, P177; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MIZOGUCHI A, 1989, BIOCHEM BIOPH RES CO, V162, P1438, DOI 10.1016/0006-291X(89)90835-8; MIZOGUCHI A, 1994, BIOCHEM BIOPH RES CO, V202, P1236; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; ORITA S, 1995, BIOCHEM BIOPH RES CO, V206, P439, DOI 10.1006/bbrc.1995.1062; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P360; Sambrook J., 2002, MOL CLONING LAB MANU; SANO K, 1989, BIOCHEM BIOPH RES CO, V158, P377, DOI 10.1016/S0006-291X(89)80058-0; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; SCHWEITZER ES, 1985, J CELL BIOL, V101, P667, DOI 10.1083/jcb.101.2.667; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1994, J BIOL CHEM, V269, P32717; SHIRATAKI H, 1992, J BIOL CHEM, V267, P12096; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TAKAI Y, 1979, BIOCHEM BIOPH RES CO, V91, P1218, DOI 10.1016/0006-291X(79)91197-5; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WICK PF, 1993, J BIOL CHEM, V268, P10983; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	39	76	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7257	7260		10.1074/jbc.271.13.7257	http://dx.doi.org/10.1074/jbc.271.13.7257			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631736	hybrid			2022-12-27	WOS:A1996UC77400004
J	vanMeijer, M; Roelofs, Y; Neels, J; Horrevoets, AJG; vanZonneveld, AJ; Pannekoek, H				vanMeijer, M; Roelofs, Y; Neels, J; Horrevoets, AJG; vanZonneveld, AJ; Pannekoek, H			Selective screening of a large phage display library of plasminogen activator inhibitor 1 mutants to localize interaction sites with either thrombin or the variable region 1 of tissue-type plasminogen activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-THROMBIN; UROKINASE-TYPE; REACTIVE SITE; VITRONECTIN; HEPARIN; SPECIFICITY; MUTAGENESIS; KINETICS; PAI-1	Phage display technology has been exploited to study in detail the interaction between plasminogen activator inhibitor 1 (PAI-1) and either thrombin or an essential positively charged ''loop'' of tissue-type plasminogen activator (t-PA), denoted variable region 1 (VR1). For this purpose, a PAI-1 mutant phage library was used that served as a reservoir of PAI-1 proteins potentially deficient in the interaction with either VR1 or thrombin. A stringent two-step selection procedure was developed. (i) A negative selection was performed by incubating the pComb3/PAI-1 mutant library with an excess of a thrombin mutant with its VR1 domain substituted with that of t-PA (thrombin-VR1). (ii) The remaining phages were complexed with t-PA (positive selection) and selected by panning with an immobilized anti-t-PA monoclonal antibody. Four consecutive panning rounds yielded an enrichment of pComb3/PAI-1 mutant phages of similar to 50-fold. Sequence analysis of 16 different cDNAs, encoding PAI-1 mutants that are hampered in the binding to thrombin-VR1, revealed the following mutations. Four independent variants share a mutation of the P4' residue (Glu(350) --> Lys). Nine independent PAI-1 variants share a substitution of P1' (Met(347) --> Lys), whereas three others share a P2 substitution (Ala(345) --> Asp). Kinetic analysis of representative PAI-1 mutants provides evidence that the P4' residue is essential for the interaction with the VR1 domain, consistent with the data of Madison et al. (Madison, E. L., Goldsmith, E. J., Gething, M. J., Sambrook, J. F., and Gerard, R. D. (1990) J. Biol. Chem. 265, 21423-21426), whereas the P1' and P2 residues confer thrombin specificity. Concordant with the design of the selection procedure, mutants were obtained that inhibit thrombin-VR1 at least 100-fold slower than wild-type PAI-1, identifying residues that are central to the interaction with either thrombin or VR1. This study demonstrates that phage technology can be used to analyze large numbers of mutants defective in their interaction with other (domains of) proteins, provided an adequate selection scheme is devised.	UNIV AMSTERDAM,ACAD MED CTR,DEPT BIOCHEM K1159,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam			van Zonneveld, Anton Jan/D-8060-2018; Neels, Jaap G/F-5534-2010	van Zonneveld, Anton Jan/0000-0002-1676-7738; Neels, Jaap G/0000-0002-5900-8395				BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; EHRLICH HJ, 1992, J BIOL CHEM, V267, P11606; EHRLICH HJ, 1991, BIOCHEMISTRY-US, V30, P1021, DOI 10.1021/bi00218a020; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; HORREVOETS AJG, 1993, J BIOL CHEM, V268, P779; KEIJER J, 1991, BLOOD, V78, P401; KEIJER J, 1991, BLOOD, V78, P1254; KRUITHOF EKO, 1984, BLOOD, V64, P907; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; NASKI MC, 1993, J BIOL CHEM, V268, P12367; PADMANABHAN J, 1995, THROMB HAEMOSTASIS, V73, P829; PANNEKOEK H, 1993, GENE, V128, P135, DOI 10.1016/0378-1119(93)90164-X; SANCHO E, 1994, EUR J BIOCHEM, V224, P125, DOI 10.1111/j.1432-1033.1994.tb20003.x; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SHERMAN PM, 1995, J BIOL CHEM, V270, P9301, DOI 10.1074/jbc.270.16.9301; THORSEN S, 1988, EUR J BIOCHEM, V175, P33, DOI 10.1111/j.1432-1033.1988.tb14162.x; VANMEIJER M, 1994, FEBS LETT, V352, P342, DOI 10.1016/0014-5793(94)00990-2; VANMEIJER M, 1995, FIBRINOLYSIS, V9, P263, DOI 10.1016/S0268-9499(95)80015-8; VANZONNEVELD AJ, 1987, THROMB HAEMOSTASIS, V57, P82; YORK JD, 1991, J BIOL CHEM, V266, P8495	24	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7423	7428		10.1074/jbc.271.13.7423	http://dx.doi.org/10.1074/jbc.271.13.7423			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631768	hybrid			2022-12-27	WOS:A1996UC77400036
J	Berlett, BS; Levine, RL; Stadtman, ER				Berlett, BS; Levine, RL; Stadtman, ER			Comparison of the effects of ozone on the modification of amino acid residues in glutamine synthetase and bovine serum albumin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; METAL-CATALYZED OXIDATION; HYDROXYL RADICALS; PROTEINS; DEGRADATION; DAMAGE; WATER; DERIVATIZATION; INACTIVATION; OZONATION	During exposure to ozone, the methionine and aromatic amino acid residues of Escherichia coli glutamine synthetase (GS) and bovine serum albumin (BSA) are oxidized rapidly in the order Met > Trp > Tyr approximate to His > Phe. The loss of His is matched by a nearly equivalent formation of aspartate or of a derivative that is converted to aspartic acid upon acid hydrolysis. Conversion of His to aspartate was confirmed by showing that the oxidation of E. coli protein in which all His residues were uniformly labeled with C-14 gave rise to C-14-labeled aspartic acid in 80% yield and also by the demonstration that His residues in the tripeptides Ala-His-Ala or Ala-Ala-His gave rise to nearly stoichiometric amounts of aspartic acid whereas oxidation of His-Ala-Ala yielded only 36% aspartate. The oxidation of BSA and GS led to formation, respectively, of 11 and 3.3 eq of carbonyl groups and 0.5 and 0.3 eq of quinoprotein per subunit. Although BSA and GS contain nearly identical amounts of each kind of aromatic amino acid residues, oxidation of these residues in BSA was about 1.5-2.0 times faster than in GS indicating that the susceptibility to oxidation is dependent on the primary, secondary, tertiary, and quaternary structure of the protein.	NHLBI,BIOCHEM LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Levine, Rodney L/D-9885-2011					ALMASSY RJ, 1986, NATURE, V323, P304, DOI 10.1038/323304a0; AMICI A, 1989, J BIOL CHEM, V264, P3341; ASWAD DW, 1984, ANAL BIOCHEM, V137, P405, DOI 10.1016/0003-2697(84)90106-4; BADA JL, 1984, METHOD ENZYMOL, V106, P98; BADER H, 1981, WATER RES, V15, P449, DOI 10.1016/0043-1354(81)90054-3; BRINKMAN R, 1958, NATURE, V181, P504; BUELL GC, 1965, ARCH ENVIRON HEALTH, V10, P213, DOI 10.1080/00039896.1965.10663986; CARTER DC, 1989, SCIENCE, V244, P1195, DOI 10.1126/science.2727704; CROSS CE, 1992, FREE RADICAL RES COM, V15, P347, DOI 10.3109/10715769209049150; CURRAN SF, 1984, FEBS LETT, V176, P155, DOI 10.1016/0014-5793(84)80931-X; DAVIES KJA, 1987, J BIOL CHEM, V262, P9908; FARBER JM, 1986, J BIOL CHEM, V261, P4574; FREEMAN BA, 1981, ARCH BIOCHEM BIOPHYS, V208, P212, DOI 10.1016/0003-9861(81)90142-9; GARRISON WARREN M., 1968, CURR TOP RADIAT RES, VVol. 4-4, P43; GARRISON WM, 1962, RADIAT RES, V16, P483, DOI 10.2307/3571084; HOIGNE J, 1975, SCIENCE, V190, P782, DOI 10.1126/science.190.4216.782; KANOFSKY JR, 1991, J BIOL CHEM, V266, P9039; KELLY FJ, 1992, FREE RADICAL BIO MED, V14, P443; KNIGHT KL, 1984, ARCH BIOCHEM BIOPHYS, V229, P259, DOI 10.1016/0003-9861(84)90152-8; KURODA M, 1975, J BIOCHEM-TOKYO, V78, P641, DOI 10.1093/oxfordjournals.jbchem.a130951; LAGERWERFF JM, 1963, AEROSPACE MED, V34, P479; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; LEVINE RL, 1982, J CHROMATOGR, V236, P499; LEVINE RL, 1983, J BIOL CHEM, V258, P1823; MEHLMAN MA, 1987, ENVIRON RES, V42, P36, DOI 10.1016/S0013-9351(87)80005-1; MEINERS BA, 1977, ENVIRON RES, V14, P99, DOI 10.1016/0013-9351(77)90072-X; Menzel DB, 1976, FREE RADICALS BIOLOG, P181; MILLER RE, 1974, ARCH BIOCHEM BIOPHYS, V163, P155, DOI 10.1016/0003-9861(74)90465-2; MUDD JB, 1969, ATMOS ENVIRON, V3, P669, DOI 10.1016/0004-6981(69)90024-9; PAZ MA, 1991, J BIOL CHEM, V266, P689; PRYOR WA, 1992, FREE RADICAL BIO MED, V12, P83, DOI 10.1016/0891-5849(92)90060-T; PRYOR WA, 1984, J AM CHEM SOC, V106, P7094, DOI 10.1021/ja00335a038; PRYOR WA, 1994, FREE RADICAL BIO MED, V17, P451, DOI 10.1016/0891-5849(94)90172-4; PRYOR WA, 1994, FREE RADICAL BIO MED, V17, P11451; RAHMAN IU, 1992, FREE RADICAL BIO MED, V12, P323, DOI 10.1016/0891-5849(92)90119-2; RIVETT AJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P26, DOI 10.1016/0003-9861(90)90226-O; SCHUSTER R, 1988, J CHROMATOGR-BIOMED, V431, P271, DOI 10.1016/S0378-4347(00)83096-0; SHINRIKI N, 1984, CHEM PHARM BULL, V32, P3636; SHINRIKI N, 1981, BIOCHIM BIOPHYS ACTA, V655, P323, DOI 10.1016/0005-2787(81)90041-1; SMITH CE, 1987, ARCH BIOCHEM BIOPHYS, V253, P146, DOI 10.1016/0003-9861(87)90647-3; STADTMAN ER, 1979, ANAL BIOCHEM, V95, P275, DOI 10.1016/0003-2697(79)90217-3; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; STOKINGER HE, 1965, ARCH ENVIRON HEALTH, V10, P719, DOI 10.1080/00039896.1965.10664082; UCHIDA K, 1989, BIOORG CHEM, V17, P330, DOI 10.1016/0045-2068(89)90035-7; VANDERZEE J, 1987, BIOCHEM J, V242, P707, DOI 10.1042/bj2420707; WHITESIDE C, 1988, FREE RADICAL BIO MED, V5, P305, DOI 10.1016/0891-5849(88)90101-3; WITZ G, 1983, ADV MOD ENV TOXICOL, V5, P263	47	101	108	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4177	4182		10.1074/jbc.271.8.4177	http://dx.doi.org/10.1074/jbc.271.8.4177			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626759	hybrid			2022-12-27	WOS:A1996TW96000037
J	Coombs, GS; Dang, AT; Madison, EL; Corey, DR				Coombs, GS; Dang, AT; Madison, EL; Corey, DR			Distinct mechanisms contribute to stringent substrate specificity of tissue-type plasminogen activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPSIN; SELECTION; KINETICS; PEPTIDE; SITES	Tissue-type plasminogen activator (t-PA) has evolved to optimize cleavage of plasminogen (Pig) while minimizing cleavage of other potential protein and peptide substrates. We find that the S2 and S2' subsites of t-PA are important determinants of specificity, and occupancy of the S3 subsite is essential for catalysis. t-PA efficiently hydrolyzes a protein substrate which incorporates an optimized substrate sequence, revealing the ability of the protease to participate in the highly selective cleavage of protein fusions. Surprisingly, t-PA cleaves this engineered protein substrate with a K-m that is reduced 950-fold relative to the K-m for hydrolysis of the same target sequence within a peptide. This reduction of K-m suggests that binding is facilitated by interactions between protein substrate and protease that are distant from the P4-P2' residues. We use this kinetic data to derive a model in which several distinct mechanisms contribute to the remarkable specificity of t-PA.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	Scripps Research Institute; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Coombs, Gary/0000-0002-0711-185X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, R01HL052475] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL31950, R01 HL52475] Funding Source: Medline; CSAP SAMHSA HHS [SP32GM08287] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); CSAP SAMHSA HHS		BAUER CA, 1981, EUR J BIOCHEM, V120, P289, DOI 10.1111/j.1432-1033.1981.tb05702.x; COREY DR, 1995, BIOCHEMISTRY-US, V34, P11521, DOI 10.1021/bi00036a027; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; EVNIN LB, 1990, P NATL ACAD SCI USA, V87, P6659, DOI 10.1073/pnas.87.17.6659; FIEDLER F, 1987, EUR J BIOCHEM, V163, P303, DOI 10.1111/j.1432-1033.1987.tb10801.x; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; HUBBARD SJ, 1991, J MOL BIOL, V220, P507, DOI 10.1016/0022-2836(91)90027-4; HUBBARD SJ, 1994, PROTEIN SCI, V3, P757; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; KITAMOTO Y, 1994, P NATL ACAD SCI USA, V91, P7588, DOI 10.1073/pnas.91.16.7588; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MADISON EL, 1994, FIBRINOLYSIS, V8, P221, DOI 10.1016/0268-9499(94)90720-X; MADISON EL, 1995, J BIOL CHEM, V270, P7558, DOI 10.1074/jbc.270.13.7558; MCGRATH ME, 1995, PROTEIN SCI, V4, P141; NOVOTNY J, 1987, FEBS LETT, V211, P185, DOI 10.1016/0014-5793(87)81433-3; OSTERMAN A, 1994, BIOCHEMISTRY-US, V33, P13662, DOI 10.1021/bi00250a016; RUHLMANN A, 1973, J MOL BIOL, V77, P417, DOI 10.1016/0022-2836(73)90448-8; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHELLENBERGER V, 1993, BIOCHEMISTRY-US, V32, P4349, DOI 10.1021/bi00067a026; SCHELLENBERGER V, 1994, BIOCHEMISTRY-US, V33, P4251, DOI 10.1021/bi00180a020; Taylor J. R., 1982, INTRO ERROR ANAL STU; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001	22	43	50	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4461	4467						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626799				2022-12-27	WOS:A1996TW96000077
J	Endo, T; Mitsui, S; Nakai, M; Roise, D				Endo, T; Mitsui, S; Nakai, M; Roise, D			Binding of mitochondrial presequences to yeast cytosolic heat shock protein 70 depends on the amphiphilicity of the presequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEINS; PEPTIDE-BINDING; IMPORT; TRANSLOCATION; SPECIFICITY; POLYPEPTIDE; KINETICS; GROEL; BIP	The interactions between a yeast cytosolic hsp70, Ssa1p, and various synthetic peptides, including mitochondrial presequences, have been studied, The interactions were monitored both indirectly, by measuring the effects of the presequences on the ATPase activity and oligomeric state of the enzyme, and directly, by measuring the increased steady-state fluorescence polarization of fluorescent derivatives of the presequences as they bind to Ssa1p, The presequences are all able to convert Ssa1p from an oligomeric to a monomeric form in a concentration-dependent manner. The presequences are also able to stimulate the ATPase activity of the enzyme at similar concentrations, Quantification of the binding by fluorescence polarization showed that the affinity for Ssa1p is directly related to the physical properties of the presequences. The most amphiphilic presequences, as measured by retention times on reversed-phase high pressure liquid chromatography or surface activity in lipid monolayers, had the highest affinity for Ssa1p, The least amphiphilic presequences, which had previously been shown to be ineffective as mitochondrial targeting sequences, had relatively low affinity for Ssa1p, The results show that Ssa1p interacts with a broad range of amino acid sequences and that the strength of these interactions is related to the physical properties of the sequence, That the physical properties recognized by Ssa1p are identical to those necessary for the targeting function of mitochondrial presequences suggests that Ssa1p may interact with mitochondrial precursor proteins in the cytosol, The interactions may serve a variety of purposes: the maintenance of precursors in translocation-competent forms, the prevention of improper association of precursors with non-mitochondrial membranes, and the delivery of precursors to the mitochondrial surface.	NAGOYA UNIV,FAC SCI,DEPT CHEM,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN; UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093	Nagoya University; University of California System; University of California San Diego								ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ENDO T, 1995, FEBS LETT, V359, P93, DOI 10.1016/0014-5793(95)00015-2; FISHER WR, 1973, J BIOL CHEM, V248, P3188; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; HAMADA D, 1993, BIOCHEMISTRY-US, V32, P10351, DOI 10.1021/bi00090a010; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P125; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; MURAKAMI K, 1990, EMBO J, V9, P3201, DOI 10.1002/j.1460-2075.1990.tb07518.x; MURAKAMI K, 1992, J BIOL CHEM, V267, P13119; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; ROISE D, 1992, P NATL ACAD SCI USA, V89, P608, DOI 10.1073/pnas.89.2.608; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SWANSON ST, 1992, BIOCHEMISTRY-US, V31, P5746, DOI 10.1021/bi00140a009	26	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4161	4167						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626757				2022-12-27	WOS:A1996TW96000035
J	CassarMalek, I; Marchal, S; Rochard, P; Casas, F; Wrutniak, C; Samarut, J; Cabello, G				CassarMalek, I; Marchal, S; Rochard, P; Casas, F; Wrutniak, C; Samarut, J; Cabello, G			Induction of c-Erb A-AP-1 interactions and c-Erb A transcriptional activity in myoblasts by RXR - Consequences for muscle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTORS; RETINOIC ACID RECEPTORS; DNA-BINDING; RESPONSE ELEMENT; X-RECEPTOR; AUXILIARY PROTEIN; DIRECT REPEAT; V-ERBA; GENE; JUN	We have previously shown that c-Erb A and v-Erb A display a cell-specific activity in avian myoblasts. In this work, we have compared the molecular basis of thyroid hormone action in HeLa cells and in QM7 myoblasts. The transcriptional activity of c-Erb A alpha 1 through a palindromic thyroid hormone response element (TRE) was similar in both cell types. However, c-Erb A did not activate gene transcription through a direct repeat sequence (DR) 4 TRE in myoblasts in contrast to results obtained in HeLa cells. Moreover, whereas retinoic acid receptor-AP-1 interactions were functional in both cell types, thyroid hormone receptor (T3R)-AP-1 interactions were only functional in HeLa cells. Using electrophoretic mobility shift assays, functional tests, and Northern blot experiments, we observed that RXR isoforms are not expressed in proliferating myoblasts. Expression of RXR gamma in these cells did not influence T3R transcriptional activity through a palindromic TRE but induced such an activity through a DR4 TRE. Moreover, it restored c-Erb A-AP-1 functionality in QM7 myoblasts and enhanced the myogenic influence of T3. We also observed that c-Jun overexpression in proliferating QM7 cells restored T3R transcriptional activity through a DR4 TRE. Therefore, alternative mechanisms are involved in the induction of T3R transcriptional activity according to the cell status (proliferation: c-Jun; differentiation: RXR). In addition we provide the first evidence that RXR is required to allow inhibition of AP-1 activity by ligand-activated T3R. Lastly, we demonstrate the importance of RXR in the regulation of myoblast differentiation by T3.	INRA,UNITE ENDOCRINOL CELLULAIRE,LAB DIFFERENCIAT CELLULAIRE & CROISSANCE,F-34060 MONTPELLIER 01,FRANCE; ECOLE NORMALE SUPER LYON,LAB BIOL MOL & CELLULAIRE,CNRS,UMR 40,INRA,F-69364 LYON,FRANCE	INRAE; INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet			Samarut, Jacques/AAD-2587-2019; , Cassar-Malek/AAW-6386-2020	, Cassar-Malek/0000-0001-7407-1408; Francois, Casas/0000-0002-5535-8195				ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERRODIN TJ, 1992, MOL ENDOCRINOL, V6, P1468, DOI 10.1210/me.6.9.1468; BOGAZZI F, 1994, J BIOL CHEM, V269, P11683; CASSARMALEK I, 1994, ONCOGENE, V9, P2197; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DOWNES M, 1994, ENDOCRINOLOGY, V134, P2658, DOI 10.1210/en.134.6.2658; DOWNES M, 1993, CELL GROWTH DIFFER, V4, P901; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GRAUPNER G, 1989, NATURE, V340, P654; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KADOWAKI Y, 1992, BIOCHEM BIOPH RES CO, V183, P492, DOI 10.1016/0006-291X(92)90509-J; KELLER H, 1993, TRENDS ENDOCRIN MET, V4, P291, DOI 10.1016/1043-2760(93)90048-J; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LUTZ B, 1994, DEVELOPMENT, V120, P25, DOI 10.1242/dev.120.1.25; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MARCHAL S, 1993, BIOL CELL, V78, P191, DOI 10.1016/0248-4900(93)90129-3; MARCHAL S, 1995, EXP CELL RES, V220, P1, DOI 10.1006/excr.1995.1285; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MUSCAT GEO, 1994, NUCLEIC ACIDS RES, V22, P583, DOI 10.1093/nar/22.4.583; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; PARK K, 1992, J BIOL CHEM, V267, P10810; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PIEDRAFITA FJ, 1995, MOL ENDOCRINOL, V9, P563, DOI 10.1210/me.9.5.563; RASCLE A, 1994, ONCOGENE, V9, P2853; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROWE A, 1991, DEVELOPMENT, V111, P771; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SCHMIDT EDL, 1993, BIOCHEM BIOPH RES CO, V192, P151, DOI 10.1006/bbrc.1993.1394; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; SELEIRO EAP, 1995, ROUX ARCH DEV BIOL, V204, P244, DOI 10.1007/BF00208491; SNEDECOR GW, 1961, STAT METHODS, P534; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YEN PM, 1992, J BIOL CHEM, V267, P3565; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	52	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11392	11399		10.1074/jbc.271.19.11392	http://dx.doi.org/10.1074/jbc.271.19.11392			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626694				2022-12-27	WOS:A1996UJ94400054
J	Jones, MD; Narhi, LO; Chang, WC; Lu, HS				Jones, MD; Narhi, LO; Chang, WC; Lu, HS			Refolding and oxidation of recombinant human stem cell factor produced in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; CONDITIONED MEDIUM; RAT; IDENTIFICATION; PURIFICATION; PROTEINS; BPTI	Oxidative folding of recombinant human stem cell factor (rhSCF) produced in Escherichia coli was investigated in vitro. Folding of denatured and reduced rhSCF involves at least five intermediate forms, I-1 to I-5, detectable by their differences in hydrophobicity using reverse-phase high performance liquid chromatography. Both I-1 and I-2 contain a native-like disulfide bond, Cys(4)-Cys(89) and Cys(43)-Cys(138), respectively, and I-3 forms a mispaired disulfide, Cys(43)-Cys89. These forms appear to reach steady state equilibrium and are important folding intermediates. I-1 was found to be the prominent intermediate that directly folds into native rhSCF (N); and the thermodynamically less stable I-2 favors rearrangment into I-1. I-3 may serve as an intermediate for disulfide rearrangement between I-1 and I-2, I-4 and I-5, which are disulfide-linked dimers, are in equilibrium with reduced rhSCF and other intermediates and may not play an important role in rhSCF folding. Both trifluoroacetic acid-trapped I-1 and I-2, after isolation by high performance liquid chromatography, proceed with the remaining oxidative folding process after reconstitution. Iodoacetate-trapped I-1 and I-2 contain low alpha-helical content and some tertiary structure, while I-3 and reduced rhSCF have little ordered structure. Gel filtration/light-scattering experiments indicate that reduced rhSCF and iodoacetate-trapped I-1, I-2, and I-3 exist as dimeric forms, indicating that rhSCF dimerization precedes formation of disulfide bonds. I-I, I-2, I-3, and the C43,138A analog lacking Cys(43)-Cys(138) bond are not biologically active or exhibit significantly lower activity. The two disulfide bonds in rhSCF seem to be essential for the molecule to maintain an active conformation required for its receptor binding and biological activities.	AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320	Amgen				Jones, Michael/0000-0001-7541-7634				ARAKAWA T, 1991, J BIOL CHEM, V266, P18942; CHANG JY, 1993, J BIOL CHEM, V268, P4043; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CREIGHTON TE, 1993, J MOL BIOL, V232, P1176, DOI 10.1006/jmbi.1993.1470; CREIGHTON TE, 1991, SCIENCE, V156, P111; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; JONES MD, 1994, ANAL BIOCHEM, V216, P135, DOI 10.1006/abio.1994.1017; KATO A, 1992, BIOCHIM BIOPHYS ACTA, V1159, P22, DOI 10.1016/0167-4838(92)90070-T; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLEY KE, 1994, ARCH BIOCHEM BIOPHYS, V311, P55, DOI 10.1006/abbi.1994.1208; LANGLEY KE, 1992, ARCH BIOCHEM BIOPHYS, V295, P21, DOI 10.1016/0003-9861(92)90482-C; LU HS, 1995, BIOCHEM J, V305, P563, DOI 10.1042/bj3050563; Lu HS, 1996, J BIOL CHEM, V271, P11309, DOI 10.1074/jbc.271.19.11309; LU HS, 1992, ARCH BIOCHEM BIOPHYS, V298, P150, DOI 10.1016/0003-9861(92)90106-7; LU HS, 1991, J BIOL CHEM, V266, P8102; LU HS, 1992, J BIOL CHEM, V267, P8770; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MUI PW, 1985, BIOCHEMISTRY-US, V24, P4481, DOI 10.1021/bi00337a033; SMITH KA, 1992, CURRENT PROTOCOLS IM; TAKAGI T, 1990, J CHROMATOGR, V280, P409; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; ZHANG JX, 1993, BIOCHEMISTRY-US, V32, P14075, DOI 10.1021/bi00214a001; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	25	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11301	11308		10.1074/jbc.271.19.11301	http://dx.doi.org/10.1074/jbc.271.19.11301			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626682	Green Published, hybrid			2022-12-27	WOS:A1996UJ94400042
J	Kobayashi, H; Gotoh, J; Hirashima, Y; Terao, T				Kobayashi, H; Gotoh, J; Hirashima, Y; Terao, T			Inter-alpha-trypsin inhibitor bound to tumor cells is cleaved into the heavy chains and the light chain on the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE DERMAL FIBROBLASTS; HYALURONIC-ACID; AFFINITY-CHROMATOGRAPHY; EXTRACELLULAR-MATRIX; LIMITED PROTEOLYSIS; SERUM; PROTEIN; PROLIFERATION; COMPLEX; FAMILY	Inter-alpha-trypsin inhibitor (ITI), a human serum protease inhibitor of molecular mass 240 kDa which may release physiological derivatives, has been shown to interact with hyaluronic acid (HA), resulting in pericellular matrix stabilization (Chen, L., Mao, S. J. T., McLean, L. R., Powers, R. W., and Larsen, W. J. (1994) J. Biol. Chem. 269, 28282-28287). The purpose of this study is to determine whether ITI binding to tumor cell surface is mediated by urinary trypsin inhibitor (UTI) receptor or cell-associated hyaluronic acid (HA). We demonstrated specific complex formation of the heavy (H) chains of ITI with HA. Binding of the H-chains of ITI to immobilized HA was detected and quantified using colorimetric immunoassays, Binding was time-, temperature-, and concentration-dependent. However, UTI and HI-8 (the carboxyl terminus of UTI) failed to bind to immobilized HA. ITI bound to RA remained functional protease inhibiting activity. After incubation of SMT-cc1 cells with purified biotinylated ITI, biotinylated ITI is bound to the cells, dissociated, and gives rise to the H-chains and UTl on the cell surface. The cell surface receptor-bound UTI derived from ITI may be the result of the limited proteolysis on the cell surface. In the cells treated with hyaluronidase, bound H-chains disappeared from the surface of the cells, while most of the cell surface ITI derivatives was present in deglycosylated UTI (28 kDa). It is suggested that the binding of ITI to the cell surface Is mediated by HA on the cells. This was confirmed by the fact that the hyaluronidase-treated cells can abolish the ITI binding. The cell surface UTI formation was inhibited by diisopropyl fluorophosphate, phenylmethylsulfonyl fluoride, and eglin C, suggesting that elastase-like enzyme(s) may be responsible for the UTI formation. Preincubation of the cells with UTI did not decrease in exogenously added ITI on the cell surface. A model for cell surface UTI formation is proposed in which ITI binding to cells hom serum used for the culture is followed by the limited proteolysis by trace amounts of active serine proteases, to form cell-surface receptor-bound UTI and the H-chains intercalated into cell surface HA. This process is subject to regulation of cell-associated UTI and of stabilization of pericellular matrix.			Kobayashi, H (corresponding author), HAMAMATSU UNIV SCH MED, DEPT OBSTET & GYNECOL, HANDACHO 3600, HAMAMATSU, SHIZUOKA 43131, JAPAN.							AUBRY M, 1976, BIOCHIM BIOPHYS ACTA, V438, P221, DOI 10.1016/0005-2744(76)90238-2; BALDUYCK M, 1993, BIOL CHEM H-S, V374, P895, DOI 10.1515/bchm3.1993.374.7-12.895; BOURGUIGNON J, 1989, BIOCHEM J, V261, P305, DOI 10.1042/bj2610305; CAMAIONI A, 1993, J BIOL CHEM, V268, P20473; CHAPMAN HA, 1990, AM J PHYSIOL, V259, pL432, DOI 10.1152/ajplung.1990.259.6.L432; CHEN L, 1992, J BIOL CHEM, V267, P12380; CHEN L, 1994, J BIOL CHEM, V269, P28282; FENDERSON BA, 1993, DIFFERENTIATION, V54, P85; GUESDON JL, 1979, J HISTOCHEM CYTOCHEM, V27, P1131, DOI 10.1177/27.8.90074; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HOCHSTRASSER K, 1981, H-S Z PHYSIOL CHEM, V362, P1357, DOI 10.1515/bchm2.1981.362.2.1357; HOCHSTRASSER K, 1989, HOPPESEYLERS Z PHYSL, V370, P1689; HUANG L, 1993, J BIOL CHEM, V268, P26725; ITOH H, 1994, J BIOL CHEM, V269, P3818; KOBAYASHI H, 1995, CANCER RES, V55, P1847; KOBAYASHI H, 1994, J BIOL CHEM, V269, P20642; KOBAYASHI H, 1994, CLIN EXP METASTAS, V12, P117, DOI 10.1007/BF01753978; KOBAYASHI H, 1994, CANCER RES, V54, P844; KOBAYASHI H, 1994, INT J CANCER, V57, P378, DOI 10.1002/ijc.2910570315; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; MAEDA M, 1987, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V39, P256; MAEHARA K, 1995, BIOCHEM BIOPH RES CO, V206, P927, DOI 10.1006/bbrc.1995.1131; PERKINS SJ, 1992, BIOCHEM J, V285, P263, DOI 10.1042/bj2850263; PRATT CW, 1987, BIOCHEMISTRY-US, V26, P2855, DOI 10.1021/bi00384a029; SALIER JP, 1980, ANAL BIOCHEM, V109, P273, DOI 10.1016/0003-2697(80)90649-1; SALIER JP, 1990, TRENDS BIOCHEM SCI, V15, P435, DOI 10.1016/0968-0004(90)90282-G; SJOBERG EM, 1992, ARCH BIOCHEM BIOPHYS, V295, P217, DOI 10.1016/0003-9861(92)90509-U; TENGBLAD A, 1979, BIOCHIM BIOPHYS ACTA, V578, P281, DOI 10.1016/0005-2795(79)90158-2; VETR H, 1990, BIOL CHEM H-S, V371, P1185, DOI 10.1515/bchm3.1990.371.2.1185; WACHTER E, 1981, H-S Z PHYSIOL CHEM, V362, P1351, DOI 10.1515/bchm2.1981.362.2.1351; YONEDA M, 1988, J CELL SCI, V90, P265; YONEDA M, 1990, J BIOL CHEM, V265, P5247; YONEDA M, 1988, J CELL SCI, V90, P275; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657	34	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11362	11367		10.1074/jbc.271.19.11362	http://dx.doi.org/10.1074/jbc.271.19.11362			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626690	hybrid			2022-12-27	WOS:A1996UJ94400050
J	Kandasamy, RA; Orlowski, J				Kandasamy, RA; Orlowski, J			Genomic organization and glucocorticoid transcriptional activation of the rat Na+/H+ exchanger Nhe3 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL EPITHELIAL-CELLS; PROTEIN-KINASE-C; NA/H ANTIPORTER ACTIVITY; PROXIMAL TUBULE CELLS; BRUSH-BORDER MEMBRANE; DNA-BINDING; MOLECULAR-CLONING; RESPONSE ELEMENTS; H+ EXCHANGE; METABOLIC-ACIDOSIS	The activity of the apical membrane Na+/H+ exchanger NHE3 isoform of renal or intestinal epithelial cells is chronically regulated by a wide variety of stimuli, including acidosis, cAMP, glucocorticoids, and thyroid hormone, To understand the molecular mechanisms responsible for long term regulation of this cation transporter, we have isolated and determined the structure of this gene from a rat genomic library. The Nhe3 gene spans >40 kilobases and contains 17 exons that are flanked by typical splice donor and acceptor sequences at the exon-intron boundaries. The transcription initiation site was mapped by S1 nuclease protection analyses of mRNA from rat kidney and intestine, Multiple start sites were clustered between nucleotides -100 and -96 relative to the translation initiation codon, An atypical TATA-box and CCAAT-box are centered 30 and 147 nucleotides, respectively, upstream of the predominant transcription initiation site, Sequence analysis of approximately 1.4 kilobases of the 5'-flanking promoter region also revealed the presence of other putative cis-acting elements recognized by various transcription factors (e.g. AP-1, AP-2, C/EBP, NF-I, OCT-1/OTF-1, PEA3, Spl, glucocorticoid, and thyroid hormone receptors), some of which may participate in the chronic regulation of this gene, The glucocorticoid responsiveness of the Nhe3 gene was assessed by fusing its 5' regulatory region to the firefly luciferase reporter gene and then by measuring the expression of the chimeric gene in transiently transfected renal epithelial OK and LLC-PK1 cells, Glucocorticoid treatment significantly increased the luciferase activity of the chimeric gene in both cell lines, thereby indicating that glucocorticoid regulation of Nhe3 is mediated primarily by a transcriptional mechanism.	MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA	McGill University				Orlowski, John/0000-0001-7371-175X				AMEMIYA M, 1995, AM J PHYSIOL-CELL PH, V269, pC126, DOI 10.1152/ajpcell.1995.269.1.C126; AZARANI A, 1995, J BIOL CHEM, V270, P20004, DOI 10.1074/jbc.270.34.20004; BAUM M, 1994, AM J PHYSIOL, V267, pF437, DOI 10.1152/ajprenal.1994.267.3.F437; BAUM M, 1993, AM J PHYSIOL, V264, pF1027, DOI 10.1152/ajprenal.1993.264.6.F1027; BOOTH IW, 1985, LANCET, V1, P1066; BRANT SR, 1993, GENOMICS, V15, P668, DOI 10.1006/geno.1993.1122; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CANO A, 1993, J CLIN INVEST, V92, P1632, DOI 10.1172/JCI116748; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DYCK JRB, 1995, J BIOL CHEM, V270, P1375, DOI 10.1074/jbc.270.3.1375; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GUILLERY EN, 1995, AM J PHYSIOL-RENAL, V268, pF710, DOI 10.1152/ajprenal.1995.268.4.F710; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HORIE S, 1990, P NATL ACAD SCI USA, V87, P4742, DOI 10.1073/pnas.87.12.4742; HORIE S, 1992, P NATL ACAD SCI USA, V89, P5236, DOI 10.1073/pnas.89.12.5236; HORIE S, 1992, J CLIN INVEST, V89, P365, DOI 10.1172/JCI115594; IGARASHI P, 1992, AM J PHYSIOL, V263, pF83, DOI 10.1152/ajprenal.1992.263.1.F83; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JUANG HH, 1995, J BIOL CHEM, V270, P12629, DOI 10.1074/jbc.270.21.12629; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KANDASAMY RK, 1995, J BIOL CHEM, V270, P29209, DOI 10.1074/jbc.270.49.29209; KAPUS A, 1994, J BIOL CHEM, V269, P23544; KINSELLA J, 1985, P NATL ACAD SCI USA, V82, P3606, DOI 10.1073/pnas.82.11.3606; KINSELLA J, 1984, J BIOL CHEM, V259, P3224; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; KOLYADA AY, 1994, BBA-GENE STRUCT EXPR, V1217, P54; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEVINE SA, 1995, J BIOL CHEM, V270, P13716, DOI 10.1074/jbc.270.23.13716; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; LIFTON RP, 1990, GENOMICS, V7, P131, DOI 10.1016/0888-7543(90)90530-8; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; MAHNENSMITH RL, 1985, CIRC RES, V56, P773, DOI 10.1161/01.RES.56.6.773; MILLER RT, 1991, J BIOL CHEM, V266, P10813; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; MOE OW, 1991, J CLIN INVEST, V88, P1703, DOI 10.1172/JCI115487; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; MORDUCHOWICZ GA, 1989, KIDNEY INT, V36, P576, DOI 10.1038/ki.1989.233; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; OVCHINNIKOV YA, 1988, FEBS LETT, V233, P87, DOI 10.1016/0014-5793(88)81361-9; PATHAK BG, 1990, GENOMICS, V8, P641, DOI 10.1016/0888-7543(90)90250-X; PITTMAN N, 1995, J BIOL CHEM, V270, P28848, DOI 10.1074/jbc.270.48.28848; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; RAHMSDORF HJ, 1990, PHARMACOL THERAPEUT, V48, P157, DOI 10.1016/0163-7258(90)90079-H; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; REILLY RF, 1991, AM J PHYSIOL, V261, pF1088, DOI 10.1152/ajprenal.1991.261.6.F1088; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SHULL MM, 1989, J BIOL CHEM, V264, P17532; SOLEIMANI M, 1994, J BIOL CHEM, V269, P15613; SOLEIMANI M, 1994, J BIOL CHEM, V269, P27973; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SZPIRER C, 1994, MAMM GENOME, V5, P153, DOI 10.1007/BF00352346; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, J BIOL CHEM, V268, P11917; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; WANG Z, 1993, J BIOL CHEM, V268, P11925; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; YAMAJI Y, 1995, P NATL ACAD SCI USA, V92, P6274, DOI 10.1073/pnas.92.14.6274; YUN CHC, 1993, J BIOL CHEM, V268, P206; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	84	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10551	10559		10.1074/jbc.271.18.10551	http://dx.doi.org/10.1074/jbc.271.18.10551			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631855	hybrid			2022-12-27	WOS:A1996UJ34200023
J	Maveyraud, L; Saves, I; BurletSchiltz, O; Swaren, P; Masson, JM; Delaire, M; Mourey, L; Prome, JC; Samama, JP				Maveyraud, L; Saves, I; BurletSchiltz, O; Swaren, P; Masson, JM; Delaire, M; Mourey, L; Prome, JC; Samama, JP			Structural basis of extended spectrum TEM beta-lactamases - Crystallographic, kinetic, and mass spectrometric investigations of enzyme mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; INTERMEDIATE; MECHANISM; CEPHALOSPORINS; INHIBITION; RESOLUTION; HYDROLYSIS; CATALYSIS; PC1	The E166Y and the E166Y/R164S TEM-1 beta-lactamase mutant enzymes display extended spectrum substrate specificities, Electrospray mass spectrometry demonstrates that, with penicillin G as substrate, the rate-limiting step in catalysis is the hydrolysis of the E166Y acyl-enzyme complex, Comparison of the 1.8-Angstrom resolution x-ray structures of the wild-type and of the E166Y mutant enzymes shows that the binding of cephalosporin substrates is improved, in the mutant enzyme, by the enlargement of the substrate binding site. This enlargement is due to the rigid body displacement of 60 residues driven by the movement of the R-loop. These structural observations strongly suggest that the link between the position of the Omega-loop and that of helix H5, plays a central role in the structural events leading to extended spectrum TEM-related enzymes, The increased Omega-loop flexibility caused by the R164S mutation, which is found in several natural mutant TEM enzymes, may lead to similar structural effects. Comparison of the kinetic data of the E166Y, E166Y/R164S, and R164S mutant enzymes supports this hypothesis.	PHARMACOL & TOXICOL FONDAMENTALES LAB,GRP CRISTALLOG BIOL,F-31077 TOULOUSE,FRANCE; PHARMACOL & TOXICOL FONDAMENTALES LAB,GRP INGN PROT,F-31077 TOULOUSE,FRANCE; PHARMACOL & TOXICOL FONDAMENTALES LAB,GRP SPECTROMETRIE MASSE,F-31077 TOULOUSE,FRANCE				Mourey, Lionel/B-5662-2009; Maveyraud, Laurent/C-6066-2011	Mourey, Lionel/0000-0002-8259-1259; Maveyraud, Laurent/0000-0003-4610-8319; Schiltz, Odile/0000-0002-3606-2356				ADACHI H, 1991, J BIOL CHEM, V266, P3186; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; APLIN RT, 1990, FEBS LETT, V277, P212, DOI 10.1016/0014-5793(90)80847-C; BLAZQUEZ J, 1995, ANTIMICROB AGENTS CH, V39, P145, DOI 10.1128/AAC.39.1.145; BRUNGER AT, X PLOR MANUAL BERSIO; CHRISTENSEN H, 1990, BIOCHEM J, V266, P853; DELAIRE M, 1991, PROTEIN ENG, V4, P805, DOI 10.1093/protein/4.7.805; FARACI WS, 1986, BIOCHEMISTRY-US, V25, P2934, DOI 10.1021/bi00358a030; FARACI WS, 1985, BIOCHEMISTRY-US, V24, P903, DOI 10.1021/bi00325a014; HENDRICKSON WA, 1980, BIOMOLECULAR STRUCTU, V1, P43; HERZBERG O, 1991, BIOCHEMISTRY-US, V30, P9503, DOI 10.1021/bi00103a017; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JACOBY GA, 1991, ANTIMICROB AGENTS CH, V35, P1697, DOI 10.1128/AAC.35.9.1697; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; JONES TA, 1985, METHOD ENZYMOL, V115, P157; MOROSINI MI, 1995, ANTIMICROB AGENTS CH, V39, P458, DOI 10.1128/AAC.39.2.458; NAUMOVSKI L, 1992, ANTIMICROB AGENTS CH, V36, P1991, DOI 10.1128/AAC.36.9.1991; PALZKILL T, 1995, ANTIMICROB AGENTS CH, V39, P1199, DOI 10.1128/AAC.39.5.1199; PETIT A, 1995, BIOCHEM J, V305, P33, DOI 10.1042/bj3050033; RAQUET X, 1994, J MOL BIOL, V244, P625, DOI 10.1006/jmbi.1994.1756; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SAVES I, 1995, BIOCHEMISTRY-US, V34, P11660, DOI 10.1021/bi00037a003; SAVES I, 1995, J BIOL CHEM, V270, P18240, DOI 10.1074/jbc.270.31.18240; SOWEK JA, 1991, BIOCHEMISTRY-US, V30, P3179, DOI 10.1021/bi00227a004; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; SWAREN P, 1995, STRUCTURE, V3, P603, DOI 10.1016/S0969-2126(01)00194-0; VENKATACHALAM KV, 1994, J BIOL CHEM, V269, P23444; VIADIU H, 1995, J BIOL CHEM, V270, P781, DOI 10.1074/jbc.270.2.781	28	30	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10482	10489		10.1074/jbc.271.18.10482	http://dx.doi.org/10.1074/jbc.271.18.10482			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631844	hybrid, Green Published			2022-12-27	WOS:A1996UJ34200012
J	Noonberg, SB; Scott, GK; Benz, CC				Noonberg, SB; Scott, GK; Benz, CC			Evidence of post-transcriptional regulation of U6 small nuclear RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III; CAP STRUCTURE; SPLICEOSOME; GENES; U1; U2; ANTIBODIES; ELEMENTS; INVITRO; SNRNAS	Mechanisms regulating the intracellular level of endogenous U6 small nuclear RNA were studied by transient transfection of ectopic U6 gene constructs into immortalized normal and malignant human cell lines, Transfection and expression of a modified U6 gene containing native promoter, capping, and termination sequences but lacking all highly conserved internal spliceosome sequences produced dose-dependent effects on endogenous U6 gene expression, At low transfection doses, no significant changes in endogenous U6 RNA levels or half-life were noted, However, as the dose of the transfected gene and its expression increased, native U6 RNA levels dramatically decreased in association with an apparent decrease in U6 RNA half-life, Down-regulation of native U6 RNA levels was transient, with recovery noted within 48-96 h in conjunction with declining expression of the ectopic gene. These modulatory effects appeared specific to endogenous U6 transcripts, because no changes were noted in 7sk, U1, U3, or 5S RNA levels or half-lives. Transfection with an unmodified U6 gene did not alter total U6 transcript levels but did produce a similar dose-dependent decrease in U6 RNA half-life, These studies suggest a hitherto unrecognized U6-specific intracellular regulatory mechanism, through which over-accumulation of U6 small nuclear RNA is prevented.	UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NCI NIH HHS [CA 36773] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGET SM, 1986, CELL, V46, P691, DOI 10.1016/0092-8674(86)90344-2; BROW DA, 1989, NATURE, V337, P14, DOI 10.1038/337014a0; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; GUPTA S, 1990, J BIOL CHEM, V265, P9491; GUPTA S, 1990, J BIOL CHEM, V265, P19137; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; Hernandez N, 1992, TRANSCRIPTIONAL REGU, P281; KUNKEL GR, 1986, P NATL ACAD SCI USA, V83, P8575, DOI 10.1073/pnas.83.22.8575; KUNKEL GR, 1989, NUCLEIC ACIDS RES, V17, P7371, DOI 10.1093/nar/17.18.7371; KUNKEL GR, 1988, GENE DEV, V2, P196, DOI 10.1101/gad.2.2.196; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MANGIN M, 1985, SCIENCE, V229, P272, DOI 10.1126/science.2409601; NOONBERG SB, 1994, NUCLEIC ACIDS RES, V22, P2830, DOI 10.1093/nar/22.14.2830; NOONBERG SB, 1994, THESIS U CALIFORNIA; RAY R, 1994, MOL CELL BIOCHEM, V131, P67, DOI 10.1007/BF01075726; REDDY R, 1987, J BIOL CHEM, V262, P75; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; RINKE J, 1982, CELL, V29, P149, DOI 10.1016/0092-8674(82)90099-X; Sambrook J., 2002, MOL CLONING LAB MANU; SAUTERER RA, 1988, EXP CELL RES, V176, P344, DOI 10.1016/0014-4827(88)90336-9; SHIMBA S, 1994, J BIOL CHEM, V269, P12419; SHUMYATSKY G, 1993, NUCLEIC ACIDS RES, V21, P4756, DOI 10.1093/nar/21.20.4756; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; Stefanovic Branko, 1994, Gene Expression, V4, P1; TERNS MP, 1993, GENE DEV, V7, P1898, DOI 10.1101/gad.7.10.1898; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; WOLFF T, 1993, GENE DEV, V7, P1377, DOI 10.1101/gad.7.7b.1377	30	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10477	10481		10.1074/jbc.271.18.10477	http://dx.doi.org/10.1074/jbc.271.18.10477			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631843	hybrid			2022-12-27	WOS:A1996UJ34200011
J	Hirano, K; Young, SG; Farese, RV; Ng, J; Sande, E; Warburton, C; PowellBraxton, LM; Davidson, NO				Hirano, K; Young, SG; Farese, RV; Ng, J; Sande, E; Warburton, C; PowellBraxton, LM; Davidson, NO			Targeted disruption of the mouse apobec-1 gene abolishes apolipoprotein B mRNA editing and eliminates apolipoprotein B48	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; INTESTINE; PROTEINS	A site-specific C to U editing reaction modifies nuclear apolipoprotein B100 (apoB100) mRNA, producing apolipoprotein B48 in the mammalian small intestine, This reaction is mediated by a multicomponent enzyme complex, which contains a catalytic subunit, Apobec-1. We have used gene targeting to disrupt mouse apobec-1 in order to establish its requisite importance in apoB mRNA editing and also, in view of its widespread tissue distribution in rodents, as a preliminary indication of other potential roles. Both heterozygous (apobec-1(+/-)) and homozygous (apobec-1(-/-)) gene-targeted mice appear healthy and fertile with no alterations in serum cholesterol or triglyceride concentrations. The apobec-1(+/-) mice demonstrated reduced levels of hepatic apoB mRNA editing. By contrast, levels of small intestinal apoB mRNA editing were indistinguishable in wild-type and apobec-1(+/-) animals, suggesting that Apobec-1 is expressed in limited quantities in the liver but not in the small intestine. The apobec-1(-/-) mice lacked detectable levels of Apobec-1 mRNA, expressed only unedited apoB mRNA in all tissues, and contained no apoB48 in their serum, demonstrating that there is no functional duplication of this gene.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; GENENTECH INC,CARDIOVASC RES,SAN FRANCISCO,CA 94080; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of California System; University of California San Francisco; The J David Gladstone Institutes; Roche Holding; Genentech; University of Chicago				Young, Stephen/0000-0001-7270-3176	NHLBI NIH HHS [HL-38180, HL-18577] Funding Source: Medline; NIDDK NIH HHS [DK-42086] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038180, R37HL038180, P01HL018577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; CALLOW MJ, 1995, J BIOL CHEM, V270, P23914, DOI 10.1074/jbc.270.41.23914; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Davidson Nicholas O., 1995, Current Opinion in Lipidology, V6, P70, DOI 10.1097/00041433-199504000-00002; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; FUNAHASHI T, 1995, J LIPID RES, V36, P414; GIANNONI F, 1994, J BIOL CHEM, V269, P5932; GIANNONI F, 1995, J LIPID RES, V36, P1664; GREEVE J, 1993, J LIPID RES, V34, P1367; HADJIAGAPIOU C, 1994, NUCLEIC ACIDS RES, V22, P1874, DOI 10.1093/nar/22.10.1874; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; HIGUCHI K, 1992, J LIPID RES, V33, P1753; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; MCCORMICK PA, 1995, P NATL ACAD SCI USA, V92, P10147; NAKAMUTA M, 1995, J BIOL CHEM, V270, P13042, DOI 10.1074/jbc.270.22.13042; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; TENG BB, 1990, J BIOL CHEM, V265, P20616; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; TENG BB, 1992, J BIOL CHEM, V267, P21265; TENG BB, 1990, BIOCHEM BIOPH RES CO, V173, P74, DOI 10.1016/S0006-291X(05)81023-X; WU JH, 1990, J BIOL CHEM, V265, P12312; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	30	120	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9887	9890		10.1074/jbc.271.17.9887	http://dx.doi.org/10.1074/jbc.271.17.9887			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626621	hybrid			2022-12-27	WOS:A1996UG25700005
J	Jakob, U; Scheibel, T; Bose, S; Reinstein, J; Buchner, J				Jakob, U; Scheibel, T; Bose, S; Reinstein, J; Buchner, J			Assessment of the ATP binding properties of Hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ALPHA-SUBUNITS	Hsp90, one of the most prominent proteins in eucaryotic cells under physiological and stress conditions, chaperones protein folding reactions in an ATP-independent way. Surprisingly, ATP binding and ATPase activity of Hsp90 has been reported by several groups. To clarify this important issue, we have reinvestigated the potential ATP binding properties and ATPase activity of highly purified Hsp90 using a number of different techniques. Hsp90 was compared to the well characterized ATP-binding chaperone Hsc70 and to two control proteins, immunoglobulin G and bovine serum albumin, that are known to not bind ATP. Hsp90 behaved very similarly to the non-ATP-binding proteins and very differently from the ATP-binding protein Hsc70. Like bovine serum albumin and immunoglobulin G, Hsp90 (i) did not bind to immobilized ATP, (ii) could not be specifically photocross-linked with azido-ATP, (iii) failed to exhibit significant changes in intrinsic protein fluorescence upon ATP addition, and (iv) did not bind to three fluorescent ADP analogues. In contrast, Hsc70 strongly bound ATP and ADP, specifically cross-linked with azido-ATP, and exhibited major shifts in fluorescence upon addition of ATP. Finally, reexamination of the amino acid sequence of Hsp90 failed to reveal any significant homologies to known ATP-binding motifs. Taken together, we conclude that highly purified Hsp90 does not bind ATP. Weak ATPase activities associated with Hsp90 preparations may be due to minor impurities or kinases copurifying with Hsp90.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,D-93040 REGENSBURG,GERMANY; MAX PLANCK INST MOL PHYSIOL,PHYS BIOCHEM ABT,D-44139 DORTMUND,GERMANY	University of Regensburg; Max Planck Society			Buchner, Johannes/A-2651-2010; Scheibel, Thomas/I-1170-2014	Scheibel, Thomas/0000-0002-0457-2423; Buchner, Johannes/0000-0003-1282-7737				BIRDSALL B, 1983, ANAL BIOCHEM, V132, P353, DOI 10.1016/0003-2697(83)90020-9; BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; CHIN DT, 1988, J BIOL CHEM, V263, P11718; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; HOLLNEUGEBAUER B, 1992, BIOCHEMISTRY-US, V30, P16009; INANO K, 1994, J BIOCHEM-TOKYO, V116, P759, DOI 10.1093/oxfordjournals.jbchem.a124593; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; JAKOB U, 1995, J BIOL CHEM, V270, P14412, DOI 10.1074/jbc.270.24.14412; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; KELLERMAYER MSZ, 1995, BIOCHEM BIOPH RES CO, V211, P166, DOI 10.1006/bbrc.1995.1792; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; MIYATA Y, 1995, BIOCHEMISTRY-US, V34, P8123, DOI 10.1021/bi00025a019; MORIMOTO RI, 1994, STRESS PROTEINS BIOL; NADEAU K, 1993, J BIOL CHEM, V268, P1479; NADEAU K, 1992, PROTEIN SCI, V1, P970, DOI 10.1002/pro.5560010802; NARDAI G, 1996, IN PRESS J BIOSCI; NOVER L., 1991, HEAT SHOCK RESPONSE; OLSSON H, 1995, FEBS LETT, V361, P282, DOI 10.1016/0014-5793(95)00194-E; PALLEROS DR, 1993, BIOCHEMISTRY-US, V32, P4314, DOI 10.1021/bi00067a021; PRATT WB, 1993, J BIOL CHEM, V268, P21455; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SHI Y, 1994, P NATL ACAD SCI USA, V91, P2767, DOI 10.1073/pnas.91.7.2767; SHUE GL, 1994, J BIOL CHEM, V269, P2707; SMITH DF, 1993, STEROID HORMONE RECE, P247; SPARRER H, 1996, IN PRESS J MOL BIOL; TODD MJ, 1995, FEBS LETT, V359, P123, DOI 10.1016/0014-5793(95)00021-Z; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WIECH H, 1993, J BIOL CHEM, V268, P7414; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0	37	82	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10035	10041		10.1074/jbc.271.17.10035	http://dx.doi.org/10.1074/jbc.271.17.10035			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626558	hybrid			2022-12-27	WOS:A1996UG25700030
J	Civil, A; Bakker, A; Rensink, I; Doerre, S; Aarden, LA; Verweij, CL				Civil, A; Bakker, A; Rensink, I; Doerre, S; Aarden, LA; Verweij, CL			Nuclear appearance of a factor that binds the CD28 response element within the interleukin-2 enhancer correlates with interleukin-2 production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; NF-KAPPA-B; ACCESSORY MOLECULE CD28; CYCLOSPORINE-A; GENE-TRANSCRIPTION; ANTIGEN RECEPTOR; CLONAL ANERGY; LYMPHOCYTES; EXPRESSION; SIGNALS	Activation of T lymphocytes requires the combined signaling of the T cell receptor and costimulatory molecules such as CD28. The ability of T cells to produce interleukin-2 (IL-2) is a critical control point in T lymphocyte activation. The IL-2 enhancer contains a functional motif named CD28 response element (CD28RE) that serves a role as a target for mitogenic T cell activation signals. The CD28RE sequence reveals similarity to the consensus kappa B binding motif. Here we demonstrate that CD28RE binds an inducible protein with a molecular mass of approximately 35 kDa called nuclear factor of mitogenic-activated T cells (NF-MATp35) that is clearly different from the known NF-kappa B/Rel family members. Induction of NF-MATp35 was shown to depend on de novo protein synthesis and was restricted to T cells that received a mitogenic combination of T cell stimuli, not necessarily including CD28 signaling. Nonmitogenic T cell stimulation did not result in appearance of NF-MATp35. These results indicate that mitogenic combinations of T cell activation signals are integrated at the level of NF-MATp35 induction. Similar to its effect on IL-2 production, cyclosporin A inhibited the induction of NF-MATp35. Taken together, these data demonstrate that the nuclear appearance of NF-MATp35 shows excellent correlation with IL-2 production, which is a unique characteristic among nuclear factors implicated in the control of IL-2 gene expression.	ACAD HOSP LEIDEN,DEPT RHEUMATOL,2300 RC LEIDEN,NETHERLANDS; NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT AUTOIMMUNE DIS,1066 CX AMSTERDAM,NETHERLANDS; BOSTON UNIV,DEPT MICROBIOL,BOSTON,MA 02118	Leiden University; Leiden University Medical Center (LUMC); Boston University			Bakker, Arnold B./F-8494-2010	Bakker, Arnold B./0000-0003-1489-1847				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BLOEMENA E, 1989, EUR J IMMUNOL, V19, P943, DOI 10.1002/eji.1830190524; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CIVIL A, 1992, EUR J IMMUNOL, V22, P3041, DOI 10.1002/eji.1830221142; CIVIL A, 1995, RES IMMUNOL, V146, P158, DOI 10.1016/0923-2494(96)80250-1; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; HANSEN JA, 1980, IMMUNOGENETICS, V10, P247, DOI 10.1007/BF01561573; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LI M, 1993, MOL CELL BIOL, V13, P6490, DOI 10.1128/MCB.13.10.6490; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RUDD CE, 1994, IMMUNOL TODAY, V15, P225, DOI 10.1016/0167-5699(94)90248-8; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; UMLAUF SW, 1995, MOL CELL BIOL, V15, P3197; VANLIER RAW, 1989, LEUKOCYTE TYPING, V4, P353; VERWEIJ CL, 1991, J BIOL CHEM, V266, P14179; WARD SG, 1993, EUR J IMMUNOL, V23, P2572, DOI 10.1002/eji.1830231029; WEAVER CT, 1990, IMMUNOL TODAY, V11, P49	46	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8321	8327		10.1074/jbc.271.14.8321	http://dx.doi.org/10.1074/jbc.271.14.8321			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626528	hybrid			2022-12-27	WOS:A1996UD60000068
J	Ghosh, S; Strum, JC; Sciorra, VA; Daniel, L; Bell, RM				Ghosh, S; Strum, JC; Sciorra, VA; Daniel, L; Bell, RM			Raf-1 kinase possesses distinct binding domains for phosphatidylserine and phosphatidic acid - Phosphatidic acid regulates the translocation of Raf-1 in 12-O-tetradecanoylphorbol-13-acetate-stimulated Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THREONINE PROTEIN-KINASE; PHOSPHOLIPASE-D; SIGNAL-TRANSDUCTION; CYTOCHROME-OXIDASE; HUMAN NEUTROPHILS; C ACTIVATION; HA-RAS; ASSOCIATION; MEMBRANES; PHOSPHATIDYLCHOLINE	Previous studies demonstrated that the cysteine-rich amino-terminal domain of Raf-1 kinase interacts selectively with phosphatidylserine (Ghosh, S., Xie, W. Q., Quest, A. F. G., Mabrouk, G. M., Strum, J. C., and Bell, R. M. (1994) J. Biol. Chem. 269, 10000-10007). Further analysis showed that full-length Raf-1 bound to both phosphatidylserine and phosphatidic acid (PA). Specifically, a carboxyl-terminal domain of Raf-1 kinase (RafC; residues 295-648 of human Raf-1) interacted strongly with phosphatidic acid. The binding of RafC to PA displayed positive cooperativity with Hill numbers between 3.3 and 6.2; the apparent K-d ranged from 4.9 +/- 0.6 to 7.8 +/- 0.9 mol % PA. The interaction of RafC with PA displayed a pH dependence distinct from the interaction between the cysteine-rich domain of Raf-1 and PA Also, the RafC-PA interaction was unaffected at high ionic strength. Of all the lipids tested, only PA and cardiolipin exhibited high affinity binding; other acidic lipids were either ineffective or weakly effective. By deletion mutagenesis, the PA binding site within RafC was narrowed down to a 35-amino acid segment between residues 389 and 423. RafC did not bind phosphatidyl alcohols; also, inhibition of PA formation in Madin-Darby canine kidney cells by treatment with 1% ethanol significantly reduced the translocation of Raf-1 from the cytosol to the membrane following stimulation with 12-O-tetradecanoylphorbol-13-acetate. These results suggest a potential role of the lipid second messenger, PA, in the regulation of translocation and subsequent activation of Raf-1 in vivo.	GLAXO WELLCOME INC,RES TRIANGLE PK,NC 27709; DUKE UNIV,MED CTR,DEPT MOLEC CANC BIOL,DURHAM,NC 27710; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,WINSTON SALEM,NC 27157	GlaxoSmithKline; Duke University; Wake Forest University; Wake Forest Baptist Medical Center			GHOSH, SUJOY/I-3729-2017	GHOSH, SUJOY/0000-0002-7601-165X	NATIONAL CANCER INSTITUTE [R01CA048995, R01CA043297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038737] Funding Source: NIH RePORTER; NCI NIH HHS [CA-43297, CA-48995] Funding Source: Medline; NIGMS NIH HHS [GM-38737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALBOA MA, 1994, J BIOL CHEM, V269, P10511; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7961, DOI 10.1021/bi00246a013; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BENAV P, 1993, EUR J BIOCHEM, V215, P455, DOI 10.1111/j.1432-1033.1993.tb18054.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONI LT, 1985, J BIOL CHEM, V260, P819; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GENNIS RB, 1988, BIOMEMBRANES MOL STR, P21; GHOSH S, 1994, J BIOL CHEM, V269, P30785; GHOSH S, 1995, ANAL BIOCHEM, V225, P376, DOI 10.1006/abio.1995.1176; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HUANG CF, 1992, J BIOL CHEM, V267, P16859; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MH, 1989, J BIOL CHEM, V264, P14797; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.biophys.18.1.113; MELNICK MB, 1993, DEVELOPMENT, V118, P127; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOSOIR M, 1993, BIOCHEMISTRY-US, V32, P66; MOSOIR M, 1992, BIOCHIM BIOPHYS ACTA, V1105, P185; MULLMANN TJ, 1990, BIOCHEM BIOPH RES CO, V170, P1197, DOI 10.1016/0006-291X(90)90520-W; NAKAMURA S, 1994, J BIOCHEM, V115, P1029, DOI 10.1093/oxfordjournals.jbchem.a124451; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; PARADIES G, 1994, BBA-MOL BASIS DIS, V1225, P165, DOI 10.1016/0925-4439(94)90074-4; PARADIES G, 1993, ARCH BIOCHEM BIOPHYS, V307, P91, DOI 10.1006/abbi.1993.1565; POWELL GL, 1987, BIOCHEMISTRY-US, V26, P8138, DOI 10.1021/bi00399a018; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; QUEST AFG, 1994, J BIOL CHEM, V269, P2961; RAPP UR, 1991, ONCOGENE, V6, P495; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SCHLAME M, 1993, J BIOL CHEM, V268, P74; SERTH J, 1991, EMBO J, V10, P1325, DOI 10.1002/j.1460-2075.1991.tb07651.x; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; SONG JG, 1993, BIOCHEM J, V294, P711, DOI 10.1042/bj2940711; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TRAVERSE S, 1993, ONCOGENE, V8, P3175; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHOU WJ, 1994, J VIROL, V68, P2556, DOI 10.1128/JVI.68.4.2556-2569.1994	64	367	372	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8472	8480		10.1074/jbc.271.14.8472	http://dx.doi.org/10.1074/jbc.271.14.8472			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626548	hybrid			2022-12-27	WOS:A1996UD60000088
J	Qiu, WQ; Borth, W; Ye, Z; Haass, C; Teplow, DB; Selkoe, DJ				Qiu, WQ; Borth, W; Ye, Z; Haass, C; Teplow, DB; Selkoe, DJ			Degradation of amyloid beta-protein by a serine protease-alpha(2)-macroglobulin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; HUMAN ALPHA-2-MACROGLOBULIN; INHIBITORS; PRECURSOR; RECEPTOR; PEPTIDE; CELLS	Progressive cerebral deposition of the amyloid beta-peptide (A beta) is an early and constant feature of Alzheimer's disease. A beta is derived by proteolysis from the beta-amyloid precursor protein. beta-Amyloid precursor protein processing and the generation of A beta have been extensively characterized, but little is known about the mechanisms of degradation of this potentially neurotoxic peptide. We identified and purified a proteolytic activity in culture medium that can degrade secreted A beta but not larger proteins in the medium. Detection of the activity in conditioned medium required the presence of fetal bovine serum and the passage of the cells with a pancreatic trypsin preparation. Its inhibitor profile showed that the activity was a serine protease other than trypsin or chymotrypsin. The protease occurs as a stable similar to 700-kDa complex with the inhibitor, alpha(2)-macroglobulin (alpha(2)M), that retains activity against small substrates such as A beta. Its NH2-terminal sequence suggests that the protease is previously unidentified. Our results indicate that the A beta-degrading protease we have detected is a non-trypsin component of a pancreatic trypsin preparation or else derives from a zymogen in serum that is activated by a protease in the latter preparation. Because A beta-bearing plaques in Alzheimer's disease brain contain both alpha(2)M and receptors of alpha(2)M-protease complexes, the same or a similar alpha(2)M-protease complex could arise in vivo and play a role in A beta clearance.	BRIGHAM & WOMENS HOSP,BIOPOLYMER LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115; MT SINAI MED CTR,DEPT HEMATOL,NEW YORK,NY 10029	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Icahn School of Medicine at Mount Sinai				Qiu, Wei Qiao (Wendy)/0000-0002-2082-2410	NATIONAL INSTITUTE ON AGING [RF1AG006173, R37AG006173, R01AG012749, R01AG006173] Funding Source: NIH RePORTER; NIA NIH HHS [AG 06173, AG 12749] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BAUER J, 1991, FEBS LETT, V285, P111, DOI 10.1016/0014-5793(91)80737-N; BEYNON RJ, 1993, PROTEOLYTIC ENZYMES, P241; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GIACCONE G, 1989, NEUROSCI LETT, V97, P232, DOI 10.1016/0304-3940(89)90169-9; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOOL DV, 1993, NEUROBIOL AGING, V14, P233; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1994, J BIOL CHEM, V269, P17741; HYMAN BT, 1995, ARCH NEUROL-CHICAGO, V52, P373, DOI 10.1001/archneur.1995.00540280059019; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LORENZO A, 1994, NATURE, V368, P756, DOI 10.1038/368756a0; MANN DMA, 1989, NEUROBIOL AGING, V10, P397, DOI 10.1016/0197-4580(89)90073-0; MCCONNELL DJ, 1972, J CLIN INVEST, V51, P1611, DOI 10.1172/JCI106962; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; NAIDU A, 1995, J BIOL CHEM, V270, P1369, DOI 10.1074/jbc.270.3.1369; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; REBECK GW, 1993, NEURON, V11, P575; RESNICK NM, 1991, CELL, V66, P541, DOI 10.1016/0092-8674(81)90017-9; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; SWEENEY PJ, 1993, ANAL BIOCHEM, V212, P179, DOI 10.1006/abio.1993.1310; TSUJI A, 1989, J BIOL CHEM, V264, P16093; TSUJI A, 1991, BIOCHIM BIOPHYS ACTA, V1078, P85, DOI 10.1016/0167-4838(91)90096-I; UCHINO T, 1993, J BIOL CHEM, V268, P527; VANLEUVEN F, 1988, J BIOL CHEM, V263, P468; VOGT W, 1976, N-S ARCH PHARMACOL, V294, P75, DOI 10.1007/BF00692787	35	85	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8443	8451		10.1074/jbc.271.14.8443	http://dx.doi.org/10.1074/jbc.271.14.8443			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626544				2022-12-27	WOS:A1996UD60000084
J	Boring, L; Gosling, J; Monteclaro, FS; Lusis, AJ; Tsou, CL; Charo, IF				Boring, L; Gosling, J; Monteclaro, FS; Lusis, AJ; Tsou, CL; Charo, IF			Molecular cloning and functional expression of murine JE (Monocyte chemoattractant protein 1) and murine macrophage inflammatory protein la receptors - Evidence for two closely linked C-C chemokine receptors on chromosome 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; MESSENGER-RNA; GROWTH-FACTOR; GENE; LESIONS; BINDING; CLUSTER; INVIVO; LIGAND; CELLS	We have isolated cDNA clones that encode two closely related, murine C-C chemokine receptors, Both receptors are members of the G-protein coupled, seven-transmembrane domain family of receptors and are most closely related to the human monocyte chemoattractant protein 1 receptor. Expression of each of the receptors was detected in murine monocyte/macrophage cell lines, but not in nonhematopoietic lines, Expression of these receptors in Xenopus oocytes revealed that one receptor signaled in response to low nanomolar concentrations of murine JE, whereas the second receptor was activated by murine macrophage inflammatory protein (MIP) 1 alpha and the human chemokines MIP-1 beta and RANTES. Binding studies revealed high affinity binding of radiolabeled mJE to the mJE receptor and murine MIP-1 alpha to the second receptor. Chromosomal localization indicated that the two receptor genes were clustered within 80 kilobases of each other on mouse chromosome 9. Creation of receptor chimeras suggested that the amino terminus was critically involved in mediating signal transduction and ligand specificity of the mJE receptor, but not the mMIP-1 alpha receptor, The identification and cloning of two functional murine chemokine receptors provides important new tools for investigating the roles of these potent cytokines in vivo.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94143; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052773] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52773] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHUJA SK, 1992, NAT GENET, V2, P31, DOI 10.1038/ng0992-31; ANTONIADES HN, 1992, P NATL ACAD SCI USA, V89, P5371, DOI 10.1073/pnas.89.12.5371; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; ERNST CA, 1994, J IMMUNOL, V152, P3541; FRANCI C, 1995, J IMMUNOL, V154, P6511; GAO JL, 1995, J BIOL CHEM, V270, P17494, DOI 10.1074/jbc.270.29.17494; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GERARD NP, 1993, BIOCHEMISTRY-US, V32, P1243, DOI 10.1021/bi00056a007; GILLITZER R, 1993, J INVEST DERMATOL, V101, P127, DOI 10.1111/1523-1747.ep12363613; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; ISHII K, 1993, J BIOL CHEM, V268, P9780; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KOCH AE, 1992, J CLIN INVEST, V90, P772, DOI 10.1172/JCI115950; LIAO F, 1991, J CLIN INVEST, V87, P2253, DOI 10.1172/JCI115261; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; ROLLINS BJ, 1991, CANCER CELL-MON REV, V3, P517; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; ROLLINS BJ, 1991, MOL CELL BIOL, V11, P3125, DOI 10.1128/MCB.11.6.3125; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALL TJ, 1994, CYTOKINE HDB, P419; SIEILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214; THIRION S, 1994, BIOCHEM BIOPH RES CO, V201, P493, DOI 10.1006/bbrc.1994.1729; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649; WARDEN CH, 1993, J LIPID RES, V34, P1451; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252	38	106	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7551	7558		10.1074/jbc.271.13.7551	http://dx.doi.org/10.1074/jbc.271.13.7551			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631787	hybrid			2022-12-27	WOS:A1996UC77400055
J	Chen, XM; Levkowitz, G; Tzahar, E; Karunagaran, D; Lavi, S; BenBaruch, N; Leitner, O; Ratzkin, BJ; Bacus, SS; Yarden, Y				Chen, XM; Levkowitz, G; Tzahar, E; Karunagaran, D; Lavi, S; BenBaruch, N; Leitner, O; Ratzkin, BJ; Bacus, SS; Yarden, Y			An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; NEU DIFFERENTIATION FACTOR; HIGH-AFFINITY RECEPTORS; BREAST-CANCER CELLS; MONOCLONAL-ANTIBODY; MAMMARY-TUMORS; A431 CELLS; EXPRESSION; GENE; HEREGULIN	The group of subtype I transmembrane tyrosine kinases includes the epidermal growth factor (EGF) receptor (ErbB-1), an orphan receptor (ErbB-2), and two receptors for the Neu differentiation factor (NDF/heregulin), namely: ErbB-3 and ErbB-4, Here we addressed the distinct functions of the two NDF receptors by using an immunological approach. Two sets of monoclonal antibodies (mAbs) to ErbB-3 and ErbB-4 were generated through immunization with recombinant ectodomains of the corresponding receptors that were fused to immunoglobulin. We found that the shared ligand binds to highly immunogenic, but immunologically distinct sites of ErbB-3 and ErbB-4. NDF receptors differed also in their kinase activities; whereas the catalytic activity of ErbB-4 was activable by mAbs, ErbB-3 underwent no activation by mAbs in living cells. Likewise, down-regulation of ErbB-4, but not ErbB-3, was induced by certain mAbs. By using the generated mAbs, we found that the major NDF receptor on mammary epithelial cells is a heterodimer of ErbB-3 with ErbB-2, whereas an ErbB-1/ErbB-2 heterodimer, or an ErbB-1 homodimer, is the predominant species that binds EGF. Consistent with ErbB-2 being a shared receptor subunit, its tyrosine phosphorylation was increased by both heterologous ligands and it mediated a trans-inhibitory effect of NDF on EGF binding. Last, we show that the effect of NDF on differentiation of breast tumor cells can be mimicked by anti-ErbB-4 antibodies, but not by mAbs to ErbB-3. Nevertheless, an ErbB-3-specific mAb partially inhibited the effect of NDF on cellular differentiation. These results suggest that homodimers of ErbB-4 are biologically active, but heterodimerization of the kinase-defective ErbB-3, probably with ErbB-2, is essential for transmission of NDF signals through ErbB-3.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; AMGEN CTR,THOUSAND OAKS,CA 91320; ADV CELLULAR DIAGNOST,ELMHURST,IL 60126	Weizmann Institute of Science; Amgen			Levkowitz, Gil/AAB-9441-2019; YARDEN, YOSEF/K-1467-2012; Karunagaran, Devarajan/A-8148-2010	Levkowitz, Gil/0000-0002-3896-1881; Karunagaran, Devarajan/0000-0001-9331-8947				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALIMANDI M, 1995, ONCOGENE, V10, P1813; BACUS SS, 1990, MOL CARCINOGEN, V3, P350, DOI 10.1002/mc.2940030607; BACUS SS, 1993, CANCER RES, V53, P5251; BACUS SS, 1992, CANCER RES, V52, P2580; BENBARUCH N, 1994, P SOC EXP BIOL MED, V206, P221; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; DEFIZE LHK, 1989, J CELL BIOL, V109, P2495, DOI 10.1083/jcb.109.5.2495; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FERNANDEZPOL JA, 1985, J BIOL CHEM, V260, P5003; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KARUNAGARAN D, 1995, J BIOL CHEM, V270, P9982, DOI 10.1074/jbc.270.17.9982; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KELMAN Z, 1993, ONCOGENE, V8, P37; KIM HH, 1994, J BIOL CHEM, V269, P24747; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEMOINE NR, 1992, J PATHOL, V168, P269, DOI 10.1002/path.1711680305; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ORRURTREGER A, 1993, P NATL ACAD SCI USA, V90, P1867, DOI 10.1073/pnas.90.5.1867; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RAJKUMAR T, 1994, BRIT J CANCER, V70, P459, DOI 10.1038/bjc.1994.328; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569	55	125	151	3	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7620	7629		10.1074/jbc.271.13.7620	http://dx.doi.org/10.1074/jbc.271.13.7620			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631797	hybrid			2022-12-27	WOS:A1996UC77400065
J	Shai, Y; Oren, Z				Shai, Y; Oren, Z			Diastereomers of cytolysins, a novel class of potent antibacterial peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA MOSES SOLE; LIPID BILAYERS; PHOSPHOLIPID-MEMBRANES; PARDAXIN; ANALOGS; DERMASEPTIN; MAGAININS; SECRETION; SEQUENCE; SKIN	An amphipathic alpha-helical structure is considered to be a prerequisite for the lytic activity of most short linear cytolytic polypeptides that act on both mammalian cells and bacteria, This structure allows them also to exert diverse pathological and pharmacological effects, presumably by mimicking protein components that are involved in membrane-related events, In this study D-amino acid-incorporated analogues (diastereomers) of the cytolysin pardaxin, which is active against mammalian cells and bacteria, were synthesized and structurally and functionally characterized, We demonstrate that the diastereomers do not retain the alpha-helical structure, which in turn abolishes their cytotoxic effects on mammalian cells. However, they retain a high antibacterial activity, which is expressed in a complete lysis of the bacteria, as revealed by negative staining electron microscopy. The disruption of the alpha-helical structure should prevent the diastereomer analogues from permeating the bacterial wall by forming transmembrane pores but rather by dissolving the membrane as a detergent, These findings open the way for a new strategy in developing a novel class of highly potent antibacterial polypeptides for the treatment of infectious diseases, due to the increasing resistance of bacteria to the available antibacterial drugs.			Shai, Y (corresponding author), WEIZMANN INST SCI, DEPT MEMBRANE RES & BIOPHYS, IL-76100 REHOVOT, ISRAEL.							ABURAYA S, 1993, NAT TOXINS, V1, P263; BENKIRANE N, 1993, J BIOL CHEM, V268, P26279; BESSALLE R, 1990, FEBS LETT, V274, P151, DOI 10.1016/0014-5793(90)81351-N; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; EHRENSTEIN G, 1977, Q REV BIOPHYS, V10, P1, DOI 10.1017/S0033583500000123; FISHER PJ, 1994, NATURE, V368, P651, DOI 10.1038/368651a0; GAZIT E, 1995, BIOCHEMISTRY-US, V34, P11479, DOI 10.1021/bi00036a021; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HOFFMANN JA, 1992, IMMUNOL TODAY, V13, P411, DOI 10.1016/0167-5699(92)90092-L; HUGOSSON M, 1994, EUR J BIOCHEM, V223, P1027, DOI 10.1111/j.1432-1033.1994.tb19081.x; LAZAROVICI P, 1986, J BIOL CHEM, V261, P6704; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; OJCIUS DM, 1991, TRENDS BIOCHEM SCI, V16, P225, DOI 10.1016/0968-0004(91)90090-I; OKADA M, 1984, BIOCHEM J, V222, P119, DOI 10.1042/bj2220119; OREN Z, 1996, IN PRESS EUR J BIOCH; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; RAPAPORT D, 1991, J BIOL CHEM, V266, P23769; RAPAPORT D, 1992, J BIOL CHEM, V267, P6502; RIZZO V, 1987, BIOCHEMISTRY-US, V26, P2751, DOI 10.1021/bi00384a015; SHAI Y, 1990, J BIOL CHEM, V265, P20202; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; SHAI Y, 1994, TOXICOLOGY, V87, P109, DOI 10.1016/0300-483X(94)90157-0; SHAI Y, 1988, FEBS LETT, V242, P161, DOI 10.1016/0014-5793(88)81007-X; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; THOMPSON SA, 1986, SCIENCE, V233, P341, DOI 10.1126/science.233.4761.341; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; WESTERHOFF HV, 1989, P NATL ACAD SCI USA, V86, P6597, DOI 10.1073/pnas.86.17.6597; ZAGORSKI MG, 1991, BIOCHEMISTRY-US, V30, P8009, DOI 10.1021/bi00246a019; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	30	153	164	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7305	7308		10.1074/jbc.271.13.7305	http://dx.doi.org/10.1074/jbc.271.13.7305			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631748	hybrid			2022-12-27	WOS:A1996UC77400016
J	Smit, MJ; Roovers, E; Timmerman, H; vandeVrede, Y; Alewijnse, AE; Leurs, R				Smit, MJ; Roovers, E; Timmerman, H; vandeVrede, Y; Alewijnse, AE; Leurs, R			Two distinct pathways for histamine H-2 receptor down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; DEPENDENT PROTEIN-KINASE; MESSENGER-RNA; BETA-2-ADRENERGIC RECEPTOR; AGONIST REGULATION; MOLECULAR-CLONING; CAMP; HISTAMINE-H2-RECEPTOR; DESENSITIZATION; EXPRESSION	Pretreatment of Chinese hamster ovary cells expressing the histamine H-2 receptor (CHOrH(2) cells) with histamine resulted in a time-dependent (t(1/2) approximate to 7 h) and dose-dependent (EC(50) = 18 nM) H-2 receptor down-regulation measured as [I-125]iodoaminopotentidine binding (44 +/- 10% down-regulation). Pretreatment of CHOrH(2) cells with cholera toxin or forskolin also led to H-2 receptor down-regulation. Forskolin time-dependently (t(1/2) approximate to 7 h) and dose-dependently (EC(50) = 0.3 mu M) induced H-2 receptor down-regulation. Both histamine and forskolin induced rapid down-regulation of H-2 receptor mRNA levels, probably caused by mRNA destabilization. Recently, Moro et al. (Moro, O., Lameh, J., Hogger, P., and Sadee, W. (1993) J. Biol. Chem. 268, 22273-22276) showed that hydrophobic amino acids in a conserved G-protein-coupled receptor motif in the second intracellular loop are implicated in G-protein coupling, To uncouple the H-2 receptor from the G(s)-protein, we introduced the Leu(124) --> Ala mutation in the second intracellular loop of the H-2 receptor. The H-2 Leu(124) --> Ala mutant showed altered agonist-binding parameters, attenuated histamine-induced cAMP production, and was down-regulated by concentrations of histamine that did not give rise to cAMP production, Taken together, in CHOrH(2) cells, H-2 receptor down-regulation appears to be induced by two distinct pathways, a cAMP-dependent and cAMP-independent pathway.	VRIJE UNIV AMSTERDAM, LEIDEN AMSTERDAM CTR DRUG RES, DEPT PHARMACOCHEM, 1081 HV AMSTERDAM, NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Vrije Universiteit Amsterdam			Leurs, Rob/AAC-8508-2022; Leurs, Rob/ABB-4299-2021	Leurs, Rob/0000-0003-1354-2848; Smit, Martine/0000-0003-2713-0238				ALLEN JM, 1989, MOL PHARMACOL, V36, P248; ARIMA N, 1993, AM J PHYSIOL, V265, pG987, DOI 10.1152/ajpgi.1993.265.5.G987; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS S, 1991, ANNU REV PHYSIOL, V53, P497, DOI 10.1146/annurev.physiol.53.1.497; COLLINS S, 1993, TRENDS BIOMED RES, V6, P480; DIAZ J, 1994, BIOCHEM BIOPH RES CO, V198, P1195, DOI 10.1006/bbrc.1994.1169; ERIKS JC, 1992, J MED CHEM, V35, P3239, DOI 10.1021/jm00095a021; FELIX SB, 1991, AGENT ACTION SUPPL, V33, P257; FUKUSHIMA Y, 1993, BIOCHEM BIOPH RES CO, V190, P1149, DOI 10.1006/bbrc.1993.1170; GANTZ I, 1991, BIOCHEM BIOPH RES CO, V178, P1386, DOI 10.1016/0006-291X(91)91047-G; GANTZ I, 1991, P NATL ACAD SCI USA, V88, P429, DOI 10.1073/pnas.88.2.429; GREEN SA, 1994, J BIOL CHEM, V269, P26215; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HADCOCK JR, 1989, J BIOL CHEM, V264, P13956; HADCOCK JR, 1993, J NEUROCHEM, V60, P1, DOI 10.1111/j.1471-4159.1993.tb05816.x; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HOLDEN CA, 1987, AGENTS ACTIONS, V22, P36, DOI 10.1007/BF01968814; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; LEE NH, 1994, J BIOL CHEM, V269, P4291; LEURS R, 1994, BRIT J PHARMACOL, V112, P847, DOI 10.1111/j.1476-5381.1994.tb13157.x; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; MAHAN LC, 1985, P NATL ACAD SCI USA, V82, P129, DOI 10.1073/pnas.82.1.129; MORO O, 1993, J BIOL CHEM, V268, P22273; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NORDSTEDT C, 1990, ANAL BIOCHEM, V189, P231, DOI 10.1016/0003-2697(90)90113-N; PORT JD, 1992, J BIOL CHEM, V267, P24103; RODGERS JR, 1985, METHOD ENZYMOL, V109, P572; RUAT M, 1991, BIOCHEM BIOPH RES CO, V179, P1470, DOI 10.1016/0006-291X(91)91738-X; SAKURAI T, 1992, BIOCHEM BIOPH RES CO, V186, P342, DOI 10.1016/S0006-291X(05)80813-7; SHEAR M, 1976, J BIOL CHEM, V251, P7572; SMIT MJ, 1995, BIOCHEM BIOPH RES CO, V214, P1138, DOI 10.1006/bbrc.1995.2404; SMIT MJ, 1994, EUR J PHARM-MOLEC PH, V288, P17, DOI 10.1016/0922-4106(94)90005-1; STERK GJ, 1987, EUR J MED CHEM, V22, P427, DOI 10.1016/0223-5234(87)90031-6; SU YF, 1980, J BIOL CHEM, V255, P7410; THOLANIKUNNEL BG, 1995, J BIOL CHEM, V270, P12787, DOI 10.1074/jbc.270.21.12787; TRAIFFORT E, 1992, P NATL ACAD SCI USA, V89, P2649, DOI 10.1073/pnas.89.7.2649; VANDERGOOT H, 1994, BIOORG MED CHEM LETT, V4, P1913, DOI 10.1016/S0960-894X(01)80533-3; ZHANG LJ, 1994, MOL PHARMACOL, V45, P878	42	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7574	7582		10.1074/jbc.271.13.7574	http://dx.doi.org/10.1074/jbc.271.13.7574			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631790	Green Submitted, hybrid, Green Published			2022-12-27	WOS:A1996UC77400058
J	Rye, KA; Hime, NJ; Barter, PJ				Rye, KA; Hime, NJ; Barter, PJ			The influence of sphingomyelin on the structure and function of reconstituted high density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; HUMAN-PLASMA-LIPOPROTEINS; CHOLESTEROL ACYLTRANSFERASE; EGG PHOSPHATIDYLCHOLINE; CELLULAR CHOLESTEROL; COMPLEXES; BILAYERS; PROTEIN; MEMBRANES; VESICLES	The effect of sphingomyelin (SPM) on the structure and function of discoidal and spherical reconstituted high density lipoproteins (rHDL) has been studied. Three preparations of discoidal rHDL with 1-palmitoyl-2-oleoyl phosphatidylcholine (POPC)/SPM/unesterified cholesterol (UC)/apolipoprotein (apo)A-I molar ratios of 99.6/0.0/10.2/1.0, 86.0/13.6/10.8/1.0, and 72.5/26.3/11.4/1.0 were prepared by cholate dialysis. SPM did not affect discoidal rHDL size or surface charge. Esterification of cholesterol by lecithin:cholesterol acyltransferase (LCAT) was inhibited in the SPM-containing discoidal rHDL, When the discoidal rHDL of POPC/SPM/UC/ apoA-I molar ratio 99.6/0.0/10.2/1.0 were incubated with low density lipoproteins (LDL) and LCAT, SPM transferred spontaneously from the LDL to the rHDL (t(1/2) = 0.8 h) and spherical particles with a POPC/SPR4/UC/CE/ apoA-I molar ratio of 24.6/4.9/3.6/24.9/1.0 were formed. Depleting the spherical rHDL of SPM head groups by incubation with sphingomyelinase increased the negative charge on the surface, but did not change their size, Cholesteryl ester transfer protein (CETP)-mediated transfers of cholesteryl esters and triglyceride between spherical rHDL and Intralipid were not affected by SPM head group depletion, The effect of SPM on rHDL structure was assessed spectroscopically. SPM increased POPC acyl chain and head group packing in the discoidal rHDL. When the spherical rHDL were depleted of SPM head groups, POPC acyl chain packing order decreased, but head group packing order was not affected. SPM inhibited the lipid-water interfacial hydration of discoidal rHDL, This parameter was not affected when the spherical rHDL were depleted of SPM head groups. The SPM molecule and the SPM head group, respectively, inhibited the unfolding of apoA-I in discoidal and spherical rHDL. It is concluded that (i) SPM influences the structure of discoidal and spherical rHDL, (ii) SPM inhibits the LCAT reaction in discoidal rHDL, and (iii) the SPM head group does not affect CETP-mediated lipid transfers into or out of spherical rHDL.	UNIV ADELAIDE,ROYAL ADELAIDE HOSP,DEPT MED,ADELAIDE,SA 5000,AUSTRALIA	Royal Adelaide Hospital; University of Adelaide	Rye, KA (corresponding author), ROYAL ADELAIDE HOSP,DIV CARDIOVASC SCI,LIPID RES LAB,LEVEL 1,HANSON CTR,FROME RD,ADELAIDE,SA 5000,AUSTRALIA.							BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; BARENHOLZ Y, 1982, PHOSPHOLIPIDS, P129; BENYASHAR V, 1991, CHEM PHYS LIPIDS, V60, P1, DOI 10.1016/0009-3084(91)90009-Z; BRADLEY CA, 1987, CLIN CHEM, V33, P81; BURSTEIN M, 1970, J LIPID RES, V11, P583; DAVIDSON WS, 1995, J BIOL CHEM, V270, P5882, DOI 10.1074/jbc.270.11.5882; EISENBERG S, 1984, J LIPID RES, V25, P1017; GUPTA AK, 1992, J LIPID RES, V33, P1741; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HOPKINS GJ, 1989, ATHEROSCLEROSIS, V75, P73, DOI 10.1016/0021-9150(89)90209-8; JONAS A, 1988, J LIPID RES, V29, P1349; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1989, J BIOL CHEM, V264, P4818; KAN CC, 1991, BIOCHEMISTRY-US, V30, P7759, DOI 10.1021/bi00245a013; KAWANO M, 1993, BIOCHEMISTRY-US, V32, P5025, DOI 10.1021/bi00070a008; KUKSIS A, 1992, BIOCHIM BIOPHYS ACTA, V1124, P205, DOI 10.1016/0005-2760(92)90132-F; LENTZ BR, 1976, BIOCHEMISTRY-US, V15, P4521, DOI 10.1021/bi00665a029; LENTZ BR, 1989, CHEM PHYS LIPIDS, V50, P171, DOI 10.1016/0009-3084(89)90049-2; MAHADEVAN V, 1983, BIOCHIM BIOPHYS ACTA, V752, P89, DOI 10.1016/0005-2760(83)90236-9; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MCINTOSH TJ, 1992, BIOCHEMISTRY-US, V31, P2012, DOI 10.1021/bi00122a017; OSBORNE JC, 1986, METHOD ENZYMOL, V128, P213; Pace C N, 1986, Methods Enzymol, V131, P266; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; PIRAN U, 1979, J LIPID RES, V20, P1040; PORN MI, 1993, J LIPID RES, V34, P1385; PRENDERGAST FG, 1981, BIOCHEMISTRY-US, V20, P7333, DOI 10.1021/bi00529a002; REICHL D, 1992, BIOCHIM BIOPHYS ACTA, V1127, P28, DOI 10.1016/0005-2760(92)90197-4; RYE KA, 1990, BIOCHIM BIOPHYS ACTA, V1042, P227, DOI 10.1016/0005-2760(90)90013-N; RYE KA, 1989, J LIPID RES, V30, P335; RYE KA, 1994, J BIOL CHEM, V269, P10298; RYE KA, 1993, BIOCHIM BIOPHYS ACTA, V1167, P316, DOI 10.1016/0005-2760(93)90235-2; RYE KA, 1995, J BIOL CHEM, V270, P189, DOI 10.1074/jbc.270.1.189; RYE KA, 1992, J LIPID RES, V33, P215; Scanu A M., 1979, BIOCH ATHEROSCLEROSI, P3; SCHERER PG, 1989, BIOCHEMISTRY-US, V28, P7720, DOI 10.1021/bi00445a030; SLATER SJ, 1993, BIOCHEMISTRY-US, V32, P3714, DOI 10.1021/bi00065a025; SPARKS DL, 1992, J LIPID RES, V33, P123; SPARKS DL, 1993, J BIOL CHEM, V268, P23250; STRAUME M, 1987, BIOCHEMISTRY-US, V26, P5113, DOI 10.1021/bi00390a033; SUBBAIAH PV, 1993, J BIOL CHEM, V268, P20156; SWANEY JB, 1983, J BIOL CHEM, V258, P1254; TOLLEFSON JH, 1988, AM J PHYSIOL, V255, pE894, DOI 10.1152/ajpendo.1988.255.6.E894; WEBER G, 1979, BIOCHEMISTRY-US, V18, P3075, DOI 10.1021/bi00581a025; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1; WETTERAU JR, 1983, J BIOL CHEM, V258, P2637; WINKLER KE, 1989, J LIPID RES, V30, P979; XU XX, 1991, J BIOL CHEM, V266, P24849	50	87	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4243	4250						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626769				2022-12-27	WOS:A1996TW96000047
J	Tsubaki, M; Mogi, T; Hori, H; SatoWatanabe, M; Anraku, Y				Tsubaki, M; Mogi, T; Hori, H; SatoWatanabe, M; Anraku, Y			Infrared and EPR studies on cyanide binding to the heme-copper binuclear center of cytochrome bo-type ubiquinol oxidase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED CONFORMATIONAL CHANGE; AEROBIC RESPIRATORY-CHAIN; C-OXIDASE; QUINOL OXIDASE; TERMINAL OXIDASES; LIGAND-BINDING; COMPLEX; IDENTIFICATION; SITE; PURIFICATION	Cyanide-binding to the heme-copper binuclear center of bo-type ubiquinol oxidase from Escherichia cell was investigated with Fourier transform-infrared and EPR spectroscopies. Upon treatment of the air-oxidized CN-inhibited enzyme with excess sodium dithionite, a C-12-N-14 stretching vibration at 2146 cm(-1) characteristic of the Fe-O(3+)-C=N-Cu-B(2+) bridging structure was quickly replaced with another stretching mode at 2034.5 cm(-1) derived from the Fe-O(2+)-C=N moiety. The presence of ubiquinone-8 or ubiquinone-1 caused a gradual autoreduction of the metal center(s) of the air-oxidized CN-inhibited enzyme and a concomitant appearance of a strong cyanide stretching band at 2169 cm(-1). This 2169 cm(-1) species could not be retained with a membrane filter (molecular weight cutoff = 10,000) and showed unusual cyanide isotope shifts and a D2O shift. These observations together with metal content analyses indicate that the 2169 cm(-1) band is due to a Cu-B . CN complex released from the enzyme. The same species could be produced by anaerobic partial reduction of the CN-inhibited ubiquinol oxidase and, furthermore, of the CN-inhibited cytochrome c oxidase; but not at all from the fully reduced CN-inhibited enzymes. These findings suggest that there is a common intermediate structure at the binuclear center of heme-copper respiratory enzymes in the partially reduced state from which the Cu-B center can be easily released upon cyanide-binding.	UNIV TOKYO,GRAD SCH SCI,DEPT BIOL SCI,BUNKYO KU,TOKYO 113,JAPAN; OSAKA UNIV,FAC ENGN SCI,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN	University of Tokyo; Osaka University	Tsubaki, M (corresponding author), HIMEJI INST TECHNOL,FAC SCI,DEPT LIFE SCI,KAMIGORI,HYOGO 67812,JAPAN.							ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; ANRAKU Y, 1988, ANNU REV BIOCHEM, V57, P101, DOI 10.1146/annurev.bi.57.070188.000533; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; CALHOUN MW, 1994, TRENDS BIOCHEM SCI, V19, P325, DOI 10.1016/0968-0004(94)90071-X; CALHOUN MW, 1994, BBA-PROTEIN STRUCT M, V1206, P143, DOI 10.1016/0167-4838(94)90083-3; GENNIS RB, 1991, BIOCHIM BIOPHYS ACTA, V1058, P21, DOI 10.1016/S0005-2728(05)80260-9; HAN J, 1992, INORG CHEM, V31, P3223, DOI 10.1021/ic00041a011; HILL J, 1992, BIOCHEMISTRY-US, V31, P11435, DOI 10.1021/bi00161a023; HIROTA S, 1994, FEBS LETT, V352, P67, DOI 10.1016/0014-5793(94)00919-8; INGLEDEW WJ, 1993, EUR J BIOCHEM, V212, P657, DOI 10.1111/j.1432-1033.1993.tb17703.x; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; JOHNSON MK, 1981, BIOCHEM J, V193, P699, DOI 10.1042/bj1930699; KILDEA JD, 1985, AUST J CHEM, V38, P1329, DOI 10.1071/CH9851329; KITA K, 1982, J BIOL CHEM, V257, P7933; KITA K, 1984, J BIOL CHEM, V259, P3368; MATSUSHITA K, 1984, BIOCHEMISTRY-US, V23, P4703, DOI 10.1021/bi00315a028; MINAGAWA J, 1992, J BIOL CHEM, V267, P2096; MINGHETTI KC, 1992, BIOCHEMISTRY-US, V31, P6917, DOI 10.1021/bi00145a008; MITCHELL R, 1994, BBA-BIOENERGETICS, V1186, P19, DOI 10.1016/0005-2728(94)90130-9; MITCHELL R, 1995, BIOCHEMISTRY-US, V34, P7576, DOI 10.1021/bi00023a003; MOGI T, 1994, J BIOCHEM-TOKYO, V116, P741; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; SALERNO JC, 1990, J BIOL CHEM, V265, P4364; SALERNO JC, 1989, FEBS LETT, V247, P101, DOI 10.1016/0014-5793(89)81249-9; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SATOWATANABE M, 1994, J BIOL CHEM, V269, P28908; SCOTT MJ, 1994, J AM CHEM SOC, V116, P11357, DOI 10.1021/ja00104a015; SHIEMKE AK, 1986, J AM CHEM SOC, V108, P2437, DOI 10.1021/ja00269a050; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P174, DOI 10.1021/bi00052a023; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; TSUBAKI M, 1994, J BIOL CHEM, V269, P30861; TSUBAKI M, 1992, BIOPHYS J, V63, P1564, DOI 10.1016/S0006-3495(92)81747-2; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P164, DOI 10.1021/bi00052a022; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; UNO T, 1994, J BIOL CHEM, V269, P11912; WEINTRAUB ST, 1982, J BIOL CHEM, V257, P4940; WEINTRAUB ST, 1981, J BIOL CHEM, V256, P1669; WIKSTROM M, 1992, J BIOL CHEM, V267, P10266; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; YOSHIKAWA S, 1985, J BIOL CHEM, V260, P3518; YOSHIKAWA S, 1977, J BIOL CHEM, V252, P5498; YOSHIKAWA S, 1988, P NATL ACAD SCI USA, V85, P1354, DOI 10.1073/pnas.85.5.1354; YOSHIKAWA S, 1990, J BIOL CHEM, V265, P7945; YOSHIKAWA S, 1995, J BIOL CHEM, V270, P4270, DOI 10.1074/jbc.270.9.4270	45	18	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4017	4022						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626734				2022-12-27	WOS:A1996TW96000012
J	Carrero, J; Mallender, WD; Voss, EW				Carrero, J; Mallender, WD; Voss, EW			Anti-metatype antibody stabilization of Fv 4-4-20 variable domain dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; FLUORESCYL ANTIBODIES; CONFORMATIONAL DRIFT; ESCHERICHIA-COLI; CONTACT RESIDUES; IDIOTYPE FAMILY; LIGAND-BINDING; DISSOCIATION; AFFINITY	Anti-metatype (anti-Met) antibodies are immunoglobulins that specifically recognize and stabilize antibodies in their liganded or metatypic state, but lack specificity for either the hapten or the unliganded antibody. Autologous anti-Met antibodies were previously observed in vivo, suggesting that a metatypic autoantibody response could play a physiological role in the immune network, e.g. controlling the clearance of immune complexes from circulation. The first elicited anti-Met antibodies were against the fluorescein-liganded high affinity murine anti-fluorescein monoclonal antibody 4-4-20. The fluorescein-hapten system has proved to be an invaluable tool for both the recognition and characterization of the metatypic response by utilization of its spectral properties. In this investigation, hydrostatic pressure measurements, in conjunction with fluorescence spectroscopy, were performed on the recombinant Fv derivative (Fv 4-4-20) of the high affinity anti-fluorescein monoclonal antibody 4-4-20 complexed to anti-Met antibodies to study the influence of anti-Met antibodies on Fv 4-4-20 intervariable domain interactions. Anti-Met antibodies bound to liganded Fv 4-4-20 were observed to cause a change in the fluorescence properties of fluorescein that was not observed when anti-Met antibodies were bound to the liganded parent immunoglobulin. The variation of these spectral properties upon addition of anti-Met antibodies was shown to be correlated with dissociation of the variable domains in Fv 4-4-20 in response to its interaction with the anti-Met antibody. The ability to cause variable domain dissociation was dependent on whether monoclonal or polyclonal anti-Met antibodies were bound to the metatype. A model was proposed that elucidated the interaction of anti-Met antibodies, polyclonal and monoclonal, with variable domains of the primary anti-antigen antibody.	UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign					NCRR NIH HHS [RR03155-01] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BALDWIN RW, 1990, MONOCLONAL ANTIBODIE; BEDZYK WD, 1989, J BIOL CHEM, V264, P1565; BEDZYK WD, 1990, J BIOL CHEM, V265, P133; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; COELHOSAMPAIO T, 1994, J BIOL CHEM, V269, P8146; COELHOSAMPAIO T, 1993, BIOCHEMISTRY-US, V32, P10929, DOI 10.1021/bi00092a001; CUMBER AJ, 1992, J IMMUNOL, V149, P120; DENNISON G, 1995, FASEB J, V9, P127; DENZIN LK, 1993, MOL IMMUNOL, V30, P1331, DOI 10.1016/0161-5890(93)90094-R; DENZIN LK, 1992, J BIOL CHEM, V267, P8925; DENZIN LK, 1991, J BIOL CHEM, V266, P14095; GULLIVER GA, 1995, BIOCHEMISTRY-US, V34, P5158, DOI 10.1021/bi00015a029; HERRON JN, 1986, BIOCHEMISTRY-US, V25, P4602, DOI 10.1021/bi00364a022; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HERRON JN, 1994, BIOPHYS J, V67, P2167, DOI 10.1016/S0006-3495(94)80738-6; HERRON JN, 1984, FLUORESCEIN HAPTEN I, P49; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; KIM ML, 1994, J BIOL CHEM, V269, P8695; KING L, 1986, BIOCHEMISTRY-US, V25, P3637, DOI 10.1021/bi00360a024; KRANZ DM, 1981, MOL IMMUNOL, V18, P889, DOI 10.1016/0161-5890(81)90012-2; KRANZ DM, 1984, FLUORESCEIN HAPTEN I, P121; MALLENDER WD, 1996, J BIOL CHEM, V270, P5338; MIKLASZ SD, 1995, J MOL RECOGNIT, V8, P258, DOI 10.1002/jmr.300080404; MULLER JD, 1994, BIOCHEMISTRY-US, V33, P6221; PALADINI AA, 1981, BIOCHEMISTRY-US, V20, P2587, DOI 10.1021/bi00512a034; PANTOLIANO MW, 1991, BIOCHEMISTRY-US, V30, P10117, DOI 10.1021/bi00106a007; REINITZ DM, 1984, J IMMUNOL, V135, P3365; REITER Y, 1994, BIOCHEMISTRY-US, V33, P5451, DOI 10.1021/bi00184a014; SELF CH, 1994, CLIN CHEM, V40, P2035; SILVA JL, 1986, BIOCHEMISTRY-US, V25, P5780, DOI 10.1021/bi00367a065; TETIN SY, 1992, BIOCHEMISTRY-US, V31, P12029, DOI 10.1021/bi00163a010; TOWBIN H, 1995, J IMMUNOL METHODS, V181, P167, DOI 10.1016/0022-1759(94)00343-U; VOSS EW, 1988, MOL IMMUNOL, V25, P751, DOI 10.1016/0161-5890(88)90111-3; VOSS EW, 1992, MOL IMMUNOL, V29, P241, DOI 10.1016/0161-5890(92)90105-7; WATT RM, 1977, IMMUNOCHEMISTRY, V14, P533, DOI 10.1016/0019-2791(77)90308-1; Weber G, 1987, HIGH PRESSURE CHEM B, P401; WEIDNER KM, 1992, J BIOL CHEM, V267, P10281; WEIDNER KM, 1993, MOL IMMUNOL, V30, P1003, DOI 10.1016/0161-5890(93)90125-U; WEIDNER KM, 1991, J BIOL CHEM, V266, P2513	39	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11247	11252		10.1074/jbc.271.19.11247	http://dx.doi.org/10.1074/jbc.271.19.11247			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626674	hybrid			2022-12-27	WOS:A1996UJ94400034
J	Trainer, VL; Brown, GB; Catterall, WA				Trainer, VL; Brown, GB; Catterall, WA			Site of covalent labeling by a photoreactive batrachotoxin derivative near transmembrane segment IS6 of the sodium channel alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCORPION TOXIN BINDING; A BENZOATE BINDING; RAT-BRAIN; RECEPTOR-SITE; NEUROTOXIN BINDING; LOCAL-ANESTHETICS; CA2+ CHANNELS; INHIBITION; 20-ALPHA-BENZOATE; IDENTIFICATION	The binding site for batrachotoxin, a lipid soluble neurotoxin acting at Na+ channel receptor site 2, was localized using a photoreactive, radiolabeled batrachotoxin derivative to covalently label purified and reconstituted rat brain Na+ channels. In the presence of the brevetoxin 1 from Ptychodiscus brevis and the pyrethroid RU51049, positive allosteric enhancers of batrachotoxin binding, a protein with an apparent molecular mass of 240 kDa corresponding to the Na+ channel alpha subunit was specifically covalently labeled. The region of the alpha subunit specifically photolabeled by the photoreactive batrachotoxin derivative was identified by antibody mapping of proteolytic fragments. Even after extensive trypsinization, an anti-peptide antibody recognizing an amino acid sequence adjacent to Na+ channel transmembrane segment IS6 was able to immunoprecipitate up to 70% of the labeled peptides. Analysis of a more complete digestion with trypsin or V8 protease indicated that the batrachotoxin receptor site is formed in part by a portion of domain I. The identification of a specifically immunoprecipitated photolabeled 7,3-kDa peptide containing transmembrane segment S6 from domain I restricted the site of labeling to residues Asn-388 to Glu-429 if V8 protease digestion was complete or Leu-380 to Glu-429 if digestion was incomplete. These results implicate the S6 transmembrane region of domain I of the Na+ channel alpha subunit as an important component of the batrachotoxin receptor site.	UNIV ALABAMA,DEPT PSYCHIAT & BEHAV NEUROBIOL,BIRMINGHAM,AL 35924	University of Alabama System; University of Alabama Birmingham	Trainer, VL (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195, USA.		Trainer, Vera/AAE-9306-2022		NIDA NIH HHS [DA07237] Funding Source: Medline; NIEHS NIH HHS [F32 ES 05586] Funding Source: Medline; NINDS NIH HHS [NS15751] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015751] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BROWN GB, 1988, MOL PHARMACOL, V34, P54; BROWN GB, 1986, J NEUROSCI, V6, P2064; BROWN GB, 1988, INT REV NEUROBIOL, V29, P76; CASEBOLT TL, 1993, TOXICON, V31, P1113, DOI 10.1016/0041-0101(93)90126-4; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; CATTERALL WA, 1981, J BIOL CHEM, V256, P8922; CATTERALL WA, 1979, J BIOL CHEM, V254, P1379; CREVELING CR, 1983, MOL PHARMACOL, V23, P350; DOUCET JP, 1990, ANAL BIOCHEM, V190, P209, DOI 10.1016/0003-2697(90)90182-9; FELLER DJ, 1985, J BIOL CHEM, V260, P1542; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; GORDON D, 1987, P NATL ACAD SCI USA, V84, P8682, DOI 10.1073/pnas.84.23.8682; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; KHODOROV BI, 1979, NEUROSCIENCE, V4, P1315, DOI 10.1016/0306-4522(79)90159-3; LOMBET A, 1988, BRAIN RES, V459, P44, DOI 10.1016/0006-8993(88)90284-3; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; NARAHASHI T, 1971, J GEN PHYSIOL, V58, P54, DOI 10.1085/jgp.58.1.54; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; Orth DN, 1979, METHOD HORM RADIOIMM, P245; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; POSTMA SW, 1984, MOL PHARMACOL, V25, P219; Rogers J. C., 1996, Biophysical Journal, V70, pA319; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; SHARKEY RG, 1984, BIOCHEMISTRY-US, V23, P6078, DOI 10.1021/bi00320a027; SHARKEY TG, 1986, MOL PHARMACOL, V31, P273; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; TAMKUN MM, 1984, J BIOL CHEM, V259, P1676; TEJEDOR FJ, 1988, P NATL ACAD SCI USA, V85, P8742, DOI 10.1073/pnas.85.22.8742; TEJEDOR FJ, 1990, CELL MOL NEUROBIOL, V10, P257, DOI 10.1007/BF00734578; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161; TRAINER VL, 1994, J BIOL CHEM, V269, P19904; TRAINER VL, 1993, J BIOL CHEM, V268, P17114; WANG GK, 1994, PFLUG ARCH EUR J PHY, V427, P309, DOI 10.1007/BF00374539; WILLOW M, 1982, MOL PHARMACOL, V22, P627; [No title captured]	42	48	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11261	11267		10.1074/jbc.271.19.11261	http://dx.doi.org/10.1074/jbc.271.19.11261			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626676	hybrid			2022-12-27	WOS:A1996UJ94400036
J	Broustas, CG; Larkins, LK; Uhler, MD; Hajra, AK				Broustas, CG; Larkins, LK; Uhler, MD; Hajra, AK			Molecular cloning and expression of cDNA encoding rat brain cytosolic acyl-coenzyme A thioester hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHASE; COA HYDROLASE; ESCHERICHIA-COLI; CLOFIBRIC ACID; PURIFICATION; LIVER; ENZYME; PROLIFERATORS; MITOCHONDRIA; MICROSOMES	The cDNA encoding rat brain cytosolic acyl-CoA thioester hydrolase (ACT) has been cloned and sequenced, and the primary structure of the enzyme has been deduced. A partial amino acid sequence (38 amino acids) of the enzyme was determined using the peptides generated after CNBr digestion of the purified enzyme. Primers synthesized on the basis of this information were used to isolate two cDNA clones, each encoding the full length of the enzyme. The nucleotide sequences of these clones contained an open reading frame encoding a 358-amino acid polypeptide with a calculated molecular mass of 39.7 kDa, similar to that determined for the purified enzyme (40.9 kDa). The deduced ACT sequence showed no homology to the known sequences of any other thioesterases nor to any other known protein sequence. However, there was a strong homology to a number of expressed sequence tag human brain cDNA clones. The identity of the ACT cDNA was confirmed by the expression of ACT activity in Escherichia coli. There was a 10-15-fold increase in ACT-specific activity in the bacterial extracts after induction with isopropyl thio-galactoside, and the properties of the expressed enzyme (fusion protein) were the same as those of the purified rat brain ACT. Northern blot analysis showed that a 1.65-kilobase ACT transcript was present in rat brain and testis but not in any other rat tissues examined. However, the ACT mRNA was induced in the liver of rats that were fed Wy-14,643, a peroxisome proliferator and inducer of rodent liver cytosolic acyl-CoA thioesterase. These results indicate that the induced rat liver ACT is homologous to the constitutive rat brain ACT.	UNIV MICHIGAN, DEPT BIOL CHEM, NEUROSCI LAB, ANN ARBOR, MI 48104 USA; UNIV MICHIGAN, MENTAL HLTH RES INST, ANN ARBOR, MI 48104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Broustas, Constantinos/0000-0001-7169-807X	NINDS NIH HHS [NS 15747] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015747] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ANDERSON AD, 1971, J NEUROCHEM, V18, P1179, DOI 10.1111/j.1471-4159.1971.tb00216.x; BERGE RK, 1979, EUR J BIOCHEM, V96, P393, DOI 10.1111/j.1432-1033.1979.tb13051.x; BERGE RK, 1979, BIOCHIM BIOPHYS ACTA, V574, P321, DOI 10.1016/0005-2760(79)90013-4; BERGE RK, 1984, EUR J BIOCHEM, V141, P637, DOI 10.1111/j.1432-1033.1984.tb08239.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROUSTAS CG, 1995, J NEUROCHEM, V64, P2345; BROUSTAS CG, 1995, THESIS U MICHIGAN; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHO HS, 1993, J BIOL CHEM, V268, P9238; DORMANN P, 1994, BBA-LIPID LIPID MET, V1212, P134, DOI 10.1016/0005-2760(94)90199-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; GROSS RW, 1983, BIOCHEMISTRY-US, V22, P5641, DOI 10.1021/bi00293a028; HWANG CS, 1993, J BIOL CHEM, V268, P14278; KATOH H, 1987, BIOCHIM BIOPHYS ACTA, V920, P171; KAWASHIMA Y, 1981, J PHARMACOBIO-DYNAM, V4, P711, DOI 10.1248/bpb1978.4.711; KUROOKA S, 1972, J BIOCHEM, V71, P625; LEHNER R, 1993, J BIOL CHEM, V268, P24726; LIN AY, 1984, NEUROCHEM RES, V9, P1571, DOI 10.1007/BF00964592; LOADER NM, 1993, PLANT MOL BIOL, V23, P769, DOI 10.1007/BF00021532; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MIYAZAWA S, 1981, EUR J BIOCHEM, V117, P425, DOI 10.1111/j.1432-1033.1981.tb06356.x; NAGGERT J, 1991, BIOCHEM J, V273, P787, DOI 10.1042/bj2730787; NAGGERT J, 1991, J BIOL CHEM, V266, P11044; POULOSE AJ, 1985, J BIOL CHEM, V260, P5953; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH RE, 1981, DEV NEUROSCI-BASEL, V4, P337, DOI 10.1159/000112773; SRERE PA, 1959, BIOCHIM BIOPHYS ACTA, V33, P313, DOI 10.1016/0006-3002(59)90118-0; SVENSSON LT, 1995, J BIOL CHEM, V270, P12177, DOI 10.1074/jbc.270.20.12177; SVENSSON LT, 1995, EUR J BIOCHEM, V230, P813; TAI MH, 1993, P NATL ACAD SCI USA, V90, P1852, DOI 10.1073/pnas.90.5.1852; UHLER MD, 1993, J BIOL CHEM, V268, P13586; WAKU K, 1992, BIOCHIM BIOPHYS ACTA, V1124, P101, DOI 10.1016/0005-2760(92)90085-A; WILCKE M, 1994, EUR J BIOCHEM, V222, P803, DOI 10.1111/j.1432-1033.1994.tb18927.x; WITKOWSKI A, 1991, J BIOL CHEM, V266, P18514; YAMADA J, 1994, ARCH BIOCHEM BIOPHYS, V308, P118, DOI 10.1006/abbi.1994.1017	39	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10470	10476		10.1074/jbc.271.18.10470	http://dx.doi.org/10.1074/jbc.271.18.10470			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631842	hybrid			2022-12-27	WOS:A1996UJ34200010
J	Das, KP; Petrash, JM; Surewicz, WK				Das, KP; Petrash, JM; Surewicz, WK			Conformational properties of substrate proteins bound to a molecular chaperone alpha-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; B-CRYSTALLIN; A-CRYSTALLIN; EXPRESSION; TISSUES; FLUORESCENCE; DISEASE; GROEL	alpha-Crystallin, the major protein of the ocular lens, acts as a molecular chaperone by suppressing the nonspecific aggregation of damaged proteins. To investigate the mechanism of the interaction between alpha-crystallin and substrate proteins, we prepared a tryptophan-free mutant of human alpha A-crystallin and assessed the conformation of thermally destabilized proteins captured by this chaperone using fluorescence spectroscopy. The fluorescence emission characteristics of bound substrates (rhodanese and gamma-crystallin) and the results of fluorescence quenching experiments indicate that the proteins captured by alpha-crystallin are characterized by a very low degree of unfolding. In particular, the structure of rhodanese bound to alpha A-crystallin appears to be considerably more native-like compared to that of the enzyme bound to the chaperonin GroEL. We postulate that alpha-crystallin (and likely other small heat shock proteins) recognize preferentially the aggregation-prone conformers that occur very early on the denaturation pathway. With its ability to capture and stabilize these early non-native structures, alpha-crystallin appears to be uniquely well suited to chaperone the transparency properties of the ocular lens.	UNIV MISSOURI,MASON EYE INST,COLUMBIA,MO 65212; UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65212; WASHINGTON UNIV,DEPT OPHTHALMOL & VISUAL SCI,ST LOUIS,MO 63110	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; Washington University (WUSTL)				Das, Kali/0000-0001-7686-9077	NEI NIH HHS [P30 EY02687, EY05856] Funding Source: Medline; NIDDK NIH HHS [P60 DK20579] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005856, P30EY002687, R55EY005856, R23EY005856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYOAMA A, 1993, MOL CELL BIOL, V13, P1824; CARVER JA, 1995, BBA-PROTEIN STRUCT M, V1252, P251, DOI 10.1016/0167-4838(95)00146-L; DAS KP, 1995, BIOCHEM J, V311, P367, DOI 10.1042/bj3110367; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1536; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LOWE J, 1992, J PATHOL, V166, P61, DOI 10.1002/path.1711660110; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1992, J BIOL CHEM, V267, P24648; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MERCK KB, 1993, J BIOL CHEM, V268, P1046; PETRASH JM, 1992, J BIOL CHEM, V267, P24833; RAMAN B, 1994, J BIOL CHEM, V269, P27264; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; SIEZEN RJ, 1983, BIOCHIM BIOPHYS ACTA, V748, P56, DOI 10.1016/0167-4838(83)90027-4; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; SUREWICZ WK, 1995, BIOCHEMISTRY-US, V34, P9655, DOI 10.1021/bi00030a001; VANDENIJSSEL PRLA, 1994, FEBS LETT, V355, P54, DOI 10.1016/0014-5793(94)01175-3; WANG KY, 1994, J BIOL CHEM, V269, P13601	34	112	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10449	10452		10.1074/jbc.271.18.10449	http://dx.doi.org/10.1074/jbc.271.18.10449			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631839	hybrid			2022-12-27	WOS:A1996UJ34200007
J	MartinezCosta, OH; Arias, P; Romero, NM; Parro, V; Mellado, RP; Malpartida, F				MartinezCosta, OH; Arias, P; Romero, NM; Parro, V; Mellado, RP; Malpartida, F			A relA/spoT homologous gene from Streptomyces coelicolor A3(2) controls antibiotic biosynthetic genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PROBE PLASMID VECTORS; ESCHERICHIA-COLI; STRINGENT RESPONSE; SECONDARY METABOLISM; NUCLEOTIDE-SEQUENCE; RIBOSOMAL-RNA; GUANOSINE TETRAPHOSPHATE; CLONING VECTORS; PHYSIOLOGICAL DIFFERENTIATION; TRANSCRIPTIONAL REGULATION	A 0.972-kilobase pair DNA fragment from Streptomyces lividans that induces the production of the blue-pigmented antibiotic actinorhodine in S, lividans when cloned on a multicopy plasmid has led to the isolation of a 4-kilobase pair DNA fragment from Streptomyces coelicolor containing homologous sequence, Computer-assisted analysis of the DNA sequence revealed three putative open reading frames (ORFs), ORF1, ORF2, and ORF3, ORF2 extends beyond the sequenced DNA fragment, and its deduced product shares no similarities with any other known proteins in the data bases, ORF3 is also truncated, and its 41-amino acid C-terminal product is identical 60 the S. coelicolor adenine phosphoribosyltransferase. The 847-amino acid ORF1 protein, with a predicted molecular mass of 94.2 kDa, strongly resembled the relA and spoT gene products from Escherichia coli and the homologs from Vibrio sp, strain S14, Haemophilus influenzae, Streptococcus equisimilis H46A, and Mycoplasma genitalium, Unlike these proteins, the ORF1 amino acid sequence analysis revealed the presence of a putative ATP/GTP-binding domain, A mutant was generated by deleting most of the ORF1 gene that showed an actinorhodine-nonproducing phenotype, while undecylprodigiosin and the calcium-dependent antibiotic were unaffected, The mutant strain grew at a much lower rate than the wild-type strain, and spore formation was delayed, When the gene was propagated on a low copy number vector, not only was actinorhodine production restored, but actinorhodine and undecylprodigiosin production was enhanced in both the mutant and wild-type strains and morphological differentiation returned to wild-type characteristics. (p)ppGpp synthetase activity was not detected in purified ribosomes from the ORF1-deleted mutant, while it was restored by complementation of this strain.	CSIC,CTR NACL BIOTECNOL,E-28049 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)			Parro, Victor/K-3788-2014; Mellado, Rafael P/D-2680-2009; Martinez-Costa, Oscar/B-7275-2014; Malpartida, Francisco/D-2563-2009	Martinez-Costa, Oscar/0000-0003-4893-2205; Parro, Victor/0000-0003-3738-0724				ADAMIDIS T, 1992, J BACTERIOL, V174, P4622, DOI 10.1128/JB.174.14.4622-4628.1992; ADAMIDIS T, 1990, J BACTERIOL, V172, P2962, DOI 10.1128/jb.172.6.2962-2969.1990; ANZAI H, 1987, J BACTERIOL, V169, P3482, DOI 10.1128/jb.169.8.3482-3488.1987; BARACCHINI E, 1988, J BIOL CHEM, V263, P2597; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BASCARAN V, 1991, J GEN MICROBIOL, V137, P1625, DOI 10.1099/00221287-137-7-1625; BIBB MJ, 1982, MOL GEN GENET, V187, P265, DOI 10.1007/BF00331128; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASHEL M, 1969, J BIOL CHEM, V244, P3133; Cashel M, 1987, ESCHERICHIA COLI SAL, P1410; CHAMPNESS W, 1992, GENE, V115, P55, DOI 10.1016/0378-1119(92)90540-6; CHAMPNESS W, 1990, J CELL BIOCHEM, V14, P88; CHAMPNESS WC, 1988, J BACTERIOL, V170, P1168, DOI 10.1128/jb.170.3.1168-1174.1988; CHAMPNESS WC, 1994, REGULATION OF BACTERIAL DIFFERENTIATION, P61; CHATER KF, 1985, EMBO J, V4, P1893, DOI 10.1002/j.1460-2075.1985.tb03866.x; CHATER KF, 1982, GENE, V19, P21, DOI 10.1016/0378-1119(82)90185-8; CHATER KF, 1983, GENE, V26, P67, DOI 10.1016/0378-1119(83)90037-9; CHATER KF, 1989, TRENDS GENET, V5, P372, DOI 10.1016/0168-9525(89)90172-8; COVARRUBIAS L, 1982, GENE, V17, P79, DOI 10.1016/0378-1119(82)90103-2; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DISTLER J, 1987, NUCLEIC ACIDS RES, V15, P8041, DOI 10.1093/nar/15.19.8041; FEHR S, 1981, J BACTERIOL, V145, P68, DOI 10.1128/JB.145.1.68-73.1981; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; FERNANDEZMORENO MA, 1992, J BACTERIOL, V174, P2958; FERNANDEZMORENO MA, 1991, CELL, V66, P769, DOI 10.1016/0092-8674(91)90120-N; FERNANDEZMORENO MA, 1994, J BIOL CHEM, V269, P24854; FLARDH K, 1994, J BACTERIOL, V176, P5949; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GALLANT JA, 1979, ANNU REV GENET, V13, P393, DOI 10.1146/annurev.ge.13.120179.002141; HARA A, 1983, J BIOL CHEM, V258, P1678; HARA O, 1983, J GEN MICROBIOL, V129, P2939; HODGSON DA, 1981, J GEN MICROBIOL, V124, P339; Hopwood D.A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1983, J GEN MICROBIOL, V129, P2257; HOPWOOD DA, 1983, J GEN MICROBIOL, V129, P3575; HOPWOOD DA, 1988, PROC R SOC SER B-BIO, V235, P121, DOI 10.1098/rspb.1988.0067; HORINOUCHI S, 1990, GENE, V95, P49, DOI 10.1016/0378-1119(90)90412-K; ISHIZUKA H, 1992, J BACTERIOL, V174, P7585, DOI 10.1128/JB.174.23.7585-7594.1992; JANSSEN GR, 1993, GENE, V124, P133, DOI 10.1016/0378-1119(93)90774-W; JONES GH, 1994, J BACTERIOL, V176, P1475, DOI 10.1128/jb.176.5.1475-1481.1994; JONES GH, 1994, J BACTERIOL, V176, P1482, DOI 10.1128/jb.176.5.1482-1487.1994; KELLY KS, 1991, J BACTERIOL, V173, P2297, DOI 10.1128/JB.173.7.2297-2300.1991; KROHN M, 1995, ANAL BIOCHEM, V225, P188, DOI 10.1006/abio.1995.1138; LAKEY JH, 1983, J GEN MICROBIOL, V129, P3565; LAWLOR EJ, 1987, GENE DEV, V1, P1305, DOI 10.1101/gad.1.10.1305; LAZZARINI RA, 1971, J BIOL CHEM, V246, P4381; LESKIW BK, 1991, P NATL ACAD SCI USA, V88, P2461, DOI 10.1073/pnas.88.6.2461; LESKIW BK, 1993, J BACTERIOL, V175, P1995, DOI 10.1128/JB.175.7.1995-2005.1993; LYDIATE DJ, 1985, GENE, V35, P223, DOI 10.1016/0378-1119(85)90001-0; MALPARTIDA F, 1986, MOL GEN GENET, V205, P66, DOI 10.1007/BF02428033; MALPARTIDA F, 1990, GENE, V93, P91, DOI 10.1016/0378-1119(90)90141-D; Maniatis T., 1982, MOL CLONING; MCCORMICK F, 1985, SCIENCE, V230, P78, DOI 10.1126/science.3898366; MECHOLD U, 1993, MOL GEN GENET, V241, P129, DOI 10.1007/BF00280210; MERRICK MJ, 1976, J GEN MICROBIOL, V96, P299, DOI 10.1099/00221287-96-2-299; METZGER S, 1989, J BIOL CHEM, V264, P21146; METZGER S, 1988, J BIOL CHEM, V263, P15699; MURRAY MG, 1986, ANAL BIOCHEM, V158, P165, DOI 10.1016/0003-2697(86)90605-6; NARVA KE, 1990, J BACTERIOL, V172, P326, DOI 10.1128/JB.172.1.326-333.1990; OCHI K, 1987, AGR BIOL CHEM TOKYO, V51, P829, DOI 10.1080/00021369.1987.10868121; OCHI K, 1984, J GEN MICROBIOL, V130, P2473; OCHI K, 1986, J GEN MICROBIOL, V132, P299; OCHI K, 1987, J GEN MICROBIOL, V133, P2787; OCHI K, 1986, J GEN MICROBIOL, V132, P2621, DOI 10.1099/00221287-132-9-2621; OCHI K, 1987, J BACTERIOL, V169, P3608, DOI 10.1128/jb.169.8.3608-3616.1987; OCHI K, 1990, J GEN MICROBIOL, V136, P2405, DOI 10.1099/00221287-136-12-2405; OCHI K, 1990, J BACTERIOL, V172, P4008, DOI 10.1128/jb.172.7.4008-4016.1990; OHNUKI T, 1985, J BACTERIOL, V164, P85, DOI 10.1128/JB.164.1.85-94.1985; PARKER J, 1976, MOL GEN GENET, V144, P111, DOI 10.1007/BF00277313; PETERSON SN, 1995, J BACTERIOL, V177, P3199, DOI 10.1128/jb.177.11.3199-3204.1995; RAMAGOPAL S, 1974, P NATL ACAD SCI USA, V71, P820, DOI 10.1073/pnas.71.3.820; RICE P, 1995, EMBNET NEWS, V2, P5; RIESENBERG D, 1984, J GEN MICROBIOL, V130, P2549; RUDD BAM, 1980, J GEN MICROBIOL, V119, P333; RYALS J, 1982, J BACTERIOL, V151, P1261, DOI 10.1128/JB.151.3.1261-1268.1982; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SARMIENTOS P, 1983, P NATL ACAD SCI-BIOL, V80, P7010, DOI 10.1073/pnas.80.22.7010; SARUBBI E, 1988, MOL GEN GENET, V213, P214, DOI 10.1007/BF00339584; SARUBBI E, 1989, J BIOL CHEM, V264, P15074; SCHREIBER G, 1991, J BIOL CHEM, V266, P3760; SHAND RF, 1989, J BACTERIOL, V171, P737, DOI 10.1128/jb.171.2.737-743.1989; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEIN D, 1989, J BACTERIOL, V171, P2258, DOI 10.1128/jb.171.4.2258-2261.1989; STEPHENS JC, 1975, P NATL ACAD SCI USA, V72, P4389, DOI 10.1073/pnas.72.11.4389; STRAUCH E, 1991, MOL MICROBIOL, V5, P289, DOI 10.1111/j.1365-2958.1991.tb02109.x; STUTZMANENGWALL KJ, 1992, J BACTERIOL, V174, P144, DOI 10.1128/jb.174.1.144-154.1992; SVITIL AL, 1993, J BIOL CHEM, V268, P2307; SY J, 1976, BIOCHEMISTRY-US, V15, P606, DOI 10.1021/bi00648a024; TAKANO E, 1992, MOL MICROBIOL, V6, P2797, DOI 10.1111/j.1365-2958.1992.tb01459.x; VOGTLI M, 1994, MOL MICROBIOL, V14, P643, DOI 10.1111/j.1365-2958.1994.tb01303.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARD JM, 1986, MOL GEN GENET, V203, P468, DOI 10.1007/BF00422072; WRIGHT F, 1992, GENE, V113, P55, DOI 10.1016/0378-1119(92)90669-G; WRIGHT LF, 1976, J GEN MICROBIOL, V95, P96, DOI 10.1099/00221287-95-1-96; WRIGHT LF, 1976, J GEN MICROBIOL, V96, P289, DOI 10.1099/00221287-96-2-289; XIAO H, 1991, J BIOL CHEM, V266, P5980; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	101	66	69	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10627	10634		10.1074/jbc.271.18.10627	http://dx.doi.org/10.1074/jbc.271.18.10627			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631867	hybrid			2022-12-27	WOS:A1996UJ34200035
J	Sackett, DL; KoskKosicka, D				Sackett, DL; KoskKosicka, D			The active species of plasma membrane Ca2+-ATPase are a dimer and a monomer-calmodulin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE CA-2+-ATPASE; MOLECULAR-CLONING; OLIGOMERIZATION; FLUORESCENCE; ASSOCIATION; ACTIVATION; ISOFORMS; BINDING; ATPASE; STATES	The purified plasma membrane Ca2+-ATPase is fully activated through the enzyme concentration-dependent self-association at physiologically relevant Ca2+ concentrations (Kosk-Kosicka, D., and Bzdega, T. (1988) J. Biol. Chem. 263, 18184-18189; Kosk-Kosicka, D., Bzdega, T., and Wawrzynow, A. (1989) J. Biol. Chem. 264, 19495-19499). We have previously shown that the Ca2+-ATPase activity of the oligomeric enzyme is independent of calmodulin, in contrast to another active enzyme species, a presumable monomer, that is activated by calmodulin binding, Presently, we have succeeded in determining the molecular mass of the two active enzyme species by equilibrium ultracentrifugation. For the calmodulin dependent species, the molecular mass is 170 +/- 30 kDa, which is consistent with predominantly monomeric Ca2+-ATPase with bound calmodulin, The molecular mass of calmodulin-independent oligomers is 260 +/- 34 kDa, indicating that they are dimers, Results of experiments performed under different calcium and potassium concentrations and in the presence of dextran that causes molecular crowding verify a strict Ca2+ requirement of the dimerization process, We conclude that the active species of the Ca2+-ATPase are a monomer-calmodulin complex and a dimer.	JOHNS HOPKINS UNIV,SCH MED,DEPT ANESTHESIOL & CRIT CARE MED,BALTIMORE,MD 21287; NIDDK,NIH,BIOCHEM PHARMACOL LAB,BETHESDA,MD 20892	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)					NIGMS NIH HHS [GM 447130] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GRAF E, 1981, ARCH BIOCHEM BIOPHYS, V210, P257, DOI 10.1016/0003-9861(81)90187-9; Harding S. E., 1992, ANAL ULTRACENTRIFUGA; KOSKKOSICKA D, 1990, ADV EXP MED BIOL, V269, P169; KOSKKOSICKA D, 1988, J BIOL CHEM, V263, P18184; KOSKKOSICKA D, 1989, J BIOL CHEM, V264, P19495; KOSKKOSICKA D, 1995, FEBS LETT, V371, P57, DOI 10.1016/0014-5793(95)00870-F; KOSKKOSICKA D, 1990, BIOCHEMISTRY-US, V29, P1875, DOI 10.1021/bi00459a030; KOSKKOSICKA D, 1990, BIOCHEMISTRY-US, V29, P3771; KOSKOSICKA D, 1986, J BIOL CHEM, V261, P3333; Laue T. M., 1994, MODERN ANAL ULTRACEN; MCCASLIN DR, 1981, BIOCHEMISTRY-US, V20, P5212, DOI 10.1021/bi00521a018; REYNOLDS JA, 1985, METHOD ENZYMOL, V117, P41; SACKETT DL, 1989, ANAL BIOCHEM, V180, P319, DOI 10.1016/0003-2697(89)90439-9; SACKETT DL, 1991, BIOCHEMISTRY-US, V30, P3511, DOI 10.1021/bi00228a023; SACKETT DL, 1993, BIOPHYS J, V64, pA334; SCHWARZENBACH G, 1957, HELV CHIM ACTA, V40, P1886, DOI 10.1002/hlca.19570400640; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; TANFORD C, 1977, J PHYS CHEM-US, V81, P1555, DOI 10.1021/j100531a007; VERMA AK, 1988, J BIOL CHEM, V263, P14152	24	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9987	9991		10.1074/jbc.271.17.9987	http://dx.doi.org/10.1074/jbc.271.17.9987			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626638	hybrid			2022-12-27	WOS:A1996UG25700022
J	Su, L; Zhao, Z; Bouchard, P; Banville, D; Fischer, EH; Krebs, EG; Shen, SH				Su, L; Zhao, Z; Bouchard, P; Banville, D; Fischer, EH; Krebs, EG; Shen, SH			Positive effect of overexpressed protein-tyrosine phosphatase PTP1C on mitogen-activated signaling in 293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SH3 DOMAINS; CORKSCREW; PHOSPHORYLATION; TRANSDUCTION; EXPRESSION; KINASES; HOMOLOG; SH-PTP2	PTP1C, an SH2 domain-containing protein-tyrosine phosphatase, is predominantly expressed in hematopoietic cells, in which it negatively regulates cellular signaling. However, this enzyme is also expressed in many non-hematopoietic cells. We demonstrate here that in non-hematopoietic 293 cells, overexpression of a catalytically inactive mutant of PTP1C strongly suppressed the stimulatory effects of the epidermal growth factor or serum on cell proliferation, early gene transcription, and DNA synthesis. Similarly, the phosphorylation of the mitogen-activated protein kinase and mitogen-activated protein kinase kinase activity was markedly inhibited by overexpression of mutant PTP1C. The inhibitory effect of mutant PTP1C was overcome by cotransfection with wild-type PTP1C, but not with the structurally related PTP2C. Furthermore, expression of the mutant phosphatase resulted in hyperphosphorylation on tyrosine of a 95-kDa protein that was co-immunoprecipitated with the mutant, but not with the wildtype protein. These results suggest that, unlike in hematopoietic cells, PTP1C in 293 cells plays a positive role in epidermal growth factor- or serum-activated mitogenesis. Thus, PTP1C participates in multiple signaling pathways, where the enzyme, depending on its target molecules, may function as either a positive or negative mediator.	NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,PHARMACEUT SECTOR,MONTREAL,PQ H4P 2R2,CANADA; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3G 1A4,CANADA	National Research Council Canada; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; McGill University								AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BANVILLE D, 1995, GENOMICS, V27, P165, DOI 10.1006/geno.1995.1020; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COSSETTE LJ, IN PRESS EXP CELL RE; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI RY, 1995, EMBO J, V14, P2519, DOI 10.1002/j.1460-2075.1995.tb07249.x; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MATOZAKI T, 1994, BIOCHEM BIOPH RES CO, V204, P874, DOI 10.1006/bbrc.1994.2541; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; REEVES SA, 1995, EUR J BIOCHEM, V233, P55, DOI 10.1111/j.1432-1033.1995.055_1.x; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; Treisman R, 1990, Semin Cancer Biol, V1, P47; UCHIDA T, 1993, J BIOL CHEM, V268, P11845; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	38	62	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10385	10390		10.1074/jbc.271.17.10385	http://dx.doi.org/10.1074/jbc.271.17.10385			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626611	hybrid			2022-12-27	WOS:A1996UG25700083
J	Charest, A; Wagner, J; Jacob, S; McGlade, CJ; Tremblay, ML				Charest, A; Wagner, J; Jacob, S; McGlade, CJ; Tremblay, ML			Phosphotyrosine-independent binding of SHC to the NPLH sequence of murine protein-tyrosine phosphatase-PEST - Evidence for extended phosphotyrosine binding phosphotyrosine interaction domain recognition specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; PHOSPHORYLATION; ASSOCIATION	The phosphotyrosine binding (PTB) or phosphotyrosine interaction (PI) domain of the proto-oncoprotein p52(SHC) binds to an NPXpY consensus sequence found in several growth factor receptors (Kavanaugh, W. M., Turck, C. W., and Williams, L. T. (1994) Science 268, 1177-1179), The amino terminal region of p52(SHC), which includes the PTB/PI domain, has been previously shown to associate with protein-tyrosine phosphatase-PEST (PTP-PEST) in vivo (Habib, T., Herrera, R., and Decker, S. J. (1994) J. Biol. Chem. 269, 25243-25246). We report here the detailed mapping of this interaction in a murine context using glutathione S-transferase fusion protein binding studies and peptide competition assays. We show that the interaction between murine SHC and murine PTP-PEST is mediated through the PTB/PI domain of murine SHC and an NPLH sequence found in the carboxyl terminus of murine PTP-PEST. Since this interaction is not dependent on the presence of a tyrosine-phosphorylated residue in the target sequence, this reveals that the PTB/PI domain of SHC can recognize both tyrosine-phosphorylated sequences and non-tyrosine-based recognition motifs.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2C1,CANADA; UNIV TORONTO,AMGEN INST,TORONTO,ON M5G 2C1,CANADA	McGill University; University of Toronto; University of Toronto								BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; Coligan JE, 1995, CURRENT PROTOCOLS PR; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; CROVELLO CS, 1995, CELL, V82, P279, DOI 10.1016/0092-8674(95)90315-1; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; HABIB T, 1994, J BIOL CHEM, V269, P25243; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; Moore DD, 1995, GLOB MOB SURV; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; TRUB T, 1995, J BIOL CHEM, V270, P18205; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	26	81	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8424	8429		10.1074/jbc.271.14.8424	http://dx.doi.org/10.1074/jbc.271.14.8424			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626541	hybrid			2022-12-27	WOS:A1996UD60000081
J	Chen, W; Steenbergen, C; Levy, LA; Vance, J; London, RE; Murphy, E				Chen, W; Steenbergen, C; Levy, LA; Vance, J; London, RE; Murphy, E			Measurement of free Ca2+ in sarcoplasmic reticulum in perfused rabbit heart loaded with 1,2-bis(2-amino-5,6-difluorophenoxy)ethane-N,N,N',N'-tetraacetic acid by F-19 NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-CONCENTRATION; INTRACELLULAR CA2+; SKELETAL-MUSCLE; ATP-HYDROLYSIS; ELECTRON-PROBE; FREE-ENERGY; CALSEQUESTRIN; RELEASE; CA-2+; MYOCYTES	Measurements of free calcium ion concentration in the sarcoplasmic reticulum ([Ca2+](SR)) and an evaluation of its relationship to changes in cytosolic free calcium and energy state of the cell, as well as heterogeneity of the SR calcium pool, were performed using F-19 NMR in Langendorff perfused rabbit hearts loaded with acetoxymethyl ester of 1,2-bis(2-amino-5,6-difiuorophenoxy)ethane-N,N,N',N'-tetraacetic acid. We report a base-line time-average [Ca2+](SR) value of 1.5 mM (n = 13) in the beating heart, similar to the value measured at diastole. We further report that [Ca2+](SR) decreases by similar to 30% at the start of systole and that there is no evidence of spacial heterogeneity in [Ca2+](SR) during the contraction cycle. However, there appears to be a heterogeneous response to SR calcium channel release activator (caffeine) and SR calcium-ATPase inhibitor (cyclopiazonic acid), consistent with studies suggesting that there are subpopulations of SR. Raising cytosolic free calcium by depolarizing the cell with 30 mM extracellular KCl, resulted in an increase in [Ca2+](SR); however, the calcium gradient was unchanged. Lowering cell phosphorylation potential, which would reduce the free energy available for the SR Ca2+-ATPase, leads to a decrease in the calcium gradient across the SR, but this reduced gradient was primarily due to an increase in cytosolic free calcium and not a net release of SR calcium.	DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA	Duke University	Chen, W (corresponding author), NIEHS, LAB MOLEC BIOPHYS, MD 4A-01, POB 12233, RES TRIANGLE PK, NC 27709 USA.		London, Robert E/F-7990-2019	London, Robert E/0000-0001-9108-8463	NHLBI NIH HHS [R01-HL39752, R01 HL039752] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039752] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN DG, 1983, J PHYSIOL-LONDON, V339, P107, DOI 10.1113/jphysiol.1983.sp014706; BARO I, 1993, J PHYSIOL-LONDON, V465, P21, DOI 10.1113/jphysiol.1993.sp019664; BASSANI JWM, 1994, J PHYSIOL-LONDON, V476, P279, DOI 10.1113/jphysiol.1994.sp020130; BASSANI JWM, 1993, AM J PHYSIOL, V265, pC533, DOI 10.1152/ajpcell.1993.265.2.C533; BASSANI JWM, 1995, AM J PHYSIOL-CELL PH, V268, pC1313, DOI 10.1152/ajpcell.1995.268.5.C1313; BAUDET S, 1993, CIRC RES, V73, P813, DOI 10.1161/01.RES.73.5.813; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; GRIESE M, 1988, J MOL CELL CARDIOL, V20, P1189, DOI 10.1016/0022-2828(88)90598-6; HASSELBACH W, 1983, ANNU REV PHYSIOL, V45, P325, DOI 10.1146/annurev.ph.45.030183.001545; HOERTER JA, 1988, AM J PHYSIOL, V255, pC192, DOI 10.1152/ajpcell.1988.255.2.C192; ISENBERG G, 1993, CARDIOVASC RES, V27, P1800, DOI 10.1093/cvr/27.10.1800; JORGENSEN AO, 1988, CIRC RES, V63, P1060, DOI 10.1161/01.RES.63.6.1060; KAMMERMEIER H, 1982, J MOL CELL CARDIOL, V14, P267, DOI 10.1016/0022-2828(82)90205-X; KIJIMA Y, 1993, J BIOL CHEM, V268, P3499; KODAMA T, 1985, PHYSIOL REV, V65, P467, DOI 10.1152/physrev.1985.65.2.467; KRAUSE KH, 1991, J BIOL CHEM, V266, P9453; KUPRIYANOV VV, 1993, J MOL CELL CARDIOL, V25, P1235, DOI 10.1006/jmcc.1993.1135; LONDON RE, 1994, AM J PHYSIOL, V266, pC1313, DOI 10.1152/ajpcell.1994.266.5.C1313; MARBAN E, 1988, CIRC RES, V63, P673, DOI 10.1161/01.RES.63.3.673; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; MURPHY E, 1994, AM J PHYSIOL, V266, pC1323, DOI 10.1152/ajpcell.1994.266.5.C1323; NIH, 1985, NIH PUBLICATION, V85-23; REIMER KA, 1981, CIRC RES, V49, P901, DOI 10.1161/01.RES.49.4.901; SMITH GL, 1992, J PHYSIOL-LONDON, V458, P457, DOI 10.1113/jphysiol.1992.sp019427; SOMLYO AV, 1985, J BIOL CHEM, V260, P6801; SOMLYO AV, 1981, J CELL BIOL, V90, P577, DOI 10.1083/jcb.90.3.577; STEENBERGEN C, 1990, CIRC RES, V66, P135, DOI 10.1161/01.RES.66.1.135; TANFORD C, 1983, ANNU REV BIOCHEM, V52, P379, DOI 10.1146/annurev.bi.52.070183.002115; VOLPE P, 1991, FEBS LETT, V278, P274, DOI 10.1016/0014-5793(91)80134-O; WATABE S, 1991, COMP BIOCHEM PHYS B, V99, P545, DOI 10.1016/0305-0491(91)90336-C; WATKINS MW, 1992, AM J PHYSIOL, V263, pH1811, DOI 10.1152/ajpheart.1992.263.6.H1811; WEBER A, 1968, J GEN PHYSIOL, V52, P750, DOI 10.1085/jgp.52.5.750; YOSHIOKA T, 1984, J CELL BIOL, V99, P558, DOI 10.1083/jcb.99.2.558	35	84	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7398	7403		10.1074/jbc.271.13.7398	http://dx.doi.org/10.1074/jbc.271.13.7398			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631764	hybrid			2022-12-27	WOS:A1996UC77400032
J	Ghosh, P; Sica, A; Cippitelli, M; Subleski, J; Lahesmaa, R; Young, HA; Rice, NR				Ghosh, P; Sica, A; Cippitelli, M; Subleski, J; Lahesmaa, R; Young, HA; Rice, NR			Activation of nuclear factor of activated T cells in a cyclosporin A-resistant pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERSUS-HOST DISEASE; REGULATORY ELEMENTS; ANTIGEN RECEPTOR; IDENTIFICATION; CALCINEURIN; EXPRESSION; PROMOTER; BINDING	The mechanism of action of the immunosuppressive drug cyclosporin A (CsA) is the inactivation of the Ca2+/calmodulin-dependent serine-threonine phosphatase calcineurin by the drug-immunophilin complex, Inactive calcineurin is unable to activate the nuclear factor of activated T cells (NFAT), a transcription factor required for expression of the interleukin 2 (IL-2) gene. IL-2 production by CsA-treated cells is therefore dramatically reduced, We demonstrate here, however, that NFAT can be activated, and significant levels of IL-2 can be produced by the CsA-resistant CD28-signaling pathway. In transient transfection assays, both multicopy NFAT- and IL-2 promoter-beta-galactosidase reporter gene constructs could be activated by phorbol 12-myristate 13-acetate (PMA)/alpha CD28 stimulation, and this activation was resistant to CsA. Electrophoretic mobility shift assay showed the induction of a CsA-resistant NFAT complex in the nuclear extracts of peripheral blood T cells stimulated with PMA plus alpha CD28. Peripheral blood T cells stimulated with PMA/alpha CD28 produced IL-2 in the presence of CsA. Collectively, these data suggest that NFAT can be activated and IL-2 can be produced in a calcineurin independent manner.	SAIC,EXPTL IMMUNOL LAB,DIV BASIC SCI,FREDERICK,MD 21702; SAIC,BIOL CARCINOGENESIS DEV PROGRAM,FREDERICK,MD 21702; SYNTEX RES,DEPT LEUKOCYTE BIOL,PALO ALTO,CA 94304; NCI,MOLEC BASIS CARCINOGENESIS LAB,ABL BASIC RES PROGRAM,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702	Science Applications International Corporation (SAIC); SAIC-Frederick; Science Applications International Corporation (SAIC); SAIC-Frederick; Syntex Corporation; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Cippitelli, Marco/AAF-4857-2021; Sica, Antonio/AAB-9546-2020; Young, Howard/A-6350-2008	Cippitelli, Marco/0000-0002-9620-538X; Young, Howard/0000-0002-3118-5111				BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; CHAN G, 1995, EUR J IMMUNOL, V25, P1999, DOI 10.1002/eji.1830250730; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GHOSH P, 1994, CANCER RES, V54, P2969; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; PAI SY, 1994, BLOOD, V84, P3974, DOI 10.1182/blood.V84.11.3974.bloodjournal84113974; PENIX L, 1993, J EXP MED, V178, P1483, DOI 10.1084/jem.178.5.1483; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; STORB R, 1985, IMMUNOL REV, V88, P215, DOI 10.1111/j.1600-065X.1985.tb01160.x; STORB R, 1986, BLOOD, V68, P119; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; VANLIER RAW, 1991, EUR J IMMUNOL, V21, P1775, DOI 10.1002/eji.1830210731; WOLFF RA, 1994, J BIOL CHEM, V269, P19605	27	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7700	7704		10.1074/jbc.271.13.7700	http://dx.doi.org/10.1074/jbc.271.13.7700			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631809	hybrid			2022-12-27	WOS:A1996UC77400077
J	Ryu, KS; Gilchrist, RL; Ji, I; Kim, SJ; Ji, TH				Ryu, KS; Gilchrist, RL; Ji, I; Kim, SJ; Ji, TH			Exoloop 3 of the luteinizing hormone choriogonadotropin receptor - Lys(583) essential and irreplaceable for human choriogonadotropin (hCG)-dependent receptor activation but not for high affinity hCG binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTROPIN RECEPTOR; SIGNAL GENERATION; ASP(397); REGIONS; DOMAIN	The luteinizing hormone/choriogonadotropin (CG) receptor belongs to a subfamily of glycoprotein hormone receptors within the seven-transmembrane receptor family, It is comprised of an extracellular N-terminal half of 341 amino acids and a membrane-associated C-terminal half of 303 amino acids. The N-terminal half is capable of high affinity hormone binding whereas the C-terminal half is capable of low affinity hormone binding and receptor activation, However, the precise location of the receptor activation site is currently unknown, We present evidence for the first time that Lys(583) of exoloop 3 is crucial and irreplaceable for receptor activation to induce cAMP synthesis, Exoloop 3 is comprised of 11 amino acids and flanked by two Lys residues, Lys(573) and Lys(583), that are located at the boundaries with the transmembrane columns 6 and 7, respectively, All substitutions including Arg for Lys(583) did not affect the high affinity human CG binding, but they resulted in the complete loss of cAMP synthesis induced by human CG, Ala substitutions of the other amino acids in exoloop 3 did not make such a dramatic impact on cAMP induction. The Ala scan revealed two distinct groups of amino acids in terms of their importance in cAMP induction, one group being more important than the other, Interestingly, these two groups of amino acids are arranged in an alternate sequence, This result suggests a specific structure similar to a beta-like structure for exoloop 3.	UNIV WYOMING,DEPT BIOL MOLEC,LARAMIE,WY 82071	University of Wyoming					NICHD NIH HHS [HD-18702] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; GROSSMANN M, 1995, MOL ENDOCRINOL, V9, P948, DOI 10.1210/me.9.8.948; JI I, 1993, J BIOL CHEM, V268, P20851; JI I, 1991, J BIOL CHEM, V266, P13076; JI I, 1981, P NATL ACAD SCI-BIOL, V78, P5465, DOI 10.1073/pnas.78.9.5465; JI I, 1990, GLYCOPROTEIN HORMONE, P355; JI IH, 1993, J BIOL CHEM, V268, P22971; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; KOSUGI S, 1993, MOL ENDOCRINOL, V7, P1009, DOI 10.1210/me.7.8.1009; KOSUGI S, 1994, FEBS LETT, V349, P89, DOI 10.1016/0014-5793(94)00646-6; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REMY JJ, 1993, BIOCHEM BIOPH RES CO, V193, P1023, DOI 10.1006/bbrc.1993.1727; ROCHE PC, 1992, ENDOCRINOLOGY, V131, P268, DOI 10.1210/en.131.1.268; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; WU DQ, 1995, J BIOL CHEM, V270, P9828, DOI 10.1074/jbc.270.17.9828; XIE YB, 1990, J BIOL CHEM, V265, P21411; YOO JK, 1993, J BIOL CHEM, V268, P13034; ZENG HW, 1995, ENDOCRINOLOGY, V136, P2948, DOI 10.1210/en.136.7.2948	22	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7301	7304		10.1074/jbc.271.13.7301	http://dx.doi.org/10.1074/jbc.271.13.7301			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631747	hybrid			2022-12-27	WOS:A1996UC77400015
J	Cole, JL; Carroll, SS; Kuo, LC				Cole, JL; Carroll, SS; Kuo, LC			Stoichiometry of 2',5' oligoadenylate-induced dimerization of ribonuclease L - A sedimentation equilibrium study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON ACTION	Ribonuclease L is an endoribonuclease that is activated by binding of 2',5'-linked oligoadenylates. Activation of ribonuclease L also induces dimerization. Here, we demonstrate using equilibrium sedimentation that dimerization requires the binding of one 5'-monophosphate 2',5'-(adenosine)(3) molecule per ribonuclease L monomer. No dimerization was observed in the absence of activator up to a protein concentration of 18 mu M, indicating that unliganded enzyme is unable to dimerize or the association is very weak. In parallel with dimerization, enzymatic activity is also maximized at a 1:1 activator: ribonuclease L stoichiometry. The same stoichiometry for dimerization is observed using a nonphosphorylated activator 2'-5'-(adenosine)(3). Adenosine triphosphate or RNA oligonucleotide substrates do not induce dimerization. The observed stoichiometry supports a model for ribonuclease L dimerization in which activator binds to monomer, which subsequently dimerizes.			Cole, JL (corresponding author), MERCK SHARP & DOHME RES LABS,DEPT BIOL CHEM,W POINT,PA 19486, USA.		Cole, James/G-2586-2011					Cohn E., 1943, PROTEINS AMINO ACIDS, P157; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; DONG BH, 1994, J BIOL CHEM, V269, P14153; DURCHSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; FLOYDSMITH G, 1981, SCIENCE, V212, P1030, DOI 10.1126/science.6165080; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; Wyman J., 1990, BINDING LINKAGE FUNC, P203; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	10	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					3979	3981						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626728				2022-12-27	WOS:A1996TW96000006
J	Derman, MP; Chen, JY; Spokes, KC; Zhou, SY; Cantley, LG				Derman, MP; Chen, JY; Spokes, KC; Zhou, SY; Cantley, LG			An 11-amino acid sequence from c-met initiates epithelial chemotaxis via phosphatidylinositol 3-kinase and phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR; CELLS; MOTILITY	Interaction of hepatocyte growth factor with its high affinity receptor c-met initiates a cascade of intracellular events leading to epithelial motility. An 11-amino acid sequence from the c-met receptor has been found to cause cell transformation in transfected fibroblasts (Ponzetto, C., Bardelli, A, Zhen, Z., Maina, F., Dalla, Z. P., Giordano, S., Graziani, A, Panayotou, G., and Comoglio, P. M. (1994) Cell 77, 261-271). We inserted this sequence into a mutant platelet-derived growth factor receptor (F5) to determine if this region of c-met can initiate cell motility and which signaling pathways it activates. The platelet-derived growth factor (PDGF) receptor/c-met hybrid (F5 met) initiated PDGF-dependent chemotaxis in renal epithelial cells (8.0 +/- 2.3 versus 70.5 +/- 4.8 cells/mm(2)), while the parental construct, F5, did not. Addition of PDGF to cells expressing F5 met caused activation of the phosphatidylinositol (PI) 3-kinase (control 2.0 +/- 0.8, +PDGF 17.1 +/- 5.1, n = 3, p < 0.05) and phospholipase C (control 478.5 +/- 67 dpm/well, +PDGF 1049.3 +/- 93, n = 4, p = 0.003), while neither pathway was activated in cells expressing F5. The chemotactic response of F5 met was inhibited by both the PI 3-kinase inhibitor wortmannin and the phospholipase C inhibitor U-71322. Selective activation of the PI 3-kinase utilizing a PDGF receptor mutant (F3) containing the native high affinity PI 3-kinase binding site also resulted in PDGF stimulated chemotaxis, although less than that generated by the c-met sequence. These findings demonstrate that the 11-amino acid sequence from c-met initiates epithelial motility via coincident activation of the PI 3-kinase and phospholipase C and that selective activation of the PI 3-kinase can initiate a partial chemotactic response.			Derman, MP (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV NEPHROL,DANA 517,330 BROOKLINE AVE,BOSTON,MA 02215, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044503, R01DK018078] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 18078, DK 44503] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BLEASDALE JE, 1993, NEUROPROTOCOLS, V3, P125; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CANTLEY LG, 1995, J AM SOC NEPHROL, V5, P1872; CANTLEY LG, 1994, AM J PHYSIOL, V267, pF271, DOI 10.1152/ajprenal.1994.267.2.F271; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; DERMAN MP, 1995, AM J PHYSIOL-RENAL, V268, pF1211, DOI 10.1152/ajprenal.1995.268.6.F1211; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; KUNDRA V, 1994, NATURE, V367, P464; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RAUCHMAN M, 1993, AM J PHYSIOL, V34, pF416; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WENNSTROM S, 1994, ONCOGENE, V9, P651	20	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4251	4255						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626770				2022-12-27	WOS:A1996TW96000048
J	Krebsbach, PH; Lee, SK; Matsuki, Y; Kozak, CA; Yamada, RM; Yamada, Y				Krebsbach, PH; Lee, SK; Matsuki, Y; Kozak, CA; Yamada, RM; Yamada, Y			Full-length sequence, localization, and chromosomal mapping of ameloblastin - A novel tooth-specific gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; ENAMEL; BONE; PHOSPHOPROTEIN; PURIFICATION; SIALOPROTEIN	We report the full-length sequencing, cell type-specific expression, and immunolocalization of a novel gene expressed in rat incisors, which we have designated ameloblastin. Northern blot analysis of RNA from multiple rat and mouse tissues demonstrated high levels of expression of two distinct transcripts of approximately 2.0 and 1.6 kilobase pairs that were expressed only in teeth. In situ hybridization using a digoxigenin-labeled RNA probe showed that the tissue distribution of ameloblastin was limited to the ameloblast in rat incisors. Immunohistochemical staining of rat incisors using a polyclonal antibody raised against a fusion protein revealed a unique localization pattern. Ameloblastin was found to be expressed during the differentiation of inner enamel epithelium into ameloblasts, with intense localization in the Tomes' processes of secretory ameloblasts. In contrast to amelogenin, only modest amounts of ameloblastin were detected in enamel matrix. The ameloblastin gene encodes an open reading frame of 422 amino acids corresponding to a putative protein of 45 kDa. The predicted protein is acidic (pI = 5.54) and the most abundant amino acids are Pro (15.2%), Gly (9.9%), and Leu (9.9%). We have also mapped the ameloblastin gene, Ambn, to a locus on mouse chromosome 5 near other genes associated with mineralized tissues. Thus, ameloblastin represents a unique ameloblast-specific gene product that may be important in enamel matrix formation and mineralization.	NIDR,DEV BIOL LAB,NIH,BETHESDA,MD 20892; NIAID,MOLEC MICROBIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Krebsbach, Paul H./AAC-4765-2021	Yamada, Kenneth/0000-0003-1512-6805				ADAMSON MC, 1991, VIROLOGY, V183, P778, DOI 10.1016/0042-6822(91)91010-E; BROOKES SJ, 1995, ARCH ORAL BIOL, V40, P1, DOI 10.1016/0003-9969(94)00135-X; Carter J., 1984, TOOTH ENAMEL, P229; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crall M G, 1992, Proc Finn Dent Soc, V88 Suppl 1, P285; CROSBY AH, 1995, GENOMICS, V27, P155, DOI 10.1006/geno.1995.1018; CROSBY AH, 1996, IN PRESS MAMMAL GENO; DEUTSCH D, 1991, J BIOL CHEM, V266, P16021; DEUTSCH D, 1989, ANAT RECORD, V224, P189, DOI 10.1002/ar.1092240209; FISHER LW, 1983, J BIOL CHEM, V258, P2723; FISHER LW, 1987, J BIOL CHEM, V262, P9702; FORSMAN K, 1994, HUM MOL GENET, V3, P1621, DOI 10.1093/hmg/3.9.1621; FUKAE M, 1987, CALCIFIED TISSUE INT, V40, P286, DOI 10.1007/BF02555263; GEORGE A, 1993, J BIOL CHEM, V268, P12624; GORSKI JP, 1988, J BIOL CHEM, V263, P15938; Green E., 1981, GENETICS PROBABILITY, DOI 10.1007/978-1-349-04904-2; JOWETT AK, 1993, DEVELOPMENT, V117, P461; KOLLAR EJ, 1991, J CRAN GENET DEV BIO, V11, P223; Kollar EJ, 1983, EPITHELIAL MESENCHYM, P27; KOZAK CA, 1990, GENOMICS, V8, P519, DOI 10.1016/0888-7543(90)90039-W; KOZAK CA, 1994, MAMM GENOME, V5, pS65; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEDOUARIN NM, 1993, DEV BIOL, V159, P24, DOI 10.1006/dbio.1993.1219; LUMSDEN AGS, 1984, C INSERM, V125, P29; LUMSDEN AGS, 1988, DEVELOPMENT S, V103, P55; LYU MS, 1995, MAMM GENOME, V6, P487, DOI 10.1007/BF00360663; MATSUKI Y, 1995, J DENT RES, V74, P307, DOI 10.1177/00220345950740010401; MATSUKI Y, 1995, ARCH ORAL BIOL, V40, P161, DOI 10.1016/0003-9969(94)00150-A; OSUMIYAMASHITA N, 1994, DEV BIOL, V164, P409, DOI 10.1006/dbio.1994.1211; Sambrook J, 1989, MOL CLONING LABORATO; SIMMER JP, 1994, CALCIFIED TISSUE INT, V55, P302, DOI 10.1007/BF00310410; TERMINE JD, 1980, J BIOL CHEM, V255, P9769; THESLEFF I, 1981, DIFFERENTIATION, V18, P75, DOI 10.1111/j.1432-0436.1981.tb01107.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WARSHAWSKY H, 1974, ANAT RECORD, V179, P423, DOI 10.1002/ar.1091790403	35	260	275	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4431	4435						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626794				2022-12-27	WOS:A1996TW96000072
J	PerezPaya, E; Houghten, RA; Blondelle, SE				PerezPaya, E; Houghten, RA; Blondelle, SE			Functionalized protein-like structures from conformationally defined synthetic combinatorial libraries	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCCURRING AMINO-ACIDS; PEPTIDES; STABILITY; ANTIBODY; MELITTIN; DESIGN	An approach is described for the de novo design of protein-like structures in which synthetic combinatorial libraries (SCLs) were incorporated into an amphipathic alpha-helical scaffold (an 18-mer sequence made up of leucine and lysine residues) to generate conformationally defined SCLs. In particular, the SCLs in which the ''combinatorialized'' positions were on the hydrophilic face showed an alpha-helical conformation in mild buffer. These SCLs were used to generate context-independent but position-dependent scales of alpha-helical propensity for the L-amino acids, These scales were then used to design highly alpha-helical peptides that self-associated in mild buffer. The same approach was also found to permit the identification of conformation-dependent decarboxylation catalysts.	TORREY PINES INST MOL STUDIES,SAN DIEGO,CA 92121	Torrey Pines Institute for Molecular Studies, California								ALTMANN KH, 1990, BIOPOLYMERS, V30, P107, DOI 10.1002/bip.360300112; BARBIER B, 1992, J AM CHEM SOC, V114, P3511, DOI 10.1021/ja00035a053; BIANCHI E, 1995, J MOL BIOL, V247, P154, DOI 10.1006/jmbi.1994.0129; BLONDELLE SE, 1992, BIOCHEMISTRY-US, V31, P12688, DOI 10.1021/bi00165a020; BLONDELLE SE, 1995, BIOPHYS J, V68, P351, DOI 10.1016/S0006-3495(95)80194-3; BLONDELLE SE, 1995, TRAC-TREND ANAL CHEM, V14, P83, DOI 10.1016/0165-9936(95)91476-9; BLONDELLE SE, 1995, PEPTIDES 94, P85; BLONDELLE SE, 1986, BIOCHEM J, V313, P141; CHAKRABARTTY A, 1994, PROTEIN SCI, V3, P843; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DEGRADO WF, 1993, NATURE, V365, P488, DOI 10.1038/365488a0; GOTO Y, 1992, BIOCHEMISTRY-US, V31, P732, DOI 10.1021/bi00118a014; HAHN KW, 1990, SCIENCE, V248, P1544, DOI 10.1126/science.2360048; HOROVITZ A, 1992, J MOL BIOL, V227, P560, DOI 10.1016/0022-2836(92)90907-2; HOUGHTEN RA, 1986, INT J PEPT PROT RES, V27, P673; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; JOHNSSON K, 1993, NATURE, V365, P530, DOI 10.1038/365530a0; LEHRMAN SR, 1990, BIOCHEMISTRY-US, V29, P5590, DOI 10.1021/bi00475a025; LEUSSING DL, 1980, J AM CHEM SOC, V102, P5635, DOI 10.1021/ja00537a039; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MUNOZ V, 1994, NAT STRUCT BIOL, V1, P399, DOI 10.1038/nsb0694-399; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSTRESH JM, 1994, BIOPOLYMERS, V34, P1681, DOI 10.1002/bip.360341212; PEREZPAYA E, 1995, J BIOL CHEM, V270, P1048, DOI 10.1074/jbc.270.3.1048; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; QUAY SC, 1985, BIOCHIM BIOPHYS ACTA, V831, P22, DOI 10.1016/0167-4838(85)90144-X; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SASAKI T, 1989, J AM CHEM SOC, V111, P380, DOI 10.1021/ja00183a065; SORAVIA E, 1988, FEBS LETT, V228, P337, DOI 10.1016/0014-5793(88)80027-9; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; ZHOU NE, 1992, J BIOL CHEM, V267, P2664; ZHOU NE, 1994, PROTEIN PEPTIDE LETT, V1, P114	34	52	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4120	4126						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626750				2022-12-27	WOS:A1996TW96000028
J	Robinson, KM; Lemire, BD				Robinson, KM; Lemire, BD			Covalent attachment of FAD to the yeast succinate dehydrogenase flavoprotein requires import into mitochondria, presequence removal, and folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C HEME LYASE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; 6-HYDROXY-D-NICOTINE OXIDASE; FUMARATE REDUCTASE; PROTEIN IMPORT; CYTOCHROME-C; SUBUNIT; PRECURSOR; MEMBRANE	Succinate dehydrogenase (EC 1.3.99.1) in the yeast Saccharomyces cerevisiae is a mitochondrial respiratory chain enzyme that utilizes the cofactor, FAD, to catalyze the oxidation of succinate and the reduction of ubiqinone. The succinate dehydrogenase enzyme is a heterotetramer composed of a flavoprotein, an iron-sulfur protein, and two hydrophobic subunits. The FAD is covalently attached to a histidine residue near the amino terminus of the flavoprotein. In this study, we have investigated the attachment of the FAD cofactor with the use of an antiserum that specifically recognizes FAD and hence, can discriminate between apo- and holoflavoproteins. Cofactor attachment, both in vivo and in vitro, occurs within the mitochondrial matrix once the presequence has been cleaved. FAD attachment is stimulated by, but not dependent upon, the presence of the iron-sulfur subunit and citric acid cycle intermediates such as succinate, malate, or fumarate. Furthermore, this modification does not occur with C-terminally truncated flavoprotein subunits that are fully competent for import. Taken together, these data suggest that cofactor addition occurs to an imported protein that has folded sufficiently to recognize both FAD and its substrate.	UNIV ALBERTA, DEPT BIOCHEM, MED RES COUNCIL CANADA, GRP MOL BIOL MEMBRANES, EDMONTON, AB T6G 2H7, CANADA	University of Alberta								Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; AHMAD PM, 1991, FASEB J, V5, P2482, DOI 10.1096/fasebj.5.10.2065895; BRANDSCH R, 1992, J BIOL CHEM, V267, P20844; BRANDSCH R, 1991, J BIOL CHEM, V266, P19056; BRANDSCH R, 1993, J BIOL CHEM, V268, P12724; BRANDSCH R, 1989, EUR J BIOCHEM, V182, P125, DOI 10.1111/j.1432-1033.1989.tb14808.x; BRANDT A, 1991, METHOD CELL BIOL, V34, P369; BULLIS BL, 1994, J BIOL CHEM, V269, P6543; CECCHINI G, 1985, FED PROC, V44, P1766; CHAPMAN KB, 1992, GENE, V118, P131, DOI 10.1016/0378-1119(92)90260-V; COLE ST, 1985, BIOCHIM BIOPHYS ACTA, V811, P381, DOI 10.1016/0304-4173(85)90008-4; DAIGNANFORNIER B, 1994, J BIOL CHEM, V269, P15469; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DUMONT ME, 1991, MOL CELL BIOL, V11, P5487, DOI 10.1128/MCB.11.11.5487; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FLEIG UN, 1986, GENE, V46, P237, DOI 10.1016/0378-1119(86)90408-7; GASSER SM, 1982, J BIOL CHEM, V257, P3034; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GROSS NH, 1984, METHOD ENZYMOL, V107, P261; HEDERSTEDT L, 1982, J BACTERIOL, V152, P157; HEDERSTEDT L, 1980, J BACTERIOL, V144, P933, DOI 10.1128/JB.144.3.933-940.1980; HOTTIGER T, 1994, YEAST, V10, P283, DOI 10.1002/yea.320100302; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; KOTLYAR AB, 1984, BIOCHIM BIOPHYS ACTA, V784, P24, DOI 10.1016/0167-4838(84)90168-7; LOMBARDO A, 1990, J BIOL CHEM, V265, P10419; LOMBARDO A, 1992, MOL CELL BIOL, V12, P2941, DOI 10.1128/MCB.12.7.2941; NARGANG FE, 1988, J BIOL CHEM, V263, P9388; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; Robinson KM, 1995, METHOD ENZYMOL, V260, P34, DOI 10.1016/0076-6879(95)60128-7; ROBINSON KM, 1991, J BIOL CHEM, V266, P21347; ROBINSON KM, 1994, EUR J BIOCHEM, V222, P983, DOI 10.1111/j.1432-1033.1994.tb18949.x; Robinson KM, 1996, J BIOL CHEM, V271, P4061; ROBINSON KM, 1992, J BIOL CHEM, V267, P10101; SCHMIDT DM, 1992, BIOCHEMISTRY-US, V31, P8442, DOI 10.1021/bi00151a008; SCHMIDT U, 1969, ADV ENZYMOL RAMB, V32, P423; SCHULKE N, 1992, P NATL ACAD SCI USA, V89, P8011, DOI 10.1073/pnas.89.17.8011; SCHWARZ E, 1994, BBA-BIOENERGETICS, V1187, P270, DOI 10.1016/0005-2728(94)90125-2; SHARMA CP, 1986, J BIOL CHEM, V261, P1146; Stuart R A, 1993, Trends Cell Biol, V3, P135, DOI 10.1016/0962-8924(93)90176-2; TARONI F, 1991, J BIOL CHEM, V266, P13267; WU M, 1995, MOL CELL BIOL, V15, P264, DOI 10.1128/MCB.15.1.264; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	43	68	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4055	4060						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626739				2022-12-27	WOS:A1996TW96000017
J	Street, JC; Mahmood, U; Ballon, D; Alfieri, AA; Koutcher, JA				Street, JC; Mahmood, U; Ballon, D; Alfieri, AA; Koutcher, JA			C-13 and P-31 NMR investigation of effect of 6-aminonicotinamide on metabolism of RIF-1 tumor cells in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; TRICARBOXYLIC-ACID CYCLE; GLYCOGEN-METABOLISM; INVITRO; INVIVO; ENERGY; LIVER	The effect of 6-aminonicotinamide on the metabolism of RIF-1 tumor cells was investigated using C-13 and P-31 NMR spectroscopy, 6-Aminonicotinamide can be metabolized to 6-amino-NAD(P), a competitive inhibitor of NAD(P)-requiring processes. 40 mu M 6-aminonicotinamide led to an inhibition of 6-phosphogluconate dehydrogenase and an accumulation of 6-phosphogluconate. A subsequent accumulation of the 6-phosphogluconate precursor 6-phosphoglucono-delta-lactone was observed in the C-13 NMR spectrum, These metabolites were shown to be intracellular, although a small amount of leakage of 6-phosphoglucono-delta-lactone occurred. The intracellular concentrations of 6-phosphogluconate and 6-phosphoglucono-delta-lactone were 1.9 +/- 0.8 mu mol/10(8) cells (+/- 1 standard deviation) and 0.8 +/- 0.4 mu mol/10(8) cells, respectively, after 15 h. Glucose utilization and lactate production were significantly inhibited by 6-aminonicotinamide (both p < 0.05), indicating inhibition of glycolysis, P-31 NMR data showed that phosphocreatine was significantly depleted in cells exposed to 6-aminonicotinamide (p < 0.05), Exposure of RLF-1 cells to 6-aminonicotinamide prior to 3- or 6-Gy x-irradiation induced a supra-additive cell kill, indicating that 6-aminonicotinamide is acting as a radiosensitizer. There was no effect of 6-aminonicotinamide alone or when the drug was given postradiation, suggesting that its mechanism of action may be by inhibition of radiation-induced repair.	MEM SLOAN KETTERING CANC CTR,DEPT RADIOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT MED,NEW YORK,NY 10021; BETH ISRAEL MED CTR,NEW YORK,NY 10003	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Harvard University; Beth Israel Deaconess Medical Center	Street, JC (corresponding author), MEM SLOAN KETTERING CANC CTR,DEPT MED PHYS,1275 YORK AVE,NEW YORK,NY 10021, USA.			Mahmood, Umar/0000-0001-7414-6123; Ballon, Douglas/0000-0002-7162-9020	NCI NIH HHS [P0 1 CA 25842] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA025842] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLON D, 1993, MAGNET RESON MED, V30, P754, DOI 10.1002/mrm.1910300615; BAUER HP, 1983, EUR J BIOCHEM, V133, P163, DOI 10.1111/j.1432-1033.1983.tb07442.x; BELL JD, 1993, BIOCHIM BIOPHYS ACTA, V1225, P71, DOI 10.1016/0925-4439(93)90124-J; BENHORIN H, 1995, CANCER RES, V55, P2814; BERGER NA, 1982, CANCER RES, V42, P4382; BHUJWALLA ZM, 1994, MAGNET RESON MED, V32, P303, DOI 10.1002/mrm.1910320305; BLAZER RM, 1980, J AM CHEM SOC, V102, P5082, DOI 10.1021/ja00535a045; BRODIE AF, 1955, J BIOL CHEM, V212, P677; COHEN SM, 1987, BIOCHEMISTRY-US, V26, P581, DOI 10.1021/bi00376a033; COPER H, 1964, BIOCHIM BIOPHYS ACTA, V82, P167, DOI 10.1016/0304-4165(64)90023-6; DIETRICH LS, 1958, J BIOL CHEM, V233, P964; DIETRICH LS, 1958, CANCER RES, V18, P1272; GALONS JP, 1990, INT J CANCER, V45, P168, DOI 10.1002/ijc.2910450130; Geschickter C.F., 1930, J CHEM EDUC, DOI [10.1021/ed007p179, DOI 10.1021/ED007P179]; HERTER FP, 1960, CANCER RES, V21, P31; HUNTING D, 1985, BIOCHEM PHARMACOL, V34, P3999, DOI 10.1016/0006-2952(85)90379-X; KAHANA SE, 1960, J BIOL CHEM, V235, P2178; KAUFFMAN FC, 1974, J NEUROBIOL, V5, P379, DOI 10.1002/neu.480050502; KENIRY MA, 1989, BIOCHEM BIOPH RES CO, V164, P947, DOI 10.1016/0006-291X(89)91550-7; KOHLER E, 1970, FEBS LETT, V6, P225, DOI 10.1016/0014-5793(70)80063-1; KUNNECKE B, 1993, NMR BIOMED, V6, P264, DOI 10.1002/nbm.1940060406; KUNNECKE B, 1991, BIOCHIM BIOPHYS ACTA, V1095, P103, DOI 10.1016/0167-4889(91)90071-5; LANGE K, 1970, N-S ARCH PHARMAKOL, V267, P177, DOI 10.1007/BF00999399; LEVINTOW L, 1961, ANNU REV BIOCHEM, V30, P605, DOI 10.1146/annurev.bi.30.070161.003133; LOWRY OH, 1964, J BIOL CHEM, V239, P18; MAHMOOD U, 1995, CANCER RES, V55, P1248; MALLOY CR, 1990, AM J PHYSIOL, V259, pH987, DOI 10.1152/ajpheart.1990.259.3.H987; MCCOMB RB, 1964, CANCER RES, V24, P198; MILLER WM, 1989, BIOTECHNOL BIOENG, V33, P477, DOI 10.1002/bit.260330413; NAVON G, 1989, FEBS LETT, V247, P86, DOI 10.1016/0014-5793(89)81246-3; NAVON G, 1977, P NATL ACAD SCI USA, V74, P87, DOI 10.1073/pnas.74.1.87; OFORINKANSAH N, 1972, N-S ARCH PHARMAKOL, V272, P156, DOI 10.1007/BF00508766; RADDA GK, 1986, SCIENCE, V233, P640, DOI 10.1126/science.3726553; REITZER LJ, 1980, J BIOL CHEM, V255, P5616; RHEINWALD JG, 1964, CELL, V2, P287; ROTHMAN DL, 1991, SCIENCE, V254, P573, DOI 10.1126/science.1948033; SHINKARENKO L, 1994, NMR BIOMED, V7, P209, DOI 10.1002/nbm.1940070503; SINGER S, 1993, CANCER RES, V53, P5808; SINGER S, 1993, SURG ONCOL, V2, P7, DOI 10.1016/0960-7404(93)90039-2; STOLFI RL, 1992, CANCER RES, V52, P4074; STREET JC, 1993, BIOCHEM J, V291, P485, DOI 10.1042/bj2910485; Varnes M E, 1988, NCI Monogr, P199; [No title captured]	43	33	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4113	4119						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626749				2022-12-27	WOS:A1996TW96000027
J	Sakano, S; Takemura, H; Yamada, K; Imoto, K; Kaneko, M; Ohshika, H				Sakano, S; Takemura, H; Yamada, K; Imoto, K; Kaneko, M; Ohshika, H			Ca2+ mobilizing action of sphingosine in Jurkat human leukemia T cells - Evidence that sphingosine releases Ca2+ from inositol trisphosphate- and phosphatidic acid-sensitive intracellular stores through a mechanism independent of inositol trisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PAROTID ACINAR-CELLS; DIACYLGLYCEROL KINASE; CALCIUM RELEASE; SIGNAL-TRANSDUCTION; HUMAN NEUTROPHILS; ANTIGEN RECEPTOR; PLASMA-MEMBRANE; PHOSPHOLIPASE-D; CA-2+ POOL	Effects of sphingosine on Ca2+ mobilization in the human Jurkat T cell line mere examined. Sphingosine increased the cytoplasmic Ca2+ concentration ([Ca2+](i)) in a dose-dependent manner with an ED(50) of around 8 mu M. Sphingosine and OKT3, a CD3 monoclonal antibody, transiently increased [Ca2+](i), which declined to the resting level in the absence of extracellular Ca2+, Under the same conditions, pretreatment with sphingosine inhibited but did not abolish an increase in [Ca2+](i) induced by the subsequent addition of OKT3 and vice versa, However, pretreatment with sphingosine did not affect an increase in [Ca2+](i) induced by OKT3 in the presence of Ca2+. OKT3 increased IP3 formation, but sphingosine did not affect the level of IP3 by itself nor did it cause IP3 formation induced by OKT3, In permeabilized Jurkat cells, the addition of IP3 released Ca2+ from nonmitochondrial intracellular stores, but the addition of sphingosine did not. Sphingosine, stearylamine, and psychosine increased [Ca2+](i) and diacylglycerol (DG) kinase activation; however, ceramide did not, whereas sphingosine 1-phosphate slightly activated DG kinase without elevation of [Ca2+](i). Pretreatment with R59022, a DG kinase inhibitor, abolished the peak but did not affect the sustained response of [Ca2+](i) to sphingosine. Phosphatidic acid (PA) elevated [Ca2+](i), after which it declined to a resting level even in the presence of extracellular Ca2+. In accordance with this, PA did not stimulate Ca-45(2+) uptake into cells, but sphingosine and OKT3 did, Pretreatment with PA partially inhibited a rise in [Ca2+](i) induced by the subsequent addition of sphingosine and vice versa in the absence of extracellular Ca2+. Under similar conditions, pretreatment with PA affected an elevation of [Ca2+](i) induced by OKT3 less, after which the subsequent addition of sphingosine did not increase [Ca2+](i). In permeabilized Jurkat cells, the addition of IP3 did not release Ca2+, but PA did in the presence of heparin. Pretreatment with thapsigargin, a microsomal Ca2+-ATPase inhibitor, abolished the rises of [Ca2+](i) induced by the subsequent addition of sphingosine, OKT3, and PA in the absence of extracellular Ca2+. The present results suggest that at least two binds of intracellular Ca2+ stores exist in Jurkat cells, both of which are IP3- and PA-sensitive, and that sphingosine mobilizes Ca2+ from both stores in an IP3-independent manner, Furthermore, the IP3- but not the PA-sensitive intracellular Ca2+ store seems to regulate Ca2+ entry induced by sphingosine.	HOKKAIDO UNIV,SCH MED,DEPT PHARMACOL,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,SCH MED,DEPT EMERGENCY & CRIT CARE MED,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,SCH HLTH SCI,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University; Hokkaido University; Hokkaido University				Sakano, Shoji/0000-0003-2509-1917				ARNOLD RS, 1991, BIOCHEMISTRY-US, V30, P7747, DOI 10.1021/bi00245a011; AVIRAM A, 1990, CELL CALCIUM, V11, P269, DOI 10.1016/0143-4160(90)90003-D; BREITTMAYER JP, 1994, J BIOL CHEM, V269, P5054; BREITTMAYER JP, 1991, IMMUNOLOGY, V73, P134; CHAO CP, 1994, J BIOL CHEM, V269, P5849; CHOW SC, 1990, CELL CALCIUM, V11, P641, DOI 10.1016/0143-4160(90)90018-P; CHOW SC, 1990, J BIOL CHEM, V265, P902; CLEMENTI E, 1994, EUR J IMMUNOL, V24, P1365, DOI 10.1002/eji.1830240619; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DESAI NN, 1992, J BIOL CHEM, V267, P23122; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; GILLO B, 1993, BLOOD, V81, P783; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUSE AH, 1993, BIOCHEM J, V291, P447, DOI 10.1042/bj2910447; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1989, CLIN CHIM ACTA, V185, P333, DOI 10.1016/0009-8981(89)90224-6; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HASHIZUME T, 1992, BIOCHEM J, V282, P243, DOI 10.1042/bj2820243; HOYT DB, 1994, SHOCK, V2, P23, DOI 10.1097/00024382-199407000-00005; IMBODEN JB, 1985, J IMMUNOL, V134, P663; IMBODEN JB, 1987, BIOCHEM J, V247, P695, DOI 10.1042/bj2470695; JEFFERSON AB, 1988, J BIOL CHEM, V263, P15241; KIM MY, 1991, J BIOL CHEM, V266, P484; KIM S, 1995, J BIOL CHEM, V270, P5266, DOI 10.1074/jbc.270.10.5266; KISS Z, 1992, BIOCHEM J, V288, P853, DOI 10.1042/bj2880853; LAVIE Y, 1990, FEBS LETT, V277, P7, DOI 10.1016/0014-5793(90)80796-L; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LEMAITRE RN, 1990, BIOCHEM J, V266, P291, DOI 10.1042/bj2660291; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MCDONALD OB, 1991, J BIOL CHEM, V266, P21773; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; NAARALA J, 1993, FEBS LETT, V330, P222, DOI 10.1016/0014-5793(93)80278-3; NATARAJAN V, 1994, AM J RESP CELL MOL, V11, P221, DOI 10.1165/ajrcmb.11.2.8049083; NG J, 1990, BIOCHIM BIOPHYS ACTA, V1053, P97, DOI 10.1016/0167-4889(90)90031-8; OISHI K, 1990, J BIOL CHEM, V265, P70; PARTISETI M, 1994, J BIOL CHEM, V269, P32327; PAWELCZYK T, 1992, ARCH BIOCHEM BIOPHYS, V297, P328, DOI 10.1016/0003-9861(92)90680-U; PREMACK BA, 1992, AM J PHYSIOL, V263, pC1119, DOI 10.1152/ajpcell.1992.263.6.C1119; PUSHKAREVA MY, 1992, J BIOL CHEM, V267, P15246; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RITCHIE T, 1992, BIOCHEM BIOPH RES CO, V186, P790, DOI 10.1016/0006-291X(92)90815-3; SABBADINI R, 1993, BIOCHEM BIOPH RES CO, V193, P752, DOI 10.1006/bbrc.1993.1689; SABBADINI RA, 1992, J BIOL CHEM, V267, P15475; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SUGIYA H, 1991, FEBS LETT, V286, P113, DOI 10.1016/0014-5793(91)80953-Z; SUGIYA H, 1990, CELL CALCIUM, V11, P469, DOI 10.1016/0143-4160(90)90079-A; TAKEMURA H, 1995, LIFE SCI, V56, P1443, DOI 10.1016/0024-3205(95)00107-H; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TENG CM, 1994, THROMB HAEMOSTASIS, V71, P517; TORNQUIST K, 1994, BIOCHEM J, V299, P213, DOI 10.1042/bj2990213; WONG K, 1993, CELL CALCIUM, V14, P493, DOI 10.1016/0143-4160(93)90008-T; YAMADA K, 1993, BIOCHIM BIOPHYS ACTA, V1169, P217; YULE DI, 1993, J BIOL CHEM, V268, P12353; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	62	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11148	11155		10.1074/jbc.271.19.11148	http://dx.doi.org/10.1074/jbc.271.19.11148			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626660	hybrid			2022-12-27	WOS:A1996UJ94400020
J	Fominaya, J; Wels, W				Fominaya, J; Wels, W			Target cell-specific DNA transfer mediated by a chimeric multidomain protein - Novel non-viral gene delivery system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS EXOTOXIN; ERBB-2 RECEPTOR; ADENOVIRUS ENHANCEMENT; EXPRESSION; INVIVO; ENDOCYTOSIS; COMPLEXES; HEPATOCYTES; FRAGMENT; CARRIER	Based on the multidomain structure of the bacterial Pseudomonas exotoxin A, a recombinant fusion protein was constructed which serves as a target cell-specific carrier for the transfer of DNA via receptor-mediated endocytosis. The protein consists of three functional do mains: 1) an ErbB-2-specific single chain antibody confers target cell specificity, 2) the exotoxin A translocation domain facilitates endosome escape, and 3) a DNA binding domain derived from the yeast GAL4 protein enables sequence-specific high affinity binding to DNA. Carrier protein purified from bacterial lysates displayed both ErbB-2-specific and DNA sequence-specific binding in vitro., Complexes which formed spontaneously by the interaction of the fusion protein with a luciferase reporter gene construct carrying a GAL4-specific recognition sequence, after condensation of the DNA and compensation of excess negative charge with poly L-lysine were able to transfect ErbB-2-expressing cells in vitro in a cell specific manner. Transient expression of the luciferase gene driven by the SV40 early promoter was observed and correlates with the amount of carrier protein in the complex, Truncated forms of the carrier protein lacking either the cell recognition domain or the translocation domain failed to facilitate efficient DNA transfer.	INST EXPTL CANC RES,TUMOR BIOL CTR,D-79106 FREIBURG,GERMANY					Wels, Winfried/0000-0001-9858-3643				BAEZA I, 1987, BIOCHEMISTRY-US, V26, P6387, DOI 10.1021/bi00394a012; BLOOMFIELD VA, 1991, BIOPOLYMERS, V31, P1471, DOI 10.1002/bip.360311305; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCHLE M, 1995, HUM GENE THER, V6, P753, DOI 10.1089/hum.1995.6.6-753; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHEN J, 1994, HUM GENE THER, V5, P429, DOI 10.1089/hum.1994.5.4-429; CHEN JB, 1994, FEBS LETT, V338, P167, DOI 10.1016/0014-5793(94)80357-9; CHEN SY, 1995, GENE THER, V2, P116; CHOWDHURY NR, 1993, J BIOL CHEM, V268, P11265; COTTEN M, 1990, P NATL ACAD SCI USA, V87, P4033, DOI 10.1073/pnas.87.11.4033; COTTEN M, 1992, P NATL ACAD SCI USA, V89, P6094, DOI 10.1073/pnas.89.13.6094; Cotten Matt, 1993, Current Opinion in Biotechnology, V4, P705, DOI 10.1016/0958-1669(93)90053-Y; CRISTIANO RJ, 1993, P NATL ACAD SCI USA, V90, P2122, DOI 10.1073/pnas.90.6.2122; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; DONNELLY JJ, 1993, P NATL ACAD SCI USA, V90, P3530, DOI 10.1073/pnas.90.8.3530; FISHER KJ, 1994, BIOCHEM J, V299, P49, DOI 10.1042/bj2990049; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOUILLEUX F, 1991, NUCLEIC ACIDS RES, V19, P1563, DOI 10.1093/nar/19.7.1563; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; LEDLEY FD, 1995, HUM GENE THER, V6, P1129, DOI 10.1089/hum.1995.6.9-1129; MCKEE TD, 1994, BIOCONJUGATE CHEM, V5, P306, DOI 10.1021/bc00028a004; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MERWIN JR, 1994, BIOCONJUGATE CHEM, V5, P612, DOI 10.1021/bc00030a017; MICHAEL SI, 1994, GENE THER, V1, P223; MIDOUX P, 1993, NUCLEIC ACIDS RES, V21, P871, DOI 10.1093/nar/21.4.871; OGATA M, 1992, J BIOL CHEM, V267, P25396; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; PERALES JC, 1994, EUR J BIOCHEM, V226, P255, DOI 10.1111/j.1432-1033.1994.tb20049.x; PLANK C, 1994, J BIOL CHEM, V269, P12918; PLANK C, 1992, BIOCONJUGATE CHEM, V3, P533, DOI 10.1021/bc00018a012; PRIOR TI, 1991, CELL, V64, P1017, DOI 10.1016/0092-8674(91)90325-S; READ RJ, 1993, CURR OPIN STRUC BIOL, V3, P853, DOI 10.1016/0959-440X(93)90148-E; REMY JS, 1995, P NATL ACAD SCI USA, V92, P1744, DOI 10.1073/pnas.92.5.1744; ROSS GF, 1995, HUM GENE THER, V6, P31, DOI 10.1089/hum.1995.6.1-31; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; STANKOVICS J, 1994, HUM GENE THER, V5, P1095, DOI 10.1089/hum.1994.5.9-1095; TRUBETSKOY VS, 1992, BIOCONJUGATE CHEM, V3, P323, DOI 10.1021/bc00016a011; WAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; WELS W, 1995, INT J CANCER, V60, P137, DOI 10.1002/ijc.2910600120; WELS W, 1992, BIO-TECHNOL, V10, P1128, DOI 10.1038/nbt1092-1128; WELS W, 1992, CANCER RES, V52, P6310; WILSON JM, 1992, J BIOL CHEM, V267, P963; WU GY, 1987, J BIOL CHEM, V262, P4429; WU GY, 1988, J BIOL CHEM, V263, P14621; WU GY, 1994, J BIOL CHEM, V269, P11542; WU GY, 1991, J BIOL CHEM, V266, P14338; YANG J, 1991, EMBO J, V10, P2291, DOI 10.1002/j.1460-2075.1991.tb07765.x; YIN WN, 1994, BIOCHEM BIOPH RES CO, V205, P826, DOI 10.1006/bbrc.1994.2739; ZENKE M, 1990, P NATL ACAD SCI USA, V87, P3655, DOI 10.1073/pnas.87.10.3655	56	118	150	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10560	10568		10.1074/jbc.271.18.10560	http://dx.doi.org/10.1074/jbc.271.18.10560			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631856	hybrid			2022-12-27	WOS:A1996UJ34200024
J	Xie, XQ; Melvin, LS; Makriyannis, A				Xie, XQ; Melvin, LS; Makriyannis, A			The conformational properties of the highly selective cannabinoid receptor ligand CP-55,940	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBIT ADENYLATE-CYCLASE; NUCLEIC-ACIDS; FORCE-FIELD; PROTEINS; SPECTROSCOPY; RESOLUTION; COSY	During a search for novel drugs possessing analgesic properties but devoid of the psychotropic effects of marijuana, a group of molecules designated as nonclassical cannabinoids was synthesized by Pfizer. Of these non classical cannabinoids CP-55,940 has received the most attention principally because it was used as the high affinity radioligand during the discovery and characterization of the G-protein-coupled cannabinoid receptor. In an effort to obtain information on the stereoelectronic requirements at the cannabinoid receptor active site, me have studied the conformational properties of CP-55,940 using a combination of solution NMR and computer modeling methods. Our data show that for the most energetically favored conformation, (i) the aromatic phenol ring is perpendicular to the cyclohexane ring, and the phenolic O-H bond is coplanar with the aromatic ring and points away from the cyclohexyl ring; ii) the dimethylheptyl chain adopts one of four preferred conformations in all of which the chain is almost perpendicular to the phenol ring; and iii) an intramolecular H-bond between the phenolic and hydroxypropyl groups allows all three hydroxyl groups of CP-55,940 to be oriented toward the upper face of the molecule. Such an orientation by the OH groups may be a characteristic requirement for cannabimimetic activity.	UNIV CONNECTICUT,SCH PHARM,DEPT PHARMACEUT SCI,STORRS,CT 06269; UNIV CONNECTICUT,INST SCI MAT,STORRS,CT 06269; MIT,FRANCIS BITTER NATL MAGNET LAB,CAMBRIDGE,MA 02139; PFIZER INC,CENT RES,GROTON,CT 06340	University of Connecticut; University of Connecticut; Massachusetts Institute of Technology (MIT); Pfizer			Makriyannis, Alexandros/GRF-1518-2022	Makriyannis, Alexandros/0000-0003-3272-3687	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007215, R01DA003801, R37DA003801] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-3801, DA-00152, DA-07215] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; *BIOS INC, BIOS INS DISC VERS 2; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; Booth H., 1969, PROGR NMR SPECTROSCO, V5, P149; BOUABOULA M, 1993, EUR J BIOCHEM, V214, P173, DOI 10.1111/j.1432-1033.1993.tb17910.x; DEWEY WL, 1986, PHARMACOL REV, V38, P151; DIEHL P, 1972, NMR BASIC PRINCIPLES, P1; FESIK SW, 1989, COMPUTER AIDED DRUG, P56; HAGLER AT, 1985, SCIENCE, V227, P1309, DOI 10.1126/science.3975616; HERBETTE LG, 1994, DRUG DEVELOP RES, V33, P214, DOI 10.1002/ddr.430330305; HOWLETT AC, 1988, MOL PHARMACOL, V33, P297; HOWLETT AC, 1990, TRENDS NEUROSCI, V13, P420, DOI 10.1016/0166-2236(90)90124-S; HOWLETT AC, 1990, NEUROPHARMACOLOGY, V29, P161, DOI 10.1016/0028-3908(90)90056-W; Jeffrey G.A., 1991, HYDROGEN BONDING BIO, DOI [10.1007/ 978- 3- 642- 85135- 3, DOI 10.1007/978-3-642-85135-3, 10.1007/978-3-642-85135-3]; Johnson M.R., 1986, CANNABINOIDS THERAPE, P121; JOHNSON MR, 1981, J CLIN PHARMACOL, V21, P271; KAMINSKI NE, 1992, MOL PHARMACOL, V42, P736; KESSLER H, 1987, METHODS STEREOCHEMIC, V9, P153; KRIWACKI RW, 1989, MOL PHARMACOL, V35, P495; MAKRIYANNIS A, 1990, LIFE SCI, V47, P2173, DOI 10.1016/0024-3205(90)90147-J; MAKRIYANNIS A, 1995, CANNABINOID RECEPTOR, P87; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Mechoulam R., 1986, CANNABINOIDS THERAPE, DOI [10.1201/9780429260667, DOI 10.1201/9780429260667]; MELVIN LS, 1984, J MED CHEM, V27, P67, DOI 10.1021/jm00367a013; MELVIN LS, 1996, IN PRESS MOL NEUROPH; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; ONDA M, 1988, B CHEM SOC JPN, V16, P4015; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REGGIO PH, 1989, J MED CHEM, V32, P1630, DOI 10.1021/jm00127a038; REGGIO PH, 1987, J MOL STRUCT, V149, P331; RHODES DG, 1985, MOL PHARMACOL, V27, P612; ROSENQVIST E, 1975, ACTA CHEM SCAND B, VB 29, P379, DOI 10.3891/acta.chem.scand.29b-0379; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; XIE XQ, 1994, J MED CHEM, V37, P1418, DOI 10.1021/jm00036a006	35	49	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10640	10647		10.1074/jbc.271.18.10640	http://dx.doi.org/10.1074/jbc.271.18.10640			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631869	hybrid			2022-12-27	WOS:A1996UJ34200037
J	Frederikse, PH; Garland, D; Zigler, JS; Piatigorsky, J				Frederikse, PH; Garland, D; Zigler, JS; Piatigorsky, J			Oxidative stress increases production of beta-amyloid precursor protein and beta-amyloid (A beta) in mammalian lenses, and A beta has toxic effects on lens epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; ALZHEIMERS-DISEASE; PHASE-SEPARATION; CATARACT FORMATION; ACTIVATION; MOUSE; OPACIFICATION; FIBROBLASTS; DEPOSITION; MECHANISM	Many amyloid diseases are characterized by protein aggregations linked to oxidative stress. Such diseases including those of the brain, muscle, and blood vessels exhibit plaques containing beta-amyloid (A beta). Here we demonstrate that Alzheimer's precursor protein (beta APP) and A beta are present at low levels in normal lenses and increase in intact cultured monkey lenses treated with H2O2 or UV radiation (known cataractogenic agents), and with phorbol 12-myristate 13-acetate. AP-1 factor binding, shown by others to up-regulate beta APP expression, increased in the monkey lenses treated with H2O2, UV radiation, or phorbol 12-myristate 13-acetate and paralleled the increase in beta APP expression. Rat lenses exposed to oxidative stress showed increased beta APP in the anterior epithelium and cortex. Incubation of cultured rabbit lens N/N1003A epithelial cells with A beta induced inclusions and vacuoles and was cytotoxic. A beta cross-reacting protein was readily detected in the cortex of a cataractous human lens. Our data show that beta APP and A beta increase in mammalian lenses as part of a response to H2O2 or UV radiation and suggest that they may contribute to the mechanism by which oxidative damage leads to lens opacification.	NEI, LAB MECHANISMS OCULAR DIS, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Frederikse, PH (corresponding author), NEI, MOLEC & DEV BIOL LAB, NIH, 6 CTR DR, MSC 2730, BETHESDA, MD 20892 USA.							APPLEBY DW, 1977, P NATL ACAD SCI USA, V74, P5579, DOI 10.1073/pnas.74.12.5579; BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; BEHL C, 1994, BRAIN RES, V645, P253, DOI 10.1016/0006-8993(94)91659-4; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BENDICH A, 1995, J AM COLL NUTR, V14, P124; BENEDEK GB, 1971, APPL OPTICS, V10, P459, DOI 10.1364/AO.10.000459; BEYREUTHER K, 1993, ANN NY ACAD SCI, V695, P91, DOI 10.1111/j.1749-6632.1993.tb23035.x; BRAS A, 1989, OPHTHALMIC PAED GEN, V10, P271, DOI 10.3109/13816818909009882; BRON AJ, 1993, EYE, V7, P260, DOI 10.1038/eye.1993.60; CLARK JI, 1982, INVEST OPHTH VIS SCI, V22, P186; CLARK JI, 1987, P NATL ACAD SCI USA, V84, P122, DOI 10.1073/pnas.84.1.122; CLARK JI, 1980, INVEST OPHTH VIS SCI, V19, P771; CLARK JI, 1983, J GERONTOL, V38, P287, DOI 10.1093/geronj/38.3.287; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; DAVISSALINAS J, 1995, J NEUROCHEM, V65, P931; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; GSELL W, 1995, J NEUROCHEM, V64, P1216; HALVERSON K, 1990, BIOCHEMISTRY-US, V29, P2639, DOI 10.1021/bi00463a003; HAYDEN JH, 1980, EXPERIENTIA, V36, P116, DOI 10.1007/BF02004009; HOLLOWS F, 1981, LANCET, V2, P1249; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; IWAKI T, 1992, AM J PATHOL, V140, P345; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1992, BIOCHEMISTRY-US, V31, P12345, DOI 10.1021/bi00164a008; JEDZINIAK JA, 1973, EXP EYE RES, V15, P185, DOI 10.1016/0014-4835(73)90118-8; JEDZINIAK JA, 1978, INVEST OPHTH VIS SCI, V171, P51; JOACHIM CL, 1989, J GERONTOL, V44, pB77, DOI 10.1093/geronj/44.4.B77; Kador P.F., 1994, PRINCIPLES PRACTICE, P146; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KUCK JFR, 1983, EXP EYE RES, V36, P351, DOI 10.1016/0014-4835(83)90117-3; LAVER NM, 1993, EXP EYE RES, V57, P493, DOI 10.1006/exer.1993.1151; LI WC, 1994, EXP EYE RES, V59, P179, DOI 10.1006/exer.1994.1096; LOFFLER KU, 1995, INVEST OPHTH VIS SCI, V36, P24; LOTT IT, 1992, PROG CLIN BIOL RES, V379, P1; LOWE J, 1990, LANCET, V336, P515, DOI 10.1016/0140-6736(90)92075-S; MAJOCHA RE, 1994, CELL MOL NEUROBIOL, V14, P425, DOI 10.1007/BF02088829; MARESPERLMAN JA, 1994, OPHTHALMOLOGY, V101, P315; MATTSON MP, 1995, BRAIN RES, V676, P219, DOI 10.1016/0006-8993(95)00148-J; MAURY CPJ, 1995, LAB INVEST, V72, P4; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; MURAKAMI N, 1995, ACTA NEUROPATHOL, V89, P29, DOI 10.1007/BF00294256; NAGATA M, 1989, EXP EYE RES, V48, P667, DOI 10.1016/0014-4835(89)90008-0; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; OSGOOD TB, 1986, INVEST OPHTH VIS SCI, V27, P1780; OYAMA F, 1994, J NEUROCHEM, V62, P1062; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PITTS DG, 1986, OPTICAL RAD VISUAL H, P5; QUERFURTH HW, 1995, MOL BRAIN RES, V28, P319, DOI 10.1016/0169-328X(94)00224-3; REDDAN JR, 1986, DIFFERENTIATION, V33, P168, DOI 10.1111/j.1432-0436.1986.tb00422.x; ROBISON WG, 1990, EXP EYE RES, V50, P641, DOI 10.1016/0014-4835(90)90107-6; ROTHSTEIN H, 1982, OPHTHALMIC RES, V14, P215, DOI 10.1159/000265195; RUSSELL P, 1977, INVEST OPHTH VIS SCI, V16, P243; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; SKODRAS G, 1993, ANN CLIN LAB SCI, V23, P275; SPECTOR A, 1995, EXP EYE RES, V60, P471, DOI 10.1016/S0014-4835(05)80062-4; SPECTOR A, 1995, EXP EYE RES, V60, P483, DOI 10.1016/S0014-4835(05)80063-6; SPECTOR A, 1972, ISRAEL J MED SCI, V8, P1577; SPECTOR A, 1984, INVEST OPHTH VIS SCI, V25, P130; Spector A, 1990, CLAO J, V16, pS8; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; Taylor J. Richard, 1994, Journal of Dermatological Science, V8, P224, DOI 10.1016/0923-1811(94)90059-0; TREJO J, 1994, J BIOL CHEM, V269, P21682; TSUKADA T, 1993, ONCOGENE, V8, P3313; TUMMINIA SJ, 1994, EXP EYE RES, V58, P367, DOI 10.1006/exer.1994.1027; UEDA K, 1989, ANN NEUROL, V25, P246, DOI 10.1002/ana.410250307; WATT JA, 1994, BRAIN RES, V661, P147, DOI 10.1016/0006-8993(94)91191-6; Worgul B V, 1989, Lens Eye Toxic Res, V6, P559; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YOSHIOKA K, 1991, BIOCHEM BIOPH RES CO, V178, P1141, DOI 10.1016/0006-291X(91)91011-Z; ZIGLER JS, 1989, INVEST OPHTH VIS SCI, V30, P2195; ZIGLER JS, 1985, EXP EYE RES, V41, P67, DOI 10.1016/0014-4835(85)90095-8; ZIGLER JS, 1990, EXP EYE RES, V50, P651, DOI 10.1016/0014-4835(90)90109-8	79	167	175	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10169	10174		10.1074/jbc.271.17.10169	http://dx.doi.org/10.1074/jbc.271.17.10169			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626578	hybrid			2022-12-27	WOS:A1996UG25700050
J	Boudreaux, JM; Towler, DA				Boudreaux, JM; Towler, DA			Synergistic induction of osteocalcin gene expression - Identification of a bipartite element conferring fibroblast growth factor 2 and cyclic AMP responsiveness in the rat osteocalcin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST PHENOTYPE; MC3T3-E1 CELLS; DIFFERENTIATION; PROLIFERATION; TRANSCRIPTION	Fibroblast growth factors (FGFs) are important regulators of calvarial osteoblast growth and differentiation. We have studied the regulation of the osteoblast-specific gene osteocalcin (OC) by FGF2 in phenotypically immature MC3T3-E1 calvarial osteoblastic cells. FGF2 markedly induces OC mRNA accumulation in MC3T3-E1 cells in She presence of forskolin (FSK). Similarly, OC promoter activity (luciferase reporter) is up-regulated 6-10-fold by FGF2/FSK or by FGF2/8-bromo cyclic AMP. Half-maximal induction of OC promoter activity occurs at 1 nM FGF2, By 5' deletion analysis and dinucleotide point mutations, we map one component of this FGF2/FSK response to a GCAGTCA motif in the region -144 to -138 relative to the OC transcription initiation site. The OC promoter region -154 to -90 confers FGF2/FSK responsiveness on the Rous sarcoma virus minimal promoter. By 3' and internal deletion analyses, the region between -90 to -99 is also found to be necessary for FGF2/FSK synergy (encodes a PuGGTCA motif previously identified as a component of FSK induction). A DNA binding activity that recognizes the region -148 to -125 of the rat OC promoter is induced in crude nuclear extracts from MC3T3-E1 cells treated with FGF2 or FGF2/FSK. This binding activity is sequence-specific and does not recognize the TCAGTCA DNA cognate of AP1. Members of the ATF, Fos, and Jun family are not immunologically detected in this inducible DNA binding activity. However, transient co-expression of ATF3 but not ATF2 selectively attenuates the FGF2 component of induction. Thus, a novel FGF2-regulated DNA-protein interaction in the OC promoter participates in the transcriptional control of OC expression by FGF and cyclic AMP in MC3T3-E1 calvarial osteoblasts.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)				Towler, Dwight/0000-0003-2107-7923				CHEN BPC, 1994, J BIOL CHEM, V269, P15819; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN MM, 1993, AM J MED GENET, V47, P581, DOI 10.1002/ajmg.1320470507; DEMAY MB, 1989, J BIOL CHEM, V264, P2279; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; DUCY P, 1995, MOL CELL BIOL, V15, P1858; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235; FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843; FRENKEL B, 1994, P NATL ACAD SCI USA, V91, P10923, DOI 10.1073/pnas.91.23.10923; GLOBUS RK, 1988, ENDOCRINOLOGY, V123, P98, DOI 10.1210/endo-123-1-98; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HOFFMANN HM, 1994, P NATL ACAD SCI USA, V91, P12887, DOI 10.1073/pnas.91.26.12887; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; HURLEY MM, 1993, J BIOL CHEM, V268, P5588; JABS EW, 1994, NAT GENET, V8, P275, DOI 10.1038/ng1194-275; KUDLA AJ, 1995, MOL CELL BIOL, V15, P3238; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LONG MW, 1995, J CLIN INVEST, V95, P881, DOI 10.1172/JCI117738; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; NAGAI H, 1993, GROWTH FACTORS, V9, P73; NAKAMURA T, 1995, ENDOCRINOLOGY, V136, P1276, DOI 10.1210/en.136.3.1276; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PITARU S, 1993, J BONE MINER RES, V8, P919; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; ROBEY PG, 1993, J BONE MINER RES, V8, P483; RODAN G A, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P85; RODAN SB, 1989, J BIOL CHEM, V264, P19934; SCHEDLICH LJ, 1994, J BONE MINER RES, V9, P143; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TAMURA M, 1994, J CELL BIOL, V126, P773, DOI 10.1083/jcb.126.3.773; TAN Y, 1994, MOL CELL BIOL, V14, P7546, DOI 10.1128/MCB.14.11.7546; TONG HS, 1994, J BONE MINER RES, V9, P577; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P1484, DOI 10.1210/me.8.11.1484; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; TOWLER DA, 1995, ENDOCRINOLOGY, V136, P1089, DOI 10.1210/en.136.3.1089; VERHEIJEN MHG, 1995, ENDOCRINOLOGY, V136, P3331, DOI 10.1210/en.136.8.3331	41	90	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7508	7515		10.1074/jbc.271.13.7508	http://dx.doi.org/10.1074/jbc.271.13.7508			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631781	hybrid			2022-12-27	WOS:A1996UC77400049
J	Johnson, RE; Kovvali, GK; Prakash, L; Prakash, S				Johnson, RE; Kovvali, GK; Prakash, L; Prakash, S			Requirement of the yeast MSH3 and MSH6 genes for MSH2-dependent genomic stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; COLORECTAL-CANCER; MISMATCH REPAIR; MUTATIONS; INSTABILITY; HOMOLOG; COLON; DNA	Defects in DNA mismatch repair result in instability of simple repetitive DNA sequences and elevated levels of spontaneous mutability. The human G/T mismatch binding protein, GTBP/p160, has been suggested to have a role in the repair of base-base and single nucleotide insertion-deletion mismatches. Here we examine the role of the yeast GTBP homolog, MSH6, in mismatch repair. We show that both MSH6 and MSH3 genes are essential for normal genomic stability. Interestingly, although mutations in either MSH3 or MSH6 do not cause the extreme microsatellite instability and spontaneous mutability observed in the msh2 mutant, yeast cells harboring null mutations in both the MSH3 and MSH6 genes exhibit microsatellite instability and mutability similar to that in the msh2 mutant. Results from epistasis analyses indicate that MSH2 functions in mismatch repair in conjunction with MSH3 or MSH6 and that MSH3 and MSH6 constitute alternate pathways of MSH2-dependent mismatch repair.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Satya/C-6420-2013; Prakash, Louise/C-7891-2012	Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261	NATIONAL CANCER INSTITUTE [R37CA041261, R01CA041261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019261] Funding Source: NIH RePORTER; NCI NIH HHS [CA 41261] Funding Source: Medline; NIGMS NIH HHS [GM 19261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HENDERSON ST, 1992, MOL CELL BIOL, V12, P2749, DOI 10.1128/MCB.12.6.2749; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; NEW L, 1993, MOL GEN GENET, V239, P97, DOI 10.1007/BF00281607; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; REENAN RAG, 1992, GENETICS, V132, P975; STRAND M, 1995, P NATL ACAD SCI USA, V92, P10418, DOI 10.1073/pnas.92.22.10418; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367	27	165	165	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7285	7288		10.1074/jbc.271.13.7285	http://dx.doi.org/10.1074/jbc.271.13.7285			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631743				2022-12-27	WOS:A1996UC77400011
J	Wang, Z; Schultheis, PJ; Shull, GE				Wang, Z; Schultheis, PJ; Shull, GE			Three n-terminal variants of the AE2 Cl-/HCO3- exchanger are encoded by mRNAs transcribed from alternative promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL INITIATION; INTRACELLULAR PH; ANION-EXCHANGER; MESSENGER-RNAS; CDNA CLONING; BAND-3 GENE; PROTEIN; KIDNEY; ORGANIZATION; LOCALIZATION	Multiple AE2 Cl-/HCO3- exchanger mRNAs have been identified in rat. To determine the genetic basis for these mRNAs and whether they encode different variants of the exchanger, we used both rapid amplification of cDNA ends and S1 nuclease protection protocols and examined the organization of the gene. mRNAs encoding three N-terminal variants of AE2 (AE2a, AE2b, and AE2c) were identified and shown to be transcribed from alternative promoters. The AE2a transcription unit consists of 23 exons, with exons 1 and 2 containing 5'-untranslated sequence and the first 17 codons. The first exon of AE2b is located in intron 2; it contains 5'-untranslated sequence and an alternative 3-amino acid N-terminal coding sequence and is spliced to exon 3. The first exon of AE2c is located in intron 5; it consists of 5'-untranslated sequence and is spliced to exon 6, which contains the translation initiation codon corresponding to Met-200 of AE2a. Northern analysis shows that AE2a is expressed in all tissues, AE2b exhibits a more restricted distribution with highest levels in stomach, and AE2c is expressed only in stomach. Thus, the use of alternative promoters leads to the production of three N-terminal variants of AE2 that exhibit tissue-specific patterns of expression.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati					NHLBI NIH HHS [HL 41496] Funding Source: Medline; NIDDK NIH HHS [DK 39626] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039626] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPER SL, 1987, KIDNEY INT, V32, pS117; ALPER SL, 1988, J BIOL CHEM, V263, P17092; ALPER SL, 1994, CELL PHYSIOL BIOCHEM, V4, P265, DOI 10.1159/000154730; ALPERN RJ, 1987, J GEN PHYSIOL, V89, P581, DOI 10.1085/jgp.89.4.581; Binder HJ, 1989, GASTROINTESTINAL DIS, V2, P1022; BOOKSTEIN C, 1994, J CLIN INVEST, V93, P106, DOI 10.1172/JCI116933; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHOW A, 1992, AM J PHYSIOL, V263, pG345, DOI 10.1152/ajpgi.1992.263.3.G345; COX KH, 1995, J BIOL CHEM, V270, P19752, DOI 10.1074/jbc.270.34.19752; COX KH, 1995, AM J PHYSIOL-RENAL, V268, pF503, DOI 10.1152/ajprenal.1995.268.3.F503; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; GEHRIG H, 1992, BIOCHIM BIOPHYS ACTA, V1130, P326, DOI 10.1016/0167-4781(92)90446-7; GREEN J, 1992, AM J PHYSIOL, V262, pC111, DOI 10.1152/ajpcell.1992.262.1.C111; HEBERT SC, 1986, AM J PHYSIOL, V250, pC290; JENNINGS ML, 1992, KIDNEY PHYSL PATHOPH, P503; KIM HRC, 1989, MOL CELL BIOL, V9, P5198, DOI 10.1128/MCB.9.11.5198; KOLLERTJONS A, 1993, AM J PHYSIOL, V265, pF813, DOI 10.1152/ajprenal.1993.265.6.F813; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1987, J BIOL CHEM, V262, P8035; KOPITO RR, 1987, P NATL ACAD SCI USA, V84, P7149, DOI 10.1073/pnas.84.20.7149; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KOZAK M, 1988, J CELL BIOL, V107, P1, DOI 10.1083/jcb.107.1.1; KUDRYCKI KE, 1993, AM J PHYSIOL, V264, pF540, DOI 10.1152/ajprenal.1993.264.3.F540; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; LINN SC, 1992, J BIOL CHEM, V267, P7927; LINN SC, 1995, CIRC RES, V76, P584, DOI 10.1161/01.RES.76.4.584; MALINOWSKA DH, 1988, BIOCHIM BIOPHYS ACTA, V972, P95, DOI 10.1016/0167-4889(88)90106-1; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; RATHJEN PD, 1990, CELL, V62, P1105, DOI 10.1016/0092-8674(90)90387-T; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SEIDLER U, 1992, AM J PHYSIOL, V262, pG81, DOI 10.1152/ajpgi.1992.262.1.G81; STUARTTILLEY A, 1994, AM J PHYSIOL, V266, pC559, DOI 10.1152/ajpcell.1994.266.2.C559; WEINERT ID, 1994, AM J PHYSIOL, V250, pF952; YANNOUKAKOS D, 1994, CIRC RES, V75, P603, DOI 10.1161/01.RES.75.4.603	38	81	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7835	7843		10.1074/jbc.271.13.7835	http://dx.doi.org/10.1074/jbc.271.13.7835			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631828	hybrid			2022-12-27	WOS:A1996UC77400096
J	Zund, G; Madara, JL; Dzus, AL; Awtrey, CS; Colgan, SP				Zund, G; Madara, JL; Dzus, AL; Awtrey, CS; Colgan, SP			Interleukin-8 and interleukin-13 differentially regulate epithelial chloride secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARRIER FUNCTION; ELECTROLYTE TRANSPORT; IMMUNE-RESPONSES; IFN-GAMMA; CELLS; MONOLAYERS; EXPRESSION; RECEPTORS; CYTOKINE; GROWTH	Intestinal epithelia are in intimate contact with subepithelial and intraepithelial lymphocytes. When stimulated, mucosal lymphocytes generate cytokines that act locally and influence functional aspects of many cell types. We have previously defined functional epithelial receptors for interferon-gamma, interleukin (IL)-4, and a recently described IL-4-like cytokine IL-13. In this study, we examine the ion transport properties of T84 cells, a crypt-like epithelial cell line, following exposure to IL-4 and IL-13. Basolateral exposure of epithelial monolayers to both IL-4 and IL-13 attenuated epithelial barrier function and increased paracellular flux of a dextran marker by greater than 65% in a dose- and time-dependent fashion. Stimulated Cl- secretion, as measured by epithelial short circuit current, however, was diminished only by IL-4 and not IL-13, demonstrating cytokine specificity in this epithelial function. Decreased Cl- secretion following IL-4 exposure was associated with diminished Cl- channel activity and IL-4 pretreatment of epithelia decreased expression of the cystic fibrosis transmembrane regulator. Finally, stimulated fluid transport across cultured epithelia was diminished following exposure to IL-4, but not IL-13. These results indicate that while post-receptor signaling events induced by IL-13 and IL-4 may be similar, end point function is cytokine-specific.	BRIGHAM & WOMENS HOSP,DEPT ANESTHESIA,CTR EXPT THERAPEUT & REPERFUS INJURY,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV GASTROINTESTINAL PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD DIGEST DIS CTR,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Colgan, Sean P./B-4573-2009		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037932, R01DK050189, R01DK047662, R37DK050189, R29DK050189] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47662, DK 37932, DK 50189] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS RB, 1993, J IMMUNOL, V150, P2356; ALAWQATI Q, 1995, SCIENCE, V269, P805, DOI 10.1126/science.7543697; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; Bensancon F, 1994, AM J PHYSIOL, V267, pC1398; CIACCI C, 1993, J CLIN INVEST, V92, P527, DOI 10.1172/JCI116598; COLGAN SP, 1993, J CELL BIOL, V120, P785, DOI 10.1083/jcb.120.3.785; COLGAN SP, 1994, J IMMUNOL, V153, P2122; COLGAN SP, 1994, AM J PHYSIOL, V267, P402; DHARMSATHAPHORN K, 1990, METHOD ENZYMOL, V192, P354; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HOLMGREN J, 1989, SCAND J IMMUNOL, V30, P499, DOI 10.1111/j.1365-3083.1989.tb02456.x; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KUROKOWA M, 1987, BIOCHEM BIOPH RES CO, V142, P775, DOI 10.1016/0006-291X(87)91481-1; MADARA JL, 1989, J CLIN INVEST, V83, P724, DOI 10.1172/JCI113938; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MULLIN JM, 1990, CANCER RES, V50, P2172; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; POWELL DW, 1981, AM J PHYSIOL, V241, pG275, DOI 10.1152/ajpgi.1981.241.4.G275; POWELL DW, 1987, PHYSL GASTROINTESTIN, P1267; QUIDING M, 1991, J CLIN INVEST, V88, P143, DOI 10.1172/JCI115270; REINECKER HC, 1995, P NATL ACAD SCI USA, V92, P8353, DOI 10.1073/pnas.92.18.8353; RIEMANN D, 1995, CLIN EXP IMMUNOL, V100, P277; Sanders SE, 1995, EPITHELIAL CELL BIOL, V4, P25; SMITH JJ, 1993, J CLIN INVEST, V91, P1590, DOI 10.1172/JCI116365; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; VITA N, 1995, J BIOL CHEM, V270, P3512, DOI 10.1074/jbc.270.8.3512; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI G, 1995, STEM CELLS, V100, P169; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	31	108	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7460	7464						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631774				2022-12-27	WOS:A1996UC77400042
J	Coso, OA; Teramoto, H; Simonds, WF; Gutkind, JS				Coso, OA; Teramoto, H; Simonds, WF; Gutkind, JS			Signaling from G protein-coupled receptors to c-Jun kinase involves beta gamma subunits of heterotrimeric G proteins acting on a Ras and Rac1-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Stimulation of a variety of cell surface receptors enhances the enzymatic activity of mitogen-activated protein kinases (MAPKs). MAPKs have been classified in three subfamilies: extracellular signal-regulated kinases (ERKs), Stress-activated protein kinases or c-Jun NH2-terminal kinases (SAPKs/JNKs), and p38 kinase. Whereas the pathway linking cell surface receptors to ERKs has been partially elucidated, the mechanism of activation of JNKs is still poorly understood. Recently, we have shown that stimulation of G protein-coupled receptors can effectively induce JNK in NIH 3T3 cells (Coso, O. A., Chiariello, M., Kalinec, G., Kyriakis, J. M., Woodgett, J., and Gutkind, J. S. (1995) J. Biol. Chem. 270, 5620-5624). In the present study, we have used the transient expression in COS-7 cells of m1 and m2 muscarinic receptors (mAChRs) as a model system to study the signaling pathway linking G protein-coupled receptors to JNK. We show that stimulation of either muscarinic receptor subtype leads to JNK activation; however, this effect was not mimicked by expression of activated forms of alpha(s), alpha(i2), alpha(q), or alpha(13) G protein alpha subunits. In contrast, overexpression of G beta gamma subunits potently induced JNK activity. Furthermore, we show that signaling from mi and m2 mAChRs to JNK involves beta gamma subunits of heterotrimeric G proteins, acting on a Ras and Rac1-dependent pathway.	NIDR,CELLULAR DEV & ONCOL LAB,MOL SIGNALING UNIT,BETHESDA,MD 20892; NIDDK,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 				ASHKENAZI A, 1989, TRENDS PHARMACOL SCI, P16; BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626	21	192	196	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					3963	3966						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626724				2022-12-27	WOS:A1996TW96000002
J	Gong, DW; Bi, S; Pratley, RE; Weintraub, BD				Gong, DW; Bi, S; Pratley, RE; Weintraub, BD			Genomic structure and promoter analysis of the human obese gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION	The human gene encoding the homolog of the mouse obese (ob) gene was isolated and partially characterized. The human ob gene consists of three exons and two introns and spans about 18 kilobase pairs (kb), encoding a 3.5-kb cDNA. A 3-kb 5'-flanking region of the gene was cloned and transient transfection assay with luciferase reporter confirmed the promoter activity in differentiated F442-A adipocytes. Potential regulatory elements are discussed in this report.	NIDDK,PHOENIX EPIDEMIOL & CLIN RES BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Gong, DW (corresponding author), NIDDK,MOL & CELLULAR ENDOCRINOL BRANCH,BLDG 10,RM 8D14,10 CTR DR,MSC 1758,BETHESDA,MD 20892, USA.		Gong, Dawei/AAB-4283-2020	bi, sheng/0000-0002-2441-0528				BOUCHARD C, 1991, P NUTR SOC, V50, P139, DOI 10.1079/PNS19910025; BOULANGER BR, 1994, CRIT CARE CLIN, V10, P613, DOI 10.1016/S0749-0704(18)30121-0; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; DJIAN P, 1985, J CELL PHYSIOL, V124, P554, DOI 10.1002/jcp.1041240327; HANKE JH, 1995, J MOL BIOL, V246, P63, DOI 10.1006/jmbi.1994.0066; HODGE AM, 1994, BAILLIERE CLIN ENDOC, V8, P577, DOI 10.1016/S0950-351X(05)80287-3; KAPLAN DJ, 1991, NUCLEIC ACIDS RES, V19, P4731, DOI 10.1093/nar/19.17.4731; LEMIEUX S, 1994, DIABETES METAB, V20, P375; LENNON GG, 1996, IN PRESS GENOMICS; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V214, P1260, DOI 10.1006/bbrc.1995.2422; PIERCE JC, 1992, MAMM GENOME, V3, P550, DOI 10.1007/BF00350620; PROIETTO J, 1994, BAILLIERE CLIN ENDOC, V8, P509, DOI 10.1016/S0950-351X(05)80284-8; SAKSELA K, 1993, MOL CELL BIOL, V13, P3698, DOI 10.1128/MCB.13.6.3698; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; THOREY IS, 1993, MOL CELL BIOL, V13, P6742, DOI 10.1128/MCB.13.11.6742; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	18	195	204	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					3971	3974						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626726				2022-12-27	WOS:A1996TW96000004
J	Margot, JB; Williams, DL				Margot, JB; Williams, DL			Estrogen induces the assembly of a multiprotein messenger ribonucleoprotein complex on the 3'-untranslated region of chicken apolipoprotein II mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERRIN RECEPTOR EXPRESSION; RNA-BINDING-PROTEIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; POLYPEPTIDE-CHAIN ELONGATION; 3' UNTRANSLATED REGION; YOLK PRECURSOR PROTEIN; AVIAN LIVER; TRANSLATIONAL CONTROL; NUCLEOTIDE-SEQUENCE; TISSUE DISTRIBUTION	UV cross-linking was used to identify estrogen-induced hepatocyte proteins that bind to apoII mRNA. Probes spanning the entire message revealed the pres ence of eight estrogen-induced proteins cross-linked to the 3'-untranslated region (UTR), but not to the coding region or the 5'-UTR. Two estrogen-induced proteins of 132 and 50 kDa were either absent or barely detectable in control animals, whereas six additional proteins of 93, 83, 74, 65, 58, and 45 kDa were clearly present in control animals and increased 2-5-fold by estrogen. A similar profile of estrogen-induced proteins was seen with the 3'-UTRs of the estrogen-regulated mRNAs for apoB and vitellogenin II, but not with the 3'-UTRs of the non-estrogen regulated mRNAs for apoA-I and glyceraldehyde-phosphate dehydrogenase. These findings indicate that the estrogen-induced proteins discriminate among mRNAs and suggest that they interact selectively with the family of estrogen-regulated mRNAs. The estrogen-induced proteins are found in the cytoplasmic fraction of liver extracts, and a subset of them are also found in adrenal glands, testes, heart, brain, and kidneys, but they are estrogen induced only in the liver. Deletion analysis defined a 150-nucleotide region of the apoII 3'-UTR that is necessary for maximal binding of the estrogen-induced proteins. An internal deletion of endonucleolytic cleavage sites previously identified within the apoII 3'-UTR selectively reduced the binding of the 58-kDa protein. These findings reveal remarkable complexity in estrogen-stimulated protein-RNA interactions within the 3'-UTRs of estrogen-regulated mRNAs. These proteins may participate in the mRNA degradation process or in other aspects of cytoplasmic mRNA metabolism that accompany estrogen-stimulated vitellogenesis.	SUNY STONY BROOK, HLTH SCI CTR, DEPT PHARMACOL SCI, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NIDDK NIH HHS [DK 18171] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018171, R37DK018171] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALNAVE D, 1974, J ENDOCRINOL, V61, P29, DOI 10.1677/joe.0.0610029; BAST RE, 1977, P NATL ACAD SCI USA, V74, P3133, DOI 10.1073/pnas.74.8.3133; BERGINK EW, 1974, AM ZOOL, V14, P1177; BETTANY AJE, 1992, J BIOL CHEM, V267, P16531; BICKEL M, 1992, P NATL ACAD SCI USA, V89, P10001, DOI 10.1073/pnas.89.21.10001; BINDER R, 1989, J BIOL CHEM, V264, P16910; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BRAWERMAN G, 1993, CONTROL MESSENGER RN; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BROCK ML, 1983, CELL, V34, P207, DOI 10.1016/0092-8674(83)90151-4; COCHRANE AW, 1984, J BIOL CHEM, V259, P5408; COOK JS, 1986, P NATL ACAD SCI USA, V83, P7583, DOI 10.1073/pnas.83.20.7583; DASHTI N, 1983, J LIPID RES, V24, P368; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DODSON RE, 1994, MOL CELL BIOL, V14, P3130, DOI 10.1128/MCB.14.5.3130; DOMPENCIEL RE, 1995, J BIOL CHEM, V270, P6108, DOI 10.1074/jbc.270.11.6108; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GAVIS ER, 1994, NATURE, V369, P315, DOI 10.1038/369315a0; GEHRKE L, 1981, J BIOL CHEM, V256, P2514; GEHRKE L, 1981, J BIOL CHEM, V256, P2522; GORDON DA, 1988, J BIOL CHEM, V263, P2625; GOTTLIEB E, 1992, P NATL ACAD SCI USA, V89, P7164, DOI 10.1073/pnas.89.15.7164; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HARFORD JB, 1990, ENZYME, V44, P28, DOI 10.1159/000468745; HUARTE J, 1987, GENE DEV, V1, P1201, DOI 10.1101/gad.1.10.1201; HWANG SPL, 1989, J BIOL CHEM, V264, P8410; KIRCHGESSNER TG, 1987, GENE, V59, P241, DOI 10.1016/0378-1119(87)90332-5; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; KUDZMA DJ, 1975, J LIPID RES, V16, P123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; LIANG HM, 1991, NUCLEIC ACIDS RES, V19, P2289, DOI 10.1093/nar/19.9.2289; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MANNING R, 1989, INT J BIOCHEM, V21, P517, DOI 10.1016/0020-711X(89)90131-6; MARGOT JB, 1989, MOL ENDOCRINOL, V3, P1053, DOI 10.1210/mend-3-7-1053; NACHALIEL N, 1993, J BIOL CHEM, V268, P24203; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; PALMITER RD, 1974, P NATL ACAD SCI USA, V71, P2357, DOI 10.1073/pnas.71.6.2357; PANDEY NB, 1991, NUCLEIC ACIDS RES, V19, P5653, DOI 10.1093/nar/19.20.5653; PARIS J, 1990, MOL CELL BIOL, V10, P5634, DOI 10.1128/MCB.10.11.5634; RAJAVASHISTH TB, 1987, J BIOL CHEM, V262, P7058; RATNASABAPATHY R, 1990, J BIOL CHEM, V265, P14050; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; Sambrook J, 1989, MOL CLONING LABORATO; SCHJEIDE OA, 1963, AM ZOOL, V3, P167; SCHJEIDE OA, 1970, CELL DIFFER, P447; SHEETS MD, 1994, GENE DEV, V8, P926, DOI 10.1101/gad.8.8.926; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VANHETSCHIP FD, 1987, J MOL BIOL, V196, P245, DOI 10.1016/0022-2836(87)90688-7; WANG XM, 1995, MOL CELL BIOL, V15, P1769; WILLIAMS DL, 1993, CONTROL MESSENGER RN, P161; WISKOCIL R, 1980, P NATL ACAD SCI-BIOL, V77, P4474, DOI 10.1073/pnas.77.8.4474; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUKER M, 1989, METHOD ENZYMOL, V180, P262	55	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4452	4460						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626798				2022-12-27	WOS:A1996TW96000076
J	Zhang, Y; Wang, ZG; Ravid, K				Zhang, Y; Wang, ZG; Ravid, K			The cell cycle in polyploid megakaryocytes is associated with reduced activity of cyclin B1-dependent Cdc2 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET FACTOR-IV; PROTEIN-KINASE; HEMATOPOIETIC-CELLS; G1-SPECIFIC CYCLINS; HUMAN FIBROBLASTS; MESSENGER-RNA; G1 PHASE; EXPRESSION; LINE; LEUKEMIA	The platelet precursor, the megakaryocyte, matures to a polyploid cell as a result of DNA replication in the absence of mitosis (endomitosis). The factors controlling endomitosis are accessible to analysis in our megakaryocytic cell line, MegT, generated by targeted expression of temperature-sensitive simian virus 40 large T antigen to megakaryocytes of transgenic mice. We aimed to define whether endomitosis consists of a continuous phase of DNA synthesis (S) or of S phases interrupted by gaps. Analysis of the cell cycle in MegT cells revealed that, upon inactivation of large T antigen, the cells shifted from a mitotic cell cycle to an endomitotic cell cycle consisting of S/Gap phases. The level of the G(1)/S cyclin, cyclin A, as well as of the G, phase cyclin, cyclin D3, were elevated at the onset of DNA synthesis, either in MegT cells undergoing a mitotic cell cycle or during endomitosis. In contrast, the level of the mitotic cyclin, cyclin B1, cycled in cells displaying a mitotic cell cycle while not detectable during endomitosis. Comparable levels of the mitotic kinase protein, Cdc2, were detected during the mitotic cell cycle or during endomitosis; however, cyclin B1-dependent Cdc2 kinase activity was largely abolished in the polyploid cells. Fibroblasts immortalized with the same heat-labile oncogene do not display reduced levels of cyclin B1 upon shifting to high temperature nor do they become polyploid, indicating that reduced levels of cyclin B1 is a property of megakaryocytes and not of the T-antigen mutant. We conclude that cellular programming during endoreduplication in megakaryocytes is associated with reduced levels of cyclin B1.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University				Ravid, Katya/0000-0002-9918-3024	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053080] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53080-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI M, 1991, EXP HEMATOL, V19, P923; AKIYAMA N, 1993, BIOCHEM BIOPH RES CO, V195, P1041, DOI 10.1006/bbrc.1993.2149; BARTLETT R, 1990, BIOESSAYS, V10, P457; CHANG MS, 1995, J BIOL CHEM, V270, P511, DOI 10.1074/jbc.270.2.511; CHAPMAN DL, 1993, DEVELOPMENT, V118, P229; CHAPMAN DL, 1992, MOL REPROD DEV, V33, P259, DOI 10.1002/mrd.1080330305; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GREENBERG SM, 1988, BLOOD, V72, P1968; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KUBIAK JZ, 1993, EMBO J, V12, P3773, DOI 10.1002/j.1460-2075.1993.tb06055.x; KUTER DJ, 1994, P NATL ACAD SCI USA, V91, P11104, DOI 10.1073/pnas.91.23.11104; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; NASMYTH KA, 1990, CELL, V63, P1117, DOI 10.1016/0092-8674(90)90404-3; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; ODELL TT, 1968, EXP CELL RES, V53, P321, DOI 10.1016/0014-4827(68)90302-9; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAVID K, 1993, BLOOD, V81, P2885; RAVID K, 1993, J CELL BIOL, V123, P1545, DOI 10.1083/jcb.123.6.1545; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; ROBINSON MO, 1994, P NATL ACAD SCI USA, V91, P12798, DOI 10.1073/pnas.91.26.12798; ROVOLIC Z, 1974, PLATELETS PRODUCTION, P143; SAMEJIMA I, 1994, MOL CELL BIOL, V14, P6361, DOI 10.1128/MCB.14.9.6361; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; SLEDGE GW, 1986, CANCER RES, V46, P2155; SMITH AV, 1991, DEVELOPMENT, V112, P997; SUDA T, 1983, P NATL ACAD SCI-BIOL, V80, P6689, DOI 10.1073/pnas.80.21.6689; TABILIO A, 1983, CANCER RES, V43, P4569; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	46	96	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4266	4272						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626773				2022-12-27	WOS:A1996TW96000051
J	Aiyar, N; Rand, K; Elshourbagy, NA; Zeng, ZZ; Adamou, JE; Bergsma, DJ; Li, Y				Aiyar, N; Rand, K; Elshourbagy, NA; Zeng, ZZ; Adamou, JE; Bergsma, DJ; Li, Y			A cDNA encoding the calcitonin gene-related peptide type 1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION CLONING; MESSENGER-RNAS; SMOOTH-MUSCLE; CELLS; HORMONE; BRAIN; IDENTIFICATION; NEUROPEPTIDE; SECRETION	Calcitonin gene-related peptide (CGRP) is a neuropeptide with diverse biological effects including potent vasodilator activity. We report here the cloning of a complementary DNA (cDNA) encoding a human CGRP(1) receptor, which shares significant peptide sequence homology with the human calcitonin receptor, a member of the G-protein coupled receptor superfamily. Northern blot analysis revealed that the messenger RNA for this receptor is predominantly expressed in the lung and heart. In situ studies showed specific localization of the receptor mRNA to alveolar cells in the lung and to cardiac myocytes in the heart. Stable expression of the cDNA in human embryonic kidney 293 (HEK 293) cells produced specific, high affinity binding sites for CGRP that displayed pharmacological and functional properties very similar to native human CGRP(1) receptor. Exposure of these cells to CGRP resulted in a 60-fold increase in cAMP production, which was inhibited in a competitive manner by the CGRP(1) receptor antagonist, CGR9-(8-37).	SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC GENET,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT CARDIOVASC PHARMACOL,KING OF PRUSSIA,PA 19406; HUMAN GENOME SCI INC,DEPT MOLEC GENET,ROCKVILLE,MD 20850	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Human Genome Sciences Inc								ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; AIYAR N, 1991, ENDOCRINOLOGY, V129, P965, DOI 10.1210/endo-129-2-965; AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; AMARA SG, 1985, SCIENCE, V229, P1094, DOI 10.1126/science.2994212; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; CHANG CP, 1993, NEURON, V11, P1187, DOI 10.1016/0896-6273(93)90230-O; DENNIS T, 1991, BRAIN RES, V539, P59, DOI 10.1016/0006-8993(91)90686-P; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FARGEAS MJ, 1985, PEPTIDES, V6, P1167, DOI 10.1016/0196-9781(85)90445-0; FLUHMANN B, 1995, BIOCHEM BIOPH RES CO, V206, P341, DOI 10.1006/bbrc.1995.1047; GOODMAN EC, 1986, LIFE SCI, V38, P2169, DOI 10.1016/0024-3205(86)90568-0; GRUNDITZ T, 1986, ENDOCRINOLOGY, V119, P2313, DOI 10.1210/endo-119-5-2313; HERMANSEN K, 1990, REGUL PEPTIDES, V27, P149, DOI 10.1016/0167-0115(90)90213-G; HIRATA Y, 1988, BIOCHEM BIOPH RES CO, V151, P1113, DOI 10.1016/S0006-291X(88)80481-9; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JACKSON T, 1991, PHARMACOL THERAPEUT, V50, P425, DOI 10.1016/0163-7258(91)90052-N; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KITAMURA K, 1994, FEBS LETT, V338, P306, DOI 10.1016/0014-5793(94)80289-0; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2662, DOI 10.1073/pnas.92.7.2662; KUBOTA M, 1985, BIOCHEM BIOPH RES CO, V132, P88, DOI 10.1016/0006-291X(85)90992-1; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MOLINA JM, 1990, DIABETES, V39, P260, DOI 10.2337/diabetes.39.2.260; MUFF R, 1995, EUR J ENDOCRINOL, V133, P17, DOI 10.1530/eje.0.1330017; NAWA H, 1984, NATURE, V312, P729, DOI 10.1038/312729a0; NUOVO JG, 1992, IN SITU HYBRIDIZATIO; POYNER DR, 1992, PHARMACOL THERAPEUT, V56, P23, DOI 10.1016/0163-7258(92)90036-Y; Sambrook J., 2002, MOL CLONING LAB MANU; SIGRIST S, 1986, ENDOCRINOLOGY, V119, P381, DOI 10.1210/endo-119-1-381; STANGL D, 1993, ENDOCRINOLOGY, V132, P744, DOI 10.1210/en.132.2.744; TANNENBAUM GS, 1985, ENDOCRINOLOGY, V116, P2685, DOI 10.1210/endo-116-6-2685; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; VANVALEN F, 1990, NEUROSCI LETT, V119, P195, DOI 10.1016/0304-3940(90)90832-T	37	289	308	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11325	11329		10.1074/jbc.271.19.11325	http://dx.doi.org/10.1074/jbc.271.19.11325			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626685	hybrid			2022-12-27	WOS:A1996UJ94400045
J	Beck, G; Cardinale, S; Wang, L; Reiner, M; Sugumaran, M				Beck, G; Cardinale, S; Wang, L; Reiner, M; Sugumaran, M			Characterization of a defense complex consisting of interleukin 1 and phenol oxidase from the hemolymph of the tobacco hornworm, Manduca sexta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPHENOLOXIDASE ACTIVATION; QUINONE METHIDE; PURIFICATION; ALPHA-2-MACROGLOBULIN; MACROGLOBULIN; RECOGNITION; CYTOKINES; IMMUNITY; INSECTS; PROTEIN	Hemolymph of fifth instar Manduca sexta larvae collected under non-sterile conditions exhibited the presence of a novel high molecular weight protein complex, which was absent from the hemolymph collected aseptically. The high molecular weight complex consisted of, at least, prophenol oxidase, phenol oxidase, and an interleukin 1-like molecule, thereby demonstrating the generation of this complex as a consequence of a host defense response. While the native phenol oxidase and the interleukin 1-like molecule possessed molecular weights of about 80,000 and 17,000, respectively, the complex had a molecular weight of about 400,000. Apart from prophenol oxidase, phenol oxidase, and interleukin 1, dopachrome isomerase and other, as of yet unidentified, proteins may be part of the complex as judged by the presence of additional bands observed during SDS-polyacrylamide gel electrophoresis. The significance of the assembly of this defense complex for insect host defense strategies is discussed.			Beck, G (corresponding author), UNIV MASSACHUSETTS,DEPT BIOL,100 MORRISSEY BLVD,BOSTON,MA 02125, USA.		Beck, Gregory/Q-2772-2019	Beck, Gregory/0000-0003-4076-1077	NIAID NIH HHS [R01 AI 14753] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014753] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ashida M., 1990, P239; BECK G, 1991, MOL IMMUNOL, V28, P577, DOI 10.1016/0161-5890(91)90126-5; BECK G, 1991, IMMUNOL TODAY, V12, P180, DOI 10.1016/0167-5699(91)90049-Y; BELL RA, 1976, ANN ENTOMOL SOC AM, V69, P365, DOI 10.1093/aesa/69.2.365; BORTH W, 1989, J BIOL CHEM, V264, P5818; COCIANCICH S, 1994, PARASITOL TODAY, V10, P132, DOI 10.1016/0169-4758(94)90260-7; DINARELLO CA, 1985, J CLIN IMMUNOL, V5, P287, DOI 10.1007/BF00918247; DUNN PE, 1990, BIOSCIENCE, V40, P738, DOI 10.2307/1311506; GUPTA AP, 1988, HEMOCYTIC HUMORAL IM; HALL M, 1995, P NATL ACAD SCI USA, V92, P7764, DOI 10.1073/pnas.92.17.7764; JAMES K, 1990, IMMUNOL TODAY, V11, P163, DOI 10.1016/0167-5699(90)90067-J; JAMES K, 1980, TRENDS BIOCHEM SCI, V5, P43, DOI 10.1016/S0968-0004(80)80094-6; KATONA LI, 1992, INFECT IMMUN, V60, P4995, DOI 10.1128/IAI.60.12.4995-5003.1992; NAPPI AJ, 1993, INSECT IMMUNITY, P131; NELLAIAPPAN K, 1994, ANAL BIOCHEM, V220, P122, DOI 10.1006/abio.1994.1307; NELLAIAPPAN K, 1986, STAIN TECHNOL, V61, P269, DOI 10.3109/10520298609109952; OBRIEN PJ, 1991, CHEM-BIOL INTERACT, V80, P1, DOI 10.1016/0009-2797(91)90029-7; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; RAMESH N, 1988, J BIOL CHEM, V263, P11523; RATCLIFFE NA, 1984, SCIENCE, V226, P557, DOI 10.1126/science.226.4674.557; SAUL SJ, 1989, FEBS LETT, V249, P155, DOI 10.1016/0014-5793(89)80614-3; SAUL SJ, 1987, ARCH INSECT BIOCHEM, V5, P1, DOI 10.1002/arch.940050102; SODERHALL K, 1982, DEV COMP IMMUNOL, V6, P601; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; SUGUMARAN M, 1990, UCLA SYM BI, V121, P47; SUGUMARAN M, 1991, J BIOL CHEM, V266, P6073; SUGUMARAN M, 1991, BIOCHEM BIOPH RES CO, V176, P1371, DOI 10.1016/0006-291X(91)90438-D; SUGUMARAN M, 1987, ARCH INSECT BIOCHEM, V6, P9, DOI 10.1002/arch.940060103; SUGUMARAN M, 1993, PARASITES PATHOGENS, V1, P317; SUN S, 1990, SCIENCE, V259, P1729	30	41	44	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11035	11038		10.1074/jbc.271.19.11035	http://dx.doi.org/10.1074/jbc.271.19.11035			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626641	hybrid			2022-12-27	WOS:A1996UJ94400001
J	Dodd, IB; Egan, JB				Dodd, IB; Egan, JB			DNA binding by the coliphage 186 repressor protein CI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATE CONTROL GENE; TEMPERATE COLIPHAGE-186; EXPRESSION; TRANSCRIPTION; SEQUENCE; REPLICATION; LYSOGENY; SWITCH; REGION	The cI gene of coliphage 186 maintains lysogeny and confers immunity to 186 infection by repressing the major early promoter, p(R), and the promoter for the late transcription activator gene, p(B). Gel mobility shift and DNase I footprinting show that CI protein binds to the DNA at p(R) and p(B) and also to sites similar to 300 base pairs upstream and downstream of p(R), called FL and FR. Mutations which cause virulence reduce CI binding to p(R). The biochemical and genetic data identify three CI operators at p(R), two at p(B), and single operators at FL and FR. The operators at the p(B), FL, FR, and central p(R) sites are inverted repeat sequences, separated by 5 base pairs (Type A) or, in the case of p(R), by 4 base pairs (Type A'). A different inverted repeat operator sequence (Type B) is proposed for the binding sites on each side of the central site at p(R). Thus, CI appears to recognize two distinct DNA sequences. CI binds cooperatively to adjacent operators, and binding at p(R) is strongly dependent on these cooperative interactions. A high order CI multimer appears to be the active DNA binding species, even at single operators.	UNIV ADELAIDE,DEPT BIOCHEM,ADELAIDE,SA 5005,AUSTRALIA	University of Adelaide				Dodd, Ian/0000-0003-2969-6841				Bertani LE, 1988, BACTERIOPHAGES, V2, P73; CARLSON NG, 1993, J MOL BIOL, V230, P1108, DOI 10.1006/jmbi.1993.1229; DEVARGAS LM, 1988, CELL, V54, P923, DOI 10.1016/0092-8674(88)90107-9; DIBBENS JA, 1992, MOL MICROBIOL, V6, P2629, DOI 10.1111/j.1365-2958.1992.tb01440.x; DIBBENS JA, 1992, MOL MICROBIOL, V6, P2643, DOI 10.1111/j.1365-2958.1992.tb01441.x; DODD IB, 1993, MOL MICROBIOL, V10, P1139, DOI 10.1111/j.1365-2958.1993.tb00983.x; DODD IB, 1990, J MOL BIOL, V214, P27, DOI 10.1016/0022-2836(90)90144-B; DODD IB, 1993, CONTROL LYSIS LYSOGE; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; EUSTANCE RJ, 1994, J MOL BIOL, V242, P330; JOHNSON AD, 1981, NATURE, V294, P217, DOI 10.1038/294217a0; KALIONIS B, 1986, J MOL BIOL, V191, P211, DOI 10.1016/0022-2836(86)90258-5; KALIONIS B, 1986, J MOL BIOL, V191, P199, DOI 10.1016/0022-2836(86)90257-3; LAMONT I, 1989, P NATL ACAD SCI USA, V86, P5492, DOI 10.1073/pnas.86.14.5492; LAMONT I, 1993, J BACTERIOL, V175, P5286, DOI 10.1128/JB.175.16.5286-5288.1993; LAMONT I, 1988, J MOL BIOL, V199, P3279; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; MAO CH, 1994, J MOL BIOL, V235, P532, DOI 10.1006/jmbi.1994.1011; Miller J.H., 1972, EXPT MOL GENETICS; Ptashne M., 1986, A GENETIC SWITCH; RICHARDSON H, 1989, J MOL BIOL, V206, P251, DOI 10.1016/0022-2836(89)90539-1; RICHARDSON H, 1989, J MOL BIOL, V206, P59, DOI 10.1016/0022-2836(89)90523-8; Sambrook J., 2002, MOL CLONING LAB MANU; SENEAR DF, 1993, BIOCHEMISTRY-US, V32, P6179, DOI 10.1021/bi00075a010; Shearwin KE, 1996, J BIOL CHEM, V271, P11525, DOI 10.1074/jbc.271.19.11525; SMITHMUNGO L, 1994, J BIOL CHEM, V269, P20798; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	29	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11532	11540		10.1074/jbc.271.19.11532	http://dx.doi.org/10.1074/jbc.271.19.11532			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626714	hybrid			2022-12-27	WOS:A1996UJ94400074
J	Dudler, T; Gelb, MH				Dudler, T; Gelb, MH			Palmitoylation of Ha-Ras facilitates membrane binding, activation of downstream effectors, and meiotic maturation in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; ONCOGENIC RAS-P21; FATTY ACYLATION; IDENTIFICATION; STIMULATION; REQUIREMENT; CONTAINS; INSULIN; P21RAS; SYSTEM	Ras proteins serve as critical relays in signal transduction pathways that control growth and differentiation and must undergo posttranslational modifications before they become functional. While it is established that farnesylation is necessary for membrane binding and cellular functions of all Ras proteins, the significance of palmitoylation is unclear. We have studied the contribution of Ha-Ras palmitoylation for biological activity in Xenopus oocytes. In contrast to wild-type Ha-Ras, which binds to membranes and induces meiosis when microinjected into oocytes, a nonpalmitoylated but farnesylated and methylated mutant mislocalizes to the cytosol and fails to promote maturation. This lack of responsiveness correlates with the inability of the mutant to induce phosphorylation and activation of mitogen-activated protein kinase and maturation promoting factor, which are both strongly activated by wild-type Ha-Ras. Costimulation of oocytes with insulin increases their responsiveness to Ras and partially rescues the biological activity of the palmitoylation-resistant mutant. However, 25-50 times higher doses of mutant were required to elicit responses equivalent to wild-type Ha-Ras. These results suggest that palmitoylation and membrane association of Ha-Ras is necessary for efficient activation of the mitogen-activated protein kinase cascade in vivo and are consistent with a biochemical function for Ras as a membrane targeting signal for downstream effectors in this pathway.	UNIV WASHINGTON,DEPT CHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				gelb, michael/0000-0001-7000-5219	NCI NIH HHS [CA52874] Funding Source: Medline; NIGMS NIH HHS [GM562] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052874] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1990, J BIOL CHEM, V265, P11487; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BHATTACHARYA S, 1995, P NATL ACAD SCI USA, V92, P2984, DOI 10.1073/pnas.92.7.2984; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; CARNERO A, 1994, J CELL BIOCHEM, V55, P465, DOI 10.1002/jcb.240550406; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CELIS JE, 1994, CELL BIOL LAB MANUAL; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CHUANG LM, 1994, J BIOL CHEM, V269, P27645; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DESCHENES RJ, 1987, MOL CELL BIOL, V7, P2344, DOI 10.1128/MCB.7.7.2344; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FUKOTO M, 1994, J BIOL CHEM, V269, P33097; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GROTOH Y, 1995, J BIOL CHEM, V270, P25898; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; ITOH T, 1993, J BIOL CHEM, V268, P3025; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P11270; KIM R, 1990, MOL CELL BIOL, V10, P5945, DOI 10.1128/MCB.10.11.5945; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KURODA S, 1995, J BIOL CHEM, V270, P2460, DOI 10.1074/jbc.270.6.2460; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVERS SJ, 1994, NATURE, V369, P411; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MAGEE AI, 1995, METHOD ENZYMOL, V250, P330; MALLER JL, 1981, DEV BIOL, V85, P309, DOI 10.1016/0012-1606(81)90262-1; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MCGEADY P, 1995, J BIOL CHEM, V270, P26347, DOI 10.1074/jbc.270.44.26347; NEBREDA AR, 1993, ONCOGENE, V8, P467; POMERANCE M, 1992, J BIOL CHEM, V267, P16155; PORFIRI E, 1995, METHOD ENZYMOL, V255, P13; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SCHAFER WR, 1992, ANNU REV GENET, V30, P206; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6	51	85	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11541	11547		10.1074/jbc.271.19.11541	http://dx.doi.org/10.1074/jbc.271.19.11541			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626715	hybrid			2022-12-27	WOS:A1996UJ94400075
J	Loyer, P; Cariou, S; Glaise, D; Bilodeau, M; Baffet, G; GuguenGuillouzo, C				Loyer, P; Cariou, S; Glaise, D; Bilodeau, M; Baffet, G; GuguenGuillouzo, C			Growth factor dependence of progression through G(1) and S phases of adult rat hepatocytes in vitro - Evidence of a mitogen restriction point in mid-late G(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE-LIVER REGENERATION; C-MYC; DNA-SYNTHESIS; CELL-CYCLE; 3T3 CELLS; G1 PHASE; EXPRESSION; PROTEIN; GENE; FOS	Several hepatocyte mitogens have been identified, but the signals triggering the G(0)/G(1) transition and cell cycle progression of hepatocytes remain unknown, Using hepatocyte primary cultures, we investigated the role of epidermal growth factor/pyruvate during the entry into and progression through the G(1) phase and analyzed the expression of cell cycle markers. we show that the G(0)/G(1) transition occurs during hepatocyte isolation as evidenced by the expression of early genes such as c-fos, c-jun, and c-myc, In culture, hepatocytes progress through G(1) regardless of growth factor stimulation until a restriction point (R point) in mid-late G(1) beyond which they cannot complete the cell cycle without mitogenic stimulation. Changes in cell. cycle gene expression were associated with progression in G(1); the cyclin E mRNA level is low early in G(1) but increases at the G(1)/S boundary, while the protein is constantly detected during cell cycle but undergoes a change of electrophoretic mobility in mid-late G(1) after the It point. In addition, a drastic induction of cyclin D1 mRNA and protein, and to a lesser extent of cyclin D2 mRNA, takes place in mitogen-stimulated cells after the It point. In contrast, cyclin D3 mRNA appears early in G(1), remains constant in stimulated cells, but accumulates in unstimulated arrested cells, paralleling the cyclin-dependent kinase 4 mRNA expression. These results characterize the different steps of G(1) phase in hepatocytes.			Loyer, P (corresponding author), HOP PONTCHAILLOU, INSERM, U49, UNITE RECH HEPATOL, F-35033 RENNES, FRANCE.		Baffet, Georges/I-2574-2015; Baffet, Georges/M-1583-2016; Bilodeau, Marc/L-2822-2017; LOYER, Pascal/K-1838-2019	LOYER, PASCAL/0000-0002-5656-2673				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ALBRECHT JH, 1995, BIOCHEM BIOPH RES CO, V209, P648, DOI 10.1006/bbrc.1995.1548; ANDREWS GK, 1982, J BIOL CHEM, V257, P5148; AZZI L, 1992, EUR J BIOCHEM, V203, P353, DOI 10.1111/j.1432-1033.1992.tb16557.x; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; CAMPISI J, 1982, P NATL ACAD SCI-BIOL, V79, P436, DOI 10.1073/pnas.79.2.436; CHANG EH, 1982, P NATL ACAD SCI-BIOL, V79, P4848, DOI 10.1073/pnas.79.16.4848; CORCOS D, 1987, ONCOGENE RES, V1, P60; CORRAL M, 1985, EXP CELL RES, V160, P427, DOI 10.1016/0014-4827(85)90190-9; CROY RG, 1983, P NATL ACAD SCI-BIOL, V80, P4699, DOI 10.1073/pnas.80.15.4699; DEFROMENTEL CC, 1987, INT J CANCER, V39, P185, DOI 10.1002/ijc.2910390211; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ETIENNE PL, 1988, ONCOGENE RES, V3, P255; FABRIKANT JI, 1968, J CELL BIOL, V36, P551, DOI 10.1083/jcb.36.3.551; FAUSTO N, 1992, TR ADV LIV, P1; GUGUEN C, 1975, BIOL GASTRO-ENTEROL, V8, P223; GUGUENGUILLOUZO C, 1983, MOL CELL BIOCHEM, V53-4, P35; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Huggins GM, 1931, ARCH PATHOL, V12, P186; IKEDA T, 1989, EXP CELL RES, V185, P292, DOI 10.1016/0014-4827(89)90058-X; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KOFF A, 1991, CELL, V66, P1212; LINDROOS PM, 1991, HEPATOLOGY, V13, P743, DOI 10.1002/hep.1840130422; LIU ML, 1994, HEPATOLOGY, V19, P1521; LOYER P, 1994, J BIOL CHEM, V269, P2491; LU XP, 1992, J BIOL CHEM, V267, P2841; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCGOWAN JA, 1986, ISOLATED CULTURED HE, P13; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MORELLO D, 1990, ONCOGENE, V5, P1511; MULLHAUPT B, 1994, J BIOL CHEM, V269, P19667; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARDEE AB, 1992, CURR OPIN CELL BIOL, V4, P141; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAYMONDJEAN M, 1983, BIOCHIM BIOPHYS ACTA, V741, P30, DOI 10.1016/0167-4781(83)90006-4; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; SARGENT TD, 1979, P NATL ACAD SCI USA, V76, P3256, DOI 10.1073/pnas.76.7.3256; SAWADA N, 1989, EXP CELL RES, V181, P584, DOI 10.1016/0014-4827(89)90115-8; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOBCZAK J, 1989, ONCOGENE, V4, P1503; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON NL, 1986, CANCER RES, V46, P3111; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YEN A, 1978, EXP CELL RES, V116, P103, DOI 10.1016/0014-4827(78)90068-X; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	54	203	205	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11484	11492		10.1074/jbc.271.19.11484	http://dx.doi.org/10.1074/jbc.271.19.11484			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626707	hybrid			2022-12-27	WOS:A1996UJ94400067
J	Quinn, KA; Treston, AM; Unsworth, EJ; Miller, MJ; Vos, M; Grimley, C; Battey, J; Mulshine, JL; Cuttitta, F				Quinn, KA; Treston, AM; Unsworth, EJ; Miller, MJ; Vos, M; Grimley, C; Battey, J; Mulshine, JL; Cuttitta, F			Insulin-like growth factor expression in human cancer cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I IGF-I; BINDING-PROTEINS; MESSENGER-RNA; BREAST-CANCER; LUNG-TUMORS; RECEPTORS; LIVER	The insulin-like growth factors (IGFs), IGF-I and IGF-II, are potent mitogens for human lung and other epithelial cancer cell lines. Previous studies in defined medium lacking added IGF or insulin suggest that an IGF-related ligand can act as an autocrine growth factor for many cancer cell lines through action via the type I IGF receptor (IGF-R). Analysis of RNA isolated from human lung and breast cancer cell lines by reverse transcription of mRNA and polymerase chain reaction reveal that IGF-I and IGF-II mRNAs were co-expressed with IGF-R in the majority of cell lines. IGF-I mRNA was detected in 11/12 small cell lung cancer cell lines (SCLC), 13/14 non-small cell lung cancer (NSCLC) cell lines, and 1/2 breast cancer cell lines. IGF-II mRNA was detected in 8/10 SCLC, 11/12 NSCLC cell lines, and 2/2 breast lines. All cell lines expressed IGF-R. For analysis of IGF peptide secretion, cell lines were adapted to growth in serum/hormone-free culture medium (R(0)), and to avoid interference by IGF-binding proteins, secreted IGF peptides were isolated under acidic conditions and analyzed by Western blotting. Based upon measurement of the sensitivity of the anti-IGF antibodies for detection of recombinant human IGFs, IGF peptides accumulated in conditioned medium at greater than picomolar concentrations should have been readily detected. In three cell lines (two lung and one breast) secreted IGF immunoreactivity was detected as three molecular mass species of 23, 14, and 6 kDa. Isolation and NH4-terminal sequencing of each of these species definitively identified them as differentially processed forms of the IGF-II prohormone. Despite the high frequency of IGF-I gene expression detected by reverse transcription-polymerase chain reaction analysis, only one lung cancer cell line, NCI-N417d, was found that unequivocally secreted IGF-I peptide. This direct sequence determination unambiguously identifies IGF-II as the predominant IGF involved in the autocrine growth stimulation of human lung and breast epithelial tumor cell lines and supports a growing body of literature that implicates IGF-II/IGF-R autocrine loops as a common growth mechanism in epithelial carcinogenesis.	NCI,NIH,BIOMARKERS & PREVENT RES BRANCH,ROCKVILLE,MD 20850; PERKIN ELMER CORP,DIV APPL BIOSYST,FOSTER CITY,CA 94404; NIDCD,NIH,GAITHERSBURG,MD 20850	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Thermo Fisher Scientific; Applied Biosystems; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)				Mulshine, James/0000-0002-4648-9177				ADAMO ML, 1992, ENDOCRINOLOGY, V131, P1858, DOI 10.1210/en.131.4.1858; ANGELLOZNICAUD P, 1995, P NATL ACAD SCI USA, V92, P11970; Battey, 1986, BASIC METHODS MOL BI; Blum W F, 1994, Growth Regul, V4 Suppl 1, P11; CHEW SL, 1995, ENDOCRINOLOGY, V136, P1939, DOI 10.1210/en.136.5.1939; DAUGHADAY WH, 1993, P NATL ACAD SCI USA, V90, P5823, DOI 10.1073/pnas.90.12.5823; GOWAN LK, 1987, ENDOCRINOLOGY, V121, P449, DOI 10.1210/endo-121-2-449; HAN VKM, 1987, SCIENCE, V236, P193, DOI 10.1126/science.3563497; HUDGINS WR, 1992, J BIOL CHEM, V267, P8153; JAQUES G, 1989, EXP CELL RES, V184, P396, DOI 10.1016/0014-4827(89)90339-X; NAKANISHI Y, 1988, J CLIN INVEST, V82, P354, DOI 10.1172/JCI113594; Nielsen Finn Cilius, 1992, Progress in Growth Factor Research, V4, P257, DOI 10.1016/0955-2235(92)90023-B; PERDUE JF, 1991, ENDOCRINOLOGY, V129, P3101, DOI 10.1210/endo-129-6-3101; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; REEVE JG, 1990, BRIT J CANCER, V61, P727, DOI 10.1038/bjc.1990.163; REEVE JG, 1993, CANCER RES, V53, P4680; REEVE JG, 1992, J NATL CANCER I, V84, P628, DOI 10.1093/jnci/84.8.628; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1995, CANCER RES, V55, P2463; ROHLIK QT, 1987, BIOCHEM BIOPH RES CO, V149, P276, DOI 10.1016/0006-291X(87)91635-4; ROHLIK QT, 1993, BIOCHEM BIOPH RES CO, V204, P22; ROTSCH M, 1992, J CANCER RES CLIN, V118, P502, DOI 10.1007/BF01225264; ROTWEIN P, 1986, P NATL ACAD SCI USA, V83, P77, DOI 10.1073/pnas.83.1.77; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHARDT C, 1993, EXP CELL RES, V204, P22, DOI 10.1006/excr.1993.1004; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SIEGFRIED JM, 1994, J BIOL CHEM, V269, P8596; Steller MA, 1995, P NATL ACAD SCI USA, V92, P11970, DOI 10.1073/pnas.92.26.11970; STILES AD, 1989, AM J RESP CELL MOL, V1, P21, DOI 10.1165/ajrcmb/1.1.21; YANG YWH, 1985, J BIOL CHEM, V260, P2570; YEE D, 1988, CANCER RES, V48, P6691; ZIA F, 1996, IN PRESS J CELL BIOC	33	166	180	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11477	11483		10.1074/jbc.271.19.11477	http://dx.doi.org/10.1074/jbc.271.19.11477			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626706	hybrid			2022-12-27	WOS:A1996UJ94400066
J	Tsu, CA; Craik, CS				Tsu, CA; Craik, CS			Substrate recognition by recombinant serine collagenase 1 from Uca pugilator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-STRUCTURE; FIDDLER CRAB; COLLAGENOLYTIC ACTIVITIES; ALPHA-CHYMOTRYPSIN; MAMMALIAN-CELLS; BINDING POCKET; TRYPSIN; SPECIFICITY; HEPATOPANCREAS; ELASTASE	Uca pugilator serine collagenase 1 was cloned and sequenced from a fiddler crab hepatopancreas cDNA library. A full-length sequence encodes a 270-amino acid pre-pro-enzyme highly identical in structure to the chymotrypsin family of serine proteases. The zymogen form of the enzyme was expressed in Saccharomyces cerevisiae as a fusion with the alpha-factor signal sequence under control of the alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase promoter. Upon activation with trypsin, the recombinant collagenase possesses collagenolytic properties identical to those of the enzyme isolated from the crab hepatopancreas. The collagenase substrate binding pocket recognizes a wide range of basic, hydrophobic, and neutral polar residues. beta-Branched and acidic amino acids are poor substrates. Acylation is rate-limiting for collagenase versus peptidyl amides, rather than deacylation, as for trypsin and chymotrypsin. Correlations relating substrate volume and hydrophobicity to catalysis were found for collagenase and compared to those for chymotrypsin and elastase. Relative enzyme efficiencies on single amino acid versus tetrapeptide amide substrates show that collagenase derives less catalytic efficiency from binding of the primary substrate residue than trypsin or chymotrypsin, but compensates in binding of the extended peptidyl residues. Serine collagenase 1 is a novel member of the chymotrypsin protease family, by virtue of its amino acid sequence and multifunctional active site.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NIGMS NIH HHS [GM07175] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1988, CURRENT PROTOCOLS MO; BENDER ML, 1965, ANNU REV BIOCHEM, V34, P49, DOI 10.1146/annurev.bi.34.070165.000405; BREDDAM K, 1992, EUR J BIOCHEM, V206, P103, DOI 10.1111/j.1432-1033.1992.tb16906.x; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; COREY DR, 1992, J AM CHEM SOC, V114, P1784, DOI 10.1021/ja00031a037; CRAIG SP, 1988, NUCLEIC ACIDS RES, V16, P7087, DOI 10.1093/nar/16.14.7087; CRAIK CS, 1985, SCIENCE, V228, P291, DOI 10.1126/science.3838593; CRAIK CS, 1983, SCIENCE, V220, P1125, DOI 10.1126/science.6344214; DELMAR EG, 1980, BIOCHEMISTRY-US, V19, P468, DOI 10.1021/bi00544a011; DELMAR EG, 1979, ANAL BIOCHEM, V99, P316, DOI 10.1016/S0003-2697(79)80013-5; DOROVSKA VN, 1972, FEBS LETT, V23, P122, DOI 10.1016/0014-5793(72)80299-0; EISEN AZ, 1973, BIOCHEMISTRY-US, V12, P1814, DOI 10.1021/bi00733a024; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; EVNIN LB, 1990, P NATL ACAD SCI USA, V87, P6659, DOI 10.1073/pnas.87.17.6659; FERSHT A, 1985, ENZYME STRUCTURE MEC, P299; FINK AL, 1987, ENZYME MECHANISMS, P159; FRIEDMAN KD, 1990, PCR PROTOCOLS GUIDE, P253; GRAF L, 1988, P NATL ACAD SCI USA, V85, P4961, DOI 10.1073/pnas.85.14.4961; GRANT GA, 1980, BIOCHEMISTRY-US, V19, P6089, DOI 10.1021/bi00567a022; GRANT GA, 1980, BIOCHEMISTRY-US, V19, P4653, DOI 10.1021/bi00561a018; GREER J, 1981, J MOL BIOL, V153, P1027, DOI 10.1016/0022-2836(81)90465-4; HANSCH C, 1970, J PHARM SCI, V59, P731, DOI 10.1002/jps.2600590602; HEDSTROM L, 1994, BIOCHEMISTRY-US, V33, P8757, DOI 10.1021/bi00195a017; HEDSTROM L, 1994, BIOCHEMISTRY-US, V33, P8764, DOI 10.1021/bi00195a018; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; KORTT AA, 1994, BIOCHEM J, V299, P521, DOI 10.1042/bj2990521; LARGMAN C, 1983, BIOCHEMISTRY-US, V22, P3763, DOI 10.1021/bi00285a008; LECROISEY A, 1979, EUR J BIOCHEM, V101, P385, DOI 10.1111/j.1432-1033.1979.tb19730.x; LIGHT A, 1989, TRENDS BIOCHEM SCI, V14, P110, DOI 10.1016/0968-0004(89)90133-3; MAINARDI CL, 1980, J BIOL CHEM, V255, P2006; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; PERONA JJ, 1994, BIOCHEMISTRY-US, V33, P3252, DOI 10.1021/bi00177a016; PERONA JJ, 1993, J MOL BIOL, V230, P934, DOI 10.1006/jmbi.1993.1211; PERONA JJ, 1995, BIOCHEMISTRY-US, V34, P1489, DOI 10.1021/bi00005a004; PERONA JJ, 1995, PROTEIN SCI, V4, P337; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90, DOI 10.1016/0003-2697(89)90019-5; SELLOS D, 1992, FEBS LETT, V309, P219, DOI 10.1016/0014-5793(92)80777-E; STROUD R, 1974, SCI AM, V23, P74; TANFORD C, 1980, HYDROPHOBIC EFFECT; THOMPSON RC, 1974, BIOCHEMISTRY-US, V13, P5495, DOI 10.1021/bi00724a007; TSU CA, 1994, J BIOL CHEM, V269, P19565; VANWORMHOUDT A, 1992, COMP BIOCHEM PHYS B, V103, P675, DOI 10.1016/0305-0491(92)90389-9; VASQUEZ JR, 1989, J CELL BIOCHEM, V39, P265, DOI 10.1002/jcb.240390306; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; WELGUS HG, 1983, BIOCHEMISTRY-US, V22, P2228, DOI 10.1021/bi00278a026; ZERNER B, 1964, J AM CHEM SOC, V86, P3669, DOI 10.1021/ja01072a015	50	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11563	11570		10.1074/jbc.271.19.11563	http://dx.doi.org/10.1074/jbc.271.19.11563			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626718				2022-12-27	WOS:A1996UJ94400078
J	Yamanaka, S; Poksay, KS; Driscoll, DM; Innerarity, TL				Yamanaka, S; Poksay, KS; Driscoll, DM; Innerarity, TL			Hyperediting of multiple cytidines of apolipoprotein B mRNA by APOBEC-1 requires auxiliary protein(s) but not a mooring sequence motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; TRANSGENIC MICE; EXPRESSION; SITES; B100	An RNA-binding cytidine deaminase (APOBEC-1) and unidentified auxiliary protein(s) are required for apolipoprotein (apo) B mRNA editing. A sequence motif on apoB mRNA (''mooring sequence,'' nucleotides 6671-6681) is obligatory for the editing of cytidine 6666 (C-6666), the only cytidine on apoB mRNA converted to uridine in normal animals. Transgenic animals with hepatic overexpression of APOBEC-1 develop liver tumors, and other non-apoB mRNAs are edited, suggesting a loss of the normally precise specificity. In this study, we examined apoB mRNA from these transgenic animals to determine if cytidines aside from C-6666 are edited. Multiple cytidines downstream from C-6666 in apoB mRNA were edited extensively by the overexpressed APOBEC-1. This pathophysiological ''hyperediting'' could be mimicked in vitro by incubating a synthetic apoB RNA substrate with the transgenic mouse liver extracts. Multiple cytidines in the synthetic apoB RNA were edited by recombinant APOBEC-1 but only with supplementation of the auxiliary protein(s). Mutations in the mooring sequence markedly decreased the normal editing of C-6666 but, surprisingly, increased the hyperediting of downstream cytidines. Furthermore, cytidines in an apoB RNA substrate lacking the mooring sequence were also edited in vitro. These results indicate that the hyperediting of apoB mRNA by overexpressed APOBEC-1 depends upon auxiliary protein(s) but is independent of the mooring sequence motif. These results suggest that hyperediting may represent the first step in a two-step recognition model for normal apoB mRNA editing.	UNIV CALIF SAN FRANCISCO, INST CARDIOVASC RES, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94141 USA; CLEVELAND CLIN FDN, DEPT CELL BIOL, CLEVELAND, OH 44195 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Cleveland Clinic Foundation	Yamanaka, S (corresponding author), UNIV CALIF SAN FRANCISCO, GLADSTONE INST CARDIOVASC DIS, POB 419100, SAN FRANCISCO, CA 94141 USA.				NHLBI NIH HHS [HL47660] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; BACKUS JW, 1994, BBA-GENE STRUCT EXPR, V1217, P65; BACKUS JW, 1991, NUCLEIC ACIDS RES, V19, P6781, DOI 10.1093/nar/19.24.6781; BACKUS JW, 1994, BBA-GENE STRUCT EXPR, V1219, P1, DOI 10.1016/0167-4781(94)90240-2; BENNE R, 1993, RNA EDITING, P13; BOSTROM K, 1989, J BIOL CHEM, V264, P15701; CHEN SH, 1990, J BIOL CHEM, V265, P6811; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CHIESA GL, 1993, J BIOL CHEM, V268, P23747; DAVIDSON NO, 1995, RNA, V1, P3; DRISCOLL DM, 1994, J BIOL CHEM, V269, P19843; DRISCOLL DM, 1993, MOL CELL BIOL, V13, P7288, DOI 10.1128/MCB.13.12.7288; GREEVE J, 1993, J LIPID RES, V34, P1367; HODGES P, 1992, TRENDS BIOCHEM SCI, V17, P77, DOI 10.1016/0968-0004(92)90506-5; JOHNSON DF, 1993, BIOCHEM BIOPH RES CO, V195, P1204, DOI 10.1006/bbrc.1993.2172; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; MANO H, 1990, ONCOGENE, V5, P1781; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; PAULAUSKIS JD, 1989, BIOCHEM BIOPH RES CO, V158, P690, DOI 10.1016/0006-291X(89)92776-9; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SHAH RR, 1991, J BIOL CHEM, V266, P16301; Smith H C, 1993, Semin Cell Biol, V4, P267, DOI 10.1006/scel.1993.1032; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483; YAMANAKA S, 1995, CIRCULATION, V92, P788	28	56	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11506	11510		10.1074/jbc.271.19.11506	http://dx.doi.org/10.1074/jbc.271.19.11506			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626710	hybrid			2022-12-27	WOS:A1996UJ94400070
J	Clarke, JL; Watkins, WM				Clarke, JL; Watkins, WM			alpha 1,3-L-Fucosyltransferase expression in developing human myeloid cells Antigenic, enzymatic, and mRNA analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; LINE HL-60; SIALYL-LEX; TERMINAL DIFFERENTIATION; NEURAMINIDASE TREATMENT; DETERMINES EXPRESSION; ACCEPTOR SPECIFICITY; CARBOHYDRATE UNITS	In an attempt to correlate the cell surface expression of Le(x) and sialyl-Le(x) structures in immature and mature myeloid cells with the genes expressing alpha 1,3-fucosyltransferase(s) we have examined: 1) the properties of the cellular alpha 1,3-fucosyltransferases and the mRNA transcripts corresponding to the five cloned genes, Fuc-TIII, Fuc-TIV, Fuc-TV, Fuc-TVI, and Fuc-TVII, in mature granulocytes and in the myeloid cell line HL-60, before and after dimethyl sulfoxide-induced differentiation and 2) the properties of the alpha 1,3-fucosyltransferases expressed in COS 7 cells transfected with plasmids containing Fuc-TIV and Fuc-TVII cDNAs. The previously shown increase in cell surface expression of sialyl-Le(x) on differentiation of HL-60 cells (Skacel P. O., Edwards A. J., Harrison C. T., and Watkins W. M. (1991) Blood 78, 1452-1460) is accompanied by a sharp fall in expression of Fuc-TIV mRNA and a persistence of expression of Fuc-TVII mRNA. The properties of the alpha 1,3-fucosyltransferase expressed in COS-7 cells transfected with Fuc-TIV are consistent with this being the major gene responsible for the expression of Le(x) in the immature myeloid cells. In Northern blot analyses, no transcripts of Fuc-TIII, Fuc-TV, or Fuc-TVI were detected in total RNA from mature granulocytes or mRNA from HL-60 cells before or after differentiation. In total RNA from mature granulocytes, Fuc-TIV transcripts were only faintly visible, whereas Fuc-TVII transcripts were quite definitely expressed. The specificity properties of Fuc-TVII expressed in COS-7 cells are consistent with this gene being the major candidate alpha 1,3-fucosyltransferase controlling the expression of sialyl-Le(x) on mature cells. However, Le(x) continues to be expressed on the surface of mature granulocytes and cell extracts retain the capacity to transfer fucose to non-sialylated acceptor substrates. The question therefore remains as to whether these properties result from the weakly expressed Fuc-TIV gene or whether another alpha 1,3-fucosyltransferase gene remains to be identified.	HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT HAEMATOL, LONDON W12 0NN, ENGLAND	Imperial College London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BETTELHEIM P, 1989, LEUKOCYTE TYPING, V4, P798; BOYER PD, 1959, ENZYMES, V1, P511; CARTRON JP, 1980, REV FR TRANSFUS IMMU, V23, P271, DOI 10.1016/S0338-4535(80)80131-0; CHOU TH, 1977, BIOCHEM BIOPH RES CO, V74, P1001, DOI 10.1016/0006-291X(77)91617-5; CIVIN CI, 1984, J IMMUNOL, V133, P157; CIVIN CI, 1981, BLOOD, V57, P842; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COUILLIN P, 1991, CYTOGENET CELL GENET, V56, P108, DOI 10.1159/000133061; DEVRIES T, 1992, HISTOCHEM J, V24, P761, DOI 10.1007/BF01046347; DONALD ASR, 1988, CARBOHYD RES, V178, P79, DOI 10.1016/0008-6215(88)80103-4; DYSON NJ, 1991, ESSENTIAL MOL BIOL, V2, P111; ELMAGHRABI MR, 1984, J BIOL CHEM, V259, P3104; FUKUDA M, 1991, Glycobiology, V1, P347, DOI 10.1093/glycob/1.4.347; FUKUDA M, 1981, P NATL ACAD SCI-BIOL, V78, P6299, DOI 10.1073/pnas.78.10.6299; FUKUSHI Y, 1984, J BIOL CHEM, V259, P511; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GAHMBERG CG, 1979, P NATL ACAD SCI USA, V76, P4087, DOI 10.1073/pnas.76.8.4087; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GREENWELL P, 1983, FEBS LETT, V164, P314, DOI 10.1016/0014-5793(83)80308-1; JOHNSON PH, 1992, GLYCOCONJUGATE J, V9, P251, DOI 10.1007/BF00731137; JOHNSON PH, 1987, BIOCHEM SOC T, V15, P396, DOI 10.1042/bst0150396; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LUBBERT M, 1991, BLOOD, V77, P909; LUNDJOHANSEN F, 1993, J LEUKOCYTE BIOL, V54, P47, DOI 10.1002/jlb.54.1.47; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; MACHER BA, 1988, J BIOL CHEM, V263, P10186; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; MORGAN WTJ, 1967, METHOD IMMUNOL IMMUN, V1, P75; NAKAMURA M, 1992, J BIOL CHEM, V267, P23507; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NILSSON B, 1979, J BIOL CHEM, V254, P4545; NORIJI H, 1984, BLOOD, V64, P534; OLSSON I, 1981, EXP CELL RES, V131, P225, DOI 10.1016/0014-4827(81)90422-5; PANTAZIS P, 1981, J CELL BIOL, V90, P396, DOI 10.1083/jcb.90.2.396; PASQUALETTO V, 1995, GLYCOBIOLOGY, V5, P59, DOI 10.1093/glycob/5.1.59; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SCHENKELBRUNNER H, 1972, EUR J BIOCHEM, V30, P269, DOI 10.1111/j.1432-1033.1972.tb02095.x; SCHMID K, 1979, BIOCHIM BIOPHYS ACTA, V581, P356, DOI 10.1016/0005-2795(79)90255-1; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHAHREDDY I, 1982, AM J HEMATOL, V12, P29, DOI 10.1002/ajh.2830120105; SKACEL PO, 1991, BLOOD, V78, P1452; SKACEL PO, 1988, BIOCHEM SOC T, V16, P1034, DOI 10.1042/bst0161034; SKACEL PO, 1987, GLYCOCONJUGATE J, V4, P267, DOI 10.1007/BF01048432; SKACEL PO, 1992, THESIS U LONDON; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; STRAUSS LC, 1983, BLOOD, V61, P1222; TABILIO A, 1984, BRIT J HAEMATOL, V58, P697, DOI 10.1111/j.1365-2141.1984.tb06117.x; TAMM I, 1950, P SOC EXP BIOL MED, V74, P108, DOI 10.3181/00379727-74-17825; TETTEROO PAT, 1984, INT J CANCER, V33, P355, DOI 10.1002/ijc.2910330312; TETTEROO PAT, 1987, J BIOL CHEM, V262, P15984; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; URDAL DL, 1983, BLOOD, V62, P1022; VANBEEK WP, 1982, CANCER RES, V42, P5222; WALTZ G, 1990, SCIENCE, V250, P1132; Watkins W. M, 1972, GLYCOPROTEINS, V5, P830; WATKINS WM, 1993, ACS SYM SER, V519, P324; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; WILKINSON M, 1991, ESSENTIAL MOL BIOL, V1, P69; WILLIAMS J, 1984, CARBOHYD RES, V134, P141, DOI 10.1016/0008-6215(84)85029-6; [No title captured]	67	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10317	10328		10.1074/jbc.271.17.10317	http://dx.doi.org/10.1074/jbc.271.17.10317			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626601	hybrid			2022-12-27	WOS:A1996UG25700073
J	Matsumine, A; Senda, T; Baeg, GH; Roy, BC; Nakamura, Y; Noda, M; Toyoshima, K; Akiyama, T				Matsumine, A; Senda, T; Baeg, GH; Roy, BC; Nakamura, Y; Noda, M; Toyoshima, K; Akiyama, T			MCC, a cytoplasmic protein that blocks cell cycle progression from the G(0)/G(1) to S phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; TUMOR SUPPRESSOR GENES; APC GENE; PHOSPHORYLATION; IDENTIFICATION; MUTATIONS; CANCER; CHROMOSOME-5Q21; ASSOCIATION; GROWTH	The MCC gene was isolated from the human chromosome 5q21 by positional cloning and was found to be mutated in several colorectal tumors. In this study, we prepared specific antibodies and detected the MCC gene product as a cytoplasmic 100-kDa phosphoprotein in mouse NIH3T3 cells. Immunoelectron microscopic analysis showed that the MCC protein is associated with the plasma membrane and membrane organelles in mouse intestinal epithelial cells and neuronal cells. The amount of the MCC protein remained constant during the cell cycle progression of NIH3T3 cells, while its phosphorylation state changed markedly in a cell cycle-dependent manner, being weakly phosphorylated in the G(0)/G(1) and highly phosphorylated during the G(1) to S transition. Overexpression of the MCC protein blocked the serum-induced cell cycle transition from the G(1) to S phase, whereas a mutant MCC, initially identified in a colorectal tumor, did not exhibit this activity. These results suggest that the MCC protein may play a role in the signaling pathway negatively regulating cell cycle progression.	OSAKA UNIV, SCH MED, DEPT ANAT, OSAKA 565, JAPAN; OSAKA UNIV, INST MICROBIAL DIS, DEPT ONCOGENE RES, OSAKA 565, JAPAN; UNIV TOKYO, INST MED SCI, MOLEC MED LAB, TOKYO 108, JAPAN; KYOTO UNIV, FAC MED, DEPT MOLEC ONCOL, KYOTO 606, JAPAN	Osaka University; Osaka University; University of Tokyo; Kyoto University			Baeg, Gyeong-Hun/A-2951-2008					AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; AKIYAMA T, 1990, ONCOGENE, V5, P179; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DAMICO D, 1992, CANCER RES, V52, P1996; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG Y, 1992, CANCER RES, V52, P6525; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NODA A, 1994, EXP CELL RES, V211; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Sal G.D., 1992, CELL, V70, P595; SENDA T, 1991, HISTOCHEMISTRY, V96, P25, DOI 10.1007/BF00266757; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1993, CANCER RES, V53, P2728; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1989, J CELL BIOL, V109, P2905, DOI 10.1083/jcb.109.6.2905; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	46	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10341	10346		10.1074/jbc.271.17.10341	http://dx.doi.org/10.1074/jbc.271.17.10341			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626604	Green Submitted, hybrid			2022-12-27	WOS:A1996UG25700076
J	PanayotovaHeiermann, M; Loo, DDF; Kong, CT; Lever, JE; Wright, EM				PanayotovaHeiermann, M; Loo, DDF; Kong, CT; Lever, JE; Wright, EM			Sugar binding to Na+/glucose cotransporters is determined by the carboxyl-terminal half of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ GLUCOSE COTRANSPORTER; EPITHELIAL-CELL LINE; RABBIT SMALL-INTESTINE; PIG-KIDNEY; ELECTROGENIC PROPERTIES; VOLTAGE-CLAMP; TRANSPORT; MEMBRANE; HETEROGENEITY; EXPRESSION	D-Glucose is absorbed across the proximal tubule of the kidney by two Na+/glucose cotransporters (SGLT1 and SGLT2). The low affinity SGLT2 is expressed in the S1 and S2 segments, has a Na+:glucose coupling ratio of 1, a K-0.5 for sugar of similar to 2 mM, and a K-0.5 for Na+ of similar to 1 mM. The high affinity SGLT1, found in the S3 segment, has a coupling ratio of 2, and K-0.5 for sugar and Na+ of similar to 0.2 and 5 mM, respectively. We have constructed a chimeric protein consisting of amino acids 1-380 of porcine SGLT2 and amino acids 381-662 of porcine SGLT1. The chimera was expressed in Xenopus oocytes, and steady-state kinetics were characterized by a two-electrode voltage-clamp. The K-0.5 for alpha-methyl-D-glucopyranoside (0.2 mM) was similar to that for SGLT1, and like SGLT1 the chimera transported D-galactose and 3-O-methylglucose. In contrast, SGLT2 transports poorly D-galactose and excludes 3-O-methylglucose. The apparent K-0.5(Na) was 3.5 mM (at -150 mV), and the Hill coefficient ranged between 0.8 and 1.5. We conclude that recognition/transport of organic substrate is mediated by interactions distal to amino acid 380, while cation binding is determined by interactions arising from the amino- and carboxyl-terminal halves of the transporters. Surprisingly, the chimera transported alpha-phenyl derivatives of D-glucose as well as the inhibitors of sugar transport: phlorizin, deoxyphlorizin, and beta-D-glucopyranosylphenyl isothiocyanate are transported with high affinity (K-0.5 for phlorizin was 5 mu M). Thus, the pocket for organic substrate binding is increased from 10 x 5 x 5 (Angstrom) for SGLT1 to 11 x 18 x 5 (Angstrom) for the chimera.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77225	University of Texas System	PanayotovaHeiermann, M (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,10833 LE CONTE AVE,LOS ANGELES,CA 90095, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027400, R37DK027400] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK4460, DK 27400] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNIR B, 1991, PFLUG ARCH EUR J PHY, V418, P79, DOI 10.1007/BF00370455; DIEDRICH DF, 1990, METHOD ENZYMOL, V191, P755; DUE AD, 1995, BIOCHEMISTRY-US, V34, P5462, DOI 10.1021/bi00016a017; FUHRMANN GF, 1992, BIOCHIM BIOPHYS ACTA, V1110, P105, DOI 10.1016/0005-2736(92)90300-B; HAGER K, 1995, J MEMBRANE BIOL, V143, P103; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; Hirayama B. A., 1995, Biophysical Journal, V68, pA439; HIRAYAMA BA, 1996, IN PRESS AM J PHYSL; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; IKEDA TS, 1989, J MEMBRANE BIOL, V110, P87, DOI 10.1007/BF01870995; INUKAI K, 1995, ENDOCRINOLOGY, V136, P4850, DOI 10.1210/en.136.11.4850; KONG CT, 1993, J BIOL CHEM, V268, P1509; KONG CT, 1993, FEBS LETT, V333, P1, DOI 10.1016/0014-5793(93)80363-Y; LEE WS, 1994, J BIOL CHEM, V269, P12032; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; LOSTAO MP, 1994, J MEMBRANE BIOL, V142, P161; MACKENZIE B, 1994, J BIOL CHEM, V269, P22488; MACKENZIE B, 1994, BIOPHYS J, V68, pA436; Martin MG, 1996, NAT GENET, V12, P216, DOI 10.1038/ng0296-216; MISFELDT DS, 1982, J MEMBRANE BIOL, V70, P191, DOI 10.1007/BF01870562; MISFELDT DS, 1981, J MEMBRANE BIOL, V59, P13, DOI 10.1007/BF01870816; MORAN A, 1982, AM J PHYSIOL, V243, pC293, DOI 10.1152/ajpcell.1982.243.5.C293; NISHIZAWA K, 1995, J BIOL CHEM, V270, P2423, DOI 10.1074/jbc.270.6.2423; OHTA T, 1990, MOL CELL BIOL, V10, P6491, DOI 10.1128/MCB.10.12.6491; Panayotova-Heiermann M., 1995, Pfluegers Archiv European Journal of Physiology, V430, pR116; PANAYOTOVAHEIERMANN M, 1994, J BIOL CHEM, V269, P21016; PANAYOTOVAHEIERMANN M, 1995, J BIOL CHEM, V270, P27099, DOI 10.1074/jbc.270.45.27099; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; RABITO CA, 1980, J MEMBRANE BIOL, V54, P31, DOI 10.1007/BF01875374; RABITO CA, 1981, BIOCHIM BIOPHYS ACTA, V649, P286, DOI 10.1016/0005-2736(81)90417-X; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; TURNER RJ, 1982, J MEMBRANE BIOL, V67, P73, DOI 10.1007/BF01868649; TURNER RJ, 1982, J MEMBRANE BIOL, V70, P37, DOI 10.1007/BF01871587; TURNER RJ, 1982, AM J PHYSIOL, V242, pF406, DOI 10.1152/ajprenal.1982.242.4.F406; UMBACH JA, 1990, BIOPHYS J, V57, P1217, DOI 10.1016/S0006-3495(90)82640-0; WRIGHT EM, 1994, J EXP BIOL, V196, P197	38	93	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10029	10034		10.1074/jbc.271.17.10029	http://dx.doi.org/10.1074/jbc.271.17.10029			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626557	hybrid			2022-12-27	WOS:A1996UG25700029
J	Helm, BA; Sayers, I; Higginbottom, A; Machado, DC; Ling, Y; Ahmad, K; Padlan, EA; Wilson, APM				Helm, BA; Sayers, I; Higginbottom, A; Machado, DC; Ling, Y; Ahmad, K; Padlan, EA; Wilson, APM			Identification of the high affinity receptor binding region in human immunoglobulin E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRAUSNITZ-KUSTNER REACTION; IGE-RECEPTOR; ESCHERICHIA-COLI; FC FRAGMENTS; SITE; INHIBITION; CHAIN; PURIFICATION; DOMAIN	We have investigated the capacity of N- and C-terminally truncated and chimeric human (h) IgE-derived peptides to inhibit the binding of I-125-labeled hIgE, and to engage cell lines expressing high and low affinity receptors (Fc epsilon RI/II). The peptide sequence Pro(343)-Ser(353) of the hC epsilon 3 domain is common to all he-chain peptides that recognize hFc epsilon RI. This region in IgE is homologous to the A loop in C gamma 2 that engages the rat neonatal IgG receptor. Optimum Fc epsilon RI occupancy by hIgE occurs at pH 6.4, with a second peak at 7.4. N- or C-terminal truncation has little effect on the association rate of the ligands with this receptor. Dissociation markedly increases following C-terminal deletion, and hFc epsilon RI occupancy at pH 6.4 is diminished. His residue(s) in the C-terminal region of the epsilon-chain may thus contribute to the high affinity of interaction. Grafting the homologous rat epsilon-chain sequence into hIgE maintains Fc epsilon RI interaction without conferring binding to rat Fc epsilon RI. hFc epsilon RII interaction is lost, suggesting that these residues also contribute to hFc epsilon RII binding. h epsilon-chain peptides comprising only this sequence do not block hIgE/hFc epsilon RI interaction or engage the receptor. Therefore, sequences N- or C-terminal to this core peptide provide structures necessary for receptor recognition.	NIDDK,NIH,BETHESDA,MD 20892; EURO DPC LTD,LLANBERIS LL55 4EL,GWYNEDD,WALES	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Helm, BA (corresponding author), UNIV SHEFFIELD,KREBS INST BIOMOLEC RES,MBB,SHEFFIELD S10 2UH,S YORKSHIRE,ENGLAND.		Machado, Denise C/G-2852-2014	Machado, Denise C/0000-0002-9371-5886; Sayers, Ian/0000-0001-5601-5410				BASU M, 1993, J BIOL CHEM, V268, P13118; BEAVIL AJ, 1993, BIOCHEM SOC T, V21, P968, DOI 10.1042/bst0210968; BINGHAM BR, 1994, J BIOL CHEM, V269, P19300; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; GEHA RS, 1985, NATURE, V315, P577, DOI 10.1038/315577a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAMBURGER RN, 1975, SCIENCE, V189, P389, DOI 10.1126/science.1145208; HELM B, 1988, NATURE, V331, P180, DOI 10.1038/331180a0; HELM BA, 1991, EUR J IMMUNOL, V21, P1543, DOI 10.1002/eji.1830210631; HELM BA, 1992, PROGR ALLERGY CLIN I, V2, P589; HELM BA, 1989, P NATL ACAD SCI USA, V186, P9465; HO SN, 1989, GENE AMST, V52, P2940; ISHIZAKA K, 1970, IMMUNOCHEMISTRY, V7, P687, DOI 10.1016/0019-2791(70)90175-8; KITANI S, 1988, J IMMUNOL, V140, P2585; Lehrer S S, 1978, Methods Enzymol, V49, P222; LINDSTROMBAHR H, 1974, THESIS U UPPSALA; LIU FT, 1984, P NATL ACAD SCI USA, V81, P5361; MARSH P, 1988, IGE ALLERGIC INFLAMM, P26; NIO N, 1989, PEPTIDE CHEM, V2, P203; NISSIM A, 1991, EMBO J, V10, P101, DOI 10.1002/j.1460-2075.1991.tb07925.x; NISSIM A, 1993, J IMMUNOL, V150, P1365; NISSIM A, 1992, MOL IMMUNOL, V29, P1065, DOI 10.1016/0161-5890(92)90038-Y; PADLAN EA, 1993, BIOCHEM SOC T, V21, P963, DOI 10.1042/bst0210963; PEREZMONTFORT R, 1982, MOL IMMUNOL, V19, P1113, DOI 10.1016/0161-5890(82)90322-4; PRESTA L, 1994, J BIOL CHEM, V269, P26368; PRESTA LG, 1993, J IMMUNOL, V151, P2632; ROBERTSON MW, 1988, MOL IMMUNOL, V25, P103, DOI 10.1016/0161-5890(88)90057-0; STANWORTH DR, 1968, LANCET, V2, P17; STANWORTH DR, 1990, LANCET, V336, P1279, DOI 10.1016/0140-6736(90)92963-I; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; VERCELLI D, 1989, NATURE, V338, P649, DOI 10.1038/338649a0; VOGEL M, 1994, EUR J IMMUNOL, V24, P1200, DOI 10.1002/eji.1830240529; WEETALL M, 1990, J IMMUNOL, V145, P3849; WILSON APM, 1993, EUR J IMMUNOL, V23, P240, DOI 10.1002/eji.1830230137; YAGI S, 1994, EUR J BIOCHEM, V220, P593, DOI 10.1111/j.1432-1033.1994.tb18660.x; ZHENG Y, 1991, BIOCHEMISTRY-US, V30, P9125, DOI 10.1021/bi00102a002	36	39	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7494	7500		10.1074/jbc.271.13.7494	http://dx.doi.org/10.1074/jbc.271.13.7494			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631779	hybrid			2022-12-27	WOS:A1996UC77400047
J	Hsu, HY; Nicholson, AC; Hajjar, DP				Hsu, HY; Nicholson, AC; Hajjar, DP			Inhibition of macrophage scavenger receptor activity by tumor necrosis factor-alpha is transcriptionally and post-transcriptionally regulated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MONOCYTE-DERIVED MACROPHAGES; SMOOTH-MUSCLE CELLS; LINE THP-1; ATHEROSCLEROTIC LESIONS; LIPID-ACCUMULATION; INTERFERON-GAMMA; EXPRESSION; GENE; ESTER	Regulation of expression of the scavenger receptor is thought to play a critical role in the accumulation of lipid by macrophages in atherosclerosis. Tumor necrosis factor-alpha (TNF-alpha) has been shown to suppress macrophage scavenger receptor function (van Lenten, B. J., and Fogelman, A. M. (1992) J. Immunol. 148, 112-116). However the mechanism by which it does so is unknown. We evaluated the mechanism by which TNF-alpha inhibited macrophage scavenger receptor surface expression and binding of acetylated low density lipoprotein (aLDL). Binding of aLDL to phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 macrophages was suppressed by TNF-alpha in a dose-dependent manner. Inhibition of aLDL binding was paralleled by a reduction of macrophage scavenger receptor protein as detected by the Western blot. TNF-alpha partially decreased macrophage scavenger receptor mRNA steady state levels in PMA-differentiated THP-1 macrophages, a result that was confirmed by reverse transcription-polymerase chain reaction. PMA increased the luciferase activity driven by the macrophage scavenger receptor promoter in the transfected cells, whereas TNF-alpha partially reduced luciferase activity. However, macrophage scavenger receptor mRNA half-life was dramatically reduced in cells treated with TNF-alpha relative to untreated cells. Reduction in macrophage scavenger receptor message in response to TNF-alpha was dependent on new protein synthesis because it was blocked by cycloheximide. These results indicate that TNF-alpha regulates macrophage scavenger receptor expression in PMA-differentiated THP-1 macrophages by transcriptional and post-transcriptional mechanisms but principally by destabilization of macrophage scavenger receptor mRNA.	CORNELL UNIV,COLL MED,DEPT BIOCHEM,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MED,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT PATHOL,NEW YORK,NY 10021	Cornell University; Cornell University; Cornell University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049666, K14HL003158, P01HL046403] Funding Source: NIH RePORTER; NHLBI NIH HHS [K14 HL-03158, HL-46403, HL-49666] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKESON AL, 1991, J LIPID RES, V32, P1699; AVIRAM M, 1990, ARTERIOSCLEROSIS, V10, P559, DOI 10.1161/01.ATV.10.4.559; AVIRAM M, 1989, METABOLISM, V38, P425, DOI 10.1016/0026-0495(89)90192-3; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BOTTALICO LA, 1991, J BIOL CHEM, V266, P22866; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5894; CONWAY EM, 1988, MOL CELL BIOL, V8, P5588, DOI 10.1128/MCB.8.12.5588; CORTON JM, 1992, EUR J BIOCHEM, V204, P203, DOI 10.1111/j.1432-1033.1992.tb16625.x; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DORSETT DL, 1983, J VIROL, V48, P218, DOI 10.1128/JVI.48.1.218-228.1983; EMI M, 1993, J BIOL CHEM, V268, P2120; FOGELMAN AM, 1982, P NATL ACAD SCI-BIOL, V79, P922, DOI 10.1073/pnas.79.3.922; FONG LG, 1990, J BIOL CHEM, V265, P11751; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; GENG YJ, 1994, ARTERIOSCLER THROMB, V14, P798, DOI 10.1161/01.ATV.14.5.798; GENG YJ, 1992, J CLIN INVEST, V89, P1322, DOI 10.1172/JCI115718; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GONG QQ, 1995, J BIOL CHEM, V270, P21672, DOI 10.1074/jbc.270.37.21672; HAJJAR DP, 1980, AM J PATHOL, V100, P683; HAJJAR DP, 1982, J CLIN INVEST, V70, P479, DOI 10.1172/JCI110639; HAJJAR DP, 1983, J LIPID RES, V24, P1176; HAJJAR DP, 1985, J BIOL CHEM, V260, P6124; HALEY NJ, 1980, J LIPID RES, V21, P961; HARA H, 1987, BIOCHEM BIOPH RES CO, V146, P802, DOI 10.1016/0006-291X(87)90601-2; HSU HY, 1994, J BIOL CHEM, V269, P9213; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI HM, 1995, J CLIN INVEST, V95, P122, DOI 10.1172/JCI117628; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARSHALL PJ, 1985, ANAL BIOCHEM, V145, P192, DOI 10.1016/0003-2697(85)90347-1; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; MOHAMED F, 1995, ARTERIOSCL THROM VAS, V15, P52, DOI 10.1161/01.ATV.15.1.52; MOHAMED F, 1995, FASEB J, V9, P326; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; MOULTON KS, 1992, P NATL ACAD SCI USA, V89, P8102, DOI 10.1073/pnas.89.17.8102; NAITO M, 1992, AM J PATHOL, V141, P591; PAPE ME, 1989, MOL CELL BIOL, V9, P974, DOI 10.1128/MCB.9.3.974; PHILLIPS DR, 1985, NATURE, V316, P746, DOI 10.1038/316746a0; RUS HG, 1991, ATHEROSCLEROSIS, V89, P247; SCHUTZE S, 1992, SEMIN ONCOL, V19, P16; SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841; STOPECK AT, 1993, J BIOL CHEM, V268, P17489; TIPPING PG, 1993, AM J PATHOL, V142, P1721; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; TSUCHIYA S, 1982, CANCER RES, V42, P1530; VANLENTEN BJ, 1985, J IMMUNOL, V134, P3718; VANLENTEN BJ, 1992, J IMMUNOL, V148, P112; VIA DP, 1989, J LIPID RES, V30, P1515; VILLIERS WJS, 1994, J EXP MED, V180, P705; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205	55	92	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7767	7773		10.1074/jbc.271.13.7767	http://dx.doi.org/10.1074/jbc.271.13.7767			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631819	hybrid			2022-12-27	WOS:A1996UC77400087
J	Nenortas, E; Beckett, D				Nenortas, E; Beckett, D			Purification and characterization of intact and truncated forms of the Escherichia coli biotin carboxyl carrier subunit of acetyl-CoA carboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE MULTIENZYME COMPLEX; AMINO-ACID SEQUENCE; INTERDOMAIN SEGMENT; PROTEIN; REPRESSOR; OPERON; ENZYMES	Biotin biosynthesis and retention in Escherichia coli is regulated by the multifunctional protein, BirA. The protein acts as both the transcriptional repressor of the biotin biosynthetic operon and as a ligase for covalent attachment of biotin to a unique lysine residue of the biotin carboxyl carrier protein (BCCP) subunit of the acetyl-CoA carboxylase. Biotinyl-5'-AMP is the activated intermediate for the ligase reaction and the allosteric effector for DNA binding. We have purified and characterized apoBCCP and a truncated form containing the COOH-terminal 87 residues (apoBCCP87). Molecular masses of the proteins measured using matrix-assisted laser desorption ionization time-of-flight mass spectrometry conformed to the expected values. The assembly states of apoBCCP and apoBCCP87 were determined using sedimentation equilibrium ultracentrifugation. Nearly quantitative enzymatic transfer of biotin from BirA-biotinyl-5'-AMP to the apoBCCP forms was assessed using two methods, mass spectrometric analysis of acceptor proteins after incubation with BirA-bio-5'-AMP and a steady state fluorescence assay. The BirA catalyzed rates of transfer of biotin from bio-5'-AMP to apoBCCP and apoBCCPS7 were measured by stopped-flow fluorescence. Kinetic parameters estimated from these measurements indicate that the intact and truncated forms of the acceptor protein are functionally identical.	UNIV MARYLAND,DEPT CHEM & BIOCHEM,BALTIMORE,MD 21228	University System of Maryland; University of Maryland Baltimore					NCRR NIH HHS [RR08937, RR08311] Funding Source: Medline; NIGMS NIH HHS [GM46511] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR008937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046511, R01GM046511] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTT J, 1993, BIOCHEMISTRY-US, V32, P9649, DOI 10.1021/bi00088a017; BROCKLEHURST SM, 1993, PROTEIN SCI, V2, P626; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P881, DOI 10.1042/bj3020881; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; CRONAN JE, 1989, CELL, V58, P427, DOI 10.1016/0092-8674(89)90421-2; CRONAN JE, 1988, J BIOL CHEM, V263, P10332; EISENBERG MA, 1982, J BIOL CHEM, V257, P5167; FALL RR, 1972, J BIOL CHEM, V247, P8005; Fersht A., 1985, ENZYME STRUCTURE MEC; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; KABATA H, 1993, SCIENCE, V262, P1561, DOI 10.1126/science.8248804; Kornberg A., 1992, DNA REPLICATION; LI SJ, 1992, J BIOL CHEM, V267, P855; Maniatis T., 1982, MOL CLONING; MILES JS, 1988, J MOL BIOL, V202, P97, DOI 10.1016/0022-2836(88)90522-0; NERVI AM, 1971, ARCH BIOCHEM BIOPHYS, V143, P401, DOI 10.1016/0003-9861(71)90227-X; OTSUKA A, 1978, NATURE, V276, P689, DOI 10.1038/276689a0; PAI CH, 1972, J BACTERIOL, V112, P1280, DOI 10.1128/JB.112.3.1280-1287.1972; PRAKASH O, 1979, P NATL ACAD SCI USA, V76, P5592, DOI 10.1073/pnas.76.11.5592; PRAKASH O, 1974, J BACTERIOL, V120, P785, DOI 10.1128/JB.120.2.785-791.1974; RADFORD SE, 1989, J BIOL CHEM, V264, P767; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SHENOY BC, 1993, J BIOL CHEM, V268, P2232; SUTTON MR, 1977, J BIOL CHEM, V252, P3934; TEXTER FL, 1988, BIOCHEMISTRY-US, V27, P289, DOI 10.1021/bi00401a044; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030; WOOD HG, 1980, J BIOL CHEM, V255, P7397; XU Y, 1994, BIOCHEMISTRY-US, V33, P7354, DOI 10.1021/bi00189a041; Xu Y, 1995, BIOCHEMISTRY-US, V34, P16624, DOI 10.1021/bi00051a010; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3	31	61	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7559	7567		10.1074/jbc.271.13.7559	http://dx.doi.org/10.1074/jbc.271.13.7559			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631788	hybrid			2022-12-27	WOS:A1996UC77400056
J	Petruzzelli, L; Takami, M; Herrera, R				Petruzzelli, L; Takami, M; Herrera, R			Adhesion through the interaction of lymphocyte function-associated antigen-1 with intracellular adhesion molecule-1 induces tyrosine phosphorylation of p130(cas) and its association with c-CrkII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; CELL-ADHESION; SH3 DOMAINS; TRANSENDOTHELIAL MIGRATION; EXTRACELLULAR-MATRIX; COUNTER-RECEPTOR; T-CELLS; V-CRK; LFA-1; ACTIVATION	The B-lymphoblastoid cell line JY undergoes homotypic aggregation in a lymphocyte function-associated antigen-1 (LFA-1)-mediated, intracellular adhesion molecule-1 (ICAM-1)-dependent manner when stimulated with phorbol 12-myristate 13-acetate or anti-LFA-1 antibodies. Under conditions that lead to cell aggregation, we observed rapid tyrosine phosphorylation of p130(cas), a protein previously identified to be phosphorylated on tyrosine in both v-src- and v-crk-transformed cells. Phosphorylation of p130(cas) was dependent on binding of LFA-1 to its ligand, ICAM-1, as demonstrated by the use of anti-ICAM-1 antibodies. Several observations suggest that this event may be an important step in the signaling pathway initiated by LFA-1. p130(cas) phosphorylation was rapidly reversible upon disengagement of the LFA-1 . ICAM-1 complex and required cell adhesion since binding of phorbol 12-myristate 13-acetate-stimulated JY cells to purified ICAM-1 or cross-linking of either LFA-1 or ICAM-1 was not sufficient to induce phosphorylation of p130(cas). The integrin-stimulated phosphorylation of p130(cas) created binding sites that were recognized in vitro by the SH2 domain of c-CrkII, a key adaptor protein involved in cell differentiation and transformation. Moreover, we also showed that the LFA-1-stimulated tyrosine phosphorylation of p130(cas) induces the formation of a p130(cas). CrkII and p130(cas). CrkL complex in intact cells. This observation suggests that adhesion mediated by the interaction of LFA-1 and ICAM-1 initiates a signaling cascade that involves the activation of protein tyrosine kinases and leads to the regulation of protein-protein interaction via SH2 domains, a key process shared with growth factor signaling pathways.	WARNER LAMBERT PARKE DAVIS, PHARMACEUT RES DIV, DEPT SIGNAL TRANSDUCT, ANN ARBOR, MI 48105 USA; UNIV MICHIGAN, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; DEPT VET AFFAIRS MED CTR, ANN ARBOR, MI 48109 USA	Pfizer; University of Michigan System; University of Michigan								ARROYO AG, 1994, J CELL BIOL, V126, P1277, DOI 10.1083/jcb.126.5.1277; BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; HELLBERG C, 1995, EXP CELL RES, V217, P140, DOI 10.1006/excr.1995.1073; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KEIZER GD, 1985, EUR J IMMUNOL, V15, P1142, DOI 10.1002/eji.1830151114; KLICKSTEIN LB, 1995, LEUCOCYTE TYPING 5, P1542; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; PATCH LA, 1995, J CELL SCI, V108, P1371; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PETRUZZELLI L, 1995, J IMMUNOL, V155, P854; REILLY PL, 1995, J IMMUNOL, V155, P529; Ribon V, 1996, MOL CELL BIOL, V16, P45; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SCHLAEPFER DD, 1994, NATURE, V372, P786; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SUGIE K, 1995, J IMMUNOL, V154, P1691; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; VANSEVENTER GA, 1992, J IMMUNOL, V149, P3872; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WANG SCT, 1995, J LEUKOCYTE BIOL, V57, P343, DOI 10.1002/jlb.57.2.343; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	58	72	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7796	7801		10.1074/jbc.271.13.7796	http://dx.doi.org/10.1074/jbc.271.13.7796			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631823	hybrid			2022-12-27	WOS:A1996UC77400091
J	Steinberg, G; Schliwa, M				Steinberg, G; Schliwa, M			Characterization of the biophysical and motility properties of kinesin from the fungus Neurospora crassa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN KINESIN; URCHIN EGG KINESIN; HEAVY-CHAIN; DROSOPHILA KINESIN; CYTOPLASMIC MICROTUBULES; ATPASE ACTIVITY; IDENTIFICATION; PROTEINS; MOVEMENT; BINDING	Neurospora kinesin (Nkin) is a distant relative of the family of conventional kinesins, members of which have been identified in various animal species. As in its animal counterparts, Nkin most likely is an organelle motor. Because it is a functional homologue of the kinesin heavy chain of higher eukaryotes, its biophysical and motility properties were compared with those of other conventional kinesins. Purified Nkin behaves as a homodimeric complex composed of two subunits of a 105-kDa polypeptide. Based on its hydrodynamic properties (Stokes radius and sedimentation coefficient), Nkin is an elongated molecule, although it is more compact than its animal counterparts. A detailed comparison of the motility properties of Nkin with those of animal conventional kinesins reveals similarities and some intriguing differences. Nkin is less effective than other kinesins in the use of natural nucleoside triphosphates but responds to a selection of ATP analogues in a similar fashion as mammalian kinesin. Even in the presence of saturating concentrations of ATP, Nkin is significantly more sensitive to ADP or tripolyphosphate than other kinesins. Both the ATP-driven microtubule gliding activity and the microtubule-stimulated ATPase activity of Nkin obey Michaelis-Menten kinetics. Surprisingly, however, the K-m values for both these activities are approximately an order of magnitude higher than those of other kinesins. Whether the low affinity for ATP suggested by these high K-m values is related to the high rate of motility remains to be determined.	INST CELL BIOL,D-80336 MUNICH,GERMANY									ALLEN RD, 1981, CELL MOTIL CYTOSKEL, V1, P291, DOI 10.1002/cm.970010303; Andrews P, 1970, Methods Biochem Anal, V18, P1, DOI 10.1002/9780470110362.ch1; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BLOOM GS, 1994, PROTEIN PROFILE, V1, P1059; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; CANTOR CR, 1980, BIOPHYSICAL CHEM, V2; COHN SA, 1987, NATURE, V328, P160, DOI 10.1038/328160a0; COHN SA, 1989, J BIOL CHEM, V264, P4290; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; GAUGER AK, 1993, J BIOL CHEM, V268, P13657; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUANG TG, 1994, J BIOL CHEM, V269, P16493; ITAYA K, 1966, CLIN CHIM ACTA, V14, P361, DOI 10.1016/0009-8981(66)90114-8; KACHAR B, 1987, J BIOL CHEM, V262, P16180; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBLER S, 1993, J CELL BIOL, V121, P1357, DOI 10.1083/jcb.121.6.1357; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MANDELKOW EM, 1985, J MOL BIOL, V185, P311, DOI 10.1016/0022-2836(85)90406-1; MCCAFFREY G, 1989, EMBO J, V8, P3229, DOI 10.1002/j.1460-2075.1989.tb08482.x; MUROFUSHI H, 1988, J BIOL CHEM, V263, P12744; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; NICLAS J, 1994, NEURON, V12, P1059, DOI 10.1016/0896-6273(94)90314-X; PATEL N, 1993, P NATL ACAD SCI USA, V90, P9181, DOI 10.1073/pnas.90.19.9181; PENNINGROTH SM, 1987, FEBS LETT, V222, P204, DOI 10.1016/0014-5793(87)80220-X; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; PORTER ME, 1987, J BIOL CHEM, V262, P2794; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; SAXTON WM, 1988, P NATL ACAD SCI USA, V85, P1109, DOI 10.1073/pnas.85.4.1109; SCHOLEY JM, 1985, NATURE, V318, P483, DOI 10.1038/318483a0; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SCHROER TA, 1988, J CELL BIOL, V107, P1785, DOI 10.1083/jcb.107.5.1785; Sebald W, 1979, Methods Enzymol, V55, P144; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SHIMIZU T, 1991, J CELL BIOL, V112, P1189, DOI 10.1083/jcb.112.6.1189; STEINBERG G, 1993, J CELL SCI, V106, P555; STEINBERG G, 1995, MOL BIOL CELL, V6, P1605, DOI 10.1091/mbc.6.11.1605; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; VALE RD, 1994, J BIOL CHEM, V269, P23769; VENIER P, 1994, J BIOL CHEM, V269, P13353; WAGNER MC, 1989, CELL MOTIL CYTOSKEL, V12, P195, DOI 10.1002/cm.970120403; WALKER RA, 1993, ANNU REV BIOCHEM, V62, P429; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	55	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7516	7521		10.1074/jbc.271.13.7516	http://dx.doi.org/10.1074/jbc.271.13.7516			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631782	hybrid			2022-12-27	WOS:A1996UC77400050
J	Stewart, L; Ireton, GC; Parker, LH; Madden, KR; Champoux, JJ				Stewart, L; Ireton, GC; Parker, LH; Madden, KR; Champoux, JJ			Biochemical and biophysical analyses of recombinant forms of human topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA UNTWISTING ENZYME; SIMIAN VIRUS-40 DNA; NICKING-CLOSING ENZYME; RAT-LIVER; EUKARYOTIC TOPOISOMERASES; SACCHAROMYCES-CEREVISIAE; CATALYTIC ACTIVITY; SV40 DNA; CAMPTOTHECIN; SITES	Amino acid sequence comparisons of human topoisomerase I (Topo I) with seven other cellular Topo I enzymes reveal that the enzyme can be divided into four major domains: the unconserved NH2-terminal domain (24 kDa), the conserved core domain (54 kDa), a poorly conserved linker region (5 kDa), and the highly conserved COOH-terminal domain (8 kDa), which contains the active site tyrosine, To investigate this predicted domain organization, recombinant baculoviruses were engineered to express the 91-kDa full-length enzyme, a 70-kDa NH2-terminally truncated enzyme that is missing the first 174 residues, and a 58-kDa NH2- and COOH-terminally truncated core fragment encompassing residues 175-659, The specific activity of the full-length and Topo70 enzymes are indistinguishable from the native human Topo I purified from HeLa cells, Each protein is inhibited by camptothecin, topotecan, and 9-amino-camptothecin, but not by ATP. Activity is stimulated by Mg2+, Ba2+, Ca2+, Mn2+, spermine, and spermidine, The magnitude of the stimulatory effect of Mg2+ is inversely proportional to the salt concentration, Furthermore, at KCl concentrations of 300 mM or greater, the addition of Mg2+ is inhibitory, The effects of Mg2+ and the polycations spermine and spermidine are partially additive, an indication that the stimulatory mechanisms of the two substances are different, Activity was strongly inhibited or abolished by Ni2+, Zn2+, Cu2+, Cd2+, and Co2+. An examination of the hydrodynamic properties of full-length Topo I, Topo70, and Topo58 demonstrates that the core, linker, and COOH-terminal domains fold into a globular structure, while the NH2-terminal domain is highly extended, A comparison of the circular dichroism spectra of full-length Topo I and Topo70 demonstrates that residues 1-174 (similar to 21 kDa) of Topo I are largely if not completely unfolded, This observation is consistent with the fact that the NH2-terminal domain is dispensable for activity.	UNIV WASHINGTON,SCH MED,DEPT MICROBIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049156] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49156, T32-GM07207] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSNER J, 1992, J BIOL CHEM, V267, P12408; BAKER SD, 1995, CYTOMETRY, V19, P134, DOI 10.1002/cyto.990190208; BEDNAR J, 1994, J MOL BIOL, V235, P825, DOI 10.1006/jmbi.1994.1042; BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; BJORNSTI MA, 1987, P NATL ACAD SCI USA, V84, P8971, DOI 10.1073/pnas.84.24.8971; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; CASTORA FJ, 1986, P NATL ACAD SCI USA, V83, P1680, DOI 10.1073/pnas.83.6.1680; CHAMPOUX JJ, 1977, P NATL ACAD SCI USA, V74, P3800, DOI 10.1073/pnas.74.9.3800; CHAMPOUX JJ, 1976, BIOCHEMISTRY-US, V15, P4638, DOI 10.1021/bi00666a014; CHAMPOUX JJ, 1989, J BIOL CHEM, V264, P1010; CHAMPOUX JJ, 1978, J MOL BIOL, V118, P441, DOI 10.1016/0022-2836(78)90238-3; CHAMPOUX JJ, 1976, P NATL ACAD SCI USA, V73, P3488, DOI 10.1073/pnas.73.10.3488; CHAMPOUX JJ, 1981, J BIOL CHEM, V256, P4805; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHEN AY, 1993, P NATL ACAD SCI USA, V90, P8131, DOI 10.1073/pnas.90.17.8131; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; EDWARDS KA, 1982, NUCLEIC ACIDS RES, V10, P2565, DOI 10.1093/nar/10.8.2565; FLEISCHMANN G, 1984, P NATL ACAD SCI-BIOL, V81, P6958, DOI 10.1073/pnas.81.22.6958; FREIFELDER D, 1982, PHYSICAL BIOCH; GILMOUR DS, 1986, CELL, V44, P401, DOI 10.1016/0092-8674(86)90461-7; GOTO T, 1984, J BIOL CHEM, V259, P422; HERTZBERG RP, 1990, J BIOL CHEM, V265, P19287; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; JOHNSON CW, 1990, PROTEIN-STRUCT FUNCT, V7, P205; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; KIKUCHI A, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P121; KJELDSEN E, 1988, J MOL BIOL, V202, P333, DOI 10.1016/0022-2836(88)90462-7; KRETZSCHMAR M, 1993, P NATL ACAD SCI USA, V90, P11508, DOI 10.1073/pnas.90.24.11508; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; LOW RL, 1985, NUCLEIC ACIDS RES, V13, P6999, DOI 10.1093/nar/13.19.6999; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MADDEN KR, 1995, EMBO J, V14, P5399, DOI 10.1002/j.1460-2075.1995.tb00224.x; MADDEN KR, 1992, CANCER RES, V52, P525; MCCONAUGHY BL, 1981, BIOCHIM BIOPHYS ACTA, V655, P1, DOI 10.1016/0005-2787(81)90059-9; MULLER MT, 1985, EMBO J, V4, P1237, DOI 10.1002/j.1460-2075.1985.tb03766.x; PARKER LH, 1993, J MOL BIOL, V231, P6, DOI 10.1006/jmbi.1993.1252; PORTER SE, 1989, MOL CELL BIOL, V9, P541, DOI 10.1128/MCB.9.2.541; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; ROSE KM, 1988, CHROMOSOMA, V96, P411, DOI 10.1007/BF00303034; ROSSINI GP, 1994, J STEROID BIOCHEM, V51, P291, DOI 10.1016/0960-0760(94)90042-6; RYBENKOV VV, 1993, P NATL ACAD SCI USA, V90, P5307, DOI 10.1073/pnas.90.11.5307; SCHMID N, 1991, BIOCHEMISTRY-US, V30, P4357, DOI 10.1021/bi00231a035; SHAW SY, 1993, SCIENCE, V260, P533, DOI 10.1126/science.8475384; SHEN CC, 1990, J MOL BIOL, V212, P67, DOI 10.1016/0022-2836(90)90305-6; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SRIVENUGOPAL KS, 1985, BIOCHEMISTRY-US, V24, P4766, DOI 10.1021/bi00339a009; STEWART L, 1991, J VIROL, V65, P6218, DOI 10.1128/JVI.65.11.6218-6231.1991; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P329; TANIZAWA A, 1993, NUCLEIC ACIDS RES, V21, P5175; WANG JC, 1969, J MOL BIOL, V43, P25, DOI 10.1016/0022-2836(69)90076-X; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	54	130	136	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7593	7601		10.1074/jbc.271.13.7593	http://dx.doi.org/10.1074/jbc.271.13.7593			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631793	hybrid			2022-12-27	WOS:A1996UC77400061
J	Couet, J; Sar, S; Jolivet, A; Hai, MTV; Milgrom, E; Misrahi, M				Couet, J; Sar, S; Jolivet, A; Hai, MTV; Milgrom, E; Misrahi, M			Shedding of human thyrotropin receptor ectodomain - Involvement of a matrix metalloprotease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TSH RECEPTOR; FUNCTIONAL EXPRESSION; TRANSMEMBRANE DOMAIN; STIMULATING-HORMONE; MOLECULAR-CLONING; GRAVES-DISEASE; CELLS; CLEAVAGE; FAMILY; CDNA	The thyrotropin (TSH) receptor in human thyroid glands has been shown to be cleaved into an extracellular alpha subunit and a transmembrane beta subunit held together by disulfide bridges. An excess of the latter component relative to the former suggested the shedding of the ectodomain. Indeed we observed such a shedding in cultures of human thyrocytes and permanently transfected L or Chinese hamster ovary cells. The shedding was increased by inhibitors of endocytosis, recycling, and lysosomal degradation, suggesting that it was dependent on receptor residency at the cell surface. It was slightly increased by TSH and phorbol esters, whereas forskolin and 8-bromo-cyclic AMP were without effect. Decreasing the serum concentration in cell culture medium enhanced the shedding by an unknown mechanism. The shedding of the TSH receptor a domain is the consequence of two events: cleavage of the receptor into alpha and beta subunits and reduction of the disulfide bridge(s). The complete inhibition of soluble TSH receptor shedding by the specific inhibitor BE-2116 indicated that the cleavage reaction is catalyzed probably at the cell surface by a matrix metalloprotease. This shedding mechanism may be responsible for the presence of soluble TSH receptor a subunit in human circulation.	HOP BICETRE, INSERM, U135, UNITE RECH HORMONES & REPROD, F-94275 LE KREMLIN BICETRE, FRANCE; HOP BICETRE, LAB HORMONOL & BIOL MOL, F-94275 LE KREMLIN BICETRE, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay				Couet, Jacques/0000-0001-5409-8689				BAN T, 1992, ENDOCRINOLOGY, V131, P815, DOI 10.1210/en.131.2.815; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; CHAZENBALK GD, 1994, J BIOL CHEM, V269, P32209; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; FRAZIER AL, 1990, MOL ENDOCRINOL, V4, P1264, DOI 10.1210/mend-4-8-1264; FURMANIAK J, 1987, ACTA ENDOCRINOL-COP, V115, P157; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GRAVES PN, 1992, BIOCHEM BIOPH RES CO, V187, P1135, DOI 10.1016/0006-291X(92)91315-H; HELDIN NE, 1994, ENDOCRINOLOGY, V134, P2032, DOI 10.1210/en.134.5.2032; HUNT N, 1992, EXP CLIN ENDOCRINOL, V100, P22, DOI 10.1055/s-0029-1211169; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; LOOSFELT H, 1992, P NATL ACAD SCI USA, V89, P3765, DOI 10.1073/pnas.89.9.3765; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; MISRAHI M, 1994, EUR J BIOCHEM, V222, P711, DOI 10.1111/j.1432-1033.1994.tb18916.x; MISRAHI M, 1994, CURR OPIN ENDOCRINOL, V1, P175; MUI ALF, 1992, P NATL ACAD SCI USA, V89, P10812, DOI 10.1073/pnas.89.22.10812; MURAKAMI M, 1992, BIOCHEM BIOPH RES CO, V186, P1074, DOI 10.1016/0006-291X(92)90856-G; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; PERRET J, 1990, BIOCHEM BIOPH RES CO, V171, P1044, DOI 10.1016/0006-291X(90)90789-P; PETERSEN VB, 1977, FEBS LETT, V83, P63, DOI 10.1016/0014-5793(77)80642-X; ROGER PP, 1987, BIOCHEM BIOPH RES CO, V149, P707, DOI 10.1016/0006-291X(87)90425-6; RUSSO D, 1991, MOL ENDOCRINOL, V5, P1607, DOI 10.1210/mend-5-11-1607; RUSSO D, 1992, ENDOCRINOLOGY, V130, P2135, DOI 10.1210/en.130.4.2135; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SIRES UI, 1993, J BIOL CHEM, V268, P2069; SMITH BR, 1988, ENDOCR REV, V9, P106, DOI 10.1210/edrv-9-1-106; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; TAKESHITA A, 1992, BIOCHEM BIOPH RES CO, V188, P1214, DOI 10.1016/0006-291X(92)91360-3; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TEDDER TF, 1991, AM J RESP CELL MOL, V5, P305, DOI 10.1165/ajrcmb/5.4.305; THI MTV, 1992, BIOCHEMISTRY-US, V31, P366; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; VUHAILUUTHI MT, 1990, ENDOCRINOLOGY, V127, P2090, DOI 10.1210/endo-127-5-2090; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; ZUPAN AA, 1991, J BIOL CHEM, V266, P15384	46	135	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4545	4552						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626810				2022-12-27	WOS:A1996TW96000088
J	David, LL; Lampi, KJ; Lund, AL; Smith, JB				David, LL; Lampi, KJ; Lund, AL; Smith, JB			The sequence of human beta B1-crystallin cDNA allows mass spectrometric detection of beta B1 protein missing portions of its N-terminal extension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LENS; GAMMA-CRYSTALLIN; EYE-LENS; CATARACT; CALPAIN	The sequence of human beta B1-crystallin cDNA encoded a protein of 251 amino acids in length. Mass spectrometric analysis of intact beta B1 from young human lens confirmed the deduced amino acid sequence. Lenses of human donors newborn to 27 years of age also contained partially degraded forms of beta B1 missing 15, 33, 34, 35, 36, 39, 40, and 41 amino acid residues from their N-terminal extensions. The similarity of the cleavage site between residues 15 and 16 in human beta B1 to the cleavage occurring in bovine beta B1 suggested that lenses of both species may contain a similar proteolytic activity. The remaining cleavage sites occurring in human beta B1 did not closely match those occurring in other species, possibly due to the widely divergent amino acid sequence of the N-terminal extension of beta B1 amoung species. Results hom animal models suggest that cleavage of the N-terminal extension of beta B1-crystallin could enhance protein insolubilization and cataract in lens. However, the presence of partially degraded beta B1-crystallins in both water-soluble and water-insoluble fractions of lenses of young donors suggested that the rate that proteolyzed beta B1-crystallins become water-insoluble is relatively slow in humans.	OREGON HLTH SCI UNIV,DEPT ORAL MOL BIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT OPHTHALMOL,PORTLAND,OR 97201; UNIV NEBRASKA,DEPT CHEM,LINCOLN,NE 68588	Oregon Health & Science University; Oregon Health & Science University; University of Nebraska System; University of Nebraska Lincoln					NEI NIH HHS [EY07609, EY07755] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007755, R29EY007755, R01EY007609] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALCALA J, 1988, CURR EYE RES, V7, P353, DOI 10.3109/02713688809031784; BATEMAN OA, 1992, EXP EYE RES, V55, P127, DOI 10.1016/0014-4835(92)90100-7; BERBERS GAM, 1983, FEBS LETT, V161, P225, DOI 10.1016/0014-5793(83)81013-8; CARVER JA, 1994, BBA-PROTEIN STRUCT M, V1204, P195, DOI 10.1016/0167-4838(94)90009-4; CHAMBERS C, 1993, GENE, V133, P295, DOI 10.1016/0378-1119(93)90655-M; COOPER PG, 1994, EXP EYE RES, V59, P607, DOI 10.1006/exer.1994.1146; DATILES MB, 1992, CURR EYE RES, V11, P669, DOI 10.3109/02713689209000740; DAVID LL, 1993, J BIOL CHEM, V268, P1937; DAVID LL, 1994, INVEST OPHTH VIS SCI, V35, P785; DAVID LL, 1993, FEBS LETT, V324, P265, DOI 10.1016/0014-5793(93)80131-D; DENDUNNEN JT, 1985, BIOCHIM BIOPHYS ACTA, V824, P295, DOI 10.1016/0167-4781(85)90035-1; DUNCAN MK, IN PRESS EXP EYE RES; FARRELL RE, 1993, RNA METHODOLOGIES LA, P58; GROTHVASSELLI B, 1986, EXP EYE RES, V43, P1057, DOI 10.1016/0014-4835(86)90082-5; HE SM, 1995, J MASS SPECTROM, V30, P424, DOI 10.1002/jms.1190300305; HEJTMANCIK JF, 1986, J BIOL CHEM, V261, P982; HOGG D, 1986, J BIOL CHEM, V261, P2420; HOPE JN, 1994, PROTEIN ENG, V7, P445, DOI 10.1093/protein/7.3.445; KROONE RC, 1994, PROTEIN ENG, V7, P1395, DOI 10.1093/protein/7.11.1395; LI LK, 1986, CURR EYE RES, V5, P127, DOI 10.3109/02713688609015101; LUBSEN NH, 1988, PROG BIOPHYS MOL BIO, V51, P47, DOI 10.1016/0079-6107(88)90010-7; MCFALNGAI M, 1986, CURR EYE RES, V5, P387, DOI 10.3109/02713688609025178; MIESBAUER LR, 1993, PROTEIN SCI, V2, P290; MIESBAUER LR, 1994, J BIOL CHEM, V269, P12494; NALINI V, 1994, J MOL BIOL, V236, P1250, DOI 10.1016/0022-2836(94)90025-6; PATTERSON SD, 1994, ANAL BIOCHEM, V221, P1, DOI 10.1006/abio.1994.1371; QUAXJEUKEN Y, 1984, J MOL BIOL, V180, P457, DOI 10.1016/0022-2836(84)90022-6; SMITH JB, 1991, INT J MASS SPECTROM, V111, P229, DOI 10.1016/0168-1176(91)85057-S; SMITH JB, 1995, J PROTEIN CHEM, V14, P179, DOI 10.1007/BF01980330; TRINKL S, 1994, PROTEIN SCI, V3, P1392, DOI 10.1002/pro.5560030905; VANRENS GLM, 1991, GENE, V102, P179, DOI 10.1016/0378-1119(91)90149-6; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; WISTOW G, 1981, FEBS LETT, V133, P9, DOI 10.1016/0014-5793(81)80460-7; ZHOU ZR, 1990, J PROTEIN CHEM, V9, P523, DOI 10.1007/BF01025005	34	60	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4273	4279						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626774				2022-12-27	WOS:A1996TW96000052
J	Wood, SJ; MacKenzie, L; Maleeff, B; Hurle, MR; Wetzel, R				Wood, SJ; MacKenzie, L; Maleeff, B; Hurle, MR; Wetzel, R			Selective inhibition of A beta fibril formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; CIRCULAR-DICHROISM; AMYLOID PROTEIN; PEPTIDES; BINDING; TRANSTHYRETIN; CONFORMATION; INVITRO	We describe here an inhibitor of in vitro fibril formation, hexadecyl-N-methylpiperidinium (HMP) bromide, which is selective for the Alzheimer's disease peptide A beta. At 10 mu M, its IC50 for inhibiting A beta aggregation at pH 5.8, HMP bromide does not inhibit fibril formation by other amyloidogenic polypeptides nor does it affect the folding stability of the beta-sheet-rich immunoglobulin V-L domain REI, In addition, small structural modifications of HMP bromide reduce or eliminate its ability to inhibit pH 5.8 aggregation of A beta, These indications of specificity, plus the ability of the molecule to inhibit A beta aggregation at concentrations almost an order of magnitude below its critical micelle concentration, suggest a mechanism of inhibition other than micellar solubilization of A beta. HMP bromide is required in approximately a 1:1 stoichiometry for effective inhibition at pH 5.8. Although stoichiometric amounts of HMP bromide with respect to total A beta inhibit A beta fibril formation at pH 7.4, the molecule is incapable, at lower concentrations, of blocking the seeding of fibril formation by small amounts of added A beta fibrils, The results suggest the existence of a binding surface on A beta capable of binding amphipathic molecules such as HMP bromide and which, when occupied, precludes assembly of A beta into amyloid fibrils. Molecules that bind to this site with high specificity may prove to be useful therapeutic agents for preventing or retarding the cerebral amyloid plaque formation implicated in Alzheimer's disease pathology.	SMITHKLINE BEECHAM PHARMACEUT,DEPT TOXICOL,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT BIOMOL CHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT MACROMOLEC SCI,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline			Wetzel, Ronald/G-7453-2011					BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; Budavari S., 1989, MERCK INDEX; CLARKE S, 1975, J BIOL CHEM, V250, P5459; CLELAND JL, 1992, J BIOL CHEM, V267, P13327; COLON W, 1992, BIOCHEMISTRY-US, V31, P8654, DOI 10.1021/bi00151a036; EPP O, 1974, EUR J BIOCHEM, V45, P513, DOI 10.1111/j.1432-1033.1974.tb03576.x; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; FINN BE, 1992, PROTEIN ENG PRACTICA, P167; FRASER PE, 1994, J MOL BIOL, V244, P64, DOI 10.1006/jmbi.1994.1704; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1971, SCIENCE, V174, P712, DOI 10.1126/science.174.4010.712; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HERRMANN KW, 1966, J COLLOID INTERF SCI, V22, P352, DOI 10.1016/0021-9797(66)90015-4; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; HOWLETT DR, 1995, NEURODEGENERATION, V4, P23, DOI 10.1006/neur.1995.0003; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; LEE JP, 1995, BIOCHEMISTRY-US, V34, P5191, DOI 10.1021/bi00015a033; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; Moeller J.V., 1993, J BIOL CHEM, V268, P18659; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; MULTHAUP G, 1993, BIOL CHEM H-S, V374, P1; PIKE CJ, 1993, J NEUROSCI, V13, P1676; ROBINSON NC, 1975, BIOCHEMISTRY-US, V14, P369, DOI 10.1021/bi00673a025; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SELKOE DJ, 1995, NATURE, V375, P734, DOI 10.1038/375734a0; SHIRAHAMA T, 1975, AM J PATHOL, V81, P101; Sisodia S S, 1992, Curr Opin Neurobiol, V2, P648, DOI 10.1016/0959-4388(92)90033-H; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P2843, DOI 10.1073/pnas.87.7.2843; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P5036, DOI 10.1073/pnas.87.13.5036; WESTERMARK P, 1994, AMYLOID, V1, P47, DOI 10.3109/13506129409148624; WETLAUFER DB, 1995, PROTEIN SCI, V4, P1535, DOI 10.1002/pro.5560040811; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003; WOOD SJ, 1996, IN PRESS J MOL BIOL, V255; YANG JT, 1986, METHOD ENZYMOL, V130, P208	42	156	164	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4086	4092						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626745				2022-12-27	WOS:A1996TW96000023
J	Yu, B; Wright, SD				Yu, B; Wright, SD			Catalytic properties of lipopolysaccharide (LPS) binding protein - Transfer of LPS to soluble CD14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS	Lipopolysaccharide (LPS) binding protein (LBP) is a lipid transfer protein that catalyzes transfer of LPS monomers from micelles to a binding site on soluble CD14 (sCD14) and transfer of LPS from LPS sCD14 complexes to HDL particles, To characterize the first of these two reactions, LPS covalently derivatized with the fluorophore, boron dipyrromethene difluoride (BODIPY), was used to monitor LBP-catalyzed movement of LPS in real time. The fluorescence efficiency of micelles of BODIPY-LPS was low but was strongly increased upon dissolution in detergent or upon binding to sCD14. Spontaneous binding of BODIPY-LPS to sCD14 was very slow but was accelerated by substoichiometric concentration of LBP, and the rate of binding was measured under a variety of conditions. LBP catalyzed transfer was first order with respect to both sCD14 and LPS concentration, and the apparent K-m values were 1 similar to 2 mu g/ml for sCD14 and 100 ng/ml for LPS. The maximum turnover number for LBP was approximately 150 molecules of LPS min(-1) LBP(-1). LBP alone caused a small but measurable increase in the fluorescence of BODIPY-LPS, suggesting that it bound LPS aggregates but did not readily remove LPS monomers. The subsequent addition of sCD14 caused a large fluorescence increase, suggesting transfer of BODIPY-LPS to sCD14. These and other observations suggest that LPS is transferred by an ordered ternary complex reaction mechanism in which LBP transfers LPS monomer from LPS aggregates to sCD14 without dissociating from the LPS aggregate.	ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021	Rockefeller University					NIAID NIH HHS [AI 30556] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030556] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		GAZZANOSANTORO H, 1994, INFECT IMMUN, V62, P1185, DOI 10.1128/IAI.62.4.1185-1191.1994; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; JUAN TSC, 1995, J BIOL CHEM, V270, P5219, DOI 10.1074/jbc.270.10.5219; KIRKLAND TN, 1993, J BIOL CHEM, V268, P24818; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; SHUMANN RR, 1990, SCIENCE, V249, P1429; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; VANVOORHIS WC, 1983, J EXP MED, V158, P126, DOI 10.1084/jem.158.1.126; WALSH C, 1979, ENZYMATIC REACTION M, P216; WRIGHT SD, 1995, J IMMUNOL, V155, P6; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; WRIGHT SD, 1989, J EXP MED, V170, P1241; WURFEL MM, 1995, J EXP MED, V181, P1743, DOI 10.1084/jem.181.5.1743; WURFEL MM, 1994, J EXP MED, V180, P1025, DOI 10.1084/jem.180.3.1025; YU B, 1995, J INFLAMM, V45, P115	18	171	181	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4100	4105						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626747				2022-12-27	WOS:A1996TW96000025
J	Bittner, MA; Bennett, MK; Holz, RW				Bittner, MA; Bennett, MK; Holz, RW			Evidence that syntaxin 1A is involved in storage in the secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; BOTULINUM NEUROTOXIN-A; MOTOR-NERVE TERMINALS; HUMAN GROWTH-HORMONE; TETANUS-TOXIN; NEUROTRANSMITTER RELEASE; CLOSTRIDIAL NEUROTOXINS; SYNAPTIC VESICLES; STREPTOLYSIN-O; LIGHT-CHAINS	Syntaxin 1A is a nervous system-specific protein thought to function during the late steps of the regulated secretory pathway by mediating the docking of secretory vesicles with the plasma membrane. We have examined the effects of transiently overexpressing syntaxin 1A on protein secretion in constitutively secreting cell lines that do not normally express the protein. Syntaxin 1A slowed the constitutive release of marker proteins human growth hormone (hGH) and vesicular stomatitis virus glycoprotein from COS-1 cells, increasing the intracellular half-life of human growth hormone from 90 min to 18 h. A similar effect was observed in HEK 293 cells. Immunofluorescence microscopy revealed that these secretory proteins were concentrated in the periphery of the cell. The effect was specific for the full-length neuronal protein. Neither a syntaxin 1A variant which lacks a membrane attachment domain nor syntaxin 2 caused the cells to retain human growth hormone. The effect of syntaxin 1A was partially reversed by incubating the cells with botulinum type C-1 neurotoxin, which specifically cleaves syntaxin Ik Release of human growth hormone from syntaxin 1A-expressing cells was maintained during a blockade of protein synthesis, suggesting that the hormone was being released from a pool of stored vesicles which accumulated before the addition of cycloheximide. The existence of a post-Golgi storage compartment in syntaxin 1A-expressing cells was confirmed using brefeldin A to collapse the Golgi stacks in both HEK 293 and COS-1 cells. Brefeldin A rapidly blocked growth hormone release in control cultures while having no effect on release in cells expressing syntaxin 1A. Reducing the temperature to 19 degrees C, which inhibits transport from the trans-Golgi network, also inhibited hGH secretion from cells without syntaxin 1A but had little effect on hGH secretion hom cells with syntaxin 1A. The present experiments indicate that syntaxin 1A enables the storage of vesicles which would otherwise be immediately released.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	Bittner, MA (corresponding author), UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,M 1301 MSRB III,ANN ARBOR,MI 48109, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027959] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK27959] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNERTHILGER G, 1993, NEUROSCIENCE, V53, P547, DOI 10.1016/0306-4522(93)90219-6; AHNERTHILGER G, 1989, J NEUROCHEM, V52, P1751, DOI 10.1111/j.1471-4159.1989.tb07253.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BINZ T, 1994, J BIOL CHEM, V269, P1617; BITTNER MA, 1989, J BIOL CHEM, V264, P10354; BITTNER MA, 1988, J NEUROCHEM, V51, P451, DOI 10.1111/j.1471-4159.1988.tb01059.x; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; DREYER F, 1987, N-S ARCH PHARMACOL, V335, P1, DOI 10.1007/BF00165027; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GANSEL M, 1987, PFLUG ARCH EUR J PHY, V409, P533, DOI 10.1007/BF00583812; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GREEN R, 1984, J CELL BIOL, V99, P97, DOI 10.1083/jcb.99.1.97; HALPERN JL, 1990, J NEUROCHEM, V55, P2072, DOI 10.1111/j.1471-4159.1990.tb05797.x; HUANG XF, 1994, J BIOL CHEM, V269, P20838; INOUE A, 1992, J BIOL CHEM, V267, P10613; LEE SA, 1986, J BIOL CHEM, V261, P7089; LEVEQUE C, 1994, J BIOL CHEM, V269, P6306; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MOORE HPH, 1985, J CELL BIOL, V101, P1773, DOI 10.1083/jcb.101.5.1773; PENNER R, 1986, NATURE, V324, P76, DOI 10.1038/324076a0; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PFEFFER SR, 1994, P NATL ACAD SCI USA, V91, P1987, DOI 10.1073/pnas.91.6.1987; POULAIN B, 1991, J BIOL CHEM, V266, P9580; SANDERS D, 1992, N-S ARCH PHARMACOL, V346, P358; SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/jbc.270.18.10566; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; SCHULZE KL, 1995, CELL, V80, P311, DOI 10.1016/0092-8674(95)90414-X; SCHWEITZER ES, 1985, J CELL BIOL, V101, P667, DOI 10.1083/jcb.101.2.667; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; SIMPSON LL, 1988, J PHARMACOL EXP THER, V245, P867; SIMPSON LL, 1989, BOTULINUM NEUROTOXIN, P153; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STROUS GJ, 1993, J BIOL CHEM, V268, P2341; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; WICK PW, 1993, J BIOL CHEM, V28, P10983; YAMASAKI S, 1994, J BIOL CHEM, V269, P12764	48	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11214	11221		10.1074/jbc.271.19.11214	http://dx.doi.org/10.1074/jbc.271.19.11214			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626670				2022-12-27	WOS:A1996UJ94400030
J	Li, M; Makkinje, A; Damuni, Z				Li, M; Makkinje, A; Damuni, Z			The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE KIDNEY CORTEX; CATALYTIC SUBUNIT; PROTAMINE-KINASE; REGULATORY SUBUNIT; OKADAIC ACID; PHOSPHORYLATION; TYPE-2A; FORMS; PURIFICATION; SEQUENCE	Two potent heat-stable protein phosphatase 2A (PP2A) inhibitor proteins designated I-1(PP2A) and I-2(PP2A) have been purified to apparent homogeneity from extracts of bovine kidney (Li, M., Guo, H., and Damuni, Z. (1995) Biochemistry 34, 1988-1996). N-terminal and internal amino acid sequencing indicated that I-2(PP2A) was a truncated form of SET, a largely nuclear protein that is fused to nucleoporin Nup214 in acute non-lymphocytic myeloid leukemia. Experiments using purified preparations of recombinant human SET confirmed that this protein inhibited PP2A. Half-maximal inhibition of the phosphatase occurred at about 2 nM SET. By contrast, SET (up to 20 nM) did not affect the activities of purified preparations of protein phosphatases 1, 2B, and 2C. The results indicate that SET is a potent and specific inhibitor of PP2A and suggest that impaired regulation of PP2A may contribute to acute myeloid leukemogenesis.	PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT CELLULAR & MOLEC PHYSIOL, COLL MED, HERSHEY, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health								ADACHI Y, 1994, J BIOL CHEM, V269, P2258; AMICK GD, 1992, BIOCHEM J, V287, P1019, DOI 10.1042/bj2871019; ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; DAMUNI Z, 1989, J BIOL CHEM, V264, P6412; Deibler G E, 1984, Prog Clin Biol Res, V146, P249; FAVRE B, 1994, J BIOL CHEM, V269, P16311; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; FORNEROD M, 1995, ONCOGENE, V10, P1739; GUO H, 1993, J BIOL CHEM, V268, P11193; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; MAKKINJE A, 1995, J BIOL CHEM, V270, P14824, DOI 10.1074/jbc.270.24.14824; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MITELMAN F, 1990, CYTOGENET CELL GENET, V55, P358, DOI 10.1159/000133022; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; REDDY SAG, 1990, J BIOL CHEM, V265, P7748; REDDY SAG, 1993, J BIOL CHEM, V268, P15298; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SILVA OBD, 1987, FEBS LETT, V221, P415, DOI 10.1016/0014-5793(87)80966-3; SILVA OBDC, 1987, FEBS LETT, V226, P176; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; VAESEN M, 1994, BIOL CHEM H-S, V375, P113, DOI 10.1515/bchm3.1994.375.2.113; VONLINDERN M, 1992, BAILLIERE CLIN HAEM, V5, P857, DOI 10.1016/S0950-3536(11)80049-1; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023	42	400	421	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11059	11062		10.1074/jbc.271.19.11059	http://dx.doi.org/10.1074/jbc.271.19.11059			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626647	hybrid			2022-12-27	WOS:A1996UJ94400007
J	Lawrie, AM; Rizzuto, R; Pozzan, T; Simpson, AWM				Lawrie, AM; Rizzuto, R; Pozzan, T; Simpson, AWM			A role for calcium influx in the regulation of mitochondrial calcium in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-TISSUES; CA2+; INACTIVATION; CA-2+; AEQUORIN; CHANNELS; CURRENTS; EXCHANGE; HEART	By using an endothelial cell line (ECV304), derived from human umbilical vein and transfected with recombinant aequorin targeted to the mitochondrial matrix, we find that stimulation with ATP evokes long lasting increases in mitochondrial Ca2+ ([Ca2+](m)) that largely depend on Ca2+ influx. In these cells, the release of stored Ca2+ is inefficient at elevating [Ca2+](m), Consequently it appears that in ECV304 cells, bulk cytosolic Ca2+ ([Ca2+](c)) is the main determinant of [Ca2+](m) changes. In ECV304 cells <4% of mitochondria are within 700 nm of the endoplasmic reticulum as opposed to 65% in HeLa cells, whereas 14% are within 700 nm of the inner surface of the plasma membrane, compared with <6% in HeLa cells, Following Ca2+ depletion, readdition of extracellular Ca2+ evokes an increase in [Ca2+](m) but not in [Ca2+](c). Under these conditions, microdomains of high [Ca2+](c) may occur beneath the plasma membrane of ECV304 cells resulting in the preferential elevation of Ca2+ in mitochondria located in this region. A model is discussed in which the localization of mitochondria with respect to Ca2+ sources is the main determinant of their in situ Ca2+ uptake kinetics, Thus, in any given cell type mitochondria may be localized to suit the energy and metabolic demands of their physiological actions.	UNIV LIVERPOOL, DEPT HUMAN ANAT & CELL BIOL, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND; UNIV PADUA, DEPT BIOMED SCI, I-35121 PADUA, ITALY	University of Liverpool; University of Padua			Rizzuto, Rosario/B-6312-2008	Rizzuto, Rosario/0000-0001-7044-5097	Telethon [495] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Telethon(Fondazione Telethon); Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLAUSTEIN MP, 1977, BIOPHYS J, V20, P79, DOI 10.1016/S0006-3495(77)85538-0; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; COBBOLD PH, 1990, CELLULAR CALCIUM PRA, P55; DENTON RM, 1990, ANNU REV PHYSIOL, V52, P451, DOI 10.1146/annurev.ph.52.030190.002315; GIANNATTASIO B, 1991, J GEN PHYSIOL, V98, P987, DOI 10.1085/jgp.98.5.987; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KOHR G, 1991, J GEN PHYSIOL, V98, P941, DOI 10.1085/jgp.98.5.941; MCCORMACK JG, 1993, BIOCHEM SOC T, V21, P793, DOI 10.1042/bst0210793; MCCORMACK JG, 1992, BIOCHEM SOC T, V20, P153, DOI 10.1042/bst0200153; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; MONCADA S, 1991, PHARMACOL REV, V43, P109; NEWBY AC, 1990, ANNU REV PHYSIOL, V52, P661; RASGADOFLORES H, 1987, AM J PHYSIOL, V252, pC499, DOI 10.1152/ajpcell.1987.252.5.C499; RIZZUTO R, 1987, BIOCHEM J, V246, P271, DOI 10.1042/bj2460271; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; RIZZUTO R, 1994, METHOD CELL BIOL, V40, P339; SHIMOMURA O, 1988, BIOCHEM J, V251, P405, DOI 10.1042/bj2510405; TAKAHASHI K, 1990, IN VITRO CELL DEV, V25, P265; YUE DT, 1990, SCIENCE, V250, P1735, DOI 10.1126/science.2176745	26	163	163	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10753	10759		10.1074/jbc.271.18.10753	http://dx.doi.org/10.1074/jbc.271.18.10753			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631885	hybrid			2022-12-27	WOS:A1996UJ34200053
J	Wu, YY; Sonnino, S; Li, YT; Li, SC				Wu, YY; Sonnino, S; Li, YT; Li, SC			Characterization of an alternatively spliced G(M2) activator protein, G(M2A) protein - An activator protein which stimulates the enzymatic hydrolysis of N-acetylneuraminic acid, but not N-acetylgalactosamine, from G(M2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-HEXOSAMINIDASE-A; GM2 GANGLIOSIDOSIS; SULFATIDE ACTIVATOR; ENZYMIC-HYDROLYSIS; MOLECULAR-GENETICS; DEGRADATION; VARIANT; DEFICIENCY; EXPRESSION	G(M2) activator protein is a protein cofactor which stimulates the enzymatic hydrolysis of both GalNAc and NeuAc from G(M2). We have previously isolated two cDNA clones, G(M2) activator cDNA and G(M2A) cDNA, for human G(M2) activator protein (Nagarajan, S., Chen, H.-C., Li, S.-C., Li, Y.-T., and Lockyer, J. M. (1992) Biochem. J. 282, 807-813). G(M2A) mRNA is an RNA alternative splicing product that contains exons 1, 2, 3, and intron 3 of the genomic DNA sequence of G(M2) activator protein (Klima, H., Tanaka, A., Schnabel, D., Nakano, T., Schroder, M., Suzuki, K., and Sandhoff, K. (1991) FEES Left. 289, 260-264). G(M2A) cDNA encodes a protein (G(M2A) protein) containing 1-109 of the 160 amino acids of human G(M2) activator protein, plus a tripeptide (VST) encoded by intron 3 at the COOH terminus. Thus, G(M2A) protein can be regarded as a form (truncated version) of G(M2) activator protein. We have expressed G(M2A) cDNA in Escherichia coli using pT7-7 as the vector. The recombinant G(M2A) protein was purified to an electrophoretically homogeneous form and was found to stimulate the hydrolysis of NeuAc from G(M2) by clostridial sialidase, but not the hydrolysis of GalNAc from G(M2) by beta-hexosaminidase A. Like G(M2) activator protein, G(M2A) protein also specifically recognized the terminal G(M2) epitope in GalNAc-GD1a and stimulated the hydrolysis of only the external NeuAc from this ganglioside by clostridial sialidase. These results enabled us to discern the enzymatic hydrolyses of GalNAc and NeuAc from the G(M2) epitope and established that the NeuAc recognition domain of G(M2) activator protein is located within amino acids 1-109. The presence of G(M2A) mRNA in human tissues and the selective stimulation of NeuAc hydrolysis by G(M2A) protein indicate that this activator protein may be involved in the catabolism of G(M2) through the asialo-G(M2) pathway.	TULANE UNIV,SCH MED,DEPT BIOCHEM,NEW ORLEANS,LA 70112; UNIV MILAN,SCH MED,DEPT MED CHEM & BIOCHEM,I-20133 MILAN,ITALY	Tulane University; University of Milan			Sonnino, Sandro/R-4154-2017	Sonnino, Sandro/0000-0001-8180-5908	NINDS NIH HHS [NS 09626] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACQUOTTI D, 1994, EUR J BIOCHEM, V225, P271, DOI 10.1111/j.1432-1033.1994.00271.x; BURG J, 1985, ANN HUM GENET, V49, P41, DOI 10.1111/j.1469-1809.1985.tb01674.x; CONZELMANN E, 1978, P NATL ACAD SCI USA, V75, P3979, DOI 10.1073/pnas.75.8.3979; CONZELMANN E, 1979, H-S Z PHYSIOL CHEM, V360, P1837, DOI 10.1515/bchm2.1979.360.2.1837; FINGERHUT R, 1992, EUR J BIOCHEM, V208, P623, DOI 10.1111/j.1432-1033.1992.tb17227.x; FURST W, 1990, EUR J BIOCHEM, V192, P709, DOI 10.1111/j.1432-1033.1990.tb19280.x; FURST W, 1988, BIOL CHEM H-S, V369, P317, DOI 10.1515/bchm3.1988.369.1.317; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; HARRIS G, 1954, CHEM IND-LONDON, P249; HECHTMAN P, 1982, PEDIATR RES, V16, P217, DOI 10.1203/00006450-198203000-00011; HIRABAYASHI Y, 1983, J NEUROCHEM, V40, P168, DOI 10.1111/j.1471-4159.1983.tb12667.x; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; KLIMA H, 1991, FEBS LETT, V289, P260, DOI 10.1016/0014-5793(91)81084-L; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SC, 1995, J BIOL CHEM, V270, P24246, DOI 10.1074/jbc.270.41.24246; LI SC, 1988, J BIOL CHEM, V263, P6588; LI SC, 1981, J BIOL CHEM, V256, P6234; LI YT, 1973, J BIOL CHEM, V248, P7512; LI YT, 1984, LYSOSOM BIOL PATHOL, P99; MEIER EM, 1991, J BIOL CHEM, V266, P1879; NAGARAJAN S, 1992, BIOCHEM J, V282, P807, DOI 10.1042/bj2820807; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; RADIN NS, 1972, METHOD ENZYMOL, V28, P300; RIBONI L, 1995, J NEUROCHEM, V64, P451; SCHRODER M, 1993, HUM GENET, V92, P437, DOI 10.1007/BF00216446; SCHRODER M, 1989, FEBS LETT, V251, P197, DOI 10.1016/0014-5793(89)81454-1; SVENNERHOLM L, 1972, METHODS CARBOHYD CHE, V6, P464; UDA Y, 1977, J BIOL CHEM, V252, P5194; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; WU YY, 1994, J BIOL CHEM, V269, P16276; XIE B, 1991, BIOCHEM BIOPH RES CO, V177, P1217, DOI 10.1016/0006-291X(91)90671-S	32	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10611	10615		10.1074/jbc.271.18.10611	http://dx.doi.org/10.1074/jbc.271.18.10611			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631864				2022-12-27	WOS:A1996UJ34200032
J	Dong, ZG; Xu, RH; Kim, JB; Zhan, SN; Ma, WY; Colburn, NH; Kung, HF				Dong, ZG; Xu, RH; Kim, JB; Zhan, SN; Ma, WY; Colburn, NH; Kung, HF			AP-1/jun is required for early Xenopus development and mediates mesoderm induction by fibroblast growth factor but not by activin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; JUN; RECEPTOR; FOS; EXPRESSION; EMBRYOS; FGF; ONCOGENE; ENHANCER; KINASE	In Xenopus, normal mesoderm formation depends on signaling through the fibroblast growth factor (FGF) tyrosine kinase receptor. An important signaling pathway from receptor tyrosine kinases involves Ras/Raf/MAP kinase, However, the downstream pathway that occurs in the nucleus to finally trigger gene expression for mesoderm formation remains unknown, We report here that a high level of activator protein-1 (AP-1)-dependent transcriptional activity is detected during the early development of Xenopus embryos. Injection of a dominant negative mutant jun (DNM-jun or TAM67) RNA into the two-cell stage embryos inhibited endogenous AP-1 activity and blocked normal embryonic development with severe posterior truncation in tadpoles. The inhibition of AP-1 activity and the phenotypic change induced by TAM67 was rescued by co-injection of wild-type c-jun RNA, but not by the control beta-galactosidase RNA. The FGF-stimulated mesoderm induction was markedly inhibited in animal cap explants from the embryos injected with TAM67. Activin induction of mesoderm, on the other hand, was normal in the embryos injected with TAM67 RNA. These findings suggest that AP-1 mediates FGF, but not activin, receptor signaling during mesoderm induction and the AP-1/Jun is a key signaling molecule in the development of posterior structure.	SAIC,LAB BIOCHEM PHYSIOL,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD; NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,NIH,CELL BIOL SECT,DIV BASIC SCI,FREDERICK,MD 21702	Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Dong, ZG (corresponding author), UNIV MINNESOTA,HORMEL INST,801 16TH AVE NE,AUSTIN,MN 55912, USA.		Xu, Ren-He/M-3125-2016; Xu, Ren-He/AAK-7392-2021; Kim, Jaebong/AAV-1986-2021	Kim, Jaebong/0000-0003-1609-338X				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KINDY MS, 1989, CELL GROWTH DIFFER, V31, P27; LABONNE C, 1995, DEVELOPMENT, V121, P1475; LAZARUS P, 1994, CANC LETT, V82, P201; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MAENO M, 1994, P NATL ACAD SCI USA, V91, P10260, DOI 10.1073/pnas.91.22.10260; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; Moon R. T., 1989, TECHNIQUE, V1, P76; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; UENO H, 1992, J BIOL CHEM, V267, P1470; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VOGT PK, 1992, CANCER, V69, P2610, DOI 10.1002/1097-0142(19920515)69:10<2610::AID-CNCR2820691035>3.0.CO;2-J; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; XU RH, 1995, BIOCHEM BIOPH RES CO, V212, P212, DOI 10.1006/bbrc.1995.1958; XU RH, 1995, IN PRESS P NATL ACAD	38	44	46	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9942	9946		10.1074/jbc.271.17.9942	http://dx.doi.org/10.1074/jbc.271.17.9942			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626631	hybrid			2022-12-27	WOS:A1996UG25700015
J	Flores, I; Casaseca, T; MartinezA, C; Kanoh, H; Merida, I				Flores, I; Casaseca, T; MartinezA, C; Kanoh, H; Merida, I			Phosphatidic acid generation through interleukin 2 (IL-2)-induced alpha-diacylglycerol kinase activation is an essential step in IL-2-mediated lymphocyte proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHOLIPASE-C; INDUCED TRANSLOCATION; SIGNAL TRANSDUCTION; IL-2 RECEPTOR; HAND MOTIFS; CELLS; RESPONSES; CLONING; ENZYME	Proliferation of T lymphocytes is triggered by the interaction of interleukin 2 (IL-2) with its high affinity specific receptor that is expressed on the cell surface following T lymphocyte activation. Significant advances have recently been made in identifying the multiple signals that follow IL-2 receptor occupancy, although the exact mechanism responsible for IL-2-induced proliferation remains an enigma. It has been shown previously that unique species of phosphatidic acid are rapidly produced in vivo following IL-2 binding. It was then suggested that, in contrast to other eukaryotic growth factor systems, phosphatidic acid was at least in part generated through IL-2-induced diacylglycerol (DG) kinase activation. In the present study me demonstrate IL-2-dependent activation of the alpha isoform of DG kinase. Confocal microscopy studies reveal that the enzyme is located in the cytosol and nuclei of resting T cells. Interleukin 2 stimulation induces translocation of the enzyme to the perinuclear region. Furthermore, our results indicate that inhibition of the alpha isoform of DG kinase has a profound effect on IL-2-induced T cell growth. Studies on cell cycle distribution demonstrate that the inhibition of IL-2-induced phosphatidic acid production induces arrest in late G1 phase of IL-2 dependent cells. Altogether, these results link previous observations of interleukin 2 and phosphatidic acid production to activation of an specific isoform of DG kinase and suggest that activation of this enzyme is part of a novel signaling cascade that utilizes phosphatidic acid as an effector molecule.	CTR NACL BIOTECNOL,DEPT IMMUNOL & ONCOL,E-28049 MADRID,SPAIN; SAPPORO MED COLL,DEPT BIOCHEM,SAPPORO,HOKKAIDO 060,JAPAN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Sapporo Medical University			Flores, Ignacio/E-8304-2016; Merida, Isabel/A-9713-2014	Flores, Ignacio/0000-0001-8789-6396; Merida, Isabel/0000-0003-2762-6241				BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P9378, DOI 10.1073/pnas.83.24.9378; BISHOP WR, 1986, J BIOL CHEM, V261, P6993; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BORCHARDT RA, 1994, BBA-LIPID LIPID MET, V1212, P327, DOI 10.1016/0005-2760(94)90207-0; CANO E, 1992, EUR J IMMUNOL, V22, P1883, DOI 10.1002/eji.1830220731; DECURCELLES DD, 1989, J BIOL CHEM, V264, P3274; EARDLEY DD, 1991, SCIENCE, V251, P78, DOI 10.1126/science.1824727; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GOMEZ J, 1995, EXP CELL RES, V218, P105, DOI 10.1006/excr.1995.1136; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; GRAVES JD, 1992, J IMMUNOL, V148, P2417; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; HAKATEYAMA M, 1989, SCIENCE, V244, P551; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1986, J BIOL CHEM, V261, P5597; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KNAUSS TC, 1990, J BIOL CHEM, V265, P14457; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; MACDONALD ML, 1988, J BIOL CHEM, V263, P1584; MARONEY AC, 1989, J BIOL CHEM, V264, P2537; MARTIN A, 1993, J BIOL CHEM, V268, P23924; MERIDA I, 1991, J IMMUNOL, V147, P2202; MERIDA I, 1993, DNA CELL BIOL, V12, P473, DOI 10.1089/dna.1993.12.473; MERIDA I, 1990, P NATL ACAD SCI USA, V87, P9421, DOI 10.1073/pnas.87.23.9421; MILLS GB, 1988, CELL, V55, P91, DOI 10.1016/0092-8674(88)90012-8; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MITCHELL RH, 1994, CURR BIOL, V4, P370; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SAKANE F, 1991, BIOCHEM BIOPH RES CO, V181, P1015, DOI 10.1016/0006-291X(91)92038-L; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SCHAAP D, 1993, BIOCHEM J, V289, P875, DOI 10.1042/bj2890875; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VALGE VE, 1988, CELL, V55, P101, DOI 10.1016/0092-8674(88)90013-X; YAMADA K, 1989, FEBS LETT, V244, P402, DOI 10.1016/0014-5793(89)80572-1; YOUNES A, 1992, J BIOL CHEM, V287, P842; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	53	108	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10334	10340		10.1074/jbc.271.17.10334	http://dx.doi.org/10.1074/jbc.271.17.10334			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626603	hybrid			2022-12-27	WOS:A1996UG25700075
J	Frank, S; Madlener, M; Werner, S				Frank, S; Madlener, M; Werner, S			Transforming growth factors beta 1, beta 2, and beta 3 and their receptors are differentially regulated during normal and impaired wound healing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; II RECEPTOR; GENE-EXPRESSION; GROWTH-FACTOR-BETA-1; PROLIFERATION; FACTOR-BETA-1; PURIFICATION; MACROPHAGES; INHIBITION; PATTERNS	A series of studies has shown that application of transforming growth factor beta (TGF-beta) to a wound has a beneficial effect, especially in animals with wound healing disorders. In this study we have investigated the regulation of TGF-beta 1, beta 2, and beta 3 and their receptors during the repair process. We found a large induction of all three TGF-beta isoforms and also of TGF-beta types I and II receptors, although the time course of induction and the absolute expression levels were different for these genes. Furthermore, each TGF-beta isoform had distinct sites of expression in the wound. Systemic treatment with glucocorticoids significantly altered the expression levels of TGF-beta s and TGF-beta receptors. Whereas expression of TGF-beta 1, TGF-beta 2, and TGF-beta type II receptor was suppressed by glucocorticoids in normal and wounded skin, expression of TGF-beta 3 and TGF-beta receptor type I mRNA was stimulated. These findings provide an explanation for the beneficial effect of exogenous TGF-beta in the treatment of impaired wound healing in glucocorticoid-treated animals. Furthermore, they suggest that a disturbed balance between the levels of the three TGF-beta isoforms and their receptors might underlie the wound healing defect seen in glucocorticoid-treated animals.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Max Planck Society				Werner, Sabine/0000-0001-7397-8710				ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Beck LS, 1991, GROWTH FACTORS, V5, DOI 10.3109/08977199109000293; BECK LS, 1993, J CLIN INVEST, V92, P2841, DOI 10.1172/JCI116904; BRAUCHLE M, 1995, J INVEST DERMATOL, V105, P579, DOI 10.1111/1523-1747.ep12323521; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark RAF, 1991, PHYSL BIOCH MOL BIOL, P576; COX DA, 1995, CELL BIOL INT, V19, P357, DOI 10.1006/cbir.1995.1082; EHRLICH HP, 1968, ANN SURG, V167, P324, DOI 10.1097/00000658-196803000-00004; Fassler R, 1996, EXP CELL RES, V222, P111, DOI 10.1006/excr.1996.0014; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GAILIT J, 1994, J INVEST DERMATOL, V103, P221, DOI 10.1111/1523-1747.ep12393176; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; GROTENDORST GR, 1989, J CELL PHYSIOL, V140, P396, DOI 10.1002/jcp.1041400226; GROTENDORST GR, 1988, GROWTH FACTORS OTHER, P47; KANE CJM, 1991, J CELL PHYSIOL, V148, P157, DOI 10.1002/jcp.1041480119; KLINGBEIL CK, 1991, PROG CLIN BIOL RES, V365, P443; LEIBOVICH SJ, 1975, AM J PATHOL, V78, P71; LEVINE JH, 1993, AM J PATHOL, V143, P368; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MILLAN FA, 1991, DEVELOPMENT, V111, P131; MULDER KM, 1993, J CELL PHYSIOL, V154, P162, DOI 10.1002/jcp.1041540120; NATH RK, 1994, J PEDIATR SURG, V29, P416, DOI 10.1016/0022-3468(94)90582-7; NORTH RJ, 1971, J EXP MED, V134, P1485, DOI 10.1084/jem.134.6.1485; PIERCE GF, 1989, P NATL ACAD SCI USA, V86, P2229, DOI 10.1073/pnas.86.7.2229; PITTELKOW MR, 1991, PHYSL BIOCH MOL BIOL, P351; SCHMID P, 1991, DEVELOPMENT, V111, P117; SCHMID P, 1993, J PATHOL, V171, P191, DOI 10.1002/path.1711710307; SHAH M, 1995, J CELL SCI, V108, P985; SHAH M, 1994, J CELL SCI, V107, P1137; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SHULL S, 1995, LUNG, V173, P71, DOI 10.1007/BF02981467; SUZUKI A, 1994, BIOCHEM BIOPH RES CO, V198, P1063, DOI 10.1006/bbrc.1994.1151; THOMPSON NL, 1989, J CELL BIOL, V108, P661, DOI 10.1083/jcb.108.2.661; TOMODA T, 1994, BIOCHEM BIOPH RES CO, V198, P1054, DOI 10.1006/bbrc.1994.1150; Wahl S, 1989, ANTIINFLAMMATORY STE, P280; WANG JX, 1995, J BIOL CHEM, V270, P2722, DOI 10.1074/jbc.270.36.21326; WEINER FR, 1987, J BIOL CHEM, V262, P6955; WERNER S, 1994, J INVEST DERMATOL, V103, P469, DOI 10.1111/1523-1747.ep12395564; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	44	306	318	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10188	10193		10.1074/jbc.271.17.10188	http://dx.doi.org/10.1074/jbc.271.17.10188			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626581	hybrid			2022-12-27	WOS:A1996UG25700053
J	Gautier, MC; Sperling, L; Madeddu, L				Gautier, MC; Sperling, L; Madeddu, L			Cloning and sequence analysis of genes coding for Paramecium secretory granule (trichocyst) proteins - A unique protein fold for a family of polypeptides with different primary structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEINS; HELICAL COILED COILS; SECONDARY STRUCTURE; TRYPANOSOMA-BRUCEI; BIOCHEMICAL-CHARACTERIZATION; TETRAURELIA; CLEAVAGE; ELECTROPHORESIS; PREDICTION; MOTIF	The architecturally complex secretory granules of Paramecium, known as trichocysts, have two unusual and seemingly contradictory features: their protein contents have crystalline organization (Sperling, L., Tardieu, A., and Gulik-Krzywicki, T. (1987) J. Cell Biol. 105, 1649-1662), yet these proteins are a heterogeneous set of molecules encoded by a large multigene family (Madeddu, L., Gautier, M.-C., Vayssie, L., Houari, A., and Sperling, L. (1995) Mol. Biol. Cell 6, 649-659). We present here the first complete sequences of three genes coding for three different precursors of the trichocyst crystalline matrix proteins. The deduced protein sequences indicate that each precursor gives rise to two of the mature polypeptides found in the crystalline trichocyst matrix. Analysis of putative processing sites suggests that a series of reactions, some of which may involve a novel endopeptidase, are involved in their proteolytic maturation. Each of the 6 mature polypeptides contains heptad segments. Characterization of the heptad segments leads us to propose that the mature polypeptides that compose the crystalline trichocyst matrix, despite their different primary structures, all share a unique protein fold, probably a 4 alpha-helical antiparallel bundle.	UNIV PARIS 06,CTR GENET MOLEC,CNRS,F-91198 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay			Sperling, Linda/C-9734-2014	Sperling, Linda/0000-0002-7772-4774				Adoutte A., 1988, P325; ADOUTTE A, 1984, J MOL BIOL, V180, P1065, DOI 10.1016/0022-2836(84)90271-7; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BLUM ML, 1993, NATURE, V362, P603, DOI 10.1038/362603a0; BONNEMAIN H, 1992, GENETICS, V130, P461; CARON F, 1985, NATURE, V314, P185, DOI 10.1038/314185a0; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COHEN J, 1980, GENETICS, V95, P797; CONWAY JF, 1990, INT J BIOL MACROMOL, V12, P328, DOI 10.1016/0141-8130(90)90023-4; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DELOUBRESSE NG, 1994, BIOL CELL, V82, P139, DOI 10.1016/S0248-4900(94)80016-2; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIRAGO JP, 1988, J BIOL CHEM, V263, P12564; FREYMANN DM, 1984, NATURE, V311, P167, DOI 10.1038/311167a0; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GAUTIER MC, 1994, J CELL BIOL, V124, P893, DOI 10.1083/jcb.124.6.893; GODISKA R, 1987, MOL GEN GENET, V208, P529, DOI 10.1007/BF00328151; HARUMOTO T, 1991, J EXP ZOOL, V260, P84, DOI 10.1002/jez.1402600111; Hausmann K, 1978, Int Rev Cytol, V52, P197, DOI 10.1016/S0074-7696(08)60757-3; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; KLUMPP S, 1994, J BIOL CHEM, V269, P32774; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECAER JP, 1990, J PROTEIN CHEM, V9, P290; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MADEDDU L, 1995, MOL BIOL CELL, V6, P649, DOI 10.1091/mbc.6.6.649; MADEDDU L, 1994, BIOCHIMIE, V76, P329, DOI 10.1016/0300-9084(94)90167-8; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; METCALF P, 1987, NATURE, V325, P84, DOI 10.1038/325084a0; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERSON JB, 1987, J CELL SCI, V87, P3; PETERSON JB, 1990, CURRENT RES PROTEIN, P79; POLLACK S, 1974, J PROTOZOOL, V21, P352, DOI 10.1111/j.1550-7408.1974.tb03669.x; PONGOR S, 1994, NUCLEIC ACIDS RES, V22, P3610; PRAT A, 1986, J MOL BIOL, V189, P47, DOI 10.1016/0022-2836(86)90380-3; PREER JR, 1985, NATURE, V314, P188, DOI 10.1038/314188a0; PRESCOTT DM, 1994, MICROBIOL REV, V58, P233, DOI 10.1128/MMBR.58.2.233-267.1994; RESNICK NM, 1991, CELL, V66, P541, DOI 10.1016/0092-8674(81)90017-9; ROST B, 1994, J MOL BIOL, V235, P13, DOI 10.1016/S0022-2836(05)80007-5; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; Sambrook J., 2002, MOL CLONING LAB MANU; SCOTT J, 1993, GENETICS, V133, P189; SEIDAH NG, 1994, METHOD ENZYMOL, V244, P175; SHIH SJ, 1991, J CELL SCI, V100, P85; SHIH SJ, 1992, J CELL SCI, V103, P349; Sonneborn T. M., 1970, Methods Cell Physiol., V4, P241, DOI 10.1016/S0091-679X(08)61758-6; Sonneborn TM, 1974, HDB GENETICS, V11, P469; SPERLING L, 1987, J CELL BIOL, V105, P1649, DOI 10.1083/jcb.105.4.1649; STEERS E, 1969, EXP CELL RES, V57, P392, DOI 10.1016/0014-4827(69)90165-7; STEINER DF, 1992, J BIOL CHEM, V267, P23435; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TINDALL SH, 1989, J CELL SCI, V92, P441; TINDALL SH, 1986, ANAL BIOCHEM, V159, P287, DOI 10.1016/0003-2697(86)90345-3; TOOZE SA, 1993, MECHANISMS INTRACELL, P157; VESTERBERG O, 1969, ACTA CHEM SCAND, V23, P2653, DOI 10.3891/acta.chem.scand.23-2653; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	60	33	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10247	10255		10.1074/jbc.271.17.10247	http://dx.doi.org/10.1074/jbc.271.17.10247			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626591	hybrid			2022-12-27	WOS:A1996UG25700063
J	Hua, XX; Sakai, J; Brown, MS; Goldstein, JL				Hua, XX; Sakai, J; Brown, MS; Goldstein, JL			Regulated cleavage of sterol regulatory element binding proteins requires sequences on both sides of the endoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER PROTEIN; HERPES-SIMPLEX VIRUS; SITE; TRANSCRIPTION; GENE	Sterol regulatory element binding proteins (SREBP-1 and SREBP-2) are attached to the endoplasmic reticulum (ER) and nuclear envelope by a hairpin domain consisting of two transmembrane regions connected by a short lumenal loop of similar to 30 hydrophilic amino acids. In sterol-depleted cells, a protease cleaves the protein in the region of the first transmembrane domain, releasing an NH2-terminal fragment of similar to 500 amino acids that activates transcription of genes encoding the low density lipoprotein receptor and enzymes of cholesterol synthesis. In sterol-overloaded cells, proteolysis does not occur, and transcription is repressed. Through mutational analysis in transfected cells, we identify two segments of SREBPs that are required for proteolysis, one on either side of the ER membrane. An arginine in the lumenal loop is essential. A tetrapeptide sequence (DRSR) on the cytosolic face adjacent to the first transmembrane domain is also required for maximal cleavage. Both of these elements are conserved in the human and hamster versions of SREBP-1 and SREBP-2. Sterol-mediated suppression of cleavage of SREBP-1 was found to be dependent on the extreme COOH-terminal region (residue 1034 to the COOH terminus), which exists in two forms as a result of alternative splicing. The form encoded by the ''a'' class exons (exons 18a and 19a) undergoes sterol-regulated cleavage. The form encoded by the ''c'' class exons (18c and 19c) is cleaved less efficiently and is not suppressed by sterols. These studies were made possible through use of a vector that achieves low level expression of epitope-tagged SREBPs under control of the relatively weak thymidine kinase promoter from herpes simplex virus. In contrast to SREBPs overproduced by high level expression vectors, the SREBPs produced at low levels were subject to the same regulated cleavage pattern as the endogenous SREBPs. These results indicate that sterol-regulated proteolysis of SREBPs is a complex process, requiring sequences on both sides of the ER membrane.			Hua, XX (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.			Sakai, Juro/0000-0003-4043-1035	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bollag D.M., 1991, PROTEIN METHODS; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; HUA XX, 1995, GENOMICS, V25, P667, DOI 10.1016/0888-7543(95)80009-B; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; ISOLA VJ, 1989, J VIROL, V63, P2325, DOI 10.1128/JVI.63.5.2325-2334.1989; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; MCKNIGHT SL, 1982, CELL, V31, P355, DOI 10.1016/0092-8674(82)90129-5; SATO R, 1994, J BIOL CHEM, V269, P17267; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	17	167	173	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10379	10384		10.1074/jbc.271.17.10379	http://dx.doi.org/10.1074/jbc.271.17.10379			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626610	hybrid			2022-12-27	WOS:A1996UG25700082
J	Trapp, T; Holsboer, F				Trapp, T; Holsboer, F			Nuclear orphan receptor as a repressor of glucocorticoid receptor transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; MINERALOCORTICOID RECEPTOR; MAMMALIAN-CELLS; EXPRESSION; DNA; SUPERFAMILY; ACTIVATION; MULTIPLE; JUN	Nuclear orphan receptors belong to the superfamily of ligand activated transcription factors that show a close structural relationship and sequence homology. Ligands and functions of most of the orphan receptors have not yet been identified. The first nuclear orphan receptors that were cloned displayed a high degree of amino acid identity with the human estrogen receptor and were termed estrogen receptor-related (ERR) 1 and 2. In the present study, we show that ERR2 functions as a potent repressor of transcriptional activity mediated by the glucocorticoid receptor (GR). Transient transfection of different cell lines with a steroid-responsive reporter plasmid and receptor expression plasmids revealed that transcriptional activity mediated by GR in response to agonists was strongly suppressed by coexpression of ERR2. The orphan receptor displayed no promoter activity when expressed without GR. The inhibitory activity of ERR2 is cell-specific and also receptor-specific because transactivation mediated by the progesterone receptor is unaffected by ERR2. Our observations provide evidence that the nuclear orphan receptor ERR2 acts as an endogenous modulator of GR transcriptional activity.			Trapp, T (corresponding author), MAX PLANCK INST PSYCHIAT,INST CLIN,DEPT NEUROENDOCRINOL,KRAEPELINSTR 10,D-80804 MUNICH,GERMANY.							ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; ARRIZA JL, 1988, NEURON, V1, P887, DOI 10.1016/0896-6273(88)90136-5; BAMBERGER CM, 1995, J CLIN INVEST, V95, P2435, DOI 10.1172/JCI117943; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CIDLOWSKI JA, 1990, MOL ENDOCRINOL, V4, P1427, DOI 10.1210/mend-4-10-1427; DASILVA SL, 1995, ENDOCRINOLOGY, V136, P2276; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KASTNER P, 1990, J BIOL CHEM, V265, P12163; MCDONNELL DP, 1994, J STEROID BIOCHEM, V48, P425, DOI 10.1016/0960-0760(94)90190-2; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; POWER RF, 1992, TRENDS PHARMACOL SCI, V13, P318, DOI 10.1016/0165-6147(92)90099-R; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; RUPPRECHT R, 1993, MOL ENDOCRINOL, V7, P597, DOI 10.1210/me.7.4.597; STRAHLE U, 1987, P NATL ACAD SCI USA, V88, P6092; TRAPP T, 1994, NEURON, V13, P1457, DOI 10.1016/0896-6273(94)90431-6; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	28	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9879	9882		10.1074/jbc.271.17.9879	http://dx.doi.org/10.1074/jbc.271.17.9879			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626619	hybrid			2022-12-27	WOS:A1996UG25700003
J	Welsh, N				Welsh, N			Interleukin-1 beta-induced ceramide and diacylglycerol generation may lead to activation of the c-Jun NH2-terminal kinase and the transcription factor ATF2 in the insulin-producing cell line RINm5F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PANCREATIC-ISLETS; NITRIC-OXIDE PRODUCTION; HL-60 CELLS; SPHINGOMYELIN; LANGERHANS; SECRETION; MECHANISMS; INHIBITION; IL-1-BETA; CYCLOOXYGENASE	The aim of this investigation was to study the putative involvement of lipid second messengers, protein kinases, and transcription factors in interleukin-1 beta (IL-1 beta)-induced signal transduction in insulin-producing cells. For this purpose, insulin-producing RINm5F cells were exposed to IL-1 beta (25 units/ml), and the ceramide, ceramide 1-phosphate, sphingomyelin, diacylglycerol, and phosphatidic acid contents of the cells were subsequently determined, It was found that IL-1 beta induced a transient increase (2-5 min) in ceramide and diacylglycerol, which was not paralleled by an increase in ceramide 1-phosphate and phosphatidic acid. A rapid decrease in the sphingomyelin content of the cells was, however, observed. The cell-permeable ceramide analogue N-acetylsphingosine and the phorbol ester phorbol 12-myristate 13-acetate (PMA) both induced the phosphorylation and increased the activities of the protein kinase JNK1 and the transcription factor ATF2. These effects were, however, not as pronounced as those induced by IL-1 beta. The DNA binding activity of transcription factors in nuclear extracts was determined using the electrophoretic mobility shift assay method. Transcription factor binding to the ATF/cAMP-responsive element consensus sequence was increased 4-5-fold by acetylsphingosine, PMA, or IL-1 beta, whereas binding to the CCAAT/enhancer-binding protein and AP-1 elements was found to be only slightly stimulated by these three agents. Binding to the NF-kappa B element was strongly induced by IL-1 beta, but not by acetylsphingosine or PMA. Finally, acetylsphingosine and PMA did not mimic the nitric oxide-inducing effects of IL-1 beta. It is concluded that IL-1 beta-stimulated formation of ceramide and diacylglycerol may contribute to JNK1 and ATF2 transcription factor activation, which may be a necessary (but not sufficient) step in beta-cell nitric-oxide synthase induction.			Welsh, N (corresponding author), UNIV UPPSALA,DEPT MED CELL BIOL,BOX 571,S-75123 UPPSALA,SWEDEN.							BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENDTZEN K, 1986, SCIENCE, V232, P1545, DOI 10.1126/science.3086977; BENDTZEN K, 1989, AUTOIMMUNITY, V2, P177, DOI 10.3109/08916938909019954; BETTS JC, 1994, J BIOL CHEM, V269, P8455; BIGDELI N, 1994, BIOCHEM BIOPH RES CO, V203, P1542, DOI 10.1006/bbrc.1994.2361; CORBETT JA, 1992, BIOCHEM J, V287, P229, DOI 10.1042/bj2870229; CORBETT JA, 1993, BIOCHEMISTRY-US, V32, P13767, DOI 10.1021/bi00213a002; CORBETT JA, 1993, FASEB J, V7, P369, DOI 10.1096/fasebj.7.2.8440413; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; EIZIRIK DL, 1992, FEBS LETT, V308, P249, DOI 10.1016/0014-5793(92)81285-T; EIZIRIK DL, 1995, MOL CELL ENDOCRINOL, V111, P159, DOI 10.1016/0303-7207(95)03561-K; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; JOHNS LD, 1994, J IMMUNOL, V152, P5877; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NERUP J, 1988, DIABETES CARE, V11, P16; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PREISS J, 1986, J BIOL CHEM, V261, P8597; RAINES MA, 1993, J BIOL CHEM, V268, P14572; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SALDEEN J, 1994, BIOCHEM BIOPH RES CO, V203, P149, DOI 10.1006/bbrc.1994.2161; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SANDLER S, 1989, ENDOCRINOLOGY, V124, P1492, DOI 10.1210/endo-124-3-1492; SANDLER S, 1987, ENDOCRINOLOGY, V121, P1424, DOI 10.1210/endo-121-4-1424; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SOUTHERN C, 1990, FEBS LETT, V276, P42, DOI 10.1016/0014-5793(90)80502-A; SVENSON M, 1988, SCAND J IMMUNOL, V27, P593, DOI 10.1111/j.1365-3083.1988.tb02387.x; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; WELSH N, 1992, BIOCHEM BIOPH RES CO, V182, P333, DOI 10.1016/S0006-291X(05)80149-4; WELSH N, 1991, ENDOCRINOLOGY, V129, P3167, DOI 10.1210/endo-129-6-3167; WELSH N, 1994, BIOSCIENCE REP, V14, P43, DOI 10.1007/BF01901637; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689	50	116	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8307	8312		10.1074/jbc.271.14.8307	http://dx.doi.org/10.1074/jbc.271.14.8307			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626526	hybrid			2022-12-27	WOS:A1996UD60000066
J	Williamson, LC; Halpern, JL; Montecucco, C; Brown, JE; Neale, EA				Williamson, LC; Halpern, JL; Montecucco, C; Brown, JE; Neale, EA			Clostridial neurotoxins and substrate proteolysis in intact neurons - Botulinum neurotoxin C acts on synaptosomal-associated protein of 25 kDa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL-CORD NEURONS; TETANUS-TOXIN; NEUROTRANSMITTER RELEASE; SYNAPTIC TRANSMISSION; MEMBRANE-PROTEIN; CULTURE; SNAP-25; FUSION; IDENTIFICATION; SYNAPTOBREVIN	Clostridial neurotoxins are zinc endopeptidases that block neurotransmission and have been shown to cleave, in vitro, specific proteins involved in synaptic vesicle docking and/or fusion. We have used immunohistochemistry and immunoblotting to demonstrate alterations in toxin substrates in intact neurons under conditions of toxin-induced blockade of neurotransmitter release. Vesicle-associated membrane protein, which colocalizes with synaptophysin, is not detectable in tetanus toxin-blocked cultures. Syntaxin, also concentrated in synaptic sites, is cleaved by botulinum neurotoxin C. Similarly, the carboxyl terminus of the synaptosomal-associated protein of 25 kDa (SNAP-25) is not detectable in botulinum neurotoxin A-treated cultures. Unexpectedly, tetanus toxin exposure causes an increase in SNAP-25 immunofluorescence, reflecting increased accessibility of antibodies to antigenic sites rather than increased expression of the protein. Furthermore, botulinum neurotoxin C causes a marked loss of the carboxyl terminus of SNAP-25 when the toxin is added to living cultures, whereas it has no action on SNAP-25 in in vitro preparations, This study is the first to demonstrate in functioning neurons that the physiologic response to these toxins is correlated with the proteolysis of their respective substrates, Furthermore, the data demonstrate that botulinum neurotoxin C, in addition to cleaving syntaxin, exerts a secondary effect on SNAP-25.	US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892; UNIV PADUA,CTR CNR BIOMEMBRANE,I-35121 PADUA,ITALY; UNIV PADUA,DIPARTIMENTO SCI BIOMED SPERIMENTALI,I-35121 PADUA,ITALY; USA,INST INFECT DIS,FT DETRICK,MD 21701	US Food & Drug Administration (FDA); University of Padua; University of Padua	Williamson, LC (corresponding author), NICHHD,DEV NEUROBIOL LAB,NIH,BLDG 49,RM 5A38,BETHESDA,MD 20892, USA.				Telethon [473] Funding Source: Medline	Telethon(Fondazione Telethon)		BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BERGEY GK, 1987, J NEUROPHYSIOL, V57, P121, DOI 10.1152/jn.1987.57.1.121; BIGALKE H, 1985, BRAIN RES, V360, P318, DOI 10.1016/0006-8993(85)91248-X; BINZ T, 1994, J BIOL CHEM, V269, P1617; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CALAKOS N, 1994, J BIOL CHEM, V269, P24534; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; DasGupta BR, 1989, BOTULINUM NEUROTOXIN, P53; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FACCHIANO F, 1993, TRENDS BIOCHEM SCI, V18, P327, DOI 10.1016/0968-0004(93)90066-V; FITZGERALD SC, 1989, DISSECTION TISSUE CU; GILOH H, 1982, SCIENCE, V217, P1252, DOI 10.1126/science.7112126; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HESS DT, 1992, J NEUROSCI, V12, P4634; INOUE A, 1992, J BIOL CHEM, V267, P10613; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MARXEN P, 1991, NEUROREPORT, V2, P33, DOI 10.1097/00001756-199101000-00008; MATSUDA M, 1989, BOTULINUM NEUROTOXIN, P69; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PRESEK P, 1992, J NEUROCHEM, V59, P1336, DOI 10.1111/j.1471-4159.1992.tb08445.x; RANSOM BR, 1977, J NEUROPHYSIOL, V40, P1132, DOI 10.1152/jn.1977.40.5.1132; SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/jbc.270.18.10566; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1992, J BIOL CHEM, V267, P23479; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; SCHIAVO G, 1994, J BIOL CHEM, V269, P20213; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TRIMBLE WS, 1990, J NEUROSCI, V10, P1380; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; WASHBOURNE P, 1995, BIOCHEM J, V305, P721, DOI 10.1042/bj3050721; WILLIAMSON LC, 1992, J NEUROCHEM, V59, P2148; YAMASAKI S, 1994, BIOCHEM BIOPH RES CO, V200, P829, DOI 10.1006/bbrc.1994.1526; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	43	169	181	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7694	7699		10.1074/jbc.271.13.7694	http://dx.doi.org/10.1074/jbc.271.13.7694			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631808	hybrid			2022-12-27	WOS:A1996UC77400076
J	Allen, RM; Chatterjee, R; Ludden, PW; Shah, VK				Allen, RM; Chatterjee, R; Ludden, PW; Shah, VK			The requirement of reductant for in vitro biosynthesis of the iron-molybdenum cofactor of nitrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII; KLEBSIELLA-PNEUMONIAE; DINITROGENASE REDUCTASE; INVITRO SYNTHESIS; PROTEIN; APODINITROGENASE; HOMOCITRATE; ACTIVATION; COMPONENT	A source of reductant is routinely added to the in vitro iron-molybdenum cofactor (FeMo-co) synthesis assay, although a requirement for reductant has not been established, This report demonstrates that the addition of reductant to the in vitro FeMo-co synthesis system is not required when Azotobacter vinelandii cell-free extract is prepared in buffer that lacks added reductant, The addition of reductant is required, however, if the A. vinelandii cell-free extract is chemically oxidized prior to addition to the assay, These results might suggest that extracts of A. vinelandii contain a physiological source of reductant that functions in the in vitro synthesis of FeMo-co, It is possible that the proteins required for FeMo-co biosynthesis (e,g, NIFNE and dinitrogenase reductase) are at the appropriate redox state to function in the in vitro reaction in the extract that is free of added reductant but not in the chemically oxidized extract, It is also possible that dinitrogenase reductase and/or NIFNE (both Fe-S proteins required for FeMo-co synthesis) might catalyze the reductant-dependent reaction for FeMo-co synthesis, Dithionite, Ti(III) citrate, and NADH are able to serve as the source of reductant for in vitro FeMo-co biosynthesis.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,COLL AGR & LIFE SCI,CTR STUDY NITROGEN FIXAT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM35332] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035332, R01GM035332] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1993, J BIOL CHEM, V268, P23670; ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; BENEMANN JR, 1971, BIOCHIM BIOPHYS ACTA, V226, P205, DOI 10.1016/0005-2728(71)90087-9; BOLIN JT, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P117; BULEN WA, 1965, P NATL ACAD SCI USA, V53, P532, DOI 10.1073/pnas.53.3.532; BULEN WA, 1966, P NATL ACAD SCI USA, V56, P979, DOI 10.1073/pnas.56.3.979; ENSIGN SA, 1990, BIOCHEMISTRY-US, V29, P2162, DOI 10.1021/bi00460a029; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HEDMAN B, 1988, J AM CHEM SOC, V110, P3798, DOI 10.1021/ja00220a013; HOLLIGER C, 1993, J AM CHEM SOC, V115, P5651, DOI 10.1021/ja00066a034; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; HOOVER TR, 1988, BIOCHEMISTRY-US, V27, P3647, DOI 10.1021/bi00410a019; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; LOACH PA, 1968, HDB BIOCH, P27; MARTIN AE, 1989, J BACTERIOL, V171, P3162, DOI 10.1128/jb.171.6.3162-3167.1989; MAYHEW SG, 1978, EUR J BIOCHEM, V85, P535, DOI 10.1111/j.1432-1033.1978.tb12269.x; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; PIENKOS PT, 1981, J BACTERIOL, V145, P743, DOI 10.1128/JB.145.2.743-751.1981; PIERIK AJ, 1993, EUR J BIOCHEM, V212, P51, DOI 10.1111/j.1432-1033.1993.tb17632.x; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; SEEFELDT LC, 1994, ANAL BIOCHEM, V221, P379, DOI 10.1006/abio.1994.1429; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; SHAH VK, 1994, J BIOL CHEM, V269, P1154; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SHAH VK, 1985, J BIOL CHEM, V260, P3891; YATES MG, 1970, BIOCHIM BIOPHYS ACTA, V197, P161, DOI 10.1016/0005-2728(70)90027-7	31	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4256	4260						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626771				2022-12-27	WOS:A1996TW96000049
J	Butch, ER; Guan, KL				Butch, ER; Guan, KL			Characterization of ERK1 activation site mutants and the effect on recognition by MEK1 and MEK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; SIGNAL-REGULATED KINASES; PROTEIN-KINASE; THREONINE KINASE; GENE-PRODUCT; PHOSPHORYLATION; INSULIN; INVITRO; CASCADE; IDENTIFICATION	To discern MEK1 and MEK2 specificity for their substrate, extracellular signal-regulated kinase (ERK), site-directed mutagenesis was performed on the amino acid residues flanking the regulatory phosphorylation sites of ERK1, These ERK1 mutants were analyzed for the ability to act as a substrate for MEK1 and MEK2. Based on both phosphorylation and activation analyses, the mutants could be divided into four classes: 1) dramatically decreased phosphorylation and activation, 2) enhanced basal kinase activity, 3) preferentially enhanced phosphorylation of tyrosine and decreased phosphorylation of threonine, and 4) increased threonine phosphorylation with an increase in activation, In general, the residues proximal to the regulatory phosphorylation sites of ERK1 had greater influence on both phosphorylation and activation. This is consistent with the highly specific recognition of the ERK1 regulatory sites by MEK, Mutation of Arg-208 or Thr-207 to an alanine residue significantly altered the relative phosphorylation on Thr-202 and Tyr-204, The Arg-208 to alanine mutant increased the phosphorylation of Tyr-204 approximately 4-fold yet almost completely eliminated the phosphorylation on Thr-202. In contrast, mutation of Gly-199 to alanine resulted in an increased phosphorylation of Thr-202 relative to Tyr-204, This suggests that both Gly-199 and Arg-208 play important roles in determining the relative phosphorylation of Thr-202 and Tyr-204, Our results demonstrate that residues in the phosphorylation lip of ERK play an important role in the recognition and phosphorylation by MEK.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,INST GERONTOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NIA NIH HHS [5T32AG00114] Funding Source: Medline; NIGMS NIH HHS [GM51586] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000114] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOWE LR, 1992, CELL, V71, P3325; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; JELINEK T, 1993, BIOTECHNIQUES, V15, P629; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NEL AE, 1990, J IMMUNOL, V144, P2683; PARK JH, 1993, BLOOD, V82, P2470; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGER R, 1992, J BIOL CHEM, V267, P14373; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TORRES L, 1991, MOL MICROBIOL, V5, P2845, DOI 10.1111/j.1365-2958.1991.tb01993.x; Wu XY, 1996, J BIOL CHEM, V271, P3265, DOI 10.1074/jbc.271.6.3265; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	50	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4230	4235						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626767				2022-12-27	WOS:A1996TW96000045
J	Cisalpino, PS; Puccia, R; Yamauchi, LM; Cano, MIN; daSilveira, JF; Travassos, LR				Cisalpino, PS; Puccia, R; Yamauchi, LM; Cano, MIN; daSilveira, JF; Travassos, LR			Cloning, characterization, and epitope expression of the major diagnostic antigen of Paracoccidioides brasiliensis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE CLEAVAGE SITES; SACCHAROMYCES-CEREVISIAE; EXOCELLULAR COMPONENTS; ESCHERICHIA-COLI; GLYCOPROTEIN; GENE; YEAST; PURIFICATION; IDENTIFICATION; PROTEINS	The 43,000-Da glycoprotein (gp43) of Paracoccidioides brasiliensis is an immunodominant antigen for antibody-dependent and immune cellular responses in patients with paracoccidioidomycosis. In order to identify the peptide epitopes involved in the immunological reactivities of the gp43 and to obtain highly specific recombinant molecules for diagnosis of the infection, genomic and cDNA clones representing the entire coding region of the antigen were sequenced. The gp43 open reading frame was found in a 1,329-base pair fragment with 2 exons interrupted by an intron of 78 nucleotides. The gene is present in very few copies per genome, as indicated by Southern blotting and chromosomal mega-restriction analysis. A single transcript of 1.5 kilobase pairs was verified in the yeast phase. The gene encodes a polypeptide of 416 amino acids (M(r) 45,947) with a leader peptide of 35 residues; the mature protein has at single N-glycosylation site. The deduced amino acid sequence showed similarities of 56-58% with exo-1,3-beta-D-glucanases hom Saccharomyces cerevisiae and Candida albicans. However, the gp43 is devoid of hydrolase activity and does not cross-react immunologically with the fungal glucanases. Internal and COOH-terminal gene fragments of the gp43 were expressed as recombinant fusion proteins, which reacted with antibodies elicited against the native antigen.	UNIV FED SAO PAULO, DEPT MICROBIOL IMUNOL & PARASITOL, DISCIPLINA BIOL CELULAR, BR-04023062 BELO HORIZONTE, SP, BRAZIL	Universidade Federal de Sao Paulo (UNIFESP)			Travassos, Luiz/V-2467-2019; Cano, Maria Isabel/A-4020-2008; Travassos, Luiz R/J-3631-2012; da Silveira, Jose Franco/F-5390-2012; Puccia, Rosana/D-7303-2012; Cano, Maria Isabel/M-7691-2019; Yamauchi, Lucy M/O-1859-2016	Puccia, Rosana/0000-0002-3332-0487; Cano, Maria Isabel/0000-0001-9798-6627; Yamauchi, Lucy M/0000-0003-2241-8814				BAIRD SD, 1990, BIOCHEM BIOPH RES CO, V169, P1035, DOI 10.1016/0006-291X(90)91998-8; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; CAMIRAND A, 1991, J BIOL CHEM, V266, P15120; CARMONA AK, 1995, BIOCHEM J, V309, P209, DOI 10.1042/bj3090209; CHAMBERS RS, 1993, J GEN MICROBIOL, V139, P325, DOI 10.1099/00221287-139-2-325; Cisalpino P, 1994, MOL BIOL PATHOGENIC, P461; DAVIS LG, 1986, METHOD MOL BIOL, P244; DEALDANA CRV, 1991, GENE, V97, P173, DOI 10.1016/0378-1119(91)90049-H; DILALLO G, 1994, GENE, V140, P51, DOI 10.1016/0378-1119(94)90729-3; DOBSON MJ, 1982, NUCLEIC ACIDS RES, V10, P2625, DOI 10.1093/nar/10.8.2625; HOEFSLOOT LH, 1988, EMBO J, V7, P1697, DOI 10.1002/j.1460-2075.1988.tb02998.x; IRNIGER S, 1994, P NATL ACAD SCI USA, V91, P257, DOI 10.1073/pnas.91.1.257; KRIZMAN DB, 1993, FOCUS, V15, P106; MENDESGIANNINI MJS, 1989, J CLIN MICROBIOL, V27, P2842, DOI 10.1128/JCM.27.12.2842-2845.1989; MUTHUKUMAR G, 1993, J BACTERIOL, V175, P386, DOI 10.1128/JB.175.2.386-394.1993; OSAKI L, 1984, GENES ANTIGENS PARAS; PERACOLI MTS, 1991, J MED VET MYCOL, V29, P373; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; PUCCIA R, 1986, INFECT IMMUN, V53, P199, DOI 10.1128/IAI.53.1.199-206.1986; PUCCIA R, 1991, J CLIN MICROBIOL, V29, P1610, DOI 10.1128/JCM.29.8.1610-1615.1991; PUCCIA R, 1991, J MED VET MYCOL, V29, P57; PUCCIA R, 1991, ARCH BIOCHEM BIOPHYS, V289, P298, DOI 10.1016/0003-9861(91)90475-X; Puccia R., 1994, MOL BIOL PATHOGENIC, P507; Queiroz-Telles F., 1994, PARACOCCIDIOIDOMYCOS, p27e44; RODRIGUES EG, 1994, J MED VET MYCOL, V32, P77; SAMBROCK J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; TABA MRM, 1989, EXP MYCOL, V13, P223, DOI 10.1016/0147-5975(89)90044-3; TABORDA CP, 1993, J MED VET MYCOL, V31, P155; TABORDA CP, 1994, J CLIN MICROBIOL, V32, P554, DOI 10.1128/JCM.32.2.554-556.1994; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAVASSOS LR, 1995, ARCH MED RES, V26, P299; VAITUKAITIS J, 1971, J CLIN ENDOCR METAB, V33, P988, DOI 10.1210/jcem-33-6-988; VICENTINI AP, 1994, INFECT IMMUN, V62, P1465, DOI 10.1128/IAI.62.4.1465-1469.1994; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WICKNER RB, 1991, MOL CELLULAR BIOL YE, P284; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2; [No title captured]	42	113	116	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4553	4560						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626811	hybrid			2022-12-27	WOS:A1996TW96000089
J	Jilling, T; Kirk, KL				Jilling, T; Kirk, KL			Cyclic AMP and chloride-dependent regulation of the apical constitutive secretory pathway in colonic epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTIC-FIBROSIS; PROTEIN-KINASE; INTRACELLULAR ORGANELLES; GOLGI-COMPLEX; BREFELDIN-A; LINE; CONDUCTANCE; EXPRESSION; CURRENTS; BINDING	Epithelial cells of the colonic crypt engage in cAMP-mediated fluid and electrolyte secretion. In addition to participating in electrolyte transport, colonic crypt cells also synthesize and secrete a number of proteins and peptides that play a crucial role in mucosal homeostasis. In the present study me show that cAMP regulates not only electrolyte secretion but also polarized protein secretion in a tissue culture model of colonic crypt cells. We found that apical but not basolateral protein secretion was stimulated by a physiological activator of the cAMP pathway, vasoactive intestinal peptide, as well as by a cell-permeant analogue of cAMP (8-(4-chlorophenylthio)cAMP) at concentrations as low as 12.5 mu M. Based on several criteria, we determined that the regulation of protein secretion by cAMP in HT29-CL19A cells occurs via stimulation of constitutive membrane traffic from the trans-Golgi network (TGN) to the apical cell surface, In addition, the regulation of apical protein secretion by cAMP was Cl--dependent with cAMP inhibiting rather than stimulating secretion in Cl--depleted cells. The locus of cAMP action on the secretory pathway is at least in part at the level of the TGN, where it stimulates the sialylation of alpha 1-antitrypsin (i.e. one of the identified secretory proteins) in addition to the traffic of secretory proteins from the TGN to the apical cell surface. We propose that a cyclic AMP and Cl--dependent regulation of TGN acidification could modulate both sialylation and secretory vesicle budding at the TGN.			Jilling, T (corresponding author), UNIV ALABAMA, DEPT PHYSIOL & BIOPHYS, GREGORY FLEMING JAMES CYST FIBROSIS RES CTR, 1918 UNIV BLVD, BIRMINGHAM, AL 35294 USA.			Jilling, Tamas/0000-0002-6200-3851	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050830] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK50830] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAWQATI Q, 1995, CURR OPIN CELL BIOL, V7, P504, DOI 10.1016/0955-0674(95)80006-9; ALAWQATI Q, 1992, J EXP BIOL, V172, P245; APPEL RD, 1994, NUCLEIC ACIDS RES, V22, P3581; AUGERON C, 1984, CANCER RES, V44, P3961; BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BARASCH J, 1993, J CELL SCI, P229; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BELL CL, 1992, AM J PHYSIOL, V262, pC555, DOI 10.1152/ajpcell.1992.262.3.C555; BOS CR, 1995, J BIOL CHEM, V270, P665, DOI 10.1074/jbc.270.2.665; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; BRADBURY NA, 1994, J BIOL CHEM, V269, P8296; BRADBURY NA, 1992, AM J PHYSIOL, V262, pC752, DOI 10.1152/ajpcell.1992.262.3.C752; CUNNINGHAM SA, 1992, AM J PHYSIOL, V262, pC783, DOI 10.1152/ajpcell.1992.262.3.C783; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; ECKMANN L, 1993, GASTROENTEROLOGY, V105, P1689, DOI 10.1016/0016-5085(93)91064-O; GREEN SA, 1990, J BIOL CHEM, V265, P21269; GRIFFITHS G, 1990, J CELL SCI, V96, P691; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HUANG KM, 1993, J BIOL CHEM, V268, P9302; KUBO M, 1992, J PHYSIOL-LONDON, V456, P351, DOI 10.1113/jphysiol.1992.sp019340; LADINSKY MS, 1994, J CELL BIOL, V127, P29, DOI 10.1083/jcb.127.1.29; LAFONT F, 1994, NATURE, V372, P801; LETHEM MI, 1993, AM J RESP CELL MOL, V9, P315, DOI 10.1165/ajrcmb/9.3.315; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MCCOOL DJ, 1990, BIOCHEM J, V267, P491, DOI 10.1042/bj2670491; MOLMENTI EP, 1993, J CLIN INVEST, V92, P2022, DOI 10.1172/JCI116797; MORRIS AP, 1994, AM J PHYSIOL, V266, pC254, DOI 10.1152/ajpcell.1994.266.1.C254; MOSTOV KE, 1995, BIOESSAYS, V17, P129, DOI 10.1002/bies.950170208; NILIUS B, 1994, BRIT J PHARMACOL, V112, P1049, DOI 10.1111/j.1476-5381.1994.tb13189.x; OGUCHI S, 1993, BIOCHEM BIOPH RES CO, V196, P789, DOI 10.1006/bbrc.1993.2318; PIMPLIKAR SW, 1994, J BIOL CHEM, V269, P19054; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; ROSA P, 1992, EUR J CELL BIOL, V59, P265; SALLENAVE JM, 1994, AM J RESP CELL MOL, V11, P733, DOI 10.1165/ajrcmb.11.6.7946401; SOLIS ROL, 1983, BIOCHIM BIOPHYS ACTA, V729, P237, DOI 10.1016/0005-2736(83)90490-X; STRONG TV, 1994, J CLIN INVEST, V93, P347, DOI 10.1172/JCI116966; VENEMBRE P, 1994, FEBS LETT, V346, P171, DOI 10.1016/0014-5793(94)80695-0; WANG XD, 1993, CAN J PHYSIOL PHARM, V71, P662, DOI 10.1139/y93-097; WELSH MJ, 1982, SCIENCE, V218, P1219, DOI 10.1126/science.6293054; YILLA M, 1993, J BIOL CHEM, V268, P19092; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619	45	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4381	4387						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626788				2022-12-27	WOS:A1996TW96000066
